rp_entity_id,category,relevance,ess,rpna_date_utc
036C6F,legal-issues-defendant,100,22,1/1/2021
3B2311,legal-issues-defendant,100,22,1/1/2021
723548,dividend,100,50,1/1/2021
7239BB,legal-issues-defendant,100,22,1/1/2021
CBFFDD,legal-issues-defendant,100,22,1/1/2021
D17F7E,business-contract,100,69,1/1/2021
EC8116,dividend,100,50,1/1/2021
F9AA02,executive-appointment,100,54,1/1/2021
1E9A6D,legal-issues-defendant,100,22,1/3/2021
47B4CC,legal-issues-defendant,100,22,1/3/2021
95F59E,legal-issues-defendant,100,22,1/3/2021
BAD655,legal-issues-defendant,100,22,1/3/2021
C9E107,legal-issues-defendant,100,22,1/3/2021
00067A,conference-participant,100,50,1/4/2021
00326D,conference-call,100,50,1/4/2021
9397,earnings,100,50,1/4/2021
03596A,asset-sale,100,62,1/4/2021
03D5F9,conference-participant,100,50,1/4/2021
55018,donation,100,54,1/4/2021
05D148,conference-participant,100,50,1/4/2021
06EE79,executive-appointment,100,54,1/4/2021
075CF7,executive-appointment,100,54,1/4/2021
099A02,executive-appointment,100,54,1/4/2021
09DE1F,note-sale,100,52,1/4/2021
0BD4E8,facility-open,100,65,1/4/2021
0BF198,clinical-trials-start,100,64,1/4/2021
0BF198,clinical-trials-start,100,64,1/4/2021
0BF198,clinical-trials-start,100,64,1/4/2021
0C355F,conference-participant,100,50,1/4/2021
0D03C8,conference-participant,100,50,1/4/2021
0E2992,conference-call,100,50,1/4/2021
0E439E,earnings,100,50,1/4/2021
0E64D4,asset-sale,100,62,1/4/2021
0F0693,conference-participant,100,50,1/4/2021
10C19B,dividend-up,100,81,1/4/2021
11074E,conference-participant,100,50,1/4/2021
125212,executive-appointment,100,54,1/4/2021
129DC8,executive-appointment,100,54,1/4/2021
12F98C,partnership,100,61,1/4/2021
131443,partnership,100,61,1/4/2021
139303,executive-appointment,100,54,1/4/2021
15B10D,conference-participant,100,50,1/4/2021
184988,conference-participant,100,50,1/4/2021
1A2D9F,acquisition-acquiree,100,76,1/4/2021
1A2D9F,acquisition-acquiree,100,76,1/4/2021
1CD09C,conference-participant,100,50,1/4/2021
1CD4B5,conference-participant,100,50,1/4/2021
1EBF8D,conference-participant,100,50,1/4/2021
1F352C,earnings,100,50,1/4/2021
1F352C,earnings,100,50,1/4/2021
1F716B,acquisition-completed-acquirer,100,49,1/4/2021
1F9D90,conference-participant,100,50,1/4/2021
21245F,executive-appointment,100,54,1/4/2021
221AD7,earnings,100,50,1/4/2021
2920D5,conference-participant,100,50,1/4/2021
2A02DC,conference-participant,100,50,1/4/2021
2A1009,conference-participant,100,50,1/4/2021
2AA6A8,conference-participant,100,50,1/4/2021
2B49F4,executive-appointment,100,54,1/4/2021
2B8179,conference-participant,100,50,1/4/2021
2B9DBB,conference-call,100,50,1/4/2021
2CF9D3,regulatory-product-approval-granted,100,81,1/4/2021
2CF9D3,conference-participant,100,50,1/4/2021
2E0445,conference-participant,100,50,1/4/2021
2EB88B,executive-resignation,100,44,1/4/2021
2F5256,conference-call,100,50,1/4/2021
30DFD3,conference-call,100,50,1/4/2021
338544,conference-call,100,50,1/4/2021
3.30E+34,executive-resignation,100,44,1/4/2021
34B411,earnings,100,50,1/4/2021
36529A,executive-appointment,100,54,1/4/2021
367E1C,conference-participant,100,50,1/4/2021
3.88E+02,dividend,100,50,1/4/2021
39D9DA,earnings,100,50,1/4/2021
39FB23,executive-appointment,100,54,1/4/2021
3A4BDB,conference-call,100,50,1/4/2021
3BBD10,credit-extension-recipient,100,69,1/4/2021
3C7F5F,business-contract,100,69,1/4/2021
3D7971,executive-appointment,100,54,1/4/2021
3D7971,executive-appointment,100,54,1/4/2021
3DD5E2,conference-participant,100,50,1/4/2021
3FACA7,conference-participant,100,50,1/4/2021
407878,executive-appointment,100,54,1/4/2021
40F7DE,executive-appointment,100,54,1/4/2021
41B53E,dividend,100,50,1/4/2021
467F2C,conference-participant,100,50,1/4/2021
46CF27,earnings,100,50,1/4/2021
4A2457,business-contract,100,69,1/4/2021
4D371E,executive-appointment,100,54,1/4/2021
4D72C8,conference-call,100,50,1/4/2021
4D72C8,conference-call,100,50,1/4/2021
4DD09F,unit-acquisition-acquirer,100,49,1/4/2021
4E4E75,conference-participant,100,50,1/4/2021
50070E,conference-organizer,100,57,1/4/2021
50070E,conference-organizer,100,57,1/4/2021
50070E,conference-organizer,100,57,1/4/2021
50070E,conference-organizer,100,57,1/4/2021
5288FC,public-offering,100,43,1/4/2021
52BF94,conference-call,100,50,1/4/2021
56B7C1,dividend,100,50,1/4/2021
57DDB9,unit-acquisition-acquirer,100,49,1/4/2021
57F3DA,unit-acquisition-acquirer,100,49,1/4/2021
594402,conference-participant,100,50,1/4/2021
59C539,conference-call,100,50,1/4/2021
59DB8C,conference-participant,100,50,1/4/2021
5C7601,executive-appointment,100,54,1/4/2021
5FC507,conference-participant,100,50,1/4/2021
5FDBD0,conference-participant,100,50,1/4/2021
5FE4B6,conference-participant,100,50,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-organizer,100,57,1/4/2021
619882,conference-call,100,50,1/4/2021
619882,conference-organizer,100,57,1/4/2021
627186,conference-participant,100,50,1/4/2021
6391C2,conference-participant,100,50,1/4/2021
63F892,earnings,100,50,1/4/2021
6474BA,earnings,100,50,1/4/2021
6830FE,conference-participant,100,50,1/4/2021
69CE71,dividend,100,50,1/4/2021
6E1E61,earnings,100,50,1/4/2021
7122EB,executive-appointment,100,54,1/4/2021
73C521,business-contract,100,69,1/4/2021
7448A3,conference-participant,100,50,1/4/2021
748EB6,conference-participant,100,50,1/4/2021
763724,dividend,100,50,1/4/2021
763DBE,conference-participant,100,50,1/4/2021
76DD0C,conference-participant,100,50,1/4/2021
7710F3,public-offering,100,43,1/4/2021
7AF907,conference-participant,100,50,1/4/2021
7F3669,conference-participant,100,50,1/4/2021
810FAD,conference-call,100,50,1/4/2021
8377DB,acquisition-completed-acquirer,100,49,1/4/2021
83B1C8,legal-issues-defendant,100,22,1/4/2021
83B1C8,legal-issues-defendant,100,22,1/4/2021
83B1C8,legal-issues-defendant,100,22,1/4/2021
85CDC9,conference-participant,100,50,1/4/2021
862941,executive-appointment,100,54,1/4/2021
881190,acquisition-completed-acquirer,100,49,1/4/2021
88193E,conference-participant,100,50,1/4/2021
8AB85C,clinical-trials,100,56,1/4/2021
8E82A6,executive-appointment,100,54,1/4/2021
8E8E6E,product-release,100,64,1/4/2021
903AB4,earnings,100,50,1/4/2021
903AB4,earnings,100,50,1/4/2021
92B625,conference-participant,100,50,1/4/2021
931AE7,conference-participant,100,50,1/4/2021
93965C,conference-participant,100,50,1/4/2021
94637C,conference-participant,100,50,1/4/2021
94637C,regulatory-product-approval-granted,100,81,1/4/2021
94637C,regulatory-product-approval-granted,100,81,1/4/2021
9470CC,award,100,58,1/4/2021
949D62,conference-participant,100,50,1/4/2021
9592FB,conference-participant,100,50,1/4/2021
96F126,conference-call,100,50,1/4/2021
9810C0,conference-call,100,50,1/4/2021
9934AD,acquisition-acquiree,100,76,1/4/2021
9934AD,acquisition-completed-acquiree,100,76,1/4/2021
9934AD,acquisition-regulatory-scrutiny-acquiree,100,38,1/4/2021
9934AD,legal-issues-defendant,100,22,1/4/2021
9978F1,conference-participant,100,50,1/4/2021
9B4066,unit-acquisition-acquirer,100,49,1/4/2021
9D30A8,acquisition-acquirer,100,49,1/4/2021
9D30A8,acquisition-acquirer,100,49,1/4/2021
9D56F2,conference-call,100,50,1/4/2021
9E5C2C,conference-call,100,50,1/4/2021
9EED50,conference-call,100,50,1/4/2021
9F37C5,dividend,100,50,1/4/2021
A26EF7,conference-participant,100,50,1/4/2021
A2C979,public-offering,100,43,1/4/2021
A3230E,conference-participant,100,50,1/4/2021
A43906,executive-appointment,100,54,1/4/2021
A5B913,earnings,100,50,1/4/2021
A60318,earnings,100,50,1/4/2021
A6828A,dividend,100,50,1/4/2021
A871B0,acquisition-acquiree,100,76,1/4/2021
A871B0,acquisition-acquiree,100,76,1/4/2021
AA5C8E,campaign-ad-release,100,59,1/4/2021
AABEA0,executive-appointment,100,54,1/4/2021
AABEA0,executive-appointment,100,54,1/4/2021
ABB493,conference-participant,100,50,1/4/2021
ADF092,partnership,100,61,1/4/2021
ADF092,partnership,100,61,1/4/2021
AEEB76,partnership,100,61,1/4/2021
AFDF2E,acquisition-acquirer,100,49,1/4/2021
B0D41A,public-offering,100,43,1/4/2021
B33E77,partnership,100,61,1/4/2021
B53C12,executive-appointment,100,54,1/4/2021
B604DF,conference-call,100,50,1/4/2021
B76C82,merger-completed,100,66,1/4/2021
B80AD1,conference-participant,100,50,1/4/2021
B8A51F,conference-participant,100,50,1/4/2021
C05839,acquisition-acquirer,100,49,1/4/2021
C05839,acquisition-acquirer,100,49,1/4/2021
C06EB6,conference-participant,100,50,1/4/2021
C2609A,acquisition-completed-acquiree,100,76,1/4/2021
C2DD02,conference-participant,100,50,1/4/2021
C45C1F,executive-appointment,100,54,1/4/2021
C5C0E9,conference-participant,100,50,1/4/2021
C5C137,executive-appointment,100,54,1/4/2021
C7AE14,dividend,100,50,1/4/2021
C81E00,conference-call,100,50,1/4/2021
C81E00,conference-call,100,50,1/4/2021
C97B2D,conference-participant,100,50,1/4/2021
CAB222,conference-participant,100,50,1/4/2021
CAC8D0,conference-participant,100,50,1/4/2021
CB89EA,conference-participant,100,50,1/4/2021
CC339B,earnings,100,50,1/4/2021
CD4DA8,executive-appointment,100,54,1/4/2021
CF073E,conference-participant,100,50,1/4/2021
CF6A5A,earnings,100,50,1/4/2021
D0C79E,executive-appointment,100,54,1/4/2021
D1588D,conference-participant,100,50,1/4/2021
D18AFC,partnership,100,61,1/4/2021
D18AFC,partnership,100,61,1/4/2021
D25249,executive-appointment,100,54,1/4/2021
D54E62,conference-call,100,50,1/4/2021
D5938F,clinical-trials,100,56,1/4/2021
D5938F,clinical-trials,100,56,1/4/2021
D6489C,acquisition-completed-acquirer,100,49,1/4/2021
D77F7E,executive-appointment,100,54,1/4/2021
D77F7E,executive-appointment,100,54,1/4/2021
DA199F,earnings,100,50,1/4/2021
DB5CA5,executive-appointment,100,54,1/4/2021
DB5CA5,dividend,100,50,1/4/2021
DBCA3F,acquisition-acquirer,100,49,1/4/2021
DBCA3F,acquisition-acquirer,100,49,1/4/2021
DC6AA0,legal-issues-defendant,100,22,1/4/2021
DD1BA1,unit-acquisition-acquiree,100,76,1/4/2021
DF1F7A,conference-call,100,50,1/4/2021
DF8855,executive-appointment,100,54,1/4/2021
DFADDB,patient-enrollment-complete,100,64,1/4/2021
DFADDB,patient-enrollment-complete,100,64,1/4/2021
E12A6E,earnings,100,50,1/4/2021
E1C16B,acquisition-completed-acquirer,100,49,1/4/2021
E21871,sponsorship,100,57,1/4/2021
E6C8DC,public-offering,100,43,1/4/2021
E829E8,conference-call,100,50,1/4/2021
E8846E,executive-appointment,100,54,1/4/2021
ECA300,conference-participant,100,50,1/4/2021
ECE814,conference-participant,100,50,1/4/2021
ED22DC,conference-participant,100,50,1/4/2021
ED9576,earnings,100,50,1/4/2021
F1529C,acquisition-completed-acquirer,100,49,1/4/2021
F1529C,acquisition-completed-acquirer,100,49,1/4/2021
F1529C,acquisition-completed-acquirer,100,49,1/4/2021
F1529C,acquisition-completed-acquirer,100,49,1/4/2021
F294DD,dividend,100,50,1/4/2021
F30508,conference-participant,100,50,1/4/2021
F3816D,conference-participant,100,50,1/4/2021
F47871,conference-participant,100,50,1/4/2021
F4CDA3,unit-acquisition-acquirer,100,49,1/4/2021
F4E992,conference-call,100,50,1/4/2021
F5D059,dividend,100,50,1/4/2021
F5D410,acquisition-acquirer,100,49,1/4/2021
F5D410,acquisition-acquirer,100,49,1/4/2021
F5D410,acquisition-acquirer,100,49,1/4/2021
F7D8AE,acquisition-completed-acquirer,100,49,1/4/2021
F9AA02,conference-participant,100,50,1/4/2021
FAAFA2,patient-enrollment-complete,100,64,1/4/2021
FC4550,dividend,100,50,1/4/2021
FD6926,conference-participant,100,50,1/4/2021
FD9526,executive-appointment,100,54,1/4/2021
00067A,earnings,100,50,1/5/2021
04EB2F,conference-participant,100,50,1/5/2021
56045,conference-participant,100,50,1/5/2021
75172,conference-participant,100,50,1/5/2021
078D52,dividend,100,50,1/5/2021
083F72,conference-call,100,50,1/5/2021
09062E,conference-participant,100,50,1/5/2021
091B6C,conference-participant,100,50,1/5/2021
095A04,conference-participant,100,50,1/5/2021
09DE1F,note-sale,100,52,1/5/2021
0BF198,conference-participant,100,50,1/5/2021
0CE204,conference-participant,100,50,1/5/2021
0FABBD,partnership,100,61,1/5/2021
12E454,earnings,100,50,1/5/2021
136B26,executive-appointment,100,54,1/5/2021
152FA5,conference-participant,100,50,1/5/2021
1782D5,note-sale,100,52,1/5/2021
1.79E+10,conference-call,100,50,1/5/2021
182BE7,conference-participant,100,50,1/5/2021
19CAC7,earnings,100,50,1/5/2021
1A2D9F,acquisition-interest-acquiree,100,82,1/5/2021
1A2D9F,acquisition-regulatory-scrutiny-acquiree,100,38,1/5/2021
1A2D9F,legal-issues-defendant,100,22,1/5/2021
1BC12C,revenues,100,50,1/5/2021
1BC12C,revenues,100,50,1/5/2021
1CD09C,conference-participant,100,50,1/5/2021
1D1B07,business-contract,100,69,1/5/2021
1D1B07,business-contract,100,69,1/5/2021
1D1B07,unit-acquisition-completed-acquiree,100,67,1/5/2021
1D943E,conference-participant,100,50,1/5/2021
1E7785,conference-participant,100,50,1/5/2021
1EBF8D,partnership,100,61,1/5/2021
1FAF22,conference-call,100,50,1/5/2021
223552,conference-participant,100,50,1/5/2021
22C58E,earnings,100,50,1/5/2021
232053,conference-participant,100,50,1/5/2021
23699B,conference-participant,100,50,1/5/2021
24C48B,partnership,100,61,1/5/2021
24FA23,conference-participant,100,50,1/5/2021
253604,conference-participant,100,50,1/5/2021
25D3CE,conference-participant,100,50,1/5/2021
2667B6,earnings,100,50,1/5/2021
2ABF77,conference-participant,100,50,1/5/2021
2ABF77,executive-appointment,100,54,1/5/2021
2C3348,conference-participant,100,50,1/5/2021
2FEA66,executive-appointment,100,54,1/5/2021
306623,stake-acquirer,100,48,1/5/2021
30DE64,conference-participant,100,50,1/5/2021
326EDD,conference-call,100,50,1/5/2021
370C50,conference-call,100,50,1/5/2021
37E18B,acquisition-completed-acquiree,100,76,1/5/2021
384CD3,partnership,100,61,1/5/2021
38C46F,dividend,100,50,1/5/2021
39BFF6,conference-call,100,50,1/5/2021
39FB23,acquisition-acquirer,100,49,1/5/2021
3AF7FD,conference-call,100,50,1/5/2021
3DDE54,earnings,100,50,1/5/2021
3F6A9C,legal-verdict-favored,100,78,1/5/2021
405762,conference-call,100,50,1/5/2021
408089,earnings,100,50,1/5/2021
416291,executive-appointment,100,54,1/5/2021
41785E,earnings,100,50,1/5/2021
42DC93,earnings,100,50,1/5/2021
434F38,conference-participant,100,50,1/5/2021
451D61,conference-participant,100,50,1/5/2021
453282,business-contract,100,69,1/5/2021
45BC35,acquisition-completed-acquirer,100,49,1/5/2021
4.60E+06,executive-appointment,100,54,1/5/2021
479930,conference-participant,100,50,1/5/2021
4A2457,conference-participant,100,50,1/5/2021
4BF3D6,conference-participant,100,50,1/5/2021
4C3FE9,conference-participant,100,50,1/5/2021
50070E,conference-organizer,100,57,1/5/2021
50070E,conference-organizer,100,57,1/5/2021
50070E,conference-organizer,100,57,1/5/2021
52015A,dividend,100,50,1/5/2021
53F491,earnings,100,50,1/5/2021
543C77,conference-participant,100,50,1/5/2021
546A9C,conference-call,100,50,1/5/2021
55438C,investment-investor,100,55,1/5/2021
56EA2B,public-offering,100,43,1/5/2021
59B229,earnings,100,50,1/5/2021
5A0FF1,conference-participant,100,50,1/5/2021
5B51D6,clinical-trials-start,100,64,1/5/2021
5B6C11,executive-appointment,100,54,1/5/2021
5D43A7,conference-call,100,50,1/5/2021
5F3E74,business-contract,100,69,1/5/2021
60AC34,executive-appointment,100,54,1/5/2021
6166D1,conference-call,100,50,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
619882,conference-organizer,100,57,1/5/2021
61A586,conference-participant,100,50,1/5/2021
61B81B,dividend,100,50,1/5/2021
620381,conference-participant,100,50,1/5/2021
62CDDE,reorganization-unit,100,53,1/5/2021
64636E,conference-participant,100,50,1/5/2021
64636E,conference-participant,100,50,1/5/2021
649CBD,executive-appointment,100,54,1/5/2021
68586A,acquisition-acquirer,100,49,1/5/2021
68AB62,conference-participant,100,50,1/5/2021
6A171E,partnership,100,61,1/5/2021
6CBF41,conference-participant,100,50,1/5/2021
6F3FA8,conference-participant,100,50,1/5/2021
70CA28,conference-participant,100,50,1/5/2021
717DB4,conference-participant,100,50,1/5/2021
7255D2,conference-call,100,50,1/5/2021
726EEA,executive-appointment,100,54,1/5/2021
75D689,conference-participant,100,50,1/5/2021
762A3E,executive-appointment,100,54,1/5/2021
7710F3,public-offering,100,43,1/5/2021
7A5097,acquisition-completed-acquirer,100,49,1/5/2021
7AB859,partnership,100,61,1/5/2021
7ADE57,acquisition-acquirer,100,49,1/5/2021
7B1E50,executive-appointment,100,54,1/5/2021
7DD584,conference-participant,100,50,1/5/2021
7FD8B9,conference-participant,100,50,1/5/2021
83B1C8,conference-participant,100,50,1/5/2021
862941,business-contract,100,69,1/5/2021
8665BA,conference-call,100,50,1/5/2021
8A0368,conference-participant,100,50,1/5/2021
8AB85C,conference-participant,100,50,1/5/2021
8C84DF,conference-call,100,50,1/5/2021
8D4486,executive-appointment,100,54,1/5/2021
8D4486,executive-appointment,100,54,1/5/2021
8D4486,executive-appointment,100,54,1/5/2021
8E0E32,asset-sale,100,62,1/5/2021
925759,conference-participant,100,50,1/5/2021
92D3A0,conference-call,100,50,1/5/2021
9.36E+10,business-contract,100,69,1/5/2021
957A07,conference-participant,100,50,1/5/2021
958938,conference-participant,100,50,1/5/2021
9592FB,legal-issues-defendant,100,22,1/5/2021
9592FB,legal-issues-defendant,100,22,1/5/2021
9592FB,legal-issues-defendant,100,22,1/5/2021
965360,earnings,100,50,1/5/2021
9673BD,executive-appointment,100,54,1/5/2021
9673BD,executive-appointment,100,54,1/5/2021
99028D,acquisition-completed-acquirer,100,49,1/5/2021
994468,executive-appointment,100,54,1/5/2021
9B71A7,executive-appointment,100,54,1/5/2021
9C8664,conference-call,100,50,1/5/2021
9CA4C6,conference-call,100,50,1/5/2021
9DDE1B,conference-participant,100,50,1/5/2021
9F048E,conference-participant,100,50,1/5/2021
9F18FA,acquisition-completed-acquirer,100,49,1/5/2021
9F18FA,acquisition-completed-acquirer,100,49,1/5/2021
9FB4B7,executive-appointment,100,54,1/5/2021
A23747,conference-participant,100,50,1/5/2021
A47F2E,earnings,100,50,1/5/2021
A49498,conference-participant,100,50,1/5/2021
A52533,conference-participant,100,50,1/5/2021
A7102F,stake-acquirer,100,48,1/5/2021
A7102F,stake-acquirer,100,48,1/5/2021
A761FE,conference-participant,100,50,1/5/2021
A868C9,conference-participant,100,50,1/5/2021
A8E72A,conference-participant,100,50,1/5/2021
A8FDE8,conference-participant,100,50,1/5/2021
AA1EAA,executive-appointment,100,54,1/5/2021
AE0CCE,executive-appointment,100,54,1/5/2021
AEEB76,conference-participant,100,50,1/5/2021
B290A2,conference-participant,100,50,1/5/2021
B4703C,conference-call,100,50,1/5/2021
B48D6A,executive-appointment,100,54,1/5/2021
B4B281,conference-participant,100,50,1/5/2021
B5766D,conference-call,100,50,1/5/2021
B60366,executive-appointment,100,54,1/5/2021
B83D67,conference-participant,100,50,1/5/2021
B840EF,conference-participant,100,50,1/5/2021
BDEC1E,conference-participant,100,50,1/5/2021
BE14CF,conference-call,100,50,1/5/2021
BE645B,conference-participant,100,50,1/5/2021
BFF98A,conference-participant,100,50,1/5/2021
C29E71,conference-participant,100,50,1/5/2021
C3DE7D,executive-appointment,100,54,1/5/2021
C45CE7,conference-participant,100,50,1/5/2021
C4A241,conference-call,100,50,1/5/2021
C501B6,conference-participant,100,50,1/5/2021
C564E4,conference-participant,100,50,1/5/2021
C5D2AE,earnings,100,50,1/5/2021
C6C702,conference-participant,100,50,1/5/2021
C7859D,dividend,100,50,1/5/2021
C81E00,acquisition-acquirer,100,49,1/5/2021
C81E00,acquisition-acquirer,100,49,1/5/2021
C85A72,public-offering,100,43,1/5/2021
C85A72,public-offering,100,43,1/5/2021
C8A059,conference-participant,100,50,1/5/2021
CBA33B,earnings,100,50,1/5/2021
CD051C,conference-participant,100,50,1/5/2021
CDD75E,conference-participant,100,50,1/5/2021
CE5664,conference-participant,100,50,1/5/2021
CEDFD5,legal-issues-defendant,100,22,1/5/2021
D13F1C,executive-resignation,100,44,1/5/2021
D13F1C,executive-resignation,100,44,1/5/2021
D13F1C,business-contract,100,69,1/5/2021
D13F1C,business-contract,100,69,1/5/2021
D33270,government-contract,100,69,1/5/2021
D6489C,partnership,100,61,1/5/2021
D8442A,executive-appointment,100,54,1/5/2021
D8760C,earnings,100,50,1/5/2021
DA0CB8,conference-call,100,50,1/5/2021
DA48E4,business-contract,100,69,1/5/2021
DB396B,legal-issues-defendant,100,22,1/5/2021
DBCA3F,acquisition-interest-acquirer,100,46,1/5/2021
DCD97F,legal-issues-defendant,100,22,1/5/2021
DE4924,acquisition-acquirer,100,49,1/5/2021
DF18E6,conference-participant,100,50,1/5/2021
DF532D,conference-call,100,50,1/5/2021
E06265,conference-participant,100,50,1/5/2021
E09556,conference-participant,100,50,1/5/2021
E1BD05,conference-participant,100,50,1/5/2021
E20392,conference-participant,100,50,1/5/2021
E28D9C,acquisition-completed-acquirer,100,49,1/5/2021
E41190,executive-appointment,100,54,1/5/2021
E5A3B6,conference-participant,100,50,1/5/2021
E754F0,conference-participant,100,50,1/5/2021
E8E899,conference-participant,100,50,1/5/2021
EB1E1A,conference-participant,100,50,1/5/2021
EB5E78,conference-participant,100,50,1/5/2021
ED1A74,conference-participant,100,50,1/5/2021
ED2A5E,conference-participant,100,50,1/5/2021
ED9C04,product-release,100,64,1/5/2021
EFA7B2,conference-participant,100,50,1/5/2021
F0B877,executive-appointment,100,54,1/5/2021
F18844,unit-acquisition-acquirer,100,49,1/5/2021
F1CD47,conference-participant,100,50,1/5/2021
F24FF0,conference-call,100,50,1/5/2021
F48947,conference-participant,100,50,1/5/2021
F4D241,conference-participant,100,50,1/5/2021
F7935D,conference-participant,100,50,1/5/2021
F7ADEB,conference-participant,100,50,1/5/2021
F7D8AE,acquisition-completed-acquirer,100,49,1/5/2021
FAAFA2,conference-participant,100,50,1/5/2021
FDD3FC,conference-participant,100,50,1/5/2021
FDE409,conference-participant,100,50,1/5/2021
FE7A63,earnings,100,50,1/5/2021
FEE4B0,earnings,100,50,1/5/2021
01478A,earnings,100,50,1/6/2021
0157B1,product-release,100,64,1/6/2021
0157B1,product-release,100,64,1/6/2021
0157B1,partnership,100,61,1/6/2021
01D03F,partnership,100,61,1/6/2021
03B431,conference-participant,100,50,1/6/2021
0560D8,conference-participant,100,50,1/6/2021
06EE79,product-release,100,64,1/6/2021
0B57D7,conference-call,100,50,1/6/2021
0E499E,conference-participant,100,50,1/6/2021
0F0693,conference-participant,100,50,1/6/2021
1065BC,executive-appointment,100,54,1/6/2021
1080C0,conference-participant,100,50,1/6/2021
119CB6,conference-call,100,50,1/6/2021
136B26,public-offering,100,43,1/6/2021
168A5D,executive-appointment,100,54,1/6/2021
184866,conference-participant,100,50,1/6/2021
1E68B3,executive-appointment,100,54,1/6/2021
1F716B,executive-appointment,100,54,1/6/2021
1F9258,index-listing,100,76,1/6/2021
223552,clinical-trials-start,100,64,1/6/2021
2667B6,executive-appointment,100,54,1/6/2021
267718,partnership,100,61,1/6/2021
28AC4E,partnership,100,61,1/6/2021
292388,conference-participant,100,50,1/6/2021
29A4CC,conference-call,100,50,1/6/2021
29B702,earnings,100,50,1/6/2021
2BDC1C,executive-appointment,100,54,1/6/2021
2CC71C,conference-participant,100,50,1/6/2021
2CC71C,clinical-trials-positive,100,87,1/6/2021
2F7474,conference-call,100,50,1/6/2021
2F9304,legal-issues-defendant,100,22,1/6/2021
2F9304,legal-issues-defendant,100,22,1/6/2021
3.20E+263,conference-participant,100,50,1/6/2021
33AD83,conference-participant,100,50,1/6/2021
341759,conference-participant,100,50,1/6/2021
36E479,conference-participant,100,50,1/6/2021
3BE00F,unit-acquisition-acquirer,100,49,1/6/2021
3BE00F,unit-acquisition-acquirer,100,49,1/6/2021
3C3B6B,conference-participant,100,50,1/6/2021
3F1C69,conference-participant,100,50,1/6/2021
407878,conference-participant,100,50,1/6/2021
417BF9,public-offering,100,43,1/6/2021
4398A2,conference-participant,100,50,1/6/2021
43A74A,conference-participant,100,50,1/6/2021
44A4FC,conference-participant,100,50,1/6/2021
450ECB,conference-participant,100,50,1/6/2021
4591D3,legal-issues-defendant,100,22,1/6/2021
4B3555,earnings,100,50,1/6/2021
4BBA23,conference-participant,100,50,1/6/2021
4BDCA7,partnership,100,61,1/6/2021
4EC4C1,earnings,100,50,1/6/2021
4EC4C1,earnings,100,50,1/6/2021
4EC4C1,earnings,100,50,1/6/2021
4EC4C1,earnings,100,50,1/6/2021
4F9926,product-release,100,64,1/6/2021
50070E,partnership,100,61,1/6/2021
50070E,conference-organizer,100,57,1/6/2021
520632,conference-call,100,50,1/6/2021
539F49,conference-participant,100,50,1/6/2021
546A27,conference-participant,100,50,1/6/2021
55438C,earnings,100,50,1/6/2021
56EA2B,public-offering,100,43,1/6/2021
583223,conference-participant,100,50,1/6/2021
586BD7,conference-participant,100,50,1/6/2021
58CA9A,price-target-upgrade-rater,20,50,1/6/2021
59872F,executive-appointment,100,54,1/6/2021
59872F,conference-participant,100,50,1/6/2021
5AA3B1,conference-participant,100,50,1/6/2021
5B97B2,earnings,100,50,1/6/2021
5C2A47,conference-participant,100,50,1/6/2021
5D0337,executive-appointment,100,54,1/6/2021
5D1956,earnings,100,50,1/6/2021
60DD84,conference-call,100,50,1/6/2021
60FE03,conference-participant,100,50,1/6/2021
6166D1,unit-acquisition-acquirer,100,49,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
619882,conference-organizer,100,57,1/6/2021
636639,acquisition-acquirer,100,49,1/6/2021
665D7D,conference-participant,100,50,1/6/2021
66A667,dividend,100,50,1/6/2021
66A667,dividend,100,50,1/6/2021
69CE71,executive-appointment,100,54,1/6/2021
69E8E1,conference-call,100,50,1/6/2021
69E8E1,conference-call,100,50,1/6/2021
6B6375,conference-participant,100,50,1/6/2021
6BBD2D,conference-participant,100,50,1/6/2021
6DDA15,facility-open,100,65,1/6/2021
6-Dec-05,conference-participant,100,50,1/6/2021
7255D2,investment-recipient,100,73,1/6/2021
7255D2,investment-recipient,100,73,1/6/2021
72CB93,executive-appointment,100,54,1/6/2021
73A213,conference-participant,100,50,1/6/2021
73BCBA,conference-participant,100,50,1/6/2021
7.45E+28,conference-participant,100,50,1/6/2021
7.40E+289,earnings,100,50,1/6/2021
7.40E+289,earnings,100,50,1/6/2021
7.40E+289,earnings,100,50,1/6/2021
76F067,conference-participant,100,50,1/6/2021
789ADD,earnings,100,50,1/6/2021
7A0EC4,conference-participant,100,50,1/6/2021
7A975D,earnings,100,50,1/6/2021
7A975D,earnings,100,50,1/6/2021
7A975D,earnings,100,50,1/6/2021
7ACFD4,conference-participant,100,50,1/6/2021
7CBC40,award,100,58,1/6/2021
7D85A9,business-contract,100,69,1/6/2021
7DC1C4,award,100,58,1/6/2021
7E2DE6,earnings,100,50,1/6/2021
82B57E,conference-participant,100,50,1/6/2021
837C04,conference-call,100,50,1/6/2021
850779,earnings,100,50,1/6/2021
862941,business-contract,100,69,1/6/2021
862941,acquisition-acquirer,100,49,1/6/2021
862941,conference-participant,100,50,1/6/2021
8665BA,conference-participant,100,50,1/6/2021
86A1B9,dividend,100,50,1/6/2021
87486A,conference-call,100,50,1/6/2021
8AB37F,conference-participant,100,50,1/6/2021
8BE916,earnings,100,50,1/6/2021
8D4486,partnership,100,61,1/6/2021
8E0E32,earnings,100,50,1/6/2021
8E3F58,conference-participant,100,50,1/6/2021
8E4F9A,conference-participant,100,50,1/6/2021
8E8E6E,executive-appointment,100,54,1/6/2021
903AB4,public-offering,100,43,1/6/2021
918D6D,clinical-trials,100,56,1/6/2021
918D6D,clinical-trials,100,56,1/6/2021
918D6D,clinical-trials,100,56,1/6/2021
918D6D,clinical-trials,100,56,1/6/2021
92D757,unit-acquisition-acquiree,100,76,1/6/2021
9.31E+77,conference-participant,100,50,1/6/2021
9.36E+10,business-contract,100,69,1/6/2021
949625,conference-call,100,50,1/6/2021
94983E,conference-participant,100,50,1/6/2021
958938,executive-resignation,100,44,1/6/2021
9592FB,legal-issues-defendant,100,22,1/6/2021
966ACE,conference-participant,100,50,1/6/2021
96A2D3,earnings,100,50,1/6/2021
96A6CD,conference-participant,100,50,1/6/2021
96B4FF,conference-participant,100,50,1/6/2021
9.74E+08,conference-participant,100,50,1/6/2021
9.97E+09,public-offering,100,43,1/6/2021
9B730A,public-offering,100,43,1/6/2021
9CE4C7,earnings,100,50,1/6/2021
9D30A8,acquisition-acquirer,100,49,1/6/2021
A4CD53,business-contract,100,69,1/6/2021
A5195E,conference-participant,100,50,1/6/2021
A5DD24,conference-participant,100,50,1/6/2021
A631A3,conference-participant,100,50,1/6/2021
A65325,executive-appointment,100,54,1/6/2021
A65325,conference-call,100,50,1/6/2021
A7A0C8,conference-participant,100,50,1/6/2021
A7F0A5,acquisition-acquirer,100,49,1/6/2021
AB4A7E,conference-participant,100,50,1/6/2021
AE3113,conference-participant,100,50,1/6/2021
B0D41A,public-offering,100,43,1/6/2021
B2DAF6,conference-participant,100,50,1/6/2021
B37FB4,earnings,100,50,1/6/2021
B446B8,earnings,100,50,1/6/2021
B446B8,earnings,100,50,1/6/2021
B60366,conference-participant,100,50,1/6/2021
B614F8,revenue-guidance-up,100,83,1/6/2021
B7202A,earnings-guidance,100,50,1/6/2021
B8EF97,revenues,100,50,1/6/2021
B9764A,conference-participant,100,50,1/6/2021
B9CD50,patent-awarded,100,72,1/6/2021
BAD9EA,acquisition-acquirer,100,49,1/6/2021
BAD9EA,acquisition-acquirer,100,49,1/6/2021
BB127B,conference-participant,100,50,1/6/2021
BB5142,conference-call,100,50,1/6/2021
BB88B6,earnings,100,50,1/6/2021
BBF349,legal-issues-defendant,100,22,1/6/2021
BD9668,conference-call,100,50,1/6/2021
BDF85E,conference-participant,100,50,1/6/2021
BF5959,revenue-guidance-up,100,83,1/6/2021
C11C46,executive-appointment,100,54,1/6/2021
C16A8F,conference-call,100,50,1/6/2021
C2E39B,conference-participant,100,50,1/6/2021
C32A39,conference-call,100,50,1/6/2021
C3BAE7,acquisition-completed-acquirer,100,49,1/6/2021
C3EE99,earnings,100,50,1/6/2021
C4A241,market-entry,100,57,1/6/2021
C4C77F,business-contract,100,69,1/6/2021
C941DC,conference-participant,100,50,1/6/2021
C97B2D,legal-issues-defendant,100,22,1/6/2021
CAD7D9,earnings,100,50,1/6/2021
CDC817,conference-participant,100,50,1/6/2021
CEDFD5,legal-issues-defendant,100,22,1/6/2021
CEDFD5,legal-issues-defendant,100,22,1/6/2021
D06755,earnings,100,50,1/6/2021
D1173F,conference-call,100,50,1/6/2021
D33270,business-contract,100,69,1/6/2021
D6EAA3,earnings-guidance,100,50,1/6/2021
D6EAA3,earnings-guidance,100,50,1/6/2021
D6EAA3,earnings-guidance,100,50,1/6/2021
D6EAA3,conference-call,100,50,1/6/2021
D76AEF,conference-participant,100,50,1/6/2021
D88EF3,business-contract,100,69,1/6/2021
D88EF3,business-contract,100,69,1/6/2021
D90F43,partnership,100,61,1/6/2021
DB396B,legal-issues-defendant,100,22,1/6/2021
DB7FA7,conference-call,100,50,1/6/2021
DC2F77,note-sale,100,52,1/6/2021
DC6AA0,legal-issues-defendant,100,22,1/6/2021
DD0099,earnings,100,50,1/6/2021
DD9E41,conference-participant,100,50,1/6/2021
DDCB34,conference-participant,100,50,1/6/2021
DF16DE,public-offering,100,43,1/6/2021
E0207A,business-contract,100,69,1/6/2021
E0339F,earnings,100,50,1/6/2021
E09E2B,acquisition-regulatory-scrutiny-acquirer,100,48,1/6/2021
E1E093,executive-appointment,100,54,1/6/2021
E21871,executive-appointment,100,54,1/6/2021
E28D9C,award,100,58,1/6/2021
E30A8F,earnings,100,50,1/6/2021
E67C2C,conference-participant,100,50,1/6/2021
E68E62,conference-participant,100,50,1/6/2021
E6C8DC,public-offering,100,43,1/6/2021
E6D89E,partnership,100,61,1/6/2021
E74B55,conference-participant,100,50,1/6/2021
E7BF32,legal-issues-defendant,100,22,1/6/2021
E829E8,conference-call,100,50,1/6/2021
E8A49A,executive-appointment,100,54,1/6/2021
E8A49A,earnings,100,50,1/6/2021
EC70EC,earnings,100,50,1/6/2021
ECE19E,conference-participant,100,50,1/6/2021
ED2A5E,conference-participant,100,50,1/6/2021
ED5171,earnings,100,50,1/6/2021
EE967B,earnings,100,50,1/6/2021
EEA6B3,executive-appointment,100,54,1/6/2021
EEB5F9,conference-participant,100,50,1/6/2021
EEBCEF,note-sale,100,52,1/6/2021
F58C23,conference-participant,100,50,1/6/2021
F5D059,earnings,100,50,1/6/2021
F5D059,earnings,100,50,1/6/2021
F5D059,earnings,100,50,1/6/2021
F5D059,earnings,100,50,1/6/2021
F5D059,earnings,100,50,1/6/2021
F5D059,earnings,100,50,1/6/2021
FA36A4,conference-participant,100,50,1/6/2021
FACF19,business-contract,100,69,1/6/2021
FB728F,conference-participant,100,50,1/6/2021
FD2565,conference-participant,100,50,1/6/2021
001F1B,operating-earnings,100,50,1/7/2021
00326D,earnings,100,50,1/7/2021
00326D,earnings,100,50,1/7/2021
0157B1,partnership,100,61,1/7/2021
55018,conference-organizer,100,57,1/7/2021
05AF14,acquisition-acquirer,100,49,1/7/2021
71860,earnings,100,50,1/7/2021
07C69F,conference-call,100,50,1/7/2021
07CA6A,conference-call,100,50,1/7/2021
96930,conference-participant,100,50,1/7/2021
09DE1F,conference-participant,100,50,1/7/2021
0E499E,revenue-up,100,69,1/7/2021
0E499E,revenue-up,100,69,1/7/2021
0FC848,conference-participant,100,50,1/7/2021
105D00,conference-call,100,50,1/7/2021
1080C0,conference-participant,100,50,1/7/2021
112694,executive-appointment,100,54,1/7/2021
12DE76,executive-appointment,100,54,1/7/2021
133644,conference-participant,100,50,1/7/2021
136B26,public-offering,100,43,1/7/2021
14BA06,merger-completed,100,66,1/7/2021
14BA06,merger-completed,100,66,1/7/2021
14BA06,earnings,100,50,1/7/2021
1AC649,clinical-trials,100,56,1/7/2021
1BDB2A,conference-participant,100,50,1/7/2021
1D1B07,earnings,100,50,1/7/2021
1D1B07,earnings,100,50,1/7/2021
1D5C51,conference-participant,100,50,1/7/2021
1E83DE,earnings,100,50,1/7/2021
1FAF22,campaign-ad-release,100,59,1/7/2021
206852,conference-call,100,50,1/7/2021
228D42,partnership,100,61,1/7/2021
228D42,partnership,100,61,1/7/2021
270B78,conference-participant,100,50,1/7/2021
279916,conference-participant,100,50,1/7/2021
2BF36E,conference-participant,100,50,1/7/2021
2C681C,business-contract,100,69,1/7/2021
2C681C,business-contract,100,69,1/7/2021
2C7505,clinical-trials-positive,100,87,1/7/2021
2D76CE,earnings,100,50,1/7/2021
2E0445,conference-participant,100,50,1/7/2021
317EC6,earnings,100,50,1/7/2021
317EC6,earnings,100,50,1/7/2021
317EC6,earnings,100,50,1/7/2021
33E9D5,trading-halt,100,43,1/7/2021
356B21,conference-participant,100,50,1/7/2021
367434,conference-participant,100,50,1/7/2021
396D7C,conference-participant,100,50,1/7/2021
3A1C46,conference-participant,100,50,1/7/2021
3BCF24,earnings,100,50,1/7/2021
3ED92D,earnings-guidance,100,50,1/7/2021
434F38,earnings,100,50,1/7/2021
442587,executive-appointment,100,54,1/7/2021
442587,business-contract,100,69,1/7/2021
458D2C,earnings,100,50,1/7/2021
47FCF2,facility-close,100,47,1/7/2021
49BBBC,earnings,100,50,1/7/2021
4A6F00,unit-acquisition-acquiree,100,76,1/7/2021
4C31F3,conference-participant,100,50,1/7/2021
50070E,conference-organizer,100,57,1/7/2021
5288FC,public-offering,100,43,1/7/2021
550D01,earnings,100,50,1/7/2021
55CD6F,note-sale,100,52,1/7/2021
5704AC,conference-participant,100,50,1/7/2021
57356F,conference-call,100,50,1/7/2021
57CAAB,conference-participant,100,50,1/7/2021
589846,conference-participant,100,50,1/7/2021
5BC2F4,partnership,100,61,1/7/2021
5CC29D,earnings,100,50,1/7/2021
5D41E4,conference-participant,100,50,1/7/2021
5EC388,earnings,100,50,1/7/2021
5F2FF7,earnings,100,50,1/7/2021
5F3E74,conference-participant,100,50,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,unit-acquisition-acquirer,100,49,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
619882,conference-organizer,100,57,1/7/2021
627186,earnings,100,50,1/7/2021
636BBF,executive-appointment,100,54,1/7/2021
65AB30,partnership,100,61,1/7/2021
66A667,earnings,100,50,1/7/2021
6830FE,award,100,58,1/7/2021
68B03F,conference-participant,100,50,1/7/2021
68E6E9,earnings,100,50,1/7/2021
6925EB,conference-participant,100,50,1/7/2021
69FDFC,partnership,100,61,1/7/2021
6AACDD,conference-participant,100,50,1/7/2021
6DBBBC,donation,100,54,1/7/2021
6F0A63,executive-appointment,100,54,1/7/2021
717DB4,product-release,100,64,1/7/2021
72609A,executive-appointment,100,54,1/7/2021
72CB93,conference-call,100,50,1/7/2021
73C9E2,conference-call,100,50,1/7/2021
7.45E+28,legal-issues-defendant,100,22,1/7/2021
7.45E+28,legal-issues-defendant,100,22,1/7/2021
7.45E+28,legal-issues-defendant,100,22,1/7/2021
7.45E+28,legal-issues-defendant,100,22,1/7/2021
7.45E+28,legal-issues-defendant,100,22,1/7/2021
751C8D,executive-appointment,100,54,1/7/2021
751C8D,executive-appointment,100,54,1/7/2021
75D689,executive-appointment,100,54,1/7/2021
75F982,acquisition-completed-acquirer,100,49,1/7/2021
76CEFB,earnings,100,50,1/7/2021
7771D7,earnings,100,50,1/7/2021
7823A3,earnings,100,50,1/7/2021
7A5097,acquisition-acquirer,100,49,1/7/2021
7ADE57,conference-participant,100,50,1/7/2021
7B9212,revenues,100,50,1/7/2021
7C4F43,conference-participant,100,50,1/7/2021
7C4F43,conference-participant,100,50,1/7/2021
7F3FBC,conference-call,100,50,1/7/2021
80D744,conference-call,100,50,1/7/2021
8.10E+32,dividend,100,50,1/7/2021
85DA04,executive-appointment,100,54,1/7/2021
86478F,earnings,100,50,1/7/2021
88193E,conference-participant,100,50,1/7/2021
8B2C4A,conference-call,100,50,1/7/2021
8B6E7E,conference-call,100,50,1/7/2021
8D4486,executive-appointment,100,54,1/7/2021
8D4486,executive-appointment,100,54,1/7/2021
8D4486,executive-appointment,100,54,1/7/2021
8E82A6,facility-upgrade,100,65,1/7/2021
8EF425,earnings,100,50,1/7/2021
903AB4,public-offering,100,43,1/7/2021
911AB8,earnings,100,50,1/7/2021
9196A2,partnership,100,61,1/7/2021
922F0C,earnings,100,50,1/7/2021
925759,executive-appointment,100,54,1/7/2021
934029,conference-call,100,50,1/7/2021
934CC3,conference-participant,100,50,1/7/2021
94637C,fundraising,100,64,1/7/2021
94637C,partnership,100,61,1/7/2021
986AF6,conference-call,100,50,1/7/2021
9.97E+09,public-offering,100,43,1/7/2021
9ABD30,executive-appointment,100,54,1/7/2021
9D3360,earnings,100,50,1/7/2021
9D5D35,trading-halt,100,43,1/7/2021
9E575E,conference-participant,100,50,1/7/2021
9F03CF,conference-call,100,50,1/7/2021
9F6B1A,business-contract,100,69,1/7/2021
A0F146,executive-resignation,100,44,1/7/2021
A15C71,stake-acquirer,100,48,1/7/2021
A15C71,stake-acquirer,100,48,1/7/2021
A1DBF0,conference-participant,100,50,1/7/2021
A433A5,conference-participant,100,50,1/7/2021
A746F6,conference-call,100,50,1/7/2021
A75D43,conference-call,100,50,1/7/2021
AADE0B,unit-acquisition-acquirer,100,49,1/7/2021
AADE0B,unit-acquisition-acquirer,100,49,1/7/2021
AEF2C3,conference-participant,100,50,1/7/2021
AF93DE,acquisition-completed-acquirer,100,49,1/7/2021
B05118,award,100,58,1/7/2021
B1DF3C,earnings,100,50,1/7/2021
B2E6B5,conference-call,100,50,1/7/2021
B614F8,conference-participant,100,50,1/7/2021
B8DD94,conference-call,100,50,1/7/2021
B8F71F,earnings,100,50,1/7/2021
B96637,conference-participant,100,50,1/7/2021
B9764A,conference-call,100,50,1/7/2021
B9CD50,conference-participant,100,50,1/7/2021
BAAA60,conference-call,100,50,1/7/2021
BBF349,earnings,100,50,1/7/2021
BD15E8,earnings,100,50,1/7/2021
BDE867,acquisition-completed-acquirer,100,49,1/7/2021
BEB756,conference-call,100,50,1/7/2021
BFF98A,public-offering,100,43,1/7/2021
C062D4,acquisition-acquirer,100,49,1/7/2021
C062D4,acquisition-acquirer,100,49,1/7/2021
C062D4,acquisition-acquirer,100,49,1/7/2021
C062D4,acquisition-acquirer,100,49,1/7/2021
C062D4,acquisition-acquirer,100,49,1/7/2021
C062D4,acquisition-acquirer,100,49,1/7/2021
C062D4,acquisition-acquirer,100,49,1/7/2021
C0BA36,conference-participant,100,50,1/7/2021
C3F99F,conference-participant,100,50,1/7/2021
C4706C,executive-resignation,100,44,1/7/2021
C4F9C6,conference-participant,100,50,1/7/2021
C5E840,conference-participant,100,50,1/7/2021
C659EB,conference-call,100,50,1/7/2021
C66B44,conference-call,100,50,1/7/2021
C83B88,partnership,100,61,1/7/2021
C85A72,public-offering,100,43,1/7/2021
C85A72,public-offering,100,43,1/7/2021
C9B932,executive-health,100,41,1/7/2021
C9D866,conference-call,100,50,1/7/2021
CAD7D9,conference-participant,100,50,1/7/2021
CEDFD5,legal-issues-defendant,100,22,1/7/2021
D17C1B,legal-issues-defendant,100,22,1/7/2021
D1C26F,conference-participant,100,50,1/7/2021
D3FD6D,conference-participant,100,50,1/7/2021
D6EAA3,partnership,100,61,1/7/2021
D7AC6E,earnings,100,50,1/7/2021
D82EF3,trading-halt,100,43,1/7/2021
D82EF3,trading-resumed,100,58,1/7/2021
D854F3,conference-call,100,50,1/7/2021
D8DA3D,conference-call,100,50,1/7/2021
D8ECA1,conference-participant,100,50,1/7/2021
DB5CA5,earnings,100,50,1/7/2021
DB7014,revenues,100,50,1/7/2021
DB9F70,conference-participant,100,50,1/7/2021
DC5299,conference-call,100,50,1/7/2021
DD1BA1,executive-appointment,100,54,1/7/2021
DD1BA1,earnings,100,50,1/7/2021
DF11D9,conference-call,100,50,1/7/2021
DF16DE,public-offering,100,43,1/7/2021
DF18E6,facility-open,100,65,1/7/2021
E0207A,conference-participant,100,50,1/7/2021
E124EB,conference-participant,100,50,1/7/2021
E124EB,conference-call,100,50,1/7/2021
E1E093,acquisition-acquirer,100,49,1/7/2021
E2F130,earnings,100,50,1/7/2021
E610CD,conference-participant,100,50,1/7/2021
E6C8DC,conference-participant,100,50,1/7/2021
E74B55,unit-acquisition-completed-acquiree,100,67,1/7/2021
E74B55,unit-acquisition-completed-acquiree,100,67,1/7/2021
E802CE,conference-participant,100,50,1/7/2021
E8846E,earnings,100,50,1/7/2021
E959F3,earnings,100,50,1/7/2021
E9FF33,earnings,100,50,1/7/2021
EB7FBF,dividend,100,50,1/7/2021
ECE19E,conference-participant,100,50,1/7/2021
EEB5F9,executive-appointment,100,54,1/7/2021
F05B1B,public-offering,100,43,1/7/2021
F0B877,conference-call,100,50,1/7/2021
F569FD,conference-participant,100,50,1/7/2021
F88A04,conference-participant,100,50,1/7/2021
FA36A4,unit-acquisition-acquirer,100,49,1/7/2021
FA40E2,earnings-up,100,68,1/7/2021
FAB97A,conference-call,100,50,1/7/2021
FACF19,earnings-above-expectations,100,88,1/7/2021
FC9A88,conference-call,100,50,1/7/2021
FD0CA4,conference-call,100,50,1/7/2021
FD2565,clinical-trials,100,56,1/7/2021
FD9526,conference-call,100,50,1/7/2021
FDF799,partnership,100,61,1/7/2021
FEC475,conference-call,100,50,1/7/2021
FEE4B0,facility-open,100,65,1/7/2021
FEE4B0,facility-open,100,65,1/7/2021
00067A,partnership,100,61,1/8/2021
31025,earnings,100,50,1/8/2021
03FAA6,conference-participant,100,50,1/8/2021
081AB9,conference-call,100,50,1/8/2021
0AAD90,conference-participant,100,50,1/8/2021
10AE08,earnings,100,50,1/8/2021
1748B3,earnings,100,50,1/8/2021
19CAC7,acquisition-acquirer,100,49,1/8/2021
1EBF8D,conference-call,100,50,1/8/2021
26E3BA,conference-participant,100,50,1/8/2021
29CEBF,executive-appointment,100,54,1/8/2021
2A6DBE,acquisition-acquiree,100,76,1/8/2021
2F9304,legal-issues-defendant,100,22,1/8/2021
30DFD3,revenue-guidance,100,50,1/8/2021
30E01D,executive-appointment,100,54,1/8/2021
3.14E+47,earnings,100,50,1/8/2021
31553A,earnings,100,50,1/8/2021
32F943,conference-participant,100,50,1/8/2021
32F943,legal-issues-defendant,100,22,1/8/2021
33E9D5,trading-resumed,100,58,1/8/2021
3.50E+27,conference-call,100,50,1/8/2021
36C09B,conference-participant,100,50,1/8/2021
384CD3,executive-appointment,100,54,1/8/2021
3BB7D3,partnership,100,61,1/8/2021
43A74A,executive-appointment,100,54,1/8/2021
4A6F00,regulatory-investigation,100,22,1/8/2021
4D371E,earnings-guidance,100,50,1/8/2021
4D971D,conference-call,100,50,1/8/2021
4E5784,merger-failed,100,21,1/8/2021
4FCC78,acquisition-completed-acquirer,100,49,1/8/2021
51B442,earnings,100,50,1/8/2021
55C289,conference-call,100,50,1/8/2021
55CD6F,note-sale,100,52,1/8/2021
56277A,conference-call,100,50,1/8/2021
5675EB,earnings,100,50,1/8/2021
56EA2B,public-offering,100,43,1/8/2021
5A0FF1,legal-issues-defendant,100,22,1/8/2021
5A0FF1,legal-issues-defendant,100,22,1/8/2021
5A0FF1,legal-issues-defendant,100,22,1/8/2021
5E7E82,executive-appointment,100,54,1/8/2021
60AC34,regulatory-product-approval-granted,100,81,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
619882,conference-organizer,100,57,1/8/2021
61BCA7,earnings,100,50,1/8/2021
6A01DF,executive-appointment,100,54,1/8/2021
6D0CAB,dividend,100,50,1/8/2021
6F5DD2,conference-participant,100,50,1/8/2021
72FCA3,market-entry,100,57,1/8/2021
7.45E+28,legal-issues-defendant,100,22,1/8/2021
7.45E+28,legal-issues-defendant,100,22,1/8/2021
7.45E+28,legal-issues-defendant,100,22,1/8/2021
7.45E+28,legal-issues-defendant,100,22,1/8/2021
7.45E+28,legal-issues-defendant,100,22,1/8/2021
7D7716,earnings,100,50,1/8/2021
877C0C,product-release,100,64,1/8/2021
902670,executive-appointment,100,54,1/8/2021
9196A2,conference-organizer,100,57,1/8/2021
9.39E+69,conference-participant,100,50,1/8/2021
93AD2E,earnings,100,50,1/8/2021
96A6CD,acquisition-acquirer,100,49,1/8/2021
96A6CD,acquisition-acquirer,100,49,1/8/2021
977A1E,conference-call,100,50,1/8/2021
97AF94,dividend,100,50,1/8/2021
9B730A,public-offering,100,43,1/8/2021
9CA432,conference-call,100,50,1/8/2021
9D5FA4,conference-participant,100,50,1/8/2021
9E298A,conference-call,100,50,1/8/2021
9F6B1A,earnings,100,50,1/8/2021
A1EAC8,executive-appointment,100,54,1/8/2021
A2CAF7,executive-appointment,100,54,1/8/2021
A48593,conference-participant,100,50,1/8/2021
A6213D,earnings,100,50,1/8/2021
A99576,conference-call,100,50,1/8/2021
AD22F2,conference-participant,100,50,1/8/2021
AFD7DD,executive-resignation,100,44,1/8/2021
B04426,conference-participant,100,50,1/8/2021
B0D41A,public-offering,100,43,1/8/2021
B2DAF6,earnings,100,50,1/8/2021
B762D3,earnings,100,50,1/8/2021
BCC13E,conference-participant,100,50,1/8/2021
C0BA36,conference-participant,100,50,1/8/2021
C4A241,product-release,100,64,1/8/2021
C951A2,earnings,100,50,1/8/2021
C951A2,earnings,100,50,1/8/2021
C951A2,earnings,100,50,1/8/2021
CC6FF5,earnings,100,50,1/8/2021
CDE118,unit-acquisition-acquiree,100,76,1/8/2021
D0909F,earnings-guidance,100,50,1/8/2021
D2C0B6,conference-participant,100,50,1/8/2021
D501DC,dividend,100,50,1/8/2021
D598E7,stake-acquirer,100,48,1/8/2021
D78CCD,conference-call,100,50,1/8/2021
DB396B,legal-issues-defendant,100,22,1/8/2021
E0D3BA,earnings,100,50,1/8/2021
E2F130,dividend,100,50,1/8/2021
E30B34,executive-appointment,100,54,1/8/2021
E592F0,earnings,100,50,1/8/2021
EAEA91,dividend,100,50,1/8/2021
EEBCEF,public-offering,100,43,1/8/2021
F50BAB,conference-call,100,50,1/8/2021
F7902B,earnings,100,50,1/8/2021
F8084B,conference-call,100,50,1/8/2021
FDC7E6,conference-call,100,50,1/8/2021
FDF799,acquisition-acquirer,100,49,1/8/2021
1A2D9F,legal-issues-defendant,100,22,1/9/2021
2F9304,legal-issues-defendant,100,22,1/9/2021
32F943,legal-issues-defendant,100,22,1/9/2021
4D371E,earnings-guidance,100,50,1/9/2021
5A0FF1,legal-issues-defendant,100,22,1/9/2021
6F39FC,dividend,100,50,1/9/2021
9934AD,legal-issues-defendant,100,22,1/9/2021
C6C702,business-contract,100,69,1/9/2021
C6C702,business-contract,100,69,1/9/2021
E09E2B,partnership,100,61,1/9/2021
1A2D9F,legal-issues-defendant,100,22,1/10/2021
1E9A6D,legal-issues-defendant,100,22,1/10/2021
2A1009,earnings-guidance,100,50,1/10/2021
619882,conference-organizer,100,57,1/10/2021
65D0AA,conference-participant,100,50,1/10/2021
830BDB,clinical-trials-positive,100,87,1/10/2021
85CDC9,earnings,100,50,1/10/2021
9D30A8,legal-issues-defendant,100,22,1/10/2021
C50B26,business-contract,100,69,1/10/2021
C50B26,business-contract,100,69,1/10/2021
C50B26,business-contract,100,69,1/10/2021
CEDFD5,legal-issues-defendant,100,22,1/10/2021
DBCA3F,legal-issues-defendant,100,22,1/10/2021
034B61,partnership,100,61,1/11/2021
034B61,partnership,100,61,1/11/2021
034B61,partnership,100,61,1/11/2021
03D5F9,partnership,100,61,1/11/2021
03D5F9,partnership,100,61,1/11/2021
48590,earnings,100,50,1/11/2021
55018,conference-organizer,100,57,1/11/2021
070B45,award,100,58,1/11/2021
0A0D9E,conference-call,100,50,1/11/2021
0A7650,conference-call,100,50,1/11/2021
0A9D0A,partnership,100,61,1/11/2021
0C355F,revenue-guidance-up,100,83,1/11/2021
0C4131,conference-call,100,50,1/11/2021
0CBC4D,earnings,100,50,1/11/2021
0DC050,earnings,100,50,1/11/2021
0DC050,earnings,100,50,1/11/2021
0ED415,conference-call,100,50,1/11/2021
129DC8,executive-appointment,100,54,1/11/2021
12F98C,product-release,100,64,1/11/2021
12F98C,product-release,100,64,1/11/2021
133644,business-contract,100,69,1/11/2021
133644,business-contract,100,69,1/11/2021
135B09,conference-call,100,50,1/11/2021
136B26,public-offering,100,43,1/11/2021
1782D5,business-contract,100,69,1/11/2021
1834C0,conference-participant,100,50,1/11/2021
184866,orphan-drug-designation,100,76,1/11/2021
184866,orphan-drug-designation,100,76,1/11/2021
1AD9CC,revenues,100,50,1/11/2021
1B5FEA,executive-appointment,100,54,1/11/2021
1FCC00,conference-participant,100,50,1/11/2021
2082EA,regulatory-product-approval-granted,100,81,1/11/2021
20BEEA,conference-call,100,50,1/11/2021
228D42,partnership,100,61,1/11/2021
228D42,partnership,100,61,1/11/2021
228D42,partnership,100,61,1/11/2021
228D42,partnership,100,61,1/11/2021
2.45E+15,executive-appointment,100,54,1/11/2021
267718,market-entry,100,57,1/11/2021
2720AB,asset-sale,100,62,1/11/2021
2.89E+11,dividend,100,50,1/11/2021
28DCA8,earnings-guidance,100,50,1/11/2021
2920D5,earnings,100,50,1/11/2021
2.90E+62,acquisition-interest-acquiree,100,82,1/11/2021
2BD89C,executive-appointment,100,54,1/11/2021
2CB4C9,partnership,100,61,1/11/2021
2CB4C9,partnership,100,61,1/11/2021
2D485F,earnings-guidance,100,50,1/11/2021
2D485F,earnings-guidance,100,50,1/11/2021
2EC172,acquisition-interest-acquirer,100,46,1/11/2021
2F9304,legal-issues-defendant,100,22,1/11/2021
315EB0,earnings,100,50,1/11/2021
317EC6,conference-participant,100,50,1/11/2021
346BF2,conference-participant,100,50,1/11/2021
36E479,award,100,58,1/11/2021
37727A,earnings,100,50,1/11/2021
39BFF6,partnership,100,61,1/11/2021
39FB23,acquisition-acquirer,100,49,1/11/2021
39FB23,executive-appointment,100,54,1/11/2021
3AAEAE,partnership,100,61,1/11/2021
3AAEAE,partnership,100,61,1/11/2021
3AAEAE,partnership,100,61,1/11/2021
3AAEAE,partnership,100,61,1/11/2021
3B37F7,dividend,100,50,1/11/2021
3B37F7,acquisition-acquirer,100,49,1/11/2021
3B37F7,acquisition-acquirer,100,49,1/11/2021
3BB7D3,executive-appointment,100,54,1/11/2021
3C75D6,conference-participant,100,50,1/11/2021
3CCC90,partnership,100,61,1/11/2021
3DE4D1,conference-call,100,50,1/11/2021
3EE65E,executive-appointment,100,54,1/11/2021
44209A,earnings,100,50,1/11/2021
45BC35,earnings,100,50,1/11/2021
4649D5,conference-participant,100,50,1/11/2021
467F2C,earnings,100,50,1/11/2021
499C75,conference-participant,100,50,1/11/2021
49A344,conference-call,100,50,1/11/2021
4A3438,legal-issues-defendant,100,22,1/11/2021
4A6F00,partnership,100,61,1/11/2021
4A6F00,partnership,100,61,1/11/2021
4A6F00,product-release,100,64,1/11/2021
4A6F00,product-release,100,64,1/11/2021
4A6F00,product-release,100,64,1/11/2021
4AE584,revenues,100,50,1/11/2021
4B49CF,earnings,100,50,1/11/2021
4BEB48,product-release,100,64,1/11/2021
4C2F17,revenues,100,50,1/11/2021
4D8124,campaign-ad-release,100,59,1/11/2021
514067,revenues,100,50,1/11/2021
520632,regulatory-product-approval-granted,100,81,1/11/2021
5288FC,public-offering,100,43,1/11/2021
52B567,legal-issues-dismissed-defendant,100,79,1/11/2021
532D47,earnings,100,50,1/11/2021
5403F8,same-store-sales,100,50,1/11/2021
5.43E+08,conference-participant,100,50,1/11/2021
54512F,conference-participant,100,50,1/11/2021
546A9C,earnings,100,50,1/11/2021
548AC0,conference-call,100,50,1/11/2021
54DF47,executive-appointment,100,54,1/11/2021
5675EB,executive-appointment,100,54,1/11/2021
57DDB9,public-offering,100,43,1/11/2021
5A423F,earnings,100,50,1/11/2021
5C2A47,earnings,100,50,1/11/2021
5D0337,executive-appointment,100,54,1/11/2021
5D41E4,partnership,100,61,1/11/2021
5DAF89,acquisition-completed-acquirer,100,49,1/11/2021
5E6959,conference-call,100,50,1/11/2021
616E3B,executive-appointment,100,54,1/11/2021
616E3B,conference-call,100,50,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
619882,conference-organizer,100,57,1/11/2021
66E04A,product-release,100,64,1/11/2021
68AB62,conference-call,100,50,1/11/2021
69CE71,executive-appointment,100,54,1/11/2021
6A01DF,revenues,100,50,1/11/2021
6B0784,conference-call,100,50,1/11/2021
6B0784,conference-call,100,50,1/11/2021
6BD606,facility-open,100,65,1/11/2021
6D3F35,award,100,58,1/11/2021
6D3F35,award,100,58,1/11/2021
6D6B40,earnings,100,50,1/11/2021
6E8864,revenues,100,50,1/11/2021
726EEA,product-release,100,64,1/11/2021
729368,earnings-guidance,100,50,1/11/2021
7.45E+28,legal-issues-defendant,100,22,1/11/2021
75F982,business-contract,100,69,1/11/2021
76F067,partnership,100,61,1/11/2021
7.83E+79,earnings,100,50,1/11/2021
78F9ED,conference-call,100,50,1/11/2021
7A0EC4,note-sale,100,52,1/11/2021
7AF5B8,executive-appointment,100,54,1/11/2021
7C790D,executive-appointment,100,54,1/11/2021
7D5384,conference-call,100,50,1/11/2021
7D7716,executive-resignation,100,44,1/11/2021
7F3665,revenues,100,50,1/11/2021
8.10E+32,business-contract,100,69,1/11/2021
895D56,partnership,100,61,1/11/2021
8BAA15,conference-participant,100,50,1/11/2021
8DBBE6,revenues,100,50,1/11/2021
8DCF18,earnings-guidance,100,50,1/11/2021
8E4F9A,regulatory-product-approval-granted,100,81,1/11/2021
8FE7A5,earnings,100,50,1/11/2021
900356,note-sale,100,52,1/11/2021
902670,executive-appointment,100,54,1/11/2021
92B047,conference-call,100,50,1/11/2021
9.36E+10,fundraising,100,64,1/11/2021
93D207,executive-appointment,100,54,1/11/2021
94637C,buybacks,100,74,1/11/2021
94637C,partnership,100,61,1/11/2021
9592FB,revenues,100,50,1/11/2021
967D92,earnings,100,50,1/11/2021
9.74E+08,earnings,100,50,1/11/2021
97693A,revenue-guidance,100,50,1/11/2021
9994DA,revenues,100,50,1/11/2021
99ACAD,note-sale,100,52,1/11/2021
99B61C,executive-appointment,100,54,1/11/2021
9A602D,conference-call,100,50,1/11/2021
9B5968,executive-appointment,100,54,1/11/2021
9B730A,conference-participant,100,50,1/11/2021
9C5174,earnings,100,50,1/11/2021
9D65C1,revenues,100,50,1/11/2021
9F5997,conference-call,100,50,1/11/2021
A01664,earnings,100,50,1/11/2021
A01983,dividend,100,50,1/11/2021
A15C71,note-sale,100,52,1/11/2021
A15C71,private-placement,100,56,1/11/2021
A26C26,earnings,100,50,1/11/2021
A5628C,earnings,100,50,1/11/2021
A60318,earnings,100,50,1/11/2021
A790A5,executive-appointment,100,54,1/11/2021
A7A0BD,award,100,58,1/11/2021
AA3AB8,revenue-up,100,69,1/11/2021
AA847A,partnership,100,61,1/11/2021
ABBAD1,earnings,100,50,1/11/2021
AD3C93,executive-appointment,100,54,1/11/2021
AD9F1D,conference-call,100,50,1/11/2021
AED61E,revenue-guidance,100,50,1/11/2021
AFDF2E,earnings,100,50,1/11/2021
B13B68,conference-participant,100,50,1/11/2021
B37FB4,product-release,100,64,1/11/2021
B3CB74,partnership,100,61,1/11/2021
B48FC9,earnings,100,50,1/11/2021
B619CB,executive-appointment,100,54,1/11/2021
B66928,acquisition-interest-acquiree,100,82,1/11/2021
B7EB38,earnings,100,50,1/11/2021
B83BCE,conference-participant,100,50,1/11/2021
B840EF,revenues,100,50,1/11/2021
B98EFA,executive-appointment,100,54,1/11/2021
B9B6B8,conference-participant,100,50,1/11/2021
BC5680,product-release,100,64,1/11/2021
BCC13E,earnings,100,50,1/11/2021
BDE867,executive-appointment,100,54,1/11/2021
BF5959,business-contract,100,69,1/11/2021
BFF98A,public-offering,100,43,1/11/2021
C062D4,earnings-guidance,100,50,1/11/2021
C062D4,earnings-guidance,100,50,1/11/2021
C062D4,earnings-guidance,100,50,1/11/2021
C0F70B,earnings,100,50,1/11/2021
C230FE,earnings,100,50,1/11/2021
C3BAE7,earnings,100,50,1/11/2021
C41C25,earnings,100,50,1/11/2021
C564E4,revenues,100,50,1/11/2021
C564E4,revenues,100,50,1/11/2021
C98CDB,partnership,100,61,1/11/2021
CB88B3,conference-participant,100,50,1/11/2021
CC176E,earnings,100,50,1/11/2021
CC339B,partnership,100,61,1/11/2021
CC8F6E,partnership,100,61,1/11/2021
CDAB24,executive-appointment,100,54,1/11/2021
CDC217,partnership,100,61,1/11/2021
CDFCC9,conference-participant,100,50,1/11/2021
CDFCC9,conference-participant,100,50,1/11/2021
CE5664,earnings,100,50,1/11/2021
CE96E7,earnings,100,50,1/11/2021
CF073E,clinical-trials-filed,100,60,1/11/2021
CFF97C,partnership,100,61,1/11/2021
D1C0B9,earnings,100,50,1/11/2021
D33D8C,executive-appointment,100,54,1/11/2021
D42DBA,revenues,100,50,1/11/2021
D42DBA,revenues,100,50,1/11/2021
D437C3,earnings,100,50,1/11/2021
D57D99,executive-appointment,100,54,1/11/2021
D598E7,partnership,100,61,1/11/2021
D6853F,business-contract,100,69,1/11/2021
D697DE,buybacks,100,74,1/11/2021
D6EAA3,partnership,100,61,1/11/2021
D96202,conference-call,100,50,1/11/2021
D9E036,executive-appointment,100,54,1/11/2021
DB396B,legal-issues-defendant,100,22,1/11/2021
DC0998,product-release,100,64,1/11/2021
DC6AA0,legal-issues-defendant,100,22,1/11/2021
DD1BA1,product-release,100,64,1/11/2021
DD682D,earnings,100,50,1/11/2021
DDEA6A,revenue-guidance,100,50,1/11/2021
DF16DE,public-offering,100,43,1/11/2021
DF18E6,patient-enrollment-complete,100,64,1/11/2021
E0207A,business-contract,100,69,1/11/2021
E12A6E,dividend,100,50,1/11/2021
E22FDE,partnership,100,61,1/11/2021
E28D9C,conference-participant,100,50,1/11/2021
E4158B,earnings,100,50,1/11/2021
E6D89E,partnership,100,61,1/11/2021
E6D89E,partnership,100,61,1/11/2021
E8B315,conference-call,100,50,1/11/2021
E96E0B,revenues,100,50,1/11/2021
EB2F14,buybacks,100,74,1/11/2021
EB43F4,conference-participant,100,50,1/11/2021
EB7FBF,earnings,100,50,1/11/2021
ECA300,same-store-sales,100,50,1/11/2021
ED1A74,executive-appointment,100,54,1/11/2021
ED2A5E,earnings,100,50,1/11/2021
F02170,note-sale,100,52,1/11/2021
F209B4,conference-participant,100,50,1/11/2021
F4D241,revenues,100,50,1/11/2021
F4E992,earnings-up,100,68,1/11/2021
F4E992,earnings,100,50,1/11/2021
F4F46F,partnership,100,61,1/11/2021
F5C78B,conference-call,100,50,1/11/2021
F6E248,stake-acquirer,100,48,1/11/2021
F7ADEB,partnership,100,61,1/11/2021
F8084B,executive-appointment,100,54,1/11/2021
F9CAF8,conference-call,100,50,1/11/2021
FAE021,earnings,100,50,1/11/2021
FAE021,earnings,100,50,1/11/2021
FCA54E,conference-participant,100,50,1/11/2021
FD4588,conference-participant,100,50,1/11/2021
FEC475,partnership,100,61,1/11/2021
FF5413,executive-appointment,100,54,1/11/2021
00067A,partnership,100,61,1/12/2021
0157B1,donation,100,54,1/12/2021
01D03F,acquisition-acquirer,100,49,1/12/2021
03D5F9,executive-appointment,100,54,1/12/2021
03D5F9,executive-appointment,100,54,1/12/2021
048B70,conference-call,100,50,1/12/2021
054B55,public-offering,100,43,1/12/2021
06EE79,executive-appointment,100,54,1/12/2021
070B45,executive-appointment,100,54,1/12/2021
71860,partnership,100,61,1/12/2021
71860,partnership,100,61,1/12/2021
09062E,executive-appointment,100,54,1/12/2021
0C8D82,business-contract,100,69,1/12/2021
0C8D82,business-contract,100,69,1/12/2021
133644,business-contract,100,69,1/12/2021
159AE4,executive-appointment,100,54,1/12/2021
1921DD,stake-acquiree,100,62,1/12/2021
1B4F31,business-contract,100,69,1/12/2021
1D1B07,business-contract,100,69,1/12/2021
1D1B07,business-contract,100,69,1/12/2021
1DF15D,conference-call,100,50,1/12/2021
1E1125,executive-appointment,100,54,1/12/2021
1E7785,executive-appointment,100,54,1/12/2021
1E7785,executive-appointment,100,54,1/12/2021
21245F,partnership,100,61,1/12/2021
21245F,conference-call,100,50,1/12/2021
21F9CA,partnership,100,61,1/12/2021
223552,partnership,100,61,1/12/2021
223552,partnership,100,61,1/12/2021
2262BD,partnership,100,61,1/12/2021
228D42,partnership,100,61,1/12/2021
228D42,partnership,100,61,1/12/2021
263216,conference-participant,100,50,1/12/2021
267718,investment-investor,100,55,1/12/2021
267718,investment-investor,100,55,1/12/2021
26CC63,board-meeting,100,51,1/12/2021
2720AB,conference-call,100,50,1/12/2021
27A791,revenues,100,50,1/12/2021
2920D5,acquisition-completed-acquirer,100,49,1/12/2021
2.90E+62,executive-appointment,100,54,1/12/2021
2CB4C9,earnings,100,50,1/12/2021
2DB344,earnings,100,50,1/12/2021
2E61CC,dividend,100,50,1/12/2021
2F9304,legal-issues-defendant,100,22,1/12/2021
2F9304,legal-issues-defendant,100,22,1/12/2021
2F9304,legal-issues-defendant,100,22,1/12/2021
30A565,conference-call,100,50,1/12/2021
3461CF,analyst-ratings-change-positive-rater,20,50,1/12/2021
3B20AB,buybacks,100,74,1/12/2021
3B37F7,public-offering,100,43,1/12/2021
3CBA2A,conference-call,100,50,1/12/2021
420168,earnings,100,50,1/12/2021
4591D3,legal-issues-defendant,100,22,1/12/2021
46A16E,conference-call,100,50,1/12/2021
4A2457,business-contract,100,69,1/12/2021
4A2457,business-contract,100,69,1/12/2021
4A3438,legal-issues-defendant,100,22,1/12/2021
4B3555,executive-appointment,100,54,1/12/2021
4F9926,donation,100,54,1/12/2021
50070E,conference-organizer,100,57,1/12/2021
507AE7,earnings,100,50,1/12/2021
510EA1,business-contract,100,69,1/12/2021
510EA1,business-contract,100,69,1/12/2021
510EA1,business-contract,100,69,1/12/2021
553949,executive-appointment,100,54,1/12/2021
55438C,business-contract,100,69,1/12/2021
56632F,conference-call,100,50,1/12/2021
5D43A7,conference-participant,100,50,1/12/2021
5E9934,earnings,100,50,1/12/2021
5F1B7B,earnings,100,50,1/12/2021
605F40,conference-call,100,50,1/12/2021
615B6D,executive-appointment,100,54,1/12/2021
619882,conference-organizer,100,57,1/12/2021
619882,conference-organizer,100,57,1/12/2021
619882,conference-organizer,100,57,1/12/2021
619882,conference-organizer,100,57,1/12/2021
61B81B,credit-extension-provider,100,57,1/12/2021
6559D8,public-offering,100,43,1/12/2021
665D7D,conference-call,100,50,1/12/2021
66ECFD,partnership,100,61,1/12/2021
698FF9,executive-appointment,100,54,1/12/2021
6B494E,dividend,100,50,1/12/2021
6CC55E,regulatory-product-application,100,69,1/12/2021
6CC55E,regulatory-product-application,100,69,1/12/2021
6CC55E,regulatory-product-application,100,69,1/12/2021
6D0CAB,executive-resignation,100,44,1/12/2021
6EB9DA,executive-appointment,100,54,1/12/2021
6F0096,joint-venture,100,62,1/12/2021
7122EB,executive-appointment,100,54,1/12/2021
7255D2,partnership,100,61,1/12/2021
728737,dividend,100,50,1/12/2021
72CB93,executive-appointment,100,54,1/12/2021
72FCA3,earnings,100,50,1/12/2021
7.44E+09,earnings,100,50,1/12/2021
771985,business-contract,100,69,1/12/2021
771985,conference-call,100,50,1/12/2021
773A17,executive-appointment,100,54,1/12/2021
773A17,earnings,100,50,1/12/2021
77B8E9,business-contract,100,69,1/12/2021
790D0D,earnings,100,50,1/12/2021
7BFF81,executive-appointment,100,54,1/12/2021
7CD98F,legal-issues-defendant,100,22,1/12/2021
7E1542,earnings,100,50,1/12/2021
7E1D5D,partnership,100,61,1/12/2021
7E1D5D,partnership,100,61,1/12/2021
8.22E+27,conference-call,100,50,1/12/2021
84A6B9,earnings,100,50,1/12/2021
859281,earnings,100,50,1/12/2021
85DA04,partnership,100,61,1/12/2021
85DA04,executive-appointment,100,54,1/12/2021
86A1B9,executive-appointment,100,54,1/12/2021
877C0C,acquisition-acquirer,100,49,1/12/2021
8A0368,award,100,58,1/12/2021
8B3B0E,partnership,100,61,1/12/2021
8E0E32,dividend,100,50,1/12/2021
8E82A6,earnings,100,50,1/12/2021
8E93A4,conference-call,100,50,1/12/2021
93F143,partnership,100,61,1/12/2021
954004,earnings-guidance-up,100,83,1/12/2021
9.62E+76,earnings,100,50,1/12/2021
9673BD,partnership,100,61,1/12/2021
990AD0,earnings,100,50,1/12/2021
9B730A,public-offering,100,43,1/12/2021
9D307D,product-release,100,64,1/12/2021
9E0811,earnings,100,50,1/12/2021
9EBAFA,public-offering,100,43,1/12/2021
9EBAFA,dividend,100,50,1/12/2021
9F71E5,partnership,100,61,1/12/2021
A01200,conference-participant,100,50,1/12/2021
A02FB1,conference-call,100,50,1/12/2021
A4386C,earnings,100,50,1/12/2021
A43906,conference-call,100,50,1/12/2021
A5151E,earnings,100,50,1/12/2021
A79F7D,conference-participant,100,50,1/12/2021
A87CD6,earnings,100,50,1/12/2021
AA7FE0,product-release,100,64,1/12/2021
AADE0B,acquisition-acquirer,100,49,1/12/2021
AADE0B,conference-call,100,50,1/12/2021
AFF43F,earnings,100,50,1/12/2021
AFF7B4,conference-call,100,50,1/12/2021
B4B281,revenues,100,50,1/12/2021
B4B281,revenues,100,50,1/12/2021
B54A74,earnings,100,50,1/12/2021
B72BE9,conference-call,100,50,1/12/2021
B98EFA,revenues,100,50,1/12/2021
BA0442,note-sale,100,52,1/12/2021
BA0442,public-offering,100,43,1/12/2021
BB5271,partnership,100,61,1/12/2021
BB58FF,conference-organizer,100,57,1/12/2021
BE5935,earnings,100,50,1/12/2021
C3EE99,partnership,100,61,1/12/2021
C425AE,business-contract,100,69,1/12/2021
C425AE,business-contract,100,69,1/12/2021
C4706C,dividend,100,50,1/12/2021
C4FBDC,donation,100,54,1/12/2021
C5C0E9,product-release,100,64,1/12/2021
C659EB,partnership,100,61,1/12/2021
C97B2D,revenues,100,50,1/12/2021
C97B2D,legal-issues-defendant,100,22,1/12/2021
CC176E,dividend-up,100,71,1/12/2021
CC339B,product-release,100,64,1/12/2021
CDE51C,earnings,100,50,1/12/2021
CDFCC9,partnership,100,61,1/12/2021
CEDFD5,legal-issues-defendant,100,22,1/12/2021
CFF97C,partnership,100,61,1/12/2021
D17C1B,product-release,100,64,1/12/2021
D3F64D,earnings,100,50,1/12/2021
D58A11,executive-appointment,100,54,1/12/2021
D90F43,partnership,100,61,1/12/2021
DA199F,public-offering,100,43,1/12/2021
DB06B0,earnings,100,50,1/12/2021
DC0D18,earnings,100,50,1/12/2021
DCD97F,conference-call,100,50,1/12/2021
DD1BA1,executive-appointment,100,54,1/12/2021
DD1BA1,executive-appointment,100,54,1/12/2021
DD682D,buybacks,100,74,1/12/2021
DF16DE,public-offering,100,43,1/12/2021
E15736,conference-call,100,50,1/12/2021
E15736,conference-call,100,50,1/12/2021
E15736,conference-call,100,50,1/12/2021
E38906,award,100,58,1/12/2021
E9C7C0,partnership,100,61,1/12/2021
E9E6FD,conference-call,100,50,1/12/2021
E9E6FD,conference-call,100,50,1/12/2021
EB2F14,facility-open,100,65,1/12/2021
EB5E78,partnership,100,61,1/12/2021
EB6965,award,100,58,1/12/2021
ED9C04,award,100,58,1/12/2021
EDF5CA,conference-call,100,50,1/12/2021
EE6F1C,product-release,100,64,1/12/2021
EF25A5,conference-participant,100,50,1/12/2021
F02170,note-sale,100,52,1/12/2021
F05B1B,public-offering,100,43,1/12/2021
F1EB39,conference-participant,100,50,1/12/2021
F48947,revenue-guidance,100,50,1/12/2021
F4E882,conference-call,100,50,1/12/2021
F4E992,conference-participant,100,50,1/12/2021
F4FBD8,executive-appointment,100,54,1/12/2021
F6E248,partnership,100,61,1/12/2021
F6E248,partnership,100,61,1/12/2021
F80389,conference-call,100,50,1/12/2021
FC1F9D,conference-call,100,50,1/12/2021
FD1312,earnings,100,50,1/12/2021
FF6644,earnings,100,50,1/12/2021
061A3B,product-price-raise,100,57,1/13/2021
07EC43,conference-call,100,50,1/13/2021
09062E,acquisition-acquirer,100,49,1/13/2021
0A1D77,executive-appointment,100,54,1/13/2021
11074E,conference-call,100,50,1/13/2021
1220D2,earnings,100,50,1/13/2021
1490F3,executive-appointment,100,54,1/13/2021
16C544,executive-appointment,100,54,1/13/2021
16FC89,earnings,100,50,1/13/2021
17EDA5,executive-appointment,100,54,1/13/2021
1DE526,conference-call,100,50,1/13/2021
1FE3CB,earnings,100,50,1/13/2021
21D903,revenues,100,50,1/13/2021
24C48B,partnership,100,61,1/13/2021
25102A,product-release,100,64,1/13/2021
270305,conference-call,100,50,1/13/2021
275300,conference-call,100,50,1/13/2021
2B7A40,award,100,58,1/13/2021
2D2D43,executive-appointment,100,54,1/13/2021
2EB88B,partnership,100,61,1/13/2021
2EB88B,partnership,100,61,1/13/2021
2EBA55,dividend,100,50,1/13/2021
2F9304,legal-issues-defendant,100,22,1/13/2021
31666F,dividend,100,50,1/13/2021
32F943,partnership,100,61,1/13/2021
3798B9,executive-appointment,100,54,1/13/2021
3A1C46,earnings,100,50,1/13/2021
3A6D90,dividend,100,50,1/13/2021
3B37F7,public-offering,100,43,1/13/2021
3B37F7,conference-organizer,100,57,1/13/2021
3BB616,partnership,100,61,1/13/2021
3C7F5F,business-contract,100,69,1/13/2021
3CBA2A,dividend,100,50,1/13/2021
3D9999,partnership,100,61,1/13/2021
4135F7,earnings,100,50,1/13/2021
416C55,earnings,100,50,1/13/2021
442587,partnership,100,61,1/13/2021
44A4FC,acquisition-acquirer,100,49,1/13/2021
458D2C,revenue-volume,100,50,1/13/2021
4591D3,legal-issues-defendant,100,22,1/13/2021
47BA98,conference-call,100,50,1/13/2021
4.91E+58,conference-call,100,50,1/13/2021
4A3438,legal-issues-defendant,100,22,1/13/2021
4A3438,legal-issues-defendant,100,22,1/13/2021
4AC91D,dividend,100,50,1/13/2021
4B3676,earnings,100,50,1/13/2021
4BBA23,conference-call,100,50,1/13/2021
4BEB48,note-sale,100,52,1/13/2021
4C92B9,conference-call,100,50,1/13/2021
4F9926,partnership,100,61,1/13/2021
4F9926,partnership,100,61,1/13/2021
4FCC78,dividend,100,50,1/13/2021
4FCC78,dividend-up,100,81,1/13/2021
51888A,conference-call,100,50,1/13/2021
525A1C,earnings,100,50,1/13/2021
53A226,earnings,100,50,1/13/2021
553949,executive-appointment,100,54,1/13/2021
564F3E,earnings,100,50,1/13/2021
564F3E,market-entry,100,57,1/13/2021
5AF08A,executive-appointment,100,54,1/13/2021
5D63F1,partnership,100,61,1/13/2021
5D63F1,partnership,100,61,1/13/2021
5E7E82,partnership,100,61,1/13/2021
5E7E82,partnership,100,61,1/13/2021
5F9CE3,earnings,100,50,1/13/2021
60AC34,revenues,100,50,1/13/2021
60DD84,executive-appointment,100,54,1/13/2021
6137BF,conference-call,100,50,1/13/2021
619882,conference-organizer,100,57,1/13/2021
619882,conference-organizer,100,57,1/13/2021
619882,conference-organizer,100,57,1/13/2021
619882,conference-organizer,100,57,1/13/2021
619882,fundraising,100,64,1/13/2021
619882,conference-organizer,100,57,1/13/2021
66ECFD,dividend,100,50,1/13/2021
69345C,earnings,100,50,1/13/2021
6C4D2F,conference-call,100,50,1/13/2021
6C6D73,business-contract,100,69,1/13/2021
6D0CAB,operating-earnings,100,50,1/13/2021
73F7F9,conference-participant,100,50,1/13/2021
789A7D,earnings,100,50,1/13/2021
78F776,earnings,100,50,1/13/2021
790D0D,executive-appointment,100,54,1/13/2021
7A0EC4,note-sale,100,52,1/13/2021
7A0EC4,public-offering,100,43,1/13/2021
7BFF81,executive-appointment,100,54,1/13/2021
7CD98F,legal-issues-defendant,100,22,1/13/2021
810FAD,executive-appointment,100,54,1/13/2021
82F088,business-contract,100,69,1/13/2021
82F088,executive-appointment,100,54,1/13/2021
88193E,business-contract,100,69,1/13/2021
885758,earnings,100,50,1/13/2021
8B3B0E,conference-call,100,50,1/13/2021
8E8E6E,award,100,58,1/13/2021
8E9CD8,earnings,100,50,1/13/2021
9043FE,earnings,100,50,1/13/2021
9043FE,earnings,100,50,1/13/2021
91E5EE,conference-participant,100,50,1/13/2021
940C3D,executive-appointment,100,54,1/13/2021
94563D,earnings,100,50,1/13/2021
99B61C,clinical-trials-start,100,64,1/13/2021
9EBAFA,public-offering,100,43,1/13/2021
9FF5F1,earnings,100,50,1/13/2021
A01200,award,100,58,1/13/2021
A01664,acquisition-interest-acquirer,100,46,1/13/2021
A1EAC8,executive-appointment,100,54,1/13/2021
A28C54,executive-appointment,100,54,1/13/2021
A350C1,executive-appointment,100,54,1/13/2021
A3AAA5,dividend,100,50,1/13/2021
A5151E,product-release,100,64,1/13/2021
A6FC89,executive-appointment,100,54,1/13/2021
A72FD9,executive-appointment,100,54,1/13/2021
AA247D,conference-call,100,50,1/13/2021
AA5C8E,earnings,100,50,1/13/2021
AC7C4F,conference-call,100,50,1/13/2021
AD1ACF,partnership,100,61,1/13/2021
AD3C93,earnings,100,50,1/13/2021
B05000,award,100,58,1/13/2021
B1FC3B,conference-participant,100,50,1/13/2021
BA218A,conference-call,100,50,1/13/2021
BD8517,earnings,100,50,1/13/2021
BFD0A7,earnings,100,50,1/13/2021
C0200F,earnings,100,50,1/13/2021
C2609A,earnings,100,50,1/13/2021
C356AC,product-release,100,64,1/13/2021
C501B6,earnings-guidance,100,50,1/13/2021
C7FC95,partnership,100,61,1/13/2021
CD4DA8,earnings,100,50,1/13/2021
CFF15D,unit-acquisition-acquirer,100,49,1/13/2021
CFF15D,legal-issues-defendant,100,22,1/13/2021
D6144F,business-contract,100,69,1/13/2021
D6489C,product-release,100,64,1/13/2021
DAFED3,conference-call,100,50,1/13/2021
DF6FDD,earnings,100,50,1/13/2021
E19A99,revenues,100,50,1/13/2021
E1E36F,earnings,100,50,1/13/2021
EEA6B3,earnings,100,50,1/13/2021
EF1AD9,conference-call,100,50,1/13/2021
EF5BED,partnership,100,61,1/13/2021
EF77A3,dividend-up,100,57,1/13/2021
F0B335,earnings,100,50,1/13/2021
F1CD47,earnings,100,50,1/13/2021
F1EB39,unit-acquisition-acquirer,100,49,1/13/2021
F46EC9,earnings,100,50,1/13/2021
F5349B,business-contract,100,69,1/13/2021
F5349B,executive-appointment,100,54,1/13/2021
F85CC0,earnings,100,50,1/13/2021
F85CC0,earnings,100,50,1/13/2021
F88A04,earnings,100,50,1/13/2021
FACF19,partnership,100,61,1/13/2021
FADF1A,facility-open,100,65,1/13/2021
FBD92D,business-contract,100,69,1/13/2021
FD4E8D,earnings,100,50,1/13/2021
0142B5,product-price-raise,100,57,1/14/2021
0358AF,earnings,100,50,1/14/2021
083F72,dividend,100,50,1/14/2021
09DE1F,business-contract,100,69,1/14/2021
09F623,conference-call,100,50,1/14/2021
0BC17A,earnings,100,50,1/14/2021
0BD4E8,business-contract,100,69,1/14/2021
0D26E0,dividend,100,50,1/14/2021
0FABBD,partnership,100,61,1/14/2021
0FDE97,conference-call,100,50,1/14/2021
12DE76,merger,100,66,1/14/2021
13C3E0,earnings,100,50,1/14/2021
157CC1,business-contract,100,69,1/14/2021
157CC1,acquisition-acquirer,100,49,1/14/2021
168A5D,unit-acquisition-acquirer,100,49,1/14/2021
1748F6,executive-appointment,100,54,1/14/2021
188394,conference-call,100,50,1/14/2021
1A6A94,dividend,100,50,1/14/2021
1B637E,dividend,100,50,1/14/2021
1F19C8,earnings,100,50,1/14/2021
219B21,conference-call,100,50,1/14/2021
222BF9,conference-call,100,50,1/14/2021
24CB56,dividend,100,50,1/14/2021
263216,conference-participant,100,50,1/14/2021
26CC63,acquisition-acquirer,100,49,1/14/2021
2920D5,note-sale,100,52,1/14/2021
2920D5,note-sale,100,52,1/14/2021
2BBE62,earnings,100,50,1/14/2021
2DA92D,conference-call,100,50,1/14/2021
2DC88B,earnings,100,50,1/14/2021
2E1322,earnings,100,50,1/14/2021
2F7A7E,conference-call,100,50,1/14/2021
2F9304,legal-issues-defendant,100,22,1/14/2021
31666F,buybacks,100,74,1/14/2021
328250,conference-call,100,50,1/14/2021
32CB22,conference-call,100,50,1/14/2021
34B97A,conference-call,100,50,1/14/2021
35F4B5,conference-call,100,50,1/14/2021
3696BF,conference-call,100,50,1/14/2021
384CD3,earnings,100,50,1/14/2021
387541,dividend-up,100,57,1/14/2021
3A113F,revenues,100,50,1/14/2021
3B2311,merger,100,66,1/14/2021
3B37F7,conference-organizer,100,57,1/14/2021
3B37F7,conference-organizer,100,57,1/14/2021
3B37F7,conference-organizer,100,57,1/14/2021
3B37F7,conference-organizer,100,57,1/14/2021
3CCC90,investment-investor,100,55,1/14/2021
3FBC9B,earnings,100,50,1/14/2021
43A74A,earnings,100,50,1/14/2021
448BF3,executive-appointment,100,54,1/14/2021
4591D3,legal-issues-defendant,100,22,1/14/2021
4A3438,legal-issues-defendant,100,22,1/14/2021
4A3438,legal-issues-defendant,100,22,1/14/2021
4B7006,product-release,100,64,1/14/2021
4B7006,product-release,100,64,1/14/2021
4E5784,merger,100,66,1/14/2021
4F9926,partnership,100,61,1/14/2021
50070E,partnership,100,61,1/14/2021
504FE2,acquisition-completed-acquirer,100,49,1/14/2021
51527B,conference-call,100,50,1/14/2021
51D876,earnings,100,50,1/14/2021
53C421,conference-call,100,50,1/14/2021
5546DA,conference-call,100,50,1/14/2021
5546DA,executive-appointment,100,54,1/14/2021
5AF08A,earnings,100,50,1/14/2021
5BC2F4,dividend,100,50,1/14/2021
5D43A7,dividend,100,50,1/14/2021
5F2FF7,earnings,100,50,1/14/2021
619882,partnership,100,61,1/14/2021
619882,conference-organizer,100,57,1/14/2021
619882,partnership,100,61,1/14/2021
68BA15,dividend-up,100,56,1/14/2021
6BF593,conference-call,100,50,1/14/2021
713810,earnings,100,50,1/14/2021
72FCA3,executive-appointment,100,54,1/14/2021
746373,conference-call,100,50,1/14/2021
78F776,patient-enrollment-start,100,58,1/14/2021
790C34,earnings,100,50,1/14/2021
793C11,earnings,100,50,1/14/2021
7A10FF,earnings,100,50,1/14/2021
7BAAE7,earnings,100,50,1/14/2021
7C4168,note-sale,100,52,1/14/2021
7C4168,note-sale,100,52,1/14/2021
7D85A9,dividend,100,50,1/14/2021
7F3A5F,earnings,100,50,1/14/2021
8.10E+32,executive-appointment,100,54,1/14/2021
855DF7,dividend,100,50,1/14/2021
85DE00,conference-call,100,50,1/14/2021
86A1B9,earnings,100,50,1/14/2021
87486A,public-offering,100,43,1/14/2021
87486A,public-offering,100,43,1/14/2021
88611B,conference-call,100,50,1/14/2021
88923D,conference-call,100,50,1/14/2021
89F693,earnings,100,50,1/14/2021
8D4486,partnership,100,61,1/14/2021
8D4486,partnership,100,61,1/14/2021
8D4486,partnership,100,61,1/14/2021
8D4486,partnership,100,61,1/14/2021
8D4486,product-release,100,64,1/14/2021
8D9993,conference-call,100,50,1/14/2021
903AB4,dividend,100,50,1/14/2021
911AB8,buybacks,100,74,1/14/2021
91C82E,dividend,100,50,1/14/2021
91C82E,buybacks,100,74,1/14/2021
93633B,conference-call,100,50,1/14/2021
93D207,earnings,100,50,1/14/2021
950AB7,earnings,100,50,1/14/2021
95F59E,merger,100,66,1/14/2021
986AF6,executive-resignation,100,44,1/14/2021
98CEBB,earnings,100,50,1/14/2021
9A02C4,conference-call,100,50,1/14/2021
9C8BC3,award,100,58,1/14/2021
9CF9B1,earnings,100,50,1/14/2021
9D2790,product-release,100,64,1/14/2021
9D2790,product-release,100,64,1/14/2021
9F18FA,note-sale,100,52,1/14/2021
9F18FA,note-sale,100,52,1/14/2021
A1EAC8,conference-call,100,50,1/14/2021
A2CAF7,donation,100,54,1/14/2021
A350C1,earnings,100,50,1/14/2021
A4F67C,note-sale,100,52,1/14/2021
A7102F,partnership,100,61,1/14/2021
A79D88,patent-filing,100,64,1/14/2021
A871B0,merger,100,66,1/14/2021
AA847A,conference-call,100,50,1/14/2021
ABB493,patient-enrollment-start,100,58,1/14/2021
AE0CCE,earnings,100,50,1/14/2021
AFDF2E,dividend,100,50,1/14/2021
AFEC35,public-offering,100,43,1/14/2021
B1B10C,conference-call,100,50,1/14/2021
B2206F,earnings,100,50,1/14/2021
B2256A,conference-call,100,50,1/14/2021
B3A166,business-contract,100,69,1/14/2021
B5734D,conference-call,100,50,1/14/2021
B77F14,partnership,100,61,1/14/2021
BA0442,public-offering,100,43,1/14/2021
BCC55F,executive-appointment,100,54,1/14/2021
BFCACF,conference-call,100,50,1/14/2021
BFD0A7,conference-participant,100,50,1/14/2021
C0030A,earnings,100,50,1/14/2021
C062D4,product-release,100,64,1/14/2021
C15DB3,executive-appointment,100,54,1/14/2021
C356AC,earnings,100,50,1/14/2021
C4C77F,dividend,100,50,1/14/2021
C62AA4,conference-participant,100,50,1/14/2021
C7859D,earnings,100,50,1/14/2021
C7859D,earnings,100,50,1/14/2021
C7859D,earnings,100,50,1/14/2021
C7859D,earnings,100,50,1/14/2021
C7859D,earnings,100,50,1/14/2021
C7859D,earnings,100,50,1/14/2021
C7859D,earnings,100,50,1/14/2021
C7859D,earnings,100,50,1/14/2021
C97B2D,product-release,100,64,1/14/2021
CA212F,earnings,100,50,1/14/2021
CA3CB9,conference-call,100,50,1/14/2021
CEC08B,conference-participant,100,50,1/14/2021
CEC5B9,conference-call,100,50,1/14/2021
CEC5B9,conference-call,100,50,1/14/2021
D08D2C,dividend,100,50,1/14/2021
D1344A,business-contract,100,69,1/14/2021
D17C1B,earnings,100,50,1/14/2021
D33270,business-contract,100,69,1/14/2021
D36B23,executive-appointment,100,54,1/14/2021
D437C3,partnership,100,61,1/14/2021
D54E62,stake-acquirer,100,48,1/14/2021
D58A11,earnings,100,50,1/14/2021
D5AF19,earnings,100,50,1/14/2021
D65A13,conference-call,100,50,1/14/2021
D6853F,conference-call,100,50,1/14/2021
D697DE,executive-appointment,100,54,1/14/2021
D75910,joint-venture,100,62,1/14/2021
D7A953,earnings,100,50,1/14/2021
D90F43,conference-call,100,50,1/14/2021
DB5CA5,partnership,100,61,1/14/2021
DB5CA5,award,100,58,1/14/2021
DC437D,earnings,100,50,1/14/2021
DC6AA0,legal-issues-defendant,100,22,1/14/2021
DD0F15,conference-participant,100,50,1/14/2021
DD3BB1,earnings,100,50,1/14/2021
DF01B1,conference-call,100,50,1/14/2021
E074A0,earnings,100,50,1/14/2021
E0A84E,partnership,100,61,1/14/2021
E11C41,conference-call,100,50,1/14/2021
E1E093,partnership,100,61,1/14/2021
E30B34,earnings,100,50,1/14/2021
E30B34,earnings,100,50,1/14/2021
E3656D,conference-call,100,50,1/14/2021
E3E68E,revenue-volume-up,100,69,1/14/2021
E3E68E,revenue-volume-up,100,69,1/14/2021
E8846E,unit-acquisition-acquiree,100,76,1/14/2021
E8846E,unit-acquisition-acquiree,100,76,1/14/2021
E8846E,unit-acquisition-acquiree,100,76,1/14/2021
E8846E,acquisition-acquiree,100,76,1/14/2021
EAA0A7,acquisition-completed-acquirer,100,49,1/14/2021
EB5E78,conference-call,100,50,1/14/2021
EB6965,dividend,100,50,1/14/2021
EEA6B3,unit-acquisition-acquiree,100,76,1/14/2021
EFA7B2,revenues,100,50,1/14/2021
F0B877,executive-appointment,100,54,1/14/2021
F294DD,earnings,100,50,1/14/2021
F30508,executive-appointment,100,54,1/14/2021
F5D410,conference-call,100,50,1/14/2021
F6DCE4,dividend,100,50,1/14/2021
F721A7,executive-appointment,100,54,1/14/2021
F721A7,earnings,100,50,1/14/2021
F721A7,earnings,100,50,1/14/2021
F90EE5,product-release,100,64,1/14/2021
FA36A4,dividend,100,50,1/14/2021
FB728F,dividend,100,50,1/14/2021
FC1F9D,executive-appointment,100,54,1/14/2021
FD554E,executive-appointment,100,54,1/14/2021
FD9A97,earnings,100,50,1/14/2021
FF5413,earnings,100,50,1/14/2021
0157B1,legal-issues-defendant,100,22,1/15/2021
31025,earnings,100,50,1/15/2021
03FB17,earnings,100,50,1/15/2021
054B55,public-offering,100,43,1/15/2021
07CA6A,conference-call,100,50,1/15/2021
091B6C,conference-participant,100,50,1/15/2021
0CC62B,conference-call,100,50,1/15/2021
0F2BC9,business-contract,100,69,1/15/2021
1065BC,conference-call,100,50,1/15/2021
10C19B,executive-appointment,100,54,1/15/2021
147C38,dividend,100,50,1/15/2021
1AB023,facility-upgrade,100,65,1/15/2021
1AB023,facility-upgrade,100,65,1/15/2021
1AB023,facility-upgrade,100,65,1/15/2021
1BDB2A,conference-call,100,50,1/15/2021
1E9A6D,earnings,100,50,1/15/2021
25102A,trading-resumed,100,58,1/15/2021
2920D5,note-sale,100,52,1/15/2021
2C681C,executive-appointment,100,54,1/15/2021
2C681C,executive-appointment,100,54,1/15/2021
2EB88B,earnings,100,50,1/15/2021
33E8C7,earnings,100,50,1/15/2021
3461CF,credit-rating-upgrade-rater,20,50,1/15/2021
34E9F9,dividend,100,50,1/15/2021
355B19,dividend,100,50,1/15/2021
43F4A8,business-contract,100,69,1/15/2021
43F4A8,business-contract,100,69,1/15/2021
43F4A8,acquisition-regulatory-scrutiny-acquiree,100,38,1/15/2021
442587,business-contract,100,69,1/15/2021
4591D3,legal-issues-defendant,100,22,1/15/2021
494EB9,earnings,100,50,1/15/2021
4A3438,legal-issues-defendant,100,22,1/15/2021
4A6F00,partnership,100,61,1/15/2021
4E2D94,acquisition-completed-acquirer,100,49,1/15/2021
504FE2,conference-call,100,50,1/15/2021
50702E,conference-call,100,50,1/15/2021
5225A4,conference-call,100,50,1/15/2021
55438C,executive-appointment,100,54,1/15/2021
55C9B5,conference-call,100,50,1/15/2021
562853,conference-call,100,50,1/15/2021
567F3D,conference-call,100,50,1/15/2021
58CA9A,earnings,100,50,1/15/2021
5C61CC,executive-appointment,100,54,1/15/2021
5EAA43,conference-call,100,50,1/15/2021
601785,earnings,100,50,1/15/2021
6166D1,dividend,100,50,1/15/2021
619882,earnings,100,50,1/15/2021
619882,conference-organizer,100,57,1/15/2021
619882,conference-organizer,100,57,1/15/2021
619882,conference-organizer,100,57,1/15/2021
619882,conference-organizer,100,57,1/15/2021
619882,conference-organizer,100,57,1/15/2021
619882,dividend,100,50,1/15/2021
61B81B,earnings-positive,100,69,1/15/2021
61B81B,earnings-positive,100,69,1/15/2021
61B81B,earnings-positive,100,69,1/15/2021
61B81B,earnings-positive,100,69,1/15/2021
61B81B,earnings-positive,100,69,1/15/2021
61B81B,earnings-positive,100,69,1/15/2021
61B81B,earnings-positive,100,69,1/15/2021
61B81B,earnings-positive,100,69,1/15/2021
63E8D5,earnings,100,50,1/15/2021
665618,dividend,100,50,1/15/2021
6CDFC6,conference-call,100,50,1/15/2021
6D3B7B,earnings,100,50,1/15/2021
6F0A63,executive-appointment,100,54,1/15/2021
73C521,dividend,100,50,1/15/2021
7.45E+28,legal-issues-defendant,100,22,1/15/2021
762A3E,conference-call,100,50,1/15/2021
762B8D,dividend,100,50,1/15/2021
767F86,earnings,100,50,1/15/2021
7A5097,conference-call,100,50,1/15/2021
7AB859,conference-call,100,50,1/15/2021
7B0BA6,earnings,100,50,1/15/2021
7B6C88,conference-call,100,50,1/15/2021
7D5384,index-listing,100,76,1/15/2021
7FEEE1,conference-participant,100,50,1/15/2021
819492,conference-participant,100,50,1/15/2021
82FD6D,conference-call,100,50,1/15/2021
83B1C8,executive-appointment,100,54,1/15/2021
8665BA,unit-acquisition-acquirer,100,49,1/15/2021
8D5145,earnings,100,50,1/15/2021
8FCA78,acquisition-completed-acquirer,100,49,1/15/2021
93F143,earnings,100,50,1/15/2021
942165,executive-appointment,100,54,1/15/2021
9.54E+32,partnership,100,61,1/15/2021
9592FB,product-release,100,64,1/15/2021
95C392,earnings,100,50,1/15/2021
977A1E,business-contract,100,69,1/15/2021
990AD0,legal-issues-defendant,100,22,1/15/2021
990AD0,dividend,100,50,1/15/2021
9C3D3C,conference-participant,100,50,1/15/2021
A1A317,conference-call,100,50,1/15/2021
A41450,dividend,100,50,1/15/2021
A4A612,earnings,100,50,1/15/2021
A4F67C,earnings,100,50,1/15/2021
A94718,conference-call,100,50,1/15/2021
AFF7B4,dividend,100,50,1/15/2021
B05118,fundraising,100,64,1/15/2021
B1FC3B,conference-participant,100,50,1/15/2021
B3ED62,conference-call,100,50,1/15/2021
B4703C,dividend,100,50,1/15/2021
B7BBFF,dividend,100,50,1/15/2021
B83BCE,earnings,100,50,1/15/2021
BCC13E,conference-participant,100,50,1/15/2021
C32A39,dividend,100,50,1/15/2021
C45C1F,conference-participant,100,50,1/15/2021
C54140,executive-appointment,100,54,1/15/2021
C598D7,acquisition-completed-acquirer,100,49,1/15/2021
C598D7,acquisition-completed-acquirer,100,49,1/15/2021
C5C0E9,conference-call,100,50,1/15/2021
C5E100,conference-participant,100,50,1/15/2021
CC0C78,conference-participant,100,50,1/15/2021
CFF97C,credit-rating-set-rater,20,50,1/15/2021
CFF97C,earnings,100,50,1/15/2021
D3FA2C,conference-call,100,50,1/15/2021
E5752F,earnings,100,50,1/15/2021
E7BF32,legal-issues-defendant,100,22,1/15/2021
E87676,acquisition-acquirer,100,49,1/15/2021
E8846E,earnings,100,50,1/15/2021
E93A40,product-release,100,64,1/15/2021
EAEBF3,conference-participant,100,50,1/15/2021
ED79D9,executive-appointment,100,54,1/15/2021
F0B877,executive-appointment,100,54,1/15/2021
F30508,conference-call,100,50,1/15/2021
F3FCC3,earnings,100,50,1/15/2021
F72E4B,asset-sale,100,62,1/15/2021
FA35C6,earnings,100,50,1/15/2021
FAEABE,earnings-per-share-positive,100,69,1/15/2021
FAEABE,earnings,100,50,1/15/2021
FAEABE,earnings,100,50,1/15/2021
FE89E0,acquisition-completed-acquirer,100,49,1/15/2021
FE89E0,acquisition-completed-acquirer,100,49,1/15/2021
FF227B,conference-participant,100,50,1/15/2021
250BEE,dividend,100,50,1/16/2021
524CE4,earnings,100,50,1/16/2021
7CD98F,legal-issues-defendant,100,22,1/16/2021
D15833,executive-resignation,100,44,1/16/2021
DC6AA0,legal-issues-defendant,100,22,1/16/2021
E96E0B,fraud-defendant,100,20,1/16/2021
5FF95F,earnings,100,50,1/17/2021
00D6B5,earnings,100,50,1/18/2021
00FC70,conference-call,100,50,1/18/2021
0142B5,conference-call,100,50,1/18/2021
0157B1,business-contract,100,69,1/18/2021
0157B1,partnership,100,61,1/18/2021
129DC8,trading-halt,100,43,1/18/2021
129DC8,trading-resumed,100,58,1/18/2021
15A388,earnings,100,50,1/18/2021
1CDD1C,conference-call,100,50,1/18/2021
1E9A6D,legal-issues-defendant,100,22,1/18/2021
2F9304,legal-issues-defendant,100,22,1/18/2021
2F9304,legal-issues-defendant,100,22,1/18/2021
3390DE,conference-call,100,50,1/18/2021
442587,business-contract,100,69,1/18/2021
47B4CC,legal-issues-defendant,100,22,1/18/2021
5.47E+28,business-contract,100,69,1/18/2021
5C8D61,earnings,100,50,1/18/2021
66749D,earnings,100,50,1/18/2021
722D55,acquisition-completed-acquirer,100,49,1/18/2021
77B8E9,patent-awarded,100,72,1/18/2021
7CD98F,legal-issues-defendant,100,22,1/18/2021
7DC1C4,earnings,100,50,1/18/2021
93965C,conference-call,100,50,1/18/2021
94C0B5,dividend,100,50,1/18/2021
95F59E,legal-issues-defendant,100,22,1/18/2021
9.74E+08,legal-issues-defendant,100,22,1/18/2021
A28C54,executive-appointment,100,54,1/18/2021
BAD655,legal-issues-defendant,100,22,1/18/2021
BBBB41,conference-call,100,50,1/18/2021
CED4D0,conference-call,100,50,1/18/2021
CF9054,earnings,100,50,1/18/2021
D13F1C,earnings,100,50,1/18/2021
DC6AA0,legal-issues-defendant,100,22,1/18/2021
E7BF32,legal-issues-defendant,100,22,1/18/2021
ED9C04,patent-infringement-plaintiff,100,47,1/18/2021
EEBCEF,earnings,100,50,1/18/2021
F02D0A,earnings,100,50,1/18/2021
F509E2,conference-call,100,50,1/18/2021
00326E,conference-call,100,50,1/19/2021
9397,executive-appointment,100,54,1/19/2021
0157B1,investment-investor,100,55,1/19/2021
0157B1,conference-call,100,50,1/19/2021
018C11,conference-call,100,50,1/19/2021
71860,acquisition-acquirer,100,49,1/19/2021
71860,acquisition-acquirer,100,49,1/19/2021
95294,earnings,100,50,1/19/2021
96930,regulatory-product-approval-granted,100,81,1/19/2021
0C2A0D,earnings,100,50,1/19/2021
0C4131,earnings,100,50,1/19/2021
0CBC4D,executive-appointment,100,54,1/19/2021
0F2BC9,business-contract,100,69,1/19/2021
0F65C9,conference-call,100,50,1/19/2021
154272,clinical-trials-positive,100,87,1/19/2021
168A5D,executive-appointment,100,54,1/19/2021
16FC89,dividend,100,50,1/19/2021
188394,earnings-guidance,100,50,1/19/2021
1A6A94,dividend,100,50,1/19/2021
1BC12C,partnership,100,61,1/19/2021
1CD09C,conference-participant,100,50,1/19/2021
1D9E55,earnings,100,50,1/19/2021
1F9D90,conference-call,100,50,1/19/2021
21022F,earnings,100,50,1/19/2021
21F9CA,partnership,100,61,1/19/2021
228D42,partnership,100,61,1/19/2021
24C48B,conference-call,100,50,1/19/2021
2571FA,earnings,100,50,1/19/2021
25DD05,earnings,100,50,1/19/2021
2667B6,executive-appointment,100,54,1/19/2021
282C18,earnings,100,50,1/19/2021
28AF37,earnings,100,50,1/19/2021
292388,product-release,100,64,1/19/2021
2.90E+62,earnings,100,50,1/19/2021
2AA6A8,public-offering,100,43,1/19/2021
2AE625,conference-call,100,50,1/19/2021
2B49F4,earnings,100,50,1/19/2021
2B49F4,earnings,100,50,1/19/2021
2B49F4,earnings,100,50,1/19/2021
2B49F4,earnings,100,50,1/19/2021
2B49F4,earnings,100,50,1/19/2021
2B7A40,earnings,100,50,1/19/2021
2CF9D3,public-offering,100,43,1/19/2021
2E902B,conference-call,100,50,1/19/2021
2EBC0B,earnings,100,50,1/19/2021
2F1299,conference-call,100,50,1/19/2021
2F9304,fraud-defendant,100,20,1/19/2021
3.14E+47,earnings,100,50,1/19/2021
326EDD,dividend,100,50,1/19/2021
353DBB,unit-acquisition-acquirer,100,49,1/19/2021
353DBB,unit-acquisition-acquirer,100,49,1/19/2021
37B120,public-offering,100,43,1/19/2021
396D7C,public-offering,100,43,1/19/2021
3B2311,legal-issues-defendant,100,22,1/19/2021
3B37F7,conference-organizer,100,57,1/19/2021
3B37F7,conference-organizer,100,57,1/19/2021
3B37F7,conference-organizer,100,57,1/19/2021
3BE00F,earnings,100,50,1/19/2021
4.03E+05,conference-call,100,50,1/19/2021
4.03E+05,award,100,58,1/19/2021
415188,conference-call,100,50,1/19/2021
416C55,acquisition-completed-acquirer,100,49,1/19/2021
447FC6,conference-call,100,50,1/19/2021
4591D3,legal-issues-defendant,100,22,1/19/2021
4A6F00,product-release,100,64,1/19/2021
4B5054,conference-call,100,50,1/19/2021
4C7DB5,donation,100,54,1/19/2021
50D1EC,conference-call,100,50,1/19/2021
51B442,earnings,100,50,1/19/2021
56277A,executive-appointment,100,54,1/19/2021
583A75,conference-call,100,50,1/19/2021
5876DC,credit-extension-recipient,100,69,1/19/2021
589803,conference-call,100,50,1/19/2021
59DB8C,business-contract,100,69,1/19/2021
5A64D5,conference-call,100,50,1/19/2021
5B15E1,legal-issues-defendant,100,22,1/19/2021
5B35C7,earnings-up,100,68,1/19/2021
5B35C7,earnings-up,100,68,1/19/2021
5B35C7,earnings-up,100,68,1/19/2021
5B51D6,fast-track-designation,100,81,1/19/2021
5B6C11,earnings,100,50,1/19/2021
5BC2F4,earnings,100,50,1/19/2021
5D0337,earnings,100,50,1/19/2021
5E9934,note-sale,100,52,1/19/2021
6.18E+08,earnings,100,50,1/19/2021
639BD6,earnings,100,50,1/19/2021
6.52E+64,conference-call,100,50,1/19/2021
66E04A,note-sale,100,52,1/19/2021
66E04A,note-sale,100,52,1/19/2021
67B923,conference-call,100,50,1/19/2021
698FF9,earnings,100,50,1/19/2021
6AACDD,public-offering,100,43,1/19/2021
6B236C,conference-call,100,50,1/19/2021
6CC55E,earnings,100,50,1/19/2021
7032D0,earnings,100,50,1/19/2021
713810,business-contract,100,69,1/19/2021
7239BB,legal-issues-defendant,100,22,1/19/2021
7255D2,executive-appointment,100,54,1/19/2021
747219,note-sale,100,52,1/19/2021
751C8D,earnings,100,50,1/19/2021
75D689,executive-appointment,100,54,1/19/2021
762B8D,earnings,100,50,1/19/2021
7AB859,executive-appointment,100,54,1/19/2021
7B1E50,donation,100,54,1/19/2021
7C4F43,public-offering,100,43,1/19/2021
7CD98F,earnings,100,50,1/19/2021
7D5FD6,market-entry,100,57,1/19/2021
7E62B5,conference-call,100,50,1/19/2021
7F3669,earnings,100,50,1/19/2021
81A88D,earnings,100,50,1/19/2021
82E58A,dividend,100,50,1/19/2021
8303CD,conference-call,100,50,1/19/2021
855DF7,dividend,100,50,1/19/2021
859D62,partnership,100,61,1/19/2021
8802B4,dividend-up,100,81,1/19/2021
8802B4,earnings-guidance,100,50,1/19/2021
8802B4,earnings-guidance,100,50,1/19/2021
880C0C,conference-call,100,50,1/19/2021
88350F,conference-call,100,50,1/19/2021
88936A,earnings,100,50,1/19/2021
895D56,partnership,100,61,1/19/2021
89F693,executive-appointment,100,54,1/19/2021
89FBB1,dividend,100,50,1/19/2021
8A8E41,partnership,100,61,1/19/2021
8A8E41,product-release,100,64,1/19/2021
8BE916,executive-appointment,100,54,1/19/2021
8CF6DD,earnings,100,50,1/19/2021
8D4486,partnership,100,61,1/19/2021
8D4486,partnership,100,61,1/19/2021
8D9993,dividend,100,50,1/19/2021
8DBBE6,conference-call,100,50,1/19/2021
8DDA23,dividend,100,50,1/19/2021
8F3231,dividend,100,50,1/19/2021
901327,business-contract,100,69,1/19/2021
901327,business-contract,100,69,1/19/2021
915E7B,conference-call,100,50,1/19/2021
9196A2,executive-appointment,100,54,1/19/2021
92D3A0,dividend,100,50,1/19/2021
92D757,executive-appointment,100,54,1/19/2021
9.36E+10,business-contract,100,69,1/19/2021
9.39E+69,executive-appointment,100,54,1/19/2021
94208D,earnings,100,50,1/19/2021
944B2E,asset-sale,100,62,1/19/2021
9592FB,product-release,100,64,1/19/2021
968103,earnings,100,50,1/19/2021
968966,executive-appointment,100,54,1/19/2021
96F126,earnings,100,50,1/19/2021
977A1E,unit-acquisition-acquirer,100,49,1/19/2021
98CEBB,partnership,100,61,1/19/2021
99028D,conference-call,100,50,1/19/2021
990AD0,dividend,100,50,1/19/2021
990AD0,earnings,100,50,1/19/2021
99DC8D,conference-call,100,50,1/19/2021
9A29F4,public-offering,100,43,1/19/2021
9B71A7,unit-acquisition-completed-acquiree,100,67,1/19/2021
9B71A7,acquisition-completed-acquiree,100,76,1/19/2021
9B71A7,executive-appointment,100,54,1/19/2021
9CA4C6,dividend-up,100,81,1/19/2021
9CA4C6,earnings,100,50,1/19/2021
9D2790,earnings,100,50,1/19/2021
9D30A8,earnings,100,50,1/19/2021
9F6B1A,executive-appointment,100,54,1/19/2021
A03EE1,earnings,100,50,1/19/2021
A0F146,conference-call,100,50,1/19/2021
A16DEA,business-contract,100,69,1/19/2021
A247F5,earnings,100,50,1/19/2021
A3F598,conference-call,100,50,1/19/2021
A403CF,earnings,100,50,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A746F6,earnings-per-share-positive,100,69,1/19/2021
A74F6F,conference-call,100,50,1/19/2021
A7A0C8,executive-appointment,100,54,1/19/2021
A7A0C8,public-offering,100,43,1/19/2021
A868C9,product-release,100,64,1/19/2021
A8CBDA,buybacks,100,74,1/19/2021
AA1EAA,conference-call,100,50,1/19/2021
AADE0B,unit-acquisition-acquirer,100,49,1/19/2021
AC3584,public-offering,100,43,1/19/2021
ACF77B,partnership,100,61,1/19/2021
AE3113,earnings,100,50,1/19/2021
B0B969,conference-call,100,50,1/19/2021
B1FC3B,business-contract,100,69,1/19/2021
B77F14,partnership,100,61,1/19/2021
B840EF,earnings,100,50,1/19/2021
B934BF,conference-call,100,50,1/19/2021
B96DF5,earnings-up,100,68,1/19/2021
B96DF5,earnings,100,50,1/19/2021
B96DF5,earnings,100,50,1/19/2021
B96DF5,earnings,100,50,1/19/2021
B96DF5,earnings,100,50,1/19/2021
B98EFA,partnership,100,61,1/19/2021
BAD9EA,private-placement,100,56,1/19/2021
BB07E4,unit-acquisition-acquiree,100,76,1/19/2021
BB07E4,unit-acquisition-acquiree,100,76,1/19/2021
BD8517,acquisition-completed-acquirer,100,49,1/19/2021
BD9668,earnings,100,50,1/19/2021
BDE867,executive-appointment,100,54,1/19/2021
BFAEB4,dividend,100,50,1/19/2021
C16A8F,facility-close,100,47,1/19/2021
C58D71,executive-appointment,100,54,1/19/2021
C94CFC,executive-appointment,100,54,1/19/2021
C97B2D,legal-issues-defendant,100,22,1/19/2021
CAD7D9,executive-appointment,100,54,1/19/2021
CDEDFE,merger-regulatory-approval,100,81,1/19/2021
CE4FD9,conference-participant,100,50,1/19/2021
CEC08B,earnings,100,50,1/19/2021
CF073E,partnership,100,61,1/19/2021
D07B07,revenues,100,50,1/19/2021
D139BC,conference-call,100,50,1/19/2021
D17C1B,executive-appointment,100,54,1/19/2021
D33D8C,earnings-per-share-positive,100,69,1/19/2021
D33D8C,earnings-per-share-positive,100,69,1/19/2021
D33D8C,earnings-per-share-positive,100,69,1/19/2021
D33D8C,earnings-per-share-positive,100,69,1/19/2021
D33D8C,earnings-per-share-positive,100,69,1/19/2021
D33D8C,earnings-per-share-positive,100,69,1/19/2021
D33D8C,earnings-per-share-positive,100,69,1/19/2021
D33D8C,earnings-per-share-positive,100,69,1/19/2021
D393DF,earnings,100,50,1/19/2021
D393DF,earnings,100,50,1/19/2021
D437C3,acquisition-completed-acquirer,100,49,1/19/2021
D437C3,acquisition-completed-acquirer,100,49,1/19/2021
D63B0F,note-sale,100,52,1/19/2021
D6489C,executive-appointment,100,54,1/19/2021
D70365,earnings,100,50,1/19/2021
D854DD,conference-call,100,50,1/19/2021
D854F3,acquisition-acquirer,100,49,1/19/2021
D8760C,earnings-positive,100,69,1/19/2021
D8760C,earnings,100,50,1/19/2021
D8760C,earnings,100,50,1/19/2021
D8760C,earnings,100,50,1/19/2021
D8760C,earnings,100,50,1/19/2021
D8760C,earnings,100,50,1/19/2021
D8760C,earnings,100,50,1/19/2021
D9B1C9,dividend,100,50,1/19/2021
DC0066,regulatory-product-approval-granted,100,81,1/19/2021
DC0998,conference-call,100,50,1/19/2021
DC1405,executive-appointment,100,54,1/19/2021
DCD97F,business-contract,100,69,1/19/2021
DD1BA1,business-contract,100,69,1/19/2021
DF532D,earnings,100,50,1/19/2021
DF532D,earnings,100,50,1/19/2021
DF8855,earnings,100,50,1/19/2021
E0207A,earnings,100,50,1/19/2021
E2CB7B,partnership,100,61,1/19/2021
E2CB7B,partnership,100,61,1/19/2021
E2CB7B,partnership,100,61,1/19/2021
E2CB7B,partnership,100,61,1/19/2021
E3E68E,partnership,100,61,1/19/2021
E3E68E,partnership,100,61,1/19/2021
E3E68E,conference-call,100,50,1/19/2021
E3E68E,conference-call,100,50,1/19/2021
E56A0D,executive-appointment,100,54,1/19/2021
E592F0,partnership,100,61,1/19/2021
E598FB,patient-enrollment-complete,100,64,1/19/2021
E6A53A,unit-acquisition-acquirer,100,49,1/19/2021
E6A53A,unit-acquisition-acquirer,100,49,1/19/2021
E6A53A,earnings,100,50,1/19/2021
E6A53A,earnings,100,50,1/19/2021
E6E012,earnings,100,50,1/19/2021
E6E012,earnings,100,50,1/19/2021
E7BF32,stake-acquiree,100,62,1/19/2021
E84500,executive-appointment,100,54,1/19/2021
E96E0B,legal-issues-defendant,100,22,1/19/2021
E96E0B,legal-issues-defendant,100,22,1/19/2021
E96E0B,legal-issues-defendant,100,22,1/19/2021
EAEBF3,note-sale,100,52,1/19/2021
EAEBF3,note-sale,100,52,1/19/2021
EB7FBF,note-sale,100,52,1/19/2021
EB7FBF,note-sale,100,52,1/19/2021
EBD89A,conference-call,100,50,1/19/2021
EBD89A,conference-call,100,50,1/19/2021
EC4E82,acquisition-completed-acquirer,100,49,1/19/2021
ECD263,earnings,100,50,1/19/2021
F30508,partnership,100,61,1/19/2021
F48947,regulatory-product-approval-granted,100,81,1/19/2021
F50BAB,dividend,100,50,1/19/2021
F8BDCE,earnings,100,50,1/19/2021
F8BDCE,earnings,100,50,1/19/2021
F8BDCE,earnings,100,50,1/19/2021
F93C8A,dividend,100,50,1/19/2021
FA36A4,dividend,100,50,1/19/2021
FA840E,earnings,100,50,1/19/2021
FA918D,conference-call,100,50,1/19/2021
FB728F,dividend,100,50,1/19/2021
FC1736,partnership,100,61,1/19/2021
FD1312,earnings,100,50,1/19/2021
FD4588,earnings,100,50,1/19/2021
FDF28E,earnings,100,50,1/19/2021
FDF799,public-offering,100,43,1/19/2021
FF227B,executive-appointment,100,54,1/19/2021
003B70,earnings,100,50,1/20/2021
03D5F9,executive-appointment,100,54,1/20/2021
58828,operating-earnings,100,50,1/20/2021
065D38,earnings,100,50,1/20/2021
0919B1,earnings,100,50,1/20/2021
09F623,dividend,100,50,1/20/2021
0AB700,dividend,100,50,1/20/2021
0CADBC,dividend,100,50,1/20/2021
102F04,executive-appointment,100,54,1/20/2021
112694,clinical-trials-start,100,64,1/20/2021
165B3A,earnings-positive,100,69,1/20/2021
165B3A,earnings-positive,100,69,1/20/2021
165B3A,earnings-positive,100,69,1/20/2021
165B3A,earnings-positive,100,69,1/20/2021
165B3A,earnings-positive,100,69,1/20/2021
16F4D8,earnings,100,50,1/20/2021
182B8C,conference-call,100,50,1/20/2021
1921DD,partnership,100,61,1/20/2021
1921DD,partnership,100,61,1/20/2021
1921DD,partnership,100,61,1/20/2021
1A9DE1,earnings,100,50,1/20/2021
1A9DE1,earnings,100,50,1/20/2021
1A9DE1,earnings,100,50,1/20/2021
1A9DE1,earnings,100,50,1/20/2021
1EBF8D,partnership,100,61,1/20/2021
1EC3E8,executive-appointment,100,54,1/20/2021
1EC3E8,executive-appointment,100,54,1/20/2021
1F08A6,conference-call,100,50,1/20/2021
1FA8F7,earnings,100,50,1/20/2021
205AD5,earnings,100,50,1/20/2021
21F9CA,earnings,100,50,1/20/2021
2.45E+15,earnings,100,50,1/20/2021
272704,earnings-positive,100,69,1/20/2021
27B191,conference-call,100,50,1/20/2021
29A4CC,dividend,100,50,1/20/2021
2CBB58,conference-call,100,50,1/20/2021
2D485F,executive-resignation,100,44,1/20/2021
2E61CC,earnings,100,50,1/20/2021
2F9304,legal-issues-defendant,100,22,1/20/2021
30A565,product-release,100,64,1/20/2021
30A565,product-release,100,64,1/20/2021
31553A,executive-appointment,100,54,1/20/2021
31A7CC,earnings,100,50,1/20/2021
31A7CC,earnings,100,50,1/20/2021
31A7CC,earnings,100,50,1/20/2021
3.30E+34,earnings-up,100,68,1/20/2021
3.30E+34,earnings-up,100,68,1/20/2021
3.30E+34,earnings-up,100,68,1/20/2021
34B411,market-entry,100,57,1/20/2021
367E1C,conference-call,100,50,1/20/2021
3A113F,acquisition-completed-acquirer,100,49,1/20/2021
3A3447,earnings,100,50,1/20/2021
3B37F7,note-sale,100,52,1/20/2021
3B37F7,conference-organizer,100,57,1/20/2021
3BB616,conference-call,100,50,1/20/2021
3CCC90,dividend,100,50,1/20/2021
3DCECC,conference-call,100,50,1/20/2021
423279,earnings-per-share-positive,100,69,1/20/2021
444CC8,conference-call,100,50,1/20/2021
44A4FC,earnings,100,50,1/20/2021
46A16E,executive-appointment,100,54,1/20/2021
4CDA2B,executive-resignation,100,44,1/20/2021
543C77,executive-appointment,100,54,1/20/2021
545272,conference-call,100,50,1/20/2021
5487B1,conference-call,100,50,1/20/2021
5675EB,dividend,100,50,1/20/2021
5675EB,earnings,100,50,1/20/2021
57F3DA,product-release,100,64,1/20/2021
589F5A,dividend,100,50,1/20/2021
5B97B2,earnings,100,50,1/20/2021
6166D1,earnings,100,50,1/20/2021
622DBE,conference-call,100,50,1/20/2021
62B20A,conference-call,100,50,1/20/2021
62EFEE,earnings,100,50,1/20/2021
67529E,earnings-positive,100,69,1/20/2021
67529E,earnings,100,50,1/20/2021
67529E,earnings,100,50,1/20/2021
67529E,earnings,100,50,1/20/2021
67529E,earnings,100,50,1/20/2021
67529E,earnings,100,50,1/20/2021
67529E,earnings,100,50,1/20/2021
67529E,earnings,100,50,1/20/2021
67529E,earnings,100,50,1/20/2021
67529E,earnings,100,50,1/20/2021
67529E,earnings,100,50,1/20/2021
67B052,clinical-trials-positive,100,87,1/20/2021
67B052,clinical-trials-positive,100,87,1/20/2021
6ABCB8,earnings,100,50,1/20/2021
6B67BD,clinical-trials,100,56,1/20/2021
6D3B7B,earnings,100,50,1/20/2021
6E705B,earnings,100,50,1/20/2021
6E705B,earnings,100,50,1/20/2021
6E705B,earnings,100,50,1/20/2021
6E705B,earnings,100,50,1/20/2021
6E705B,earnings,100,50,1/20/2021
6E705B,earnings,100,50,1/20/2021
6E705B,earnings,100,50,1/20/2021
713810,legal-issues-defendant,100,22,1/20/2021
713810,legal-issues-defendant,100,22,1/20/2021
7ACD98,earnings,100,50,1/20/2021
7B492C,conference-call,100,50,1/20/2021
7C62A3,conference-call,100,50,1/20/2021
7D97DE,conference-call,100,50,1/20/2021
7E1542,earnings,100,50,1/20/2021
7E1542,public-offering,100,43,1/20/2021
7F9984,earnings,100,50,1/20/2021
7FEEE1,business-contract,100,69,1/20/2021
80D744,dividend,100,50,1/20/2021
8275FE,earnings,100,50,1/20/2021
82C202,earnings,100,50,1/20/2021
835C86,operating-earnings,100,50,1/20/2021
845655,conference-call,100,50,1/20/2021
845655,conference-call,100,50,1/20/2021
84920B,supply-increase,100,74,1/20/2021
84AB66,dividend,100,50,1/20/2021
850779,earnings-per-share-positive,100,69,1/20/2021
850779,earnings-per-share,100,50,1/20/2021
850779,earnings-per-share,100,50,1/20/2021
850779,earnings-per-share,100,50,1/20/2021
85DA04,earnings,100,50,1/20/2021
860AB6,dividend,100,50,1/20/2021
860AB6,dividend,100,50,1/20/2021
8AC65D,conference-call,100,50,1/20/2021
8B1F37,executive-appointment,100,54,1/20/2021
902670,earnings,100,50,1/20/2021
905356,conference-call,100,50,1/20/2021
90D6A5,conference-call,100,50,1/20/2021
918D6D,executive-appointment,100,54,1/20/2021
92D3A0,earnings,100,50,1/20/2021
972356,executive-appointment,100,54,1/20/2021
980C14,conference-call,100,50,1/20/2021
9.92E+94,earnings,100,50,1/20/2021
9B4066,unit-acquisition-acquirer,100,49,1/20/2021
9B5968,dividend,100,50,1/20/2021
9B5968,dividend,100,50,1/20/2021
9D5D35,earnings,100,50,1/20/2021
9DDE1B,conference-call,100,50,1/20/2021
9E5C2C,note-sale,100,52,1/20/2021
9E98F2,earnings,100,50,1/20/2021
9F048E,earnings,100,50,1/20/2021
A16DEA,market-entry,100,57,1/20/2021
A1EAC8,executive-appointment,100,54,1/20/2021
A2CAF7,earnings,100,50,1/20/2021
A65325,dividend-up,100,81,1/20/2021
A6ABE9,earnings,100,50,1/20/2021
A79F7D,public-offering,100,43,1/20/2021
A7A0C8,public-offering,100,43,1/20/2021
A8CBDA,earnings-positive,100,69,1/20/2021
AA5C8E,earnings,100,50,1/20/2021
AABEA0,dividend,100,50,1/20/2021
AC7C4F,executive-death,100,31,1/20/2021
B13B68,conference-call,100,50,1/20/2021
B33E77,public-offering,100,43,1/20/2021
B48FC9,public-offering,100,43,1/20/2021
B7BDA3,earnings,100,50,1/20/2021
B9CD50,award,100,58,1/20/2021
BB5271,conference-call,100,50,1/20/2021
BC4876,dividend,100,50,1/20/2021
BC5680,earnings,100,50,1/20/2021
BD682F,public-offering,100,43,1/20/2021
BDD12C,earnings,100,50,1/20/2021
BE7BA4,conference-call,100,50,1/20/2021
BF5959,patent-awarded,100,72,1/20/2021
BFE02C,earnings-positive,100,69,1/20/2021
C037A8,conference-call,100,50,1/20/2021
C2F597,earnings,100,50,1/20/2021
C32A39,earnings-per-share-positive,100,69,1/20/2021
C32A39,earnings,100,50,1/20/2021
C32A39,earnings,100,50,1/20/2021
C32A39,earnings,100,50,1/20/2021
C32A39,earnings,100,50,1/20/2021
C32A39,earnings,100,50,1/20/2021
C32A39,earnings,100,50,1/20/2021
C32A39,earnings,100,50,1/20/2021
C32A39,earnings,100,50,1/20/2021
C32A39,earnings,100,50,1/20/2021
C4452A,dividend,100,50,1/20/2021
C4706C,conference-call,100,50,1/20/2021
C4C77F,legal-issues-defendant,100,22,1/20/2021
C7AE14,conference-call,100,50,1/20/2021
C97B2D,legal-issues-defendant,100,22,1/20/2021
C9B932,earnings,100,50,1/20/2021
C9F39B,earnings,100,50,1/20/2021
C9F39B,earnings,100,50,1/20/2021
C9F39B,earnings,100,50,1/20/2021
C9F39B,earnings,100,50,1/20/2021
C9F39B,earnings,100,50,1/20/2021
C9F39B,earnings,100,50,1/20/2021
C9F39B,earnings,100,50,1/20/2021
C9F39B,earnings,100,50,1/20/2021
CB7AB2,conference-call,100,50,1/20/2021
CBDB4D,patent-infringement-plaintiff,100,47,1/20/2021
CC6FF5,acquisition-acquirer,100,49,1/20/2021
CDC217,conference-participant,100,50,1/20/2021
CDE118,earnings,100,50,1/20/2021
CFF15D,dividend,100,50,1/20/2021
D1AE3B,buybacks,100,74,1/20/2021
D25249,earnings,100,50,1/20/2021
D33270,campaign-ad-retired,100,48,1/20/2021
D33D8C,earnings,100,50,1/20/2021
D78BF1,stake-acquirer,100,48,1/20/2021
D8C09D,reorganization-complete,100,74,1/20/2021
D93A25,earnings,100,50,1/20/2021
DC1405,earnings,100,50,1/20/2021
DC6AA0,earnings,100,50,1/20/2021
E0F4E5,executive-appointment,100,54,1/20/2021
E1E093,settlement,100,56,1/20/2021
E6D89E,legal-verdict-favored,100,78,1/20/2021
E96E0B,fraud-defendant,100,20,1/20/2021
E96E0B,partnership,100,61,1/20/2021
E96E0B,legal-issues-defendant,100,22,1/20/2021
E96E0B,legal-issues-defendant,100,22,1/20/2021
EAEBF3,dividend,100,50,1/20/2021
EB6965,conference-call,100,50,1/20/2021
ECDEB2,earnings-up,100,72,1/20/2021
ECE814,earnings,100,50,1/20/2021
ED2A5E,conference-call,100,50,1/20/2021
EE74E1,earnings,100,50,1/20/2021
EF5BED,dividend,100,50,1/20/2021
EF5BED,earnings-positive,100,69,1/20/2021
EF5BED,earnings,100,50,1/20/2021
EF5BED,earnings,100,50,1/20/2021
EF5BED,earnings,100,50,1/20/2021
EF5BED,earnings,100,50,1/20/2021
EF5BED,earnings,100,50,1/20/2021
EF7163,conference-call,100,50,1/20/2021
F179ED,earnings,100,50,1/20/2021
F32F88,conference-call,100,50,1/20/2021
F7FCA4,executive-appointment,100,54,1/20/2021
FAAFA2,conference-participant,100,50,1/20/2021
FACCF6,earnings,100,50,1/20/2021
FD2565,executive-appointment,100,54,1/20/2021
FDC08C,dividend,100,50,1/20/2021
00698D,dividend,100,50,1/21/2021
040DBB,facility-open,100,65,1/21/2021
55018,patent-awarded,100,72,1/21/2021
0A1D77,earnings-up,100,68,1/21/2021
0A7650,earnings,100,50,1/21/2021
0AB700,earnings,100,50,1/21/2021
0BB9E5,earnings,100,50,1/21/2021
0BC29E,executive-appointment,100,54,1/21/2021
0BD4E8,business-contract,100,69,1/21/2021
0C8D82,earnings,100,50,1/21/2021
105D00,earnings-up,100,68,1/21/2021
105D00,earnings,100,50,1/21/2021
105D00,earnings,100,50,1/21/2021
105D00,earnings,100,50,1/21/2021
105D00,earnings,100,50,1/21/2021
105D00,earnings,100,50,1/21/2021
105D00,earnings,100,50,1/21/2021
105D00,earnings,100,50,1/21/2021
105D00,earnings,100,50,1/21/2021
10AE08,executive-appointment,100,54,1/21/2021
10C19B,earnings,100,50,1/21/2021
159AE4,dividend,100,50,1/21/2021
159AE4,dividend,100,50,1/21/2021
16B183,conference-call,100,50,1/21/2021
1748B3,earnings,100,50,1/21/2021
1748B3,earnings,100,50,1/21/2021
1748B3,earnings,100,50,1/21/2021
1748B3,earnings,100,50,1/21/2021
1748B3,earnings,100,50,1/21/2021
1748B3,earnings,100,50,1/21/2021
1748B3,earnings,100,50,1/21/2021
1748B3,earnings,100,50,1/21/2021
18EC17,earnings,100,50,1/21/2021
18EC17,earnings,100,50,1/21/2021
18EC17,earnings,100,50,1/21/2021
18EC17,earnings,100,50,1/21/2021
190B91,earnings,100,50,1/21/2021
19C105,earnings,100,50,1/21/2021
1A2D9F,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1A3E1B,earnings,100,50,1/21/2021
1B9535,partnership,100,61,1/21/2021
1DDEDA,conference-call,100,50,1/21/2021
1EC3E8,executive-appointment,100,54,1/21/2021
1EC3E8,executive-appointment,100,54,1/21/2021
1FA886,supply-increase,100,74,1/21/2021
1FAF22,conference-participant,100,50,1/21/2021
228D42,partnership,100,61,1/21/2021
24CB56,earnings-positive,100,69,1/21/2021
24CB56,earnings,100,50,1/21/2021
24CB56,earnings,100,50,1/21/2021
24CB56,earnings,100,50,1/21/2021
24CB56,earnings,100,50,1/21/2021
24CB56,earnings,100,50,1/21/2021
24CB56,earnings,100,50,1/21/2021
24CB56,earnings,100,50,1/21/2021
24CB56,earnings,100,50,1/21/2021
24CB56,earnings,100,50,1/21/2021
267718,partnership,100,61,1/21/2021
26CC63,dividend,100,50,1/21/2021
26E3BA,partnership,100,61,1/21/2021
270305,merger,100,66,1/21/2021
270305,merger,100,66,1/21/2021
270B78,dividend,100,50,1/21/2021
282C18,dividend,100,60,1/21/2021
2950FF,earnings,100,50,1/21/2021
2950FF,earnings,100,50,1/21/2021
2B9DBB,earnings,100,50,1/21/2021
2DC88B,investment-investor,100,55,1/21/2021
2F9304,legal-issues-defendant,100,22,1/21/2021
2FEA66,dividend,100,50,1/21/2021
3159AA,conference-call,100,50,1/21/2021
3.30E+34,dividend,100,50,1/21/2021
343996,dividend-up,100,81,1/21/2021
343996,dividend,100,50,1/21/2021
3461CF,executive-appointment,100,54,1/21/2021
3471C0,conference-call,100,50,1/21/2021
371B0A,conference-call,100,50,1/21/2021
387375,earnings,100,50,1/21/2021
39FB23,dividend,100,50,1/21/2021
39FB23,earnings,100,50,1/21/2021
3B2311,legal-issues-defendant,100,22,1/21/2021
3B2311,merger,100,66,1/21/2021
3B37F7,conference-organizer,100,57,1/21/2021
3BB7D3,executive-appointment,100,54,1/21/2021
3BC360,dividend,100,50,1/21/2021
3C8A04,earnings,100,50,1/21/2021
3CCC90,earnings,100,50,1/21/2021
3DC887,earnings,100,50,1/21/2021
3E39A5,dividend,100,50,1/21/2021
3F6A9C,executive-appointment,100,54,1/21/2021
3FACA7,grant-recipient,100,63,1/21/2021
422A82,acquisition-interest-acquirer,100,46,1/21/2021
422CE3,sponsorship,100,57,1/21/2021
435ACE,conference-call,100,50,1/21/2021
43F4A8,legal-issues-defendant,100,22,1/21/2021
449A26,earnings-positive,100,69,1/21/2021
449A26,dividend,100,50,1/21/2021
453282,earnings-per-share-positive,100,69,1/21/2021
453282,executive-resignation,100,44,1/21/2021
47BA98,dividend,100,50,1/21/2021
487B7A,earnings,100,50,1/21/2021
487B7A,earnings,100,50,1/21/2021
487B7A,earnings,100,50,1/21/2021
487B7A,earnings,100,50,1/21/2021
487B7A,earnings,100,50,1/21/2021
487B7A,earnings,100,50,1/21/2021
487B7A,earnings,100,50,1/21/2021
4A6F00,business-contract,100,69,1/21/2021
4A6F00,award,100,58,1/21/2021
4B3555,earnings,100,50,1/21/2021
4B3555,earnings,100,50,1/21/2021
4B3555,earnings,100,50,1/21/2021
4B3555,earnings,100,50,1/21/2021
4B3555,earnings,100,50,1/21/2021
4B3555,earnings,100,50,1/21/2021
4B49CF,dividend,100,50,1/21/2021
4EEE7E,earnings,100,50,1/21/2021
4F0A80,dividend,100,50,1/21/2021
4F9487,earnings-positive,100,69,1/21/2021
4F9487,earnings-positive,100,69,1/21/2021
4F9487,earnings-positive,100,69,1/21/2021
4F9487,earnings-positive,100,69,1/21/2021
4F9487,earnings-positive,100,69,1/21/2021
4F9487,earnings-positive,100,69,1/21/2021
4F9487,earnings-positive,100,69,1/21/2021
4F9487,earnings-positive,100,69,1/21/2021
4F9487,earnings-positive,100,69,1/21/2021
4F9487,earnings,100,50,1/21/2021
4F9487,earnings,100,50,1/21/2021
4FCC78,acquisition-completed-acquirer,100,49,1/21/2021
5225A4,earnings,100,50,1/21/2021
53F491,dividend,100,50,1/21/2021
546A27,public-offering,100,43,1/21/2021
550D01,conference-call,100,50,1/21/2021
56AFF4,operating-earnings,100,50,1/21/2021
586FFD,conference-call,100,50,1/21/2021
5876DC,dividend,100,50,1/21/2021
58CA9A,product-release,100,64,1/21/2021
58CA9A,business-contract,100,69,1/21/2021
58CA9A,dividend,100,50,1/21/2021
5A0FF1,earnings,100,50,1/21/2021
5A0FF1,legal-issues-defendant,100,22,1/21/2021
5A64D5,dividend,100,50,1/21/2021
5B15E1,legal-issues-defendant,100,22,1/21/2021
5FDBD0,earnings,100,50,1/21/2021
622037,earnings,100,50,1/21/2021
66E04A,earnings,100,50,1/21/2021
68BA15,conference-call,100,50,1/21/2021
69FDFC,patent-awarded,100,72,1/21/2021
6AACDD,public-offering,100,43,1/21/2021
6CB7F9,conference-call,100,50,1/21/2021
6D3F35,conference-call,100,50,1/21/2021
713810,legal-issues-defendant,100,22,1/21/2021
722D55,executive-appointment,100,54,1/21/2021
722DE3,business-contract,100,69,1/21/2021
7262F2,earnings,100,50,1/21/2021
72DF04,dividend,100,50,1/21/2021
72FCA3,dividend,100,50,1/21/2021
73A71F,conference-call,100,50,1/21/2021
7A2A49,conference-call,100,50,1/21/2021
7A51FE,conference-call,100,50,1/21/2021
7BAAE7,dividend-up,100,81,1/21/2021
7C75FD,dividend,100,50,1/21/2021
8.10E+205,earnings,100,50,1/21/2021
82E58A,conference-call,100,50,1/21/2021
8377DB,earnings,100,50,1/21/2021
8377DB,earnings,100,50,1/21/2021
8377DB,earnings,100,50,1/21/2021
8377DB,earnings,100,50,1/21/2021
8377DB,earnings,100,50,1/21/2021
8377DB,earnings,100,50,1/21/2021
838ADD,earnings-estimate,100,50,1/21/2021
838ADD,earnings-estimate,100,50,1/21/2021
838ADD,dividend,100,50,1/21/2021
8802B4,conference-call,100,50,1/21/2021
896771,product-release,100,64,1/21/2021
8AB37F,conference-participant,100,50,1/21/2021
8D4486,earnings,100,50,1/21/2021
8D4AE6,earnings,100,50,1/21/2021
8DAAB9,earnings,100,50,1/21/2021
8DAAB9,dividend-up,100,55,1/21/2021
8DBE73,conference-call,100,50,1/21/2021
8DCBBB,note-sale,100,52,1/21/2021
8DE56F,earnings,100,50,1/21/2021
8DE56F,earnings,100,50,1/21/2021
8E8E6E,earnings,100,50,1/21/2021
8F3BCC,earnings-per-share-positive,100,69,1/21/2021
90B678,dividend,100,50,1/21/2021
92D6A5,dividend,100,50,1/21/2021
92D757,earnings,100,50,1/21/2021
94637C,earnings,100,50,1/21/2021
94983E,business-contract,100,69,1/21/2021
9548BB,earnings,100,50,1/21/2021
9.54E+32,dividend,100,50,1/21/2021
96A6CD,public-offering,100,43,1/21/2021
9.74E+08,executive-appointment,100,54,1/21/2021
97644E,business-contract,100,69,1/21/2021
97AAF6,dividend,100,50,1/21/2021
A02FB1,earnings,100,50,1/21/2021
A21649,conference-call,100,50,1/21/2021
A398B9,earnings,100,50,1/21/2021
A3AAA5,earnings,100,50,1/21/2021
A4D173,conference-call,100,50,1/21/2021
A4D173,conference-call,100,50,1/21/2021
A5628C,earnings-positive,100,69,1/21/2021
A65325,earnings-positive,100,69,1/21/2021
A868C9,conference-call,100,50,1/21/2021
A9ED24,conference-call,100,50,1/21/2021
AA247D,earnings,100,50,1/21/2021
AC3584,public-offering,100,43,1/21/2021
AD1ACF,legal-issues-defendant,100,22,1/21/2021
AF210D,earnings,100,50,1/21/2021
B290A2,conference-organizer,100,57,1/21/2021
B33E77,public-offering,100,43,1/21/2021
B5734D,earnings,100,50,1/21/2021
B5766D,earnings-per-share-positive,100,69,1/21/2021
B5766D,earnings,100,50,1/21/2021
B5766D,earnings,100,50,1/21/2021
B5766D,earnings,100,50,1/21/2021
B5766D,earnings,100,50,1/21/2021
B5766D,earnings,100,50,1/21/2021
B5766D,earnings,100,50,1/21/2021
B8A51F,business-contract,100,69,1/21/2021
B8DD94,earnings,100,50,1/21/2021
B8EF97,dividend,100,50,1/21/2021
B9764A,dividend,100,50,1/21/2021
B98EFA,executive-appointment,100,54,1/21/2021
BAD9EA,private-placement,100,56,1/21/2021
BBBB41,dividend,100,50,1/21/2021
BD682F,public-offering,100,43,1/21/2021
BEB756,dividend,100,50,1/21/2021
BEB756,earnings,100,50,1/21/2021
C564E4,regulatory-product-approval-granted,100,81,1/21/2021
C65004,earnings,100,50,1/21/2021
C66A8C,earnings,100,50,1/21/2021
C6C702,conference-call,100,50,1/21/2021
C72B8F,earnings,100,50,1/21/2021
C97B2D,acquisition-acquirer,100,49,1/21/2021
CDAA0E,earnings,100,50,1/21/2021
CDAB24,earnings,100,50,1/21/2021
CF6A5A,executive-appointment,100,54,1/21/2021
D06755,dividend,100,50,1/21/2021
D0DFE5,earnings,100,50,1/21/2021
D1AE3B,earnings,100,50,1/21/2021
D29B44,earnings,100,50,1/21/2021
D2B9E5,earnings,100,50,1/21/2021
D437C3,executive-appointment,100,54,1/21/2021
D437C3,executive-appointment,100,54,1/21/2021
D5AF19,dividend,100,50,1/21/2021
D6534D,conference-call,100,50,1/21/2021
D7918D,conference-call,100,50,1/21/2021
D8F347,earnings,100,50,1/21/2021
DBCA3F,earnings,100,50,1/21/2021
DC6AA0,legal-issues-defendant,100,22,1/21/2021
DD7A96,conference-call,100,50,1/21/2021
DE4924,conference-call,100,50,1/21/2021
E12A6E,executive-appointment,100,54,1/21/2021
E1BD05,earnings,100,50,1/21/2021
E26FC3,earnings-per-share-positive,100,69,1/21/2021
E393B0,earnings,100,50,1/21/2021
E393B0,earnings,100,50,1/21/2021
E393B0,earnings,100,50,1/21/2021
E393B0,earnings,100,50,1/21/2021
E393B0,earnings,100,50,1/21/2021
E393B0,earnings,100,50,1/21/2021
E393B0,earnings,100,50,1/21/2021
E393B0,buybacks,100,74,1/21/2021
E68C3D,earnings,100,50,1/21/2021
E70531,legal-issues-defendant,100,22,1/21/2021
E84500,conference-call,100,50,1/21/2021
E8B315,executive-appointment,100,54,1/21/2021
E8B315,earnings-positive,100,69,1/21/2021
E94704,conference-call,100,50,1/21/2021
E96E0B,fraud-defendant,100,20,1/21/2021
E96E0B,legal-issues-defendant,100,22,1/21/2021
E96E0B,fraud-defendant,100,20,1/21/2021
E96E0B,fraud-defendant,100,20,1/21/2021
E96E0B,legal-issues-defendant,100,22,1/21/2021
EB2F14,earnings,100,50,1/21/2021
F4F46F,conference-call,100,50,1/21/2021
F6581D,acquisition-completed-acquirer,100,49,1/21/2021
F6E248,earnings,100,50,1/21/2021
FA36A4,conference-call,100,50,1/21/2021
FC9A88,earnings,100,50,1/21/2021
FD39EB,dividend,100,50,1/21/2021
FD4BBE,earnings,100,50,1/21/2021
FD9526,investment-investor,100,55,1/21/2021
FDF799,public-offering,100,43,1/21/2021
03596A,conference-call,100,50,1/22/2021
71860,acquisition-acquirer,100,49,1/22/2021
099A02,earnings,100,50,1/22/2021
099A02,earnings,100,50,1/22/2021
190B91,acquisition-completed-acquirer,100,49,1/22/2021
1A6A94,conference-call,100,50,1/22/2021
1E9A6D,dividend,100,50,1/22/2021
228D42,partnership,100,61,1/22/2021
25102A,executive-appointment,100,54,1/22/2021
25D3CE,legal-issues-defendant,100,22,1/22/2021
267718,business-contract,100,69,1/22/2021
267718,business-contract,100,69,1/22/2021
267718,business-contract,100,69,1/22/2021
279916,legal-issues-defendant,100,22,1/22/2021
28DCF3,operating-earnings,100,50,1/22/2021
2A17B1,conference-call,100,50,1/22/2021
2C681C,executive-appointment,100,54,1/22/2021
2C681C,business-contract,100,69,1/22/2021
2CF9D3,public-offering,100,43,1/22/2021
2D485F,earnings,100,50,1/22/2021
2F9304,legal-issues-defendant,100,22,1/22/2021
2F98A5,dividend,100,50,1/22/2021
306623,conference-call,100,50,1/22/2021
3B20AB,earnings,100,50,1/22/2021
422A82,dividend,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4B3DC9,earnings,100,50,1/22/2021
4D203E,earnings,100,50,1/22/2021
4D8124,earnings,100,50,1/22/2021
553949,conference-call,100,50,1/22/2021
57CAAB,earnings,100,50,1/22/2021
5BFE94,dividend,100,50,1/22/2021
5D87DF,earnings,100,50,1/22/2021
5DAF89,conference-call,100,50,1/22/2021
647143,dividend,100,50,1/22/2021
69494C,conference-call,100,50,1/22/2021
6C987C,earnings-positive,100,69,1/22/2021
6F6559,dividend,100,50,1/22/2021
713810,legal-issues-defendant,100,22,1/22/2021
7255D2,conference-call,100,50,1/22/2021
73A71F,settlement,100,56,1/22/2021
73C521,earnings-positive,100,69,1/22/2021
73C521,earnings-positive,100,69,1/22/2021
73C521,earnings-positive,100,69,1/22/2021
73C521,earnings-positive,100,69,1/22/2021
73C521,earnings-positive,100,69,1/22/2021
73C521,earnings-positive,100,69,1/22/2021
7.45E+28,legal-issues-defendant,100,22,1/22/2021
76CEFB,earnings,100,50,1/22/2021
7710F3,ownership-decrease-held,100,49,1/22/2021
7710F3,ownership-decrease-held,100,49,1/22/2021
7710F3,ownership-decrease-held,100,49,1/22/2021
797C20,conference-call,100,50,1/22/2021
7B4B91,conference-call,100,50,1/22/2021
7DD8CC,dividend,100,50,1/22/2021
7E1542,public-offering,100,43,1/22/2021
859281,dividend,100,50,1/22/2021
86AA9C,conference-call,100,50,1/22/2021
89FBB1,unit-acquisition-acquirer,100,49,1/22/2021
8C1238,conference-call,100,50,1/22/2021
8D4486,earnings,100,50,1/22/2021
8DCBBB,note-sale,100,52,1/22/2021
8E4F9A,conference-participant,100,50,1/22/2021
8E8E6E,product-release,100,64,1/22/2021
900356,conference-call,100,50,1/22/2021
911ACB,earnings,100,50,1/22/2021
911ACB,earnings,100,50,1/22/2021
911ACB,earnings,100,50,1/22/2021
9.39E+69,conference-participant,100,50,1/22/2021
954A47,earnings-positive,100,69,1/22/2021
977A1E,donation,100,54,1/22/2021
977A1E,dividend,100,50,1/22/2021
977A1E,award,100,58,1/22/2021
979451,earnings,100,50,1/22/2021
97AAF6,earnings,100,50,1/22/2021
990AD0,executive-appointment,100,54,1/22/2021
9981C6,earnings,100,50,1/22/2021
9A29F4,public-offering,100,43,1/22/2021
A7A0C8,public-offering,100,43,1/22/2021
A7CCF0,conference-call,100,50,1/22/2021
AABEA0,earnings-up,100,68,1/22/2021
B0B969,earnings,100,50,1/22/2021
B48FC9,public-offering,100,43,1/22/2021
C598D7,dividend,100,50,1/22/2021
C7863D,conference-call,100,50,1/22/2021
C9739A,acquisition-completed-acquiree,100,76,1/22/2021
C97B2D,regulatory-product-approval-granted,100,81,1/22/2021
C9E107,dividend,100,50,1/22/2021
C9E107,earnings,100,50,1/22/2021
CFF15D,conference-call,100,50,1/22/2021
D04D9F,earnings,100,50,1/22/2021
D17F7E,earnings,100,50,1/22/2021
D29F43,unit-acquisition-acquiree,100,76,1/22/2021
D63B0F,conference-call,100,50,1/22/2021
D8442A,public-offering,100,43,1/22/2021
DA0CB8,dividend,100,50,1/22/2021
E22FDE,unit-acquisition-acquirer,100,49,1/22/2021
E49AA3,earnings,100,50,1/22/2021
E8D221,dividend,100,50,1/22/2021
E96E0B,legal-issues-defendant,100,22,1/22/2021
E96E0B,legal-issues-defendant,100,22,1/22/2021
EB7D6C,ipo-pricing,100,50,1/22/2021
F18844,executive-appointment,100,54,1/22/2021
F18844,executive-appointment,100,54,1/22/2021
F30508,acquisition-completed-acquirer,100,49,1/22/2021
F72E4B,legal-issues-defendant,100,22,1/22/2021
F82D37,earnings,100,50,1/22/2021
FDC08C,earnings,100,50,1/22/2021
FDC08C,earnings,100,50,1/22/2021
FDC08C,earnings,100,50,1/22/2021
FDC08C,earnings,100,50,1/22/2021
FDC08C,earnings,100,50,1/22/2021
FDC08C,earnings,100,50,1/22/2021
722DE3,partnership,100,61,1/23/2021
AD1ACF,legal-issues-defendant,100,22,1/23/2021
E96E0B,legal-issues-defendant,100,22,1/23/2021
EEA734,legal-issues-defendant,100,22,1/23/2021
1E9A6D,legal-issues-defendant,100,22,1/24/2021
384CD3,partnership,100,61,1/24/2021
5B15E1,legal-issues-defendant,100,22,1/24/2021
7.45E+28,legal-issues-defendant,100,22,1/24/2021
7CD98F,legal-issues-defendant,100,22,1/24/2021
BAD655,legal-issues-defendant,100,22,1/24/2021
E96E0B,legal-issues-defendant,100,22,1/24/2021
00067A,executive-appointment,100,54,1/25/2021
003B70,executive-appointment,100,54,1/25/2021
0157B1,facility-open,100,65,1/25/2021
01D03F,partnership,100,61,1/25/2021
20751,regulatory-product-approval-granted,100,81,1/25/2021
20751,regulatory-product-approval-granted,100,81,1/25/2021
02ACBD,partnership,100,61,1/25/2021
03D5F9,earnings,100,50,1/25/2021
04EB2F,earnings,100,50,1/25/2021
054B55,acquisition-acquirer,100,49,1/25/2021
61366,business-contract,100,69,1/25/2021
08A40F,earnings-per-share-positive,100,69,1/25/2021
08A40F,earnings-per-share-positive,100,69,1/25/2021
08A40F,earnings-per-share-positive,100,69,1/25/2021
08A40F,earnings-per-share-positive,100,69,1/25/2021
08A40F,earnings-per-share-positive,100,69,1/25/2021
08A40F,earnings-per-share-positive,100,69,1/25/2021
08A40F,earnings-per-share-positive,100,69,1/25/2021
0C136E,earnings,100,50,1/25/2021
0CC01F,earnings,100,50,1/25/2021
0F2BC9,business-contract,100,69,1/25/2021
10673F,earnings,100,50,1/25/2021
10673F,earnings,100,50,1/25/2021
10943B,conference-call,100,50,1/25/2021
14391F,stake-acquirer,100,48,1/25/2021
156A99,earnings,100,50,1/25/2021
1CF3A8,conference-call,100,50,1/25/2021
1E5786,buybacks,100,74,1/25/2021
1E5786,executive-appointment,100,54,1/25/2021
1F2B5D,earnings,100,50,1/25/2021
1F2B5D,earnings,100,50,1/25/2021
1F2B5D,earnings,100,50,1/25/2021
1F2B5D,earnings,100,50,1/25/2021
1F2B5D,earnings,100,50,1/25/2021
1F2B5D,earnings,100,50,1/25/2021
1F2B5D,earnings,100,50,1/25/2021
1F2B5D,earnings,100,50,1/25/2021
1F2B5D,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
206852,earnings,100,50,1/25/2021
20BEEA,earnings,100,50,1/25/2021
20F5E2,earnings,100,50,1/25/2021
21245F,product-release,100,64,1/25/2021
2158DF,earnings,100,50,1/25/2021
221445,executive-appointment,100,54,1/25/2021
228D42,partnership,100,61,1/25/2021
24C48B,executive-appointment,100,54,1/25/2021
2720AB,earnings-up,100,68,1/25/2021
2A1009,business-contract,100,69,1/25/2021
2C35B5,product-release,100,64,1/25/2021
2E61CC,partnership,100,61,1/25/2021
2E6514,executive-appointment,100,54,1/25/2021
2E6514,executive-appointment,100,54,1/25/2021
2EB04E,earnings,100,50,1/25/2021
2EC172,business-contract,100,69,1/25/2021
2F9304,legal-issues-defendant,100,22,1/25/2021
309922,earnings,100,50,1/25/2021
31F25C,earnings,100,50,1/25/2021
332F87,earnings-per-share-up,100,62,1/25/2021
33A0F1,executive-appointment,100,54,1/25/2021
342218,conference-call,100,50,1/25/2021
346BF2,earnings,100,50,1/25/2021
34B411,earnings,100,50,1/25/2021
372037,merger,100,66,1/25/2021
38FB49,earnings,100,50,1/25/2021
38FB49,earnings,100,50,1/25/2021
38FB49,earnings,100,50,1/25/2021
38FB49,earnings,100,50,1/25/2021
38FB49,earnings,100,50,1/25/2021
38FB49,earnings,100,50,1/25/2021
38FB49,earnings,100,50,1/25/2021
38FB49,earnings,100,50,1/25/2021
3B37F7,note-sale,100,52,1/25/2021
3BBD10,earnings,100,50,1/25/2021
3DE4D1,earnings,100,50,1/25/2021
3DE4D1,earnings,100,50,1/25/2021
3DE4D1,earnings,100,50,1/25/2021
3DE4D1,earnings,100,50,1/25/2021
3DE4D1,earnings,100,50,1/25/2021
3F6A9C,conference-call,100,50,1/25/2021
416291,conference-call,100,50,1/25/2021
43A060,product-release,100,64,1/25/2021
442769,conference-call,100,50,1/25/2021
4595EF,conference-call,100,50,1/25/2021
4.91E+58,executive-appointment,100,54,1/25/2021
4A2457,business-contract,100,69,1/25/2021
4B3676,fundraising,100,64,1/25/2021
4B49CF,earnings,100,50,1/25/2021
4B6EF9,dividend,100,50,1/25/2021
4B6EF9,earnings,100,50,1/25/2021
4CDA2B,clinical-trials-start,100,64,1/25/2021
4D8313,revenues,100,50,1/25/2021
4D8313,revenues,100,50,1/25/2021
4D8313,revenues,100,50,1/25/2021
4D8313,revenues,100,50,1/25/2021
4D8E5E,earnings-up,100,68,1/25/2021
4EC4C1,executive-appointment,100,54,1/25/2021
5088A5,earnings,100,50,1/25/2021
51B442,earnings,100,50,1/25/2021
520632,partnership,100,61,1/25/2021
5.43E+08,clinical-trials,100,56,1/25/2021
553949,executive-appointment,100,54,1/25/2021
55438C,product-release,100,64,1/25/2021
55C9B5,conference-participant,100,50,1/25/2021
56EFC7,campaign-ad-release,100,59,1/25/2021
57634F,earnings,100,50,1/25/2021
58CA9A,product-release,100,64,1/25/2021
596116,executive-appointment,100,54,1/25/2021
5A9F54,earnings,100,50,1/25/2021
5B3415,conference-call,100,50,1/25/2021
5B7739,earnings,100,50,1/25/2021
5B7739,note-sale,100,52,1/25/2021
5DA8B3,earnings,100,50,1/25/2021
5E1DF3,public-offering,100,43,1/25/2021
5E1DF3,public-offering,100,43,1/25/2021
5FF95F,earnings,100,50,1/25/2021
647143,earnings,100,50,1/25/2021
647143,earnings,100,50,1/25/2021
647143,earnings,100,50,1/25/2021
647143,earnings,100,50,1/25/2021
647143,earnings,100,50,1/25/2021
647143,earnings,100,50,1/25/2021
647143,earnings,100,50,1/25/2021
657097,unit-acquisition-acquirer,100,49,1/25/2021
65CF8E,dividend,100,50,1/25/2021
65CF8E,dividend,100,50,1/25/2021
665D7D,regulatory-product-approval-granted,100,81,1/25/2021
665D7D,regulatory-product-approval-granted,100,81,1/25/2021
665D7D,regulatory-product-approval-granted,100,81,1/25/2021
6A961B,conference-call,100,50,1/25/2021
6B0E45,conference-call,100,50,1/25/2021
6B236C,dividend,100,50,1/25/2021
6B5379,earnings,100,50,1/25/2021
6D9ECA,note-sale,100,52,1/25/2021
6DBBBC,executive-appointment,100,54,1/25/2021
6E705B,product-release,100,64,1/25/2021
70B3D6,public-offering,100,43,1/25/2021
722D55,earnings,100,50,1/25/2021
726EEA,earnings,100,50,1/25/2021
728737,earnings,100,50,1/25/2021
72FCA3,executive-appointment,100,54,1/25/2021
73C521,executive-appointment,100,54,1/25/2021
741937,earnings,100,50,1/25/2021
7.45E+28,legal-issues-defendant,100,22,1/25/2021
7.45E+28,legal-issues-defendant,100,22,1/25/2021
76959C,public-offering,100,43,1/25/2021
76D79A,conference-call,100,50,1/25/2021
7712CB,earnings,100,50,1/25/2021
7B6EB1,earnings,100,50,1/25/2021
7BAAE7,executive-appointment,100,54,1/25/2021
7E3390,earnings,100,50,1/25/2021
819492,patent-awarded,100,72,1/25/2021
84A6B9,earnings,100,50,1/25/2021
84A6B9,earnings,100,50,1/25/2021
84A6B9,earnings,100,50,1/25/2021
84A6B9,earnings,100,50,1/25/2021
84A6B9,earnings,100,50,1/25/2021
84A6B9,earnings,100,50,1/25/2021
84A6B9,earnings,100,50,1/25/2021
84A6B9,executive-appointment,100,54,1/25/2021
859281,earnings,100,50,1/25/2021
85AD00,earnings,100,50,1/25/2021
85CDC9,clinical-trials-start,100,64,1/25/2021
873DB9,dividend,100,50,1/25/2021
8A8E41,earnings,100,50,1/25/2021
8AB37F,revenue-guidance-up,100,91,1/25/2021
8C5519,dividend,100,50,1/25/2021
8E8E6E,partnership,100,61,1/25/2021
901327,earnings,100,50,1/25/2021
907ED2,earnings-up,100,68,1/25/2021
907ED2,earnings,100,50,1/25/2021
907ED2,earnings,100,50,1/25/2021
907ED2,earnings,100,50,1/25/2021
907ED2,earnings,100,50,1/25/2021
907ED2,earnings,100,50,1/25/2021
907ED2,earnings,100,50,1/25/2021
93633B,earnings,100,50,1/25/2021
93633B,earnings,100,50,1/25/2021
93633B,earnings,100,50,1/25/2021
93633B,earnings,100,50,1/25/2021
93633B,earnings,100,50,1/25/2021
93633B,earnings,100,50,1/25/2021
944B2E,note-sale,100,52,1/25/2021
96A6CD,public-offering,100,43,1/25/2021
9A02C4,campaign-ad-release,100,59,1/25/2021
9A29F4,conference-call,100,50,1/25/2021
9C8BC3,conference-call,100,50,1/25/2021
9CA619,dividend,100,50,1/25/2021
9D5FA4,earnings,100,50,1/25/2021
9D6A24,cyber-attacks,100,26,1/25/2021
9EBAFA,dividend,100,50,1/25/2021
A3800A,fundraising,100,64,1/25/2021
A3BFAA,earnings,100,50,1/25/2021
A6828A,drilling,100,68,1/25/2021
A806FA,conference-call,100,50,1/25/2021
AAEE21,conference-call,100,50,1/25/2021
AC3584,public-offering,100,43,1/25/2021
ACDF88,product-release,100,64,1/25/2021
AED61E,conference-call,100,50,1/25/2021
AEFC90,clinical-trials-filed,100,60,1/25/2021
B2206F,partnership,100,61,1/25/2021
B2F431,earnings,100,50,1/25/2021
B33E77,public-offering,100,43,1/25/2021
B46E12,dividend,100,50,1/25/2021
B604DF,earnings,100,50,1/25/2021
B72BE9,revenues,100,50,1/25/2021
B72BE9,revenues,100,50,1/25/2021
B72BE9,revenues,100,50,1/25/2021
B9CD50,earnings,100,50,1/25/2021
BCC13E,executive-appointment,100,54,1/25/2021
C16A8F,conference-call,100,50,1/25/2021
C45CE7,unit-acquisition-acquirer,100,49,1/25/2021
C54140,note-sale,100,52,1/25/2021
C54140,note-sale,100,52,1/25/2021
C598D7,revenue-up,100,61,1/25/2021
C598D7,revenues,100,50,1/25/2021
C598D7,revenues,100,50,1/25/2021
C598D7,revenues,100,50,1/25/2021
C83B88,product-release,100,64,1/25/2021
CD2A4D,executive-appointment,100,54,1/25/2021
CE1002,dividend,100,50,1/25/2021
CEC5B9,partnership,100,61,1/25/2021
CEC5B9,partnership,100,61,1/25/2021
D08D2C,conference-call,100,50,1/25/2021
D0DFE5,earnings,100,50,1/25/2021
D17C1B,partnership,100,61,1/25/2021
D501DC,index-listing,100,76,1/25/2021
D54E62,business-contract,100,69,1/25/2021
D77F7E,earnings,100,50,1/25/2021
D8ECA1,partnership,100,61,1/25/2021
D90F43,product-release,100,64,1/25/2021
DAC66A,earnings,100,50,1/25/2021
DB88A1,partnership,100,61,1/25/2021
DF46C5,dividend,100,50,1/25/2021
DF46C5,earnings,100,50,1/25/2021
DF46C5,earnings,100,50,1/25/2021
DF46C5,earnings,100,50,1/25/2021
DF46C5,earnings,100,50,1/25/2021
DF46C5,earnings,100,50,1/25/2021
DF46C5,earnings,100,50,1/25/2021
E0D3BA,index-listing,100,76,1/25/2021
E10D31,conference-call,100,50,1/25/2021
E114F4,conference-call,100,50,1/25/2021
E11C41,business-contract,100,69,1/25/2021
E124EB,product-release,100,64,1/25/2021
E1F30A,earnings,100,50,1/25/2021
E35610,conference-call,100,50,1/25/2021
E393B0,executive-appointment,100,54,1/25/2021
E6D89E,earnings,100,50,1/25/2021
E70531,earnings,100,50,1/25/2021
E87676,dividend,100,50,1/25/2021
E96E0B,fraud-defendant,100,20,1/25/2021
E99180,acquisition-acquirer,100,49,1/25/2021
EA62FC,dividend,100,50,1/25/2021
EC99D0,business-contract,100,69,1/25/2021
ED5171,dividend,100,50,1/25/2021
ED5171,executive-resignation,100,44,1/25/2021
EEA734,legal-issues-defendant,100,22,1/25/2021
EEA734,legal-issues-defendant,100,22,1/25/2021
EEA734,legal-issues-defendant,100,22,1/25/2021
EEA734,legal-issues-defendant,100,22,1/25/2021
F04E05,dividend,100,50,1/25/2021
F1529C,product-release,100,64,1/25/2021
F179ED,partnership,100,61,1/25/2021
F24FF0,earnings,100,50,1/25/2021
F3FCC3,dividend,100,50,1/25/2021
F5349B,earnings,100,50,1/25/2021
F5C78B,earnings,100,50,1/25/2021
F6FA6A,executive-appointment,100,54,1/25/2021
F702CA,product-price-raise,100,57,1/25/2021
F702CA,partnership,100,61,1/25/2021
F748C7,donation,100,54,1/25/2021
F95726,earnings,100,50,1/25/2021
FA40E2,acquisition-completed-acquirer,100,49,1/25/2021
FC1F9D,executive-appointment,100,54,1/25/2021
FC9A88,dividend-up,100,70,1/25/2021
FD0CA4,conference-call,100,50,1/25/2021
FD2565,clinical-trials,100,56,1/25/2021
FDF28E,note-sale,100,52,1/25/2021
FDF799,public-offering,100,43,1/25/2021
FE609F,facility-open,100,65,1/25/2021
FF6644,unit-acquisition-acquiree,100,76,1/25/2021
FF6644,asset-sale,100,62,1/25/2021
FFE543,earnings,100,50,1/25/2021
00D6B5,conference-call,100,50,1/26/2021
0157B1,business-contract,100,69,1/26/2021
0157B1,facility-upgrade,100,65,1/26/2021
0157B1,partnership,100,61,1/26/2021
03B8CF,earnings,100,50,1/26/2021
55018,earnings-positive,100,69,1/26/2021
75172,conference-call,100,50,1/26/2021
07C907,earnings,100,50,1/26/2021
0A748B,earnings,100,50,1/26/2021
0C6861,product-release,100,64,1/26/2021
0E439E,earnings-up,100,68,1/26/2021
0E439E,earnings-up,100,68,1/26/2021
0E439E,earnings-up,100,68,1/26/2021
0E439E,earnings-up,100,68,1/26/2021
0E499E,stake-acquirer,100,48,1/26/2021
102727,earnings,100,50,1/26/2021
10AE08,product-release,100,64,1/26/2021
12DE76,conference-call,100,50,1/26/2021
149301,conference-call,100,50,1/26/2021
159AE4,dividend,100,50,1/26/2021
168A5D,product-release,100,64,1/26/2021
16C544,earnings,100,50,1/26/2021
1A3E1B,dividend,100,50,1/26/2021
1AB808,executive-appointment,100,54,1/26/2021
1D1B07,executive-appointment,100,54,1/26/2021
1DA44F,dividend-up,100,81,1/26/2021
1E1125,conference-organizer,100,57,1/26/2021
1E9A6D,earnings,100,50,1/26/2021
1EBF8D,clinical-trials,100,56,1/26/2021
1EBF8D,dividend,100,50,1/26/2021
1F19C8,credit-extension-provider,100,57,1/26/2021
1FE3CB,dividend,100,50,1/26/2021
1FE3CB,earnings,100,50,1/26/2021
20BEEA,conference-call,100,50,1/26/2021
214051,earnings,100,50,1/26/2021
225CA2,earnings,100,50,1/26/2021
228D42,business-contract,100,69,1/26/2021
228D42,business-contract,100,69,1/26/2021
228D42,executive-appointment,100,54,1/26/2021
228D42,partnership,100,61,1/26/2021
22C58E,earnings,100,50,1/26/2021
24C48B,business-contract,100,69,1/26/2021
2667B6,earnings,100,50,1/26/2021
267718,clinical-trials-positive,100,87,1/26/2021
26F31D,earnings,100,50,1/26/2021
270305,dividend,100,50,1/26/2021
270305,earnings,100,50,1/26/2021
270305,earnings,100,50,1/26/2021
270305,earnings,100,50,1/26/2021
270305,earnings,100,50,1/26/2021
270305,earnings,100,50,1/26/2021
28AC4E,earnings,100,50,1/26/2021
292388,executive-appointment,100,54,1/26/2021
29A4CC,earnings,100,50,1/26/2021
2ABF77,executive-appointment,100,54,1/26/2021
2B7A40,earnings-per-share-positive,100,69,1/26/2021
2B7A40,earnings-positive,100,69,1/26/2021
2B7A40,earnings-positive,100,69,1/26/2021
2B7A40,earnings-positive,100,69,1/26/2021
2B7A40,earnings-positive,100,69,1/26/2021
2C3348,partnership,100,61,1/26/2021
2D2D43,earnings,100,50,1/26/2021
2D981A,public-offering,100,43,1/26/2021
2E2E6E,earnings-up,100,68,1/26/2021
2EBA55,earnings,100,50,1/26/2021
32DCB3,partnership,100,61,1/26/2021
370C50,business-contract,100,69,1/26/2021
371C01,conference-call,100,50,1/26/2021
372037,legal-issues-defendant,100,22,1/26/2021
37E18B,conference-call,100,50,1/26/2021
396D7C,public-offering,100,43,1/26/2021
39BFF6,earnings,100,50,1/26/2021
39BFF6,earnings,100,50,1/26/2021
39BFF6,earnings,100,50,1/26/2021
3BCF24,earnings,100,50,1/26/2021
3CBA2A,earnings,100,50,1/26/2021
3CBA2A,earnings,100,50,1/26/2021
3CBA2A,earnings,100,50,1/26/2021
3CBA2A,earnings,100,50,1/26/2021
3CBA2A,earnings,100,50,1/26/2021
3CBA2A,earnings,100,50,1/26/2021
3D9999,buybacks,100,74,1/26/2021
407878,public-offering,100,43,1/26/2021
416C55,earnings,100,50,1/26/2021
41785E,earnings,100,50,1/26/2021
41EC04,executive-appointment,100,54,1/26/2021
420168,earnings,100,50,1/26/2021
42AABD,conference-call,100,50,1/26/2021
43A060,partnership,100,61,1/26/2021
447FC6,executive-appointment,100,54,1/26/2021
449447,partnership,100,61,1/26/2021
449447,partnership,100,61,1/26/2021
467F2C,conference-call,100,50,1/26/2021
485445,earnings,100,50,1/26/2021
490D4B,conference-call,100,50,1/26/2021
49BBBC,product-release,100,64,1/26/2021
4A6F00,partnership,100,61,1/26/2021
4B3DC9,dividend,100,50,1/26/2021
4BEB48,earnings,100,50,1/26/2021
4BEB48,award,100,58,1/26/2021
4BF3D6,executive-appointment,100,54,1/26/2021
4C2F17,public-offering,100,43,1/26/2021
4C37C5,revenues,100,50,1/26/2021
4C37C5,revenues,100,50,1/26/2021
4C37C5,revenues,100,50,1/26/2021
4E7C1F,earnings,100,50,1/26/2021
4E7C1F,earnings,100,50,1/26/2021
4E7C1F,earnings,100,50,1/26/2021
4F9926,product-release,100,64,1/26/2021
4F9926,product-release,100,64,1/26/2021
520632,regulatory-product-approval-granted,100,81,1/26/2021
545272,public-offering,100,43,1/26/2021
546A27,public-offering,100,43,1/26/2021
5480A7,earnings,100,50,1/26/2021
54F271,earnings,100,50,1/26/2021
567F3D,dividend,100,50,1/26/2021
56AFF4,dividend,100,50,1/26/2021
57B174,conference-call,100,50,1/26/2021
57CAAB,regulatory-product-approval-granted,100,81,1/26/2021
583A75,earnings,100,50,1/26/2021
59C539,dividend,100,50,1/26/2021
5B6C11,earnings,100,50,1/26/2021
5B7739,note-sale,100,52,1/26/2021
5D63F1,earnings,100,50,1/26/2021
5FE4B6,earnings,100,50,1/26/2021
60EA12,acquisition-acquirer,100,49,1/26/2021
619882,conference-participant,100,50,1/26/2021
673C9A,conference-call,100,50,1/26/2021
67529E,executive-appointment,100,54,1/26/2021
6810DE,partnership,100,61,1/26/2021
6844D2,executive-resignation,100,44,1/26/2021
69345C,earnings,100,50,1/26/2021
6A024C,executive-appointment,100,54,1/26/2021
6BC6F9,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6C4D2F,earnings,100,50,1/26/2021
6D4636,conference-call,100,50,1/26/2021
6D9ECA,merger-completed,100,66,1/26/2021
6F6559,award,100,58,1/26/2021
7255D2,earnings-above-expectations,100,88,1/26/2021
7255D2,public-offering,100,43,1/26/2021
726DDF,conference-call,100,50,1/26/2021
75F665,dividend,100,50,1/26/2021
75F665,earnings,100,50,1/26/2021
75F665,executive-appointment,100,54,1/26/2021
762A3E,executive-appointment,100,54,1/26/2021
762A3E,dividend,100,50,1/26/2021
765913,earnings,100,50,1/26/2021
773A17,revenues,100,50,1/26/2021
7.83E+79,dividend-up,100,81,1/26/2021
7.83E+79,dividend-up,100,81,1/26/2021
7.83E+79,dividend-up,100,81,1/26/2021
7.83E+79,dividend-up,100,81,1/26/2021
7.83E+79,dividend-up,100,81,1/26/2021
7.83E+79,dividend-up,100,81,1/26/2021
7.83E+79,dividend-up,100,81,1/26/2021
7.83E+79,dividend-up,100,81,1/26/2021
7B1156,earnings,100,50,1/26/2021
7E1542,public-offering,100,43,1/26/2021
7E3F8F,earnings,100,50,1/26/2021
81F4BE,earnings,100,50,1/26/2021
830BDB,conference-call,100,50,1/26/2021
8377DB,earnings,100,50,1/26/2021
8377DB,earnings,100,50,1/26/2021
873DB9,executive-appointment,100,54,1/26/2021
8C5519,earnings,100,50,1/26/2021
8D4486,dividend,100,50,1/26/2021
8D4486,dividend,100,50,1/26/2021
8F3231,legal-issues-defendant,100,22,1/26/2021
92D757,executive-appointment,100,54,1/26/2021
9368BE,conference-call,100,50,1/26/2021
943239,earnings,100,50,1/26/2021
94C0B5,partnership,100,61,1/26/2021
965360,earnings,100,50,1/26/2021
966ACE,patient-enrollment-start,100,58,1/26/2021
968B00,earnings,100,50,1/26/2021
96F126,earnings,100,50,1/26/2021
98CAED,earnings,100,50,1/26/2021
997348,earnings,100,50,1/26/2021
997348,earnings,100,50,1/26/2021
9994DA,partnership,100,61,1/26/2021
99ACAD,earnings,100,50,1/26/2021
9A29F4,public-offering,100,43,1/26/2021
9C5BA5,earnings,100,50,1/26/2021
9CE4C7,executive-appointment,100,54,1/26/2021
9CE4C7,dividend,100,50,1/26/2021
9D4EC7,conference-call,100,50,1/26/2021
9D4EC7,conference-call,100,50,1/26/2021
9EA947,award,100,58,1/26/2021
9F62D1,earnings-per-share-down,100,23,1/26/2021
9FF5F1,executive-appointment,100,54,1/26/2021
A05C43,earnings,100,50,1/26/2021
A1A317,earnings,100,50,1/26/2021
A1A317,earnings,100,50,1/26/2021
A1A317,earnings,100,50,1/26/2021
A1A317,earnings,100,50,1/26/2021
A1A317,earnings,100,50,1/26/2021
A60354,conference-call,100,50,1/26/2021
A6213D,executive-appointment,100,54,1/26/2021
A6828A,drilling,100,68,1/26/2021
A6828A,earnings,100,50,1/26/2021
A871B0,merger,100,66,1/26/2021
AB7726,earnings,100,50,1/26/2021
AC7C4F,government-contract,100,69,1/26/2021
AE4125,product-release,100,64,1/26/2021
AEF2C3,note-sale,100,52,1/26/2021
AEF2C3,note-sale,100,52,1/26/2021
AFDF2E,revenues,100,50,1/26/2021
AFF43F,earnings,100,50,1/26/2021
AFF43F,dividend,100,50,1/26/2021
B2D799,business-contract,100,69,1/26/2021
B4528F,conference-call,100,50,1/26/2021
B5766D,dividend,100,50,1/26/2021
B66928,executive-appointment,100,54,1/26/2021
B840EF,partnership,100,61,1/26/2021
B8F71F,earnings,100,50,1/26/2021
BB0587,conference-call,100,50,1/26/2021
BB127B,partnership,100,61,1/26/2021
BB5271,award,100,58,1/26/2021
BBBB41,executive-appointment,100,54,1/26/2021
BCE9DA,earnings,100,50,1/26/2021
BCE9DA,earnings,100,50,1/26/2021
BD15E8,earnings,100,50,1/26/2021
BD682F,earnings,100,50,1/26/2021
BDE867,executive-appointment,100,54,1/26/2021
BE14CF,earnings,100,50,1/26/2021
BFEA04,conference-call,100,50,1/26/2021
C0030A,partnership,100,61,1/26/2021
C0BA36,conference-call,100,50,1/26/2021
C27E19,earnings,100,50,1/26/2021
C356AC,partnership,100,61,1/26/2021
C45C1F,legal-issues-defendant,100,22,1/26/2021
C659EB,earnings,100,50,1/26/2021
C659EB,earnings,100,50,1/26/2021
C659EB,earnings,100,50,1/26/2021
C659EB,earnings,100,50,1/26/2021
C83B88,award,100,58,1/26/2021
C83B88,award,100,58,1/26/2021
C97B2D,legal-issues-defendant,100,22,1/26/2021
C99CC8,conference-call,100,50,1/26/2021
CBA33B,dividend,100,50,1/26/2021
CE2791,earnings,100,50,1/26/2021
CF6A5A,earnings,100,50,1/26/2021
CFE5BE,earnings,100,50,1/26/2021
CFE5BE,dividend,100,50,1/26/2021
CFF15D,business-contract,100,69,1/26/2021
CFF15D,business-contract,100,69,1/26/2021
CFF15D,business-contract,100,69,1/26/2021
D25249,acquisition-acquiree,100,76,1/26/2021
D25249,note-sale,100,52,1/26/2021
D60BB2,partnership,100,61,1/26/2021
D6EAA3,product-release,100,64,1/26/2021
D88EF3,award,100,58,1/26/2021
D9CAF0,earnings,100,50,1/26/2021
DA9443,public-offering,100,43,1/26/2021
DB7FA7,earnings-positive,100,69,1/26/2021
DC2F77,dividend,100,50,1/26/2021
DD1BA1,revenue-volume-up,100,69,1/26/2021
DD1BA1,earnings,100,50,1/26/2021
DDC415,earnings,100,50,1/26/2021
DF11D9,earnings,100,50,1/26/2021
DF42A0,conference-call,100,50,1/26/2021
E00373,earnings,100,50,1/26/2021
E21871,dividend,100,50,1/26/2021
E3E68E,partnership,100,61,1/26/2021
E3E68E,partnership,100,61,1/26/2021
E82A2D,name-change,100,49,1/26/2021
E8846E,dividend,100,50,1/26/2021
E90C84,conference-call,100,50,1/26/2021
E96E0B,legal-issues-defendant,100,22,1/26/2021
E96E0B,fraud-defendant,100,20,1/26/2021
E9E6FD,earnings,100,50,1/26/2021
E9FF33,earnings,100,50,1/26/2021
EB43F4,executive-appointment,100,54,1/26/2021
ED9C04,award,100,58,1/26/2021
EDF5CA,earnings,100,50,1/26/2021
EDF5CA,earnings,100,50,1/26/2021
EDF5CA,earnings,100,50,1/26/2021
EDF5CA,earnings,100,50,1/26/2021
EDF5CA,earnings,100,50,1/26/2021
EDF5CA,earnings,100,50,1/26/2021
EDF5CA,earnings,100,50,1/26/2021
EDF5CA,earnings,100,50,1/26/2021
EDF5CA,earnings,100,50,1/26/2021
EE6F1C,business-contract,100,69,1/26/2021
EEA734,legal-issues-defendant,100,22,1/26/2021
EF76C8,dividend,100,50,1/26/2021
F0A9DE,earnings,100,50,1/26/2021
F2E253,dividend,100,50,1/26/2021
F3016C,earnings,100,50,1/26/2021
F4F46F,partnership,100,61,1/26/2021
F5349B,executive-appointment,100,54,1/26/2021
F57F6F,earnings,100,50,1/26/2021
F6DCE4,partnership,100,61,1/26/2021
F6FA6A,earnings,100,50,1/26/2021
F92DBC,asset-sale,100,62,1/26/2021
F92DBC,asset-sale,100,62,1/26/2021
FACF19,executive-appointment,100,54,1/26/2021
FAEABE,dividend-up,100,54,1/26/2021
FC01C0,conference-call,100,50,1/26/2021
FC9A88,buybacks,100,74,1/26/2021
FDF28E,note-sale,100,52,1/26/2021
FE7A63,earnings,100,50,1/26/2021
FE7A63,earnings,100,50,1/26/2021
FE7A63,earnings,100,50,1/26/2021
FE7A63,earnings,100,50,1/26/2021
FE7A63,earnings,100,50,1/26/2021
FE7A63,earnings,100,50,1/26/2021
FE7A63,earnings,100,50,1/26/2021
FE7A63,earnings,100,50,1/26/2021
FF6644,partnership,100,61,1/26/2021
FFA9B9,executive-appointment,100,54,1/26/2021
003B70,dividend,100,50,1/27/2021
0142B5,dividend,100,50,1/27/2021
03F5A4,earnings-positive,100,69,1/27/2021
03FAA6,partnership,100,61,1/27/2021
03FB17,product-release,100,64,1/27/2021
48781,executive-appointment,100,54,1/27/2021
58828,earnings-per-share-up,100,64,1/27/2021
58828,dividend,100,50,1/27/2021
0624BE,executive-appointment,100,54,1/27/2021
081AB9,earnings,100,50,1/27/2021
0A59F8,executive-appointment,100,54,1/27/2021
0B4D10,earnings,100,50,1/27/2021
0B57D7,earnings,100,50,1/27/2021
0E6027,earnings-positive,100,69,1/27/2021
0E6027,earnings,100,50,1/27/2021
0E6027,earnings,100,50,1/27/2021
0F91FC,conference-call,100,50,1/27/2021
0FDE97,executive-appointment,100,54,1/27/2021
1216D1,earnings-up,100,68,1/27/2021
12731D,acquisition-interest-acquirer,100,46,1/27/2021
12731D,acquisition-interest-acquirer,100,46,1/27/2021
1279ED,conference-call,100,50,1/27/2021
129DC8,conference-call,100,50,1/27/2021
12E454,earnings,100,50,1/27/2021
139303,conference-call,100,50,1/27/2021
16F4D8,executive-appointment,100,54,1/27/2021
17EDA5,executive-appointment,100,54,1/27/2021
17EDA5,conference-call,100,50,1/27/2021
1866B2,conference-call,100,50,1/27/2021
1BC12C,partnership,100,61,1/27/2021
1BC12C,conference-call,100,50,1/27/2021
1BDB2A,earnings,100,50,1/27/2021
1C2593,partnership,100,61,1/27/2021
1C599A,earnings,100,50,1/27/2021
1CD4B5,clinical-trials,100,56,1/27/2021
1D943E,earnings,100,50,1/27/2021
1DA44F,conference-call,100,50,1/27/2021
1E5786,dividend,100,50,1/27/2021
1E8A99,earnings,100,50,1/27/2021
2031CE,earnings-up,100,68,1/27/2021
2031CE,earnings,100,50,1/27/2021
2031CE,earnings,100,50,1/27/2021
2031CE,earnings,100,50,1/27/2021
2031CE,earnings,100,50,1/27/2021
2031CE,earnings,100,50,1/27/2021
2031CE,earnings,100,50,1/27/2021
2031CE,earnings,100,50,1/27/2021
2031CE,merger,100,66,1/27/2021
2262BD,earnings,100,50,1/27/2021
228D42,partnership,100,61,1/27/2021
228D42,partnership,100,61,1/27/2021
228D42,partnership,100,61,1/27/2021
241252,clinical-trials,100,56,1/27/2021
2.45E+15,earnings,100,50,1/27/2021
249674,executive-appointment,100,54,1/27/2021
249B39,earnings-positive,100,69,1/27/2021
25102A,dividend,100,50,1/27/2021
25102A,earnings,100,50,1/27/2021
251988,earnings,100,50,1/27/2021
251988,earnings,100,50,1/27/2021
251988,earnings,100,50,1/27/2021
251988,earnings,100,50,1/27/2021
251988,earnings,100,50,1/27/2021
251988,earnings,100,50,1/27/2021
251988,earnings,100,50,1/27/2021
25DD05,dividend,100,50,1/27/2021
264EB3,earnings,100,50,1/27/2021
264EB3,earnings,100,50,1/27/2021
267718,partnership,100,61,1/27/2021
26D8ED,conference-call,100,50,1/27/2021
26F99F,clinical-trials,100,56,1/27/2021
275300,earnings,100,50,1/27/2021
275300,partnership,100,61,1/27/2021
279916,partnership,100,61,1/27/2021
27BFA1,earnings-per-share-positive,100,69,1/27/2021
27BFA1,earnings-per-share,100,50,1/27/2021
27BFA1,earnings-per-share,100,50,1/27/2021
27BFA1,earnings-per-share,100,50,1/27/2021
27BFA1,earnings-per-share,100,50,1/27/2021
27BFA1,earnings-per-share,100,50,1/27/2021
27BFA1,earnings-per-share,100,50,1/27/2021
27BFA1,earnings-per-share,100,50,1/27/2021
27BFA1,earnings-per-share,100,50,1/27/2021
28DCF3,earnings,100,50,1/27/2021
28F905,earnings,100,50,1/27/2021
2A6DBE,legal-issues-defendant,100,22,1/27/2021
2A9C0A,earnings-positive,100,69,1/27/2021
2A9C0A,earnings,100,50,1/27/2021
2A9C0A,earnings,100,50,1/27/2021
2A9C0A,earnings,100,50,1/27/2021
2A9C0A,earnings,100,50,1/27/2021
2A9C0A,earnings,100,50,1/27/2021
2A9C0A,earnings,100,50,1/27/2021
2D643C,earnings,100,50,1/27/2021
2D643C,dividend-up,100,81,1/27/2021
2DB344,earnings,100,50,1/27/2021
2E0496,earnings,100,50,1/27/2021
2E0496,earnings,100,50,1/27/2021
2E6514,earnings,100,50,1/27/2021
2E6514,earnings,100,50,1/27/2021
2E6514,earnings,100,50,1/27/2021
2E6514,earnings,100,50,1/27/2021
2E6514,earnings,100,50,1/27/2021
2E6514,earnings,100,50,1/27/2021
2E6514,earnings,100,50,1/27/2021
2E6514,earnings,100,50,1/27/2021
2E89AE,earnings,100,50,1/27/2021
2F1299,partnership,100,61,1/27/2021
2F9304,legal-issues-defendant,100,22,1/27/2021
31643A,product-release,100,64,1/27/2021
31666F,earnings,100,50,1/27/2021
32CB22,earnings,100,50,1/27/2021
34B411,dividend,100,50,1/27/2021
35AE32,earnings,100,50,1/27/2021
366A08,conference-call,100,50,1/27/2021
373B06,executive-appointment,100,54,1/27/2021
3.73E+87,earnings,100,50,1/27/2021
3A4BDB,earnings-positive,100,69,1/27/2021
3A4BDB,earnings-positive,100,69,1/27/2021
3A4BDB,earnings-positive,100,69,1/27/2021
3A4BDB,earnings-positive,100,69,1/27/2021
3A4BDB,earnings-positive,100,69,1/27/2021
3A4BDB,earnings-positive,100,69,1/27/2021
3A4BDB,earnings-positive,100,69,1/27/2021
407878,public-offering,100,43,1/27/2021
41EC04,conference-call,100,50,1/27/2021
427F32,executive-appointment,100,54,1/27/2021
435ACE,dividend,100,50,1/27/2021
43A060,partnership,100,61,1/27/2021
43A060,partnership,100,61,1/27/2021
447FC6,earnings-up,100,68,1/27/2021
45444E,conference-call,100,50,1/27/2021
460C93,earnings-up,100,68,1/27/2021
460C93,earnings,100,50,1/27/2021
460C93,earnings,100,50,1/27/2021
460C93,earnings,100,50,1/27/2021
460C93,earnings,100,50,1/27/2021
460C93,earnings,100,50,1/27/2021
47752F,earnings,100,50,1/27/2021
47BA98,earnings,100,50,1/27/2021
4806CE,dividend,100,50,1/27/2021
4B3676,product-release,100,64,1/27/2021
4C2F17,public-offering,100,43,1/27/2021
4C37C5,dividend,100,50,1/27/2021
4C37C5,executive-appointment,100,54,1/27/2021
4D971D,dividend,100,50,1/27/2021
4D971D,earnings,100,50,1/27/2021
4D971D,earnings,100,50,1/27/2021
4D971D,earnings,100,50,1/27/2021
4D971D,earnings,100,50,1/27/2021
4D971D,earnings,100,50,1/27/2021
4D971D,earnings,100,50,1/27/2021
4D971D,earnings,100,50,1/27/2021
4F9926,business-contract,100,69,1/27/2021
4FB770,conference-call,100,50,1/27/2021
50070E,conference-organizer,100,57,1/27/2021
513A86,earnings,100,50,1/27/2021
520632,earnings,100,50,1/27/2021
520632,earnings,100,50,1/27/2021
520632,earnings,100,50,1/27/2021
520632,earnings,100,50,1/27/2021
520632,earnings,100,50,1/27/2021
520632,regulatory-product-approval-granted,100,81,1/27/2021
53A226,earnings,100,50,1/27/2021
53E575,earnings,100,50,1/27/2021
53F491,earnings-per-share-positive,100,69,1/27/2021
545272,note-sale,100,52,1/27/2021
55438C,earnings,100,50,1/27/2021
55438C,earnings,100,50,1/27/2021
55438C,earnings,100,50,1/27/2021
55438C,earnings,100,50,1/27/2021
55438C,earnings,100,50,1/27/2021
55C289,earnings,100,50,1/27/2021
562853,earnings,100,50,1/27/2021
5D0337,executive-appointment,100,54,1/27/2021
5F3E74,earnings,100,50,1/27/2021
5F6D73,earnings,100,50,1/27/2021
60DD84,revenues,100,50,1/27/2021
60DD84,revenues,100,50,1/27/2021
60DD84,revenues,100,50,1/27/2021
6137BF,earnings,100,50,1/27/2021
6166D1,executive-appointment,100,54,1/27/2021
63E8D5,earnings,100,50,1/27/2021
65D0AA,clinical-trials-positive,100,87,1/27/2021
66ECFD,earnings,100,50,1/27/2021
6A01DF,earnings,100,50,1/27/2021
6ACFBF,earnings,100,50,1/27/2021
6B5379,executive-appointment,100,54,1/27/2021
6B5379,dividend,100,50,1/27/2021
6D1ADF,conference-call,100,50,1/27/2021
6D9B53,conference-participant,100,50,1/27/2021
6DBBBC,investment-investor,100,55,1/27/2021
6EB9DA,dividend,100,50,1/27/2021
6ED519,earnings,100,50,1/27/2021
6ED519,dividend-up,100,81,1/27/2021
6F0A63,conference-call,100,50,1/27/2021
6F3FA8,conference-call,100,50,1/27/2021
70B3D6,donation,100,54,1/27/2021
70B3D6,public-offering,100,43,1/27/2021
722DE3,earnings-up,100,68,1/27/2021
7255D2,public-offering,100,43,1/27/2021
731675,conference-call,100,50,1/27/2021
732449,earnings,100,50,1/27/2021
7.44E+09,dividend,100,50,1/27/2021
78A1BB,earnings,100,50,1/27/2021
7A3633,earnings,100,50,1/27/2021
7AB859,earnings,100,50,1/27/2021
7B9AFA,earnings,100,50,1/27/2021
7DD584,earnings,100,50,1/27/2021
7E62B5,earnings,100,50,1/27/2021
8.10E+205,product-release,100,64,1/27/2021
837C04,dividend,100,50,1/27/2021
837C04,earnings,100,50,1/27/2021
837C04,earnings,100,50,1/27/2021
837C04,earnings,100,50,1/27/2021
837C04,earnings,100,50,1/27/2021
837C04,earnings,100,50,1/27/2021
837C04,earnings,100,50,1/27/2021
84920B,earnings,100,50,1/27/2021
859D62,executive-appointment,100,54,1/27/2021
859D62,dividend,100,50,1/27/2021
85CDC9,earnings,100,50,1/27/2021
86BAC7,earnings,100,50,1/27/2021
86BAC7,dividend,100,50,1/27/2021
87B81A,earnings,100,50,1/27/2021
8A8E41,partnership,100,61,1/27/2021
8BE916,earnings-up,100,68,1/27/2021
8BE916,earnings-up,100,68,1/27/2021
8BE916,earnings-up,100,68,1/27/2021
8BE916,earnings-up,100,68,1/27/2021
8BE916,earnings-up,100,68,1/27/2021
8BE916,earnings-up,100,68,1/27/2021
8BE916,earnings-up,100,68,1/27/2021
8BE916,earnings-up,100,68,1/27/2021
8BE916,earnings-up,100,68,1/27/2021
8C1238,earnings,100,50,1/27/2021
8C1238,earnings,100,50,1/27/2021
8C311A,earnings,100,50,1/27/2021
8E8E6E,partnership,100,61,1/27/2021
8E8E6E,product-release,100,64,1/27/2021
8FF2EF,earnings,100,50,1/27/2021
902670,dividend,100,50,1/27/2021
902670,executive-salary,100,52,1/27/2021
902670,executive-salary,100,52,1/27/2021
91E5EE,earnings,100,50,1/27/2021
93D207,partnership,100,61,1/27/2021
93F143,earnings,100,50,1/27/2021
94208D,business-contract,100,69,1/27/2021
94208D,business-contract,100,69,1/27/2021
942165,dividend,100,50,1/27/2021
95DC1F,executive-appointment,100,54,1/27/2021
9.62E+76,earnings,100,50,1/27/2021
986AF6,conference-call,100,50,1/27/2021
98CAED,executive-appointment,100,54,1/27/2021
990AD0,conference-organizer,100,57,1/27/2021
990AD0,conference-organizer,100,57,1/27/2021
9.92E+94,earnings,100,50,1/27/2021
9.92E+94,earnings,100,50,1/27/2021
9.92E+94,earnings,100,50,1/27/2021
9A02C4,earnings,100,50,1/27/2021
9A02C4,dividend,100,50,1/27/2021
9C8664,earnings,100,50,1/27/2021
9CE4C7,earnings,100,50,1/27/2021
9D30A8,earnings,100,50,1/27/2021
9E298A,dividend,100,50,1/27/2021
9EA947,conference-call,100,50,1/27/2021
A26C26,executive-appointment,100,54,1/27/2021
A429A5,operating-earnings,100,50,1/27/2021
A666C8,investment-investor,100,55,1/27/2021
A6FE1C,unit-acquisition-acquirer,100,49,1/27/2021
A70BF5,conference-participant,100,50,1/27/2021
AADE0B,dividend-up,100,81,1/27/2021
AC775C,conference-call,100,50,1/27/2021
AD3008,earnings,100,50,1/27/2021
B08954,earnings,100,50,1/27/2021
B0FE08,executive-appointment,100,54,1/27/2021
B2DAF6,earnings,100,50,1/27/2021
B6082A,earnings,100,50,1/27/2021
BA218A,earnings-positive,100,69,1/27/2021
BA218A,earnings,100,50,1/27/2021
BA218A,earnings,100,50,1/27/2021
BA218A,earnings,100,50,1/27/2021
BA218A,earnings,100,50,1/27/2021
BA218A,earnings,100,50,1/27/2021
BA218A,earnings,100,50,1/27/2021
BA218A,earnings,100,50,1/27/2021
BB02FB,stock-loss,100,40,1/27/2021
BB07E4,earnings-up,100,68,1/27/2021
BB07E4,earnings,100,50,1/27/2021
BB07E4,earnings,100,50,1/27/2021
BB07E4,earnings,100,50,1/27/2021
BB07E4,earnings,100,50,1/27/2021
BB5271,partnership,100,61,1/27/2021
BB88B6,earnings,100,50,1/27/2021
BD8517,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BDEF34,earnings,100,50,1/27/2021
BFE02C,partnership,100,61,1/27/2021
C06EB6,earnings,100,50,1/27/2021
C188F8,earnings,100,50,1/27/2021
C2609A,conference-participant,100,50,1/27/2021
C356AC,product-release,100,64,1/27/2021
C4A912,conference-call,100,50,1/27/2021
C5E100,public-offering,100,43,1/27/2021
C66B44,earnings,100,50,1/27/2021
C66B44,earnings,100,50,1/27/2021
C7AE14,unit-acquisition-acquiree,100,76,1/27/2021
C7AE14,acquisition-acquiree,100,76,1/27/2021
C7FC95,partnership,100,61,1/27/2021
C7FC95,partnership,100,61,1/27/2021
C81E00,operating-earnings,100,50,1/27/2021
C81E00,operating-earnings,100,50,1/27/2021
C81E00,operating-earnings,100,50,1/27/2021
C81E00,operating-earnings,100,50,1/27/2021
C81E00,operating-earnings,100,50,1/27/2021
C81E00,operating-earnings,100,50,1/27/2021
C8A248,partnership,100,61,1/27/2021
C951A2,earnings,100,50,1/27/2021
C951A2,earnings,100,50,1/27/2021
C951A2,earnings,100,50,1/27/2021
C951A2,earnings,100,50,1/27/2021
C951A2,earnings,100,50,1/27/2021
C9B932,earnings,100,50,1/27/2021
C9E107,earnings-up,100,68,1/27/2021
C9E107,earnings-up,100,68,1/27/2021
CBA33B,earnings,100,50,1/27/2021
CBBFBF,dividend,100,50,1/27/2021
CDAA0E,business-contract,100,69,1/27/2021
CDAA0E,business-contract,100,69,1/27/2021
CFF97C,dividend-up,100,65,1/27/2021
D0909F,earnings,100,50,1/27/2021
D1173F,partnership,100,61,1/27/2021
D1344A,business-contract,100,69,1/27/2021
D15833,dividend,100,50,1/27/2021
D21D8A,earnings,100,50,1/27/2021
D21D8A,earnings,100,50,1/27/2021
D21D8A,earnings,100,50,1/27/2021
D21D8A,earnings,100,50,1/27/2021
D21D8A,earnings,100,50,1/27/2021
D21D8A,earnings,100,50,1/27/2021
D21D8A,earnings,100,50,1/27/2021
D21D8A,earnings,100,50,1/27/2021
D27FAB,executive-appointment,100,54,1/27/2021
D33D8C,dividend,100,50,1/27/2021
D36B23,legal-issues-defendant,100,22,1/27/2021
D437C3,earnings,100,50,1/27/2021
D437C3,earnings,100,50,1/27/2021
D437C3,earnings,100,50,1/27/2021
D54E62,dividend,100,50,1/27/2021
D56E4C,conference-call,100,50,1/27/2021
D56E4C,conference-call,100,50,1/27/2021
D58A11,earnings,100,50,1/27/2021
D58A11,earnings,100,50,1/27/2021
D58A11,earnings,100,50,1/27/2021
D58A11,earnings,100,50,1/27/2021
D5A350,dividend,100,50,1/27/2021
D78CCD,earnings,100,50,1/27/2021
D78CCD,earnings,100,50,1/27/2021
D78CCD,earnings,100,50,1/27/2021
D78CCD,earnings,100,50,1/27/2021
D78CCD,earnings,100,50,1/27/2021
D78CCD,earnings,100,50,1/27/2021
D78CCD,earnings,100,50,1/27/2021
D7A953,earnings,100,50,1/27/2021
D8442A,earnings,100,50,1/27/2021
D8442A,earnings,100,50,1/27/2021
D8442A,earnings,100,50,1/27/2021
DA9443,public-offering,100,43,1/27/2021
DCD97F,earnings,100,50,1/27/2021
DD1BA1,revenue-volume-up,100,89,1/27/2021
DD3BB1,earnings,100,50,1/27/2021
DF6FDD,earnings,100,50,1/27/2021
E0339F,earnings,100,50,1/27/2021
E0339F,earnings,100,50,1/27/2021
E0339F,earnings,100,50,1/27/2021
E0339F,earnings,100,50,1/27/2021
E70531,executive-appointment,100,54,1/27/2021
E70531,dividend,100,50,1/27/2021
E802CE,conference-call,100,50,1/27/2021
E829E8,earnings-up,100,68,1/27/2021
E829E8,earnings,100,50,1/27/2021
E829E8,earnings,100,50,1/27/2021
E829E8,earnings,100,50,1/27/2021
E829E8,earnings,100,50,1/27/2021
E866D2,partnership,100,61,1/27/2021
E8A49A,earnings,100,50,1/27/2021
E96E0B,legal-issues-defendant,100,22,1/27/2021
EA4E68,earnings,100,50,1/27/2021
EA4E68,earnings,100,50,1/27/2021
EA4E68,earnings,100,50,1/27/2021
EC99D0,acquisition-completed-acquirer,100,49,1/27/2021
ECDEB2,earnings,100,50,1/27/2021
ED9576,earnings,100,50,1/27/2021
ED9C04,earnings,100,50,1/27/2021
EE6F1C,stock-gain,100,63,1/27/2021
EEA734,legal-issues-defendant,100,22,1/27/2021
EF25A5,earnings,100,50,1/27/2021
F0B2B5,conference-call,100,50,1/27/2021
F1CD47,earnings,100,50,1/27/2021
F2526D,earnings,100,50,1/27/2021
F294DD,earnings,100,50,1/27/2021
F31B13,dividend,100,50,1/27/2021
F40EE2,earnings,100,50,1/27/2021
F40EE2,earnings,100,50,1/27/2021
F40EE2,earnings,100,50,1/27/2021
F40EE2,earnings,100,50,1/27/2021
F40EE2,earnings,100,50,1/27/2021
F40EE2,earnings,100,50,1/27/2021
F40EE2,earnings,100,50,1/27/2021
F40EE2,earnings,100,50,1/27/2021
F4F46F,conference-participant,100,50,1/27/2021
F50BAB,earnings,100,50,1/27/2021
F58C23,public-offering,100,43,1/27/2021
F7902B,partnership,100,61,1/27/2021
F7FCA4,dividend,100,50,1/27/2021
F80FF9,conference-call,100,50,1/27/2021
FB7724,executive-appointment,100,54,1/27/2021
FBDA0F,earnings,100,50,1/27/2021
FD9A97,dividend,100,50,1/27/2021
FDC7E6,earnings,100,50,1/27/2021
FDC7E6,dividend-up,100,72,1/27/2021
FEE4B0,dividend,100,50,1/27/2021
FF4343,earnings-up,100,68,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
FF4343,earnings,100,50,1/27/2021
13528,executive-appointment,100,54,1/28/2021
01478A,earnings,100,50,1/28/2021
0157B1,business-contract,100,69,1/28/2021
0157B1,product-release,100,64,1/28/2021
0560D8,dividend,100,50,1/28/2021
070B45,earnings,100,50,1/28/2021
075CF7,earnings-positive,100,69,1/28/2021
075CF7,earnings-positive,100,69,1/28/2021
075CF7,earnings-positive,100,69,1/28/2021
075CF7,earnings-positive,100,69,1/28/2021
075CF7,earnings-positive,100,69,1/28/2021
07CA6A,earnings,100,50,1/28/2021
07CA6A,earnings,100,50,1/28/2021
0986B5,earnings,100,50,1/28/2021
0B9E6F,earnings-up,100,68,1/28/2021
0B9E6F,earnings,100,50,1/28/2021
0BD4E8,executive-appointment,100,54,1/28/2021
0C4131,dividend-up,100,70,1/28/2021
0CBC4D,partnership,100,61,1/28/2021
0CCCB7,award,100,58,1/28/2021
0ED415,earnings,100,50,1/28/2021
0F04E5,earnings,100,50,1/28/2021
105D00,dividend-up,100,81,1/28/2021
108FDA,earnings,100,50,1/28/2021
1151F4,earnings,100,50,1/28/2021
1151F4,earnings,100,50,1/28/2021
1151F4,earnings,100,50,1/28/2021
1151F4,earnings,100,50,1/28/2021
1151F4,earnings,100,50,1/28/2021
1151F4,earnings,100,50,1/28/2021
1151F4,earnings,100,50,1/28/2021
13C3E0,earnings,100,50,1/28/2021
152B9E,conference-call,100,50,1/28/2021
182B8C,earnings,100,50,1/28/2021
1A3E1B,business-contract,100,69,1/28/2021
1B9535,earnings,100,50,1/28/2021
1BDB2A,partnership,100,61,1/28/2021
1DB6A6,earnings,100,50,1/28/2021
1DB6A6,earnings,100,50,1/28/2021
1DB6A6,earnings,100,50,1/28/2021
1DB6A6,earnings,100,50,1/28/2021
1DB6A6,earnings,100,50,1/28/2021
1DB6A6,earnings,100,50,1/28/2021
1DB6A6,earnings,100,50,1/28/2021
1DDEDA,earnings,100,50,1/28/2021
1EC3E8,dividend,100,50,1/28/2021
1EC3E8,dividend,100,50,1/28/2021
2093B1,earnings,100,50,1/28/2021
20DC4E,dividend,100,50,1/28/2021
20DC4E,earnings,100,50,1/28/2021
219B21,earnings,100,50,1/28/2021
221783,conference-participant,100,50,1/28/2021
222BF9,earnings,100,50,1/28/2021
225CA2,acquisition-acquirer,100,49,1/28/2021
238302,dividend,100,50,1/28/2021
249674,conference-call,100,50,1/28/2021
25529C,earnings,100,50,1/28/2021
272472,buybacks,100,74,1/28/2021
272472,earnings-per-share-positive,100,69,1/28/2021
272704,dividend-up,100,81,1/28/2021
278C18,earnings,100,50,1/28/2021
284289,earnings,100,50,1/28/2021
28DCA8,earnings-positive,100,69,1/28/2021
28DCA8,earnings,100,50,1/28/2021
28DCA8,earnings,100,50,1/28/2021
29B702,earnings,100,50,1/28/2021
29CEBF,conference-call,100,50,1/28/2021
2BA977,earnings,100,50,1/28/2021
2C3348,business-contract,100,69,1/28/2021
2CF9D3,regulatory-product-approval-granted,100,81,1/28/2021
2DA92D,earnings,100,50,1/28/2021
2DC88B,earnings,100,50,1/28/2021
2DDB22,earnings-guidance,100,50,1/28/2021
2EC172,partnership,100,61,1/28/2021
2F7474,earnings,100,50,1/28/2021
2F7474,earnings,100,50,1/28/2021
2F7474,earnings,100,50,1/28/2021
2F94A5,earnings,100,50,1/28/2021
2FF046,earnings,100,50,1/28/2021
30E01D,earnings,100,50,1/28/2021
328250,earnings,100,50,1/28/2021
343996,earnings,100,50,1/28/2021
346BF2,legal-issues-defendant,100,22,1/28/2021
370C50,dividend-up,100,60,1/28/2021
370C50,earnings,100,50,1/28/2021
3A3447,dividend,100,50,1/28/2021
3C3B6B,earnings,100,50,1/28/2021
3E15F6,conference-call,100,50,1/28/2021
3ED92D,earnings,100,50,1/28/2021
3ED92D,earnings,100,50,1/28/2021
3ED92D,earnings,100,50,1/28/2021
3ED92D,earnings,100,50,1/28/2021
3ED92D,earnings,100,50,1/28/2021
3ED92D,earnings,100,50,1/28/2021
3ED92D,earnings,100,50,1/28/2021
3ED92D,earnings,100,50,1/28/2021
408089,earnings,100,50,1/28/2021
41A93D,earnings,100,50,1/28/2021
41ED98,executive-appointment,100,54,1/28/2021
422A82,earnings,100,50,1/28/2021
422A82,earnings,100,50,1/28/2021
422A82,earnings,100,50,1/28/2021
434F38,earnings,100,50,1/28/2021
449217,earnings-up,100,68,1/28/2021
449217,earnings-up,100,68,1/28/2021
449217,earnings-up,100,68,1/28/2021
449217,earnings-up,100,68,1/28/2021
449217,earnings-up,100,68,1/28/2021
449217,earnings-up,100,68,1/28/2021
449217,earnings-up,100,68,1/28/2021
449217,earnings-up,100,68,1/28/2021
449217,earnings-up,100,68,1/28/2021
44ED36,dividend,100,50,1/28/2021
46CF27,earnings,100,50,1/28/2021
479930,earnings,100,50,1/28/2021
499C75,public-offering,100,43,1/28/2021
49F4D0,earnings,100,50,1/28/2021
4A5C8D,dividend,100,50,1/28/2021
4A6F00,partnership,100,61,1/28/2021
4B7006,acquisition-interest-acquirer,100,46,1/28/2021
4BD6DB,earnings,100,50,1/28/2021
4C6C63,dividend,100,50,1/28/2021
4D7BD8,earnings,100,50,1/28/2021
4E2D94,earnings,100,50,1/28/2021
4E2D94,dividend,100,50,1/28/2021
4E913D,earnings-up,100,52,1/28/2021
4EC4C1,executive-appointment,100,54,1/28/2021
50070E,conference-organizer,100,57,1/28/2021
50070E,conference-organizer,100,57,1/28/2021
50070E,conference-organizer,100,57,1/28/2021
50070E,conference-organizer,100,57,1/28/2021
51D876,partnership,100,61,1/28/2021
525A1C,earnings,100,50,1/28/2021
543900,executive-appointment,100,54,1/28/2021
54A646,earnings-positive,100,69,1/28/2021
54A646,earnings-positive,100,69,1/28/2021
54A646,earnings-positive,100,69,1/28/2021
54A646,earnings-positive,100,69,1/28/2021
54A646,dividend,100,50,1/28/2021
5546DA,earnings,100,50,1/28/2021
556A57,earnings,100,50,1/28/2021
556A57,dividend,100,50,1/28/2021
55C9B5,partnership,100,61,1/28/2021
5704AC,earnings,100,50,1/28/2021
577033,earnings,100,50,1/28/2021
57CAAB,regulatory-product-approval-granted,100,81,1/28/2021
57DDB9,earnings,100,50,1/28/2021
589F5A,earnings,100,50,1/28/2021
59C539,earnings,100,50,1/28/2021
59DB8C,earnings,100,50,1/28/2021
5A64D5,earnings,100,50,1/28/2021
5D16CF,conference-call,100,50,1/28/2021
5D1956,earnings,100,50,1/28/2021
5E9934,note-sale,100,52,1/28/2021
5EAA43,business-contract,100,69,1/28/2021
5EF130,conference-call,100,50,1/28/2021
5F1B7B,earnings,100,50,1/28/2021
619882,partnership,100,61,1/28/2021
622037,dividend,100,50,1/28/2021
636639,earnings,100,50,1/28/2021
636931,earnings,100,50,1/28/2021
641F17,earnings,100,50,1/28/2021
6474BA,earnings-positive,100,69,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
6474BA,earnings,100,50,1/28/2021
65CF8E,earnings,100,50,1/28/2021
65CF8E,earnings,100,50,1/28/2021
67B052,public-offering,100,43,1/28/2021
67B052,public-offering,100,43,1/28/2021
693ECD,earnings,100,50,1/28/2021
69494C,earnings,100,50,1/28/2021
6BC6F9,conference-participant,100,50,1/28/2021
6BC6F9,product-release,100,64,1/28/2021
6CDFC6,earnings,100,50,1/28/2021
6CF43C,earnings,100,50,1/28/2021
6F39FC,executive-appointment,100,54,1/28/2021
6F92A9,earnings,100,50,1/28/2021
719477,executive-appointment,100,54,1/28/2021
724F84,earnings,100,50,1/28/2021
735388,earnings,100,50,1/28/2021
73C9E2,earnings,100,50,1/28/2021
742AAB,conference-call,100,50,1/28/2021
7520CC,earnings,100,50,1/28/2021
76F067,earnings,100,50,1/28/2021
7734AC,earnings,100,50,1/28/2021
7734AC,earnings,100,50,1/28/2021
7823A3,conference-participant,100,50,1/28/2021
782B46,earnings,100,50,1/28/2021
782B46,dividend,100,50,1/28/2021
790C34,executive-appointment,100,54,1/28/2021
791D59,earnings,100,50,1/28/2021
7999F3,earnings,100,50,1/28/2021
7A10FF,earnings,100,50,1/28/2021
7A5D58,earnings,100,50,1/28/2021
7AB859,partnership,100,61,1/28/2021
7AC86E,dividend,100,50,1/28/2021
7B6C88,earnings,100,50,1/28/2021
7BC92D,executive-appointment,100,54,1/28/2021
7D35D8,patent-infringement-plaintiff,100,47,1/28/2021
7D5384,earnings,100,50,1/28/2021
7D5384,earnings,100,50,1/28/2021
7D5384,earnings,100,50,1/28/2021
7D5384,earnings,100,50,1/28/2021
7D5384,earnings,100,50,1/28/2021
7D5384,earnings,100,50,1/28/2021
7D5FD6,earnings,100,50,1/28/2021
7DC1C4,earnings,100,50,1/28/2021
7DD8CC,conference-call,100,50,1/28/2021
8.22E+27,earnings,100,50,1/28/2021
824CCA,earnings,100,50,1/28/2021
82F088,award,100,58,1/28/2021
83598E,dividend,100,50,1/28/2021
860AB6,conference-call,100,50,1/28/2021
86478F,earnings,100,50,1/28/2021
8817D5,earnings-up,100,68,1/28/2021
895D56,partnership,100,61,1/28/2021
89E771,partnership,100,61,1/28/2021
8A8E41,business-contract,100,69,1/28/2021
8AC740,executive-appointment,100,54,1/28/2021
8B2C4A,earnings,100,50,1/28/2021
8B6E7E,earnings-up,100,68,1/28/2021
8BAA15,earnings-guidance,100,50,1/28/2021
8C84DF,earnings,100,50,1/28/2021
8D5145,earnings,100,50,1/28/2021
8D9993,earnings,100,50,1/28/2021
8D9993,earnings,100,50,1/28/2021
8D9993,earnings,100,50,1/28/2021
8D9993,earnings,100,50,1/28/2021
8DDA23,earnings,100,50,1/28/2021
8F3231,earnings,100,50,1/28/2021
902255,earnings,100,50,1/28/2021
922F0C,earnings-per-share,100,50,1/28/2021
92B047,facility-open,100,65,1/28/2021
92D6A5,earnings,100,50,1/28/2021
93C130,earnings,100,50,1/28/2021
93C130,dividend,100,50,1/28/2021
93D207,earnings,100,50,1/28/2021
949625,earnings,100,50,1/28/2021
94983E,business-contract,100,69,1/28/2021
94983E,partnership,100,61,1/28/2021
950AB7,earnings,100,50,1/28/2021
9.54E+32,earnings,100,50,1/28/2021
95DC1F,award,100,58,1/28/2021
965360,dividend,100,50,1/28/2021
96A2D3,legal-issues-defendant,100,22,1/28/2021
986AF6,earnings,100,50,1/28/2021
986AF6,earnings,100,50,1/28/2021
986AF6,earnings,100,50,1/28/2021
989E2F,earnings,100,50,1/28/2021
989E2F,earnings,100,50,1/28/2021
989E2F,earnings,100,50,1/28/2021
989E2F,earnings,100,50,1/28/2021
989E2F,earnings,100,50,1/28/2021
9.97E+09,earnings,100,50,1/28/2021
9B5968,earnings,100,50,1/28/2021
9B5968,earnings,100,50,1/28/2021
9D56F2,earnings,100,50,1/28/2021
9D56F2,earnings,100,50,1/28/2021
9D56F2,earnings,100,50,1/28/2021
9D56F2,earnings,100,50,1/28/2021
9D56F2,earnings,100,50,1/28/2021
9D6A24,earnings,100,50,1/28/2021
9D6A24,earnings,100,50,1/28/2021
9DDE1B,dividend,100,50,1/28/2021
9E298A,earnings,100,50,1/28/2021
9E298A,earnings,100,50,1/28/2021
9E298A,earnings,100,50,1/28/2021
9E3224,earnings,100,50,1/28/2021
9EED50,earnings,100,50,1/28/2021
9F37C5,dividend,100,50,1/28/2021
A16DEA,earnings,100,50,1/28/2021
A247F5,earnings-per-share-positive,100,69,1/28/2021
A247F5,earnings-per-share-positive,100,69,1/28/2021
A2CA3F,dividend,100,50,1/28/2021
A3AAA5,public-offering,100,43,1/28/2021
A4D173,earnings,100,50,1/28/2021
A4D173,earnings,100,50,1/28/2021
A5628C,executive-appointment,100,54,1/28/2021
A666C8,unit-acquisition-acquiree,100,76,1/28/2021
A6FE1C,unit-acquisition-acquirer,100,49,1/28/2021
A79D88,executive-appointment,100,54,1/28/2021
A806FA,dividend,100,50,1/28/2021
A868C9,product-release,100,64,1/28/2021
A8B137,dividend-up,100,81,1/28/2021
AADE0B,earnings,100,50,1/28/2021
ABBAD1,earnings,100,50,1/28/2021
AC1952,earnings,100,50,1/28/2021
AFBEB4,conference-call,100,50,1/28/2021
B13B68,partnership,100,61,1/28/2021
B1FC3B,business-contract,100,69,1/28/2021
B2206F,earnings,100,50,1/28/2021
B4703C,earnings-per-share-positive,100,69,1/28/2021
B4703C,earnings-positive,100,69,1/28/2021
B4703C,earnings-positive,100,69,1/28/2021
B5BA39,earnings,100,50,1/28/2021
B619CB,earnings,100,50,1/28/2021
B6CD92,earnings,100,50,1/28/2021
B8A51F,executive-appointment,100,54,1/28/2021
B8A51F,executive-appointment,100,54,1/28/2021
BB02FB,conference-call,100,50,1/28/2021
BBAE2A,dividend-up,100,58,1/28/2021
BC3AD2,earnings,100,50,1/28/2021
BCC55F,executive-appointment,100,54,1/28/2021
BCC55F,conference-call,100,50,1/28/2021
BEB756,earnings,100,50,1/28/2021
BFCACF,earnings,100,50,1/28/2021
C062D4,dividend,100,50,1/28/2021
C16A8F,earnings,100,50,1/28/2021
C16A8F,earnings,100,50,1/28/2021
C16A8F,earnings,100,50,1/28/2021
C16A8F,earnings,100,50,1/28/2021
C1CBA4,earnings-positive,100,69,1/28/2021
C1CBA4,earnings-positive,100,69,1/28/2021
C1CBA4,earnings-positive,100,69,1/28/2021
C1CBA4,earnings-positive,100,69,1/28/2021
C1CBA4,earnings-positive,100,69,1/28/2021
C1CBA4,earnings-positive,100,69,1/28/2021
C1CBA4,earnings-positive,100,69,1/28/2021
C1CBA4,earnings-positive,100,69,1/28/2021
C1CBA4,earnings-positive,100,69,1/28/2021
C2609A,dividend,100,50,1/28/2021
C29715,earnings,100,50,1/28/2021
C41C25,earnings,100,50,1/28/2021
C5E100,public-offering,100,43,1/28/2021
C62AA4,conference-call,100,50,1/28/2021
C72B8F,earnings,100,50,1/28/2021
C83B88,earnings,100,50,1/28/2021
C83B88,dividend-up,100,81,1/28/2021
C97B2D,legal-issues-defendant,100,22,1/28/2021
C97B2D,legal-issues-defendant,100,22,1/28/2021
CA99D7,conference-call,100,50,1/28/2021
CA99D7,conference-call,100,50,1/28/2021
CB6A9C,conference-call,100,50,1/28/2021
CCBBAD,earnings,100,50,1/28/2021
CD051C,conference-call,100,50,1/28/2021
CDEDFE,earnings,100,50,1/28/2021
CE1002,earnings,100,50,1/28/2021
CE96E7,earnings,100,50,1/28/2021
D064D5,executive-resignation,100,44,1/28/2021
D1173F,earnings,100,50,1/28/2021
D1173F,earnings,100,50,1/28/2021
D1173F,earnings,100,50,1/28/2021
D1173F,earnings,100,50,1/28/2021
D1173F,earnings,100,50,1/28/2021
D1344A,earnings,100,50,1/28/2021
D17C1B,earnings,100,50,1/28/2021
D17C1B,earnings,100,50,1/28/2021
D17C1B,earnings,100,50,1/28/2021
D17C1B,earnings,100,50,1/28/2021
D1C0B9,revenue-up,100,69,1/28/2021
D1C0B9,revenue-up,100,69,1/28/2021
D1C0B9,revenue-up,100,69,1/28/2021
D1C0B9,revenue-up,100,69,1/28/2021
D1C0B9,revenue-up,100,69,1/28/2021
D1C26F,partnership,100,61,1/28/2021
D25249,note-sale,100,52,1/28/2021
D29B44,acquisition-acquirer,100,49,1/28/2021
D36B23,legal-issues-defendant,100,22,1/28/2021
D3FA2C,dividend,100,50,1/28/2021
D4070C,earnings,100,50,1/28/2021
D501DC,earnings,100,50,1/28/2021
D501DC,earnings,100,50,1/28/2021
D65A13,revenue-up,100,55,1/28/2021
D65A13,revenue-up,100,69,1/28/2021
D78BF1,product-release,100,64,1/28/2021
D82EF3,trading-halt,100,43,1/28/2021
D82EF3,trading-resumed,100,58,1/28/2021
D8760C,dividend,100,50,1/28/2021
D8DBA3,earnings,100,50,1/28/2021
D96202,partnership,100,61,1/28/2021
DA48E4,dividend-up,100,62,1/28/2021
DA90E1,earnings,100,50,1/28/2021
DB5CA5,partnership,100,61,1/28/2021
DBB28E,partnership,100,61,1/28/2021
DC437D,earnings,100,50,1/28/2021
DC437D,dividend-up,100,55,1/28/2021
DD0099,earnings,100,50,1/28/2021
DD1BA1,revenues,100,50,1/28/2021
DD1BA1,revenues,100,50,1/28/2021
DD1BA1,revenues,100,50,1/28/2021
DD1BA1,revenues,100,50,1/28/2021
DD9E41,award,100,58,1/28/2021
DE4924,dividend,100,50,1/28/2021
DE4924,earnings,100,50,1/28/2021
DE5611,dividend,100,50,1/28/2021
DEF058,earnings-up,100,68,1/28/2021
DEF058,earnings,100,50,1/28/2021
DEF058,earnings,100,50,1/28/2021
DEF058,earnings,100,50,1/28/2021
DF46C5,executive-appointment,100,54,1/28/2021
DF46C5,executive-appointment,100,54,1/28/2021
DF46C5,executive-appointment,100,54,1/28/2021
E124EB,earnings,100,50,1/28/2021
E1BD05,revenue-up,100,68,1/28/2021
E1BD05,revenue-up,100,68,1/28/2021
E40FB6,earnings,100,50,1/28/2021
E4CE73,conference-call,100,50,1/28/2021
E5F0A8,earnings-positive,100,69,1/28/2021
E5F0A8,earnings,100,50,1/28/2021
E5F0A8,earnings,100,50,1/28/2021
E5F0A8,earnings,100,50,1/28/2021
E5F0A8,earnings,100,50,1/28/2021
E5F0A8,earnings,100,50,1/28/2021
E7BF32,legal-issues-defendant,100,22,1/28/2021
E866D2,earnings,100,50,1/28/2021
EAA0A7,earnings,100,50,1/28/2021
EB5E78,buybacks,100,74,1/28/2021
EB5E78,earnings,100,50,1/28/2021
EB5E78,earnings,100,50,1/28/2021
EB5E78,earnings,100,50,1/28/2021
EB5E78,earnings,100,50,1/28/2021
EBD89A,earnings,100,50,1/28/2021
EC70EC,earnings,100,50,1/28/2021
EC99D0,earnings,100,50,1/28/2021
ED2EFD,dividend,100,50,1/28/2021
ED3CA8,earnings,100,50,1/28/2021
ED7F13,earnings,100,50,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,earnings-positive,100,69,1/28/2021
ED8676,dividend,100,50,1/28/2021
EDD234,conference-call,100,50,1/28/2021
EDF5CA,dividend-up,100,72,1/28/2021
EDF5CA,executive-appointment,100,54,1/28/2021
EE1E44,earnings-up,100,68,1/28/2021
EE1E44,earnings-up,100,68,1/28/2021
EE1E44,earnings-up,100,68,1/28/2021
EE1E44,earnings-up,100,68,1/28/2021
EE1E44,earnings-up,100,68,1/28/2021
EE1E44,earnings-up,100,68,1/28/2021
EE1E44,earnings-up,100,68,1/28/2021
EE6F1C,dividend,100,50,1/28/2021
EF1AD9,dividend,100,50,1/28/2021
EF1AD9,partnership,100,61,1/28/2021
EF1AD9,partnership,100,61,1/28/2021
EF1AD9,earnings,100,50,1/28/2021
EF76C8,earnings,100,50,1/28/2021
F04E05,earnings,100,50,1/28/2021
F11638,earnings,100,50,1/28/2021
F209B4,acquisition-acquirer,100,49,1/28/2021
F294DD,dividend-up,100,81,1/28/2021
F30508,business-contract,100,69,1/28/2021
F3D2EB,operating-earnings,100,50,1/28/2021
F57F6F,conference-participant,100,50,1/28/2021
F58C23,public-offering,100,43,1/28/2021
F793FA,earnings-up,100,68,1/28/2021
F793FA,earnings,100,50,1/28/2021
F793FA,earnings,100,50,1/28/2021
F793FA,earnings,100,50,1/28/2021
F793FA,earnings,100,50,1/28/2021
F793FA,earnings,100,50,1/28/2021
F793FA,earnings,100,50,1/28/2021
F88A04,business-contract,100,69,1/28/2021
F9CAF8,operating-earnings-positive,100,69,1/28/2021
F9CAF8,earnings,100,50,1/28/2021
F9CAF8,earnings,100,50,1/28/2021
FACF19,dividend,100,50,1/28/2021
FB728F,conference-call,100,50,1/28/2021
FC1B7B,earnings,100,50,1/28/2021
FC1F9D,earnings,100,50,1/28/2021
FC4550,earnings,100,50,1/28/2021
FD0CA4,earnings,100,50,1/28/2021
FD9A97,revenues,100,50,1/28/2021
FD9A97,revenues,100,50,1/28/2021
FD9A97,revenues,100,50,1/28/2021
FD9A97,revenues,100,50,1/28/2021
FD9A97,revenues,100,50,1/28/2021
FEC475,partnership,100,61,1/28/2021
FF4343,dividend,100,50,1/28/2021
FF9FF6,conference-participant,100,50,1/28/2021
FF9FF6,conference-participant,100,50,1/28/2021
00067A,business-contract,100,69,1/29/2021
0142B5,stake-acquiree,100,62,1/29/2021
43862,conference-call,100,50,1/29/2021
065D38,earnings,100,50,1/29/2021
0B2071,earnings,100,50,1/29/2021
0B2071,earnings,100,50,1/29/2021
0B2071,earnings,100,50,1/29/2021
0DE3D5,conference-call,100,50,1/29/2021
0FDE97,earnings,100,50,1/29/2021
0FDE97,earnings,100,50,1/29/2021
0FDE97,earnings,100,50,1/29/2021
0FDE97,earnings,100,50,1/29/2021
0FDE97,earnings,100,50,1/29/2021
0FDE97,earnings,100,50,1/29/2021
0FDE97,earnings,100,50,1/29/2021
10AE08,earnings,100,50,1/29/2021
16C544,dividend,100,50,1/29/2021
180DA0,public-offering,100,43,1/29/2021
197019,dividend-up,100,81,1/29/2021
19C105,earnings,100,50,1/29/2021
19C105,earnings,100,50,1/29/2021
19C105,earnings,100,50,1/29/2021
19C105,dividend,100,50,1/29/2021
19CAC7,earnings,100,50,1/29/2021
1B4F31,earnings,100,50,1/29/2021
1C2593,facility-open,100,65,1/29/2021
1DF15D,earnings,100,50,1/29/2021
1F43A1,earnings,100,50,1/29/2021
272472,dividend-up,100,59,1/29/2021
2C19A4,conference-call,100,50,1/29/2021
2D2D43,facility-close,100,47,1/29/2021
2D2D43,dividend,100,50,1/29/2021
2D5011,earnings,100,50,1/29/2021
2D981A,public-offering,100,43,1/29/2021
2EC172,conference-call,100,50,1/29/2021
2F9304,legal-issues-defendant,100,22,1/29/2021
2F9304,legal-issues-defendant,100,22,1/29/2021
2F9304,legal-issues-defendant,100,22,1/29/2021
31A7CC,dividend,100,50,1/29/2021
338544,earnings,100,50,1/29/2021
3461CF,award,100,58,1/29/2021
3D9999,earnings-positive,100,69,1/29/2021
3D9999,earnings,100,50,1/29/2021
3D9999,earnings,100,50,1/29/2021
3D9999,earnings,100,50,1/29/2021
3D9999,earnings,100,50,1/29/2021
3D9999,earnings,100,50,1/29/2021
3FACA7,earnings,100,50,1/29/2021
405762,earnings,100,50,1/29/2021
41D61C,earnings,100,50,1/29/2021
4885C8,dividend,100,50,1/29/2021
49914B,buybacks,100,74,1/29/2021
4A3438,legal-issues-defendant,100,22,1/29/2021
4B3DC9,merger,100,66,1/29/2021
4EE167,earnings,100,50,1/29/2021
51E682,dividend-up,100,81,1/29/2021
545272,dividend,100,50,1/29/2021
553949,earnings,100,50,1/29/2021
553949,earnings,100,50,1/29/2021
553949,earnings,100,50,1/29/2021
553949,earnings,100,50,1/29/2021
553949,earnings,100,50,1/29/2021
553949,earnings,100,50,1/29/2021
553949,earnings,100,50,1/29/2021
553949,earnings,100,50,1/29/2021
56B7C1,earnings,100,50,1/29/2021
57EF50,dividend,100,50,1/29/2021
5BFE94,conference-call,100,50,1/29/2021
5E6959,earnings,100,50,1/29/2021
633043,earnings,100,50,1/29/2021
67B052,public-offering,100,43,1/29/2021
67B052,public-offering,100,43,1/29/2021
6B236C,dividend-up,100,63,1/29/2021
6CC55E,regulatory-product-review-positive,100,73,1/29/2021
6CD55A,earnings,100,50,1/29/2021
6E7060,dividend,100,50,1/29/2021
713810,partnership,100,61,1/29/2021
71B0CF,acquisition-acquirer,100,49,1/29/2021
722DE3,unit-acquisition-acquiree,100,76,1/29/2021
72EF75,dividend,100,50,1/29/2021
72F0FC,dividend,100,50,1/29/2021
72F0FC,earnings-up,100,68,1/29/2021
752A70,earnings,100,50,1/29/2021
75F665,buybacks,100,74,1/29/2021
767F86,earnings,100,50,1/29/2021
767F86,earnings,100,50,1/29/2021
767F86,earnings,100,50,1/29/2021
76D79A,dividend,100,50,1/29/2021
789ADD,earnings,100,50,1/29/2021
789ADD,earnings,100,50,1/29/2021
789ADD,earnings,100,50,1/29/2021
789ADD,earnings,100,50,1/29/2021
789ADD,earnings,100,50,1/29/2021
7B4B91,earnings,100,50,1/29/2021
82FD6D,earnings,100,50,1/29/2021
84AB66,earnings-positive,100,69,1/29/2021
860AB6,earnings,100,50,1/29/2021
8BAA15,earnings,100,50,1/29/2021
8DCBBB,acquisition-completed-acquirer,100,49,1/29/2021
940C3D,dividend,100,50,1/29/2021
95C575,earnings-positive,100,69,1/29/2021
95DC1F,dividend,100,50,1/29/2021
96F126,dividend,100,50,1/29/2021
96F126,executive-appointment,100,54,1/29/2021
97B027,dividend,100,50,1/29/2021
98CAED,unit-acquisition-acquirer,100,49,1/29/2021
9D6A24,dividend,100,50,1/29/2021
9EED50,executive-appointment,100,54,1/29/2021
9F5CBB,dividend,100,50,1/29/2021
9FD2D9,conference-call,100,50,1/29/2021
A01983,dividend,100,50,1/29/2021
A0F146,earnings,100,50,1/29/2021
A3AAA5,public-offering,100,43,1/29/2021
A6FE1C,unit-acquisition-acquirer,100,49,1/29/2021
AE7D16,earnings,100,50,1/29/2021
B48FC9,product-release,100,64,1/29/2021
BE86A1,earnings,100,50,1/29/2021
C32A39,earnings,100,50,1/29/2021
C9A96E,regulatory-investigation-completed,100,50,1/29/2021
CBA475,earnings,100,50,1/29/2021
CBA475,earnings,100,50,1/29/2021
CBA475,earnings,100,50,1/29/2021
CBA475,earnings,100,50,1/29/2021
CBA475,earnings,100,50,1/29/2021
CBA475,earnings,100,50,1/29/2021
CBA475,earnings,100,50,1/29/2021
CBCC6A,earnings,100,50,1/29/2021
CBCC6A,earnings,100,50,1/29/2021
CC339B,earnings,100,50,1/29/2021
CD2A4D,earnings,100,50,1/29/2021
CDE118,executive-resignation,100,44,1/29/2021
CE4E6D,sponsorship,100,57,1/29/2021
D13F1C,earnings,100,50,1/29/2021
D13F1C,earnings,100,50,1/29/2021
D13F1C,earnings,100,50,1/29/2021
D13F1C,earnings,100,50,1/29/2021
D13F1C,earnings,100,50,1/29/2021
D13F1C,earnings,100,50,1/29/2021
D13F1C,earnings,100,50,1/29/2021
D13F1C,earnings,100,50,1/29/2021
D13F1C,earnings,100,50,1/29/2021
D54E62,earnings,100,50,1/29/2021
D54E62,earnings,100,50,1/29/2021
D54E62,earnings,100,50,1/29/2021
D54E62,earnings,100,50,1/29/2021
D54E62,earnings,100,50,1/29/2021
D598E7,earnings,100,50,1/29/2021
D721C6,earnings-positive,100,69,1/29/2021
D7F569,dividend,100,50,1/29/2021
D82EF3,conference-call,100,50,1/29/2021
D88EF3,earnings,100,50,1/29/2021
DA9443,public-offering,100,43,1/29/2021
DB5CA5,executive-appointment,100,54,1/29/2021
DD1BA1,executive-appointment,100,54,1/29/2021
DE5611,conference-call,100,50,1/29/2021
E16133,earnings,100,50,1/29/2021
E5752F,conference-participant,100,50,1/29/2021
E68733,regulatory-product-approval-granted,100,81,1/29/2021
E6A53A,dividend,100,50,1/29/2021
E6A53A,dividend,100,50,1/29/2021
E6E012,dividend,100,50,1/29/2021
E6E012,dividend,100,50,1/29/2021
E70531,legal-issues-defendant,100,22,1/29/2021
E70531,legal-issues-defendant,100,22,1/29/2021
E7BF32,legal-issues-defendant,100,22,1/29/2021
E7BF32,legal-issues-defendant,100,22,1/29/2021
EB6965,earnings,100,50,1/29/2021
EB6965,earnings,100,50,1/29/2021
EB6965,earnings,100,50,1/29/2021
EB6965,earnings,100,50,1/29/2021
EB6965,earnings,100,50,1/29/2021
EB6965,earnings,100,50,1/29/2021
EB6965,earnings,100,50,1/29/2021
ED0402,earnings,100,50,1/29/2021
ED0D7C,conference-call,100,50,1/29/2021
EE6F1C,earnings,100,50,1/29/2021
EE6F1C,earnings,100,50,1/29/2021
EE6F1C,earnings,100,50,1/29/2021
EE6F1C,earnings,100,50,1/29/2021
EE6F1C,earnings,100,50,1/29/2021
EEBCEF,dividend,100,50,1/29/2021
EFD406,conference-call,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F294DD,earnings,100,50,1/29/2021
F30508,earnings-positive,100,69,1/29/2021
F31B13,earnings-up,100,68,1/29/2021
F31B13,earnings-up,100,68,1/29/2021
F31B13,earnings-up,100,68,1/29/2021
F31B13,earnings-up,100,68,1/29/2021
F31B13,earnings-up,100,68,1/29/2021
F31B13,earnings-up,100,68,1/29/2021
F31B13,earnings-up,100,68,1/29/2021
F47871,regulatory-product-review-positive,100,73,1/29/2021
F5C78B,dividend-up,100,81,1/29/2021
F793FA,executive-appointment,100,54,1/29/2021
FD0CA4,dividend-up,100,81,1/29/2021
FE609F,executive-resignation,100,44,1/29/2021
FF4BA4,earnings,100,50,1/29/2021
1F08A6,dividend,100,50,1/30/2021
6D156D,legal-issues-defendant,100,22,1/30/2021
E70531,legal-issues-defendant,100,22,1/30/2021
E96E0B,legal-issues-defendant,100,22,1/30/2021
00067A,partnership,100,61,2/1/2021
00326E,executive-appointment,100,54,2/1/2021
0142B5,stake-acquiree,100,62,2/1/2021
01D03F,clinical-trials-start,100,64,2/1/2021
02870F,conference-call,100,50,2/1/2021
048B70,executive-appointment,100,54,2/1/2021
51332,merger-completed,100,66,2/1/2021
51332,dividend,100,50,2/1/2021
0624BE,partnership,100,61,2/1/2021
06A456,acquisition-acquirer,100,49,2/1/2021
083F72,earnings,100,50,2/1/2021
0A6824,dividend,100,50,2/1/2021
0A7650,earnings,100,50,2/1/2021
0A7650,earnings,100,50,2/1/2021
0A7650,earnings,100,50,2/1/2021
0A7650,earnings,100,50,2/1/2021
0A7650,earnings,100,50,2/1/2021
0A7650,earnings,100,50,2/1/2021
0A7650,earnings,100,50,2/1/2021
0B2071,dividend,100,50,2/1/2021
0BC29E,earnings,100,50,2/1/2021
0BC853,unit-acquisition-acquiree,100,76,2/1/2021
0BF528,earnings,100,50,2/1/2021
0C355F,executive-appointment,100,54,2/1/2021
0C466B,dividend-up,100,70,2/1/2021
0F2BC9,conference-call,100,50,2/1/2021
11074E,partnership,100,61,2/1/2021
1151F4,award,100,58,2/1/2021
126F95,earnings,100,50,2/1/2021
126F95,earnings,100,50,2/1/2021
126F95,earnings,100,50,2/1/2021
126F95,earnings,100,50,2/1/2021
138DDE,public-offering,100,43,2/1/2021
147C38,award,100,58,2/1/2021
165B86,product-release,100,64,2/1/2021
16FC89,conference-call,100,50,2/1/2021
1748F6,executive-appointment,100,54,2/1/2021
188394,partnership,100,61,2/1/2021
18A98C,executive-appointment,100,54,2/1/2021
190B91,award,100,58,2/1/2021
1A3E1B,business-contract,100,69,2/1/2021
1A5957,earnings,100,50,2/1/2021
1E7785,credit-rating-outlook-stable,100,50,2/1/2021
1EBF8D,executive-appointment,100,54,2/1/2021
1EC3E8,earnings,100,50,2/1/2021
1EC3E8,earnings,100,50,2/1/2021
20BEEA,award,100,58,2/1/2021
21D903,earnings,100,50,2/1/2021
2262BD,legal-issues-defendant,100,22,2/1/2021
227D48,earnings,100,50,2/1/2021
228D42,partnership,100,61,2/1/2021
23207A,conference-call,100,50,2/1/2021
241252,regulatory-product-approval-granted,100,81,2/1/2021
2571FA,executive-appointment,100,54,2/1/2021
270305,merger-completed,100,66,2/1/2021
27BFA1,dividend,100,50,2/1/2021
292388,earnings,100,50,2/1/2021
2ABF77,conference-call,100,50,2/1/2021
2D2D43,executive-appointment,100,54,2/1/2021
2E0496,partnership,100,61,2/1/2021
2E61CC,partnership,100,61,2/1/2021
2E89AE,conference-participant,100,50,2/1/2021
2E89AE,conference-participant,100,50,2/1/2021
2F9304,legal-issues-defendant,100,22,2/1/2021
326EDD,earnings,100,50,2/1/2021
3461CF,credit-rating-upgrade-rater,20,50,2/1/2021
3461CF,credit-rating-upgrade-rater,20,50,2/1/2021
382EAE,acquisition-acquirer,100,49,2/1/2021
39FB23,investment-investor,100,55,2/1/2021
3A94DF,earnings-per-share-up,100,68,2/1/2021
3A94DF,earnings,100,50,2/1/2021
3A94DF,earnings,100,50,2/1/2021
3A94DF,earnings,100,50,2/1/2021
3A94DF,earnings,100,50,2/1/2021
3A94DF,earnings,100,50,2/1/2021
3A94DF,earnings,100,50,2/1/2021
3AF7FD,dividend,100,50,2/1/2021
3B2311,legal-issues-defendant,100,22,2/1/2021
3BC360,earnings,100,50,2/1/2021
3C7F5F,product-release,100,64,2/1/2021
3C7F5F,product-release,100,64,2/1/2021
3D6933,business-contract,100,69,2/1/2021
4.03E+05,executive-resignation,100,44,2/1/2021
414FFF,executive-appointment,100,54,2/1/2021
43F4A8,legal-issues-defendant,100,22,2/1/2021
449217,executive-appointment,100,54,2/1/2021
45BC35,conference-participant,100,50,2/1/2021
45BC35,conference-call,100,50,2/1/2021
485445,merger-completed,100,66,2/1/2021
4.91E+58,award,100,58,2/1/2021
494EB9,settlement,100,56,2/1/2021
494EB9,earnings,100,50,2/1/2021
4A6F00,partnership,100,61,2/1/2021
4AC91D,executive-appointment,100,54,2/1/2021
4B3DC9,business-contract,100,69,2/1/2021
4B7006,executive-appointment,100,54,2/1/2021
4BAF2E,public-offering,100,43,2/1/2021
50070E,conference-organizer,100,57,2/1/2021
50070E,conference-organizer,100,57,2/1/2021
50070E,acquisition-completed-acquiree,100,76,2/1/2021
514067,earnings,100,50,2/1/2021
51888A,merger-completed,100,66,2/1/2021
524CE4,executive-appointment,100,54,2/1/2021
5340D0,earnings,100,50,2/1/2021
545272,note-sale,100,52,2/1/2021
567F3D,executive-appointment,100,54,2/1/2021
56EA2B,earnings-per-share,100,50,2/1/2021
57634F,earnings,100,50,2/1/2021
57CAAB,earnings,100,50,2/1/2021
57F3DA,earnings,100,50,2/1/2021
5876DC,earnings,100,50,2/1/2021
5F9CE3,award,100,58,2/1/2021
61A586,earnings,100,50,2/1/2021
627186,executive-appointment,100,54,2/1/2021
64854A,conference-call,100,50,2/1/2021
66ECFD,award,100,58,2/1/2021
6D0CAB,earnings,100,50,2/1/2021
6D156D,legal-issues-defendant,100,22,2/1/2021
6D156D,legal-issues-defendant,100,22,2/1/2021
6D156D,legal-issues-defendant,100,22,2/1/2021
6D156D,legal-issues-defendant,100,22,2/1/2021
7032D0,partnership,100,61,2/1/2021
70CA28,earnings,100,50,2/1/2021
7239BB,legal-issues-defendant,100,22,2/1/2021
729368,earnings,100,50,2/1/2021
72EF75,earnings,100,50,2/1/2021
72EF75,buybacks,100,74,2/1/2021
76BD96,dividend,100,50,2/1/2021
76F067,clinical-trials,100,56,2/1/2021
790C34,earnings,100,50,2/1/2021
791EC1,conference-call,100,50,2/1/2021
79340A,earnings,100,50,2/1/2021
7999F3,credit-extension-recipient,100,69,2/1/2021
7B0BA6,buybacks,100,74,2/1/2021
7CD98F,legal-issues-defendant,100,22,2/1/2021
7E3F8F,award,100,58,2/1/2021
7F3669,earnings,100,50,2/1/2021
7FEEE1,partnership,100,61,2/1/2021
80C400,dividend,100,50,2/1/2021
8.10E+32,award,100,58,2/1/2021
855DF7,conference-call,100,50,2/1/2021
85CDC9,business-contract,100,69,2/1/2021
85CDC9,partnership,100,61,2/1/2021
8665BA,earnings,100,50,2/1/2021
88193E,executive-appointment,100,54,2/1/2021
88611B,executive-resignation,100,44,2/1/2021
896771,conference-call,100,50,2/1/2021
896771,buybacks,100,74,2/1/2021
8B9B3B,product-release,100,64,2/1/2021
8E0E32,award,100,58,2/1/2021
8E93A4,earnings,100,50,2/1/2021
8F6995,dividend,100,50,2/1/2021
902255,dividend,100,50,2/1/2021
92005C,executive-appointment,100,54,2/1/2021
92D9C9,earnings,100,50,2/1/2021
93D207,conference-participant,100,50,2/1/2021
940C3D,partnership,100,61,2/1/2021
94208D,acquisition-acquirer,100,49,2/1/2021
94563D,earnings,100,50,2/1/2021
958938,executive-appointment,100,54,2/1/2021
95DE39,earnings-positive,100,69,2/1/2021
95DE39,earnings-positive,100,69,2/1/2021
95DE39,earnings-positive,100,69,2/1/2021
95DE39,earnings-positive,100,69,2/1/2021
95DE39,earnings-positive,100,69,2/1/2021
95DE39,earnings-positive,100,69,2/1/2021
95DE39,earnings-positive,100,69,2/1/2021
979451,acquisition-acquirer,100,49,2/1/2021
979451,acquisition-acquirer,100,49,2/1/2021
9810C0,executive-appointment,100,54,2/1/2021
99B61C,clinical-trials-positive,100,87,2/1/2021
99B61C,public-offering,100,43,2/1/2021
9A602D,acquisition-acquiree,100,76,2/1/2021
9ABD30,partnership,100,61,2/1/2021
9ABD30,partnership,100,61,2/1/2021
9CA432,conference-participant,100,50,2/1/2021
9E91C6,award,100,58,2/1/2021
9F18FA,earnings,100,50,2/1/2021
9F18FA,earnings,100,50,2/1/2021
9F6B1A,award,100,58,2/1/2021
A15C71,acquisition-completed-acquirer,100,49,2/1/2021
A1EAC8,business-contract,100,69,2/1/2021
A28C54,business-contract,100,69,2/1/2021
A2CA3F,earnings,100,50,2/1/2021
A47A7D,business-contract,100,69,2/1/2021
A4CD53,earnings,100,50,2/1/2021
A63387,earnings,100,50,2/1/2021
A6FC89,conference-participant,100,50,2/1/2021
A7102F,award,100,58,2/1/2021
A96867,buybacks,100,74,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
A96867,earnings-positive,100,69,2/1/2021
ACDF88,patent-infringement-defendant,100,26,2/1/2021
B05118,earnings,100,50,2/1/2021
B1DF3C,acquisition-acquirer,100,49,2/1/2021
B3CB74,conference-organizer,100,57,2/1/2021
B4C673,dividend-up,100,56,2/1/2021
B642E8,award,100,58,2/1/2021
B6843B,earnings,100,50,2/1/2021
BB58FF,earnings,100,50,2/1/2021
C11C46,earnings,100,50,2/1/2021
C4A432,executive-resignation,100,44,2/1/2021
C4F9C6,partnership,100,61,2/1/2021
C4FBDC,executive-appointment,100,54,2/1/2021
C5E100,public-offering,100,43,2/1/2021
C8A248,merger-completed,100,66,2/1/2021
C951A2,executive-appointment,100,54,2/1/2021
C951A2,partnership,100,61,2/1/2021
C97B2D,legal-issues-defendant,100,22,2/1/2021
C9C62A,earnings,100,50,2/1/2021
C9F39B,dividend,100,50,2/1/2021
CC6FF5,executive-appointment,100,54,2/1/2021
CEC5B9,acquisition-completed-acquirer,100,49,2/1/2021
CF073E,conference-participant,100,50,2/1/2021
D07B07,regulatory-investigation-completed,100,50,2/1/2021
D1CFC8,award,100,58,2/1/2021
D3CEDF,acquisition-completed-acquirer,100,49,2/1/2021
D4070C,executive-appointment,100,54,2/1/2021
D501DC,merger-completed,100,66,2/1/2021
D5AF19,acquisition-completed-acquirer,100,49,2/1/2021
D6489C,acquisition-acquirer,100,49,2/1/2021
D697DE,earnings,100,50,2/1/2021
D77F7E,business-contract,100,69,2/1/2021
D77F7E,business-contract,100,69,2/1/2021
D854F3,acquisition-acquirer,100,49,2/1/2021
DB5CA5,award,100,58,2/1/2021
DD9E41,earnings,100,50,2/1/2021
E1BD05,note-sale,100,52,2/1/2021
E21871,earnings,100,50,2/1/2021
E2F130,executive-appointment,100,54,2/1/2021
E6D89E,partnership,100,61,2/1/2021
E8B21D,executive-appointment,100,54,2/1/2021
E90C84,conference-call,100,50,2/1/2021
EE6F1C,award,100,58,2/1/2021
EEEA9F,acquisition-completed-acquirer,100,49,2/1/2021
EF45B6,earnings,100,50,2/1/2021
F0027C,clinical-trials,100,56,2/1/2021
F30508,partnership,100,61,2/1/2021
F39E1E,earnings,100,50,2/1/2021
F48947,conference-participant,100,50,2/1/2021
F4CDA3,conference-call,100,50,2/1/2021
F6581D,unit-acquisition-completed-acquirer,100,49,2/1/2021
F6E248,partnership,100,61,2/1/2021
F721A7,unit-acquisition-acquirer,100,49,2/1/2021
F721A7,unit-acquisition-acquirer,100,49,2/1/2021
F85CC0,award,100,58,2/1/2021
F85CC0,award,100,58,2/1/2021
FBDA0F,buybacks,100,74,2/1/2021
FC1B7B,buybacks,100,74,2/1/2021
FC1B7B,unit-acquisition-completed-acquiree,100,67,2/1/2021
FC1B7B,unit-acquisition-completed-acquiree,100,67,2/1/2021
FD39EB,earnings,100,50,2/1/2021
01478A,acquisition-completed-acquirer,100,49,2/2/2021
0157B1,product-release,100,64,2/2/2021
0157B1,settlement,100,56,2/2/2021
0157B1,partnership,100,61,2/2/2021
0157B1,earnings,100,50,2/2/2021
0157B1,earnings,100,50,2/2/2021
0157B1,earnings,100,50,2/2/2021
0157B1,earnings,100,50,2/2/2021
0157B1,earnings,100,50,2/2/2021
0157B1,earnings,100,50,2/2/2021
0157B1,earnings,100,50,2/2/2021
0157B1,earnings,100,50,2/2/2021
01D03F,business-contract,100,69,2/2/2021
31025,earnings,100,50,2/2/2021
31025,earnings,100,50,2/2/2021
31025,earnings,100,50,2/2/2021
31025,earnings,100,50,2/2/2021
31025,earnings,100,50,2/2/2021
98977,earnings,100,50,2/2/2021
099C88,conference-call,100,50,2/2/2021
0A59F8,earnings,100,50,2/2/2021
0BC853,unit-acquisition-acquiree,100,76,2/2/2021
0C466B,conference-call,100,50,2/2/2021
0C8D82,investment-investor,100,55,2/2/2021
0CE204,business-contract,100,69,2/2/2021
0F2BC9,business-contract,100,69,2/2/2021
108BD2,earnings-up,100,68,2/2/2021
1220D2,acquisition-acquirer,100,49,2/2/2021
131443,executive-resignation,100,44,2/2/2021
1348C9,earnings,100,50,2/2/2021
168A5D,partnership,100,61,2/2/2021
1B5FEA,partnership,100,61,2/2/2021
1B5FEA,partnership,100,61,2/2/2021
1B5FEA,partnership,100,61,2/2/2021
1CDD1C,award,100,58,2/2/2021
1E1125,conference-organizer,100,57,2/2/2021
1F9D90,earnings,100,50,2/2/2021
21F9CA,revenues,100,50,2/2/2021
221783,earnings,100,50,2/2/2021
2262BD,facility-open,100,65,2/2/2021
228D42,partnership,100,61,2/2/2021
22C58E,product-release,100,64,2/2/2021
24C48B,earnings,100,50,2/2/2021
24CB56,earnings,100,50,2/2/2021
2667B6,conference-participant,100,50,2/2/2021
267718,earnings,100,50,2/2/2021
2950FF,dividend,100,50,2/2/2021
2950FF,dividend,100,50,2/2/2021
2CBB58,operating-earnings-up,100,68,2/2/2021
2CBB58,operating-earnings,100,50,2/2/2021
2CBB58,operating-earnings,100,50,2/2/2021
2CBB58,operating-earnings,100,50,2/2/2021
2D2D43,earnings,100,50,2/2/2021
2E902B,revenues,100,50,2/2/2021
2F1299,dividend,100,50,2/2/2021
2F24A5,earnings,100,50,2/2/2021
2F5256,earnings,100,50,2/2/2021
30A565,earnings,100,50,2/2/2021
3.30E+34,donation,100,54,2/2/2021
33E8C7,earnings,100,50,2/2/2021
34B97A,earnings,100,50,2/2/2021
372037,partnership,100,61,2/2/2021
38C46F,dividend,100,50,2/2/2021
3D9999,business-contract,100,69,2/2/2021
3DC887,partnership,100,61,2/2/2021
4.03E+05,earnings,100,50,2/2/2021
4.03E+05,earnings,100,50,2/2/2021
4.03E+05,earnings,100,50,2/2/2021
4.03E+05,earnings,100,50,2/2/2021
4.03E+05,dividend,100,50,2/2/2021
4.00E+163,earnings,100,50,2/2/2021
449217,earnings-up,100,68,2/2/2021
44A4FC,earnings,100,50,2/2/2021
453282,dividend,100,50,2/2/2021
47FCF2,earnings,100,50,2/2/2021
492117,earnings,100,50,2/2/2021
4A5C8D,earnings,100,50,2/2/2021
4A5C8D,earnings,100,50,2/2/2021
4A6F00,partnership,100,61,2/2/2021
4BF3D6,conference-participant,100,50,2/2/2021
4C6C63,earnings,100,50,2/2/2021
4E2D94,public-offering,100,43,2/2/2021
4F71DC,executive-appointment,100,54,2/2/2021
4F9926,business-contract,100,69,2/2/2021
4FCC78,conference-call,100,50,2/2/2021
51F541,conference-call,100,50,2/2/2021
54F1D2,earnings,100,50,2/2/2021
56EFC7,partnership,100,61,2/2/2021
57DDB9,business-contract,100,69,2/2/2021
587EDF,earnings,100,50,2/2/2021
5A423F,earnings,100,50,2/2/2021
5B6C11,earnings,100,50,2/2/2021
5C8D61,dividend,100,50,2/2/2021
5CCDAD,acquisition-completed-acquirer,100,49,2/2/2021
601785,dividend,100,50,2/2/2021
616E3B,award,100,58,2/2/2021
6.18E+08,earnings,100,50,2/2/2021
6.18E+08,earnings,100,50,2/2/2021
6.18E+08,earnings,100,50,2/2/2021
6.18E+08,earnings,100,50,2/2/2021
6.18E+08,executive-appointment,100,54,2/2/2021
61BCA7,product-release,100,64,2/2/2021
622DBE,earnings,100,50,2/2/2021
62B20A,earnings,100,50,2/2/2021
62CDDE,conference-call,100,50,2/2/2021
66CB62,note-sale,100,52,2/2/2021
67B923,earnings,100,50,2/2/2021
69CE71,conference-call,100,50,2/2/2021
6BDA0C,dividend,100,50,2/2/2021
6D156D,legal-issues-defendant,100,22,2/2/2021
6D156D,legal-issues-defendant,100,22,2/2/2021
6D156D,stock-loss,100,40,2/2/2021
6D156D,legal-issues-defendant,100,22,2/2/2021
6D3B7B,acquisition-acquiree,100,76,2/2/2021
6D4636,earnings,100,50,2/2/2021
7032D0,earnings,100,50,2/2/2021
717DB4,earnings,100,50,2/2/2021
73529F,conference-call,100,50,2/2/2021
73F70F,earnings,100,50,2/2/2021
747219,note-sale,100,52,2/2/2021
751C8D,note-sale,100,52,2/2/2021
767F86,unit-acquisition-acquirer,100,49,2/2/2021
767F86,unit-acquisition-acquirer,100,49,2/2/2021
76B926,asset-sale,100,62,2/2/2021
76F067,earnings,100,50,2/2/2021
797C20,dividend-up,100,81,2/2/2021
7999F3,executive-appointment,100,54,2/2/2021
7AB859,acquisition-acquirer,100,49,2/2/2021
7AC86E,partnership,100,61,2/2/2021
7B492C,earnings,100,50,2/2/2021
7CBC40,earnings,100,50,2/2/2021
804708,conference-call,100,50,2/2/2021
81222C,earnings,100,50,2/2/2021
858942,earnings,100,50,2/2/2021
85DE00,dividend,100,50,2/2/2021
85DE00,earnings,100,50,2/2/2021
8665BA,product-release,100,64,2/2/2021
8AC65D,earnings,100,50,2/2/2021
8D5145,dividend-up,100,81,2/2/2021
8DE56F,earnings,100,50,2/2/2021
8DE56F,earnings,100,50,2/2/2021
8E82A6,public-offering,100,43,2/2/2021
92B73F,dividend,100,50,2/2/2021
94637C,facility-sale,100,52,2/2/2021
94637C,clinical-trials-positive,100,87,2/2/2021
94C0B5,conference-call,100,50,2/2/2021
9548BB,buybacks,100,74,2/2/2021
9548BB,dividend,100,50,2/2/2021
968966,earnings,100,50,2/2/2021
968966,dividend,100,50,2/2/2021
971F7B,earnings,100,50,2/2/2021
99DC8D,earnings,100,50,2/2/2021
99DC8D,dividend,100,50,2/2/2021
9ABD30,investment-recipient,100,73,2/2/2021
9ABD30,investment-recipient,100,73,2/2/2021
9CF9B1,executive-appointment,100,54,2/2/2021
9CF9B1,earnings,100,50,2/2/2021
9D2790,earnings,100,50,2/2/2021
9D2790,earnings,100,50,2/2/2021
9D2790,earnings,100,50,2/2/2021
9D2790,earnings,100,50,2/2/2021
9D2790,earnings,100,50,2/2/2021
9D2790,earnings,100,50,2/2/2021
9D2790,earnings,100,50,2/2/2021
9D2790,earnings,100,50,2/2/2021
9E0811,earnings,100,50,2/2/2021
9F62D1,dividend,100,50,2/2/2021
9F6B1A,stake-acquiree,100,62,2/2/2021
A01200,product-release,100,64,2/2/2021
A1EAC8,dividend,100,50,2/2/2021
A23747,earnings,100,50,2/2/2021
A52B6B,earnings,100,50,2/2/2021
A63820,earnings,100,50,2/2/2021
A666C8,earnings,100,50,2/2/2021
A6828A,regulatory-product-approval-granted,100,81,2/2/2021
A6ABE9,partnership,100,61,2/2/2021
A790A5,conference-call,100,50,2/2/2021
A868C9,revenue-up,100,55,2/2/2021
A868C9,revenue-up,100,55,2/2/2021
A868C9,revenue-up,100,55,2/2/2021
A8E72A,product-release,100,64,2/2/2021
A96867,executive-appointment,100,54,2/2/2021
ACD9A4,earnings,100,50,2/2/2021
ACDF88,hirings,100,65,2/2/2021
AD1ACF,legal-issues-defendant,100,22,2/2/2021
AD1ACF,legal-issues-defendant,100,22,2/2/2021
AE7D16,product-release,100,64,2/2/2021
AF93DE,earnings-guidance,100,50,2/2/2021
AF93DE,earnings-guidance,100,50,2/2/2021
AFD1CA,earnings,100,50,2/2/2021
B08954,index-listing,100,76,2/2/2021
B1FC3B,business-contract,100,69,2/2/2021
B2E6B5,dividend,100,50,2/2/2021
B2E6B5,earnings,100,50,2/2/2021
B2E6B5,earnings,100,50,2/2/2021
B4C673,executive-appointment,100,54,2/2/2021
B7EB38,earnings,100,50,2/2/2021
B9764A,earnings,100,50,2/2/2021
BB127B,partnership,100,61,2/2/2021
BDD12C,award,100,58,2/2/2021
C0200F,earnings,100,50,2/2/2021
C062D4,earnings,100,50,2/2/2021
C062D4,earnings,100,50,2/2/2021
C062D4,earnings,100,50,2/2/2021
C062D4,earnings,100,50,2/2/2021
C062D4,earnings,100,50,2/2/2021
C062D4,earnings,100,50,2/2/2021
C062D4,earnings,100,50,2/2/2021
C062D4,earnings,100,50,2/2/2021
C15F8F,earnings,100,50,2/2/2021
C32A39,earnings,100,50,2/2/2021
C32A39,earnings,100,50,2/2/2021
C54140,partnership,100,61,2/2/2021
C54140,partnership,100,61,2/2/2021
C54140,partnership,100,61,2/2/2021
C6C702,executive-appointment,100,54,2/2/2021
C6C702,executive-appointment,100,54,2/2/2021
C97B2D,legal-issues-defendant,100,22,2/2/2021
CB9E13,conference-call,100,50,2/2/2021
CC176E,product-release,100,64,2/2/2021
CE5C6E,patient-enrollment-complete,100,64,2/2/2021
D04D9F,earnings,100,50,2/2/2021
D17C1B,product-release,100,64,2/2/2021
D4463B,executive-appointment,100,54,2/2/2021
D4463B,dividend,100,50,2/2/2021
D48275,earnings,100,50,2/2/2021
D60BB2,partnership,100,61,2/2/2021
D64EDF,earnings,100,50,2/2/2021
D88EF3,business-contract,100,69,2/2/2021
DC2F77,earnings,100,50,2/2/2021
DF8855,earnings,100,50,2/2/2021
DF8855,earnings,100,50,2/2/2021
DF8855,earnings,100,50,2/2/2021
DF8855,earnings,100,50,2/2/2021
E07573,dividend-guidance,100,50,2/2/2021
E22FDE,clinical-trials,100,56,2/2/2021
E30A8F,earnings,100,50,2/2/2021
E30A8F,earnings,100,50,2/2/2021
E30A8F,earnings,100,50,2/2/2021
E30A8F,earnings,100,50,2/2/2021
E30A8F,earnings,100,50,2/2/2021
E592F0,earnings,100,50,2/2/2021
E592F0,earnings,100,50,2/2/2021
E6E012,earnings,100,50,2/2/2021
E6E012,earnings,100,50,2/2/2021
E70531,earnings,100,50,2/2/2021
E70531,earnings,100,50,2/2/2021
E70531,earnings,100,50,2/2/2021
E70531,earnings,100,50,2/2/2021
E70531,earnings,100,50,2/2/2021
E70531,earnings,100,50,2/2/2021
E70531,earnings,100,50,2/2/2021
E70531,executive-appointment,100,54,2/2/2021
E70531,legal-issues-defendant,100,22,2/2/2021
E74B55,facility-upgrade,100,65,2/2/2021
E7BF32,legal-issues-defendant,100,22,2/2/2021
E87676,conference-call,100,50,2/2/2021
E90C84,earnings,100,50,2/2/2021
E96E0B,earnings,100,50,2/2/2021
EA79C7,executive-appointment,100,54,2/2/2021
EB36DE,conference-call,100,50,2/2/2021
EB61C4,conference-participant,100,50,2/2/2021
ECDEB2,earnings,100,50,2/2/2021
ECDEB2,earnings,100,50,2/2/2021
ECDEB2,earnings,100,50,2/2/2021
ED4560,revenues,100,50,2/2/2021
EF1AD9,product-release,100,64,2/2/2021
EF5BED,conference-participant,100,50,2/2/2021
F0B2B5,partnership,100,61,2/2/2021
F0B2B5,earnings,100,50,2/2/2021
F0B2B5,earnings,100,50,2/2/2021
F0B2B5,earnings,100,50,2/2/2021
F0B2B5,earnings,100,50,2/2/2021
F0B2B5,earnings,100,50,2/2/2021
F0B2B5,earnings,100,50,2/2/2021
F0B2B5,earnings,100,50,2/2/2021
F11638,partnership,100,61,2/2/2021
F4CDA3,unit-acquisition-acquirer,100,49,2/2/2021
F4E992,business-contract,100,69,2/2/2021
F5349B,business-contract,100,69,2/2/2021
F85CC0,conference-participant,100,50,2/2/2021
F85CC0,conference-participant,100,50,2/2/2021
FA918D,earnings,100,50,2/2/2021
FA918D,earnings,100,50,2/2/2021
FADF1A,conference-call,100,50,2/2/2021
FAE021,earnings,100,50,2/2/2021
FAE021,earnings,100,50,2/2/2021
FAE021,earnings,100,50,2/2/2021
FAE021,earnings,100,50,2/2/2021
FC1B7B,conference-participant,100,50,2/2/2021
FC4550,dividend,100,50,2/2/2021
FC4550,dividend,100,50,2/2/2021
FD9526,product-release,100,64,2/2/2021
FDD3FC,earnings,100,50,2/2/2021
FE89E0,earnings,100,50,2/2/2021
FEC475,product-release,100,64,2/2/2021
00067A,earnings,100,50,2/3/2021
001F1B,facility-open,100,65,2/3/2021
00326E,earnings,100,50,2/3/2021
0157B1,revenue-up,100,76,2/3/2021
01D03F,partnership,100,61,2/3/2021
01D03F,partnership,100,61,2/3/2021
02870F,partnership,100,61,2/3/2021
03B8CF,executive-appointment,100,54,2/3/2021
03CF95,earnings,100,50,2/3/2021
03FAA6,acquisition-acquirer,100,49,2/3/2021
078D52,earnings,100,50,2/3/2021
078D52,earnings,100,50,2/3/2021
078D52,earnings,100,50,2/3/2021
07EC43,earnings,100,50,2/3/2021
099A92,conference-call,100,50,2/3/2021
0C8D82,executive-appointment,100,54,2/3/2021
0CBC4D,revenue-up,100,69,2/3/2021
0D03C8,public-offering,100,43,2/3/2021
0DBB81,public-offering,100,43,2/3/2021
0E439E,note-sale,100,52,2/3/2021
0E5223,conference-call,100,50,2/3/2021
0EC508,earnings,100,50,2/3/2021
102F04,earnings,100,50,2/3/2021
11074E,earnings,100,50,2/3/2021
135B09,earnings-up,100,66,2/3/2021
135B09,earnings-up,100,66,2/3/2021
135B09,earnings-up,100,66,2/3/2021
135B09,earnings-up,100,66,2/3/2021
135B09,earnings-up,100,66,2/3/2021
1834C0,conference-call,100,50,2/3/2021
1866B2,note-sale,100,52,2/3/2021
18D9FA,executive-appointment,100,54,2/3/2021
190B91,partnership,100,61,2/3/2021
1A1CB0,earnings,100,50,2/3/2021
1A3E1B,earnings,100,50,2/3/2021
1D943E,dividend,100,50,2/3/2021
1DB6A6,dividend,100,50,2/3/2021
1F19C8,fundraising,100,64,2/3/2021
200D8B,earnings,100,50,2/3/2021
21245F,public-offering,100,43,2/3/2021
214051,earnings,100,50,2/3/2021
214051,earnings,100,50,2/3/2021
214051,earnings,100,50,2/3/2021
214051,earnings,100,50,2/3/2021
214051,earnings,100,50,2/3/2021
214051,earnings,100,50,2/3/2021
214051,earnings,100,50,2/3/2021
221AD7,earnings,100,50,2/3/2021
221AD7,earnings,100,50,2/3/2021
221AD7,earnings,100,50,2/3/2021
221AD7,earnings,100,50,2/3/2021
221AD7,earnings,100,50,2/3/2021
225CA2,partnership,100,61,2/3/2021
228D42,partnership,100,61,2/3/2021
228D42,partnership,100,61,2/3/2021
228D42,partnership,100,61,2/3/2021
25529C,buybacks,100,74,2/3/2021
263216,revenue-up,100,69,2/3/2021
263216,revenue-up,100,69,2/3/2021
263216,revenue-up,100,69,2/3/2021
263216,revenue-up,100,69,2/3/2021
263216,revenue-up,100,69,2/3/2021
263216,revenue-up,100,69,2/3/2021
263216,revenue-up,100,69,2/3/2021
28B730,earnings,100,50,2/3/2021
292388,award,100,58,2/3/2021
2A6DBE,clinical-trials-positive,100,87,2/3/2021
2B49F4,business-contract,100,69,2/3/2021
2C3348,earnings,100,50,2/3/2021
2FEA66,dividend,100,50,2/3/2021
2FEA66,operating-earnings,100,50,2/3/2021
31643A,earnings,100,50,2/3/2021
33FD66,earnings,100,50,2/3/2021
35579D,earnings,100,50,2/3/2021
3.50E+27,earnings,100,50,2/3/2021
3A3447,earnings,100,50,2/3/2021
3A3447,earnings,100,50,2/3/2021
3A3447,earnings,100,50,2/3/2021
3A3447,earnings,100,50,2/3/2021
3A3447,earnings,100,50,2/3/2021
3AF7FD,earnings,100,50,2/3/2021
3B318A,conference-participant,100,50,2/3/2021
3BA1BF,award,100,58,2/3/2021
408089,stock-splits,100,49,2/3/2021
40F7DE,conference-call,100,50,2/3/2021
416C55,dividend,100,50,2/3/2021
435ACE,earnings,100,50,2/3/2021
43A060,partnership,100,61,2/3/2021
47FCF2,product-release,100,64,2/3/2021
4885C8,earnings,100,50,2/3/2021
4BBA23,supply-increase,100,74,2/3/2021
4C1FA1,executive-appointment,100,54,2/3/2021
4F9926,partnership,100,61,2/3/2021
50070E,conference-organizer,100,57,2/3/2021
504FE2,conference-participant,100,50,2/3/2021
507AE7,earnings,100,50,2/3/2021
54F271,earnings-up,100,68,2/3/2021
553949,dividend,100,50,2/3/2021
55C9B5,partnership,100,61,2/3/2021
55C9B5,conference-participant,100,50,2/3/2021
56EA2B,note-sale,100,52,2/3/2021
587EDF,earnings,100,50,2/3/2021
587EDF,earnings,100,50,2/3/2021
587EDF,earnings,100,50,2/3/2021
587EDF,earnings,100,50,2/3/2021
587EDF,earnings,100,50,2/3/2021
5C7601,earnings,100,50,2/3/2021
5EAA43,earnings,100,50,2/3/2021
605F40,buybacks,100,74,2/3/2021
605F40,earnings,100,50,2/3/2021
60AC34,conference-participant,100,50,2/3/2021
6166D1,executive-appointment,100,54,2/3/2021
61E975,dividend,100,50,2/3/2021
61E975,conference-call,100,50,2/3/2021
6284B5,earnings,100,50,2/3/2021
641F17,partnership,100,61,2/3/2021
662682,earnings,100,50,2/3/2021
662682,dividend,100,50,2/3/2021
665D7D,earnings,100,50,2/3/2021
66CB62,note-sale,100,52,2/3/2021
6830FE,partnership,100,61,2/3/2021
6A961B,earnings,100,50,2/3/2021
6D156D,legal-issues-defendant,100,22,2/3/2021
6D156D,legal-issues-defendant,100,22,2/3/2021
6.00E+19,partnership,100,61,2/3/2021
6EB9DA,earnings,100,50,2/3/2021
6EB9DA,earnings,100,50,2/3/2021
6EB9DA,earnings,100,50,2/3/2021
6EB9DA,earnings,100,50,2/3/2021
6ED519,executive-appointment,100,54,2/3/2021
6F39FC,conference-call,100,50,2/3/2021
71E2EF,earnings,100,50,2/3/2021
722DE3,acquisition-acquirer,100,49,2/3/2021
7262F2,earnings,100,50,2/3/2021
7273FF,earnings,100,50,2/3/2021
73A213,earnings,100,50,2/3/2021
73BCBA,conference-call,100,50,2/3/2021
73C521,dividend,100,50,2/3/2021
750DFF,acquisition-acquirer,100,49,2/3/2021
751C8D,note-sale,100,52,2/3/2021
7A2A49,earnings,100,50,2/3/2021
7B4B91,dividend,100,50,2/3/2021
7C62A3,earnings,100,50,2/3/2021
7D5FD6,dividend,100,50,2/3/2021
7E1D5D,earnings,100,50,2/3/2021
7E3390,executive-appointment,100,54,2/3/2021
8.10E+32,award,100,58,2/3/2021
8.10E+32,earnings,100,50,2/3/2021
810FAD,partnership,100,61,2/3/2021
810FAD,revenue-up,100,69,2/3/2021
810FAD,revenue-up,100,69,2/3/2021
810FAD,revenue-up,100,69,2/3/2021
810FAD,revenue-up,100,69,2/3/2021
810FAD,revenue-up,100,69,2/3/2021
810FAD,revenue-up,100,69,2/3/2021
810FAD,revenue-up,100,69,2/3/2021
82C202,earnings,100,50,2/3/2021
87486A,dividend,100,50,2/3/2021
8AC65D,conference-participant,100,50,2/3/2021
8AC740,conference-call,100,50,2/3/2021
8DA42F,conference-call,100,50,2/3/2021
8DCBBB,earnings,100,50,2/3/2021
8E4F9A,public-offering,100,43,2/3/2021
8EF425,earnings,100,50,2/3/2021
8EF425,earnings,100,50,2/3/2021
8EF425,earnings,100,50,2/3/2021
8EF425,earnings,100,50,2/3/2021
8EF425,earnings,100,50,2/3/2021
8EF425,earnings,100,50,2/3/2021
8F6995,conference-call,100,50,2/3/2021
8FE7A5,earnings,100,50,2/3/2021
949625,dividend,100,50,2/3/2021
96A2D3,earnings,100,50,2/3/2021
98CAED,acquisition-completed-acquirer,100,49,2/3/2021
990AD0,conference-organizer,100,57,2/3/2021
99B61C,public-offering,100,43,2/3/2021
9AF3DC,partnership,100,61,2/3/2021
9B0C9C,earnings,100,50,2/3/2021
9D5D35,earnings,100,50,2/3/2021
9EA947,business-contract,100,69,2/3/2021
9FA83B,earnings,100,50,2/3/2021
9FB4B7,public-offering,100,43,2/3/2021
A05C43,earnings,100,50,2/3/2021
A072C4,executive-appointment,100,54,2/3/2021
A3230E,conference-participant,100,50,2/3/2021
A350C1,dividend,100,50,2/3/2021
A5195E,regulatory-product-approval-granted,100,81,2/3/2021
A631A3,partnership,100,61,2/3/2021
A6ABE9,earnings,100,50,2/3/2021
A70BF5,earnings,100,50,2/3/2021
A70BF5,earnings,100,50,2/3/2021
A70BF5,earnings,100,50,2/3/2021
A70BF5,earnings,100,50,2/3/2021
A70BF5,earnings,100,50,2/3/2021
A70BF5,earnings,100,50,2/3/2021
A7102F,conference-call,100,50,2/3/2021
A746F6,executive-appointment,100,54,2/3/2021
A75D43,earnings,100,50,2/3/2021
A80FE0,conference-call,100,50,2/3/2021
AAC8B6,conference-call,100,50,2/3/2021
AAC8B6,conference-call,100,50,2/3/2021
AB4A7E,product-release,100,64,2/3/2021
AB7F05,earnings,100,50,2/3/2021
AC642C,earnings,100,50,2/3/2021
AC642C,earnings,100,50,2/3/2021
AD1ACF,legal-issues-defendant,100,22,2/3/2021
AD1ACF,legal-issues-defendant,100,22,2/3/2021
AD1ACF,legal-issues-defendant,100,22,2/3/2021
AD23DE,conference-call,100,50,2/3/2021
AD23DE,executive-appointment,100,54,2/3/2021
AD3C93,earnings,100,50,2/3/2021
AE4125,partnership,100,61,2/3/2021
AECCA9,conference-call,100,50,2/3/2021
AEF2C3,conference-call,100,50,2/3/2021
AFEC35,earnings,100,50,2/3/2021
B08C51,acquisition-acquirer,100,49,2/3/2021
B0FE08,dividend,100,50,2/3/2021
B0FE08,earnings-up,100,68,2/3/2021
B0FE08,earnings-up,100,68,2/3/2021
B0FE08,earnings-up,100,68,2/3/2021
B0FE08,earnings-up,100,68,2/3/2021
B2256A,debt-extension-recipient,100,73,2/3/2021
B3ED62,product-release,100,64,2/3/2021
B48FC9,earnings,100,50,2/3/2021
B7FA9B,conference-call,100,50,2/3/2021
B83BCE,earnings,100,50,2/3/2021
B8EF97,revenues,100,50,2/3/2021
B8F71F,note-sale,100,52,2/3/2021
BA0442,credit-extension-recipient,100,69,2/3/2021
BAAA60,earnings,100,50,2/3/2021
BB127B,partnership,100,61,2/3/2021
BBF349,legal-issues-defendant,100,22,2/3/2021
BC5680,earnings,100,50,2/3/2021
BFE02C,conference-participant,100,50,2/3/2021
C0BA36,award,100,58,2/3/2021
C188F8,earnings,100,50,2/3/2021
C3DE7D,earnings,100,50,2/3/2021
C7AE14,earnings,100,50,2/3/2021
C941DC,earnings,100,50,2/3/2021
C941DC,public-offering,100,43,2/3/2021
C97B2D,earnings,100,50,2/3/2021
C98CDB,earnings,100,50,2/3/2021
CBB77B,business-contract,100,69,2/3/2021
CBB77B,business-contract,100,69,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CD4DA8,earnings,100,50,2/3/2021
CDAB24,earnings,100,50,2/3/2021
CE96E7,conference-participant,100,50,2/3/2021
CFF15D,earnings,100,50,2/3/2021
CFF15D,earnings,100,50,2/3/2021
D06755,earnings,100,50,2/3/2021
D42DBA,executive-appointment,100,54,2/3/2021
D4463B,dividend,100,50,2/3/2021
D56D6D,earnings,100,50,2/3/2021
D6489C,product-release,100,64,2/3/2021
D82EF3,trading-halt,100,43,2/3/2021
D82EF3,trading-resumed,100,58,2/3/2021
D854DD,earnings,100,50,2/3/2021
D8ECA1,earnings,100,50,2/3/2021
D90F43,acquisition-acquirer,100,49,2/3/2021
D9164D,earnings,100,50,2/3/2021
D96202,award,100,58,2/3/2021
DCD97F,executive-appointment,100,54,2/3/2021
E09556,patent-awarded,100,72,2/3/2021
E09E2B,conference-call,100,50,2/3/2021
E1E36F,earnings,100,50,2/3/2021
E1E36F,earnings,100,50,2/3/2021
E1E36F,earnings,100,50,2/3/2021
E1E36F,earnings,100,50,2/3/2021
E1E36F,earnings,100,50,2/3/2021
E1E36F,earnings,100,50,2/3/2021
E1E36F,earnings,100,50,2/3/2021
E1E36F,earnings,100,50,2/3/2021
E3A829,conference-participant,100,50,2/3/2021
E3E68E,award,100,58,2/3/2021
E3E68E,award,100,58,2/3/2021
E5D914,earnings,100,50,2/3/2021
E5D914,earnings,100,50,2/3/2021
E6A53A,earnings,100,50,2/3/2021
E6A53A,earnings,100,50,2/3/2021
E6A53A,earnings,100,50,2/3/2021
E8B21D,earnings,100,50,2/3/2021
E90C84,conference-participant,100,50,2/3/2021
E96E0B,legal-issues-defendant,100,22,2/3/2021
E96E0B,legal-issues-defendant,100,22,2/3/2021
EA62FC,conference-call,100,50,2/3/2021
EBC84C,earnings,100,50,2/3/2021
ED2A5E,earnings,100,50,2/3/2021
F02170,acquisition-interest-acquirer,100,46,2/3/2021
F02170,acquisition-interest-acquirer,100,46,2/3/2021
F3FCC3,earnings-up,100,68,2/3/2021
F3FCC3,earnings,100,50,2/3/2021
F3FCC3,earnings,100,50,2/3/2021
F3FCC3,earnings,100,50,2/3/2021
F3FCC3,earnings,100,50,2/3/2021
F40EE2,dividend-up,100,81,2/3/2021
F40EE2,dividend-up,100,81,2/3/2021
F40EE2,executive-appointment,100,54,2/3/2021
F40EE2,executive-appointment,100,54,2/3/2021
F4CDA3,earnings,100,50,2/3/2021
F702CA,product-price-raise,100,57,2/3/2021
F7902B,earnings,100,50,2/3/2021
F80389,business-contract,100,69,2/3/2021
F80389,note-sale,100,52,2/3/2021
F85CC0,earnings,100,50,2/3/2021
F85CC0,earnings,100,50,2/3/2021
F8BA6C,patent-awarded,100,72,2/3/2021
FA35C6,earnings,100,50,2/3/2021
FAAFA2,public-offering,100,43,2/3/2021
FC80E6,conference-call,100,50,2/3/2021
9397,earnings,100,50,2/4/2021
13528,dividend,100,50,2/4/2021
0142B5,earnings-per-share-positive,100,69,2/4/2021
0157B1,product-release,100,64,2/4/2021
01D03F,earnings,100,50,2/4/2021
01D03F,earnings,100,50,2/4/2021
0358AF,revenue-up,100,69,2/4/2021
0358AF,revenue-up,100,69,2/4/2021
0358AF,revenue-up,100,69,2/4/2021
48590,earnings,100,50,2/4/2021
048B70,earnings,100,50,2/4/2021
048B70,earnings,100,50,2/4/2021
048B70,earnings,100,50,2/4/2021
55018,dividend,100,50,2/4/2021
0560D8,conference-participant,100,50,2/4/2021
0624BE,earnings,100,50,2/4/2021
07EC43,conference-participant,100,50,2/4/2021
95294,earnings,100,50,2/4/2021
09DE1F,earnings,100,50,2/4/2021
0A59F8,partnership,100,61,2/4/2021
0B13E8,executive-appointment,100,54,2/4/2021
0BC17A,earnings,100,50,2/4/2021
0BC17A,dividend-up,100,55,2/4/2021
0BC29E,acquisition-acquiree,100,76,2/4/2021
0DC050,earnings,100,50,2/4/2021
0F65C9,dividend,100,50,2/4/2021
119CB6,earnings-per-share-positive,100,69,2/4/2021
11AEDE,conference-participant,100,50,2/4/2021
1201B5,earnings,100,50,2/4/2021
131443,earnings,100,50,2/4/2021
1348C9,executive-appointment,100,54,2/4/2021
139303,earnings,100,50,2/4/2021
143C52,partnership,100,61,2/4/2021
15A388,conference-participant,100,50,2/4/2021
1.79E+10,conference-call,100,50,2/4/2021
182BE7,conference-call,100,50,2/4/2021
1921DD,partnership,100,61,2/4/2021
1A5D5D,donation,100,54,2/4/2021
1AF7E2,conference-call,100,50,2/4/2021
1B16C1,conference-call,100,50,2/4/2021
1CD4B5,executive-appointment,100,54,2/4/2021
1E68B3,acquisition-acquirer,100,49,2/4/2021
1EBF8D,executive-resignation,100,44,2/4/2021
1EBF8D,executive-resignation,100,44,2/4/2021
1EBF8D,earnings,100,50,2/4/2021
1F19C8,revenue-up,100,83,2/4/2021
1F19C8,revenue-up,100,83,2/4/2021
1F19C8,revenue-up,100,83,2/4/2021
1F19C8,revenue-up,100,83,2/4/2021
1F19C8,revenue-up,100,83,2/4/2021
1F19C8,revenue-up,100,83,2/4/2021
1F464F,earnings,100,50,2/4/2021
1FA886,business-contract,100,69,2/4/2021
1FAF22,earnings,100,50,2/4/2021
222BF9,dividend,100,50,2/4/2021
225CA2,executive-appointment,100,54,2/4/2021
2262BD,earnings,100,50,2/4/2021
227F04,conference-participant,100,50,2/4/2021
228D42,executive-appointment,100,54,2/4/2021
228D42,partnership,100,61,2/4/2021
2491BC,partnership,100,61,2/4/2021
253604,conference-participant,100,50,2/4/2021
26D8ED,earnings,100,50,2/4/2021
270B78,earnings,100,50,2/4/2021
284289,earnings,100,50,2/4/2021
28AF37,award,100,58,2/4/2021
2920D5,dividend-up,100,81,2/4/2021
292388,conference-participant,100,50,2/4/2021
2A1009,earnings,100,50,2/4/2021
2A17B1,earnings-positive,100,69,2/4/2021
2A17B1,earnings-positive,100,69,2/4/2021
2A17B1,earnings-positive,100,69,2/4/2021
2A17B1,earnings-positive,100,69,2/4/2021
2EB88B,revenues,100,50,2/4/2021
2F9304,earnings,100,50,2/4/2021
2FF046,earnings,100,50,2/4/2021
2FF046,earnings,100,50,2/4/2021
2FF046,earnings,100,50,2/4/2021
2FF046,earnings,100,50,2/4/2021
314D88,earnings,100,50,2/4/2021
3159AA,earnings,100,50,2/4/2021
3159AA,dividend,100,50,2/4/2021
3224CC,earnings,100,50,2/4/2021
339F20,earnings,100,50,2/4/2021
343996,earnings-up,100,68,2/4/2021
343996,earnings-up,100,68,2/4/2021
35F4B5,earnings,100,50,2/4/2021
367E1C,earnings,100,50,2/4/2021
37020C,dividend,100,50,2/4/2021
372037,partnership,100,61,2/4/2021
3.73E+87,partnership,100,61,2/4/2021
385DD4,facility-open,100,65,2/4/2021
3BE00F,earnings,100,50,2/4/2021
3DED49,dividend,100,50,2/4/2021
3F4668,earnings,100,50,2/4/2021
3F868D,earnings,100,50,2/4/2021
3FBC9B,earnings,100,50,2/4/2021
3FBC9B,earnings,100,50,2/4/2021
3FBC9B,earnings,100,50,2/4/2021
41785E,regulatory-product-approval-granted,100,81,2/4/2021
41785E,dividend,100,50,2/4/2021
44A4FC,business-contract,100,69,2/4/2021
44ED36,earnings,100,50,2/4/2021
44ED36,earnings,100,50,2/4/2021
44ED36,earnings,100,50,2/4/2021
44ED36,earnings,100,50,2/4/2021
44ED36,earnings,100,50,2/4/2021
44ED36,earnings,100,50,2/4/2021
4595EF,earnings,100,50,2/4/2021
47752F,dividend,100,50,2/4/2021
48F795,earnings,100,50,2/4/2021
49F4D0,earnings,100,50,2/4/2021
4A6F00,partnership,100,61,2/4/2021
4A6F00,partnership,100,61,2/4/2021
4A6F00,partnership,100,61,2/4/2021
4A6F00,partnership,100,61,2/4/2021
4A6F00,partnership,100,61,2/4/2021
4AC91D,earnings,100,50,2/4/2021
4B3676,conference-participant,100,50,2/4/2021
4B7006,earnings,100,50,2/4/2021
4BDCA7,conference-participant,100,50,2/4/2021
4C2F17,conference-participant,100,50,2/4/2021
4EE167,earnings,100,50,2/4/2021
4EEE7E,earnings,100,50,2/4/2021
50070E,conference-organizer,100,57,2/4/2021
50070E,conference-organizer,100,57,2/4/2021
514067,conference-participant,100,50,2/4/2021
519FE0,earnings,100,50,2/4/2021
51D876,executive-appointment,100,54,2/4/2021
52015A,conference-call,100,50,2/4/2021
5225A4,public-offering,100,43,2/4/2021
5225A4,public-offering,100,43,2/4/2021
52FB2F,earnings,100,50,2/4/2021
53C421,earnings,100,50,2/4/2021
548AC0,earnings,100,50,2/4/2021
55ACCB,earnings,100,50,2/4/2021
55C9B5,partnership,100,61,2/4/2021
562853,dividend,100,50,2/4/2021
567F3D,earnings,100,50,2/4/2021
567F3D,earnings,100,50,2/4/2021
567F3D,earnings,100,50,2/4/2021
567F3D,earnings,100,50,2/4/2021
567F3D,earnings,100,50,2/4/2021
567F3D,earnings,100,50,2/4/2021
56EA2B,note-sale,100,52,2/4/2021
57356F,earnings,100,50,2/4/2021
57356F,earnings,100,50,2/4/2021
57356F,earnings,100,50,2/4/2021
586FFD,revenues,100,50,2/4/2021
586FFD,revenues,100,50,2/4/2021
59872F,conference-call,100,50,2/4/2021
59DB8C,earnings,100,50,2/4/2021
5B7739,conference-call,100,50,2/4/2021
5D0337,earnings,100,50,2/4/2021
5DD486,dividend,100,50,2/4/2021
5DD486,executive-appointment,100,54,2/4/2021
5EF130,earnings,100,50,2/4/2021
5EF130,earnings,100,50,2/4/2021
5EF130,earnings,100,50,2/4/2021
5F9CE3,dividend-up,100,61,2/4/2021
5F9CE3,earnings,100,50,2/4/2021
619882,partnership,100,61,2/4/2021
62EFEE,dividend,100,50,2/4/2021
62EFEE,earnings-up,100,68,2/4/2021
63F892,earnings,100,50,2/4/2021
64E615,earnings,100,50,2/4/2021
665618,conference-call,100,50,2/4/2021
66749D,earnings,100,50,2/4/2021
6810DE,clinical-trials-positive,100,87,2/4/2021
68BA15,earnings,100,50,2/4/2021
693ECD,earnings,100,50,2/4/2021
6ABCB8,earnings,100,50,2/4/2021
6B0784,earnings,100,50,2/4/2021
6B5379,earnings,100,50,2/4/2021
6B5379,earnings,100,50,2/4/2021
6B5379,earnings,100,50,2/4/2021
6B5379,earnings,100,50,2/4/2021
6C987C,buybacks,100,74,2/4/2021
6D156D,legal-issues-defendant,100,22,2/4/2021
6D156D,legal-issues-defendant,100,22,2/4/2021
6D2BF6,earnings,100,50,2/4/2021
6DDA15,executive-appointment,100,54,2/4/2021
6.00E+19,earnings,100,50,2/4/2021
6E705B,partnership,100,61,2/4/2021
6E7060,executive-appointment,100,54,2/4/2021
6F0096,conference-call,100,50,2/4/2021
6F92A9,earnings,100,50,2/4/2021
70FCEF,earnings,100,50,2/4/2021
719477,earnings,100,50,2/4/2021
719477,earnings,100,50,2/4/2021
719477,earnings,100,50,2/4/2021
72C2CE,conference-call,100,50,2/4/2021
72CB93,earnings,100,50,2/4/2021
747219,earnings,100,50,2/4/2021
766047,earnings,100,50,2/4/2021
7712CB,executive-salary-increase,100,44,2/4/2021
7823A3,earnings,100,50,2/4/2021
791D59,conference-participant,100,50,2/4/2021
793C11,earnings,100,50,2/4/2021
7999F3,executive-appointment,100,54,2/4/2021
7A10FF,conference-participant,100,50,2/4/2021
7A10FF,dividend,100,50,2/4/2021
7B9212,revenues,100,50,2/4/2021
7BAAE7,earnings,100,50,2/4/2021
7BAAE7,earnings,100,50,2/4/2021
7CD98F,earnings,100,50,2/4/2021
7D85A9,earnings,100,50,2/4/2021
7DA412,earnings,100,50,2/4/2021
81A88D,earnings,100,50,2/4/2021
8.10E+205,earnings,100,50,2/4/2021
82E58A,earnings,100,50,2/4/2021
83598E,earnings,100,50,2/4/2021
837C04,executive-appointment,100,54,2/4/2021
8.40E+120,clinical-trials-positive,100,87,2/4/2021
8614A2,earnings,100,50,2/4/2021
86A1B9,earnings,100,50,2/4/2021
873DB9,earnings,100,50,2/4/2021
873DB9,earnings,100,50,2/4/2021
873DB9,earnings,100,50,2/4/2021
873DB9,earnings,100,50,2/4/2021
877C0C,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8B1F37,earnings,100,50,2/4/2021
8D4AE6,dividend,100,50,2/4/2021
8DE74B,dividend,100,50,2/4/2021
8E0E32,earnings,100,50,2/4/2021
8E4F9A,public-offering,100,43,2/4/2021
8E82A6,public-offering,100,43,2/4/2021
92D757,earnings,100,50,2/4/2021
934CC3,executive-appointment,100,54,2/4/2021
93965C,earnings,100,50,2/4/2021
945DE6,trading-listing,100,61,2/4/2021
94637C,earnings,100,50,2/4/2021
94756D,earnings,100,50,2/4/2021
9548BB,earnings-per-share-positive,100,69,2/4/2021
96B4FF,earnings,100,50,2/4/2021
979451,earnings,100,50,2/4/2021
9810C0,earnings,100,50,2/4/2021
9.86E+03,award,100,58,2/4/2021
98D33E,dividend,100,50,2/4/2021
990AD0,legal-issues-defendant,100,22,2/4/2021
990AD0,conference-organizer,100,57,2/4/2021
9.97E+09,earnings,100,50,2/4/2021
9E91C6,earnings,100,50,2/4/2021
9E98F2,earnings,100,50,2/4/2021
9E98F2,earnings,100,50,2/4/2021
9E98F2,earnings,100,50,2/4/2021
9F03CF,earnings,100,50,2/4/2021
9F03CF,dividend,100,50,2/4/2021
9F71E5,dividend-up,100,60,2/4/2021
A1E3B3,partnership,100,61,2/4/2021
A1E3B3,partnership,100,61,2/4/2021
A3AAA5,earnings,100,50,2/4/2021
A403CF,earnings,100,50,2/4/2021
A403CF,dividend,100,50,2/4/2021
A6213D,investment-investor,100,55,2/4/2021
A6213D,investment-investor,100,55,2/4/2021
A6ABE9,business-contract,100,69,2/4/2021
A753BB,revenues,100,50,2/4/2021
A79F7D,public-offering,100,43,2/4/2021
A7CCF0,earnings,100,50,2/4/2021
AB4A7E,conference-call,100,50,2/4/2021
ABE7DC,executive-appointment,100,54,2/4/2021
AC7C4F,award,100,58,2/4/2021
AC7C4F,conference-participant,100,50,2/4/2021
AD1ACF,legal-issues-defendant,100,22,2/4/2021
AD1ACF,legal-issues-defendant,100,22,2/4/2021
AD1ACF,legal-issues-defendant,100,22,2/4/2021
AD1ACF,product-release,100,64,2/4/2021
AD23DE,dividend,100,50,2/4/2021
AD3C93,conference-participant,100,50,2/4/2021
AEFC90,earnings,100,50,2/4/2021
AFBEB4,product-release,100,64,2/4/2021
AFD7DD,executive-appointment,100,54,2/4/2021
AFD7DD,executive-appointment,100,54,2/4/2021
AFDF2E,executive-appointment,100,54,2/4/2021
AFF7B4,earnings,100,50,2/4/2021
AFF7B4,earnings,100,50,2/4/2021
AFF7B4,earnings,100,50,2/4/2021
AFF7B4,earnings,100,50,2/4/2021
B4C673,earnings,100,50,2/4/2021
B4C673,earnings,100,50,2/4/2021
B4C673,earnings,100,50,2/4/2021
B4C673,earnings,100,50,2/4/2021
B4C673,earnings,100,50,2/4/2021
B4C673,earnings,100,50,2/4/2021
B4C673,earnings,100,50,2/4/2021
B4C673,earnings,100,50,2/4/2021
B642E8,earnings,100,50,2/4/2021
B8F71F,executive-appointment,100,54,2/4/2021
BB0787,earnings,100,50,2/4/2021
BB07E4,dividend,100,50,2/4/2021
BB127B,conference-call,100,50,2/4/2021
BB88B6,conference-participant,100,50,2/4/2021
BBBB41,earnings,100,50,2/4/2021
BBBB41,earnings,100,50,2/4/2021
BBBB41,earnings,100,50,2/4/2021
BBBB41,earnings,100,50,2/4/2021
BBBB41,earnings,100,50,2/4/2021
BBBB41,earnings,100,50,2/4/2021
BBBB41,earnings,100,50,2/4/2021
BBF349,earnings,100,50,2/4/2021
BD8517,partnership,100,61,2/4/2021
BF79F5,conference-call,100,50,2/4/2021
C1114B,conference-call,100,50,2/4/2021
C2F597,earnings,100,50,2/4/2021
C4706C,earnings,100,50,2/4/2021
C4A241,earnings,100,50,2/4/2021
C4A241,earnings,100,50,2/4/2021
C4A241,earnings,100,50,2/4/2021
C4A241,earnings,100,50,2/4/2021
C4A241,earnings,100,50,2/4/2021
C4FBDC,note-sale,100,52,2/4/2021
C4FBDC,note-sale,100,52,2/4/2021
C564E4,conference-call,100,50,2/4/2021
C5C0E9,earnings,100,50,2/4/2021
C5D2AE,earnings,100,50,2/4/2021
C65004,earnings,100,50,2/4/2021
C659EB,dividend,100,50,2/4/2021
C85A72,partnership,100,61,2/4/2021
C85A72,partnership,100,61,2/4/2021
C9E4EC,earnings,100,50,2/4/2021
CA1620,earnings,100,50,2/4/2021
CAC8D0,facility-open,100,65,2/4/2021
CC35BE,earnings,100,50,2/4/2021
CD2DA4,executive-resignation,100,44,2/4/2021
CDAF5B,conference-call,100,50,2/4/2021
CDFCC9,earnings,100,50,2/4/2021
CDFCC9,earnings,100,50,2/4/2021
CDFCC9,earnings,100,50,2/4/2021
CDFCC9,earnings,100,50,2/4/2021
CDFCC9,earnings,100,50,2/4/2021
CDFCC9,dividend-up,100,81,2/4/2021
CEC5B9,earnings,100,50,2/4/2021
CEC5B9,earnings,100,50,2/4/2021
CEDFD5,note-sale,100,52,2/4/2021
D17F7E,earnings,100,50,2/4/2021
D17F7E,earnings,100,50,2/4/2021
D17F7E,earnings,100,50,2/4/2021
D17F7E,earnings,100,50,2/4/2021
D17F7E,earnings,100,50,2/4/2021
D20C8F,earnings,100,50,2/4/2021
D25249,conference-call,100,50,2/4/2021
D29B44,earnings,100,50,2/4/2021
D29F43,conference-call,100,50,2/4/2021
D4AC65,partnership,100,61,2/4/2021
D518D8,conference-call,100,50,2/4/2021
D5938F,earnings,100,50,2/4/2021
D6489C,partnership,100,61,2/4/2021
D69D42,earnings,100,50,2/4/2021
D78BF1,earnings,100,50,2/4/2021
D78BF1,earnings,100,50,2/4/2021
D78BF1,earnings,100,50,2/4/2021
D78BF1,earnings,100,50,2/4/2021
D78BF1,earnings,100,50,2/4/2021
D7918D,earnings,100,50,2/4/2021
D88EF3,executive-appointment,100,54,2/4/2021
D8F347,dividend,100,50,2/4/2021
DA48E4,earnings-per-share,100,50,2/4/2021
DAFED3,earnings,100,50,2/4/2021
DB5CA5,executive-appointment,100,54,2/4/2021
DC5299,operating-earnings,100,50,2/4/2021
DD1BA1,partnership,100,61,2/4/2021
DD1BA1,earnings,100,50,2/4/2021
DD1BA1,earnings,100,50,2/4/2021
DD1BA1,earnings,100,50,2/4/2021
DD1BA1,earnings,100,50,2/4/2021
DD1BA1,earnings,100,50,2/4/2021
DD1BA1,earnings,100,50,2/4/2021
DD1BA1,earnings,100,50,2/4/2021
DD1BA1,earnings,100,50,2/4/2021
E05DC8,earnings,100,50,2/4/2021
E074A0,earnings,100,50,2/4/2021
E07573,acquisition-acquirer,100,49,2/4/2021
E07573,acquisition-acquirer,100,49,2/4/2021
E09997,business-contract,100,69,2/4/2021
E0D3BA,earnings,100,50,2/4/2021
E114F4,earnings,100,50,2/4/2021
E114F4,earnings,100,50,2/4/2021
E114F4,earnings,100,50,2/4/2021
E114F4,earnings,100,50,2/4/2021
E19A99,earnings,100,50,2/4/2021
E2CB7B,earnings,100,50,2/4/2021
E2CFD2,conference-call,100,50,2/4/2021
E30A8F,executive-appointment,100,54,2/4/2021
E38906,partnership,100,61,2/4/2021
E49AA3,earnings,100,50,2/4/2021
E4CE73,product-release,100,64,2/4/2021
E5752F,earnings-up,100,68,2/4/2021
E70531,legal-issues-defendant,100,22,2/4/2021
E8A49A,executive-appointment,100,54,2/4/2021
E94704,earnings,100,50,2/4/2021
E96E0B,legal-issues-defendant,100,22,2/4/2021
EA79C7,conference-participant,100,50,2/4/2021
ECF4F8,earnings,100,50,2/4/2021
EEEA9F,earnings,100,50,2/4/2021
EF5BED,partnership,100,61,2/4/2021
F179ED,partnership,100,61,2/4/2021
F294DD,dividend,100,50,2/4/2021
F2BC3D,earnings,100,50,2/4/2021
F44EA2,earnings,100,50,2/4/2021
F46EC9,earnings,100,50,2/4/2021
F47871,regulatory-product-approval-granted,100,81,2/4/2021
F47871,earnings,100,50,2/4/2021
F4F46F,earnings,100,50,2/4/2021
F51DB0,conference-call,100,50,2/4/2021
F58C23,conference-organizer,100,57,2/4/2021
F6E248,earnings,100,50,2/4/2021
F6E248,dividend-up,100,54,2/4/2021
F748C7,partnership,100,61,2/4/2021
F7D8AE,earnings,100,50,2/4/2021
F8084B,earnings-per-share-positive,100,69,2/4/2021
F8084B,earnings,100,50,2/4/2021
F8084B,earnings,100,50,2/4/2021
F80FF9,earnings,100,50,2/4/2021
F82D37,dividend-up,100,81,2/4/2021
F88A04,earnings,100,50,2/4/2021
F8BA6C,public-offering,100,43,2/4/2021
FAAFA2,public-offering,100,43,2/4/2021
FD39EB,executive-appointment,100,54,2/4/2021
FD4BBE,earnings,100,50,2/4/2021
FD4E8D,conference-participant,100,50,2/4/2021
FDD3FC,conference-participant,100,50,2/4/2021
FEC475,earnings,100,50,2/4/2021
FEC475,earnings,100,50,2/4/2021
FEC475,earnings,100,50,2/4/2021
FEC475,earnings,100,50,2/4/2021
FEE4B0,earnings-up,100,68,2/4/2021
FEE4B0,earnings-up,100,68,2/4/2021
FEE4B0,earnings-up,100,68,2/4/2021
FEE4B0,earnings-up,100,68,2/4/2021
FEE4B0,earnings-up,100,68,2/4/2021
FF5413,earnings,100,50,2/4/2021
FFE543,earnings,100,50,2/4/2021
01D03F,clinical-trials,100,56,2/5/2021
036C6F,conference-call,100,50,2/5/2021
0DBB81,public-offering,100,43,2/5/2021
0EF1AF,dividend,100,50,2/5/2021
1272B3,partnership,100,61,2/5/2021
12A3A3,dividend,100,50,2/5/2021
133644,conference-participant,100,50,2/5/2021
14ED2B,dividend,100,50,2/5/2021
14ED2B,earnings,100,50,2/5/2021
168A5D,partnership,100,61,2/5/2021
168A5D,partnership,100,61,2/5/2021
16B183,dividend,100,50,2/5/2021
1782D5,conference-call,100,50,2/5/2021
228D42,partnership,100,61,2/5/2021
239106,conference-call,100,50,2/5/2021
253B2F,conference-call,100,50,2/5/2021
28F905,earnings,100,50,2/5/2021
2B5483,earnings,100,50,2/5/2021
2BF36E,conference-call,100,50,2/5/2021
33FD66,executive-appointment,100,54,2/5/2021
353DBB,earnings,100,50,2/5/2021
3587B4,earnings,100,50,2/5/2021
3587B4,earnings,100,50,2/5/2021
3587B4,earnings,100,50,2/5/2021
3587B4,earnings,100,50,2/5/2021
3587B4,earnings,100,50,2/5/2021
3587B4,earnings,100,50,2/5/2021
37020C,earnings,100,50,2/5/2021
41ED98,dividend,100,50,2/5/2021
423279,dividend,100,50,2/5/2021
47752F,executive-appointment,100,54,2/5/2021
4A3438,legal-issues-defendant,100,22,2/5/2021
4A6F00,partnership,100,61,2/5/2021
4D371E,buybacks,100,74,2/5/2021
4EC4C1,joint-venture,100,62,2/5/2021
50070E,conference-organizer,100,57,2/5/2021
50070E,partnership,100,61,2/5/2021
50070E,conference-organizer,100,57,2/5/2021
50070E,conference-organizer,100,57,2/5/2021
504FE2,award,100,58,2/5/2021
5225A4,public-offering,100,43,2/5/2021
53EF9E,conference-call,100,50,2/5/2021
54DF47,conference-call,100,50,2/5/2021
56277A,earnings,100,50,2/5/2021
583223,earnings,100,50,2/5/2021
589803,earnings,100,50,2/5/2021
698FF9,dividend,100,50,2/5/2021
6A6BDC,earnings,100,50,2/5/2021
6BD606,conference-call,100,50,2/5/2021
6BD606,dividend,100,50,2/5/2021
6D156D,legal-issues-defendant,100,22,2/5/2021
6DD6BA,earnings,100,50,2/5/2021
6EB9DA,executive-appointment,100,54,2/5/2021
6F6559,award,100,58,2/5/2021
6FCEF9,earnings,100,50,2/5/2021
79167B,conference-call,100,50,2/5/2021
7AC86E,earnings,100,50,2/5/2021
868808,earnings-up,100,68,2/5/2021
883D82,earnings,100,50,2/5/2021
8A0368,conference-call,100,50,2/5/2021
8DE74B,conference-call,100,50,2/5/2021
8E8E6E,award,100,58,2/5/2021
90B678,stock-splits,100,49,2/5/2021
954004,partnership,100,61,2/5/2021
95DC1F,product-release,100,64,2/5/2021
990AD0,analyst-ratings-set-positive-rater,20,50,2/5/2021
990AD0,conference-organizer,100,57,2/5/2021
9981C6,earnings,100,50,2/5/2021
9E4A5F,earnings,100,50,2/5/2021
9F71E5,conference-participant,100,50,2/5/2021
9FA83B,conference-participant,100,50,2/5/2021
A16DEA,conference-participant,100,50,2/5/2021
A4BCDE,earnings,100,50,2/5/2021
AB7726,dividend,100,50,2/5/2021
AD3008,market-entry,100,57,2/5/2021
AD9F1D,dividend,100,50,2/5/2021
B7BBFF,earnings,100,50,2/5/2021
BD8517,business-contract,100,69,2/5/2021
BD8517,award,100,58,2/5/2021
C941DC,public-offering,100,43,2/5/2021
C9C62A,earnings,100,50,2/5/2021
CA3CB9,earnings-up,100,68,2/5/2021
D29B44,conference-participant,100,50,2/5/2021
D3FD6D,conference-call,100,50,2/5/2021
D54E62,acquisition-interest-acquirer,100,46,2/5/2021
D54E62,acquisition-interest-acquirer,100,46,2/5/2021
D6EAA3,executive-appointment,100,54,2/5/2021
D7F569,earnings,100,50,2/5/2021
D854F3,earnings,100,50,2/5/2021
D854F3,earnings,100,50,2/5/2021
D854F3,earnings,100,50,2/5/2021
DBEF02,earnings,100,50,2/5/2021
E1C16B,conference-participant,100,50,2/5/2021
E3656D,earnings,100,50,2/5/2021
E7BF32,legal-issues-defendant,100,22,2/5/2021
E7BF32,legal-issues-defendant,100,22,2/5/2021
E7BF32,legal-issues-defendant,100,22,2/5/2021
ED9576,dividend,100,50,2/5/2021
F1529C,earnings,100,50,2/5/2021
F1529C,earnings,100,50,2/5/2021
F1C04C,dividend,100,50,2/5/2021
F7ADEB,conference-call,100,50,2/5/2021
F80389,public-offering,100,43,2/5/2021
F8C5D7,conference-call,100,50,2/5/2021
F93C8A,conference-call,100,50,2/5/2021
FACCF6,conference-participant,100,50,2/5/2021
FC4550,dividend,100,50,2/5/2021
6D156D,legal-issues-defendant,100,22,2/6/2021
6F39FC,dividend,100,50,2/6/2021
A63387,business-contract,100,69,2/6/2021
AD1ACF,legal-issues-defendant,100,22,2/6/2021
D11C1C,conference-call,100,50,2/6/2021
E7BF32,legal-issues-defendant,100,22,2/6/2021
E96E0B,fraud-defendant,100,20,2/6/2021
E96E0B,legal-issues-defendant,100,22,2/6/2021
7CD98F,legal-issues-defendant,100,22,2/7/2021
AD1ACF,legal-issues-defendant,100,22,2/7/2021
E7BF32,legal-issues-defendant,100,22,2/7/2021
E96E0B,legal-issues-defendant,100,22,2/7/2021
FE1A1D,product-release,100,64,2/7/2021
00067A,settlement,100,56,2/8/2021
0157B1,partnership,100,61,2/8/2021
01D03F,settlement,100,56,2/8/2021
03596A,earnings,100,50,2/8/2021
03596A,credit-extension-recipient,100,69,2/8/2021
03FB17,earnings,100,50,2/8/2021
04996E,executive-appointment,100,54,2/8/2021
05AF14,conference-participant,100,50,2/8/2021
0A6824,earnings,100,50,2/8/2021
0B57D7,dividend,100,50,2/8/2021
0C2A0D,executive-appointment,100,54,2/8/2021
0C6861,conference-call,100,50,2/8/2021
0F0440,partnership,100,61,2/8/2021
0F0693,earnings,100,50,2/8/2021
12A3A3,executive-appointment,100,54,2/8/2021
138DDE,earnings,100,50,2/8/2021
14833D,executive-appointment,100,54,2/8/2021
152AB9,earnings,100,50,2/8/2021
152AB9,public-offering,100,43,2/8/2021
152B9E,executive-appointment,100,54,2/8/2021
1921DD,business-contract,100,69,2/8/2021
1921DD,facility-open,100,65,2/8/2021
1A46A1,conference-participant,100,50,2/8/2021
1CF3A8,earnings,100,50,2/8/2021
1D3A00,conference-call,100,50,2/8/2021
1D9E55,partnership,100,61,2/8/2021
1D9E55,earnings,100,50,2/8/2021
1E1125,conference-organizer,100,57,2/8/2021
1E68B3,earnings,100,50,2/8/2021
1F08A6,executive-appointment,100,54,2/8/2021
21245F,public-offering,100,43,2/8/2021
23699B,executive-appointment,100,54,2/8/2021
2667B6,dividend,100,50,2/8/2021
26F31D,earnings,100,50,2/8/2021
275300,note-sale,100,52,2/8/2021
275300,note-sale,100,52,2/8/2021
279916,award,100,58,2/8/2021
292388,earnings-up,100,68,2/8/2021
292388,earnings,100,50,2/8/2021
292388,earnings,100,50,2/8/2021
292388,earnings,100,50,2/8/2021
292388,earnings,100,50,2/8/2021
2AA6A8,executive-appointment,100,54,2/8/2021
2ABF77,earnings,100,50,2/8/2021
2ABF77,earnings,100,50,2/8/2021
2E902B,conference-participant,100,50,2/8/2021
2EC172,acquisition-acquirer,100,49,2/8/2021
326EDD,dividend,100,50,2/8/2021
36E479,earnings,100,50,2/8/2021
382EAE,conference-call,100,50,2/8/2021
387541,conference-call,100,50,2/8/2021
3AF7FD,conference-participant,100,50,2/8/2021
3DB18B,earnings,100,50,2/8/2021
4017AD,earnings,100,50,2/8/2021
407878,acquisition-completed-acquirer,100,49,2/8/2021
4.00E+163,public-offering,100,43,2/8/2021
425BDC,conference-call,100,50,2/8/2021
4455C4,conference-call,100,50,2/8/2021
44A4FC,business-contract,100,69,2/8/2021
4806CE,earnings,100,50,2/8/2021
490D4B,earnings-positive,100,69,2/8/2021
490D4B,earnings,100,50,2/8/2021
490D4B,earnings,100,50,2/8/2021
490D4B,earnings,100,50,2/8/2021
4A6F00,partnership,100,61,2/8/2021
4BAF2E,public-offering,100,43,2/8/2021
4C2F17,hirings,100,65,2/8/2021
4C7DB5,public-offering,100,43,2/8/2021
4E2D94,note-sale,100,52,2/8/2021
4E2D94,note-sale,100,52,2/8/2021
50070E,conference-organizer,100,57,2/8/2021
50070E,conference-organizer,100,57,2/8/2021
5.43E+08,conference-participant,100,50,2/8/2021
55C9B5,dividend,100,50,2/8/2021
56765E,earnings,100,50,2/8/2021
57DDB9,product-release,100,64,2/8/2021
58EA22,clinical-trials-start,100,64,2/8/2021
5AA3B1,earnings,100,50,2/8/2021
5C8D61,earnings,100,50,2/8/2021
5C8D61,earnings,100,50,2/8/2021
5C8D61,earnings,100,50,2/8/2021
5C8D61,earnings,100,50,2/8/2021
5DAF89,earnings,100,50,2/8/2021
639BD6,revenues,100,50,2/8/2021
639BD6,revenues,100,50,2/8/2021
639BD6,revenues,100,50,2/8/2021
639BD6,revenues,100,50,2/8/2021
66749D,conference-participant,100,50,2/8/2021
67B923,public-offering,100,43,2/8/2021
6830FE,executive-appointment,100,54,2/8/2021
68B03F,earnings,100,50,2/8/2021
6ABCB8,index-listing,100,76,2/8/2021
6D156D,legal-issues-defendant,100,22,2/8/2021
6D156D,legal-issues-defendant,100,22,2/8/2021
6D156D,legal-issues-defendant,100,22,2/8/2021
6F92A9,note-sale,100,52,2/8/2021
705636,dividend,100,50,2/8/2021
713810,legal-issues-defendant,100,22,2/8/2021
71553E,public-offering,100,43,2/8/2021
73A213,earnings,100,50,2/8/2021
73A213,earnings,100,50,2/8/2021
7448A3,earnings,100,50,2/8/2021
7.45E+28,legal-issues-defendant,100,22,2/8/2021
748EB6,conference-participant,100,50,2/8/2021
762B8D,earnings,100,50,2/8/2021
76CEFB,buybacks,100,74,2/8/2021
78F776,earnings,100,50,2/8/2021
7C75FD,earnings,100,50,2/8/2021
7F9BE2,conference-call,100,50,2/8/2021
845655,earnings,100,50,2/8/2021
845655,earnings,100,50,2/8/2021
845655,earnings,100,50,2/8/2021
845655,earnings,100,50,2/8/2021
845655,earnings,100,50,2/8/2021
85AD00,earnings-per-share-positive,100,69,2/8/2021
89F693,product-release,100,64,2/8/2021
8AB37F,public-offering,100,43,2/8/2021
8D4486,partnership,100,61,2/8/2021
8D4486,partnership,100,61,2/8/2021
8D4486,partnership,100,61,2/8/2021
8E4F9A,public-offering,100,43,2/8/2021
900356,earnings,100,50,2/8/2021
91E5EE,dividend,100,50,2/8/2021
91E5EE,earnings,100,50,2/8/2021
9.31E+77,clinical-trials-filed,100,60,2/8/2021
93D207,product-release,100,64,2/8/2021
94637C,regulatory-product-approval-granted,100,81,2/8/2021
949625,executive-appointment,100,54,2/8/2021
949D62,earnings,100,50,2/8/2021
957A07,earnings,100,50,2/8/2021
968B00,earnings-positive,100,69,2/8/2021
968B00,earnings-positive,100,69,2/8/2021
9.86E+03,earnings,100,50,2/8/2021
990AD0,conference-organizer,100,57,2/8/2021
9.92E+94,partnership,100,61,2/8/2021
9B730A,clinical-trials-positive,100,87,2/8/2021
9C5174,conference-participant,100,50,2/8/2021
9D307D,earnings,100,50,2/8/2021
9D30A8,conference-participant,100,50,2/8/2021
9D4EC7,earnings,100,50,2/8/2021
9E91C6,public-offering,100,43,2/8/2021
A01664,earnings,100,50,2/8/2021
A03EE1,earnings,100,50,2/8/2021
A05C43,note-sale,100,52,2/8/2021
A15C71,earnings,100,50,2/8/2021
A41450,earnings,100,50,2/8/2021
A4CD53,acquisition-acquirer,100,49,2/8/2021
A52533,product-release,100,64,2/8/2021
A58224,conference-call,100,50,2/8/2021
A63387,acquisition-acquiree,100,76,2/8/2021
A63387,earnings,100,50,2/8/2021
A63387,acquisition-regulatory-scrutiny-acquiree,100,38,2/8/2021
A63387,legal-issues-defendant,100,22,2/8/2021
A7F0A5,conference-call,100,50,2/8/2021
A8CBDA,conference-participant,100,50,2/8/2021
AA98ED,earnings,100,50,2/8/2021
AADE0B,acquisition-completed-acquirer,100,49,2/8/2021
AAEE21,earnings,100,50,2/8/2021
AD1ACF,legal-issues-defendant,100,22,2/8/2021
AE4125,conference-call,100,50,2/8/2021
AED61E,revenues,100,50,2/8/2021
AED61E,revenues,100,50,2/8/2021
AFF7B4,conference-participant,100,50,2/8/2021
B13B68,business-contract,100,69,2/8/2021
B1B10C,dividend,100,50,2/8/2021
B381D8,earnings,100,50,2/8/2021
B803B1,conference-call,100,50,2/8/2021
B83D67,executive-appointment,100,54,2/8/2021
B83D67,executive-appointment,100,54,2/8/2021
B96637,conference-call,100,50,2/8/2021
B9B6B8,earnings,100,50,2/8/2021
BAD655,merger-regulatory-approval,100,81,2/8/2021
BB58FF,note-sale,100,52,2/8/2021
BC948D,conference-call,100,50,2/8/2021
BDE867,sponsorship,100,57,2/8/2021
C06EB6,clinical-trials-positive,100,87,2/8/2021
C06EB6,clinical-trials-positive,100,87,2/8/2021
C0F70B,earnings,100,50,2/8/2021
C230FE,earnings-up,100,68,2/8/2021
C230FE,earnings-up,100,68,2/8/2021
C230FE,earnings-up,100,68,2/8/2021
C2609A,acquisition-acquiree,100,76,2/8/2021
C425AE,earnings,100,50,2/8/2021
C50B26,earnings,100,50,2/8/2021
C5D2AE,conference-participant,100,50,2/8/2021
C94CFC,executive-appointment,100,54,2/8/2021
CBA475,executive-appointment,100,54,2/8/2021
CBBFBF,partnership,100,61,2/8/2021
CBBFBF,partnership,100,61,2/8/2021
CBBFBF,partnership,100,61,2/8/2021
CC176E,executive-appointment,100,54,2/8/2021
D15833,executive-appointment,100,54,2/8/2021
D1C26F,earnings,100,50,2/8/2021
D296C6,dividend,100,50,2/8/2021
D33270,product-release,100,64,2/8/2021
D54E62,acquisition-interest-acquirer,100,46,2/8/2021
D60BB2,earnings,100,50,2/8/2021
D75910,conference-call,100,50,2/8/2021
D7918D,public-offering,100,43,2/8/2021
DB06B0,acquisition-acquirer,100,49,2/8/2021
DB06B0,acquisition-acquirer,100,49,2/8/2021
DF42A0,dividend,100,50,2/8/2021
DF42A0,earnings,100,50,2/8/2021
DF42A0,earnings,100,50,2/8/2021
DF42A0,earnings,100,50,2/8/2021
DF42A0,earnings,100,50,2/8/2021
DF42A0,earnings,100,50,2/8/2021
DF5F14,public-offering,100,43,2/8/2021
E05026,earnings,100,50,2/8/2021
E5752F,acquisition-acquirer,100,49,2/8/2021
E5752F,earnings,100,50,2/8/2021
E5752F,earnings,100,50,2/8/2021
E5752F,earnings,100,50,2/8/2021
E5752F,earnings,100,50,2/8/2021
E67C2C,earnings,100,50,2/8/2021
E7BF32,legal-issues-defendant,100,22,2/8/2021
E93A40,earnings,100,50,2/8/2021
E96E0B,legal-issues-defendant,100,22,2/8/2021
E9C7C0,earnings,100,50,2/8/2021
E9C7C0,earnings,100,50,2/8/2021
E9C7C0,earnings,100,50,2/8/2021
E9C7C0,earnings,100,50,2/8/2021
E9C7C0,earnings,100,50,2/8/2021
E9C7C0,earnings,100,50,2/8/2021
E9C7C0,earnings,100,50,2/8/2021
EB5E78,conference-participant,100,50,2/8/2021
EB5E78,conference-participant,100,50,2/8/2021
EC1AF3,conference-call,100,50,2/8/2021
ECF709,executive-appointment,100,54,2/8/2021
ED79D9,conference-participant,100,50,2/8/2021
EE6F1C,government-contract,100,69,2/8/2021
EFA7B2,earnings,100,50,2/8/2021
F0EEFB,earnings,100,50,2/8/2021
F1EB39,conference-participant,100,50,2/8/2021
F32F88,dividend,100,50,2/8/2021
F4D241,clinical-trials-positive,100,87,2/8/2021
F6E248,executive-appointment,100,54,2/8/2021
F769E9,conference-call,100,50,2/8/2021
F8BA6C,public-offering,100,43,2/8/2021
FD2565,executive-appointment,100,54,2/8/2021
FEC475,business-contract,100,69,2/8/2021
FF6644,conference-participant,100,50,2/8/2021
03FB17,product-release,100,64,2/9/2021
51332,credit-rating-affirmation,100,51,2/9/2021
68396,executive-appointment,100,54,2/9/2021
75172,earnings,100,50,2/9/2021
0A0D9E,acquisition-completed-acquirer,100,49,2/9/2021
0B6EED,executive-appointment,100,54,2/9/2021
0BC853,earnings,100,50,2/9/2021
0C28D1,business-contract,100,69,2/9/2021
0C6861,conference-call,100,50,2/9/2021
0CE204,award,100,58,2/9/2021
10100E,earnings,100,50,2/9/2021
11AEDE,executive-appointment,100,54,2/9/2021
12731D,conference-call,100,50,2/9/2021
12731D,conference-call,100,50,2/9/2021
12731D,credit-extension-recipient,100,69,2/9/2021
12731D,credit-extension-recipient,100,69,2/9/2021
12731D,credit-extension-recipient,100,69,2/9/2021
12DE76,earnings,100,50,2/9/2021
12DE76,earnings,100,50,2/9/2021
12DE76,earnings,100,50,2/9/2021
12DE76,earnings,100,50,2/9/2021
12DE76,earnings,100,50,2/9/2021
131443,dividend,100,50,2/9/2021
14391F,earnings,100,50,2/9/2021
15A388,business-contract,100,69,2/9/2021
188394,earnings-meet-expectations,100,59,2/9/2021
188394,earnings,100,50,2/9/2021
188394,earnings,100,50,2/9/2021
188394,earnings,100,50,2/9/2021
188394,earnings,100,50,2/9/2021
190B91,earnings,100,50,2/9/2021
19BF16,earnings,100,50,2/9/2021
1BDB2A,dividend,100,50,2/9/2021
1D5C51,executive-appointment,100,54,2/9/2021
1DE526,earnings,100,50,2/9/2021
1E9A6D,merger-regulatory-approval,100,81,2/9/2021
1E9A6D,merger-regulatory-approval,100,81,2/9/2021
1EBF8D,partnership,100,61,2/9/2021
1F19C8,acquisition-acquirer,100,49,2/9/2021
1FE3CB,facility-open,100,65,2/9/2021
228D42,partnership,100,61,2/9/2021
228D42,partnership,100,61,2/9/2021
241252,public-offering,100,43,2/9/2021
2491BC,earnings,100,50,2/9/2021
26008A,conference-call,100,50,2/9/2021
2667B6,conference-participant,100,50,2/9/2021
273BA3,partnership,100,61,2/9/2021
2.90E+62,earnings,100,50,2/9/2021
2.90E+62,dividend-up,100,81,2/9/2021
2BAE5F,dividend,100,50,2/9/2021
2CA60F,partnership,100,61,2/9/2021
2D643C,conference-participant,100,50,2/9/2021
2EB04E,earnings,100,50,2/9/2021
2EC172,earnings,100,50,2/9/2021
2F1299,earnings,100,50,2/9/2021
2F1299,earnings,100,50,2/9/2021
2F1299,earnings,100,50,2/9/2021
2F1299,earnings,100,50,2/9/2021
2F1299,earnings,100,50,2/9/2021
2F1299,earnings,100,50,2/9/2021
2F1299,earnings,100,50,2/9/2021
2F6782,conference-call,100,50,2/9/2021
2F94A5,dividend,100,50,2/9/2021
306623,business-contract,100,69,2/9/2021
306623,earnings,100,50,2/9/2021
3.14E+47,buybacks,100,74,2/9/2021
34E9F9,earnings,100,50,2/9/2021
37727A,earnings,100,50,2/9/2021
3798B9,earnings,100,50,2/9/2021
385DD4,business-contract,100,69,2/9/2021
385DD4,business-contract,100,69,2/9/2021
389CFB,conference-call,100,50,2/9/2021
38FB49,executive-appointment,100,54,2/9/2021
3B50FE,conference-call,100,50,2/9/2021
3C7F5F,dividend,100,50,2/9/2021
3CBA2A,partnership,100,61,2/9/2021
3E39A5,dividend,100,50,2/9/2021
3E70FC,earnings,100,50,2/9/2021
3F4497,earnings,100,50,2/9/2021
3F6A9C,earnings-positive,100,69,2/9/2021
3F6A9C,earnings-positive,100,69,2/9/2021
3F6A9C,earnings-positive,100,69,2/9/2021
3F6A9C,earnings-positive,100,69,2/9/2021
3F6A9C,earnings-positive,100,69,2/9/2021
3F6A9C,earnings-positive,100,69,2/9/2021
3F6A9C,earnings-positive,100,69,2/9/2021
3F96D5,executive-appointment,100,54,2/9/2021
4.00E+163,public-offering,100,43,2/9/2021
416C55,conference-participant,100,50,2/9/2021
417BF9,conference-call,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
43A74A,earnings,100,50,2/9/2021
44209A,earnings-up,100,68,2/9/2021
44209A,earnings-up,100,68,2/9/2021
44209A,earnings-up,100,68,2/9/2021
44209A,earnings-up,100,68,2/9/2021
449447,executive-appointment,100,54,2/9/2021
44DDBD,conference-call,100,50,2/9/2021
4.91E+58,earnings,100,50,2/9/2021
4A6F00,partnership,100,61,2/9/2021
4C1FA1,earnings,100,50,2/9/2021
4C7DB5,public-offering,100,43,2/9/2021
4C7DB5,public-offering,100,43,2/9/2021
4C7DB5,ownership-decrease-held,100,49,2/9/2021
4C7DB5,ownership-decrease-held,100,49,2/9/2021
4C7DB5,note-sale,100,52,2/9/2021
4EE14A,earnings,100,50,2/9/2021
4EE14A,earnings,100,50,2/9/2021
4F0A80,earnings,100,50,2/9/2021
50070E,conference-organizer,100,57,2/9/2021
50702E,earnings,100,50,2/9/2021
507AE7,dividend,100,50,2/9/2021
52B567,legal-issues-dismissed-defendant,100,79,2/9/2021
545272,earnings,100,50,2/9/2021
5480A7,dividend-up,100,57,2/9/2021
548AC0,conference-participant,100,50,2/9/2021
54A713,dividend-up,100,81,2/9/2021
556F08,executive-appointment,100,54,2/9/2021
587EDF,conference-call,100,50,2/9/2021
59A832,earnings,100,50,2/9/2021
5A9F54,fundraising,100,64,2/9/2021
5B6C11,dividend,100,50,2/9/2021
5CCDAD,earnings,100,50,2/9/2021
5E6959,partnership,100,61,2/9/2021
5FE4B6,earnings,100,50,2/9/2021
61BCA7,earnings,100,50,2/9/2021
6251A3,public-offering,100,43,2/9/2021
629F0F,earnings,100,50,2/9/2021
64854A,earnings,100,50,2/9/2021
657097,earnings,100,50,2/9/2021
665440,conference-call,100,50,2/9/2021
673C9A,earnings,100,50,2/9/2021
6810DE,executive-appointment,100,54,2/9/2021
69FDFC,earnings,100,50,2/9/2021
6CC55E,earnings,100,50,2/9/2021
6D9B53,public-offering,100,43,2/9/2021
6DDA15,earnings,100,50,2/9/2021
6F92A9,note-sale,100,52,2/9/2021
709AED,conference-participant,100,50,2/9/2021
71553E,public-offering,100,43,2/9/2021
719477,dividend,100,50,2/9/2021
73C521,executive-appointment,100,54,2/9/2021
7.44E+09,earnings,100,50,2/9/2021
74404C,conference-call,100,50,2/9/2021
762A3E,conference-organizer,100,57,2/9/2021
76B926,campaign-ad-release,100,59,2/9/2021
76BD96,conference-call,100,50,2/9/2021
76DD0C,earnings,100,50,2/9/2021
7734AC,dividend,100,50,2/9/2021
78F776,conference-participant,100,50,2/9/2021
7B0BA6,earnings,100,50,2/9/2021
7B1156,earnings,100,50,2/9/2021
7BAAE7,dividend,100,50,2/9/2021
7BFF81,earnings-positive,100,69,2/9/2021
7BFF81,earnings,100,50,2/9/2021
7BFF81,earnings,100,50,2/9/2021
7DC1C4,conference-participant,100,50,2/9/2021
7E1D5D,award,100,58,2/9/2021
7E3390,earnings,100,50,2/9/2021
7F3665,executive-appointment,100,54,2/9/2021
824CCA,earnings,100,50,2/9/2021
824CCA,earnings,100,50,2/9/2021
824CCA,earnings,100,50,2/9/2021
824CCA,earnings,100,50,2/9/2021
824CCA,earnings,100,50,2/9/2021
824CCA,buybacks,100,74,2/9/2021
8.40E+120,public-offering,100,43,2/9/2021
8665BA,partnership,100,61,2/9/2021
8AB37F,public-offering,100,43,2/9/2021
8D4486,partnership,100,61,2/9/2021
8D4486,asset-sale,100,62,2/9/2021
8F6995,earnings,100,50,2/9/2021
92B047,earnings,100,50,2/9/2021
92D9C9,earnings,100,50,2/9/2021
94208D,earnings,100,50,2/9/2021
943239,earnings,100,50,2/9/2021
957A07,conference-participant,100,50,2/9/2021
95C575,dividend,100,50,2/9/2021
9673BD,dividend,100,50,2/9/2021
968B00,dividend,100,50,2/9/2021
99028D,earnings,100,50,2/9/2021
9A29F4,earnings,100,50,2/9/2021
9CA432,note-sale,100,52,2/9/2021
9D307D,public-offering,100,43,2/9/2021
9D6A24,acquisition-acquiree,100,76,2/9/2021
9E91C6,public-offering,100,43,2/9/2021
9F18FA,earnings,100,50,2/9/2021
9F18FA,earnings,100,50,2/9/2021
A4386C,earnings,100,50,2/9/2021
A49498,conference-call,100,50,2/9/2021
A4B899,earnings,100,50,2/9/2021
A4F67C,earnings,100,50,2/9/2021
A60354,earnings,100,50,2/9/2021
A60354,earnings,100,50,2/9/2021
A60354,earnings,100,50,2/9/2021
A60354,earnings,100,50,2/9/2021
A62FD6,earnings,100,50,2/9/2021
A62FD6,earnings,100,50,2/9/2021
A666C8,earnings,100,50,2/9/2021
A6ABE9,executive-appointment,100,54,2/9/2021
A79F7D,public-offering,100,43,2/9/2021
A94718,earnings,100,50,2/9/2021
ACDF88,conference-call,100,50,2/9/2021
AD6141,earnings,100,50,2/9/2021
AE3113,conference-participant,100,50,2/9/2021
B01111,earnings,100,50,2/9/2021
B1B10C,earnings,100,50,2/9/2021
B1DF3C,earnings,100,50,2/9/2021
B1FC3B,business-contract,100,69,2/9/2021
B3CB74,conference-organizer,100,57,2/9/2021
B508E5,earnings,100,50,2/9/2021
B54A74,earnings,100,50,2/9/2021
BB5271,earnings,100,50,2/9/2021
BC5680,partnership,100,61,2/9/2021
BCC55F,award,100,58,2/9/2021
BEA527,earnings,100,50,2/9/2021
BFCACF,executive-appointment,100,54,2/9/2021
BFEA04,earnings,100,50,2/9/2021
C0BA36,earnings,100,50,2/9/2021
C0F70B,public-offering,100,43,2/9/2021
C2609A,earnings,100,50,2/9/2021
C38440,earnings,100,50,2/9/2021
C490F9,drilling,100,68,2/9/2021
C490F9,drilling,100,68,2/9/2021
C4A432,conference-call,100,50,2/9/2021
C5C137,earnings,100,50,2/9/2021
C5E100,conference-call,100,50,2/9/2021
C5F463,award,100,58,2/9/2021
C66B44,earnings,100,50,2/9/2021
C74887,public-offering,100,43,2/9/2021
C8A248,earnings,100,50,2/9/2021
C8A248,earnings,100,50,2/9/2021
C8A248,earnings,100,50,2/9/2021
C8A248,earnings,100,50,2/9/2021
C8A248,earnings,100,50,2/9/2021
C8A248,earnings,100,50,2/9/2021
C8A248,earnings,100,50,2/9/2021
C8A248,earnings,100,50,2/9/2021
C941DC,public-offering,100,43,2/9/2021
CA1620,executive-appointment,100,54,2/9/2021
CB9E13,conference-call,100,50,2/9/2021
CDC217,conference-participant,100,50,2/9/2021
CDFCC9,product-release,100,64,2/9/2021
CDFCC9,conference-participant,100,50,2/9/2021
CE4FD9,earnings,100,50,2/9/2021
CE4FD9,earnings,100,50,2/9/2021
CE4FD9,earnings,100,50,2/9/2021
CE4FD9,earnings,100,50,2/9/2021
CE5664,earnings,100,50,2/9/2021
CE5664,earnings,100,50,2/9/2021
CE5664,earnings,100,50,2/9/2021
CE5664,earnings,100,50,2/9/2021
CED4D0,earnings,100,50,2/9/2021
CFB6CA,legal-issues-dismissed-defendant,100,79,2/9/2021
CFF97C,earnings,100,50,2/9/2021
D06755,sponsorship,100,57,2/9/2021
D11C1C,executive-appointment,100,54,2/9/2021
D60BB2,partnership,100,61,2/9/2021
D6489C,product-release,100,64,2/9/2021
D6489C,reorganization-unit,100,53,2/9/2021
D6489C,reorganization-unit,100,53,2/9/2021
D64C6D,partnership,100,61,2/9/2021
D6534D,earnings,100,50,2/9/2021
D8442A,partnership,100,61,2/9/2021
D8C09D,earnings-guidance,100,50,2/9/2021
D8DA3D,earnings,100,50,2/9/2021
D8DA3D,earnings,100,50,2/9/2021
D8DA3D,earnings,100,50,2/9/2021
D8DA3D,earnings,100,50,2/9/2021
D8DA3D,earnings,100,50,2/9/2021
D8DA3D,earnings,100,50,2/9/2021
D90F43,partnership,100,61,2/9/2021
DA0CB8,earnings,100,50,2/9/2021
DA199F,partnership,100,61,2/9/2021
DA48E4,conference-participant,100,50,2/9/2021
DB06B0,note-sale,100,52,2/9/2021
DB06B0,note-sale,100,52,2/9/2021
DB396B,conference-call,100,50,2/9/2021
DBB28E,conference-call,100,50,2/9/2021
DD682D,earnings,100,50,2/9/2021
DDC415,earnings,100,50,2/9/2021
DDC415,earnings,100,50,2/9/2021
DE20DF,executive-appointment,100,54,2/9/2021
E074A0,dividend,100,50,2/9/2021
E20BFE,revenues,100,50,2/9/2021
E6EDED,earnings,100,50,2/9/2021
E72599,conference-call,100,50,2/9/2021
E74FED,executive-appointment,100,54,2/9/2021
E96E0B,legal-issues-defendant,100,22,2/9/2021
EC4E82,earnings,100,50,2/9/2021
EC4E82,earnings,100,50,2/9/2021
EC4E82,earnings,100,50,2/9/2021
EE74E1,award,100,58,2/9/2021
F0B335,earnings,100,50,2/9/2021
F11638,earnings-guidance,100,50,2/9/2021
F11638,earnings-guidance,100,50,2/9/2021
F30508,executive-appointment,100,54,2/9/2021
F4E882,earnings,100,50,2/9/2021
F509E2,earnings,100,50,2/9/2021
F57F6F,earnings,100,50,2/9/2021
F5D410,earnings,100,50,2/9/2021
F5D410,earnings,100,50,2/9/2021
F5D410,earnings,100,50,2/9/2021
F5D410,earnings,100,50,2/9/2021
F5D410,earnings,100,50,2/9/2021
F5D410,earnings,100,50,2/9/2021
F769E9,earnings,100,50,2/9/2021
F90EE5,earnings,100,50,2/9/2021
FACF19,partnership,100,61,2/9/2021
FADF1A,earnings,100,50,2/9/2021
FB7724,earnings,100,50,2/9/2021
FDD3FC,earnings,100,50,2/9/2021
FE609F,public-offering,100,43,2/9/2021
FFAB4A,earnings,100,50,2/9/2021
03B431,earnings,100,50,2/10/2021
03B431,earnings,100,50,2/10/2021
03C94A,conference-call,100,50,2/10/2021
048B70,public-offering,100,43,2/10/2021
061A3B,earnings,100,50,2/10/2021
06EF42,conference-participant,100,50,2/10/2021
07C69F,earnings,100,50,2/10/2021
98977,earnings,100,50,2/10/2021
0B4D10,earnings,100,50,2/10/2021
0C8D82,business-contract,100,69,2/10/2021
0C8D82,business-contract,100,69,2/10/2021
0C8D82,business-contract,100,69,2/10/2021
0CE204,earnings,100,50,2/10/2021
0CE7F6,earnings,100,50,2/10/2021
0DBB81,public-offering,100,43,2/10/2021
1065BC,dividend,100,50,2/10/2021
108A2B,earnings,100,50,2/10/2021
1220D2,conference-participant,100,50,2/10/2021
125212,public-offering,100,43,2/10/2021
1279ED,board-meeting,100,51,2/10/2021
136B26,business-contract,100,69,2/10/2021
149301,earnings,100,50,2/10/2021
16B183,executive-appointment,100,54,2/10/2021
1866B2,earnings,100,50,2/10/2021
1AB808,earnings,100,50,2/10/2021
1B6F77,public-offering,100,43,2/10/2021
1BC12C,earnings,100,50,2/10/2021
1D5C51,conference-call,100,50,2/10/2021
1D943E,earnings,100,50,2/10/2021
1D943E,executive-resignation,100,44,2/10/2021
1DA44F,earnings-up,100,68,2/10/2021
1DA44F,earnings-up,100,68,2/10/2021
1DA44F,earnings-up,100,68,2/10/2021
1DA44F,earnings-up,100,68,2/10/2021
1DA44F,earnings-up,100,68,2/10/2021
1DA44F,earnings-up,100,68,2/10/2021
1E1125,conference-organizer,100,57,2/10/2021
1E1125,conference-organizer,100,57,2/10/2021
1E1125,conference-organizer,100,57,2/10/2021
1E7785,conference-participant,100,50,2/10/2021
1F716B,earnings,100,50,2/10/2021
1FE7F0,earnings,100,50,2/10/2021
21153F,executive-appointment,100,54,2/10/2021
21153F,executive-appointment,100,54,2/10/2021
227F04,earnings,100,50,2/10/2021
228D42,partnership,100,61,2/10/2021
228D42,partnership,100,61,2/10/2021
2491BC,partnership,100,61,2/10/2021
24FA23,earnings,100,50,2/10/2021
25A6CC,conference-participant,100,50,2/10/2021
25DD05,earnings,100,50,2/10/2021
25DD05,board-meeting,100,51,2/10/2021
27B191,earnings,100,50,2/10/2021
27B191,earnings,100,50,2/10/2021
27B191,earnings,100,50,2/10/2021
27B191,earnings,100,50,2/10/2021
27B191,earnings,100,50,2/10/2021
27B191,dividend,100,50,2/10/2021
2950FF,earnings,100,50,2/10/2021
2950FF,earnings,100,50,2/10/2021
297DA8,conference-call,100,50,2/10/2021
2E61CC,executive-appointment,100,54,2/10/2021
315EB0,earnings,100,50,2/10/2021
315EB0,dividend,100,50,2/10/2021
31803E,earnings,100,50,2/10/2021
31DB20,earnings,100,50,2/10/2021
3.30E+30,business-contract,100,69,2/10/2021
339F20,earnings,100,50,2/10/2021
356B21,earnings,100,50,2/10/2021
39FB23,revenue-up,100,69,2/10/2021
39FB23,revenue-up,100,69,2/10/2021
39FB23,executive-appointment,100,54,2/10/2021
3A1C46,earnings,100,50,2/10/2021
3B20AB,conference-participant,100,50,2/10/2021
3B2311,earnings,100,50,2/10/2021
3FACA7,dividend,100,50,2/10/2021
401072,earnings,100,50,2/10/2021
40B903,earnings,100,50,2/10/2021
414FFF,executive-appointment,100,54,2/10/2021
414FFF,executive-appointment,100,54,2/10/2021
416C55,conference-participant,100,50,2/10/2021
41EC04,earnings,100,50,2/10/2021
43A060,business-contract,100,69,2/10/2021
442769,acquisition-acquirer,100,49,2/10/2021
442769,acquisition-acquirer,100,49,2/10/2021
442769,earnings,100,50,2/10/2021
442769,earnings,100,50,2/10/2021
442769,earnings,100,50,2/10/2021
442769,earnings,100,50,2/10/2021
444CC8,earnings-up,100,68,2/10/2021
444CC8,earnings,100,50,2/10/2021
444CC8,earnings,100,50,2/10/2021
444CC8,earnings,100,50,2/10/2021
449217,note-sale,100,52,2/10/2021
44A4FC,note-sale,100,52,2/10/2021
44A4FC,note-sale,100,52,2/10/2021
45ABCC,earnings,100,50,2/10/2021
46017C,conference-call,100,50,2/10/2021
468DD4,earnings,100,50,2/10/2021
485445,earnings,100,50,2/10/2021
4A6F00,partnership,100,61,2/10/2021
4D8313,resource-discovery,100,88,2/10/2021
50070E,conference-organizer,100,57,2/10/2021
50070E,conference-organizer,100,57,2/10/2021
504FE2,conference-participant,100,50,2/10/2021
513A86,earnings,100,50,2/10/2021
51E682,earnings,100,50,2/10/2021
532D47,earnings,100,50,2/10/2021
532D47,earnings,100,50,2/10/2021
532D47,earnings,100,50,2/10/2021
532D47,earnings,100,50,2/10/2021
56277A,conference-participant,100,50,2/10/2021
564F3E,earnings,100,50,2/10/2021
567F3D,conference-participant,100,50,2/10/2021
567F3D,conference-participant,100,50,2/10/2021
594402,campaign-ad-release,100,59,2/10/2021
5968F9,public-offering,100,43,2/10/2021
5A423F,conference-participant,100,50,2/10/2021
5AF08A,earnings,100,50,2/10/2021
5B15E1,earnings,100,50,2/10/2021
5B3FA2,earnings,100,50,2/10/2021
5C8D61,index-listing,100,76,2/10/2021
5CEE02,earnings,100,50,2/10/2021
5DD486,earnings,100,50,2/10/2021
5DD48B,earnings,100,50,2/10/2021
6166D1,executive-appointment,100,54,2/10/2021
61B81B,conference-participant,100,50,2/10/2021
622DBE,partnership,100,61,2/10/2021
63F892,partnership,100,61,2/10/2021
63F892,partnership,100,61,2/10/2021
64FF65,conference-call,100,50,2/10/2021
665D7D,partnership,100,61,2/10/2021
66E3C0,earnings,100,50,2/10/2021
69E8E1,executive-appointment,100,54,2/10/2021
69E8E1,executive-appointment,100,54,2/10/2021
69FDFC,earnings,100,50,2/10/2021
69FDFC,earnings,100,50,2/10/2021
6A01DF,investment-investor,100,55,2/10/2021
6A01DF,earnings,100,50,2/10/2021
6BC6F9,earnings,100,50,2/10/2021
6BF593,credit-extension-recipient,100,69,2/10/2021
6CB7F9,earnings,100,50,2/10/2021
6D156D,legal-issues-defendant,100,22,2/10/2021
6DBBBC,investment-investor,100,55,2/10/2021
6DBBBC,donation,100,54,2/10/2021
6E1E61,earnings,100,50,2/10/2021
6E705B,partnership,100,61,2/10/2021
6E705B,partnership,100,61,2/10/2021
6F22E7,conference-call,100,50,2/10/2021
6F3FA8,earnings,100,50,2/10/2021
6F3FA8,earnings,100,50,2/10/2021
6F3FA8,earnings,100,50,2/10/2021
6F3FA8,earnings,100,50,2/10/2021
6F3FA8,earnings,100,50,2/10/2021
6F3FA8,earnings,100,50,2/10/2021
701531,public-offering,100,43,2/10/2021
71E2EF,partnership,100,61,2/10/2021
722D55,earnings,100,50,2/10/2021
731675,earnings,100,50,2/10/2021
73A71F,dividend,100,50,2/10/2021
7A51FE,buybacks,100,74,2/10/2021
7A51FE,earnings,100,50,2/10/2021
7D35D8,earnings,100,50,2/10/2021
7DD584,revenue-up,100,70,2/10/2021
7E3F8F,earnings,100,50,2/10/2021
7F3665,executive-appointment,100,54,2/10/2021
7F3FBC,executive-appointment,100,54,2/10/2021
7F9984,earnings,100,50,2/10/2021
7F9BE2,earnings,100,50,2/10/2021
7F9BE2,dividend-up,100,81,2/10/2021
834152,note-sale,100,52,2/10/2021
834152,note-sale,100,52,2/10/2021
834152,note-sale,100,52,2/10/2021
834152,note-sale,100,52,2/10/2021
834152,note-sale,100,52,2/10/2021
834152,note-sale,100,52,2/10/2021
834152,note-sale,100,52,2/10/2021
834152,note-sale,100,52,2/10/2021
834152,note-sale,100,52,2/10/2021
84920B,earnings,100,50,2/10/2021
85CDC9,earnings,100,50,2/10/2021
85DE00,conference-participant,100,50,2/10/2021
86A1B9,business-contract,100,69,2/10/2021
87B81A,earnings,100,50,2/10/2021
87B81A,buybacks,100,74,2/10/2021
885758,earnings,100,50,2/10/2021
8AC65D,acquisition-interest-acquirer,100,46,2/10/2021
8D4AE6,earnings,100,50,2/10/2021
8D4AE6,earnings,100,50,2/10/2021
8D4AE6,earnings,100,50,2/10/2021
8D4AE6,earnings,100,50,2/10/2021
8D4AE6,earnings,100,50,2/10/2021
8D4AE6,earnings,100,50,2/10/2021
8D5145,acquisition-acquirer,100,49,2/10/2021
8DBE73,executive-appointment,100,54,2/10/2021
8DCF18,conference-call,100,50,2/10/2021
8E8E6E,earnings,100,50,2/10/2021
901327,earnings,100,50,2/10/2021
901327,earnings,100,50,2/10/2021
901327,earnings,100,50,2/10/2021
901327,earnings,100,50,2/10/2021
901327,earnings,100,50,2/10/2021
922F0C,dividend,100,50,2/10/2021
93AD2E,executive-appointment,100,54,2/10/2021
966DBE,product-release,100,64,2/10/2021
96F126,conference-participant,100,50,2/10/2021
9.74E+08,earnings,100,50,2/10/2021
9934AD,merger,100,66,2/10/2021
9B4066,dividend,100,50,2/10/2021
9B5968,executive-appointment,100,54,2/10/2021
9BB35A,conference-call,100,50,2/10/2021
9BF177,executive-appointment,100,54,2/10/2021
9C25FF,legal-issues-defendant,100,22,2/10/2021
9D307D,public-offering,100,43,2/10/2021
9D65C1,earnings,100,50,2/10/2021
9DDE1B,earnings,100,50,2/10/2021
9E8F70,dividend,100,50,2/10/2021
9F62D1,dividend,100,50,2/10/2021
9FF5F1,earnings,100,50,2/10/2021
A05C43,note-sale,100,52,2/10/2021
A16DEA,earnings,100,50,2/10/2021
A1E3B3,partnership,100,61,2/10/2021
A29DBD,earnings,100,50,2/10/2021
A398B9,buybacks,100,74,2/10/2021
A398B9,buybacks,100,74,2/10/2021
A398F8,earnings,100,50,2/10/2021
A3AAA5,dividend,100,50,2/10/2021
A48593,conference-call,100,50,2/10/2021
A4A612,earnings,100,50,2/10/2021
A6FC89,conference-call,100,50,2/10/2021
A7102F,executive-appointment,100,54,2/10/2021
AA09AD,earnings,100,50,2/10/2021
AA1EAA,earnings,100,50,2/10/2021
AA3AB8,operating-earnings,100,50,2/10/2021
AA847A,earnings,100,50,2/10/2021
AAEE21,public-offering,100,43,2/10/2021
AC7C4F,conference-participant,100,50,2/10/2021
AD1ACF,partnership,100,61,2/10/2021
AD1ACF,legal-issues-defendant,100,22,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD23DE,earnings,100,50,2/10/2021
AD3008,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
AE4EEB,earnings,100,50,2/10/2021
B1DF3C,conference-participant,100,50,2/10/2021
B1FC3B,business-contract,100,69,2/10/2021
B1FC3B,conference-participant,100,50,2/10/2021
B48FC9,conference-participant,100,50,2/10/2021
B66928,earnings,100,50,2/10/2021
B77F14,partnership,100,61,2/10/2021
BCC13E,earnings,100,50,2/10/2021
BD682F,dividend,100,50,2/10/2021
BDE867,operating-earnings,100,50,2/10/2021
BFE02C,conference-call,100,50,2/10/2021
C037A8,earnings-up,100,68,2/10/2021
C03C8B,dividend,100,50,2/10/2021
C15F8F,conference-participant,100,50,2/10/2021
C27E19,earnings,100,50,2/10/2021
C3BCD5,dividend,100,50,2/10/2021
C3CF29,earnings,100,50,2/10/2021
C3EE99,conference-call,100,50,2/10/2021
C4A912,earnings,100,50,2/10/2021
C62AA4,earnings,100,50,2/10/2021
C941DC,earnings,100,50,2/10/2021
CB88B3,earnings,100,50,2/10/2021
CBBFBF,earnings,100,50,2/10/2021
CC35BE,award,100,58,2/10/2021
CDE51C,executive-resignation,100,44,2/10/2021
CDE51C,earnings,100,50,2/10/2021
CE1002,executive-appointment,100,54,2/10/2021
CE1002,conference-participant,100,50,2/10/2021
CF3FF9,conference-participant,100,50,2/10/2021
D064D5,earnings,100,50,2/10/2021
D11C1C,earnings,100,50,2/10/2021
D139BC,earnings,100,50,2/10/2021
D17F7E,acquisition-interest-acquirer,100,46,2/10/2021
D21D8A,executive-appointment,100,54,2/10/2021
D296C6,earnings,100,50,2/10/2021
D2C0B6,earnings,100,50,2/10/2021
D45285,conference-call,100,50,2/10/2021
D4AC65,earnings,100,50,2/10/2021
D56D6D,dividend,100,50,2/10/2021
D6EAA3,award,100,58,2/10/2021
D6EAA3,partnership,100,61,2/10/2021
D76AEF,conference-call,100,50,2/10/2021
D78CCD,product-release,100,64,2/10/2021
D8442A,partnership,100,61,2/10/2021
D90F43,earnings,100,50,2/10/2021
D90F43,earnings,100,50,2/10/2021
D90F43,earnings,100,50,2/10/2021
D90F43,earnings,100,50,2/10/2021
D90F43,earnings,100,50,2/10/2021
D90F43,earnings,100,50,2/10/2021
D90F43,earnings,100,50,2/10/2021
DAFED3,dividend,100,50,2/10/2021
DB7014,conference-call,100,50,2/10/2021
DCD97F,conference-participant,100,50,2/10/2021
DDCB34,buybacks,100,74,2/10/2021
DF18E6,clinical-trials,100,56,2/10/2021
DF5F14,note-sale,100,52,2/10/2021
E00373,earnings,100,50,2/10/2021
E0207A,earnings,100,50,2/10/2021
E0D3BA,note-sale,100,52,2/10/2021
E12A6E,earnings,100,50,2/10/2021
E259C7,revenue-up,100,69,2/10/2021
E259C7,revenue-up,100,69,2/10/2021
E259C7,revenue-up,100,69,2/10/2021
E259C7,revenue-up,100,69,2/10/2021
E259C7,revenue-up,100,69,2/10/2021
E259C7,revenue-up,100,69,2/10/2021
E26FC3,dividend-up,100,81,2/10/2021
E30B34,earnings,100,50,2/10/2021
E30B34,earnings,100,50,2/10/2021
E3E68E,earnings,100,50,2/10/2021
E3E68E,earnings,100,50,2/10/2021
E592F0,headquarters-change,100,50,2/10/2021
E802CE,dividend-up,100,52,2/10/2021
E8846E,dividend,100,50,2/10/2021
E96E0B,conference-participant,100,50,2/10/2021
E96E0B,legal-issues-defendant,100,22,2/10/2021
ED0D7C,dividend,100,50,2/10/2021
ED5171,stake-acquirer,100,48,2/10/2021
EE74E1,acquisition-acquiree,100,76,2/10/2021
EE74E1,acquisition-acquiree,100,76,2/10/2021
EE74E1,earnings,100,50,2/10/2021
EE74E1,earnings,100,50,2/10/2021
EE74E1,earnings,100,50,2/10/2021
EE74E1,earnings,100,50,2/10/2021
EE74E1,legal-issues-defendant,100,22,2/10/2021
EE967B,earnings,100,50,2/10/2021
EEA6B3,earnings,100,50,2/10/2021
EEA734,legal-issues-defendant,100,22,2/10/2021
F32F88,earnings,100,50,2/10/2021
F569FD,conference-participant,100,50,2/10/2021
F5D410,note-sale,100,52,2/10/2021
F5D410,note-sale,100,52,2/10/2021
F5D410,note-sale,100,52,2/10/2021
F5D410,public-offering,100,43,2/10/2021
F6E248,clinical-trials-suspended,100,24,2/10/2021
F6E248,clinical-trials-suspended,100,24,2/10/2021
F6E248,clinical-trials-suspended,100,24,2/10/2021
F88A04,partnership,100,61,2/10/2021
F8DE55,earnings,100,50,2/10/2021
FAB97A,partnership,100,61,2/10/2021
FAB97A,earnings,100,50,2/10/2021
FAE021,dividend,100,50,2/10/2021
FAE021,dividend,100,50,2/10/2021
FC1A6E,earnings,100,50,2/10/2021
FC1B7B,conference-participant,100,50,2/10/2021
FD4BBE,conference-participant,100,50,2/10/2021
FE1A1D,product-release,100,64,2/10/2021
FF6644,partnership,100,61,2/10/2021
00067A,partnership,100,61,2/11/2021
00698D,conference-call,100,50,2/11/2021
00E601,operating-earnings,100,50,2/11/2021
0157B1,partnership,100,61,2/11/2021
02870F,earnings,100,50,2/11/2021
04996E,earnings,100,50,2/11/2021
054E7E,conference-participant,100,50,2/11/2021
61366,earnings,100,50,2/11/2021
070B45,earnings,100,50,2/11/2021
07CA6A,dividend,100,50,2/11/2021
07CA6A,dividend,100,50,2/11/2021
083F72,executive-appointment,100,54,2/11/2021
0968A5,conference-call,100,50,2/11/2021
0A0D9E,earnings,100,50,2/11/2021
0A0D9E,executive-resignation,100,44,2/11/2021
0A6824,legal-issues-defendant,100,22,2/11/2021
0CCCB7,conference-call,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0E64D4,earnings,100,50,2/11/2021
0F91FC,earnings,100,50,2/11/2021
0FABBD,conference-call,100,50,2/11/2021
10943B,earnings,100,50,2/11/2021
1096C6,earnings,100,50,2/11/2021
1201B5,revenue-up,100,69,2/11/2021
1201B5,earnings,100,50,2/11/2021
1201B5,earnings,100,50,2/11/2021
12DE76,partnership,100,61,2/11/2021
12E454,partnership,100,61,2/11/2021
131443,executive-appointment,100,54,2/11/2021
131443,executive-appointment,100,54,2/11/2021
135B09,dividend,100,50,2/11/2021
1490F3,earnings,100,50,2/11/2021
1490F3,earnings,100,50,2/11/2021
157D9F,earnings,100,50,2/11/2021
159739,executive-appointment,100,54,2/11/2021
159739,executive-appointment,100,54,2/11/2021
159AE4,earnings,100,50,2/11/2021
1.79E+10,revenue-up,100,69,2/11/2021
1.79E+10,revenues,100,50,2/11/2021
1.79E+10,revenues,100,50,2/11/2021
1.79E+10,revenues,100,50,2/11/2021
1.79E+10,dividend,100,50,2/11/2021
184866,earnings,100,50,2/11/2021
1A6A94,trading-halt,100,43,2/11/2021
1B16C1,earnings,100,50,2/11/2021
1B6F77,public-offering,100,43,2/11/2021
1CB9D3,settlement,100,56,2/11/2021
1CD09C,conference-call,100,50,2/11/2021
1E1125,conference-organizer,100,57,2/11/2021
1E1125,conference-organizer,100,57,2/11/2021
1E1125,conference-organizer,100,57,2/11/2021
1E1125,settlement,100,56,2/11/2021
2096DE,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
21153F,earnings,100,50,2/11/2021
228D42,partnership,100,61,2/11/2021
228D42,partnership,100,61,2/11/2021
241AF7,conference-call,100,50,2/11/2021
249674,earnings,100,50,2/11/2021
249674,earnings,100,50,2/11/2021
249674,earnings,100,50,2/11/2021
249674,earnings,100,50,2/11/2021
25102A,acquisition-completed-acquirer,100,49,2/11/2021
27A791,earnings,100,50,2/11/2021
27A791,conference-participant,100,50,2/11/2021
27C10F,earnings,100,50,2/11/2021
28AC4E,market-entry,100,57,2/11/2021
2C7505,earnings,100,50,2/11/2021
2CA60F,earnings,100,50,2/11/2021
2CA60F,earnings,100,50,2/11/2021
2CA60F,earnings,100,50,2/11/2021
2CA60F,earnings,100,50,2/11/2021
2D643C,executive-appointment,100,54,2/11/2021
2D981A,reverse-stock-splits,100,51,2/11/2021
2EBA55,earnings,100,50,2/11/2021
2F94A5,executive-appointment,100,54,2/11/2021
30AB63,earnings,100,50,2/11/2021
31553A,earnings,100,50,2/11/2021
31803E,conference-participant,100,50,2/11/2021
32F24A,conference-call,100,50,2/11/2021
3390DE,earnings,100,50,2/11/2021
33AD83,conference-call,100,50,2/11/2021
349DA4,earnings,100,50,2/11/2021
35F4B5,executive-appointment,100,54,2/11/2021
35F4B5,dividend-up,100,81,2/11/2021
367434,earnings,100,50,2/11/2021
36E479,earnings,100,50,2/11/2021
372037,conference-call,100,50,2/11/2021
39692D,earnings,100,50,2/11/2021
3A3948,conference-call,100,50,2/11/2021
3ACF46,earnings,100,50,2/11/2021
3C3B6B,earnings,100,50,2/11/2021
3C3B6B,earnings,100,50,2/11/2021
3C3B6B,earnings,100,50,2/11/2021
3C3B6B,earnings,100,50,2/11/2021
3C7F5F,partnership,100,61,2/11/2021
3DD5E2,earnings,100,50,2/11/2021
3DDE54,earnings,100,50,2/11/2021
3DDE54,earnings,100,50,2/11/2021
3DDE54,earnings,100,50,2/11/2021
3DDE54,earnings,100,50,2/11/2021
3DDE54,earnings,100,50,2/11/2021
3DDE54,earnings,100,50,2/11/2021
3DDE54,earnings,100,50,2/11/2021
3E39A5,earnings,100,50,2/11/2021
429BFB,earnings,100,50,2/11/2021
43E8F5,conference-call,100,50,2/11/2021
451D61,conference-call,100,50,2/11/2021
479930,earnings,100,50,2/11/2021
485445,conference-participant,100,50,2/11/2021
49F4D0,dividend,100,50,2/11/2021
4A2457,conference-call,100,50,2/11/2021
4A3438,legal-issues-defendant,100,22,2/11/2021
4A6F00,partnership,100,61,2/11/2021
4AC91D,product-release,100,64,2/11/2021
4AC91D,product-release,100,64,2/11/2021
4C2F17,earnings,100,50,2/11/2021
4C5CC9,conference-call,100,50,2/11/2021
52BF94,earnings,100,50,2/11/2021
5.43E+08,executive-appointment,100,54,2/11/2021
54A713,earnings,100,50,2/11/2021
56632F,earnings,100,50,2/11/2021
56EFC7,partnership,100,61,2/11/2021
56FB7C,dividend-up,100,81,2/11/2021
58CA9A,conference-participant,100,50,2/11/2021
5B3415,earnings,100,50,2/11/2021
5D16CF,earnings,100,50,2/11/2021
5DE5A5,earnings-up,100,68,2/11/2021
5DE5A5,earnings-up,100,68,2/11/2021
5DE5A5,earnings-up,100,68,2/11/2021
5DE5A5,earnings-up,100,68,2/11/2021
5DE5A5,conference-participant,100,50,2/11/2021
5FC507,earnings,100,50,2/11/2021
5FC507,earnings,100,50,2/11/2021
5FE4B6,dividend,100,50,2/11/2021
60EA12,dividend-up,100,81,2/11/2021
60EA12,executive-appointment,100,54,2/11/2021
60EA12,revenue-up,100,73,2/11/2021
619882,partnership,100,61,2/11/2021
64636E,conference-participant,100,50,2/11/2021
64636E,conference-participant,100,50,2/11/2021
665618,earnings-per-share-up,100,71,2/11/2021
665618,earnings-per-share-up,100,71,2/11/2021
665618,earnings-per-share-up,100,71,2/11/2021
665618,dividend-up,100,60,2/11/2021
694749,earnings,100,50,2/11/2021
69E8E1,earnings,100,50,2/11/2021
69E8E1,earnings,100,50,2/11/2021
69E8E1,earnings,100,50,2/11/2021
69E8E1,earnings,100,50,2/11/2021
69E8E1,earnings,100,50,2/11/2021
69E8E1,earnings,100,50,2/11/2021
6BDA0C,conference-call,100,50,2/11/2021
6CC55E,conference-participant,100,50,2/11/2021
6D156D,fraud-defendant,100,20,2/11/2021
6D156D,legal-issues-defendant,100,22,2/11/2021
6D156D,fraud-defendant,100,20,2/11/2021
6D156D,earnings,100,50,2/11/2021
6D2BF6,conference-participant,100,50,2/11/2021
6D9ECA,public-offering,100,43,2/11/2021
6DBBBC,unit-acquisition-acquirer,100,49,2/11/2021
6-Dec-05,conference-participant,100,50,2/11/2021
709AED,dividend,100,50,2/11/2021
709AED,executive-resignation,100,44,2/11/2021
709AED,earnings,100,50,2/11/2021
709AED,earnings,100,50,2/11/2021
709AED,earnings,100,50,2/11/2021
71553E,conference-participant,100,50,2/11/2021
717DB4,earnings,100,50,2/11/2021
7255D2,executive-appointment,100,54,2/11/2021
728737,dividend,100,50,2/11/2021
73A71F,earnings,100,50,2/11/2021
762A3E,earnings,100,50,2/11/2021
762A3E,earnings,100,50,2/11/2021
762A3E,earnings,100,50,2/11/2021
762A3E,earnings,100,50,2/11/2021
762A3E,earnings,100,50,2/11/2021
762A3E,earnings,100,50,2/11/2021
762A3E,earnings,100,50,2/11/2021
762A3E,earnings,100,50,2/11/2021
76B926,conference-call,100,50,2/11/2021
7710F3,executive-appointment,100,54,2/11/2021
789ADD,conference-participant,100,50,2/11/2021
78F9ED,earnings,100,50,2/11/2021
791D59,earnings,100,50,2/11/2021
7C790D,conference-call,100,50,2/11/2021
7F0372,earnings,100,50,2/11/2021
7F3FBC,dividend-up,100,59,2/11/2021
7F3FBC,earnings,100,50,2/11/2021
803FED,dividend,100,50,2/11/2021
80D744,earnings,100,50,2/11/2021
817ED9,earnings,100,50,2/11/2021
82F088,earnings,100,50,2/11/2021
834152,note-sale,100,52,2/11/2021
83B1C8,earnings,100,50,2/11/2021
8665BA,investment-investor,100,55,2/11/2021
88193E,conference-call,100,50,2/11/2021
895D56,conference-call,100,50,2/11/2021
89B2E7,earnings,100,50,2/11/2021
8AB85C,conference-participant,100,50,2/11/2021
8B9B3B,earnings,100,50,2/11/2021
8D0EEA,executive-appointment,100,54,2/11/2021
8DCBBB,dividend,100,50,2/11/2021
8E0E32,conference-participant,100,50,2/11/2021
8E4250,earnings,100,50,2/11/2021
8E9CD8,executive-appointment,100,54,2/11/2021
8F8F2F,conference-call,100,50,2/11/2021
903AB4,dividend,100,50,2/11/2021
915E7B,earnings,100,50,2/11/2021
922F0C,executive-appointment,100,54,2/11/2021
934029,earnings,100,50,2/11/2021
93AD2E,earnings,100,50,2/11/2021
94637C,partnership,100,61,2/11/2021
95C392,earnings,100,50,2/11/2021
9.62E+76,dividend,100,50,2/11/2021
9.65E+09,conference-call,100,50,2/11/2021
9673BD,conference-call,100,50,2/11/2021
97644E,earnings,100,50,2/11/2021
990AD0,conference-organizer,100,57,2/11/2021
9994DA,earnings,100,50,2/11/2021
9994DA,conference-participant,100,50,2/11/2021
9A2760,earnings,100,50,2/11/2021
9AF3DC,dividend,100,50,2/11/2021
9AF3DC,earnings,100,50,2/11/2021
9B5968,executive-appointment,100,54,2/11/2021
9B5968,executive-appointment,100,54,2/11/2021
9D5FA4,earnings,100,50,2/11/2021
9EA947,dividend-up,100,62,2/11/2021
9F5CBB,conference-call,100,50,2/11/2021
9F6B1A,earnings,100,50,2/11/2021
A01983,conference-call,100,50,2/11/2021
A072C4,earnings,100,50,2/11/2021
A1EAC8,earnings,100,50,2/11/2021
A398B9,earnings,100,50,2/11/2021
A398B9,earnings,100,50,2/11/2021
A398B9,earnings,100,50,2/11/2021
A398B9,earnings,100,50,2/11/2021
A3AAA5,dividend,100,50,2/11/2021
A4D173,dividend,100,50,2/11/2021
A4D173,dividend,100,50,2/11/2021
A5195E,earnings,100,50,2/11/2021
A5B913,earnings,100,50,2/11/2021
A631A3,earnings,100,50,2/11/2021
A72FD9,executive-appointment,100,54,2/11/2021
A790A5,executive-appointment,100,54,2/11/2021
A806FA,earnings,100,50,2/11/2021
AAEE21,public-offering,100,43,2/11/2021
AD1ACF,earnings,100,50,2/11/2021
AD1ACF,earnings,100,50,2/11/2021
AD1ACF,earnings,100,50,2/11/2021
AD1ACF,earnings,100,50,2/11/2021
AD1ACF,earnings,100,50,2/11/2021
AD1ACF,executive-appointment,100,54,2/11/2021
AD1ACF,dividend,100,50,2/11/2021
AD23DE,acquisition-completed-acquirer,100,49,2/11/2021
AD375D,earnings,100,50,2/11/2021
AD9F1D,earnings,100,50,2/11/2021
ADF092,earnings,100,50,2/11/2021
AEBB80,earnings,100,50,2/11/2021
AFD1CA,earnings,100,50,2/11/2021
B08C51,credit-extension-recipient,100,69,2/11/2021
B0998E,earnings,100,50,2/11/2021
B09B1F,conference-call,100,50,2/11/2021
B3CB74,executive-appointment,100,54,2/11/2021
B5DE80,earnings,100,50,2/11/2021
B66928,partnership,100,61,2/11/2021
B7202A,conference-call,100,50,2/11/2021
B72BE9,dividend,100,50,2/11/2021
B840EF,earnings,100,50,2/11/2021
BB127B,partnership,100,61,2/11/2021
BB88B6,executive-appointment,100,54,2/11/2021
BD8517,conference-participant,100,50,2/11/2021
C0030A,earnings,100,50,2/11/2021
C0030A,earnings,100,50,2/11/2021
C0030A,earnings,100,50,2/11/2021
C0030A,earnings,100,50,2/11/2021
C0030A,earnings,100,50,2/11/2021
C0030A,earnings,100,50,2/11/2021
C0030A,dividend,100,50,2/11/2021
C0F70B,public-offering,100,43,2/11/2021
C2F597,buybacks,100,74,2/11/2021
C32A39,award,100,58,2/11/2021
C356AC,earnings,100,50,2/11/2021
C356AC,dividend,100,50,2/11/2021
C356AC,unit-acquisition-acquiree,100,76,2/11/2021
C3BAE7,earnings,100,50,2/11/2021
C3EE99,award,100,58,2/11/2021
C4A432,unit-acquisition-acquirer,100,49,2/11/2021
C564E4,earnings,100,50,2/11/2021
C65004,conference-participant,100,50,2/11/2021
C66A8C,earnings,100,50,2/11/2021
C7FC95,business-contract,100,69,2/11/2021
C8923A,earnings,100,50,2/11/2021
C941DC,conference-participant,100,50,2/11/2021
C98CDB,earnings,100,50,2/11/2021
CA212F,dividend,100,50,2/11/2021
CA99D7,earnings,100,50,2/11/2021
CAB222,conference-call,100,50,2/11/2021
CBDB4D,conference-participant,100,50,2/11/2021
CC176E,earnings,100,50,2/11/2021
CC35BE,partnership,100,61,2/11/2021
CDAA0E,earnings,100,50,2/11/2021
CDE118,earnings,100,50,2/11/2021
D03C7A,dividend,100,50,2/11/2021
D1C26F,earnings,100,50,2/11/2021
D1C26F,earnings,100,50,2/11/2021
D1C26F,earnings,100,50,2/11/2021
D1C26F,earnings,100,50,2/11/2021
D36B23,legal-issues-defendant,100,22,2/11/2021
D3F64D,earnings,100,50,2/11/2021
D3F64D,earnings,100,50,2/11/2021
D3F64D,earnings,100,50,2/11/2021
D3F64D,earnings,100,50,2/11/2021
D3F64D,earnings,100,50,2/11/2021
D3F64D,earnings,100,50,2/11/2021
D3F64D,earnings,100,50,2/11/2021
D57D99,earnings,100,50,2/11/2021
D5B13D,conference-participant,100,50,2/11/2021
D6489C,partnership,100,61,2/11/2021
D64C6D,dividend,100,50,2/11/2021
D78CCD,product-release,100,64,2/11/2021
D854DD,dividend,100,50,2/11/2021
D8DA3D,dividend,100,50,2/11/2021
DB5CA5,earnings,100,50,2/11/2021
DB7014,operating-earnings,100,50,2/11/2021
DC0066,partnership,100,61,2/11/2021
DC0D18,earnings,100,50,2/11/2021
DC1405,conference-participant,100,50,2/11/2021
DDB002,conference-call,100,50,2/11/2021
E124EB,partnership,100,61,2/11/2021
E28D9C,conference-call,100,50,2/11/2021
E2F66E,conference-call,100,50,2/11/2021
E49AA3,dividend,100,50,2/11/2021
E6D89E,earnings,100,50,2/11/2021
E6D89E,earnings,100,50,2/11/2021
E6D89E,earnings,100,50,2/11/2021
E6D89E,earnings,100,50,2/11/2021
E754F0,earnings,100,50,2/11/2021
E94704,dividend,100,50,2/11/2021
E9C7C0,partnership,100,61,2/11/2021
EAA0A7,earnings,100,50,2/11/2021
EEA6B3,partnership,100,61,2/11/2021
EF25A5,partnership,100,61,2/11/2021
EF25A5,earnings,100,50,2/11/2021
EFD406,earnings,100,50,2/11/2021
EFD406,earnings,100,50,2/11/2021
EFD406,earnings,100,50,2/11/2021
EFD406,earnings,100,50,2/11/2021
EFD406,earnings,100,50,2/11/2021
EFD406,earnings,100,50,2/11/2021
EFD406,earnings,100,50,2/11/2021
F1529C,dividend,100,50,2/11/2021
F179ED,partnership,100,61,2/11/2021
F209B4,earnings,100,50,2/11/2021
F2E253,conference-call,100,50,2/11/2021
F30508,partnership,100,61,2/11/2021
F39E1E,partnership,100,61,2/11/2021
F47871,earnings,100,50,2/11/2021
F58C23,earnings,100,50,2/11/2021
F58C23,earnings,100,50,2/11/2021
F702CA,earnings,100,50,2/11/2021
FA044A,earnings,100,50,2/11/2021
FA044A,earnings,100,50,2/11/2021
FA044A,earnings,100,50,2/11/2021
FA044A,earnings,100,50,2/11/2021
FA044A,earnings,100,50,2/11/2021
FA36A4,executive-appointment,100,54,2/11/2021
FAE021,investment-investor,100,55,2/11/2021
FAE021,investment-investor,100,55,2/11/2021
FC80E6,dividend,100,50,2/11/2021
FD2565,earnings,100,50,2/11/2021
FD6926,conference-call,100,50,2/11/2021
002A99,conference-participant,100,50,2/12/2021
13528,conference-participant,100,50,2/12/2021
0157B1,product-release,100,64,2/12/2021
03FAA6,earnings,100,50,2/12/2021
43862,earnings,100,50,2/12/2021
84625,dividend,100,50,2/12/2021
0BC853,unit-acquisition-acquiree,100,76,2/12/2021
0BF198,conference-call,100,50,2/12/2021
10943B,acquisition-acquirer,100,49,2/12/2021
10943B,unit-acquisition-acquiree,100,76,2/12/2021
1096C6,business-contract,100,69,2/12/2021
125212,public-offering,100,43,2/12/2021
1348C9,merger,100,66,2/12/2021
14BA33,product-release,100,64,2/12/2021
1921DD,dividend,100,50,2/12/2021
19CAC7,dividend,100,50,2/12/2021
1E1125,conference-organizer,100,57,2/12/2021
1E1125,conference-organizer,100,57,2/12/2021
1EBF8D,business-contract,100,69,2/12/2021
1F43A1,earnings,100,50,2/12/2021
241252,public-offering,100,43,2/12/2021
24C48B,dividend,100,50,2/12/2021
25A6CC,earnings,100,50,2/12/2021
273BA3,conference-call,100,50,2/12/2021
273BA3,conference-call,100,50,2/12/2021
2C19A4,executive-appointment,100,54,2/12/2021
2CB4C9,dividend,100,50,2/12/2021
2CB4C9,dividend,100,50,2/12/2021
2CB4C9,executive-appointment,100,54,2/12/2021
30DE64,regulatory-product-approval-granted,100,81,2/12/2021
3.30E+30,business-contract,100,69,2/12/2021
3461CF,earnings,100,50,2/12/2021
34B411,fundraising,100,64,2/12/2021
353DBB,dividend,100,50,2/12/2021
383ADA,dividend,100,50,2/12/2021
407878,earnings,100,50,2/12/2021
43A060,business-contract,100,69,2/12/2021
43E8F5,conference-participant,100,50,2/12/2021
4D72C8,conference-call,100,50,2/12/2021
4D72C8,conference-call,100,50,2/12/2021
4D8313,dividend,100,50,2/12/2021
4E2D94,earnings-up,100,68,2/12/2021
53A226,dividend,100,50,2/12/2021
57B174,dividend-up,100,81,2/12/2021
5BFE94,earnings,100,50,2/12/2021
5FE4B6,executive-appointment,100,54,2/12/2021
6166D1,dividend,100,50,2/12/2021
619882,dividend,100,50,2/12/2021
6251A3,public-offering,100,43,2/12/2021
636639,dividend,100,50,2/12/2021
665D7D,conference-participant,100,50,2/12/2021
66749D,dividend,100,50,2/12/2021
67303E,legal-issues-defendant,100,22,2/12/2021
6844D2,dividend,100,50,2/12/2021
6C987C,partnership,100,61,2/12/2021
6D156D,legal-issues-defendant,100,22,2/12/2021
6D156D,legal-issues-defendant,100,22,2/12/2021
6D9ECA,public-offering,100,43,2/12/2021
701531,public-offering,100,43,2/12/2021
713810,partnership,100,61,2/12/2021
741937,dividend,100,50,2/12/2021
743C70,earnings,100,50,2/12/2021
743C70,earnings,100,50,2/12/2021
789A7D,dividend-up,100,57,2/12/2021
7AF5B8,clinical-trials-positive,100,87,2/12/2021
8377DB,executive-appointment,100,54,2/12/2021
855DF7,headquarters-change,100,50,2/12/2021
85CDC9,clinical-trials,100,56,2/12/2021
85CDC9,clinical-trials,100,56,2/12/2021
85CDC9,clinical-trials,100,56,2/12/2021
873DB9,conference-participant,100,50,2/12/2021
881190,conference-call,100,50,2/12/2021
8B4A45,earnings,100,50,2/12/2021
8FCA78,earnings,100,50,2/12/2021
934029,regulatory-product-approval-granted,100,81,2/12/2021
934029,regulatory-product-approval-granted,100,81,2/12/2021
934029,clinical-trials,100,56,2/12/2021
934029,clinical-trials,100,56,2/12/2021
934029,clinical-trials,100,56,2/12/2021
934029,clinical-trials,100,56,2/12/2021
94563D,conference-participant,100,50,2/12/2021
971334,conference-call,100,50,2/12/2021
977A1E,earnings,100,50,2/12/2021
97AF94,earnings,100,50,2/12/2021
9AF3DC,donation,100,54,2/12/2021
9C25FF,earnings,100,50,2/12/2021
9C8BC3,partnership,100,61,2/12/2021
9CE4C7,conference-participant,100,50,2/12/2021
9E575E,earnings,100,50,2/12/2021
A47A7D,business-contract,100,69,2/12/2021
A495F7,earnings,100,50,2/12/2021
A70BF5,conference-participant,100,50,2/12/2021
B04426,executive-appointment,100,54,2/12/2021
B076A1,conference-call,100,50,2/12/2021
BB58FF,conference-participant,100,50,2/12/2021
BCC13E,business-contract-terminated,100,31,2/12/2021
BDCC11,earnings,100,50,2/12/2021
BE379D,conference-call,100,50,2/12/2021
BF5959,conference-participant,100,50,2/12/2021
C0BA36,acquisition-interest-acquirer,100,46,2/12/2021
C0BA36,acquisition-interest-acquirer,100,46,2/12/2021
C0BA36,acquisition-interest-acquirer,100,46,2/12/2021
C2609A,investment-investor,100,55,2/12/2021
C3BCD5,earnings,100,50,2/12/2021
C3BCD5,conference-participant,100,50,2/12/2021
C4FBDC,conference-call,100,50,2/12/2021
CF351E,merger,100,66,2/12/2021
DA0A9E,dividend,100,50,2/12/2021
DB23C8,earnings,100,50,2/12/2021
DB9829,earnings,100,50,2/12/2021
DBFB51,dividend-up,100,81,2/12/2021
DF204B,conference-call,100,50,2/12/2021
E0E4B7,earnings,100,50,2/12/2021
E6C8DC,conference-call,100,50,2/12/2021
EB61C4,earnings,100,50,2/12/2021
ED0D7C,earnings,100,50,2/12/2021
ED0D7C,earnings,100,50,2/12/2021
ED0D7C,earnings,100,50,2/12/2021
ED0D7C,earnings,100,50,2/12/2021
ED0D7C,earnings,100,50,2/12/2021
ED0D7C,earnings,100,50,2/12/2021
F6DA75,earnings,100,50,2/12/2021
F85CC0,joint-venture,100,62,2/12/2021
F85CC0,joint-venture,100,62,2/12/2021
FD554E,conference-call,100,50,2/12/2021
FDF799,earnings,100,50,2/12/2021
FE609F,public-offering,100,43,2/12/2021
FF4BA4,dividend,100,50,2/12/2021
FF6644,dividend,100,50,2/12/2021
67303E,legal-issues-defendant,100,22,2/13/2021
6D156D,legal-issues-defendant,100,22,2/13/2021
966DBE,earnings,100,50,2/13/2021
A6213D,revenues,100,50,2/13/2021
A63387,legal-issues-defendant,100,22,2/13/2021
E96E0B,fraud-defendant,100,20,2/13/2021
ED0D7C,earnings,100,50,2/13/2021
EE74E1,legal-issues-defendant,100,22,2/13/2021
3B2311,legal-issues-defendant,100,22,2/14/2021
6D156D,legal-issues-defendant,100,22,2/14/2021
7CD98F,legal-issues-defendant,100,22,2/14/2021
9934AD,legal-issues-defendant,100,22,2/14/2021
A63387,legal-issues-defendant,100,22,2/14/2021
10943B,unit-acquisition-acquiree,100,76,2/15/2021
1151F4,product-release,100,64,2/15/2021
12F98C,conference-call,100,50,2/15/2021
143C52,donation,100,54,2/15/2021
143C9C,dividend-guidance,100,50,2/15/2021
1.79E+10,acquisition-acquirer,100,49,2/15/2021
1.79E+10,acquisition-acquirer,100,49,2/15/2021
1921DD,dividend,100,50,2/15/2021
1B5FEA,conference-participant,100,50,2/15/2021
1B637E,product-release,100,64,2/15/2021
1CD708,conference-call,100,50,2/15/2021
2.89E+11,dividend,100,50,2/15/2021
2E902B,conference-participant,100,50,2/15/2021
385DD4,facility-open,100,65,2/15/2021
39FB23,product-release,100,64,2/15/2021
4DD09F,business-contract,100,69,2/15/2021
51F541,earnings,100,50,2/15/2021
5FDBD0,operating-earnings,100,50,2/15/2021
67303E,legal-issues-defendant,100,22,2/15/2021
67303E,legal-issues-defendant,100,22,2/15/2021
67303E,legal-issues-defendant,100,22,2/15/2021
6BDA0C,acquisition-acquirer,100,49,2/15/2021
6BDA0C,acquisition-acquirer,100,49,2/15/2021
6BDA0C,acquisition-acquirer,100,49,2/15/2021
6D156D,legal-issues-defendant,100,22,2/15/2021
6D156D,legal-issues-defendant,100,22,2/15/2021
797C20,earnings-per-share-up,100,58,2/15/2021
8A8E41,acquisition-acquirer,100,49,2/15/2021
8A8E41,acquisition-acquirer,100,49,2/15/2021
8E82A6,executive-appointment,100,54,2/15/2021
901327,award,100,58,2/15/2021
9EBAFA,conference-call,100,50,2/15/2021
A47F2E,earnings,100,50,2/15/2021
A63387,legal-issues-defendant,100,22,2/15/2021
AD1ACF,legal-issues-defendant,100,22,2/15/2021
B3CB74,conference-organizer,100,57,2/15/2021
C16A8F,dividend,100,50,2/15/2021
C9A96E,conference-participant,100,50,2/15/2021
C9A96E,conference-participant,100,50,2/15/2021
CB89EA,earnings,100,50,2/15/2021
CDEDFE,earnings-revision,100,29,2/15/2021
CF351E,earnings,100,50,2/15/2021
CFD4B6,dividend,100,50,2/15/2021
CFF15D,partnership,100,61,2/15/2021
CFF97C,credit-rating-upgrade-rater,20,50,2/15/2021
E0647D,earnings,100,50,2/15/2021
E96E0B,legal-issues-defendant,100,22,2/15/2021
ECF709,earnings,100,50,2/15/2021
EEA734,legal-issues-defendant,100,22,2/15/2021
F6A987,earnings,100,50,2/15/2021
9397,executive-resignation,100,44,2/16/2021
01B8D6,earnings,100,50,2/16/2021
01B8D6,conference-participant,100,50,2/16/2021
03B8CF,investment-investor,100,55,2/16/2021
03B8CF,investment-investor,100,55,2/16/2021
03D5F9,award,100,58,2/16/2021
03D5F9,award,100,58,2/16/2021
040DBB,conference-call,100,50,2/16/2021
04EB2F,earnings,100,50,2/16/2021
09062E,conference-participant,100,50,2/16/2021
099C88,government-contract,100,69,2/16/2021
0A9D0A,earnings,100,50,2/16/2021
0BC29E,earnings,100,50,2/16/2021
0BF198,conference-call,100,50,2/16/2021
0C355F,conference-call,100,50,2/16/2021
0CE204,business-contract,100,69,2/16/2021
0CE204,business-contract,100,69,2/16/2021
0F65C9,earnings,100,50,2/16/2021
0F65C9,dividend,100,50,2/16/2021
0FC848,executive-appointment,100,54,2/16/2021
1220D2,earnings,100,50,2/16/2021
126F95,dividend,100,50,2/16/2021
1272B3,earnings,100,50,2/16/2021
12731D,conference-call,100,50,2/16/2021
12731D,conference-call,100,50,2/16/2021
12E454,partnership,100,61,2/16/2021
1348C9,dividend,100,50,2/16/2021
14BA06,earnings,100,50,2/16/2021
157CC1,conference-participant,100,50,2/16/2021
1A6A94,trading-resumed,100,58,2/16/2021
1AE482,earnings,100,50,2/16/2021
1BC12C,product-release,100,64,2/16/2021
1CDD1C,earnings,100,50,2/16/2021
1DEBBE,earnings,100,50,2/16/2021
1E1125,conference-organizer,100,57,2/16/2021
1E1125,conference-organizer,100,57,2/16/2021
1E4FB9,earnings,100,50,2/16/2021
1F19C8,credit-extension-provider,100,57,2/16/2021
1F43A1,note-sale,100,52,2/16/2021
1FAF22,dividend,100,50,2/16/2021
1FAF22,executive-appointment,100,54,2/16/2021
223216,ebitda-up,100,58,2/16/2021
23207A,revenue-up,100,57,2/16/2021
23207A,revenue-up,100,57,2/16/2021
24C48B,conference-participant,100,50,2/16/2021
26E3BA,revenues,100,50,2/16/2021
284289,dividend-up,100,81,2/16/2021
28B730,earnings,100,50,2/16/2021
2920D5,conference-call,100,50,2/16/2021
2.90E+62,conference-participant,100,50,2/16/2021
2A17B1,dividend-up,100,81,2/16/2021
2B5483,going-private,100,74,2/16/2021
2B8179,conference-participant,100,50,2/16/2021
2BAE5F,earnings,100,50,2/16/2021
2BAE5F,earnings,100,50,2/16/2021
2BAE5F,earnings,100,50,2/16/2021
2C681C,partnership,100,61,2/16/2021
2C681C,partnership,100,61,2/16/2021
2C681C,conference-call,100,50,2/16/2021
2F960F,earnings,100,50,2/16/2021
31643A,facility-close,100,47,2/16/2021
317EC6,conference-participant,100,50,2/16/2021
34E9F9,earnings,100,50,2/16/2021
37020C,business-combination,100,54,2/16/2021
37020C,business-combination,100,54,2/16/2021
37020C,business-combination,100,54,2/16/2021
37020C,earnings,100,50,2/16/2021
37E18B,earnings,100,50,2/16/2021
3B318A,conference-call,100,50,2/16/2021
3BB616,earnings,100,50,2/16/2021
3C8A04,dividend,100,50,2/16/2021
3DCECC,conference-participant,100,50,2/16/2021
3F96D5,earnings,100,50,2/16/2021
3FBC9B,note-sale,100,52,2/16/2021
4017AD,earnings,100,50,2/16/2021
416C55,executive-appointment,100,54,2/16/2021
41785E,conference-participant,100,50,2/16/2021
427F32,executive-appointment,100,54,2/16/2021
429BFB,conference-participant,100,50,2/16/2021
42AABD,earnings,100,50,2/16/2021
4398A2,public-offering,100,43,2/16/2021
43A060,business-contract,100,69,2/16/2021
448BF3,earnings,100,50,2/16/2021
44DDBD,earnings-up,100,68,2/16/2021
45BC35,earnings,100,50,2/16/2021
467F2C,earnings,100,50,2/16/2021
4.60E+06,executive-appointment,100,54,2/16/2021
48F795,conference-participant,100,50,2/16/2021
49BBBC,executive-appointment,100,54,2/16/2021
4A3438,legal-issues-defendant,100,22,2/16/2021
4BDCA7,conference-call,100,50,2/16/2021
4C2F17,conference-participant,100,50,2/16/2021
4D371E,award,100,58,2/16/2021
4D72C8,earnings,100,50,2/16/2021
4D72C8,earnings,100,50,2/16/2021
4D72C8,earnings,100,50,2/16/2021
4D72C8,earnings,100,50,2/16/2021
4D8313,executive-resignation,100,44,2/16/2021
4DD09F,earnings,100,50,2/16/2021
4F9926,partnership,100,61,2/16/2021
4F9926,partnership,100,61,2/16/2021
4F9926,partnership,100,61,2/16/2021
504FE2,legal-issues-defendant,100,22,2/16/2021
50702E,award,100,58,2/16/2021
50702E,award,100,58,2/16/2021
51888A,dividend,100,50,2/16/2021
53EF9E,earnings,100,50,2/16/2021
53F491,facility-sale,100,52,2/16/2021
545272,conference-participant,100,50,2/16/2021
54B889,conference-call,100,50,2/16/2021
54F271,acquisition-completed-acquirer,100,49,2/16/2021
556F08,conference-participant,100,50,2/16/2021
56765E,dividend-up,100,81,2/16/2021
56B7C1,executive-appointment,100,54,2/16/2021
56FB7C,earnings,100,50,2/16/2021
57B174,earnings,100,50,2/16/2021
596116,earnings,100,50,2/16/2021
5968F9,public-offering,100,43,2/16/2021
5A53BF,earnings,100,50,2/16/2021
5AA3B1,earnings,100,50,2/16/2021
5C2A47,earnings,100,50,2/16/2021
5D41E4,executive-appointment,100,54,2/16/2021
615B6D,earnings,100,50,2/16/2021
615B6D,earnings,100,50,2/16/2021
619882,conference-organizer,100,57,2/16/2021
633054,executive-appointment,100,54,2/16/2021
65AB30,earnings,100,50,2/16/2021
6634D9,earnings,100,50,2/16/2021
67303E,legal-issues-defendant,100,22,2/16/2021
67303E,legal-issues-defendant,100,22,2/16/2021
67A658,executive-appointment,100,54,2/16/2021
67A658,executive-appointment,100,54,2/16/2021
67B052,executive-appointment,100,54,2/16/2021
67B052,executive-appointment,100,54,2/16/2021
69C99E,earnings,100,50,2/16/2021
69CE71,earnings,100,50,2/16/2021
6A6BDC,product-release,100,64,2/16/2021
6B236C,earnings,100,50,2/16/2021
6B494E,earnings,100,50,2/16/2021
6D156D,legal-issues-defendant,100,22,2/16/2021
6D6B40,earnings,100,50,2/16/2021
6F5DD2,earnings,100,50,2/16/2021
701531,earnings,100,50,2/16/2021
7255D2,partnership,100,61,2/16/2021
7255D2,partnership,100,61,2/16/2021
72609A,earnings,100,50,2/16/2021
751C8D,award,100,58,2/16/2021
751C8D,award,100,58,2/16/2021
767F86,conference-participant,100,50,2/16/2021
769F40,acquisition-acquiree,100,76,2/16/2021
7732C2,partnership,100,61,2/16/2021
78F776,executive-appointment,100,54,2/16/2021
7A51FE,dividend,100,50,2/16/2021
7AD81E,earnings,100,50,2/16/2021
7B9AFA,conference-participant,100,50,2/16/2021
7BAAE7,dividend,100,50,2/16/2021
7CBC40,earnings,100,50,2/16/2021
7E3F8F,note-sale,100,52,2/16/2021
7E3F8F,note-sale,100,52,2/16/2021
8.10E+32,dividend,100,50,2/16/2021
810FAD,executive-appointment,100,54,2/16/2021
8303CD,earnings,100,50,2/16/2021
83066C,conference-call,100,50,2/16/2021
834152,note-sale,100,52,2/16/2021
859D62,earnings,100,50,2/16/2021
85DA04,earnings,100,50,2/16/2021
85DA04,earnings,100,50,2/16/2021
85DA04,earnings,100,50,2/16/2021
85DA04,earnings,100,50,2/16/2021
85DA04,earnings,100,50,2/16/2021
85DA04,earnings,100,50,2/16/2021
85DE00,conference-participant,100,50,2/16/2021
860AB6,earnings,100,50,2/16/2021
862941,earnings,100,50,2/16/2021
881190,dividend,100,50,2/16/2021
88350F,operating-earnings-positive,100,69,2/16/2021
88350F,earnings-per-share,100,50,2/16/2021
88350F,earnings-per-share,100,50,2/16/2021
88350F,earnings-per-share,100,50,2/16/2021
88350F,earnings-per-share,100,50,2/16/2021
88350F,executive-appointment,100,54,2/16/2021
8A8E41,executive-appointment,100,54,2/16/2021
8AB37F,conference-participant,100,50,2/16/2021
8AC740,executive-appointment,100,54,2/16/2021
8AC740,earnings,100,50,2/16/2021
8C6C1B,conference-call,100,50,2/16/2021
8D4AE6,executive-appointment,100,54,2/16/2021
8E3F58,partnership,100,61,2/16/2021
8E9CD8,earnings,100,50,2/16/2021
8EEA28,earnings,100,50,2/16/2021
8FF2EF,acquisition-acquirer,100,49,2/16/2021
8FF2EF,acquisition-acquirer,100,49,2/16/2021
8FF2EF,campaign-ad-release,100,59,2/16/2021
902670,conference-call,100,50,2/16/2021
905356,earnings-per-share-positive,100,69,2/16/2021
905356,earnings,100,50,2/16/2021
905356,earnings,100,50,2/16/2021
9087B9,conference-call,100,50,2/16/2021
911CA9,executive-appointment,100,54,2/16/2021
911CA9,executive-appointment,100,54,2/16/2021
911CA9,partnership,100,61,2/16/2021
911CA9,business-contract,100,69,2/16/2021
9196A2,conference-organizer,100,57,2/16/2021
9196A2,dividend,100,50,2/16/2021
93D207,conference-participant,100,50,2/16/2021
93F143,executive-appointment,100,54,2/16/2021
94983E,earnings,100,50,2/16/2021
949D62,conference-participant,100,50,2/16/2021
94C0B5,conference-call,100,50,2/16/2021
9507FF,earnings,100,50,2/16/2021
95DC1F,partnership,100,61,2/16/2021
95DE39,dividend,100,50,2/16/2021
968103,earnings,100,50,2/16/2021
96A2D3,public-offering,100,43,2/16/2021
972356,acquisition-interest-acquiree,100,82,2/16/2021
972356,acquisition-interest-acquiree,100,82,2/16/2021
972356,acquisition-interest-acquiree,100,82,2/16/2021
990AD0,conference-organizer,100,57,2/16/2021
99B61C,public-offering,100,43,2/16/2021
99B61C,earnings,100,50,2/16/2021
9ABD30,executive-appointment,100,54,2/16/2021
9E8F70,executive-resignation,100,44,2/16/2021
9EA947,executive-resignation,100,44,2/16/2021
9EA947,partnership,100,61,2/16/2021
9F6B1A,executive-appointment,100,54,2/16/2021
A01983,dividend,100,50,2/16/2021
A23747,earnings,100,50,2/16/2021
A350C1,earnings,100,50,2/16/2021
A41450,earnings,100,50,2/16/2021
A4CD53,conference-participant,100,50,2/16/2021
A52B6B,acquisition-interest-acquirer,100,46,2/16/2021
A7102F,executive-appointment,100,54,2/16/2021
A753BB,executive-appointment,100,54,2/16/2021
A790A5,executive-resignation,100,44,2/16/2021
A790A5,executive-resignation,100,44,2/16/2021
A790A5,earnings-positive,100,69,2/16/2021
A790A5,earnings,100,50,2/16/2021
A790A5,earnings,100,50,2/16/2021
A790A5,earnings,100,50,2/16/2021
A868C9,conference-participant,100,50,2/16/2021
A87CD6,earnings-per-share-down,100,24,2/16/2021
A87CD6,earnings-per-share-positive,100,69,2/16/2021
A87CD6,earnings-per-share-positive,100,69,2/16/2021
A87CD6,earnings-per-share-positive,100,69,2/16/2021
A87CD6,earnings-per-share-positive,100,69,2/16/2021
A87CD6,earnings-per-share-positive,100,69,2/16/2021
A87CD6,earnings-per-share-positive,100,69,2/16/2021
A87CD6,earnings-per-share-positive,100,69,2/16/2021
A87CD6,earnings-per-share-positive,100,69,2/16/2021
A87CD6,earnings-per-share-down,100,24,2/16/2021
A8CBDA,conference-participant,100,50,2/16/2021
AA247D,acquisition-acquirer,100,49,2/16/2021
AA247D,acquisition-acquirer,100,49,2/16/2021
AA247D,unit-acquisition-acquirer,100,49,2/16/2021
AAC8B6,dividend,100,50,2/16/2021
AAC8B6,dividend,100,50,2/16/2021
ACDF88,donation,100,54,2/16/2021
ACDF88,conference-participant,100,50,2/16/2021
AD22F2,earnings,100,50,2/16/2021
AD6141,executive-appointment,100,54,2/16/2021
ADF1B0,conference-call,100,50,2/16/2021
B1A85D,earnings,100,50,2/16/2021
B33E77,earnings,100,50,2/16/2021
B37FB4,earnings,100,50,2/16/2021
B37FB4,earnings,100,50,2/16/2021
B37FB4,earnings,100,50,2/16/2021
B37FB4,earnings,100,50,2/16/2021
B37FB4,earnings,100,50,2/16/2021
B37FB4,earnings,100,50,2/16/2021
B37FB4,earnings,100,50,2/16/2021
B37FB4,earnings,100,50,2/16/2021
B3A166,dividend,100,50,2/16/2021
B3CB74,conference-organizer,100,57,2/16/2021
B3CB74,conference-organizer,100,57,2/16/2021
B3CB74,conference-organizer,100,57,2/16/2021
B3CB74,conference-organizer,100,57,2/16/2021
B3CB74,conference-organizer,100,57,2/16/2021
B3CB74,conference-organizer,100,57,2/16/2021
B7EB38,conference-participant,100,50,2/16/2021
B83BCE,partnership,100,61,2/16/2021
B8F71F,conference-participant,100,50,2/16/2021
B98EFA,conference-participant,100,50,2/16/2021
B9B6B8,partnership,100,61,2/16/2021
BB0587,earnings,100,50,2/16/2021
BC4876,earnings,100,50,2/16/2021
BCE9DA,earnings,100,50,2/16/2021
BCE9DA,earnings,100,50,2/16/2021
BCE9DA,earnings,100,50,2/16/2021
BDD12C,dividend,100,50,2/16/2021
BEA527,executive-appointment,100,54,2/16/2021
BEA527,earnings,100,50,2/16/2021
C03C8B,earnings,100,50,2/16/2021
C062D4,conference-participant,100,50,2/16/2021
C0BA36,conference-participant,100,50,2/16/2021
C2E426,earnings,100,50,2/16/2021
C2F597,conference-participant,100,50,2/16/2021
C3DE7D,partnership,100,61,2/16/2021
C45CE7,dividend,100,50,2/16/2021
C54140,earnings,100,50,2/16/2021
C5C137,executive-appointment,100,54,2/16/2021
C72B8F,note-sale,100,52,2/16/2021
C7859D,conference-participant,100,50,2/16/2021
C8257F,earnings,100,50,2/16/2021
C8A248,partnership,100,61,2/16/2021
CA14CC,dividend,100,50,2/16/2021
CC8F6E,earnings,100,50,2/16/2021
CD4DA8,conference-organizer,100,57,2/16/2021
CDC817,conference-call,100,50,2/16/2021
CE5C6E,executive-appointment,100,54,2/16/2021
CE5C6E,earnings,100,50,2/16/2021
CEC08B,executive-appointment,100,54,2/16/2021
CEC08B,partnership,100,61,2/16/2021
D06755,sponsorship,100,57,2/16/2021
D1AE3B,executive-appointment,100,54,2/16/2021
D296C6,earnings,100,50,2/16/2021
D60BB2,dividend-up,100,81,2/16/2021
D854DD,executive-appointment,100,54,2/16/2021
DB23C8,conference-participant,100,50,2/16/2021
DD1BA1,business-contract,100,69,2/16/2021
DD3BB1,executive-appointment,100,54,2/16/2021
DD3BB1,executive-appointment,100,54,2/16/2021
DF01B1,revenue-up,100,69,2/16/2021
DF01B1,revenue-up,100,69,2/16/2021
DF01B1,revenue-up,100,69,2/16/2021
DF01B1,revenue-up,100,69,2/16/2021
E30B34,executive-appointment,100,54,2/16/2021
E4CE73,product-release,100,64,2/16/2021
E68733,earnings,100,50,2/16/2021
E68733,earnings,100,50,2/16/2021
E68C3D,dividend-up,100,61,2/16/2021
E69BA5,earnings,100,50,2/16/2021
E6BC2C,earnings,100,50,2/16/2021
E6BC2C,private-placement,100,56,2/16/2021
E82A2D,conference-call,100,50,2/16/2021
E87676,earnings,100,50,2/16/2021
E87676,earnings,100,50,2/16/2021
E87676,earnings,100,50,2/16/2021
EA62FC,business-combination,100,54,2/16/2021
EA62FC,business-combination,100,54,2/16/2021
EA62FC,business-combination,100,54,2/16/2021
EA62FC,earnings,100,50,2/16/2021
EB2F14,dividend,100,50,2/16/2021
EB36DE,earnings,100,50,2/16/2021
ECE814,conference-participant,100,50,2/16/2021
ED0402,acquisition-interest-acquirer,100,46,2/16/2021
ED79D9,earnings,100,50,2/16/2021
ED7F13,earnings,100,50,2/16/2021
EDF5CA,buybacks,100,74,2/16/2021
EE04F0,earnings,100,50,2/16/2021
EEEA9F,ownership-decrease-owner,100,46,2/16/2021
EEEA9F,business-contract,100,69,2/16/2021
EF25A5,partnership,100,61,2/16/2021
F31B13,executive-appointment,100,54,2/16/2021
F3816D,conference-participant,100,50,2/16/2021
F39E1E,earnings,100,50,2/16/2021
F4F46F,conference-participant,100,50,2/16/2021
F57F6F,conference-participant,100,50,2/16/2021
F5C8AB,earnings-per-share-positive,100,69,2/16/2021
F5C8AB,earnings-per-share,100,50,2/16/2021
F5C8AB,earnings-per-share,100,50,2/16/2021
F5C8AB,earnings-per-share,100,50,2/16/2021
F6E248,partnership,100,61,2/16/2021
F793FA,executive-appointment,100,54,2/16/2021
F93C8A,dividend,100,50,2/16/2021
F9AA02,public-offering,100,43,2/16/2021
FC1B7B,dividend,100,50,2/16/2021
FD2565,conference-participant,100,50,2/16/2021
FD6926,conference-participant,100,50,2/16/2021
FD9526,dividend,100,50,2/16/2021
FDF28E,earnings,100,50,2/16/2021
00D6B5,earnings,100,50,2/17/2021
00FC70,dividend,100,50,2/17/2021
018C11,earnings,100,50,2/17/2021
01D03F,product-release,100,64,2/17/2021
02FC1A,conference-participant,100,50,2/17/2021
03D5F9,earnings,100,50,2/17/2021
06EE79,earnings,100,50,2/17/2021
091B6C,conference-participant,100,50,2/17/2021
95294,business-contract,100,69,2/17/2021
0A7650,buybacks,100,74,2/17/2021
0A9D0A,business-contract,100,69,2/17/2021
0B13E8,conference-call,100,50,2/17/2021
0B4D10,dividend,100,50,2/17/2021
0C28D1,credit-rating-outlook-revision,100,50,2/17/2021
0C28D1,partnership,100,61,2/17/2021
0EF1AF,conference-participant,100,50,2/17/2021
0F0440,executive-appointment,100,54,2/17/2021
10673F,dividend-up,100,81,2/17/2021
1080C0,earnings,100,50,2/17/2021
112694,conference-participant,100,50,2/17/2021
1151F4,dividend-up,100,56,2/17/2021
1279ED,earnings,100,50,2/17/2021
143C52,conference-call,100,50,2/17/2021
152B9E,earnings,100,50,2/17/2021
154272,clinical-trials-filed,100,60,2/17/2021
159739,earnings,100,50,2/17/2021
159739,earnings,100,50,2/17/2021
16C544,executive-appointment,100,54,2/17/2021
184988,conference-participant,100,50,2/17/2021
197612,dividend,100,50,2/17/2021
1A5957,earnings,100,50,2/17/2021
1B637E,partnership,100,61,2/17/2021
1DB833,executive-appointment,100,54,2/17/2021
1E1125,conference-organizer,100,57,2/17/2021
1E1125,conference-organizer,100,57,2/17/2021
1E1125,conference-organizer,100,57,2/17/2021
1E1125,conference-organizer,100,57,2/17/2021
1F08A6,earnings,100,50,2/17/2021
2031CE,dividend,100,50,2/17/2021
20D00A,earnings,100,50,2/17/2021
20D00A,earnings,100,50,2/17/2021
20D00A,earnings,100,50,2/17/2021
20D00A,earnings,100,50,2/17/2021
20D00A,earnings,100,50,2/17/2021
20D00A,earnings,100,50,2/17/2021
20D00A,earnings,100,50,2/17/2021
20D00A,earnings,100,50,2/17/2021
21022F,earnings,100,50,2/17/2021
221445,conference-call,100,50,2/17/2021
223552,partnership,100,61,2/17/2021
223552,partnership,100,61,2/17/2021
223552,partnership,100,61,2/17/2021
228D42,partnership,100,61,2/17/2021
228D42,revenue-up,100,67,2/17/2021
228D42,revenue-up,100,67,2/17/2021
228D42,revenue-up,100,67,2/17/2021
24FA23,earnings,100,50,2/17/2021
267718,executive-appointment,100,54,2/17/2021
267718,executive-appointment,100,54,2/17/2021
26DC29,conference-call,100,50,2/17/2021
28AC4E,acquisition-acquirer,100,49,2/17/2021
297DA8,business-contract,100,69,2/17/2021
2B49F4,executive-appointment,100,54,2/17/2021
2B5483,acquisition-completed-acquiree,100,76,2/17/2021
2CC60C,earnings,100,50,2/17/2021
2F5256,executive-appointment,100,54,2/17/2021
2F6782,dividend-up,100,54,2/17/2021
341759,conference-participant,100,50,2/17/2021
34E9F9,note-sale,100,52,2/17/2021
35AE32,earnings,100,50,2/17/2021
366A08,earnings,100,50,2/17/2021
384CD3,dividend,100,50,2/17/2021
396D7C,earnings,100,50,2/17/2021
3B8484,earnings,100,50,2/17/2021
3BB7D3,conference-participant,100,50,2/17/2021
3DCECC,earnings,100,50,2/17/2021
401072,earnings,100,50,2/17/2021
4017AD,dividend,100,50,2/17/2021
408089,dividend,100,50,2/17/2021
4455C4,earnings,100,50,2/17/2021
4455C4,earnings,100,50,2/17/2021
4455C4,earnings,100,50,2/17/2021
4455C4,earnings,100,50,2/17/2021
4455C4,earnings,100,50,2/17/2021
458D2C,revenue-volume,100,50,2/17/2021
47752F,earnings,100,50,2/17/2021
47FCF2,earnings,100,50,2/17/2021
4.91E+58,executive-appointment,100,54,2/17/2021
49A344,earnings,100,50,2/17/2021
49A344,earnings,100,50,2/17/2021
49A344,earnings,100,50,2/17/2021
4A3438,business-contract,100,69,2/17/2021
4A3438,legal-issues-defendant,100,22,2/17/2021
4A6F00,partnership,100,61,2/17/2021
4A6F00,partnership,100,61,2/17/2021
4A6F00,partnership,100,61,2/17/2021
4AC91D,executive-appointment,100,54,2/17/2021
4B5054,dividend,100,50,2/17/2021
4C2F17,partnership,100,61,2/17/2021
4C2F17,partnership,100,61,2/17/2021
4C350A,earnings,100,50,2/17/2021
4C37C5,facility-open,100,65,2/17/2021
4C92B9,acquisition-acquirer,100,49,2/17/2021
4D8124,dividend-up,100,81,2/17/2021
4E6F5A,conference-participant,100,50,2/17/2021
504FE2,fraud,100,44,2/17/2021
504FE2,legal-issues-defendant,100,22,2/17/2021
504FE2,legal-issues-defendant,100,22,2/17/2021
513A86,conference-participant,100,50,2/17/2021
53F491,dividend,100,50,2/17/2021
55438C,executive-resignation,100,44,2/17/2021
57A854,earnings,100,50,2/17/2021
583223,dividend,100,50,2/17/2021
58C2D4,earnings,100,50,2/17/2021
58EA22,executive-appointment,100,54,2/17/2021
594402,earnings,100,50,2/17/2021
59F0B0,conference-call,100,50,2/17/2021
5AF08A,executive-appointment,100,54,2/17/2021
5C2A47,executive-appointment,100,54,2/17/2021
5D63F1,earnings,100,50,2/17/2021
5D87DF,dividend,100,50,2/17/2021
5FC507,conference-participant,100,50,2/17/2021
61A586,conference-participant,100,50,2/17/2021
61E975,earnings-positive,100,69,2/17/2021
649CBD,partnership,100,61,2/17/2021
649CBD,partnership,100,61,2/17/2021
649CBD,clinical-trials,100,56,2/17/2021
64E346,executive-appointment,100,54,2/17/2021
64E346,executive-appointment,100,54,2/17/2021
64E615,earnings,100,50,2/17/2021
6559D8,partnership,100,61,2/17/2021
66E04A,earnings,100,50,2/17/2021
67303E,legal-issues-defendant,100,22,2/17/2021
67303E,legal-issues-defendant,100,22,2/17/2021
67303E,legal-issues-defendant,100,22,2/17/2021
676FFD,earnings,100,50,2/17/2021
68E3E0,conference-call,100,50,2/17/2021
68E6E9,dividend,100,50,2/17/2021
698FF9,credit-extension-recipient,100,69,2/17/2021
698FF9,earnings,100,50,2/17/2021
6A171E,campaign-ad-release,100,59,2/17/2021
6A3C35,earnings,100,50,2/17/2021
6A3C35,earnings,100,50,2/17/2021
6A3C35,earnings,100,50,2/17/2021
6A3C35,earnings,100,50,2/17/2021
6A3C35,earnings,100,50,2/17/2021
6A3C35,earnings,100,50,2/17/2021
6D156D,legal-issues-defendant,100,22,2/17/2021
6D156D,legal-issues-defendant,100,22,2/17/2021
6D3B7B,dividend,100,50,2/17/2021
6DC1D7,conference-call,100,50,2/17/2021
6E7060,earnings,100,50,2/17/2021
6E8864,earnings,100,50,2/17/2021
6EB9DA,executive-appointment,100,54,2/17/2021
6ED519,earnings,100,50,2/17/2021
6ED519,earnings,100,50,2/17/2021
6ED519,earnings,100,50,2/17/2021
6F0096,earnings,100,50,2/17/2021
6F22E7,earnings,100,50,2/17/2021
701531,public-offering,100,43,2/17/2021
722DE3,business-contract,100,69,2/17/2021
7273FF,earnings,100,50,2/17/2021
729368,earnings,100,50,2/17/2021
72C2CE,earnings,100,50,2/17/2021
73BCBA,earnings,100,50,2/17/2021
73BCBA,earnings,100,50,2/17/2021
73BCBA,earnings,100,50,2/17/2021
73BCBA,earnings,100,50,2/17/2021
73F70F,dividend,100,50,2/17/2021
769F40,acquisition-interest-acquiree,100,82,2/17/2021
769F40,legal-issues-defendant,100,22,2/17/2021
769F40,acquisition-regulatory-scrutiny-acquiree,100,38,2/17/2021
769F40,legal-issues-defendant,100,22,2/17/2021
76B926,dividend,100,50,2/17/2021
76BECC,conference-call,100,50,2/17/2021
76E80F,conference-call,100,50,2/17/2021
771985,earnings,100,50,2/17/2021
790D0D,earnings,100,50,2/17/2021
7BFF81,product-release,100,64,2/17/2021
7C75FD,earnings-up,100,68,2/17/2021
7E1D5D,earnings,100,50,2/17/2021
7E1D5D,earnings,100,50,2/17/2021
7E1D5D,earnings,100,50,2/17/2021
7E1D5D,earnings,100,50,2/17/2021
7E3F8F,note-sale,100,52,2/17/2021
7F3665,earnings,100,50,2/17/2021
7F3A5F,note-sale,100,52,2/17/2021
7F3A5F,note-sale,100,52,2/17/2021
804708,dividend-up,100,81,2/17/2021
81222C,earnings,100,50,2/17/2021
83A065,conference-call,100,50,2/17/2021
83B1C8,executive-appointment,100,54,2/17/2021
83B1C8,executive-appointment,100,54,2/17/2021
845533,earnings,100,50,2/17/2021
8.40E+120,public-offering,100,43,2/17/2021
85AD00,dividend,100,50,2/17/2021
862941,conference-participant,100,50,2/17/2021
86F123,earnings,100,50,2/17/2021
88611B,earnings,100,50,2/17/2021
8A8E41,credit-extension-provider,100,57,2/17/2021
8E82A6,earnings,100,50,2/17/2021
8FF2EF,earnings,100,50,2/17/2021
9004C4,conference-call,100,50,2/17/2021
901327,dividend,100,50,2/17/2021
901327,executive-resignation,100,44,2/17/2021
902255,earnings,100,50,2/17/2021
90DD65,conference-participant,100,50,2/17/2021
911AB8,dividend-up,100,76,2/17/2021
9196A2,conference-organizer,100,57,2/17/2021
9196A2,conference-organizer,100,57,2/17/2021
9196A2,conference-call,100,50,2/17/2021
93633B,facility-open,100,65,2/17/2021
94756D,executive-appointment,100,54,2/17/2021
958938,conference-call,100,50,2/17/2021
9.65E+07,conference-call,100,50,2/17/2021
98CEBB,business-contract,100,69,2/17/2021
9BB35A,dividend,100,50,2/17/2021
9C5BA5,earnings,100,50,2/17/2021
9CA432,note-sale,100,52,2/17/2021
9EA947,earnings,100,50,2/17/2021
9F37C5,dividend,100,50,2/17/2021
9F37C5,earnings,100,50,2/17/2021
A16DEA,conference-participant,100,50,2/17/2021
A631A3,conference-participant,100,50,2/17/2021
A7102F,earnings,100,50,2/17/2021
AB7F05,earnings,100,50,2/17/2021
AB7F05,earnings,100,50,2/17/2021
AB7F05,earnings,100,50,2/17/2021
AB7F05,earnings,100,50,2/17/2021
AC775C,earnings,100,50,2/17/2021
AD3C93,conference-participant,100,50,2/17/2021
AD6141,buybacks,100,74,2/17/2021
AD6141,dividend,100,50,2/17/2021
AED61E,public-offering,100,43,2/17/2021
AEF2C3,earnings,100,50,2/17/2021
AFD7DD,conference-call,100,50,2/17/2021
B076A1,earnings,100,50,2/17/2021
B0FE08,business-contract,100,69,2/17/2021
B13B68,acquisition-acquirer,100,49,2/17/2021
B13B68,acquisition-acquirer,100,49,2/17/2021
B13B68,earnings,100,50,2/17/2021
B1FC3B,business-contract,100,69,2/17/2021
B48FC9,revenues,100,50,2/17/2021
B48FC9,revenues,100,50,2/17/2021
B48FC9,revenues,100,50,2/17/2021
B48FC9,revenues,100,50,2/17/2021
B560AF,executive-resignation,100,44,2/17/2021
B83D67,earnings,100,50,2/17/2021
B8A51F,earnings,100,50,2/17/2021
B96637,conference-call,100,50,2/17/2021
BCC55F,executive-appointment,100,54,2/17/2021
BDEC1E,conference-call,100,50,2/17/2021
C06EB6,public-offering,100,43,2/17/2021
C15DB3,earnings,100,50,2/17/2021
C2609A,conference-participant,100,50,2/17/2021
C45CE7,earnings,100,50,2/17/2021
C4C77F,earnings,100,50,2/17/2021
C4FBDC,acquisition-completed-acquirer,100,49,2/17/2021
C564E4,conference-participant,100,50,2/17/2021
C5F463,partnership,100,61,2/17/2021
C81E00,conference-participant,100,50,2/17/2021
C81E00,conference-participant,100,50,2/17/2021
C83B88,conference-participant,100,50,2/17/2021
C8A059,earnings,100,50,2/17/2021
C8A248,partnership,100,61,2/17/2021
C941DC,earnings,100,50,2/17/2021
C99CC8,executive-appointment,100,54,2/17/2021
C9D866,earnings,100,50,2/17/2021
CB6A9C,business-contract,100,69,2/17/2021
CB7AB2,earnings,100,50,2/17/2021
CB7AB2,executive-appointment,100,54,2/17/2021
CBDB4D,partnership,100,61,2/17/2021
CBDB4D,partnership,100,61,2/17/2021
CC0C78,earnings,100,50,2/17/2021
CE1002,conference-participant,100,50,2/17/2021
CF211D,buybacks,100,74,2/17/2021
CFF97C,credit-rating-outlook-revision-rater,20,50,2/17/2021
CFF97C,analyst-ratings-change-positive-rater,20,50,2/17/2021
D08D2C,earnings,100,50,2/17/2021
D1AE3B,dividend,100,50,2/17/2021
D29F43,dividend,100,50,2/17/2021
D2B9E5,earnings,100,50,2/17/2021
D2B9E5,earnings,100,50,2/17/2021
D2B9E5,earnings,100,50,2/17/2021
D56E4C,earnings,100,50,2/17/2021
D56E4C,earnings,100,50,2/17/2021
D58A11,conference-participant,100,50,2/17/2021
D65A13,conference-participant,100,50,2/17/2021
D65A13,executive-appointment,100,54,2/17/2021
D6EAA3,dividend,100,50,2/17/2021
D8DBA3,dividend-up,100,81,2/17/2021
D9FC89,earnings,100,50,2/17/2021
DB396B,executive-appointment,100,54,2/17/2021
DC0066,public-offering,100,43,2/17/2021
DC486E,executive-appointment,100,54,2/17/2021
DC486E,executive-appointment,100,54,2/17/2021
DD1BA1,executive-appointment,100,54,2/17/2021
DD1BA1,revenue-up,100,94,2/17/2021
DD1BA1,earnings,100,50,2/17/2021
DD7A96,earnings,100,50,2/17/2021
DDEA6A,conference-participant,100,50,2/17/2021
DF6FDD,conference-participant,100,50,2/17/2021
E13782,earnings,100,50,2/17/2021
E22FDE,conference-call,100,50,2/17/2021
E49AA3,facility-open,100,65,2/17/2021
E56A0D,conference-participant,100,50,2/17/2021
E5D914,earnings,100,50,2/17/2021
E610CD,earnings,100,50,2/17/2021
E68733,product-recall,100,29,2/17/2021
E68733,product-recall,100,29,2/17/2021
E68C3D,earnings,100,50,2/17/2021
E69BA5,dividend,100,50,2/17/2021
E70531,fraud-defendant,100,20,2/17/2021
E8846E,conference-participant,100,50,2/17/2021
E8F0E2,conference-participant,100,50,2/17/2021
EB61C4,dividend,100,50,2/17/2021
ED9C04,earnings,100,50,2/17/2021
F02D0A,earnings-per-share-positive,100,69,2/17/2021
F02D0A,earnings-positive,100,69,2/17/2021
F1529C,conference-participant,100,50,2/17/2021
F179ED,earnings,100,50,2/17/2021
F2BC3D,acquisition-acquirer,100,49,2/17/2021
F30508,executive-appointment,100,54,2/17/2021
F4D241,earnings,100,50,2/17/2021
F4E882,partnership,100,61,2/17/2021
F4E882,partnership,100,61,2/17/2021
F4F46F,business-contract,100,69,2/17/2021
F8C5D7,earnings,100,50,2/17/2021
F8C5D7,note-sale,100,52,2/17/2021
F90EE5,dividend,100,50,2/17/2021
FA36A4,earnings,100,50,2/17/2021
FA840E,earnings,100,50,2/17/2021
FADF1A,government-contract,100,69,2/17/2021
FC80E6,earnings,100,50,2/17/2021
FD6926,patient-enrollment-complete,100,64,2/17/2021
FE1A1D,earnings,100,50,2/17/2021
FF227B,conference-participant,100,50,2/17/2021
FF4BA4,executive-appointment,100,54,2/17/2021
FFAB4A,dividend,100,50,2/17/2021
00067A,executive-appointment,100,54,2/18/2021
002A99,earnings,100,50,2/18/2021
9397,product-release,100,64,2/18/2021
9397,conference-participant,100,50,2/18/2021
00FC70,earnings,100,50,2/18/2021
0157B1,demand-increase,100,83,2/18/2021
20751,earnings,100,50,2/18/2021
0358AF,board-meeting,100,51,2/18/2021
03B8CF,product-release,100,64,2/18/2021
68396,earnings,100,50,2/18/2021
095A04,earnings,100,50,2/18/2021
0BD199,conference-participant,100,50,2/18/2021
0C136E,earnings,100,50,2/18/2021
0C2A0D,earnings,100,50,2/18/2021
0C2A0D,earnings,100,50,2/18/2021
0C2A0D,earnings,100,50,2/18/2021
0C2A0D,earnings,100,50,2/18/2021
0C2A0D,earnings,100,50,2/18/2021
0C6861,dividend,100,50,2/18/2021
0C8D82,earnings,100,50,2/18/2021
0E499E,earnings,100,50,2/18/2021
0F04E5,earnings,100,50,2/18/2021
0F04E5,earnings,100,50,2/18/2021
0F04E5,earnings,100,50,2/18/2021
0F0693,executive-appointment,100,54,2/18/2021
102F04,earnings,100,50,2/18/2021
106394,earnings,100,50,2/18/2021
12731D,earnings,100,50,2/18/2021
12731D,earnings,100,50,2/18/2021
129DC8,earnings-delayed,100,26,2/18/2021
136B26,earnings,100,50,2/18/2021
147C38,earnings,100,50,2/18/2021
152E1D,conference-call,100,50,2/18/2021
15B10D,conference-call,100,50,2/18/2021
16C544,earnings,100,50,2/18/2021
180DA0,conference-call,100,50,2/18/2021
184866,executive-appointment,100,54,2/18/2021
197019,earnings,100,50,2/18/2021
197612,earnings-up,100,68,2/18/2021
1A2D9F,executive-appointment,100,54,2/18/2021
1A6A94,earnings,100,50,2/18/2021
1AC649,conference-participant,100,50,2/18/2021
1AF7E2,earnings,100,50,2/18/2021
1B4F31,earnings,100,50,2/18/2021
1C2593,conference-call,100,50,2/18/2021
1D5C51,executive-appointment,100,54,2/18/2021
1E1125,conference-organizer,100,57,2/18/2021
1E1125,conference-organizer,100,57,2/18/2021
1E1125,conference-organizer,100,57,2/18/2021
1E1125,conference-organizer,100,57,2/18/2021
1E1125,conference-organizer,100,57,2/18/2021
2082EA,earnings,100,50,2/18/2021
2093B1,dividend-up,100,63,2/18/2021
221AD7,legal-issues-defendant,100,22,2/18/2021
225CA2,dividend,100,50,2/18/2021
228D42,partnership,100,61,2/18/2021
228D42,partnership,100,61,2/18/2021
228D42,partnership,100,61,2/18/2021
238302,conference-call,100,50,2/18/2021
239106,earnings,100,50,2/18/2021
239106,earnings,100,50,2/18/2021
239106,earnings,100,50,2/18/2021
26CC63,regulatory-product-approval-granted,100,81,2/18/2021
275300,dividend,100,50,2/18/2021
278C18,dividend,100,50,2/18/2021
279916,earnings,100,50,2/18/2021
2A1009,earnings,100,50,2/18/2021
2A1009,earnings,100,50,2/18/2021
2A1009,earnings,100,50,2/18/2021
2A1009,earnings,100,50,2/18/2021
2A1009,earnings,100,50,2/18/2021
2A1009,earnings,100,50,2/18/2021
2AA6A8,conference-call,100,50,2/18/2021
2ABF77,conference-participant,100,50,2/18/2021
2C3348,earnings,100,50,2/18/2021
2C681C,business-contract,100,69,2/18/2021
2C681C,business-contract,100,69,2/18/2021
2CB4C9,partnership,100,61,2/18/2021
2CB4C9,partnership,100,61,2/18/2021
2DB344,dividend,100,50,2/18/2021
2DDB22,earnings,100,50,2/18/2021
2E1322,earnings,100,50,2/18/2021
301493,conference-call,100,50,2/18/2021
314D88,earnings,100,50,2/18/2021
3471C0,earnings,100,50,2/18/2021
34B97A,conference-participant,100,50,2/18/2021
35557B,conference-participant,100,50,2/18/2021
3587B4,partnership,100,61,2/18/2021
3.50E+27,dividend,100,50,2/18/2021
36A1CB,conference-call,100,50,2/18/2021
36E479,conference-participant,100,50,2/18/2021
385DD4,earnings,100,50,2/18/2021
387375,earnings,100,50,2/18/2021
3.88E+02,conference-call,100,50,2/18/2021
3A113F,earnings,100,50,2/18/2021
3AAEAE,conference-call,100,50,2/18/2021
3B37F7,earnings,100,50,2/18/2021
3BE00F,dividend,100,50,2/18/2021
3DC887,earnings,100,50,2/18/2021
3F1C69,earnings,100,50,2/18/2021
3F868D,executive-resignation,100,44,2/18/2021
3F868D,earnings,100,50,2/18/2021
407878,partnership,100,61,2/18/2021
408380,market-entry,100,57,2/18/2021
415188,dividend-up,100,81,2/18/2021
415188,earnings,100,50,2/18/2021
417BF9,conference-call,100,50,2/18/2021
41B53E,earnings,100,50,2/18/2021
41B53E,earnings,100,50,2/18/2021
41B53E,earnings,100,50,2/18/2021
41ED98,conference-call,100,50,2/18/2021
427F32,conference-call,100,50,2/18/2021
4398A2,public-offering,100,43,2/18/2021
43A060,partnership,100,61,2/18/2021
44740A,conference-call,100,50,2/18/2021
449A26,executive-appointment,100,54,2/18/2021
44A4FC,business-contract,100,69,2/18/2021
45ABCC,conference-participant,100,50,2/18/2021
4649D5,earnings,100,50,2/18/2021
49CC59,facility-sale,100,52,2/18/2021
4A6F00,partnership,100,61,2/18/2021
4A6F00,business-contract,100,69,2/18/2021
4C5CC9,acquisition-completed-acquirer,100,49,2/18/2021
4C5CC9,dividend-up,100,63,2/18/2021
4D72C8,note-sale,100,52,2/18/2021
4D72C8,note-sale,100,52,2/18/2021
4EE167,earnings,100,50,2/18/2021
4F783B,executive-appointment,100,54,2/18/2021
5088A5,earnings,100,50,2/18/2021
50D1EC,acquisition-interest-acquirer,100,46,2/18/2021
51888A,earnings,100,50,2/18/2021
51F541,dividend,100,50,2/18/2021
5225A4,conference-participant,100,50,2/18/2021
524CE4,earnings,100,50,2/18/2021
5.43E+08,conference-call,100,50,2/18/2021
54F271,conference-participant,100,50,2/18/2021
56277A,conference-participant,100,50,2/18/2021
564F3E,market-entry,100,57,2/18/2021
57F3DA,earnings,100,50,2/18/2021
5A9A82,earnings,100,50,2/18/2021
5A9A82,earnings,100,50,2/18/2021
5A9A82,earnings,100,50,2/18/2021
5A9A82,earnings,100,50,2/18/2021
5BC2F4,executive-appointment,100,54,2/18/2021
5BC2F4,dividend,100,50,2/18/2021
5C7601,dividend,100,50,2/18/2021
5D1329,conference-call,100,50,2/18/2021
5D43A7,earnings,100,50,2/18/2021
5F2FF7,business-contract,100,69,2/18/2021
5F2FF7,business-contract,100,69,2/18/2021
616E3B,earnings,100,50,2/18/2021
619882,conference-organizer,100,57,2/18/2021
6391C2,conference-participant,100,50,2/18/2021
649CBD,earnings,100,50,2/18/2021
6.52E+64,product-release,100,64,2/18/2021
6559D8,earnings,100,50,2/18/2021
665D7D,dividend,100,50,2/18/2021
67303E,legal-issues-defendant,100,22,2/18/2021
67303E,legal-issues-defendant,100,22,2/18/2021
67303E,legal-issues-defendant,100,22,2/18/2021
67303E,legal-issues-defendant,100,22,2/18/2021
67303E,legal-issues-defendant,100,22,2/18/2021
6830FE,earnings,100,50,2/18/2021
68586A,conference-call,100,50,2/18/2021
6B0E45,dividend,100,50,2/18/2021
6B6375,earnings,100,50,2/18/2021
6BBCBA,conference-call,100,50,2/18/2021
6BF593,earnings,100,50,2/18/2021
6BF593,earnings,100,50,2/18/2021
6BF593,earnings,100,50,2/18/2021
6DBBBC,executive-appointment,100,54,2/18/2021
6F0A63,earnings,100,50,2/18/2021
6F39FC,earnings,100,50,2/18/2021
701531,orphan-drug-designation,100,76,2/18/2021
713810,revenue-up,100,69,2/18/2021
713810,dividend-up,100,81,2/18/2021
7255D2,earnings,100,50,2/18/2021
72DF04,partnership,100,61,2/18/2021
73F7F9,conference-call,100,50,2/18/2021
751C8D,earnings,100,50,2/18/2021
763724,conference-call,100,50,2/18/2021
766047,dividend,100,50,2/18/2021
76DD0C,conference-participant,100,50,2/18/2021
789A7D,earnings-guidance,100,50,2/18/2021
789A7D,earnings,100,50,2/18/2021
789A7D,earnings,100,50,2/18/2021
789A7D,earnings,100,50,2/18/2021
78A1BB,dividend,100,50,2/18/2021
79340A,conference-participant,100,50,2/18/2021
7999F3,earnings,100,50,2/18/2021
7A0EC4,conference-call,100,50,2/18/2021
7A0EC4,conference-participant,100,50,2/18/2021
7B0BA6,conference-participant,100,50,2/18/2021
7B1E50,earnings,100,50,2/18/2021
7B1E50,executive-appointment,100,54,2/18/2021
7DD8CC,earnings,100,50,2/18/2021
7E3F8F,note-sale,100,52,2/18/2021
7FDE1C,conference-call,100,50,2/18/2021
8275FE,executive-appointment,100,54,2/18/2021
830BDB,executive-appointment,100,54,2/18/2021
86AA9C,earnings,100,50,2/18/2021
88193E,conference-participant,100,50,2/18/2021
8876D6,legal-issues-defendant,100,22,2/18/2021
88923D,earnings,100,50,2/18/2021
88923D,earnings,100,50,2/18/2021
88923D,earnings,100,50,2/18/2021
88923D,earnings,100,50,2/18/2021
88923D,earnings,100,50,2/18/2021
88923D,earnings,100,50,2/18/2021
890FF4,earnings,100,50,2/18/2021
8AB37F,conference-call,100,50,2/18/2021
8B3B0E,earnings,100,50,2/18/2021
8B4A45,earnings,100,50,2/18/2021
8B9B3B,conference-participant,100,50,2/18/2021
8BAA15,earnings,100,50,2/18/2021
8BE916,dividend,100,50,2/18/2021
8BFAA4,conference-call,100,50,2/18/2021
8D4486,partnership,100,61,2/18/2021
8D4486,business-contract,100,69,2/18/2021
8D4486,business-contract,100,69,2/18/2021
8DBBE6,earnings,100,50,2/18/2021
8DE74B,earnings,100,50,2/18/2021
8E3F58,earnings,100,50,2/18/2021
8E4F9A,conference-participant,100,50,2/18/2021
90D6A5,dividend,100,50,2/18/2021
9196A2,conference-organizer,100,57,2/18/2021
9196A2,conference-organizer,100,57,2/18/2021
9196A2,conference-organizer,100,57,2/18/2021
9196A2,conference-organizer,100,57,2/18/2021
9196A2,conference-organizer,100,57,2/18/2021
92B625,conference-call,100,50,2/18/2021
92B625,conference-participant,100,50,2/18/2021
934029,clinical-trials-filed,100,60,2/18/2021
940C3D,acquisition-acquirer,100,49,2/18/2021
945DE6,earnings,100,50,2/18/2021
94983E,dividend,100,50,2/18/2021
954A47,dividend,100,50,2/18/2021
9592FB,product-release,100,64,2/18/2021
95DC1F,conference-call,100,50,2/18/2021
96A2D3,public-offering,100,43,2/18/2021
96A6CD,earnings,100,50,2/18/2021
96B4FF,conference-participant,100,50,2/18/2021
971334,earnings,100,50,2/18/2021
971334,dividend,100,50,2/18/2021
97644E,partnership,100,61,2/18/2021
97AAF6,earnings,100,50,2/18/2021
97AAF6,earnings,100,50,2/18/2021
97AAF6,earnings,100,50,2/18/2021
97AAF6,earnings,100,50,2/18/2021
98CAED,dividend,100,50,2/18/2021
98CAED,earnings-up,100,68,2/18/2021
98CAED,earnings-up,100,68,2/18/2021
98CAED,earnings-up,100,68,2/18/2021
98CAED,earnings-up,100,68,2/18/2021
990AD0,conference-organizer,100,57,2/18/2021
9.97E+09,dividend-up,100,54,2/18/2021
9978F1,conference-participant,100,50,2/18/2021
99B61C,executive-appointment,100,54,2/18/2021
9ABD30,earnings,100,50,2/18/2021
9C3D3C,earnings,100,50,2/18/2021
9DDE1B,conference-participant,100,50,2/18/2021
9FD2D9,earnings,100,50,2/18/2021
9FD2D9,earnings,100,50,2/18/2021
9FD2D9,earnings,100,50,2/18/2021
9FD2D9,earnings,100,50,2/18/2021
A01200,executive-appointment,100,54,2/18/2021
A03EE1,conference-participant,100,50,2/18/2021
A072C4,conference-participant,100,50,2/18/2021
A11CF4,conference-participant,100,50,2/18/2021
A1BB98,earnings,100,50,2/18/2021
A47A7D,earnings,100,50,2/18/2021
A4BCDE,earnings,100,50,2/18/2021
A4CD53,earnings,100,50,2/18/2021
A5151E,earnings,100,50,2/18/2021
A5195E,conference-participant,100,50,2/18/2021
A5DD24,earnings,100,50,2/18/2021
A63387,business-contract,100,69,2/18/2021
A63387,business-contract,100,69,2/18/2021
A72AB6,conference-call,100,50,2/18/2021
A753BB,business-contract,100,69,2/18/2021
A79D88,earnings,100,50,2/18/2021
A7F0A5,earnings,100,50,2/18/2021
A7F0A5,earnings,100,50,2/18/2021
A7F0A5,earnings,100,50,2/18/2021
A7F0A5,earnings,100,50,2/18/2021
A7F0A5,earnings,100,50,2/18/2021
A8B137,executive-resignation,100,44,2/18/2021
A8CBDA,business-contract,100,69,2/18/2021
A94637,conference-call,100,50,2/18/2021
AB4A7E,earnings,100,50,2/18/2021
AB4A7E,earnings-up,100,68,2/18/2021
AB4A7E,earnings-up,100,68,2/18/2021
AB4A7E,earnings-up,100,68,2/18/2021
ABEE43,legal-issues-defendant,100,22,2/18/2021
B04426,earnings,100,50,2/18/2021
B1FC3B,business-contract,100,69,2/18/2021
B290A2,conference-call,100,50,2/18/2021
B3A166,executive-appointment,100,54,2/18/2021
B3CB74,conference-organizer,100,57,2/18/2021
B6843B,earnings,100,50,2/18/2021
B6843B,earnings,100,50,2/18/2021
B6843B,earnings,100,50,2/18/2021
B6843B,earnings,100,50,2/18/2021
B6843B,earnings,100,50,2/18/2021
B6843B,earnings,100,50,2/18/2021
B80AD1,earnings,100,50,2/18/2021
B8F71F,dividend,100,50,2/18/2021
B96637,operating-earnings,100,50,2/18/2021
B9764A,conference-participant,100,50,2/18/2021
B9CD50,earnings-positive,100,69,2/18/2021
BA0442,earnings,100,50,2/18/2021
BA0442,conference-participant,100,50,2/18/2021
BB02FB,revenue-up,100,69,2/18/2021
BB5271,executive-appointment,100,54,2/18/2021
BCC55F,earnings,100,50,2/18/2021
BD9668,dividend,100,50,2/18/2021
BE7BA4,earnings,100,50,2/18/2021
BF79F5,earnings,100,50,2/18/2021
BFF98A,executive-appointment,100,54,2/18/2021
C06EB6,public-offering,100,43,2/18/2021
C1114B,earnings,100,50,2/18/2021
C2E39B,earnings,100,50,2/18/2021
C3F99F,partnership,100,61,2/18/2021
C4A432,earnings,100,50,2/18/2021
C4A432,earnings,100,50,2/18/2021
C4A432,earnings,100,50,2/18/2021
C62AA4,executive-appointment,100,54,2/18/2021
C6C702,earnings,100,50,2/18/2021
C74887,conference-participant,100,50,2/18/2021
C7FC95,earnings,100,50,2/18/2021
C8257F,dividend-up,100,58,2/18/2021
C8257F,earnings,100,50,2/18/2021
C8A248,dividend,100,50,2/18/2021
C941DC,conference-participant,100,50,2/18/2021
C9E4EC,earnings,100,50,2/18/2021
CB22CD,earnings,100,50,2/18/2021
CB88B3,earnings,100,50,2/18/2021
CBDB4D,conference-call,100,50,2/18/2021
CBFFDD,dividend,100,50,2/18/2021
CC0C78,conference-participant,100,50,2/18/2021
CC35BE,business-contract,100,69,2/18/2021
CC35BE,earnings-positive,100,69,2/18/2021
CDAF5B,earnings,100,50,2/18/2021
CE1002,executive-appointment,100,54,2/18/2021
CE1002,dividend,100,50,2/18/2021
CE4E6D,conference-call,100,50,2/18/2021
CFF57D,conference-call,100,50,2/18/2021
D03C7A,earnings,100,50,2/18/2021
D09938,earnings,100,50,2/18/2021
D0DE27,earnings,100,50,2/18/2021
D3CEDF,earnings,100,50,2/18/2021
D4070C,dividend,100,50,2/18/2021
D57D99,dividend,100,50,2/18/2021
D64C6D,conference-call,100,50,2/18/2021
D650A7,conference-call,100,50,2/18/2021
D6534D,dividend,100,50,2/18/2021
D90F43,partnership,100,61,2/18/2021
D9164D,conference-call,100,50,2/18/2021
DA9443,conference-participant,100,50,2/18/2021
DB2E4E,debt-reduction,100,74,2/18/2021
DC2B00,conference-call,100,50,2/18/2021
DD1BA1,partnership,100,61,2/18/2021
DDCB34,conference-call,100,50,2/18/2021
DF18E6,executive-appointment,100,54,2/18/2021
DF1F7A,earnings,100,50,2/18/2021
DF6FDD,dividend,100,50,2/18/2021
DFADDB,earnings,100,50,2/18/2021
DFADDB,conference-participant,100,50,2/18/2021
E05DC8,earnings,100,50,2/18/2021
E0E4B7,earnings,100,50,2/18/2021
E38906,earnings,100,50,2/18/2021
E3A829,conference-call,100,50,2/18/2021
E4CE73,earnings,100,50,2/18/2021
E592F0,executive-appointment,100,54,2/18/2021
E68733,regulatory-product-approval-granted,100,81,2/18/2021
E69BA5,executive-appointment,100,54,2/18/2021
E74FED,earnings,100,50,2/18/2021
E96E0B,legal-issues-defendant,100,22,2/18/2021
E9C7C0,acquisition-completed-acquirer,100,49,2/18/2021
EAEBF3,earnings,100,50,2/18/2021
EEA6B3,dividend-up,100,81,2/18/2021
EEA734,earnings,100,50,2/18/2021
EEB5F9,conference-call,100,50,2/18/2021
EEEA9F,business-contract,100,69,2/18/2021
F0027C,earnings,100,50,2/18/2021
F0B877,earnings,100,50,2/18/2021
F179ED,public-offering,100,43,2/18/2021
F30508,partnership,100,61,2/18/2021
F4D241,conference-participant,100,50,2/18/2021
F509E2,executive-appointment,100,54,2/18/2021
F5C78B,buybacks,100,74,2/18/2021
F5D059,earnings-guidance,100,50,2/18/2021
F66B58,conference-call,100,50,2/18/2021
F6E248,conference-participant,100,50,2/18/2021
F6FF0D,earnings,100,50,2/18/2021
F721A7,earnings,100,50,2/18/2021
F721A7,earnings,100,50,2/18/2021
F93C8A,earnings,100,50,2/18/2021
F93C8A,earnings,100,50,2/18/2021
F93C8A,earnings,100,50,2/18/2021
F93C8A,earnings,100,50,2/18/2021
F93C8A,earnings,100,50,2/18/2021
FBD92D,earnings,100,50,2/18/2021
FD9526,earnings,100,50,2/18/2021
FDD3FC,conference-participant,100,50,2/18/2021
FDE409,earnings,100,50,2/18/2021
00E601,board-meeting,100,51,2/19/2021
03B8CF,acquisition-acquiree,100,76,2/19/2021
84625,earnings,100,50,2/19/2021
84625,earnings,100,50,2/19/2021
0A59F8,partnership,100,61,2/19/2021
0BD4E8,earnings,100,50,2/19/2021
0BD4E8,earnings,100,50,2/19/2021
0BD4E8,earnings,100,50,2/19/2021
0BD4E8,earnings,100,50,2/19/2021
0BF198,clinical-trials,100,56,2/19/2021
12DE76,acquisition-completed-acquirer,100,49,2/19/2021
14391F,executive-appointment,100,54,2/19/2021
1834C0,dividend,100,50,2/19/2021
1E1125,conference-organizer,100,57,2/19/2021
1F505C,executive-appointment,100,54,2/19/2021
1FCC00,earnings,100,50,2/19/2021
20F5E2,dividend,100,50,2/19/2021
275300,conference-participant,100,50,2/19/2021
28AF37,conference-participant,100,50,2/19/2021
2AE625,earnings,100,50,2/19/2021
2CF9D3,executive-appointment,100,54,2/19/2021
2EB04E,partnership,100,61,2/19/2021
2F24A5,dividend,100,50,2/19/2021
319BE2,conference-call,100,50,2/19/2021
34E9F9,note-sale,100,52,2/19/2021
3B9886,conference-call,100,50,2/19/2021
408089,business-contract,100,69,2/19/2021
431B74,earnings-positive,100,69,2/19/2021
431B74,earnings-positive,100,69,2/19/2021
431B74,earnings-positive,100,69,2/19/2021
431B74,earnings-positive,100,69,2/19/2021
431B74,earnings-positive,100,69,2/19/2021
431B74,earnings-positive,100,69,2/19/2021
431B74,earnings-positive,100,69,2/19/2021
431B74,earnings-positive,100,69,2/19/2021
431B74,earnings,100,50,2/19/2021
431B74,earnings,100,50,2/19/2021
431B74,earnings,100,50,2/19/2021
431B74,earnings,100,50,2/19/2021
431B74,earnings,100,50,2/19/2021
431B74,earnings,100,50,2/19/2021
4398A2,earnings,100,50,2/19/2021
44A4FC,conference-participant,100,50,2/19/2021
45ABCC,acquisition-acquirer,100,49,2/19/2021
4B3DC9,award,100,58,2/19/2021
4B5054,earnings,100,50,2/19/2021
4DAF5F,buybacks,100,74,2/19/2021
4DAF5F,buybacks,100,74,2/19/2021
4FB770,dividend,100,50,2/19/2021
504FE2,dividend,100,50,2/19/2021
520632,dividend,100,50,2/19/2021
583223,conference-participant,100,50,2/19/2021
58B46F,executive-appointment,100,54,2/19/2021
59DB8C,conference-participant,100,50,2/19/2021
5B51D6,conference-participant,100,50,2/19/2021
651C85,conference-call,100,50,2/19/2021
665440,executive-appointment,100,54,2/19/2021
665D7D,conference-participant,100,50,2/19/2021
69C99E,conference-participant,100,50,2/19/2021
69CE71,partnership,100,61,2/19/2021
6BBCBA,conference-participant,100,50,2/19/2021
6D156D,legal-issues-defendant,100,22,2/19/2021
6D9ECA,clinical-trials-start,100,64,2/19/2021
6-Dec-05,earnings,100,50,2/19/2021
726EEA,earnings-up,100,68,2/19/2021
726EEA,earnings-up,100,68,2/19/2021
726EEA,earnings-up,100,68,2/19/2021
726EEA,earnings-up,100,68,2/19/2021
726EEA,earnings-up,100,68,2/19/2021
726EEA,earnings-up,100,68,2/19/2021
726EEA,earnings-up,100,68,2/19/2021
751C8D,earnings,100,50,2/19/2021
756045,dividend,100,50,2/19/2021
756BB4,earnings,100,50,2/19/2021
76B926,executive-appointment,100,54,2/19/2021
76BD96,earnings,100,50,2/19/2021
76D79A,earnings,100,50,2/19/2021
7710F3,conference-call,100,50,2/19/2021
7AC86E,earnings,100,50,2/19/2021
7AC86E,earnings,100,50,2/19/2021
7AC86E,earnings,100,50,2/19/2021
7AC86E,earnings,100,50,2/19/2021
7B8CB5,dividend,100,50,2/19/2021
80C400,conference-call,100,50,2/19/2021
83B1C8,conference-participant,100,50,2/19/2021
83E0AC,conference-call,100,50,2/19/2021
88611B,dividend,100,50,2/19/2021
893904,conference-participant,100,50,2/19/2021
8CF6DD,executive-appointment,100,54,2/19/2021
8E8E6E,business-combination,100,54,2/19/2021
8FCA78,executive-appointment,100,54,2/19/2021
90D6A5,dividend,100,50,2/19/2021
918D6D,conference-participant,100,50,2/19/2021
9196A2,conference-organizer,100,57,2/19/2021
9196A2,acquisition-completed-acquirer,100,49,2/19/2021
91E5EE,fundraising,100,64,2/19/2021
925759,conference-participant,100,50,2/19/2021
938D89,earnings,100,50,2/19/2021
94637C,acquisition-acquirer,100,49,2/19/2021
A1EAC8,business-contract,100,69,2/19/2021
A204A7,earnings,100,50,2/19/2021
A21649,dividend,100,50,2/19/2021
A4B899,dividend,100,50,2/19/2021
A52B6B,conference-participant,100,50,2/19/2021
A52B6B,executive-appointment,100,54,2/19/2021
A6213D,partnership,100,61,2/19/2021
A666C8,conference-participant,100,50,2/19/2021
A7A0C8,conference-participant,100,50,2/19/2021
A87CD6,dividend,100,50,2/19/2021
ACF0B4,executive-appointment,100,54,2/19/2021
ACF0B4,executive-resignation,100,44,2/19/2021
AD1ACF,legal-issues-defendant,100,22,2/19/2021
AED61E,public-offering,100,43,2/19/2021
B2DAF6,executive-appointment,100,54,2/19/2021
B3CB74,conference-organizer,100,57,2/19/2021
B83D67,conference-participant,100,50,2/19/2021
BAD655,merger-completed,100,66,2/19/2021
BBC05B,executive-appointment,100,54,2/19/2021
BCE9DA,dividend,100,50,2/19/2021
BCE9DA,dividend,100,50,2/19/2021
BDEC1E,conference-participant,100,50,2/19/2021
BE14CF,award,100,58,2/19/2021
C2E120,earnings,100,50,2/19/2021
C4C77F,acquisition-completed-acquiree,100,76,2/19/2021
C584BE,earnings,100,50,2/19/2021
C72B8F,note-sale,100,52,2/19/2021
CA99D7,dividend,100,50,2/19/2021
D1C26F,partnership,100,61,2/19/2021
D27FAB,conference-call,100,50,2/19/2021
D3FD6D,revenue-up,100,69,2/19/2021
D3FD6D,earnings,100,50,2/19/2021
D3FD6D,earnings,100,50,2/19/2021
D3FD6D,earnings,100,50,2/19/2021
D88EF3,note-sale,100,52,2/19/2021
DA0A9E,earnings,100,50,2/19/2021
DBFB51,conference-call,100,50,2/19/2021
E1E36F,conference-participant,100,50,2/19/2021
E592F0,conference-participant,100,50,2/19/2021
E5A3B6,conference-participant,100,50,2/19/2021
E70531,legal-issues-defendant,100,22,2/19/2021
E96E0B,legal-issues-defendant,100,22,2/19/2021
EBC84C,dividend,100,50,2/19/2021
EE967B,dividend,100,50,2/19/2021
EEB5F9,conference-participant,100,50,2/19/2021
EEBCEF,board-meeting,100,51,2/19/2021
F1C04C,conference-call,100,50,2/19/2021
F6E1B5,earnings,100,50,2/19/2021
F72E4B,earnings,100,50,2/19/2021
FCA54E,earnings,100,50,2/19/2021
FF227B,conference-call,100,50,2/19/2021
5B226B,legal-issues-defendant,100,22,2/20/2021
615B6D,legal-issues-defendant,100,22,2/20/2021
615B6D,legal-issues-defendant,100,22,2/20/2021
6D156D,legal-issues-defendant,100,22,2/20/2021
769F40,legal-issues-defendant,100,22,2/20/2021
C9E107,legal-issues-defendant,100,22,2/20/2021
D64EDF,donation,100,54,2/20/2021
68E3E0,dividend,100,50,2/21/2021
880C0C,earnings,100,50,2/21/2021
00067A,conference-participant,100,50,2/22/2021
003B70,operating-earnings,100,50,2/22/2021
0157B1,partnership,100,61,2/22/2021
02ACBD,conference-call,100,50,2/22/2021
054B55,acquisition-acquiree,100,76,2/22/2021
054B55,acquisition-acquiree,100,76,2/22/2021
55018,partnership,100,61,2/22/2021
099C88,earnings,100,50,2/22/2021
0C466B,acquisition-acquirer,100,49,2/22/2021
0D03C8,executive-appointment,100,54,2/22/2021
0E2992,dividend,100,50,2/22/2021
138DDE,earnings,100,50,2/22/2021
13C3E0,executive-appointment,100,54,2/22/2021
14391F,earnings,100,50,2/22/2021
14833D,earnings,100,50,2/22/2021
15789A,earnings,100,50,2/22/2021
159AE4,dividend,100,50,2/22/2021
15A388,business-contract,100,69,2/22/2021
19BF16,executive-appointment,100,54,2/22/2021
1B6F77,public-offering,100,43,2/22/2021
1CB9D3,conference-call,100,50,2/22/2021
1E04A5,earnings,100,50,2/22/2021
1E7785,earnings,100,50,2/22/2021
1E7785,earnings,100,50,2/22/2021
1E7785,earnings,100,50,2/22/2021
1E7785,earnings,100,50,2/22/2021
1E7785,earnings,100,50,2/22/2021
1E7785,earnings,100,50,2/22/2021
1EBF8D,partnership,100,61,2/22/2021
1FC422,earnings,100,50,2/22/2021
202E5A,conference-participant,100,50,2/22/2021
21268E,conference-call,100,50,2/22/2021
2158DF,partnership,100,61,2/22/2021
228D42,partnership,100,61,2/22/2021
228D42,product-release,100,64,2/22/2021
239106,conference-participant,100,50,2/22/2021
241AF7,earnings,100,50,2/22/2021
2.45E+15,executive-appointment,100,54,2/22/2021
249B39,dividend,100,50,2/22/2021
24A89A,conference-participant,100,50,2/22/2021
25AB8E,earnings,100,50,2/22/2021
2C3348,partnership,100,61,2/22/2021
2C681C,patient-enrollment-complete,100,64,2/22/2021
2C681C,patient-enrollment-complete,100,64,2/22/2021
2E902B,conference-participant,100,50,2/22/2021
2F6782,conference-participant,100,50,2/22/2021
31643A,facility-close,100,47,2/22/2021
32DCB3,earnings,100,50,2/22/2021
32F943,earnings,100,50,2/22/2021
3461CF,conference-participant,100,50,2/22/2021
396D7C,conference-participant,100,50,2/22/2021
39FB23,acquisition-completed-acquirer,100,49,2/22/2021
3E70FC,executive-appointment,100,54,2/22/2021
3ED92D,product-release,100,64,2/22/2021
407878,earnings,100,50,2/22/2021
408380,earnings,100,50,2/22/2021
416C55,executive-appointment,100,54,2/22/2021
41785E,executive-appointment,100,54,2/22/2021
417BF9,public-offering,100,43,2/22/2021
4398A2,public-offering,100,43,2/22/2021
449A26,acquisition-acquiree,100,76,2/22/2021
449A26,acquisition-regulatory-scrutiny-acquiree,100,38,2/22/2021
449A26,legal-issues-defendant,100,22,2/22/2021
45BC35,conference-participant,100,50,2/22/2021
4BD6DB,acquisition-completed-acquirer,100,49,2/22/2021
4C1FA1,earnings,100,50,2/22/2021
4C3FE9,conference-participant,100,50,2/22/2021
4DAF5F,buybacks,100,74,2/22/2021
4DAF5F,buybacks,100,74,2/22/2021
4ECD1A,earnings,100,50,2/22/2021
4ECD1A,earnings,100,50,2/22/2021
4FB770,earnings,100,50,2/22/2021
5065B1,earnings,100,50,2/22/2021
50D1EC,acquisition-completed-acquirer,100,49,2/22/2021
514067,earnings,100,50,2/22/2021
51D876,stake-acquirer,100,48,2/22/2021
546A27,earnings,100,50,2/22/2021
5487B1,earnings,100,50,2/22/2021
5487B1,earnings,100,50,2/22/2021
5487B1,earnings,100,50,2/22/2021
5487B1,earnings,100,50,2/22/2021
5487B1,earnings,100,50,2/22/2021
5487B1,earnings,100,50,2/22/2021
5487B1,earnings,100,50,2/22/2021
5546DA,trading-halt,100,43,2/22/2021
5546DA,trading-resumed,100,58,2/22/2021
56277A,executive-appointment,100,54,2/22/2021
56B7C1,earnings,100,50,2/22/2021
56EFC7,earnings,100,50,2/22/2021
59F0B0,earnings,100,50,2/22/2021
59F0B0,earnings,100,50,2/22/2021
59F0B0,earnings,100,50,2/22/2021
59F0B0,earnings,100,50,2/22/2021
59F0B0,earnings,100,50,2/22/2021
5B226B,dividend,100,50,2/22/2021
5B226B,legal-issues-defendant,100,22,2/22/2021
5B226B,legal-issues-defendant,100,22,2/22/2021
5B226B,legal-issues-defendant,100,22,2/22/2021
5D41E4,conference-participant,100,50,2/22/2021
615B6D,legal-issues-defendant,100,22,2/22/2021
619882,conference-organizer,100,57,2/22/2021
619882,conference-organizer,100,57,2/22/2021
61A586,earnings,100,50,2/22/2021
61A586,public-offering,100,43,2/22/2021
62CDDE,earnings,100,50,2/22/2021
67303E,conference-participant,100,50,2/22/2021
67529E,executive-appointment,100,54,2/22/2021
68B03F,earnings,100,50,2/22/2021
69345C,conference-participant,100,50,2/22/2021
6BD606,earnings,100,50,2/22/2021
6CBF41,conference-participant,100,50,2/22/2021
6D156D,legal-issues-defendant,100,22,2/22/2021
6D156D,legal-issues-defendant,100,22,2/22/2021
6D156D,legal-issues-defendant,100,22,2/22/2021
6DD6BA,earnings,100,50,2/22/2021
6DDA15,earnings,100,50,2/22/2021
6DDA15,earnings,100,50,2/22/2021
6DDA15,earnings,100,50,2/22/2021
6DDA15,earnings,100,50,2/22/2021
6DDA15,earnings,100,50,2/22/2021
6DDA15,earnings,100,50,2/22/2021
6E8349,earnings,100,50,2/22/2021
6F6559,award,100,58,2/22/2021
701531,conference-participant,100,50,2/22/2021
704B78,earnings,100,50,2/22/2021
70FCEF,earnings,100,50,2/22/2021
713810,legal-issues-defendant,100,22,2/22/2021
7.45E+28,legal-issues-defendant,100,22,2/22/2021
7.45E+28,earnings,100,50,2/22/2021
748EB6,earnings,100,50,2/22/2021
752A70,earnings,100,50,2/22/2021
75F982,partnership,100,61,2/22/2021
75F982,partnership,100,61,2/22/2021
75F982,partnership,100,61,2/22/2021
76B926,product-release,100,64,2/22/2021
76F067,clinical-trials-filed,100,60,2/22/2021
76F067,clinical-trials-filed,100,60,2/22/2021
76F067,clinical-trials-filed,100,60,2/22/2021
7712CB,earnings,100,50,2/22/2021
7712CB,earnings,100,50,2/22/2021
7712CB,earnings,100,50,2/22/2021
7712CB,earnings,100,50,2/22/2021
7712CB,earnings,100,50,2/22/2021
7712CB,earnings,100,50,2/22/2021
7C4168,business-contract,100,69,2/22/2021
7C4168,earnings,100,50,2/22/2021
7C4F43,conference-participant,100,50,2/22/2021
7CBC40,note-sale,100,52,2/22/2021
7E0EB0,conference-call,100,50,2/22/2021
7FDE1C,earnings,100,50,2/22/2021
7FDE1C,business-contract,100,69,2/22/2021
835C86,acquisition-completed-acquiree,100,76,2/22/2021
8AB85C,conference-participant,100,50,2/22/2021
8B6E7E,conference-participant,100,50,2/22/2021
8C5519,fundraising,100,64,2/22/2021
8D4486,business-contract,100,69,2/22/2021
8DA42F,earnings,100,50,2/22/2021
8F8F2F,earnings,100,50,2/22/2021
903AB4,executive-appointment,100,54,2/22/2021
903AB4,executive-appointment,100,54,2/22/2021
90D6A5,earnings,100,50,2/22/2021
9196A2,conference-organizer,100,57,2/22/2021
9196A2,conference-organizer,100,57,2/22/2021
9196A2,conference-organizer,100,57,2/22/2021
94563D,executive-appointment,100,54,2/22/2021
94637C,business-contract,100,69,2/22/2021
94983E,conference-participant,100,50,2/22/2021
94C0B5,earnings,100,50,2/22/2021
963A02,conference-participant,100,50,2/22/2021
97B027,conference-call,100,50,2/22/2021
9A02C4,product-release,100,64,2/22/2021
9B5968,executive-appointment,100,54,2/22/2021
9B730A,conference-call,100,50,2/22/2021
9D5FA4,conference-participant,100,50,2/22/2021
9E575E,executive-appointment,100,54,2/22/2021
9E575E,earnings,100,50,2/22/2021
9E575E,clinical-trials-positive,100,87,2/22/2021
9E575E,clinical-trials-positive,100,87,2/22/2021
9E5C2C,earnings,100,50,2/22/2021
9FD2D9,executive-appointment,100,54,2/22/2021
A11CF4,clinical-trials,100,56,2/22/2021
A29A46,earnings,100,50,2/22/2021
A3800A,market-entry,100,57,2/22/2021
A3800A,market-entry,100,57,2/22/2021
A52533,earnings,100,50,2/22/2021
A52B6B,earnings,100,50,2/22/2021
A63387,legal-issues-defendant,100,22,2/22/2021
A63387,government-contract,100,69,2/22/2021
A63387,dividend,100,50,2/22/2021
A666C8,acquisition-acquirer,100,49,2/22/2021
A666C8,acquisition-acquirer,100,49,2/22/2021
A7102F,conference-participant,100,50,2/22/2021
A790A5,conference-participant,100,50,2/22/2021
ABB493,conference-participant,100,50,2/22/2021
AC7C4F,conference-participant,100,50,2/22/2021
ACD9A4,dividend-up,100,73,2/22/2021
ACF0B4,conference-call,100,50,2/22/2021
ADD9DC,earnings,100,50,2/22/2021
ADF092,earnings,100,50,2/22/2021
ADF1B0,earnings,100,50,2/22/2021
AE7D16,earnings,100,50,2/22/2021
AEEB76,conference-participant,100,50,2/22/2021
AFD7DD,business-contract,100,69,2/22/2021
AFD7DD,business-contract,100,69,2/22/2021
B0D41A,conference-participant,100,50,2/22/2021
B1FC3B,business-contract,100,69,2/22/2021
B290A2,conference-participant,100,50,2/22/2021
B3CB74,conference-organizer,100,57,2/22/2021
B3CB74,conference-organizer,100,57,2/22/2021
B3CB74,conference-organizer,100,57,2/22/2021
B3CB74,conference-organizer,100,57,2/22/2021
B3CB74,conference-organizer,100,57,2/22/2021
B48FC9,conference-participant,100,50,2/22/2021
B66928,partnership,100,61,2/22/2021
B934BF,earnings,100,50,2/22/2021
BCC13E,conference-participant,100,50,2/22/2021
BD15E8,dividend,100,50,2/22/2021
BE379D,earnings,100,50,2/22/2021
C03C8B,conference-participant,100,50,2/22/2021
C0F70B,conference-participant,100,50,2/22/2021
C11C46,earnings,100,50,2/22/2021
C4A432,executive-appointment,100,54,2/22/2021
C4F9C6,conference-participant,100,50,2/22/2021
C5D2AE,acquisition-acquirer,100,49,2/22/2021
C83B88,executive-appointment,100,54,2/22/2021
C951A2,acquisition-completed-acquirer,100,49,2/22/2021
C99CC8,earnings,100,50,2/22/2021
C99CC8,earnings,100,50,2/22/2021
C99CC8,earnings,100,50,2/22/2021
C99CC8,earnings,100,50,2/22/2021
C99CC8,earnings,100,50,2/22/2021
CA212F,earnings,100,50,2/22/2021
CC6FF5,earnings,100,50,2/22/2021
D06996,earnings,100,50,2/22/2021
D1AE3B,acquisition-acquirer,100,49,2/22/2021
D56D6D,earnings,100,50,2/22/2021
D57D99,acquisition-acquiree,100,76,2/22/2021
D57D99,acquisition-acquiree,100,76,2/22/2021
D57D99,earnings,100,50,2/22/2021
D57D99,legal-issues-defendant,100,22,2/22/2021
D63B0F,earnings,100,50,2/22/2021
D63B0F,earnings,100,50,2/22/2021
D63B0F,earnings,100,50,2/22/2021
D70365,earnings,100,50,2/22/2021
D90F43,conference-participant,100,50,2/22/2021
D9164D,earnings,100,50,2/22/2021
D96202,earnings,100,50,2/22/2021
D9E036,earnings-positive,100,69,2/22/2021
D9E036,earnings,100,50,2/22/2021
D9E036,earnings,100,50,2/22/2021
DB23C8,award,100,58,2/22/2021
DB7EC3,executive-appointment,100,54,2/22/2021
DF18E6,executive-appointment,100,54,2/22/2021
DF18E6,conference-call,100,50,2/22/2021
E0647D,acquisition-acquiree,100,76,2/22/2021
E124EB,conference-participant,100,50,2/22/2021
E15736,earnings,100,50,2/22/2021
E15736,earnings,100,50,2/22/2021
E1C16B,dividend-up,100,81,2/22/2021
E1E36F,dividend,100,50,2/22/2021
E21871,earnings,100,50,2/22/2021
E22FDE,clinical-trials-positive,100,87,2/22/2021
E4CE73,partnership,100,61,2/22/2021
E68C3D,executive-appointment,100,54,2/22/2021
E93A40,earnings,100,50,2/22/2021
E96E0B,legal-issues-defendant,100,22,2/22/2021
E9C7C0,conference-participant,100,50,2/22/2021
EB1E1A,conference-participant,100,50,2/22/2021
EB7FBF,conference-call,100,50,2/22/2021
EBD89A,business-contract,100,69,2/22/2021
ED79D9,regulatory-product-approval-granted,100,81,2/22/2021
EE1E44,dividend,100,50,2/22/2021
EEEA9F,earnings,100,50,2/22/2021
F1EB39,unit-acquisition-completed-acquirer,100,49,2/22/2021
F2BC3D,conference-participant,100,50,2/22/2021
F44EA2,earnings,100,50,2/22/2021
F67165,note-sale,100,52,2/22/2021
F6E1B5,private-placement,100,56,2/22/2021
F7FCA4,earnings,100,50,2/22/2021
FC1736,executive-appointment,100,54,2/22/2021
FD4BBE,partnership,100,61,2/22/2021
00D6B5,public-offering,100,43,2/23/2021
00E601,buybacks,100,74,2/23/2021
03596A,award,100,58,2/23/2021
03B8CF,partnership,100,61,2/23/2021
03B8CF,award,100,58,2/23/2021
03B8CF,partnership,100,61,2/23/2021
03B8CF,partnership,100,61,2/23/2021
0490C6,earnings,100,50,2/23/2021
053EFF,earnings,100,50,2/23/2021
0560D8,earnings,100,50,2/23/2021
06EF42,conference-participant,100,50,2/23/2021
09062E,earnings,100,50,2/23/2021
091B6C,conference-participant,100,50,2/23/2021
0968A5,executive-appointment,100,54,2/23/2021
0986B5,dividend,100,50,2/23/2021
099A92,executive-appointment,100,54,2/23/2021
0A0D9E,note-sale,100,52,2/23/2021
0A9D0A,dividend-up,100,57,2/23/2021
0B400D,earnings,100,50,2/23/2021
0B7375,conference-call,100,50,2/23/2021
0BC17A,conference-participant,100,50,2/23/2021
0BD4E8,earnings,100,50,2/23/2021
0C136E,dividend,100,50,2/23/2021
0C2A0D,executive-appointment,100,54,2/23/2021
0C355F,revenue-up,100,63,2/23/2021
0C355F,revenue-up,100,69,2/23/2021
0C355F,revenue-up,100,69,2/23/2021
0C355F,revenue-up,100,69,2/23/2021
0C355F,revenue-up,100,69,2/23/2021
0C6861,conference-participant,100,50,2/23/2021
0CC62B,earnings,100,50,2/23/2021
0CE204,earnings,100,50,2/23/2021
0E439E,dividend-up,100,67,2/23/2021
0E5223,earnings,100,50,2/23/2021
0EF1AF,earnings,100,50,2/23/2021
0F0440,donation,100,54,2/23/2021
1220D2,product-release,100,64,2/23/2021
1220D2,earnings,100,50,2/23/2021
125212,conference-participant,100,50,2/23/2021
1272B3,conference-participant,100,50,2/23/2021
1348C9,earnings,100,50,2/23/2021
13A782,earnings,100,50,2/23/2021
149301,executive-resignation,100,44,2/23/2021
14BA33,earnings,100,50,2/23/2021
152FA5,conference-participant,100,50,2/23/2021
16FC89,earnings,100,50,2/23/2021
1782D5,earnings,100,50,2/23/2021
1782D5,earnings,100,50,2/23/2021
1782D5,earnings,100,50,2/23/2021
1782D5,earnings,100,50,2/23/2021
1782D5,earnings,100,50,2/23/2021
1782D5,earnings,100,50,2/23/2021
1782D5,earnings,100,50,2/23/2021
1782D5,earnings,100,50,2/23/2021
180DA0,business-contract,100,69,2/23/2021
184988,conference-participant,100,50,2/23/2021
196D18,conference-participant,100,50,2/23/2021
1A2D9F,partnership,100,61,2/23/2021
1A5D5D,earnings,100,50,2/23/2021
1B637E,dividend,100,50,2/23/2021
1B6F77,conference-participant,100,50,2/23/2021
1D5C51,executive-appointment,100,54,2/23/2021
1E1125,conference-organizer,100,57,2/23/2021
1E5786,conference-participant,100,50,2/23/2021
1F9258,executive-appointment,100,54,2/23/2021
228D42,partnership,100,61,2/23/2021
228D42,partnership,100,61,2/23/2021
228D42,partnership,100,61,2/23/2021
228D42,product-release,100,64,2/23/2021
2920D5,earnings,100,50,2/23/2021
297DA8,earnings,100,50,2/23/2021
2B0AF4,conference-participant,100,50,2/23/2021
2B7A40,award,100,58,2/23/2021
2CA60F,partnership,100,61,2/23/2021
2D981A,earnings,100,50,2/23/2021
2E0445,conference-participant,100,50,2/23/2021
2E0496,earnings,100,50,2/23/2021
2F6782,earnings,100,50,2/23/2021
30A565,partnership,100,61,2/23/2021
34B97A,award,100,58,2/23/2021
35557B,earnings,100,50,2/23/2021
36529A,conference-participant,100,50,2/23/2021
367E1C,conference-participant,100,50,2/23/2021
385DD4,executive-appointment,100,54,2/23/2021
3.88E+02,earnings,100,50,2/23/2021
3B50FE,earnings,100,50,2/23/2021
3B8484,dividend,100,50,2/23/2021
3BBD10,executive-appointment,100,54,2/23/2021
3C6CCC,earnings,100,50,2/23/2021
3D7971,dividend,100,50,2/23/2021
3E15F6,dividend,100,50,2/23/2021
3ED92D,product-release,100,64,2/23/2021
3F6A9C,award,100,58,2/23/2021
4017AD,earnings,100,50,2/23/2021
416C55,partnership,100,61,2/23/2021
416C55,partnership,100,61,2/23/2021
444CC8,sponsorship,100,57,2/23/2021
4455C4,executive-resignation,100,44,2/23/2021
448215,earnings,100,50,2/23/2021
449447,conference-call,100,50,2/23/2021
44A4FC,unit-acquisition-acquirer,100,49,2/23/2021
451D61,conference-participant,100,50,2/23/2021
453282,conference-participant,100,50,2/23/2021
46A16E,earnings,100,50,2/23/2021
47752F,award,100,58,2/23/2021
479930,conference-participant,100,50,2/23/2021
4.91E+58,award,100,58,2/23/2021
4A6F00,partnership,100,61,2/23/2021
4A6F00,partnership,100,61,2/23/2021
4A6F00,partnership,100,61,2/23/2021
4A6F00,partnership,100,61,2/23/2021
4B3676,partnership,100,61,2/23/2021
4B6EF9,earnings,100,50,2/23/2021
4B6EF9,dividend,100,50,2/23/2021
4BDCA7,earnings,100,50,2/23/2021
4C2F17,earnings,100,50,2/23/2021
4DAF5F,buybacks,100,74,2/23/2021
4DAF5F,buybacks,100,74,2/23/2021
4EE167,conference-participant,100,50,2/23/2021
4F783B,earnings,100,50,2/23/2021
4F783B,earnings,100,50,2/23/2021
4F783B,earnings,100,50,2/23/2021
4F783B,earnings,100,50,2/23/2021
4F783B,earnings,100,50,2/23/2021
4F783B,earnings,100,50,2/23/2021
504FE2,earnings,100,50,2/23/2021
504FE2,award,100,58,2/23/2021
504FE2,fraud,100,44,2/23/2021
51D876,earnings,100,50,2/23/2021
51D876,earnings,100,50,2/23/2021
51D876,earnings,100,50,2/23/2021
51D876,earnings,100,50,2/23/2021
51D876,earnings,100,50,2/23/2021
51D876,earnings,100,50,2/23/2021
51D876,earnings,100,50,2/23/2021
51D876,earnings,100,50,2/23/2021
51D876,award,100,58,2/23/2021
53EF9E,dividend,100,50,2/23/2021
5403F8,earnings,100,50,2/23/2021
543C77,conference-participant,100,50,2/23/2021
54F271,conference-participant,100,50,2/23/2021
550D01,earnings,100,50,2/23/2021
550D01,earnings,100,50,2/23/2021
550D01,earnings,100,50,2/23/2021
550D01,earnings,100,50,2/23/2021
55438C,business-contract,100,69,2/23/2021
55ACCB,conference-participant,100,50,2/23/2021
56EA2B,conference-call,100,50,2/23/2021
5704AC,conference-participant,100,50,2/23/2021
57EF50,conference-call,100,50,2/23/2021
583553,earnings,100,50,2/23/2021
589803,regulatory-product-approval-granted,100,81,2/23/2021
58CA9A,conference-organizer,100,57,2/23/2021
596116,earnings,100,50,2/23/2021
5968F9,earnings,100,50,2/23/2021
5A423F,earnings,100,50,2/23/2021
5AF08A,partnership,100,61,2/23/2021
5B226B,fraud-defendant,100,20,2/23/2021
5B226B,acquisition-acquiree,100,76,2/23/2021
5B226B,legal-issues-defendant,100,22,2/23/2021
5B226B,legal-issues-defendant,100,22,2/23/2021
5B226B,legal-issues-defendant,100,22,2/23/2021
5CCDAD,earnings,100,50,2/23/2021
5EAA43,business-contract,100,69,2/23/2021
5F9CE3,partnership,100,61,2/23/2021
605F40,note-sale,100,52,2/23/2021
60AC34,earnings,100,50,2/23/2021
615B6D,legal-issues-defendant,100,22,2/23/2021
615B6D,legal-issues-defendant,100,22,2/23/2021
615B6D,legal-issues-defendant,100,22,2/23/2021
615B6D,legal-issues-defendant,100,22,2/23/2021
6166D1,award,100,58,2/23/2021
616E3B,dividend,100,50,2/23/2021
619882,stake-acquirer,100,48,2/23/2021
619882,conference-organizer,100,57,2/23/2021
66ECFD,award,100,58,2/23/2021
67303E,legal-issues-defendant,100,22,2/23/2021
67303E,legal-issues-defendant,100,22,2/23/2021
67303E,earnings,100,50,2/23/2021
693ECD,conference-participant,100,50,2/23/2021
69CE71,investment-investor,100,55,2/23/2021
6CD55A,dividend,100,50,2/23/2021
6D156D,legal-issues-defendant,100,22,2/23/2021
6D156D,legal-issues-defendant,100,22,2/23/2021
6D156D,legal-issues-defendant,100,22,2/23/2021
6D3F35,earnings,100,50,2/23/2021
6E8864,operating-earnings,100,50,2/23/2021
6E8864,operating-earnings,100,50,2/23/2021
6E8864,operating-earnings,100,50,2/23/2021
6F0096,dividend-up,100,61,2/23/2021
6F0A63,dividend,100,50,2/23/2021
70FCEF,partnership,100,61,2/23/2021
71E2EF,dividend-up,100,73,2/23/2021
722DE3,business-contract,100,69,2/23/2021
7.45E+28,legal-issues-defendant,100,22,2/23/2021
747219,conference-participant,100,50,2/23/2021
76DD0C,earnings,100,50,2/23/2021
7A3633,earnings,100,50,2/23/2021
7AB859,partnership,100,61,2/23/2021
7ACFD4,earnings,100,50,2/23/2021
7AF907,partnership,100,61,2/23/2021
7B0BA6,note-sale,100,52,2/23/2021
7B0BA6,note-sale,100,52,2/23/2021
7B6EB1,earnings,100,50,2/23/2021
7B8CB5,earnings,100,50,2/23/2021
7BFF81,executive-appointment,100,54,2/23/2021
7C790D,conference-participant,100,50,2/23/2021
7CBC40,note-sale,100,52,2/23/2021
7F2922,earnings,100,50,2/23/2021
7F9E16,conference-call,100,50,2/23/2021
7FDE1C,partnership,100,61,2/23/2021
803FED,conference-call,100,50,2/23/2021
80C400,earnings,100,50,2/23/2021
82F088,conference-participant,100,50,2/23/2021
8303CD,buybacks,100,74,2/23/2021
838ADD,earnings-up,100,68,2/23/2021
838ADD,earnings-up,100,68,2/23/2021
838ADD,earnings-up,100,68,2/23/2021
838ADD,earnings-up,100,68,2/23/2021
838ADD,earnings-up,100,68,2/23/2021
838ADD,earnings-up,100,68,2/23/2021
838ADD,earnings-up,100,68,2/23/2021
838ADD,earnings-up,100,68,2/23/2021
838ADD,earnings-up,100,68,2/23/2021
83B1C8,executive-appointment,100,54,2/23/2021
85DE00,business-contract,100,69,2/23/2021
8665BA,dividend-up,100,81,2/23/2021
8802B4,conference-call,100,50,2/23/2021
893904,revenues,100,50,2/23/2021
895D56,partnership,100,61,2/23/2021
8AC65D,product-release,100,64,2/23/2021
8BFE9A,conference-call,100,50,2/23/2021
8CF6DD,dividend,100,50,2/23/2021
8DCF18,earnings,100,50,2/23/2021
8DCF18,earnings,100,50,2/23/2021
8DCF18,note-sale,100,52,2/23/2021
8DE56F,award,100,58,2/23/2021
8DE56F,award,100,58,2/23/2021
8E0E32,award,100,58,2/23/2021
8E10BF,executive-appointment,100,54,2/23/2021
8E4F9A,earnings,100,50,2/23/2021
8FF2EF,conference-call,100,50,2/23/2021
9196A2,conference-organizer,100,57,2/23/2021
9196A2,conference-organizer,100,57,2/23/2021
9196A2,conference-organizer,100,57,2/23/2021
9196A2,conference-organizer,100,57,2/23/2021
9196A2,conference-organizer,100,57,2/23/2021
9196A2,conference-organizer,100,57,2/23/2021
9196A2,conference-organizer,100,57,2/23/2021
9.31E+77,conference-call,100,50,2/23/2021
94637C,conference-participant,100,50,2/23/2021
957A07,earnings,100,50,2/23/2021
9.65E+09,conference-participant,100,50,2/23/2021
9.65E+07,earnings,100,50,2/23/2021
9.65E+07,earnings,100,50,2/23/2021
9.65E+07,earnings,100,50,2/23/2021
971F7B,earnings,100,50,2/23/2021
97644E,partnership,100,61,2/23/2021
986AF6,dividend,100,50,2/23/2021
990AD0,conference-organizer,100,57,2/23/2021
990AD0,conference-organizer,100,57,2/23/2021
990AD0,conference-organizer,100,57,2/23/2021
994468,dividend,100,50,2/23/2021
9A2760,conference-participant,100,50,2/23/2021
9A602D,award,100,58,2/23/2021
9BF177,earnings,100,50,2/23/2021
9C5174,revenue-up,100,71,2/23/2021
9C5174,revenues,100,50,2/23/2021
9C5174,revenues,100,50,2/23/2021
9CA432,conference-participant,100,50,2/23/2021
9D3360,operating-earnings,100,50,2/23/2021
9F6B1A,partnership,100,61,2/23/2021
A204A7,earnings,100,50,2/23/2021
A21649,earnings,100,50,2/23/2021
A26EF7,conference-participant,100,50,2/23/2021
A29DBD,earnings,100,50,2/23/2021
A2CAF7,executive-appointment,100,54,2/23/2021
A350C1,conference-participant,100,50,2/23/2021
A398B9,conference-participant,100,50,2/23/2021
A3F598,award,100,58,2/23/2021
A4B899,earnings,100,50,2/23/2021
A58224,conference-participant,100,50,2/23/2021
A5A4F5,public-offering,100,43,2/23/2021
A5A4F5,public-offering,100,43,2/23/2021
A5E715,dividend,100,50,2/23/2021
A60354,dividend,100,50,2/23/2021
A6213D,donation,100,54,2/23/2021
A6FE1C,unit-acquisition-acquirer,100,49,2/23/2021
A79F7D,trading-listing,100,61,2/23/2021
A8AC4C,conference-call,100,50,2/23/2021
A8CBDA,executive-appointment,100,54,2/23/2021
AA98ED,award,100,58,2/23/2021
ACDF88,earnings,100,50,2/23/2021
ACDF88,earnings,100,50,2/23/2021
AD3C93,conference-participant,100,50,2/23/2021
AD6141,earnings,100,50,2/23/2021
ADF092,business-contract,100,69,2/23/2021
AE3113,earnings,100,50,2/23/2021
AECCA9,dividend,100,50,2/23/2021
B04426,conference-participant,100,50,2/23/2021
B05000,conference-participant,100,50,2/23/2021
B1FC3B,business-contract,100,69,2/23/2021
B2206F,conference-participant,100,50,2/23/2021
B2DAF6,conference-participant,100,50,2/23/2021
B33E77,clinical-trials-start,100,64,2/23/2021
B381D8,earnings,100,50,2/23/2021
B3CB74,conference-organizer,100,57,2/23/2021
B3CB74,conference-organizer,100,57,2/23/2021
B3CB74,conference-organizer,100,57,2/23/2021
B3CB74,conference-organizer,100,57,2/23/2021
B3CB74,conference-organizer,100,57,2/23/2021
B3CB74,conference-organizer,100,57,2/23/2021
B3CB74,conference-organizer,100,57,2/23/2021
B3CB74,conference-organizer,100,57,2/23/2021
B446B8,earnings,100,50,2/23/2021
B446B8,earnings,100,50,2/23/2021
B446B8,earnings,100,50,2/23/2021
B446B8,earnings,100,50,2/23/2021
B4528F,executive-appointment,100,54,2/23/2021
B48D6A,conference-participant,100,50,2/23/2021
B53C12,earnings,100,50,2/23/2021
B5767B,earnings,100,50,2/23/2021
B5BA39,earnings,100,50,2/23/2021
B614F8,executive-appointment,100,54,2/23/2021
B803B1,conference-participant,100,50,2/23/2021
B83BCE,partnership,100,61,2/23/2021
B9CD50,conference-participant,100,50,2/23/2021
BBC05B,earnings,100,50,2/23/2021
BC948D,conference-participant,100,50,2/23/2021
BD8517,award,100,58,2/23/2021
BE14CF,conference-participant,100,50,2/23/2021
BE5935,earnings,100,50,2/23/2021
BFE02C,conference-participant,100,50,2/23/2021
C01737,executive-appointment,100,54,2/23/2021
C01737,earnings,100,50,2/23/2021
C05839,earnings,100,50,2/23/2021
C06EB6,clinical-trials-filed,100,60,2/23/2021
C06EB6,clinical-trials-filed,100,60,2/23/2021
C15F8F,conference-participant,100,50,2/23/2021
C3BAE7,conference-participant,100,50,2/23/2021
C3CF29,earnings,100,50,2/23/2021
C3CF29,earnings,100,50,2/23/2021
C3CF29,earnings,100,50,2/23/2021
C3CF29,earnings,100,50,2/23/2021
C3CF29,earnings,100,50,2/23/2021
C3F99F,conference-call,100,50,2/23/2021
C501B6,private-placement,100,56,2/23/2021
C584BE,credit-extension-recipient,100,69,2/23/2021
C584BE,earnings,100,50,2/23/2021
C5C137,earnings,100,50,2/23/2021
C624A1,earnings,100,50,2/23/2021
C624A1,earnings,100,50,2/23/2021
C7863D,executive-appointment,100,54,2/23/2021
C8A248,business-contract,100,69,2/23/2021
CB89EA,partnership,100,61,2/23/2021
CB9E13,earnings,100,50,2/23/2021
CBBFBF,earnings,100,50,2/23/2021
CBDB4D,conference-participant,100,50,2/23/2021
CE1002,executive-appointment,100,54,2/23/2021
CE1002,conference-participant,100,50,2/23/2021
CE5664,dividend,100,50,2/23/2021
CE5C6E,earnings,100,50,2/23/2021
CE5C6E,earnings,100,50,2/23/2021
CE96E7,award,100,58,2/23/2021
CFF97C,business-contract,100,69,2/23/2021
D06755,sponsorship,100,57,2/23/2021
D15833,dividend,100,50,2/23/2021
D20C8F,earnings,100,50,2/23/2021
D29B44,conference-participant,100,50,2/23/2021
D2B9E5,award,100,58,2/23/2021
D42DBA,executive-resignation,100,44,2/23/2021
D518D8,revenues,100,50,2/23/2021
D6489C,fundraising,100,64,2/23/2021
D6489C,award,100,58,2/23/2021
D6489C,award,100,58,2/23/2021
D64EDF,dividend-up,100,61,2/23/2021
D75910,earnings,100,50,2/23/2021
D75910,earnings,100,50,2/23/2021
D75910,earnings,100,50,2/23/2021
D75910,earnings,100,50,2/23/2021
D78CCD,award,100,58,2/23/2021
D7A953,executive-appointment,100,54,2/23/2021
DB23C8,conference-participant,100,50,2/23/2021
DC1405,earnings,100,50,2/23/2021
DC6AA0,earnings,100,50,2/23/2021
DD0099,dividend,100,50,2/23/2021
DD1BA1,partnership,100,61,2/23/2021
DDEA6A,earnings,100,50,2/23/2021
E124EB,dividend,100,50,2/23/2021
E1C16B,conference-participant,100,50,2/23/2021
E1E093,business-contract,100,69,2/23/2021
E30B34,note-sale,100,52,2/23/2021
E30B34,note-sale,100,52,2/23/2021
E38906,conference-participant,100,50,2/23/2021
E68733,earnings,100,50,2/23/2021
E68733,earnings,100,50,2/23/2021
E6C8DC,conference-participant,100,50,2/23/2021
E6D89E,legal-issues-defendant,100,22,2/23/2021
E6D89E,legal-issues-defendant,100,22,2/23/2021
E70531,legal-issues-defendant,100,22,2/23/2021
E84500,earnings,100,50,2/23/2021
E8846E,business-contract,100,69,2/23/2021
E8846E,business-contract,100,69,2/23/2021
E8846E,acquisition-acquiree,100,76,2/23/2021
E959F3,award,100,58,2/23/2021
E96E0B,legal-issues-defendant,100,22,2/23/2021
E96E0B,legal-issues-defendant,100,22,2/23/2021
E96E0B,fraud-defendant,100,20,2/23/2021
E96E0B,earnings,100,50,2/23/2021
EBC84C,earnings,100,50,2/23/2021
EBC84C,earnings,100,50,2/23/2021
EBC84C,earnings,100,50,2/23/2021
EBC84C,earnings,100,50,2/23/2021
EBC84C,earnings,100,50,2/23/2021
EBC84C,earnings,100,50,2/23/2021
EBC84C,earnings,100,50,2/23/2021
EC1AF3,earnings,100,50,2/23/2021
ECE814,earnings,100,50,2/23/2021
ED0402,revenue-up,100,69,2/23/2021
ED1A74,acquisition-acquirer,100,49,2/23/2021
EEBCEF,earnings,100,50,2/23/2021
EF1AD9,sponsorship,100,57,2/23/2021
F0B335,earnings,100,50,2/23/2021
F11638,earnings,100,50,2/23/2021
F11638,earnings,100,50,2/23/2021
F11638,earnings,100,50,2/23/2021
F11638,earnings,100,50,2/23/2021
F11638,earnings,100,50,2/23/2021
F1529C,conference-participant,100,50,2/23/2021
F1CD47,dividend,100,50,2/23/2021
F1EB39,conference-call,100,50,2/23/2021
F3016C,earnings,100,50,2/23/2021
F48947,earnings,100,50,2/23/2021
F4FBD8,earnings,100,50,2/23/2021
F509E2,business-contract,100,69,2/23/2021
F7ADEB,conference-participant,100,50,2/23/2021
F80389,earnings,100,50,2/23/2021
F80389,earnings,100,50,2/23/2021
F80389,earnings,100,50,2/23/2021
F80389,earnings,100,50,2/23/2021
F80389,earnings,100,50,2/23/2021
F80389,earnings,100,50,2/23/2021
F80389,earnings,100,50,2/23/2021
F80389,earnings,100,50,2/23/2021
F85CC0,award,100,58,2/23/2021
F85CC0,award,100,58,2/23/2021
FD6926,conference-participant,100,50,2/23/2021
FFAB4A,earnings,100,50,2/23/2021
00D6B5,dividend,100,50,2/24/2021
0157B1,donation,100,54,2/24/2021
018C11,conference-participant,100,50,2/24/2021
02FC1A,earnings,100,50,2/24/2021
02FC1A,earnings,100,50,2/24/2021
03FB17,dividend,100,50,2/24/2021
053EFF,dividend,100,50,2/24/2021
054E7E,earnings,100,50,2/24/2021
061A3B,product-price-raise,100,57,2/24/2021
06C826,conference-call,100,50,2/24/2021
06EE79,earnings,100,50,2/24/2021
070B45,award,100,58,2/24/2021
070B45,conference-participant,100,50,2/24/2021
96930,conference-participant,100,50,2/24/2021
0B7375,executive-appointment,100,54,2/24/2021
0BF198,conference-participant,100,50,2/24/2021
0C466B,earnings-up,100,68,2/24/2021
0C466B,earnings-up,100,68,2/24/2021
0C466B,earnings-up,100,68,2/24/2021
0CCCB7,dividend,100,50,2/24/2021
0CCCB7,earnings-up,100,68,2/24/2021
0DBB81,conference-participant,100,50,2/24/2021
0DC050,product-release,100,64,2/24/2021
0DE3D5,earnings,100,50,2/24/2021
0DE3D5,earnings,100,50,2/24/2021
0DE3D5,earnings,100,50,2/24/2021
0DE3D5,earnings,100,50,2/24/2021
0DE3D5,earnings,100,50,2/24/2021
0DE3D5,earnings,100,50,2/24/2021
1065BC,earnings,100,50,2/24/2021
1080C0,earnings,100,50,2/24/2021
108A2B,operating-earnings,100,50,2/24/2021
1201B5,conference-participant,100,50,2/24/2021
1220D2,conference-participant,100,50,2/24/2021
13D576,earnings,100,50,2/24/2021
15789A,earnings,100,50,2/24/2021
15789A,earnings,100,50,2/24/2021
15A388,earnings,100,50,2/24/2021
16B183,fraud-defendant,100,20,2/24/2021
16B183,legal-issues-defendant,100,22,2/24/2021
16B183,earnings,100,50,2/24/2021
16B183,legal-issues-defendant,100,22,2/24/2021
16B183,legal-issues-defendant,100,22,2/24/2021
16F4D8,earnings,100,50,2/24/2021
1748F6,earnings,100,50,2/24/2021
182BE7,conference-participant,100,50,2/24/2021
1834C0,earnings,100,50,2/24/2021
1AB808,earnings,100,50,2/24/2021
1B637E,earnings,100,50,2/24/2021
1C599A,earnings,100,50,2/24/2021
1CD708,earnings,100,50,2/24/2021
1D5C51,earnings,100,50,2/24/2021
1E1125,conference-organizer,100,57,2/24/2021
1EBF8D,conference-participant,100,50,2/24/2021
1F3CFB,earnings,100,50,2/24/2021
1F9D90,partnership,100,61,2/24/2021
2003A5,earnings,100,50,2/24/2021
2158DF,earnings,100,50,2/24/2021
2158DF,earnings,100,50,2/24/2021
2158DF,earnings,100,50,2/24/2021
2158DF,earnings,100,50,2/24/2021
2158DF,earnings,100,50,2/24/2021
227D48,earnings,100,50,2/24/2021
228D42,partnership,100,61,2/24/2021
228D42,partnership,100,61,2/24/2021
25A6CC,earnings,100,50,2/24/2021
25A6CC,earnings,100,50,2/24/2021
25A6CC,earnings,100,50,2/24/2021
25A6CC,earnings,100,50,2/24/2021
25A6CC,earnings,100,50,2/24/2021
26DC29,conference-participant,100,50,2/24/2021
26FA41,revenues,100,50,2/24/2021
270B78,dividend,100,50,2/24/2021
28AC4E,earnings,100,50,2/24/2021
292388,conference-participant,100,50,2/24/2021
29CEBF,earnings,100,50,2/24/2021
2B0AF4,conference-call,100,50,2/24/2021
2CC71C,conference-call,100,50,2/24/2021
2CF9D3,earnings,100,50,2/24/2021
2D485F,earnings,100,50,2/24/2021
2D485F,earnings,100,50,2/24/2021
2D485F,earnings,100,50,2/24/2021
2D485F,earnings,100,50,2/24/2021
2E2E6E,dividend-up,100,72,2/24/2021
2E89AE,earnings,100,50,2/24/2021
2F9304,acquisition-acquiree,100,76,2/24/2021
315EB0,partnership,100,61,2/24/2021
315EB0,partnership,100,61,2/24/2021
31643A,facility-close,100,47,2/24/2021
31803E,earnings,100,50,2/24/2021
31DB20,earnings,100,50,2/24/2021
3224CC,earnings,100,50,2/24/2021
32C8CD,earnings,100,50,2/24/2021
32CB22,conference-participant,100,50,2/24/2021
3.20E+263,earnings,100,50,2/24/2021
32F943,conference-participant,100,50,2/24/2021
33AD83,conference-participant,100,50,2/24/2021
342218,earnings,100,50,2/24/2021
355B19,earnings,100,50,2/24/2021
356B21,earnings,100,50,2/24/2021
356B21,earnings,100,50,2/24/2021
356B21,earnings,100,50,2/24/2021
373B06,public-offering,100,43,2/24/2021
384CD3,executive-appointment,100,54,2/24/2021
384CD3,earnings,100,50,2/24/2021
387541,earnings,100,50,2/24/2021
396D7C,earnings,100,50,2/24/2021
3A1C46,earnings,100,50,2/24/2021
3B8484,earnings-up,100,68,2/24/2021
3BC360,earnings,100,50,2/24/2021
3C7F5F,earnings,100,50,2/24/2021
3C7F5F,earnings,100,50,2/24/2021
3C7F5F,earnings,100,50,2/24/2021
3C7F5F,earnings,100,50,2/24/2021
3C7F5F,earnings,100,50,2/24/2021
3C7F5F,earnings,100,50,2/24/2021
3DED49,earnings,100,50,2/24/2021
40B903,earnings,100,50,2/24/2021
416291,earnings,100,50,2/24/2021
425BDC,earnings,100,50,2/24/2021
427F32,product-price-raise,100,57,2/24/2021
42DC93,conference-participant,100,50,2/24/2021
431B74,dividend-up,100,68,2/24/2021
431B74,dividend-up,100,68,2/24/2021
43A060,business-contract,100,69,2/24/2021
45444E,earnings,100,50,2/24/2021
45ABCC,earnings,100,50,2/24/2021
468DD4,earnings-positive,100,69,2/24/2021
49CC59,earnings,100,50,2/24/2021
49F4D0,executive-appointment,100,54,2/24/2021
4A6F00,partnership,100,61,2/24/2021
4B7006,executive-appointment,100,54,2/24/2021
4C350A,conference-call,100,50,2/24/2021
4C6C63,conference-participant,100,50,2/24/2021
4C7DB5,index-listing,100,76,2/24/2021
4DAF5F,buybacks,100,74,2/24/2021
4DAF5F,buybacks,100,74,2/24/2021
4E4E75,conference-call,100,50,2/24/2021
4F0A80,dividend,100,50,2/24/2021
52FB2F,executive-resignation,100,44,2/24/2021
543900,earnings,100,50,2/24/2021
553949,conference-participant,100,50,2/24/2021
564F3E,dividend,100,50,2/24/2021
5675EB,partnership,100,61,2/24/2021
577033,earnings,100,50,2/24/2021
57CAAB,conference-participant,100,50,2/24/2021
583223,earnings,100,50,2/24/2021
586FFD,executive-appointment,100,54,2/24/2021
594402,earnings,100,50,2/24/2021
594402,conference-participant,100,50,2/24/2021
59872F,earnings,100,50,2/24/2021
5A0FF1,earnings,100,50,2/24/2021
5A0FF1,earnings,100,50,2/24/2021
5A0FF1,earnings,100,50,2/24/2021
5A0FF1,earnings,100,50,2/24/2021
5A0FF1,earnings,100,50,2/24/2021
5B226B,fraud-defendant,100,20,2/24/2021
5B226B,legal-issues-defendant,100,22,2/24/2021
5B226B,legal-issues-defendant,100,22,2/24/2021
5B226B,legal-issues-defendant,100,22,2/24/2021
5B226B,fraud-defendant,100,20,2/24/2021
5B226B,legal-issues-defendant,100,22,2/24/2021
5B226B,legal-issues-defendant,100,22,2/24/2021
5B3FA2,earnings,100,50,2/24/2021
5D16CF,dividend,100,50,2/24/2021
619882,conference-organizer,100,57,2/24/2021
619882,conference-organizer,100,57,2/24/2021
61A586,public-offering,100,43,2/24/2021
6284B5,earnings,100,50,2/24/2021
6391C2,conference-participant,100,50,2/24/2021
63F892,note-sale,100,52,2/24/2021
64E346,acquisition-acquirer,100,49,2/24/2021
657097,earnings,100,50,2/24/2021
67303E,legal-issues-defendant,100,22,2/24/2021
68AB62,public-offering,100,43,2/24/2021
68E6E9,earnings,100,50,2/24/2021
6B0E45,earnings,100,50,2/24/2021
6CBF41,earnings,100,50,2/24/2021
6D1ADF,earnings,100,50,2/24/2021
6D3F35,conference-participant,100,50,2/24/2021
6DBBBC,earnings,100,50,2/24/2021
6DBBBC,earnings,100,50,2/24/2021
6DBBBC,earnings,100,50,2/24/2021
6DBBBC,earnings,100,50,2/24/2021
6E705B,executive-appointment,100,54,2/24/2021
6E7060,earnings,100,50,2/24/2021
6E7060,earnings,100,50,2/24/2021
6E7060,earnings,100,50,2/24/2021
6E7060,earnings,100,50,2/24/2021
6E7060,earnings,100,50,2/24/2021
6E7060,earnings,100,50,2/24/2021
6E7060,earnings,100,50,2/24/2021
6E7060,earnings,100,50,2/24/2021
6E7060,earnings,100,50,2/24/2021
6F92A9,executive-appointment,100,54,2/24/2021
723548,earnings,100,50,2/24/2021
72FCA3,product-release,100,64,2/24/2021
73F70F,earnings,100,50,2/24/2021
74404C,dividend,100,50,2/24/2021
746373,earnings,100,50,2/24/2021
746373,dividend-up,100,57,2/24/2021
751C8D,award,100,58,2/24/2021
751C8D,award,100,58,2/24/2021
762A3E,conference-organizer,100,57,2/24/2021
762A3E,conference-organizer,100,57,2/24/2021
76BECC,earnings,100,50,2/24/2021
76E80F,revenues,100,50,2/24/2021
76E80F,revenues,100,50,2/24/2021
76E80F,revenues,100,50,2/24/2021
76F067,conference-participant,100,50,2/24/2021
7823A3,conference-participant,100,50,2/24/2021
7ACFD4,executive-appointment,100,54,2/24/2021
7CD98F,dividend-up,100,81,2/24/2021
7DA412,acquisition-acquiree,100,76,2/24/2021
7DA412,acquisition-acquiree,100,76,2/24/2021
7DA412,earnings,100,50,2/24/2021
7E1D5D,product-release,100,64,2/24/2021
7FD8B9,conference-call,100,50,2/24/2021
805CD8,earnings,100,50,2/24/2021
818A2F,dividend,100,50,2/24/2021
818A2F,dividend,100,50,2/24/2021
82B57E,earnings,100,50,2/24/2021
82B57E,earnings,100,50,2/24/2021
82B57E,earnings,100,50,2/24/2021
82B57E,earnings,100,50,2/24/2021
82B57E,earnings,100,50,2/24/2021
82B57E,executive-appointment,100,54,2/24/2021
834152,conference-participant,100,50,2/24/2021
83A065,earnings,100,50,2/24/2021
8665BA,conference-participant,100,50,2/24/2021
88936A,earnings,100,50,2/24/2021
890FF4,earnings,100,50,2/24/2021
895D56,earnings,100,50,2/24/2021
896771,earnings,100,50,2/24/2021
8A0368,earnings,100,50,2/24/2021
8AA108,clinical-trials,100,56,2/24/2021
8AB37F,revenue-up,100,91,2/24/2021
8AB37F,revenue-up,100,91,2/24/2021
8AB37F,revenue-up,100,91,2/24/2021
8B1E11,earnings,100,50,2/24/2021
8DAAB9,buybacks,100,74,2/24/2021
8E8E6E,product-release,100,64,2/24/2021
8EDACA,conference-call,100,50,2/24/2021
9043FE,earnings,100,50,2/24/2021
9043FE,earnings,100,50,2/24/2021
9196A2,conference-organizer,100,57,2/24/2021
9196A2,conference-organizer,100,57,2/24/2021
9196A2,conference-organizer,100,57,2/24/2021
9196A2,conference-organizer,100,57,2/24/2021
9196A2,conference-organizer,100,57,2/24/2021
9196A2,conference-organizer,100,57,2/24/2021
925759,earnings,100,50,2/24/2021
931AE7,executive-appointment,100,54,2/24/2021
934029,conference-participant,100,50,2/24/2021
934CC3,earnings,100,50,2/24/2021
942165,earnings,100,50,2/24/2021
94637C,donation,100,54,2/24/2021
94637C,conference-participant,100,50,2/24/2021
9.54E+32,partnership,100,61,2/24/2021
958938,earnings,100,50,2/24/2021
96BFF4,partnership,100,61,2/24/2021
980C14,earnings,100,50,2/24/2021
98CEBB,earnings,100,50,2/24/2021
990AD0,conference-organizer,100,57,2/24/2021
9A2760,executive-appointment,100,54,2/24/2021
9ABD30,earnings,100,50,2/24/2021
9B730A,conference-participant,100,50,2/24/2021
9BB35A,operating-earnings-positive,100,69,2/24/2021
9BB35A,earnings-per-share,100,50,2/24/2021
9BB35A,earnings-per-share,100,50,2/24/2021
9BB35A,earnings-per-share,100,50,2/24/2021
9BB35A,earnings-per-share,100,50,2/24/2021
9C3D3C,earnings,100,50,2/24/2021
9C5BA5,revenues,100,50,2/24/2021
9C8BC3,name-change,100,49,2/24/2021
9C8BC3,name-change,100,49,2/24/2021
9CDA4F,earnings,100,50,2/24/2021
9EBAFA,earnings,100,50,2/24/2021
9EBAFA,earnings,100,50,2/24/2021
A01200,earnings,100,50,2/24/2021
A15C71,earnings,100,50,2/24/2021
A1BB98,executive-appointment,100,54,2/24/2021
A23747,conference-participant,100,50,2/24/2021
A26C26,earnings,100,50,2/24/2021
A37D68,earnings,100,50,2/24/2021
A38F30,earnings,100,50,2/24/2021
A398F8,earnings,100,50,2/24/2021
A3F598,earnings,100,50,2/24/2021
A3F598,earnings,100,50,2/24/2021
A3F598,earnings,100,50,2/24/2021
A3F598,earnings,100,50,2/24/2021
A5DD24,conference-participant,100,50,2/24/2021
A631A3,partnership,100,61,2/24/2021
A80FE0,conference-participant,100,50,2/24/2021
A80FE0,conference-participant,100,50,2/24/2021
A9ED24,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AAC8B6,earnings,100,50,2/24/2021
AC642C,conference-participant,100,50,2/24/2021
AC642C,conference-participant,100,50,2/24/2021
AD3008,note-sale,100,52,2/24/2021
AD3C93,partnership,100,61,2/24/2021
AECCA9,earnings,100,50,2/24/2021
AECCA9,earnings,100,50,2/24/2021
AECCA9,earnings,100,50,2/24/2021
AECCA9,earnings,100,50,2/24/2021
AECCA9,earnings,100,50,2/24/2021
AFEC35,earnings,100,50,2/24/2021
B0998E,earnings,100,50,2/24/2021
B09B1F,executive-appointment,100,54,2/24/2021
B09B1F,earnings,100,50,2/24/2021
B0D41A,earnings,100,50,2/24/2021
B1FC3B,government-contract,100,69,2/24/2021
B2206F,award,100,58,2/24/2021
B303A6,earnings,100,50,2/24/2021
B33E77,partnership,100,61,2/24/2021
B33E77,partnership,100,61,2/24/2021
B33E77,partnership,100,61,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B3CB74,conference-organizer,100,57,2/24/2021
B6082A,dividend,100,50,2/24/2021
B66928,earnings,100,50,2/24/2021
B7BDA3,earnings,100,50,2/24/2021
B7FA9B,earnings,100,50,2/24/2021
B83BCE,buybacks,100,74,2/24/2021
B98EFA,conference-participant,100,50,2/24/2021
B9CD50,award,100,58,2/24/2021
BCC13E,earnings,100,50,2/24/2021
BD8517,conference-participant,100,50,2/24/2021
BDD12C,conference-participant,100,50,2/24/2021
BE14CF,dividend,100,50,2/24/2021
BE7BA4,conference-participant,100,50,2/24/2021
BF79F5,dividend,100,50,2/24/2021
BFD0A7,executive-appointment,100,54,2/24/2021
C03C8B,conference-participant,100,50,2/24/2021
C07E05,earnings,100,50,2/24/2021
C22BE8,executive-appointment,100,54,2/24/2021
C2E39B,earnings,100,50,2/24/2021
C2E39B,earnings,100,50,2/24/2021
C2E39B,earnings,100,50,2/24/2021
C2E39B,earnings,100,50,2/24/2021
C3DE7D,earnings,100,50,2/24/2021
C45CE7,earnings,100,50,2/24/2021
C4FBDC,earnings,100,50,2/24/2021
C72B8F,acquisition-acquirer,100,49,2/24/2021
C83B88,conference-participant,100,50,2/24/2021
C85A72,revenue-up,100,68,2/24/2021
C85A72,revenue-up,100,68,2/24/2021
C85A72,revenue-up,100,68,2/24/2021
C85A72,revenue-up,100,68,2/24/2021
C8923A,partnership,100,61,2/24/2021
C99CC8,business-contract,100,69,2/24/2021
C9E04B,conference-call,100,50,2/24/2021
C9E107,conference-participant,100,50,2/24/2021
CA14CC,earnings,100,50,2/24/2021
CBFFDD,earnings,100,50,2/24/2021
CC0C78,revenues,100,50,2/24/2021
CC6FF5,acquisition-completed-acquirer,100,49,2/24/2021
CD2A4D,earnings,100,50,2/24/2021
CD4DA8,conference-organizer,100,57,2/24/2021
CD4DA8,conference-organizer,100,57,2/24/2021
CDC817,conference-participant,100,50,2/24/2021
CEC5B9,note-sale,100,52,2/24/2021
CEC5B9,note-sale,100,52,2/24/2021
CF211D,executive-appointment,100,54,2/24/2021
CF3FF9,conference-participant,100,50,2/24/2021
CFF15D,partnership,100,61,2/24/2021
CFF97C,credit-rating-set-rater,20,50,2/24/2021
CFF97C,conference-participant,100,50,2/24/2021
D0909F,donation,100,54,2/24/2021
D0DE27,dividend,100,50,2/24/2021
D139BC,conference-participant,100,50,2/24/2021
D15833,earnings-positive,100,69,2/24/2021
D15833,earnings,100,50,2/24/2021
D1C26F,partnership,100,61,2/24/2021
D29F43,earnings,100,50,2/24/2021
D2C0B6,earnings,100,50,2/24/2021
D2C0B6,earnings,100,50,2/24/2021
D45285,earnings,100,50,2/24/2021
D48275,conference-call,100,50,2/24/2021
D6489C,executive-appointment,100,54,2/24/2021
D6489C,executive-appointment,100,54,2/24/2021
D6489C,executive-appointment,100,54,2/24/2021
D697DE,conference-participant,100,50,2/24/2021
D76AEF,earnings,100,50,2/24/2021
D77F7E,earnings,100,50,2/24/2021
D77F7E,earnings,100,50,2/24/2021
D77F7E,earnings,100,50,2/24/2021
D77F7E,earnings,100,50,2/24/2021
D77F7E,earnings,100,50,2/24/2021
D77F7E,earnings,100,50,2/24/2021
D77F7E,earnings,100,50,2/24/2021
D78BF1,facility-open,100,65,2/24/2021
D78CCD,executive-appointment,100,54,2/24/2021
D8ECA1,earnings,100,50,2/24/2021
DA48E4,conference-participant,100,50,2/24/2021
DB2E4E,earnings,100,50,2/24/2021
DD9E41,conference-participant,100,50,2/24/2021
DDEA6A,conference-participant,100,50,2/24/2021
E0339F,dividend,100,50,2/24/2021
E06265,dividend,100,50,2/24/2021
E0647D,legal-issues-defendant,100,22,2/24/2021
E0647D,earnings,100,50,2/24/2021
E09997,conference-call,100,50,2/24/2021
E09E2B,earnings,100,50,2/24/2021
E09E2B,earnings,100,50,2/24/2021
E09E2B,earnings,100,50,2/24/2021
E09E2B,earnings,100,50,2/24/2021
E09E2B,earnings,100,50,2/24/2021
E11C41,earnings,100,50,2/24/2021
E15736,earnings,100,50,2/24/2021
E20392,conference-participant,100,50,2/24/2021
E3A829,conference-participant,100,50,2/24/2021
E3E68E,executive-appointment,100,54,2/24/2021
E3E68E,executive-appointment,100,54,2/24/2021
E69BA5,earnings,100,50,2/24/2021
E70531,asset-sale,100,62,2/24/2021
E72599,earnings,100,50,2/24/2021
E74B55,earnings,100,50,2/24/2021
E802CE,earnings,100,50,2/24/2021
E8846E,partnership,100,61,2/24/2021
E8846E,donation,100,54,2/24/2021
E96E0B,legal-issues-defendant,100,22,2/24/2021
E96E0B,legal-issues-defendant,100,22,2/24/2021
EC8116,earnings,100,50,2/24/2021
EDD234,earnings,100,50,2/24/2021
EEB5F9,earnings,100,50,2/24/2021
EF45B6,dividend,100,50,2/24/2021
EFD406,note-sale,100,52,2/24/2021
EFD406,note-sale,100,52,2/24/2021
F0B877,award,100,58,2/24/2021
F15E41,earnings,100,50,2/24/2021
F15E41,earnings,100,50,2/24/2021
F1EB39,acquisition-acquirer,100,49,2/24/2021
F3016C,note-sale,100,52,2/24/2021
F3016C,note-sale,100,52,2/24/2021
F5349B,earnings,100,50,2/24/2021
F5349B,dividend,100,50,2/24/2021
F5D410,conference-participant,100,50,2/24/2021
F6DCE4,partnership,100,61,2/24/2021
F7902B,conference-participant,100,50,2/24/2021
FB728F,earnings,100,50,2/24/2021
FB7724,earnings,100,50,2/24/2021
FC1F9D,conference-participant,100,50,2/24/2021
FD6926,clinical-trials-filed,100,60,2/24/2021
FDF799,earnings,100,50,2/24/2021
FE7A63,conference-participant,100,50,2/24/2021
00067A,partnership,100,61,2/25/2021
00067A,conference-participant,100,50,2/25/2021
00698D,earnings,100,50,2/25/2021
0157B1,partnership,100,61,2/25/2021
0157B1,partnership,100,61,2/25/2021
01D03F,executive-appointment,100,54,2/25/2021
01D03F,partnership,100,61,2/25/2021
20751,earnings,100,50,2/25/2021
02870F,dividend,100,50,2/25/2021
02ACBD,earnings,100,50,2/25/2021
0325B7,conference-call,100,50,2/25/2021
03FAA6,earnings,100,50,2/25/2021
03FAA6,earnings,100,50,2/25/2021
03FAA6,earnings,100,50,2/25/2021
03FAA6,earnings,100,50,2/25/2021
03FAA6,earnings,100,50,2/25/2021
03FAA6,earnings,100,50,2/25/2021
04996E,earnings,100,50,2/25/2021
55018,executive-appointment,100,54,2/25/2021
61366,earnings,100,50,2/25/2021
061A3B,earnings,100,50,2/25/2021
68396,earnings,100,50,2/25/2021
71860,conference-participant,100,50,2/25/2021
07CA6A,conference-participant,100,50,2/25/2021
07CA6A,conference-participant,100,50,2/25/2021
095A04,earnings,100,50,2/25/2021
0968A5,earnings,100,50,2/25/2021
0A0D9E,conference-participant,100,50,2/25/2021
0A59F8,earnings,100,50,2/25/2021
0A59F8,earnings,100,50,2/25/2021
0A59F8,earnings,100,50,2/25/2021
0A59F8,earnings,100,50,2/25/2021
0A59F8,earnings,100,50,2/25/2021
0A59F8,earnings,100,50,2/25/2021
0A59F8,earnings,100,50,2/25/2021
0A59F8,earnings,100,50,2/25/2021
0A59F8,earnings,100,50,2/25/2021
0B2071,buybacks,100,74,2/25/2021
0B7375,conference-participant,100,50,2/25/2021
0BA8CE,earnings,100,50,2/25/2021
0BD4E8,earnings,100,50,2/25/2021
0BD4E8,earnings,100,50,2/25/2021
0BD4E8,earnings,100,50,2/25/2021
0BD4E8,earnings,100,50,2/25/2021
0BF198,earnings,100,50,2/25/2021
0C6293,executive-appointment,100,54,2/25/2021
0E499E,earnings,100,50,2/25/2021
0F0693,earnings,100,50,2/25/2021
0F65C9,conference-participant,100,50,2/25/2021
0FABBD,earnings,100,50,2/25/2021
1096C6,earnings,100,50,2/25/2021
11A49E,earnings,100,50,2/25/2021
129DC8,conference-call,100,50,2/25/2021
12DE76,partnership,100,61,2/25/2021
12F98C,partnership,100,61,2/25/2021
131443,executive-appointment,100,54,2/25/2021
152E1D,operating-earnings,100,50,2/25/2021
152E1D,operating-earnings,100,50,2/25/2021
152E1D,operating-earnings,100,50,2/25/2021
152E1D,operating-earnings,100,50,2/25/2021
152E1D,operating-earnings,100,50,2/25/2021
152E1D,operating-earnings,100,50,2/25/2021
152E1D,operating-earnings,100,50,2/25/2021
16B183,legal-issues-defendant,100,22,2/25/2021
16B183,legal-issues-defendant,100,22,2/25/2021
16B183,legal-issues-defendant,100,22,2/25/2021
16B183,legal-issues-defendant,100,22,2/25/2021
182BE7,earnings,100,50,2/25/2021
184866,earnings,100,50,2/25/2021
188394,dividend,100,50,2/25/2021
1A2D9F,facility-upgrade,100,65,2/25/2021
1AC649,earnings,100,50,2/25/2021
1AE9D5,conference-call,100,50,2/25/2021
1B9535,earnings,100,50,2/25/2021
1CD09C,earnings,100,50,2/25/2021
1CD09C,business-contract,100,69,2/25/2021
1CD09C,business-contract-terminated,100,31,2/25/2021
1DEBBE,facility-open,100,65,2/25/2021
1E1125,conference-organizer,100,57,2/25/2021
1E7785,conference-participant,100,50,2/25/2021
1E83DE,earnings,100,50,2/25/2021
1E8A99,dividend-up,100,81,2/25/2021
1EBF8D,acquisition-acquirer,100,49,2/25/2021
1EBF8D,acquisition-acquirer,100,49,2/25/2021
1EBF8D,business-contract,100,69,2/25/2021
1F464F,earnings,100,50,2/25/2021
1FA886,business-contract,100,69,2/25/2021
1FE7F0,earnings,100,50,2/25/2021
2082EA,earnings,100,50,2/25/2021
2096DE,earnings,100,50,2/25/2021
221445,earnings,100,50,2/25/2021
221783,earnings,100,50,2/25/2021
232053,earnings,100,50,2/25/2021
2.45E+15,dividend,100,50,2/25/2021
24CB56,conference-participant,100,50,2/25/2021
253604,conference-participant,100,50,2/25/2021
253B2F,earnings,100,50,2/25/2021
2571FA,earnings,100,50,2/25/2021
25AB8E,earnings,100,50,2/25/2021
270B78,earnings,100,50,2/25/2021
272704,conference-participant,100,50,2/25/2021
28F905,earnings,100,50,2/25/2021
2920D5,conference-participant,100,50,2/25/2021
295F9F,conference-call,100,50,2/25/2021
29A4CC,dividend-up,100,81,2/25/2021
2.90E+62,acquisition-acquirer,100,49,2/25/2021
2A02DC,earnings,100,50,2/25/2021
2A17B1,buybacks,100,74,2/25/2021
2AA6A8,earnings,100,50,2/25/2021
2BBE62,earnings,100,50,2/25/2021
2BBE62,earnings,100,50,2/25/2021
2BBE62,earnings,100,50,2/25/2021
2BBE62,earnings,100,50,2/25/2021
2BF36E,dividend,100,50,2/25/2021
2C19A4,earnings,100,50,2/25/2021
2D5011,dividend,100,50,2/25/2021
2D5011,executive-appointment,100,54,2/25/2021
2EC172,conference-participant,100,50,2/25/2021
2F5256,dividend,100,50,2/25/2021
2F7A7E,earnings,100,50,2/25/2021
2F9304,conference-participant,100,50,2/25/2021
2F98A5,earnings,100,50,2/25/2021
2FEA66,executive-resignation,100,44,2/25/2021
306623,conference-participant,100,50,2/25/2021
30DFD3,earnings,100,50,2/25/2021
315EB0,note-sale,100,52,2/25/2021
319BE2,dividend-up,100,81,2/25/2021
319BE2,earnings,100,50,2/25/2021
32F24A,earnings,100,50,2/25/2021
3.30E+30,product-release,100,64,2/25/2021
332F87,buybacks,100,74,2/25/2021
3461CF,credit-rating-confirmation-rater,20,50,2/25/2021
37020C,executive-appointment,100,54,2/25/2021
371B0A,earnings,100,50,2/25/2021
371C01,earnings,100,50,2/25/2021
372037,dividend,100,50,2/25/2021
372037,earnings,100,50,2/25/2021
3798B9,earnings,100,50,2/25/2021
382EAE,dividend,100,50,2/25/2021
382EAE,executive-appointment,100,54,2/25/2021
389CFB,earnings,100,50,2/25/2021
39692D,conference-participant,100,50,2/25/2021
39FB23,supply-guidance-increase,100,74,2/25/2021
3A3948,earnings,100,50,2/25/2021
3A94DF,dividend,100,50,2/25/2021
3B37F7,acquisition-completed-acquirer,100,49,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3B37F7,earnings,100,50,2/25/2021
3D7971,earnings,100,50,2/25/2021
3E15F6,earnings,100,50,2/25/2021
3E15F6,earnings,100,50,2/25/2021
3E15F6,earnings,100,50,2/25/2021
3E15F6,earnings,100,50,2/25/2021
3E39A5,earnings,100,50,2/25/2021
3F1C69,earnings,100,50,2/25/2021
3F4668,revenues,100,50,2/25/2021
3F4668,revenues,100,50,2/25/2021
3F4668,revenues,100,50,2/25/2021
3F4668,revenues,100,50,2/25/2021
417BF9,public-offering,100,43,2/25/2021
41C36B,earnings,100,50,2/25/2021
41ED98,earnings,100,50,2/25/2021
4290EF,dividend,100,50,2/25/2021
429BFB,earnings,100,50,2/25/2021
4398A2,earnings,100,50,2/25/2021
4398A2,earnings,100,50,2/25/2021
43E8F5,earnings,100,50,2/25/2021
449447,conference-participant,100,50,2/25/2021
451D61,earnings,100,50,2/25/2021
46017C,earnings,100,50,2/25/2021
47B4CC,conference-call,100,50,2/25/2021
4806CE,earnings,100,50,2/25/2021
48F795,earnings,100,50,2/25/2021
499C75,earnings,100,50,2/25/2021
4A2457,earnings,100,50,2/25/2021
4A6F00,business-contract,100,69,2/25/2021
4A6F00,partnership,100,61,2/25/2021
4AC91D,earnings,100,50,2/25/2021
4AC91D,earnings,100,50,2/25/2021
4AC91D,earnings,100,50,2/25/2021
4AC91D,earnings,100,50,2/25/2021
4AC91D,earnings,100,50,2/25/2021
4B7006,earnings,100,50,2/25/2021
4BDCA7,partnership,100,61,2/25/2021
4BEB48,earnings,100,50,2/25/2021
4BF3D6,earnings,100,50,2/25/2021
4C2F17,earnings,100,50,2/25/2021
4C5CC9,earnings-up,100,68,2/25/2021
4C7DB5,earnings,100,50,2/25/2021
4C92B9,earnings,100,50,2/25/2021
4CDA2B,earnings,100,50,2/25/2021
4D8124,earnings,100,50,2/25/2021
4DAF5F,buybacks,100,74,2/25/2021
4DAF5F,buybacks,100,74,2/25/2021
4DD203,conference-call,100,50,2/25/2021
4F9487,executive-appointment,100,54,2/25/2021
50070E,business-contract,100,69,2/25/2021
50070E,partnership,100,61,2/25/2021
504FE2,clinical-trials-start,100,64,2/25/2021
5088A5,unit-acquisition-acquiree,100,76,2/25/2021
50D1EC,earnings,100,50,2/25/2021
52015A,earnings,100,50,2/25/2021
52FB2F,earnings,100,50,2/25/2021
52FB2F,earnings,100,50,2/25/2021
52FB2F,earnings,100,50,2/25/2021
52FB2F,earnings,100,50,2/25/2021
52FB2F,earnings,100,50,2/25/2021
545272,board-meeting,100,51,2/25/2021
5.47E+28,conference-participant,100,50,2/25/2021
55CD6F,dividend,100,50,2/25/2021
5704AC,earnings,100,50,2/25/2021
5704AC,executive-resignation,100,44,2/25/2021
58B46F,earnings,100,50,2/25/2021
58C2D4,conference-participant,100,50,2/25/2021
58C2D4,earnings,100,50,2/25/2021
59872F,conference-participant,100,50,2/25/2021
59B229,earnings-guidance,100,50,2/25/2021
59B229,earnings-guidance,100,50,2/25/2021
5AAE17,conference-call,100,50,2/25/2021
5B226B,legal-issues-defendant,100,22,2/25/2021
5B226B,legal-issues-defendant,100,22,2/25/2021
5B7739,earnings,100,50,2/25/2021
5D1329,earnings,100,50,2/25/2021
5DE5A5,dividend,100,50,2/25/2021
5E7E82,earnings,100,50,2/25/2021
5E7E82,earnings,100,50,2/25/2021
5E7E82,earnings,100,50,2/25/2021
5E7E82,earnings,100,50,2/25/2021
5E7E82,earnings,100,50,2/25/2021
5E7E82,earnings,100,50,2/25/2021
5E9934,conference-call,100,50,2/25/2021
60DD84,conference-participant,100,50,2/25/2021
615B6D,legal-issues-defendant,100,22,2/25/2021
619882,conference-organizer,100,57,2/25/2021
641F17,conference-participant,100,50,2/25/2021
649CBD,earnings,100,50,2/25/2021
64E346,earnings,100,50,2/25/2021
6.52E+64,earnings,100,50,2/25/2021
6559D8,earnings,100,50,2/25/2021
67A658,earnings,100,50,2/25/2021
6830FE,conference-participant,100,50,2/25/2021
6925EB,earnings,100,50,2/25/2021
694749,earnings,100,50,2/25/2021
6A024C,clinical-trials-start,100,64,2/25/2021
6BBCBA,business-contract,100,69,2/25/2021
6BC6F9,conference-participant,100,50,2/25/2021
6BDA0C,earnings,100,50,2/25/2021
6C987C,dividend,100,50,2/25/2021
6D156D,earnings,100,50,2/25/2021
6D2BF6,earnings,100,50,2/25/2021
6D9ECA,earnings,100,50,2/25/2021
6DC1D7,earnings,100,50,2/25/2021
6EA292,earnings,100,50,2/25/2021
6F30F9,earnings,100,50,2/25/2021
7032D0,dividend,100,50,2/25/2021
713810,conference-participant,100,50,2/25/2021
713810,product-release,100,64,2/25/2021
71553E,earnings,100,50,2/25/2021
7255D2,earnings,100,50,2/25/2021
72609A,earnings,100,50,2/25/2021
726DDF,earnings,100,50,2/25/2021
73529F,earnings,100,50,2/25/2021
741937,earnings,100,50,2/25/2021
7448A3,earnings,100,50,2/25/2021
7.45E+28,earnings,100,50,2/25/2021
747219,dividend,100,50,2/25/2021
763724,earnings,100,50,2/25/2021
767F86,executive-appointment,100,54,2/25/2021
76B926,earnings,100,50,2/25/2021
76B926,earnings,100,50,2/25/2021
7712CB,note-sale,100,52,2/25/2021
789A7D,note-sale,100,52,2/25/2021
79167B,earnings,100,50,2/25/2021
7AC86E,executive-appointment,100,54,2/25/2021
7ADE57,conference-call,100,50,2/25/2021
7AF5B8,earnings,100,50,2/25/2021
7B6C88,executive-appointment,100,54,2/25/2021
7B9AFA,earnings,100,50,2/25/2021
7B9AFA,earnings,100,50,2/25/2021
7C4F43,earnings,100,50,2/25/2021
7C790D,earnings,100,50,2/25/2021
7E0EB0,earnings,100,50,2/25/2021
7F0372,earnings,100,50,2/25/2021
7F0372,executive-appointment,100,54,2/25/2021
7FC386,earnings,100,50,2/25/2021
805CD8,conference-participant,100,50,2/25/2021
8.10E+32,business-contract,100,69,2/25/2021
82F088,earnings,100,50,2/25/2021
830BDB,earnings,100,50,2/25/2021
83B1C8,earnings,100,50,2/25/2021
83E0AC,earnings,100,50,2/25/2021
850779,dividend,100,50,2/25/2021
858942,earnings,100,50,2/25/2021
85DA04,facility-open,100,65,2/25/2021
868808,dividend,100,50,2/25/2021
8802B4,earnings,100,50,2/25/2021
8802B4,earnings,100,50,2/25/2021
8802B4,earnings,100,50,2/25/2021
8802B4,earnings,100,50,2/25/2021
88193E,earnings,100,50,2/25/2021
8A0368,conference-participant,100,50,2/25/2021
8AA108,partnership,100,61,2/25/2021
8C5519,dividend,100,50,2/25/2021
8CF6DD,conference-participant,100,50,2/25/2021
8DCF18,note-sale,100,52,2/25/2021
8E0E32,unit-acquisition-acquirer,100,49,2/25/2021
8E4F9A,conference-participant,100,50,2/25/2021
9196A2,conference-organizer,100,57,2/25/2021
9196A2,conference-organizer,100,57,2/25/2021
9196A2,conference-organizer,100,57,2/25/2021
9196A2,conference-organizer,100,57,2/25/2021
92B047,dividend,100,50,2/25/2021
92B625,earnings,100,50,2/25/2021
9.31E+77,earnings,100,50,2/25/2021
938D89,earnings,100,50,2/25/2021
9.39E+69,conference-participant,100,50,2/25/2021
942633,joint-venture,100,62,2/25/2021
94756D,earnings,100,50,2/25/2021
9.65E+09,executive-resignation,100,44,2/25/2021
9.65E+09,earnings,100,50,2/25/2021
9673BD,revenue-above-expectations,100,86,2/25/2021
967D92,board-meeting,100,51,2/25/2021
96A6CD,earnings,100,50,2/25/2021
97644E,earnings,100,50,2/25/2021
97644E,patent-infringement-defendant,100,26,2/25/2021
9810C0,conference-participant,100,50,2/25/2021
9.86E+03,earnings,100,50,2/25/2021
990AD0,conference-organizer,100,57,2/25/2021
9978F1,earnings,100,50,2/25/2021
9994DA,earnings,100,50,2/25/2021
99ACAD,earnings,100,50,2/25/2021
99B61C,conference-participant,100,50,2/25/2021
9A2760,earnings,100,50,2/25/2021
9A602D,dividend,100,50,2/25/2021
9C25FF,earnings,100,50,2/25/2021
9D2790,dividend,100,50,2/25/2021
9D307D,conference-call,100,50,2/25/2021
9F048E,earnings,100,50,2/25/2021
9F5997,earnings,100,50,2/25/2021
9FB4B7,earnings,100,50,2/25/2021
A01200,award,100,58,2/25/2021
A01983,credit-extension-recipient,100,69,2/25/2021
A01983,earnings,100,50,2/25/2021
A05C43,note-sale,100,52,2/25/2021
A072C4,earnings,100,50,2/25/2021
A0F146,earnings,100,50,2/25/2021
A11CF4,acquisition-acquiree,100,76,2/25/2021
A11CF4,acquisition-acquiree,100,76,2/25/2021
A11CF4,legal-issues-defendant,100,22,2/25/2021
A1BB98,earnings,100,50,2/25/2021
A1BB98,earnings,100,50,2/25/2021
A1BB98,earnings,100,50,2/25/2021
A1BB98,earnings,100,50,2/25/2021
A1BB98,earnings,100,50,2/25/2021
A1BB98,earnings,100,50,2/25/2021
A2C979,conference-participant,100,50,2/25/2021
A43906,earnings,100,50,2/25/2021
A48593,earnings,100,50,2/25/2021
A49498,earnings,100,50,2/25/2021
A49498,earnings,100,50,2/25/2021
A49498,earnings,100,50,2/25/2021
A49498,earnings,100,50,2/25/2021
A5195E,earnings,100,50,2/25/2021
A5195E,regulatory-product-review-positive,100,73,2/25/2021
A6213D,partnership,100,61,2/25/2021
A631A3,earnings,100,50,2/25/2021
A666C8,executive-appointment,100,54,2/25/2021
A6FE1C,unit-acquisition-acquirer,100,49,2/25/2021
A7102F,partnership,100,61,2/25/2021
A79D88,earnings,100,50,2/25/2021
A79F7D,investment-investor,100,55,2/25/2021
A80FE0,earnings,100,50,2/25/2021
A8B137,conference-participant,100,50,2/25/2021
A94637,revenue-up,100,69,2/25/2021
A94637,revenue-up,100,69,2/25/2021
ABEE43,legal-issues-defendant,100,22,2/25/2021
AC3584,earnings,100,50,2/25/2021
AC642C,earnings,100,50,2/25/2021
AC642C,earnings,100,50,2/25/2021
AD3008,note-sale,100,52,2/25/2021
AEBB80,earnings,100,50,2/25/2021
AFF43F,conference-participant,100,50,2/25/2021
B04426,earnings,100,50,2/25/2021
B05118,earnings,100,50,2/25/2021
B13B68,partnership,100,61,2/25/2021
B290A2,earnings,100,50,2/25/2021
B37FB4,dividend,100,50,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3CB74,conference-organizer,100,57,2/25/2021
B3ED62,partnership,100,61,2/25/2021
B4528F,executive-appointment,100,54,2/25/2021
B4C673,partnership,100,61,2/25/2021
B508E5,earnings,100,50,2/25/2021
B7202A,revenue-up,100,69,2/25/2021
B7202A,revenue-up,100,69,2/25/2021
B7202A,revenue-up,100,69,2/25/2021
B77F14,partnership,100,61,2/25/2021
B80AD1,earnings,100,50,2/25/2021
B934BF,dividend,100,50,2/25/2021
BAAA60,dividend,100,50,2/25/2021
BB0587,dividend,100,50,2/25/2021
BB127B,earnings,100,50,2/25/2021
BB88B6,conference-participant,100,50,2/25/2021
BBF349,conference-participant,100,50,2/25/2021
BD682F,earnings,100,50,2/25/2021
BDCC11,earnings,100,50,2/25/2021
BDEC1E,earnings,100,50,2/25/2021
BE86A1,dividend,100,50,2/25/2021
C58D71,earnings,100,50,2/25/2021
C5E100,earnings,100,50,2/25/2021
C83B88,business-contract,100,69,2/25/2021
C85A72,conference-participant,100,50,2/25/2021
C85A72,conference-participant,100,50,2/25/2021
C8923A,earnings,100,50,2/25/2021
C8923A,earnings,100,50,2/25/2021
C8923A,earnings,100,50,2/25/2021
C8A248,product-release,100,64,2/25/2021
C8FAC7,earnings,100,50,2/25/2021
C9A96E,earnings,100,50,2/25/2021
C9D866,conference-participant,100,50,2/25/2021
C9E4EC,conference-participant,100,50,2/25/2021
C9E4EC,public-offering,100,43,2/25/2021
CAB222,earnings,100,50,2/25/2021
CB6A9C,earnings,100,50,2/25/2021
CB6A9C,earnings,100,50,2/25/2021
CB6A9C,earnings,100,50,2/25/2021
CB6A9C,earnings,100,50,2/25/2021
CB6A9C,earnings,100,50,2/25/2021
CB6A9C,earnings,100,50,2/25/2021
CB6A9C,award,100,58,2/25/2021
CBDB4D,earnings,100,50,2/25/2021
CC35BE,business-contract,100,69,2/25/2021
CC3EC4,earnings,100,50,2/25/2021
CCB623,earnings,100,50,2/25/2021
CDAA0E,executive-appointment,100,54,2/25/2021
CDC217,conference-participant,100,50,2/25/2021
CE2791,earnings,100,50,2/25/2021
CE4E6D,earnings,100,50,2/25/2021
CE4E6D,earnings,100,50,2/25/2021
CE4E6D,earnings,100,50,2/25/2021
CE4E6D,earnings,100,50,2/25/2021
CE4E6D,earnings,100,50,2/25/2021
CEC08B,earnings,100,50,2/25/2021
CF7292,conference-call,100,50,2/25/2021
CFD4B6,conference-call,100,50,2/25/2021
D09938,earnings,100,50,2/25/2021
D0DE27,earnings,100,50,2/25/2021
D0DE27,earnings,100,50,2/25/2021
D0DE27,earnings,100,50,2/25/2021
D0DE27,earnings,100,50,2/25/2021
D0DE27,earnings,100,50,2/25/2021
D0DE27,earnings,100,50,2/25/2021
D0DE27,earnings,100,50,2/25/2021
D1C26F,conference-participant,100,50,2/25/2021
D3FA2C,earnings,100,50,2/25/2021
D4AC65,product-release,100,64,2/25/2021
D5B13D,conference-participant,100,50,2/25/2021
D78BF1,dividend-up,100,81,2/25/2021
D82EF3,product-release,100,64,2/25/2021
D854F3,conference-participant,100,50,2/25/2021
D9B1C9,earnings,100,50,2/25/2021
D9B1C9,earnings,100,50,2/25/2021
D9B1C9,earnings,100,50,2/25/2021
D9E036,conference-participant,100,50,2/25/2021
DE5611,earnings,100,50,2/25/2021
DE5611,partnership,100,61,2/25/2021
DF204B,conference-participant,100,50,2/25/2021
DFADDB,earnings,100,50,2/25/2021
E0E4B7,conference-participant,100,50,2/25/2021
E10D31,earnings,100,50,2/25/2021
E10D31,dividend,100,50,2/25/2021
E16133,earnings,100,50,2/25/2021
E16133,earnings,100,50,2/25/2021
E16133,earnings,100,50,2/25/2021
E16133,earnings,100,50,2/25/2021
E16133,earnings,100,50,2/25/2021
E19A99,clinical-trials-positive,100,87,2/25/2021
E19A99,clinical-trials-positive,100,87,2/25/2021
E19A99,earnings,100,50,2/25/2021
E21871,conference-participant,100,50,2/25/2021
E21871,note-sale,100,52,2/25/2021
E28D9C,earnings,100,50,2/25/2021
E2CB7B,earnings,100,50,2/25/2021
E2CFD2,earnings,100,50,2/25/2021
E2F66E,earnings-positive,100,69,2/25/2021
E35610,earnings,100,50,2/25/2021
E5C910,earnings,100,50,2/25/2021
E67C2C,earnings,100,50,2/25/2021
E68E62,earnings,100,50,2/25/2021
E754F0,earnings,100,50,2/25/2021
E96E0B,legal-issues-defendant,100,22,2/25/2021
EB1E1A,earnings,100,50,2/25/2021
EB43F4,earnings,100,50,2/25/2021
EB7D6C,executive-resignation,100,44,2/25/2021
EC70EC,partnership,100,61,2/25/2021
ECA300,conference-call,100,50,2/25/2021
ECF4F8,earnings,100,50,2/25/2021
ED2EFD,earnings,100,50,2/25/2021
ED3CA8,earnings,100,50,2/25/2021
ED4560,earnings,100,50,2/25/2021
ED7F13,conference-participant,100,50,2/25/2021
EE74E1,award,100,58,2/25/2021
EEA734,legal-issues-defendant,100,22,2/25/2021
EEA734,earnings,100,50,2/25/2021
EF25A5,executive-appointment,100,54,2/25/2021
EF25A5,earnings,100,50,2/25/2021
EF25A5,earnings,100,50,2/25/2021
EF25A5,earnings,100,50,2/25/2021
EF25A5,earnings,100,50,2/25/2021
EF7163,earnings,100,50,2/25/2021
F0027C,earnings,100,50,2/25/2021
F0A9DE,dividend,100,50,2/25/2021
F0B2B5,partnership,100,61,2/25/2021
F294DD,earnings,100,50,2/25/2021
F2E253,earnings,100,50,2/25/2021
F30508,partnership,100,61,2/25/2021
F51DB0,earnings,100,50,2/25/2021
F569FD,conference-participant,100,50,2/25/2021
F73DD1,dividend,100,50,2/25/2021
F73DD1,dividend,100,50,2/25/2021
F769E9,earnings-guidance,100,50,2/25/2021
F7ADEB,award,100,58,2/25/2021
F83279,earnings-guidance,100,50,2/25/2021
F83279,earnings,100,50,2/25/2021
F83279,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
F92DBC,earnings,100,50,2/25/2021
FC1A6E,conference-participant,100,50,2/25/2021
FC1A6E,earnings,100,50,2/25/2021
FD2565,earnings,100,50,2/25/2021
FD4588,earnings,100,50,2/25/2021
FD554E,earnings,100,50,2/25/2021
FD6926,earnings,100,50,2/25/2021
FD6926,dividend,100,50,2/25/2021
FDF1C0,dividend,100,50,2/25/2021
FEE4B0,conference-participant,100,50,2/25/2021
00698D,conference-participant,100,50,2/26/2021
13528,earnings,100,50,2/26/2021
01D03F,regulatory-product-review-positive,100,73,2/26/2021
02870F,executive-resignation,100,44,2/26/2021
099A92,conference-participant,100,50,2/26/2021
0A6824,legal-issues-defendant,100,22,2/26/2021
0C6861,earnings,100,50,2/26/2021
0CADBC,executive-appointment,100,54,2/26/2021
0CC01F,executive-appointment,100,54,2/26/2021
0CE7F6,earnings,100,50,2/26/2021
0E5619,conference-participant,100,50,2/26/2021
0FABBD,executive-appointment,100,54,2/26/2021
11A49E,clinical-trials-start,100,64,2/26/2021
129DC8,trading-halt,100,43,2/26/2021
129DC8,trading-resumed,100,58,2/26/2021
14391F,stake-acquirer,100,48,2/26/2021
14391F,stake-acquirer,100,48,2/26/2021
147098,dividend,100,50,2/26/2021
147098,earnings,100,50,2/26/2021
147098,earnings,100,50,2/26/2021
1490F3,dividend-up,100,81,2/26/2021
16B183,legal-issues-defendant,100,22,2/26/2021
1748B3,dividend,100,50,2/26/2021
1.79E+10,donation,100,54,2/26/2021
1AD9CC,earnings,100,50,2/26/2021
1E1125,conference-organizer,100,57,2/26/2021
202E5A,conference-participant,100,50,2/26/2021
20BEEA,dividend-up,100,81,2/26/2021
228D42,partnership,100,61,2/26/2021
238302,board-meeting,100,51,2/26/2021
267718,regulatory-product-approval-granted,100,81,2/26/2021
26F99F,conference-participant,100,50,2/26/2021
27A791,earnings,100,50,2/26/2021
2B7A40,conference-participant,100,50,2/26/2021
2BA977,dividend,100,50,2/26/2021
2C681C,clinical-trials-start,100,64,2/26/2021
2DA92D,dividend,100,50,2/26/2021
2FDEE3,earnings,100,50,2/26/2021
36C09B,conference-call,100,50,2/26/2021
3798B9,conference-participant,100,50,2/26/2021
383ADA,earnings,100,50,2/26/2021
3D9999,conference-participant,100,50,2/26/2021
4135F7,earnings,100,50,2/26/2021
490D4B,executive-appointment,100,54,2/26/2021
4B6EF9,executive-resignation,100,44,2/26/2021
4C92B9,earnings-guidance,100,50,2/26/2021
4C92B9,dividend,100,50,2/26/2021
4DAF5F,buybacks,100,74,2/26/2021
4DAF5F,buybacks,100,74,2/26/2021
4ECD1A,dividend,100,50,2/26/2021
4F9926,partnership,100,61,2/26/2021
504FE2,fraud,100,44,2/26/2021
51B442,executive-appointment,100,54,2/26/2021
51D876,conference-participant,100,50,2/26/2021
52015A,executive-appointment,100,54,2/26/2021
52FB2F,conference-participant,100,50,2/26/2021
539F49,conference-participant,100,50,2/26/2021
5.43E+08,conference-participant,100,50,2/26/2021
54DF47,earnings,100,50,2/26/2021
55CD6F,earnings,100,50,2/26/2021
58C2D4,legal-issues-defendant,100,22,2/26/2021
58C2D4,legal-issues-defendant,100,22,2/26/2021
58C2D4,legal-issues-defendant,100,22,2/26/2021
5B226B,legal-issues-defendant,100,22,2/26/2021
5B226B,legal-issues-defendant,100,22,2/26/2021
5B226B,legal-issues-defendant,100,22,2/26/2021
5DD48B,award,100,58,2/26/2021
5E7E82,dividend,100,50,2/26/2021
5F2FF7,partnership,100,61,2/26/2021
615B6D,legal-issues-defendant,100,22,2/26/2021
61E975,conference-participant,100,50,2/26/2021
62B1C6,earnings,100,50,2/26/2021
64636E,earnings,100,50,2/26/2021
67303E,conference-participant,100,50,2/26/2021
6A01DF,conference-participant,100,50,2/26/2021
6ACFBF,executive-resignation,100,44,2/26/2021
6C4D2F,dividend,100,50,2/26/2021
6CB7F9,executive-resignation,100,44,2/26/2021
6E8349,earnings,100,50,2/26/2021
762A3E,conference-organizer,100,57,2/26/2021
7A2A49,acquisition-acquirer,100,49,2/26/2021
83E0AC,conference-call,100,50,2/26/2021
855DF7,earnings,100,50,2/26/2021
8665BA,acquisition-completed-acquirer,100,49,2/26/2021
877C0C,earnings,100,50,2/26/2021
877C0C,regulatory-product-approval-granted,100,81,2/26/2021
893904,executive-appointment,100,54,2/26/2021
8E82A6,dividend,100,50,2/26/2021
8F8F2F,dividend,100,50,2/26/2021
8FCA78,dividend,100,50,2/26/2021
9196A2,conference-organizer,100,57,2/26/2021
9196A2,conference-organizer,100,57,2/26/2021
9196A2,conference-organizer,100,57,2/26/2021
9196A2,conference-organizer,100,57,2/26/2021
9196A2,conference-organizer,100,57,2/26/2021
92005C,conference-participant,100,50,2/26/2021
9.31E+77,conference-participant,100,50,2/26/2021
940C3D,business-contract,100,69,2/26/2021
944B2E,earnings,100,50,2/26/2021
94637C,regulatory-product-review-positive,100,73,2/26/2021
95F59E,earnings,100,50,2/26/2021
97AF94,earnings,100,50,2/26/2021
990AD0,conference-organizer,100,57,2/26/2021
9934AD,earnings,100,50,2/26/2021
9934AD,earnings,100,50,2/26/2021
9934AD,earnings,100,50,2/26/2021
9934AD,earnings,100,50,2/26/2021
997348,dividend,100,50,2/26/2021
9981C6,dividend,100,50,2/26/2021
9B4066,unit-acquisition-acquirer,100,49,2/26/2021
9CA432,earnings,100,50,2/26/2021
9F5CBB,dividend,100,50,2/26/2021
A16DEA,conference-participant,100,50,2/26/2021
A6213D,product-release,100,64,2/26/2021
A70BF5,dividend,100,50,2/26/2021
A7A0BD,conference-participant,100,50,2/26/2021
A7A0C8,conference-call,100,50,2/26/2021
A96867,dividend-up,100,81,2/26/2021
AFD7DD,earnings,100,50,2/26/2021
AFD7DD,earnings,100,50,2/26/2021
B2256A,earnings,100,50,2/26/2021
B2AA0A,dividend-guidance,100,50,2/26/2021
B3CB74,conference-organizer,100,57,2/26/2021
B3CB74,conference-organizer,100,57,2/26/2021
B3CB74,conference-organizer,100,57,2/26/2021
B3CB74,conference-organizer,100,57,2/26/2021
B3CB74,conference-organizer,100,57,2/26/2021
B3CB74,conference-organizer,100,57,2/26/2021
B508E5,conference-participant,100,50,2/26/2021
B54A74,conference-participant,100,50,2/26/2021
B560AF,earnings,100,50,2/26/2021
B560AF,earnings,100,50,2/26/2021
B560AF,earnings,100,50,2/26/2021
B560AF,earnings,100,50,2/26/2021
B560AF,earnings,100,50,2/26/2021
B803B1,earnings,100,50,2/26/2021
BA0442,partnership,100,61,2/26/2021
BB127B,conference-participant,100,50,2/26/2021
BC948D,earnings,100,50,2/26/2021
BC948D,earnings,100,50,2/26/2021
BDE867,earnings,100,50,2/26/2021
BDE867,earnings,100,50,2/26/2021
BDE867,earnings,100,50,2/26/2021
BDE867,earnings,100,50,2/26/2021
BFE02C,dividend,100,50,2/26/2021
C0030A,product-release,100,64,2/26/2021
C01737,conference-participant,100,50,2/26/2021
C062D4,conference-participant,100,50,2/26/2021
C48574,executive-resignation,100,44,2/26/2021
C54140,earnings,100,50,2/26/2021
C584BE,earnings,100,50,2/26/2021
C83B88,partnership,100,61,2/26/2021
C9E4EC,public-offering,100,43,2/26/2021
CD4DA8,conference-organizer,100,57,2/26/2021
CD4DA8,conference-organizer,100,57,2/26/2021
CDAA0E,conference-participant,100,50,2/26/2021
CF351E,earnings,100,50,2/26/2021
CF351E,earnings,100,50,2/26/2021
CF351E,earnings,100,50,2/26/2021
D36B23,sponsorship,100,57,2/26/2021
D5A350,acquisition-acquirer,100,49,2/26/2021
D64EDF,earnings,100,50,2/26/2021
D64EDF,earnings,100,50,2/26/2021
D64EDF,earnings,100,50,2/26/2021
D64EDF,earnings,100,50,2/26/2021
D64EDF,earnings,100,50,2/26/2021
D6853F,earnings,100,50,2/26/2021
D89753,acquisition-acquiree,100,76,2/26/2021
DC2F77,conference-participant,100,50,2/26/2021
DF204B,earnings,100,50,2/26/2021
E30B34,conference-participant,100,50,2/26/2021
E30B34,conference-participant,100,50,2/26/2021
EE1E44,conference-participant,100,50,2/26/2021
EE6F1C,dividend,100,50,2/26/2021
EF5914,earnings,100,50,2/26/2021
F6DE54,earnings,100,50,2/26/2021
F92DBC,partnership,100,61,2/26/2021
FC1B7B,government-contract,100,69,2/26/2021
FC4550,dividend,100,50,2/26/2021
FF227B,earnings,100,50,2/26/2021
1E1125,conference-organizer,100,57,2/27/2021
589803,clinical-trials-positive,100,87,2/27/2021
589803,clinical-trials-positive,100,87,2/27/2021
5B226B,legal-issues-defendant,100,22,2/27/2021
6D156D,legal-issues-defendant,100,22,2/27/2021
7DA412,legal-issues-defendant,100,22,2/27/2021
918D6D,conference-call,100,50,2/27/2021
A11CF4,legal-issues-defendant,100,22,2/27/2021
D0909F,conference-participant,100,50,2/27/2021
D57D99,legal-issues-defendant,100,22,2/27/2021
E0647D,legal-issues-defendant,100,22,2/27/2021
E96E0B,acquisition-acquiree,100,76,2/27/2021
EA62FC,legal-issues-defendant,100,22,2/27/2021
67303E,legal-issues-defendant,100,22,2/28/2021
6D156D,legal-issues-defendant,100,22,2/28/2021
A6828A,regulatory-product-approval-granted,100,81,2/28/2021
EB36DE,ownership-decrease-owner,100,46,2/28/2021
00067A,business-contract,100,69,3/1/2021
002A99,earnings,100,50,3/1/2021
9397,business-contract,100,69,3/1/2021
00D6B5,note-sale,100,52,3/1/2021
0157B1,revenue-up,100,69,3/1/2021
0157B1,business-contract,100,69,3/1/2021
036C6F,dividend,100,50,3/1/2021
03FB17,unit-acquisition-completed-acquiree,100,67,3/1/2021
040DBB,award,100,58,3/1/2021
71860,acquisition-completed-acquirer,100,49,3/1/2021
07C69F,buybacks,100,74,3/1/2021
07C69F,executive-appointment,100,54,3/1/2021
09062E,public-offering,100,43,3/1/2021
0A59F8,partnership,100,61,3/1/2021
0A9D0A,asset-sale,100,62,3/1/2021
0A9D0A,earnings,100,50,3/1/2021
0B7375,earnings,100,50,3/1/2021
0BD4E8,award,100,58,3/1/2021
0C2A0D,acquisition-acquirer,100,49,3/1/2021
0C6861,conference-participant,100,50,3/1/2021
0DBB81,earnings,100,50,3/1/2021
0FE3A6,earnings,100,50,3/1/2021
1272B3,earnings,100,50,3/1/2021
129DC8,earnings,100,50,3/1/2021
12DE76,executive-appointment,100,54,3/1/2021
12DE76,acquisition-completed-acquirer,100,49,3/1/2021
131443,executive-appointment,100,54,3/1/2021
14391F,buybacks,100,74,3/1/2021
15A388,business-contract,100,69,3/1/2021
180DA0,business-contract,100,69,3/1/2021
184988,partnership,100,61,3/1/2021
184988,partnership,100,61,3/1/2021
184988,partnership,100,61,3/1/2021
188394,partnership,100,61,3/1/2021
18D9FA,earnings,100,50,3/1/2021
1921DD,partnership,100,61,3/1/2021
1CB9D3,earnings,100,50,3/1/2021
1DEBBE,earnings,100,50,3/1/2021
1E04A5,acquisition-acquiree,100,76,3/1/2021
1E04A5,acquisition-acquiree,100,76,3/1/2021
1E04A5,earnings,100,50,3/1/2021
1E04A5,legal-issues-defendant,100,22,3/1/2021
1E04A5,acquisition-regulatory-scrutiny-acquiree,100,38,3/1/2021
1EBF8D,regulatory-product-approval-granted,100,81,3/1/2021
1FC422,earnings,100,50,3/1/2021
2158DF,conference-participant,100,50,3/1/2021
221445,dividend,100,50,3/1/2021
2491BC,note-sale,100,52,3/1/2021
272704,conference-participant,100,50,3/1/2021
284289,executive-appointment,100,54,3/1/2021
2.89E+11,note-sale,100,52,3/1/2021
295F9F,buybacks,100,74,3/1/2021
2A1009,conference-participant,100,50,3/1/2021
2BBE62,partnership,100,61,3/1/2021
2BF36E,earnings,100,50,3/1/2021
2C681C,earnings,100,50,3/1/2021
2D981A,conference-participant,100,50,3/1/2021
2EB88B,partnership,100,61,3/1/2021
2F5256,note-sale,100,52,3/1/2021
2F5256,note-sale,100,52,3/1/2021
2F94A5,facility-open,100,65,3/1/2021
30AB63,conference-participant,100,50,3/1/2021
32F943,earnings,100,50,3/1/2021
3461CF,award,100,58,3/1/2021
35AE32,executive-appointment,100,54,3/1/2021
39FB23,executive-appointment,100,54,3/1/2021
39FB23,executive-appointment,100,54,3/1/2021
3AAEAE,earnings,100,50,3/1/2021
3B8484,acquisition-acquirer,100,49,3/1/2021
3CCC90,conference-call,100,50,3/1/2021
3DD5E2,product-release,100,64,3/1/2021
3DD5E2,earnings,100,50,3/1/2021
3DED49,conference-participant,100,50,3/1/2021
3EE65E,earnings,100,50,3/1/2021
3F96D5,earnings,100,50,3/1/2021
3FACA7,executive-appointment,100,54,3/1/2021
4.03E+05,product-release,100,64,3/1/2021
408089,executive-resignation,100,44,3/1/2021
422CE3,partnership,100,61,3/1/2021
4290EF,earnings,100,50,3/1/2021
43A060,business-contract,100,69,3/1/2021
44A4FC,partnership,100,61,3/1/2021
450ECB,earnings,100,50,3/1/2021
451D61,regulatory-product-application,100,69,3/1/2021
451D61,clinical-trials-filed,100,60,3/1/2021
46A16E,executive-appointment,100,54,3/1/2021
49A344,executive-appointment,100,54,3/1/2021
49BBBC,earnings,100,50,3/1/2021
49F4D0,note-sale,100,52,3/1/2021
4AC91D,conference-participant,100,50,3/1/2021
4BF3D6,public-offering,100,43,3/1/2021
4E5784,acquisition-completed-acquiree,100,76,3/1/2021
4EE167,conference-participant,100,50,3/1/2021
514067,executive-appointment,100,54,3/1/2021
523039,private-placement,100,56,3/1/2021
5340D0,acquisition-acquirer,100,49,3/1/2021
545272,conference-participant,100,50,3/1/2021
546A27,earnings,100,50,3/1/2021
54DF47,dividend,100,50,3/1/2021
56765E,earnings,100,50,3/1/2021
56EA2B,dividend,100,50,3/1/2021
58CA9A,investment-investor,100,55,3/1/2021
58EA22,conference-participant,100,50,3/1/2021
5D41E4,earnings,100,50,3/1/2021
615B6D,legal-issues-defendant,100,22,3/1/2021
619882,conference-organizer,100,57,3/1/2021
619882,conference-organizer,100,57,3/1/2021
619882,conference-organizer,100,57,3/1/2021
627186,conference-participant,100,50,3/1/2021
62B1C6,earnings,100,50,3/1/2021
651C85,earnings,100,50,3/1/2021
66A667,executive-appointment,100,54,3/1/2021
66A667,executive-appointment,100,54,3/1/2021
67529E,executive-appointment,100,54,3/1/2021
68AB62,public-offering,100,43,3/1/2021
68E3E0,dividend,100,50,3/1/2021
69C99E,earnings,100,50,3/1/2021
6B236C,executive-appointment,100,54,3/1/2021
6B6375,earnings,100,50,3/1/2021
6BBCBA,conference-participant,100,50,3/1/2021
6BDA0C,note-sale,100,52,3/1/2021
6D156D,legal-issues-defendant,100,22,3/1/2021
6D9B53,conference-participant,100,50,3/1/2021
6-Dec-05,earnings,100,50,3/1/2021
701531,earnings,100,50,3/1/2021
7032D0,executive-appointment,100,54,3/1/2021
7032D0,executive-appointment,100,54,3/1/2021
704B78,earnings,100,50,3/1/2021
713810,stock-loss,100,40,3/1/2021
713810,partnership,100,61,3/1/2021
717DB4,public-offering,100,43,3/1/2021
72CB93,executive-appointment,100,54,3/1/2021
732A9B,earnings,100,50,3/1/2021
7.45E+28,legal-issues-defendant,100,22,3/1/2021
747219,earnings-guidance,100,50,3/1/2021
747219,earnings-guidance,100,50,3/1/2021
747219,earnings-guidance,100,50,3/1/2021
747219,earnings-guidance,100,50,3/1/2021
747219,earnings-guidance,100,50,3/1/2021
75768D,conference-call,100,50,3/1/2021
76959C,executive-appointment,100,54,3/1/2021
7734AC,executive-firing,100,36,3/1/2021
7734AC,executive-firing,100,36,3/1/2021
775439,earnings,100,50,3/1/2021
791EC1,earnings,100,50,3/1/2021
7AB859,acquisition-completed-acquirer,100,49,3/1/2021
7ACD98,earnings,100,50,3/1/2021
7ACD98,earnings,100,50,3/1/2021
7ACD98,earnings,100,50,3/1/2021
7ACFD4,earnings,100,50,3/1/2021
7BFF81,conference-participant,100,50,3/1/2021
804708,dividend,100,50,3/1/2021
8.10E+32,executive-appointment,100,54,3/1/2021
810FAD,executive-appointment,100,54,3/1/2021
83066C,earnings,100,50,3/1/2021
834152,executive-appointment,100,54,3/1/2021
86AA9C,executive-appointment,100,54,3/1/2021
87486A,public-offering,100,43,3/1/2021
881190,earnings,100,50,3/1/2021
881190,earnings,100,50,3/1/2021
881190,earnings,100,50,3/1/2021
881190,earnings,100,50,3/1/2021
881190,earnings,100,50,3/1/2021
881190,earnings,100,50,3/1/2021
88611B,conference-participant,100,50,3/1/2021
8A0368,conference-participant,100,50,3/1/2021
8C1238,executive-appointment,100,54,3/1/2021
8D4486,partnership,100,61,3/1/2021
8DE56F,executive-appointment,100,54,3/1/2021
8DE56F,executive-appointment,100,54,3/1/2021
8DE74B,partnership,100,61,3/1/2021
8E10BF,executive-appointment,100,54,3/1/2021
8EF425,dividend,100,50,3/1/2021
9196A2,conference-organizer,100,57,3/1/2021
9196A2,conference-organizer,100,57,3/1/2021
9196A2,acquisition-completed-acquirer,100,49,3/1/2021
9196A2,conference-organizer,100,57,3/1/2021
9196A2,conference-organizer,100,57,3/1/2021
9196A2,conference-organizer,100,57,3/1/2021
92B625,note-sale,100,52,3/1/2021
9.39E+69,orphan-drug-designation,100,76,3/1/2021
94208D,acquisition-completed-acquirer,100,49,3/1/2021
94208D,note-sale,100,52,3/1/2021
94637C,dividend,100,50,3/1/2021
9507FF,earnings,100,50,3/1/2021
95A92E,earnings,100,50,3/1/2021
95DC1F,executive-resignation,100,44,3/1/2021
966DBE,earnings,100,50,3/1/2021
966DBE,earnings,100,50,3/1/2021
966DBE,earnings,100,50,3/1/2021
966DBE,earnings,100,50,3/1/2021
966DBE,earnings,100,50,3/1/2021
967D92,earnings,100,50,3/1/2021
9.86E+03,conference-participant,100,50,3/1/2021
990AD0,conference-organizer,100,57,3/1/2021
9A29F4,conference-participant,100,50,3/1/2021
9B730A,earnings,100,50,3/1/2021
9BBFA5,conference-call,100,50,3/1/2021
9C8BC3,executive-resignation,100,44,3/1/2021
9E0811,public-offering,100,43,3/1/2021
9EF4CF,note-sale,100,52,3/1/2021
9FF5F1,conference-participant,100,50,3/1/2021
A01200,conference-participant,100,50,3/1/2021
A01664,conference-participant,100,50,3/1/2021
A03EE1,public-offering,100,43,3/1/2021
A58224,conference-participant,100,50,3/1/2021
A631A3,executive-appointment,100,54,3/1/2021
A63387,legal-issues-defendant,100,22,3/1/2021
A6828A,regulatory-product-approval-granted,100,81,3/1/2021
A70BF5,executive-appointment,100,54,3/1/2021
A868C9,acquisition-interest-acquiree,100,82,3/1/2021
A868C9,acquisition-bid-rejected-acquiree,100,18,3/1/2021
A87CD6,note-sale,100,52,3/1/2021
A87CD6,note-sale,100,52,3/1/2021
A8AC4C,earnings,100,50,3/1/2021
A8E72A,earnings,100,50,3/1/2021
AC3584,earnings-up,100,68,3/1/2021
AC3584,earnings-up,100,68,3/1/2021
AC3584,earnings-up,100,68,3/1/2021
AC3584,earnings-up,100,68,3/1/2021
AC642C,public-offering,100,43,3/1/2021
AC642C,public-offering,100,43,3/1/2021
AC7AAE,earnings,100,50,3/1/2021
AC7C4F,business-contract,100,69,3/1/2021
ACF0B4,earnings,100,50,3/1/2021
B1A85D,business-contract,100,69,3/1/2021
B1A85D,earnings,100,50,3/1/2021
B1A85D,business-contract,100,69,3/1/2021
B303A6,executive-resignation,100,44,3/1/2021
B33E77,earnings,100,50,3/1/2021
B3CB74,conference-organizer,100,57,3/1/2021
B3CB74,conference-organizer,100,57,3/1/2021
B3CB74,conference-organizer,100,57,3/1/2021
B3CB74,conference-organizer,100,57,3/1/2021
B642E8,unit-acquisition-acquirer,100,49,3/1/2021
B76C82,earnings,100,50,3/1/2021
B77F14,conference-call,100,50,3/1/2021
B803B1,conference-participant,100,50,3/1/2021
B98EFA,operating-earnings,100,50,3/1/2021
B9CD50,product-release,100,64,3/1/2021
BA0442,earnings,100,50,3/1/2021
BC948D,conference-participant,100,50,3/1/2021
BDEF34,dividend,100,50,3/1/2021
BDF2BD,acquisition-acquiree,100,76,3/1/2021
C037A8,conference-participant,100,50,3/1/2021
C15DB3,executive-appointment,100,54,3/1/2021
C3DE7D,partnership,100,61,3/1/2021
C4706C,unit-acquisition-acquirer,100,49,3/1/2021
C4C77F,acquisition-completed-acquiree,100,76,3/1/2021
C4F9C6,regulatory-product-approval-granted,100,81,3/1/2021
C4FBDC,conference-participant,100,50,3/1/2021
C5D2AE,executive-appointment,100,54,3/1/2021
C65004,conference-participant,100,50,3/1/2021
C7859D,dividend,100,50,3/1/2021
C7859D,public-offering,100,43,3/1/2021
C8257F,business-contract,100,69,3/1/2021
C85A72,conference-participant,100,50,3/1/2021
C9732E,earnings,100,50,3/1/2021
CB89EA,earnings,100,50,3/1/2021
CBB77B,earnings,100,50,3/1/2021
CC35BE,partnership,100,61,3/1/2021
CD051C,earnings,100,50,3/1/2021
CD051C,earnings,100,50,3/1/2021
CD051C,earnings,100,50,3/1/2021
CD051C,earnings,100,50,3/1/2021
CD051C,earnings,100,50,3/1/2021
CD051C,earnings,100,50,3/1/2021
CDAF5B,public-offering,100,43,3/1/2021
CDC817,acquisition-acquirer,100,49,3/1/2021
CDC817,earnings,100,50,3/1/2021
CDE118,asset-sale,100,62,3/1/2021
CDFCC9,conference-participant,100,50,3/1/2021
CDFCC9,conference-participant,100,50,3/1/2021
CF073E,conference-participant,100,50,3/1/2021
D06996,earnings,100,50,3/1/2021
D08D2C,conference-participant,100,50,3/1/2021
D18AFC,earnings,100,50,3/1/2021
D1AE3B,conference-participant,100,50,3/1/2021
D54E62,stake-acquirer,100,48,3/1/2021
D58A11,business-contract,100,69,3/1/2021
D6489C,partnership,100,61,3/1/2021
D6EAA3,earnings,100,50,3/1/2021
D6EAA3,earnings,100,50,3/1/2021
D6EAA3,earnings,100,50,3/1/2021
D6EAA3,earnings,100,50,3/1/2021
D6EAA3,earnings,100,50,3/1/2021
D6EAA3,earnings,100,50,3/1/2021
D6EAA3,earnings,100,50,3/1/2021
D90F43,executive-appointment,100,54,3/1/2021
D95385,earnings,100,50,3/1/2021
D95385,clinical-trials-positive,100,87,3/1/2021
D9E036,business-contract,100,69,3/1/2021
DA0A9E,executive-appointment,100,54,3/1/2021
DD0F15,earnings,100,50,3/1/2021
DD7A96,conference-participant,100,50,3/1/2021
DDB002,earnings,100,50,3/1/2021
DDB002,earnings,100,50,3/1/2021
DDB002,earnings,100,50,3/1/2021
DDB002,earnings,100,50,3/1/2021
DF01B1,public-offering,100,43,3/1/2021
E09556,earnings,100,50,3/1/2021
E11C41,dividend,100,50,3/1/2021
E19A99,executive-appointment,100,54,3/1/2021
E20392,earnings,100,50,3/1/2021
E22FDE,executive-appointment,100,54,3/1/2021
E67C2C,note-sale,100,52,3/1/2021
E7BF32,earnings,100,50,3/1/2021
E7BF32,earnings,100,50,3/1/2021
E96E0B,acquisition-acquiree,100,76,3/1/2021
EB43F4,earnings,100,50,3/1/2021
ECD263,partnership,100,61,3/1/2021
EE6F1C,asset-sale,100,62,3/1/2021
EE6F1C,unit-acquisition-acquiree,100,76,3/1/2021
EE6F1C,acquisition-acquiree,100,76,3/1/2021
EE6F1C,acquisition-acquiree,100,76,3/1/2021
EE6F1C,unit-acquisition-acquiree,100,76,3/1/2021
EE6F1C,acquisition-acquiree,100,76,3/1/2021
EE6F1C,acquisition-acquiree,100,76,3/1/2021
EEA6B3,note-sale,100,52,3/1/2021
EEA6B3,note-sale,100,52,3/1/2021
EEA6B3,note-sale,100,52,3/1/2021
EEA6B3,note-sale,100,52,3/1/2021
EF25A5,partnership,100,61,3/1/2021
EF5BED,unit-acquisition-completed-acquiree,100,67,3/1/2021
F02170,conference-participant,100,50,3/1/2021
F05B1B,executive-appointment,100,54,3/1/2021
F179ED,partnership,100,61,3/1/2021
F1C04C,operating-earnings,100,50,3/1/2021
F4D241,earnings,100,50,3/1/2021
F702CA,award,100,58,3/1/2021
FAAFA2,conference-participant,100,50,3/1/2021
FAB97A,regulatory-product-approval-granted,100,81,3/1/2021
FC4550,conference-participant,100,50,3/1/2021
FD2565,conference-participant,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FD39EB,earnings,100,50,3/1/2021
FF6644,partnership,100,61,3/1/2021
FF6644,conference-participant,100,50,3/1/2021
FFCD0E,earnings,100,50,3/1/2021
FFCD0E,earnings,100,50,3/1/2021
FFE543,award,100,58,3/1/2021
01B8D6,earnings,100,50,3/2/2021
0325B7,earnings,100,50,3/2/2021
48590,executive-appointment,100,54,3/2/2021
054B55,dividend,100,50,3/2/2021
054B55,dividend,100,50,3/2/2021
05D148,conference-participant,100,50,3/2/2021
0624BE,earnings,100,50,3/2/2021
06C826,earnings,100,50,3/2/2021
07C907,dividend,100,50,3/2/2021
099A92,earnings,100,50,3/2/2021
0BC29E,executive-appointment,100,54,3/2/2021
0C6293,conference-call,100,50,3/2/2021
0E3436,earnings,100,50,3/2/2021
0EF1AF,legal-issues-defendant,100,22,3/2/2021
0F0440,earnings,100,50,3/2/2021
0F0440,earnings,100,50,3/2/2021
0F0693,conference-participant,100,50,3/2/2021
0F2BC9,earnings,100,50,3/2/2021
0F2BC9,earnings,100,50,3/2/2021
0F2BC9,earnings,100,50,3/2/2021
1096C6,partnership,100,61,3/2/2021
11AEDE,business-contract,100,69,3/2/2021
11AEDE,executive-appointment,100,54,3/2/2021
1272B3,conference-participant,100,50,3/2/2021
14391F,ipo-completed,100,76,3/2/2021
14391F,ipo-completed,100,76,3/2/2021
14ED2B,note-sale,100,52,3/2/2021
152E1D,executive-appointment,100,54,3/2/2021
157D9F,conference-call,100,50,3/2/2021
16F4D8,executive-appointment,100,54,3/2/2021
184866,conference-participant,100,50,3/2/2021
184988,conference-participant,100,50,3/2/2021
190B91,conference-participant,100,50,3/2/2021
1BC12C,award,100,58,3/2/2021
1CD09C,conference-participant,100,50,3/2/2021
1D3A00,earnings,100,50,3/2/2021
1DB833,earnings,100,50,3/2/2021
1DDEDA,facility-open,100,65,3/2/2021
1E5786,conference-participant,100,50,3/2/2021
1F08A6,executive-appointment,100,54,3/2/2021
1F9258,conference-participant,100,50,3/2/2021
202E5A,conference-call,100,50,3/2/2021
228D42,partnership,100,61,3/2/2021
2491BC,note-sale,100,52,3/2/2021
267718,partnership,100,61,3/2/2021
26CC63,earnings,100,50,3/2/2021
2A02DC,business-contract,100,69,3/2/2021
2A02DC,business-contract,100,69,3/2/2021
2A4131,earnings,100,50,3/2/2021
2ABF77,conference-participant,100,50,3/2/2021
2CC71C,earnings,100,50,3/2/2021
2CF9D3,conference-participant,100,50,3/2/2021
30AB63,note-sale,100,52,3/2/2021
30DE64,earnings,100,50,3/2/2021
367E1C,clinical-trials,100,56,3/2/2021
37426C,partnership,100,61,3/2/2021
37727A,award,100,58,3/2/2021
38C46F,dividend,100,50,3/2/2021
39FB23,executive-appointment,100,54,3/2/2021
3CCC90,business-contract,100,69,3/2/2021
40F7DE,conference-participant,100,50,3/2/2021
41785E,partnership,100,61,3/2/2021
420168,note-sale,100,52,3/2/2021
422CE3,earnings,100,50,3/2/2021
42978B,dividend,100,50,3/2/2021
449447,executive-appointment,100,54,3/2/2021
45ABCC,conference-participant,100,50,3/2/2021
468DD4,conference-participant,100,50,3/2/2021
4A6F00,partnership,100,61,3/2/2021
4AE584,conference-participant,100,50,3/2/2021
4AE584,conference-participant,100,50,3/2/2021
4BAF2E,earnings,100,50,3/2/2021
4BF3D6,public-offering,100,43,3/2/2021
4BF3D6,public-offering,100,43,3/2/2021
4BF3D6,public-offering,100,43,3/2/2021
4C3FE9,conference-participant,100,50,3/2/2021
4C92B9,acquisition-acquirer,100,49,3/2/2021
4D229C,earnings,100,50,3/2/2021
4D371E,conference-participant,100,50,3/2/2021
4DD09F,earnings,100,50,3/2/2021
4EE167,executive-appointment,100,54,3/2/2021
504FE2,partnership,100,61,3/2/2021
54B889,earnings,100,50,3/2/2021
556F08,conference-participant,100,50,3/2/2021
56765E,note-sale,100,52,3/2/2021
56765E,note-sale,100,52,3/2/2021
57EF50,earnings,100,50,3/2/2021
58B46F,note-sale,100,52,3/2/2021
58CA9A,conference-organizer,100,57,3/2/2021
5968F9,earnings,100,50,3/2/2021
59DB8C,partnership,100,61,3/2/2021
5A423F,conference-participant,100,50,3/2/2021
5B226B,legal-issues-defendant,100,22,3/2/2021
5B51D6,conference-participant,100,50,3/2/2021
5D41E4,conference-participant,100,50,3/2/2021
5DE5A5,conference-participant,100,50,3/2/2021
5E7E82,executive-appointment,100,54,3/2/2021
5F3D91,conference-participant,100,50,3/2/2021
609208,conference-call,100,50,3/2/2021
615B6D,legal-issues-defendant,100,22,3/2/2021
619882,conference-organizer,100,57,3/2/2021
619882,conference-organizer,100,57,3/2/2021
64FF65,earnings,100,50,3/2/2021
65AB30,public-offering,100,43,3/2/2021
65D0AA,regulatory-product-approval-granted,100,81,3/2/2021
65D0AA,regulatory-product-approval-granted,100,81,3/2/2021
67B052,earnings,100,50,3/2/2021
67B052,earnings,100,50,3/2/2021
68E3E0,revenue-up,100,69,3/2/2021
68E3E0,revenue-up,100,69,3/2/2021
68E3E0,revenue-up,100,69,3/2/2021
68E3E0,revenue-up,100,69,3/2/2021
68E3E0,revenue-up,100,69,3/2/2021
68E3E0,revenue-up,100,69,3/2/2021
6A171E,earnings,100,50,3/2/2021
6A961B,executive-appointment,100,54,3/2/2021
6AACDD,conference-participant,100,50,3/2/2021
6D156D,legal-issues-defendant,100,22,3/2/2021
6DBBBC,investment-investor,100,55,3/2/2021
6F3FA8,conference-participant,100,50,3/2/2021
71B0CF,conference-participant,100,50,3/2/2021
7255D2,partnership,100,61,3/2/2021
74404C,earnings,100,50,3/2/2021
7.45E+28,legal-issues-defendant,100,22,3/2/2021
747219,conference-participant,100,50,3/2/2021
752A70,executive-appointment,100,54,3/2/2021
763DBE,earnings,100,50,3/2/2021
76D79A,dividend,100,50,3/2/2021
787D14,earnings,100,50,3/2/2021
793C11,executive-appointment,100,54,3/2/2021
7A2A49,acquisition-acquirer,100,49,3/2/2021
7AD81E,earnings,100,50,3/2/2021
7CBC40,product-release,100,64,3/2/2021
7E3F8F,conference-participant,100,50,3/2/2021
7F0372,executive-appointment,100,54,3/2/2021
7FEEE1,conference-participant,100,50,3/2/2021
817ED9,dividend,100,50,3/2/2021
819492,conference-participant,100,50,3/2/2021
82B57E,note-sale,100,52,3/2/2021
85DE00,conference-participant,100,50,3/2/2021
890FF4,conference-participant,100,50,3/2/2021
8AB85C,earnings,100,50,3/2/2021
8C6C1B,facility-open,100,65,3/2/2021
8C6C1B,earnings,100,50,3/2/2021
8DA42F,note-sale,100,52,3/2/2021
8E4F9A,operating-earnings,100,50,3/2/2021
9087B9,earnings,100,50,3/2/2021
90DD65,clinical-trials,100,56,3/2/2021
9196A2,conference-organizer,100,57,3/2/2021
92B625,note-sale,100,52,3/2/2021
93AD2E,business-contract,100,69,3/2/2021
93AD2E,business-contract,100,69,3/2/2021
940C3D,joint-venture,100,62,3/2/2021
940C3D,joint-venture,100,62,3/2/2021
940C3D,joint-venture,100,62,3/2/2021
940C3D,joint-venture,100,62,3/2/2021
940C3D,joint-venture,100,62,3/2/2021
949625,note-sale,100,52,3/2/2021
949625,note-sale,100,52,3/2/2021
96A6CD,conference-participant,100,50,3/2/2021
972356,business-contract,100,69,3/2/2021
9B0C9C,conference-participant,100,50,3/2/2021
9D30A8,partnership,100,61,3/2/2021
9D3360,credit-extension-recipient,100,69,3/2/2021
9D3360,executive-appointment,100,54,3/2/2021
9D56F2,conference-call,100,50,3/2/2021
9D6A24,executive-resignation,100,44,3/2/2021
9E0811,public-offering,100,43,3/2/2021
9F18FA,business-contract,100,69,3/2/2021
9F71E5,executive-resignation,100,44,3/2/2021
A1E3B3,earnings,100,50,3/2/2021
A3230E,conference-participant,100,50,3/2/2021
A3800A,earnings,100,50,3/2/2021
A52533,earnings-above-expectations,100,88,3/2/2021
A52B6B,acquisition-completed-acquirer,100,49,3/2/2021
A63820,earnings,100,50,3/2/2021
A6828A,business-contract,100,69,3/2/2021
A6828A,business-contract,100,69,3/2/2021
A6FE1C,unit-acquisition-acquirer,100,49,3/2/2021
A75D43,public-offering,100,43,3/2/2021
A8E72A,conference-participant,100,50,3/2/2021
AC642C,public-offering,100,43,3/2/2021
AC642C,public-offering,100,43,3/2/2021
AE0CCE,earnings,100,50,3/2/2021
AE79CD,credit-extension-provider,100,57,3/2/2021
AE7D16,legal-issues-defendant,100,22,3/2/2021
AE7D16,legal-issues-defendant,100,22,3/2/2021
AEEB76,earnings,100,50,3/2/2021
AFF7B4,conference-participant,100,50,3/2/2021
B05118,executive-appointment,100,54,3/2/2021
B08C51,executive-appointment,100,54,3/2/2021
B48FC9,partnership,100,61,3/2/2021
B4B281,conference-call,100,50,3/2/2021
B5DE80,executive-resignation,100,44,3/2/2021
B77F14,earnings,100,50,3/2/2021
B77F14,executive-appointment,100,54,3/2/2021
B80AD1,conference-participant,100,50,3/2/2021
B8A51F,legal-issues-defendant,100,22,3/2/2021
B8A51F,legal-issues-defendant,100,22,3/2/2021
B8A51F,legal-issues-defendant,100,22,3/2/2021
B8F71F,conference-participant,100,50,3/2/2021
BBC05B,earnings,100,50,3/2/2021
BC3AD2,dividend,100,50,3/2/2021
BD682F,public-offering,100,43,3/2/2021
BDE867,product-release,100,64,3/2/2021
BFE02C,partnership,100,61,3/2/2021
C01737,earnings,100,50,3/2/2021
C22BE8,product-release,100,64,3/2/2021
C2DD02,conference-call,100,50,3/2/2021
C2E39B,public-offering,100,43,3/2/2021
C3F99F,earnings,100,50,3/2/2021
C4A241,product-release,100,64,3/2/2021
C50B26,stake-acquirer,100,48,3/2/2021
C584BE,conference-participant,100,50,3/2/2021
C5C137,note-sale,100,52,3/2/2021
C5C137,note-sale,100,52,3/2/2021
C5C137,note-sale,100,52,3/2/2021
C5C137,note-sale,100,52,3/2/2021
C7859D,public-offering,100,43,3/2/2021
C83B88,product-release,100,64,3/2/2021
C8A248,executive-appointment,100,54,3/2/2021
C97B2D,acquisition-completed-acquiree,100,76,3/2/2021
C9D866,executive-appointment,100,54,3/2/2021
C9D866,partnership,100,61,3/2/2021
CC339B,dividend,100,50,3/2/2021
CD4DA8,conference-organizer,100,57,3/2/2021
CDAF5B,public-offering,100,43,3/2/2021
CDC217,conference-participant,100,50,3/2/2021
CDE118,buybacks,100,74,3/2/2021
CDFCC9,executive-appointment,100,54,3/2/2021
CE5C6E,clinical-trials,100,56,3/2/2021
D06755,conference-participant,100,50,3/2/2021
D25249,conference-participant,100,50,3/2/2021
D36B23,sponsorship,100,57,3/2/2021
D48275,conference-participant,100,50,3/2/2021
D57D99,legal-issues-defendant,100,22,3/2/2021
D58A11,executive-appointment,100,54,3/2/2021
D5938F,conference-participant,100,50,3/2/2021
D70365,public-offering,100,43,3/2/2021
DB396B,earnings,100,50,3/2/2021
DB396B,earnings,100,50,3/2/2021
DB396B,earnings,100,50,3/2/2021
DB396B,earnings,100,50,3/2/2021
DB5CA5,partnership,100,61,3/2/2021
DB7014,conference-participant,100,50,3/2/2021
DB9F70,conference-participant,100,50,3/2/2021
DBB28E,earnings,100,50,3/2/2021
DBB28E,earnings,100,50,3/2/2021
DBB28E,earnings,100,50,3/2/2021
DBB28E,earnings,100,50,3/2/2021
DBB28E,earnings,100,50,3/2/2021
DBB28E,earnings,100,50,3/2/2021
DBB28E,earnings,100,50,3/2/2021
DDEA6A,earnings,100,50,3/2/2021
E09E2B,partnership,100,61,3/2/2021
E20BFE,earnings,100,50,3/2/2021
E20BFE,earnings,100,50,3/2/2021
E20BFE,earnings,100,50,3/2/2021
E20BFE,earnings,100,50,3/2/2021
E22FDE,earnings,100,50,3/2/2021
E28D9C,partnership,100,61,3/2/2021
E3656D,executive-appointment,100,54,3/2/2021
E48E44,operating-earnings,100,50,3/2/2021
E4CE73,product-release,100,64,3/2/2021
E592F0,business-contract,100,69,3/2/2021
E74B55,earnings,100,50,3/2/2021
E8F0E2,conference-participant,100,50,3/2/2021
ECF709,same-store-sales-up,100,65,3/2/2021
ECF709,same-store-sales-up,100,62,3/2/2021
ECF709,same-store-sales-up,100,62,3/2/2021
F0027C,conference-participant,100,50,3/2/2021
F02170,revenue-up,100,61,3/2/2021
F02170,revenues,100,50,3/2/2021
F02170,revenues,100,50,3/2/2021
F02170,revenues,100,50,3/2/2021
F02170,revenues,100,50,3/2/2021
F58C23,conference-participant,100,50,3/2/2021
F67165,conference-participant,100,50,3/2/2021
F6DCE4,earnings,100,50,3/2/2021
F90EE5,earnings-up,100,68,3/2/2021
FD554E,dividend,100,50,3/2/2021
FDD3FC,conference-participant,100,50,3/2/2021
9397,conference-participant,100,50,3/3/2021
0157B1,business-contract,100,69,3/3/2021
0157B1,partnership,100,61,3/3/2021
01D03F,partnership,100,61,3/3/2021
0358AF,dividend-up,100,81,3/3/2021
04EB2F,conference-participant,100,50,3/3/2021
053EFF,earnings,100,50,3/3/2021
06A456,conference-call,100,50,3/3/2021
09062E,public-offering,100,43,3/3/2021
0B13E8,earnings,100,50,3/3/2021
0BF528,acquisition-acquirer,100,49,3/3/2021
0BF528,earnings,100,50,3/3/2021
0C6861,conference-participant,100,50,3/3/2021
0E499E,conference-participant,100,50,3/3/2021
0EF1AF,legal-issues-defendant,100,22,3/3/2021
0EF1AF,legal-issues-defendant,100,22,3/3/2021
106394,unit-acquisition-acquirer,100,49,3/3/2021
106394,public-offering,100,43,3/3/2021
12E454,business-contract,100,69,3/3/2021
143C52,earnings,100,50,3/3/2021
1A46A1,conference-call,100,50,3/3/2021
1D9E55,conference-participant,100,50,3/3/2021
1DB6A6,business-contract,100,69,3/3/2021
1EBF8D,conference-participant,100,50,3/3/2021
1EF224,earnings,100,50,3/3/2021
1F716B,conference-call,100,50,3/3/2021
2003A5,earnings,100,50,3/3/2021
225CA2,award,100,58,3/3/2021
228D42,partnership,100,61,3/3/2021
228D42,partnership,100,61,3/3/2021
228D42,partnership,100,61,3/3/2021
232053,conference-participant,100,50,3/3/2021
241252,conference-participant,100,50,3/3/2021
291651,conference-call,100,50,3/3/2021
2B49F4,conference-call,100,50,3/3/2021
2B8179,earnings,100,50,3/3/2021
2CC60C,earnings,100,50,3/3/2021
2CF9D3,earnings,100,50,3/3/2021
2F1299,conference-participant,100,50,3/3/2021
2F9304,earnings,100,50,3/3/2021
2F960F,earnings,100,50,3/3/2021
2FDEE3,executive-appointment,100,54,3/3/2021
2FDEE3,executive-appointment,100,54,3/3/2021
315EB0,partnership,100,61,3/3/2021
356B21,conference-participant,100,50,3/3/2021
36A1CB,earnings,100,50,3/3/2021
3B318A,conference-participant,100,50,3/3/2021
3B37F7,conference-organizer,100,57,3/3/2021
3B37F7,conference-organizer,100,57,3/3/2021
3BA1BF,conference-call,100,50,3/3/2021
3CCC90,business-contract,100,69,3/3/2021
3F6A9C,executive-appointment,100,54,3/3/2021
417BF9,debt-reduction,100,74,3/3/2021
41C528,conference-call,100,50,3/3/2021
442769,note-sale,100,52,3/3/2021
44ED36,note-sale,100,52,3/3/2021
45444E,legal-issues-defendant,100,22,3/3/2021
45444E,legal-issues-defendant,100,22,3/3/2021
45444E,legal-issues-defendant,100,22,3/3/2021
45ABCC,conference-participant,100,50,3/3/2021
485445,dividend,100,50,3/3/2021
4.91E+58,campaign-ad-release,100,59,3/3/2021
49BBBC,earnings-guidance,100,50,3/3/2021
49F4D0,executive-appointment,100,54,3/3/2021
4B3676,conference-participant,100,50,3/3/2021
4BDCA7,conference-participant,100,50,3/3/2021
4D72C8,note-sale,100,52,3/3/2021
4D72C8,note-sale,100,52,3/3/2021
4D72C8,note-sale,100,52,3/3/2021
4D72C8,note-sale,100,52,3/3/2021
4E4E75,operating-earnings,100,50,3/3/2021
4EEB00,clinical-trials-start,100,64,3/3/2021
4F9926,partnership,100,61,3/3/2021
51888A,unit-acquisition-acquirer,100,49,3/3/2021
52B567,unit-acquisition-acquirer,100,49,3/3/2021
52D936,partnership,100,61,3/3/2021
5487B1,dividend,100,50,3/3/2021
56EFC7,dividend,100,50,3/3/2021
589846,conference-call,100,50,3/3/2021
58C2D4,fraud-defendant,100,20,3/3/2021
58C2D4,fraud-defendant,100,20,3/3/2021
58C2D4,legal-issues-defendant,100,22,3/3/2021
58C2D4,legal-issues-defendant,100,22,3/3/2021
59F0B0,conference-participant,100,50,3/3/2021
5AAE17,earnings,100,50,3/3/2021
5B226B,legal-issues-defendant,100,22,3/3/2021
5B226B,legal-issues-defendant,100,22,3/3/2021
615B6D,legal-issues-defendant,100,22,3/3/2021
619882,conference-organizer,100,57,3/3/2021
619882,conference-organizer,100,57,3/3/2021
620381,earnings,100,50,3/3/2021
633043,earnings,100,50,3/3/2021
665440,conference-participant,100,50,3/3/2021
6830FE,earnings,100,50,3/3/2021
6BDA0C,note-sale,100,52,3/3/2021
6D156D,legal-issues-defendant,100,22,3/3/2021
6F92A9,executive-appointment,100,54,3/3/2021
705636,earnings,100,50,3/3/2021
70B3D6,executive-appointment,100,54,3/3/2021
71E2EF,earnings,100,50,3/3/2021
7448A3,conference-participant,100,50,3/3/2021
7.45E+28,patent-awarded,100,72,3/3/2021
7.45E+28,legal-issues-defendant,100,22,3/3/2021
747219,conference-participant,100,50,3/3/2021
76E80F,facility-close,100,47,3/3/2021
76F067,dividend,100,50,3/3/2021
787D14,dividend,100,50,3/3/2021
79167B,executive-resignation,100,44,3/3/2021
7B4B91,buybacks,100,74,3/3/2021
7C790D,conference-participant,100,50,3/3/2021
7D5384,executive-appointment,100,54,3/3/2021
7F3665,earnings,100,50,3/3/2021
7FC386,dividend,100,50,3/3/2021
7FD8B9,earnings,100,50,3/3/2021
803FED,earnings,100,50,3/3/2021
805CD8,earnings,100,50,3/3/2021
81222C,note-sale,100,52,3/3/2021
8295B8,conference-call,100,50,3/3/2021
82B57E,note-sale,100,52,3/3/2021
830BDB,patient-enrollment-complete,100,64,3/3/2021
830BDB,patient-enrollment-complete,100,64,3/3/2021
8377DB,conference-participant,100,50,3/3/2021
838ADD,conference-participant,100,50,3/3/2021
845533,earnings,100,50,3/3/2021
845533,earnings,100,50,3/3/2021
845533,earnings,100,50,3/3/2021
85DE00,acquisition-acquirer,100,49,3/3/2021
862941,fundraising,100,64,3/3/2021
868808,executive-appointment,100,54,3/3/2021
86F123,earnings,100,50,3/3/2021
881190,partnership,100,61,3/3/2021
88936A,conference-participant,100,50,3/3/2021
89E771,earnings,100,50,3/3/2021
8A8E41,dividend,100,50,3/3/2021
8AB37F,conference-participant,100,50,3/3/2021
8AC740,dividend,100,50,3/3/2021
8C6C1B,facility-open,100,65,3/3/2021
8D4486,partnership,100,61,3/3/2021
8EDACA,earnings,100,50,3/3/2021
8EDACA,buybacks,100,74,3/3/2021
8EEA28,earnings,100,50,3/3/2021
915E7B,executive-appointment,100,54,3/3/2021
94208D,note-sale,100,52,3/3/2021
954004,conference-call,100,50,3/3/2021
9546A5,conference-call,100,50,3/3/2021
9592FB,earnings,100,50,3/3/2021
990AD0,conference-organizer,100,57,3/3/2021
990AD0,conference-organizer,100,57,3/3/2021
990AD0,conference-organizer,100,57,3/3/2021
990AD0,conference-organizer,100,57,3/3/2021
9ABD30,regulatory-product-application,100,69,3/3/2021
9ABD30,regulatory-product-application,100,69,3/3/2021
9ABD30,regulatory-product-application,100,69,3/3/2021
9C009A,earnings,100,50,3/3/2021
9EBAFA,market-entry,100,57,3/3/2021
9EF4CF,note-sale,100,52,3/3/2021
9EF4CF,partnership,100,61,3/3/2021
9FB4B7,conference-participant,100,50,3/3/2021
A03EE1,public-offering,100,43,3/3/2021
A1EAC8,product-release,100,64,3/3/2021
A3AAA5,public-offering,100,43,3/3/2021
A433A5,conference-call,100,50,3/3/2021
A79F7D,earnings,100,50,3/3/2021
A80FE0,conference-participant,100,50,3/3/2021
A80FE0,conference-participant,100,50,3/3/2021
A8FDE8,earnings,100,50,3/3/2021
A8FDE8,earnings,100,50,3/3/2021
AC3584,executive-appointment,100,54,3/3/2021
AE7D16,legal-issues-defendant,100,22,3/3/2021
AE7D16,legal-issues-defendant,100,22,3/3/2021
AE7D16,legal-issues-defendant,100,22,3/3/2021
B106FA,earnings,100,50,3/3/2021
B1FC3B,acquisition-completed-acquirer,100,49,3/3/2021
B5767B,note-sale,100,52,3/3/2021
B5BA39,partnership,100,61,3/3/2021
B5DE80,conference-participant,100,50,3/3/2021
B8A51F,legal-issues-defendant,100,22,3/3/2021
B8A51F,legal-issues-defendant,100,22,3/3/2021
B8A51F,legal-issues-defendant,100,22,3/3/2021
B8A51F,legal-issues-defendant,100,22,3/3/2021
B9B6B8,conference-participant,100,50,3/3/2021
BB0787,conference-participant,100,50,3/3/2021
BD682F,public-offering,100,43,3/3/2021
BDF2BD,conference-call,100,50,3/3/2021
C037A8,partnership,100,61,3/3/2021
C07E05,earnings,100,50,3/3/2021
C27E19,executive-appointment,100,54,3/3/2021
C36189,conference-participant,100,50,3/3/2021
C3DE7D,partnership,100,61,3/3/2021
C45C1F,conference-participant,100,50,3/3/2021
C4F9C6,earnings,100,50,3/3/2021
C564E4,conference-participant,100,50,3/3/2021
C8A248,facility-upgrade,100,65,3/3/2021
C97B2D,unit-acquisition-acquirer,100,49,3/3/2021
C97B2D,unit-acquisition-acquirer,100,49,3/3/2021
C9B932,asset-sale,100,62,3/3/2021
CBB77B,dividend,100,50,3/3/2021
CD4DA8,executive-appointment,100,54,3/3/2021
CDAF5B,conference-participant,100,50,3/3/2021
CDC817,public-offering,100,43,3/3/2021
CDE51C,partnership,100,61,3/3/2021
CEC08B,conference-participant,100,50,3/3/2021
CFE5BE,executive-appointment,100,54,3/3/2021
D0909F,dividend,100,50,3/3/2021
D18AFC,earnings,100,50,3/3/2021
D1CFC8,conference-call,100,50,3/3/2021
D33270,product-release,100,64,3/3/2021
D518D8,dividend,100,50,3/3/2021
D5AF19,reverse-stock-splits,100,51,3/3/2021
D697DE,earnings,100,50,3/3/2021
D70365,public-offering,100,43,3/3/2021
D78CCD,executive-appointment,100,54,3/3/2021
D81463,dividend-up,100,81,3/3/2021
D81463,dividend-up,100,81,3/3/2021
D81463,earnings,100,50,3/3/2021
D81463,earnings,100,50,3/3/2021
D8442A,product-release,100,64,3/3/2021
D8442A,partnership,100,61,3/3/2021
D8442A,acquisition-completed-acquirer,100,49,3/3/2021
D90441,dividend,100,50,3/3/2021
D90441,dividend,100,50,3/3/2021
DBCA3F,conference-participant,100,50,3/3/2021
DCD97F,dividend-up,100,81,3/3/2021
E0207A,acquisition-completed-acquirer,100,49,3/3/2021
E0207A,acquisition-completed-acquirer,100,49,3/3/2021
E05026,earnings,100,50,3/3/2021
E07573,earnings,100,50,3/3/2021
E07573,earnings,100,50,3/3/2021
E07573,earnings,100,50,3/3/2021
E12A6E,unit-acquisition-acquirer,100,49,3/3/2021
E13782,earnings,100,50,3/3/2021
E1C16B,dividend,100,50,3/3/2021
E41190,earnings,100,50,3/3/2021
E5A3B6,conference-participant,100,50,3/3/2021
E610CD,public-offering,100,43,3/3/2021
E6E012,note-sale,100,52,3/3/2021
E6E012,note-sale,100,52,3/3/2021
E94704,conference-participant,100,50,3/3/2021
E96E0B,legal-issues-defendant,100,22,3/3/2021
E9FF33,executive-appointment,100,54,3/3/2021
ED3CA8,conference-participant,100,50,3/3/2021
ED79D9,note-sale,100,52,3/3/2021
ED79D9,note-sale,100,52,3/3/2021
ED9C04,award,100,58,3/3/2021
EF1AD9,conference-participant,100,50,3/3/2021
F0EEFB,earnings,100,50,3/3/2021
F179ED,note-sale,100,52,3/3/2021
F6FA6A,note-sale,100,52,3/3/2021
F7935D,legal-issues-defendant,100,22,3/3/2021
F7935D,legal-issues-defendant,100,22,3/3/2021
F7935D,legal-issues-defendant,100,22,3/3/2021
F7935D,legal-issues-defendant,100,22,3/3/2021
F80389,conference-call,100,50,3/3/2021
FAAFA2,earnings,100,50,3/3/2021
FE7A63,dividend,100,50,3/3/2021
9397,note-sale,100,52,3/4/2021
0157B1,partnership,100,61,3/4/2021
03596A,joint-venture,100,62,3/4/2021
054B55,earnings,100,50,3/4/2021
061A3B,product-price-raise,100,57,3/4/2021
070B45,conference-participant,100,50,3/4/2021
07CA6A,award,100,58,3/4/2021
07CA6A,award,100,58,3/4/2021
09DE1F,earnings,100,50,3/4/2021
0AD2E3,earnings,100,50,3/4/2021
0AD2E3,earnings,100,50,3/4/2021
0BC853,dividend,100,50,3/4/2021
0BF528,conference-participant,100,50,3/4/2021
0EF1AF,fraud-defendant,100,20,3/4/2021
0EF1AF,fraud-defendant,100,20,3/4/2021
0EF1AF,legal-issues-defendant,100,22,3/4/2021
0EF1AF,legal-issues-defendant,100,22,3/4/2021
0F0440,donation,100,54,3/4/2021
0FABBD,partnership,100,61,3/4/2021
106394,public-offering,100,43,3/4/2021
11AEDE,earnings,100,50,3/4/2021
1272B3,public-offering,100,43,3/4/2021
129DC8,conference-participant,100,50,3/4/2021
12A3A3,conference-call,100,50,3/4/2021
12E454,executive-appointment,100,54,3/4/2021
136B26,earnings,100,50,3/4/2021
154272,earnings,100,50,3/4/2021
157CC1,earnings,100,50,3/4/2021
15901B,earnings,100,50,3/4/2021
15901B,earnings,100,50,3/4/2021
15901B,earnings,100,50,3/4/2021
159739,public-offering,100,43,3/4/2021
159739,public-offering,100,43,3/4/2021
168A5D,partnership,100,61,3/4/2021
16B183,legal-issues-defendant,100,22,3/4/2021
1748F6,partnership,100,61,3/4/2021
1748F6,partnership,100,61,3/4/2021
180DA0,dividend,100,50,3/4/2021
180DA0,earnings,100,50,3/4/2021
182546,earnings,100,50,3/4/2021
1880C5,conference-call,100,50,3/4/2021
18A98C,earnings,100,50,3/4/2021
1AB023,product-release,100,64,3/4/2021
1B9535,buybacks,100,74,3/4/2021
1C2593,earnings,100,50,3/4/2021
1CD09C,conference-participant,100,50,3/4/2021
1D1B07,earnings,100,50,3/4/2021
1D1B07,earnings,100,50,3/4/2021
1EBF8D,acquisition-acquirer,100,49,3/4/2021
1F19C8,executive-appointment,100,54,3/4/2021
1F716B,award,100,58,3/4/2021
1F9258,earnings,100,50,3/4/2021
202E5A,acquisition-acquiree,100,76,3/4/2021
202E5A,acquisition-acquiree,100,76,3/4/2021
202E5A,acquisition-acquiree,100,76,3/4/2021
202E5A,acquisition-acquiree,100,76,3/4/2021
202E5A,legal-issues-defendant,100,22,3/4/2021
21245F,conference-participant,100,50,3/4/2021
227D48,dividend,100,50,3/4/2021
228D42,partnership,100,61,3/4/2021
228D42,executive-appointment,100,54,3/4/2021
228D42,partnership,100,61,3/4/2021
228D42,partnership,100,61,3/4/2021
23699B,executive-appointment,100,54,3/4/2021
23699B,earnings,100,50,3/4/2021
238302,earnings,100,50,3/4/2021
24FA23,conference-participant,100,50,3/4/2021
25D3CE,conference-participant,100,50,3/4/2021
25DD05,conference-participant,100,50,3/4/2021
263216,dividend,100,50,3/4/2021
26CC63,partnership,100,61,3/4/2021
274B8A,conference-call,100,50,3/4/2021
279916,earnings,100,50,3/4/2021
27C10F,earnings,100,50,3/4/2021
292A70,partnership,100,61,3/4/2021
2A6DBE,conference-participant,100,50,3/4/2021
2D981A,earnings,100,50,3/4/2021
2D981A,conference-participant,100,50,3/4/2021
2E36AD,earnings,100,50,3/4/2021
2E36AD,earnings,100,50,3/4/2021
2F9304,executive-appointment,100,54,3/4/2021
2FF046,conference-participant,100,50,3/4/2021
315EB0,facility-open,100,65,3/4/2021
315EB0,facility-open,100,65,3/4/2021
317EC6,acquisition-completed-acquirer,100,49,3/4/2021
326EDD,conference-participant,100,50,3/4/2021
32DCB3,earnings,100,50,3/4/2021
367434,earnings,100,50,3/4/2021
36C09B,conference-participant,100,50,3/4/2021
36C09B,clinical-trials,100,56,3/4/2021
36E479,conference-participant,100,50,3/4/2021
383ADA,earnings,100,50,3/4/2021
385DD4,executive-shares-options,100,51,3/4/2021
3AAEAE,conference-participant,100,50,3/4/2021
3B37F7,executive-appointment,100,54,3/4/2021
407878,acquisition-acquirer,100,49,3/4/2021
4649D5,earnings,100,50,3/4/2021
467F2C,conference-participant,100,50,3/4/2021
47B4CC,earnings,100,50,3/4/2021
47B4CC,earnings,100,50,3/4/2021
49BBBC,executive-appointment,100,54,3/4/2021
4A2457,business-contract,100,69,3/4/2021
4A6F00,partnership,100,61,3/4/2021
4AE584,earnings,100,50,3/4/2021
4AE584,earnings,100,50,3/4/2021
4B3676,partnership,100,61,3/4/2021
4BBA23,conference-participant,100,50,3/4/2021
4CDA2B,conference-participant,100,50,3/4/2021
4E913D,executive-appointment,100,54,3/4/2021
519FE0,earnings,100,50,3/4/2021
5403F8,earnings,100,50,3/4/2021
543900,dividend,100,50,3/4/2021
55C9B5,business-contract,100,69,3/4/2021
55C9B5,conference-participant,100,50,3/4/2021
55D0F3,earnings,100,50,3/4/2021
586BD7,conference-call,100,50,3/4/2021
5876DC,earnings,100,50,3/4/2021
58B46F,conference-call,100,50,3/4/2021
58C2D4,legal-issues-defendant,100,22,3/4/2021
58C2D4,legal-issues-defendant,100,22,3/4/2021
5B226B,fraud-defendant,100,20,3/4/2021
5B226B,legal-issues-defendant,100,22,3/4/2021
5B226B,legal-issues-defendant,100,22,3/4/2021
5CC29D,conference-call,100,50,3/4/2021
5DD486,conference-call,100,50,3/4/2021
619882,conference-organizer,100,57,3/4/2021
619882,conference-organizer,100,57,3/4/2021
64E346,conference-participant,100,50,3/4/2021
6559D8,conference-participant,100,50,3/4/2021
665440,earnings,100,50,3/4/2021
66667F,conference-call,100,50,3/4/2021
67303E,legal-issues-defendant,100,22,3/4/2021
67303E,legal-issues-defendant,100,22,3/4/2021
673C9A,conference-participant,100,50,3/4/2021
68586A,earnings,100,50,3/4/2021
69CE71,investment-investor,100,55,3/4/2021
6B236C,conference-participant,100,50,3/4/2021
6BBCBA,earnings,100,50,3/4/2021
6BBCBA,earnings,100,50,3/4/2021
6BBCBA,earnings,100,50,3/4/2021
6C6D73,patent-awarded,100,72,3/4/2021
6D156D,legal-issues-defendant,100,22,3/4/2021
6.00E+19,earnings,100,50,3/4/2021
6F22E7,conference-participant,100,50,3/4/2021
70CA28,conference-participant,100,50,3/4/2021
70CA28,conference-participant,100,50,3/4/2021
713810,conference-participant,100,50,3/4/2021
713810,partnership,100,61,3/4/2021
717DB4,public-offering,100,43,3/4/2021
722D55,executive-appointment,100,54,3/4/2021
73F7F9,earnings,100,50,3/4/2021
7.45E+28,legal-issues-defendant,100,22,3/4/2021
7.45E+28,legal-issues-defendant,100,22,3/4/2021
7.45E+28,legal-issues-defendant,100,22,3/4/2021
756045,earnings,100,50,3/4/2021
769F40,earnings,100,50,3/4/2021
76B926,executive-appointment,100,54,3/4/2021
76F067,acquisition-acquirer,100,49,3/4/2021
76F067,acquisition-acquirer,100,49,3/4/2021
76F067,acquisition-acquirer,100,49,3/4/2021
76F067,acquisition-acquirer,100,49,3/4/2021
7710F3,earnings,100,50,3/4/2021
790D0D,conference-participant,100,50,3/4/2021
7A5097,conference-participant,100,50,3/4/2021
7ADE57,earnings,100,50,3/4/2021
7ADE57,earnings,100,50,3/4/2021
7ADE57,earnings,100,50,3/4/2021
7ADE57,earnings,100,50,3/4/2021
7ADE57,earnings,100,50,3/4/2021
7B9212,revenues,100,50,3/4/2021
7C4F43,earnings,100,50,3/4/2021
7E0EB0,partnership,100,61,3/4/2021
7FDE1C,business-contract,100,69,3/4/2021
817ED9,executive-appointment,100,54,3/4/2021
817ED9,earnings,100,50,3/4/2021
826FD6,earnings,100,50,3/4/2021
8303CD,award,100,58,3/4/2021
834152,earnings,100,50,3/4/2021
85DA04,award,100,58,3/4/2021
8B3B0E,dividend,100,50,3/4/2021
8BFE9A,earnings,100,50,3/4/2021
8C6C1B,donation,100,54,3/4/2021
8C6C1B,facility-open,100,65,3/4/2021
8C6C1B,executive-appointment,100,54,3/4/2021
8D4486,partnership,100,61,3/4/2021
8DA42F,note-sale,100,52,3/4/2021
8DA42F,public-offering,100,43,3/4/2021
8E10BF,conference-call,100,50,3/4/2021
8E3F58,earnings,100,50,3/4/2021
8E3F58,earnings,100,50,3/4/2021
8E3F58,earnings,100,50,3/4/2021
8E4250,earnings,100,50,3/4/2021
8EEA28,conference-participant,100,50,3/4/2021
96B4FF,conference-participant,100,50,3/4/2021
97FE80,conference-call,100,50,3/4/2021
9810C0,dividend,100,50,3/4/2021
981656,earnings,100,50,3/4/2021
990AD0,conference-organizer,100,57,3/4/2021
990AD0,conference-organizer,100,57,3/4/2021
9C3D3C,conference-participant,100,50,3/4/2021
9CDA4F,earnings,100,50,3/4/2021
9D2790,donation,100,54,3/4/2021
9FB4B7,earnings,100,50,3/4/2021
A11CF4,acquisition-acquiree,100,76,3/4/2021
A37D68,earnings,100,50,3/4/2021
A3AAA5,public-offering,100,43,3/4/2021
A4386C,conference-participant,100,50,3/4/2021
A72AB6,earnings,100,50,3/4/2021
A75D43,public-offering,100,43,3/4/2021
A79F7D,business-contract,100,69,3/4/2021
A7A0C8,executive-appointment,100,54,3/4/2021
A7A0C8,earnings,100,50,3/4/2021
A8CBDA,facility-open,100,65,3/4/2021
ACC7D3,earnings,100,50,3/4/2021
AD23DE,campaign-ad-release,100,59,3/4/2021
AE7D16,legal-issues-defendant,100,22,3/4/2021
AE7D16,legal-issues-defendant,100,22,3/4/2021
AEF2C3,conference-participant,100,50,3/4/2021
AF93DE,conference-call,100,50,3/4/2021
AFBEB4,earnings,100,50,3/4/2021
AFF7B4,executive-appointment,100,54,3/4/2021
AFF7B4,executive-appointment,100,54,3/4/2021
B05118,note-sale,100,52,3/4/2021
B2206F,executive-appointment,100,54,3/4/2021
B2D492,earnings,100,50,3/4/2021
B33E77,conference-participant,100,50,3/4/2021
B37FB4,partnership,100,61,3/4/2021
B3A166,earnings,100,50,3/4/2021
B4703C,executive-appointment,100,54,3/4/2021
B48FC9,conference-participant,100,50,3/4/2021
B4F5F4,executive-appointment,100,54,3/4/2021
B5766D,executive-appointment,100,54,3/4/2021
B60366,earnings,100,50,3/4/2021
B72D2E,conference-call,100,50,3/4/2021
B85DCE,executive-appointment,100,54,3/4/2021
B85DCE,executive-appointment,100,54,3/4/2021
B8A51F,legal-issues-defendant,100,22,3/4/2021
B8A51F,legal-issues-defendant,100,22,3/4/2021
B8A51F,legal-issues-defendant,100,22,3/4/2021
B8DD94,conference-participant,100,50,3/4/2021
B8EF97,earnings,100,50,3/4/2021
BB07E4,merger-regulatory-approval,100,81,3/4/2021
BBC05B,executive-appointment,100,54,3/4/2021
BDA775,earnings,100,50,3/4/2021
BE645B,conference-participant,100,50,3/4/2021
C1114B,conference-participant,100,50,3/4/2021
C29E71,partnership,100,61,3/4/2021
C2DD02,dividend,100,50,3/4/2021
C2E39B,conference-participant,100,50,3/4/2021
C38440,earnings,100,50,3/4/2021
C58D71,earnings,100,50,3/4/2021
C8A059,earnings,100,50,3/4/2021
C93C44,conference-participant,100,50,3/4/2021
CA1620,dividend,100,50,3/4/2021
CB22CD,earnings,100,50,3/4/2021
CC176E,partnership,100,61,3/4/2021
CC6F6E,earnings,100,50,3/4/2021
CDD75E,conference-participant,100,50,3/4/2021
CFF57D,earnings,100,50,3/4/2021
CFF57D,earnings,100,50,3/4/2021
CFF57D,earnings,100,50,3/4/2021
CFF57D,earnings,100,50,3/4/2021
D1588D,conference-participant,100,50,3/4/2021
D1C26F,executive-appointment,100,54,3/4/2021
D54E62,partnership,100,61,3/4/2021
D54E62,partnership,100,61,3/4/2021
D56E4C,executive-appointment,100,54,3/4/2021
D56E4C,executive-appointment,100,54,3/4/2021
D58A11,conference-participant,100,50,3/4/2021
D6489C,acquisition-acquiree,100,76,3/4/2021
D8ECA1,conference-participant,100,50,3/4/2021
DA48E4,product-release,100,64,3/4/2021
DA91AE,merger-regulatory-approval,100,81,3/4/2021
DA9443,earnings,100,50,3/4/2021
DB7EC3,dividend,100,50,3/4/2021
DB7EC3,dividend,100,50,3/4/2021
DB9829,earnings-up,100,68,3/4/2021
DBFB51,earnings,100,50,3/4/2021
DD1BA1,conference-participant,100,50,3/4/2021
DDCB34,dividend,100,50,3/4/2021
DDCB34,earnings,100,50,3/4/2021
DF16DE,earnings,100,50,3/4/2021
DF204B,note-sale,100,52,3/4/2021
DF5F14,earnings,100,50,3/4/2021
E124EB,conference-participant,100,50,3/4/2021
E1F30A,earnings,100,50,3/4/2021
E28D9C,conference-participant,100,50,3/4/2021
E38906,earnings,100,50,3/4/2021
E610CD,public-offering,100,43,3/4/2021
E6C8DC,earnings,100,50,3/4/2021
E70531,legal-issues-defendant,100,22,3/4/2021
E74B55,legal-issues-defendant,100,22,3/4/2021
E74B55,legal-issues-defendant,100,22,3/4/2021
E96E0B,legal-issues-defendant,100,22,3/4/2021
E96E0B,legal-issues-defendant,100,22,3/4/2021
E96E0B,legal-issues-defendant,100,22,3/4/2021
ED0402,acquisition-failed-acquirer,100,41,3/4/2021
ED1A74,conference-participant,100,50,3/4/2021
EE74E1,business-contract,100,69,3/4/2021
EFA7B2,conference-participant,100,50,3/4/2021
F05B1B,conference-participant,100,50,3/4/2021
F1C04C,conference-participant,100,50,3/4/2021
F294DD,dividend,100,50,3/4/2021
F3816D,conference-call,100,50,3/4/2021
F42FAE,dividend-up,100,53,3/4/2021
F57F6F,conference-participant,100,50,3/4/2021
F66B58,earnings-guidance-up,100,83,3/4/2021
F6E248,acquisition-completed-acquirer,100,49,3/4/2021
F769E9,public-offering,100,43,3/4/2021
F7935D,legal-issues-defendant,100,22,3/4/2021
F7935D,legal-issues-defendant,100,22,3/4/2021
F7935D,legal-issues-defendant,100,22,3/4/2021
F7935D,legal-issues-defendant,100,22,3/4/2021
FBD92D,earnings,100,50,3/4/2021
FBD92D,earnings,100,50,3/4/2021
FBD92D,earnings,100,50,3/4/2021
FC4550,dividend,100,50,3/4/2021
FCA54E,earnings,100,50,3/4/2021
FCA54E,earnings,100,50,3/4/2021
FCA54E,earnings,100,50,3/4/2021
FCA54E,earnings,100,50,3/4/2021
FDE409,earnings,100,50,3/4/2021
001F1B,conference-call,100,50,3/5/2021
00E601,earnings,100,50,3/5/2021
00E601,conference-participant,100,50,3/5/2021
06C826,earnings,100,50,3/5/2021
07C69F,conference-participant,100,50,3/5/2021
0CE7F6,executive-appointment,100,54,3/5/2021
0EF1AF,legal-issues-defendant,100,22,3/5/2021
0EF1AF,legal-issues-defendant,100,22,3/5/2021
0EF1AF,legal-issues-defendant,100,22,3/5/2021
0F0440,earnings,100,50,3/5/2021
108A2B,conference-participant,100,50,3/5/2021
1272B3,public-offering,100,43,3/5/2021
12DE76,executive-appointment,100,54,3/5/2021
159739,public-offering,100,43,3/5/2021
159739,public-offering,100,43,3/5/2021
159739,dividend,100,50,3/5/2021
159739,dividend,100,50,3/5/2021
159739,conference-call,100,50,3/5/2021
159739,conference-call,100,50,3/5/2021
1782D5,legal-issues-defendant,100,22,3/5/2021
1782D5,legal-issues-defendant,100,22,3/5/2021
1782D5,legal-issues-defendant,100,22,3/5/2021
1782D5,legal-issues-defendant,100,22,3/5/2021
1782D5,legal-issues-defendant,100,22,3/5/2021
1782D5,legal-issues-defendant,100,22,3/5/2021
190B91,conference-participant,100,50,3/5/2021
1AB023,earnings,100,50,3/5/2021
1AB023,earnings,100,50,3/5/2021
1AB023,earnings,100,50,3/5/2021
1B9535,facility-open,100,65,3/5/2021
1B9535,facility-open,100,65,3/5/2021
1FCC00,dividend,100,50,3/5/2021
1FCC00,earnings,100,50,3/5/2021
1FCC00,earnings,100,50,3/5/2021
1FCC00,earnings,100,50,3/5/2021
238302,conference-participant,100,50,3/5/2021
251988,legal-issues-defendant,100,22,3/5/2021
295F9F,conference-participant,100,50,3/5/2021
3.30E+30,unit-acquisition-acquirer,100,49,3/5/2021
3B9886,earnings,100,50,3/5/2021
3CCC90,executive-appointment,100,54,3/5/2021
3DDE54,conference-participant,100,50,3/5/2021
3DE4D1,executive-appointment,100,54,3/5/2021
3F6A9C,executive-appointment,100,54,3/5/2021
420168,conference-participant,100,50,3/5/2021
427F32,dividend,100,50,3/5/2021
43A74A,conference-participant,100,50,3/5/2021
442769,note-sale,100,52,3/5/2021
45ABCC,conference-participant,100,50,3/5/2021
499C75,earnings,100,50,3/5/2021
504FE2,fraud-defendant,100,20,3/5/2021
504FE2,legal-issues-defendant,100,22,3/5/2021
51D876,conference-participant,100,50,3/5/2021
520632,regulatory-product-approval-granted,100,81,3/5/2021
55C9B5,acquisition-completed-acquirer,100,49,3/5/2021
55CD6F,conference-participant,100,50,3/5/2021
58C2D4,legal-issues-defendant,100,22,3/5/2021
5B226B,executive-resignation,100,44,3/5/2021
5B226B,legal-issues-defendant,100,22,3/5/2021
5BC2F4,executive-appointment,100,54,3/5/2021
641F17,conference-participant,100,50,3/5/2021
651C85,conference-participant,100,50,3/5/2021
65AB30,public-offering,100,43,3/5/2021
6F39FC,dividend,100,50,3/5/2021
7255D2,legal-issues-defendant,100,22,3/5/2021
7255D2,legal-issues-defendant,100,22,3/5/2021
7255D2,legal-issues-defendant,100,22,3/5/2021
7.45E+28,legal-issues-defendant,100,22,3/5/2021
751C8D,conference-participant,100,50,3/5/2021
75F982,partnership,100,61,3/5/2021
762A3E,conference-organizer,100,57,3/5/2021
7710F3,conference-participant,100,50,3/5/2021
7999F3,conference-participant,100,50,3/5/2021
7ACBA4,earnings,100,50,3/5/2021
8.10E+32,dividend,100,50,3/5/2021
81222C,note-sale,100,52,3/5/2021
817ED9,earnings,100,50,3/5/2021
877734,conference-call,100,50,3/5/2021
880C0C,dividend,100,50,3/5/2021
8C6C1B,facility-open,100,65,3/5/2021
8CF6DD,executive-appointment,100,54,3/5/2021
8E3F58,conference-participant,100,50,3/5/2021
8FF2EF,dividend,100,50,3/5/2021
9087B9,public-offering,100,43,3/5/2021
911ACB,executive-appointment,100,54,3/5/2021
918D6D,earnings,100,50,3/5/2021
918D6D,earnings,100,50,3/5/2021
990AD0,conference-organizer,100,57,3/5/2021
99DC8D,executive-resignation,100,44,3/5/2021
9D5FA4,conference-participant,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
9E9147,earnings,100,50,3/5/2021
A16DEA,conference-participant,100,50,3/5/2021
A4386C,conference-participant,100,50,3/5/2021
A6828A,legal-issues-defendant,100,22,3/5/2021
AA1EAA,conference-participant,100,50,3/5/2021
AB7726,donation,100,54,3/5/2021
AD1ACF,legal-issues-defendant,100,22,3/5/2021
AE4EEB,conference-participant,100,50,3/5/2021
AE7D16,legal-issues-defendant,100,22,3/5/2021
B01111,partnership,100,61,3/5/2021
B1FC3B,earnings,100,50,3/5/2021
B2D492,conference-call,100,50,3/5/2021
B762D3,earnings,100,50,3/5/2021
B762D3,earnings,100,50,3/5/2021
B762D3,earnings,100,50,3/5/2021
B8A51F,legal-issues-defendant,100,22,3/5/2021
BE379D,conference-participant,100,50,3/5/2021
C062D4,note-sale,100,52,3/5/2021
C0BA36,product-release,100,64,3/5/2021
C27E19,conference-participant,100,50,3/5/2021
D54E62,acquisition-acquirer,100,49,3/5/2021
D6144F,conference-call,100,50,3/5/2021
D76AEF,dividend,100,50,3/5/2021
DA0CB8,conference-participant,100,50,3/5/2021
DF1F7A,executive-appointment,100,54,3/5/2021
DF1F7A,dividend,100,50,3/5/2021
E6EDED,dividend,100,50,3/5/2021
E70531,legal-issues-defendant,100,22,3/5/2021
E74B55,legal-issues-defendant,100,22,3/5/2021
E96E0B,legal-issues-defendant,100,22,3/5/2021
EEA6B3,note-sale,100,52,3/5/2021
F179ED,note-sale,100,52,3/5/2021
F7935D,legal-issues-defendant,100,22,3/5/2021
F7935D,legal-issues-defendant,100,22,3/5/2021
FC1736,earnings,100,50,3/5/2021
FC1B7B,executive-resignation,100,44,3/5/2021
16B183,legal-issues-defendant,100,22,3/6/2021
16B183,legal-issues-defendant,100,22,3/6/2021
1782D5,legal-issues-defendant,100,22,3/6/2021
1E04A5,legal-issues-defendant,100,22,3/6/2021
1EBF8D,clinical-trials,100,56,3/6/2021
202E5A,legal-issues-defendant,100,22,3/6/2021
43F4A8,legal-issues-defendant,100,22,3/6/2021
504FE2,legal-issues-defendant,100,22,3/6/2021
8EF425,conference-participant,100,50,3/6/2021
ABAA03,clinical-trials,100,56,3/6/2021
E96E0B,legal-issues-defendant,100,22,3/6/2021
384CD3,partnership,100,61,3/7/2021
4A3438,legal-issues-defendant,100,22,3/7/2021
5B226B,legal-issues-defendant,100,22,3/7/2021
7.45E+28,legal-issues-defendant,100,22,3/7/2021
7DA412,legal-issues-defendant,100,22,3/7/2021
9934AD,legal-issues-defendant,100,22,3/7/2021
D57D99,legal-issues-defendant,100,22,3/7/2021
E96E0B,legal-issues-defendant,100,22,3/7/2021
EE74E1,legal-issues-defendant,100,22,3/7/2021
03D5F9,partnership,100,61,3/8/2021
03D5F9,partnership,100,61,3/8/2021
0490C6,earnings,100,50,3/8/2021
0490C6,earnings,100,50,3/8/2021
0490C6,earnings,100,50,3/8/2021
0490C6,earnings,100,50,3/8/2021
0490C6,earnings,100,50,3/8/2021
08A40F,donation,100,54,3/8/2021
0A77DB,earnings,100,50,3/8/2021
0B7375,executive-appointment,100,54,3/8/2021
0BD4E8,business-contract,100,69,3/8/2021
0C355F,note-sale,100,52,3/8/2021
0E5619,conference-call,100,50,3/8/2021
0EF1AF,legal-issues-defendant,100,22,3/8/2021
0EF1AF,legal-issues-defendant,100,22,3/8/2021
0F2BC9,business-contract,100,69,3/8/2021
10100E,earnings,100,50,3/8/2021
106394,public-offering,100,43,3/8/2021
1201B5,clinical-trials-positive,100,87,3/8/2021
125212,conference-participant,100,50,3/8/2021
12F98C,earnings-per-share-up,100,64,3/8/2021
12F98C,earnings-per-share-up,100,64,3/8/2021
12F98C,earnings-per-share-up,100,64,3/8/2021
13C3E0,note-sale,100,52,3/8/2021
15901B,executive-appointment,100,54,3/8/2021
15A388,business-contract,100,69,3/8/2021
1782D5,legal-issues-defendant,100,22,3/8/2021
1782D5,legal-issues-defendant,100,22,3/8/2021
17EDA5,partnership,100,61,3/8/2021
1834C0,conference-participant,100,50,3/8/2021
197019,public-offering,100,43,3/8/2021
1B637E,partnership,100,61,3/8/2021
1BDB2A,acquisition-acquirer,100,49,3/8/2021
1C2593,conference-participant,100,50,3/8/2021
1EBF8D,regulatory-product-approval-granted,100,81,3/8/2021
1EBF8D,partnership,100,61,3/8/2021
1EBF8D,clinical-trials,100,56,3/8/2021
1F08A6,conference-participant,100,50,3/8/2021
228D42,partnership,100,61,3/8/2021
228D42,partnership,100,61,3/8/2021
228D42,partnership,100,61,3/8/2021
267718,clinical-trials-start,100,64,3/8/2021
267718,clinical-trials-start,100,64,3/8/2021
270B78,conference-participant,100,50,3/8/2021
292388,conference-participant,100,50,3/8/2021
295F9F,earnings,100,50,3/8/2021
2BF36E,partnership,100,61,3/8/2021
3.20E+263,conference-participant,100,50,3/8/2021
3461CF,award,100,58,3/8/2021
346BF2,earnings,100,50,3/8/2021
371B0A,conference-participant,100,50,3/8/2021
384CD3,partnership,100,61,3/8/2021
385DD4,conference-participant,100,50,3/8/2021
38FB49,conference-participant,100,50,3/8/2021
3B318A,earnings,100,50,3/8/2021
3BC360,public-offering,100,43,3/8/2021
3BE00F,conference-participant,100,50,3/8/2021
3C7F5F,partnership,100,61,3/8/2021
3DED49,executive-appointment,100,54,3/8/2021
3F1C69,regulatory-product-application,100,69,3/8/2021
3F1C69,regulatory-product-application,100,69,3/8/2021
3FACA7,donation,100,54,3/8/2021
408380,earnings,100,50,3/8/2021
416C55,conference-participant,100,50,3/8/2021
450ECB,executive-appointment,100,54,3/8/2021
450ECB,executive-appointment,100,54,3/8/2021
450ECB,ebitda-positive,100,69,3/8/2021
485445,business-contract,100,69,3/8/2021
485445,partnership,100,61,3/8/2021
4C2F17,executive-appointment,100,54,3/8/2021
4E6F5A,earnings,100,50,3/8/2021
504FE2,legal-issues-defendant,100,22,3/8/2021
504FE2,legal-issues-defendant,100,22,3/8/2021
510EA1,earnings,100,50,3/8/2021
52BF94,conference-call,100,50,3/8/2021
54512F,earnings,100,50,3/8/2021
546A9C,conference-participant,100,50,3/8/2021
548AC0,buybacks,100,74,3/8/2021
556F08,earnings,100,50,3/8/2021
58CA9A,conference-organizer,100,57,3/8/2021
59872F,legal-issues-defendant,100,22,3/8/2021
5B226B,exchange-noncompliance,100,24,3/8/2021
5B6C11,partnership,100,61,3/8/2021
5E1DF3,earnings,100,50,3/8/2021
5F2FF7,conference-participant,100,50,3/8/2021
5F6D73,executive-resignation,100,44,3/8/2021
619882,conference-organizer,100,57,3/8/2021
619882,conference-organizer,100,57,3/8/2021
619882,conference-organizer,100,57,3/8/2021
619882,conference-organizer,100,57,3/8/2021
619882,conference-organizer,100,57,3/8/2021
65D0AA,clinical-trials-start,100,64,3/8/2021
67303E,legal-issues-defendant,100,22,3/8/2021
6925EB,clinical-trials,100,56,3/8/2021
69FDFC,product-release,100,64,3/8/2021
6A171E,earnings,100,50,3/8/2021
6AACDD,executive-appointment,100,54,3/8/2021
6BF593,conference-participant,100,50,3/8/2021
6DBBBC,investment-investor,100,55,3/8/2021
6DD6BA,business-contract,100,69,3/8/2021
6E705B,facility-open,100,65,3/8/2021
713810,legal-issues-defendant,100,22,3/8/2021
71E2EF,executive-appointment,100,54,3/8/2021
73C521,conference-call,100,50,3/8/2021
7.45E+28,legal-issues-defendant,100,22,3/8/2021
748EB6,earnings,100,50,3/8/2021
791D59,note-sale,100,52,3/8/2021
7B1E50,executive-appointment,100,54,3/8/2021
7B1E50,executive-appointment,100,54,3/8/2021
7E3F8F,partnership,100,61,3/8/2021
7F3A5F,executive-appointment,100,54,3/8/2021
7FDE1C,acquisition-acquirer,100,49,3/8/2021
80C400,unit-acquisition-acquirer,100,49,3/8/2021
84A6B9,executive-appointment,100,54,3/8/2021
85CDC9,business-contract,100,69,3/8/2021
8A0368,conference-participant,100,50,3/8/2021
8A8E41,partnership,100,61,3/8/2021
8C1238,executive-appointment,100,54,3/8/2021
8C5519,conference-participant,100,50,3/8/2021
8C6C1B,facility-open,100,65,3/8/2021
91C82E,conference-call,100,50,3/8/2021
92005C,executive-appointment,100,54,3/8/2021
9470CC,earnings,100,50,3/8/2021
97B027,earnings,100,50,3/8/2021
97FE80,earnings,100,50,3/8/2021
98CEBB,public-offering,100,43,3/8/2021
990AD0,conference-organizer,100,57,3/8/2021
A03EE1,public-offering,100,43,3/8/2021
A433A5,earnings,100,50,3/8/2021
A433A5,public-offering,100,43,3/8/2021
A433A5,business-contract,100,69,3/8/2021
A433A5,business-contract,100,69,3/8/2021
A6213D,partnership,100,61,3/8/2021
A79D88,buybacks,100,74,3/8/2021
A9ED24,conference-participant,100,50,3/8/2021
AC7AAE,earnings,100,50,3/8/2021
AC7C4F,conference-participant,100,50,3/8/2021
ACDCFA,earnings,100,50,3/8/2021
AE4125,earnings,100,50,3/8/2021
AE4125,earnings,100,50,3/8/2021
AE4125,earnings,100,50,3/8/2021
AE7D16,legal-issues-defendant,100,22,3/8/2021
B01215,conference-call,100,50,3/8/2021
B08C51,earnings,100,50,3/8/2021
B0D41A,conference-participant,100,50,3/8/2021
B13B68,conference-participant,100,50,3/8/2021
B13B68,note-sale,100,52,3/8/2021
B8F71F,executive-appointment,100,54,3/8/2021
B9BDE8,earnings,100,50,3/8/2021
B9CD50,note-sale,100,52,3/8/2021
BB58FF,conference-participant,100,50,3/8/2021
BBF349,note-sale,100,52,3/8/2021
BCC55F,conference-participant,100,50,3/8/2021
BDCC11,note-sale,100,52,3/8/2021
C2E39B,public-offering,100,43,3/8/2021
C45CE7,buybacks,100,74,3/8/2021
C564E4,regulatory-product-approval-granted,100,81,3/8/2021
C8A248,buybacks,100,74,3/8/2021
CBB77B,earnings,100,50,3/8/2021
CBB77B,earnings,100,50,3/8/2021
CC3EC4,earnings,100,50,3/8/2021
CC6FF5,award,100,58,3/8/2021
CCB623,executive-appointment,100,54,3/8/2021
CE4FD9,conference-participant,100,50,3/8/2021
D0909F,product-release,100,64,3/8/2021
D4C0CB,partnership,100,61,3/8/2021
D58A11,executive-appointment,100,54,3/8/2021
D6489C,executive-appointment,100,54,3/8/2021
D64C6D,partnership,100,61,3/8/2021
D697DE,public-offering,100,43,3/8/2021
D90F43,partnership,100,61,3/8/2021
D93A25,note-sale,100,52,3/8/2021
D93A25,note-sale,100,52,3/8/2021
D9E036,joint-venture,100,62,3/8/2021
D9FC89,conference-participant,100,50,3/8/2021
DB88A1,business-contract,100,69,3/8/2021
DBB28E,business-contract,100,69,3/8/2021
DD1BA1,acquisition-acquiree,100,76,3/8/2021
E259C7,merger-completed,100,66,3/8/2021
E259C7,merger-completed,100,66,3/8/2021
E41190,earnings,100,50,3/8/2021
E592F0,partnership,100,61,3/8/2021
E67C2C,conference-participant,100,50,3/8/2021
E68733,dividend,100,50,3/8/2021
E68733,dividend,100,50,3/8/2021
E71AE6,earnings,100,50,3/8/2021
E7BF32,earnings,100,50,3/8/2021
E7BF32,earnings,100,50,3/8/2021
E8A49A,conference-participant,100,50,3/8/2021
E96E0B,legal-issues-defendant,100,22,3/8/2021
E9C7C0,partnership,100,61,3/8/2021
EEA6B3,note-sale,100,52,3/8/2021
EEEA9F,executive-appointment,100,54,3/8/2021
F05B1B,earnings,100,50,3/8/2021
F05B1B,earnings,100,50,3/8/2021
F30508,conference-participant,100,50,3/8/2021
F30508,partnership,100,61,3/8/2021
F6581D,conference-call,100,50,3/8/2021
F6A987,dividend,100,50,3/8/2021
F9AA02,clinical-trials-start,100,64,3/8/2021
FE609F,conference-participant,100,50,3/8/2021
0157B1,partnership,100,61,3/9/2021
0157B1,business-contract,100,69,3/9/2021
0157B1,partnership,100,61,3/9/2021
0157B1,product-release,100,64,3/9/2021
0157B1,product-release,100,64,3/9/2021
01D03F,regulatory-product-approval-granted,100,81,3/9/2021
01D03F,regulatory-product-approval-granted,100,81,3/9/2021
01D03F,partnership,100,61,3/9/2021
033B58,earnings,100,50,3/9/2021
03542C,conference-call,100,50,3/9/2021
03C94A,business-contract,100,69,3/9/2021
04EB2F,executive-appointment,100,54,3/9/2021
06CB5B,earnings,100,50,3/9/2021
06EF42,earnings,100,50,3/9/2021
0BD970,earnings,100,50,3/9/2021
0C355F,conference-participant,100,50,3/9/2021
0C355F,award,100,58,3/9/2021
0C355F,note-sale,100,52,3/9/2021
0EF1AF,legal-issues-defendant,100,22,3/9/2021
0EF1AF,earnings,100,50,3/9/2021
0FC848,earnings,100,50,3/9/2021
125212,business-contract,100,69,3/9/2021
15901B,conference-participant,100,50,3/9/2021
15A388,product-release,100,64,3/9/2021
15B10D,earnings,100,50,3/9/2021
15B10D,earnings,100,50,3/9/2021
15B10D,earnings,100,50,3/9/2021
15B10D,earnings,100,50,3/9/2021
165B86,acquisition-acquirer,100,49,3/9/2021
165B86,acquisition-acquirer,100,49,3/9/2021
165B86,earnings,100,50,3/9/2021
1782D5,legal-issues-defendant,100,22,3/9/2021
17EDA5,partnership,100,61,3/9/2021
18D9FA,legal-issues-defendant,100,22,3/9/2021
18D9FA,legal-issues-defendant,100,22,3/9/2021
18D9FA,legal-issues-defendant,100,22,3/9/2021
18D9FA,legal-issues-defendant,100,22,3/9/2021
1CD4B5,earnings,100,50,3/9/2021
1DB833,earnings,100,50,3/9/2021
1DF15D,dividend,100,50,3/9/2021
1EBF8D,partnership,100,61,3/9/2021
1F08A6,dividend,100,50,3/9/2021
1FCC00,conference-participant,100,50,3/9/2021
202E5A,conference-call,100,50,3/9/2021
2158DF,award,100,58,3/9/2021
21F9CA,executive-appointment,100,54,3/9/2021
228D42,partnership,100,61,3/9/2021
2BF36E,conference-participant,100,50,3/9/2021
2C35B5,earnings,100,50,3/9/2021
2D643C,conference-participant,100,50,3/9/2021
2EB88B,product-release,100,64,3/9/2021
306623,conference-participant,100,50,3/9/2021
30DE64,earnings,100,50,3/9/2021
3.30E+30,earnings,100,50,3/9/2021
337024,earnings,100,50,3/9/2021
33A0F1,executive-appointment,100,54,3/9/2021
349DA4,conference-participant,100,50,3/9/2021
367E1C,conference-participant,100,50,3/9/2021
36C09B,clinical-trials,100,56,3/9/2021
397A8F,earnings,100,50,3/9/2021
3C6CCC,earnings,100,50,3/9/2021
3DB18B,executive-appointment,100,54,3/9/2021
3DD5E2,executive-appointment,100,54,3/9/2021
3DE4D1,executive-appointment,100,54,3/9/2021
416291,board-meeting,100,51,3/9/2021
416C55,conference-participant,100,50,3/9/2021
41C528,earnings,100,50,3/9/2021
42978B,conference-call,100,50,3/9/2021
435ACE,business-contract,100,69,3/9/2021
448215,dividend,100,50,3/9/2021
458D2C,revenue-volume,100,50,3/9/2021
4591D3,partnership,100,61,3/9/2021
4A2457,conference-participant,100,50,3/9/2021
4A3438,legal-issues-defendant,100,22,3/9/2021
4A6F00,partnership,100,61,3/9/2021
4B7006,acquisition-completed-acquirer,100,49,3/9/2021
4B7006,acquisition-completed-acquirer,100,49,3/9/2021
4BAF2E,conference-participant,100,50,3/9/2021
4C37C5,executive-appointment,100,54,3/9/2021
4C37C5,dividend,100,50,3/9/2021
4DAF5F,buybacks,100,74,3/9/2021
4DAF5F,buybacks,100,74,3/9/2021
4EEB00,operating-earnings,100,50,3/9/2021
4F71DC,partnership,100,61,3/9/2021
4F71DC,partnership,100,61,3/9/2021
504FE2,legal-issues-defendant,100,22,3/9/2021
504FE2,conference-participant,100,50,3/9/2021
504FE2,legal-issues-defendant,100,22,3/9/2021
52BF94,executive-appointment,100,54,3/9/2021
567F3D,conference-participant,100,50,3/9/2021
56EFC7,earnings,100,50,3/9/2021
587D25,earnings,100,50,3/9/2021
594402,conference-participant,100,50,3/9/2021
59DB8C,award,100,58,3/9/2021
5B226B,legal-issues-defendant,100,22,3/9/2021
5B226B,legal-issues-defendant,100,22,3/9/2021
5B226B,legal-issues-defendant,100,22,3/9/2021
5B51D6,clinical-trials-start,100,64,3/9/2021
5D41E4,executive-appointment,100,54,3/9/2021
5F1B7B,executive-appointment,100,54,3/9/2021
609208,award,100,58,3/9/2021
60AC34,earnings,100,50,3/9/2021
60FE03,earnings,100,50,3/9/2021
615B6D,legal-issues-defendant,100,22,3/9/2021
619882,conference-organizer,100,57,3/9/2021
619882,conference-organizer,100,57,3/9/2021
619882,conference-organizer,100,57,3/9/2021
619882,conference-organizer,100,57,3/9/2021
619882,conference-organizer,100,57,3/9/2021
619882,conference-organizer,100,57,3/9/2021
619882,conference-organizer,100,57,3/9/2021
619882,conference-organizer,100,57,3/9/2021
619882,conference-organizer,100,57,3/9/2021
620381,conference-participant,100,50,3/9/2021
627186,earnings,100,50,3/9/2021
65AB30,public-offering,100,43,3/9/2021
65D0AA,business-contract,100,69,3/9/2021
66667F,earnings,100,50,3/9/2021
66667F,earnings,100,50,3/9/2021
66667F,earnings,100,50,3/9/2021
66E04A,legal-issues-defendant,100,22,3/9/2021
67303E,legal-issues-defendant,100,22,3/9/2021
67B052,earnings,100,50,3/9/2021
67B052,earnings,100,50,3/9/2021
68AB62,earnings,100,50,3/9/2021
6B6375,conference-participant,100,50,3/9/2021
6D156D,legal-issues-defendant,100,22,3/9/2021
6D156D,legal-issues-defendant,100,22,3/9/2021
6D156D,legal-issues-defendant,100,22,3/9/2021
6D156D,legal-issues-defendant,100,22,3/9/2021
6D1ADF,executive-appointment,100,54,3/9/2021
6E705B,conference-participant,100,50,3/9/2021
7255D2,fraud-defendant,100,20,3/9/2021
7255D2,legal-issues-defendant,100,22,3/9/2021
7255D2,legal-issues-defendant,100,22,3/9/2021
767F86,executive-appointment,100,54,3/9/2021
773A17,partnership,100,61,3/9/2021
77B8E9,partnership,100,61,3/9/2021
7A10FF,acquisition-acquirer,100,49,3/9/2021
7A2A49,conference-participant,100,50,3/9/2021
7AF907,conference-participant,100,50,3/9/2021
7B1156,conference-participant,100,50,3/9/2021
7B6C88,award,100,58,3/9/2021
7C790D,conference-participant,100,50,3/9/2021
7F3A5F,note-sale,100,52,3/9/2021
810FAD,conference-participant,100,50,3/9/2021
848C0B,earnings,100,50,3/9/2021
863350,earnings,100,50,3/9/2021
873DB9,partnership,100,61,3/9/2021
89F693,award,100,58,3/9/2021
8BFAA4,executive-appointment,100,54,3/9/2021
8BFE9A,award,100,58,3/9/2021
8C84DF,executive-appointment,100,54,3/9/2021
8F3BCC,earnings,100,50,3/9/2021
9196A2,award,100,58,3/9/2021
91E5EE,conference-participant,100,50,3/9/2021
92D230,earnings,100,50,3/9/2021
94983E,partnership,100,61,3/9/2021
95C392,note-sale,100,52,3/9/2021
95C575,buybacks,100,74,3/9/2021
95DC1F,partnership,100,61,3/9/2021
95DC1F,partnership,100,61,3/9/2021
966ACE,earnings,100,50,3/9/2021
96BFF4,conference-call,100,50,3/9/2021
97B027,conference-participant,100,50,3/9/2021
97FE80,acquisition-acquirer,100,49,3/9/2021
98D33E,earnings,100,50,3/9/2021
990AD0,conference-organizer,100,57,3/9/2021
990AD0,conference-organizer,100,57,3/9/2021
990AD0,conference-organizer,100,57,3/9/2021
9BF177,earnings,100,50,3/9/2021
9C5BA5,partnership,100,61,3/9/2021
9F6B1A,award,100,58,3/9/2021
A16DEA,partnership,100,61,3/9/2021
A398B9,executive-appointment,100,54,3/9/2021
A48593,conference-participant,100,50,3/9/2021
A495F7,executive-appointment,100,54,3/9/2021
A4CD53,conference-participant,100,50,3/9/2021
A52B6B,partnership,100,61,3/9/2021
A6213D,partnership,100,61,3/9/2021
A74F6F,earnings,100,50,3/9/2021
A94637,product-price-raise,100,57,3/9/2021
ABB493,earnings,100,50,3/9/2021
AD23DE,acquisition-acquirer,100,49,3/9/2021
AD375D,conference-participant,100,50,3/9/2021
AD6141,executive-appointment,100,54,3/9/2021
AE79CD,conference-call,100,50,3/9/2021
AFEC35,conference-participant,100,50,3/9/2021
B01111,earnings,100,50,3/9/2021
B04426,public-offering,100,43,3/9/2021
B0998E,award,100,58,3/9/2021
B13B68,note-sale,100,52,3/9/2021
B2D492,stake-acquirer,100,48,3/9/2021
B2D492,earnings,100,50,3/9/2021
B5734D,conference-call,100,50,3/9/2021
B8A51F,earnings,100,50,3/9/2021
B8F71F,note-sale,100,52,3/9/2021
B96637,business-contract,100,69,3/9/2021
B98EFA,operating-earnings,100,50,3/9/2021
BBF349,note-sale,100,52,3/9/2021
BD8517,conference-participant,100,50,3/9/2021
BDCC11,note-sale,100,52,3/9/2021
BDF2BD,earnings,100,50,3/9/2021
BEA527,conference-participant,100,50,3/9/2021
C062D4,acquisition-completed-acquirer,100,49,3/9/2021
C062D4,product-release,100,64,3/9/2021
C06EB6,conference-participant,100,50,3/9/2021
C0BA36,conference-call,100,50,3/9/2021
C22BE8,conference-call,100,50,3/9/2021
C2DD02,earnings,100,50,3/9/2021
C490F9,drilling,100,68,3/9/2021
C99CC8,award,100,58,3/9/2021
CAB222,partnership,100,61,3/9/2021
CDC817,acquisition-completed-acquirer,100,49,3/9/2021
CE69E9,facility-open,100,65,3/9/2021
D11C1C,unit-acquisition-acquirer,100,49,3/9/2021
D1588D,earnings,100,50,3/9/2021
D1AE3B,executive-appointment,100,54,3/9/2021
D2E553,revenue-up,100,75,3/9/2021
D2E553,revenue-up,100,75,3/9/2021
D2E553,revenue-up,100,75,3/9/2021
D3FD6D,conference-participant,100,50,3/9/2021
D42DBA,earnings,100,50,3/9/2021
D57D99,award,100,58,3/9/2021
D58A11,conference-participant,100,50,3/9/2021
D6489C,fundraising,100,64,3/9/2021
D697DE,public-offering,100,43,3/9/2021
D75910,dividend-up,100,82,3/9/2021
DA48E4,conference-participant,100,50,3/9/2021
DA90E1,buybacks,100,74,3/9/2021
DB88A1,award,100,58,3/9/2021
DCD97F,government-contract,100,69,3/9/2021
DD682D,acquisition-acquiree,100,76,3/9/2021
DF16DE,conference-participant,100,50,3/9/2021
DF8855,partnership,100,61,3/9/2021
E0207A,executive-appointment,100,54,3/9/2021
E56A0D,conference-participant,100,50,3/9/2021
E70531,legal-issues-defendant,100,22,3/9/2021
E71AE6,conference-participant,100,50,3/9/2021
E96E0B,legal-issues-defendant,100,22,3/9/2021
EC99D0,partnership,100,61,3/9/2021
EFD406,conference-participant,100,50,3/9/2021
F02170,conference-participant,100,50,3/9/2021
F1EB39,earnings,100,50,3/9/2021
F209B4,conference-participant,100,50,3/9/2021
F3EDB4,earnings,100,50,3/9/2021
F48947,earnings,100,50,3/9/2021
F4E882,note-sale,100,52,3/9/2021
F4E882,note-sale,100,52,3/9/2021
F4E992,conference-participant,100,50,3/9/2021
F4FBD8,earnings,100,50,3/9/2021
F6E1B5,conference-participant,100,50,3/9/2021
FF6644,award,100,58,3/9/2021
FF6644,business-contract,100,69,3/9/2021
0157B1,partnership,100,61,3/10/2021
054B55,acquisition-completed-acquirer,100,49,3/10/2021
054B55,earnings,100,50,3/10/2021
06A456,earnings,100,50,3/10/2021
08A40F,business-combination,100,54,3/10/2021
0BD199,earnings,100,50,3/10/2021
0CADBC,earnings,100,50,3/10/2021
0EF1AF,legal-issues-defendant,100,22,3/10/2021
13C3E0,conference-participant,100,50,3/10/2021
147C38,executive-appointment,100,54,3/10/2021
14833D,earnings,100,50,3/10/2021
159AE4,conference-call,100,50,3/10/2021
15A388,investment-investor,100,55,3/10/2021
1748F6,earnings,100,50,3/10/2021
1748F6,business-contract,100,69,3/10/2021
1748F6,business-contract,100,69,3/10/2021
1782D5,legal-issues-defendant,100,22,3/10/2021
1921DD,acquisition-acquiree,100,76,3/10/2021
1921DD,acquisition-acquiree,100,76,3/10/2021
1A3E1B,fraud-defendant,100,20,3/10/2021
1A46A1,earnings,100,50,3/10/2021
1DEBBE,acquisition-acquirer,100,49,3/10/2021
1E83DE,earnings-up,100,68,3/10/2021
1F352C,conference-participant,100,50,3/10/2021
1F3CFB,conference-participant,100,50,3/10/2021
1FAF22,conference-participant,100,50,3/10/2021
21153F,executive-appointment,100,54,3/10/2021
21153F,executive-appointment,100,54,3/10/2021
232053,earnings,100,50,3/10/2021
241252,clinical-trials,100,56,3/10/2021
267718,partnership,100,61,3/10/2021
270305,award,100,58,3/10/2021
273BA3,earnings,100,50,3/10/2021
273BA3,acquisition-acquirer,100,49,3/10/2021
27A791,product-release,100,64,3/10/2021
292A70,earnings,100,50,3/10/2021
2B0AF4,executive-appointment,100,54,3/10/2021
2B8179,earnings,100,50,3/10/2021
2EC172,partnership,100,61,3/10/2021
2EC172,executive-appointment,100,54,3/10/2021
32C8CD,revenue-up,100,69,3/10/2021
371B0A,conference-participant,100,50,3/10/2021
3798B9,note-sale,100,52,3/10/2021
382EAE,stake-acquirer,100,48,3/10/2021
3AAEAE,clinical-trials,100,56,3/10/2021
3BBD10,product-release,100,64,3/10/2021
3BC360,public-offering,100,43,3/10/2021
408380,market-entry,100,57,3/10/2021
414FFF,conference-call,100,50,3/10/2021
43A060,earnings,100,50,3/10/2021
44740A,earnings,100,50,3/10/2021
449447,earnings,100,50,3/10/2021
450ECB,conference-participant,100,50,3/10/2021
453282,executive-appointment,100,54,3/10/2021
4.60E+06,earnings,100,50,3/10/2021
4A3438,legal-issues-defendant,100,22,3/10/2021
4B49CF,earnings,100,50,3/10/2021
4C3FE9,earnings,100,50,3/10/2021
4C92B9,acquisition-acquirer,100,49,3/10/2021
4C92B9,market-entry,100,57,3/10/2021
4C92B9,market-entry,100,57,3/10/2021
4D229C,earnings,100,50,3/10/2021
4DD203,earnings,100,50,3/10/2021
4E3D15,operating-earnings,100,50,3/10/2021
4EE14A,earnings,100,50,3/10/2021
4EE14A,earnings,100,50,3/10/2021
4FCC78,earnings,100,50,3/10/2021
4FCC78,earnings,100,50,3/10/2021
523039,conference-participant,100,50,3/10/2021
53A226,business-contract,100,69,3/10/2021
543900,earnings,100,50,3/10/2021
543C77,clinical-trials,100,56,3/10/2021
553949,conference-organizer,100,57,3/10/2021
5546DA,buybacks,100,74,3/10/2021
55D0F3,earnings,100,50,3/10/2021
586BD7,earnings,100,50,3/10/2021
58C2D4,fraud-defendant,100,20,3/10/2021
5B226B,legal-issues-defendant,100,22,3/10/2021
5B226B,legal-issues-defendant,100,22,3/10/2021
5BFE94,business-contract,100,69,3/10/2021
5BFE94,business-contract,100,69,3/10/2021
5C7601,executive-appointment,100,54,3/10/2021
5F3D91,executive-appointment,100,54,3/10/2021
605F40,note-sale,100,52,3/10/2021
615B6D,legal-issues-defendant,100,22,3/10/2021
619882,conference-organizer,100,57,3/10/2021
61B81B,conference-call,100,50,3/10/2021
6251A3,earnings,100,50,3/10/2021
636BBF,earnings,100,50,3/10/2021
66E04A,facility-open,100,65,3/10/2021
66E04A,facility-open,100,65,3/10/2021
6810DE,clinical-trials,100,56,3/10/2021
69CE71,dividend,100,50,3/10/2021
6A024C,clinical-trials,100,56,3/10/2021
6BBCBA,clinical-trials,100,56,3/10/2021
6BBD2D,clinical-trials,100,56,3/10/2021
6D156D,legal-issues-defendant,100,22,3/10/2021
6D156D,legal-issues-defendant,100,22,3/10/2021
70FCEF,award,100,58,3/10/2021
722D55,dividend,100,50,3/10/2021
7255D2,legal-issues-defendant,100,22,3/10/2021
7255D2,legal-issues-defendant,100,22,3/10/2021
7255D2,legal-issues-defendant,100,22,3/10/2021
7255D2,legal-issues-defendant,100,22,3/10/2021
72FCA3,earnings,100,50,3/10/2021
76959C,earnings,100,50,3/10/2021
76DD0C,clinical-trials,100,56,3/10/2021
78F9ED,partnership,100,61,3/10/2021
791D59,note-sale,100,52,3/10/2021
791D59,public-offering,100,43,3/10/2021
7A975D,earnings,100,50,3/10/2021
7BC92D,earnings,100,50,3/10/2021
7BEA98,public-offering,100,43,3/10/2021
7F3669,partnership,100,61,3/10/2021
7F3A5F,note-sale,100,52,3/10/2021
7FD8B9,conference-participant,100,50,3/10/2021
810FAD,dividend,100,50,3/10/2021
817ED9,donation,100,54,3/10/2021
818A2F,earnings,100,50,3/10/2021
818A2F,earnings,100,50,3/10/2021
83B1C8,executive-resignation,100,44,3/10/2021
83B1C8,executive-resignation,100,44,3/10/2021
83E0AC,conference-participant,100,50,3/10/2021
8665BA,product-release,100,64,3/10/2021
877734,earnings,100,50,3/10/2021
88936A,earnings,100,50,3/10/2021
895D56,business-contract,100,69,3/10/2021
896771,note-sale,100,52,3/10/2021
8A8E41,executive-appointment,100,54,3/10/2021
8A8E41,executive-appointment,100,54,3/10/2021
8B8656,earnings,100,50,3/10/2021
8C311A,product-release,100,64,3/10/2021
8D4486,acquisition-acquirer,100,49,3/10/2021
8FF2EF,executive-resignation,100,44,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
8FF57A,earnings,100,50,3/10/2021
911AB8,acquisition-acquirer,100,49,3/10/2021
911AB8,acquisition-acquirer,100,49,3/10/2021
913437,earnings,100,50,3/10/2021
92B625,conference-participant,100,50,3/10/2021
92D757,executive-appointment,100,54,3/10/2021
944B2E,earnings,100,50,3/10/2021
945DE6,dividend,100,50,3/10/2021
94A326,conference-participant,100,50,3/10/2021
9592FB,earnings,100,50,3/10/2021
95C392,award,100,58,3/10/2021
979451,acquisition-completed-acquirer,100,49,3/10/2021
9.86E+03,partnership,100,61,3/10/2021
98CEBB,public-offering,100,43,3/10/2021
990AD0,conference-organizer,100,57,3/10/2021
9C5BA5,revenues,100,50,3/10/2021
9D2790,debt-reduction,100,74,3/10/2021
9DDE1B,dividend-up,100,81,3/10/2021
9F5997,credit-extension-recipient,100,69,3/10/2021
A26C26,earnings,100,50,3/10/2021
A26EF7,earnings,100,50,3/10/2021
A2A9BA,earnings,100,50,3/10/2021
A3800A,earnings,100,50,3/10/2021
A3F598,executive-resignation,100,44,3/10/2021
A47F2E,earnings,100,50,3/10/2021
A4BCDE,board-meeting,100,51,3/10/2021
A5628C,business-combination,100,54,3/10/2021
A60354,executive-appointment,100,54,3/10/2021
A6828A,award,100,58,3/10/2021
A6FB29,earnings,100,50,3/10/2021
AE7D16,legal-issues-defendant,100,22,3/10/2021
AEF2C3,conference-participant,100,50,3/10/2021
AF93DE,earnings,100,50,3/10/2021
B04426,clinical-trials,100,56,3/10/2021
B076A1,dividend,100,50,3/10/2021
B3CB74,executive-appointment,100,54,3/10/2021
BCC13E,conference-participant,100,50,3/10/2021
BF5959,patent-awarded,100,72,3/10/2021
C4F9C6,earnings,100,50,3/10/2021
C58D71,clinical-trials,100,56,3/10/2021
C7FC95,business-contract,100,69,3/10/2021
C7FC95,business-contract,100,69,3/10/2021
C83B88,executive-appointment,100,54,3/10/2021
C8A248,conference-participant,100,50,3/10/2021
C9E04B,earnings,100,50,3/10/2021
C9E04B,executive-appointment,100,54,3/10/2021
CBCC6A,conference-organizer,100,57,3/10/2021
CBCC6A,conference-organizer,100,57,3/10/2021
CBDB4D,clinical-trials-start,100,64,3/10/2021
CDAF5B,dividend,100,50,3/10/2021
CE1002,conference-participant,100,50,3/10/2021
CFB6CA,earnings,100,50,3/10/2021
CFB6CA,earnings,100,50,3/10/2021
CFF15D,dividend-up,100,55,3/10/2021
D064D5,earnings,100,50,3/10/2021
D3CEDF,earnings,100,50,3/10/2021
D4C0CB,conference-participant,100,50,3/10/2021
D6489C,partnership,100,61,3/10/2021
D6489C,earnings,100,50,3/10/2021
D650A7,earnings,100,50,3/10/2021
D650A7,stock-splits,100,49,3/10/2021
D77F7E,business-contract,100,69,3/10/2021
D77F7E,business-contract,100,69,3/10/2021
D854F3,conference-participant,100,50,3/10/2021
D90441,earnings,100,50,3/10/2021
D90441,earnings,100,50,3/10/2021
D90441,earnings,100,50,3/10/2021
DBB28E,product-outage,100,36,3/10/2021
DD3BB1,partnership,100,61,3/10/2021
DE20DF,earnings,100,50,3/10/2021
DF16DE,earnings,100,50,3/10/2021
E09997,earnings,100,50,3/10/2021
E22FDE,conference-participant,100,50,3/10/2021
E6BC2C,conference-call,100,50,3/10/2021
E70531,legal-issues-defendant,100,22,3/10/2021
E96E0B,legal-issues-defendant,100,22,3/10/2021
E96E0B,legal-issues-defendant,100,22,3/10/2021
EA79C7,conference-participant,100,50,3/10/2021
EC4E82,conference-participant,100,50,3/10/2021
F48947,conference-participant,100,50,3/10/2021
F4E882,acquisition-acquiree,100,76,3/10/2021
F6581D,earnings,100,50,3/10/2021
F6E1B5,earnings,100,50,3/10/2021
FC1F9D,donation,100,54,3/10/2021
FD6926,conference-participant,100,50,3/10/2021
FF6644,stake-acquirer,100,48,3/10/2021
0157B1,facility-open,100,65,3/11/2021
03542C,earnings,100,50,3/11/2021
03C94A,drilling,100,68,3/11/2021
040DBB,dividend,100,50,3/11/2021
05D148,clinical-trials,100,56,3/11/2021
05D148,clinical-trials,100,56,3/11/2021
61366,acquisition-acquiree,100,76,3/11/2021
083F72,earnings,100,50,3/11/2021
96930,earnings,100,50,3/11/2021
0B73A7,earnings,100,50,3/11/2021
0B73A7,earnings,100,50,3/11/2021
0BC29E,executive-appointment,100,54,3/11/2021
0EF1AF,legal-issues-defendant,100,22,3/11/2021
0F2BC9,public-offering,100,43,3/11/2021
106394,dividend,100,50,3/11/2021
149301,dividend,100,50,3/11/2021
152AB9,earnings,100,50,3/11/2021
152AB9,earnings,100,50,3/11/2021
15789A,earnings,100,50,3/11/2021
17EDA5,dividend,100,50,3/11/2021
17EDA5,partnership,100,61,3/11/2021
190BE6,earnings,100,50,3/11/2021
1A1CB0,earnings,100,50,3/11/2021
1AD9CC,earnings,100,50,3/11/2021
1AE9D5,revenue-up,100,69,3/11/2021
1AE9D5,revenue-up,100,69,3/11/2021
1CD708,dividend,100,50,3/11/2021
1F43A1,dividend-up,100,81,3/11/2021
1F9258,earnings,100,50,3/11/2021
2082EA,conference-participant,100,50,3/11/2021
21153F,award,100,58,3/11/2021
21268E,earnings,100,50,3/11/2021
228D42,partnership,100,61,3/11/2021
251988,partnership,100,61,3/11/2021
253604,earnings,100,50,3/11/2021
26CC63,investment-investor,100,55,3/11/2021
26DC29,earnings,100,50,3/11/2021
2920D5,conference-participant,100,50,3/11/2021
301493,revenue-up,100,56,3/11/2021
301493,revenues,100,50,3/11/2021
301493,revenues,100,50,3/11/2021
301493,revenues,100,50,3/11/2021
301493,revenues,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
30CBF9,earnings,100,50,3/11/2021
32C8CD,executive-appointment,100,54,3/11/2021
3.30E+30,conference-participant,100,50,3/11/2021
39FB23,acquisition-regulatory-approval-acquirer,100,54,3/11/2021
3ACF46,earnings,100,50,3/11/2021
3ACF46,government-contract,100,69,3/11/2021
3C75D6,earnings,100,50,3/11/2021
3C75D6,earnings,100,50,3/11/2021
3C75D6,earnings,100,50,3/11/2021
3C75D6,earnings,100,50,3/11/2021
3CCC90,executive-appointment,100,54,3/11/2021
3E149C,partnership,100,61,3/11/2021
4.03E+05,partnership,100,61,3/11/2021
427F32,earnings,100,50,3/11/2021
42978B,executive-appointment,100,54,3/11/2021
42DC93,executive-appointment,100,54,3/11/2021
43A060,business-contract,100,69,3/11/2021
4A3438,legal-issues-defendant,100,22,3/11/2021
4BDCA7,clinical-trials,100,56,3/11/2021
4BF3D6,conference-participant,100,50,3/11/2021
4EE167,partnership,100,61,3/11/2021
4EEB00,public-offering,100,43,3/11/2021
5065B1,dividend,100,50,3/11/2021
5065B1,earnings,100,50,3/11/2021
51888A,unit-acquisition-acquirer,100,49,3/11/2021
54512F,earnings,100,50,3/11/2021
5.47E+28,earnings,100,50,3/11/2021
56277A,dividend,100,50,3/11/2021
567F3D,executive-appointment,100,54,3/11/2021
58CA9A,executive-resignation,100,44,3/11/2021
58CA9A,executive-resignation,100,44,3/11/2021
59872F,legal-issues-defendant,100,22,3/11/2021
5B226B,legal-issues-defendant,100,22,3/11/2021
5B51D6,conference-call,100,50,3/11/2021
5B51D6,clinical-trials,100,56,3/11/2021
5E9934,earnings-up,100,68,3/11/2021
615B6D,legal-issues-defendant,100,22,3/11/2021
6391C2,conference-participant,100,50,3/11/2021
639BD6,unit-acquisition-acquirer,100,49,3/11/2021
657097,unit-acquisition-acquirer,100,49,3/11/2021
6634D9,earnings,100,50,3/11/2021
6D156D,legal-issues-defendant,100,22,3/11/2021
6EA292,dividend,100,50,3/11/2021
6FCEF9,earnings,100,50,3/11/2021
705636,conference-participant,100,50,3/11/2021
71553E,executive-resignation,100,44,3/11/2021
71553E,earnings,100,50,3/11/2021
71B0CF,earnings,100,50,3/11/2021
7255D2,legal-issues-defendant,100,22,3/11/2021
728737,dividend,100,50,3/11/2021
728737,dividend,100,50,3/11/2021
756BB4,earnings,100,50,3/11/2021
756BB4,earnings,100,50,3/11/2021
76F067,conference-participant,100,50,3/11/2021
787D14,earnings,100,50,3/11/2021
7A0EC4,earnings,100,50,3/11/2021
7AB859,executive-appointment,100,54,3/11/2021
7AF5B8,fast-track-designation,100,81,3/11/2021
7BEA98,public-offering,100,43,3/11/2021
7E62B5,dividend,100,50,3/11/2021
7FEEE1,earnings,100,50,3/11/2021
804708,executive-appointment,100,54,3/11/2021
80B32C,partnership,100,61,3/11/2021
850779,award,100,58,3/11/2021
89FBB1,earnings,100,50,3/11/2021
8A8E41,partnership,100,61,3/11/2021
8A8E41,product-release,100,64,3/11/2021
8B1F37,dividend,100,50,3/11/2021
8BFAA4,earnings,100,50,3/11/2021
8D0EEA,business-contract,100,69,3/11/2021
8D0EEA,business-contract,100,69,3/11/2021
8E10BF,regulatory-product-application,100,69,3/11/2021
8E10BF,earnings,100,50,3/11/2021
9004C4,earnings-positive,100,69,3/11/2021
9004C4,earnings-up,100,68,3/11/2021
9004C4,earnings-up,100,68,3/11/2021
913437,conference-participant,100,50,3/11/2021
92D230,earnings,100,50,3/11/2021
92D757,partnership,100,61,3/11/2021
942633,dividend,100,50,3/11/2021
942633,dividend,100,50,3/11/2021
94637C,earnings,100,50,3/11/2021
947B0B,fast-track-designation,100,81,3/11/2021
94A326,earnings,100,50,3/11/2021
950CDB,revenue-up,100,69,3/11/2021
950CDB,revenue-up,100,69,3/11/2021
950CDB,revenue-up,100,69,3/11/2021
9546A5,earnings,100,50,3/11/2021
95C392,note-sale,100,52,3/11/2021
95DC1F,dividend,100,50,3/11/2021
990AD0,conference-organizer,100,57,3/11/2021
990AD0,conference-organizer,100,57,3/11/2021
990AD0,conference-organizer,100,57,3/11/2021
990AD0,conference-organizer,100,57,3/11/2021
990AD0,conference-organizer,100,57,3/11/2021
9C5BA5,dividend-up,100,81,3/11/2021
9D2790,partnership,100,61,3/11/2021
9D307D,earnings,100,50,3/11/2021
A017F4,earnings,100,50,3/11/2021
A28675,earnings,100,50,3/11/2021
A3AAA5,dividend,100,50,3/11/2021
A433A5,public-offering,100,43,3/11/2021
A43906,conference-participant,100,50,3/11/2021
A495F7,earnings,100,50,3/11/2021
A52533,earnings,100,50,3/11/2021
A5628C,legal-issues-defendant,100,22,3/11/2021
A5628C,acquisition-regulatory-scrutiny-acquiree,100,38,3/11/2021
A6FC89,earnings,100,50,3/11/2021
A80FE0,executive-appointment,100,54,3/11/2021
AA3AB8,earnings,100,50,3/11/2021
ABBAD1,partnership,100,61,3/11/2021
AC775C,conference-participant,100,50,3/11/2021
AC7C4F,buybacks,100,74,3/11/2021
ACC7D3,earnings,100,50,3/11/2021
AD22F2,dividend,100,50,3/11/2021
AE7D16,legal-issues-defendant,100,22,3/11/2021
AE7D16,legal-issues-defendant,100,22,3/11/2021
B01111,campaign-ad-release,100,59,3/11/2021
B01111,campaign-ad-release,100,59,3/11/2021
B01215,earnings,100,50,3/11/2021
B05000,earnings,100,50,3/11/2021
B05000,earnings,100,50,3/11/2021
B05000,earnings,100,50,3/11/2021
B106FA,earnings,100,50,3/11/2021
B1FC3B,dividend,100,50,3/11/2021
B37FB4,conference-participant,100,50,3/11/2021
B3ED62,revenue-up,100,72,3/11/2021
B3ED62,revenue-volume-up,100,69,3/11/2021
B3ED62,revenue-volume-up,100,69,3/11/2021
B3ED62,revenue-volume-up,100,69,3/11/2021
B48D6A,earnings,100,50,3/11/2021
B73395,earnings,100,50,3/11/2021
B73395,earnings,100,50,3/11/2021
B73395,earnings,100,50,3/11/2021
B73395,earnings,100,50,3/11/2021
B9B6B8,earnings,100,50,3/11/2021
BB88B6,product-release,100,64,3/11/2021
BB88B6,product-release,100,64,3/11/2021
BB88B6,product-release,100,64,3/11/2021
C0030A,note-sale,100,52,3/11/2021
C0030A,note-sale,100,52,3/11/2021
C38440,conference-participant,100,50,3/11/2021
C3F99F,patient-enrollment-complete,100,64,3/11/2021
C3F99F,patient-enrollment-complete,100,64,3/11/2021
C4A241,facility-open,100,65,3/11/2021
C74887,earnings,100,50,3/11/2021
C9881C,partnership,100,61,3/11/2021
CB6A9C,partnership,100,61,3/11/2021
CBBFBF,executive-appointment,100,54,3/11/2021
CBCC6A,conference-organizer,100,57,3/11/2021
CCB623,earnings,100,50,3/11/2021
CD4DA8,conference-organizer,100,57,3/11/2021
CE2791,dividend,100,50,3/11/2021
CF3FF9,conference-participant,100,50,3/11/2021
CF7292,executive-appointment,100,54,3/11/2021
CF7292,earnings,100,50,3/11/2021
CFD4B6,earnings,100,50,3/11/2021
CFF97C,merger,100,66,3/11/2021
D4AC65,partnership,100,61,3/11/2021
D6144F,conference-participant,100,50,3/11/2021
D622D5,operating-earnings,100,50,3/11/2021
D6489C,revenue-up,100,69,3/11/2021
D6489C,revenue-up,100,69,3/11/2021
D6489C,revenue-up,100,69,3/11/2021
D854DD,unit-acquisition-acquiree,100,76,3/11/2021
D854F3,dividend-up,100,59,3/11/2021
D8760C,executive-appointment,100,54,3/11/2021
D9E036,business-contract,100,69,3/11/2021
DB06B0,business-contract,100,69,3/11/2021
DC6EF3,executive-resignation,100,44,3/11/2021
DD0F15,earnings,100,50,3/11/2021
DF5F14,earnings,100,50,3/11/2021
E15736,acquisition-interest-acquirer,100,46,3/11/2021
E3A829,earnings,100,50,3/11/2021
E4CE73,partnership,100,61,3/11/2021
E5A3B6,earnings,100,50,3/11/2021
E70531,legal-issues-defendant,100,22,3/11/2021
E82A2D,earnings,100,50,3/11/2021
E8B21D,acquisition-completed-acquirer,100,49,3/11/2021
E8B21D,unit-acquisition-acquirer,100,49,3/11/2021
E96E0B,acquisition-acquiree,100,76,3/11/2021
E96E0B,legal-issues-defendant,100,22,3/11/2021
EA4E68,dividend,100,50,3/11/2021
EA79C7,earnings,100,50,3/11/2021
EB6965,executive-appointment,100,54,3/11/2021
EB6965,dividend-up,100,81,3/11/2021
ECA300,earnings,100,50,3/11/2021
EEA6B3,trading-halt,100,43,3/11/2021
EEA6B3,trading-resumed,100,58,3/11/2021
EF5914,earnings,100,50,3/11/2021
F2BC3D,executive-appointment,100,54,3/11/2021
F2BC3D,earnings,100,50,3/11/2021
F3816D,earnings,100,50,3/11/2021
F3FCC3,note-sale,100,52,3/11/2021
F48947,executive-appointment,100,54,3/11/2021
F4CDA3,conference-participant,100,50,3/11/2021
F569FD,earnings,100,50,3/11/2021
F5D410,executive-appointment,100,54,3/11/2021
F5D499,earnings,100,50,3/11/2021
F6DCE4,dividend,100,50,3/11/2021
F72E4B,earnings,100,50,3/11/2021
FA918D,executive-resignation,100,44,3/11/2021
FC1736,revenue-up,100,69,3/11/2021
FC1736,earnings,100,50,3/11/2021
FC1736,earnings,100,50,3/11/2021
FDF799,executive-appointment,100,54,3/11/2021
FE9C0D,earnings,100,50,3/11/2021
FF227B,executive-appointment,100,54,3/11/2021
0919B1,earnings,100,50,3/12/2021
0BD4E8,dividend,100,50,3/12/2021
0EF1AF,legal-issues-defendant,100,22,3/12/2021
15A388,conference-participant,100,50,3/12/2021
16B183,legal-issues-defendant,100,22,3/12/2021
1782D5,legal-issues-defendant,100,22,3/12/2021
1A3E1B,conference-call,100,50,3/12/2021
1AB023,earnings,100,50,3/12/2021
1AB023,earnings,100,50,3/12/2021
1AB023,earnings,100,50,3/12/2021
1AC649,clinical-trials-start,100,64,3/12/2021
1AC649,clinical-trials-start,100,64,3/12/2021
1AC649,clinical-trials-start,100,64,3/12/2021
24CB56,investment-investor,100,55,3/12/2021
250BEE,earnings,100,50,3/12/2021
250BEE,earnings,100,50,3/12/2021
250BEE,earnings,100,50,3/12/2021
282C18,dividend,100,50,3/12/2021
2BC05E,executive-appointment,100,54,3/12/2021
2CC71C,conference-participant,100,50,3/12/2021
2E902B,dividend,100,50,3/12/2021
2EBA55,dividend,100,50,3/12/2021
2EBC0B,dividend,100,50,3/12/2021
3587B4,unit-acquisition-acquiree,100,76,3/12/2021
3587B4,unit-acquisition-acquiree,100,76,3/12/2021
3587B4,unit-acquisition-acquiree,100,76,3/12/2021
3798B9,note-sale,100,52,3/12/2021
37B618,dividend,100,50,3/12/2021
37B618,earnings,100,50,3/12/2021
38FB49,dividend,100,50,3/12/2021
3ED92D,note-sale,100,52,3/12/2021
4A3438,legal-issues-defendant,100,22,3/12/2021
4B49CF,conference-call,100,50,3/12/2021
4C31F3,conference-call,100,50,3/12/2021
4C3FE9,earnings,100,50,3/12/2021
4DAF5F,buybacks,100,74,3/12/2021
4DAF5F,buybacks,100,74,3/12/2021
4E2D94,earnings-guidance,100,50,3/12/2021
4EEB00,public-offering,100,43,3/12/2021
504FE2,legal-issues-defendant,100,22,3/12/2021
504FE2,fraud-defendant,100,20,3/12/2021
50D1EC,acquisition-interest-acquirer,100,46,3/12/2021
550D01,facility-open,100,65,3/12/2021
58B46F,board-meeting,100,51,3/12/2021
58B46F,legal-issues-defendant,100,22,3/12/2021
5B226B,legal-issues-defendant,100,22,3/12/2021
5F3D91,partnership,100,61,3/12/2021
5F3D91,partnership,100,61,3/12/2021
615B6D,legal-issues-defendant,100,22,3/12/2021
619882,conference-organizer,100,57,3/12/2021
619882,conference-organizer,100,57,3/12/2021
67303E,legal-issues-defendant,100,22,3/12/2021
6D156D,legal-issues-defendant,100,22,3/12/2021
6D156D,fraud-defendant,100,20,3/12/2021
6D3B7B,dividend,100,50,3/12/2021
6F3FA8,note-sale,100,52,3/12/2021
6F3FA8,public-offering,100,43,3/12/2021
7255D2,fraud-defendant,100,20,3/12/2021
7255D2,legal-issues-defendant,100,22,3/12/2021
72FCA3,market-entry,100,57,3/12/2021
7B9212,earnings,100,50,3/12/2021
7F7464,earnings,100,50,3/12/2021
819492,earnings,100,50,3/12/2021
826FD6,dividend,100,50,3/12/2021
94637C,partnership,100,61,3/12/2021
950CDB,executive-appointment,100,54,3/12/2021
968B00,executive-appointment,100,54,3/12/2021
989E2F,buybacks,100,74,3/12/2021
990AD0,conference-organizer,100,57,3/12/2021
990AD0,conference-organizer,100,57,3/12/2021
990AD0,conference-organizer,100,57,3/12/2021
990AD0,dividend,100,50,3/12/2021
9D5D35,trading-resumed,100,58,3/12/2021
A1EAC8,business-contract,100,69,3/12/2021
A21649,dividend,100,50,3/12/2021
A47A7D,conference-participant,100,50,3/12/2021
A4BCDE,dividend-up,100,81,3/12/2021
A6FE1C,unit-acquisition-acquirer,100,49,3/12/2021
AC7C4F,buybacks,100,74,3/12/2021
AE4125,conference-participant,100,50,3/12/2021
AE7D16,legal-issues-defendant,100,22,3/12/2021
B01111,partnership,100,61,3/12/2021
B04426,public-offering,100,43,3/12/2021
B72D2E,earnings,100,50,3/12/2021
B762D3,dividend,100,50,3/12/2021
B98EFA,conference-participant,100,50,3/12/2021
BBBB41,conference-participant,100,50,3/12/2021
BF5959,conference-participant,100,50,3/12/2021
C0BA36,acquisition-acquirer,100,49,3/12/2021
C356AC,executive-appointment,100,54,3/12/2021
C501B6,earnings,100,50,3/12/2021
C9E107,earnings,100,50,3/12/2021
CF3FF9,earnings,100,50,3/12/2021
D1C26F,business-contract,100,69,3/12/2021
D63B0F,dividend,100,50,3/12/2021
DA0CB8,dividend,100,50,3/12/2021
E70531,legal-issues-defendant,100,22,3/12/2021
E8D221,earnings,100,50,3/12/2021
E96E0B,legal-issues-defendant,100,22,3/12/2021
E96E0B,legal-issues-defendant,100,22,3/12/2021
E96E0B,legal-issues-defendant,100,22,3/12/2021
EBC84C,conference-participant,100,50,3/12/2021
EEA734,legal-issues-defendant,100,22,3/12/2021
F9AA02,clinical-trials,100,56,3/12/2021
18D9FA,fraud-defendant,100,20,3/13/2021
18D9FA,legal-issues-defendant,100,22,3/13/2021
18D9FA,legal-issues-defendant,100,22,3/13/2021
18D9FA,fraud-defendant,100,20,3/13/2021
1E04A5,legal-issues-defendant,100,22,3/13/2021
34A959,index-listing,100,76,3/13/2021
3ED92D,note-sale,100,52,3/13/2021
504FE2,fraud-defendant,100,20,3/13/2021
504FE2,legal-issues-defendant,100,22,3/13/2021
7255D2,legal-issues-defendant,100,22,3/13/2021
A5628C,legal-issues-defendant,100,22,3/13/2021
DF204B,facility-open,100,65,3/13/2021
E96E0B,legal-issues-defendant,100,22,3/13/2021
18D9FA,legal-issues-defendant,100,22,3/14/2021
202E5A,legal-issues-defendant,100,22,3/14/2021
4A3438,legal-issues-defendant,100,22,3/14/2021
4E2D94,earnings-guidance,100,50,3/14/2021
6D156D,legal-issues-defendant,100,22,3/14/2021
7CD98F,legal-issues-defendant,100,22,3/14/2021
9934AD,legal-issues-defendant,100,22,3/14/2021
A63387,legal-issues-defendant,100,22,3/14/2021
D57D99,legal-issues-defendant,100,22,3/14/2021
E96E0B,legal-issues-defendant,100,22,3/14/2021
9397,credit-extension-recipient,100,69,3/15/2021
00D6B5,note-sale,100,52,3/15/2021
01D03F,merger,100,66,3/15/2021
01D03F,merger-completed,100,66,3/15/2021
03542C,dividend,100,50,3/15/2021
061A3B,product-price-raise,100,57,3/15/2021
68396,dividend,100,50,3/15/2021
0C6293,earnings,100,50,3/15/2021
0C6293,earnings,100,50,3/15/2021
0C6293,earnings,100,50,3/15/2021
0C6293,earnings,100,50,3/15/2021
0CC01F,dividend,100,50,3/15/2021
0CE204,conference-participant,100,50,3/15/2021
0E5223,note-sale,100,52,3/15/2021
0E5619,earnings,100,50,3/15/2021
0EF1AF,legal-issues-defendant,100,22,3/15/2021
0F2BC9,public-offering,100,43,3/15/2021
10943B,executive-appointment,100,54,3/15/2021
10AE08,executive-appointment,100,54,3/15/2021
12E454,business-contract,100,69,3/15/2021
133644,executive-appointment,100,54,3/15/2021
138DDE,board-meeting,100,51,3/15/2021
14BA33,conference-participant,100,50,3/15/2021
152AB9,public-offering,100,43,3/15/2021
16FC89,earnings,100,50,3/15/2021
1782D5,legal-issues-defendant,100,22,3/15/2021
1880C5,earnings,100,50,3/15/2021
18D9FA,legal-issues-defendant,100,22,3/15/2021
1CD4B5,clinical-trials,100,56,3/15/2021
1EBF8D,business-contract,100,69,3/15/2021
1EBF8D,business-contract,100,69,3/15/2021
20403D,earnings,100,50,3/15/2021
2158DF,executive-appointment,100,54,3/15/2021
228D42,partnership,100,61,3/15/2021
228D42,partnership,100,61,3/15/2021
228D42,partnership,100,61,3/15/2021
26F99F,earnings,100,50,3/15/2021
2720AB,dividend,100,50,3/15/2021
28F905,executive-appointment,100,54,3/15/2021
37B120,earnings,100,50,3/15/2021
385DD4,executive-appointment,100,54,3/15/2021
39D9DA,earnings,100,50,3/15/2021
3BA1BF,executive-appointment,100,54,3/15/2021
3BB7D3,earnings,100,50,3/15/2021
3C6CCC,executive-appointment,100,54,3/15/2021
3D6933,pretax-earnings-positive,100,69,3/15/2021
3E149C,executive-resignation,100,44,3/15/2021
3FACA7,conference-participant,100,50,3/15/2021
429BFB,merger,100,66,3/15/2021
429BFB,legal-issues-defendant,100,22,3/15/2021
4806CE,acquisition-acquirer,100,49,3/15/2021
4A3438,legal-issues-defendant,100,22,3/15/2021
4A6F00,partnership,100,61,3/15/2021
4A6F00,partnership,100,61,3/15/2021
4E6F5A,executive-appointment,100,54,3/15/2021
4EEB00,conference-participant,100,50,3/15/2021
504FE2,legal-issues-defendant,100,22,3/15/2021
50D1EC,acquisition-completed-acquirer,100,49,3/15/2021
539F49,earnings,100,50,3/15/2021
53A226,executive-appointment,100,54,3/15/2021
5675EB,dividend,100,50,3/15/2021
5704AC,dividend,100,50,3/15/2021
58C2D4,legal-issues-defendant,100,22,3/15/2021
58CA9A,earnings,100,50,3/15/2021
596116,conference-participant,100,50,3/15/2021
5A0FF1,note-sale,100,52,3/15/2021
5B226B,legal-issues-defendant,100,22,3/15/2021
5B226B,legal-issues-defendant,100,22,3/15/2021
5D16CF,acquisition-completed-acquirer,100,49,3/15/2021
5D41E4,earnings,100,50,3/15/2021
5FE4B6,conference-participant,100,50,3/15/2021
615B6D,legal-issues-defendant,100,22,3/15/2021
6166D1,conference-call,100,50,3/15/2021
616E3B,executive-appointment,100,54,3/15/2021
619882,conference-organizer,100,57,3/15/2021
619882,dividend,100,50,3/15/2021
620381,clinical-trials,100,56,3/15/2021
622DBE,partnership,100,61,3/15/2021
657097,dividend,100,50,3/15/2021
66A667,earnings,100,50,3/15/2021
67303E,legal-issues-defendant,100,22,3/15/2021
6CF43C,dividend,100,50,3/15/2021
6D156D,legal-issues-defendant,100,22,3/15/2021
6DC1D7,dividend-up,100,70,3/15/2021
705636,earnings,100,50,3/15/2021
70CA28,conference-participant,100,50,3/15/2021
713810,legal-issues-defendant,100,22,3/15/2021
7255D2,legal-issues-defendant,100,22,3/15/2021
7255D2,legal-issues-defendant,100,22,3/15/2021
73F70F,conference-participant,100,50,3/15/2021
76DD0C,clinical-trials,100,56,3/15/2021
76DD0C,public-offering,100,43,3/15/2021
7710F3,executive-resignation,100,44,3/15/2021
7732C2,earnings,100,50,3/15/2021
79167B,note-sale,100,52,3/15/2021
79167B,note-sale,100,52,3/15/2021
7BEA98,public-offering,100,43,3/15/2021
7DD8CC,dividend,100,50,3/15/2021
7FDE1C,business-contract,100,69,3/15/2021
8.10E+32,executive-appointment,100,54,3/15/2021
8303CD,partnership,100,61,3/15/2021
838ADD,conference-participant,100,50,3/15/2021
83A065,dividend,100,50,3/15/2021
84A6B9,dividend,100,50,3/15/2021
877734,conference-participant,100,50,3/15/2021
8.79E+06,earnings,100,50,3/15/2021
8C84DF,executive-resignation,100,44,3/15/2021
8E3F58,government-contract,100,69,3/15/2021
8EEA28,dividend,100,50,3/15/2021
9087B9,public-offering,100,43,3/15/2021
915E7B,executive-appointment,100,54,3/15/2021
957A07,executive-appointment,100,54,3/15/2021
96F126,business-contract,100,69,3/15/2021
981656,executive-appointment,100,54,3/15/2021
98CEBB,government-contract,100,69,3/15/2021
990AD0,conference-organizer,100,57,3/15/2021
990AD0,conference-organizer,100,57,3/15/2021
990AD0,conference-organizer,100,57,3/15/2021
9EA947,conference-participant,100,50,3/15/2021
9EBAFA,unit-acquisition-acquirer,100,49,3/15/2021
9FD2D9,public-offering,100,43,3/15/2021
A01983,dividend,100,50,3/15/2021
A247F5,product-release,100,64,3/15/2021
A247F5,buybacks,100,74,3/15/2021
A3800A,executive-appointment,100,54,3/15/2021
A3800A,executive-appointment,100,54,3/15/2021
A433A5,public-offering,100,43,3/15/2021
A6213D,executive-appointment,100,54,3/15/2021
A6828A,product-release,100,64,3/15/2021
A80FE0,business-contract,100,69,3/15/2021
A871B0,merger-regulatory-approval,100,81,3/15/2021
A871B0,earnings,100,50,3/15/2021
A871B0,acquisition-acquiree,100,76,3/15/2021
AA1EAA,dividend,100,50,3/15/2021
ACDCFA,operating-earnings,100,50,3/15/2021
AD1ACF,conference-organizer,100,57,3/15/2021
ADFB3A,earnings,100,50,3/15/2021
AE7D16,legal-issues-defendant,100,22,3/15/2021
AED61E,earnings,100,50,3/15/2021
B1DF3C,note-sale,100,52,3/15/2021
B33E77,executive-appointment,100,54,3/15/2021
B381D8,clinical-trials-start,100,64,3/15/2021
B4C673,credit-extension-recipient,100,69,3/15/2021
B73395,ipo-considered,100,60,3/15/2021
B7FA9B,public-offering,100,43,3/15/2021
B9CD50,note-sale,100,52,3/15/2021
BC948D,dividend,100,50,3/15/2021
C05839,merger-regulatory-approval,100,81,3/15/2021
C05839,acquisition-acquirer,100,49,3/15/2021
C05839,conference-participant,100,50,3/15/2021
C27E19,dividend,100,50,3/15/2021
C29E71,executive-appointment,100,54,3/15/2021
C45CE7,unit-acquisition-completed-acquirer,100,49,3/15/2021
C4F9C6,conference-participant,100,50,3/15/2021
C941DC,acquisition-completed-acquirer,100,49,3/15/2021
C99CC8,award,100,58,3/15/2021
CBFFDD,trading-halt,100,43,3/15/2021
CD06A2,earnings,100,50,3/15/2021
CE1002,executive-appointment,100,54,3/15/2021
D11C1C,dividend-up,100,81,3/15/2021
D139BC,dividend,100,50,3/15/2021
D3FA2C,dividend,100,50,3/15/2021
D437C3,conference-participant,100,50,3/15/2021
D6144F,earnings,100,50,3/15/2021
D721C6,partnership,100,61,3/15/2021
D75910,partnership,100,61,3/15/2021
D77F7E,partnership,100,61,3/15/2021
D77F7E,partnership,100,61,3/15/2021
D9164D,dividend,100,50,3/15/2021
DBCA3F,credit-extension-provider,100,57,3/15/2021
DBCA3F,credit-extension-provider,100,57,3/15/2021
DD1BA1,business-contract,100,69,3/15/2021
DF46C5,donation,100,54,3/15/2021
E06265,conference-call,100,50,3/15/2021
E09556,earnings,100,50,3/15/2021
E261E9,conference-participant,100,50,3/15/2021
E28D9C,conference-participant,100,50,3/15/2021
E3A829,conference-participant,100,50,3/15/2021
E6A53A,supply-guidance-increase,100,74,3/15/2021
E70531,legal-issues-defendant,100,22,3/15/2021
E71AE6,earnings,100,50,3/15/2021
E96E0B,legal-issues-defendant,100,22,3/15/2021
E96E0B,legal-issues-defendant,100,22,3/15/2021
ECD263,earnings,100,50,3/15/2021
ECE19E,earnings,100,50,3/15/2021
ECF4F8,acquisition-regulatory-scrutiny-acquiree,100,38,3/15/2021
ECF4F8,legal-issues-defendant,100,22,3/15/2021
ED1A74,executive-appointment,100,54,3/15/2021
ED7F13,dividend,100,50,3/15/2021
ED8676,executive-resignation,100,44,3/15/2021
F00285,earnings,100,50,3/15/2021
F294DD,dividend-up,100,81,3/15/2021
F3016C,note-sale,100,52,3/15/2021
F5D059,earnings,100,50,3/15/2021
F5D410,partnership,100,61,3/15/2021
F5D410,partnership,100,61,3/15/2021
F6E248,business-contract,100,69,3/15/2021
F6E248,business-contract,100,69,3/15/2021
F6E248,partnership,100,61,3/15/2021
F748C7,product-release,100,64,3/15/2021
F7935D,legal-issues-defendant,100,22,3/15/2021
F80389,dividend,100,50,3/15/2021
00E601,note-sale,100,52,3/16/2021
01D03F,regulatory-product-approval-granted,100,81,3/16/2021
06C826,conference-participant,100,50,3/16/2021
070B45,award,100,58,3/16/2021
71860,partnership,100,61,3/16/2021
09F623,conference-participant,100,50,3/16/2021
0A77DB,earnings,100,50,3/16/2021
0AAD90,earnings,100,50,3/16/2021
0BF528,executive-appointment,100,54,3/16/2021
0C8D82,business-contract,100,69,3/16/2021
0CCCB7,conference-participant,100,50,3/16/2021
0DC050,partnership,100,61,3/16/2021
0E3436,earnings,100,50,3/16/2021
0E3436,earnings,100,50,3/16/2021
0E64D4,unit-acquisition-acquiree,100,76,3/16/2021
0EF1AF,executive-appointment,100,54,3/16/2021
0EF1AF,legal-issues-defendant,100,22,3/16/2021
0FC848,earnings,100,50,3/16/2021
108A2B,dividend,100,50,3/16/2021
1096C6,acquisition-acquirer,100,49,3/16/2021
139303,conference-organizer,100,57,3/16/2021
139303,conference-organizer,100,57,3/16/2021
152AB9,public-offering,100,43,3/16/2021
157CC1,earnings,100,50,3/16/2021
168A5D,partnership,100,61,3/16/2021
1782D5,legal-issues-defendant,100,22,3/16/2021
184988,patient-enrollment-start,100,58,3/16/2021
18D9FA,legal-issues-defendant,100,22,3/16/2021
1B5FEA,earnings,100,50,3/16/2021
1B637E,partnership,100,61,3/16/2021
1E9A6D,award,100,58,3/16/2021
1EBF8D,partnership,100,61,3/16/2021
1EBF8D,partnership,100,61,3/16/2021
1EC3E8,facility-open,100,65,3/16/2021
1EC3E8,facility-open,100,65,3/16/2021
228D42,partnership,100,61,3/16/2021
228D42,partnership,100,61,3/16/2021
228D42,dividend,100,50,3/16/2021
25102A,product-release,100,64,3/16/2021
253604,executive-appointment,100,54,3/16/2021
25DD05,dividend,100,50,3/16/2021
26CC63,earnings,100,50,3/16/2021
26CC63,earnings,100,50,3/16/2021
26CC63,earnings,100,50,3/16/2021
284289,acquisition-acquirer,100,49,3/16/2021
28B730,investment-investor,100,55,3/16/2021
2920D5,conference-participant,100,50,3/16/2021
2E0445,earnings,100,50,3/16/2021
2E0496,acquisition-acquirer,100,49,3/16/2021
2EB04E,partnership,100,61,3/16/2021
2F960F,public-offering,100,43,3/16/2021
3.14E+47,dividend,100,50,3/16/2021
31803E,executive-resignation,100,44,3/16/2021
31AA84,dividend,100,50,3/16/2021
33FD66,stake-acquirer,100,48,3/16/2021
3461CF,award,100,58,3/16/2021
355B19,conference-participant,100,50,3/16/2021
385DD4,market-entry,100,57,3/16/2021
3DED49,executive-appointment,100,54,3/16/2021
442587,partnership,100,61,3/16/2021
442587,partnership,100,61,3/16/2021
499C75,earnings,100,50,3/16/2021
4C31F3,earnings,100,50,3/16/2021
4C3FE9,earnings,100,50,3/16/2021
4EEB00,public-offering,100,43,3/16/2021
504FE2,legal-issues-defendant,100,22,3/16/2021
51D876,note-sale,100,52,3/16/2021
5288FC,earnings,100,50,3/16/2021
54DF47,dividend,100,50,3/16/2021
556F08,earnings,100,50,3/16/2021
57DDB9,public-offering,100,43,3/16/2021
58C2D4,legal-issues-defendant,100,22,3/16/2021
58C2D4,public-offering,100,43,3/16/2021
58EA22,earnings,100,50,3/16/2021
59872F,legal-issues-defendant,100,22,3/16/2021
5A0FF1,note-sale,100,52,3/16/2021
5B226B,legal-issues-defendant,100,22,3/16/2021
5B97B2,dividend,100,50,3/16/2021
5BC2F4,earnings,100,50,3/16/2021
5F2FF7,partnership,100,61,3/16/2021
5F3D91,earnings,100,50,3/16/2021
6166D1,dividend,100,50,3/16/2021
619882,dividend,100,50,3/16/2021
62CDDE,public-offering,100,43,3/16/2021
665618,acquisition-acquirer,100,49,3/16/2021
66ECFD,earnings,100,50,3/16/2021
68AB62,conference-participant,100,50,3/16/2021
69345C,product-release,100,64,3/16/2021
6D0CAB,product-release,100,64,3/16/2021
6D156D,legal-issues-defendant,100,22,3/16/2021
6DBBBC,donation,100,54,3/16/2021
6DBBBC,investment-investor,100,55,3/16/2021
6ED519,dividend,100,50,3/16/2021
70B3D6,conference-call,100,50,3/16/2021
713810,executive-appointment,100,54,3/16/2021
713810,legal-issues-defendant,100,22,3/16/2021
722DE3,business-contract,100,69,3/16/2021
7255D2,legal-issues-defendant,100,22,3/16/2021
7255D2,legal-issues-defendant,100,22,3/16/2021
7255D2,legal-issues-defendant,100,22,3/16/2021
7255D2,earnings-revision,100,29,3/16/2021
765913,donation,100,54,3/16/2021
76D79A,conference-call,100,50,3/16/2021
78F776,earnings,100,50,3/16/2021
7A5097,award,100,58,3/16/2021
7B1E50,dividend,100,50,3/16/2021
7B1E50,business-contract,100,69,3/16/2021
7B1E50,business-contract,100,69,3/16/2021
7E1D5D,business-contract,100,69,3/16/2021
7E3390,public-offering,100,43,3/16/2021
7F3669,executive-appointment,100,54,3/16/2021
86A1B9,executive-appointment,100,54,3/16/2021
86A1B9,executive-appointment,100,54,3/16/2021
877734,conference-participant,100,50,3/16/2021
87B81A,acquisition-acquirer,100,49,3/16/2021
8C6C1B,executive-appointment,100,54,3/16/2021
900356,note-sale,100,52,3/16/2021
9043FE,conference-participant,100,50,3/16/2021
9043FE,conference-participant,100,50,3/16/2021
913437,earnings,100,50,3/16/2021
91C82E,earnings-per-share-positive,100,69,3/16/2021
91C82E,earnings-per-share-positive,100,69,3/16/2021
91C82E,earnings-per-share-positive,100,69,3/16/2021
93D207,executive-appointment,100,54,3/16/2021
9470CC,executive-appointment,100,54,3/16/2021
96BFF4,earnings,100,50,3/16/2021
96BFF4,earnings,100,50,3/16/2021
96BFF4,earnings,100,50,3/16/2021
97693A,conference-call,100,50,3/16/2021
986AF6,earnings-guidance-up,100,83,3/16/2021
9CF9B1,executive-appointment,100,54,3/16/2021
9FF5F1,partnership,100,61,3/16/2021
A11CF4,business-contract,100,69,3/16/2021
A16DEA,award,100,58,3/16/2021
A28675,earnings,100,50,3/16/2021
A5DD24,conference-participant,100,50,3/16/2021
A790A5,conference-participant,100,50,3/16/2021
A868C9,business-contract,100,69,3/16/2021
A9ED24,dividend,100,50,3/16/2021
AB4A7E,conference-participant,100,50,3/16/2021
AD22F2,earnings,100,50,3/16/2021
AEEB76,earnings,100,50,3/16/2021
B4B281,earnings,100,50,3/16/2021
B5734D,earnings,100,50,3/16/2021
B60366,executive-appointment,100,54,3/16/2021
BB02FB,executive-appointment,100,54,3/16/2021
BB5271,partnership,100,61,3/16/2021
C16A8F,earnings-guidance,100,50,3/16/2021
C16A8F,earnings-guidance,100,50,3/16/2021
C2F597,partnership,100,61,3/16/2021
C48574,revenue-up,100,74,3/16/2021
C48574,revenue-up,100,74,3/16/2021
C48574,revenue-up,100,74,3/16/2021
C48574,revenue-up,100,74,3/16/2021
C48574,revenue-up,100,74,3/16/2021
C48574,revenue-up,100,74,3/16/2021
C8257F,executive-appointment,100,54,3/16/2021
C83B88,facility-open,100,65,3/16/2021
C85A72,partnership,100,61,3/16/2021
C85A72,partnership,100,61,3/16/2021
C9881C,conference-call,100,50,3/16/2021
C9B932,legal-issues-defendant,100,22,3/16/2021
CBCC6A,conference-organizer,100,57,3/16/2021
CBFFDD,trading-resumed,100,58,3/16/2021
CDC217,earnings,100,50,3/16/2021
CFF15D,acquisition-completed-acquirer,100,49,3/16/2021
CFF97C,conference-participant,100,50,3/16/2021
D08D2C,conference-call,100,50,3/16/2021
D17F7E,legal-issues-defendant,100,22,3/16/2021
D6489C,partnership,100,61,3/16/2021
D6EAA3,partnership,100,61,3/16/2021
D7AC6E,dividend-up,100,81,3/16/2021
D88EF3,product-release,100,64,3/16/2021
D90F43,business-contract,100,69,3/16/2021
DB396B,dividend,100,50,3/16/2021
DB9829,dividend,100,50,3/16/2021
DBCA3F,partnership,100,61,3/16/2021
DD1BA1,partnership,100,61,3/16/2021
E00373,unit-acquisition-acquirer,100,49,3/16/2021
E00373,unit-acquisition-acquirer,100,49,3/16/2021
E06265,earnings,100,50,3/16/2021
E1BD05,conference-participant,100,50,3/16/2021
E22FDE,partnership,100,61,3/16/2021
E30A8F,product-release,100,64,3/16/2021
E3A829,executive-appointment,100,54,3/16/2021
E6BC2C,earnings,100,50,3/16/2021
E6BC2C,earnings,100,50,3/16/2021
E6D89E,business-contract,100,69,3/16/2021
E6D89E,business-contract,100,69,3/16/2021
E70531,legal-issues-defendant,100,22,3/16/2021
E8E899,unit-acquisition-acquiree,100,76,3/16/2021
E96E0B,legal-issues-defendant,100,22,3/16/2021
EB7D6C,earnings,100,50,3/16/2021
EBD89A,award,100,58,3/16/2021
ECE19E,executive-appointment,100,54,3/16/2021
ED22DC,earnings,100,50,3/16/2021
EF45B6,product-release,100,64,3/16/2021
F1529C,conference-call,100,50,3/16/2021
F209B4,conference-participant,100,50,3/16/2021
F3D2EB,dividend,100,50,3/16/2021
F702CA,business-contract,100,69,3/16/2021
F73DD1,earnings,100,50,3/16/2021
F7935D,legal-issues-defendant,100,22,3/16/2021
F85CC0,dividend,100,50,3/16/2021
F85CC0,dividend,100,50,3/16/2021
F9AA02,earnings,100,50,3/16/2021
FA40E2,earnings,100,50,3/16/2021
FC1F9D,fundraising,100,64,3/16/2021
FE609F,conference-call,100,50,3/16/2021
0157B1,partnership,100,61,3/17/2021
01D03F,product-release,100,64,3/17/2021
01D03F,product-release,100,64,3/17/2021
0490C6,conference-participant,100,50,3/17/2021
099A92,executive-resignation,100,44,3/17/2021
0A0CF0,dividend,100,50,3/17/2021
0B4D10,dividend,100,50,3/17/2021
0BD199,earnings,100,50,3/17/2021
0C6293,award,100,58,3/17/2021
0CCCB7,executive-appointment,100,54,3/17/2021
0E5223,note-sale,100,52,3/17/2021
0F2BC9,business-contract,100,69,3/17/2021
1216D1,dividend-up,100,58,3/17/2021
1490F3,facility-sale,100,52,3/17/2021
154272,business-contract,100,69,3/17/2021
157CC1,executive-appointment,100,54,3/17/2021
18D9FA,legal-issues-defendant,100,22,3/17/2021
1A3E1B,executive-appointment,100,54,3/17/2021
1AC649,clinical-trials,100,56,3/17/2021
1B16C1,conference-participant,100,50,3/17/2021
1BC12C,partnership,100,61,3/17/2021
1BC12C,partnership,100,61,3/17/2021
1CD4B5,patent-awarded,100,72,3/17/2021
1EBF8D,partnership,100,61,3/17/2021
1EBF8D,partnership,100,61,3/17/2021
1F352C,conference-participant,100,50,3/17/2021
200D8B,conference-participant,100,50,3/17/2021
2093B1,public-offering,100,43,3/17/2021
20BEEA,earnings-guidance,100,50,3/17/2021
2158DF,executive-appointment,100,54,3/17/2021
267718,unit-acquisition-acquiree,100,76,3/17/2021
26F99F,public-offering,100,43,3/17/2021
28AF37,conference-participant,100,50,3/17/2021
291651,earnings,100,50,3/17/2021
292A70,dividend,100,50,3/17/2021
2CBB58,conference-participant,100,50,3/17/2021
2EC172,partnership,100,61,3/17/2021
2F6782,conference-participant,100,50,3/17/2021
33FD66,earnings,100,50,3/17/2021
341759,public-offering,100,43,3/17/2021
3CBA2A,dividend,100,50,3/17/2021
405762,trading-listing,100,61,3/17/2021
41B53E,executive-appointment,100,54,3/17/2021
42AABD,acquisition-acquirer,100,49,3/17/2021
434F38,product-release,100,64,3/17/2021
44A4FC,partnership,100,61,3/17/2021
4AE584,acquisition-acquirer,100,49,3/17/2021
53F491,dividend,100,50,3/17/2021
583A75,product-release,100,64,3/17/2021
589846,earnings,100,50,3/17/2021
58C2D4,legal-issues-defendant,100,22,3/17/2021
58C2D4,legal-issues-defendant,100,22,3/17/2021
5B226B,legal-issues-defendant,100,22,3/17/2021
5B226B,legal-issues-defendant,100,22,3/17/2021
609208,earnings,100,50,3/17/2021
615B6D,legal-issues-defendant,100,22,3/17/2021
6166D1,dividend,100,50,3/17/2021
62F41C,business-combination,100,54,3/17/2021
63E8D5,dividend,100,50,3/17/2021
64854A,conference-participant,100,50,3/17/2021
67529E,conference-participant,100,50,3/17/2021
67A658,public-offering,100,43,3/17/2021
6BF593,acquisition-acquirer,100,49,3/17/2021
6D156D,legal-issues-defendant,100,22,3/17/2021
713810,legal-issues-defendant,100,22,3/17/2021
71694D,conference-call,100,50,3/17/2021
7255D2,legal-issues-defendant,100,22,3/17/2021
76DD0C,public-offering,100,43,3/17/2021
775439,dividend,100,50,3/17/2021
7999F3,dividend,100,50,3/17/2021
7B0BA6,fundraising,100,64,3/17/2021
7B0BA6,conference-participant,100,50,3/17/2021
7E1D5D,product-release,100,64,3/17/2021
7F7C87,earnings,100,50,3/17/2021
84A6B9,executive-appointment,100,54,3/17/2021
84AB66,dividend,100,50,3/17/2021
8.40E+120,earnings,100,50,3/17/2021
863350,facility-open,100,65,3/17/2021
877734,conference-participant,100,50,3/17/2021
8D0EEA,public-offering,100,43,3/17/2021
8FF2EF,earnings,100,50,3/17/2021
902670,executive-appointment,100,54,3/17/2021
90D6A5,conference-participant,100,50,3/17/2021
90DD65,clinical-trials,100,56,3/17/2021
90DD65,clinical-trials,100,56,3/17/2021
911ACB,dividend,100,50,3/17/2021
9470CC,executive-appointment,100,54,3/17/2021
954004,earnings,100,50,3/17/2021
9B5968,dividend,100,50,3/17/2021
9B5968,dividend,100,50,3/17/2021
9CF9B1,settlement,100,56,3/17/2021
9FD2D9,public-offering,100,43,3/17/2021
A52B6B,executive-appointment,100,54,3/17/2021
A631A3,executive-appointment,100,54,3/17/2021
A6828A,partnership,100,61,3/17/2021
A6FE1C,unit-acquisition-acquirer,100,49,3/17/2021
AD1ACF,legal-issues-defendant,100,22,3/17/2021
AD23DE,executive-appointment,100,54,3/17/2021
B08C51,earnings,100,50,3/17/2021
B13B68,partnership,100,61,3/17/2021
B3A166,earnings,100,50,3/17/2021
B4C673,product-release,100,64,3/17/2021
B7FA9B,public-offering,100,43,3/17/2021
BCC13E,index-listing,100,76,3/17/2021
BD682F,dividend,100,50,3/17/2021
BFAEB4,earnings,100,50,3/17/2021
C05839,dividend,100,50,3/17/2021
C1114B,conference-participant,100,50,3/17/2021
C6C702,business-contract,100,69,3/17/2021
C8A248,product-release,100,64,3/17/2021
D0DFE5,executive-appointment,100,54,3/17/2021
D21D8A,dividend,100,50,3/17/2021
D2B9E5,acquisition-acquiree,100,76,3/17/2021
D58A11,partnership,100,61,3/17/2021
D650A7,conference-participant,100,50,3/17/2021
D82EF3,partnership,100,61,3/17/2021
DA0A9E,conference-call,100,50,3/17/2021
DDCB34,conference-participant,100,50,3/17/2021
DF5F14,merger-regulatory-approval,100,81,3/17/2021
DF5F14,merger,100,66,3/17/2021
E074A0,conference-participant,100,50,3/17/2021
E07573,conference-participant,100,50,3/17/2021
E09556,conference-participant,100,50,3/17/2021
E15736,acquisition-completed-acquirer,100,49,3/17/2021
E5D914,executive-appointment,100,54,3/17/2021
E754F0,executive-appointment,100,54,3/17/2021
E8846E,executive-appointment,100,54,3/17/2021
E99180,dividend,100,50,3/17/2021
EB7FBF,dividend,100,50,3/17/2021
ED0D7C,conference-participant,100,50,3/17/2021
ED79D9,dividend,100,50,3/17/2021
EEA6B3,earnings,100,50,3/17/2021
EEA734,legal-issues-defendant,100,22,3/17/2021
F39E1E,unit-acquisition-acquiree,100,76,3/17/2021
F6FA6A,note-sale,100,52,3/17/2021
F748C7,earnings,100,50,3/17/2021
F748C7,dividend-up,100,81,3/17/2021
F7935D,legal-issues-defendant,100,22,3/17/2021
FC9869,earnings,100,50,3/17/2021
FD4588,partnership,100,61,3/17/2021
FDF799,acquisition-acquirer,100,49,3/17/2021
FEBFE1,earnings,100,50,3/17/2021
FF9FF6,acquisition-completed-acquirer,100,49,3/17/2021
FF9FF6,acquisition-completed-acquirer,100,49,3/17/2021
00326D,dividend,100,50,3/18/2021
00D6B5,executive-appointment,100,54,3/18/2021
00E601,note-sale,100,52,3/18/2021
0157B1,partnership,100,61,3/18/2021
0157B1,partnership,100,61,3/18/2021
033B58,earnings,100,50,3/18/2021
0A0CF0,earnings,100,50,3/18/2021
0CBC4D,award,100,58,3/18/2021
0D03C8,earnings,100,50,3/18/2021
11AEDE,earnings,100,50,3/18/2021
11AEDE,earnings,100,50,3/18/2021
152FA5,earnings,100,50,3/18/2021
1A3E1B,trading-halt,100,43,3/18/2021
1B6F77,earnings,100,50,3/18/2021
1BC12C,legal-issues-defendant,100,22,3/18/2021
1D9E55,business-contract,100,69,3/18/2021
1EBF8D,partnership,100,61,3/18/2021
225CA2,partnership,100,61,3/18/2021
238302,dividend,100,50,3/18/2021
241252,earnings,100,50,3/18/2021
25102A,conference-call,100,50,3/18/2021
2571FA,conference-participant,100,50,3/18/2021
267718,business-contract,100,69,3/18/2021
26F99F,public-offering,100,43,3/18/2021
292A70,executive-appointment,100,54,3/18/2021
2A02DC,executive-resignation,100,44,3/18/2021
2BC05E,facility-open,100,65,3/18/2021
2D2D43,earnings,100,50,3/18/2021
37727A,dividend-up,100,81,3/18/2021
3CBA2A,acquisition-acquiree,100,76,3/18/2021
420168,dividend,100,50,3/18/2021
4C31F3,conference-participant,100,50,3/18/2021
4E4E75,partnership,100,61,3/18/2021
4FB770,public-offering,100,43,3/18/2021
504FE2,legal-issues-defendant,100,22,3/18/2021
52D936,executive-appointment,100,54,3/18/2021
53EF9E,conference-participant,100,50,3/18/2021
545272,dividend,100,50,3/18/2021
546A27,orphan-drug-designation,100,76,3/18/2021
56632F,note-sale,100,52,3/18/2021
56632F,note-sale,100,52,3/18/2021
5A9A82,unit-acquisition-acquiree,100,76,3/18/2021
5A9A82,asset-sale,100,62,3/18/2021
5A9A82,acquisition-interest-acquiree,100,82,3/18/2021
5A9A82,acquisition-interest-acquiree,100,82,3/18/2021
5B226B,legal-issues-defendant,100,22,3/18/2021
5B226B,exchange-noncompliance,100,24,3/18/2021
615B6D,legal-issues-defendant,100,22,3/18/2021
615B6D,legal-issues-defendant,100,22,3/18/2021
61BCA7,business-contract,100,69,3/18/2021
62CDDE,public-offering,100,43,3/18/2021
62F41C,business-contract,100,69,3/18/2021
641F17,conference-participant,100,50,3/18/2021
66667F,business-contract,100,69,3/18/2021
67303E,legal-issues-defendant,100,22,3/18/2021
6844D2,earnings-up,100,68,3/18/2021
6844D2,earnings-up,100,68,3/18/2021
6844D2,earnings-up,100,68,3/18/2021
6D156D,legal-issues-defendant,100,22,3/18/2021
6E7060,dividend,100,50,3/18/2021
6FCEF9,dividend-up,100,81,3/18/2021
713810,legal-issues-defendant,100,22,3/18/2021
7255D2,legal-issues-defendant,100,22,3/18/2021
7255D2,legal-issues-defendant,100,22,3/18/2021
76E80F,product-release,100,64,3/18/2021
7771D7,earnings,100,50,3/18/2021
7ACBA4,dividend,100,50,3/18/2021
7E2DE6,earnings,100,50,3/18/2021
803FED,conference-participant,100,50,3/18/2021
819492,earnings,100,50,3/18/2021
8295B8,earnings,100,50,3/18/2021
8377DB,dividend,100,50,3/18/2021
838ADD,executive-appointment,100,54,3/18/2021
84A6B9,executive-appointment,100,54,3/18/2021
85CDC9,business-contract,100,69,3/18/2021
896771,product-release,100,64,3/18/2021
8BAA15,earnings-guidance,100,50,3/18/2021
8C311A,partnership,100,61,3/18/2021
8D0EEA,public-offering,100,43,3/18/2021
903AB4,dividend,100,50,3/18/2021
931AE7,earnings,100,50,3/18/2021
93633B,dividend-up,100,81,3/18/2021
9.39E+69,earnings,100,50,3/18/2021
9.82E+06,earnings,100,50,3/18/2021
9.86E+03,partnership,100,61,3/18/2021
98A286,earnings,100,50,3/18/2021
99B61C,patient-enrollment-start,100,58,3/18/2021
9B4066,unit-acquisition-acquirer,100,49,3/18/2021
9C5BA5,acquisition-completed-acquirer,100,49,3/18/2021
9D5D35,conference-participant,100,50,3/18/2021
A1EAC8,partnership,100,61,3/18/2021
A26EF7,product-release,100,64,3/18/2021
A26EF7,product-release,100,64,3/18/2021
A631A3,conference-participant,100,50,3/18/2021
A6FE1C,acquisition-acquirer,100,49,3/18/2021
A761FE,conference-call,100,50,3/18/2021
A8E2FE,earnings,100,50,3/18/2021
A94637,conference-participant,100,50,3/18/2021
AA7FE0,conference-call,100,50,3/18/2021
ACF0B4,partnership,100,61,3/18/2021
ADD9DC,earnings,100,50,3/18/2021
AE4EEB,dividend,100,50,3/18/2021
AEBB80,dividend,100,50,3/18/2021
B614F8,earnings,100,50,3/18/2021
B96637,award,100,58,3/18/2021
BDF85E,earnings,100,50,3/18/2021
BFF98A,earnings,100,50,3/18/2021
C062D4,product-release,100,64,3/18/2021
C0BA36,acquisition-acquirer,100,49,3/18/2021
C29E71,earnings,100,50,3/18/2021
C4452A,unit-acquisition-acquirer,100,49,3/18/2021
C4452A,acquisition-interest-acquirer,100,46,3/18/2021
C4452A,acquisition-interest-acquirer,100,46,3/18/2021
C83B88,conference-call,100,50,3/18/2021
C97B2D,regulatory-product-approval-granted,100,81,3/18/2021
CC6F6E,earnings,100,50,3/18/2021
CC6F6E,earnings,100,50,3/18/2021
CC6F6E,earnings,100,50,3/18/2021
CC6F6E,earnings,100,50,3/18/2021
CDD75E,earnings,100,50,3/18/2021
D07B07,earnings,100,50,3/18/2021
D0909F,ownership-decrease-owner,100,46,3/18/2021
D17F7E,executive-appointment,100,54,3/18/2021
D1AE3B,conference-call,100,50,3/18/2021
D2E553,dividend,100,50,3/18/2021
D622D5,dividend,100,50,3/18/2021
D64C6D,earnings,100,50,3/18/2021
D88EF3,partnership,100,61,3/18/2021
D8C09D,earnings,100,50,3/18/2021
D9B1C9,executive-appointment,100,54,3/18/2021
DB7FA7,business-contract,100,69,3/18/2021
DB9F70,conference-call,100,50,3/18/2021
DC0066,earnings,100,50,3/18/2021
DC2B00,earnings,100,50,3/18/2021
DE4924,conference-participant,100,50,3/18/2021
DF01B1,executive-appointment,100,54,3/18/2021
E0F4E5,product-release,100,64,3/18/2021
E15736,note-sale,100,52,3/18/2021
E15736,note-sale,100,52,3/18/2021
E16133,executive-appointment,100,54,3/18/2021
E26FC3,product-release,100,64,3/18/2021
E3656D,public-offering,100,43,3/18/2021
E3E68E,spin-off,100,58,3/18/2021
E3E68E,spin-off,100,58,3/18/2021
E74B55,partnership,100,61,3/18/2021
E8B315,dividend-up,100,54,3/18/2021
E959F3,conference-call,100,50,3/18/2021
E96E0B,product-release,100,64,3/18/2021
EB7FBF,earnings,100,50,3/18/2021
ECDEB2,dividend,100,50,3/18/2021
EE967B,conference-participant,100,50,3/18/2021
EEA734,legal-issues-defendant,100,22,3/18/2021
EF77A3,earnings,100,50,3/18/2021
F42FAE,executive-resignation,100,44,3/18/2021
F58C23,conference-participant,100,50,3/18/2021
F6E1B5,conference-participant,100,50,3/18/2021
F6E248,partnership,100,61,3/18/2021
F721A7,acquisition-completed-acquirer,100,49,3/18/2021
F721A7,acquisition-completed-acquirer,100,49,3/18/2021
F7935D,legal-issues-defendant,100,22,3/18/2021
F92DBC,partnership,100,61,3/18/2021
F92DBC,partnership,100,61,3/18/2021
03596A,business-contract,100,69,3/19/2021
61366,executive-appointment,100,54,3/19/2021
1348C9,partnership,100,61,3/19/2021
13A782,conference-participant,100,50,3/19/2021
16B183,legal-issues-defendant,100,22,3/19/2021
18D9FA,legal-issues-defendant,100,22,3/19/2021
1A1CB0,public-offering,100,43,3/19/2021
1A1CB0,public-offering,100,43,3/19/2021
1AB023,facility-close,100,47,3/19/2021
1AB023,facility-close,100,47,3/19/2021
1AB023,facility-close,100,47,3/19/2021
1FE3CB,executive-resignation,100,44,3/19/2021
2158DF,award,100,58,3/19/2021
2CB4C9,partnership,100,61,3/19/2021
2CB4C9,partnership,100,61,3/19/2021
2EB88B,product-release,100,64,3/19/2021
2FDEE3,dividend-suspended,100,13,3/19/2021
339F20,dividend,100,50,3/19/2021
341759,public-offering,100,43,3/19/2021
3461CF,acquisition-completed-acquirer,100,49,3/19/2021
346BF2,executive-appointment,100,54,3/19/2021
37E18B,trading-listing,100,61,3/19/2021
3C7F5F,business-contract,100,69,3/19/2021
3DDE54,conference-participant,100,50,3/19/2021
4A7C1F,conference-call,100,50,3/19/2021
504FE2,legal-issues-defendant,100,22,3/19/2021
5088A5,executive-appointment,100,54,3/19/2021
56FB7C,debt-increase,100,26,3/19/2021
58C2D4,legal-issues-defendant,100,22,3/19/2021
59872F,legal-issues-defendant,100,22,3/19/2021
5E6959,dividend,100,50,3/19/2021
62A48D,conference-call,100,50,3/19/2021
6830FE,partnership,100,61,3/19/2021
6D156D,legal-issues-defendant,100,22,3/19/2021
6F30F9,dividend,100,50,3/19/2021
713810,legal-issues-defendant,100,22,3/19/2021
7255D2,legal-issues-defendant,100,22,3/19/2021
7255D2,legal-issues-defendant,100,22,3/19/2021
76E80F,dividend,100,50,3/19/2021
7E3390,public-offering,100,43,3/19/2021
8817D5,conference-call,100,50,3/19/2021
905356,executive-appointment,100,54,3/19/2021
94637C,regulatory-product-approval-granted,100,81,3/19/2021
981656,conference-organizer,100,57,3/19/2021
A5195E,executive-appointment,100,54,3/19/2021
A6ABE9,dividend,100,50,3/19/2021
A75D43,credit-extension-recipient,100,69,3/19/2021
AD375D,dividend,100,50,3/19/2021
B1FC3B,conference-participant,100,50,3/19/2021
B5BA39,executive-appointment,100,54,3/19/2021
C74887,executive-appointment,100,54,3/19/2021
CBFFDD,conference-participant,100,50,3/19/2021
D0909F,conference-participant,100,50,3/19/2021
D82EF3,trading-halt,100,43,3/19/2021
D82EF3,trading-resumed,100,58,3/19/2021
DF5F14,merger-completed,100,66,3/19/2021
DF5F14,merger-completed,100,66,3/19/2021
E11C41,conference-call,100,50,3/19/2021
E3656D,public-offering,100,43,3/19/2021
E56A0D,earnings,100,50,3/19/2021
E70531,legal-issues-defendant,100,22,3/19/2021
EBD89A,business-contract,100,69,3/19/2021
ED2EFD,investment-investor,100,55,3/19/2021
EEA734,legal-issues-defendant,100,22,3/19/2021
F294DD,merger-completed,100,66,3/19/2021
F4CDA3,dividend,100,50,3/19/2021
F5D410,conference-call,100,50,3/19/2021
F7935D,legal-issues-defendant,100,22,3/19/2021
F82D37,conference-call,100,50,3/19/2021
FD4BBE,acquisition-acquirer,100,49,3/19/2021
18D9FA,legal-issues-defendant,100,22,3/20/2021
429BFB,legal-issues-defendant,100,22,3/20/2021
6D156D,legal-issues-defendant,100,22,3/20/2021
C9E107,buybacks,100,74,3/20/2021
ECF4F8,legal-issues-defendant,100,22,3/20/2021
1E04A5,legal-issues-defendant,100,22,3/21/2021
202E5A,legal-issues-defendant,100,22,3/21/2021
713810,legal-issues-defendant,100,22,3/21/2021
9934AD,legal-issues-defendant,100,22,3/21/2021
ECF4F8,legal-issues-defendant,100,22,3/21/2021
13528,acquisition-completed-acquirer,100,49,3/22/2021
01D03F,business-contract,100,69,3/22/2021
04996E,executive-appointment,100,54,3/22/2021
0A59F8,partnership,100,61,3/22/2021
0B6EED,earnings,100,50,3/22/2021
0CCCB7,conference-participant,100,50,3/22/2021
0E499E,regulatory-product-approval-granted,100,81,3/22/2021
11074E,acquisition-acquirer,100,49,3/22/2021
1201B5,merger-completed,100,66,3/22/2021
1201B5,merger-completed,100,66,3/22/2021
12DE76,partnership,100,61,3/22/2021
12F98C,unit-acquisition-acquirer,100,49,3/22/2021
154272,public-offering,100,43,3/22/2021
15A388,business-contract,100,69,3/22/2021
168A5D,product-release,100,64,3/22/2021
1880C5,buybacks,100,74,3/22/2021
1AC649,executive-appointment,100,54,3/22/2021
1D3A00,executive-appointment,100,54,3/22/2021
1DA44F,donation,100,54,3/22/2021
228D42,partnership,100,61,3/22/2021
228D42,partnership,100,61,3/22/2021
228D42,partnership,100,61,3/22/2021
228D42,business-contract,100,69,3/22/2021
228D42,business-contract,100,69,3/22/2021
24A89A,executive-appointment,100,54,3/22/2021
24C48B,business-contract,100,69,3/22/2021
251988,earnings,100,50,3/22/2021
25AB8E,note-sale,100,52,3/22/2021
26F99F,public-offering,100,43,3/22/2021
272704,earnings,100,50,3/22/2021
2920D5,unit-acquisition-acquiree,100,76,3/22/2021
2B9DBB,unit-acquisition-acquirer,100,49,3/22/2021
2BC05E,facility-open,100,65,3/22/2021
2CF9D3,executive-appointment,100,54,3/22/2021
2EB88B,product-release,100,64,3/22/2021
2EC172,note-sale,100,52,3/22/2021
2EC172,note-sale,100,52,3/22/2021
306623,conference-participant,100,50,3/22/2021
30AB63,earnings-guidance,100,50,3/22/2021
3461CF,award,100,58,3/22/2021
35B907,dividend,100,50,3/22/2021
3A3447,partnership,100,61,3/22/2021
3A3447,partnership,100,61,3/22/2021
3C8A04,conference-call,100,50,3/22/2021
3D9999,earnings,100,50,3/22/2021
3FACA7,earnings,100,50,3/22/2021
43A060,business-contract,100,69,3/22/2021
44A4FC,business-contract,100,69,3/22/2021
44A4FC,business-contract,100,69,3/22/2021
45ABCC,note-sale,100,52,3/22/2021
4.60E+06,business-contract,100,69,3/22/2021
4.60E+06,earnings,100,50,3/22/2021
499C75,conference-participant,100,50,3/22/2021
49BBBC,executive-appointment,100,54,3/22/2021
4A6F00,business-contract,100,69,3/22/2021
4B7006,board-meeting,100,51,3/22/2021
4F9926,product-release,100,64,3/22/2021
52B567,conference-call,100,50,3/22/2021
5A9A82,executive-appointment,100,54,3/22/2021
5B226B,fraud-defendant,100,20,3/22/2021
5DA8B3,acquisition-acquirer,100,49,3/22/2021
5E6959,executive-appointment,100,54,3/22/2021
5F1B7B,note-sale,100,52,3/22/2021
5F3D91,product-release,100,64,3/22/2021
5F3D91,public-offering,100,43,3/22/2021
5FC507,executive-appointment,100,54,3/22/2021
63F892,partnership,100,61,3/22/2021
6BDA0C,executive-appointment,100,54,3/22/2021
704B78,acquisition-acquirer,100,49,3/22/2021
713810,legal-issues-defendant,100,22,3/22/2021
7255D2,legal-issues-defendant,100,22,3/22/2021
742AAB,executive-appointment,100,54,3/22/2021
7A2A49,acquisition-interest-acquirer,100,46,3/22/2021
7B1E50,executive-appointment,100,54,3/22/2021
7BFF81,executive-appointment,100,54,3/22/2021
83598E,conference-participant,100,50,3/22/2021
85AD00,conference-call,100,50,3/22/2021
85DA04,acquisition-acquirer,100,49,3/22/2021
8665BA,product-release,100,64,3/22/2021
8665BA,partnership,100,61,3/22/2021
8BAA15,conference-participant,100,50,3/22/2021
8D0EEA,public-offering,100,43,3/22/2021
8D9993,dividend,100,50,3/22/2021
90DD65,earnings,100,50,3/22/2021
91C82E,partnership,100,61,3/22/2021
931AE7,business-contract,100,69,3/22/2021
931AE7,business-contract,100,69,3/22/2021
93AD2E,executive-appointment,100,54,3/22/2021
9CA432,conference-call,100,50,3/22/2021
9CE4C7,executive-appointment,100,54,3/22/2021
9D30A8,acquisition-completed-acquirer,100,49,3/22/2021
9D30A8,fundraising,100,64,3/22/2021
9D65C1,executive-appointment,100,54,3/22/2021
A0F146,conference-participant,100,50,3/22/2021
A1EAC8,executive-appointment,100,54,3/22/2021
A247F5,partnership,100,61,3/22/2021
A26EF7,dividend,100,50,3/22/2021
A8CBDA,partnership,100,61,3/22/2021
AD375D,conference-participant,100,50,3/22/2021
AEEB76,public-offering,100,43,3/22/2021
B08C51,conference-participant,100,50,3/22/2021
B77F14,partnership,100,61,3/22/2021
B8DD94,conference-participant,100,50,3/22/2021
BB127B,conference-participant,100,50,3/22/2021
C22BE8,earnings,100,50,3/22/2021
C230FE,facility-open,100,65,3/22/2021
C4A432,dividend,100,50,3/22/2021
C941DC,executive-appointment,100,54,3/22/2021
CDE51C,executive-resignation,100,44,3/22/2021
CF351E,dividend,100,50,3/22/2021
CF6A5A,executive-appointment,100,54,3/22/2021
D13F1C,buybacks,100,74,3/22/2021
D15833,dividend,100,50,3/22/2021
D17C1B,note-sale,100,52,3/22/2021
D1AE3B,partnership,100,61,3/22/2021
D1AE3B,partnership,100,61,3/22/2021
D36686,earnings,100,50,3/22/2021
D3F64D,acquisition-acquirer,100,49,3/22/2021
D6144F,conference-participant,100,50,3/22/2021
D76AEF,executive-resignation,100,44,3/22/2021
D82EF3,note-sale,100,52,3/22/2021
DB88A1,earnings,100,50,3/22/2021
DBCA3F,public-offering,100,43,3/22/2021
DD1BA1,conference-organizer,100,57,3/22/2021
DF5F14,dividend,100,50,3/22/2021
E2CFD2,executive-appointment,100,54,3/22/2021
E56A0D,executive-appointment,100,54,3/22/2021
E5A3B6,patient-enrollment-complete,100,64,3/22/2021
E68E62,clinical-trials,100,56,3/22/2021
E70531,legal-issues-defendant,100,22,3/22/2021
E84500,conference-call,100,50,3/22/2021
EB1E1A,executive-appointment,100,54,3/22/2021
EC99D0,conference-call,100,50,3/22/2021
EEA734,legal-issues-defendant,100,22,3/22/2021
EF25A5,executive-appointment,100,54,3/22/2021
EF5BED,partnership,100,61,3/22/2021
EF5BED,partnership,100,61,3/22/2021
EF5BED,partnership,100,61,3/22/2021
F5D499,earnings,100,50,3/22/2021
F5D499,earnings,100,50,3/22/2021
F5D499,earnings,100,50,3/22/2021
F82D37,legal-issues-defendant,100,22,3/22/2021
F82D37,acquisition-regulatory-scrutiny-acquiree,100,38,3/22/2021
FA840E,joint-venture,100,62,3/22/2021
FE609F,earnings,100,50,3/22/2021
FF9FF6,fundraising,100,64,3/22/2021
FF9FF6,fundraising,100,64,3/22/2021
FF9FF6,fundraising,100,64,3/22/2021
0157B1,partnership,100,61,3/23/2021
01D03F,product-release,100,64,3/23/2021
03F5A4,acquisition-acquiree,100,76,3/23/2021
03F5A4,acquisition-acquiree,100,76,3/23/2021
0BD4E8,conference-call,100,50,3/23/2021
0CE204,partnership,100,61,3/23/2021
0EF1AF,legal-issues-defendant,100,22,3/23/2021
112694,earnings,100,50,3/23/2021
125212,earnings,100,50,3/23/2021
13C3E0,business-contract,100,69,3/23/2021
1490F3,product-release,100,64,3/23/2021
154272,public-offering,100,43,3/23/2021
15A388,business-contract,100,69,3/23/2021
1866B2,executive-appointment,100,54,3/23/2021
19BF16,campaign-ad-release,100,59,3/23/2021
1A1CB0,public-offering,100,43,3/23/2021
1E7785,unit-acquisition-acquirer,100,49,3/23/2021
1E7785,conference-participant,100,50,3/23/2021
1EBF8D,regulatory-product-approval-granted,100,81,3/23/2021
1EBF8D,regulatory-product-approval-granted,100,81,3/23/2021
1EBF8D,regulatory-product-approval-granted,100,81,3/23/2021
1EBF8D,regulatory-product-approval-granted,100,81,3/23/2021
1EBF8D,regulatory-product-approval-granted,100,81,3/23/2021
1EBF8D,regulatory-product-approval-granted,100,81,3/23/2021
200D8B,buybacks,100,74,3/23/2021
221AD7,legal-issues-defendant,100,22,3/23/2021
24C48B,partnership,100,61,3/23/2021
25AB8E,note-sale,100,52,3/23/2021
267718,conference-call,100,50,3/23/2021
267718,clinical-trials-start,100,64,3/23/2021
26CC63,product-release,100,64,3/23/2021
26E3BA,public-offering,100,43,3/23/2021
275300,legal-issues-defendant,100,22,3/23/2021
2BA977,executive-resignation,100,44,3/23/2021
2BF36E,legal-issues-defendant,100,22,3/23/2021
2C7505,clinical-trials,100,56,3/23/2021
2E36AD,partnership,100,61,3/23/2021
2E36AD,partnership,100,61,3/23/2021
306623,asset-sale,100,62,3/23/2021
317EC6,note-sale,100,52,3/23/2021
317EC6,earnings,100,50,3/23/2021
3.20E+263,patent-awarded,100,72,3/23/2021
3.30E+30,revenue-up,100,83,3/23/2021
3.30E+30,revenue-up,100,83,3/23/2021
3.30E+30,revenue-up,100,83,3/23/2021
341759,public-offering,100,43,3/23/2021
346BF2,earnings,100,50,3/23/2021
3B318A,executive-appointment,100,54,3/23/2021
3B37F7,note-sale,100,52,3/23/2021
4135F7,partnership,100,61,3/23/2021
45ABCC,note-sale,100,52,3/23/2021
45ABCC,public-offering,100,43,3/23/2021
46CF27,acquisition-acquirer,100,49,3/23/2021
46CF27,acquisition-acquirer,100,49,3/23/2021
47752F,executive-appointment,100,54,3/23/2021
510EA6,earnings,100,50,3/23/2021
510EA6,earnings,100,50,3/23/2021
519FE0,acquisition-completed-acquirer,100,49,3/23/2021
55438C,business-contract,100,69,3/23/2021
55C9B5,partnership,100,61,3/23/2021
5F1B7B,note-sale,100,52,3/23/2021
62A48D,earnings,100,50,3/23/2021
633043,dividend,100,50,3/23/2021
641F17,earnings,100,50,3/23/2021
6.52E+64,conference-call,100,50,3/23/2021
67303E,legal-issues-defendant,100,22,3/23/2021
67B052,partnership,100,61,3/23/2021
67B052,partnership,100,61,3/23/2021
68E6E9,earnings,100,50,3/23/2021
69FDFC,executive-appointment,100,54,3/23/2021
6A024C,earnings,100,50,3/23/2021
6D156D,legal-issues-defendant,100,22,3/23/2021
6F6559,earnings,100,50,3/23/2021
7255D2,legal-issues-defendant,100,22,3/23/2021
751C8D,product-release,100,64,3/23/2021
751C8D,product-release,100,64,3/23/2021
765913,executive-appointment,100,54,3/23/2021
766047,acquisition-bid-rejected-acquiree,100,18,3/23/2021
773A17,product-release,100,64,3/23/2021
7AB859,partnership,100,61,3/23/2021
7B9212,dividend-up,100,60,3/23/2021
7BC92D,earnings,100,50,3/23/2021
7E3390,public-offering,100,43,3/23/2021
7FD8B9,business-contract,100,69,3/23/2021
7FD8B9,business-contract,100,69,3/23/2021
8.10E+32,executive-appointment,100,54,3/23/2021
8.10E+32,executive-appointment,100,54,3/23/2021
8295B8,note-sale,100,52,3/23/2021
859281,note-sale,100,52,3/23/2021
859281,note-sale,100,52,3/23/2021
863350,earnings,100,50,3/23/2021
8665BA,partnership,100,61,3/23/2021
88611B,conference-participant,100,50,3/23/2021
893904,earnings,100,50,3/23/2021
896771,product-release,100,64,3/23/2021
8D4486,partnership,100,61,3/23/2021
8EF425,dividend,100,50,3/23/2021
92005C,earnings,100,50,3/23/2021
92B047,conference-call,100,50,3/23/2021
940C3D,business-contract,100,69,3/23/2021
940C3D,business-contract,100,69,3/23/2021
94C0B5,conference-call,100,50,3/23/2021
98CEBB,revenue-up,100,69,3/23/2021
9A602D,conference-call,100,50,3/23/2021
9C5BA5,partnership,100,61,3/23/2021
9D3360,conference-call,100,50,3/23/2021
9F71E5,executive-appointment,100,54,3/23/2021
9F71E5,executive-appointment,100,54,3/23/2021
A1DBF0,earnings,100,50,3/23/2021
A26C26,dividend,100,50,3/23/2021
A26EF7,business-contract,100,69,3/23/2021
A3230E,earnings,100,50,3/23/2021
A43906,conference-call,100,50,3/23/2021
A70BF5,earnings,100,50,3/23/2021
A868C9,business-contract,100,69,3/23/2021
ABAA03,conference-call,100,50,3/23/2021
AE79CD,earnings,100,50,3/23/2021
AEEB76,public-offering,100,43,3/23/2021
AFDF2E,conference-participant,100,50,3/23/2021
AFF43F,executive-resignation,100,44,3/23/2021
B13B68,note-sale,100,52,3/23/2021
B1DF3C,partnership,100,61,3/23/2021
B2AA0A,unit-acquisition-acquiree,100,76,3/23/2021
B66928,conference-participant,100,50,3/23/2021
B72D2E,acquisition-regulatory-approval-acquirer,100,54,3/23/2021
B72D2E,acquisition-interest-acquirer,100,46,3/23/2021
B840EF,executive-appointment,100,54,3/23/2021
B8F71F,earnings,100,50,3/23/2021
B9BDE8,earnings,100,50,3/23/2021
BB02FB,business-contract,100,69,3/23/2021
BB02FB,business-contract,100,69,3/23/2021
BD8517,executive-appointment,100,54,3/23/2021
BDE867,executive-appointment,100,54,3/23/2021
BFD0A7,conference-call,100,50,3/23/2021
C490F9,earnings,100,50,3/23/2021
C4A432,executive-appointment,100,54,3/23/2021
C7AE14,partnership,100,61,3/23/2021
C83B88,partnership,100,61,3/23/2021
C9881C,executive-resignation,100,44,3/23/2021
CAD7D9,conference-call,100,50,3/23/2021
CF073E,earnings,100,50,3/23/2021
CFF97C,partnership,100,61,3/23/2021
D17C1B,note-sale,100,52,3/23/2021
D1CFC8,earnings,100,50,3/23/2021
D42DBA,earnings,100,50,3/23/2021
D42DBA,executive-appointment,100,54,3/23/2021
D5B13D,earnings,100,50,3/23/2021
D6EAA3,executive-appointment,100,54,3/23/2021
D82EF3,note-sale,100,52,3/23/2021
D8442A,executive-appointment,100,54,3/23/2021
E2F130,conference-call,100,50,3/23/2021
E30A8F,award,100,58,3/23/2021
E70531,legal-issues-defendant,100,22,3/23/2021
E70531,legal-issues-defendant,100,22,3/23/2021
E8846E,business-contract,100,69,3/23/2021
E8846E,unit-acquisition-acquiree,100,76,3/23/2021
EBD89A,business-contract,100,69,3/23/2021
ECF709,buybacks,100,74,3/23/2021
ED9576,executive-appointment,100,54,3/23/2021
EEA734,legal-issues-defendant,100,22,3/23/2021
EF5BED,partnership,100,61,3/23/2021
EF7163,dividend,100,50,3/23/2021
F1529C,executive-appointment,100,54,3/23/2021
F1529C,executive-appointment,100,54,3/23/2021
F1CD47,board-meeting,100,51,3/23/2021
F2BC3D,acquisition-acquirer,100,49,3/23/2021
F30508,partnership,100,61,3/23/2021
F3EDB4,earnings,100,50,3/23/2021
F3EDB4,earnings,100,50,3/23/2021
F7935D,legal-issues-defendant,100,22,3/23/2021
F88147,earnings,100,50,3/23/2021
FADF1A,business-contract,100,69,3/23/2021
FC1A6E,legal-issues-defendant,100,22,3/23/2021
0157B1,partnership,100,61,3/24/2021
01B8D6,executive-appointment,100,54,3/24/2021
03F5A4,dividend,100,50,3/24/2021
03FB17,product-release,100,64,3/24/2021
55018,conference-call,100,50,3/24/2021
05AF14,earnings,100,50,3/24/2021
05AF14,dividend-up,100,81,3/24/2021
091B6C,earnings,100,50,3/24/2021
091B6C,earnings,100,50,3/24/2021
099C88,business-contract,100,69,3/24/2021
0B73A7,product-price-cut,100,49,3/24/2021
0EF1AF,legal-issues-defendant,100,22,3/24/2021
11074E,conference-participant,100,50,3/24/2021
12DE76,partnership,100,61,3/24/2021
133644,earnings,100,50,3/24/2021
18D9FA,legal-issues-defendant,100,22,3/24/2021
1B637E,executive-appointment,100,54,3/24/2021
1E1125,business-contract,100,69,3/24/2021
1EBF8D,executive-appointment,100,54,3/24/2021
1FAF22,conference-call,100,50,3/24/2021
205AD5,earnings,100,50,3/24/2021
21153F,executive-resignation,100,44,3/24/2021
21153F,executive-resignation,100,44,3/24/2021
24A89A,earnings,100,50,3/24/2021
2571FA,conference-call,100,50,3/24/2021
267718,clinical-trials-positive,100,87,3/24/2021
26DC29,product-release,100,64,3/24/2021
270B78,conference-participant,100,50,3/24/2021
292A70,earnings-up,100,68,3/24/2021
2D485F,earnings,100,50,3/24/2021
2F98A5,partnership,100,61,3/24/2021
2F98A5,partnership,100,61,3/24/2021
2F98A5,partnership,100,61,3/24/2021
370C50,earnings-guidance-up,100,83,3/24/2021
370C50,earnings-guidance-up,100,83,3/24/2021
396D7C,sponsorship,100,57,3/24/2021
3B37F7,note-sale,100,52,3/24/2021
3C7F5F,public-offering,100,43,3/24/2021
41A93D,partnership,100,61,3/24/2021
42EFC7,conference-call,100,50,3/24/2021
435ACE,executive-appointment,100,54,3/24/2021
460C93,buybacks,100,74,3/24/2021
49A344,executive-appointment,100,54,3/24/2021
49F4D0,dividend,100,50,3/24/2021
4A6F00,partnership,100,61,3/24/2021
4A6F00,partnership,100,61,3/24/2021
4A6F00,product-release,100,64,3/24/2021
4AE584,earnings,100,50,3/24/2021
4AE584,earnings,100,50,3/24/2021
4AE584,earnings,100,50,3/24/2021
4AE584,executive-appointment,100,54,3/24/2021
4B49CF,earnings,100,50,3/24/2021
4C37C5,conference-call,100,50,3/24/2021
4C92B9,facility-open,100,65,3/24/2021
504FE2,legal-issues-defendant,100,22,3/24/2021
53F491,earnings,100,50,3/24/2021
57CAAB,regulatory-product-approval-granted,100,81,3/24/2021
583553,earnings,100,50,3/24/2021
589846,product-release,100,64,3/24/2021
58B46F,product-release,100,64,3/24/2021
594402,conference-participant,100,50,3/24/2021
5AF08A,executive-appointment,100,54,3/24/2021
5BC2F4,product-price-cut,100,49,3/24/2021
5E6959,product-release,100,64,3/24/2021
5E6959,product-release,100,64,3/24/2021
6166D1,executive-appointment,100,54,3/24/2021
616E3B,conference-call,100,50,3/24/2021
619882,conference-organizer,100,57,3/24/2021
61BCA7,earnings,100,50,3/24/2021
6391C2,earnings,100,50,3/24/2021
6.52E+64,executive-appointment,100,54,3/24/2021
66ECFD,award,100,58,3/24/2021
67529E,executive-appointment,100,54,3/24/2021
676FFD,legal-issues-defendant,100,22,3/24/2021
693ECD,clinical-trials-positive,100,87,3/24/2021
6AACDD,conference-participant,100,50,3/24/2021
6B0784,acquisition-acquirer,100,49,3/24/2021
6BF593,conference-call,100,50,3/24/2021
6D156D,legal-issues-defendant,100,22,3/24/2021
6D9B53,conference-participant,100,50,3/24/2021
6F3936,conference-call,100,50,3/24/2021
6FCEF9,earnings,100,50,3/24/2021
713810,partnership,100,61,3/24/2021
7255D2,legal-issues-defendant,100,22,3/24/2021
72FCA3,earnings,100,50,3/24/2021
72FCA3,earnings,100,50,3/24/2021
72FCA3,earnings,100,50,3/24/2021
72FCA3,earnings,100,50,3/24/2021
73C521,earnings,100,50,3/24/2021
75768D,earnings,100,50,3/24/2021
793C11,award,100,58,3/24/2021
7A5097,earnings,100,50,3/24/2021
7E1D5D,partnership,100,61,3/24/2021
8295B8,note-sale,100,52,3/24/2021
85DA04,partnership,100,61,3/24/2021
893904,earnings,100,50,3/24/2021
89B2E7,dividend,100,50,3/24/2021
8AB85C,earnings,100,50,3/24/2021
8D4486,product-release,100,64,3/24/2021
8E8E6E,award,100,58,3/24/2021
8EDACA,note-sale,100,52,3/24/2021
9087B9,board-meeting,100,51,3/24/2021
92D9C9,dividend,100,50,3/24/2021
966ACE,executive-appointment,100,54,3/24/2021
9.74E+08,partnership,100,61,3/24/2021
986AF6,acquisition-completed-acquirer,100,49,3/24/2021
9CA619,earnings,100,50,3/24/2021
A52B6B,partnership,100,61,3/24/2021
A62FD6,index-listing,100,76,3/24/2021
A6FB29,earnings,100,50,3/24/2021
A7A0C8,executive-appointment,100,54,3/24/2021
A80FE0,note-sale,100,52,3/24/2021
A8CBDA,board-meeting,100,51,3/24/2021
AD23DE,acquisition-acquirer,100,49,3/24/2021
AE0CCE,earnings,100,50,3/24/2021
AE7D16,product-release,100,64,3/24/2021
B37FB4,partnership,100,61,3/24/2021
B60366,earnings,100,50,3/24/2021
BB0587,unit-acquisition-acquiree,100,76,3/24/2021
BB0587,unit-acquisition-acquiree,100,76,3/24/2021
BE645B,earnings,100,50,3/24/2021
C2E120,dividend,100,50,3/24/2021
C5E840,earnings,100,50,3/24/2021
C81E00,board-meeting,100,51,3/24/2021
C81E00,board-meeting,100,51,3/24/2021
C85A72,acquisition-acquirer,100,49,3/24/2021
CC8F6E,legal-issues-defendant,100,22,3/24/2021
D0DE27,executive-appointment,100,54,3/24/2021
D1588D,conference-participant,100,50,3/24/2021
D4463B,dividend,100,50,3/24/2021
D56E4C,trading-halt,100,43,3/24/2021
D56E4C,trading-resumed,100,58,3/24/2021
D5AF19,executive-appointment,100,54,3/24/2021
D82EF3,partnership,100,61,3/24/2021
D8F347,partnership,100,61,3/24/2021
D90F43,partnership,100,61,3/24/2021
D93A25,note-sale,100,52,3/24/2021
D96202,conference-call,100,50,3/24/2021
D9B1C9,award,100,58,3/24/2021
DA199F,earnings,100,50,3/24/2021
DF16DE,executive-appointment,100,54,3/24/2021
E38906,public-offering,100,43,3/24/2021
E3E68E,partnership,100,61,3/24/2021
E4CE73,partnership,100,61,3/24/2021
E70531,legal-issues-defendant,100,22,3/24/2021
E845D9,earnings,100,50,3/24/2021
ED5171,earnings,100,50,3/24/2021
EEA734,legal-issues-defendant,100,22,3/24/2021
F0B877,conference-call,100,50,3/24/2021
F1529C,acquisition-acquirer,100,49,3/24/2021
F1529C,acquisition-acquirer,100,49,3/24/2021
F1529C,executive-appointment,100,54,3/24/2021
F1529C,executive-appointment,100,54,3/24/2021
F1529C,executive-appointment,100,54,3/24/2021
F1529C,acquisition-acquirer,100,49,3/24/2021
F1529C,acquisition-acquirer,100,49,3/24/2021
F24FF0,conference-call,100,50,3/24/2021
F39E1E,executive-resignation,100,44,3/24/2021
F43A11,conference-call,100,50,3/24/2021
F4FBD8,executive-appointment,100,54,3/24/2021
F6E1B5,conference-participant,100,50,3/24/2021
F7935D,legal-issues-defendant,100,22,3/24/2021
F7935D,legal-issues-defendant,100,22,3/24/2021
FBD92D,business-contract,100,69,3/24/2021
FD4BBE,partnership,100,61,3/24/2021
00067A,earnings,100,50,3/25/2021
13528,stock-loss,100,40,3/25/2021
01478A,executive-appointment,100,54,3/25/2021
56045,earnings,100,50,3/25/2021
075CF7,note-sale,100,52,3/25/2021
07EC43,acquisition-acquirer,100,49,3/25/2021
07EC43,acquisition-acquirer,100,49,3/25/2021
099C88,dividend,100,50,3/25/2021
0B400D,partnership,100,61,3/25/2021
0BF528,executive-appointment,100,54,3/25/2021
0CE7F6,executive-appointment,100,54,3/25/2021
0D03C8,earnings,100,50,3/25/2021
0EF1AF,legal-issues-defendant,100,22,3/25/2021
119CB6,conference-call,100,50,3/25/2021
16B183,legal-issues-defendant,100,22,3/25/2021
1.79E+10,conference-call,100,50,3/25/2021
190B91,acquisition-acquirer,100,49,3/25/2021
196D18,partnership,100,61,3/25/2021
1A9DE1,dividend,100,50,3/25/2021
1BC12C,partnership,100,61,3/25/2021
1BC12C,partnership,100,61,3/25/2021
228D42,business-contract,100,69,3/25/2021
24A89A,executive-appointment,100,54,3/25/2021
24C48B,partnership,100,61,3/25/2021
251988,analyst-ratings-change-positive,100,78,3/25/2021
2CF9D3,conference-participant,100,50,3/25/2021
317EC6,note-sale,100,52,3/25/2021
3BB7D3,conference-participant,100,50,3/25/2021
408089,earnings,100,50,3/25/2021
414FFF,executive-appointment,100,54,3/25/2021
43A74A,earnings,100,50,3/25/2021
451D61,unit-acquisition-acquiree,100,76,3/25/2021
47FCF2,executive-resignation,100,44,3/25/2021
4A7C1F,earnings,100,50,3/25/2021
4B3DC9,merger-regulatory-approval,100,81,3/25/2021
4D8124,product-release,100,64,3/25/2021
4E7C1F,investment-investor,100,55,3/25/2021
523039,earnings,100,50,3/25/2021
543C77,earnings,100,50,3/25/2021
553949,executive-appointment,100,54,3/25/2021
577033,executive-appointment,100,54,3/25/2021
59DB8C,partnership,100,61,3/25/2021
5B226B,legal-issues-defendant,100,22,3/25/2021
5C7601,earnings,100,50,3/25/2021
6166D1,partnership,100,61,3/25/2021
620381,conference-participant,100,50,3/25/2021
65D0AA,clinical-trials-positive,100,87,3/25/2021
66A667,dividend,100,50,3/25/2021
66A667,dividend,100,50,3/25/2021
6AACDD,earnings,100,50,3/25/2021
6BBD2D,earnings,100,50,3/25/2021
6F3FA8,executive-appointment,100,54,3/25/2021
75F665,conference-call,100,50,3/25/2021
76BD96,public-offering,100,43,3/25/2021
76BD96,public-offering,100,43,3/25/2021
789ADD,earnings,100,50,3/25/2021
789ADD,earnings,100,50,3/25/2021
791D59,executive-appointment,100,54,3/25/2021
7ADE57,dividend,100,50,3/25/2021
7BFF81,partnership,100,61,3/25/2021
7C790D,executive-appointment,100,54,3/25/2021
7D85A9,note-sale,100,52,3/25/2021
810A4B,executive-appointment,100,54,3/25/2021
82BB33,earnings,100,50,3/25/2021
88193E,executive-resignation,100,44,3/25/2021
8A8E41,earnings,100,50,3/25/2021
8AA108,earnings,100,50,3/25/2021
8C5519,earnings,100,50,3/25/2021
8DBE73,note-sale,100,52,3/25/2021
8EDACA,note-sale,100,52,3/25/2021
911CA9,earnings,100,50,3/25/2021
911CA9,earnings,100,50,3/25/2021
934029,partnership,100,61,3/25/2021
967D92,conference-call,100,50,3/25/2021
980C14,ownership-decrease-owner,100,46,3/25/2021
981656,earnings,100,50,3/25/2021
98A286,earnings,100,50,3/25/2021
9.97E+09,partnership,100,61,3/25/2021
9BBFA5,earnings,100,50,3/25/2021
9DDE1B,partnership,100,61,3/25/2021
A3AAA5,dividend,100,50,3/25/2021
A4CD53,acquisition-completed-acquirer,100,49,3/25/2021
A52B6B,partnership,100,61,3/25/2021
A63820,stake-acquirer,100,48,3/25/2021
A761FE,earnings,100,50,3/25/2021
ABE7DC,earnings,100,50,3/25/2021
AEEB76,public-offering,100,43,3/25/2021
B05118,partnership,100,61,3/25/2021
B0D41A,executive-resignation,100,44,3/25/2021
B614F8,earnings,100,50,3/25/2021
B72D2E,business-contract,100,69,3/25/2021
BFD0A7,earnings,100,50,3/25/2021
C0030A,note-sale,100,52,3/25/2021
C07E05,executive-appointment,100,54,3/25/2021
C16A8F,conference-call,100,50,3/25/2021
C3CF29,product-price-raise,100,57,3/25/2021
C4FBDC,dividend,100,50,3/25/2021
C83B88,partnership,100,61,3/25/2021
C9A96E,conference-participant,100,50,3/25/2021
C9A96E,conference-participant,100,50,3/25/2021
C9E107,merger-regulatory-approval,100,81,3/25/2021
CA1620,executive-appointment,100,54,3/25/2021
CD2A4D,partnership,100,61,3/25/2021
CE4FD9,note-sale,100,52,3/25/2021
CF3FF9,earnings,100,50,3/25/2021
D07B07,earnings,100,50,3/25/2021
D47D56,earnings,100,50,3/25/2021
D6489C,partnership,100,61,3/25/2021
D8442A,business-contract,100,69,3/25/2021
D93A25,conference-call,100,50,3/25/2021
D9E036,business-contract,100,69,3/25/2021
DB9F70,earnings,100,50,3/25/2021
DC486E,earnings,100,50,3/25/2021
DC486E,earnings,100,50,3/25/2021
DD1BA1,acquisition-acquirer,100,49,3/25/2021
DD1BA1,partnership,100,61,3/25/2021
DD3BB1,partnership,100,61,3/25/2021
E124EB,conference-call,100,50,3/25/2021
E28D9C,partnership,100,61,3/25/2021
E3656D,conference-call,100,50,3/25/2021
E8F0E2,earnings,100,50,3/25/2021
E9E6FD,executive-resignation,100,44,3/25/2021
F02170,executive-appointment,100,54,3/25/2021
F1EB39,business-contract,100,69,3/25/2021
F51DB0,facility-open,100,65,3/25/2021
F6FA6A,partnership,100,61,3/25/2021
F748C7,partnership,100,61,3/25/2021
FA840E,executive-appointment,100,54,3/25/2021
FC1A6E,joint-venture,100,62,3/25/2021
FC1A6E,partnership,100,61,3/25/2021
FC1B7B,conference-call,100,50,3/25/2021
01D03F,regulatory-product-review-positive,100,73,3/26/2021
0E2992,executive-appointment,100,54,3/26/2021
0EF1AF,legal-issues-defendant,100,22,3/26/2021
138DDE,dividend,100,50,3/26/2021
251988,dividend,100,50,3/26/2021
253B2F,dividend,100,50,3/26/2021
267718,regulatory-product-approval-granted,100,81,3/26/2021
267718,regulatory-product-approval-granted,100,81,3/26/2021
2B7A40,executive-appointment,100,54,3/26/2021
2F7A7E,conference-call,100,50,3/26/2021
346BF2,legal-issues-defendant,100,22,3/26/2021
346BF2,fraud-defendant,100,20,3/26/2021
346BF2,fraud-defendant,100,20,3/26/2021
346BF2,legal-issues-defendant,100,22,3/26/2021
3BE00F,acquisition-completed-acquirer,100,49,3/26/2021
3ED92D,note-sale,100,52,3/26/2021
3F4497,conference-call,100,50,3/26/2021
3F96D5,note-sale,100,52,3/26/2021
453282,conference-call,100,50,3/26/2021
504FE2,fraud-defendant,100,20,3/26/2021
510EA6,donation,100,54,3/26/2021
58B46F,product-release,100,64,3/26/2021
5DA8B3,note-sale,100,52,3/26/2021
5F3D91,public-offering,100,43,3/26/2021
67303E,legal-issues-defendant,100,22,3/26/2021
6A024C,executive-appointment,100,54,3/26/2021
6A171E,executive-appointment,100,54,3/26/2021
6C987C,executive-appointment,100,54,3/26/2021
723548,dividend,100,50,3/26/2021
7255D2,fraud-defendant,100,20,3/26/2021
78F9ED,conference-call,100,50,3/26/2021
83066C,conference-participant,100,50,3/26/2021
859281,note-sale,100,52,3/26/2021
8E93A4,executive-appointment,100,54,3/26/2021
925759,conference-participant,100,50,3/26/2021
947B0B,earnings,100,50,3/26/2021
971F7B,executive-appointment,100,54,3/26/2021
9.74E+08,dividend,100,50,3/26/2021
9D6A24,conference-call,100,50,3/26/2021
9F6B1A,executive-appointment,100,54,3/26/2021
A58224,note-sale,100,52,3/26/2021
A6FE1C,unit-acquisition-acquirer,100,49,3/26/2021
A6FE1C,unit-acquisition-acquirer,100,49,3/26/2021
B6CD92,dividend,100,50,3/26/2021
BFE02C,earnings,100,50,3/26/2021
C97B2D,conference-call,100,50,3/26/2021
CC176E,earnings,100,50,3/26/2021
D3FA2C,conference-call,100,50,3/26/2021
D45285,executive-appointment,100,54,3/26/2021
D96202,executive-appointment,100,54,3/26/2021
E68733,regulatory-product-approval-granted,100,81,3/26/2021
E802CE,dividend,100,50,3/26/2021
EC8116,dividend,100,50,3/26/2021
F6E248,executive-appointment,100,54,3/26/2021
18D9FA,fraud-defendant,100,20,3/27/2021
BDF85E,shareholder-rights-plan-suspended,100,57,3/27/2021
E90C84,dividend,100,50,3/27/2021
F82D37,legal-issues-defendant,100,22,3/27/2021
504FE2,legal-issues-defendant,100,22,3/28/2021
6D156D,legal-issues-defendant,100,22,3/28/2021
7255D2,legal-issues-defendant,100,22,3/28/2021
7CD98F,legal-issues-defendant,100,22,3/28/2021
A63387,legal-issues-defendant,100,22,3/28/2021
ECF4F8,legal-issues-defendant,100,22,3/28/2021
F82D37,legal-issues-defendant,100,22,3/28/2021
0157B1,partnership,100,61,3/29/2021
0157B1,partnership,100,61,3/29/2021
01D03F,executive-appointment,100,54,3/29/2021
03C94A,earnings,100,50,3/29/2021
48590,earnings,100,50,3/29/2021
48590,executive-appointment,100,54,3/29/2021
04CCCD,dividend,100,50,3/29/2021
06EE79,buybacks,100,74,3/29/2021
0BC29E,executive-appointment,100,54,3/29/2021
0C136E,earnings,100,50,3/29/2021
0CC01F,earnings,100,50,3/29/2021
0E439E,earnings,100,50,3/29/2021
0E5619,regulatory-product-approval-granted,100,81,3/29/2021
1151F4,conference-call,100,50,3/29/2021
156A99,partnership,100,61,3/29/2021
16C7F0,conference-call,100,50,3/29/2021
18D9FA,legal-issues-defendant,100,22,3/29/2021
1EBF8D,conference-call,100,50,3/29/2021
227D48,note-sale,100,52,3/29/2021
228D42,partnership,100,61,3/29/2021
228D42,partnership,100,61,3/29/2021
228D42,partnership,100,61,3/29/2021
24C48B,acquisition-acquirer,100,49,3/29/2021
24C48B,acquisition-acquirer,100,49,3/29/2021
27BFA1,conference-call,100,50,3/29/2021
284289,conference-participant,100,50,3/29/2021
30CBF9,executive-appointment,100,54,3/29/2021
3587B4,partnership,100,61,3/29/2021
36529A,conference-participant,100,50,3/29/2021
389CFB,executive-appointment,100,54,3/29/2021
39692D,product-release,100,64,3/29/2021
3B37F7,note-sale,100,52,3/29/2021
3DDE54,earnings,100,50,3/29/2021
42DC93,earnings,100,50,3/29/2021
4A6F00,partnership,100,61,3/29/2021
4A6F00,partnership,100,61,3/29/2021
4C2F17,partnership,100,61,3/29/2021
4D72C8,conference-call,100,50,3/29/2021
4D72C8,conference-call,100,50,3/29/2021
4F0A80,merger,100,66,3/29/2021
4F0A80,acquisition-regulatory-scrutiny-acquiree,100,38,3/29/2021
4F0A80,legal-issues-defendant,100,22,3/29/2021
504FE2,legal-issues-defendant,100,22,3/29/2021
51888A,conference-call,100,50,3/29/2021
520632,conference-call,100,50,3/29/2021
55438C,business-contract,100,69,3/29/2021
55C9B5,partnership,100,61,3/29/2021
55C9B5,partnership,100,61,3/29/2021
579E8F,earnings,100,50,3/29/2021
59F0B0,conference-call,100,50,3/29/2021
5B226B,legal-issues-defendant,100,22,3/29/2021
5B6C11,executive-appointment,100,54,3/29/2021
6474BA,earnings,100,50,3/29/2021
66667F,business-contract,100,69,3/29/2021
6830FE,award,100,58,3/29/2021
6DBBBC,business-contract,100,69,3/29/2021
71694D,partnership,100,61,3/29/2021
7255D2,legal-issues-defendant,100,22,3/29/2021
746373,conference-call,100,50,3/29/2021
748EB6,conference-participant,100,50,3/29/2021
75D689,partnership,100,61,3/29/2021
75F665,merger,100,66,3/29/2021
76E80F,note-sale,100,52,3/29/2021
7A10FF,partnership,100,61,3/29/2021
7D5FD6,earnings,100,50,3/29/2021
7F3FBC,conference-call,100,50,3/29/2021
85AD00,executive-appointment,100,54,3/29/2021
86AA9C,conference-participant,100,50,3/29/2021
8.79E+06,earnings,100,50,3/29/2021
8C84DF,conference-call,100,50,3/29/2021
8E8E6E,executive-appointment,100,54,3/29/2021
8F3231,conference-call,100,50,3/29/2021
925759,clinical-trials-positive,100,87,3/29/2021
92D3A0,conference-call,100,50,3/29/2021
940C3D,acquisition-acquirer,100,49,3/29/2021
94637C,regulatory-product-approval-granted,100,81,3/29/2021
949625,conference-call,100,50,3/29/2021
94983E,partnership,100,61,3/29/2021
9.54E+32,executive-appointment,100,54,3/29/2021
990AD0,conference-organizer,100,57,3/29/2021
990AD0,conference-organizer,100,57,3/29/2021
990AD0,conference-organizer,100,57,3/29/2021
9F37C5,earnings-guidance,100,50,3/29/2021
9FF5F1,partnership,100,61,3/29/2021
A1EAC8,partnership,100,61,3/29/2021
A4BCDE,business-contract-terminated,100,31,3/29/2021
A6D095,earnings,100,50,3/29/2021
A8B137,conference-call,100,50,3/29/2021
A94A7B,partnership,100,61,3/29/2021
AA98ED,stake-acquiree,100,62,3/29/2021
ABB493,regulatory-product-approval-granted,100,81,3/29/2021
AE4125,acquisition-acquirer,100,49,3/29/2021
B13B68,acquisition-completed-acquirer,100,49,3/29/2021
B4F5F4,conference-call,100,50,3/29/2021
B5DE80,conference-call,100,50,3/29/2021
BE14CF,conference-call,100,50,3/29/2021
C07E05,executive-appointment,100,54,3/29/2021
C407A0,product-price-raise,100,57,3/29/2021
C45CE7,executive-appointment,100,54,3/29/2021
C4A241,conference-call,100,50,3/29/2021
C81E00,conference-call,100,50,3/29/2021
C81E00,conference-call,100,50,3/29/2021
C83B88,product-release,100,64,3/29/2021
C99CC8,executive-appointment,100,54,3/29/2021
CBFFDD,business-contract,100,69,3/29/2021
CBFFDD,product-release,100,64,3/29/2021
CDAB24,executive-appointment,100,54,3/29/2021
CDC217,patient-enrollment-complete,100,64,3/29/2021
CEC5B9,unit-acquisition-acquirer,100,49,3/29/2021
D17F7E,legal-issues-defendant,100,22,3/29/2021
D1C26F,partnership,100,61,3/29/2021
D1C26F,partnership,100,61,3/29/2021
D36686,earnings,100,50,3/29/2021
D6EAA3,dividend-up,100,81,3/29/2021
D88EF3,conference-call,100,50,3/29/2021
D9E036,note-sale,100,52,3/29/2021
D9E036,note-sale,100,52,3/29/2021
DB23C8,conference-participant,100,50,3/29/2021
DC6EF3,earnings,100,50,3/29/2021
DCD97F,partnership,100,61,3/29/2021
DD1BA1,unit-acquisition-acquirer,100,49,3/29/2021
DD1BA1,acquisition-acquirer,100,49,3/29/2021
E2CFD2,unit-acquisition-acquiree,100,76,3/29/2021
E2CFD2,acquisition-acquiree,100,76,3/29/2021
E38906,public-offering,100,43,3/29/2021
E56A0D,public-offering,100,43,3/29/2021
E67C2C,executive-resignation,100,44,3/29/2021
E6EDED,conference-call,100,50,3/29/2021
E829E8,conference-call,100,50,3/29/2021
E866D2,business-contract,100,69,3/29/2021
EFA7B2,earnings,100,50,3/29/2021
F05B1B,business-contract,100,69,3/29/2021
F3FCC3,partnership,100,61,3/29/2021
F4E992,conference-call,100,50,3/29/2021
F50BAB,credit-extension-recipient,100,69,3/29/2021
F5D059,acquisition-acquirer,100,49,3/29/2021
F7ADEB,award,100,58,3/29/2021
FE609F,executive-appointment,100,54,3/29/2021
FF4343,executive-resignation,100,44,3/29/2021
13528,product-release,100,64,3/30/2021
01D03F,executive-appointment,100,54,3/30/2021
0A0D9E,partnership,100,61,3/30/2021
0A6824,executive-appointment,100,54,3/30/2021
0BD4E8,earnings,100,50,3/30/2021
0EF1AF,legal-issues-defendant,100,22,3/30/2021
0F0693,regulatory-product-application,100,69,3/30/2021
0F0693,clinical-trials-filed,100,60,3/30/2021
10C19B,conference-call,100,50,3/30/2021
112694,earnings,100,50,3/30/2021
11AEDE,conference-participant,100,50,3/30/2021
1216D1,conference-call,100,50,3/30/2021
12A3A3,earnings,100,50,3/30/2021
12A3A3,earnings,100,50,3/30/2021
12A3A3,earnings,100,50,3/30/2021
12A3A3,earnings,100,50,3/30/2021
12A3A3,earnings,100,50,3/30/2021
12DE76,product-release,100,64,3/30/2021
133644,earnings,100,50,3/30/2021
1348C9,settlement,100,56,3/30/2021
14BA06,conference-call,100,50,3/30/2021
14ED2B,business-contract,100,69,3/30/2021
14ED2B,business-contract,100,69,3/30/2021
14ED2B,business-contract,100,69,3/30/2021
168A5D,partnership,100,61,3/30/2021
16B183,legal-issues-defendant,100,22,3/30/2021
196D18,earnings,100,50,3/30/2021
1B5FEA,earnings,100,50,3/30/2021
1B5FEA,earnings,100,50,3/30/2021
1B5FEA,earnings,100,50,3/30/2021
1D5C51,partnership,100,61,3/30/2021
1EBF8D,acquisition-acquirer,100,49,3/30/2021
228D42,partnership,100,61,3/30/2021
228D42,partnership,100,61,3/30/2021
249B39,note-sale,100,52,3/30/2021
26E3BA,earnings,100,50,3/30/2021
2AE625,conference-call,100,50,3/30/2021
346BF2,legal-issues-defendant,100,22,3/30/2021
34B97A,conference-call,100,50,3/30/2021
36529A,patient-enrollment-complete,100,64,3/30/2021
37727A,public-offering,100,43,3/30/2021
39692D,partnership,100,61,3/30/2021
3BCF24,dividend-up,100,59,3/30/2021
3C3B6B,executive-appointment,100,54,3/30/2021
3CBA2A,product-release,100,64,3/30/2021
3CBA2A,unit-acquisition-acquiree,100,76,3/30/2021
40B903,dividend,100,50,3/30/2021
4135F7,conference-call,100,50,3/30/2021
414FFF,earnings,100,50,3/30/2021
425BDC,executive-appointment,100,54,3/30/2021
43E8F5,business-contract,100,69,3/30/2021
4A6F00,partnership,100,61,3/30/2021
4C7DB5,earnings,100,50,3/30/2021
4EC4C1,conference-call,100,50,3/30/2021
4F71DC,partnership,100,61,3/30/2021
4F71DC,earnings,100,50,3/30/2021
4F71DC,earnings,100,50,3/30/2021
4F71DC,earnings,100,50,3/30/2021
4F71DC,earnings,100,50,3/30/2021
539F49,conference-participant,100,50,3/30/2021
546A27,executive-resignation,100,44,3/30/2021
57356F,conference-call,100,50,3/30/2021
589803,orphan-drug-designation,100,76,3/30/2021
5AF08A,earnings,100,50,3/30/2021
5B226B,legal-issues-defendant,100,22,3/30/2021
5B226B,legal-issues-defendant,100,22,3/30/2021
5DAF89,product-release,100,64,3/30/2021
601785,earnings,100,50,3/30/2021
627186,earnings,100,50,3/30/2021
665D7D,regulatory-product-approval-granted,100,81,3/30/2021
665D7D,regulatory-product-approval-granted,100,81,3/30/2021
67303E,legal-issues-defendant,100,22,3/30/2021
6A961B,acquisition-acquirer,100,49,3/30/2021
6C6D73,patent-awarded,100,72,3/30/2021
6D156D,legal-issues-defendant,100,22,3/30/2021
6D9B53,clinical-trials,100,56,3/30/2021
6-Dec-05,conference-participant,100,50,3/30/2021
6F3FA8,conference-participant,100,50,3/30/2021
70B3D6,revenue-up,100,69,3/30/2021
70B3D6,revenue-up,100,69,3/30/2021
70B3D6,revenue-up,100,69,3/30/2021
70B3D6,revenue-up,100,69,3/30/2021
713810,conference-participant,100,50,3/30/2021
713810,board-meeting,100,51,3/30/2021
71694D,earnings,100,50,3/30/2021
72609A,product-release,100,64,3/30/2021
72609A,product-release,100,64,3/30/2021
73BCBA,partnership,100,61,3/30/2021
7.40E+289,dividend,100,50,3/30/2021
76F067,acquisition-acquirer,100,49,3/30/2021
76F067,acquisition-acquirer,100,49,3/30/2021
7AC86E,note-sale,100,52,3/30/2021
7B492C,executive-appointment,100,54,3/30/2021
850779,earnings,100,50,3/30/2021
85CDC9,patient-enrollment-complete,100,64,3/30/2021
8AC740,executive-appointment,100,54,3/30/2021
8D0EEA,earnings,100,50,3/30/2021
8D4486,partnership,100,61,3/30/2021
8E0E32,unit-acquisition-acquirer,100,49,3/30/2021
900356,dividend,100,50,3/30/2021
94637C,partnership,100,61,3/30/2021
947B0B,earnings,100,50,3/30/2021
97693A,earnings,100,50,3/30/2021
9E0811,partnership,100,61,3/30/2021
9E3224,dividend,100,50,3/30/2021
9F6B1A,earnings,100,50,3/30/2021
9F71E5,product-release,100,64,3/30/2021
A398B9,earnings,100,50,3/30/2021
A4BCDE,award,100,58,3/30/2021
A63387,executive-appointment,100,54,3/30/2021
A63820,executive-appointment,100,54,3/30/2021
A6FE1C,unit-acquisition-acquirer,100,49,3/30/2021
A72FD9,public-offering,100,43,3/30/2021
A72FD9,public-offering,100,43,3/30/2021
A8B137,partnership,100,61,3/30/2021
A9ED24,conference-call,100,50,3/30/2021
AA98ED,conference-call,100,50,3/30/2021
ABAA03,earnings,100,50,3/30/2021
ADFB3A,business-contract,100,69,3/30/2021
AE3113,earnings,100,50,3/30/2021
B2206F,product-release,100,64,3/30/2021
B2D492,executive-appointment,100,54,3/30/2021
BB5271,product-release,100,64,3/30/2021
BCC55F,partnership,100,61,3/30/2021
BD9668,conference-call,100,50,3/30/2021
BF5959,conference-call,100,50,3/30/2021
C3BAE7,product-release,100,64,3/30/2021
C8257F,business-contract,100,69,3/30/2021
C8A248,product-release,100,64,3/30/2021
C9F39B,conference-call,100,50,3/30/2021
C9F39B,partnership,100,61,3/30/2021
CDC217,earnings,100,50,3/30/2021
D1344A,trading-halt,100,43,3/30/2021
D1344A,trading-resumed,100,58,3/30/2021
D33270,government-contract,100,69,3/30/2021
D42DBA,executive-appointment,100,54,3/30/2021
D6489C,partnership,100,61,3/30/2021
D78BF1,earnings,100,50,3/30/2021
D8ECA1,executive-appointment,100,54,3/30/2021
DA48E4,acquisition-completed-acquirer,100,49,3/30/2021
DC2F77,earnings,100,50,3/30/2021
DC6EF3,public-offering,100,43,3/30/2021
DF18E6,executive-appointment,100,54,3/30/2021
E0339F,partnership,100,61,3/30/2021
E074A0,executive-appointment,100,54,3/30/2021
E15736,conference-call,100,50,3/30/2021
E15736,conference-call,100,50,3/30/2021
E15736,conference-call,100,50,3/30/2021
E30A8F,business-contract,100,69,3/30/2021
E598FB,earnings,100,50,3/30/2021
E6D89E,acquisition-interest-acquirer,100,46,3/30/2021
EA4E68,buybacks,100,74,3/30/2021
EBD89A,business-contract,100,69,3/30/2021
EE6F1C,earnings,100,50,3/30/2021
EF5BED,executive-appointment,100,54,3/30/2021
F6DE54,product-price-raise,100,57,3/30/2021
F88147,earnings,100,50,3/30/2021
FC1A6E,partnership,100,61,3/30/2021
FC1A6E,joint-venture,100,62,3/30/2021
FC4550,conference-call,100,50,3/30/2021
FD4588,conference-call,100,50,3/30/2021
FE609F,executive-appointment,100,54,3/30/2021
FE7A63,earnings,100,50,3/30/2021
FF4BA4,earnings,100,50,3/30/2021
0157B1,partnership,100,61,3/31/2021
0157B1,partnership,100,61,3/31/2021
018C11,conference-call,100,50,3/31/2021
01D03F,product-release,100,64,3/31/2021
03FAA6,partnership,100,61,3/31/2021
48781,earnings,100,50,3/31/2021
61366,asset-sale,100,62,3/31/2021
0A59F8,unit-acquisition-acquirer,100,49,3/31/2021
0A7650,conference-call,100,50,3/31/2021
0B57D7,conference-call,100,50,3/31/2021
0C6861,executive-appointment,100,54,3/31/2021
0C8D82,acquisition-acquirer,100,49,3/31/2021
0E2992,conference-call,100,50,3/31/2021
0FABBD,note-sale,100,52,3/31/2021
0FC848,credit-extension-recipient,100,69,3/31/2021
12DE76,product-release,100,64,3/31/2021
12DE76,product-release,100,64,3/31/2021
12DE76,product-release,100,64,3/31/2021
1490F3,conference-call,100,50,3/31/2021
16F4D8,conference-call,100,50,3/31/2021
17EDA5,partnership,100,61,3/31/2021
18D9FA,legal-issues-defendant,100,22,3/31/2021
1A6A94,trading-halt,100,43,3/31/2021
1DEBBE,legal-issues-defendant,100,22,3/31/2021
1DEBBE,legal-issues-defendant,100,22,3/31/2021
1EBF8D,executive-appointment,100,54,3/31/2021
1F19C8,fundraising,100,64,3/31/2021
1FA8F7,executive-resignation,100,44,3/31/2021
21022F,earnings,100,50,3/31/2021
21D903,earnings,100,50,3/31/2021
227D48,note-sale,100,52,3/31/2021
25D3CE,earnings-up,100,68,3/31/2021
25D3CE,earnings,100,50,3/31/2021
25D3CE,earnings,100,50,3/31/2021
25D3CE,earnings,100,50,3/31/2021
25D3CE,earnings,100,50,3/31/2021
2DB344,facility-open,100,65,3/31/2021
2F7474,dividend-up,100,81,3/31/2021
31553A,executive-appointment,100,54,3/31/2021
31F25C,conference-call,100,50,3/31/2021
3390DE,conference-call,100,50,3/31/2021
33E9D5,earnings,100,50,3/31/2021
346BF2,legal-issues-defendant,100,22,3/31/2021
3471C0,conference-call,100,50,3/31/2021
37727A,public-offering,100,43,3/31/2021
37B120,executive-appointment,100,54,3/31/2021
39FB23,business-contract,100,69,3/31/2021
39FB23,earnings,100,50,3/31/2021
3DE4D1,product-price-raise,100,57,3/31/2021
3DE4D1,product-price-raise,100,57,3/31/2021
3F1C69,sponsorship,100,57,3/31/2021
408380,facility-open,100,65,3/31/2021
431B74,investment-investor,100,55,3/31/2021
431B74,investment-investor,100,55,3/31/2021
44A4FC,acquisition-completed-acquiree,100,76,3/31/2021
460C93,note-sale,100,52,3/31/2021
4885C8,earnings,100,50,3/31/2021
49914B,conference-call,100,50,3/31/2021
49BBBC,earnings,100,50,3/31/2021
4B3555,dividend,100,50,3/31/2021
4D8313,conference-call,100,50,3/31/2021
504FE2,business-contract,100,69,3/31/2021
504FE2,legal-issues-defendant,100,22,3/31/2021
52B567,merger,100,66,3/31/2021
52B567,merger,100,66,3/31/2021
52B567,legal-issues-defendant,100,22,3/31/2021
55438C,business-contract,100,69,3/31/2021
55C9B5,partnership,100,61,3/31/2021
564F3E,earnings,100,50,3/31/2021
56EFC7,executive-appointment,100,54,3/31/2021
58C2D4,partnership,100,61,3/31/2021
5B226B,fraud-defendant,100,20,3/31/2021
5EAA43,joint-venture,100,62,3/31/2021
64636E,business-contract,100,69,3/31/2021
64636E,business-contract,100,69,3/31/2021
64636E,business-contract,100,69,3/31/2021
64636E,business-contract,100,69,3/31/2021
64E346,acquisition-completed-acquirer,100,49,3/31/2021
65CF8E,facility-open,100,65,3/31/2021
65CF8E,facility-open,100,65,3/31/2021
665D7D,conference-call,100,50,3/31/2021
66A667,earnings,100,50,3/31/2021
66E04A,conference-organizer,100,57,3/31/2021
66E04A,conference-organizer,100,57,3/31/2021
69FDFC,award,100,58,3/31/2021
6B236C,conference-call,100,50,3/31/2021
6D156D,legal-issues-defendant,100,22,3/31/2021
6D156D,legal-issues-defendant,100,22,3/31/2021
6D9ECA,partnership,100,61,3/31/2021
6D9ECA,partnership,100,61,3/31/2021
6DBBBC,investment-investor,100,55,3/31/2021
6F3936,earnings,100,50,3/31/2021
6F3936,earnings,100,50,3/31/2021
6F3936,earnings,100,50,3/31/2021
6F3936,earnings,100,50,3/31/2021
6F3936,earnings,100,50,3/31/2021
6F3936,earnings,100,50,3/31/2021
6F3936,earnings,100,50,3/31/2021
704B78,partnership,100,61,3/31/2021
7239BB,earnings,100,50,3/31/2021
75D689,earnings,100,50,3/31/2021
762A3E,conference-call,100,50,3/31/2021
765913,earnings,100,50,3/31/2021
7A975D,earnings,100,50,3/31/2021
7A975D,earnings,100,50,3/31/2021
7A975D,earnings,100,50,3/31/2021
7B492C,executive-appointment,100,54,3/31/2021
88D80A,earnings,100,50,3/31/2021
8A0368,award,100,58,3/31/2021
8B2C4A,conference-call,100,50,3/31/2021
8BAA15,dividend,100,50,3/31/2021
8E10BF,clinical-trials,100,56,3/31/2021
8E8E6E,business-contract,100,69,3/31/2021
915E7B,conference-call,100,50,3/31/2021
9592FB,conference-participant,100,50,3/31/2021
9A602D,product-release,100,64,3/31/2021
9B71A7,earnings,100,50,3/31/2021
9D56F2,dividend,100,50,3/31/2021
9F5CBB,dividend,100,50,3/31/2021
A60318,earnings,100,50,3/31/2021
A666C8,note-sale,100,52,3/31/2021
AC7AAE,orphan-drug-designation,100,76,3/31/2021
AD375D,credit-extension-recipient,100,69,3/31/2021
B05000,business-contract,100,69,3/31/2021
B1FC3B,reorganization-unit,100,53,3/31/2021
B4F5F4,earnings,100,50,3/31/2021
B803B1,dividend,100,50,3/31/2021
B83BCE,executive-appointment,100,54,3/31/2021
BA218A,dividend,100,50,3/31/2021
BDE867,unit-acquisition-acquiree,100,76,3/31/2021
BDF85E,earnings,100,50,3/31/2021
BEB756,conference-call,100,50,3/31/2021
C03C8B,conference-call,100,50,3/31/2021
C2609A,product-release,100,64,3/31/2021
C2609A,product-release,100,64,3/31/2021
C2609A,product-price-cut,100,49,3/31/2021
C27E19,earnings,100,50,3/31/2021
C598D7,conference-call,100,50,3/31/2021
C7859D,conference-call,100,50,3/31/2021
C93C44,earnings,100,50,3/31/2021
CBDB4D,partnership,100,61,3/31/2021
CC6FF5,partnership,100,61,3/31/2021
CF9054,partnership,100,61,3/31/2021
D139BC,conference-call,100,50,3/31/2021
D33270,business-contract,100,69,3/31/2021
D5AF19,fundraising,100,64,3/31/2021
D5AF19,fundraising,100,64,3/31/2021
D5AF19,fundraising,100,64,3/31/2021
D5AF19,fundraising,100,64,3/31/2021
D5AF19,fundraising,100,64,3/31/2021
DB88A1,executive-appointment,100,54,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DB88A1,earnings,100,50,3/31/2021
DD7A96,credit-extension-recipient,100,69,3/31/2021
DDCB34,executive-appointment,100,54,3/31/2021
DE4924,executive-appointment,100,54,3/31/2021
E10D31,conference-call,100,50,3/31/2021
E22FDE,unit-acquisition-acquiree,100,76,3/31/2021
E22FDE,business-contract,100,69,3/31/2021
E829E8,note-sale,100,52,3/31/2021
E829E8,note-sale,100,52,3/31/2021
E9FF33,earnings,100,50,3/31/2021
EBD89A,business-contract,100,69,3/31/2021
ECF4F8,legal-issues-defendant,100,22,3/31/2021
ED79D9,business-contract,100,69,3/31/2021
ED79D9,business-contract,100,69,3/31/2021
F179ED,partnership,100,61,3/31/2021
F43A11,earnings,100,50,3/31/2021
F4E882,earnings,100,50,3/31/2021
F58C23,conference-participant,100,50,3/31/2021
FA36A4,conference-call,100,50,3/31/2021
FACF19,earnings-above-expectations,100,88,3/31/2021
FDE409,buybacks,100,74,3/31/2021
13528,business-contract,100,69,4/1/2021
0157B1,partnership,100,61,4/1/2021
0358AF,acquisition-completed-acquirer,100,49,4/1/2021
03B8CF,product-release,100,64,4/1/2021
03FB17,partnership,100,61,4/1/2021
08A40F,facility-open,100,65,4/1/2021
09F623,conference-call,100,50,4/1/2021
0C28D1,business-contract,100,69,4/1/2021
0C8D82,conference-call,100,50,4/1/2021
0EF1AF,business-contract,100,69,4/1/2021
108FDA,dividend-up,100,81,4/1/2021
10C19B,dividend-up,100,81,4/1/2021
1279ED,merger-completed,100,66,4/1/2021
12E454,earnings,100,50,4/1/2021
135B09,unit-acquisition-acquirer,100,49,4/1/2021
14391F,investment-investor,100,55,4/1/2021
16B882,earnings,100,50,4/1/2021
19CAC7,conference-call,100,50,4/1/2021
1A6A94,conference-call,100,50,4/1/2021
1BC12C,revenue-volume-up,100,69,4/1/2021
1EBF8D,acquisition-completed-acquirer,100,49,4/1/2021
221AD7,earnings,100,50,4/1/2021
228D42,facility-open,100,65,4/1/2021
249B39,earnings,100,50,4/1/2021
251988,unit-acquisition-completed-acquiree,100,67,4/1/2021
28AC4E,acquisition-completed-acquirer,100,49,4/1/2021
2.90E+62,acquisition-interest-acquiree,100,82,4/1/2021
2BDC1C,regulatory-product-review-positive,100,73,4/1/2021
2BDC1C,regulatory-product-review-positive,100,73,4/1/2021
2DB344,buybacks,100,74,4/1/2021
2F7474,conference-call,100,50,4/1/2021
301493,market-entry,100,57,4/1/2021
309922,conference-call,100,50,4/1/2021
30DFD3,conference-call,100,50,4/1/2021
31553A,earnings,100,50,4/1/2021
338544,conference-call,100,50,4/1/2021
346BF2,legal-issues-defendant,100,22,4/1/2021
34A959,earnings,100,50,4/1/2021
34B411,earnings,100,50,4/1/2021
3.50E+27,conference-call,100,50,4/1/2021
370C50,conference-call,100,50,4/1/2021
372037,acquisition-completed-acquirer,100,49,4/1/2021
387541,acquisition-completed-acquirer,100,49,4/1/2021
39FB23,facility-open,100,65,4/1/2021
3A113F,executive-appointment,100,54,4/1/2021
3A4BDB,conference-call,100,50,4/1/2021
3B318A,executive-appointment,100,54,4/1/2021
415188,business-contract,100,69,4/1/2021
41B53E,dividend,100,50,4/1/2021
41ED98,unit-acquisition-acquiree,100,76,4/1/2021
43A060,executive-appointment,100,54,4/1/2021
43E8F5,executive-resignation,100,44,4/1/2021
451D61,unit-acquisition-completed-acquiree,100,67,4/1/2021
46CF27,earnings,100,50,4/1/2021
4A5C8D,earnings,100,50,4/1/2021
4A6F00,product-release,100,64,4/1/2021
4B3555,earnings,100,50,4/1/2021
4B5054,conference-call,100,50,4/1/2021
4B6EF9,earnings,100,50,4/1/2021
4BBA23,earnings,100,50,4/1/2021
4C6C63,product-release,100,64,4/1/2021
4F9926,product-release,100,64,4/1/2021
4FCC78,dividend,100,50,4/1/2021
524CE4,conference-call,100,50,4/1/2021
55C289,partnership,100,61,4/1/2021
55C9B5,investment-investor,100,55,4/1/2021
55C9B5,partnership,100,61,4/1/2021
55C9B5,partnership,100,61,4/1/2021
56632F,note-sale,100,52,4/1/2021
567F3D,conference-call,100,50,4/1/2021
56B7C1,dividend,100,50,4/1/2021
58CA9A,dividend,100,50,4/1/2021
594402,product-release,100,64,4/1/2021
5B226B,legal-issues-defendant,100,22,4/1/2021
5D0337,executive-appointment,100,54,4/1/2021
5EC388,earnings,100,50,4/1/2021
5F2FF7,earnings,100,50,4/1/2021
5F9CE3,ownership-decrease-owner,100,46,4/1/2021
619882,conference-organizer,100,57,4/1/2021
61B81B,dividend,100,50,4/1/2021
665618,dividend-up,100,60,4/1/2021
67303E,legal-issues-defendant,100,22,4/1/2021
68BA15,dividend,100,50,4/1/2021
698FF9,executive-appointment,100,54,4/1/2021
69CE71,revenue-volume-up,100,69,4/1/2021
6E1E61,conference-call,100,50,4/1/2021
704B78,executive-appointment,100,54,4/1/2021
722DE3,business-contract,100,69,4/1/2021
723548,dividend,100,50,4/1/2021
751C8D,partnership,100,61,4/1/2021
751C8D,partnership,100,61,4/1/2021
763724,dividend,100,50,4/1/2021
76B926,executive-appointment,100,54,4/1/2021
7771D7,earnings-up,100,68,4/1/2021
791EC1,executive-resignation,100,44,4/1/2021
79340A,earnings,100,50,4/1/2021
7BFF81,business-contract,100,69,4/1/2021
7E1542,earnings,100,50,4/1/2021
7E3F8F,stake-acquirer,100,48,4/1/2021
7E3F8F,stake-acquirer,100,48,4/1/2021
8.10E+32,partnership,100,61,4/1/2021
834152,clinical-trials-start,100,64,4/1/2021
84A6B9,earnings,100,50,4/1/2021
85CDC9,stake-acquiree,100,62,4/1/2021
8665BA,product-release,100,64,4/1/2021
873DB9,investment-investor,100,55,4/1/2021
87486A,conference-call,100,50,4/1/2021
88923D,conference-call,100,50,4/1/2021
8A8E41,business-contract,100,69,4/1/2021
8A8E41,partnership,100,61,4/1/2021
8B4A45,partnership,100,61,4/1/2021
8D4486,partnership,100,61,4/1/2021
8D4486,partnership,100,61,4/1/2021
8D4486,partnership,100,61,4/1/2021
8DA42F,partnership,100,61,4/1/2021
911AB8,conference-call,100,50,4/1/2021
911CA9,conference-participant,100,50,4/1/2021
91C82E,unit-acquisition-acquirer,100,49,4/1/2021
91C82E,unit-acquisition-acquirer,100,49,4/1/2021
922F0C,earnings,100,50,4/1/2021
94563D,earnings,100,50,4/1/2021
95F59E,acquisition-completed-acquiree,100,76,4/1/2021
96F126,earnings,100,50,4/1/2021
9.74E+08,acquisition-completed-acquirer,100,49,4/1/2021
9B4066,unit-acquisition-acquirer,100,49,4/1/2021
9CA4C6,conference-call,100,50,4/1/2021
9F03CF,conference-call,100,50,4/1/2021
9F37C5,dividend,100,50,4/1/2021
A11CF4,acquisition-completed-acquiree,100,76,4/1/2021
A28C54,acquisition-acquirer,100,49,4/1/2021
A350C1,conference-call,100,50,4/1/2021
A5B913,earnings,100,50,4/1/2021
A6213D,revenue-up,100,86,4/1/2021
A666C8,note-sale,100,52,4/1/2021
A6FE1C,acquisition-acquirer,100,49,4/1/2021
A72FD9,public-offering,100,43,4/1/2021
A8CBDA,earnings,100,50,4/1/2021
A8E2FE,clinical-trials-start,100,64,4/1/2021
A99576,conference-call,100,50,4/1/2021
AA7FE0,stake-acquirer,100,48,4/1/2021
AA7FE0,earnings,100,50,4/1/2021
ACDF88,conference-participant,100,50,4/1/2021
AD1ACF,legal-verdict-disfavored,100,22,4/1/2021
AD9F1D,conference-call,100,50,4/1/2021
ADF092,product-release,100,64,4/1/2021
B2F431,executive-appointment,100,54,4/1/2021
B37FB4,earnings,100,50,4/1/2021
B48FC9,product-release,100,64,4/1/2021
B604DF,conference-call,100,50,4/1/2021
B840EF,conference-call,100,50,4/1/2021
BA0442,partnership,100,61,4/1/2021
BAAA60,conference-call,100,50,4/1/2021
BBAE2A,conference-call,100,50,4/1/2021
BFAEB4,executive-resignation,100,44,4/1/2021
C0200F,earnings,100,50,4/1/2021
C188F8,clinical-trials-filed,100,60,4/1/2021
C4706C,executive-appointment,100,54,4/1/2021
C7AE14,dividend,100,50,4/1/2021
C9D866,conference-call,100,50,4/1/2021
CBFFDD,trading-halt,100,43,4/1/2021
CCB623,product-release,100,64,4/1/2021
CFF97C,product-release,100,64,4/1/2021
D1173F,conference-call,100,50,4/1/2021
D25249,acquisition-completed-acquirer,100,49,4/1/2021
D33270,acquisition-acquiree,100,76,4/1/2021
D5AF19,earnings,100,50,4/1/2021
D60BB2,partnership,100,61,4/1/2021
D8760C,conference-call,100,50,4/1/2021
DC6EF3,public-offering,100,43,4/1/2021
DD1BA1,earnings,100,50,4/1/2021
DEF058,earnings,100,50,4/1/2021
E0339F,earnings,100,50,4/1/2021
E12A6E,earnings,100,50,4/1/2021
E15736,note-sale,100,52,4/1/2021
E261E9,earnings,100,50,4/1/2021
E3E68E,award,100,58,4/1/2021
E3E68E,award,100,58,4/1/2021
E4CE73,partnership,100,61,4/1/2021
E56A0D,public-offering,100,43,4/1/2021
E87676,acquisition-acquirer,100,49,4/1/2021
E99180,acquisition-completed-acquirer,100,49,4/1/2021
EAEA91,earnings,100,50,4/1/2021
EAEA91,dividend,100,50,4/1/2021
EC8116,dividend,100,50,4/1/2021
ED9576,earnings,100,50,4/1/2021
EEEA9F,unit-acquisition-acquiree,100,76,4/1/2021
F1CD47,earnings,100,50,4/1/2021
F294DD,dividend,100,50,4/1/2021
F50BAB,conference-call,100,50,4/1/2021
F6E248,regulatory-product-application,100,69,4/1/2021
F6E248,clinical-trials-filed,100,60,4/1/2021
F85CC0,acquisition-acquirer,100,49,4/1/2021
F85CC0,acquisition-acquirer,100,49,4/1/2021
F8BA6C,executive-appointment,100,54,4/1/2021
FC4550,dividend,100,50,4/1/2021
0EF1AF,legal-issues-defendant,100,22,4/2/2021
149301,executive-resignation,100,44,4/2/2021
152B9E,executive-appointment,100,54,4/2/2021
184866,clinical-trials,100,56,4/2/2021
1F19C8,fundraising,100,64,4/2/2021
2B9DBB,conference-call,100,50,4/2/2021
2D643C,conference-call,100,50,4/2/2021
63F892,earnings,100,50,4/2/2021
6D156D,legal-issues-defendant,100,22,4/2/2021
76CEFB,earnings,100,50,4/2/2021
7F9984,executive-appointment,100,54,4/2/2021
A41450,dividend,100,50,4/2/2021
C941DC,conference-participant,100,50,4/2/2021
DD0099,earnings,100,50,4/2/2021
F5D059,dividend,100,50,4/2/2021
1DEBBE,legal-issues-defendant,100,22,4/3/2021
449A26,legal-issues-defendant,100,22,4/3/2021
4F0A80,legal-issues-defendant,100,22,4/3/2021
504FE2,fraud-defendant,100,20,4/3/2021
52B567,legal-issues-defendant,100,22,4/3/2021
7255D2,fraud-defendant,100,20,4/3/2021
834152,legal-issues-defendant,100,22,4/3/2021
18D9FA,fraud-defendant,100,20,4/4/2021
1E04A5,legal-issues-defendant,100,22,4/4/2021
01478A,conference-call,100,50,4/5/2021
078D52,dividend,100,50,4/5/2021
07CA6A,product-release,100,64,4/5/2021
07CA6A,product-release,100,64,4/5/2021
0CBC4D,earnings,100,50,4/5/2021
0CC62B,conference-call,100,50,4/5/2021
11AEDE,clinical-trials-start,100,64,4/5/2021
1201B5,executive-appointment,100,54,4/5/2021
1279ED,earnings-guidance,100,50,4/5/2021
1279ED,earnings-guidance,100,50,4/5/2021
184866,conference-participant,100,50,4/5/2021
188394,conference-call,100,50,4/5/2021
18D9FA,legal-issues-defendant,100,22,4/5/2021
1A3E1B,partnership,100,61,4/5/2021
1A6A94,trading-resumed,100,58,4/5/2021
1B637E,acquisition-acquirer,100,49,4/5/2021
1B637E,acquisition-acquirer,100,49,4/5/2021
1B637E,acquisition-acquirer,100,49,4/5/2021
1DE526,conference-call,100,50,4/5/2021
1EC3E8,executive-appointment,100,54,4/5/2021
1EC3E8,executive-appointment,100,54,4/5/2021
228D42,partnership,100,61,4/5/2021
228D42,partnership,100,61,4/5/2021
228D42,partnership,100,61,4/5/2021
228D42,partnership,100,61,4/5/2021
22C58E,partnership,100,61,4/5/2021
22C58E,earnings,100,50,4/5/2021
28DCA8,earnings-guidance,100,50,4/5/2021
2A9C0A,conference-call,100,50,4/5/2021
2B0AF4,conference-call,100,50,4/5/2021
2C681C,clinical-trials-start,100,64,4/5/2021
2C681C,clinical-trials-start,100,64,4/5/2021
2C681C,clinical-trials-start,100,64,4/5/2021
2CB4C9,earnings,100,50,4/5/2021
2CF9D3,orphan-drug-designation,100,76,4/5/2021
2F9304,executive-appointment,100,54,4/5/2021
315EB0,conference-call,100,50,4/5/2021
326EDD,conference-call,100,50,4/5/2021
342218,conference-call,100,50,4/5/2021
38C46F,dividend,100,50,4/5/2021
3AAEAE,clinical-trials,100,56,4/5/2021
3BB616,earnings,100,50,4/5/2021
3DB18B,executive-appointment,100,54,4/5/2021
3E15F6,conference-call,100,50,4/5/2021
3F1C69,index-listing,100,76,4/5/2021
3FACA7,earnings-guidance,100,50,4/5/2021
416291,business-contract,100,69,4/5/2021
416291,business-contract,100,69,4/5/2021
41785E,earnings,100,50,4/5/2021
45ABCC,acquisition-completed-acquirer,100,49,4/5/2021
49A344,award,100,58,4/5/2021
4A2457,business-contract,100,69,4/5/2021
4F9487,conference-call,100,50,4/5/2021
4FCC78,conference-call,100,50,4/5/2021
504FE2,partnership,100,61,4/5/2021
52015A,dividend,100,50,4/5/2021
52B567,legal-issues-defendant,100,22,4/5/2021
5487B1,conference-call,100,50,4/5/2021
5675EB,business-contract,100,69,4/5/2021
57F3DA,executive-appointment,100,54,4/5/2021
59C539,conference-call,100,50,4/5/2021
5A9A82,executive-appointment,100,54,4/5/2021
5B226B,legal-issues-defendant,100,22,4/5/2021
5B226B,legal-issues-defendant,100,22,4/5/2021
5B51D6,executive-appointment,100,54,4/5/2021
5C8D61,earnings,100,50,4/5/2021
5D41E4,business-contract,100,69,4/5/2021
60AC34,patient-enrollment-start,100,58,4/5/2021
60EA12,earnings,100,50,4/5/2021
615B6D,legal-issues-defendant,100,22,4/5/2021
627186,conference-participant,100,50,4/5/2021
636639,fundraising,100,64,4/5/2021
65D0AA,merger,100,66,4/5/2021
65D0AA,merger,100,66,4/5/2021
67303E,legal-issues-defendant,100,22,4/5/2021
67529E,executive-resignation,100,44,4/5/2021
67B052,conference-participant,100,50,4/5/2021
67B052,conference-participant,100,50,4/5/2021
69E8E1,conference-call,100,50,4/5/2021
69E8E1,conference-call,100,50,4/5/2021
6C6D73,conference-participant,100,50,4/5/2021
6F39FC,dividend-up,100,77,4/5/2021
704B78,earnings,100,50,4/5/2021
70FCEF,executive-appointment,100,54,4/5/2021
7122EB,conference-participant,100,50,4/5/2021
726DDF,business-contract,100,69,4/5/2021
731675,conference-call,100,50,4/5/2021
7B9AFA,conference-participant,100,50,4/5/2021
805CD8,executive-resignation,100,44,4/5/2021
845655,executive-appointment,100,54,4/5/2021
845655,executive-appointment,100,54,4/5/2021
85CDC9,regulatory-product-application,100,69,4/5/2021
8665BA,conference-call,100,50,4/5/2021
873DB9,earnings,100,50,4/5/2021
877C0C,acquisition-completed-acquirer,100,49,4/5/2021
8BE916,earnings,100,50,4/5/2021
8DBBE6,conference-call,100,50,4/5/2021
8E93A4,conference-call,100,50,4/5/2021
8FCA78,executive-resignation,100,44,4/5/2021
925759,clinical-trials-start,100,64,4/5/2021
93AD2E,earnings,100,50,4/5/2021
965360,earnings,100,50,4/5/2021
96A2D3,executive-appointment,100,54,4/5/2021
96F126,product-release,100,64,4/5/2021
97644E,executive-appointment,100,54,4/5/2021
9810C0,conference-call,100,50,4/5/2021
9C5174,earnings,100,50,4/5/2021
9E5C2C,conference-call,100,50,4/5/2021
A0F146,executive-appointment,100,54,4/5/2021
A70BF5,board-meeting,100,51,4/5/2021
A87CD6,earnings,100,50,4/5/2021
B01111,facility-open,100,65,4/5/2021
B05118,earnings,100,50,4/5/2021
B4703C,conference-call,100,50,4/5/2021
B48FC9,investment-investor,100,55,4/5/2021
B48FC9,acquisition-acquirer,100,49,4/5/2021
B6082A,conference-call,100,50,4/5/2021
B642E8,ownership-decrease-held,100,49,4/5/2021
B840EF,partnership,100,61,4/5/2021
C2E39B,revenues,100,50,4/5/2021
C36189,business-contract,100,69,4/5/2021
C38440,conference-participant,100,50,4/5/2021
C564E4,partnership,100,61,4/5/2021
C5C0E9,conference-call,100,50,4/5/2021
C7859D,dividend,100,50,4/5/2021
C7863D,conference-call,100,50,4/5/2021
CE5664,board-meeting,100,51,4/5/2021
CF3FF9,executive-appointment,100,54,4/5/2021
CF6A5A,earnings,100,50,4/5/2021
D18AFC,conference-participant,100,50,4/5/2021
D1C26F,earnings-guidance-up,100,83,4/5/2021
D1C26F,earnings-guidance-up,100,83,4/5/2021
D36686,conference-participant,100,50,4/5/2021
D42DBA,revenues,100,50,4/5/2021
D54E62,conference-call,100,50,4/5/2021
D5938F,conference-participant,100,50,4/5/2021
D6853F,investment-investor,100,55,4/5/2021
D854F3,conference-call,100,50,4/5/2021
D88EF3,product-release,100,64,4/5/2021
DB88A1,note-sale,100,52,4/5/2021
DD682D,earnings,100,50,4/5/2021
DF11D9,market-entry,100,57,4/5/2021
E0E4B7,executive-appointment,100,54,4/5/2021
E1F30A,public-offering,100,43,4/5/2021
E22FDE,conference-participant,100,50,4/5/2021
E2F130,dividend-up,100,81,4/5/2021
E6D89E,revenue-guidance,100,50,4/5/2021
E74FED,note-sale,100,52,4/5/2021
EBD89A,business-contract,100,69,4/5/2021
F3016C,acquisition-completed-acquirer,100,49,4/5/2021
F3816D,conference-participant,100,50,4/5/2021
F40EE2,partnership,100,61,4/5/2021
F40EE2,partnership,100,61,4/5/2021
F48947,executive-appointment,100,54,4/5/2021
FC01C0,conference-participant,100,50,4/5/2021
FC9A88,conference-call,100,50,4/5/2021
FD0CA4,conference-call,100,50,4/5/2021
002A99,regulatory-investigation,100,22,4/6/2021
13528,partnership,100,61,4/6/2021
0157B1,partnership,100,61,4/6/2021
01D03F,product-release,100,64,4/6/2021
20751,conference-participant,100,50,4/6/2021
31025,earnings,100,50,4/6/2021
040DBB,executive-appointment,100,54,4/6/2021
55018,partnership,100,61,4/6/2021
07C69F,conference-call,100,50,4/6/2021
081AB9,conference-call,100,50,4/6/2021
0919B1,conference-call,100,50,4/6/2021
0A0D9E,conference-call,100,50,4/6/2021
0BC853,conference-call,100,50,4/6/2021
0BF528,partnership,100,61,4/6/2021
0E5619,conference-participant,100,50,4/6/2021
0F0440,facility-open,100,65,4/6/2021
1220D2,conference-participant,100,50,4/6/2021
1272B3,partnership,100,61,4/6/2021
12DE76,executive-appointment,100,54,4/6/2021
157D9F,executive-appointment,100,54,4/6/2021
165B86,acquisition-acquirer,100,49,4/6/2021
16B183,legal-issues-defendant,100,22,4/6/2021
17EDA5,partnership,100,61,4/6/2021
1CD4B5,clinical-trials-positive,100,87,4/6/2021
1D1B07,partnership,100,61,4/6/2021
1D1B07,partnership,100,61,4/6/2021
206852,conference-call,100,50,4/6/2021
223552,conference-participant,100,50,4/6/2021
228D42,partnership,100,61,4/6/2021
228D42,partnership,100,61,4/6/2021
228D42,partnership,100,61,4/6/2021
241252,conference-participant,100,50,4/6/2021
2667B6,earnings,100,50,4/6/2021
26F31D,executive-appointment,100,54,4/6/2021
29A4CC,conference-call,100,50,4/6/2021
2B7A40,earnings,100,50,4/6/2021
2E0496,earnings,100,50,4/6/2021
2F5256,conference-call,100,50,4/6/2021
3.14E+47,earnings,100,50,4/6/2021
338544,partnership,100,61,4/6/2021
37727A,conference-call,100,50,4/6/2021
3.88E+02,conference-call,100,50,4/6/2021
39BFF6,conference-call,100,50,4/6/2021
3A3948,executive-appointment,100,54,4/6/2021
3A3948,executive-appointment,100,54,4/6/2021
3B37F7,dividend,100,50,4/6/2021
3C3B6B,executive-appointment,100,54,4/6/2021
3C6CCC,executive-resignation,100,44,4/6/2021
3DC887,earnings,100,50,4/6/2021
3DD5E2,conference-call,100,50,4/6/2021
3DED49,conference-call,100,50,4/6/2021
407878,executive-appointment,100,54,4/6/2021
4.00E+163,acquisition-completed-acquirer,100,49,4/6/2021
415188,conference-call,100,50,4/6/2021
422CE3,market-entry,100,57,4/6/2021
422CE3,market-entry,100,57,4/6/2021
44A4FC,partnership,100,61,4/6/2021
44A4FC,partnership,100,61,4/6/2021
4591D3,conference-call,100,50,4/6/2021
4.60E+06,executive-appointment,100,54,4/6/2021
4EC4C1,earnings,100,50,4/6/2021
4EC4C1,earnings,100,50,4/6/2021
4EC4C1,earnings,100,50,4/6/2021
4EC4C1,earnings,100,50,4/6/2021
4F71DC,public-offering,100,43,4/6/2021
4F783B,executive-appointment,100,54,4/6/2021
4FB770,conference-call,100,50,4/6/2021
504FE2,conference-call,100,50,4/6/2021
51888A,unit-acquisition-acquiree,100,76,4/6/2021
54512F,award,100,58,4/6/2021
54512F,award,100,58,4/6/2021
54DF47,conference-call,100,50,4/6/2021
56277A,conference-call,100,50,4/6/2021
562853,facility-open,100,65,4/6/2021
589803,earnings,100,50,4/6/2021
596116,partnership,100,61,4/6/2021
5A423F,earnings,100,50,4/6/2021
5D43A7,partnership,100,61,4/6/2021
60DD84,conference-call,100,50,4/6/2021
61BCA7,executive-appointment,100,54,4/6/2021
639BD6,earnings,100,50,4/6/2021
69FDFC,executive-appointment,100,54,4/6/2021
6D0CAB,operating-earnings,100,50,4/6/2021
6D6B40,earnings,100,50,4/6/2021
6F6559,earnings,100,50,4/6/2021
6F6559,earnings,100,50,4/6/2021
6F6559,earnings,100,50,4/6/2021
6F6559,earnings,100,50,4/6/2021
70FCEF,executive-appointment,100,54,4/6/2021
722DE3,business-contract,100,69,4/6/2021
72CB93,earnings,100,50,4/6/2021
7.44E+09,conference-call,100,50,4/6/2021
747219,note-sale,100,52,4/6/2021
747219,note-sale,100,52,4/6/2021
771985,conference-call,100,50,4/6/2021
7823A3,executive-appointment,100,54,4/6/2021
7.83E+79,earnings,100,50,4/6/2021
7A5097,acquisition-acquirer,100,49,4/6/2021
7BFF81,stake-acquirer,100,48,4/6/2021
7E3F8F,earnings,100,50,4/6/2021
7F3FBC,unit-acquisition-acquirer,100,49,4/6/2021
7FD8B9,executive-appointment,100,54,4/6/2021
819492,executive-appointment,100,54,4/6/2021
834152,legal-issues-defendant,100,22,4/6/2021
834152,legal-issues-defendant,100,22,4/6/2021
838ADD,unit-acquisition-acquirer,100,49,4/6/2021
85DE00,conference-call,100,50,4/6/2021
85DE00,acquisition-completed-acquirer,100,49,4/6/2021
8665BA,sponsorship,100,57,4/6/2021
8802B4,conference-call,100,50,4/6/2021
883D82,legal-issues-defendant,100,22,4/6/2021
8A8E41,partnership,100,61,4/6/2021
8A8E41,partnership,100,61,4/6/2021
8D5145,earnings,100,50,4/6/2021
8E0E32,earnings,100,50,4/6/2021
90D6A5,conference-call,100,50,4/6/2021
925759,business-contract,100,69,4/6/2021
925759,note-sale,100,52,4/6/2021
93D207,earnings,100,50,4/6/2021
95C392,conference-call,100,50,4/6/2021
977A1E,conference-call,100,50,4/6/2021
980C14,conference-call,100,50,4/6/2021
9.86E+03,executive-appointment,100,54,4/6/2021
98CAED,earnings,100,50,4/6/2021
9C5BA5,earnings,100,50,4/6/2021
9C8BC3,conference-call,100,50,4/6/2021
9E575E,conference-participant,100,50,4/6/2021
9F5CBB,executive-appointment,100,54,4/6/2021
9F71E5,partnership,100,61,4/6/2021
A01200,executive-appointment,100,54,4/6/2021
A017F4,public-offering,100,43,4/6/2021
A26EF7,public-offering,100,43,4/6/2021
A3F598,conference-call,100,50,4/6/2021
A4386C,earnings,100,50,4/6/2021
A79F7D,conference-participant,100,50,4/6/2021
A868C9,business-contract,100,69,4/6/2021
ACF77B,business-contract,100,69,4/6/2021
ACF77B,partnership,100,61,4/6/2021
AE4125,executive-appointment,100,54,4/6/2021
AE7D16,executive-appointment,100,54,4/6/2021
AFBEB4,earnings,100,50,4/6/2021
B13B68,partnership,100,61,4/6/2021
B446B8,earnings,100,50,4/6/2021
B934BF,conference-call,100,50,4/6/2021
B96637,business-contract,100,69,4/6/2021
B9764A,conference-call,100,50,4/6/2021
B9CD50,acquisition-acquirer,100,49,4/6/2021
BB02FB,note-sale,100,52,4/6/2021
BB02FB,note-sale,100,52,4/6/2021
BB5271,executive-appointment,100,54,4/6/2021
BBBB41,conference-call,100,50,4/6/2021
BE7BA4,conference-call,100,50,4/6/2021
C0030A,business-contract,100,69,4/6/2021
C188F8,note-sale,100,52,4/6/2021
C3BAE7,earnings,100,50,4/6/2021
C501B6,business-contract,100,69,4/6/2021
CB7AB2,conference-call,100,50,4/6/2021
CBA33B,executive-resignation,100,44,4/6/2021
CC176E,executive-appointment,100,54,4/6/2021
CC176E,executive-appointment,100,54,4/6/2021
CC35BE,partnership,100,61,4/6/2021
CDAB24,award,100,58,4/6/2021
CE2791,conference-call,100,50,4/6/2021
CF211D,earnings,100,50,4/6/2021
CFF15D,partnership,100,61,4/6/2021
CFF15D,partnership,100,61,4/6/2021
CFF97C,conference-call,100,50,4/6/2021
D17C1B,product-release,100,64,4/6/2021
D1AE3B,partnership,100,61,4/6/2021
D4463B,executive-appointment,100,54,4/6/2021
D518D8,conference-call,100,50,4/6/2021
D6EAA3,conference-call,100,50,4/6/2021
D90F43,partnership,100,61,4/6/2021
D90F43,partnership,100,61,4/6/2021
DA0CB8,conference-call,100,50,4/6/2021
DC1405,earnings,100,50,4/6/2021
DC6EF3,public-offering,100,43,4/6/2021
DD1BA1,facility-open,100,65,4/6/2021
DF01B1,conference-call,100,50,4/6/2021
DF11D9,conference-call,100,50,4/6/2021
DF532D,conference-call,100,50,4/6/2021
E2F130,earnings,100,50,4/6/2021
E3E68E,conference-call,100,50,4/6/2021
E3E68E,conference-call,100,50,4/6/2021
E56A0D,public-offering,100,43,4/6/2021
E598FB,conference-participant,100,50,4/6/2021
E5C910,conference-participant,100,50,4/6/2021
E802CE,executive-appointment,100,54,4/6/2021
EB36DE,merger-failed,100,21,4/6/2021
ECD263,defamation-defendant,100,35,4/6/2021
ED3CA8,conference-call,100,50,4/6/2021
EE967B,earnings,100,50,4/6/2021
EF5BED,executive-appointment,100,54,4/6/2021
F0B335,conference-participant,100,50,4/6/2021
F294DD,earnings,100,50,4/6/2021
F30508,conference-call,100,50,4/6/2021
F4CDA3,unit-acquisition-acquirer,100,49,4/6/2021
F5D499,acquisition-completed-acquirer,100,49,4/6/2021
F7ADEB,conference-call,100,50,4/6/2021
FA40E2,executive-appointment,100,54,4/6/2021
FDC7E6,conference-call,100,50,4/6/2021
FEE4B0,earnings,100,50,4/6/2021
002A99,legal-issues-defendant,100,22,4/7/2021
002A99,legal-issues-defendant,100,22,4/7/2021
002A99,legal-issues-defendant,100,22,4/7/2021
0157B1,partnership,100,61,4/7/2021
0157B1,partnership,100,61,4/7/2021
0157B1,partnership,100,61,4/7/2021
01D03F,product-release,100,64,4/7/2021
51332,earnings,100,50,4/7/2021
070B45,product-release,100,64,4/7/2021
07EC43,conference-call,100,50,4/7/2021
0BF528,product-release,100,64,4/7/2021
0DBB81,conference-participant,100,50,4/7/2021
0DBB81,conference-participant,100,50,4/7/2021
10AE08,earnings,100,50,4/7/2021
16B882,earnings,100,50,4/7/2021
1748F6,product-release,100,64,4/7/2021
1748F6,product-release,100,64,4/7/2021
190B91,earnings,100,50,4/7/2021
1921DD,business-contract,100,69,4/7/2021
1F08A6,conference-call,100,50,4/7/2021
1FAF22,conference-participant,100,50,4/7/2021
2082EA,conference-participant,100,50,4/7/2021
20BEEA,conference-call,100,50,4/7/2021
21153F,unit-acquisition-acquiree,100,76,4/7/2021
21153F,unit-acquisition-acquiree,100,76,4/7/2021
228D42,partnership,100,61,4/7/2021
228D42,partnership,100,61,4/7/2021
228D42,partnership,100,61,4/7/2021
24FA23,conference-participant,100,50,4/7/2021
251988,partnership,100,61,4/7/2021
25D3CE,conference-participant,100,50,4/7/2021
25DD05,conference-call,100,50,4/7/2021
26F99F,conference-participant,100,50,4/7/2021
275300,conference-call,100,50,4/7/2021
278C18,dividend,100,50,4/7/2021
282C18,conference-call,100,50,4/7/2021
292388,executive-appointment,100,54,4/7/2021
2950FF,earnings,100,50,4/7/2021
2950FF,earnings,100,50,4/7/2021
29B702,earnings,100,50,4/7/2021
2B49F4,partnership,100,61,4/7/2021
2BF36E,conference-call,100,50,4/7/2021
2CB4C9,earnings,100,50,4/7/2021
2E0445,conference-participant,100,50,4/7/2021
2E89AE,earnings,100,50,4/7/2021
349DA4,conference-participant,100,50,4/7/2021
34B411,merger-regulatory-approval,100,81,4/7/2021
34E9F9,dividend-suspended,100,13,4/7/2021
35557B,executive-appointment,100,54,4/7/2021
367434,conference-participant,100,50,4/7/2021
3.73E+87,acquisition-regulatory-approval-acquiree,100,81,4/7/2021
384CD3,business-contract,100,69,4/7/2021
387375,conference-call,100,50,4/7/2021
39D9DA,note-sale,100,52,4/7/2021
3AF7FD,conference-participant,100,50,4/7/2021
3C7F5F,earnings,100,50,4/7/2021
3ED92D,earnings-guidance,100,50,4/7/2021
3F1C69,conference-participant,100,50,4/7/2021
42EFC7,public-offering,100,43,4/7/2021
46017C,conference-call,100,50,4/7/2021
47752F,earnings,100,50,4/7/2021
4A6F00,partnership,100,61,4/7/2021
4A6F00,partnership,100,61,4/7/2021
4D8124,earnings,100,50,4/7/2021
507AE7,earnings,100,50,4/7/2021
519FE0,acquisition-completed-acquirer,100,49,4/7/2021
532D47,conference-call,100,50,4/7/2021
54DF47,executive-appointment,100,54,4/7/2021
55438C,earnings,100,50,4/7/2021
56AFF4,executive-appointment,100,54,4/7/2021
56B7C1,conference-call,100,50,4/7/2021
5B226B,legal-issues-defendant,100,22,4/7/2021
5B226B,legal-issues-defendant,100,22,4/7/2021
5B97B2,earnings,100,50,4/7/2021
5CC29D,earnings,100,50,4/7/2021
5F9CE3,earnings,100,50,4/7/2021
605F40,conference-call,100,50,4/7/2021
619882,conference-organizer,100,57,4/7/2021
6.52E+64,executive-appointment,100,54,4/7/2021
66749D,earnings,100,50,4/7/2021
66ECFD,dividend,100,50,4/7/2021
67303E,legal-issues-defendant,100,22,4/7/2021
69345C,acquisition-regulatory-approval-acquirer,100,54,4/7/2021
6CB7F9,conference-call,100,50,4/7/2021
6F0096,conference-call,100,50,4/7/2021
729368,earnings,100,50,4/7/2021
741937,earnings,100,50,4/7/2021
7.40E+289,earnings,100,50,4/7/2021
76E80F,conference-participant,100,50,4/7/2021
7771D7,partnership,100,61,4/7/2021
78F9ED,product-release,100,64,4/7/2021
7A0EC4,partnership,100,61,4/7/2021
7AC86E,executive-appointment,100,54,4/7/2021
7ACD98,earnings,100,50,4/7/2021
7B1E50,investment-investor,100,55,4/7/2021
7B1E50,investment-investor,100,55,4/7/2021
7D7716,earnings,100,50,4/7/2021
7E2DE6,earnings,100,50,4/7/2021
8.10E+32,conference-call,100,50,4/7/2021
8.10E+32,acquisition-completed-acquiree,100,76,4/7/2021
8.10E+32,unit-acquisition-completed-acquiree,100,67,4/7/2021
883D82,legal-issues-defendant,100,22,4/7/2021
883D82,legal-issues-defendant,100,22,4/7/2021
88923D,acquisition-acquirer,100,49,4/7/2021
8D9993,acquisition-completed-acquirer,100,49,4/7/2021
8DCBBB,conference-call,100,50,4/7/2021
8E82A6,earnings,100,50,4/7/2021
902670,conference-call,100,50,4/7/2021
91C82E,dividend,100,50,4/7/2021
934029,conference-call,100,50,4/7/2021
94637C,business-contract,100,69,4/7/2021
949625,dividend,100,50,4/7/2021
9.62E+76,earnings,100,50,4/7/2021
96A2D3,earnings,100,50,4/7/2021
981656,product-release,100,64,4/7/2021
990AD0,conference-organizer,100,57,4/7/2021
9B4066,unit-acquisition-acquirer,100,49,4/7/2021
9CE4C7,earnings,100,50,4/7/2021
9EED50,conference-call,100,50,4/7/2021
9FF5F1,earnings,100,50,4/7/2021
A017F4,public-offering,100,43,4/7/2021
A247F5,regulatory-product-approval-granted,100,81,4/7/2021
A5195E,conference-participant,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A5A4F5,earnings,100,50,4/7/2021
A6828A,partnership,100,61,4/7/2021
A72FD9,conference-call,100,50,4/7/2021
A7E2AB,business-contract,100,69,4/7/2021
A80FE0,conference-call,100,50,4/7/2021
AA1EAA,conference-call,100,50,4/7/2021
AA247D,business-contract,100,69,4/7/2021
AADE0B,conference-call,100,50,4/7/2021
AB7F05,earnings,100,50,4/7/2021
AE79CD,conference-participant,100,50,4/7/2021
AFF7B4,conference-call,100,50,4/7/2021
B2206F,partnership,100,61,4/7/2021
B5766D,conference-call,100,50,4/7/2021
B8EF97,revenues,100,50,4/7/2021
B96637,product-release,100,64,4/7/2021
BA218A,conference-call,100,50,4/7/2021
BB07E4,acquisition-completed-acquirer,100,49,4/7/2021
BB88B6,earnings,100,50,4/7/2021
C22BE8,unit-acquisition-acquirer,100,49,4/7/2021
C32A39,conference-call,100,50,4/7/2021
C356AC,earnings,100,50,4/7/2021
C36189,conference-participant,100,50,4/7/2021
C3BAE7,acquisition-completed-acquirer,100,49,4/7/2021
C3EE99,earnings,100,50,4/7/2021
C3F99F,partnership,100,61,4/7/2021
C45C1F,conference-participant,100,50,4/7/2021
C5D2AE,earnings,100,50,4/7/2021
C62AA4,note-sale,100,52,4/7/2021
C8FAC7,partnership,100,61,4/7/2021
C951A2,earnings,100,50,4/7/2021
CAD7D9,earnings,100,50,4/7/2021
CBFFDD,trading-resumed,100,58,4/7/2021
CE4E6D,note-sale,100,52,4/7/2021
CF7292,conference-participant,100,50,4/7/2021
CFF15D,partnership,100,61,4/7/2021
D06755,earnings,100,50,4/7/2021
D29F43,conference-call,100,50,4/7/2021
D33270,business-contract,100,69,4/7/2021
D36B23,conference-participant,100,50,4/7/2021
D3CEDF,conference-call,100,50,4/7/2021
D54E62,business-contract,100,69,4/7/2021
D56E4C,conference-call,100,50,4/7/2021
D56E4C,conference-call,100,50,4/7/2021
D6853F,business-contract,100,69,4/7/2021
D6853F,conference-call,100,50,4/7/2021
D77F7E,earnings,100,50,4/7/2021
D7A953,earnings,100,50,4/7/2021
DA0CB8,executive-appointment,100,54,4/7/2021
DA91AE,acquisition-completed-acquiree,100,76,4/7/2021
DA9443,conference-participant,100,50,4/7/2021
DB06B0,partnership,100,61,4/7/2021
DB7FA7,conference-call,100,50,4/7/2021
DB88A1,note-sale,100,52,4/7/2021
DD1BA1,partnership,100,61,4/7/2021
DD1BA1,partnership,100,61,4/7/2021
DD1BA1,partnership,100,61,4/7/2021
DD1BA1,note-sale,100,52,4/7/2021
DD7A96,conference-call,100,50,4/7/2021
DF1F7A,conference-call,100,50,4/7/2021
E0207A,earnings,100,50,4/7/2021
E1F30A,public-offering,100,43,4/7/2021
E22FDE,public-offering,100,43,4/7/2021
E28D9C,conference-call,100,50,4/7/2021
E30A8F,earnings,100,50,4/7/2021
E68C3D,partnership,100,61,4/7/2021
E8846E,earnings,100,50,4/7/2021
E8E899,executive-appointment,100,54,4/7/2021
E959F3,earnings,100,50,4/7/2021
E9C7C0,partnership,100,61,4/7/2021
EBC84C,earnings,100,50,4/7/2021
EC70EC,earnings,100,50,4/7/2021
ED0402,earnings,100,50,4/7/2021
ED5171,earnings,100,50,4/7/2021
F2E253,market-entry,100,57,4/7/2021
F30508,partnership,100,61,4/7/2021
F5C78B,conference-call,100,50,4/7/2021
F5D059,earnings,100,50,4/7/2021
F5D059,earnings,100,50,4/7/2021
F5D059,earnings,100,50,4/7/2021
F5D059,earnings,100,50,4/7/2021
F5D059,earnings,100,50,4/7/2021
F5D059,earnings,100,50,4/7/2021
F5D059,earnings,100,50,4/7/2021
F6E248,regulatory-product-approval-granted,100,81,4/7/2021
F83279,partnership,100,61,4/7/2021
F88147,conference-participant,100,50,4/7/2021
FB7724,executive-appointment,100,54,4/7/2021
FD4E8D,earnings,100,50,4/7/2021
FEC475,conference-call,100,50,4/7/2021
001F1B,operating-earnings,100,50,4/8/2021
0157B1,revenue-up,100,77,4/8/2021
036C6F,revenue-up,100,59,4/8/2021
09062E,earnings,100,50,4/8/2021
099C88,conference-call,100,50,4/8/2021
0AAD90,orphan-drug-designation,100,76,4/8/2021
0BC17A,conference-call,100,50,4/8/2021
0DC050,product-release,100,64,4/8/2021
0DC050,earnings,100,50,4/8/2021
105D00,conference-call,100,50,4/8/2021
10943B,conference-call,100,50,4/8/2021
129DC8,conference-call,100,50,4/8/2021
13C3E0,earnings,100,50,4/8/2021
143C52,hirings,100,65,4/8/2021
147C38,earnings,100,50,4/8/2021
152FA5,conference-participant,100,50,4/8/2021
15A388,earnings,100,50,4/8/2021
168A5D,partnership,100,61,4/8/2021
16B183,legal-issues-defendant,100,22,4/8/2021
1748B3,conference-call,100,50,4/8/2021
17EDA5,demand-increase,100,83,4/8/2021
184988,conference-participant,100,50,4/8/2021
1AF7E2,conference-call,100,50,4/8/2021
1B9535,earnings,100,50,4/8/2021
1CDD1C,conference-call,100,50,4/8/2021
1D1B07,earnings,100,50,4/8/2021
1D1B07,earnings,100,50,4/8/2021
1FC422,earnings,100,50,4/8/2021
2158DF,executive-appointment,100,54,4/8/2021
222BF9,conference-call,100,50,4/8/2021
228D42,partnership,100,61,4/8/2021
2491BC,reorganization-unit,100,53,4/8/2021
251988,partnership,100,61,4/8/2021
25A6CC,conference-participant,100,50,4/8/2021
267718,business-contract,100,69,4/8/2021
2720AB,conference-call,100,50,4/8/2021
2C7505,acquisition-acquiree,100,76,4/8/2021
2CA60F,partnership,100,61,4/8/2021
2D76CE,earnings,100,50,4/8/2021
2DA92D,conference-call,100,50,4/8/2021
2DB344,earnings,100,50,4/8/2021
2DC88B,earnings,100,50,4/8/2021
2EB88B,earnings,100,50,4/8/2021
30DFD3,conference-participant,100,50,4/8/2021
3.30E+30,acquisition-acquirer,100,49,4/8/2021
36E479,conference-participant,100,50,4/8/2021
371C01,conference-call,100,50,4/8/2021
385DD4,facility-open,100,65,4/8/2021
3A113F,conference-call,100,50,4/8/2021
3A3948,conference-call,100,50,4/8/2021
3AF7FD,conference-call,100,50,4/8/2021
3BCF24,earnings,100,50,4/8/2021
3F4668,donation,100,54,4/8/2021
405762,merger,100,66,4/8/2021
407878,conference-call,100,50,4/8/2021
417BF9,conference-participant,100,50,4/8/2021
434F38,earnings,100,50,4/8/2021
43A060,business-contract,100,69,4/8/2021
45444E,earnings,100,50,4/8/2021
45BC35,conference-call,100,50,4/8/2021
4806CE,conference-call,100,50,4/8/2021
4.91E+58,conference-call,100,50,4/8/2021
4A6F00,partnership,100,61,4/8/2021
4B49CF,dividend-up,100,81,4/8/2021
4E7C1F,partnership,100,61,4/8/2021
4F71DC,public-offering,100,43,4/8/2021
5088A5,earnings,100,50,4/8/2021
55C9B5,conference-call,100,50,4/8/2021
56632F,earnings,100,50,4/8/2021
567F3D,dividend,100,50,4/8/2021
5704AC,earnings,100,50,4/8/2021
579E8F,conference-participant,100,50,4/8/2021
586BD7,conference-participant,100,50,4/8/2021
5876DC,earnings,100,50,4/8/2021
5A423F,executive-appointment,100,54,4/8/2021
5B226B,legal-issues-defendant,100,22,4/8/2021
5B35C7,merger,100,66,4/8/2021
5B35C7,acquisition-regulatory-scrutiny-acquiree,100,38,4/8/2021
5C2A47,conference-call,100,50,4/8/2021
5D1956,earnings,100,50,4/8/2021
6166D1,executive-appointment,100,54,4/8/2021
633043,earnings,100,50,4/8/2021
641F17,earnings-guidance,100,50,4/8/2021
6844D2,analyst-ratings-change-positive-rater,20,50,4/8/2021
69CE71,partnership,100,61,4/8/2021
6A3C35,dividend,100,50,4/8/2021
6B236C,partnership,100,61,4/8/2021
6BD606,executive-appointment,100,54,4/8/2021
6DBBBC,executive-appointment,100,54,4/8/2021
6F0A63,conference-call,100,50,4/8/2021
728737,dividend,100,50,4/8/2021
72FCA3,dividend,100,50,4/8/2021
73C9E2,conference-call,100,50,4/8/2021
7.45E+28,conference-participant,100,50,4/8/2021
78F9ED,executive-appointment,100,54,4/8/2021
79167B,conference-call,100,50,4/8/2021
791EC1,conference-call,100,50,4/8/2021
7A3633,earnings,100,50,4/8/2021
7B0BA6,earnings,100,50,4/8/2021
7B9212,revenues,100,50,4/8/2021
7BAAE7,earnings,100,50,4/8/2021
7D97DE,conference-call,100,50,4/8/2021
8303CD,conference-call,100,50,4/8/2021
837C04,conference-call,100,50,4/8/2021
85DA04,partnership,100,61,4/8/2021
86478F,earnings,100,50,4/8/2021
880C0C,conference-call,100,50,4/8/2021
881190,conference-call,100,50,4/8/2021
88350F,partnership,100,61,4/8/2021
88611B,earnings,100,50,4/8/2021
895D56,partnership,100,61,4/8/2021
8A0368,acquisition-acquiree,100,76,4/8/2021
8A0368,legal-issues-defendant,100,22,4/8/2021
8A0368,acquisition-regulatory-scrutiny-acquiree,100,38,4/8/2021
8A8E41,product-release,100,64,4/8/2021
8A8E41,product-recall,100,29,4/8/2021
8B3B0E,conference-call,100,50,4/8/2021
8B9B3B,conference-participant,100,50,4/8/2021
8D4486,partnership,100,61,4/8/2021
8DBE73,conference-call,100,50,4/8/2021
8DBE73,note-sale,100,52,4/8/2021
902255,executive-appointment,100,54,4/8/2021
925759,note-sale,100,52,4/8/2021
92B047,unit-acquisition-acquiree,100,76,4/8/2021
92B047,unit-acquisition-acquiree,100,76,4/8/2021
92B047,unit-acquisition-acquiree,100,76,4/8/2021
92B047,unit-acquisition-acquiree,100,76,4/8/2021
9368BE,executive-appointment,100,54,4/8/2021
94756D,earnings,100,50,4/8/2021
9548BB,earnings,100,50,4/8/2021
957A07,earnings,100,50,4/8/2021
977A1E,business-contract,100,69,4/8/2021
9.86E+03,partnership,100,61,4/8/2021
986AF6,conference-call,100,50,4/8/2021
990AD0,conference-organizer,100,57,4/8/2021
990AD0,earnings,100,50,4/8/2021
9D2790,business-contract,100,69,4/8/2021
9D65C1,earnings,100,50,4/8/2021
A02FB1,conference-call,100,50,4/8/2021
A16DEA,partnership,100,61,4/8/2021
A1EAC8,conference-call,100,50,4/8/2021
A6213D,earnings,100,50,4/8/2021
A631A3,executive-appointment,100,54,4/8/2021
A75D43,conference-call,100,50,4/8/2021
AC7AAE,orphan-drug-designation,100,76,4/8/2021
AC7C4F,award,100,58,4/8/2021
AD1ACF,investment-investor,100,55,4/8/2021
AF210D,earnings,100,50,4/8/2021
AFDF2E,dividend,100,50,4/8/2021
B1DF3C,earnings,100,50,4/8/2021
B1FC3B,business-contract,100,69,4/8/2021
B2E6B5,conference-call,100,50,4/8/2021
B5BA39,earnings,100,50,4/8/2021
B7EB38,earnings,100,50,4/8/2021
B8DD94,conference-call,100,50,4/8/2021
B9764A,partnership,100,61,4/8/2021
BB0587,unit-acquisition-acquiree,100,76,4/8/2021
BB5142,conference-call,100,50,4/8/2021
BBF349,earnings,100,50,4/8/2021
BCE9DA,earnings,100,50,4/8/2021
BCE9DA,earnings,100,50,4/8/2021
BD15E8,conference-call,100,50,4/8/2021
BE14CF,conference-participant,100,50,4/8/2021
BFF98A,conference-participant,100,50,4/8/2021
C0F70B,earnings,100,50,4/8/2021
C230FE,earnings,100,50,4/8/2021
C41C25,earnings,100,50,4/8/2021
C4F9C6,conference-participant,100,50,4/8/2021
C4FBDC,award,100,58,4/8/2021
C659EB,earnings,100,50,4/8/2021
C951A2,acquisition-acquirer,100,49,4/8/2021
C951A2,acquisition-acquirer,100,49,4/8/2021
C99CC8,earnings,100,50,4/8/2021
CA212F,earnings,100,50,4/8/2021
CC35BE,award,100,58,4/8/2021
CC6FF5,partnership,100,61,4/8/2021
CD4DA8,executive-appointment,100,54,4/8/2021
CDE51C,earnings,100,50,4/8/2021
CE4E6D,product-release,100,64,4/8/2021
CEDFD5,business-contract,100,69,4/8/2021
CEDFD5,business-contract,100,69,4/8/2021
CF6A5A,facility-open,100,65,4/8/2021
D0909F,ownership-decrease-owner,100,46,4/8/2021
D1AE3B,executive-appointment,100,54,4/8/2021
D29B44,investment-investor,100,55,4/8/2021
D2B9E5,earnings,100,50,4/8/2021
D3CEDF,partnership,100,61,4/8/2021
D6144F,acquisition-acquirer,100,49,4/8/2021
D65A13,conference-call,100,50,4/8/2021
D70365,conference-call,100,50,4/8/2021
D7AC6E,earnings,100,50,4/8/2021
DB396B,conference-call,100,50,4/8/2021
DC0998,conference-call,100,50,4/8/2021
DC0D18,earnings,100,50,4/8/2021
DD1BA1,note-sale,100,52,4/8/2021
DDC415,earnings,100,50,4/8/2021
DF11D9,executive-appointment,100,54,4/8/2021
DFADDB,ownership-decrease-owner,100,46,4/8/2021
E05DC8,earnings,100,50,4/8/2021
E0D3BA,earnings,100,50,4/8/2021
E35610,conference-call,100,50,4/8/2021
E94704,conference-call,100,50,4/8/2021
EBD89A,business-contract,100,69,4/8/2021
ECE814,earnings,100,50,4/8/2021
ED9C04,spin-off,100,58,4/8/2021
ED9C04,spin-off,100,58,4/8/2021
EDD234,conference-call,100,50,4/8/2021
EF77A3,earnings,100,50,4/8/2021
EFA7B2,earnings,100,50,4/8/2021
F02170,partnership,100,61,4/8/2021
F02170,partnership,100,61,4/8/2021
F02D0A,earnings,100,50,4/8/2021
F3016C,earnings,100,50,4/8/2021
F51DB0,executive-appointment,100,54,4/8/2021
FA40E2,earnings-up,100,68,4/8/2021
FAB97A,earnings,100,50,4/8/2021
FAEABE,partnership,100,61,4/8/2021
FAEABE,partnership,100,61,4/8/2021
FB728F,conference-call,100,50,4/8/2021
FDF799,product-release,100,64,4/8/2021
FE9C0D,conference-participant,100,50,4/8/2021
FF5413,earnings,100,50,4/8/2021
083F72,conference-call,100,50,4/9/2021
0AAD90,orphan-drug-designation,100,76,4/9/2021
0C2A0D,earnings,100,50,4/9/2021
1782D5,conference-call,100,50,4/9/2021
227D48,acquisition-completed-acquirer,100,49,4/9/2021
25A6CC,earnings,100,50,4/9/2021
2667B6,executive-appointment,100,54,4/9/2021
26D8ED,conference-call,100,50,4/9/2021
284289,earnings,100,50,4/9/2021
36A1CB,executive-appointment,100,54,4/9/2021
384CD3,earnings,100,50,4/9/2021
3AAEAE,clinical-trials,100,56,4/9/2021
3DE4D1,earnings,100,50,4/9/2021
458D2C,revenue-volume,100,50,4/9/2021
4D971D,conference-call,100,50,4/9/2021
4E3D15,facility-sale,100,52,4/9/2021
504FE2,legal-issues-defendant,100,22,4/9/2021
51D876,earnings,100,50,4/9/2021
562853,conference-call,100,50,4/9/2021
58C2D4,legal-issues-defendant,100,22,4/9/2021
59A832,dividend,100,50,4/9/2021
59B229,earnings,100,50,4/9/2021
5B226B,legal-issues-defendant,100,22,4/9/2021
5B35C7,legal-issues-defendant,100,22,4/9/2021
5E6959,conference-call,100,50,4/9/2021
63E8D5,earnings,100,50,4/9/2021
662682,conference-call,100,50,4/9/2021
67303E,legal-issues-defendant,100,22,4/9/2021
7255D2,legal-issues-defendant,100,22,4/9/2021
726EEA,earnings,100,50,4/9/2021
729368,public-offering,100,43,4/9/2021
752A70,earnings,100,50,4/9/2021
762B8D,dividend,100,50,4/9/2021
76DD0C,clinical-trials,100,56,4/9/2021
77F01E,note-sale,100,52,4/9/2021
77F01E,note-sale,100,52,4/9/2021
7A10FF,earnings,100,50,4/9/2021
7AB859,conference-call,100,50,4/9/2021
7B6EB1,earnings,100,50,4/9/2021
80D744,conference-call,100,50,4/9/2021
8.22E+27,conference-call,100,50,4/9/2021
8295B8,dividend,100,50,4/9/2021
855DF7,conference-call,100,50,4/9/2021
88350F,partnership,100,61,4/9/2021
97AF94,dividend,100,50,4/9/2021
990AD0,dividend,100,50,4/9/2021
9A02C4,conference-call,100,50,4/9/2021
9C8664,conference-call,100,50,4/9/2021
9E298A,conference-call,100,50,4/9/2021
A1A317,conference-call,100,50,4/9/2021
A5151E,earnings,100,50,4/9/2021
A65325,conference-call,100,50,4/9/2021
A74F6F,conference-call,100,50,4/9/2021
A94718,conference-call,100,50,4/9/2021
AC642C,earnings,100,50,4/9/2021
AC642C,earnings,100,50,4/9/2021
AC7C4F,conference-call,100,50,4/9/2021
AFEC35,earnings,100,50,4/9/2021
BCC13E,conference-participant,100,50,4/9/2021
C188F8,note-sale,100,52,4/9/2021
C94CFC,conference-participant,100,50,4/9/2021
CA3CB9,conference-call,100,50,4/9/2021
CC6FF5,earnings,100,50,4/9/2021
CFF97C,credit-rating-confirmation-rater,20,50,4/9/2021
D0909F,earnings-guidance,100,50,4/9/2021
D0C79E,executive-appointment,100,54,4/9/2021
D78BF1,partnership,100,61,4/9/2021
DBEF02,dividend,100,50,4/9/2021
DC5299,conference-call,100,50,4/9/2021
DCD97F,conference-call,100,50,4/9/2021
DD3BB1,earnings,100,50,4/9/2021
E05026,executive-appointment,100,54,4/9/2021
E74B55,legal-issues-defendant,100,22,4/9/2021
E74FED,note-sale,100,52,4/9/2021
E8E899,conference-call,100,50,4/9/2021
ED7F13,public-offering,100,43,4/9/2021
ED7F13,public-offering,100,43,4/9/2021
EDD234,business-contract,100,69,4/9/2021
EF5BED,earnings,100,50,4/9/2021
FB728F,business-contract,100,69,4/9/2021
FF227B,conference-call,100,50,4/9/2021
FF6644,conference-call,100,50,4/9/2021
FF9FF6,fundraising,100,64,4/9/2021
FF9FF6,fundraising,100,64,4/9/2021
033B58,clinical-trials-positive,100,87,4/10/2021
43862,clinical-trials,100,56,4/10/2021
96930,clinical-trials,100,56,4/10/2021
18D9FA,legal-issues-defendant,100,22,4/10/2021
241252,clinical-trials,100,56,4/10/2021
401072,clinical-trials,100,56,4/10/2021
401072,clinical-trials,100,56,4/10/2021
543C77,clinical-trials,100,56,4/10/2021
5B226B,legal-issues-defendant,100,22,4/10/2021
6A024C,clinical-trials,100,56,4/10/2021
6D156D,conference-call,100,50,4/10/2021
9978F1,clinical-trials,100,56,4/10/2021
B04426,clinical-trials,100,56,4/10/2021
D36B23,clinical-trials,100,56,4/10/2021
D5938F,clinical-trials,100,56,4/10/2021
E74B55,legal-issues-defendant,100,22,4/10/2021
F569FD,clinical-trials,100,56,4/10/2021
FF227B,clinical-trials,100,56,4/10/2021
FF227B,clinical-trials,100,56,4/10/2021
1DEBBE,legal-issues-defendant,100,22,4/11/2021
1E04A5,legal-issues-defendant,100,22,4/11/2021
2C7505,clinical-trials,100,56,4/11/2021
5B15E1,legal-issues-defendant,100,22,4/11/2021
5FF95F,earnings,100,50,4/11/2021
7CD98F,legal-issues-defendant,100,22,4/11/2021
A6D095,clinical-trials,100,56,4/11/2021
ECF4F8,legal-issues-defendant,100,22,4/11/2021
00067A,business-contract,100,69,4/12/2021
002A99,fast-track-designation,100,81,4/12/2021
01D03F,regulatory-product-approval-granted,100,81,4/12/2021
03CF95,product-release,100,64,4/12/2021
095A04,clinical-trials-start,100,64,4/12/2021
099A92,conference-call,100,50,4/12/2021
099C88,market-entry,100,57,4/12/2021
0C355F,conference-call,100,50,4/12/2021
0C4131,conference-call,100,50,4/12/2021
0C466B,acquisition-completed-acquirer,100,49,4/12/2021
0DE3D5,conference-call,100,50,4/12/2021
0F0693,conference-participant,100,50,4/12/2021
0F65C9,conference-call,100,50,4/12/2021
133644,executive-appointment,100,54,4/12/2021
1348C9,conference-call,100,50,4/12/2021
14833D,partnership,100,61,4/12/2021
14ED2B,executive-resignation,100,44,4/12/2021
152B9E,conference-call,100,50,4/12/2021
168A5D,executive-appointment,100,54,4/12/2021
16B183,executive-appointment,100,54,4/12/2021
17EDA5,business-contract,100,69,4/12/2021
184866,clinical-trials,100,56,4/12/2021
184866,clinical-trials,100,56,4/12/2021
18A98C,trading-halt,100,43,4/12/2021
18A98C,trading-resumed,100,58,4/12/2021
18A98C,trading-halt,100,43,4/12/2021
18A98C,trading-resumed,100,58,4/12/2021
18D9FA,legal-issues-defendant,100,22,4/12/2021
1A1CB0,earnings,100,50,4/12/2021
1BDB2A,conference-call,100,50,4/12/2021
1D5C51,executive-resignation,100,44,4/12/2021
1D9E55,earnings,100,50,4/12/2021
1DA44F,conference-call,100,50,4/12/2021
1E83DE,executive-appointment,100,54,4/12/2021
1F9D90,conference-call,100,50,4/12/2021
2158DF,partnership,100,61,4/12/2021
21D903,earnings,100,50,4/12/2021
227D48,conference-call,100,50,4/12/2021
228D42,partnership,100,61,4/12/2021
232053,executive-appointment,100,54,4/12/2021
275300,business-contract,100,69,4/12/2021
2EBA55,dividend,100,50,4/12/2021
31F25C,business-combination,100,54,4/12/2021
31F25C,legal-issues-defendant,100,22,4/12/2021
31F25C,acquisition-regulatory-scrutiny-acquiree,100,38,4/12/2021
34B411,business-combination,100,54,4/12/2021
371B0A,conference-call,100,50,4/12/2021
3B37F7,index-listing,100,76,4/12/2021
3E149C,partnership,100,61,4/12/2021
42EFC7,public-offering,100,43,4/12/2021
43A060,product-release,100,64,4/12/2021
448215,public-offering,100,43,4/12/2021
4C6C63,business-contract,100,69,4/12/2021
4E2D94,earnings,100,50,4/12/2021
4E7C1F,award,100,58,4/12/2021
4F71DC,public-offering,100,43,4/12/2021
50070E,executive-appointment,100,54,4/12/2021
519FE0,business-contract,100,69,4/12/2021
548AC0,conference-call,100,50,4/12/2021
5546DA,conference-call,100,50,4/12/2021
55C9B5,product-release,100,64,4/12/2021
5675EB,business-contract,100,69,4/12/2021
5675EB,earnings,100,50,4/12/2021
56765E,earnings,100,50,4/12/2021
57DDB9,executive-appointment,100,54,4/12/2021
5B226B,legal-issues-defendant,100,22,4/12/2021
5BFE94,conference-call,100,50,4/12/2021
5D1329,executive-appointment,100,54,4/12/2021
5D16CF,acquisition-completed-acquirer,100,49,4/12/2021
60DD84,acquisition-completed-acquirer,100,49,4/12/2021
61A586,earnings,100,50,4/12/2021
62B20A,conference-call,100,50,4/12/2021
62CDDE,conference-call,100,50,4/12/2021
636BBF,partnership,100,61,4/12/2021
665618,acquisition-completed-acquirer,100,49,4/12/2021
67303E,legal-issues-defendant,100,22,4/12/2021
68B03F,earnings,100,50,4/12/2021
6925EB,executive-appointment,100,54,4/12/2021
6B0784,conference-call,100,50,4/12/2021
6B0784,conference-call,100,50,4/12/2021
6BBCBA,clinical-trials,100,56,4/12/2021
6BBCBA,partnership,100,61,4/12/2021
6DBBBC,business-contract,100,69,4/12/2021
6E7060,dividend,100,50,4/12/2021
7255D2,legal-issues-defendant,100,22,4/12/2021
726DDF,conference-call,100,50,4/12/2021
731675,executive-appointment,100,54,4/12/2021
73529F,conference-call,100,50,4/12/2021
76DD0C,clinical-trials-start,100,64,4/12/2021
7823A3,earnings,100,50,4/12/2021
78F776,earnings,100,50,4/12/2021
7BFF81,executive-appointment,100,54,4/12/2021
7C4168,business-contract,100,69,4/12/2021
7CBC40,earnings,100,50,4/12/2021
7D5384,conference-call,100,50,4/12/2021
7D85A9,donation,100,54,4/12/2021
7E1D5D,acquisition-acquirer,100,49,4/12/2021
819492,executive-appointment,100,54,4/12/2021
86AA9C,conference-participant,100,50,4/12/2021
885758,earnings,100,50,4/12/2021
896771,conference-call,100,50,4/12/2021
89FBB1,conference-call,100,50,4/12/2021
8A8E41,business-contract,100,69,4/12/2021
8A8E41,partnership,100,61,4/12/2021
8AA108,business-contract,100,69,4/12/2021
8E9CD8,earnings,100,50,4/12/2021
8FE7A5,earnings,100,50,4/12/2021
9043FE,earnings,100,50,4/12/2021
9043FE,earnings,100,50,4/12/2021
91E5EE,acquisition-acquiree,100,76,4/12/2021
91E5EE,acquisition-acquiree,100,76,4/12/2021
91E5EE,acquisition-acquiree,100,76,4/12/2021
91E5EE,legal-issues-defendant,100,22,4/12/2021
91E5EE,acquisition-regulatory-scrutiny-acquiree,100,38,4/12/2021
92D3A0,dividend,100,50,4/12/2021
99ACAD,earnings,100,50,4/12/2021
9A02C4,unit-acquisition-acquirer,100,49,4/12/2021
9A02C4,unit-acquisition-acquirer,100,49,4/12/2021
9CF9B1,earnings,100,50,4/12/2021
9D5D35,earnings,100,50,4/12/2021
9E3224,acquisition-acquiree,100,76,4/12/2021
9E3224,acquisition-acquiree,100,76,4/12/2021
9F5997,conference-call,100,50,4/12/2021
A017F4,executive-appointment,100,54,4/12/2021
A26C26,joint-venture,100,62,4/12/2021
A26EF7,public-offering,100,43,4/12/2021
A3AAA5,dividend,100,50,4/12/2021
A4A612,conference-call,100,50,4/12/2021
A5628C,earnings,100,50,4/12/2021
AA09AD,award,100,58,4/12/2021
AA09AD,award,100,58,4/12/2021
AA09AD,award,100,58,4/12/2021
ABB493,business-contract,100,69,4/12/2021
AC7C4F,executive-appointment,100,54,4/12/2021
AE4125,conference-call,100,50,4/12/2021
AFF43F,earnings,100,50,4/12/2021
B04426,executive-appointment,100,54,4/12/2021
B0FE08,executive-appointment,100,54,4/12/2021
B446B8,executive-appointment,100,54,4/12/2021
B4703C,dividend,100,50,4/12/2021
B560AF,acquisition-completed-acquiree,100,76,4/12/2021
B72BE9,conference-call,100,50,4/12/2021
B72D2E,acquisition-interest-acquirer,100,46,4/12/2021
B96637,business-contract,100,69,4/12/2021
B96DF5,acquisition-acquirer,100,49,4/12/2021
B96DF5,acquisition-acquirer,100,49,4/12/2021
B9CD50,award,100,58,4/12/2021
BB02FB,conference-call,100,50,4/12/2021
C11C46,earnings,100,50,4/12/2021
C1CBA4,buybacks,100,74,4/12/2021
C2609A,executive-appointment,100,54,4/12/2021
C99CC8,executive-appointment,100,54,4/12/2021
C99CC8,executive-appointment,100,54,4/12/2021
CB88B3,earnings,100,50,4/12/2021
CBA33B,executive-resignation,100,44,4/12/2021
CE96E7,earnings,100,50,4/12/2021
CED4D0,conference-call,100,50,4/12/2021
CF351E,earnings,100,50,4/12/2021
CFF57D,note-sale,100,52,4/12/2021
D08D2C,dividend,100,50,4/12/2021
D3C794,earnings,100,50,4/12/2021
D4070C,product-release,100,64,4/12/2021
D437C3,earnings,100,50,4/12/2021
D90F43,conference-call,100,50,4/12/2021
DB5CA5,earnings,100,50,4/12/2021
DBB28E,partnership,100,61,4/12/2021
DC437D,conference-participant,100,50,4/12/2021
DC6AA0,earnings,100,50,4/12/2021
DD9E41,business-contract,100,69,4/12/2021
E0207A,acquisition-interest-acquirer,100,46,4/12/2021
E09E2B,partnership,100,61,4/12/2021
E09E2B,partnership,100,61,4/12/2021
E09E2B,revenue-above-expectations,100,86,4/12/2021
E12A6E,dividend,100,50,4/12/2021
E13782,conference-participant,100,50,4/12/2021
E16133,conference-call,100,50,4/12/2021
E1F30A,public-offering,100,43,4/12/2021
E21871,earnings,100,50,4/12/2021
E30B34,earnings,100,50,4/12/2021
E30B34,earnings,100,50,4/12/2021
E4158B,earnings,100,50,4/12/2021
E5752F,legal-issues-defendant,100,22,4/12/2021
E74B55,earnings,100,50,4/12/2021
E74B55,fraud-defendant,100,20,4/12/2021
E8A49A,earnings,100,50,4/12/2021
E93A40,earnings,100,50,4/12/2021
EB1E1A,clinical-trials-start,100,64,4/12/2021
ECF4F8,legal-issues-defendant,100,22,4/12/2021
ED0D7C,conference-call,100,50,4/12/2021
EEEA9F,unit-acquisition-acquiree,100,76,4/12/2021
EEEA9F,unit-acquisition-acquiree,100,76,4/12/2021
F0B335,earnings,100,50,4/12/2021
F4E992,earnings-up,100,68,4/12/2021
F4E992,earnings,100,50,4/12/2021
F5349B,business-contract,100,69,4/12/2021
F6FA6A,conference-call,100,50,4/12/2021
F8084B,earnings,100,50,4/12/2021
F83279,earnings,100,50,4/12/2021
F92DBC,business-contract,100,69,4/12/2021
F92DBC,business-contract,100,69,4/12/2021
FA35C6,product-release,100,64,4/12/2021
FA840E,earnings,100,50,4/12/2021
FACF19,product-release,100,64,4/12/2021
FAE021,earnings,100,50,4/12/2021
FD9526,earnings,100,50,4/12/2021
002A99,legal-issues-defendant,100,22,4/13/2021
002A99,legal-issues-defendant,100,22,4/13/2021
002A99,fraud-defendant,100,20,4/13/2021
0157B1,donation,100,54,4/13/2021
01D03F,partnership,100,61,4/13/2021
01D03F,partnership,100,61,4/13/2021
07CA6A,conference-call,100,50,4/13/2021
07CA6A,conference-call,100,50,4/13/2021
083F72,award,100,58,4/13/2021
099C88,business-contract,100,69,4/13/2021
09DE1F,partnership,100,61,4/13/2021
0F0440,award,100,58,4/13/2021
0FDE97,conference-call,100,50,4/13/2021
1065BC,conference-call,100,50,4/13/2021
1096C6,partnership,100,61,4/13/2021
1096C6,partnership,100,61,4/13/2021
1348C9,dividend,100,50,4/13/2021
1834C0,conference-call,100,50,4/13/2021
1866B2,conference-call,100,50,4/13/2021
18A98C,trading-halt,100,43,4/13/2021
18A98C,trading-resumed,100,58,4/13/2021
1A5957,earnings,100,50,4/13/2021
1DA44F,acquisition-completed-acquirer,100,49,4/13/2021
1DF15D,conference-call,100,50,4/13/2021
1F352C,earnings,100,50,4/13/2021
1F9D90,partnership,100,61,4/13/2021
21153F,executive-appointment,100,54,4/13/2021
21153F,executive-appointment,100,54,4/13/2021
228D42,partnership,100,61,4/13/2021
228D42,partnership,100,61,4/13/2021
228D42,partnership,100,61,4/13/2021
25A6CC,legal-issues-defendant,100,22,4/13/2021
25A6CC,legal-issues-defendant,100,22,4/13/2021
270305,executive-appointment,100,54,4/13/2021
28DCF3,earnings,100,50,4/13/2021
2950FF,award,100,58,4/13/2021
2950FF,award,100,58,4/13/2021
2BBE62,earnings,100,50,4/13/2021
2E61CC,dividend-up,100,81,4/13/2021
2E89AE,conference-participant,100,50,4/13/2021
2E902B,conference-call,100,50,4/13/2021
2F1299,conference-call,100,50,4/13/2021
326EDD,award,100,58,4/13/2021
32CB22,conference-call,100,50,4/13/2021
33E8C7,earnings,100,50,4/13/2021
3587B4,business-contract,100,69,4/13/2021
373B06,earnings,100,50,4/13/2021
3.73E+87,partnership,100,61,4/13/2021
382EAE,conference-call,100,50,4/13/2021
387541,dividend,100,50,4/13/2021
3B20AB,dividend,100,50,4/13/2021
3B318A,executive-appointment,100,54,4/13/2021
3B8484,acquisition-acquirer,100,49,4/13/2021
3BC360,conference-call,100,50,4/13/2021
3C7F5F,partnership,100,61,4/13/2021
3CBA2A,conference-call,100,50,4/13/2021
3F4668,earnings,100,50,4/13/2021
4.03E+05,award,100,58,4/13/2021
416291,conference-call,100,50,4/13/2021
416C55,earnings,100,50,4/13/2021
420168,award,100,58,4/13/2021
425BDC,conference-call,100,50,4/13/2021
44209A,earnings,100,50,4/13/2021
467F2C,conference-call,100,50,4/13/2021
47B4CC,note-sale,100,52,4/13/2021
47B4CC,note-sale,100,52,4/13/2021
47BA98,conference-call,100,50,4/13/2021
49A344,conference-call,100,50,4/13/2021
4A6F00,partnership,100,61,4/13/2021
4C6C63,business-contract,100,69,4/13/2021
4E3D15,facility-sale,100,52,4/13/2021
4EE167,earnings,100,50,4/13/2021
51527B,conference-call,100,50,4/13/2021
519FE0,earnings,100,50,4/13/2021
519FE0,partnership,100,61,4/13/2021
55C9B5,government-contract,100,69,4/13/2021
577033,conference-call,100,50,4/13/2021
583A75,conference-call,100,50,4/13/2021
5B35C7,earnings-up,100,61,4/13/2021
5B35C7,earnings,100,50,4/13/2021
5B35C7,earnings,100,50,4/13/2021
5D16CF,note-sale,100,52,4/13/2021
5F1B7B,earnings,100,50,4/13/2021
5FDBD0,conference-call,100,50,4/13/2021
6137BF,conference-call,100,50,4/13/2021
62EFEE,earnings,100,50,4/13/2021
65AB30,earnings,100,50,4/13/2021
66E04A,facility-open,100,65,4/13/2021
68AB62,conference-call,100,50,4/13/2021
694749,executive-appointment,100,54,4/13/2021
6B494E,dividend,100,50,4/13/2021
6C6D73,patient-enrollment-complete,100,64,4/13/2021
6CC55E,earnings,100,50,4/13/2021
6CD55A,buybacks,100,74,4/13/2021
6D9ECA,partnership,100,61,4/13/2021
6D9ECA,partnership,100,61,4/13/2021
6D9ECA,partnership,100,61,4/13/2021
6D9ECA,partnership,100,61,4/13/2021
6D9ECA,partnership,100,61,4/13/2021
6D9ECA,partnership,100,61,4/13/2021
6D9ECA,partnership,100,61,4/13/2021
6DBBBC,conference-call,100,50,4/13/2021
6E8349,product-release,100,64,4/13/2021
6F0A63,partnership,100,61,4/13/2021
6F30F9,award,100,58,4/13/2021
722DE3,business-contract,100,69,4/13/2021
73A71F,conference-call,100,50,4/13/2021
76E80F,product-release,100,64,4/13/2021
7AC86E,earnings,100,50,4/13/2021
7B1E50,partnership,100,61,4/13/2021
7DA412,business-contract,100,69,4/13/2021
7DA412,business-contract,100,69,4/13/2021
804708,conference-call,100,50,4/13/2021
8.10E+32,award,100,58,4/13/2021
810FAD,conference-call,100,50,4/13/2021
810FAD,conference-call,100,50,4/13/2021
817ED9,government-contract,100,69,4/13/2021
81A88D,earnings,100,50,4/13/2021
830BDB,conference-call,100,50,4/13/2021
838ADD,earnings,100,50,4/13/2021
859281,earnings,100,50,4/13/2021
868808,earnings,100,50,4/13/2021
88350F,conference-call,100,50,4/13/2021
885758,business-contract,100,69,4/13/2021
895D56,product-release,100,64,4/13/2021
8A8E41,award,100,58,4/13/2021
8A8E41,award,100,58,4/13/2021
8D4486,business-contract,100,69,4/13/2021
92D3A0,earnings,100,50,4/13/2021
93633B,conference-call,100,50,4/13/2021
94983E,revenues,100,50,4/13/2021
96F126,earnings,100,50,4/13/2021
98CEBB,earnings,100,50,4/13/2021
99028D,conference-call,100,50,4/13/2021
990AD0,conference-organizer,100,57,4/13/2021
99DC8D,conference-call,100,50,4/13/2021
9E3224,legal-issues-defendant,100,22,4/13/2021
9EBAFA,dividend,100,50,4/13/2021
9FF5F1,partnership,100,61,4/13/2021
A49498,conference-call,100,50,4/13/2021
A495F7,earnings,100,50,4/13/2021
A60318,earnings,100,50,4/13/2021
A72FD9,earnings,100,50,4/13/2021
A746F6,conference-call,100,50,4/13/2021
A87CD6,executive-death,100,31,4/13/2021
AA98ED,partnership,100,61,4/13/2021
AAEE21,conference-call,100,50,4/13/2021
AD23DE,conference-call,100,50,4/13/2021
AE79CD,private-placement,100,56,4/13/2021
AED6CF,conference-call,100,50,4/13/2021
AFD1CA,conference-call,100,50,4/13/2021
B13B68,conference-call,100,50,4/13/2021
B2DAF6,earnings,100,50,4/13/2021
B54A74,earnings,100,50,4/13/2021
BB02FB,executive-appointment,100,54,4/13/2021
BB5271,conference-call,100,50,4/13/2021
BB58FF,conference-organizer,100,57,4/13/2021
BFAEB4,dividend,100,50,4/13/2021
C3BCD5,partnership,100,61,4/13/2021
C4F9C6,revenues,100,50,4/13/2021
C66B44,executive-appointment,100,54,4/13/2021
C7AE14,conference-call,100,50,4/13/2021
C85A72,conference-participant,100,50,4/13/2021
CD051C,conference-call,100,50,4/13/2021
CDC817,acquisition-acquirer,100,49,4/13/2021
CDE118,earnings,100,50,4/13/2021
CE4FD9,award,100,58,4/13/2021
CFF97C,product-release,100,64,4/13/2021
D17C1B,partnership,100,61,4/13/2021
D17C1B,earnings,100,50,4/13/2021
D25249,conference-call,100,50,4/13/2021
D33270,executive-appointment,100,54,4/13/2021
D6489C,partnership,100,61,4/13/2021
D697DE,earnings,100,50,4/13/2021
D88EF3,business-contract,100,69,4/13/2021
D8DA3D,conference-call,100,50,4/13/2021
D9E036,note-sale,100,52,4/13/2021
DD0F15,clinical-trials-start,100,64,4/13/2021
DD7A96,award,100,58,4/13/2021
E05026,executive-appointment,100,54,4/13/2021
E09E2B,partnership,100,61,4/13/2021
E74B55,legal-issues-defendant,100,22,4/13/2021
E74B55,fraud-defendant,100,20,4/13/2021
E74B55,legal-issues-defendant,100,22,4/13/2021
E87676,conference-call,100,50,4/13/2021
E8D221,trading-halt,100,43,4/13/2021
E8D221,trading-resumed,100,58,4/13/2021
E90C84,conference-call,100,50,4/13/2021
E96E0B,conference-call,100,50,4/13/2021
E9E6FD,conference-call,100,50,4/13/2021
EA62FC,conference-call,100,50,4/13/2021
EB61C4,executive-appointment,100,54,4/13/2021
EB6965,award,100,58,4/13/2021
EBD89A,business-contract,100,69,4/13/2021
EDF5CA,conference-call,100,50,4/13/2021
EEBCEF,executive-appointment,100,54,4/13/2021
EF5BED,executive-appointment,100,54,4/13/2021
F30508,clinical-trials,100,56,4/13/2021
F30508,clinical-trials,100,56,4/13/2021
F30508,executive-appointment,100,54,4/13/2021
F40EE2,award,100,58,4/13/2021
F40EE2,award,100,58,4/13/2021
F46EC9,earnings,100,50,4/13/2021
F4FBD8,public-offering,100,43,4/13/2021
F5349B,partnership,100,61,4/13/2021
F58C23,business-contract,100,69,4/13/2021
F6DCE4,conference-participant,100,50,4/13/2021
F6E248,regulatory-product-approval-granted,100,81,4/13/2021
F7902B,earnings,100,50,4/13/2021
F7ADEB,business-contract,100,69,4/13/2021
F85CC0,earnings,100,50,4/13/2021
F85CC0,earnings,100,50,4/13/2021
FAEABE,earnings-per-share-positive,100,69,4/13/2021
FAEABE,earnings,100,50,4/13/2021
FAEABE,earnings,100,50,4/13/2021
FD9526,award,100,58,4/13/2021
FFAB4A,earnings,100,50,4/13/2021
FFE543,earnings,100,50,4/13/2021
002A99,legal-issues-defendant,100,22,4/14/2021
002A99,legal-issues-defendant,100,22,4/14/2021
002A99,fraud-defendant,100,20,4/14/2021
00D6B5,conference-call,100,50,4/14/2021
0157B1,product-release,100,64,4/14/2021
033B58,conference-participant,100,50,4/14/2021
03596A,business-contract,100,69,4/14/2021
03D5F9,earnings,100,50,4/14/2021
0B4D10,earnings,100,50,4/14/2021
0BA2EF,earnings,100,50,4/14/2021
0BC29E,earnings,100,50,4/14/2021
0C4131,acquisition-acquirer,100,49,4/14/2021
0C4131,acquisition-acquirer,100,49,4/14/2021
0CADBC,dividend,100,50,4/14/2021
0EF1AF,legal-issues-defendant,100,22,4/14/2021
0F04E5,earnings,100,50,4/14/2021
0F2BC9,government-contract,100,69,4/14/2021
1220D2,earnings,100,50,4/14/2021
1272B3,earnings,100,50,4/14/2021
12DE76,award,100,58,4/14/2021
16B183,legal-issues-defendant,100,22,4/14/2021
19BF16,executive-appointment,100,54,4/14/2021
19BF16,executive-appointment,100,54,4/14/2021
1A5D5D,partnership,100,61,4/14/2021
1BC12C,conference-call,100,50,4/14/2021
1EBF8D,partnership,100,61,4/14/2021
1FE3CB,conference-call,100,50,4/14/2021
221445,conference-call,100,50,4/14/2021
225CA2,award,100,58,4/14/2021
228D42,partnership,100,61,4/14/2021
2.45E+15,earnings,100,50,4/14/2021
270305,earnings,100,50,4/14/2021
2EC172,conference-call,100,50,4/14/2021
30A565,conference-call,100,50,4/14/2021
31666F,dividend,100,50,4/14/2021
3.30E+30,acquisition-acquirer,100,49,4/14/2021
33AD83,business-contract,100,69,4/14/2021
33AD83,business-contract,100,69,4/14/2021
33E9D5,earnings,100,50,4/14/2021
33E9D5,earnings,100,50,4/14/2021
33E9D5,earnings,100,50,4/14/2021
33E9D5,earnings,100,50,4/14/2021
35F4B5,conference-call,100,50,4/14/2021
367E1C,earnings,100,50,4/14/2021
3696BF,conference-call,100,50,4/14/2021
370C50,dividend,100,50,4/14/2021
387541,conference-call,100,50,4/14/2021
389CFB,conference-call,100,50,4/14/2021
3D7971,executive-appointment,100,54,4/14/2021
3DCECC,conference-call,100,50,4/14/2021
4.03E+05,conference-call,100,50,4/14/2021
416C55,dividend,100,50,4/14/2021
420168,earnings,100,50,4/14/2021
42978B,earnings-positive,100,69,4/14/2021
43A060,business-contract,100,69,4/14/2021
44ED36,executive-appointment,100,54,4/14/2021
45BC35,acquisition-completed-acquirer,100,49,4/14/2021
4806CE,executive-appointment,100,54,4/14/2021
499C75,executive-appointment,100,54,4/14/2021
4B3676,earnings,100,50,4/14/2021
4B3676,earnings,100,50,4/14/2021
4EC4C1,note-sale,100,52,4/14/2021
504FE2,legal-issues-defendant,100,22,4/14/2021
513A86,earnings,100,50,4/14/2021
514067,conference-call,100,50,4/14/2021
53C421,conference-call,100,50,4/14/2021
545272,conference-call,100,50,4/14/2021
57F3DA,earnings,100,50,4/14/2021
59C539,earnings,100,50,4/14/2021
59C539,earnings,100,50,4/14/2021
5A0FF1,earnings,100,50,4/14/2021
5A64D5,conference-call,100,50,4/14/2021
5D16CF,note-sale,100,52,4/14/2021
5DAF89,conference-call,100,50,4/14/2021
5F3E74,executive-appointment,100,54,4/14/2021
60AC34,partnership,100,61,4/14/2021
619882,earnings,100,50,4/14/2021
622DBE,conference-call,100,50,4/14/2021
665618,conference-call,100,50,4/14/2021
6810DE,clinical-trials-start,100,64,4/14/2021
6D3F35,conference-call,100,50,4/14/2021
6DBBBC,executive-appointment,100,54,4/14/2021
7032D0,earnings,100,50,4/14/2021
71E2EF,earnings,100,50,4/14/2021
72609A,acquisition-acquirer,100,49,4/14/2021
7273FF,earnings,100,50,4/14/2021
73BCBA,conference-call,100,50,4/14/2021
7448A3,conference-call,100,50,4/14/2021
767F86,dividend,100,50,4/14/2021
76F067,business-contract,100,69,4/14/2021
7732C2,orphan-drug-designation,100,76,4/14/2021
789A7D,earnings,100,50,4/14/2021
78F9ED,partnership,100,61,4/14/2021
797C20,conference-call,100,50,4/14/2021
7999F3,award,100,58,4/14/2021
7A5097,partnership,100,61,4/14/2021
7AC86E,partnership,100,61,4/14/2021
7B9AFA,earnings,100,50,4/14/2021
7F3A5F,earnings,100,50,4/14/2021
803FED,conference-call,100,50,4/14/2021
834152,legal-issues-defendant,100,22,4/14/2021
8AC65D,conference-call,100,50,4/14/2021
8B4A45,facility-upgrade,100,65,4/14/2021
8B6E7E,award,100,58,4/14/2021
8D4AE6,earnings,100,50,4/14/2021
8F8F2F,conference-call,100,50,4/14/2021
92D9C9,acquisition-acquirer,100,49,4/14/2021
92D9C9,public-offering,100,43,4/14/2021
92D9C9,public-offering,100,43,4/14/2021
93AD2E,executive-appointment,100,54,4/14/2021
94208D,earnings,100,50,4/14/2021
942165,earnings,100,50,4/14/2021
942165,dividend-up,100,81,4/14/2021
94637C,regulatory-product-approval-granted,100,81,4/14/2021
950AB7,earnings,100,50,4/14/2021
9673BD,executive-appointment,100,54,4/14/2021
972356,revenues,100,50,4/14/2021
97AAF6,award,100,58,4/14/2021
986AF6,executive-resignation,100,44,4/14/2021
9.92E+94,earnings,100,50,4/14/2021
9B4066,unit-acquisition-acquirer,100,49,4/14/2021
9B71A7,earnings,100,50,4/14/2021
9C8BC3,dividend,100,50,4/14/2021
9EA947,conference-call,100,50,4/14/2021
9FD2D9,conference-call,100,50,4/14/2021
A2CA3F,note-sale,100,52,4/14/2021
A4D173,conference-call,100,50,4/14/2021
A4D173,conference-call,100,50,4/14/2021
A631A3,business-contract,100,69,4/14/2021
A631A3,business-contract,100,69,4/14/2021
AA5C8E,earnings,100,50,4/14/2021
AC7C4F,business-contract,100,69,4/14/2021
AD3008,earnings,100,50,4/14/2021
AEF2C3,conference-call,100,50,4/14/2021
AFEC35,public-offering,100,43,4/14/2021
B1B10C,conference-call,100,50,4/14/2021
B2206F,executive-appointment,100,54,4/14/2021
B303A6,unit-acquisition-acquiree,100,76,4/14/2021
B642E8,earnings,100,50,4/14/2021
B7BDA3,conference-call,100,50,4/14/2021
B7FA9B,conference-call,100,50,4/14/2021
B8EF97,dividend-up,100,81,4/14/2021
B9764A,business-contract,100,69,4/14/2021
BC5680,earnings,100,50,4/14/2021
BCC55F,board-meeting,100,51,4/14/2021
BD8517,earnings,100,50,4/14/2021
BDD12C,earnings,100,50,4/14/2021
BFCACF,conference-call,100,50,4/14/2021
C0030A,earnings,100,50,4/14/2021
C32A39,dividend,100,50,4/14/2021
C66B44,conference-call,100,50,4/14/2021
C6C702,conference-call,100,50,4/14/2021
C7859D,earnings,100,50,4/14/2021
C7859D,earnings,100,50,4/14/2021
C7859D,earnings,100,50,4/14/2021
C7859D,earnings,100,50,4/14/2021
C7859D,earnings,100,50,4/14/2021
C7859D,earnings,100,50,4/14/2021
C83B88,product-release,100,64,4/14/2021
CBBFBF,earnings,100,50,4/14/2021
CC3EC4,earnings,100,50,4/14/2021
CC3EC4,note-sale,100,52,4/14/2021
CD4DA8,conference-call,100,50,4/14/2021
CDAA0E,earnings,100,50,4/14/2021
CDC217,conference-participant,100,50,4/14/2021
CEC5B9,conference-call,100,50,4/14/2021
CEC5B9,conference-call,100,50,4/14/2021
CF6A5A,partnership,100,61,4/14/2021
CFF15D,partnership,100,61,4/14/2021
CFF15D,dividend,100,50,4/14/2021
D17C1B,executive-appointment,100,54,4/14/2021
D64EDF,partnership,100,61,4/14/2021
D90F43,partnership,100,61,4/14/2021
DA48E4,acquisition-acquirer,100,49,4/14/2021
DDB002,conference-call,100,50,4/14/2021
DF6FDD,earnings,100,50,4/14/2021
E074A0,earnings,100,50,4/14/2021
E0F4E5,business-contract,100,69,4/14/2021
E19A99,earnings,100,50,4/14/2021
E1E36F,earnings,100,50,4/14/2021
E22FDE,acquisition-acquirer,100,49,4/14/2021
E6E012,earnings,100,50,4/14/2021
E6E012,earnings,100,50,4/14/2021
E74B55,legal-issues-defendant,100,22,4/14/2021
E754F0,earnings,100,50,4/14/2021
E8846E,earnings,100,50,4/14/2021
E8B315,conference-call,100,50,4/14/2021
ED0402,acquisition-acquirer,100,49,4/14/2021
ED2A5E,conference-call,100,50,4/14/2021
ED7F13,earnings,100,50,4/14/2021
EE6F1C,partnership,100,61,4/14/2021
EF1AD9,executive-appointment,100,54,4/14/2021
EF5914,earnings,100,50,4/14/2021
EF5BED,business-contract,100,69,4/14/2021
F179ED,earnings,100,50,4/14/2021
F30508,business-contract,100,69,4/14/2021
F32F88,conference-call,100,50,4/14/2021
F5349B,executive-appointment,100,54,4/14/2021
F8BDCE,earnings,100,50,4/14/2021
FA35C6,earnings,100,50,4/14/2021
FACF19,partnership,100,61,4/14/2021
FF6644,product-release,100,64,4/14/2021
FF6644,product-release,100,64,4/14/2021
002A99,legal-issues-defendant,100,22,4/15/2021
002A99,legal-issues-defendant,100,22,4/15/2021
002A99,legal-issues-defendant,100,22,4/15/2021
002A99,fraud-defendant,100,20,4/15/2021
00326E,conference-call,100,50,4/15/2021
00FC70,acquisition-interest-acquirer,100,46,4/15/2021
0157B1,conference-call,100,50,4/15/2021
0358AF,earnings,100,50,4/15/2021
03B431,conference-call,100,50,4/15/2021
048B70,conference-call,100,50,4/15/2021
04EB2F,earnings,100,50,4/15/2021
61366,earnings,100,50,4/15/2021
71860,earnings,100,50,4/15/2021
07C907,earnings,100,50,4/15/2021
07C907,earnings,100,50,4/15/2021
083F72,dividend,100,50,4/15/2021
09F623,dividend,100,50,4/15/2021
0A77DB,executive-appointment,100,54,4/15/2021
0BB9E5,earnings,100,50,4/15/2021
0BF528,executive-appointment,100,54,4/15/2021
0D26E0,dividend,100,50,4/15/2021
0E3436,partnership,100,61,4/15/2021
0ED415,conference-call,100,50,4/15/2021
0F2BC9,conference-call,100,50,4/15/2021
10100E,earnings,100,50,4/15/2021
1096C6,executive-appointment,100,54,4/15/2021
11074E,conference-call,100,50,4/15/2021
12731D,acquisition-completed-acquirer,100,49,4/15/2021
12731D,acquisition-completed-acquirer,100,49,4/15/2021
12F98C,facility-open,100,65,4/15/2021
135B09,conference-call,100,50,4/15/2021
152AB9,earnings,100,50,4/15/2021
159AE4,merger,100,66,4/15/2021
159AE4,merger,100,66,4/15/2021
1.79E+10,conference-call,100,50,4/15/2021
180DA0,conference-call,100,50,4/15/2021
182B8C,conference-call,100,50,4/15/2021
182BE7,earnings,100,50,4/15/2021
19BF16,earnings,100,50,4/15/2021
1A2D9F,merger,100,66,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A3E1B,earnings,100,50,4/15/2021
1A6A94,dividend,100,50,4/15/2021
1B4F31,earnings,100,50,4/15/2021
1D5C51,conference-call,100,50,4/15/2021
1DEBBE,earnings,100,50,4/15/2021
1DEBBE,legal-issues-defendant,100,22,4/15/2021
1EBF8D,business-contract-terminated,100,31,4/15/2021
2158DF,earnings,100,50,4/15/2021
221783,earnings,100,50,4/15/2021
223552,regulatory-investigation,100,22,4/15/2021
223552,regulatory-investigation,100,22,4/15/2021
228D42,acquisition-acquirer,100,49,4/15/2021
2.45E+15,award,100,58,4/15/2021
253B2F,conference-call,100,50,4/15/2021
2667B6,partnership,100,61,4/15/2021
267718,board-meeting,100,51,4/15/2021
267718,donation,100,54,4/15/2021
26F31D,earnings,100,50,4/15/2021
270B78,earnings,100,50,4/15/2021
27C10F,earnings,100,50,4/15/2021
28F905,earnings,100,50,4/15/2021
292388,award,100,58,4/15/2021
2A1009,conference-call,100,50,4/15/2021
2A17B1,conference-call,100,50,4/15/2021
2B49F4,legal-issues-defendant,100,22,4/15/2021
2B9DBB,executive-appointment,100,54,4/15/2021
2CC71C,conference-participant,100,50,4/15/2021
2EB04E,earnings,100,50,4/15/2021
2EBA55,earnings,100,50,4/15/2021
306623,conference-call,100,50,4/15/2021
314D88,earnings,100,50,4/15/2021
328250,conference-call,100,50,4/15/2021
343996,dividend,100,50,4/15/2021
343996,dividend,100,50,4/15/2021
349DA4,earnings,100,50,4/15/2021
34A959,partnership,100,61,4/15/2021
372037,conference-call,100,50,4/15/2021
37426C,earnings,100,50,4/15/2021
39FB23,dividend,100,50,4/15/2021
39FB23,earnings-up,100,68,4/15/2021
39FB23,earnings,100,50,4/15/2021
39FB23,earnings,100,50,4/15/2021
39FB23,earnings,100,50,4/15/2021
3A3447,earnings,100,50,4/15/2021
3ACF46,conference-call,100,50,4/15/2021
3BBD10,earnings,100,50,4/15/2021
3BE00F,earnings,100,50,4/15/2021
3C3B6B,earnings,100,50,4/15/2021
3F868D,conference-call,100,50,4/15/2021
3FBC9B,earnings,100,50,4/15/2021
408380,earnings,100,50,4/15/2021
423279,earnings-per-share-positive,100,69,4/15/2021
423279,partnership,100,61,4/15/2021
42AABD,conference-call,100,50,4/15/2021
43A060,business-contract,100,69,4/15/2021
442769,conference-call,100,50,4/15/2021
451D61,conference-call,100,50,4/15/2021
479930,earnings,100,50,4/15/2021
48F795,earnings,100,50,4/15/2021
4A6F00,business-contract,100,69,4/15/2021
4A6F00,partnership,100,61,4/15/2021
4A6F00,partnership,100,61,4/15/2021
4A6F00,business-contract,100,69,4/15/2021
4BEB48,earnings,100,50,4/15/2021
4EEE7E,earnings,100,50,4/15/2021
52015A,conference-call,100,50,4/15/2021
5225A4,conference-organizer,100,57,4/15/2021
52FB2F,earnings,100,50,4/15/2021
53EF9E,conference-call,100,50,4/15/2021
5.43E+08,partnership,100,61,4/15/2021
5.43E+08,partnership,100,61,4/15/2021
5.43E+08,partnership,100,61,4/15/2021
55ACCB,earnings,100,50,4/15/2021
55C9B5,executive-appointment,100,54,4/15/2021
58C2D4,executive-appointment,100,54,4/15/2021
58CA9A,earnings,100,50,4/15/2021
59F0B0,merger,100,66,4/15/2021
59F0B0,merger,100,66,4/15/2021
59F0B0,legal-issues-defendant,100,22,4/15/2021
59F0B0,acquisition-regulatory-scrutiny-acquiree,100,38,4/15/2021
5D0337,earnings,100,50,4/15/2021
5D16CF,conference-call,100,50,4/15/2021
5D43A7,dividend-up,100,81,4/15/2021
5F2FF7,earnings,100,50,4/15/2021
5F3E74,earnings,100,50,4/15/2021
601785,dividend,100,50,4/15/2021
6166D1,earnings,100,50,4/15/2021
6.18E+08,earnings,100,50,4/15/2021
619882,dividend,100,50,4/15/2021
622037,earnings,100,50,4/15/2021
6284B5,conference-call,100,50,4/15/2021
633054,partnership,100,61,4/15/2021
633054,partnership,100,61,4/15/2021
64636E,clinical-trials,100,56,4/15/2021
64636E,clinical-trials,100,56,4/15/2021
64E346,acquisition-acquirer,100,49,4/15/2021
64FF65,conference-call,100,50,4/15/2021
665440,conference-call,100,50,4/15/2021
67B052,executive-appointment,100,54,4/15/2021
67B052,executive-appointment,100,54,4/15/2021
69345C,earnings,100,50,4/15/2021
6A01DF,earnings,100,50,4/15/2021
6ABCB8,earnings,100,50,4/15/2021
6C4D2F,conference-call,100,50,4/15/2021
6C6D73,hirings,100,65,4/15/2021
6C987C,earnings-positive,100,69,4/15/2021
6CBF41,index-listing,100,76,4/15/2021
6D1ADF,conference-call,100,50,4/15/2021
6DC1D7,conference-call,100,50,4/15/2021
704B78,public-offering,100,43,4/15/2021
717DB4,earnings,100,50,4/15/2021
722D55,earnings,100,50,4/15/2021
74404C,conference-call,100,50,4/15/2021
747219,earnings,100,50,4/15/2021
75F982,dividend,100,50,4/15/2021
767F86,earnings,100,50,4/15/2021
7712CB,earnings,100,50,4/15/2021
7732C2,executive-appointment,100,54,4/15/2021
77B8E9,conference-participant,100,50,4/15/2021
790C34,earnings,100,50,4/15/2021
791D59,earnings,100,50,4/15/2021
7A5097,dividend,100,50,4/15/2021
7B492C,conference-call,100,50,4/15/2021
7C75FD,conference-call,100,50,4/15/2021
7E62B5,conference-call,100,50,4/15/2021
80B32C,earnings,100,50,4/15/2021
819492,executive-appointment,100,54,4/15/2021
8303CD,index-listing,100,76,4/15/2021
855DF7,dividend,100,50,4/15/2021
85AD00,earnings-up,100,68,4/15/2021
860AB6,executive-appointment,100,54,4/15/2021
8665BA,acquisition-acquirer,100,49,4/15/2021
8665BA,acquisition-acquirer,100,49,4/15/2021
86A1B9,earnings,100,50,4/15/2021
877C0C,earnings,100,50,4/15/2021
8A8E41,partnership,100,61,4/15/2021
8B6E7E,conference-call,100,50,4/15/2021
8CF6DD,executive-appointment,100,54,4/15/2021
8D4486,acquisition-acquirer,100,49,4/15/2021
8DE74B,conference-call,100,50,4/15/2021
8FF2EF,earnings,100,50,4/15/2021
903AB4,dividend-up,100,81,4/15/2021
90D6A5,legal-issues-defendant,100,22,4/15/2021
92D757,earnings,100,50,4/15/2021
934CC3,headquarters-change,100,50,4/15/2021
9507FF,executive-appointment,100,54,4/15/2021
971F7B,earnings,100,50,4/15/2021
97AAF6,dividend,100,50,4/15/2021
990AD0,buybacks,100,74,4/15/2021
990AD0,earnings,100,50,4/15/2021
990AD0,earnings,100,50,4/15/2021
9AF3DC,partnership,100,61,4/15/2021
9D56F2,partnership,100,61,4/15/2021
9D5FA4,earnings,100,50,4/15/2021
9E98F2,earnings,100,50,4/15/2021
9F5CBB,conference-call,100,50,4/15/2021
A1E3B3,partnership,100,61,4/15/2021
A1E3B3,partnership,100,61,4/15/2021
A28C54,facility-open,100,65,4/15/2021
A3AAA5,conference-call,100,50,4/15/2021
A3F598,partnership,100,61,4/15/2021
AA247D,earnings,100,50,4/15/2021
AC775C,conference-call,100,50,4/15/2021
AC7AAE,conference-call,100,50,4/15/2021
ACDF88,facility-open,100,65,4/15/2021
B1A85D,executive-appointment,100,54,4/15/2021
B2206F,earnings,100,50,4/15/2021
B303A6,unit-acquisition-acquiree,100,76,4/15/2021
B3ED62,conference-call,100,50,4/15/2021
B5BA39,partnership,100,61,4/15/2021
B6843B,earnings,100,50,4/15/2021
B7202A,conference-call,100,50,4/15/2021
B7BBFF,dividend-up,100,61,4/15/2021
B9B6B8,earnings,100,50,4/15/2021
BAD9EA,earnings,100,50,4/15/2021
BB0787,executive-appointment,100,54,4/15/2021
BB88B6,product-release,100,64,4/15/2021
BE14CF,conference-call,100,50,4/15/2021
BF79F5,conference-call,100,50,4/15/2021
C0BA36,product-release,100,64,4/15/2021
C38440,earnings,100,50,4/15/2021
C4706C,dividend,100,50,4/15/2021
C4A912,conference-call,100,50,4/15/2021
C8257F,conference-call,100,50,4/15/2021
C8257F,partnership,100,61,4/15/2021
C941DC,executive-resignation,100,44,4/15/2021
C9B932,earnings,100,50,4/15/2021
C9E107,earnings-up,100,68,4/15/2021
CAB222,regulatory-product-approval-granted,100,81,4/15/2021
CAC8D0,earnings,100,50,4/15/2021
CC6FF5,acquisition-acquirer,100,49,4/15/2021
CE4FD9,partnership,100,61,4/15/2021
CE5664,earnings-guidance,100,50,4/15/2021
CEC08B,earnings,100,50,4/15/2021
CF073E,clinical-trials,100,56,4/15/2021
CF211D,earnings,100,50,4/15/2021
D1C0B9,earnings,100,50,4/15/2021
D33D8C,earnings-per-share-up,100,68,4/15/2021
D33D8C,earnings-up,100,68,4/15/2021
D33D8C,earnings-up,100,68,4/15/2021
D33D8C,earnings-up,100,68,4/15/2021
D33D8C,earnings-up,100,68,4/15/2021
D33D8C,earnings-up,100,68,4/15/2021
D33D8C,earnings-up,100,68,4/15/2021
D3F64D,conference-call,100,50,4/15/2021
D58A11,earnings,100,50,4/15/2021
D5AF19,earnings,100,50,4/15/2021
D6489C,partnership,100,61,4/15/2021
D7918D,earnings,100,50,4/15/2021
D8442A,product-release,100,64,4/15/2021
D8ECA1,earnings,100,50,4/15/2021
D93A25,earnings,100,50,4/15/2021
DB7EC3,earnings,100,50,4/15/2021
DB7EC3,earnings,100,50,4/15/2021
DBCA3F,merger,100,66,4/15/2021
E28D9C,award,100,58,4/15/2021
E2CFD2,conference-call,100,50,4/15/2021
E4CE73,product-release,100,64,4/15/2021
E5752F,acquisition-acquiree,100,76,4/15/2021
E67C2C,earnings,100,50,4/15/2021
E84500,dividend-up,100,81,4/15/2021
EAEBF3,dividend,100,50,4/15/2021
EB36DE,conference-call,100,50,4/15/2021
EB5E78,conference-call,100,50,4/15/2021
ED79D9,acquisition-completed-acquirer,100,49,4/15/2021
ED9C04,executive-resignation,100,44,4/15/2021
EF1AD9,conference-call,100,50,4/15/2021
EF25A5,earnings,100,50,4/15/2021
F4E882,partnership,100,61,4/15/2021
F51DB0,conference-call,100,50,4/15/2021
F5349B,earnings,100,50,4/15/2021
F6E248,earnings,100,50,4/15/2021
F721A7,earnings,100,50,4/15/2021
F721A7,earnings,100,50,4/15/2021
F82D37,executive-appointment,100,54,4/15/2021
FA36A4,dividend,100,50,4/15/2021
FB728F,dividend,100,50,4/15/2021
FD4BBE,earnings,100,50,4/15/2021
FD6926,conference-call,100,50,4/15/2021
FF6644,partnership,100,61,4/15/2021
002A99,legal-issues-defendant,100,22,4/16/2021
09062E,board-meeting,100,51,4/16/2021
0A77DB,earnings,100,50,4/16/2021
108FDA,buybacks,100,74,4/16/2021
15A388,business-contract,100,69,4/16/2021
1E9A6D,earnings,100,50,4/16/2021
1F19C8,earnings,100,50,4/16/2021
1F43A1,earnings,100,50,4/16/2021
202E5A,acquisition-completed-acquiree,100,76,4/16/2021
2F98A5,dividend,100,50,4/16/2021
32CB22,acquisition-acquirer,100,49,4/16/2021
32CB22,acquisition-acquirer,100,49,4/16/2021
367E1C,executive-appointment,100,54,4/16/2021
36C09B,clinical-trials-positive,100,87,4/16/2021
3ACF46,executive-appointment,100,54,4/16/2021
3B20AB,earnings,100,50,4/16/2021
3CCC90,product-release,100,64,4/16/2021
41785E,executive-appointment,100,54,4/16/2021
458D2C,conference-call,100,50,4/16/2021
504FE2,legal-issues-defendant,100,22,4/16/2021
519FE0,public-offering,100,43,4/16/2021
51B442,executive-appointment,100,54,4/16/2021
54F271,note-sale,100,52,4/16/2021
54F271,note-sale,100,52,4/16/2021
5B226B,legal-issues-defendant,100,22,4/16/2021
5B226B,legal-issues-defendant,100,22,4/16/2021
5B226B,legal-issues-defendant,100,22,4/16/2021
5B3415,conference-call,100,50,4/16/2021
5BC2F4,earnings,100,50,4/16/2021
5DE5A5,conference-participant,100,50,4/16/2021
5F3D91,executive-appointment,100,54,4/16/2021
5FE4B6,conference-call,100,50,4/16/2021
6166D1,dividend,100,50,4/16/2021
61B81B,earnings-positive,100,69,4/16/2021
61B81B,earnings-positive,100,69,4/16/2021
61B81B,earnings-positive,100,69,4/16/2021
61B81B,earnings-positive,100,69,4/16/2021
61B81B,earnings-positive,100,69,4/16/2021
61B81B,earnings-positive,100,69,4/16/2021
61B81B,earnings-positive,100,69,4/16/2021
61B81B,earnings-positive,100,69,4/16/2021
647143,dividend,100,50,4/16/2021
6BD606,conference-call,100,50,4/16/2021
6CDFC6,conference-call,100,50,4/16/2021
6D3B7B,earnings,100,50,4/16/2021
6.00E+19,conference-call,100,50,4/16/2021
704B78,public-offering,100,43,4/16/2021
70FCEF,partnership,100,61,4/16/2021
762B8D,acquisition-acquiree,100,76,4/16/2021
762B8D,acquisition-acquiree,100,76,4/16/2021
762B8D,legal-issues-defendant,100,22,4/16/2021
766047,settlement,100,56,4/16/2021
76F067,acquisition-completed-acquirer,100,49,4/16/2021
82E58A,conference-call,100,50,4/16/2021
8BAA15,earnings,100,50,4/16/2021
8C1238,conference-call,100,50,4/16/2021
8E3F58,earnings,100,50,4/16/2021
911ACB,earnings,100,50,4/16/2021
911ACB,earnings,100,50,4/16/2021
9196A2,earnings,100,50,4/16/2021
9196A2,earnings,100,50,4/16/2021
9196A2,earnings,100,50,4/16/2021
9196A2,earnings,100,50,4/16/2021
938D89,executive-appointment,100,54,4/16/2021
93F143,earnings,100,50,4/16/2021
9.74E+08,earnings,100,50,4/16/2021
9DDE1B,conference-call,100,50,4/16/2021
9E9147,earnings,100,50,4/16/2021
A01983,dividend,100,50,4/16/2021
A21649,conference-call,100,50,4/16/2021
AF210D,executive-appointment,100,54,4/16/2021
AFF7B4,dividend,100,50,4/16/2021
B09B1F,conference-call,100,50,4/16/2021
B33E77,legal-issues-defendant,100,22,4/16/2021
B96637,conference-call,100,50,4/16/2021
BDE867,operating-earnings,100,50,4/16/2021
BFE02C,earnings-positive,100,69,4/16/2021
C4FBDC,conference-call,100,50,4/16/2021
C4FBDC,conference-call,100,50,4/16/2021
C83B88,product-release,100,64,4/16/2021
CFF15D,conference-call,100,50,4/16/2021
D17C1B,market-entry,100,57,4/16/2021
D33D8C,earnings,100,50,4/16/2021
D3FD6D,conference-call,100,50,4/16/2021
D518D8,executive-appointment,100,54,4/16/2021
D598E7,conference-call,100,50,4/16/2021
E592F0,earnings,100,50,4/16/2021
E72599,conference-call,100,50,4/16/2021
E74B55,legal-issues-defendant,100,22,4/16/2021
E74B55,legal-issues-defendant,100,22,4/16/2021
E802CE,conference-call,100,50,4/16/2021
E8D221,dividend-up,100,55,4/16/2021
EB6965,conference-call,100,50,4/16/2021
EC99D0,award,100,58,4/16/2021
ED9C04,earnings,100,50,4/16/2021
EF5BED,earnings-positive,100,69,4/16/2021
EF5BED,earnings,100,50,4/16/2021
EF5BED,earnings,100,50,4/16/2021
EF5BED,earnings,100,50,4/16/2021
EF5BED,earnings,100,50,4/16/2021
EF5BED,dividend,100,50,4/16/2021
F18844,note-sale,100,52,4/16/2021
F3EDB4,executive-appointment,100,54,4/16/2021
F82D37,earnings,100,50,4/16/2021
F82D37,earnings,100,50,4/16/2021
F8C5D7,conference-call,100,50,4/16/2021
F93C8A,conference-call,100,50,4/16/2021
FA40E2,dividend,100,50,4/16/2021
FDF799,conference-participant,100,50,4/16/2021
18D9FA,legal-issues-defendant,100,22,4/17/2021
1E1125,legal-issues-defendant,100,22,4/17/2021
31F25C,legal-issues-defendant,100,22,4/17/2021
499C75,legal-issues-defendant,100,22,4/17/2021
59F0B0,legal-issues-defendant,100,22,4/17/2021
7255D2,legal-issues-defendant,100,22,4/17/2021
762B8D,legal-issues-defendant,100,22,4/17/2021
8A0368,legal-issues-defendant,100,22,4/17/2021
91E5EE,legal-issues-defendant,100,22,4/17/2021
9E3224,legal-issues-defendant,100,22,4/17/2021
E5752F,legal-issues-defendant,100,22,4/17/2021
1E04A5,legal-issues-defendant,100,22,4/18/2021
405762,legal-issues-defendant,100,22,4/18/2021
5B226B,legal-issues-defendant,100,22,4/18/2021
5B35C7,legal-issues-defendant,100,22,4/18/2021
8A0368,legal-issues-defendant,100,22,4/18/2021
DD0F15,legal-issues-defendant,100,22,4/18/2021
E74B55,legal-issues-defendant,100,22,4/18/2021
F82D37,legal-issues-defendant,100,22,4/18/2021
002A99,legal-issues-defendant,100,22,4/19/2021
0142B5,conference-call,100,50,4/19/2021
0142B5,business-contract,100,69,4/19/2021
0157B1,business-contract,100,69,4/19/2021
0157B1,partnership,100,61,4/19/2021
03C94A,conference-call,100,50,4/19/2021
03FAA6,earnings,100,50,4/19/2021
03FB17,earnings,100,50,4/19/2021
71860,business-contract,100,69,4/19/2021
75172,conference-call,100,50,4/19/2021
095A04,regulatory-product-approval-granted,100,81,4/19/2021
0A59F8,partnership,100,61,4/19/2021
0A9D0A,dividend,100,50,4/19/2021
0C2A0D,supply-increase,100,74,4/19/2021
0C6861,partnership,100,61,4/19/2021
0CC01F,earnings,100,50,4/19/2021
0CC62B,investment-investor,100,55,4/19/2021
0E5223,conference-call,100,50,4/19/2021
0E64D4,executive-appointment,100,54,4/19/2021
0EF1AF,legal-issues-defendant,100,22,4/19/2021
10100E,executive-appointment,100,54,4/19/2021
108A2B,conference-call,100,50,4/19/2021
1220D2,conference-call,100,50,4/19/2021
147C38,dividend-up,100,81,4/19/2021
147C38,dividend-up,100,81,4/19/2021
168A5D,award,100,58,4/19/2021
16B183,legal-issues-defendant,100,22,4/19/2021
197612,stake-acquirer,100,48,4/19/2021
1C2593,executive-appointment,100,54,4/19/2021
20BEEA,conference-call,100,50,4/19/2021
20BEEA,earnings-up,100,68,4/19/2021
20BEEA,earnings,100,50,4/19/2021
20BEEA,earnings,100,50,4/19/2021
20F5E2,earnings,100,50,4/19/2021
20F5E2,earnings,100,50,4/19/2021
20F5E2,earnings,100,50,4/19/2021
219B21,legal-issues-defendant,100,22,4/19/2021
228D42,partnership,100,61,4/19/2021
228D42,partnership,100,61,4/19/2021
22C58E,partnership,100,61,4/19/2021
24A89A,executive-appointment,100,54,4/19/2021
251988,partnership,100,61,4/19/2021
2667B6,executive-appointment,100,54,4/19/2021
272704,earnings-positive,100,69,4/19/2021
272704,earnings,100,50,4/19/2021
272704,earnings,100,50,4/19/2021
272704,earnings,100,50,4/19/2021
272704,earnings,100,50,4/19/2021
272704,earnings,100,50,4/19/2021
272704,earnings,100,50,4/19/2021
272704,earnings,100,50,4/19/2021
279916,product-release,100,64,4/19/2021
282C18,earnings,100,50,4/19/2021
2A1009,fraud-defendant,100,20,4/19/2021
2C7505,clinical-trials-positive,100,87,4/19/2021
2E89AE,executive-appointment,100,54,4/19/2021
30CBF9,partnership,100,61,4/19/2021
317EC6,earnings,100,50,4/19/2021
32C8CD,earnings,100,50,4/19/2021
32F24A,conference-call,100,50,4/19/2021
38FB49,earnings,100,50,4/19/2021
38FB49,earnings,100,50,4/19/2021
38FB49,earnings,100,50,4/19/2021
38FB49,earnings,100,50,4/19/2021
38FB49,earnings,100,50,4/19/2021
38FB49,earnings,100,50,4/19/2021
38FB49,earnings,100,50,4/19/2021
39FB23,acquisition-acquirer,100,49,4/19/2021
3B8484,unit-acquisition-acquirer,100,49,4/19/2021
3E39A5,earnings,100,50,4/19/2021
435ACE,conference-call,100,50,4/19/2021
43A74A,executive-appointment,100,54,4/19/2021
4455C4,conference-call,100,50,4/19/2021
44740A,conference-call,100,50,4/19/2021
44A4FC,earnings,100,50,4/19/2021
494EB9,settlement,100,56,4/19/2021
4A6F00,partnership,100,61,4/19/2021
4BBA23,conference-call,100,50,4/19/2021
4D371E,earnings,100,50,4/19/2021
53F491,award,100,58,4/19/2021
5.43E+08,earnings,100,50,4/19/2021
5675EB,dividend,100,50,4/19/2021
5675EB,earnings,100,50,4/19/2021
5675EB,legal-issues-defendant,100,22,4/19/2021
57B174,conference-call,100,50,4/19/2021
57CAAB,earnings,100,50,4/19/2021
58C2D4,legal-issues-defendant,100,22,4/19/2021
58C2D4,legal-issues-defendant,100,22,4/19/2021
5B226B,legal-issues-defendant,100,22,4/19/2021
5B226B,earnings-guidance,100,50,4/19/2021
5B7739,conference-call,100,50,4/19/2021
5D63F1,earnings,100,50,4/19/2021
601785,unit-acquisition-acquirer,100,49,4/19/2021
601785,unit-acquisition-acquirer,100,49,4/19/2021
609208,business-combination,100,54,4/19/2021
609208,business-combination,100,54,4/19/2021
609208,business-combination,100,54,4/19/2021
609208,business-combination,100,54,4/19/2021
609208,business-combination,100,54,4/19/2021
609208,business-combination,100,54,4/19/2021
620381,executive-appointment,100,54,4/19/2021
636639,acquisition-acquirer,100,49,4/19/2021
641F17,dividend,100,50,4/19/2021
647143,earnings-up,100,68,4/19/2021
647143,earnings-up,100,68,4/19/2021
647143,earnings-up,100,68,4/19/2021
647143,earnings-up,100,68,4/19/2021
647143,earnings-up,100,68,4/19/2021
657097,unit-acquisition-acquirer,100,49,4/19/2021
6634D9,partnership,100,61,4/19/2021
6634D9,partnership,100,61,4/19/2021
6810DE,clinical-trials-filed,100,60,4/19/2021
68B03F,executive-appointment,100,54,4/19/2021
693ECD,earnings,100,50,4/19/2021
6A6BDC,business-contract,100,69,4/19/2021
6B0E45,conference-call,100,50,4/19/2021
6D2BF6,earnings,100,50,4/19/2021
6E705B,earnings,100,50,4/19/2021
6E705B,earnings,100,50,4/19/2021
6E705B,earnings,100,50,4/19/2021
6E705B,earnings,100,50,4/19/2021
6E705B,earnings,100,50,4/19/2021
6E705B,earnings,100,50,4/19/2021
6F39FC,conference-call,100,50,4/19/2021
722D55,executive-resignation,100,44,4/19/2021
7710F3,conference-call,100,50,4/19/2021
77B8E9,conference-participant,100,50,4/19/2021
791EC1,unit-acquisition-acquiree,100,76,4/19/2021
7DD8CC,conference-call,100,50,4/19/2021
7F3669,earnings,100,50,4/19/2021
83066C,conference-call,100,50,4/19/2021
8377DB,executive-appointment,100,54,4/19/2021
85DA04,earnings,100,50,4/19/2021
86F123,earnings,100,50,4/19/2021
88193E,conference-call,100,50,4/19/2021
8A8E41,business-contract,100,69,4/19/2021
8AC740,conference-call,100,50,4/19/2021
8BAA15,executive-appointment,100,54,4/19/2021
8C5519,earnings,100,50,4/19/2021
8C5519,earnings,100,50,4/19/2021
8C5519,earnings,100,50,4/19/2021
8C5519,earnings,100,50,4/19/2021
8C5519,earnings,100,50,4/19/2021
8C5519,earnings,100,50,4/19/2021
8D4486,earnings,100,50,4/19/2021
8D4486,earnings,100,50,4/19/2021
8D4486,earnings,100,50,4/19/2021
8D4486,earnings,100,50,4/19/2021
8D4AE6,business-combination,100,54,4/19/2021
8D4AE6,business-combination,100,54,4/19/2021
8D4AE6,business-combination,100,54,4/19/2021
8D4AE6,business-combination,100,54,4/19/2021
8D4AE6,business-combination,100,54,4/19/2021
8D4AE6,business-combination,100,54,4/19/2021
8D4AE6,legal-issues-defendant,100,22,4/19/2021
8D4AE6,acquisition-regulatory-scrutiny-acquiree,100,38,4/19/2021
9087B9,conference-call,100,50,4/19/2021
92B047,earnings-up,100,68,4/19/2021
934029,regulatory-product-application,100,69,4/19/2021
934029,regulatory-product-application,100,69,4/19/2021
93965C,executive-appointment,100,54,4/19/2021
94208D,executive-appointment,100,54,4/19/2021
949D62,earnings,100,50,4/19/2021
94C0B5,earnings,100,50,4/19/2021
9.54E+32,partnership,100,61,4/19/2021
9.54E+32,partnership,100,61,4/19/2021
96BFF4,unit-acquisition-acquirer,100,49,4/19/2021
971F7B,acquisition-acquirer,100,49,4/19/2021
97AF94,facility-open,100,65,4/19/2021
990AD0,conference-organizer,100,57,4/19/2021
9994DA,earnings,100,50,4/19/2021
9994DA,conference-participant,100,50,4/19/2021
99B61C,product-release,100,64,4/19/2021
9A2760,credit-extension-recipient,100,69,4/19/2021
9A29F4,conference-call,100,50,4/19/2021
9D30A8,earnings,100,50,4/19/2021
9F048E,earnings,100,50,4/19/2021
9F62D1,earnings-per-share-positive,100,69,4/19/2021
A1EAC8,business-contract,100,69,4/19/2021
A2CA3F,earnings,100,50,4/19/2021
A2CA3F,dividend,100,50,4/19/2021
A433A5,unit-acquisition-completed-acquirer,100,49,4/19/2021
A6D095,clinical-trials-start,100,64,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A746F6,earnings-per-share-positive,100,69,4/19/2021
A79D88,conference-call,100,50,4/19/2021
A79F7D,market-entry,100,57,4/19/2021
A7A0BD,award,100,58,4/19/2021
A7F0A5,earnings,100,50,4/19/2021
AADE0B,stake-acquirer,100,48,4/19/2021
AC7C4F,business-contract,100,69,4/19/2021
B2F431,earnings-positive,100,69,4/19/2021
B2F431,merger,100,66,4/19/2021
B2F431,merger,100,66,4/19/2021
B5766D,earnings-per-share-positive,100,69,4/19/2021
B5766D,earnings,100,50,4/19/2021
B5766D,earnings,100,50,4/19/2021
B5766D,earnings,100,50,4/19/2021
B5766D,earnings,100,50,4/19/2021
B5766D,earnings,100,50,4/19/2021
B604DF,earnings,100,50,4/19/2021
B604DF,earnings,100,50,4/19/2021
B604DF,earnings,100,50,4/19/2021
B604DF,earnings,100,50,4/19/2021
B83BCE,earnings,100,50,4/19/2021
BB0587,conference-call,100,50,4/19/2021
BD682F,earnings,100,50,4/19/2021
BDD12C,buybacks,100,74,4/19/2021
BEB756,dividend,100,50,4/19/2021
BEB756,earnings,100,50,4/19/2021
C32A39,earnings,100,50,4/19/2021
C3CF29,earnings,100,50,4/19/2021
C54140,earnings,100,50,4/19/2021
C5E100,conference-call,100,50,4/19/2021
C8FAC7,partnership,100,61,4/19/2021
C8FAC7,partnership,100,61,4/19/2021
C9732E,executive-appointment,100,54,4/19/2021
C9C62A,executive-appointment,100,54,4/19/2021
CB6A9C,conference-call,100,50,4/19/2021
D0DFE5,earnings,100,50,4/19/2021
D15833,conference-call,100,50,4/19/2021
D1AE3B,earnings,100,50,4/19/2021
D1CFC8,executive-resignation,100,44,4/19/2021
D4AC65,partnership,100,61,4/19/2021
D6534D,conference-call,100,50,4/19/2021
D8760C,earnings-positive,100,69,4/19/2021
D8760C,earnings,100,50,4/19/2021
D8760C,earnings,100,50,4/19/2021
D8760C,earnings,100,50,4/19/2021
D8760C,earnings,100,50,4/19/2021
D8760C,earnings,100,50,4/19/2021
DA0A9E,business-contract,100,69,4/19/2021
DD1BA1,product-release,100,64,4/19/2021
DD1BA1,acquisition-acquiree,100,76,4/19/2021
DF8855,investment-investor,100,55,4/19/2021
E20BFE,partnership,100,61,4/19/2021
E2CB7B,earnings,100,50,4/19/2021
E3A829,executive-appointment,100,54,4/19/2021
E5D914,earnings,100,50,4/19/2021
E5D914,earnings,100,50,4/19/2021
E6C8DC,conference-call,100,50,4/19/2021
E866D2,partnership,100,61,4/19/2021
E90C84,conference-call,100,50,4/19/2021
EA79C7,executive-appointment,100,54,4/19/2021
EB36DE,ipo-considered,100,60,4/19/2021
ED9576,dividend-up,100,81,4/19/2021
EE04F0,earnings,100,50,4/19/2021
EEA6B3,earnings,100,50,4/19/2021
EEA6B3,earnings,100,50,4/19/2021
EEA6B3,earnings,100,50,4/19/2021
F0EEFB,conference-call,100,50,4/19/2021
F2BC3D,earnings,100,50,4/19/2021
F44EA2,earnings,100,50,4/19/2021
F509E2,conference-call,100,50,4/19/2021
F57F6F,executive-appointment,100,54,4/19/2021
F58C23,business-contract,100,69,4/19/2021
F6E1B5,executive-appointment,100,54,4/19/2021
FB7724,earnings,100,50,4/19/2021
FBD92D,executive-appointment,100,54,4/19/2021
FC01C0,conference-call,100,50,4/19/2021
FC1B7B,business-contract,100,69,4/19/2021
FD39EB,dividend,100,50,4/19/2021
FDF28E,earnings,100,50,4/19/2021
002A99,legal-issues-defendant,100,22,4/20/2021
01B8D6,earnings,100,50,4/20/2021
03596A,conference-call,100,50,4/20/2021
070B45,earnings,100,50,4/20/2021
08A40F,legal-issues-defendant,100,22,4/20/2021
98977,earnings,100,50,4/20/2021
099C88,business-contract,100,69,4/20/2021
0A59F8,partnership,100,61,4/20/2021
0B13E8,executive-appointment,100,54,4/20/2021
0B400D,earnings,100,50,4/20/2021
0C4131,legal-issues-defendant,100,22,4/20/2021
0C4131,earnings,100,50,4/20/2021
0E499E,stake-acquirer,100,48,4/20/2021
0F91FC,conference-call,100,50,4/20/2021
11AEDE,conference-participant,100,50,4/20/2021
126F95,earnings,100,50,4/20/2021
126F95,earnings,100,50,4/20/2021
126F95,earnings,100,50,4/20/2021
126F95,earnings,100,50,4/20/2021
12A3A3,executive-appointment,100,54,4/20/2021
138DDE,earnings,100,50,4/20/2021
152FA5,executive-appointment,100,54,4/20/2021
15A388,executive-appointment,100,54,4/20/2021
16B183,legal-issues-defendant,100,22,4/20/2021
16C544,credit-extension-recipient,100,69,4/20/2021
180DA0,business-contract,100,69,4/20/2021
1866B2,business-contract,100,69,4/20/2021
18D9FA,legal-issues-defendant,100,22,4/20/2021
18EC17,earnings,100,50,4/20/2021
18EC17,earnings,100,50,4/20/2021
18EC17,earnings,100,50,4/20/2021
19CAC7,earnings,100,50,4/20/2021
19CAC7,earnings,100,50,4/20/2021
1B16C1,conference-call,100,50,4/20/2021
1C599A,earnings,100,50,4/20/2021
1CDD1C,product-release,100,64,4/20/2021
1D943E,earnings,100,50,4/20/2021
1E1125,legal-issues-defendant,100,22,4/20/2021
1E1125,legal-issues-defendant,100,22,4/20/2021
1FA8F7,earnings,100,50,4/20/2021
205AD5,donation,100,54,4/20/2021
225CA2,earnings,100,50,4/20/2021
225CA2,earnings,100,50,4/20/2021
225CA2,earnings,100,50,4/20/2021
225CA2,earnings,100,50,4/20/2021
225CA2,earnings,100,50,4/20/2021
225CA2,earnings,100,50,4/20/2021
249674,conference-call,100,50,4/20/2021
24CB56,earnings-positive,100,69,4/20/2021
24CB56,earnings,100,50,4/20/2021
24CB56,earnings,100,50,4/20/2021
24CB56,earnings,100,50,4/20/2021
24CB56,earnings,100,50,4/20/2021
24CB56,earnings,100,50,4/20/2021
24CB56,earnings,100,50,4/20/2021
24CB56,earnings,100,50,4/20/2021
251988,partnership,100,61,4/20/2021
263216,business-contract,100,69,4/20/2021
263216,business-contract,100,69,4/20/2021
28AF37,earnings,100,50,4/20/2021
2A1009,fraud-defendant,100,20,4/20/2021
2E61CC,earnings,100,50,4/20/2021
3.14E+47,earnings,100,50,4/20/2021
31803E,earnings,100,50,4/20/2021
3.30E+30,acquisition-completed-acquirer,100,49,4/20/2021
339F20,facility-open,100,65,4/20/2021
341759,conference-participant,100,50,4/20/2021
356B21,product-release,100,64,4/20/2021
35B907,earnings,100,50,4/20/2021
35B907,earnings,100,50,4/20/2021
366A08,conference-call,100,50,4/20/2021
37020C,conference-call,100,50,4/20/2021
3798B9,earnings,100,50,4/20/2021
39FB23,revenue-up,100,69,4/20/2021
3BBD10,award,100,58,4/20/2021
3CCC90,earnings,100,50,4/20/2021
3CCC90,dividend,100,50,4/20/2021
3E149C,revenues,100,50,4/20/2021
3E149C,revenues,100,50,4/20/2021
4017AD,earnings,100,50,4/20/2021
416C55,partnership,100,61,4/20/2021
41EC04,conference-call,100,50,4/20/2021
422CE3,hirings,100,65,4/20/2021
422CE3,hirings,100,65,4/20/2021
427F32,conference-call,100,50,4/20/2021
43A74A,earnings,100,50,4/20/2021
43A74A,earnings,100,50,4/20/2021
43A74A,earnings,100,50,4/20/2021
43A74A,earnings,100,50,4/20/2021
43A74A,earnings,100,50,4/20/2021
43A74A,earnings,100,50,4/20/2021
43A74A,earnings,100,50,4/20/2021
43A74A,earnings,100,50,4/20/2021
43A74A,earnings,100,50,4/20/2021
43E8F5,conference-call,100,50,4/20/2021
444CC8,product-release,100,64,4/20/2021
447FC6,conference-call,100,50,4/20/2021
449A26,partnership,100,61,4/20/2021
449A26,partnership,100,61,4/20/2021
4591D3,revenues,100,50,4/20/2021
4591D3,revenues,100,50,4/20/2021
4591D3,revenues,100,50,4/20/2021
4591D3,revenues,100,50,4/20/2021
4591D3,revenues,100,50,4/20/2021
490D4B,conference-call,100,50,4/20/2021
494EB9,earnings,100,50,4/20/2021
4AC91D,award,100,58,4/20/2021
4C1FA1,earnings,100,50,4/20/2021
4C5CC9,conference-call,100,50,4/20/2021
4C6C63,dividend,100,50,4/20/2021
4F9926,executive-appointment,100,54,4/20/2021
513A86,facility-open,100,65,4/20/2021
519FE0,public-offering,100,43,4/20/2021
520632,earnings,100,50,4/20/2021
520632,earnings,100,50,4/20/2021
520632,earnings,100,50,4/20/2021
525A1C,earnings,100,50,4/20/2021
5480A7,earnings,100,50,4/20/2021
55C9B5,partnership,100,61,4/20/2021
55C9B5,conference-participant,100,50,4/20/2021
56277A,regulatory-product-approval-granted,100,81,4/20/2021
57A854,earnings,100,50,4/20/2021
57B174,conference-call,100,50,4/20/2021
57CAAB,partnership,100,61,4/20/2021
57DDB9,conference-call,100,50,4/20/2021
586FFD,conference-call,100,50,4/20/2021
58C2D4,earnings,100,50,4/20/2021
58C2D4,legal-issues-defendant,100,22,4/20/2021
59872F,product-release,100,64,4/20/2021
59C539,dividend,100,50,4/20/2021
5B6C11,earnings,100,50,4/20/2021
5CCDAD,earnings,100,50,4/20/2021
5EC388,earnings-up,100,68,4/20/2021
5FF95F,earnings-positive,100,69,4/20/2021
60EA12,award,100,58,4/20/2021
6137BF,earnings,100,50,4/20/2021
6137BF,earnings,100,50,4/20/2021
62B20A,earnings,100,50,4/20/2021
633054,investment-investor,100,55,4/20/2021
636639,earnings,100,50,4/20/2021
636639,earnings,100,50,4/20/2021
636639,earnings,100,50,4/20/2021
636639,earnings,100,50,4/20/2021
64854A,conference-call,100,50,4/20/2021
651C85,earnings,100,50,4/20/2021
65D0AA,clinical-trials-positive,100,87,4/20/2021
665440,conference-participant,100,50,4/20/2021
67B052,clinical-trials-positive,100,87,4/20/2021
67B052,clinical-trials-positive,100,87,4/20/2021
69494C,conference-call,100,50,4/20/2021
698FF9,earnings,100,50,4/20/2021
69CE71,conference-call,100,50,4/20/2021
6A3C35,earnings,100,50,4/20/2021
6B5379,earnings,100,50,4/20/2021
6BC6F9,earnings,100,50,4/20/2021
6D3B7B,earnings,100,50,4/20/2021
6D9B53,award,100,58,4/20/2021
723548,unit-acquisition-acquirer,100,49,4/20/2021
7255D2,legal-issues-defendant,100,22,4/20/2021
74404C,executive-appointment,100,54,4/20/2021
75F665,earnings,100,50,4/20/2021
75F665,dividend,100,50,4/20/2021
762B8D,earnings,100,50,4/20/2021
76B926,conference-call,100,50,4/20/2021
789ADD,product-recall,100,29,4/20/2021
791D59,award,100,58,4/20/2021
7A51FE,conference-call,100,50,4/20/2021
7AD81E,earnings,100,50,4/20/2021
7B6C88,conference-call,100,50,4/20/2021
7C790D,conference-call,100,50,4/20/2021
7DD584,product-release,100,64,4/20/2021
7DD584,product-release,100,64,4/20/2021
7E1542,earnings,100,50,4/20/2021
7E1D5D,product-release,100,64,4/20/2021
82E58A,dividend,100,50,4/20/2021
82F088,conference-call,100,50,4/20/2021
8303CD,index-listing,100,76,4/20/2021
8377DB,earnings,100,50,4/20/2021
8377DB,earnings,100,50,4/20/2021
8377DB,earnings,100,50,4/20/2021
8377DB,earnings,100,50,4/20/2021
8377DB,earnings,100,50,4/20/2021
83A065,conference-call,100,50,4/20/2021
845655,conference-call,100,50,4/20/2021
845655,conference-call,100,50,4/20/2021
84AB66,dividend,100,50,4/20/2021
850779,earnings-per-share-positive,100,69,4/20/2021
850779,earnings-per-share,100,50,4/20/2021
850779,earnings-per-share,100,50,4/20/2021
862941,earnings,100,50,4/20/2021
88350F,operating-earnings-positive,100,69,4/20/2021
88350F,earnings-per-share,100,50,4/20/2021
88350F,earnings-per-share,100,50,4/20/2021
88350F,earnings-per-share,100,50,4/20/2021
895D56,conference-call,100,50,4/20/2021
8A8E41,earnings,100,50,4/20/2021
8BAA15,business-contract,100,69,4/20/2021
8CF6DD,earnings,100,50,4/20/2021
8D4486,earnings,100,50,4/20/2021
8DCF18,conference-call,100,50,4/20/2021
8DDA23,dividend,100,50,4/20/2021
8F3231,dividend,100,50,4/20/2021
8F3BCC,earnings-per-share-positive,100,69,4/20/2021
901327,earnings,100,50,4/20/2021
925759,clinical-trials-start,100,64,4/20/2021
93633B,earnings,100,50,4/20/2021
93633B,earnings,100,50,4/20/2021
93633B,earnings,100,50,4/20/2021
93633B,earnings,100,50,4/20/2021
93633B,earnings,100,50,4/20/2021
938D89,executive-appointment,100,54,4/20/2021
93965C,earnings,100,50,4/20/2021
9470CC,earnings,100,50,4/20/2021
9507FF,earnings,100,50,4/20/2021
957A07,executive-appointment,100,54,4/20/2021
966DBE,earnings,100,50,4/20/2021
968B00,earnings,100,50,4/20/2021
96F126,earnings,100,50,4/20/2021
96F126,earnings,100,50,4/20/2021
977A1E,donation,100,54,4/20/2021
9.86E+03,earnings,100,50,4/20/2021
9CA4C6,dividend,100,50,4/20/2021
9CA4C6,earnings-up,100,68,4/20/2021
9CE4C7,partnership,100,61,4/20/2021
9D2790,earnings,100,50,4/20/2021
9D4EC7,conference-call,100,50,4/20/2021
9D4EC7,conference-call,100,50,4/20/2021
9E4A5F,earnings,100,50,4/20/2021
9F03CF,business-contract,100,69,4/20/2021
9F5997,executive-appointment,100,54,4/20/2021
9F6B1A,product-release,100,64,4/20/2021
9FD2D9,partnership,100,61,4/20/2021
A01664,earnings,100,50,4/20/2021
A0F146,conference-call,100,50,4/20/2021
A15C71,conference-call,100,50,4/20/2021
A16DEA,market-entry,100,57,4/20/2021
A23747,earnings,100,50,4/20/2021
A29DBD,earnings,100,50,4/20/2021
A398B9,earnings,100,50,4/20/2021
A398B9,earnings,100,50,4/20/2021
A398B9,earnings,100,50,4/20/2021
A4B899,conference-call,100,50,4/20/2021
A4CD53,earnings,100,50,4/20/2021
A60354,conference-call,100,50,4/20/2021
A666C8,product-release,100,64,4/20/2021
A666C8,product-release,100,64,4/20/2021
A6828A,dividend-up,100,81,4/20/2021
A6828A,earnings,100,50,4/20/2021
A7102F,conference-call,100,50,4/20/2021
A746F6,dividend,100,50,4/20/2021
A79D88,executive-appointment,100,54,4/20/2021
A7A0BD,award,100,58,4/20/2021
A8CBDA,dividend,100,50,4/20/2021
AC7C4F,government-contract,100,69,4/20/2021
ACD9A4,earnings,100,50,4/20/2021
ADF092,earnings,100,50,4/20/2021
AEBB80,earnings,100,50,4/20/2021
AFD7DD,conference-call,100,50,4/20/2021
B05118,product-release,100,64,4/20/2021
B48FC9,earnings,100,50,4/20/2021
B48FC9,facility-open,100,65,4/20/2021
B508E5,conference-call,100,50,4/20/2021
B560AF,dividend,100,50,4/20/2021
B8F71F,earnings,100,50,4/20/2021
B96DF5,earnings,100,50,4/20/2021
B9BDE8,partnership,100,61,4/20/2021
BD15E8,earnings-per-share-up,100,91,4/20/2021
BD9668,earnings,100,50,4/20/2021
BDEC1E,executive-appointment,100,54,4/20/2021
BDF85E,revenue-guidance,100,50,4/20/2021
BE14CF,conference-participant,100,50,4/20/2021
C0200F,executive-appointment,100,54,4/20/2021
C0200F,earnings,100,50,4/20/2021
C0200F,earnings,100,50,4/20/2021
C2E39B,earnings,100,50,4/20/2021
C32A39,dividend,100,50,4/20/2021
C3CF29,buybacks,100,74,4/20/2021
C4452A,business-contract,100,69,4/20/2021
C65004,earnings,100,50,4/20/2021
C8257F,earnings,100,50,4/20/2021
C8257F,earnings,100,50,4/20/2021
C83B88,revenue-up,100,69,4/20/2021
C83B88,revenue-up,100,69,4/20/2021
C8923A,earnings,100,50,4/20/2021
C8A248,facility-open,100,65,4/20/2021
C941DC,earnings,100,50,4/20/2021
C98CDB,earnings,100,50,4/20/2021
CAB222,conference-call,100,50,4/20/2021
CB9E13,conference-call,100,50,4/20/2021
CC3EC4,note-sale,100,52,4/20/2021
CD2A4D,executive-appointment,100,54,4/20/2021
CD2A4D,conference-participant,100,50,4/20/2021
CDC817,earnings,100,50,4/20/2021
CEC08B,executive-appointment,100,54,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
CFE5BE,earnings,100,50,4/20/2021
D0DE27,joint-venture,100,62,4/20/2021
D393DF,earnings,100,50,4/20/2021
D393DF,earnings,100,50,4/20/2021
D6489C,partnership,100,61,4/20/2021
D82EF3,conference-call,100,50,4/20/2021
D8442A,product-release,100,64,4/20/2021
D8442A,product-release,100,64,4/20/2021
D8442A,product-release,100,64,4/20/2021
D8442A,partnership,100,61,4/20/2021
D8442A,product-release,100,64,4/20/2021
D8442A,product-release,100,64,4/20/2021
D854DD,conference-call,100,50,4/20/2021
D88EF3,note-sale,100,52,4/20/2021
D9164D,earnings,100,50,4/20/2021
D9B1C9,dividend,100,50,4/20/2021
D9E036,business-contract,100,69,4/20/2021
DB06B0,earnings,100,50,4/20/2021
DBB28E,award,100,58,4/20/2021
DC2B00,partnership,100,61,4/20/2021
DD1BA1,business-contract,100,69,4/20/2021
DD1BA1,business-contract,100,69,4/20/2021
DEF058,unit-acquisition-acquirer,100,49,4/20/2021
DF532D,earnings,100,50,4/20/2021
DF532D,earnings,100,50,4/20/2021
DF8855,earnings,100,50,4/20/2021
E05026,earnings,100,50,4/20/2021
E26FC3,earnings,100,50,4/20/2021
E68733,partnership,100,61,4/20/2021
E68E62,partnership,100,61,4/20/2021
E68E62,partnership,100,61,4/20/2021
E71AE6,patient-enrollment-complete,100,64,4/20/2021
E74B55,legal-issues-defendant,100,22,4/20/2021
EC1AF3,conference-call,100,50,4/20/2021
ECD263,earnings,100,50,4/20/2021
ED5171,dividend,100,50,4/20/2021
EF76C8,dividend,100,50,4/20/2021
F04E05,dividend,100,50,4/20/2021
F1C04C,conference-call,100,50,4/20/2021
F39E1E,buybacks,100,74,4/20/2021
F3FCC3,earnings,100,50,4/20/2021
F42FAE,earnings,100,50,4/20/2021
F48947,earnings,100,50,4/20/2021
F57F6F,earnings,100,50,4/20/2021
F7935D,legal-issues-defendant,100,22,4/20/2021
F793FA,executive-appointment,100,54,4/20/2021
F82D37,acquisition-interest-acquiree,100,82,4/20/2021
F88A04,earnings,100,50,4/20/2021
F93C8A,dividend,100,50,4/20/2021
FAAFA2,partnership,100,61,4/20/2021
FACF19,partnership,100,61,4/20/2021
FC80E6,conference-call,100,50,4/20/2021
FD0CA4,earnings,100,50,4/20/2021
FE7A63,earnings,100,50,4/20/2021
FE7A63,earnings,100,50,4/20/2021
FE7A63,earnings,100,50,4/20/2021
FE7A63,earnings,100,50,4/20/2021
FE7A63,earnings,100,50,4/20/2021
FE7A63,earnings,100,50,4/20/2021
FE7A63,earnings,100,50,4/20/2021
FFAB4A,dividend,100,50,4/20/2021
FFCD0E,revenue-up,100,76,4/20/2021
0157B1,partnership,100,61,4/21/2021
0157B1,partnership,100,61,4/21/2021
01D03F,earnings,100,50,4/21/2021
31025,executive-appointment,100,54,4/21/2021
034B61,partnership,100,61,4/21/2021
03F5A4,earnings-positive,100,69,4/21/2021
054B55,earnings,100,50,4/21/2021
58828,operating-earnings,100,50,4/21/2021
06EF42,executive-appointment,100,54,4/21/2021
06EF42,buybacks,100,74,4/21/2021
0A1D77,earnings,100,50,4/21/2021
0B57D7,earnings,100,50,4/21/2021
0C2A0D,dividend,100,50,4/21/2021
0CCCB7,conference-call,100,50,4/21/2021
0CE204,earnings,100,50,4/21/2021
0D26E0,earnings,100,50,4/21/2021
0E499E,earnings,100,50,4/21/2021
0E6027,earnings-positive,100,69,4/21/2021
0E6027,earnings,100,50,4/21/2021
0E6027,earnings,100,50,4/21/2021
0FABBD,conference-call,100,50,4/21/2021
125212,earnings,100,50,4/21/2021
1348C9,business-contract,100,69,4/21/2021
139303,conference-call,100,50,4/21/2021
14833D,earnings,100,50,4/21/2021
152E1D,acquisition-acquiree,100,76,4/21/2021
152E1D,acquisition-acquiree,100,76,4/21/2021
152E1D,legal-issues-defendant,100,22,4/21/2021
152E1D,acquisition-regulatory-scrutiny-acquiree,100,38,4/21/2021
15B10D,conference-call,100,50,4/21/2021
165B3A,earnings-positive,100,69,4/21/2021
165B3A,earnings-positive,100,69,4/21/2021
165B3A,earnings-positive,100,69,4/21/2021
165B3A,earnings-positive,100,69,4/21/2021
1748B3,earnings,100,50,4/21/2021
1748B3,earnings,100,50,4/21/2021
1748B3,earnings,100,50,4/21/2021
1748B3,earnings,100,50,4/21/2021
1748B3,earnings,100,50,4/21/2021
1748B3,earnings,100,50,4/21/2021
1748B3,earnings,100,50,4/21/2021
17EDA5,partnership,100,61,4/21/2021
17EDA5,partnership,100,61,4/21/2021
18D9FA,executive-appointment,100,54,4/21/2021
1921DD,business-contract,100,69,4/21/2021
1A9DE1,earnings-up,100,68,4/21/2021
1A9DE1,earnings,100,50,4/21/2021
1A9DE1,earnings,100,50,4/21/2021
1A9DE1,earnings,100,50,4/21/2021
1AB808,earnings,100,50,4/21/2021
1E1125,fraud-defendant,100,20,4/21/2021
1E1125,fraud-defendant,100,20,4/21/2021
1E5786,dividend,100,50,4/21/2021
1E9A6D,dividend,100,50,4/21/2021
1FAF22,grant-recipient,100,63,4/21/2021
2031CE,earnings-up,100,68,4/21/2021
2031CE,earnings,100,50,4/21/2021
2031CE,earnings,100,50,4/21/2021
2031CE,earnings,100,50,4/21/2021
2031CE,earnings,100,50,4/21/2021
2031CE,earnings,100,50,4/21/2021
21153F,partnership,100,61,4/21/2021
223552,clinical-trials-start,100,64,4/21/2021
223552,clinical-trials-start,100,64,4/21/2021
223552,clinical-trials-start,100,64,4/21/2021
241AF7,conference-call,100,50,4/21/2021
2.45E+15,earnings,100,50,4/21/2021
24C48B,conference-call,100,50,4/21/2021
24FA23,earnings,100,50,4/21/2021
25102A,earnings,100,50,4/21/2021
25102A,earnings,100,50,4/21/2021
25102A,earnings,100,50,4/21/2021
25102A,earnings,100,50,4/21/2021
25102A,earnings,100,50,4/21/2021
25102A,earnings,100,50,4/21/2021
25102A,earnings,100,50,4/21/2021
25102A,dividend-up,100,60,4/21/2021
2720AB,earnings,100,50,4/21/2021
275300,earnings,100,50,4/21/2021
275300,earnings,100,50,4/21/2021
275300,earnings,100,50,4/21/2021
275300,earnings,100,50,4/21/2021
275300,earnings,100,50,4/21/2021
275300,earnings,100,50,4/21/2021
275300,earnings,100,50,4/21/2021
275300,earnings,100,50,4/21/2021
275300,earnings,100,50,4/21/2021
27BFA1,earnings,100,50,4/21/2021
28B730,earnings,100,50,4/21/2021
295F9F,executive-appointment,100,54,4/21/2021
2A1009,legal-issues-defendant,100,22,4/21/2021
2A1009,fraud-defendant,100,20,4/21/2021
2A1009,legal-issues-defendant,100,22,4/21/2021
2B49F4,earnings,100,50,4/21/2021
2B49F4,earnings,100,50,4/21/2021
2B49F4,earnings,100,50,4/21/2021
2B49F4,earnings,100,50,4/21/2021
2CB4C9,earnings,100,50,4/21/2021
2DDB22,conference-call,100,50,4/21/2021
3.14E+47,earnings,100,50,4/21/2021
319BE2,conference-call,100,50,4/21/2021
31A7CC,earnings-up,100,68,4/21/2021
31DB20,earnings,100,50,4/21/2021
339F20,earnings-up,100,68,4/21/2021
33A0F1,partnership,100,61,4/21/2021
3.30E+34,earnings-up,100,68,4/21/2021
3.30E+34,earnings-up,100,68,4/21/2021
3.30E+34,earnings-up,100,68,4/21/2021
342218,dividend,100,50,4/21/2021
3461CF,credit-rating-upgrade-rater,20,50,4/21/2021
34A959,investment-investor,100,55,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
34B411,earnings,100,50,4/21/2021
35557B,partnership,100,61,4/21/2021
36A1CB,conference-call,100,50,4/21/2021
36C09B,clinical-trials-start,100,64,4/21/2021
385DD4,business-contract,100,69,4/21/2021
3A1C46,earnings,100,50,4/21/2021
3C6CCC,earnings,100,50,4/21/2021
3ED92D,partnership,100,61,4/21/2021
3ED92D,partnership,100,61,4/21/2021
408089,dividend,100,50,4/21/2021
408089,executive-appointment,100,54,4/21/2021
41C528,executive-appointment,100,54,4/21/2021
423279,dividend,100,50,4/21/2021
442769,acquisition-completed-acquirer,100,49,4/21/2021
444CC8,conference-call,100,50,4/21/2021
448215,earnings,100,50,4/21/2021
449447,conference-call,100,50,4/21/2021
453282,conference-participant,100,50,4/21/2021
458D2C,conference-call,100,50,4/21/2021
45ABCC,earnings,100,50,4/21/2021
460C93,dividend-up,100,81,4/21/2021
460C93,dividend-up,100,81,4/21/2021
460C93,dividend-up,100,81,4/21/2021
460C93,dividend-up,100,81,4/21/2021
460C93,dividend-up,100,81,4/21/2021
4A5C8D,business-contract,100,69,4/21/2021
4BAF2E,clinical-trials-start,100,64,4/21/2021
4C2F17,earnings,100,50,4/21/2021
4D7BD8,earnings,100,50,4/21/2021
4D7BD8,earnings,100,50,4/21/2021
4D7BD8,earnings,100,50,4/21/2021
4D7BD8,earnings,100,50,4/21/2021
4D7BD8,earnings,100,50,4/21/2021
4D7BD8,earnings,100,50,4/21/2021
4D7BD8,earnings,100,50,4/21/2021
4D8313,product-release,100,64,4/21/2021
4D8313,earnings-up,100,68,4/21/2021
4D8313,earnings-up,100,68,4/21/2021
4EE14A,earnings,100,50,4/21/2021
4EE14A,earnings,100,50,4/21/2021
4F9487,earnings-positive,100,69,4/21/2021
4F9487,earnings-positive,100,69,4/21/2021
4F9487,earnings-positive,100,69,4/21/2021
4F9487,earnings-positive,100,69,4/21/2021
4F9487,earnings-positive,100,69,4/21/2021
4F9487,earnings-positive,100,69,4/21/2021
4F9487,earnings-positive,100,69,4/21/2021
4F9487,earnings-positive,100,69,4/21/2021
4F9487,earnings-positive,100,69,4/21/2021
4F9926,product-release,100,64,4/21/2021
4F9926,product-release,100,64,4/21/2021
504FE2,legal-issues-defendant,100,22,4/21/2021
51F541,conference-call,100,50,4/21/2021
5225A4,earnings,100,50,4/21/2021
5225A4,earnings,100,50,4/21/2021
5225A4,earnings,100,50,4/21/2021
5225A4,earnings,100,50,4/21/2021
5225A4,earnings,100,50,4/21/2021
53F491,ownership-decrease-owner,100,46,4/21/2021
53F491,earnings-per-share,100,50,4/21/2021
54B889,conference-call,100,50,4/21/2021
553949,conference-call,100,50,4/21/2021
55C9B5,partnership,100,61,4/21/2021
55C9B5,product-release,100,64,4/21/2021
55C9B5,business-contract,100,69,4/21/2021
56AFF4,operating-earnings,100,50,4/21/2021
5876DC,dividend,100,50,4/21/2021
589F5A,dividend,100,50,4/21/2021
58CA9A,business-contract,100,69,4/21/2021
5A64D5,dividend,100,50,4/21/2021
5A9F54,earnings-up,100,68,4/21/2021
5B3FA2,earnings,100,50,4/21/2021
5B97B2,earnings,100,50,4/21/2021
5BC2F4,dividend,100,50,4/21/2021
5D16CF,note-sale,100,52,4/21/2021
5DD48B,earnings,100,50,4/21/2021
5DD48B,earnings,100,50,4/21/2021
5E9934,executive-appointment,100,54,4/21/2021
5F60CE,earnings,100,50,4/21/2021
60EA12,executive-appointment,100,54,4/21/2021
6137BF,partnership,100,61,4/21/2021
6166D1,dividend,100,50,4/21/2021
61E975,business-contract,100,69,4/21/2021
6284B5,business-contract,100,69,4/21/2021
66BDA1,earnings,100,50,4/21/2021
67529E,earnings-positive,100,69,4/21/2021
6AACDD,conference-participant,100,50,4/21/2021
6C4D2F,dividend,100,50,4/21/2021
6CB7F9,earnings,100,50,4/21/2021
6CF43C,earnings,100,50,4/21/2021
6E7060,earnings,100,50,4/21/2021
6E8864,conference-call,100,50,4/21/2021
6ED519,earnings,100,50,4/21/2021
6F0096,earnings,100,50,4/21/2021
6F0096,earnings,100,50,4/21/2021
6F0096,earnings,100,50,4/21/2021
704B78,earnings,100,50,4/21/2021
722D55,executive-appointment,100,54,4/21/2021
7255D2,legal-issues-defendant,100,22,4/21/2021
72C2CE,conference-call,100,50,4/21/2021
73C521,dividend,100,50,4/21/2021
7410C3,earnings,100,50,4/21/2021
74404C,dividend,100,50,4/21/2021
775439,earnings,100,50,4/21/2021
7.83E+79,earnings,100,50,4/21/2021
793C11,earnings,100,50,4/21/2021
7A10FF,partnership,100,61,4/21/2021
7AB859,earnings,100,50,4/21/2021
7AB859,earnings,100,50,4/21/2021
7AB859,earnings,100,50,4/21/2021
7AB859,earnings,100,50,4/21/2021
7AB859,earnings,100,50,4/21/2021
7AB859,executive-appointment,100,54,4/21/2021
7B0BA6,facility-open,100,65,4/21/2021
7B1156,conference-call,100,50,4/21/2021
7B6C88,product-release,100,64,4/21/2021
7C62A3,conference-call,100,50,4/21/2021
7C75FD,earnings-up,100,68,4/21/2021
7C75FD,earnings,100,50,4/21/2021
7C75FD,earnings,100,50,4/21/2021
7C75FD,earnings,100,50,4/21/2021
7C75FD,earnings,100,50,4/21/2021
7C75FD,earnings,100,50,4/21/2021
7C75FD,earnings,100,50,4/21/2021
7C75FD,earnings,100,50,4/21/2021
7C75FD,earnings,100,50,4/21/2021
7C75FD,earnings,100,50,4/21/2021
7F0372,earnings,100,50,4/21/2021
7F3FBC,dividend-up,100,54,4/21/2021
7FDE1C,partnership,100,61,4/21/2021
7FDE1C,partnership,100,61,4/21/2021
8275FE,earnings,100,50,4/21/2021
834152,clinical-trials,100,56,4/21/2021
845533,earnings,100,50,4/21/2021
860AB6,conference-call,100,50,4/21/2021
863350,facility-open,100,65,4/21/2021
87B81A,earnings,100,50,4/21/2021
893904,public-offering,100,43,4/21/2021
896771,earnings,100,50,4/21/2021
89B2E7,earnings,100,50,4/21/2021
8C1238,earnings-up,100,68,4/21/2021
8C1238,earnings,100,50,4/21/2021
8C1238,earnings,100,50,4/21/2021
8C1238,earnings,100,50,4/21/2021
8C1238,earnings,100,50,4/21/2021
8C1238,earnings,100,50,4/21/2021
8D4486,partnership,100,61,4/21/2021
8D4486,product-release,100,64,4/21/2021
8E4250,note-sale,100,52,4/21/2021
8E4F9A,executive-appointment,100,54,4/21/2021
901327,facility-open,100,65,4/21/2021
907ED2,earnings,100,50,4/21/2021
907ED2,earnings,100,50,4/21/2021
907ED2,earnings,100,50,4/21/2021
907ED2,earnings,100,50,4/21/2021
907ED2,earnings,100,50,4/21/2021
907ED2,earnings,100,50,4/21/2021
940C3D,earnings,100,50,4/21/2021
9592FB,earnings,100,50,4/21/2021
9.62E+76,earnings,100,50,4/21/2021
9.62E+76,earnings,100,50,4/21/2021
9.62E+76,earnings,100,50,4/21/2021
96B4FF,executive-appointment,100,54,4/21/2021
96F126,partnership,100,61,4/21/2021
96F126,dividend,100,50,4/21/2021
972356,revenues,100,50,4/21/2021
97AAF6,earnings,100,50,4/21/2021
986AF6,conference-call,100,50,4/21/2021
990AD0,conference-organizer,100,57,4/21/2021
990AD0,trading-halt,100,43,4/21/2021
990AD0,trading-resumed,100,58,4/21/2021
9.92E+94,earnings,100,50,4/21/2021
9.92E+94,earnings,100,50,4/21/2021
9.92E+94,earnings,100,50,4/21/2021
9C8664,earnings,100,50,4/21/2021
9CE4C7,earnings,100,50,4/21/2021
9EA947,product-release,100,64,4/21/2021
9F37C5,dividend,100,50,4/21/2021
9F37C5,earnings,100,50,4/21/2021
A16DEA,earnings,100,50,4/21/2021
A2CAF7,earnings,100,50,4/21/2021
A398F8,earnings,100,50,4/21/2021
A433A5,conference-call,100,50,4/21/2021
A4D173,earnings,100,50,4/21/2021
A4D173,earnings,100,50,4/21/2021
A6213D,executive-appointment,100,54,4/21/2021
A63387,market-entry,100,57,4/21/2021
A63820,earnings,100,50,4/21/2021
A63820,earnings,100,50,4/21/2021
A63820,earnings,100,50,4/21/2021
A63820,earnings,100,50,4/21/2021
A6828A,product-release,100,64,4/21/2021
A8CBDA,earnings-positive,100,69,4/21/2021
A8E72A,conference-participant,100,50,4/21/2021
AA5C8E,dividend-up,100,53,4/21/2021
AA5C8E,dividend-up,100,53,4/21/2021
AA5C8E,dividend-up,100,53,4/21/2021
AA5C8E,dividend-up,100,53,4/21/2021
AA5C8E,dividend-up,100,53,4/21/2021
AA5C8E,dividend-up,100,53,4/21/2021
AA847A,conference-call,100,50,4/21/2021
AABEA0,dividend,100,50,4/21/2021
AB7F05,earnings-up,100,68,4/21/2021
AB7F05,earnings,100,50,4/21/2021
AB7F05,earnings,100,50,4/21/2021
AB7F05,earnings,100,50,4/21/2021
AC7C4F,business-contract,100,69,4/21/2021
ACF0B4,acquisition-acquirer,100,49,4/21/2021
ACF0B4,acquisition-acquirer,100,49,4/21/2021
AD23DE,earnings,100,50,4/21/2021
AD23DE,earnings,100,50,4/21/2021
AD23DE,earnings,100,50,4/21/2021
AD23DE,earnings,100,50,4/21/2021
AD23DE,earnings,100,50,4/21/2021
AD23DE,earnings,100,50,4/21/2021
AD3C93,earnings,100,50,4/21/2021
ADF1B0,conference-call,100,50,4/21/2021
AE7D16,earnings,100,50,4/21/2021
B290A2,conference-call,100,50,4/21/2021
B37FB4,partnership,100,61,4/21/2021
B53C12,conference-call,100,50,4/21/2021
B5766D,dividend,100,50,4/21/2021
B66928,earnings,100,50,4/21/2021
B83BCE,partnership,100,61,4/21/2021
B8A51F,earnings,100,50,4/21/2021
BA218A,earnings,100,50,4/21/2021
BA218A,earnings-up,100,68,4/21/2021
BA218A,earnings-up,100,68,4/21/2021
BA218A,earnings-up,100,68,4/21/2021
BA218A,earnings-up,100,68,4/21/2021
BA218A,earnings-up,100,68,4/21/2021
BA218A,earnings-up,100,68,4/21/2021
BAAA60,earnings,100,50,4/21/2021
BB127B,product-release,100,64,4/21/2021
BB127B,product-release,100,64,4/21/2021
BCC13E,earnings,100,50,4/21/2021
BDD12C,earnings-positive,100,69,4/21/2021
BE645B,conference-participant,100,50,4/21/2021
C0030A,unit-acquisition-acquirer,100,49,4/21/2021
C062D4,conference-participant,100,50,4/21/2021
C06EB6,clinical-trials-start,100,64,4/21/2021
C06EB6,clinical-trials-start,100,64,4/21/2021
C16A8F,dividend,100,50,4/21/2021
C29715,earnings,100,50,4/21/2021
C29715,earnings,100,50,4/21/2021
C2F597,earnings,100,50,4/21/2021
C4706C,unit-acquisition-acquirer,100,49,4/21/2021
C490F9,reorganization,100,53,4/21/2021
C490F9,reorganization,100,53,4/21/2021
C9B932,earnings,100,50,4/21/2021
C9B932,earnings,100,50,4/21/2021
C9F39B,earnings,100,50,4/21/2021
C9F39B,earnings,100,50,4/21/2021
C9F39B,earnings,100,50,4/21/2021
C9F39B,earnings,100,50,4/21/2021
C9F39B,earnings,100,50,4/21/2021
C9F39B,earnings,100,50,4/21/2021
C9F39B,earnings,100,50,4/21/2021
CB22CD,conference-call,100,50,4/21/2021
CB89EA,earnings,100,50,4/21/2021
CD06A2,earnings,100,50,4/21/2021
CDC217,clinical-trials-complete,100,56,4/21/2021
CF351E,business-contract,100,69,4/21/2021
D04D9F,conference-call,100,50,4/21/2021
D17F7E,earnings,100,50,4/21/2021
D21D8A,earnings,100,50,4/21/2021
D21D8A,earnings,100,50,4/21/2021
D21D8A,earnings,100,50,4/21/2021
D21D8A,earnings,100,50,4/21/2021
D21D8A,earnings,100,50,4/21/2021
D21D8A,earnings,100,50,4/21/2021
D21D8A,earnings,100,50,4/21/2021
D27FAB,conference-call,100,50,4/21/2021
D29B44,earnings,100,50,4/21/2021
D48275,earnings,100,50,4/21/2021
D4AC65,conference-call,100,50,4/21/2021
D58A11,executive-appointment,100,54,4/21/2021
D77F7E,partnership,100,61,4/21/2021
D7A953,earnings,100,50,4/21/2021
D82EF3,partnership,100,61,4/21/2021
DA90E1,dividend-up,100,81,4/21/2021
DBB28E,partnership,100,61,4/21/2021
DBEF02,buybacks,100,74,4/21/2021
DC0998,earnings,100,50,4/21/2021
DC0998,earnings,100,50,4/21/2021
DC0998,earnings,100,50,4/21/2021
DC0998,earnings,100,50,4/21/2021
DD1BA1,market-entry,100,57,4/21/2021
DD1BA1,fundraising,100,64,4/21/2021
DF18E6,campaign-ad-release,100,59,4/21/2021
E22FDE,conference-call,100,50,4/21/2021
E68733,regulatory-product-approval-granted,100,81,4/21/2021
E68733,regulatory-product-approval-granted,100,81,4/21/2021
E74B55,legal-issues-defendant,100,22,4/21/2021
E90C84,earnings,100,50,4/21/2021
E90C84,earnings,100,50,4/21/2021
EB61C4,dividend,100,50,4/21/2021
EBD89A,conference-call,100,50,4/21/2021
ECDEB2,earnings,100,50,4/21/2021
ECF709,executive-appointment,100,54,4/21/2021
ED9576,earnings,100,50,4/21/2021
EE74E1,acquisition-completed-acquiree,100,76,4/21/2021
EEA6B3,executive-appointment,100,54,4/21/2021
EEA6B3,executive-appointment,100,54,4/21/2021
EEEA9F,earnings,100,50,4/21/2021
EF77A3,dividend,100,50,4/21/2021
F209B4,public-offering,100,43,4/21/2021
F4FBD8,earnings,100,50,4/21/2021
F702CA,dividend,100,50,4/21/2021
F7935D,legal-issues-defendant,100,22,4/21/2021
F8DE55,earnings,100,50,4/21/2021
FA044A,earnings,100,50,4/21/2021
FA918D,conference-call,100,50,4/21/2021
FACCF6,earnings,100,50,4/21/2021
FBD92D,earnings,100,50,4/21/2021
FDC08C,dividend,100,50,4/21/2021
FDF799,earnings,100,50,4/21/2021
002A99,legal-issues-defendant,100,22,4/22/2021
00698D,dividend,100,50,4/22/2021
01D03F,stake-acquirer,100,48,4/22/2021
02870F,conference-call,100,50,4/22/2021
04CCCD,partnership,100,61,4/22/2021
0560D8,dividend,100,50,4/22/2021
061A3B,earnings,100,50,4/22/2021
08A40F,earnings-per-share-positive,100,69,4/22/2021
08A40F,earnings-per-share-positive,100,69,4/22/2021
08A40F,earnings-per-share-positive,100,69,4/22/2021
08A40F,earnings-per-share-positive,100,69,4/22/2021
08A40F,earnings-per-share-positive,100,69,4/22/2021
08A40F,earnings-per-share-positive,100,69,4/22/2021
08A40F,earnings-per-share-positive,100,69,4/22/2021
0968A5,credit-extension-recipient,100,69,4/22/2021
0A59F8,earnings,100,50,4/22/2021
0A7650,earnings,100,50,4/22/2021
0AB700,earnings-up,100,68,4/22/2021
0B2071,dividend,100,50,4/22/2021
0B7375,conference-call,100,50,4/22/2021
0B9E6F,earnings-up,100,68,4/22/2021
0B9E6F,earnings,100,50,4/22/2021
0BF198,conference-call,100,50,4/22/2021
0C466B,dividend,100,50,4/22/2021
0C8D82,earnings,100,50,4/22/2021
0DC050,earnings,100,50,4/22/2021
0DC050,earnings,100,50,4/22/2021
0DC050,earnings,100,50,4/22/2021
0EF1AF,earnings,100,50,4/22/2021
10100E,conference-participant,100,50,4/22/2021
102F04,earnings,100,50,4/22/2021
105D00,earnings-positive,100,69,4/22/2021
10C19B,earnings-up,100,68,4/22/2021
10C19B,earnings,100,50,4/22/2021
10C19B,earnings,100,50,4/22/2021
10C19B,earnings,100,50,4/22/2021
10C19B,earnings,100,50,4/22/2021
10C19B,earnings,100,50,4/22/2021
10C19B,earnings,100,50,4/22/2021
119CB6,earnings-per-share-positive,100,69,4/22/2021
13C3E0,earnings,100,50,4/22/2021
149301,earnings,100,50,4/22/2021
152B9E,dividend,100,50,4/22/2021
15789A,earnings,100,50,4/22/2021
16B183,legal-issues-defendant,100,22,4/22/2021
17EDA5,partnership,100,61,4/22/2021
17EDA5,partnership,100,61,4/22/2021
182B8C,earnings,100,50,4/22/2021
182B8C,earnings,100,50,4/22/2021
182B8C,earnings,100,50,4/22/2021
184866,earnings,100,50,4/22/2021
190B91,executive-appointment,100,54,4/22/2021
19C105,earnings,100,50,4/22/2021
1A2D9F,earnings,100,50,4/22/2021
1A2D9F,earnings,100,50,4/22/2021
1A2D9F,earnings,100,50,4/22/2021
1A2D9F,earnings,100,50,4/22/2021
1A2D9F,earnings,100,50,4/22/2021
1A2D9F,earnings,100,50,4/22/2021
1A2D9F,earnings,100,50,4/22/2021
1AF7E2,earnings,100,50,4/22/2021
1AF7E2,earnings,100,50,4/22/2021
1BDB2A,market-share-gain,100,81,4/22/2021
1CD09C,conference-call,100,50,4/22/2021
1CD708,earnings,100,50,4/22/2021
1E1125,legal-issues-defendant,100,22,4/22/2021
1E1125,legal-issues-defendant,100,22,4/22/2021
1F716B,unit-acquisition-acquirer,100,49,4/22/2021
2096DE,earnings,100,50,4/22/2021
20DC4E,earnings,100,50,4/22/2021
21268E,conference-call,100,50,4/22/2021
221445,dividend,100,50,4/22/2021
222BF9,earnings,100,50,4/22/2021
223552,earnings,100,50,4/22/2021
228D42,patent-awarded,100,72,4/22/2021
238302,conference-call,100,50,4/22/2021
239106,conference-call,100,50,4/22/2021
251988,business-contract,100,69,4/22/2021
251988,business-contract,100,69,4/22/2021
251988,earnings,100,50,4/22/2021
251988,earnings,100,50,4/22/2021
251988,earnings,100,50,4/22/2021
251988,earnings,100,50,4/22/2021
251988,earnings,100,50,4/22/2021
251988,earnings,100,50,4/22/2021
25AB8E,earnings,100,50,4/22/2021
25DD05,earnings,100,50,4/22/2021
267718,dividend,100,50,4/22/2021
26CC63,dividend,100,50,4/22/2021
272704,dividend,100,50,4/22/2021
278C18,earnings,100,50,4/22/2021
27A791,conference-call,100,50,4/22/2021
28AF37,partnership,100,61,4/22/2021
28DCF3,earnings,100,50,4/22/2021
28DCF3,conference-participant,100,50,4/22/2021
29A4CC,dividend,100,50,4/22/2021
29CEBF,conference-call,100,50,4/22/2021
2A1009,legal-issues-defendant,100,22,4/22/2021
2A1009,legal-issues-defendant,100,22,4/22/2021
2B9DBB,earnings,100,50,4/22/2021
2C3348,earnings,100,50,4/22/2021
2C35B5,executive-appointment,100,54,4/22/2021
2DA92D,earnings,100,50,4/22/2021
2DC88B,earnings,100,50,4/22/2021
2E2E6E,acquisition-acquiree,100,76,4/22/2021
2E2E6E,earnings-up,100,68,4/22/2021
2E2E6E,earnings,100,50,4/22/2021
2E2E6E,earnings,100,50,4/22/2021
2E2E6E,earnings,100,50,4/22/2021
2E6514,earnings-positive,100,69,4/22/2021
2F7474,earnings,100,50,4/22/2021
2F960F,earnings,100,50,4/22/2021
2FF046,earnings,100,50,4/22/2021
301493,conference-call,100,50,4/22/2021
30CBF9,product-release,100,64,4/22/2021
3159AA,facility-open,100,65,4/22/2021
3159AA,conference-call,100,50,4/22/2021
31666F,earnings,100,50,4/22/2021
31F25C,earnings,100,50,4/22/2021
3.30E+34,dividend,100,50,4/22/2021
3471C0,earnings-guidance-up,100,83,4/22/2021
3471C0,earnings,100,50,4/22/2021
3471C0,earnings,100,50,4/22/2021
3471C0,earnings,100,50,4/22/2021
34A959,acquisition-completed-acquirer,100,49,4/22/2021
34B97A,earnings,100,50,4/22/2021
34B97A,earnings,100,50,4/22/2021
34B97A,earnings,100,50,4/22/2021
34B97A,earnings,100,50,4/22/2021
367434,earnings,100,50,4/22/2021
370C50,earnings,100,50,4/22/2021
3A3447,dividend,100,50,4/22/2021
3A3948,earnings,100,50,4/22/2021
3A94DF,earnings-per-share-up,100,68,4/22/2021
3A94DF,earnings,100,50,4/22/2021
3A94DF,earnings,100,50,4/22/2021
3A94DF,earnings,100,50,4/22/2021
3A94DF,earnings,100,50,4/22/2021
3B2311,acquisition-completed-acquiree,100,76,4/22/2021
3C8A04,earnings,100,50,4/22/2021
3D9999,dividend,100,50,4/22/2021
3E39A5,dividend,100,50,4/22/2021
3FACA7,partnership,100,61,4/22/2021
401072,earnings,100,50,4/22/2021
415188,business-contract,100,69,4/22/2021
41A93D,earnings,100,50,4/22/2021
4290EF,dividend,100,50,4/22/2021
43A060,business-contract,100,69,4/22/2021
449A26,earnings-positive,100,69,4/22/2021
449A26,dividend,100,50,4/22/2021
44ED36,dividend,100,50,4/22/2021
453282,earnings,100,50,4/22/2021
46CF27,earnings,100,50,4/22/2021
46CF27,earnings,100,50,4/22/2021
46CF27,earnings,100,50,4/22/2021
46CF27,earnings,100,50,4/22/2021
46CF27,earnings,100,50,4/22/2021
46CF27,earnings,100,50,4/22/2021
46CF27,earnings,100,50,4/22/2021
46CF27,earnings,100,50,4/22/2021
46CF27,earnings,100,50,4/22/2021
487B7A,earnings-up,100,68,4/22/2021
4B3555,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4B3DC9,earnings,100,50,4/22/2021
4C7DB5,earnings-guidance,100,50,4/22/2021
4D203E,earnings,100,50,4/22/2021
4D203E,earnings,100,50,4/22/2021
4DD203,conference-call,100,50,4/22/2021
4E913D,earnings,100,50,4/22/2021
4F9926,partnership,100,61,4/22/2021
504FE2,award,100,58,4/22/2021
53F491,dividend,100,50,4/22/2021
5546DA,earnings,100,50,4/22/2021
556A57,dividend,100,50,4/22/2021
57CAAB,partnership,100,61,4/22/2021
57EF50,acquisition-completed-acquirer,100,49,4/22/2021
59C539,earnings-up,100,68,4/22/2021
59C539,earnings,100,50,4/22/2021
59C539,earnings,100,50,4/22/2021
59C539,earnings,100,50,4/22/2021
59DB8C,earnings,100,50,4/22/2021
5AAE17,conference-call,100,50,4/22/2021
5B226B,legal-issues-defendant,100,22,4/22/2021
5BE42C,dividend,100,50,4/22/2021
5BE42C,dividend,100,50,4/22/2021
5BFE94,dividend,100,50,4/22/2021
5D1956,earnings,100,50,4/22/2021
5DA8B3,earnings,100,50,4/22/2021
5DE5A5,earnings-up,100,68,4/22/2021
5DE5A5,earnings,100,50,4/22/2021
5DE5A5,earnings,100,50,4/22/2021
5F6D73,earnings,100,50,4/22/2021
5F9CE3,earnings,100,50,4/22/2021
60DD84,revenue-up,100,69,4/22/2021
60DD84,earnings,100,50,4/22/2021
60DD84,earnings,100,50,4/22/2021
622037,dividend,100,50,4/22/2021
641F17,earnings,100,50,4/22/2021
641F17,earnings,100,50,4/22/2021
641F17,earnings,100,50,4/22/2021
641F17,earnings,100,50,4/22/2021
641F17,earnings,100,50,4/22/2021
641F17,earnings,100,50,4/22/2021
641F17,earnings,100,50,4/22/2021
641F17,earnings,100,50,4/22/2021
6474BA,earnings-positive,100,69,4/22/2021
6474BA,earnings,100,50,4/22/2021
6474BA,earnings,100,50,4/22/2021
6474BA,earnings,100,50,4/22/2021
6474BA,earnings,100,50,4/22/2021
6474BA,earnings,100,50,4/22/2021
6474BA,earnings,100,50,4/22/2021
6474BA,earnings,100,50,4/22/2021
6474BA,earnings,100,50,4/22/2021
6474BA,earnings,100,50,4/22/2021
64E615,conference-call,100,50,4/22/2021
662682,dividend-up,100,81,4/22/2021
665618,earnings-per-share-up,100,90,4/22/2021
665618,earnings-per-share-up,100,90,4/22/2021
665D7D,regulatory-product-approval-granted,100,81,4/22/2021
67A658,dividend,100,50,4/22/2021
67A658,dividend,100,50,4/22/2021
67B052,earnings,100,50,4/22/2021
67B052,earnings,100,50,4/22/2021
68586A,conference-call,100,50,4/22/2021
694749,earnings,100,50,4/22/2021
6B5379,executive-appointment,100,54,4/22/2021
6B5379,dividend-up,100,81,4/22/2021
6BDA0C,conference-call,100,50,4/22/2021
6CD55A,earnings,100,50,4/22/2021
6D156D,earnings,100,50,4/22/2021
6D2BF6,legal-issues-defendant,100,22,4/22/2021
6F0096,facility-open,100,65,4/22/2021
72DF04,dividend-up,100,81,4/22/2021
73A71F,investment-investor,100,55,4/22/2021
751C8D,partnership,100,61,4/22/2021
751C8D,partnership,100,61,4/22/2021
751C8D,earnings,100,50,4/22/2021
751C8D,earnings,100,50,4/22/2021
7520CC,earnings,100,50,4/22/2021
766047,earnings,100,50,4/22/2021
766047,earnings,100,50,4/22/2021
766047,earnings,100,50,4/22/2021
766047,earnings,100,50,4/22/2021
766047,earnings,100,50,4/22/2021
766047,earnings,100,50,4/22/2021
766047,earnings,100,50,4/22/2021
766047,earnings,100,50,4/22/2021
76CEFB,executive-appointment,100,54,4/22/2021
76F067,earnings,100,50,4/22/2021
7734AC,earnings,100,50,4/22/2021
7734AC,earnings,100,50,4/22/2021
78A1BB,earnings,100,50,4/22/2021
7A5D58,earnings,100,50,4/22/2021
7B1E50,earnings,100,50,4/22/2021
7B4B91,conference-call,100,50,4/22/2021
7BAAE7,dividend,100,50,4/22/2021
7C75FD,dividend,100,50,4/22/2021
7C790D,business-contract,100,69,4/22/2021
7C790D,business-contract,100,69,4/22/2021
7CBC40,product-release,100,64,4/22/2021
7D35D8,earnings,100,50,4/22/2021
7D5384,earnings,100,50,4/22/2021
7D5384,earnings,100,50,4/22/2021
7D5384,earnings,100,50,4/22/2021
7D5384,earnings,100,50,4/22/2021
7D5384,earnings,100,50,4/22/2021
7DC1C4,earnings,100,50,4/22/2021
7E0EB0,earnings,100,50,4/22/2021
7E3F8F,earnings,100,50,4/22/2021
7E3F8F,earnings,100,50,4/22/2021
7E3F8F,earnings,100,50,4/22/2021
7E3F8F,earnings,100,50,4/22/2021
7EA323,exchange-noncompliance,100,24,4/22/2021
7F3FBC,operating-earnings,100,50,4/22/2021
7FD8B9,conference-call,100,50,4/22/2021
7FDE1C,product-release,100,64,4/22/2021
80D744,earnings,100,50,4/22/2021
81222C,earnings,100,50,4/22/2021
8.10E+205,earnings,100,50,4/22/2021
824CCA,earnings,100,50,4/22/2021
82B57E,earnings,100,50,4/22/2021
82C202,earnings,100,50,4/22/2021
85CDC9,earnings,100,50,4/22/2021
86A1B9,unit-acquisition-acquiree,100,76,4/22/2021
893904,public-offering,100,43,4/22/2021
8B2C4A,earnings,100,50,4/22/2021
8B2C4A,earnings,100,50,4/22/2021
8B2C4A,earnings,100,50,4/22/2021
8B2C4A,earnings,100,50,4/22/2021
8B2C4A,earnings,100,50,4/22/2021
8B2C4A,earnings,100,50,4/22/2021
8B2C4A,earnings,100,50,4/22/2021
8B9B3B,earnings,100,50,4/22/2021
8BFAA4,conference-call,100,50,4/22/2021
8C84DF,earnings,100,50,4/22/2021
8D4486,partnership,100,61,4/22/2021
8D5145,earnings,100,50,4/22/2021
8DAAB9,earnings,100,50,4/22/2021
8DDA23,earnings,100,50,4/22/2021
8DE56F,earnings,100,50,4/22/2021
8DE56F,earnings,100,50,4/22/2021
900356,conference-call,100,50,4/22/2021
922F0C,earnings-per-share,100,50,4/22/2021
92B047,dividend,100,50,4/22/2021
92D6A5,dividend-up,100,59,4/22/2021
934CC3,partnership,100,61,4/22/2021
943239,earnings,100,50,4/22/2021
9548BB,earnings,100,50,4/22/2021
9548BB,earnings,100,50,4/22/2021
9548BB,earnings,100,50,4/22/2021
9548BB,earnings,100,50,4/22/2021
954A47,earnings-positive,100,69,4/22/2021
9592FB,conference-participant,100,50,4/22/2021
9.65E+09,conference-call,100,50,4/22/2021
965360,earnings,100,50,4/22/2021
97FE80,partnership,100,61,4/22/2021
986AF6,earnings,100,50,4/22/2021
986AF6,earnings-up,100,68,4/22/2021
986AF6,earnings-up,100,68,4/22/2021
989E2F,earnings,100,50,4/22/2021
989E2F,earnings,100,50,4/22/2021
989E2F,earnings,100,50,4/22/2021
989E2F,earnings,100,50,4/22/2021
990AD0,dividend,100,50,4/22/2021
9.97E+09,earnings,100,50,4/22/2021
9A2760,earnings,100,50,4/22/2021
9AF3DC,partnership,100,61,4/22/2021
9B4066,unit-acquisition-acquirer,100,49,4/22/2021
9BB35A,conference-call,100,50,4/22/2021
9C25FF,conference-call,100,50,4/22/2021
9EF4CF,earnings,100,50,4/22/2021
A02FB1,earnings,100,50,4/22/2021
A03EE1,earnings,100,50,4/22/2021
A072C4,earnings,100,50,4/22/2021
A5195E,earnings,100,50,4/22/2021
A52533,earnings,100,50,4/22/2021
A5628C,earnings-positive,100,69,4/22/2021
A5B913,earnings,100,50,4/22/2021
A5B913,earnings,100,50,4/22/2021
A666C8,earnings,100,50,4/22/2021
A7CCF0,conference-call,100,50,4/22/2021
A94637,revenues,100,50,4/22/2021
AB4A7E,conference-call,100,50,4/22/2021
AD23DE,executive-appointment,100,54,4/22/2021
AD375D,earnings,100,50,4/22/2021
AFD1CA,earnings,100,50,4/22/2021
AFF7B4,analyst-ratings-change-positive,100,78,4/22/2021
B05000,earnings,100,50,4/22/2021
B1A85D,earnings,100,50,4/22/2021
B2256A,conference-call,100,50,4/22/2021
B2D492,earnings,100,50,4/22/2021
B8DD94,earnings,100,50,4/22/2021
B9764A,business-contract,100,69,4/22/2021
BAAA60,dividend,100,50,4/22/2021
BCC55F,conference-call,100,50,4/22/2021
BDCC11,earnings,100,50,4/22/2021
BEB756,earnings,100,50,4/22/2021
C15DB3,earnings,100,50,4/22/2021
C1CBA4,earnings-positive,100,69,4/22/2021
C1CBA4,earnings-positive,100,69,4/22/2021
C1CBA4,earnings-positive,100,69,4/22/2021
C1CBA4,earnings-positive,100,69,4/22/2021
C1CBA4,earnings-positive,100,69,4/22/2021
C1CBA4,earnings-positive,100,69,4/22/2021
C1CBA4,earnings-positive,100,69,4/22/2021
C41C25,earnings,100,50,4/22/2021
C66A8C,earnings,100,50,4/22/2021
C72B8F,earnings,100,50,4/22/2021
C8A059,earnings,100,50,4/22/2021
C9E107,dividend,100,50,4/22/2021
C9E107,earnings,100,50,4/22/2021
C9E4EC,earnings,100,50,4/22/2021
CB89EA,partnership,100,61,4/22/2021
CBFFDD,dividend,100,50,4/22/2021
CCB623,earnings,100,50,4/22/2021
CDAB24,earnings,100,50,4/22/2021
CDAF5B,operating-earnings,100,50,4/22/2021
CF6A5A,earnings,100,50,4/22/2021
CFD4B6,conference-call,100,50,4/22/2021
D0DE27,earnings,100,50,4/22/2021
D0DFE5,earnings,100,50,4/22/2021
D1AE3B,executive-appointment,100,54,4/22/2021
D1C26F,partnership,100,61,4/22/2021
D63B0F,conference-call,100,50,4/22/2021
D650A7,earnings,100,50,4/22/2021
D721C6,earnings-positive,100,69,4/22/2021
D78CCD,executive-appointment,100,54,4/22/2021
D7F569,earnings,100,50,4/22/2021
D8442A,award,100,58,4/22/2021
D8F347,earnings,100,50,4/22/2021
D8F347,earnings,100,50,4/22/2021
D8F347,earnings,100,50,4/22/2021
D90F43,partnership,100,61,4/22/2021
D9B1C9,earnings,100,50,4/22/2021
D9B1C9,earnings,100,50,4/22/2021
DA90E1,earnings,100,50,4/22/2021
DBCA3F,earnings,100,50,4/22/2021
DBFB51,conference-call,100,50,4/22/2021
DDC415,earnings,100,50,4/22/2021
DDC415,earnings,100,50,4/22/2021
DDC415,earnings,100,50,4/22/2021
DDC415,earnings,100,50,4/22/2021
DDC415,earnings,100,50,4/22/2021
DDCB34,conference-call,100,50,4/22/2021
DE4924,conference-call,100,50,4/22/2021
E05DC8,earnings-up,100,68,4/22/2021
E10D31,dividend,100,50,4/22/2021
E124EB,earnings,100,50,4/22/2021
E124EB,earnings,100,50,4/22/2021
E124EB,earnings,100,50,4/22/2021
E124EB,earnings,100,50,4/22/2021
E19A99,business-contract,100,69,4/22/2021
E1BD05,earnings,100,50,4/22/2021
E38906,earnings,100,50,4/22/2021
E393B0,earnings-up,100,68,4/22/2021
E393B0,earnings,100,50,4/22/2021
E393B0,earnings,100,50,4/22/2021
E393B0,earnings,100,50,4/22/2021
E393B0,earnings,100,50,4/22/2021
E393B0,earnings,100,50,4/22/2021
E5752F,earnings,100,50,4/22/2021
E5F0A8,earnings-positive,100,69,4/22/2021
E5F0A8,earnings,100,50,4/22/2021
E5F0A8,earnings,100,50,4/22/2021
E5F0A8,earnings,100,50,4/22/2021
E5F0A8,earnings,100,50,4/22/2021
E68C3D,earnings,100,50,4/22/2021
E6D89E,partnership,100,61,4/22/2021
E74B55,legal-issues-defendant,100,22,4/22/2021
E82A2D,conference-call,100,50,4/22/2021
E866D2,earnings,100,50,4/22/2021
E866D2,earnings,100,50,4/22/2021
E866D2,earnings,100,50,4/22/2021
E866D2,earnings,100,50,4/22/2021
E866D2,earnings,100,50,4/22/2021
E866D2,earnings,100,50,4/22/2021
E866D2,earnings,100,50,4/22/2021
E866D2,earnings,100,50,4/22/2021
E866D2,partnership,100,61,4/22/2021
E8B315,acquisition-acquirer,100,49,4/22/2021
E8B315,earnings-positive,100,69,4/22/2021
E8E899,earnings,100,50,4/22/2021
E94704,earnings,100,50,4/22/2021
E94704,earnings,100,50,4/22/2021
E94704,earnings,100,50,4/22/2021
E94704,earnings,100,50,4/22/2021
E94704,earnings,100,50,4/22/2021
E99180,earnings,100,50,4/22/2021
E9C7C0,executive-appointment,100,54,4/22/2021
EAA0A7,earnings,100,50,4/22/2021
EB2F14,earnings,100,50,4/22/2021
EB5E78,unit-acquisition-acquirer,100,49,4/22/2021
EBD89A,business-contract,100,69,4/22/2021
ED8676,earnings,100,50,4/22/2021
ED8676,earnings,100,50,4/22/2021
ED8676,dividend,100,50,4/22/2021
EEA6B3,partnership,100,61,4/22/2021
EEA6B3,partnership,100,61,4/22/2021
EF7163,conference-call,100,50,4/22/2021
EFD406,conference-call,100,50,4/22/2021
F0B2B5,conference-call,100,50,4/22/2021
F0B877,earnings,100,50,4/22/2021
F4E882,earnings,100,50,4/22/2021
F4F46F,conference-call,100,50,4/22/2021
F702CA,earnings,100,50,4/22/2021
F702CA,earnings,100,50,4/22/2021
F702CA,earnings,100,50,4/22/2021
F702CA,earnings,100,50,4/22/2021
F702CA,earnings,100,50,4/22/2021
F702CA,earnings,100,50,4/22/2021
F7902B,unit-acquisition-acquiree,100,76,4/22/2021
F7902B,facility-sale,100,52,4/22/2021
F7902B,executive-appointment,100,54,4/22/2021
F793FA,earnings-up,100,68,4/22/2021
F88A04,acquisition-acquirer,100,49,4/22/2021
F88A04,acquisition-acquirer,100,49,4/22/2021
FACF19,dividend,100,50,4/22/2021
FC1F9D,earnings-up,100,68,4/22/2021
FC9A88,earnings,100,50,4/22/2021
FD2565,conference-call,100,50,4/22/2021
FFE543,earnings-up,100,68,4/22/2021
FFE543,earnings,100,50,4/22/2021
FFE543,earnings,100,50,4/22/2021
00698D,credit-extension-recipient,100,69,4/23/2021
04CCCD,hirings,100,65,4/23/2021
065D38,earnings,100,50,4/23/2021
099A02,earnings,100,50,4/23/2021
099A02,earnings,100,50,4/23/2021
0AB700,dividend,100,50,4/23/2021
0C6861,conference-call,100,50,4/23/2021
1096C6,earnings,100,50,4/23/2021
12F98C,executive-appointment,100,54,4/23/2021
15901B,executive-appointment,100,54,4/23/2021
1E1125,fraud-defendant,100,20,4/23/2021
1E1125,legal-issues-defendant,100,22,4/23/2021
228D42,partnership,100,61,4/23/2021
228D42,partnership,100,61,4/23/2021
2920D5,earnings,100,50,4/23/2021
297DA8,earnings,100,50,4/23/2021
2A1009,fraud-defendant,100,20,4/23/2021
2A1009,legal-issues-defendant,100,22,4/23/2021
2A1009,legal-issues-defendant,100,22,4/23/2021
2A6DBE,executive-appointment,100,54,4/23/2021
2C19A4,conference-call,100,50,4/23/2021
2C681C,conference-call,100,50,4/23/2021
2E2E6E,acquisition-regulatory-scrutiny-acquiree,100,38,4/23/2021
2E2E6E,legal-issues-defendant,100,22,4/23/2021
2F6782,conference-call,100,50,4/23/2021
3B8484,earnings,100,50,4/23/2021
3DE4D1,earnings,100,50,4/23/2021
435ACE,dividend,100,50,4/23/2021
487B7A,executive-appointment,100,54,4/23/2021
4A6F00,partnership,100,61,4/23/2021
4A6F00,regulatory-product-approval-granted,100,81,4/23/2021
4C37C5,revenues,100,50,4/23/2021
4C37C5,revenues,100,50,4/23/2021
4C37C5,revenues,100,50,4/23/2021
4D203E,legal-issues-defendant,100,22,4/23/2021
50070E,partnership,100,61,4/23/2021
562853,earnings,100,50,4/23/2021
57634F,earnings,100,50,4/23/2021
57EF50,dividend,100,50,4/23/2021
58B46F,dividend,100,50,4/23/2021
58B46F,board-meeting,100,51,4/23/2021
5BFE94,earnings,100,50,4/23/2021
5D0337,executive-appointment,100,54,4/23/2021
5D87DF,earnings,100,50,4/23/2021
665D7D,regulatory-product-review-positive,100,73,4/23/2021
6B236C,dividend,100,50,4/23/2021
6CC55E,clinical-trials,100,56,4/23/2021
6F3FA8,conference-call,100,50,4/23/2021
7255D2,legal-issues-defendant,100,22,4/23/2021
72EF75,earnings,100,50,4/23/2021
73C521,earnings-positive,100,69,4/23/2021
76CEFB,earnings,100,50,4/23/2021
7A5097,conference-call,100,50,4/23/2021
7F2922,earnings,100,50,4/23/2021
868808,earnings-up,100,68,4/23/2021
873DB9,partnership,100,61,4/23/2021
9004C4,conference-call,100,50,4/23/2021
94637C,regulatory-product-review-positive,100,73,4/23/2021
94637C,clinical-trials-positive,100,87,4/23/2021
997348,earnings,100,50,4/23/2021
997348,earnings,100,50,4/23/2021
9981C6,earnings,100,50,4/23/2021
9C009A,executive-appointment,100,54,4/23/2021
9EED50,executive-appointment,100,54,4/23/2021
A204A7,earnings,100,50,4/23/2021
A48593,conference-call,100,50,4/23/2021
A58224,conference-call,100,50,4/23/2021
A8AC4C,conference-call,100,50,4/23/2021
AABEA0,earnings-up,100,68,4/23/2021
AFDF2E,earnings,100,50,4/23/2021
AFDF2E,earnings,100,50,4/23/2021
AFDF2E,earnings,100,50,4/23/2021
B0998E,earnings,100,50,4/23/2021
B803B1,conference-call,100,50,4/23/2021
BB88B6,award,100,58,4/23/2021
BC948D,conference-call,100,50,4/23/2021
C037A8,conference-call,100,50,4/23/2021
C0BA36,conference-call,100,50,4/23/2021
C62AA4,conference-call,100,50,4/23/2021
CC339B,earnings,100,50,4/23/2021
CE1002,dividend,100,50,4/23/2021
CE1002,dividend,100,50,4/23/2021
CE4E6D,conference-call,100,50,4/23/2021
D15833,executive-resignation,100,44,4/23/2021
D45285,conference-call,100,50,4/23/2021
D7F569,dividend,100,50,4/23/2021
D7F569,executive-appointment,100,54,4/23/2021
D88EF3,partnership,100,61,4/23/2021
DAC66A,earnings,100,50,4/23/2021
DBEF02,earnings,100,50,4/23/2021
DF204B,conference-call,100,50,4/23/2021
E2F66E,conference-call,100,50,4/23/2021
E49AA3,earnings,100,50,4/23/2021
E6A53A,earnings,100,50,4/23/2021
E6A53A,earnings,100,50,4/23/2021
E6E012,dividend,100,50,4/23/2021
E6E012,dividend,100,50,4/23/2021
E74B55,legal-issues-defendant,100,22,4/23/2021
E866D2,partnership,100,61,4/23/2021
EA4E68,earnings,100,50,4/23/2021
EBD89A,business-contract,100,69,4/23/2021
ED0D7C,conference-participant,100,50,4/23/2021
ED2EFD,dividend,100,50,4/23/2021
ED7F13,dividend,100,50,4/23/2021
EE1E44,earnings-up,100,68,4/23/2021
EE1E44,earnings-up,100,68,4/23/2021
EE1E44,earnings-up,100,68,4/23/2021
EE1E44,earnings-up,100,68,4/23/2021
EE1E44,earnings-up,100,68,4/23/2021
EE6F1C,dividend,100,50,4/23/2021
F2E253,partnership,100,61,4/23/2021
F44EA2,trading-halt,100,43,4/23/2021
F44EA2,trading-resumed,100,58,4/23/2021
F6E248,clinical-trials-filed,100,60,4/23/2021
F6E248,clinical-trials-filed,100,60,4/23/2021
F702CA,product-price-raise,100,57,4/23/2021
F7902B,executive-appointment,100,54,4/23/2021
FC9A88,dividend,100,50,4/23/2021
FD0CA4,dividend,100,50,4/23/2021
FDC08C,earnings,100,50,4/23/2021
FDC08C,earnings,100,50,4/23/2021
FDC08C,earnings,100,50,4/23/2021
FDC08C,earnings,100,50,4/23/2021
FDC08C,earnings,100,50,4/23/2021
FDC08C,buybacks,100,74,4/23/2021
FF6644,earnings,100,50,4/23/2021
FF6644,earnings,100,50,4/23/2021
FF6644,earnings,100,50,4/23/2021
FF6644,earnings,100,50,4/23/2021
FF6644,earnings,100,50,4/23/2021
FF6644,earnings,100,50,4/23/2021
FF6644,earnings,100,50,4/23/2021
002A99,legal-issues-defendant,100,22,4/24/2021
002A99,legal-issues-defendant,100,22,4/24/2021
18D9FA,legal-issues-defendant,100,22,4/24/2021
18D9FA,legal-issues-defendant,100,22,4/24/2021
1E1125,legal-issues-defendant,100,22,4/24/2021
2A1009,legal-issues-defendant,100,22,4/24/2021
2A1009,legal-issues-defendant,100,22,4/24/2021
5675EB,legal-issues-defendant,100,22,4/24/2021
5B226B,legal-issues-defendant,100,22,4/24/2021
7255D2,legal-issues-defendant,100,22,4/24/2021
8D4AE6,legal-issues-defendant,100,22,4/24/2021
D89753,legal-issues-defendant,100,22,4/24/2021
D89753,legal-issues-defendant,100,22,4/24/2021
F82D37,merger-completed,100,66,4/24/2021
002A99,legal-issues-defendant,100,22,4/25/2021
1E04A5,legal-issues-defendant,100,22,4/25/2021
25A6CC,legal-issues-defendant,100,22,4/25/2021
36C09B,partnership,100,61,4/25/2021
504FE2,legal-issues-defendant,100,22,4/25/2021
5B35C7,legal-issues-defendant,100,22,4/25/2021
609208,legal-issues-defendant,100,22,4/25/2021
8D4AE6,legal-issues-defendant,100,22,4/25/2021
91E5EE,legal-issues-defendant,100,22,4/25/2021
B96DF5,legal-issues-defendant,100,22,4/25/2021
DF01B1,legal-issues-defendant,100,22,4/25/2021
ECF4F8,legal-issues-defendant,100,22,4/25/2021
00FC70,conference-call,100,50,4/26/2021
040DBB,conference-call,100,50,4/26/2021
43862,conference-call,100,50,4/26/2021
04996E,earnings,100,50,4/26/2021
06EE79,earnings,100,50,4/26/2021
0E2992,acquisition-acquirer,100,49,4/26/2021
0E2992,earnings-per-share-positive,100,69,4/26/2021
0EF1AF,legal-issues-defendant,100,22,4/26/2021
0F2BC9,business-contract,100,69,4/26/2021
10673F,earnings,100,50,4/26/2021
10673F,earnings,100,50,4/26/2021
1220D2,earnings,100,50,4/26/2021
12731D,conference-call,100,50,4/26/2021
12731D,conference-call,100,50,4/26/2021
12E454,partnership,100,61,4/26/2021
156A99,earnings,100,50,4/26/2021
15789A,earnings,100,50,4/26/2021
157D9F,executive-appointment,100,54,4/26/2021
159739,earnings,100,50,4/26/2021
159739,earnings,100,50,4/26/2021
15A388,partnership,100,61,4/26/2021
1782D5,earnings,100,50,4/26/2021
17EDA5,partnership,100,61,4/26/2021
18D9FA,executive-appointment,100,54,4/26/2021
18EC17,executive-appointment,100,54,4/26/2021
1BDB2A,earnings,100,50,4/26/2021
1CD4B5,patent-awarded,100,72,4/26/2021
1E04A5,earnings,100,50,4/26/2021
1E1125,legal-issues-defendant,100,22,4/26/2021
1EBF8D,business-contract,100,69,4/26/2021
1EC3E8,executive-appointment,100,54,4/26/2021
1EC3E8,executive-appointment,100,54,4/26/2021
1F19C8,product-release,100,64,4/26/2021
1F2B5D,earnings,100,50,4/26/2021
1F2B5D,earnings,100,50,4/26/2021
1F2B5D,earnings,100,50,4/26/2021
1F2B5D,earnings,100,50,4/26/2021
1F2B5D,earnings,100,50,4/26/2021
1F2B5D,earnings,100,50,4/26/2021
1F2B5D,earnings,100,50,4/26/2021
1FA886,facility-open,100,65,4/26/2021
206852,earnings,100,50,4/26/2021
20DC4E,dividend,100,50,4/26/2021
228D42,partnership,100,61,4/26/2021
228D42,partnership,100,61,4/26/2021
2571FA,government-contract,100,69,4/26/2021
2667B6,dividend,100,50,4/26/2021
2667B6,executive-appointment,100,54,4/26/2021
2.90E+62,acquisition-regulatory-scrutiny-acquiree,100,38,4/26/2021
2A02DC,executive-appointment,100,54,4/26/2021
2A1009,legal-issues-defendant,100,22,4/26/2021
2A9C0A,earnings-positive,100,69,4/26/2021
2A9C0A,earnings,100,50,4/26/2021
2A9C0A,earnings,100,50,4/26/2021
2A9C0A,earnings,100,50,4/26/2021
2A9C0A,earnings,100,50,4/26/2021
2A9C0A,earnings,100,50,4/26/2021
2DB344,earnings,100,50,4/26/2021
2E902B,revenues,100,50,4/26/2021
2E902B,earnings,100,50,4/26/2021
2E902B,earnings,100,50,4/26/2021
2E902B,earnings,100,50,4/26/2021
2EB04E,unit-acquisition-acquiree,100,76,4/26/2021
2EB04E,unit-acquisition-acquiree,100,76,4/26/2021
2EC172,partnership,100,61,4/26/2021
309922,acquisition-acquirer,100,49,4/26/2021
309922,earnings,100,50,4/26/2021
32CB22,acquisition-interest-acquirer,100,46,4/26/2021
32CB22,acquisition-interest-acquirer,100,46,4/26/2021
3.30E+30,business-contract,100,69,4/26/2021
343996,earnings,100,50,4/26/2021
3461CF,partnership,100,61,4/26/2021
34E9F9,conference-call,100,50,4/26/2021
356B21,earnings,100,50,4/26/2021
36C09B,partnership,100,61,4/26/2021
36E479,conference-participant,100,50,4/26/2021
3A4BDB,earnings-positive,100,69,4/26/2021
3AAEAE,conference-call,100,50,4/26/2021
4.03E+05,award,100,58,4/26/2021
43A060,earnings,100,50,4/26/2021
449217,earnings-positive,100,69,4/26/2021
449217,earnings,100,50,4/26/2021
449217,earnings,100,50,4/26/2021
449217,earnings,100,50,4/26/2021
449217,earnings,100,50,4/26/2021
449217,earnings,100,50,4/26/2021
44DDBD,conference-call,100,50,4/26/2021
47FCF2,earnings,100,50,4/26/2021
49914B,earnings,100,50,4/26/2021
49914B,earnings,100,50,4/26/2021
49CC59,conference-call,100,50,4/26/2021
4A2457,conference-call,100,50,4/26/2021
4A6F00,partnership,100,61,4/26/2021
4C92B9,partnership,100,61,4/26/2021
4D203E,conference-participant,100,50,4/26/2021
4D8E5E,earnings,100,50,4/26/2021
5065B1,earnings,100,50,4/26/2021
53EF9E,earnings,100,50,4/26/2021
53EF9E,earnings,100,50,4/26/2021
550D01,facility-open,100,65,4/26/2021
5546DA,executive-appointment,100,54,4/26/2021
564F3E,facility-open,100,65,4/26/2021
56765E,acquisition-completed-acquirer,100,49,4/26/2021
56EA2B,earnings-per-share,100,50,4/26/2021
594402,earnings,100,50,4/26/2021
59F0B0,earnings,100,50,4/26/2021
59F0B0,earnings,100,50,4/26/2021
59F0B0,earnings,100,50,4/26/2021
59F0B0,earnings,100,50,4/26/2021
5BE42C,earnings-up,100,68,4/26/2021
5C8D61,earnings,100,50,4/26/2021
5C8D61,earnings,100,50,4/26/2021
5C8D61,earnings,100,50,4/26/2021
610D47,earnings,100,50,4/26/2021
6.52E+64,executive-appointment,100,54,4/26/2021
68B03F,earnings-up,100,68,4/26/2021
68B03F,earnings,100,50,4/26/2021
68B03F,earnings,100,50,4/26/2021
68B03F,earnings,100,50,4/26/2021
693ECD,earnings,100,50,4/26/2021
6A6BDC,partnership,100,61,4/26/2021
6DD6BA,earnings,100,50,4/26/2021
6DD6BA,earnings,100,50,4/26/2021
6DD6BA,earnings,100,50,4/26/2021
6DDA15,earnings,100,50,4/26/2021
6E7060,executive-appointment,100,54,4/26/2021
6E7060,executive-appointment,100,54,4/26/2021
6E8349,earnings,100,50,4/26/2021
701531,earnings,100,50,4/26/2021
728737,earnings,100,50,4/26/2021
7.44E+09,dividend,100,50,4/26/2021
7448A3,earnings,100,50,4/26/2021
748EB6,conference-call,100,50,4/26/2021
762B8D,acquisition-interest-acquiree,100,82,4/26/2021
762B8D,acquisition-interest-acquiree,100,82,4/26/2021
767F86,business-contract,100,69,4/26/2021
767F86,business-contract,100,69,4/26/2021
767F86,business-contract,100,69,4/26/2021
76DD0C,earnings,100,50,4/26/2021
79340A,earnings,100,50,4/26/2021
7C4168,earnings,100,50,4/26/2021
7C75FD,note-sale,100,52,4/26/2021
7CBC40,earnings,100,50,4/26/2021
7CBC40,earnings,100,50,4/26/2021
7CBC40,earnings,100,50,4/26/2021
7CBC40,earnings,100,50,4/26/2021
7CBC40,earnings,100,50,4/26/2021
7F3669,partnership,100,61,4/26/2021
7F9E16,conference-call,100,50,4/26/2021
7FC386,earnings,100,50,4/26/2021
80D744,patent-awarded,100,72,4/26/2021
8303CD,partnership,100,61,4/26/2021
8377DB,earnings,100,50,4/26/2021
8377DB,earnings,100,50,4/26/2021
83B1C8,earnings,100,50,4/26/2021
859281,dividend,100,50,4/26/2021
859281,earnings,100,50,4/26/2021
859281,earnings,100,50,4/26/2021
859281,earnings,100,50,4/26/2021
859281,earnings,100,50,4/26/2021
859281,earnings,100,50,4/26/2021
859281,earnings,100,50,4/26/2021
85AD00,earnings,100,50,4/26/2021
896771,product-release,100,64,4/26/2021
8C1238,buybacks,100,74,4/26/2021
8DA42F,conference-call,100,50,4/26/2021
8E93A4,earnings,100,50,4/26/2021
8F6995,dividend,100,50,4/26/2021
8F8F2F,earnings,100,50,4/26/2021
8F8F2F,earnings,100,50,4/26/2021
93965C,executive-appointment,100,54,4/26/2021
950AB7,earnings,100,50,4/26/2021
95DE39,earnings-positive,100,69,4/26/2021
95DE39,earnings,100,50,4/26/2021
95DE39,earnings,100,50,4/26/2021
95DE39,earnings,100,50,4/26/2021
95DE39,earnings,100,50,4/26/2021
96A6CD,executive-appointment,100,54,4/26/2021
979451,earnings,100,50,4/26/2021
97B027,conference-call,100,50,4/26/2021
9A02C4,earnings,100,50,4/26/2021
9A02C4,dividend-up,100,81,4/26/2021
9D2790,partnership,100,61,4/26/2021
9D5D35,earnings,100,50,4/26/2021
9D5D35,earnings,100,50,4/26/2021
9D5D35,earnings,100,50,4/26/2021
A01983,conference-call,100,50,4/26/2021
A3BFAA,dividend,100,50,4/26/2021
A41450,earnings,100,50,4/26/2021
A47A7D,earnings,100,50,4/26/2021
A47F2E,earnings,100,50,4/26/2021
A65325,dividend,100,50,4/26/2021
A65325,acquisition-acquiree,100,76,4/26/2021
A65325,earnings-positive,100,69,4/26/2021
A70BF5,executive-appointment,100,54,4/26/2021
A96867,earnings-up,100,68,4/26/2021
A96867,earnings-up,100,68,4/26/2021
A96867,earnings-up,100,68,4/26/2021
A96867,earnings-up,100,68,4/26/2021
A96867,earnings-up,100,68,4/26/2021
A96867,earnings-up,100,68,4/26/2021
A96867,earnings-up,100,68,4/26/2021
A96867,earnings-up,100,68,4/26/2021
A96867,earnings-up,100,68,4/26/2021
A96867,earnings-up,100,68,4/26/2021
AA98ED,unit-acquisition-acquiree,100,76,4/26/2021
AAEE21,earnings,100,50,4/26/2021
AB7726,acquisition-acquiree,100,76,4/26/2021
AB7726,earnings,100,50,4/26/2021
AB7726,dividend,100,50,4/26/2021
AC7C4F,government-contract,100,69,4/26/2021
ADF1B0,earnings,100,50,4/26/2021
ADF1B0,earnings,100,50,4/26/2021
ADF1B0,earnings,100,50,4/26/2021
ADF1B0,earnings,100,50,4/26/2021
AE4125,partnership,100,61,4/26/2021
B106FA,earnings,100,50,4/26/2021
B2DAF6,executive-appointment,100,54,4/26/2021
B60366,executive-appointment,100,54,4/26/2021
B6082A,earnings,100,50,4/26/2021
B72BE9,revenues,100,50,4/26/2021
B72BE9,revenues,100,50,4/26/2021
B72BE9,revenues,100,50,4/26/2021
B96637,conference-call,100,50,4/26/2021
B96DF5,executive-appointment,100,54,4/26/2021
B9764A,dividend,100,50,4/26/2021
B9CD50,earnings,100,50,4/26/2021
BBC05B,operating-earnings,100,50,4/26/2021
BDF2BD,earnings,100,50,4/26/2021
BDF2BD,public-offering,100,43,4/26/2021
BE379D,conference-call,100,50,4/26/2021
BFAEB4,executive-resignation,100,44,4/26/2021
C01737,earnings,100,50,4/26/2021
C45C1F,clinical-trials,100,56,4/26/2021
C598D7,revenue-up,100,67,4/26/2021
C598D7,revenues,100,50,4/26/2021
C598D7,revenues,100,50,4/26/2021
C5D2AE,acquisition-acquiree,100,76,4/26/2021
C5D2AE,earnings,100,50,4/26/2021
C81E00,conference-participant,100,50,4/26/2021
C81E00,conference-participant,100,50,4/26/2021
C83B88,executive-appointment,100,54,4/26/2021
C99CC8,executive-appointment,100,54,4/26/2021
C9C62A,earnings,100,50,4/26/2021
CC6FF5,earnings,100,50,4/26/2021
CFE5BE,dividend,100,50,4/26/2021
D07B07,facility-open,100,65,4/26/2021
D20C8F,dividend,100,50,4/26/2021
D3C794,earnings,100,50,4/26/2021
D74613,partnership,100,61,4/26/2021
D76AEF,executive-appointment,100,54,4/26/2021
D76AEF,executive-appointment,100,54,4/26/2021
D8ECA1,business-contract,100,69,4/26/2021
D90F43,partnership,100,61,4/26/2021
DAC66A,executive-resignation,100,44,4/26/2021
DC1405,business-contract,100,69,4/26/2021
DD1BA1,product-release,100,64,4/26/2021
DD1BA1,earnings,100,50,4/26/2021
DD3BB1,earnings,100,50,4/26/2021
DDEA6A,executive-appointment,100,54,4/26/2021
E0207A,earnings,100,50,4/26/2021
E0207A,earnings,100,50,4/26/2021
E0207A,earnings,100,50,4/26/2021
E0207A,earnings,100,50,4/26/2021
E074A0,dividend,100,50,4/26/2021
E09997,conference-call,100,50,4/26/2021
E68733,partnership,100,61,4/26/2021
E70531,earnings,100,50,4/26/2021
E74B55,legal-issues-defendant,100,22,4/26/2021
E84500,earnings,100,50,4/26/2021
E87676,dividend,100,50,4/26/2021
E93A40,earnings,100,50,4/26/2021
EA62FC,dividend-up,100,81,4/26/2021
EB61C4,executive-resignation,100,44,4/26/2021
ED22DC,executive-appointment,100,54,4/26/2021
ED7F13,earnings,100,50,4/26/2021
EE967B,earnings,100,50,4/26/2021
EEA734,regulatory-product-approval-granted,100,81,4/26/2021
EF45B6,earnings,100,50,4/26/2021
F0B335,partnership,100,61,4/26/2021
F0B335,fundraising,100,64,4/26/2021
F209B4,public-offering,100,43,4/26/2021
F24FF0,earnings,100,50,4/26/2021
F294DD,buybacks,100,74,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F294DD,earnings,100,50,4/26/2021
F2BC3D,acquisition-acquirer,100,49,4/26/2021
F2E253,conference-call,100,50,4/26/2021
F3D2EB,operating-earnings,100,50,4/26/2021
F3FCC3,dividend,100,50,4/26/2021
F4D241,earnings,100,50,4/26/2021
F58C23,executive-resignation,100,44,4/26/2021
F5C78B,earnings,100,50,4/26/2021
F95726,earnings,100,50,4/26/2021
FA36A4,earnings,100,50,4/26/2021
FADF1A,business-contract,100,69,4/26/2021
FD1312,earnings,100,50,4/26/2021
FF227B,executive-appointment,100,54,4/26/2021
FF6644,partnership,100,61,4/26/2021
FF6644,dividend,100,50,4/26/2021
0157B1,product-release,100,64,4/27/2021
0157B1,product-release,100,64,4/27/2021
31025,revenue-up,100,69,4/27/2021
31025,earnings,100,50,4/27/2021
31025,earnings,100,50,4/27/2021
31025,earnings,100,50,4/27/2021
03542C,conference-call,100,50,4/27/2021
03B8CF,earnings,100,50,4/27/2021
03B8CF,earnings,100,50,4/27/2021
03B8CF,earnings,100,50,4/27/2021
03B8CF,earnings,100,50,4/27/2021
03B8CF,earnings,100,50,4/27/2021
053EFF,conference-call,100,50,4/27/2021
55018,earnings-positive,100,69,4/27/2021
55018,earnings,100,50,4/27/2021
55018,earnings,100,50,4/27/2021
55018,earnings,100,50,4/27/2021
55018,earnings,100,50,4/27/2021
55018,earnings,100,50,4/27/2021
55018,earnings,100,50,4/27/2021
55018,earnings,100,50,4/27/2021
0560D8,earnings,100,50,4/27/2021
0560D8,earnings,100,50,4/27/2021
0560D8,earnings,100,50,4/27/2021
095A04,earnings,100,50,4/27/2021
099C88,business-contract,100,69,4/27/2021
09F623,earnings-up,100,68,4/27/2021
0A9D0A,earnings,100,50,4/27/2021
0B13E8,conference-call,100,50,4/27/2021
0BA8CE,earnings,100,50,4/27/2021
0BD199,earnings,100,50,4/27/2021
0BD4E8,conference-call,100,50,4/27/2021
0C136E,credit-rating-upgrade-rater,20,50,4/27/2021
0C136E,credit-rating-upgrade-rater,20,50,4/27/2021
0C136E,credit-rating-upgrade-rater,20,50,4/27/2021
0C355F,revenues,100,50,4/27/2021
0C355F,revenues,100,50,4/27/2021
0C355F,revenues,100,50,4/27/2021
0C355F,revenues,100,50,4/27/2021
0F65C9,earnings,100,50,4/27/2021
0F65C9,dividend,100,50,4/27/2021
102727,earnings,100,50,4/27/2021
108FDA,earnings,100,50,4/27/2021
11074E,conference-participant,100,50,4/27/2021
131443,partnership,100,61,4/27/2021
133644,conference-participant,100,50,4/27/2021
152E1D,conference-call,100,50,4/27/2021
152E1D,legal-issues-defendant,100,22,4/27/2021
1834C0,unit-acquisition-acquirer,100,49,4/27/2021
1866B2,earnings,100,50,4/27/2021
188394,dividend,100,50,4/27/2021
18D9FA,conference-call,100,50,4/27/2021
18D9FA,legal-issues-defendant,100,22,4/27/2021
190B91,partnership,100,61,4/27/2021
190B91,earnings,100,50,4/27/2021
190B91,earnings,100,50,4/27/2021
190B91,earnings,100,50,4/27/2021
190B91,earnings,100,50,4/27/2021
190B91,earnings,100,50,4/27/2021
190B91,earnings,100,50,4/27/2021
1921DD,partnership,100,61,4/27/2021
1A3E1B,dividend,100,50,4/27/2021
1DB833,earnings,100,50,4/27/2021
1E1125,fraud-defendant,100,20,4/27/2021
1EBF8D,business-contract,100,69,4/27/2021
1EC3E8,dividend,100,50,4/27/2021
1EC3E8,dividend,100,50,4/27/2021
1FE3CB,dividend,100,50,4/27/2021
1FE3CB,partnership,100,61,4/27/2021
1FE3CB,operating-earnings,100,50,4/27/2021
21022F,business-contract,100,69,4/27/2021
21022F,business-contract,100,69,4/27/2021
2262BD,credit-extension-recipient,100,69,4/27/2021
228D42,partnership,100,61,4/27/2021
228D42,partnership,100,61,4/27/2021
22C58E,earnings,100,50,4/27/2021
25A6CC,legal-issues-defendant,100,22,4/27/2021
2667B6,earnings,100,50,4/27/2021
28DCF3,earnings,100,50,4/27/2021
295F9F,conference-call,100,50,4/27/2021
29A4CC,earnings,100,50,4/27/2021
2.90E+62,legal-issues-defendant,100,22,4/27/2021
2.90E+62,legal-issues-defendant,100,22,4/27/2021
2A1009,fraud-defendant,100,20,4/27/2021
2B7A40,earnings-per-share-positive,100,69,4/27/2021
2B7A40,earnings-positive,100,69,4/27/2021
2B7A40,earnings-positive,100,69,4/27/2021
2B7A40,earnings-positive,100,69,4/27/2021
2B8179,patient-enrollment-complete,100,64,4/27/2021
2D643C,executive-appointment,100,54,4/27/2021
2D643C,dividend,100,50,4/27/2021
2E2E6E,legal-issues-defendant,100,22,4/27/2021
2E89AE,conference-participant,100,50,4/27/2021
2EC172,partnership,100,61,4/27/2021
2EC172,earnings,100,50,4/27/2021
2EC172,earnings,100,50,4/27/2021
2EC172,earnings,100,50,4/27/2021
2EC172,earnings,100,50,4/27/2021
2EC172,earnings,100,50,4/27/2021
2F5256,earnings,100,50,4/27/2021
2F94A5,credit-rating-upgrade,100,77,4/27/2021
2F94A5,credit-rating-upgrade,100,77,4/27/2021
2F94A5,credit-rating-upgrade,100,77,4/27/2021
332F87,earnings,100,50,4/27/2021
33FD66,earnings,100,50,4/27/2021
33FD66,earnings,100,50,4/27/2021
33FD66,earnings,100,50,4/27/2021
33FD66,earnings,100,50,4/27/2021
33FD66,earnings,100,50,4/27/2021
34B97A,conference-participant,100,50,4/27/2021
37020C,earnings,100,50,4/27/2021
373B06,earnings,100,50,4/27/2021
37727A,earnings,100,50,4/27/2021
37727A,earnings,100,50,4/27/2021
37727A,earnings,100,50,4/27/2021
37727A,earnings,100,50,4/27/2021
37727A,earnings,100,50,4/27/2021
37727A,earnings,100,50,4/27/2021
37727A,earnings,100,50,4/27/2021
37727A,earnings,100,50,4/27/2021
37727A,earnings,100,50,4/27/2021
39BFF6,earnings,100,50,4/27/2021
39BFF6,earnings,100,50,4/27/2021
3A3447,acquisition-acquirer,100,49,4/27/2021
3B37F7,earnings,100,50,4/27/2021
3BB616,earnings,100,50,4/27/2021
3BB616,earnings,100,50,4/27/2021
3BB616,earnings,100,50,4/27/2021
3BCF24,earnings,100,50,4/27/2021
3CBA2A,earnings,100,50,4/27/2021
3CBA2A,earnings,100,50,4/27/2021
3CBA2A,earnings,100,50,4/27/2021
3CBA2A,earnings,100,50,4/27/2021
3CBA2A,earnings,100,50,4/27/2021
3CBA2A,earnings,100,50,4/27/2021
3CBA2A,earnings,100,50,4/27/2021
3D9999,earnings-positive,100,69,4/27/2021
3D9999,earnings,100,50,4/27/2021
3D9999,earnings,100,50,4/27/2021
3D9999,earnings,100,50,4/27/2021
3D9999,earnings,100,50,4/27/2021
3ED92D,earnings,100,50,4/27/2021
3ED92D,earnings,100,50,4/27/2021
3ED92D,earnings,100,50,4/27/2021
3ED92D,earnings,100,50,4/27/2021
3ED92D,earnings,100,50,4/27/2021
3ED92D,earnings,100,50,4/27/2021
3ED92D,earnings,100,50,4/27/2021
408089,earnings,100,50,4/27/2021
41785E,earnings,100,50,4/27/2021
41ED98,conference-call,100,50,4/27/2021
420168,earnings,100,50,4/27/2021
434F38,conference-participant,100,50,4/27/2021
44A4FC,partnership,100,61,4/27/2021
46A16E,conference-call,100,50,4/27/2021
47752F,executive-appointment,100,54,4/27/2021
47B4CC,note-sale,100,52,4/27/2021
47BA98,earnings,100,50,4/27/2021
492117,earnings-up,100,68,4/27/2021
4A6F00,partnership,100,61,4/27/2021
4A6F00,partnership,100,61,4/27/2021
4A6F00,partnership,100,61,4/27/2021
4A6F00,partnership,100,61,4/27/2021
4C37C5,dividend,100,50,4/27/2021
4C5CC9,dividend,100,50,4/27/2021
4C92B9,investment-investor,100,55,4/27/2021
4D8313,executive-appointment,100,54,4/27/2021
4DD09F,earnings,100,50,4/27/2021
4E7C1F,partnership,100,61,4/27/2021
4EE14A,executive-appointment,100,54,4/27/2021
4EE14A,executive-appointment,100,54,4/27/2021
504FE2,legal-issues-defendant,100,22,4/27/2021
52BF94,earnings,100,50,4/27/2021
52BF94,earnings,100,50,4/27/2021
52BF94,earnings,100,50,4/27/2021
52BF94,earnings,100,50,4/27/2021
539F49,partnership,100,61,4/27/2021
539F49,partnership,100,61,4/27/2021
539F49,partnership,100,61,4/27/2021
546A9C,conference-call,100,50,4/27/2021
54A646,earnings-positive,100,69,4/27/2021
54A646,earnings-positive,100,69,4/27/2021
54A646,earnings-positive,100,69,4/27/2021
54A646,earnings-positive,100,69,4/27/2021
54F271,partnership,100,61,4/27/2021
54F271,earnings,100,50,4/27/2021
550D01,facility-open,100,65,4/27/2021
553949,earnings,100,50,4/27/2021
553949,earnings,100,50,4/27/2021
553949,earnings,100,50,4/27/2021
553949,earnings,100,50,4/27/2021
553949,earnings,100,50,4/27/2021
553949,earnings,100,50,4/27/2021
55C9B5,donation,100,54,4/27/2021
55C9B5,partnership,100,61,4/27/2021
55C9B5,partnership,100,61,4/27/2021
56277A,conference-participant,100,50,4/27/2021
56AFF4,dividend,100,50,4/27/2021
56EFC7,conference-participant,100,50,4/27/2021
57DDB9,partnership,100,61,4/27/2021
57EF50,conference-call,100,50,4/27/2021
583A75,earnings,100,50,4/27/2021
58C2D4,legal-issues-defendant,100,22,4/27/2021
596116,earnings,100,50,4/27/2021
59B229,earnings,100,50,4/27/2021
59B229,executive-appointment,100,54,4/27/2021
5A423F,earnings,100,50,4/27/2021
5AF08A,partnership,100,61,4/27/2021
5B226B,earnings-per-share-positive,100,69,4/27/2021
5B226B,earnings-per-share-positive,100,69,4/27/2021
5B226B,earnings-per-share-positive,100,69,4/27/2021
5B226B,earnings-per-share-positive,100,69,4/27/2021
5B35C7,legal-issues-defendant,100,22,4/27/2021
5BC2F4,executive-appointment,100,54,4/27/2021
5D02B7,earnings,100,50,4/27/2021
5DD48B,note-sale,100,52,4/27/2021
5E6959,earnings-up,100,68,4/27/2021
5E6959,earnings,100,50,4/27/2021
5E6959,earnings,100,50,4/27/2021
5F1B7B,product-release,100,64,4/27/2021
60AC34,earnings,100,50,4/27/2021
616E3B,earnings,100,50,4/27/2021
616E3B,earnings,100,50,4/27/2021
616E3B,earnings,100,50,4/27/2021
616E3B,earnings,100,50,4/27/2021
616E3B,earnings,100,50,4/27/2021
61BCA7,partnership,100,61,4/27/2021
61BCA7,earnings,100,50,4/27/2021
649CBD,earnings,100,50,4/27/2021
65CF8E,dividend,100,50,4/27/2021
65CF8E,dividend,100,50,4/27/2021
65D0AA,regulatory-product-approval-granted,100,81,4/27/2021
6634D9,earnings,100,50,4/27/2021
66CB62,executive-resignation,100,44,4/27/2021
673C9A,conference-call,100,50,4/27/2021
6830FE,partnership,100,61,4/27/2021
6844D2,partnership,100,61,4/27/2021
69345C,earnings,100,50,4/27/2021
69345C,earnings,100,50,4/27/2021
69345C,earnings,100,50,4/27/2021
69345C,earnings,100,50,4/27/2021
69C99E,earnings,100,50,4/27/2021
6A01DF,executive-appointment,100,54,4/27/2021
6A961B,conference-call,100,50,4/27/2021
6B0E45,dividend,100,50,4/27/2021
6B6375,earnings,100,50,4/27/2021
6BBCBA,conference-call,100,50,4/27/2021
6C4D2F,earnings,100,50,4/27/2021
6C4D2F,earnings,100,50,4/27/2021
6C4D2F,earnings,100,50,4/27/2021
6C4D2F,earnings,100,50,4/27/2021
6C4D2F,earnings,100,50,4/27/2021
6C4D2F,earnings,100,50,4/27/2021
6C4D2F,earnings,100,50,4/27/2021
6C4D2F,earnings,100,50,4/27/2021
6CC55E,conference-participant,100,50,4/27/2021
6D4636,conference-call,100,50,4/27/2021
701531,conference-participant,100,50,4/27/2021
70FCEF,executive-appointment,100,54,4/27/2021
71553E,earnings,100,50,4/27/2021
7255D2,legal-issues-defendant,100,22,4/27/2021
74404C,partnership,100,61,4/27/2021
7.45E+28,earnings,100,50,4/27/2021
748EB6,acquisition-acquirer,100,49,4/27/2021
752A70,earnings,100,50,4/27/2021
75D689,conference-participant,100,50,4/27/2021
762B8D,acquisition-interest-acquiree,100,82,4/27/2021
765913,earnings,100,50,4/27/2021
766047,donation,100,54,4/27/2021
76BD96,conference-call,100,50,4/27/2021
76F067,earnings,100,50,4/27/2021
76F067,earnings,100,50,4/27/2021
782B46,earnings,100,50,4/27/2021
782B46,dividend,100,50,4/27/2021
782B46,buybacks,100,74,4/27/2021
793C11,partnership,100,61,4/27/2021
7A10FF,earnings,100,50,4/27/2021
7AC86E,earnings,100,50,4/27/2021
7AC86E,earnings,100,50,4/27/2021
7AC86E,earnings,100,50,4/27/2021
7AD81E,conference-participant,100,50,4/27/2021
7B9AFA,conference-participant,100,50,4/27/2021
7C790D,conference-participant,100,50,4/27/2021
7D5FD6,buybacks,100,74,4/27/2021
7D5FD6,earnings,100,50,4/27/2021
7D5FD6,earnings,100,50,4/27/2021
7FD8B9,business-contract,100,69,4/27/2021
7FDE1C,conference-call,100,50,4/27/2021
81F4BE,earnings,100,50,4/27/2021
81F4BE,earnings,100,50,4/27/2021
81F4BE,earnings,100,50,4/27/2021
81F4BE,earnings,100,50,4/27/2021
81F4BE,earnings,100,50,4/27/2021
81F4BE,earnings,100,50,4/27/2021
81F4BE,earnings,100,50,4/27/2021
82F088,conference-participant,100,50,4/27/2021
83A065,note-sale,100,52,4/27/2021
8.40E+120,clinical-trials,100,56,4/27/2021
873DB9,dividend,100,50,4/27/2021
885758,product-release,100,64,4/27/2021
89F693,partnership,100,61,4/27/2021
89F693,partnership,100,61,4/27/2021
8AC65D,earnings,100,50,4/27/2021
8AC65D,acquisition-completed-acquirer,100,49,4/27/2021
8B9B3B,product-release,100,64,4/27/2021
8BE916,earnings-positive,100,69,4/27/2021
8BE916,earnings,100,50,4/27/2021
8BE916,earnings,100,50,4/27/2021
8BE916,earnings,100,50,4/27/2021
8BE916,earnings,100,50,4/27/2021
8BE916,earnings,100,50,4/27/2021
8BE916,earnings,100,50,4/27/2021
8BE916,earnings,100,50,4/27/2021
8C311A,earnings,100,50,4/27/2021
8CF6DD,dividend,100,50,4/27/2021
8D4486,partnership,100,61,4/27/2021
8D4486,dividend-up,100,81,4/27/2021
8D4486,dividend-up,100,81,4/27/2021
91E5EE,legal-issues-defendant,100,22,4/27/2021
92D6A5,earnings,100,50,4/27/2021
9.31E+77,conference-call,100,50,4/27/2021
93D207,earnings,100,50,4/27/2021
93F143,earnings,100,50,4/27/2021
93F143,earnings,100,50,4/27/2021
93F143,earnings,100,50,4/27/2021
93F143,earnings,100,50,4/27/2021
958938,conference-call,100,50,4/27/2021
95C575,earnings,100,50,4/27/2021
96F126,business-contract,100,69,4/27/2021
972356,revenues,100,50,4/27/2021
97AF94,earnings,100,50,4/27/2021
97FE80,partnership,100,61,4/27/2021
981656,earnings,100,50,4/27/2021
98CAED,dividend,100,50,4/27/2021
98CAED,earnings-up,100,68,4/27/2021
98CAED,earnings-up,100,68,4/27/2021
98CAED,earnings-up,100,68,4/27/2021
990AD0,conference-organizer,100,57,4/27/2021
990AD0,conference-organizer,100,57,4/27/2021
990AD0,conference-organizer,100,57,4/27/2021
990AD0,conference-organizer,100,57,4/27/2021
990AD0,conference-organizer,100,57,4/27/2021
990AD0,conference-organizer,100,57,4/27/2021
990AD0,conference-organizer,100,57,4/27/2021
990AD0,conference-organizer,100,57,4/27/2021
990AD0,conference-organizer,100,57,4/27/2021
9B5968,earnings,100,50,4/27/2021
9B5968,earnings,100,50,4/27/2021
9B5968,earnings,100,50,4/27/2021
9B5968,earnings,100,50,4/27/2021
9B5968,earnings,100,50,4/27/2021
9CDA4F,earnings,100,50,4/27/2021
9E575E,patient-enrollment-start,100,58,4/27/2021
9F71E5,product-release,100,64,4/27/2021
9FB4B7,earnings,100,50,4/27/2021
9FF5F1,executive-appointment,100,54,4/27/2021
A1A317,dividend,100,50,4/27/2021
A1A317,earnings,100,50,4/27/2021
A1A317,earnings,100,50,4/27/2021
A1A317,earnings,100,50,4/27/2021
A1DBF0,executive-appointment,100,54,4/27/2021
A350C1,operating-earnings,100,50,4/27/2021
A350C1,operating-earnings,100,50,4/27/2021
A350C1,operating-earnings,100,50,4/27/2021
A350C1,operating-earnings,100,50,4/27/2021
A350C1,operating-earnings,100,50,4/27/2021
A350C1,operating-earnings,100,50,4/27/2021
A43906,conference-participant,100,50,4/27/2021
A4F67C,earnings,100,50,4/27/2021
A5628C,legal-issues-defendant,100,22,4/27/2021
A63387,merger-regulatory-approval,100,81,4/27/2021
A65325,legal-issues-defendant,100,22,4/27/2021
A65325,legal-issues-defendant,100,22,4/27/2021
A7102F,conference-participant,100,50,4/27/2021
A868C9,partnership,100,61,4/27/2021
A868C9,partnership,100,61,4/27/2021
A87CD6,revenue-up,100,57,4/27/2021
A87CD6,revenues,100,50,4/27/2021
A87CD6,revenues,100,50,4/27/2021
A87CD6,revenues,100,50,4/27/2021
A87CD6,revenues,100,50,4/27/2021
A87CD6,revenues,100,50,4/27/2021
A8B137,earnings,100,50,4/27/2021
A8B137,earnings,100,50,4/27/2021
A8B137,earnings,100,50,4/27/2021
A8B137,earnings,100,50,4/27/2021
A8B137,earnings,100,50,4/27/2021
AA98ED,earnings,100,50,4/27/2021
AB7726,legal-issues-defendant,100,22,4/27/2021
AC3584,earnings,100,50,4/27/2021
ACF77B,dividend-up,100,81,4/27/2021
ADD9DC,executive-appointment,100,54,4/27/2021
AE4EEB,earnings,100,50,4/27/2021
AEEB76,earnings,100,50,4/27/2021
AFF43F,earnings,100,50,4/27/2021
AFF43F,dividend,100,50,4/27/2021
B04426,conference-call,100,50,4/27/2021
B2206F,product-release,100,64,4/27/2021
B2DAF6,earnings,100,50,4/27/2021
B303A6,dividend,100,50,4/27/2021
B33E77,earnings,100,50,4/27/2021
B37FB4,earnings-up,100,68,4/27/2021
B60366,earnings,100,50,4/27/2021
B96637,operating-earnings,100,50,4/27/2021
B98EFA,operating-earnings,100,50,4/27/2021
BB5142,earnings,100,50,4/27/2021
BBAE2A,earnings,100,50,4/27/2021
BBBB41,conference-participant,100,50,4/27/2021
BE14CF,earnings,100,50,4/27/2021
BFEA04,executive-appointment,100,54,4/27/2021
BFF98A,trading-listing,100,61,4/27/2021
C05839,earnings,100,50,4/27/2021
C05839,earnings,100,50,4/27/2021
C05839,earnings,100,50,4/27/2021
C05839,earnings,100,50,4/27/2021
C05839,earnings,100,50,4/27/2021
C16A8F,earnings,100,50,4/27/2021
C16A8F,earnings,100,50,4/27/2021
C16A8F,earnings,100,50,4/27/2021
C16A8F,earnings,100,50,4/27/2021
C32A39,earnings,100,50,4/27/2021
C3CF29,earnings,100,50,4/27/2021
C3CF29,earnings,100,50,4/27/2021
C3CF29,earnings,100,50,4/27/2021
C3CF29,earnings,100,50,4/27/2021
C41C25,dividend,100,50,4/27/2021
C45CE7,earnings,100,50,4/27/2021
C5C137,earnings,100,50,4/27/2021
C5D2AE,legal-issues-defendant,100,22,4/27/2021
C659EB,earnings,100,50,4/27/2021
C659EB,earnings,100,50,4/27/2021
C659EB,earnings,100,50,4/27/2021
C659EB,earnings,100,50,4/27/2021
C81E00,operating-earnings,100,50,4/27/2021
C81E00,operating-earnings,100,50,4/27/2021
C8FAC7,product-release,100,64,4/27/2021
C97B2D,executive-appointment,100,54,4/27/2021
C9881C,partnership,100,61,4/27/2021
CBA33B,dividend,100,50,4/27/2021
CBBFBF,joint-venture,100,62,4/27/2021
CC176E,earnings,100,50,4/27/2021
CC3EC4,earnings,100,50,4/27/2021
CC6FF5,partnership,100,61,4/27/2021
CC8F6E,business-contract,100,69,4/27/2021
CC8F6E,acquisition-acquiree,100,76,4/27/2021
CC8F6E,earnings,100,50,4/27/2021
CD06A2,dividend,100,50,4/27/2021
CDC217,executive-appointment,100,54,4/27/2021
D04D9F,earnings,100,50,4/27/2021
D08D2C,partnership,100,61,4/27/2021
D0909F,resource-discovery,100,88,4/27/2021
D17C1B,earnings,100,50,4/27/2021
D17C1B,earnings,100,50,4/27/2021
D17C1B,earnings,100,50,4/27/2021
D17C1B,earnings,100,50,4/27/2021
D33D8C,dividend,100,50,4/27/2021
D518D8,revenues,100,50,4/27/2021
D88EF3,business-contract-terminated,100,31,4/27/2021
D89753,legal-issues-defendant,100,22,4/27/2021
D9CAF0,earnings,100,50,4/27/2021
DB7FA7,earnings-positive,100,69,4/27/2021
DB7FA7,dividend,100,50,4/27/2021
DBCA3F,acquisition-acquirer,100,49,4/27/2021
DBCA3F,acquisition-acquirer,100,49,4/27/2021
DC2F77,dividend,100,50,4/27/2021
DDEA6A,earnings,100,50,4/27/2021
DF01B1,legal-issues-defendant,100,22,4/27/2021
DF11D9,earnings,100,50,4/27/2021
E0207A,acquisition-acquirer,100,49,4/27/2021
E10D31,earnings,100,50,4/27/2021
E21871,dividend,100,50,4/27/2021
E2F130,conference-participant,100,50,4/27/2021
E30A8F,earnings,100,50,4/27/2021
E30A8F,earnings,100,50,4/27/2021
E30A8F,earnings,100,50,4/27/2021
E30A8F,earnings,100,50,4/27/2021
E30A8F,earnings,100,50,4/27/2021
E40FB6,earnings,100,50,4/27/2021
E40FB6,earnings,100,50,4/27/2021
E40FB6,earnings,100,50,4/27/2021
E40FB6,earnings,100,50,4/27/2021
E40FB6,earnings,100,50,4/27/2021
E68733,regulatory-product-approval-granted,100,81,4/27/2021
E69BA5,conference-call,100,50,4/27/2021
E6D89E,earnings,100,50,4/27/2021
E6D89E,earnings,100,50,4/27/2021
E6D89E,earnings,100,50,4/27/2021
E6D89E,earnings,100,50,4/27/2021
E6E012,earnings,100,50,4/27/2021
E6E012,earnings,100,50,4/27/2021
E6E012,earnings,100,50,4/27/2021
E6E012,earnings,100,50,4/27/2021
E6E012,earnings,100,50,4/27/2021
E6E012,earnings,100,50,4/27/2021
E6EDED,earnings,100,50,4/27/2021
E87676,earnings-up,100,68,4/27/2021
E87676,earnings,100,50,4/27/2021
E87676,earnings,100,50,4/27/2021
E8846E,dividend,100,50,4/27/2021
E8B21D,acquisition-acquirer,100,49,4/27/2021
E8B21D,earnings,100,50,4/27/2021
E8B21D,earnings,100,50,4/27/2021
E8B21D,earnings,100,50,4/27/2021
E8B21D,earnings,100,50,4/27/2021
E8B21D,earnings,100,50,4/27/2021
E96E0B,conference-participant,100,50,4/27/2021
E9E6FD,earnings,100,50,4/27/2021
E9FF33,earnings,100,50,4/27/2021
EB36DE,index-listing,100,76,4/27/2021
EB61C4,earnings,100,50,4/27/2021
EBC84C,earnings,100,50,4/27/2021
EBC84C,earnings,100,50,4/27/2021
EBC84C,earnings,100,50,4/27/2021
EBC84C,earnings,100,50,4/27/2021
EBC84C,earnings,100,50,4/27/2021
EC99D0,earnings,100,50,4/27/2021
ECDEB2,earnings,100,50,4/27/2021
ED0402,revenue-up,100,67,4/27/2021
ED0402,revenue-up,100,69,4/27/2021
ED0402,revenue-up,100,69,4/27/2021
ED0402,revenue-up,100,69,4/27/2021
ED0D7C,dividend,100,50,4/27/2021
EDF5CA,earnings,100,50,4/27/2021
EDF5CA,earnings,100,50,4/27/2021
EDF5CA,earnings,100,50,4/27/2021
EDF5CA,earnings,100,50,4/27/2021
EDF5CA,earnings,100,50,4/27/2021
EDF5CA,earnings,100,50,4/27/2021
EDF5CA,earnings,100,50,4/27/2021
EDF5CA,earnings,100,50,4/27/2021
EEB5F9,conference-call,100,50,4/27/2021
EF1AD9,partnership,100,61,4/27/2021
F0027C,earnings,100,50,4/27/2021
F04E05,earnings,100,50,4/27/2021
F0A9DE,earnings,100,50,4/27/2021
F179ED,partnership,100,61,4/27/2021
F1EB39,business-contract,100,69,4/27/2021
F209B4,conference-participant,100,50,4/27/2021
F2526D,earnings,100,50,4/27/2021
F294DD,earnings,100,50,4/27/2021
F294DD,earnings,100,50,4/27/2021
F294DD,earnings,100,50,4/27/2021
F294DD,earnings,100,50,4/27/2021
F40EE2,earnings,100,50,4/27/2021
F40EE2,earnings,100,50,4/27/2021
F40EE2,earnings,100,50,4/27/2021
F40EE2,earnings,100,50,4/27/2021
F40EE2,earnings,100,50,4/27/2021
F40EE2,earnings,100,50,4/27/2021
F4CDA3,conference-call,100,50,4/27/2021
F4FBD8,conference-participant,100,50,4/27/2021
F5D410,earnings-guidance-up,100,83,4/27/2021
F5D499,executive-appointment,100,54,4/27/2021
F6DCE4,partnership,100,61,4/27/2021
FA840E,conference-participant,100,50,4/27/2021
FA918D,index-listing,100,76,4/27/2021
FAE021,earnings,100,50,4/27/2021
FAE021,earnings,100,50,4/27/2021
FAE021,earnings,100,50,4/27/2021
FAEABE,dividend,100,50,4/27/2021
FC80E6,earnings,100,50,4/27/2021
FD39EB,earnings,100,50,4/27/2021
FD6926,conference-participant,100,50,4/27/2021
FDD3FC,earnings,100,50,4/27/2021
FE9C0D,trading-listing,100,61,4/27/2021
FFAB4A,earnings,100,50,4/27/2021
00067A,earnings,100,50,4/28/2021
002A99,conference-participant,100,50,4/28/2021
00D6B5,earnings,100,50,4/28/2021
01478A,earnings,100,50,4/28/2021
018C11,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03B8CF,earnings,100,50,4/28/2021
03D5F9,earnings,100,50,4/28/2021
58828,earnings-per-share-up,100,59,4/28/2021
081AB9,earnings,100,50,4/28/2021
0986B5,earnings,100,50,4/28/2021
0A748B,earnings,100,50,4/28/2021
0A748B,earnings,100,50,4/28/2021
0B4D10,earnings,100,50,4/28/2021
0C136E,earnings,100,50,4/28/2021
0C2A0D,earnings,100,50,4/28/2021
0CBC4D,earnings-up,100,68,4/28/2021
0CC62B,earnings,100,50,4/28/2021
0CC62B,earnings,100,50,4/28/2021
0CC62B,earnings,100,50,4/28/2021
0CC62B,earnings,100,50,4/28/2021
0E439E,earnings-up,100,68,4/28/2021
0E439E,earnings-up,100,68,4/28/2021
0E439E,earnings-up,100,68,4/28/2021
0EC508,earnings,100,50,4/28/2021
0F0693,earnings,100,50,4/28/2021
10AE08,earnings-positive,100,69,4/28/2021
10AE08,earnings,100,50,4/28/2021
10AE08,earnings,100,50,4/28/2021
10AE08,earnings,100,50,4/28/2021
10AE08,earnings,100,50,4/28/2021
10AE08,earnings,100,50,4/28/2021
10AE08,earnings,100,50,4/28/2021
10AE08,earnings,100,50,4/28/2021
10AE08,earnings,100,50,4/28/2021
11AEDE,earnings,100,50,4/28/2021
1216D1,earnings,100,50,4/28/2021
129DC8,trading-halt,100,43,4/28/2021
129DC8,trading-resumed,100,58,4/28/2021
12E454,earnings,100,50,4/28/2021
12E454,earnings,100,50,4/28/2021
12E454,earnings,100,50,4/28/2021
14BA06,conference-participant,100,50,4/28/2021
14BA33,earnings,100,50,4/28/2021
15901B,partnership,100,61,4/28/2021
168A5D,partnership,100,61,4/28/2021
16F4D8,earnings,100,50,4/28/2021
16F4D8,earnings,100,50,4/28/2021
16F4D8,earnings,100,50,4/28/2021
16F4D8,earnings,100,50,4/28/2021
16F4D8,earnings,100,50,4/28/2021
16FC89,earnings,100,50,4/28/2021
1.79E+10,conference-call,100,50,4/28/2021
180DA0,earnings,100,50,4/28/2021
197019,earnings,100,50,4/28/2021
1A46A1,conference-call,100,50,4/28/2021
1CF3A8,conference-call,100,50,4/28/2021
1D5C51,earnings,100,50,4/28/2021
1E8A99,earnings,100,50,4/28/2021
1E9A6D,earnings,100,50,4/28/2021
1EBF8D,partnership,100,61,4/28/2021
1EBF8D,partnership,100,61,4/28/2021
1F3CFB,earnings,100,50,4/28/2021
1F716B,earnings,100,50,4/28/2021
2003A5,earnings,100,50,4/28/2021
2082EA,conference-call,100,50,4/28/2021
2093B1,earnings,100,50,4/28/2021
20D00A,operating-earnings,100,50,4/28/2021
21022F,earnings,100,50,4/28/2021
214051,earnings,100,50,4/28/2021
221445,earnings,100,50,4/28/2021
221AD7,earnings-up,100,68,4/28/2021
221AD7,earnings,100,50,4/28/2021
221AD7,earnings,100,50,4/28/2021
221AD7,earnings,100,50,4/28/2021
221AD7,earnings,100,50,4/28/2021
249B39,earnings-positive,100,69,4/28/2021
24CB56,executive-appointment,100,54,4/28/2021
24FA23,earnings,100,50,4/28/2021
25AB8E,business-contract,100,69,4/28/2021
264EB3,earnings,100,50,4/28/2021
264EB3,earnings,100,50,4/28/2021
264EB3,earnings,100,50,4/28/2021
264EB3,earnings,100,50,4/28/2021
264EB3,earnings,100,50,4/28/2021
264EB3,earnings,100,50,4/28/2021
267718,acquisition-acquirer,100,49,4/28/2021
267718,acquisition-acquirer,100,49,4/28/2021
267718,acquisition-acquirer,100,49,4/28/2021
26F31D,earnings,100,50,4/28/2021
26F31D,earnings,100,50,4/28/2021
26F31D,earnings,100,50,4/28/2021
26FA41,earnings,100,50,4/28/2021
270305,earnings,100,50,4/28/2021
270305,earnings,100,50,4/28/2021
270305,earnings,100,50,4/28/2021
270305,earnings,100,50,4/28/2021
270305,dividend,100,50,4/28/2021
270B78,dividend,100,50,4/28/2021
28AC4E,earnings,100,50,4/28/2021
28DCA8,earnings,100,50,4/28/2021
2950FF,earnings,100,50,4/28/2021
2950FF,earnings,100,50,4/28/2021
2A1009,legal-issues-defendant,100,22,4/28/2021
2AA6A8,conference-call,100,50,4/28/2021
2C3348,earnings,100,50,4/28/2021
2CA60F,earnings,100,50,4/28/2021
2CA60F,earnings,100,50,4/28/2021
2CA60F,earnings,100,50,4/28/2021
2CC71C,conference-call,100,50,4/28/2021
2D2D43,dividend,100,50,4/28/2021
2D643C,earnings,100,50,4/28/2021
2D981A,earnings,100,50,4/28/2021
2FEA66,operating-earnings,100,50,4/28/2021
315EB0,earnings,100,50,4/28/2021
315EB0,earnings,100,50,4/28/2021
315EB0,earnings,100,50,4/28/2021
315EB0,earnings,100,50,4/28/2021
315EB0,earnings,100,50,4/28/2021
315EB0,earnings,100,50,4/28/2021
315EB0,dividend,100,50,4/28/2021
31803E,conference-participant,100,50,4/28/2021
319BE2,dividend,100,50,4/28/2021
319BE2,earnings,100,50,4/28/2021
326EDD,earnings,100,50,4/28/2021
32CB22,earnings-guidance-up,100,83,4/28/2021
32F943,earnings,100,50,4/28/2021
33E8C7,earnings,100,50,4/28/2021
33E8C7,earnings,100,50,4/28/2021
3461CF,earnings,100,50,4/28/2021
346BF2,earnings,100,50,4/28/2021
34B411,dividend,100,50,4/28/2021
3.50E+27,earnings,100,50,4/28/2021
384CD3,business-contract,100,69,4/28/2021
387541,earnings,100,50,4/28/2021
3A113F,earnings,100,50,4/28/2021
3A3447,earnings,100,50,4/28/2021
3A3447,earnings,100,50,4/28/2021
3A3447,earnings,100,50,4/28/2021
3A3447,earnings,100,50,4/28/2021
3A3447,earnings,100,50,4/28/2021
3C75D6,executive-appointment,100,54,4/28/2021
3F4497,earnings,100,50,4/28/2021
40F7DE,partnership,100,61,4/28/2021
416C55,earnings,100,50,4/28/2021
41D61C,earnings,100,50,4/28/2021
425BDC,earnings,100,50,4/28/2021
442769,earnings,100,50,4/28/2021
442769,earnings,100,50,4/28/2021
442769,earnings,100,50,4/28/2021
442769,earnings,100,50,4/28/2021
4455C4,earnings,100,50,4/28/2021
4455C4,earnings,100,50,4/28/2021
4455C4,earnings,100,50,4/28/2021
4455C4,earnings,100,50,4/28/2021
447FC6,earnings-up,100,68,4/28/2021
46017C,earnings,100,50,4/28/2021
4649D5,earnings,100,50,4/28/2021
468DD4,earnings,100,50,4/28/2021
47752F,earnings,100,50,4/28/2021
47752F,earnings,100,50,4/28/2021
47752F,earnings,100,50,4/28/2021
47752F,earnings,100,50,4/28/2021
4806CE,dividend,100,50,4/28/2021
4885C8,dividend,100,50,4/28/2021
4.91E+58,partnership,100,61,4/28/2021
4AC91D,partnership,100,61,4/28/2021
4B5054,dividend,100,50,4/28/2021
4B6EF9,earnings,100,50,4/28/2021
4B6EF9,dividend,100,50,4/28/2021
4BD6DB,earnings,100,50,4/28/2021
4BDCA7,conference-call,100,50,4/28/2021
4BDCA7,clinical-trials-start,100,64,4/28/2021
4C6C63,earnings,100,50,4/28/2021
4C6C63,earnings,100,50,4/28/2021
4C6C63,earnings,100,50,4/28/2021
4C6C63,earnings,100,50,4/28/2021
4C6C63,earnings,100,50,4/28/2021
4C92B9,executive-appointment,100,54,4/28/2021
4D971D,earnings,100,50,4/28/2021
4D971D,earnings,100,50,4/28/2021
4D971D,earnings,100,50,4/28/2021
4D971D,earnings,100,50,4/28/2021
4D971D,earnings,100,50,4/28/2021
4D971D,earnings,100,50,4/28/2021
4D971D,earnings,100,50,4/28/2021
4D971D,dividend,100,50,4/28/2021
4ECD1A,credit-extension-recipient,100,69,4/28/2021
4FB770,earnings,100,50,4/28/2021
51888A,dividend,100,50,4/28/2021
519FE0,earnings,100,50,4/28/2021
51E682,earnings,100,50,4/28/2021
532D47,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55438C,earnings,100,50,4/28/2021
55C289,earnings,100,50,4/28/2021
564F3E,earnings,100,50,4/28/2021
583223,earnings-up,100,68,4/28/2021
583553,earnings,100,50,4/28/2021
58C2D4,legal-issues-defendant,100,22,4/28/2021
59DB8C,partnership,100,61,4/28/2021
5AAE17,earnings,100,50,4/28/2021
5AF08A,earnings,100,50,4/28/2021
5DD486,earnings,100,50,4/28/2021
5DE5A5,conference-participant,100,50,4/28/2021
5F3E74,earnings,100,50,4/28/2021
5F3E74,earnings,100,50,4/28/2021
5F3E74,earnings,100,50,4/28/2021
5F3E74,earnings,100,50,4/28/2021
5F3E74,earnings,100,50,4/28/2021
5F3E74,earnings,100,50,4/28/2021
5FDBD0,executive-appointment,100,54,4/28/2021
605F40,earnings,100,50,4/28/2021
61E975,dividend,100,50,4/28/2021
62EFEE,dividend,100,50,4/28/2021
62EFEE,earnings-up,100,68,4/28/2021
62F41C,settlement,100,56,4/28/2021
63E8D5,earnings,100,50,4/28/2021
63E8D5,earnings,100,50,4/28/2021
63E8D5,earnings,100,50,4/28/2021
63E8D5,earnings,100,50,4/28/2021
63E8D5,earnings,100,50,4/28/2021
63E8D5,earnings,100,50,4/28/2021
63E8D5,earnings,100,50,4/28/2021
64854A,earnings,100,50,4/28/2021
662682,earnings,100,50,4/28/2021
66749D,earnings-up,100,68,4/28/2021
66749D,earnings-up,100,68,4/28/2021
66749D,earnings-up,100,68,4/28/2021
66749D,earnings-up,100,68,4/28/2021
66749D,earnings-up,100,68,4/28/2021
66BDA1,earnings,100,50,4/28/2021
66CB62,conference-call,100,50,4/28/2021
66E3C0,earnings,100,50,4/28/2021
66E3C0,earnings,100,50,4/28/2021
66ECFD,earnings,100,50,4/28/2021
69CE71,business-contract,100,69,4/28/2021
6ACFBF,earnings,100,50,4/28/2021
6B236C,earnings,100,50,4/28/2021
6B67BD,earnings,100,50,4/28/2021
6DBBBC,dividend,100,50,4/28/2021
6E1E61,earnings,100,50,4/28/2021
6E7060,earnings,100,50,4/28/2021
6E7060,earnings,100,50,4/28/2021
6E7060,earnings,100,50,4/28/2021
6E7060,earnings,100,50,4/28/2021
6E7060,earnings,100,50,4/28/2021
6E7060,earnings,100,50,4/28/2021
6E7060,earnings,100,50,4/28/2021
6E8864,conference-participant,100,50,4/28/2021
6EB9DA,executive-appointment,100,54,4/28/2021
6F22E7,conference-call,100,50,4/28/2021
7032D0,earnings,100,50,4/28/2021
705636,revenue-up,100,62,4/28/2021
705636,dividend,100,50,4/28/2021
722D55,business-contract,100,69,4/28/2021
722DE3,earnings-up,100,68,4/28/2021
72609A,earnings,100,50,4/28/2021
72609A,earnings,100,50,4/28/2021
72609A,earnings,100,50,4/28/2021
7273FF,earnings,100,50,4/28/2021
729368,earnings,100,50,4/28/2021
732449,earnings,100,50,4/28/2021
735388,earnings,100,50,4/28/2021
73BCBA,earnings,100,50,4/28/2021
73BCBA,earnings,100,50,4/28/2021
73BCBA,earnings,100,50,4/28/2021
73BCBA,earnings,100,50,4/28/2021
762A3E,campaign-ad-retired,100,48,4/28/2021
763724,conference-call,100,50,4/28/2021
76B926,dividend,100,50,4/28/2021
76BECC,conference-call,100,50,4/28/2021
771985,earnings,100,50,4/28/2021
771985,earnings,100,50,4/28/2021
771985,earnings,100,50,4/28/2021
771985,earnings,100,50,4/28/2021
771985,earnings,100,50,4/28/2021
771985,earnings,100,50,4/28/2021
771985,earnings,100,50,4/28/2021
771985,earnings,100,50,4/28/2021
771985,earnings,100,50,4/28/2021
7771D7,acquisition-acquirer,100,49,4/28/2021
789ADD,dividend,100,50,4/28/2021
793C11,business-contract,100,69,4/28/2021
7C4168,conference-participant,100,50,4/28/2021
7DA412,earnings,100,50,4/28/2021
7E62B5,earnings,100,50,4/28/2021
805CD8,conference-call,100,50,4/28/2021
82BB33,auditor-appointment,100,50,4/28/2021
830BDB,partnership,100,61,4/28/2021
83598E,dividend,100,50,4/28/2021
838ADD,earnings,100,50,4/28/2021
838ADD,earnings,100,50,4/28/2021
838ADD,earnings,100,50,4/28/2021
838ADD,earnings,100,50,4/28/2021
838ADD,earnings,100,50,4/28/2021
838ADD,earnings,100,50,4/28/2021
838ADD,earnings,100,50,4/28/2021
84A6B9,buybacks,100,74,4/28/2021
84A6B9,earnings,100,50,4/28/2021
84A6B9,earnings,100,50,4/28/2021
84A6B9,earnings,100,50,4/28/2021
84A6B9,earnings,100,50,4/28/2021
84A6B9,earnings,100,50,4/28/2021
84A6B9,earnings,100,50,4/28/2021
860AB6,dividend,100,50,4/28/2021
860AB6,dividend,100,50,4/28/2021
868808,earnings,100,50,4/28/2021
86A1B9,dividend,100,50,4/28/2021
86BAC7,earnings,100,50,4/28/2021
86BAC7,dividend,100,50,4/28/2021
873DB9,executive-appointment,100,54,4/28/2021
881190,earnings,100,50,4/28/2021
881190,earnings,100,50,4/28/2021
881190,earnings,100,50,4/28/2021
881190,earnings,100,50,4/28/2021
8A8E41,executive-appointment,100,54,4/28/2021
8AB37F,conference-call,100,50,4/28/2021
8B1E11,earnings,100,50,4/28/2021
8D4AE6,earnings,100,50,4/28/2021
8D4AE6,earnings,100,50,4/28/2021
8D4AE6,earnings,100,50,4/28/2021
8D4AE6,earnings,100,50,4/28/2021
8D9993,earnings,100,50,4/28/2021
8DBE73,revenues,100,50,4/28/2021
8DBE73,revenues,100,50,4/28/2021
8DBE73,revenues,100,50,4/28/2021
8DBE73,revenues,100,50,4/28/2021
8DBE73,revenues,100,50,4/28/2021
8DCBBB,earnings,100,50,4/28/2021
8DCBBB,earnings,100,50,4/28/2021
8E4250,earnings,100,50,4/28/2021
8E4250,earnings,100,50,4/28/2021
8E4250,earnings,100,50,4/28/2021
8E4250,earnings,100,50,4/28/2021
8E4F9A,executive-appointment,100,54,4/28/2021
8E4F9A,earnings,100,50,4/28/2021
8E8E6E,earnings,100,50,4/28/2021
8EF425,earnings,100,50,4/28/2021
8EF425,earnings,100,50,4/28/2021
8EF425,earnings,100,50,4/28/2021
8EF425,earnings,100,50,4/28/2021
8EF425,earnings,100,50,4/28/2021
8EF425,earnings,100,50,4/28/2021
8FCA78,dividend-up,100,65,4/28/2021
8FF2EF,conference-call,100,50,4/28/2021
902255,earnings,100,50,4/28/2021
905356,earnings,100,50,4/28/2021
911AB8,dividend,100,50,4/28/2021
911CA9,conference-participant,100,50,4/28/2021
915E7B,acquisition-acquirer,100,49,4/28/2021
92005C,clinical-trials,100,56,4/28/2021
92D9C9,conference-call,100,50,4/28/2021
93D207,partnership,100,61,4/28/2021
94637C,conference-participant,100,50,4/28/2021
94C0B5,dividend,100,50,4/28/2021
9546A5,conference-call,100,50,4/28/2021
963A02,executive-appointment,100,54,4/28/2021
966ACE,conference-participant,100,50,4/28/2021
9673BD,conference-call,100,50,4/28/2021
96B4FF,sponsorship,100,57,4/28/2021
972356,earnings-above-expectations,100,88,4/28/2021
97644E,earnings,100,50,4/28/2021
990AD0,conference-organizer,100,57,4/28/2021
990AD0,conference-organizer,100,57,4/28/2021
990AD0,conference-organizer,100,57,4/28/2021
990AD0,conference-organizer,100,57,4/28/2021
990AD0,conference-organizer,100,57,4/28/2021
99B61C,conference-participant,100,50,4/28/2021
9B730A,conference-call,100,50,4/28/2021
9D307D,acquisition-acquirer,100,49,4/28/2021
9D30A8,earnings,100,50,4/28/2021
9D65C1,earnings,100,50,4/28/2021
9D65C1,executive-appointment,100,54,4/28/2021
9DDE1B,earnings,100,50,4/28/2021
9E298A,dividend,100,50,4/28/2021
9EA947,earnings,100,50,4/28/2021
A017F4,product-release,100,64,4/28/2021
A247F5,earnings,100,50,4/28/2021
A3230E,clinical-trials,100,56,4/28/2021
A3800A,earnings,100,50,4/28/2021
A3AAA5,earnings,100,50,4/28/2021
A429A5,operating-earnings,100,50,4/28/2021
A4A612,earnings-up,100,68,4/28/2021
A4A612,earnings,100,50,4/28/2021
A4A612,earnings,100,50,4/28/2021
A62FD6,earnings,100,50,4/28/2021
A62FD6,earnings,100,50,4/28/2021
A62FD6,earnings,100,50,4/28/2021
A62FD6,earnings,100,50,4/28/2021
A6ABE9,earnings,100,50,4/28/2021
A6D095,conference-participant,100,50,4/28/2021
A70BF5,product-release,100,64,4/28/2021
A75D43,product-release,100,64,4/28/2021
A806FA,conference-call,100,50,4/28/2021
A99576,earnings,100,50,4/28/2021
AA1EAA,earnings,100,50,4/28/2021
AA847A,earnings,100,50,4/28/2021
AADE0B,dividend,100,50,4/28/2021
AAEE21,public-offering,100,43,4/28/2021
AD3008,earnings,100,50,4/28/2021
AD375D,note-sale,100,52,4/28/2021
AD3C93,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
AD9F1D,earnings,100,50,4/28/2021
ADF092,earnings,100,50,4/28/2021
ADF092,earnings,100,50,4/28/2021
AEF2C3,earnings,100,50,4/28/2021
AFEC35,earnings,100,50,4/28/2021
B08954,earnings,100,50,4/28/2021
B09B1F,earnings,100,50,4/28/2021
B09B1F,earnings,100,50,4/28/2021
B09B1F,earnings,100,50,4/28/2021
B09B1F,earnings,100,50,4/28/2021
B290A2,earnings,100,50,4/28/2021
B4C673,earnings,100,50,4/28/2021
B4C673,earnings,100,50,4/28/2021
B4C673,earnings,100,50,4/28/2021
B4C673,earnings,100,50,4/28/2021
B4C673,earnings,100,50,4/28/2021
B4C673,earnings,100,50,4/28/2021
B54A74,partnership,100,61,4/28/2021
B80AD1,earnings,100,50,4/28/2021
B83BCE,earnings,100,50,4/28/2021
BB07E4,earnings,100,50,4/28/2021
BB07E4,earnings,100,50,4/28/2021
BB07E4,earnings,100,50,4/28/2021
BB07E4,earnings,100,50,4/28/2021
BB07E4,earnings,100,50,4/28/2021
BB07E4,earnings,100,50,4/28/2021
BB88B6,earnings,100,50,4/28/2021
BC4876,dividend,100,50,4/28/2021
BC5680,earnings,100,50,4/28/2021
BC5680,earnings,100,50,4/28/2021
BC5680,earnings,100,50,4/28/2021
BD8517,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDEF34,earnings,100,50,4/28/2021
BDF2BD,public-offering,100,43,4/28/2021
BFAEB4,executive-appointment,100,54,4/28/2021
BFCACF,earnings,100,50,4/28/2021
C06EB6,earnings,100,50,4/28/2021
C188F8,earnings,100,50,4/28/2021
C230FE,earnings-up,100,68,4/28/2021
C230FE,earnings-up,100,68,4/28/2021
C27E19,operating-earnings,100,50,4/28/2021
C2E39B,earnings,100,50,4/28/2021
C2E39B,earnings,100,50,4/28/2021
C2E39B,earnings,100,50,4/28/2021
C2E39B,earnings,100,50,4/28/2021
C3F99F,earnings,100,50,4/28/2021
C4706C,conference-call,100,50,4/28/2021
C4A241,earnings-up,100,68,4/28/2021
C4A241,earnings,100,50,4/28/2021
C4A241,earnings,100,50,4/28/2021
C4A241,earnings,100,50,4/28/2021
C564E4,conference-call,100,50,4/28/2021
C564E4,conference-participant,100,50,4/28/2021
C5E840,credit-extension-recipient,100,69,4/28/2021
C66B44,earnings,100,50,4/28/2021
C7FC95,business-contract,100,69,4/28/2021
C8257F,note-sale,100,52,4/28/2021
C8A248,dividend,100,50,4/28/2021
C8A248,investment-investor,100,55,4/28/2021
C951A2,earnings,100,50,4/28/2021
C951A2,earnings,100,50,4/28/2021
C951A2,earnings,100,50,4/28/2021
C951A2,earnings,100,50,4/28/2021
C951A2,earnings,100,50,4/28/2021
C951A2,earnings,100,50,4/28/2021
C97B2D,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9D866,earnings,100,50,4/28/2021
C9E04B,conference-call,100,50,4/28/2021
CA3CB9,business-contract,100,69,4/28/2021
CAC8D0,partnership,100,61,4/28/2021
CB88B3,earnings,100,50,4/28/2021
CBA33B,earnings,100,50,4/28/2021
CBBFBF,dividend,100,50,4/28/2021
CC35BE,earnings,100,50,4/28/2021
CC6FF5,business-contract,100,69,4/28/2021
CD06A2,public-offering,100,43,4/28/2021
CD4DA8,earnings-up,100,68,4/28/2021
CD4DA8,earnings,100,50,4/28/2021
CD4DA8,earnings,100,50,4/28/2021
CD4DA8,earnings,100,50,4/28/2021
CD4DA8,earnings,100,50,4/28/2021
CD4DA8,earnings,100,50,4/28/2021
CD4DA8,earnings,100,50,4/28/2021
CD4DA8,earnings,100,50,4/28/2021
CD4DA8,earnings,100,50,4/28/2021
CE1002,earnings-up,100,68,4/28/2021
CE1002,earnings,100,50,4/28/2021
CE1002,earnings,100,50,4/28/2021
CE1002,earnings,100,50,4/28/2021
CE4FD9,partnership,100,61,4/28/2021
CE4FD9,earnings,100,50,4/28/2021
CE4FD9,earnings,100,50,4/28/2021
CE4FD9,earnings,100,50,4/28/2021
CE4FD9,earnings,100,50,4/28/2021
CE4FD9,earnings,100,50,4/28/2021
CE5C6E,earnings,100,50,4/28/2021
CF6A5A,product-release,100,64,4/28/2021
CF6A5A,product-release,100,64,4/28/2021
CFF15D,earnings,100,50,4/28/2021
CFF15D,earnings,100,50,4/28/2021
D06755,earnings,100,50,4/28/2021
D06755,earnings,100,50,4/28/2021
D06755,earnings,100,50,4/28/2021
D0909F,earnings,100,50,4/28/2021
D139BC,earnings,100,50,4/28/2021
D139BC,executive-appointment,100,54,4/28/2021
D15833,earnings-positive,100,69,4/28/2021
D20C8F,earnings,100,50,4/28/2021
D3CEDF,earnings,100,50,4/28/2021
D3CEDF,earnings,100,50,4/28/2021
D3CEDF,earnings,100,50,4/28/2021
D3CEDF,earnings,100,50,4/28/2021
D437C3,earnings,100,50,4/28/2021
D437C3,earnings,100,50,4/28/2021
D437C3,earnings,100,50,4/28/2021
D54E62,dividend-up,100,81,4/28/2021
D56E4C,earnings,100,50,4/28/2021
D56E4C,earnings,100,50,4/28/2021
D58A11,earnings,100,50,4/28/2021
D58A11,earnings,100,50,4/28/2021
D58A11,earnings,100,50,4/28/2021
D5A350,dividend,100,50,4/28/2021
D6489C,executive-appointment,100,54,4/28/2021
D65A13,executive-appointment,100,54,4/28/2021
D78BF1,earnings,100,50,4/28/2021
D7918D,operating-earnings,100,50,4/28/2021
D8442A,earnings,100,50,4/28/2021
D8442A,earnings,100,50,4/28/2021
D8442A,earnings,100,50,4/28/2021
D854F3,conference-participant,100,50,4/28/2021
D90F43,product-release,100,64,4/28/2021
DC1405,conference-participant,100,50,4/28/2021
DCD97F,earnings,100,50,4/28/2021
DD7A96,earnings,100,50,4/28/2021
DDEA6A,conference-participant,100,50,4/28/2021
DF6FDD,earnings,100,50,4/28/2021
E00373,earnings,100,50,4/28/2021
E0339F,dividend,100,50,4/28/2021
E0647D,earnings,100,50,4/28/2021
E0647D,earnings,100,50,4/28/2021
E0647D,earnings,100,50,4/28/2021
E0647D,earnings,100,50,4/28/2021
E0647D,earnings,100,50,4/28/2021
E13782,earnings,100,50,4/28/2021
E30B34,earnings,100,50,4/28/2021
E30B34,earnings,100,50,4/28/2021
E30B34,earnings,100,50,4/28/2021
E30B34,earnings,100,50,4/28/2021
E5D914,earnings,100,50,4/28/2021
E6A53A,earnings,100,50,4/28/2021
E6A53A,earnings,100,50,4/28/2021
E6A53A,earnings,100,50,4/28/2021
E70531,dividend,100,50,4/28/2021
E829E8,earnings,100,50,4/28/2021
E829E8,earnings,100,50,4/28/2021
E829E8,earnings,100,50,4/28/2021
E829E8,earnings,100,50,4/28/2021
EAA0A7,executive-appointment,100,54,4/28/2021
EB61C4,conference-participant,100,50,4/28/2021
EC4E82,conference-participant,100,50,4/28/2021
ED2A5E,earnings,100,50,4/28/2021
ED2A5E,earnings,100,50,4/28/2021
ED2A5E,earnings,100,50,4/28/2021
ED2A5E,earnings,100,50,4/28/2021
ED2A5E,earnings,100,50,4/28/2021
ED2A5E,earnings,100,50,4/28/2021
EEA6B3,note-sale,100,52,4/28/2021
EEA6B3,note-sale,100,52,4/28/2021
EEA6B3,note-sale,100,52,4/28/2021
EEA6B3,note-sale,100,52,4/28/2021
EEBCEF,executive-appointment,100,54,4/28/2021
EEEA9F,earnings,100,50,4/28/2021
EEEA9F,earnings,100,50,4/28/2021
EEEA9F,earnings,100,50,4/28/2021
EEEA9F,earnings,100,50,4/28/2021
EEEA9F,earnings,100,50,4/28/2021
EEEA9F,earnings,100,50,4/28/2021
EEEA9F,earnings,100,50,4/28/2021
EEEA9F,earnings,100,50,4/28/2021
EEEA9F,earnings,100,50,4/28/2021
F0B2B5,earnings,100,50,4/28/2021
F15E41,earnings,100,50,4/28/2021
F15E41,earnings,100,50,4/28/2021
F15E41,earnings,100,50,4/28/2021
F15E41,earnings,100,50,4/28/2021
F1C04C,operating-earnings,100,50,4/28/2021
F1CD47,earnings,100,50,4/28/2021
F294DD,dividend,100,50,4/28/2021
F31B13,dividend,100,50,4/28/2021
F47871,earnings,100,50,4/28/2021
F50BAB,earnings,100,50,4/28/2021
F50BAB,earnings,100,50,4/28/2021
F50BAB,earnings,100,50,4/28/2021
F50BAB,earnings,100,50,4/28/2021
F702CA,note-sale,100,52,4/28/2021
F72E4B,executive-appointment,100,54,4/28/2021
F7902B,revenues,100,50,4/28/2021
F7902B,revenues,100,50,4/28/2021
F7902B,revenues,100,50,4/28/2021
F7FCA4,dividend,100,50,4/28/2021
F88147,conference-participant,100,50,4/28/2021
F90EE5,earnings,100,50,4/28/2021
F9CAF8,earnings,100,50,4/28/2021
FA35C6,earnings,100,50,4/28/2021
FA918D,dividend,100,50,4/28/2021
FA918D,executive-appointment,100,54,4/28/2021
FACF19,product-release,100,64,4/28/2021
FADF1A,conference-call,100,50,4/28/2021
FBDA0F,earnings,100,50,4/28/2021
FC1B7B,product-release,100,64,4/28/2021
FC4550,earnings,100,50,4/28/2021
FD0CA4,executive-appointment,100,54,4/28/2021
FD4E8D,conference-participant,100,50,4/28/2021
FD554E,conference-call,100,50,4/28/2021
FDC7E6,earnings,100,50,4/28/2021
FDC7E6,dividend-up,100,70,4/28/2021
FDD3FC,conference-participant,100,50,4/28/2021
FDE409,conference-participant,100,50,4/28/2021
FE1A1D,earnings,100,50,4/28/2021
FE1A1D,earnings,100,50,4/28/2021
FE1A1D,earnings,100,50,4/28/2021
FE1A1D,earnings,100,50,4/28/2021
FE1A1D,earnings,100,50,4/28/2021
FE1A1D,earnings,100,50,4/28/2021
FEE4B0,dividend,100,50,4/28/2021
FF4343,earnings,100,50,4/28/2021
FFCD0E,conference-call,100,50,4/28/2021
002A99,fraud-defendant,100,20,4/29/2021
003B70,merger,100,66,4/29/2021
003B70,merger,100,66,4/29/2021
003B70,merger,100,66,4/29/2021
9397,earnings,100,50,4/29/2021
9397,earnings,100,50,4/29/2021
00E601,operating-earnings,100,50,4/29/2021
0157B1,earnings,100,50,4/29/2021
0157B1,earnings,100,50,4/29/2021
0157B1,earnings,100,50,4/29/2021
0157B1,earnings,100,50,4/29/2021
0157B1,earnings,100,50,4/29/2021
0157B1,earnings,100,50,4/29/2021
0157B1,earnings,100,50,4/29/2021
0157B1,earnings,100,50,4/29/2021
20751,earnings,100,50,4/29/2021
033B58,conference-participant,100,50,4/29/2021
03FAA6,earnings,100,50,4/29/2021
03FAA6,earnings,100,50,4/29/2021
03FAA6,earnings,100,50,4/29/2021
03FAA6,earnings,100,50,4/29/2021
03FAA6,earnings,100,50,4/29/2021
0490C6,earnings,100,50,4/29/2021
51332,dividend,100,50,4/29/2021
61366,earnings,100,50,4/29/2021
68396,earnings,100,50,4/29/2021
71860,earnings,100,50,4/29/2021
71860,partnership,100,61,4/29/2021
07CA6A,earnings,100,50,4/29/2021
07CA6A,earnings,100,50,4/29/2021
07CA6A,dividend,100,50,4/29/2021
07CA6A,dividend,100,50,4/29/2021
08A40F,executive-appointment,100,54,4/29/2021
099C88,earnings,100,50,4/29/2021
0B2071,earnings,100,50,4/29/2021
0B7375,earnings,100,50,4/29/2021
0BC17A,dividend,100,50,4/29/2021
0BC17A,earnings,100,50,4/29/2021
0C2A0D,note-sale,100,52,4/29/2021
0C466B,unit-acquisition-acquirer,100,49,4/29/2021
0C6861,conference-participant,100,50,4/29/2021
0E5619,conference-call,100,50,4/29/2021
0ED415,earnings,100,50,4/29/2021
0ED415,earnings,100,50,4/29/2021
0ED415,earnings,100,50,4/29/2021
0F04E5,earnings,100,50,4/29/2021
0F04E5,earnings,100,50,4/29/2021
0F04E5,earnings,100,50,4/29/2021
105D00,dividend,100,50,4/29/2021
106394,earnings,100,50,4/29/2021
1080C0,earnings,100,50,4/29/2021
10943B,earnings,100,50,4/29/2021
1151F4,earnings,100,50,4/29/2021
1151F4,earnings,100,50,4/29/2021
1151F4,earnings,100,50,4/29/2021
1151F4,earnings,100,50,4/29/2021
1151F4,earnings,100,50,4/29/2021
1151F4,earnings,100,50,4/29/2021
129DC8,earnings,100,50,4/29/2021
129DC8,earnings,100,50,4/29/2021
129DC8,earnings,100,50,4/29/2021
129DC8,earnings,100,50,4/29/2021
136B26,earnings,100,50,4/29/2021
147C38,earnings,100,50,4/29/2021
1490F3,earnings,100,50,4/29/2021
1490F3,earnings,100,50,4/29/2021
1490F3,earnings,100,50,4/29/2021
1490F3,earnings,100,50,4/29/2021
1490F3,earnings,100,50,4/29/2021
1490F3,earnings,100,50,4/29/2021
15901B,earnings,100,50,4/29/2021
15901B,earnings,100,50,4/29/2021
159AE4,earnings,100,50,4/29/2021
159AE4,earnings,100,50,4/29/2021
159AE4,earnings,100,50,4/29/2021
159AE4,earnings,100,50,4/29/2021
1.79E+10,dividend,100,50,4/29/2021
190B91,public-offering,100,43,4/29/2021
1A6A94,earnings,100,50,4/29/2021
1AE9D5,conference-call,100,50,4/29/2021
1B5FEA,earnings,100,50,4/29/2021
1DB6A6,earnings,100,50,4/29/2021
1DE526,earnings,100,50,4/29/2021
1DEBBE,earnings,100,50,4/29/2021
1DEBBE,legal-issues-defendant,100,22,4/29/2021
1DF15D,earnings,100,50,4/29/2021
1DF15D,earnings,100,50,4/29/2021
1DF15D,earnings,100,50,4/29/2021
1E1125,legal-issues-defendant,100,22,4/29/2021
1EBF8D,earnings,100,50,4/29/2021
1EC3E8,earnings-up,100,68,4/29/2021
1EC3E8,earnings-up,100,68,4/29/2021
1F9D90,conference-participant,100,50,4/29/2021
1FAF22,earnings,100,50,4/29/2021
1FAF22,earnings,100,50,4/29/2021
1FAF22,earnings,100,50,4/29/2021
1FAF22,earnings,100,50,4/29/2021
1FAF22,earnings,100,50,4/29/2021
2082EA,patient-enrollment-complete,100,64,4/29/2021
219B21,earnings,100,50,4/29/2021
219B21,earnings,100,50,4/29/2021
219B21,earnings,100,50,4/29/2021
219B21,earnings,100,50,4/29/2021
219B21,earnings,100,50,4/29/2021
21F9CA,executive-appointment,100,54,4/29/2021
2262BD,earnings,100,50,4/29/2021
227D48,earnings,100,50,4/29/2021
227D48,earnings,100,50,4/29/2021
227D48,earnings,100,50,4/29/2021
227D48,earnings,100,50,4/29/2021
227D48,earnings,100,50,4/29/2021
2491BC,earnings,100,50,4/29/2021
2491BC,earnings,100,50,4/29/2021
2491BC,earnings,100,50,4/29/2021
2491BC,earnings,100,50,4/29/2021
24D81E,earnings,100,50,4/29/2021
25529C,earnings,100,50,4/29/2021
25A6CC,earnings,100,50,4/29/2021
25A6CC,earnings,100,50,4/29/2021
25A6CC,earnings,100,50,4/29/2021
25A6CC,earnings,100,50,4/29/2021
270B78,earnings,100,50,4/29/2021
272472,earnings-up,100,68,4/29/2021
272472,earnings-up,100,68,4/29/2021
272472,earnings-up,100,68,4/29/2021
272472,earnings-up,100,68,4/29/2021
272472,earnings-up,100,68,4/29/2021
272472,earnings-up,100,68,4/29/2021
272472,earnings-up,100,68,4/29/2021
272472,earnings-up,100,68,4/29/2021
284289,earnings-up,100,68,4/29/2021
284289,earnings,100,50,4/29/2021
284289,earnings,100,50,4/29/2021
284289,earnings,100,50,4/29/2021
284289,earnings,100,50,4/29/2021
284289,earnings,100,50,4/29/2021
284289,earnings,100,50,4/29/2021
29B702,earnings,100,50,4/29/2021
2A1009,earnings,100,50,4/29/2021
2A1009,earnings,100,50,4/29/2021
2A1009,earnings,100,50,4/29/2021
2A1009,earnings,100,50,4/29/2021
2A1009,earnings,100,50,4/29/2021
2A17B1,earnings-positive,100,69,4/29/2021
2A17B1,earnings-positive,100,69,4/29/2021
2A17B1,earnings-positive,100,69,4/29/2021
2A17B1,earnings-positive,100,69,4/29/2021
2ABF77,conference-call,100,50,4/29/2021
2BA977,earnings,100,50,4/29/2021
2BA977,earnings,100,50,4/29/2021
2BA977,earnings,100,50,4/29/2021
2BA977,earnings,100,50,4/29/2021
2BA977,earnings,100,50,4/29/2021
2BA977,earnings,100,50,4/29/2021
2BA977,earnings,100,50,4/29/2021
2BA977,earnings,100,50,4/29/2021
2C19A4,earnings,100,50,4/29/2021
2C19A4,earnings,100,50,4/29/2021
2C19A4,earnings,100,50,4/29/2021
2C19A4,earnings,100,50,4/29/2021
2C35B5,conference-call,100,50,4/29/2021
2C7505,earnings,100,50,4/29/2021
2CF9D3,earnings,100,50,4/29/2021
2D5011,earnings,100,50,4/29/2021
2EB88B,facility-open,100,65,4/29/2021
2F94A5,earnings,100,50,4/29/2021
30DE64,regulatory-product-approval-granted,100,81,4/29/2021
30E01D,earnings,100,50,4/29/2021
314D88,earnings,100,50,4/29/2021
31553A,earnings,100,50,4/29/2021
31553A,earnings,100,50,4/29/2021
31553A,earnings,100,50,4/29/2021
31A7CC,dividend,100,50,4/29/2021
328250,earnings,100,50,4/29/2021
339F20,earnings-up,100,68,4/29/2021
349DA4,earnings,100,50,4/29/2021
35557B,earnings,100,50,4/29/2021
35AE32,earnings,100,50,4/29/2021
35F4B5,acquisition-completed-acquirer,100,49,4/29/2021
371C01,earnings,100,50,4/29/2021
371C01,earnings,100,50,4/29/2021
382EAE,unit-acquisition-acquiree,100,76,4/29/2021
387375,earnings,100,50,4/29/2021
3.88E+02,earnings,100,50,4/29/2021
389CFB,earnings,100,50,4/29/2021
396D7C,earnings,100,50,4/29/2021
3DCECC,executive-appointment,100,54,4/29/2021
3DDE54,earnings,100,50,4/29/2021
3DDE54,earnings,100,50,4/29/2021
3DDE54,earnings,100,50,4/29/2021
3DDE54,earnings,100,50,4/29/2021
3DDE54,earnings,100,50,4/29/2021
3DE4D1,dividend,100,50,4/29/2021
3E15F6,earnings,100,50,4/29/2021
3E15F6,earnings,100,50,4/29/2021
3E15F6,earnings,100,50,4/29/2021
3E15F6,earnings,100,50,4/29/2021
3F4668,hirings,100,65,4/29/2021
3F6A9C,executive-appointment,100,54,4/29/2021
3F868D,executive-appointment,100,54,4/29/2021
3F868D,earnings,100,50,4/29/2021
401072,earnings,100,50,4/29/2021
405762,earnings,100,50,4/29/2021
408380,earnings,100,50,4/29/2021
4135F7,earnings,100,50,4/29/2021
41B53E,earnings,100,50,4/29/2021
41B53E,earnings,100,50,4/29/2021
41B53E,earnings,100,50,4/29/2021
41C528,conference-call,100,50,4/29/2021
42AABD,partnership,100,61,4/29/2021
434F38,earnings,100,50,4/29/2021
4398A2,earnings,100,50,4/29/2021
43A060,business-contract,100,69,4/29/2021
448BF3,earnings,100,50,4/29/2021
44A4FC,partnership,100,61,4/29/2021
44DDBD,earnings,100,50,4/29/2021
451D61,earnings,100,50,4/29/2021
46017C,note-sale,100,52,4/29/2021
479930,earnings,100,50,4/29/2021
4806CE,earnings,100,50,4/29/2021
485445,earnings,100,50,4/29/2021
4885C8,earnings,100,50,4/29/2021
49A344,partnership,100,61,4/29/2021
49BBBC,executive-appointment,100,54,4/29/2021
4A5C8D,dividend,100,50,4/29/2021
4A6F00,partnership,100,61,4/29/2021
4A6F00,partnership,100,61,4/29/2021
4A6F00,revenue-up,100,69,4/29/2021
4C2F17,conference-participant,100,50,4/29/2021
4C92B9,dividend-up,100,59,4/29/2021
4E2D94,earnings,100,50,4/29/2021
4E2D94,dividend,100,50,4/29/2021
4EE167,earnings,100,50,4/29/2021
4EEB00,conference-call,100,50,4/29/2021
4EEE7E,earnings,100,50,4/29/2021
4F783B,dividend,100,50,4/29/2021
50070E,conference-organizer,100,57,4/29/2021
50070E,conference-organizer,100,57,4/29/2021
504FE2,legal-issues-defendant,100,22,4/29/2021
504FE2,legal-issues-defendant,100,22,4/29/2021
507AE7,earnings,100,50,4/29/2021
5088A5,earnings,100,50,4/29/2021
51888A,operating-earnings,100,50,4/29/2021
51D876,earnings,100,50,4/29/2021
51D876,earnings,100,50,4/29/2021
51D876,earnings,100,50,4/29/2021
51D876,earnings,100,50,4/29/2021
51D876,earnings,100,50,4/29/2021
51D876,earnings,100,50,4/29/2021
51D876,earnings,100,50,4/29/2021
51D876,earnings,100,50,4/29/2021
52015A,earnings,100,50,4/29/2021
524CE4,earnings,100,50,4/29/2021
53E575,business-contract,100,69,4/29/2021
54512F,earnings,100,50,4/29/2021
5.47E+28,earnings,100,50,4/29/2021
54A646,dividend,100,50,4/29/2021
550D01,product-release,100,64,4/29/2021
55C9B5,earnings,100,50,4/29/2021
55D0F3,earnings,100,50,4/29/2021
56632F,earnings,100,50,4/29/2021
567F3D,earnings-up,100,68,4/29/2021
56AFF4,note-sale,100,52,4/29/2021
56FB7C,dividend-up,100,81,4/29/2021
57356F,earnings,100,50,4/29/2021
57356F,earnings,100,50,4/29/2021
57356F,earnings,100,50,4/29/2021
57634F,executive-resignation,100,44,4/29/2021
57634F,earnings,100,50,4/29/2021
57CAAB,earnings,100,50,4/29/2021
57F3DA,earnings,100,50,4/29/2021
57F3DA,earnings,100,50,4/29/2021
57F3DA,earnings,100,50,4/29/2021
586BD7,conference-call,100,50,4/29/2021
5968F9,earnings,100,50,4/29/2021
5A53BF,earnings,100,50,4/29/2021
5A64D5,earnings,100,50,4/29/2021
5B35C7,legal-issues-defendant,100,22,4/29/2021
5D0337,earnings,100,50,4/29/2021
5D1329,conference-call,100,50,4/29/2021
5D16CF,earnings,100,50,4/29/2021
5D43A7,earnings,100,50,4/29/2021
5D43A7,earnings,100,50,4/29/2021
5D43A7,earnings,100,50,4/29/2021
5D43A7,earnings,100,50,4/29/2021
5F1B7B,earnings,100,50,4/29/2021
5FE4B6,earnings,100,50,4/29/2021
5FE4B6,earnings,100,50,4/29/2021
60AC34,conference-participant,100,50,4/29/2021
616E3B,note-sale,100,52,4/29/2021
6.18E+08,earnings,100,50,4/29/2021
6.18E+08,earnings,100,50,4/29/2021
6.18E+08,earnings,100,50,4/29/2021
6.18E+08,earnings,100,50,4/29/2021
6284B5,executive-appointment,100,54,4/29/2021
63F892,partnership,100,61,4/29/2021
63F892,earnings,100,50,4/29/2021
63F892,earnings,100,50,4/29/2021
6.52E+64,earnings,100,50,4/29/2021
6559D8,earnings,100,50,4/29/2021
65CF8E,earnings,100,50,4/29/2021
65CF8E,earnings,100,50,4/29/2021
67B052,earnings,100,50,4/29/2021
67B052,earnings,100,50,4/29/2021
69494C,earnings,100,50,4/29/2021
69CE71,partnership,100,61,4/29/2021
69E8E1,earnings,100,50,4/29/2021
69E8E1,earnings,100,50,4/29/2021
69E8E1,earnings,100,50,4/29/2021
69E8E1,earnings,100,50,4/29/2021
69E8E1,earnings,100,50,4/29/2021
6A01DF,earnings,100,50,4/29/2021
6A3C35,earnings,100,50,4/29/2021
6A3C35,earnings,100,50,4/29/2021
6A3C35,earnings,100,50,4/29/2021
6A3C35,earnings,100,50,4/29/2021
6B5379,earnings-guidance-up,100,83,4/29/2021
6B5379,earnings,100,50,4/29/2021
6B5379,earnings,100,50,4/29/2021
6B5379,earnings,100,50,4/29/2021
6CDFC6,earnings,100,50,4/29/2021
6DC1D7,earnings,100,50,4/29/2021
6F0A63,earnings,100,50,4/29/2021
717DB4,earnings,100,50,4/29/2021
717DB4,earnings,100,50,4/29/2021
717DB4,earnings,100,50,4/29/2021
717DB4,earnings,100,50,4/29/2021
724F84,partnership,100,61,4/29/2021
7255D2,partnership,100,61,4/29/2021
731675,earnings,100,50,4/29/2021
73529F,earnings,100,50,4/29/2021
73A71F,dividend,100,50,4/29/2021
73C9E2,earnings,100,50,4/29/2021
746373,earnings,100,50,4/29/2021
746373,earnings,100,50,4/29/2021
751C8D,investment-investor,100,55,4/29/2021
751C8D,investment-investor,100,55,4/29/2021
762A3E,earnings,100,50,4/29/2021
762A3E,earnings,100,50,4/29/2021
762A3E,earnings,100,50,4/29/2021
762A3E,earnings,100,50,4/29/2021
762A3E,earnings,100,50,4/29/2021
762A3E,earnings,100,50,4/29/2021
762A3E,dividend,100,50,4/29/2021
762B8D,legal-issues-defendant,100,22,4/29/2021
767F86,earnings,100,50,4/29/2021
767F86,earnings,100,50,4/29/2021
767F86,earnings,100,50,4/29/2021
767F86,earnings,100,50,4/29/2021
767F86,earnings,100,50,4/29/2021
767F86,earnings,100,50,4/29/2021
767F86,earnings,100,50,4/29/2021
767F86,earnings,100,50,4/29/2021
767F86,earnings,100,50,4/29/2021
767F86,earnings,100,50,4/29/2021
76F067,partnership,100,61,4/29/2021
7732C2,executive-appointment,100,54,4/29/2021
7823A3,earnings,100,50,4/29/2021
7823A3,earnings,100,50,4/29/2021
7823A3,earnings,100,50,4/29/2021
7823A3,earnings,100,50,4/29/2021
7823A3,earnings,100,50,4/29/2021
7823A3,earnings,100,50,4/29/2021
789ADD,earnings,100,50,4/29/2021
789ADD,earnings,100,50,4/29/2021
789ADD,earnings,100,50,4/29/2021
789ADD,earnings,100,50,4/29/2021
78F9ED,earnings,100,50,4/29/2021
78F9ED,earnings,100,50,4/29/2021
78F9ED,earnings,100,50,4/29/2021
78F9ED,earnings,100,50,4/29/2021
78F9ED,earnings,100,50,4/29/2021
78F9ED,earnings,100,50,4/29/2021
78F9ED,earnings,100,50,4/29/2021
79167B,earnings,100,50,4/29/2021
79167B,earnings,100,50,4/29/2021
79167B,earnings,100,50,4/29/2021
79167B,earnings,100,50,4/29/2021
791D59,earnings,100,50,4/29/2021
7A2A49,acquisition-completed-acquirer,100,49,4/29/2021
7AB859,acquisition-completed-acquirer,100,49,4/29/2021
7ACBA4,earnings,100,50,4/29/2021
7B492C,earnings,100,50,4/29/2021
7B8CB5,earnings,100,50,4/29/2021
7B9AFA,earnings,100,50,4/29/2021
7B9AFA,earnings,100,50,4/29/2021
7BAAE7,earnings-per-share-positive,100,69,4/29/2021
7BAAE7,earnings,100,50,4/29/2021
7BC92D,earnings,100,50,4/29/2021
7BFF81,executive-appointment,100,54,4/29/2021
7C4F43,earnings,100,50,4/29/2021
7C75FD,note-sale,100,52,4/29/2021
7CBC40,award,100,58,4/29/2021
7E0EB0,earnings,100,50,4/29/2021
7F3665,earnings,100,50,4/29/2021
7FDE1C,earnings,100,50,4/29/2021
81A88D,earnings-up,100,68,4/29/2021
8.22E+27,earnings,100,50,4/29/2021
8295B8,earnings,100,50,4/29/2021
830BDB,earnings,100,50,4/29/2021
837C04,dividend,100,50,4/29/2021
837C04,earnings,100,50,4/29/2021
837C04,earnings,100,50,4/29/2021
837C04,earnings,100,50,4/29/2021
837C04,earnings,100,50,4/29/2021
837C04,earnings,100,50,4/29/2021
837C04,earnings,100,50,4/29/2021
837C04,earnings,100,50,4/29/2021
86478F,earnings,100,50,4/29/2021
8665BA,earnings,100,50,4/29/2021
86AA9C,conference-call,100,50,4/29/2021
873DB9,conference-participant,100,50,4/29/2021
877734,conference-call,100,50,4/29/2021
8802B4,partnership,100,61,4/29/2021
8817D5,earnings,100,50,4/29/2021
885758,executive-appointment,100,54,4/29/2021
893904,conference-participant,100,50,4/29/2021
8A0368,earnings,100,50,4/29/2021
8A0368,earnings,100,50,4/29/2021
8A0368,earnings,100,50,4/29/2021
8A0368,earnings,100,50,4/29/2021
8A0368,award,100,58,4/29/2021
8A8E41,partnership,100,61,4/29/2021
8A8E41,executive-appointment,100,54,4/29/2021
8AB85C,clinical-trials-positive,100,87,4/29/2021
8AB85C,earnings,100,50,4/29/2021
8B3B0E,earnings-guidance-up,100,83,4/29/2021
8B6E7E,earnings-up,100,68,4/29/2021
8C5519,dividend,100,50,4/29/2021
8D4486,acquisition-acquirer,100,49,4/29/2021
8D4486,acquisition-acquirer,100,49,4/29/2021
8D4486,acquisition-acquirer,100,49,4/29/2021
8DCF18,conference-participant,100,50,4/29/2021
8DE74B,earnings,100,50,4/29/2021
8E0E32,earnings,100,50,4/29/2021
8E8E6E,product-release,100,64,4/29/2021
8F3231,earnings,100,50,4/29/2021
9043FE,earnings,100,50,4/29/2021
9043FE,earnings,100,50,4/29/2021
91E5EE,legal-issues-defendant,100,22,4/29/2021
92D757,earnings,100,50,4/29/2021
934029,earnings,100,50,4/29/2021
93C130,earnings,100,50,4/29/2021
93C130,dividend,100,50,4/29/2021
93D207,conference-participant,100,50,4/29/2021
94208D,unit-acquisition-acquirer,100,49,4/29/2021
944B2E,earnings,100,50,4/29/2021
94563D,earnings,100,50,4/29/2021
94563D,earnings,100,50,4/29/2021
94563D,earnings,100,50,4/29/2021
94563D,earnings,100,50,4/29/2021
94563D,earnings,100,50,4/29/2021
945DE6,earnings,100,50,4/29/2021
945DE6,earnings,100,50,4/29/2021
945DE6,earnings,100,50,4/29/2021
945DE6,earnings,100,50,4/29/2021
94637C,earnings,100,50,4/29/2021
94756D,earnings,100,50,4/29/2021
9.54E+32,earnings,100,50,4/29/2021
9.54E+32,earnings,100,50,4/29/2021
96A6CD,earnings,100,50,4/29/2021
9810C0,earnings,100,50,4/29/2021
98D33E,dividend,100,50,4/29/2021
98D33E,capex-guidance,100,50,4/29/2021
990AD0,conference-organizer,100,57,4/29/2021
990AD0,conference-organizer,100,57,4/29/2021
990AD0,conference-organizer,100,57,4/29/2021
990AD0,conference-organizer,100,57,4/29/2021
990AD0,conference-organizer,100,57,4/29/2021
990AD0,conference-organizer,100,57,4/29/2021
990AD0,executive-appointment,100,54,4/29/2021
9.97E+09,earnings,100,50,4/29/2021
9B5968,partnership,100,61,4/29/2021
9CE4C7,dividend,100,50,4/29/2021
9CF9B1,earnings,100,50,4/29/2021
9D2790,executive-appointment,100,54,4/29/2021
9D5FA4,earnings,100,50,4/29/2021
9E298A,earnings,100,50,4/29/2021
9E298A,earnings,100,50,4/29/2021
9E298A,earnings,100,50,4/29/2021
9E298A,earnings,100,50,4/29/2021
9E3224,earnings,100,50,4/29/2021
9EED50,earnings,100,50,4/29/2021
9F03CF,earnings,100,50,4/29/2021
9F03CF,dividend,100,50,4/29/2021
9F6B1A,earnings,100,50,4/29/2021
9F6B1A,earnings,100,50,4/29/2021
9F6B1A,earnings,100,50,4/29/2021
9F6B1A,earnings,100,50,4/29/2021
9F71E5,dividend,100,50,4/29/2021
9FD2D9,earnings,100,50,4/29/2021
9FD2D9,earnings,100,50,4/29/2021
9FD2D9,earnings,100,50,4/29/2021
9FD2D9,earnings,100,50,4/29/2021
A1BB98,earnings,100,50,4/29/2021
A1EAC8,dividend,100,50,4/29/2021
A204A7,earnings,100,50,4/29/2021
A3800A,donation,100,54,4/29/2021
A3800A,donation,100,54,4/29/2021
A4386C,dividend,100,50,4/29/2021
A4D173,dividend,100,50,4/29/2021
A4D173,dividend,100,50,4/29/2021
A5151E,earnings,100,50,4/29/2021
A5628C,legal-issues-defendant,100,22,4/29/2021
A58224,conference-participant,100,50,4/29/2021
A631A3,facility-open,100,65,4/29/2021
A70BF5,earnings,100,50,4/29/2021
A70BF5,earnings,100,50,4/29/2021
A70BF5,earnings,100,50,4/29/2021
A70BF5,earnings,100,50,4/29/2021
A70BF5,earnings,100,50,4/29/2021
A79D88,earnings,100,50,4/29/2021
A79D88,earnings,100,50,4/29/2021
A7A0C8,conference-call,100,50,4/29/2021
A806FA,dividend,100,50,4/29/2021
A80FE0,earnings,100,50,4/29/2021
A8B137,dividend,100,50,4/29/2021
AADE0B,earnings,100,50,4/29/2021
AAEE21,public-offering,100,43,4/29/2021
AB4A7E,award,100,58,4/29/2021
ABB493,business-contract,100,69,4/29/2021
ABB493,business-contract,100,69,4/29/2021
ABB493,conference-call,100,50,4/29/2021
ABBAD1,earnings,100,50,4/29/2021
ABEE43,revenues,100,50,4/29/2021
ABEE43,earnings,100,50,4/29/2021
ABEE43,earnings,100,50,4/29/2021
ABEE43,earnings,100,50,4/29/2021
AC1952,earnings-positive,100,69,4/29/2021
AC642C,earnings,100,50,4/29/2021
AC642C,earnings,100,50,4/29/2021
AD6141,executive-appointment,100,54,4/29/2021
AE0CCE,earnings,100,50,4/29/2021
AF93DE,conference-call,100,50,4/29/2021
AFEC35,acquisition-completed-acquirer,100,49,4/29/2021
B05118,earnings,100,50,4/29/2021
B076A1,conference-call,100,50,4/29/2021
B08C51,earnings,100,50,4/29/2021
B0B969,conference-call,100,50,4/29/2021
B0D41A,earnings,100,50,4/29/2021
B1FC3B,business-contract,100,69,4/29/2021
B2D492,earnings,100,50,4/29/2021
B37FB4,business-contract,100,69,4/29/2021
B381D8,earnings,100,50,4/29/2021
B4703C,earnings,100,50,4/29/2021
B4703C,earnings,100,50,4/29/2021
B5BA39,earnings,100,50,4/29/2021
B6CD92,earnings,100,50,4/29/2021
B73395,conference-call,100,50,4/29/2021
B77F14,conference-call,100,50,4/29/2021
B803B1,conference-participant,100,50,4/29/2021
B840EF,earnings,100,50,4/29/2021
B8F71F,executive-appointment,100,54,4/29/2021
BB02FB,earnings,100,50,4/29/2021
BB0787,executive-appointment,100,54,4/29/2021
BBBB41,earnings,100,50,4/29/2021
BBBB41,earnings,100,50,4/29/2021
BBBB41,earnings,100,50,4/29/2021
BBBB41,earnings,100,50,4/29/2021
BBBB41,earnings,100,50,4/29/2021
BC3AD2,earnings-up,100,68,4/29/2021
BC3AD2,earnings,100,50,4/29/2021
BC3AD2,earnings,100,50,4/29/2021
BC3AD2,earnings,100,50,4/29/2021
BC3AD2,earnings,100,50,4/29/2021
BC3AD2,earnings,100,50,4/29/2021
BC3AD2,earnings,100,50,4/29/2021
BC3AD2,earnings,100,50,4/29/2021
BC3AD2,earnings,100,50,4/29/2021
BC948D,conference-participant,100,50,4/29/2021
BD682F,earnings,100,50,4/29/2021
BE14CF,conference-participant,100,50,4/29/2021
BE7BA4,earnings,100,50,4/29/2021
BE86A1,earnings,100,50,4/29/2021
BF79F5,earnings,100,50,4/29/2021
BF79F5,earnings,100,50,4/29/2021
C0030A,earnings-up,100,68,4/29/2021
C0030A,earnings-up,100,68,4/29/2021
C0030A,earnings-up,100,68,4/29/2021
C0030A,earnings-up,100,68,4/29/2021
C0030A,dividend,100,50,4/29/2021
C062D4,dividend,100,50,4/29/2021
C1114B,conference-call,100,50,4/29/2021
C15DB3,dividend,100,50,4/29/2021
C15F8F,earnings,100,50,4/29/2021
C15F8F,earnings,100,50,4/29/2021
C15F8F,earnings,100,50,4/29/2021
C15F8F,earnings,100,50,4/29/2021
C15F8F,earnings,100,50,4/29/2021
C2609A,dividend,100,50,4/29/2021
C32A39,executive-appointment,100,54,4/29/2021
C356AC,earnings,100,50,4/29/2021
C356AC,earnings,100,50,4/29/2021
C356AC,earnings,100,50,4/29/2021
C356AC,earnings,100,50,4/29/2021
C356AC,earnings,100,50,4/29/2021
C356AC,dividend,100,50,4/29/2021
C4A912,earnings,100,50,4/29/2021
C4A912,earnings,100,50,4/29/2021
C4A912,earnings,100,50,4/29/2021
C4A912,earnings,100,50,4/29/2021
C584BE,earnings,100,50,4/29/2021
C58D71,earnings,100,50,4/29/2021
C5C0E9,earnings,100,50,4/29/2021
C5C0E9,earnings,100,50,4/29/2021
C72B8F,earnings,100,50,4/29/2021
C7863D,merger,100,66,4/29/2021
C7863D,merger,100,66,4/29/2021
C7863D,merger,100,66,4/29/2021
C7863D,legal-issues-defendant,100,22,4/29/2021
C7863D,acquisition-regulatory-scrutiny-acquiree,100,38,4/29/2021
C83B88,earnings,100,50,4/29/2021
C83B88,earnings,100,50,4/29/2021
C83B88,earnings,100,50,4/29/2021
C83B88,earnings,100,50,4/29/2021
C83B88,earnings,100,50,4/29/2021
C83B88,product-release,100,64,4/29/2021
C9A96E,earnings,100,50,4/29/2021
CBDB4D,conference-call,100,50,4/29/2021
CDAB24,executive-resignation,100,44,4/29/2021
CDE51C,executive-appointment,100,54,4/29/2021
CDEDFE,earnings,100,50,4/29/2021
CE1002,conference-participant,100,50,4/29/2021
CE96E7,earnings,100,50,4/29/2021
CFF97C,revenue-up,100,63,4/29/2021
CFF97C,revenue-up,100,63,4/29/2021
CFF97C,revenue-up,100,63,4/29/2021
CFF97C,revenue-up,100,63,4/29/2021
CFF97C,revenue-up,100,63,4/29/2021
D03C7A,earnings,100,50,4/29/2021
D09938,earnings,100,50,4/29/2021
D1173F,earnings,100,50,4/29/2021
D1173F,earnings,100,50,4/29/2021
D1173F,earnings,100,50,4/29/2021
D1173F,earnings,100,50,4/29/2021
D1344A,earnings,100,50,4/29/2021
D1344A,partnership,100,61,4/29/2021
D1344A,partnership,100,61,4/29/2021
D15833,dividend,100,50,4/29/2021
D17F7E,earnings,100,50,4/29/2021
D17F7E,earnings,100,50,4/29/2021
D17F7E,earnings,100,50,4/29/2021
D17F7E,earnings,100,50,4/29/2021
D1C0B9,revenue-up,100,69,4/29/2021
D1C0B9,revenue-up,100,69,4/29/2021
D1C0B9,revenue-up,100,69,4/29/2021
D1C0B9,revenue-up,100,69,4/29/2021
D1C0B9,revenue-up,100,69,4/29/2021
D33270,partnership,100,61,4/29/2021
D4070C,earnings,100,50,4/29/2021
D56D6D,conference-participant,100,50,4/29/2021
D64EDF,dividend,100,50,4/29/2021
D65A13,revenue-up,100,67,4/29/2021
D65A13,revenue-up,100,69,4/29/2021
D65A13,revenue-up,100,69,4/29/2021
D8760C,dividend,100,50,4/29/2021
D8DBA3,earnings,100,50,4/29/2021
D8ECA1,earnings,100,50,4/29/2021
D95385,earnings,100,50,4/29/2021
DA0A9E,executive-appointment,100,54,4/29/2021
DB06B0,acquisition-completed-acquirer,100,49,4/29/2021
DBB28E,partnership,100,61,4/29/2021
DC2F77,earnings,100,50,4/29/2021
DC5299,operating-earnings,100,50,4/29/2021
DD0099,earnings-up,100,74,4/29/2021
DD1BA1,revenue-up,100,69,4/29/2021
DD1BA1,revenue-up,100,69,4/29/2021
DD1BA1,revenue-up,100,69,4/29/2021
DD1BA1,revenue-up,100,69,4/29/2021
DE20DF,operating-earnings,100,50,4/29/2021
DE4924,dividend,100,50,4/29/2021
DE4924,earnings,100,50,4/29/2021
DEF058,earnings,100,50,4/29/2021
DF18E6,clinical-trials,100,56,4/29/2021
DF5F14,earnings,100,50,4/29/2021
DFADDB,earnings,100,50,4/29/2021
E0207A,acquisition-acquirer,100,49,4/29/2021
E0339F,earnings,100,50,4/29/2021
E0339F,earnings,100,50,4/29/2021
E0339F,earnings,100,50,4/29/2021
E0339F,earnings,100,50,4/29/2021
E07573,dividend-guidance,100,50,4/29/2021
E1BD05,revenues,100,50,4/29/2021
E1BD05,revenues,100,50,4/29/2021
E1F30A,earnings,100,50,4/29/2021
E28D9C,joint-venture,100,62,4/29/2021
E3A829,earnings,100,50,4/29/2021
E4CE73,conference-call,100,50,4/29/2021
E598FB,clinical-trials-positive,100,87,4/29/2021
E74B55,fraud-defendant,100,20,4/29/2021
E754F0,earnings,100,50,4/29/2021
E8846E,conference-organizer,100,57,4/29/2021
E8846E,conference-organizer,100,57,4/29/2021
E94704,dividend,100,50,4/29/2021
EB36DE,earnings,100,50,4/29/2021
EB5E78,earnings,100,50,4/29/2021
EB5E78,earnings,100,50,4/29/2021
EB5E78,earnings,100,50,4/29/2021
EB5E78,earnings,100,50,4/29/2021
EBD89A,earnings,100,50,4/29/2021
EC70EC,earnings,100,50,4/29/2021
ED0D7C,earnings,100,50,4/29/2021
ED0D7C,earnings,100,50,4/29/2021
ED0D7C,earnings,100,50,4/29/2021
ED0D7C,earnings,100,50,4/29/2021
ED0D7C,earnings,100,50,4/29/2021
ED0D7C,earnings,100,50,4/29/2021
ED4560,earnings,100,50,4/29/2021
EDF5CA,dividend-up,100,70,4/29/2021
EF1AD9,dividend,100,50,4/29/2021
EF1AD9,earnings,100,50,4/29/2021
EF1AD9,earnings,100,50,4/29/2021
EF1AD9,earnings,100,50,4/29/2021
EF76C8,earnings,100,50,4/29/2021
EFD406,earnings,100,50,4/29/2021
EFD406,earnings,100,50,4/29/2021
EFD406,earnings,100,50,4/29/2021
EFD406,earnings,100,50,4/29/2021
EFD406,earnings,100,50,4/29/2021
EFD406,earnings,100,50,4/29/2021
F02170,business-contract,100,69,4/29/2021
F02D0A,dividend,100,50,4/29/2021
F11638,earnings,100,50,4/29/2021
F2E253,dividend,100,50,4/29/2021
F40EE2,dividend,100,50,4/29/2021
F40EE2,dividend,100,50,4/29/2021
F48947,earnings,100,50,4/29/2021
F4CDA3,earnings,100,50,4/29/2021
F6581D,executive-appointment,100,54,4/29/2021
F6E1B5,earnings,100,50,4/29/2021
F6E248,earnings,100,50,4/29/2021
F6E248,dividend,100,50,4/29/2021
F7935D,legal-issues-defendant,100,22,4/29/2021
F7D8AE,earnings-up,100,68,4/29/2021
F7D8AE,earnings,100,50,4/29/2021
F7D8AE,earnings,100,50,4/29/2021
F7FCA4,earnings,100,50,4/29/2021
F7FCA4,earnings,100,50,4/29/2021
F7FCA4,earnings,100,50,4/29/2021
F7FCA4,earnings,100,50,4/29/2021
F80389,earnings,100,50,4/29/2021
F8084B,earnings,100,50,4/29/2021
F8084B,earnings,100,50,4/29/2021
F82D37,legal-issues-defendant,100,22,4/29/2021
FC1A6E,earnings-guidance-up,100,83,4/29/2021
FC1B7B,earnings,100,50,4/29/2021
FD4588,earnings,100,50,4/29/2021
FD4588,earnings,100,50,4/29/2021
FD4588,earnings,100,50,4/29/2021
FD4588,earnings,100,50,4/29/2021
FD4BBE,earnings,100,50,4/29/2021
FD4BBE,earnings,100,50,4/29/2021
FD4BBE,earnings,100,50,4/29/2021
FD6926,earnings,100,50,4/29/2021
FD6926,earnings,100,50,4/29/2021
FD6926,earnings,100,50,4/29/2021
FD6926,earnings,100,50,4/29/2021
FD6926,earnings,100,50,4/29/2021
FD9526,earnings,100,50,4/29/2021
FF5413,earnings-positive,100,69,4/29/2021
FF5413,earnings-positive,100,69,4/29/2021
002A99,legal-issues-defendant,100,22,4/30/2021
00326E,product-release,100,64,4/30/2021
9397,unit-acquisition-completed-acquirer,100,49,4/30/2021
0325B7,conference-call,100,50,4/30/2021
51332,earnings,100,50,4/30/2021
0BD4E8,settlement,100,56,4/30/2021
0BD970,earnings,100,50,4/30/2021
0C2A0D,note-sale,100,52,4/30/2021
0EF1AF,legal-issues-defendant,100,22,4/30/2021
0FDE97,earnings,100,50,4/30/2021
0FDE97,earnings,100,50,4/30/2021
0FDE97,earnings,100,50,4/30/2021
0FDE97,earnings,100,50,4/30/2021
0FDE97,earnings,100,50,4/30/2021
0FDE97,earnings,100,50,4/30/2021
0FDE97,earnings,100,50,4/30/2021
0FE3A6,conference-call,100,50,4/30/2021
12E454,business-contract,100,69,4/30/2021
12F98C,hirings,100,65,4/30/2021
139303,dividend-up,100,81,4/30/2021
17EDA5,executive-appointment,100,54,4/30/2021
1834C0,dividend,100,50,4/30/2021
190B91,public-offering,100,43,4/30/2021
19C105,earnings,100,50,4/30/2021
19C105,earnings,100,50,4/30/2021
19C105,earnings,100,50,4/30/2021
19C105,dividend,100,50,4/30/2021
19CAC7,dividend,100,50,4/30/2021
1AB023,conference-call,100,50,4/30/2021
1AB023,conference-call,100,50,4/30/2021
1AB023,conference-call,100,50,4/30/2021
1BC12C,business-contract,100,69,4/30/2021
1D943E,dividend,100,50,4/30/2021
1E1125,legal-issues-defendant,100,22,4/30/2021
1F43A1,earnings,100,50,4/30/2021
228D42,executive-appointment,100,54,4/30/2021
26D8ED,earnings,100,50,4/30/2021
272472,dividend,100,50,4/30/2021
27A791,earnings,100,50,4/30/2021
27A791,earnings,100,50,4/30/2021
27A791,earnings,100,50,4/30/2021
27A791,earnings,100,50,4/30/2021
2A1009,legal-issues-defendant,100,22,4/30/2021
2AE625,earnings,100,50,4/30/2021
2F24A5,acquisition-completed-acquiree,100,76,4/30/2021
2F24A5,unit-acquisition-completed-acquiree,100,67,4/30/2021
30E01D,investment-investor,100,55,4/30/2021
338544,earnings,100,50,4/30/2021
339F20,acquisition-completed-acquirer,100,49,4/30/2021
353DBB,earnings-up,100,68,4/30/2021
353DBB,earnings-up,100,68,4/30/2021
353DBB,earnings-up,100,68,4/30/2021
383ADA,earnings,100,50,4/30/2021
3B20AB,conference-participant,100,50,4/30/2021
3D6933,note-sale,100,52,4/30/2021
3ED92D,note-sale,100,52,4/30/2021
3ED92D,note-sale,100,52,4/30/2021
3FACA7,earnings,100,50,4/30/2021
422A82,earnings,100,50,4/30/2021
422A82,earnings,100,50,4/30/2021
422A82,earnings,100,50,4/30/2021
442587,earnings,100,50,4/30/2021
44ED36,credit-extension-recipient,100,69,4/30/2021
4806CE,award,100,58,4/30/2021
49914B,buybacks,100,74,4/30/2021
4B5054,earnings,100,50,4/30/2021
4C31F3,conference-call,100,50,4/30/2021
4C3FE9,earnings,100,50,4/30/2021
4D371E,executive-appointment,100,54,4/30/2021
4F0A80,earnings,100,50,4/30/2021
504FE2,dividend,100,50,4/30/2021
52B567,partnership,100,61,4/30/2021
52B567,partnership,100,61,4/30/2021
589F5A,earnings,100,50,4/30/2021
596116,conference-participant,100,50,4/30/2021
636931,earnings-up,100,68,4/30/2021
636931,earnings,100,50,4/30/2021
636931,earnings,100,50,4/30/2021
636931,earnings,100,50,4/30/2021
636931,earnings,100,50,4/30/2021
665D7D,earnings,100,50,4/30/2021
698FF9,dividend,100,50,4/30/2021
6E8349,earnings,100,50,4/30/2021
6EB9DA,earnings,100,50,4/30/2021
6EB9DA,earnings,100,50,4/30/2021
6EB9DA,earnings,100,50,4/30/2021
6F6559,dividend-up,100,81,4/30/2021
71553E,partnership,100,61,4/30/2021
719477,earnings,100,50,4/30/2021
719477,earnings,100,50,4/30/2021
719477,earnings,100,50,4/30/2021
719477,earnings,100,50,4/30/2021
7255D2,legal-issues-defendant,100,22,4/30/2021
72EF75,dividend,100,50,4/30/2021
72F0FC,dividend,100,50,4/30/2021
72F0FC,earnings-up,100,68,4/30/2021
742AAB,conference-call,100,50,4/30/2021
76BD96,dividend,100,50,4/30/2021
7732C2,orphan-drug-designation,100,76,4/30/2021
7B0BA6,dividend,100,50,4/30/2021
7B4B91,earnings,100,50,4/30/2021
83E0AC,conference-call,100,50,4/30/2021
84920B,earnings,100,50,4/30/2021
84AB66,earnings-positive,100,69,4/30/2021
86BAC7,buybacks,100,74,4/30/2021
88611B,earnings-guidance-down,100,19,4/30/2021
8FCA78,earnings-up,100,68,4/30/2021
8FCA78,earnings,100,50,4/30/2021
8FCA78,earnings,100,50,4/30/2021
8FCA78,earnings,100,50,4/30/2021
9.65E+07,conference-call,100,50,4/30/2021
968966,earnings,100,50,4/30/2021
971334,conference-call,100,50,4/30/2021
97B027,dividend,100,50,4/30/2021
990AD0,earnings,100,50,4/30/2021
990AD0,conference-organizer,100,57,4/30/2021
9934AD,earnings,100,50,4/30/2021
9ABD30,earnings,100,50,4/30/2021
9AF3DC,dividend,100,50,4/30/2021
9F5CBB,dividend,100,50,4/30/2021
A28C54,business-contract,100,69,4/30/2021
A28C54,business-contract,100,69,4/30/2021
A495F7,executive-resignation,100,44,4/30/2021
A4CD53,conference-participant,100,50,4/30/2021
A5195E,regulatory-product-approval-granted,100,81,4/30/2021
A666C8,earnings,100,50,4/30/2021
A666C8,earnings,100,50,4/30/2021
A666C8,earnings,100,50,4/30/2021
A6ABE9,dividend,100,50,4/30/2021
A6FE1C,unit-acquisition-acquirer,100,49,4/30/2021
A7F0A5,earnings,100,50,4/30/2021
A806FA,conference-call,100,50,4/30/2021
A94637,executive-resignation,100,44,4/30/2021
ACF0B4,conference-call,100,50,4/30/2021
B1B10C,earnings-up,100,68,4/30/2021
B1B10C,earnings,100,50,4/30/2021
B1B10C,earnings,100,50,4/30/2021
B1B10C,earnings,100,50,4/30/2021
B1B10C,earnings,100,50,4/30/2021
B66928,donation,100,54,4/30/2021
BA0442,earnings,100,50,4/30/2021
BFD0A7,conference-call,100,50,4/30/2021
BFEA04,conference-call,100,50,4/30/2021
C3BCD5,earnings,100,50,4/30/2021
C3BCD5,earnings,100,50,4/30/2021
C8A248,executive-appointment,100,54,4/30/2021
C9C62A,earnings,100,50,4/30/2021
CBA475,earnings,100,50,4/30/2021
CBA475,earnings,100,50,4/30/2021
CBA475,earnings,100,50,4/30/2021
CBA475,earnings,100,50,4/30/2021
CBA475,earnings,100,50,4/30/2021
CBCC6A,earnings,100,50,4/30/2021
CBCC6A,earnings,100,50,4/30/2021
CF351E,earnings,100,50,4/30/2021
CF351E,earnings,100,50,4/30/2021
D0909F,ownership-decrease-owner,100,46,4/30/2021
D11C1C,conference-call,100,50,4/30/2021
D3FD6D,revenue-up,100,69,4/30/2021
D3FD6D,earnings,100,50,4/30/2021
D3FD6D,earnings,100,50,4/30/2021
D3FD6D,earnings,100,50,4/30/2021
D54E62,earnings,100,50,4/30/2021
D54E62,earnings,100,50,4/30/2021
D54E62,earnings,100,50,4/30/2021
D54E62,earnings,100,50,4/30/2021
D5938F,executive-resignation,100,44,4/30/2021
D6144F,conference-call,100,50,4/30/2021
D697DE,earnings,100,50,4/30/2021
D854F3,earnings,100,50,4/30/2021
D854F3,earnings,100,50,4/30/2021
D854F3,earnings,100,50,4/30/2021
D854F3,earnings,100,50,4/30/2021
D88EF3,earnings,100,50,4/30/2021
D88EF3,earnings,100,50,4/30/2021
D88EF3,earnings,100,50,4/30/2021
D88EF3,earnings,100,50,4/30/2021
D88EF3,earnings,100,50,4/30/2021
DA0A9E,earnings,100,50,4/30/2021
DBCA3F,partnership,100,61,4/30/2021
E06265,conference-call,100,50,4/30/2021
E0E4B7,earnings,100,50,4/30/2021
E20392,conference-call,100,50,4/30/2021
E48E44,operating-earnings,100,50,4/30/2021
E6A53A,unit-acquisition-acquirer,100,49,4/30/2021
E6A53A,unit-acquisition-acquirer,100,49,4/30/2021
E70531,earnings,100,50,4/30/2021
E70531,earnings,100,50,4/30/2021
E70531,earnings,100,50,4/30/2021
E70531,earnings,100,50,4/30/2021
E70531,earnings,100,50,4/30/2021
E70531,earnings,100,50,4/30/2021
E74B55,legal-issues-defendant,100,22,4/30/2021
E74B55,legal-issues-defendant,100,22,4/30/2021
E866D2,market-entry,100,57,4/30/2021
E8846E,conference-organizer,100,57,4/30/2021
E8846E,conference-organizer,100,57,4/30/2021
E8846E,conference-organizer,100,57,4/30/2021
E8846E,conference-organizer,100,57,4/30/2021
E94704,conference-participant,100,50,4/30/2021
EB6965,earnings,100,50,4/30/2021
EB6965,earnings,100,50,4/30/2021
EB6965,earnings,100,50,4/30/2021
EB6965,earnings,100,50,4/30/2021
EB6965,earnings,100,50,4/30/2021
EE6F1C,earnings-up,100,68,4/30/2021
EE6F1C,earnings-up,100,68,4/30/2021
EEBCEF,dividend,100,50,4/30/2021
F1529C,earnings,100,50,4/30/2021
F1529C,earnings,100,50,4/30/2021
F1EB39,conference-participant,100,50,4/30/2021
F31B13,earnings,100,50,4/30/2021
F5C78B,dividend,100,50,4/30/2021
F6DE54,earnings,100,50,4/30/2021
F793FA,public-offering,100,43,4/30/2021
FD0CA4,conference-participant,100,50,4/30/2021
FF4343,dividend,100,50,4/30/2021
FF4BA4,earnings,100,50,4/30/2021
FF4BA4,earnings,100,50,4/30/2021
FF4BA4,earnings,100,50,4/30/2021
FF4BA4,earnings,100,50,4/30/2021
FF4BA4,earnings,100,50,4/30/2021
FF6644,earnings,100,50,4/30/2021
FF6644,earnings,100,50,4/30/2021
FF6644,trading-listing,100,61,4/30/2021
FF6644,trading-listing,100,61,4/30/2021
FF6644,trading-listing,100,61,4/30/2021
002A99,legal-issues-defendant,100,22,5/1/2021
159AE4,legal-issues-defendant,100,22,5/1/2021
18D9FA,legal-issues-defendant,100,22,5/1/2021
1A9DE1,earnings,100,50,5/1/2021
2A1009,legal-issues-defendant,100,22,5/1/2021
2AA6A8,clinical-trials,100,56,5/1/2021
32CB22,legal-issues-defendant,100,22,5/1/2021
3CBA2A,partnership,100,61,5/1/2021
7AF5B8,clinical-trials-positive,100,87,5/1/2021
AB7726,legal-issues-defendant,100,22,5/1/2021
B96DF5,legal-issues-defendant,100,22,5/1/2021
C5D2AE,legal-issues-defendant,100,22,5/1/2021
FCA54E,partnership,100,61,5/1/2021
1E1125,legal-issues-defendant,100,22,5/2/2021
810FAD,partnership,100,61,5/2/2021
E74B55,legal-issues-defendant,100,22,5/2/2021
002A99,earnings,100,50,5/3/2021
002A99,legal-issues-defendant,100,22,5/3/2021
00326E,executive-appointment,100,54,5/3/2021
00326E,executive-appointment,100,54,5/3/2021
003B70,operating-earnings,100,50,5/3/2021
02870F,earnings,100,50,5/3/2021
02870F,earnings,100,50,5/3/2021
02870F,earnings,100,50,5/3/2021
02870F,earnings,100,50,5/3/2021
033B58,earnings,100,50,5/3/2021
0490C6,executive-appointment,100,54,5/3/2021
61366,partnership,100,61,5/3/2021
61366,partnership,100,61,5/3/2021
61366,partnership,100,61,5/3/2021
09DE1F,earnings,100,50,5/3/2021
0A6824,dividend,100,50,5/3/2021
0A7650,earnings-up,100,68,5/3/2021
0BD4E8,business-contract,100,69,5/3/2021
0BF528,earnings,100,50,5/3/2021
0BF528,acquisition-completed-acquirer,100,49,5/3/2021
0C4131,acquisition-acquirer,100,49,5/3/2021
0C6293,conference-call,100,50,5/3/2021
0DBB81,earnings,100,50,5/3/2021
0DBB81,earnings,100,50,5/3/2021
0E5619,regulatory-product-approval-granted,100,81,5/3/2021
0EF1AF,legal-issues-defendant,100,22,5/3/2021
0FC848,earnings,100,50,5/3/2021
0FE3A6,earnings,100,50,5/3/2021
10100E,earnings,100,50,5/3/2021
108BD2,earnings-up,100,78,5/3/2021
12731D,conference-call,100,50,5/3/2021
12731D,conference-call,100,50,5/3/2021
1279ED,earnings,100,50,5/3/2021
1348C9,earnings,100,50,5/3/2021
14ED2B,dividend,100,50,5/3/2021
14ED2B,earnings,100,50,5/3/2021
152E1D,partnership,100,61,5/3/2021
16B882,earnings,100,50,5/3/2021
17EDA5,investment-investor,100,55,5/3/2021
1880C5,conference-call,100,50,5/3/2021
1A9DE1,executive-appointment,100,54,5/3/2021
1AF7E2,public-offering,100,43,5/3/2021
1B5FEA,conference-participant,100,50,5/3/2021
1CD708,dividend,100,50,5/3/2021
1DEBBE,acquisition-interest-acquirer,100,46,5/3/2021
1E04A5,business-contract,100,69,5/3/2021
1E1125,legal-issues-defendant,100,22,5/3/2021
1FAF22,dividend-up,100,81,5/3/2021
221AD7,buybacks,100,74,5/3/2021
241AF7,earnings,100,50,5/3/2021
25AB8E,campaign-ad-release,100,59,5/3/2021
26F31D,executive-appointment,100,54,5/3/2021
292388,earnings,100,50,5/3/2021
292388,conference-participant,100,50,5/3/2021
2.90E+62,legal-issues-defendant,100,22,5/3/2021
2A1009,legal-issues-defendant,100,22,5/3/2021
2A4131,earnings,100,50,5/3/2021
2A6DBE,earnings,100,50,5/3/2021
2C681C,clinical-trials-start,100,64,5/3/2021
2C7505,clinical-trials-positive,100,87,5/3/2021
2E0445,earnings,100,50,5/3/2021
2EB88B,product-release,100,64,5/3/2021
2F960F,credit-extension-recipient,100,69,5/3/2021
306623,earnings,100,50,5/3/2021
30AB63,earnings,100,50,5/3/2021
32F943,clinical-trials-positive,100,87,5/3/2021
33AD83,acquisition-acquiree,100,76,5/3/2021
343996,earnings-positive,100,69,5/3/2021
343996,earnings,100,50,5/3/2021
34B411,merger-completed,100,66,5/3/2021
36529A,executive-appointment,100,54,5/3/2021
37E18B,conference-call,100,50,5/3/2021
382EAE,operating-earnings,100,50,5/3/2021
382EAE,operating-earnings,100,50,5/3/2021
382EAE,operating-earnings,100,50,5/3/2021
382EAE,operating-earnings,100,50,5/3/2021
382EAE,acquisition-acquirer,100,49,5/3/2021
3AF7FD,dividend,100,50,5/3/2021
3B37F7,earnings,100,50,5/3/2021
3BA1BF,executive-appointment,100,54,5/3/2021
3BA1BF,conference-call,100,50,5/3/2021
3BB7D3,sponsorship,100,57,5/3/2021
3CCC90,executive-appointment,100,54,5/3/2021
3DCECC,executive-appointment,100,54,5/3/2021
3E39A5,acquisition-acquirer,100,49,5/3/2021
3EE65E,earnings,100,50,5/3/2021
3F1C69,earnings,100,50,5/3/2021
4017AD,earnings,100,50,5/3/2021
407878,earnings,100,50,5/3/2021
417BF9,conference-call,100,50,5/3/2021
41C528,acquisition-acquirer,100,49,5/3/2021
41EC04,regulatory-investigation,100,22,5/3/2021
4290EF,earnings,100,50,5/3/2021
435ACE,conference-participant,100,50,5/3/2021
435ACE,earnings,100,50,5/3/2021
448215,earnings,100,50,5/3/2021
44ED36,earnings,100,50,5/3/2021
44ED36,earnings,100,50,5/3/2021
44ED36,earnings,100,50,5/3/2021
44ED36,earnings,100,50,5/3/2021
44ED36,earnings,100,50,5/3/2021
44ED36,earnings,100,50,5/3/2021
450ECB,earnings,100,50,5/3/2021
45BC35,conference-participant,100,50,5/3/2021
4.60E+06,acquisition-completed-acquirer,100,49,5/3/2021
490D4B,earnings-positive,100,69,5/3/2021
494EB9,earnings,100,50,5/3/2021
499C75,earnings,100,50,5/3/2021
4A2457,conference-participant,100,50,5/3/2021
4A6F00,partnership,100,61,5/3/2021
4A6F00,partnership,100,61,5/3/2021
4AE584,earnings,100,50,5/3/2021
4C1FA1,earnings,100,50,5/3/2021
4C1FA1,earnings,100,50,5/3/2021
4C1FA1,earnings,100,50,5/3/2021
4C1FA1,earnings,100,50,5/3/2021
4C1FA1,earnings,100,50,5/3/2021
4D229C,earnings,100,50,5/3/2021
50070E,conference-organizer,100,57,5/3/2021
50070E,conference-organizer,100,57,5/3/2021
504FE2,partnership,100,61,5/3/2021
504FE2,legal-issues-defendant,100,22,5/3/2021
50702E,executive-appointment,100,54,5/3/2021
51F541,earnings,100,50,5/3/2021
5340D0,executive-appointment,100,54,5/3/2021
546A9C,business-contract,100,69,5/3/2021
546A9C,unit-acquisition-acquirer,100,49,5/3/2021
553949,executive-appointment,100,54,5/3/2021
55438C,acquisition-acquiree,100,76,5/3/2021
5546DA,conference-participant,100,50,5/3/2021
556F08,earnings,100,50,5/3/2021
58C2D4,earnings,100,50,5/3/2021
5B226B,executive-appointment,100,54,5/3/2021
5D16CF,acquisition-completed-acquirer,100,49,5/3/2021
5D41E4,earnings,100,50,5/3/2021
5EAA43,business-contract,100,69,5/3/2021
5F2FF7,business-contract,100,69,5/3/2021
5F3D91,earnings,100,50,5/3/2021
5F9CE3,partnership,100,61,5/3/2021
61A586,earnings,100,50,5/3/2021
639BD6,revenue-up,100,60,5/3/2021
639BD6,revenues,100,50,5/3/2021
639BD6,revenues,100,50,5/3/2021
67A658,acquisition-completed-acquiree,100,76,5/3/2021
67A658,acquisition-completed-acquiree,100,76,5/3/2021
6A6BDC,partnership,100,61,5/3/2021
6BDA0C,acquisition-completed-acquirer,100,49,5/3/2021
6D0CAB,earnings,100,50,5/3/2021
6D3B7B,dividend,100,50,5/3/2021
6D3F35,award,100,58,5/3/2021
6D4636,earnings,100,50,5/3/2021
6DBBBC,earnings,100,50,5/3/2021
6DBBBC,earnings,100,50,5/3/2021
6DBBBC,earnings,100,50,5/3/2021
6-Dec-05,earnings,100,50,5/3/2021
7032D0,executive-appointment,100,54,5/3/2021
704B78,earnings,100,50,5/3/2021
70B3D6,public-offering,100,43,5/3/2021
70CA28,revenue-up,100,69,5/3/2021
70CA28,earnings,100,50,5/3/2021
70CA28,earnings,100,50,5/3/2021
719477,conference-participant,100,50,5/3/2021
726DDF,credit-extension-recipient,100,69,5/3/2021
73A71F,earnings-up,100,68,5/3/2021
73F7F9,executive-appointment,100,54,5/3/2021
742AAB,business-contract,100,69,5/3/2021
7448A3,conference-participant,100,50,5/3/2021
762B8D,legal-issues-defendant,100,22,5/3/2021
787D14,conference-call,100,50,5/3/2021
790C34,earnings,100,50,5/3/2021
790D0D,earnings,100,50,5/3/2021
797C20,earnings,100,50,5/3/2021
7A3633,partnership,100,61,5/3/2021
7AF5B8,earnings,100,50,5/3/2021
7C790D,earnings,100,50,5/3/2021
7CD98F,earnings,100,50,5/3/2021
7D35D8,earnings,100,50,5/3/2021
7F3669,earnings,100,50,5/3/2021
7FEEE1,name-change,100,49,5/3/2021
80C400,conference-call,100,50,5/3/2021
82C202,earnings,100,50,5/3/2021
83066C,earnings,100,50,5/3/2021
83066C,earnings,100,50,5/3/2021
860AB6,earnings,100,50,5/3/2021
86F123,earnings,100,50,5/3/2021
87486A,dividend,100,50,5/3/2021
8802B4,earnings,100,50,5/3/2021
880C0C,earnings,100,50,5/3/2021
88193E,conference-participant,100,50,5/3/2021
8A8E41,unit-acquisition-acquiree,100,76,5/3/2021
8AC740,earnings,100,50,5/3/2021
8B1F37,executive-appointment,100,54,5/3/2021
8B3B0E,conference-participant,100,50,5/3/2021
8BFE9A,conference-call,100,50,5/3/2021
8E10BF,conference-call,100,50,5/3/2021
8FE7A5,earnings,100,50,5/3/2021
902255,dividend,100,50,5/3/2021
903AB4,earnings,100,50,5/3/2021
915E7B,earnings,100,50,5/3/2021
931AE7,clinical-trials-complete,100,56,5/3/2021
93965C,earnings,100,50,5/3/2021
93965C,earnings,100,50,5/3/2021
9507FF,conference-participant,100,50,5/3/2021
957A07,earnings,100,50,5/3/2021
95DC1F,partnership,100,61,5/3/2021
968966,dividend,100,50,5/3/2021
968B00,earnings-positive,100,69,5/3/2021
968B00,earnings-positive,100,69,5/3/2021
979451,earnings,100,50,5/3/2021
97FE80,partnership,100,61,5/3/2021
98CEBB,earnings,100,50,5/3/2021
98D33E,earnings,100,50,5/3/2021
990AD0,conference-organizer,100,57,5/3/2021
990AD0,conference-organizer,100,57,5/3/2021
990AD0,conference-organizer,100,57,5/3/2021
99B61C,product-release,100,64,5/3/2021
9C5BA5,earnings,100,50,5/3/2021
9CA432,earnings,100,50,5/3/2021
9CE4C7,executive-appointment,100,54,5/3/2021
9D307D,earnings,100,50,5/3/2021
9D4EC7,earnings,100,50,5/3/2021
9D4EC7,earnings,100,50,5/3/2021
9D4EC7,earnings,100,50,5/3/2021
9E575E,earnings,100,50,5/3/2021
9F18FA,earnings,100,50,5/3/2021
9F18FA,earnings,100,50,5/3/2021
9F62D1,dividend,100,50,5/3/2021
9F6B1A,unit-acquisition-acquirer,100,49,5/3/2021
A4CD53,index-listing,100,76,5/3/2021
A6213D,ownership-increase-owner,100,56,5/3/2021
A6828A,product-delayed,100,36,5/3/2021
AA3AB8,operating-earnings,100,50,5/3/2021
AA847A,executive-appointment,100,54,5/3/2021
AED6CF,earnings,100,50,5/3/2021
B01111,earnings,100,50,5/3/2021
B01215,conference-call,100,50,5/3/2021
B8F71F,executive-appointment,100,54,5/3/2021
BB58FF,earnings,100,50,5/3/2021
BBBB41,conference-participant,100,50,5/3/2021
BBC05B,operating-earnings,100,50,5/3/2021
BC4876,earnings,100,50,5/3/2021
BDF2BD,conference-call,100,50,5/3/2021
BF5959,revenues,100,50,5/3/2021
C01737,earnings,100,50,5/3/2021
C01737,earnings,100,50,5/3/2021
C07E05,partnership,100,61,5/3/2021
C0F70B,earnings,100,50,5/3/2021
C11C46,earnings,100,50,5/3/2021
C22DC2,earnings,100,50,5/3/2021
C2609A,business-contract,100,69,5/3/2021
C2DD02,conference-call,100,50,5/3/2021
C4452A,dividend,100,50,5/3/2021
C4A432,conference-call,100,50,5/3/2021
C5F463,partnership,100,61,5/3/2021
C74887,executive-appointment,100,54,5/3/2021
C83B88,partnership,100,61,5/3/2021
C8A059,executive-appointment,100,54,5/3/2021
C99CC8,executive-appointment,100,54,5/3/2021
CBFFDD,earnings,100,50,5/3/2021
CBFFDD,trading-halt,100,43,5/3/2021
CBFFDD,trading-resumed,100,58,5/3/2021
CC8F6E,unit-acquisition-acquiree,100,76,5/3/2021
CC8F6E,business-contract,100,69,5/3/2021
CDC217,earnings,100,50,5/3/2021
CDD75E,earnings,100,50,5/3/2021
D064D5,earnings,100,50,5/3/2021
D06996,earnings,100,50,5/3/2021
D1C26F,executive-appointment,100,54,5/3/2021
D296C6,earnings,100,50,5/3/2021
D29F43,dividend,100,50,5/3/2021
D33270,partnership,100,61,5/3/2021
D56D6D,earnings,100,50,5/3/2021
D57D99,earnings,100,50,5/3/2021
D60BB2,earnings,100,50,5/3/2021
D76AEF,executive-appointment,100,54,5/3/2021
D77F7E,partnership,100,61,5/3/2021
D77F7E,partnership,100,61,5/3/2021
D78CCD,conference-call,100,50,5/3/2021
D9B1C9,business-contract,100,69,5/3/2021
D9E036,earnings,100,50,5/3/2021
DB9829,earnings,100,50,5/3/2021
DB9F70,executive-appointment,100,54,5/3/2021
DD0F15,earnings,100,50,5/3/2021
DD1BA1,partnership,100,61,5/3/2021
DD9E41,earnings,100,50,5/3/2021
DD9E41,earnings,100,50,5/3/2021
DD9E41,earnings,100,50,5/3/2021
DD9E41,earnings,100,50,5/3/2021
DD9E41,earnings,100,50,5/3/2021
DF1F7A,executive-resignation,100,44,5/3/2021
DF204B,conference-participant,100,50,5/3/2021
DF46C5,dividend,100,50,5/3/2021
DF46C5,earnings-guidance-up,100,83,5/3/2021
DF46C5,earnings,100,50,5/3/2021
DF46C5,earnings,100,50,5/3/2021
DF46C5,earnings,100,50,5/3/2021
E05026,acquisition-acquirer,100,49,5/3/2021
E15736,earnings,100,50,5/3/2021
E15736,earnings,100,50,5/3/2021
E21871,earnings-up,100,68,5/3/2021
E21871,earnings-up,100,68,5/3/2021
E21871,earnings-up,100,68,5/3/2021
E21871,earnings-up,100,68,5/3/2021
E21871,earnings-up,100,68,5/3/2021
E21871,earnings-up,100,68,5/3/2021
E21871,earnings-up,100,68,5/3/2021
E22FDE,partnership,100,61,5/3/2021
E22FDE,partnership,100,61,5/3/2021
E22FDE,partnership,100,61,5/3/2021
E22FDE,partnership,100,61,5/3/2021
E22FDE,partnership,100,61,5/3/2021
E22FDE,partnership,100,61,5/3/2021
E3E68E,earnings,100,50,5/3/2021
E3E68E,earnings,100,50,5/3/2021
E3E68E,earnings,100,50,5/3/2021
E6BC2C,product-release,100,64,5/3/2021
E8846E,unit-acquisition-completed-acquiree,100,67,5/3/2021
E8846E,acquisition-completed-acquiree,100,76,5/3/2021
E8846E,conference-organizer,100,57,5/3/2021
E8846E,conference-organizer,100,57,5/3/2021
E8846E,conference-organizer,100,57,5/3/2021
E8D221,trading-halt,100,43,5/3/2021
E90C84,dividend,100,50,5/3/2021
EA62FC,earnings-up,100,68,5/3/2021
F294DD,dividend,100,50,5/3/2021
F30508,dividend,100,50,5/3/2021
F32F88,dividend,100,50,5/3/2021
F44EA2,earnings,100,50,5/3/2021
F47871,executive-appointment,100,54,5/3/2021
F47871,earnings,100,50,5/3/2021
F4CDA3,unit-acquisition-acquirer,100,49,5/3/2021
F6E1B5,conference-participant,100,50,5/3/2021
F6FF0D,earnings,100,50,5/3/2021
F6FF0D,earnings,100,50,5/3/2021
F6FF0D,earnings,100,50,5/3/2021
F702CA,product-price-raise,100,57,5/3/2021
F85CC0,partnership,100,61,5/3/2021
F85CC0,partnership,100,61,5/3/2021
F85CC0,partnership,100,61,5/3/2021
F85CC0,partnership,100,61,5/3/2021
F85CC0,partnership,100,61,5/3/2021
F85CC0,partnership,100,61,5/3/2021
FC4550,dividend,100,50,5/3/2021
FD1312,earnings,100,50,5/3/2021
FD4588,business-contract,100,69,5/3/2021
FD6926,dividend,100,50,5/3/2021
FF227B,earnings,100,50,5/3/2021
00067A,conference-participant,100,50,5/4/2021
002A99,legal-issues-defendant,100,22,5/4/2021
00326E,earnings,100,50,5/4/2021
00326E,business-contract,100,69,5/4/2021
13528,dividend,100,50,5/4/2021
01B8D6,earnings,100,50,5/4/2021
02ACBD,conference-call,100,50,5/4/2021
03B431,earnings,100,50,5/4/2021
48590,earnings,100,50,5/4/2021
054B55,dividend,100,50,5/4/2021
054B55,dividend,100,50,5/4/2021
070B45,earnings,100,50,5/4/2021
07C69F,earnings,100,50,5/4/2021
07C907,executive-appointment,100,54,5/4/2021
07C907,dividend,100,50,5/4/2021
08A40F,legal-issues-defendant,100,22,5/4/2021
98977,legal-issues-defendant,100,22,5/4/2021
0A77DB,earnings,100,50,5/4/2021
0AD2E3,earnings-up,100,68,5/4/2021
0B400D,earnings,100,50,5/4/2021
0B400D,earnings,100,50,5/4/2021
0B400D,earnings,100,50,5/4/2021
0CADBC,earnings,100,50,5/4/2021
0CCCB7,earnings,100,50,5/4/2021
0E439E,dividend,100,50,5/4/2021
0E499E,earnings,100,50,5/4/2021
0E5223,earnings,100,50,5/4/2021
0E64D4,executive-appointment,100,54,5/4/2021
1065BC,dividend-up,100,62,5/4/2021
1065BC,earnings,100,50,5/4/2021
108A2B,operating-earnings,100,50,5/4/2021
1272B3,earnings,100,50,5/4/2021
131443,earnings,100,50,5/4/2021
131443,earnings,100,50,5/4/2021
131443,earnings,100,50,5/4/2021
131443,earnings,100,50,5/4/2021
131443,earnings,100,50,5/4/2021
13A782,earnings,100,50,5/4/2021
14833D,earnings-positive,100,69,5/4/2021
14BA06,operating-earnings,100,50,5/4/2021
157CC1,earnings,100,50,5/4/2021
157D9F,earnings,100,50,5/4/2021
157D9F,earnings,100,50,5/4/2021
157D9F,earnings,100,50,5/4/2021
157D9F,earnings,100,50,5/4/2021
15A388,award,100,58,5/4/2021
15A388,government-contract,100,69,5/4/2021
16C544,earnings,100,50,5/4/2021
16F4D8,conference-participant,100,50,5/4/2021
1834C0,earnings,100,50,5/4/2021
1866B2,dividend,100,50,5/4/2021
1A2D9F,merger-regulatory-approval,100,81,5/4/2021
1A5D5D,earnings,100,50,5/4/2021
1A5D5D,earnings,100,50,5/4/2021
1A5D5D,earnings,100,50,5/4/2021
1A5D5D,earnings,100,50,5/4/2021
1A5D5D,earnings,100,50,5/4/2021
1A5D5D,earnings,100,50,5/4/2021
1AF7E2,public-offering,100,43,5/4/2021
1B16C1,earnings,100,50,5/4/2021
1CDD1C,earnings,100,50,5/4/2021
1D9E55,earnings,100,50,5/4/2021
1D9E55,earnings,100,50,5/4/2021
1D9E55,business-contract,100,69,5/4/2021
1E9A6D,award,100,58,5/4/2021
1F9258,earnings,100,50,5/4/2021
1FAF22,conference-participant,100,50,5/4/2021
227D48,dividend,100,50,5/4/2021
249674,earnings,100,50,5/4/2021
24C48B,earnings,100,50,5/4/2021
253604,conference-participant,100,50,5/4/2021
2571FA,earnings,100,50,5/4/2021
2571FA,earnings,100,50,5/4/2021
2571FA,earnings,100,50,5/4/2021
2571FA,earnings,100,50,5/4/2021
267718,earnings-up,100,68,5/4/2021
267718,earnings-up,100,68,5/4/2021
267718,earnings-up,100,68,5/4/2021
267718,earnings-up,100,68,5/4/2021
267718,earnings-up,100,68,5/4/2021
267718,earnings-up,100,68,5/4/2021
267718,earnings-up,100,68,5/4/2021
267718,earnings-up,100,68,5/4/2021
28B730,earnings,100,50,5/4/2021
291651,executive-appointment,100,54,5/4/2021
2920D5,acquisition-completed-acquirer,100,49,5/4/2021
2920D5,earnings,100,50,5/4/2021
295F9F,earnings,100,50,5/4/2021
2AA6A8,clinical-trials,100,56,5/4/2021
2B8179,earnings,100,50,5/4/2021
2CC71C,earnings,100,50,5/4/2021
2D2D43,earnings,100,50,5/4/2021
2DDB22,earnings,100,50,5/4/2021
2E0496,earnings,100,50,5/4/2021
2E0496,earnings,100,50,5/4/2021
2E36AD,product-release,100,64,5/4/2021
2EB04E,earnings,100,50,5/4/2021
2EB04E,earnings,100,50,5/4/2021
2EB04E,earnings,100,50,5/4/2021
2EB04E,earnings,100,50,5/4/2021
2F6782,dividend,100,50,5/4/2021
2F9304,earnings,100,50,5/4/2021
309922,buybacks,100,74,5/4/2021
30A565,earnings,100,50,5/4/2021
315EB0,note-sale,100,52,5/4/2021
31803E,earnings,100,50,5/4/2021
31DB20,earnings,100,50,5/4/2021
32DCB3,earnings,100,50,5/4/2021
32F943,conference-participant,100,50,5/4/2021
3390DE,earnings,100,50,5/4/2021
339F20,acquisition-acquirer,100,49,5/4/2021
34A959,earnings,100,50,5/4/2021
34B97A,partnership,100,61,5/4/2021
35F4B5,earnings-guidance-up,100,83,5/4/2021
35F4B5,earnings,100,50,5/4/2021
367E1C,conference-participant,100,50,5/4/2021
37020C,dividend,100,50,5/4/2021
3.73E+87,earnings,100,50,5/4/2021
3798B9,award,100,58,5/4/2021
38C46F,dividend,100,50,5/4/2021
39692D,unit-acquisition-acquiree,100,76,5/4/2021
39692D,partnership,100,61,5/4/2021
39692D,partnership,100,61,5/4/2021
39692D,partnership,100,61,5/4/2021
39692D,partnership,100,61,5/4/2021
3B2311,partnership,100,61,5/4/2021
3BE00F,earnings,100,50,5/4/2021
3BE00F,earnings,100,50,5/4/2021
3BE00F,earnings,100,50,5/4/2021
3BE00F,earnings,100,50,5/4/2021
3D6933,pretax-earnings-negative,100,33,5/4/2021
3D7971,earnings,100,50,5/4/2021
3D7971,earnings,100,50,5/4/2021
3D7971,earnings,100,50,5/4/2021
3D7971,earnings,100,50,5/4/2021
3D7971,earnings,100,50,5/4/2021
3D7971,earnings,100,50,5/4/2021
3DC887,earnings,100,50,5/4/2021
3DCECC,conference-participant,100,50,5/4/2021
4.03E+05,executive-appointment,100,54,5/4/2021
416C55,conference-participant,100,50,5/4/2021
41EC04,earnings,100,50,5/4/2021
41EC04,earnings,100,50,5/4/2021
41EC04,earnings,100,50,5/4/2021
41EC04,earnings,100,50,5/4/2021
43A060,business-contract,100,69,5/4/2021
43A74A,partnership,100,61,5/4/2021
43E8F5,earnings,100,50,5/4/2021
44A4FC,earnings,100,50,5/4/2021
458D2C,earnings,100,50,5/4/2021
45BC35,earnings,100,50,5/4/2021
467F2C,earnings,100,50,5/4/2021
46A16E,earnings,100,50,5/4/2021
49A344,earnings,100,50,5/4/2021
49A344,earnings,100,50,5/4/2021
49A344,earnings,100,50,5/4/2021
4A6F00,product-release,100,64,5/4/2021
4AC91D,product-release,100,64,5/4/2021
4BEB48,earnings,100,50,5/4/2021
4BEB48,earnings,100,50,5/4/2021
4BEB48,earnings,100,50,5/4/2021
4BEB48,earnings,100,50,5/4/2021
4BEB48,earnings,100,50,5/4/2021
4BF3D6,conference-participant,100,50,5/4/2021
4C37C5,unit-acquisition-acquirer,100,49,5/4/2021
4C5CC9,demand-increase,100,83,5/4/2021
4C5CC9,demand-increase,100,83,5/4/2021
4C5CC9,demand-increase,100,83,5/4/2021
4C92B9,earnings-guidance-up,100,83,5/4/2021
4D371E,executive-appointment,100,54,5/4/2021
4D72C8,earnings,100,50,5/4/2021
4D72C8,earnings,100,50,5/4/2021
4E3D15,operating-earnings,100,50,5/4/2021
4F783B,earnings,100,50,5/4/2021
4F783B,earnings,100,50,5/4/2021
4F783B,earnings,100,50,5/4/2021
4F783B,earnings,100,50,5/4/2021
4F783B,earnings,100,50,5/4/2021
50070E,conference-organizer,100,57,5/4/2021
50070E,conference-organizer,100,57,5/4/2021
50070E,conference-organizer,100,57,5/4/2021
504FE2,earnings,100,50,5/4/2021
504FE2,executive-appointment,100,54,5/4/2021
513A86,earnings,100,50,5/4/2021
51B442,earnings,100,50,5/4/2021
5340D0,earnings,100,50,5/4/2021
54A713,earnings,100,50,5/4/2021
54B889,earnings,100,50,5/4/2021
54B889,supply-increase,100,74,5/4/2021
550D01,earnings-up,100,68,5/4/2021
550D01,earnings,100,50,5/4/2021
550D01,earnings,100,50,5/4/2021
55C9B5,conference-participant,100,50,5/4/2021
56277A,earnings,100,50,5/4/2021
56B7C1,earnings,100,50,5/4/2021
56FB7C,earnings,100,50,5/4/2021
577033,earnings,100,50,5/4/2021
57B174,earnings,100,50,5/4/2021
57B174,earnings,100,50,5/4/2021
57B174,earnings,100,50,5/4/2021
57B174,earnings,100,50,5/4/2021
57DDB9,earnings-guidance-up,100,83,5/4/2021
57DDB9,earnings-guidance-up,100,83,5/4/2021
57DDB9,earnings-guidance-up,100,83,5/4/2021
57DDB9,earnings-guidance-up,100,83,5/4/2021
57DDB9,earnings-guidance-up,100,83,5/4/2021
57EF50,earnings,100,50,5/4/2021
57EF50,earnings,100,50,5/4/2021
57EF50,earnings,100,50,5/4/2021
586FFD,revenues,100,50,5/4/2021
586FFD,revenues,100,50,5/4/2021
587EDF,earnings,100,50,5/4/2021
587EDF,executive-appointment,100,54,5/4/2021
58C2D4,note-sale,100,52,5/4/2021
596116,earnings,100,50,5/4/2021
59A832,earnings,100,50,5/4/2021
5B3415,earnings,100,50,5/4/2021
5B3415,earnings,100,50,5/4/2021
5B6C11,earnings,100,50,5/4/2021
5CCDAD,earnings,100,50,5/4/2021
5DAF89,revenue-up,100,69,5/4/2021
5DE5A5,dividend-up,100,76,5/4/2021
5E1DF3,earnings-up,100,68,5/4/2021
5EAA43,conference-call,100,50,5/4/2021
5F3E74,conference-participant,100,50,5/4/2021
5FDBD0,operating-earnings,100,50,5/4/2021
6166D1,fundraising,100,64,5/4/2021
619882,earnings,100,50,5/4/2021
622DBE,earnings,100,50,5/4/2021
6251A3,earnings,100,50,5/4/2021
62F41C,earnings,100,50,5/4/2021
62F41C,dividend,100,50,5/4/2021
62F41C,executive-resignation,100,44,5/4/2021
62F41C,executive-resignation,100,44,5/4/2021
64FF65,earnings,100,50,5/4/2021
651C85,earnings,100,50,5/4/2021
665440,product-release,100,64,5/4/2021
67B923,conference-call,100,50,5/4/2021
6844D2,debt-reduction,100,70,5/4/2021
68E6E9,acquisition-acquirer,100,49,5/4/2021
6925EB,earnings,100,50,5/4/2021
69CE71,earnings-up,100,68,5/4/2021
69CE71,earnings-up,100,68,5/4/2021
69CE71,earnings-up,100,68,5/4/2021
69CE71,earnings-up,100,68,5/4/2021
69CE71,earnings-up,100,68,5/4/2021
69CE71,earnings-up,100,68,5/4/2021
6A01DF,conference-participant,100,50,5/4/2021
6ABCB8,earnings,100,50,5/4/2021
6B6375,earnings,100,50,5/4/2021
6BBCBA,conference-participant,100,50,5/4/2021
6BC6F9,award,100,58,5/4/2021
6BC6F9,earnings,100,50,5/4/2021
6BF593,earnings,100,50,5/4/2021
6BF593,earnings,100,50,5/4/2021
6C4D2F,reorganization-complete,100,74,5/4/2021
6CC55E,earnings,100,50,5/4/2021
6D6B40,earnings,100,50,5/4/2021
6DBBBC,partnership,100,61,5/4/2021
6E705B,fundraising,100,64,5/4/2021
7255D2,legal-issues-defendant,100,22,5/4/2021
726EEA,conference-participant,100,50,5/4/2021
72CB93,earnings,100,50,5/4/2021
732A9B,earnings,100,50,5/4/2021
7.44E+09,earnings,100,50,5/4/2021
747219,dividend,100,50,5/4/2021
748EB6,partnership,100,61,5/4/2021
75D689,regulatory-product-approval-granted,100,81,5/4/2021
76B926,earnings-guidance-up,100,83,5/4/2021
773A17,earnings,100,50,5/4/2021
7ACD98,earnings-up,100,68,5/4/2021
7ACD98,earnings,100,50,5/4/2021
7ACD98,earnings,100,50,5/4/2021
7ACFD4,executive-appointment,100,54,5/4/2021
7AD81E,earnings,100,50,5/4/2021
7B4B91,dividend,100,50,5/4/2021
7B6C88,earnings,100,50,5/4/2021
7B6C88,executive-resignation,100,44,5/4/2021
7D7716,earnings,100,50,5/4/2021
7D7716,earnings,100,50,5/4/2021
7D7716,earnings,100,50,5/4/2021
7D7716,earnings,100,50,5/4/2021
7DD584,earnings,100,50,5/4/2021
7E1D5D,acquisition-completed-acquirer,100,49,5/4/2021
7F3669,executive-appointment,100,54,5/4/2021
7F9984,earnings,100,50,5/4/2021
7F9BE2,dividend,100,50,5/4/2021
8.10E+205,partnership,100,61,5/4/2021
8303CD,earnings,100,50,5/4/2021
845655,earnings,100,50,5/4/2021
845655,earnings,100,50,5/4/2021
845655,earnings,100,50,5/4/2021
845655,earnings,100,50,5/4/2021
845655,earnings,100,50,5/4/2021
845655,earnings,100,50,5/4/2021
848C0B,earnings,100,50,5/4/2021
85CDC9,acquisition-acquirer,100,49,5/4/2021
85DA04,earnings,100,50,5/4/2021
85DA04,earnings,100,50,5/4/2021
85DA04,earnings,100,50,5/4/2021
85DA04,earnings,100,50,5/4/2021
85DA04,earnings,100,50,5/4/2021
85DE00,partnership,100,61,5/4/2021
85DE00,partnership,100,61,5/4/2021
893904,earnings,100,50,5/4/2021
89FBB1,dividend,100,50,5/4/2021
8D5145,dividend,100,50,5/4/2021
8D9993,public-offering,100,43,5/4/2021
8DAAB9,dividend-up,100,81,5/4/2021
8DE56F,earnings,100,50,5/4/2021
8DE56F,earnings,100,50,5/4/2021
8E82A6,dividend,100,50,5/4/2021
8E9CD8,earnings,100,50,5/4/2021
8EEA28,earnings,100,50,5/4/2021
9004C4,executive-appointment,100,54,5/4/2021
9087B9,earnings,100,50,5/4/2021
918D6D,conference-call,100,50,5/4/2021
9196A2,investment-investor,100,55,5/4/2021
92D757,legal-issues-defendant,100,22,5/4/2021
9470CC,executive-appointment,100,54,5/4/2021
9470CC,earnings,100,50,5/4/2021
9507FF,earnings,100,50,5/4/2021
9548BB,dividend,100,50,5/4/2021
958938,earnings,100,50,5/4/2021
96A2D3,earnings,100,50,5/4/2021
96F126,executive-appointment,100,54,5/4/2021
972356,business-contract,100,69,5/4/2021
977A1E,earnings,100,50,5/4/2021
97FE80,conference-call,100,50,5/4/2021
980C14,earnings,100,50,5/4/2021
9.86E+03,earnings,100,50,5/4/2021
99028D,earnings-up,100,68,5/4/2021
99028D,earnings,100,50,5/4/2021
99028D,earnings,100,50,5/4/2021
99028D,earnings,100,50,5/4/2021
99028D,earnings,100,50,5/4/2021
990AD0,conference-organizer,100,57,5/4/2021
990AD0,conference-organizer,100,57,5/4/2021
990AD0,conference-organizer,100,57,5/4/2021
990AD0,conference-organizer,100,57,5/4/2021
990AD0,conference-organizer,100,57,5/4/2021
990AD0,conference-organizer,100,57,5/4/2021
990AD0,conference-organizer,100,57,5/4/2021
990AD0,conference-organizer,100,57,5/4/2021
994468,dividend,100,50,5/4/2021
99ACAD,earnings,100,50,5/4/2021
99ACAD,earnings,100,50,5/4/2021
99ACAD,earnings,100,50,5/4/2021
99ACAD,earnings,100,50,5/4/2021
99ACAD,earnings,100,50,5/4/2021
99B61C,earnings,100,50,5/4/2021
99DC8D,earnings,100,50,5/4/2021
99DC8D,dividend,100,50,5/4/2021
9A29F4,earnings-up,100,68,5/4/2021
9A29F4,earnings,100,50,5/4/2021
9A29F4,earnings,100,50,5/4/2021
9A29F4,earnings,100,50,5/4/2021
9C3D3C,earnings,100,50,5/4/2021
9C5174,conference-participant,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9D2790,earnings,100,50,5/4/2021
9F5997,earnings,100,50,5/4/2021
9F5997,conference-participant,100,50,5/4/2021
9FB4B7,earnings,100,50,5/4/2021
A0F146,earnings,100,50,5/4/2021
A16DEA,earnings,100,50,5/4/2021
A16DEA,earnings,100,50,5/4/2021
A16DEA,earnings,100,50,5/4/2021
A16DEA,earnings,100,50,5/4/2021
A16DEA,earnings,100,50,5/4/2021
A16DEA,earnings,100,50,5/4/2021
A16DEA,earnings,100,50,5/4/2021
A23747,earnings,100,50,5/4/2021
A23747,executive-appointment,100,54,5/4/2021
A26C26,joint-venture,100,62,5/4/2021
A28675,earnings,100,50,5/4/2021
A29DBD,earnings,100,50,5/4/2021
A41450,earnings,100,50,5/4/2021
A4386C,earnings,100,50,5/4/2021
A4386C,earnings,100,50,5/4/2021
A4386C,earnings,100,50,5/4/2021
A4386C,earnings,100,50,5/4/2021
A4B899,earnings,100,50,5/4/2021
A4CD53,earnings,100,50,5/4/2021
A4CD53,earnings,100,50,5/4/2021
A4CD53,earnings,100,50,5/4/2021
A52B6B,earnings,100,50,5/4/2021
A5628C,legal-issues-defendant,100,22,5/4/2021
A60354,earnings-up,100,68,5/4/2021
A60354,earnings,100,50,5/4/2021
A60354,earnings,100,50,5/4/2021
A60354,earnings,100,50,5/4/2021
A7102F,earnings-up,100,68,5/4/2021
A7102F,earnings,100,50,5/4/2021
A7102F,earnings,100,50,5/4/2021
A7102F,earnings,100,50,5/4/2021
A7102F,earnings,100,50,5/4/2021
A74F6F,revenues,100,50,5/4/2021
A74F6F,revenues,100,50,5/4/2021
A790A5,dividend,100,50,5/4/2021
A79F7D,earnings,100,50,5/4/2021
A868C9,conference-participant,100,50,5/4/2021
A87CD6,dividend,100,50,5/4/2021
A8AC4C,earnings-up,100,68,5/4/2021
A8B137,executive-appointment,100,54,5/4/2021
A94718,business-contract,100,69,5/4/2021
A94718,earnings,100,50,5/4/2021
AC3584,revenue-up,100,69,5/4/2021
AC3584,revenue-up,100,69,5/4/2021
AC3584,revenue-up,100,69,5/4/2021
AC7AAE,earnings,100,50,5/4/2021
ACDCFA,earnings,100,50,5/4/2021
ACDF88,conference-call,100,50,5/4/2021
ADD9DC,earnings,100,50,5/4/2021
AE3113,earnings,100,50,5/4/2021
AE3113,campaign-ad-release,100,59,5/4/2021
AEBB80,earnings,100,50,5/4/2021
AEFC90,earnings,100,50,5/4/2021
B04426,earnings,100,50,5/4/2021
B076A1,earnings,100,50,5/4/2021
B076A1,earnings,100,50,5/4/2021
B076A1,earnings,100,50,5/4/2021
B0FE08,partnership,100,61,5/4/2021
B0FE08,executive-appointment,100,54,5/4/2021
B13B68,earnings,100,50,5/4/2021
B33E77,conference-participant,100,50,5/4/2021
B446B8,earnings,100,50,5/4/2021
B446B8,earnings,100,50,5/4/2021
B446B8,earnings,100,50,5/4/2021
B446B8,earnings,100,50,5/4/2021
B48FC9,revenues,100,50,5/4/2021
B48FC9,revenues,100,50,5/4/2021
B48FC9,revenues,100,50,5/4/2021
B53C12,earnings,100,50,5/4/2021
B5767B,earnings,100,50,5/4/2021
B5767B,earnings,100,50,5/4/2021
B5767B,earnings,100,50,5/4/2021
B5767B,earnings,100,50,5/4/2021
B5767B,earnings,100,50,5/4/2021
B5767B,earnings,100,50,5/4/2021
B7EB38,earnings,100,50,5/4/2021
B7EB38,earnings,100,50,5/4/2021
B8A51F,earnings,100,50,5/4/2021
B934BF,earnings,100,50,5/4/2021
B9764A,earnings-guidance-up,100,83,5/4/2021
B98EFA,operating-earnings,100,50,5/4/2021
BB0587,acquisition-completed-acquiree,100,76,5/4/2021
BB0587,earnings-up,100,68,5/4/2021
BB127B,partnership,100,61,5/4/2021
BB5271,earnings,100,50,5/4/2021
BCE9DA,earnings,100,50,5/4/2021
BCE9DA,earnings,100,50,5/4/2021
BCE9DA,earnings,100,50,5/4/2021
BCE9DA,earnings,100,50,5/4/2021
BCE9DA,earnings,100,50,5/4/2021
BDEC1E,conference-call,100,50,5/4/2021
BE14CF,joint-venture,100,62,5/4/2021
BE7BA4,partnership,100,61,5/4/2021
C062D4,earnings,100,50,5/4/2021
C062D4,earnings,100,50,5/4/2021
C062D4,earnings,100,50,5/4/2021
C062D4,earnings,100,50,5/4/2021
C062D4,earnings,100,50,5/4/2021
C062D4,earnings,100,50,5/4/2021
C2E120,earnings,100,50,5/4/2021
C2E426,earnings,100,50,5/4/2021
C3BAE7,conference-participant,100,50,5/4/2021
C3BCD5,dividend,100,50,5/4/2021
C407A0,earnings,100,50,5/4/2021
C45CE7,earnings-up,100,68,5/4/2021
C45CE7,earnings,100,50,5/4/2021
C564E4,earnings,100,50,5/4/2021
C7AE14,earnings,100,50,5/4/2021
C8257F,dividend,100,50,5/4/2021
C83B88,conference-participant,100,50,5/4/2021
C8923A,earnings,100,50,5/4/2021
C8A248,earnings,100,50,5/4/2021
C8A248,earnings,100,50,5/4/2021
C8A248,earnings,100,50,5/4/2021
C8A248,earnings,100,50,5/4/2021
C8A248,earnings,100,50,5/4/2021
C98CDB,earnings,100,50,5/4/2021
CA3CB9,earnings-up,100,68,5/4/2021
CAB222,earnings,100,50,5/4/2021
CB7AB2,earnings,100,50,5/4/2021
CC6FF5,award,100,58,5/4/2021
CCBBAD,earnings,100,50,5/4/2021
CDC817,earnings,100,50,5/4/2021
CDE118,trading-halt,100,43,5/4/2021
CDE118,trading-resumed,100,58,5/4/2021
CE5664,earnings,100,50,5/4/2021
CE5664,earnings,100,50,5/4/2021
CE5664,earnings,100,50,5/4/2021
CED4D0,earnings,100,50,5/4/2021
CFF97C,acquisition-acquirer,100,49,5/4/2021
D18AFC,earnings,100,50,5/4/2021
D2B9E5,earnings,100,50,5/4/2021
D2B9E5,earnings,100,50,5/4/2021
D2B9E5,earnings,100,50,5/4/2021
D33270,business-contract,100,69,5/4/2021
D3F64D,earnings,100,50,5/4/2021
D3F64D,earnings,100,50,5/4/2021
D3F64D,earnings,100,50,5/4/2021
D3F64D,earnings,100,50,5/4/2021
D3F64D,earnings,100,50,5/4/2021
D4C0CB,conference-participant,100,50,5/4/2021
D598E7,acquisition-acquirer,100,49,5/4/2021
D60BB2,executive-resignation,100,44,5/4/2021
D6534D,earnings,100,50,5/4/2021
D6534D,earnings,100,50,5/4/2021
D6853F,unit-acquisition-acquiree,100,76,5/4/2021
D6EAA3,product-release,100,64,5/4/2021
D70365,earnings,100,50,5/4/2021
D81463,earnings,100,50,5/4/2021
D81463,earnings,100,50,5/4/2021
D854DD,earnings,100,50,5/4/2021
D854F3,dividend,100,50,5/4/2021
D8DA3D,earnings,100,50,5/4/2021
D8DA3D,earnings,100,50,5/4/2021
D8DA3D,earnings,100,50,5/4/2021
D8DA3D,earnings,100,50,5/4/2021
D8DA3D,earnings,100,50,5/4/2021
D8F347,facility-open,100,65,5/4/2021
D90F43,partnership,100,61,5/4/2021
DA0CB8,earnings,100,50,5/4/2021
DB9F70,conference-participant,100,50,5/4/2021
DBCA3F,merger-regulatory-approval,100,81,5/4/2021
DC1405,earnings,100,50,5/4/2021
DC6AA0,earnings-up,100,68,5/4/2021
DD1BA1,acquisition-acquirer,100,49,5/4/2021
DD1BA1,acquisition-acquirer,100,49,5/4/2021
DD682D,earnings,100,50,5/4/2021
DE5611,conference-call,100,50,5/4/2021
DF8855,earnings,100,50,5/4/2021
DF8855,earnings,100,50,5/4/2021
DF8855,earnings,100,50,5/4/2021
DF8855,earnings,100,50,5/4/2021
DF8855,earnings,100,50,5/4/2021
E0207A,business-contract,100,69,5/4/2021
E074A0,earnings,100,50,5/4/2021
E124EB,conference-participant,100,50,5/4/2021
E12A6E,earnings,100,50,5/4/2021
E12A6E,executive-appointment,100,54,5/4/2021
E15736,earnings,100,50,5/4/2021
E41190,earnings,100,50,5/4/2021
E41190,earnings,100,50,5/4/2021
E41190,earnings,100,50,5/4/2021
E41190,earnings,100,50,5/4/2021
E41190,earnings,100,50,5/4/2021
E41190,earnings,100,50,5/4/2021
E4CE73,partnership,100,61,5/4/2021
E592F0,earnings,100,50,5/4/2021
E592F0,earnings,100,50,5/4/2021
E592F0,earnings,100,50,5/4/2021
E592F0,earnings,100,50,5/4/2021
E5D914,conference-participant,100,50,5/4/2021
E69BA5,earnings,100,50,5/4/2021
E6BC2C,conference-call,100,50,5/4/2021
E802CE,earnings,100,50,5/4/2021
E802CE,earnings,100,50,5/4/2021
E8A49A,earnings,100,50,5/4/2021
E96E0B,earnings,100,50,5/4/2021
EBC84C,conference-participant,100,50,5/4/2021
ECE814,earnings,100,50,5/4/2021
EE04F0,earnings,100,50,5/4/2021
EE04F0,earnings,100,50,5/4/2021
EE04F0,earnings,100,50,5/4/2021
EEBCEF,earnings,100,50,5/4/2021
F0027C,earnings,100,50,5/4/2021
F02170,earnings,100,50,5/4/2021
F0B335,earnings,100,50,5/4/2021
F0EEFB,earnings,100,50,5/4/2021
F0EEFB,earnings,100,50,5/4/2021
F0EEFB,earnings,100,50,5/4/2021
F0EEFB,earnings,100,50,5/4/2021
F0EEFB,earnings,100,50,5/4/2021
F0EEFB,earnings,100,50,5/4/2021
F1EB39,acquisition-completed-acquirer,100,49,5/4/2021
F32F88,earnings,100,50,5/4/2021
F42FAE,earnings-positive,100,69,5/4/2021
F42FAE,earnings,100,50,5/4/2021
F42FAE,earnings,100,50,5/4/2021
F42FAE,earnings,100,50,5/4/2021
F42FAE,earnings,100,50,5/4/2021
F46EC9,earnings,100,50,5/4/2021
F46EC9,earnings,100,50,5/4/2021
F46EC9,earnings,100,50,5/4/2021
F46EC9,earnings,100,50,5/4/2021
F46EC9,earnings,100,50,5/4/2021
F48947,executive-appointment,100,54,5/4/2021
F5349B,partnership,100,61,5/4/2021
F57F6F,earnings,100,50,5/4/2021
F5C8AB,earnings-per-share-positive,100,69,5/4/2021
F5C8AB,earnings-per-share-positive,100,69,5/4/2021
F5C8AB,earnings-per-share,100,50,5/4/2021
F5C8AB,dividend,100,50,5/4/2021
F5D499,earnings,100,50,5/4/2021
F7935D,acquisition-acquirer,100,49,5/4/2021
F7935D,acquisition-acquirer,100,49,5/4/2021
F793FA,public-offering,100,43,5/4/2021
F85CC0,earnings,100,50,5/4/2021
F85CC0,earnings,100,50,5/4/2021
F8C5D7,operating-earnings,100,50,5/4/2021
FA918D,earnings,100,50,5/4/2021
FA918D,earnings,100,50,5/4/2021
FAAFA2,earnings,100,50,5/4/2021
FB7724,earnings,100,50,5/4/2021
FC1A6E,legal-issues-defendant,100,22,5/4/2021
FDD3FC,earnings,100,50,5/4/2021
FE89E0,earnings,100,50,5/4/2021
FEC475,earnings,100,50,5/4/2021
00D6B5,dividend,100,50,5/5/2021
0325B7,earnings,100,50,5/5/2021
0358AF,revenue-up,100,69,5/5/2021
0358AF,revenue-up,100,69,5/5/2021
0358AF,revenue-up,100,69,5/5/2021
0358AF,revenue-up,100,69,5/5/2021
03CF95,earnings,100,50,5/5/2021
053EFF,earnings,100,50,5/5/2021
054E7E,earnings,100,50,5/5/2021
55018,dividend,100,50,5/5/2021
56045,conference-participant,100,50,5/5/2021
0624BE,earnings,100,50,5/5/2021
065D38,earnings,100,50,5/5/2021
065D38,buybacks,100,74,5/5/2021
06C826,conference-call,100,50,5/5/2021
06EE79,earnings,100,50,5/5/2021
07C69F,acquisition-acquirer,100,49,5/5/2021
07C69F,acquisition-acquirer,100,49,5/5/2021
07EC43,earnings,100,50,5/5/2021
07EC43,earnings,100,50,5/5/2021
07EC43,earnings,100,50,5/5/2021
095A04,earnings,100,50,5/5/2021
98977,earnings,100,50,5/5/2021
099A92,earnings,100,50,5/5/2021
0A0D9E,earnings,100,50,5/5/2021
0A0D9E,earnings,100,50,5/5/2021
0A0D9E,earnings,100,50,5/5/2021
0A0D9E,executive-appointment,100,54,5/5/2021
0B7375,fraud-defendant,100,20,5/5/2021
0CCCB7,dividend-up,100,59,5/5/2021
0CE204,earnings,100,50,5/5/2021
0CE7F6,earnings,100,50,5/5/2021
0D03C8,earnings,100,50,5/5/2021
0DBB81,conference-participant,100,50,5/5/2021
0DBB81,conference-participant,100,50,5/5/2021
0DE3D5,earnings,100,50,5/5/2021
0EF1AF,dividend,100,50,5/5/2021
0F91FC,earnings,100,50,5/5/2021
0FABBD,earnings,100,50,5/5/2021
0FABBD,earnings,100,50,5/5/2021
0FABBD,earnings,100,50,5/5/2021
0FABBD,earnings,100,50,5/5/2021
0FABBD,earnings,100,50,5/5/2021
12731D,earnings,100,50,5/5/2021
12731D,earnings,100,50,5/5/2021
12731D,earnings,100,50,5/5/2021
12731D,earnings,100,50,5/5/2021
12731D,earnings,100,50,5/5/2021
12731D,earnings,100,50,5/5/2021
12A3A3,dividend-up,100,81,5/5/2021
12DE76,partnership,100,61,5/5/2021
12DE76,conference-call,100,50,5/5/2021
12E454,product-release,100,64,5/5/2021
138DDE,earnings,100,50,5/5/2021
149301,earnings,100,50,5/5/2021
149301,dividend,100,50,5/5/2021
159AE4,legal-issues-defendant,100,22,5/5/2021
15A388,earnings,100,50,5/5/2021
15A388,earnings,100,50,5/5/2021
15A388,earnings,100,50,5/5/2021
15A388,earnings,100,50,5/5/2021
15A388,business-contract,100,69,5/5/2021
15B10D,earnings,100,50,5/5/2021
1.79E+10,revenue-up,100,86,5/5/2021
1.79E+10,revenue-up,100,69,5/5/2021
1.79E+10,revenue-up,100,69,5/5/2021
1.79E+10,revenue-up,100,69,5/5/2021
17EDA5,earnings,100,50,5/5/2021
180DA0,dividend,100,50,5/5/2021
188394,earnings-meet-expectations,100,59,5/5/2021
18D9FA,partnership,100,61,5/5/2021
1A46A1,earnings,100,50,5/5/2021
1AB808,revenue-up,100,78,5/5/2021
1AB808,earnings,100,50,5/5/2021
1AB808,earnings,100,50,5/5/2021
1B4F31,earnings-up,100,68,5/5/2021
1B637E,earnings,100,50,5/5/2021
1BC12C,earnings-up,100,68,5/5/2021
1BC12C,earnings-up,100,68,5/5/2021
1C599A,earnings,100,50,5/5/2021
1CB9D3,conference-call,100,50,5/5/2021
1D943E,earnings,100,50,5/5/2021
1DB6A6,dividend,100,50,5/5/2021
1E7785,earnings,100,50,5/5/2021
1E7785,earnings,100,50,5/5/2021
1E7785,earnings,100,50,5/5/2021
1E7785,earnings,100,50,5/5/2021
1E7785,earnings,100,50,5/5/2021
1E7785,earnings,100,50,5/5/2021
1EBF8D,regulatory-product-approval-granted,100,81,5/5/2021
1EBF8D,regulatory-product-approval-granted,100,81,5/5/2021
1EBF8D,regulatory-product-approval-granted,100,81,5/5/2021
1EBF8D,regulatory-product-approval-granted,100,81,5/5/2021
1EBF8D,regulatory-product-approval-granted,100,81,5/5/2021
1EBF8D,regulatory-product-approval-granted,100,81,5/5/2021
1F08A6,earnings,100,50,5/5/2021
1F9D90,earnings,100,50,5/5/2021
1FE7F0,earnings,100,50,5/5/2021
1FE7F0,earnings,100,50,5/5/2021
1FE7F0,earnings,100,50,5/5/2021
1FE7F0,earnings,100,50,5/5/2021
1FE7F0,earnings,100,50,5/5/2021
2003A5,earnings,100,50,5/5/2021
2082EA,earnings,100,50,5/5/2021
20D00A,executive-appointment,100,54,5/5/2021
21245F,earnings,100,50,5/5/2021
2158DF,earnings,100,50,5/5/2021
2158DF,earnings,100,50,5/5/2021
2158DF,earnings,100,50,5/5/2021
2158DF,earnings,100,50,5/5/2021
221783,executive-appointment,100,54,5/5/2021
227F04,acquisition-acquirer,100,49,5/5/2021
227F04,earnings,100,50,5/5/2021
228D42,partnership,100,61,5/5/2021
241252,conference-participant,100,50,5/5/2021
253604,executive-appointment,100,54,5/5/2021
26008A,conference-call,100,50,5/5/2021
263216,revenue-up,100,69,5/5/2021
263216,revenue-up,100,69,5/5/2021
263216,revenue-up,100,69,5/5/2021
263216,revenue-up,100,69,5/5/2021
263216,revenue-up,100,69,5/5/2021
263216,revenue-up,100,69,5/5/2021
263216,revenue-up,100,69,5/5/2021
27BFA1,dividend,100,50,5/5/2021
29CEBF,earnings,100,50,5/5/2021
29CEBF,earnings,100,50,5/5/2021
29CEBF,earnings,100,50,5/5/2021
29CEBF,earnings,100,50,5/5/2021
2A1009,conference-participant,100,50,5/5/2021
2AA6A8,executive-appointment,100,54,5/5/2021
2AA6A8,earnings,100,50,5/5/2021
2B7A40,conference-participant,100,50,5/5/2021
2B7A40,dividend,100,50,5/5/2021
2CBB58,conference-call,100,50,5/5/2021
2CF9D3,earnings,100,50,5/5/2021
2D485F,executive-appointment,100,54,5/5/2021
2D485F,earnings,100,50,5/5/2021
2D485F,earnings,100,50,5/5/2021
2D485F,earnings,100,50,5/5/2021
2E2E6E,legal-issues-defendant,100,22,5/5/2021
2E89AE,earnings,100,50,5/5/2021
2F9304,product-release,100,64,5/5/2021
2F960F,earnings,100,50,5/5/2021
2FF046,earnings,100,50,5/5/2021
2FF046,earnings,100,50,5/5/2021
2FF046,earnings,100,50,5/5/2021
2FF046,earnings,100,50,5/5/2021
2FF046,earnings,100,50,5/5/2021
315EB0,credit-rating-upgrade,100,64,5/5/2021
315EB0,partnership,100,61,5/5/2021
317EC6,earnings,100,50,5/5/2021
317EC6,earnings,100,50,5/5/2021
317EC6,earnings,100,50,5/5/2021
317EC6,earnings,100,50,5/5/2021
3224CC,earnings,100,50,5/5/2021
3.20E+263,earnings,100,50,5/5/2021
32F24A,earnings,100,50,5/5/2021
32F943,earnings,100,50,5/5/2021
3.30E+30,conference-call,100,50,5/5/2021
33AD83,partnership,100,61,5/5/2021
342218,earnings,100,50,5/5/2021
342218,earnings,100,50,5/5/2021
346BF2,legal-issues-defendant,100,22,5/5/2021
35AE32,earnings,100,50,5/5/2021
35AE32,earnings,100,50,5/5/2021
35AE32,earnings,100,50,5/5/2021
35AE32,earnings,100,50,5/5/2021
35AE32,earnings,100,50,5/5/2021
366A08,earnings,100,50,5/5/2021
366A08,earnings,100,50,5/5/2021
366A08,earnings,100,50,5/5/2021
366A08,earnings,100,50,5/5/2021
366A08,earnings,100,50,5/5/2021
367E1C,earnings,100,50,5/5/2021
36A1CB,earnings,100,50,5/5/2021
36E479,executive-appointment,100,54,5/5/2021
372037,dividend,100,50,5/5/2021
372037,earnings-up,100,68,5/5/2021
372037,earnings,100,50,5/5/2021
372037,earnings,100,50,5/5/2021
372037,earnings,100,50,5/5/2021
3798B9,earnings,100,50,5/5/2021
37B618,earnings,100,50,5/5/2021
384CD3,earnings,100,50,5/5/2021
3A1C46,earnings,100,50,5/5/2021
3AAEAE,earnings,100,50,5/5/2021
3B8484,dividend,100,50,5/5/2021
3BC360,earnings,100,50,5/5/2021
3BC360,earnings,100,50,5/5/2021
3BC360,earnings,100,50,5/5/2021
3BC360,earnings,100,50,5/5/2021
3C6CCC,earnings,100,50,5/5/2021
3C6CCC,earnings,100,50,5/5/2021
3C6CCC,earnings,100,50,5/5/2021
3C6CCC,earnings,100,50,5/5/2021
3C6CCC,earnings,100,50,5/5/2021
3C6CCC,earnings,100,50,5/5/2021
3DCECC,earnings,100,50,5/5/2021
3DED49,dividend,100,50,5/5/2021
3DED49,earnings,100,50,5/5/2021
3F96D5,business-contract,100,69,5/5/2021
4.03E+05,earnings,100,50,5/5/2021
4.03E+05,earnings,100,50,5/5/2021
4.03E+05,earnings,100,50,5/5/2021
4.03E+05,earnings,100,50,5/5/2021
4.03E+05,dividend,100,50,5/5/2021
40B903,earnings,100,50,5/5/2021
4.00E+163,earnings,100,50,5/5/2021
416291,earnings,100,50,5/5/2021
43A74A,conference-participant,100,50,5/5/2021
449447,earnings,100,50,5/5/2021
45444E,earnings,100,50,5/5/2021
458D2C,public-offering,100,43,5/5/2021
45ABCC,earnings,100,50,5/5/2021
47FCF2,earnings,100,50,5/5/2021
47FCF2,earnings,100,50,5/5/2021
47FCF2,earnings,100,50,5/5/2021
47FCF2,earnings,100,50,5/5/2021
47FCF2,earnings,100,50,5/5/2021
47FCF2,earnings,100,50,5/5/2021
47FCF2,earnings,100,50,5/5/2021
485445,dividend,100,50,5/5/2021
4.91E+58,earnings-up,100,68,5/5/2021
4.91E+58,earnings-up,100,68,5/5/2021
4.91E+58,earnings-up,100,68,5/5/2021
4.91E+58,earnings-up,100,68,5/5/2021
4.91E+58,earnings-up,100,68,5/5/2021
4.91E+58,earnings-up,100,68,5/5/2021
4.91E+58,partnership,100,61,5/5/2021
4A2457,earnings,100,50,5/5/2021
4A2457,earnings,100,50,5/5/2021
4A2457,earnings,100,50,5/5/2021
4A2457,earnings,100,50,5/5/2021
4A2457,earnings,100,50,5/5/2021
4A2457,earnings,100,50,5/5/2021
4A6F00,partnership,100,61,5/5/2021
4AC91D,earnings,100,50,5/5/2021
4B3676,earnings,100,50,5/5/2021
4B7006,earnings,100,50,5/5/2021
4BDCA7,earnings,100,50,5/5/2021
4C2F17,earnings,100,50,5/5/2021
4C31F3,earnings,100,50,5/5/2021
4C31F3,earnings,100,50,5/5/2021
4C350A,earnings,100,50,5/5/2021
4C350A,earnings,100,50,5/5/2021
4C92B9,acquisition-acquirer,100,49,5/5/2021
4CDA2B,earnings,100,50,5/5/2021
4D8124,dividend,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4EE14A,earnings,100,50,5/5/2021
4F9926,product-release,100,64,5/5/2021
50070E,conference-organizer,100,57,5/5/2021
50070E,conference-organizer,100,57,5/5/2021
514067,earnings,100,50,5/5/2021
5288FC,conference-participant,100,50,5/5/2021
53E575,conference-call,100,50,5/5/2021
53EF9E,dividend,100,50,5/5/2021
545272,earnings,100,50,5/5/2021
5487B1,earnings,100,50,5/5/2021
5487B1,earnings,100,50,5/5/2021
5487B1,earnings,100,50,5/5/2021
5487B1,earnings,100,50,5/5/2021
54F1D2,earnings,100,50,5/5/2021
54F271,earnings-up,100,68,5/5/2021
54F271,earnings,100,50,5/5/2021
54F271,earnings,100,50,5/5/2021
54F271,earnings,100,50,5/5/2021
553949,executive-appointment,100,54,5/5/2021
553949,dividend,100,50,5/5/2021
583223,acquisition-acquirer,100,49,5/5/2021
5876DC,earnings,100,50,5/5/2021
587EDF,earnings,100,50,5/5/2021
587EDF,earnings,100,50,5/5/2021
587EDF,earnings,100,50,5/5/2021
587EDF,earnings,100,50,5/5/2021
587EDF,earnings,100,50,5/5/2021
587EDF,earnings,100,50,5/5/2021
594402,earnings,100,50,5/5/2021
5B3FA2,earnings,100,50,5/5/2021
5B7739,earnings,100,50,5/5/2021
5C7601,earnings,100,50,5/5/2021
5DAF89,earnings,100,50,5/5/2021
5DD486,dividend,100,50,5/5/2021
609208,legal-issues-defendant,100,22,5/5/2021
60EA12,dividend,100,50,5/5/2021
60EA12,earnings-up,100,68,5/5/2021
60EA12,earnings,100,50,5/5/2021
619882,conference-participant,100,50,5/5/2021
619882,conference-participant,100,50,5/5/2021
61E975,earnings-positive,100,69,5/5/2021
62B1C6,merger-completed,100,66,5/5/2021
62CDDE,earnings,100,50,5/5/2021
633043,earnings,100,50,5/5/2021
6391C2,conference-participant,100,50,5/5/2021
657097,earnings,100,50,5/5/2021
66667F,conference-call,100,50,5/5/2021
66E04A,earnings,100,50,5/5/2021
66E04A,earnings,100,50,5/5/2021
66E04A,earnings,100,50,5/5/2021
66E04A,earnings,100,50,5/5/2021
66E04A,earnings,100,50,5/5/2021
66E04A,earnings,100,50,5/5/2021
67303E,earnings,100,50,5/5/2021
676FFD,earnings,100,50,5/5/2021
68BA15,acquisition-acquiree,100,76,5/5/2021
68BA15,acquisition-acquiree,100,76,5/5/2021
68BA15,earnings,100,50,5/5/2021
68BA15,acquisition-regulatory-scrutiny-acquiree,100,38,5/5/2021
68E6E9,earnings,100,50,5/5/2021
698FF9,earnings,100,50,5/5/2021
698FF9,earnings,100,50,5/5/2021
6B0E45,earnings,100,50,5/5/2021
6B67BD,earnings,100,50,5/5/2021
6BBD2D,conference-participant,100,50,5/5/2021
6D3F35,earnings,100,50,5/5/2021
6D3F35,earnings,100,50,5/5/2021
6D3F35,earnings,100,50,5/5/2021
6D3F35,earnings,100,50,5/5/2021
6D3F35,earnings,100,50,5/5/2021
6DDA15,earnings,100,50,5/5/2021
6DDA15,earnings,100,50,5/5/2021
6DDA15,earnings,100,50,5/5/2021
6DDA15,earnings,100,50,5/5/2021
6DDA15,earnings,100,50,5/5/2021
6DDA15,earnings,100,50,5/5/2021
6DDA15,earnings,100,50,5/5/2021
6E8864,operating-earnings,100,50,5/5/2021
6ED519,earnings,100,50,5/5/2021
6ED519,earnings,100,50,5/5/2021
6ED519,earnings,100,50,5/5/2021
6F30F9,earnings,100,50,5/5/2021
6F39FC,earnings,100,50,5/5/2021
6F3FA8,earnings,100,50,5/5/2021
6F3FA8,earnings,100,50,5/5/2021
6F3FA8,earnings,100,50,5/5/2021
6F3FA8,earnings,100,50,5/5/2021
70B3D6,public-offering,100,43,5/5/2021
70CA28,conference-participant,100,50,5/5/2021
71553E,business-contract,100,69,5/5/2021
722D55,earnings,100,50,5/5/2021
7255D2,legal-issues-defendant,100,22,5/5/2021
72C2CE,earnings,100,50,5/5/2021
73A213,earnings,100,50,5/5/2021
7410C3,earnings,100,50,5/5/2021
762B8D,earnings,100,50,5/5/2021
762B8D,legal-issues-defendant,100,22,5/5/2021
763724,earnings,100,50,5/5/2021
763724,earnings,100,50,5/5/2021
763724,earnings,100,50,5/5/2021
76959C,earnings,100,50,5/5/2021
76BECC,earnings,100,50,5/5/2021
76BECC,earnings,100,50,5/5/2021
76BECC,earnings,100,50,5/5/2021
76D79A,earnings,100,50,5/5/2021
76F067,regulatory-product-approval-granted,100,81,5/5/2021
76F067,regulatory-product-approval-granted,100,81,5/5/2021
790D0D,dividend,100,50,5/5/2021
7AC86E,partnership,100,61,5/5/2021
7AF907,earnings,100,50,5/5/2021
7B1156,earnings,100,50,5/5/2021
7BFF81,earnings-positive,100,69,5/5/2021
7BFF81,earnings,100,50,5/5/2021
7BFF81,earnings,100,50,5/5/2021
7BFF81,acquisition-acquirer,100,49,5/5/2021
7C62A3,earnings,100,50,5/5/2021
7D85A9,earnings,100,50,5/5/2021
7E1D5D,earnings,100,50,5/5/2021
7F0372,earnings,100,50,5/5/2021
7F9BE2,earnings,100,50,5/5/2021
803FED,earnings,100,50,5/5/2021
805CD8,earnings,100,50,5/5/2021
80C400,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
8.10E+32,earnings,100,50,5/5/2021
810FAD,earnings,100,50,5/5/2021
81222C,earnings,100,50,5/5/2021
818A2F,earnings,100,50,5/5/2021
818A2F,earnings,100,50,5/5/2021
82B57E,earnings,100,50,5/5/2021
82F088,earnings,100,50,5/5/2021
82F088,earnings,100,50,5/5/2021
83E0AC,dividend,100,50,5/5/2021
845533,earnings-up,100,68,5/5/2021
845533,earnings,100,50,5/5/2021
845533,earnings,100,50,5/5/2021
87486A,earnings,100,50,5/5/2021
87486A,earnings,100,50,5/5/2021
87486A,earnings,100,50,5/5/2021
87486A,earnings,100,50,5/5/2021
877734,earnings,100,50,5/5/2021
877734,earnings,100,50,5/5/2021
877734,earnings,100,50,5/5/2021
87B81A,earnings,100,50,5/5/2021
87B81A,earnings,100,50,5/5/2021
87B81A,earnings,100,50,5/5/2021
87B81A,earnings,100,50,5/5/2021
87B81A,dividend,100,50,5/5/2021
87B81A,executive-appointment,100,54,5/5/2021
88193E,earnings,100,50,5/5/2021
885758,earnings,100,50,5/5/2021
885758,partnership,100,61,5/5/2021
885758,partnership,100,61,5/5/2021
88611B,earnings,100,50,5/5/2021
8DCBBB,dividend,100,50,5/5/2021
8E4F9A,operating-earnings,100,50,5/5/2021
8E82A6,revenue-up,100,62,5/5/2021
8E82A6,revenue-up,100,69,5/5/2021
8E82A6,revenue-up,100,69,5/5/2021
8E82A6,revenue-up,100,69,5/5/2021
8F6995,conference-call,100,50,5/5/2021
901327,earnings,100,50,5/5/2021
901327,earnings,100,50,5/5/2021
901327,earnings,100,50,5/5/2021
901327,earnings,100,50,5/5/2021
902255,earnings-up,100,68,5/5/2021
902255,earnings-up,100,68,5/5/2021
902255,earnings-up,100,68,5/5/2021
902670,earnings,100,50,5/5/2021
902670,earnings,100,50,5/5/2021
902670,earnings,100,50,5/5/2021
902670,earnings,100,50,5/5/2021
90D6A5,earnings,100,50,5/5/2021
925759,earnings,100,50,5/5/2021
92B625,conference-call,100,50,5/5/2021
92D757,legal-issues-defendant,100,22,5/5/2021
92D9C9,earnings,100,50,5/5/2021
9.31E+77,earnings,100,50,5/5/2021
93C130,buybacks,100,74,5/5/2021
940C3D,partnership,100,61,5/5/2021
940C3D,partnership,100,61,5/5/2021
94208D,earnings,100,50,5/5/2021
94208D,earnings,100,50,5/5/2021
94208D,earnings,100,50,5/5/2021
94208D,earnings,100,50,5/5/2021
94208D,earnings,100,50,5/5/2021
94637C,conference-participant,100,50,5/5/2021
94983E,earnings,100,50,5/5/2021
94A326,conference-participant,100,50,5/5/2021
9592FB,earnings,100,50,5/5/2021
965360,buybacks,100,74,5/5/2021
9673BD,dividend,100,50,5/5/2021
972356,executive-appointment,100,54,5/5/2021
9.74E+08,earnings,100,50,5/5/2021
97644E,earnings,100,50,5/5/2021
97644E,earnings,100,50,5/5/2021
97644E,earnings,100,50,5/5/2021
97644E,earnings,100,50,5/5/2021
97644E,earnings,100,50,5/5/2021
977A1E,dividend,100,50,5/5/2021
9.86E+03,partnership,100,61,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
990AD0,conference-organizer,100,57,5/5/2021
9A2760,earnings-up,100,68,5/5/2021
9A2760,earnings,100,50,5/5/2021
9A2760,earnings,100,50,5/5/2021
9A2760,earnings,100,50,5/5/2021
9B0C9C,earnings-up,100,68,5/5/2021
9B0C9C,earnings-up,100,68,5/5/2021
9B0C9C,earnings-up,100,68,5/5/2021
9B4066,dividend,100,50,5/5/2021
9B730A,earnings,100,50,5/5/2021
9C009A,earnings,100,50,5/5/2021
9D6A24,dividend-up,100,70,5/5/2021
9D6A24,earnings,100,50,5/5/2021
9F03CF,product-recall,100,29,5/5/2021
9F048E,earnings,100,50,5/5/2021
9F048E,earnings,100,50,5/5/2021
9F048E,earnings,100,50,5/5/2021
9F048E,earnings,100,50,5/5/2021
9F048E,earnings,100,50,5/5/2021
9FF5F1,earnings,100,50,5/5/2021
A01200,earnings,100,50,5/5/2021
A01200,earnings,100,50,5/5/2021
A01200,earnings,100,50,5/5/2021
A01200,earnings,100,50,5/5/2021
A1DBF0,earnings,100,50,5/5/2021
A1E3B3,earnings,100,50,5/5/2021
A247F5,earnings-per-share-positive,100,69,5/5/2021
A247F5,earnings-per-share-positive,100,69,5/5/2021
A38F30,earnings,100,50,5/5/2021
A398F8,earnings,100,50,5/5/2021
A3F598,earnings,100,50,5/5/2021
A3F598,earnings,100,50,5/5/2021
A3F598,earnings,100,50,5/5/2021
A433A5,earnings,100,50,5/5/2021
A4BCDE,product-release,100,64,5/5/2021
A5195E,conference-participant,100,50,5/5/2021
A6213D,partnership,100,61,5/5/2021
A63387,earnings,100,50,5/5/2021
A75D43,earnings,100,50,5/5/2021
A7CCF0,earnings,100,50,5/5/2021
A7CCF0,earnings,100,50,5/5/2021
A80FE0,partnership,100,61,5/5/2021
A80FE0,partnership,100,61,5/5/2021
A80FE0,partnership,100,61,5/5/2021
A80FE0,partnership,100,61,5/5/2021
A80FE0,public-offering,100,43,5/5/2021
A8FDE8,earnings,100,50,5/5/2021
A8FDE8,earnings,100,50,5/5/2021
A9ED24,earnings,100,50,5/5/2021
A9ED24,earnings,100,50,5/5/2021
A9ED24,earnings,100,50,5/5/2021
A9ED24,earnings,100,50,5/5/2021
A9ED24,earnings,100,50,5/5/2021
AAC8B6,earnings,100,50,5/5/2021
AAC8B6,earnings,100,50,5/5/2021
AAC8B6,earnings,100,50,5/5/2021
AAC8B6,earnings,100,50,5/5/2021
AAC8B6,earnings,100,50,5/5/2021
AAC8B6,earnings,100,50,5/5/2021
AD1ACF,facility-open,100,65,5/5/2021
AD22F2,earnings,100,50,5/5/2021
AD6141,earnings,100,50,5/5/2021
AF93DE,earnings,100,50,5/5/2021
AFF7B4,earnings,100,50,5/5/2021
AFF7B4,earnings,100,50,5/5/2021
AFF7B4,earnings,100,50,5/5/2021
AFF7B4,earnings,100,50,5/5/2021
B0D41A,earnings,100,50,5/5/2021
B0FE08,dividend-up,100,81,5/5/2021
B0FE08,earnings-up,100,68,5/5/2021
B0FE08,earnings-up,100,68,5/5/2021
B0FE08,earnings-up,100,68,5/5/2021
B0FE08,earnings-up,100,68,5/5/2021
B2E6B5,dividend,100,50,5/5/2021
B2E6B5,earnings,100,50,5/5/2021
B2E6B5,earnings,100,50,5/5/2021
B2E6B5,earnings,100,50,5/5/2021
B303A6,earnings,100,50,5/5/2021
B303A6,earnings,100,50,5/5/2021
B303A6,earnings,100,50,5/5/2021
B303A6,earnings,100,50,5/5/2021
B303A6,earnings,100,50,5/5/2021
B303A6,earnings,100,50,5/5/2021
B4C673,hirings,100,65,5/5/2021
B54A74,partnership,100,61,5/5/2021
B560AF,earnings,100,50,5/5/2021
B560AF,earnings,100,50,5/5/2021
B560AF,earnings,100,50,5/5/2021
B560AF,earnings,100,50,5/5/2021
B6082A,dividend,100,50,5/5/2021
B642E8,earnings,100,50,5/5/2021
B66928,earnings,100,50,5/5/2021
B73395,earnings,100,50,5/5/2021
B73395,earnings,100,50,5/5/2021
B73395,earnings,100,50,5/5/2021
B73395,earnings,100,50,5/5/2021
B77F14,earnings,100,50,5/5/2021
B77F14,earnings,100,50,5/5/2021
B77F14,earnings,100,50,5/5/2021
B7FA9B,earnings,100,50,5/5/2021
B80AD1,earnings,100,50,5/5/2021
B8EF97,revenues,100,50,5/5/2021
B96DF5,legal-issues-defendant,100,22,5/5/2021
B9764A,conference-participant,100,50,5/5/2021
B9BDE8,earnings,100,50,5/5/2021
BB127B,partnership,100,61,5/5/2021
BB127B,conference-call,100,50,5/5/2021
BCC13E,earnings,100,50,5/5/2021
BDD12C,partnership,100,61,5/5/2021
BDEC1E,conference-participant,100,50,5/5/2021
BE379D,rights-issue,100,43,5/5/2021
BE379D,rights-issue,100,43,5/5/2021
BF79F5,dividend,100,50,5/5/2021
C06EB6,clinical-trials-positive,100,87,5/5/2021
C188F8,earnings,100,50,5/5/2021
C27E19,dividend,100,50,5/5/2021
C29715,buybacks,100,74,5/5/2021
C2F597,earnings,100,50,5/5/2021
C3DE7D,earnings,100,50,5/5/2021
C3EE99,conference-call,100,50,5/5/2021
C3F99F,earnings,100,50,5/5/2021
C4F9C6,earnings,100,50,5/5/2021
C4FBDC,earnings,100,50,5/5/2021
C58D71,acquisition-acquiree,100,76,5/5/2021
C58D71,acquisition-acquiree,100,76,5/5/2021
C58D71,acquisition-acquiree,100,76,5/5/2021
C58D71,acquisition-acquiree,100,76,5/5/2021
C58D71,acquisition-acquiree,100,76,5/5/2021
C58D71,acquisition-acquiree,100,76,5/5/2021
C58D71,acquisition-acquiree,100,76,5/5/2021
C58D71,earnings,100,50,5/5/2021
C58D71,earnings,100,50,5/5/2021
C58D71,acquisition-regulatory-scrutiny-acquiree,100,38,5/5/2021
C5D2AE,legal-issues-defendant,100,22,5/5/2021
C5E100,earnings,100,50,5/5/2021
C62AA4,earnings,100,50,5/5/2021
C85A72,acquisition-acquirer,100,49,5/5/2021
C85A72,acquisition-acquirer,100,49,5/5/2021
C85A72,acquisition-acquirer,100,49,5/5/2021
C85A72,revenue-up,100,59,5/5/2021
C85A72,revenue-up,100,59,5/5/2021
C85A72,revenue-up,100,59,5/5/2021
C85A72,revenue-up,100,59,5/5/2021
C9A96E,conference-participant,100,50,5/5/2021
C9F39B,dividend,100,50,5/5/2021
CA14CC,earnings,100,50,5/5/2021
CA14CC,earnings,100,50,5/5/2021
CA14CC,earnings,100,50,5/5/2021
CAD7D9,business-contract,100,69,5/5/2021
CB22CD,earnings,100,50,5/5/2021
CB6A9C,earnings,100,50,5/5/2021
CB6A9C,earnings,100,50,5/5/2021
CB6A9C,earnings,100,50,5/5/2021
CB6A9C,earnings,100,50,5/5/2021
CB6A9C,earnings,100,50,5/5/2021
CB89EA,earnings,100,50,5/5/2021
CBBFBF,earnings,100,50,5/5/2021
CBFFDD,conference-participant,100,50,5/5/2021
CBFFDD,conference-call,100,50,5/5/2021
CC35BE,earnings,100,50,5/5/2021
CD051C,earnings,100,50,5/5/2021
CD2A4D,earnings,100,50,5/5/2021
CDAB24,earnings,100,50,5/5/2021
CDC817,acquisition-completed-acquirer,100,49,5/5/2021
CDE51C,executive-appointment,100,54,5/5/2021
CDE51C,earnings,100,50,5/5/2021
CE4E6D,earnings,100,50,5/5/2021
CE4E6D,earnings,100,50,5/5/2021
CE4E6D,earnings,100,50,5/5/2021
CE4E6D,earnings,100,50,5/5/2021
CE4E6D,earnings,100,50,5/5/2021
CE5C6E,earnings,100,50,5/5/2021
CE5C6E,earnings,100,50,5/5/2021
CEC5B9,executive-appointment,100,54,5/5/2021
CF6A5A,partnership,100,61,5/5/2021
CFB6CA,earnings,100,50,5/5/2021
CFB6CA,earnings,100,50,5/5/2021
CFF97C,dividend,100,50,5/5/2021
D03C7A,dividend,100,50,5/5/2021
D07B07,earnings,100,50,5/5/2021
D08D2C,earnings,100,50,5/5/2021
D08D2C,earnings,100,50,5/5/2021
D08D2C,earnings,100,50,5/5/2021
D08D2C,earnings,100,50,5/5/2021
D08D2C,earnings,100,50,5/5/2021
D08D2C,earnings,100,50,5/5/2021
D0909F,conference-participant,100,50,5/5/2021
D25249,earnings,100,50,5/5/2021
D29B44,earnings,100,50,5/5/2021
D29F43,earnings,100,50,5/5/2021
D36B23,conference-participant,100,50,5/5/2021
D3FA2C,earnings,100,50,5/5/2021
D4AC65,earnings-guidance-up,100,83,5/5/2021
D4AC65,earnings,100,50,5/5/2021
D4AC65,earnings,100,50,5/5/2021
D4AC65,earnings,100,50,5/5/2021
D4AC65,earnings,100,50,5/5/2021
D518D8,dividend,100,50,5/5/2021
D64EDF,note-sale,100,52,5/5/2021
D650A7,executive-resignation,100,44,5/5/2021
D650A7,revenue-up,100,69,5/5/2021
D650A7,revenue-up,100,69,5/5/2021
D650A7,revenue-up,100,69,5/5/2021
D650A7,dividend-up,100,72,5/5/2021
D75910,conference-call,100,50,5/5/2021
D90441,earnings,100,50,5/5/2021
D90441,earnings,100,50,5/5/2021
D90441,earnings,100,50,5/5/2021
D90F43,earnings,100,50,5/5/2021
D90F43,earnings,100,50,5/5/2021
D90F43,earnings,100,50,5/5/2021
D90F43,earnings,100,50,5/5/2021
D90F43,earnings,100,50,5/5/2021
D90F43,earnings,100,50,5/5/2021
D90F43,earnings,100,50,5/5/2021
D90F43,earnings,100,50,5/5/2021
D96202,earnings,100,50,5/5/2021
D9FC89,earnings,100,50,5/5/2021
D9FC89,earnings,100,50,5/5/2021
D9FC89,earnings,100,50,5/5/2021
D9FC89,earnings,100,50,5/5/2021
D9FC89,earnings,100,50,5/5/2021
DA48E4,conference-participant,100,50,5/5/2021
DB2E4E,earnings,100,50,5/5/2021
DB7014,operating-earnings,100,50,5/5/2021
DBFB51,earnings,100,50,5/5/2021
DD1BA1,acquisition-completed-acquirer,100,49,5/5/2021
DD1BA1,business-contract,100,69,5/5/2021
DDB002,earnings,100,50,5/5/2021
DDB002,earnings,100,50,5/5/2021
DDB002,earnings,100,50,5/5/2021
DDB002,earnings,100,50,5/5/2021
DDCB34,executive-appointment,100,54,5/5/2021
DF11D9,executive-appointment,100,54,5/5/2021
E06265,earnings,100,50,5/5/2021
E09E2B,conference-call,100,50,5/5/2021
E0A84E,legal-issues-defendant,100,22,5/5/2021
E11C41,executive-appointment,100,54,5/5/2021
E124EB,dividend,100,50,5/5/2021
E13782,earnings,100,50,5/5/2021
E19A99,earnings,100,50,5/5/2021
E1E36F,earnings,100,50,5/5/2021
E1E36F,earnings,100,50,5/5/2021
E1E36F,earnings,100,50,5/5/2021
E1E36F,earnings,100,50,5/5/2021
E1E36F,earnings,100,50,5/5/2021
E1E36F,earnings,100,50,5/5/2021
E20392,earnings,100,50,5/5/2021
E28D9C,earnings,100,50,5/5/2021
E2F66E,facility-upgrade,100,65,5/5/2021
E2F66E,facility-upgrade,100,65,5/5/2021
E74B55,legal-issues-defendant,100,22,5/5/2021
E74FED,earnings,100,50,5/5/2021
E7BF32,earnings,100,50,5/5/2021
E7BF32,earnings,100,50,5/5/2021
E8B315,legal-issues-defendant,100,22,5/5/2021
EB43F4,earnings,100,50,5/5/2021
EC8116,earnings,100,50,5/5/2021
ED0D7C,conference-participant,100,50,5/5/2021
ED2A5E,conference-participant,100,50,5/5/2021
ED2EFD,earnings,100,50,5/5/2021
EDD234,earnings,100,50,5/5/2021
EEA6B3,note-sale,100,52,5/5/2021
EF5BED,executive-appointment,100,54,5/5/2021
F02170,partnership,100,61,5/5/2021
F05B1B,clinical-trials-start,100,64,5/5/2021
F0B2B5,partnership,100,61,5/5/2021
F179ED,earnings,100,50,5/5/2021
F179ED,earnings,100,50,5/5/2021
F179ED,earnings,100,50,5/5/2021
F179ED,earnings,100,50,5/5/2021
F2BC3D,executive-appointment,100,54,5/5/2021
F30508,conference-participant,100,50,5/5/2021
F3FCC3,earnings-up,100,68,5/5/2021
F3FCC3,earnings,100,50,5/5/2021
F3FCC3,earnings,100,50,5/5/2021
F3FCC3,earnings,100,50,5/5/2021
F3FCC3,earnings,100,50,5/5/2021
F3FCC3,earnings,100,50,5/5/2021
F4FBD8,earnings,100,50,5/5/2021
F5349B,earnings,100,50,5/5/2021
F5349B,dividend,100,50,5/5/2021
F58C23,conference-call,100,50,5/5/2021
F6A987,earnings-up,100,68,5/5/2021
F7935D,acquisition-acquirer,100,49,5/5/2021
F7935D,acquisition-acquirer,100,49,5/5/2021
F88147,earnings,100,50,5/5/2021
FB728F,earnings,100,50,5/5/2021
FBD92D,earnings-up,100,68,5/5/2021
FC1A6E,conference-participant,100,50,5/5/2021
FD554E,earnings,100,50,5/5/2021
FDF28E,conference-participant,100,50,5/5/2021
FDF799,earnings,100,50,5/5/2021
FDF799,earnings,100,50,5/5/2021
FDF799,earnings,100,50,5/5/2021
FE7A63,executive-appointment,100,54,5/5/2021
FE9C0D,conference-participant,100,50,5/5/2021
FF6644,conference-participant,100,50,5/5/2021
13528,executive-appointment,100,54,5/6/2021
0142B5,earnings-per-share-positive,100,69,5/6/2021
01D03F,partnership,100,61,5/6/2021
01D03F,partnership,100,61,5/6/2021
20751,earnings,100,50,5/6/2021
20751,earnings,100,50,5/6/2021
02ACBD,earnings,100,50,5/6/2021
03542C,earnings,100,50,5/6/2021
036C6F,conference-call,100,50,5/6/2021
03FB17,earnings,100,50,5/6/2021
04EB2F,earnings,100,50,5/6/2021
054B55,earnings,100,50,5/6/2021
061A3B,earnings,100,50,5/6/2021
061A3B,earnings,100,50,5/6/2021
061A3B,earnings,100,50,5/6/2021
061A3B,earnings,100,50,5/6/2021
68396,earnings,100,50,5/6/2021
070B45,business-contract,100,69,5/6/2021
75172,earnings,100,50,5/6/2021
07EC43,conference-participant,100,50,5/6/2021
84625,dividend,100,50,5/6/2021
08A40F,executive-appointment,100,54,5/6/2021
09062E,earnings,100,50,5/6/2021
0919B1,earnings,100,50,5/6/2021
091B6C,earnings,100,50,5/6/2021
091B6C,earnings,100,50,5/6/2021
099C88,business-contract,100,69,5/6/2021
099C88,partnership,100,61,5/6/2021
0A59F8,earnings,100,50,5/6/2021
0A59F8,earnings,100,50,5/6/2021
0A59F8,earnings,100,50,5/6/2021
0A59F8,earnings,100,50,5/6/2021
0A59F8,earnings,100,50,5/6/2021
0A59F8,earnings,100,50,5/6/2021
0AAD90,earnings,100,50,5/6/2021
0B7375,legal-issues-defendant,100,22,5/6/2021
0B7375,fraud-defendant,100,20,5/6/2021
0B7375,legal-issues-defendant,100,22,5/6/2021
0B7375,legal-issues-defendant,100,22,5/6/2021
0B7375,legal-issues-defendant,100,22,5/6/2021
0B7375,legal-issues-defendant,100,22,5/6/2021
0BC29E,earnings,100,50,5/6/2021
0BC29E,earnings,100,50,5/6/2021
0BC29E,earnings,100,50,5/6/2021
0BC29E,earnings,100,50,5/6/2021
0BC29E,earnings,100,50,5/6/2021
0BC29E,earnings,100,50,5/6/2021
0BC29E,earnings,100,50,5/6/2021
0BC29E,earnings,100,50,5/6/2021
0BC853,earnings,100,50,5/6/2021
0BD199,earnings,100,50,5/6/2021
0BD199,earnings,100,50,5/6/2021
0BF198,earnings,100,50,5/6/2021
0E5619,earnings,100,50,5/6/2021
0EF1AF,earnings,100,50,5/6/2021
1080C0,earnings,100,50,5/6/2021
1096C6,earnings,100,50,5/6/2021
11074E,earnings,100,50,5/6/2021
112694,earnings,100,50,5/6/2021
11A49E,earnings,100,50,5/6/2021
131443,business-contract,100,69,5/6/2021
131443,partnership,100,61,5/6/2021
133644,earnings,100,50,5/6/2021
1348C9,executive-appointment,100,54,5/6/2021
1348C9,merger-regulatory-approval,100,81,5/6/2021
1348C9,merger,100,66,5/6/2021
152AB9,earnings,100,50,5/6/2021
152AB9,earnings,100,50,5/6/2021
152E1D,operating-earnings,100,50,5/6/2021
168A5D,partnership,100,61,5/6/2021
1748F6,partnership,100,61,5/6/2021
182BE7,earnings,100,50,5/6/2021
184866,earnings,100,50,5/6/2021
190B91,conference-participant,100,50,5/6/2021
1A2D9F,award,100,58,5/6/2021
1A3E1B,earnings,100,50,5/6/2021
1A5957,earnings,100,50,5/6/2021
1A5957,earnings,100,50,5/6/2021
1A5957,earnings,100,50,5/6/2021
1A5957,earnings,100,50,5/6/2021
1AC649,earnings,100,50,5/6/2021
1B637E,dividend,100,50,5/6/2021
1B9535,earnings,100,50,5/6/2021
1C2593,conference-call,100,50,5/6/2021
1CD09C,earnings,100,50,5/6/2021
1DB833,conference-participant,100,50,5/6/2021
1E1125,conference-organizer,100,57,5/6/2021
1E4FB9,earnings,100,50,5/6/2021
1E68B3,earnings,100,50,5/6/2021
1EBF8D,partnership,100,61,5/6/2021
1EBF8D,partnership,100,61,5/6/2021
1F19C8,earnings-per-share-up,100,70,5/6/2021
1F464F,earnings,100,50,5/6/2021
20403D,earnings,100,50,5/6/2021
2082EA,conference-participant,100,50,5/6/2021
2096DE,earnings,100,50,5/6/2021
21268E,earnings,100,50,5/6/2021
221783,earnings,100,50,5/6/2021
221783,earnings,100,50,5/6/2021
221783,earnings,100,50,5/6/2021
221783,earnings,100,50,5/6/2021
221783,earnings,100,50,5/6/2021
221AD7,award,100,58,5/6/2021
223552,earnings,100,50,5/6/2021
2262BD,earnings,100,50,5/6/2021
23699B,earnings,100,50,5/6/2021
238302,earnings,100,50,5/6/2021
2.45E+15,dividend,100,50,5/6/2021
24C48B,note-sale,100,52,5/6/2021
253604,earnings,100,50,5/6/2021
253B2F,earnings,100,50,5/6/2021
253B2F,earnings,100,50,5/6/2021
25AB8E,earnings,100,50,5/6/2021
26DC29,conference-call,100,50,5/6/2021
27C10F,earnings,100,50,5/6/2021
27C10F,earnings,100,50,5/6/2021
27C10F,earnings,100,50,5/6/2021
27C10F,earnings,100,50,5/6/2021
27C10F,earnings,100,50,5/6/2021
28F905,earnings,100,50,5/6/2021
297DA8,earnings,100,50,5/6/2021
2.90E+62,earnings,100,50,5/6/2021
2.90E+62,earnings,100,50,5/6/2021
2.90E+62,earnings,100,50,5/6/2021
2.90E+62,earnings,100,50,5/6/2021
2.90E+62,earnings,100,50,5/6/2021
2.90E+62,earnings,100,50,5/6/2021
2A1009,board-meeting,100,51,5/6/2021
2ABF77,earnings,100,50,5/6/2021
2ABF77,earnings,100,50,5/6/2021
2ABF77,clinical-trials-positive,100,87,5/6/2021
2BF36E,earnings,100,50,5/6/2021
2BF36E,earnings,100,50,5/6/2021
2C35B5,earnings,100,50,5/6/2021
2C681C,business-contract,100,69,5/6/2021
2C681C,business-contract,100,69,5/6/2021
2C681C,business-contract,100,69,5/6/2021
2D981A,earnings,100,50,5/6/2021
2E36AD,earnings,100,50,5/6/2021
2E36AD,earnings,100,50,5/6/2021
2EB88B,revenues,100,50,5/6/2021
2F7A7E,earnings,100,50,5/6/2021
2FDEE3,earnings,100,50,5/6/2021
301493,revenue-up,100,76,5/6/2021
301493,revenues,100,50,5/6/2021
301493,revenues,100,50,5/6/2021
301493,revenues,100,50,5/6/2021
306623,conference-participant,100,50,5/6/2021
30DE64,debt-extension-recipient,100,73,5/6/2021
30DE64,earnings,100,50,5/6/2021
30DFD3,earnings,100,50,5/6/2021
3159AA,earnings,100,50,5/6/2021
3159AA,dividend,100,50,5/6/2021
337024,earnings,100,50,5/6/2021
34A959,partnership,100,61,5/6/2021
355B19,earnings,100,50,5/6/2021
3587B4,earnings,100,50,5/6/2021
3587B4,earnings,100,50,5/6/2021
3587B4,earnings,100,50,5/6/2021
3587B4,earnings,100,50,5/6/2021
3587B4,earnings,100,50,5/6/2021
366A08,business-contract,100,69,5/6/2021
366A08,business-contract,100,69,5/6/2021
366A08,business-contract,100,69,5/6/2021
367434,earnings,100,50,5/6/2021
36C09B,conference-call,100,50,5/6/2021
36E479,earnings,100,50,5/6/2021
371B0A,earnings,100,50,5/6/2021
37426C,earnings,100,50,5/6/2021
383ADA,earnings,100,50,5/6/2021
387375,patent-infringement-plaintiff,100,47,5/6/2021
39692D,earnings,100,50,5/6/2021
396D7C,earnings,100,50,5/6/2021
3A1C46,conference-participant,100,50,5/6/2021
3ACF46,earnings,100,50,5/6/2021
3ACF46,earnings,100,50,5/6/2021
3ACF46,earnings,100,50,5/6/2021
3ACF46,earnings,100,50,5/6/2021
3AF7FD,earnings,100,50,5/6/2021
3BA1BF,earnings,100,50,5/6/2021
3BA1BF,earnings,100,50,5/6/2021
3BA1BF,earnings,100,50,5/6/2021
3BA1BF,earnings,100,50,5/6/2021
3BA1BF,earnings,100,50,5/6/2021
3BA1BF,earnings,100,50,5/6/2021
3BA1BF,earnings,100,50,5/6/2021
3BA1BF,earnings,100,50,5/6/2021
3BA1BF,earnings,100,50,5/6/2021
3BE00F,dividend-up,100,81,5/6/2021
3C3B6B,earnings,100,50,5/6/2021
3C3B6B,executive-appointment,100,54,5/6/2021
3C3B6B,executive-appointment,100,54,5/6/2021
3C7F5F,earnings,100,50,5/6/2021
3C7F5F,earnings,100,50,5/6/2021
3C7F5F,earnings,100,50,5/6/2021
3C7F5F,earnings,100,50,5/6/2021
3C7F5F,earnings,100,50,5/6/2021
3CCC90,acquisition-completed-acquirer,100,49,5/6/2021
3E39A5,earnings,100,50,5/6/2021
3E39A5,earnings,100,50,5/6/2021
3E39A5,earnings,100,50,5/6/2021
3E70FC,earnings,100,50,5/6/2021
3F1C69,conference-participant,100,50,5/6/2021
3F4668,revenue-up,100,53,5/6/2021
3F4668,revenues,100,50,5/6/2021
3F4668,revenues,100,50,5/6/2021
3F4668,revenues,100,50,5/6/2021
3FBC9B,earnings,100,50,5/6/2021
3FBC9B,earnings,100,50,5/6/2021
3FBC9B,earnings,100,50,5/6/2021
3FBC9B,earnings,100,50,5/6/2021
3FBC9B,earnings,100,50,5/6/2021
415188,dividend,100,50,5/6/2021
415188,earnings,100,50,5/6/2021
41A93D,earnings,100,50,5/6/2021
41C36B,earnings,100,50,5/6/2021
427F32,earnings,100,50,5/6/2021
42AABD,earnings,100,50,5/6/2021
42EFC7,earnings,100,50,5/6/2021
4398A2,earnings,100,50,5/6/2021
4398A2,earnings,100,50,5/6/2021
43A060,earnings,100,50,5/6/2021
43A060,earnings,100,50,5/6/2021
43A060,earnings,100,50,5/6/2021
442587,partnership,100,61,5/6/2021
44740A,earnings,100,50,5/6/2021
448BF3,earnings,100,50,5/6/2021
44A4FC,unit-acquisition-acquirer,100,49,5/6/2021
4.60E+06,earnings,100,50,5/6/2021
48F795,earnings,100,50,5/6/2021
48F795,conference-participant,100,50,5/6/2021
49F4D0,earnings,100,50,5/6/2021
4A5C8D,earnings,100,50,5/6/2021
4BF3D6,earnings,100,50,5/6/2021
4C37C5,dividend,100,50,5/6/2021
4C3FE9,earnings,100,50,5/6/2021
4CDA2B,conference-participant,100,50,5/6/2021
4D8124,earnings,100,50,5/6/2021
4DD203,earnings-up,100,68,5/6/2021
4DD203,earnings,100,50,5/6/2021
4DD203,earnings,100,50,5/6/2021
4DD203,earnings,100,50,5/6/2021
4E2D94,investment-investor,100,55,5/6/2021
4E6F5A,earnings,100,50,5/6/2021
4EE167,conference-participant,100,50,5/6/2021
4EE167,executive-appointment,100,54,5/6/2021
4FB770,note-sale,100,52,5/6/2021
4FCC78,earnings,100,50,5/6/2021
50070E,conference-organizer,100,57,5/6/2021
50070E,conference-organizer,100,57,5/6/2021
50070E,conference-organizer,100,57,5/6/2021
50070E,conference-organizer,100,57,5/6/2021
50070E,conference-organizer,100,57,5/6/2021
50070E,conference-organizer,100,57,5/6/2021
504FE2,business-contract,100,69,5/6/2021
5065B1,earnings,100,50,5/6/2021
507AE7,dividend,100,50,5/6/2021
514067,conference-participant,100,50,5/6/2021
525A1C,earnings,100,50,5/6/2021
52FB2F,earnings,100,50,5/6/2021
52FB2F,earnings,100,50,5/6/2021
52FB2F,earnings,100,50,5/6/2021
52FB2F,earnings,100,50,5/6/2021
53A226,earnings,100,50,5/6/2021
53C421,executive-appointment,100,54,5/6/2021
53C421,earnings,100,50,5/6/2021
5403F8,earnings,100,50,5/6/2021
54512F,earnings,100,50,5/6/2021
54512F,earnings,100,50,5/6/2021
5.47E+28,operating-earnings,100,50,5/6/2021
548AC0,earnings,100,50,5/6/2021
55ACCB,earnings,100,50,5/6/2021
55ACCB,earnings,100,50,5/6/2021
55ACCB,earnings,100,50,5/6/2021
55C9B5,partnership,100,61,5/6/2021
55C9B5,partnership,100,61,5/6/2021
55D0F3,earnings,100,50,5/6/2021
56632F,dividend,100,50,5/6/2021
56765E,earnings,100,50,5/6/2021
5704AC,operating-earnings,100,50,5/6/2021
57A854,earnings,100,50,5/6/2021
586BD7,earnings,100,50,5/6/2021
589803,earnings,100,50,5/6/2021
58B46F,earnings,100,50,5/6/2021
58B46F,earnings,100,50,5/6/2021
58C2D4,conference-participant,100,50,5/6/2021
58EA22,conference-participant,100,50,5/6/2021
5968F9,earnings,100,50,5/6/2021
59872F,conference-call,100,50,5/6/2021
59DB8C,earnings,100,50,5/6/2021
5A53BF,earnings,100,50,5/6/2021
5A9A82,earnings,100,50,5/6/2021
5AA3B1,earnings,100,50,5/6/2021
5CEE02,earnings,100,50,5/6/2021
5D1329,earnings,100,50,5/6/2021
5D43A7,product-price-raise,100,57,5/6/2021
5FC507,earnings,100,50,5/6/2021
60FE03,earnings,100,50,5/6/2021
619882,dividend,100,50,5/6/2021
620381,earnings,100,50,5/6/2021
6284B5,earnings,100,50,5/6/2021
6284B5,earnings,100,50,5/6/2021
6284B5,earnings,100,50,5/6/2021
6284B5,earnings,100,50,5/6/2021
62A48D,conference-call,100,50,5/6/2021
636BBF,product-release,100,64,5/6/2021
64636E,earnings,100,50,5/6/2021
649CBD,earnings,100,50,5/6/2021
64E615,earnings-up,100,68,5/6/2021
6559D8,earnings,100,50,5/6/2021
6634D9,earnings,100,50,5/6/2021
665440,earnings,100,50,5/6/2021
68586A,earnings,100,50,5/6/2021
68BA15,legal-issues-defendant,100,22,5/6/2021
694749,earnings,100,50,5/6/2021
694749,earnings,100,50,5/6/2021
694749,earnings,100,50,5/6/2021
69FDFC,earnings,100,50,5/6/2021
6B0784,earnings,100,50,5/6/2021
6BD606,dividend,100,50,5/6/2021
6BD606,earnings,100,50,5/6/2021
6BDA0C,earnings,100,50,5/6/2021
6BDA0C,earnings,100,50,5/6/2021
6BDA0C,earnings,100,50,5/6/2021
6BDA0C,earnings,100,50,5/6/2021
6CBF41,earnings,100,50,5/6/2021
6CBF41,earnings,100,50,5/6/2021
6D156D,earnings,100,50,5/6/2021
6D1ADF,earnings,100,50,5/6/2021
6D9ECA,earnings,100,50,5/6/2021
6.00E+19,earnings,100,50,5/6/2021
6EA292,earnings,100,50,5/6/2021
6F92A9,earnings,100,50,5/6/2021
701531,earnings,100,50,5/6/2021
709AED,dividend,100,50,5/6/2021
709AED,earnings-up,100,68,5/6/2021
709AED,earnings-up,100,68,5/6/2021
709AED,earnings-up,100,68,5/6/2021
722D55,product-release,100,64,5/6/2021
723548,earnings,100,50,5/6/2021
726DDF,earnings,100,50,5/6/2021
72FCA3,partnership,100,61,5/6/2021
742AAB,revenue-up,100,69,5/6/2021
742AAB,revenue-up,100,69,5/6/2021
742AAB,revenue-up,100,69,5/6/2021
742AAB,revenue-up,100,69,5/6/2021
742AAB,revenue-up,100,69,5/6/2021
74404C,earnings,100,50,5/6/2021
74404C,executive-appointment,100,54,5/6/2021
7.45E+28,earnings,100,50,5/6/2021
7.45E+28,earnings,100,50,5/6/2021
746373,executive-appointment,100,54,5/6/2021
747219,earnings,100,50,5/6/2021
756045,earnings,100,50,5/6/2021
769F40,earnings,100,50,5/6/2021
76F067,conference-participant,100,50,5/6/2021
7710F3,earnings,100,50,5/6/2021
7710F3,earnings,100,50,5/6/2021
77B8E9,award,100,58,5/6/2021
7823A3,partnership,100,61,5/6/2021
787D14,earnings,100,50,5/6/2021
791D59,award,100,58,5/6/2021
793C11,earnings,100,50,5/6/2021
7A3633,earnings,100,50,5/6/2021
7AB859,product-release,100,64,5/6/2021
7AC86E,dividend,100,50,5/6/2021
7ACFD4,earnings,100,50,5/6/2021
7ACFD4,earnings,100,50,5/6/2021
7ACFD4,earnings,100,50,5/6/2021
7ACFD4,earnings,100,50,5/6/2021
7ACFD4,earnings,100,50,5/6/2021
7B0BA6,earnings,100,50,5/6/2021
7B0BA6,earnings,100,50,5/6/2021
7B0BA6,earnings,100,50,5/6/2021
7B0BA6,earnings,100,50,5/6/2021
7B0BA6,earnings,100,50,5/6/2021
7B1156,conference-participant,100,50,5/6/2021
7B9212,revenues,100,50,5/6/2021
7BAAE7,dividend,100,50,5/6/2021
7C4F43,earnings,100,50,5/6/2021
7DC1C4,earnings,100,50,5/6/2021
7FD8B9,earnings,100,50,5/6/2021
7FEEE1,earnings,100,50,5/6/2021
817ED9,earnings,100,50,5/6/2021
819492,earnings,100,50,5/6/2021
8.10E+205,earnings,100,50,5/6/2021
824CCA,earnings,100,50,5/6/2021
824CCA,earnings,100,50,5/6/2021
824CCA,earnings,100,50,5/6/2021
824CCA,earnings,100,50,5/6/2021
82E58A,earnings,100,50,5/6/2021
834152,earnings,100,50,5/6/2021
83598E,executive-appointment,100,54,5/6/2021
83598E,earnings,100,50,5/6/2021
83A065,earnings,100,50,5/6/2021
83B1C8,earnings,100,50,5/6/2021
83E0AC,earnings,100,50,5/6/2021
8.40E+120,earnings,100,50,5/6/2021
858942,executive-appointment,100,54,5/6/2021
858942,earnings,100,50,5/6/2021
85CDC9,earnings,100,50,5/6/2021
85DE00,dividend,100,50,5/6/2021
85DE00,earnings,100,50,5/6/2021
8614A2,earnings,100,50,5/6/2021
863350,acquisition-acquiree,100,76,5/6/2021
863350,acquisition-acquiree,100,76,5/6/2021
863350,legal-issues-defendant,100,22,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
86AA9C,earnings,100,50,5/6/2021
873DB9,earnings,100,50,5/6/2021
873DB9,earnings,100,50,5/6/2021
873DB9,earnings,100,50,5/6/2021
873DB9,earnings,100,50,5/6/2021
873DB9,earnings,100,50,5/6/2021
873DB9,earnings,100,50,5/6/2021
8876D6,business-contract,100,69,5/6/2021
8876D6,business-contract,100,69,5/6/2021
8876D6,business-contract,100,69,5/6/2021
88923D,earnings,100,50,5/6/2021
88923D,earnings,100,50,5/6/2021
88923D,earnings,100,50,5/6/2021
88923D,earnings,100,50,5/6/2021
88923D,earnings,100,50,5/6/2021
88923D,earnings,100,50,5/6/2021
890FF4,earnings,100,50,5/6/2021
890FF4,earnings,100,50,5/6/2021
890FF4,earnings,100,50,5/6/2021
890FF4,earnings,100,50,5/6/2021
890FF4,earnings,100,50,5/6/2021
890FF4,earnings,100,50,5/6/2021
890FF4,earnings,100,50,5/6/2021
895D56,earnings,100,50,5/6/2021
896771,executive-appointment,100,54,5/6/2021
89FBB1,earnings,100,50,5/6/2021
89FBB1,earnings,100,50,5/6/2021
89FBB1,earnings,100,50,5/6/2021
8AB37F,revenue-up,100,79,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B1F37,earnings,100,50,5/6/2021
8B9B3B,earnings,100,50,5/6/2021
8BAA15,earnings,100,50,5/6/2021
8BAA15,earnings,100,50,5/6/2021
8BFAA4,revenue-up,100,69,5/6/2021
8BFAA4,revenue-up,100,69,5/6/2021
8BFAA4,revenue-up,100,69,5/6/2021
8BFAA4,revenue-up,100,69,5/6/2021
8BFE9A,earnings,100,50,5/6/2021
8C6C1B,conference-call,100,50,5/6/2021
8DBBE6,earnings,100,50,5/6/2021
8DE74B,dividend-up,100,81,5/6/2021
8E3F58,executive-appointment,100,54,5/6/2021
8E3F58,earnings-up,100,68,5/6/2021
8E3F58,earnings,100,50,5/6/2021
8E3F58,earnings,100,50,5/6/2021
8FF2EF,business-contract,100,69,5/6/2021
911CA9,earnings,100,50,5/6/2021
911CA9,earnings,100,50,5/6/2021
913437,earnings,100,50,5/6/2021
9196A2,conference-organizer,100,57,5/6/2021
925759,conference-participant,100,50,5/6/2021
9.36E+10,earnings,100,50,5/6/2021
9.36E+10,earnings,100,50,5/6/2021
9.36E+10,earnings,100,50,5/6/2021
9.36E+10,earnings,100,50,5/6/2021
9.36E+10,earnings,100,50,5/6/2021
9.36E+10,earnings,100,50,5/6/2021
9.36E+10,earnings,100,50,5/6/2021
938D89,earnings,100,50,5/6/2021
93AD2E,earnings,100,50,5/6/2021
93F143,dividend,100,50,5/6/2021
943239,earnings,100,50,5/6/2021
943239,earnings,100,50,5/6/2021
94637C,partnership,100,61,5/6/2021
94637C,partnership,100,61,5/6/2021
94637C,partnership,100,61,5/6/2021
947B0B,earnings,100,50,5/6/2021
949625,earnings,100,50,5/6/2021
9546A5,earnings,100,50,5/6/2021
95A92E,earnings,100,50,5/6/2021
95C392,earnings,100,50,5/6/2021
9.62E+76,dividend-up,100,81,5/6/2021
9.65E+09,earnings,100,50,5/6/2021
9.65E+07,earnings,100,50,5/6/2021
9.65E+07,earnings,100,50,5/6/2021
966DBE,conference-call,100,50,5/6/2021
967D92,earnings,100,50,5/6/2021
96A6CD,earnings,100,50,5/6/2021
96F126,conference-participant,100,50,5/6/2021
971334,earnings,100,50,5/6/2021
971334,earnings,100,50,5/6/2021
971334,earnings,100,50,5/6/2021
971334,earnings,100,50,5/6/2021
971F7B,earnings,100,50,5/6/2021
971F7B,earnings,100,50,5/6/2021
971F7B,earnings,100,50,5/6/2021
971F7B,earnings,100,50,5/6/2021
971F7B,earnings,100,50,5/6/2021
97AAF6,earnings,100,50,5/6/2021
97AAF6,earnings,100,50,5/6/2021
97AAF6,earnings,100,50,5/6/2021
97FE80,earnings,100,50,5/6/2021
97FE80,earnings,100,50,5/6/2021
97FE80,earnings,100,50,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
990AD0,conference-organizer,100,57,5/6/2021
9978F1,earnings,100,50,5/6/2021
9A602D,product-release,100,64,5/6/2021
9A602D,dividend,100,50,5/6/2021
9ABD30,earnings,100,50,5/6/2021
9AF3DC,earnings,100,50,5/6/2021
9B730A,conference-participant,100,50,5/6/2021
9BB35A,dividend,100,50,5/6/2021
9BB35A,operating-earnings-positive,100,69,5/6/2021
9BB35A,earnings-per-share,100,50,5/6/2021
9BB35A,earnings-per-share,100,50,5/6/2021
9BB35A,earnings-per-share,100,50,5/6/2021
9C25FF,earnings,100,50,5/6/2021
9C3D3C,earnings,100,50,5/6/2021
9C3D3C,earnings,100,50,5/6/2021
9C3D3C,earnings,100,50,5/6/2021
9C3D3C,earnings,100,50,5/6/2021
9C3D3C,earnings,100,50,5/6/2021
9C5174,revenue-up,100,72,5/6/2021
9C5174,revenues,100,50,5/6/2021
9C5174,revenues,100,50,5/6/2021
9CDA4F,earnings,100,50,5/6/2021
9CF9B1,product-release,100,64,5/6/2021
9D3360,operating-earnings,100,50,5/6/2021
9E0811,earnings,100,50,5/6/2021
9E4A5F,earnings,100,50,5/6/2021
9E5C2C,earnings,100,50,5/6/2021
9E98F2,earnings,100,50,5/6/2021
9E98F2,earnings,100,50,5/6/2021
9E98F2,earnings,100,50,5/6/2021
9EA947,dividend,100,50,5/6/2021
9EF4CF,earnings,100,50,5/6/2021
9F5CBB,earnings,100,50,5/6/2021
9F71E5,partnership,100,61,5/6/2021
A017F4,earnings,100,50,5/6/2021
A072C4,earnings,100,50,5/6/2021
A1BB98,earnings,100,50,5/6/2021
A1BB98,earnings,100,50,5/6/2021
A1BB98,earnings,100,50,5/6/2021
A1BB98,earnings,100,50,5/6/2021
A1BB98,earnings,100,50,5/6/2021
A1E3B3,product-release,100,64,5/6/2021
A1E3B3,product-release,100,64,5/6/2021
A1EAC8,earnings,100,50,5/6/2021
A21649,unit-acquisition-acquirer,100,49,5/6/2021
A21649,earnings,100,50,5/6/2021
A26EF7,earnings,100,50,5/6/2021
A26EF7,earnings,100,50,5/6/2021
A29A46,conference-call,100,50,5/6/2021
A2C979,earnings,100,50,5/6/2021
A3230E,earnings,100,50,5/6/2021
A350C1,dividend,100,50,5/6/2021
A3800A,earnings,100,50,5/6/2021
A403CF,earnings,100,50,5/6/2021
A43906,earnings,100,50,5/6/2021
A49498,partnership,100,61,5/6/2021
A5195E,earnings,100,50,5/6/2021
A52533,earnings,100,50,5/6/2021
A7A0C8,executive-appointment,100,54,5/6/2021
A7A0C8,earnings,100,50,5/6/2021
A80FE0,public-offering,100,43,5/6/2021
A868C9,business-contract,100,69,5/6/2021
A871B0,earnings,100,50,5/6/2021
A8CBDA,partnership,100,61,5/6/2021
A8E2FE,earnings,100,50,5/6/2021
A94637,earnings,100,50,5/6/2021
A94637,earnings,100,50,5/6/2021
AB4A7E,earnings,100,50,5/6/2021
AB4A7E,earnings,100,50,5/6/2021
AB4A7E,earnings,100,50,5/6/2021
AB4A7E,earnings,100,50,5/6/2021
ABAA03,conference-call,100,50,5/6/2021
ABB493,earnings,100,50,5/6/2021
ABE7DC,conference-participant,100,50,5/6/2021
AC3584,partnership,100,61,5/6/2021
ACC7D3,earnings,100,50,5/6/2021
ACF0B4,earnings,100,50,5/6/2021
AD23DE,dividend,100,50,5/6/2021
AD9F1D,executive-appointment,100,54,5/6/2021
AE79CD,earnings,100,50,5/6/2021
AFBEB4,earnings,100,50,5/6/2021
AFD7DD,earnings,100,50,5/6/2021
AFD7DD,earnings,100,50,5/6/2021
B01215,earnings,100,50,5/6/2021
B05000,earnings-up,100,68,5/6/2021
B05000,earnings,100,50,5/6/2021
B08C51,earnings,100,50,5/6/2021
B0998E,earnings,100,50,5/6/2021
B0B969,earnings,100,50,5/6/2021
B106FA,earnings,100,50,5/6/2021
B1DF3C,earnings,100,50,5/6/2021
B2256A,earnings-up,100,68,5/6/2021
B2256A,earnings,100,50,5/6/2021
B2256A,earnings,100,50,5/6/2021
B381D8,earnings,100,50,5/6/2021
B3ED62,revenue-up,100,69,5/6/2021
B508E5,earnings,100,50,5/6/2021
B508E5,earnings,100,50,5/6/2021
B5DE80,earnings,100,50,5/6/2021
B5DE80,earnings,100,50,5/6/2021
B6843B,earnings,100,50,5/6/2021
B7202A,revenue-up,100,69,5/6/2021
B7202A,revenues,100,50,5/6/2021
B7202A,revenues,100,50,5/6/2021
B72D2E,revenues,100,50,5/6/2021
B80AD1,conference-participant,100,50,5/6/2021
B83D67,earnings,100,50,5/6/2021
B83D67,buybacks,100,74,5/6/2021
BB0787,earnings,100,50,5/6/2021
BB07E4,dividend,100,50,5/6/2021
BB58FF,conference-participant,100,50,5/6/2021
BBF349,earnings,100,50,5/6/2021
BCC55F,earnings,100,50,5/6/2021
BD8517,conference-participant,100,50,5/6/2021
BDA775,earnings,100,50,5/6/2021
BDCC11,product-release,100,64,5/6/2021
BDCC11,earnings,100,50,5/6/2021
BDF2BD,earnings-positive,100,69,5/6/2021
BDF2BD,earnings-positive,100,69,5/6/2021
BDF2BD,earnings-positive,100,69,5/6/2021
BDF2BD,earnings-positive,100,69,5/6/2021
BE14CF,dividend,100,50,5/6/2021
BE5935,earnings,100,50,5/6/2021
C03C8B,earnings,100,50,5/6/2021
C03C8B,earnings,100,50,5/6/2021
C03C8B,earnings,100,50,5/6/2021
C03C8B,earnings,100,50,5/6/2021
C03C8B,earnings,100,50,5/6/2021
C0BA36,earnings,100,50,5/6/2021
C38440,earnings,100,50,5/6/2021
C38440,earnings,100,50,5/6/2021
C4706C,earnings,100,50,5/6/2021
C501B6,earnings,100,50,5/6/2021
C584BE,earnings,100,50,5/6/2021
C584BE,earnings,100,50,5/6/2021
C58D71,legal-issues-defendant,100,22,5/6/2021
C5C0E9,conference-participant,100,50,5/6/2021
C5C0E9,government-contract,100,69,5/6/2021
C5D2AE,award,100,58,5/6/2021
C65004,earnings,100,50,5/6/2021
C659EB,dividend,100,50,5/6/2021
C6C702,earnings,100,50,5/6/2021
C83B88,product-release,100,64,5/6/2021
C8A059,earnings,100,50,5/6/2021
C99CC8,earnings,100,50,5/6/2021
C99CC8,earnings,100,50,5/6/2021
C99CC8,earnings,100,50,5/6/2021
C99CC8,earnings,100,50,5/6/2021
C9E4EC,earnings,100,50,5/6/2021
CA212F,dividend,100,50,5/6/2021
CA99D7,conference-call,100,50,5/6/2021
CA99D7,conference-call,100,50,5/6/2021
CBDB4D,earnings,100,50,5/6/2021
CCB623,earnings,100,50,5/6/2021
CD06A2,conference-participant,100,50,5/6/2021
CDAA0E,earnings,100,50,5/6/2021
CDE118,earnings,100,50,5/6/2021
CDFCC9,earnings,100,50,5/6/2021
CDFCC9,dividend-up,100,81,5/6/2021
CE2791,earnings,100,50,5/6/2021
CEC5B9,earnings,100,50,5/6/2021
CEC5B9,earnings,100,50,5/6/2021
CEC5B9,earnings,100,50,5/6/2021
CEC5B9,earnings,100,50,5/6/2021
CF073E,conference-participant,100,50,5/6/2021
CF351E,merger-regulatory-approval,100,81,5/6/2021
CF351E,merger,100,66,5/6/2021
CF3FF9,earnings,100,50,5/6/2021
CFD4B6,earnings-up,100,68,5/6/2021
CFD4B6,earnings-up,100,68,5/6/2021
D09938,earnings,100,50,5/6/2021
D0DE27,earnings,100,50,5/6/2021
D11C1C,operating-earnings,100,50,5/6/2021
D296C6,earnings,100,50,5/6/2021
D36686,conference-participant,100,50,5/6/2021
D36B23,earnings,100,50,5/6/2021
D4070C,dividend,100,50,5/6/2021
D45285,earnings,100,50,5/6/2021
D45285,earnings,100,50,5/6/2021
D45285,earnings,100,50,5/6/2021
D45285,earnings,100,50,5/6/2021
D45285,earnings,100,50,5/6/2021
D47D56,partnership,100,61,5/6/2021
D57D99,dividend,100,50,5/6/2021
D58A11,partnership,100,61,5/6/2021
D5938F,earnings,100,50,5/6/2021
D6144F,conference-call,100,50,5/6/2021
D64C6D,dividend,100,50,5/6/2021
D6EAA3,executive-appointment,100,54,5/6/2021
D90F43,conference-participant,100,50,5/6/2021
D9164D,earnings-up,100,68,5/6/2021
DA9443,earnings,100,50,5/6/2021
DB5CA5,dividend,100,50,5/6/2021
DC0D18,earnings,100,50,5/6/2021
DC0D18,earnings,100,50,5/6/2021
DC0D18,earnings,100,50,5/6/2021
DC0D18,earnings,100,50,5/6/2021
DC2B00,conference-call,100,50,5/6/2021
DC437D,earnings,100,50,5/6/2021
DD1BA1,earnings,100,50,5/6/2021
DD1BA1,earnings,100,50,5/6/2021
DD1BA1,earnings,100,50,5/6/2021
DD1BA1,earnings,100,50,5/6/2021
DD1BA1,earnings,100,50,5/6/2021
DD1BA1,earnings,100,50,5/6/2021
DD1BA1,earnings,100,50,5/6/2021
DD1BA1,earnings,100,50,5/6/2021
DD3BB1,executive-appointment,100,54,5/6/2021
DDCB34,dividend,100,50,5/6/2021
DDCB34,earnings,100,50,5/6/2021
DDEA6A,earnings,100,50,5/6/2021
DDEA6A,executive-appointment,100,54,5/6/2021
DF16DE,earnings,100,50,5/6/2021
DF18E6,earnings,100,50,5/6/2021
DF18E6,earnings,100,50,5/6/2021
DF1F7A,earnings,100,50,5/6/2021
DF5F14,earnings,100,50,5/6/2021
DFADDB,earnings,100,50,5/6/2021
E0E4B7,earnings,100,50,5/6/2021
E11C41,earnings,100,50,5/6/2021
E11C41,business-contract,100,69,5/6/2021
E16133,earnings,100,50,5/6/2021
E16133,earnings,100,50,5/6/2021
E16133,earnings,100,50,5/6/2021
E16133,earnings,100,50,5/6/2021
E22FDE,earnings,100,50,5/6/2021
E2CB7B,earnings,100,50,5/6/2021
E2CFD2,earnings,100,50,5/6/2021
E2F66E,unit-acquisition-acquirer,100,49,5/6/2021
E2F66E,earnings-up,100,68,5/6/2021
E2F66E,earnings,100,50,5/6/2021
E2F66E,earnings,100,50,5/6/2021
E2F66E,earnings,100,50,5/6/2021
E35610,earnings,100,50,5/6/2021
E35610,earnings,100,50,5/6/2021
E35610,earnings,100,50,5/6/2021
E35610,earnings,100,50,5/6/2021
E38906,earnings,100,50,5/6/2021
E3A829,earnings,100,50,5/6/2021
E3A829,earnings,100,50,5/6/2021
E3A829,earnings,100,50,5/6/2021
E3A829,earnings,100,50,5/6/2021
E49AA3,earnings,100,50,5/6/2021
E4CE73,government-contract,100,69,5/6/2021
E56A0D,conference-participant,100,50,5/6/2021
E598FB,conference-participant,100,50,5/6/2021
E610CD,earnings,100,50,5/6/2021
E610CD,earnings,100,50,5/6/2021
E610CD,earnings,100,50,5/6/2021
E67C2C,earnings,100,50,5/6/2021
E6C8DC,earnings,100,50,5/6/2021
E72599,earnings,100,50,5/6/2021
E74B55,fraud-defendant,100,20,5/6/2021
E82A2D,earnings,100,50,5/6/2021
E8F0E2,earnings,100,50,5/6/2021
EA79C7,earnings,100,50,5/6/2021
EAA0A7,earnings,100,50,5/6/2021
EAA0A7,earnings,100,50,5/6/2021
EAA0A7,earnings,100,50,5/6/2021
EAA0A7,earnings,100,50,5/6/2021
EAA0A7,earnings,100,50,5/6/2021
EAEBF3,earnings,100,50,5/6/2021
EB1E1A,earnings,100,50,5/6/2021
ECF709,earnings,100,50,5/6/2021
ED3CA8,earnings,100,50,5/6/2021
ED9C04,earnings,100,50,5/6/2021
ED9C04,earnings,100,50,5/6/2021
ED9C04,earnings,100,50,5/6/2021
EEA6B3,note-sale,100,52,5/6/2021
EF1AD9,sponsorship,100,57,5/6/2021
EF25A5,earnings,100,50,5/6/2021
EF25A5,earnings,100,50,5/6/2021
EF25A5,earnings,100,50,5/6/2021
EF5914,earnings,100,50,5/6/2021
F02D0A,earnings-per-share-positive,100,69,5/6/2021
F02D0A,earnings,100,50,5/6/2021
F18844,partnership,100,61,5/6/2021
F2E253,earnings,100,50,5/6/2021
F3016C,earnings,100,50,5/6/2021
F3016C,earnings,100,50,5/6/2021
F3016C,earnings,100,50,5/6/2021
F3016C,earnings,100,50,5/6/2021
F30508,partnership,100,61,5/6/2021
F30508,partnership,100,61,5/6/2021
F30508,partnership,100,61,5/6/2021
F30508,partnership,100,61,5/6/2021
F3816D,conference-call,100,50,5/6/2021
F4D241,executive-appointment,100,54,5/6/2021
F4F46F,earnings,100,50,5/6/2021
F51DB0,earnings,100,50,5/6/2021
F6E1B5,earnings,100,50,5/6/2021
F6E248,conference-participant,100,50,5/6/2021
F6FA6A,earnings-positive,100,69,5/6/2021
F6FA6A,earnings-positive,100,69,5/6/2021
F721A7,earnings,100,50,5/6/2021
F721A7,earnings,100,50,5/6/2021
F72E4B,earnings,100,50,5/6/2021
F72E4B,earnings,100,50,5/6/2021
F73DD1,dividend,100,50,5/6/2021
F769E9,conference-call,100,50,5/6/2021
F80FF9,earnings,100,50,5/6/2021
F83279,earnings,100,50,5/6/2021
F83279,earnings,100,50,5/6/2021
F88A04,earnings,100,50,5/6/2021
F88A04,earnings,100,50,5/6/2021
F88A04,earnings,100,50,5/6/2021
F88A04,earnings,100,50,5/6/2021
F93C8A,earnings,100,50,5/6/2021
F9AA02,earnings,100,50,5/6/2021
FAB97A,revenues,100,50,5/6/2021
FACF19,partnership,100,61,5/6/2021
FC1F9D,dividend,100,50,5/6/2021
FC4550,dividend,100,50,5/6/2021
FD2565,earnings,100,50,5/6/2021
FD39EB,executive-appointment,100,54,5/6/2021
FD39EB,earnings,100,50,5/6/2021
FE609F,conference-call,100,50,5/6/2021
FEE4B0,earnings-up,100,68,5/6/2021
FEE4B0,earnings-up,100,68,5/6/2021
FEE4B0,earnings-up,100,68,5/6/2021
FEE4B0,earnings-up,100,68,5/6/2021
002A99,legal-issues-defendant,100,22,5/7/2021
002A99,legal-issues-defendant,100,22,5/7/2021
0157B1,investment-investor,100,55,5/7/2021
0157B1,facility-open,100,65,5/7/2021
03C94A,earnings,100,50,5/7/2021
03C94A,earnings,100,50,5/7/2021
048B70,earnings,100,50,5/7/2021
048B70,earnings,100,50,5/7/2021
048B70,earnings,100,50,5/7/2021
083F72,earnings,100,50,5/7/2021
84625,earnings,100,50,5/7/2021
84625,earnings,100,50,5/7/2021
0B7375,legal-issues-defendant,100,22,5/7/2021
0B7375,legal-issues-defendant,100,22,5/7/2021
0BD4E8,earnings,100,50,5/7/2021
0BD4E8,earnings,100,50,5/7/2021
0BD4E8,earnings,100,50,5/7/2021
0BD4E8,earnings,100,50,5/7/2021
0C6861,earnings,100,50,5/7/2021
0C8D82,business-contract,100,69,5/7/2021
0E5619,buybacks,100,74,5/7/2021
0E64D4,earnings,100,50,5/7/2021
0E64D4,earnings,100,50,5/7/2021
0E64D4,earnings,100,50,5/7/2021
0E64D4,earnings,100,50,5/7/2021
0E64D4,earnings,100,50,5/7/2021
0E64D4,earnings,100,50,5/7/2021
0E64D4,earnings,100,50,5/7/2021
102F04,earnings,100,50,5/7/2021
12E454,partnership,100,61,5/7/2021
152FA5,earnings,100,50,5/7/2021
154272,earnings,100,50,5/7/2021
165B86,earnings,100,50,5/7/2021
16B882,earnings,100,50,5/7/2021
1AB023,earnings,100,50,5/7/2021
1AB023,earnings,100,50,5/7/2021
1AB023,earnings,100,50,5/7/2021
1AB023,facility-upgrade,100,65,5/7/2021
1AB023,facility-upgrade,100,65,5/7/2021
1AB023,facility-upgrade,100,65,5/7/2021
1AF7E2,public-offering,100,43,5/7/2021
1D943E,conference-participant,100,50,5/7/2021
1E1125,legal-issues-defendant,100,22,5/7/2021
239106,earnings,100,50,5/7/2021
239106,earnings,100,50,5/7/2021
239106,earnings,100,50,5/7/2021
263216,conference-participant,100,50,5/7/2021
2920D5,conference-participant,100,50,5/7/2021
2A1009,legal-issues-defendant,100,22,5/7/2021
2C3348,business-contract,100,69,5/7/2021
2E902B,conference-participant,100,50,5/7/2021
2EC172,executive-appointment,100,54,5/7/2021
2EC172,earnings,100,50,5/7/2021
2F6782,earnings-up,100,68,5/7/2021
2F6782,earnings-up,100,68,5/7/2021
2F6782,earnings-up,100,68,5/7/2021
2F6782,earnings-up,100,68,5/7/2021
2F6782,earnings-up,100,68,5/7/2021
2F6782,earnings-up,100,68,5/7/2021
32F24A,executive-appointment,100,54,5/7/2021
353DBB,dividend,100,50,5/7/2021
35F4B5,dividend,100,50,5/7/2021
3798B9,conference-participant,100,50,5/7/2021
39BFF6,unit-acquisition-acquiree,100,76,5/7/2021
3B8484,earnings-up,100,68,5/7/2021
3F96D5,conference-call,100,50,5/7/2021
4017AD,conference-participant,100,50,5/7/2021
41C528,earnings,100,50,5/7/2021
41C528,earnings,100,50,5/7/2021
41ED98,earnings,100,50,5/7/2021
44A4FC,conference-participant,100,50,5/7/2021
49CC59,earnings-up,100,68,5/7/2021
4BBA23,revenue-up,100,69,5/7/2021
50070E,conference-organizer,100,57,5/7/2021
50070E,conference-organizer,100,57,5/7/2021
50070E,conference-organizer,100,57,5/7/2021
50070E,conference-organizer,100,57,5/7/2021
504FE2,acquisition-completed-acquirer,100,49,5/7/2021
504FE2,acquisition-completed-acquirer,100,49,5/7/2021
510EA1,earnings,100,50,5/7/2021
52B567,conference-call,100,50,5/7/2021
543C77,earnings,100,50,5/7/2021
54DF47,earnings,100,50,5/7/2021
550D01,unit-acquisition-acquirer,100,49,5/7/2021
579E8F,conference-participant,100,50,5/7/2021
579E8F,executive-appointment,100,54,5/7/2021
5C2A47,earnings,100,50,5/7/2021
5D63F1,dividend,100,50,5/7/2021
61E975,conference-participant,100,50,5/7/2021
636639,dividend,100,50,5/7/2021
66667F,revenue-up,100,94,5/7/2021
66667F,revenue-up,100,69,5/7/2021
66749D,dividend-up,100,81,5/7/2021
6830FE,conference-participant,100,50,5/7/2021
69CE71,sponsorship,100,57,5/7/2021
6CBF41,conference-participant,100,50,5/7/2021
6F39FC,dividend-up,100,57,5/7/2021
726EEA,earnings-up,100,68,5/7/2021
726EEA,earnings-up,100,68,5/7/2021
726EEA,earnings-up,100,68,5/7/2021
726EEA,earnings-up,100,68,5/7/2021
726EEA,earnings-up,100,68,5/7/2021
741937,earnings,100,50,5/7/2021
741937,earnings,100,50,5/7/2021
741937,earnings,100,50,5/7/2021
76BD96,earnings,100,50,5/7/2021
789A7D,dividend,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7999F3,earnings,100,50,5/7/2021
7AB859,product-release,100,64,5/7/2021
7AC86E,dividend,100,50,5/7/2021
7B8CB5,executive-resignation,100,44,5/7/2021
7D7716,investment-investor,100,55,5/7/2021
7DD8CC,earnings,100,50,5/7/2021
7F2922,earnings,100,50,5/7/2021
817ED9,board-meeting,100,51,5/7/2021
82F088,earnings,100,50,5/7/2021
82F088,earnings,100,50,5/7/2021
838ADD,dividend-up,100,81,5/7/2021
83E0AC,conference-call,100,50,5/7/2021
855DF7,earnings,100,50,5/7/2021
862941,earnings,100,50,5/7/2021
862941,earnings,100,50,5/7/2021
862941,earnings,100,50,5/7/2021
86A1B9,earnings-positive,100,69,5/7/2021
86A1B9,earnings-positive,100,69,5/7/2021
86A1B9,earnings-positive,100,69,5/7/2021
86A1B9,earnings-positive,100,69,5/7/2021
877C0C,earnings,100,50,5/7/2021
883D82,earnings,100,50,5/7/2021
8D4486,executive-appointment,100,54,5/7/2021
92D230,conference-call,100,50,5/7/2021
93F143,executive-appointment,100,54,5/7/2021
944B2E,earnings,100,50,5/7/2021
944B2E,earnings,100,50,5/7/2021
944B2E,earnings,100,50,5/7/2021
944B2E,earnings,100,50,5/7/2021
944B2E,earnings,100,50,5/7/2021
94983E,conference-participant,100,50,5/7/2021
966ACE,earnings,100,50,5/7/2021
97B027,executive-appointment,100,54,5/7/2021
990AD0,conference-organizer,100,57,5/7/2021
990AD0,conference-organizer,100,57,5/7/2021
990AD0,conference-organizer,100,57,5/7/2021
990AD0,conference-organizer,100,57,5/7/2021
990AD0,conference-organizer,100,57,5/7/2021
990AD0,conference-organizer,100,57,5/7/2021
990AD0,conference-organizer,100,57,5/7/2021
990AD0,conference-organizer,100,57,5/7/2021
9981C6,earnings,100,50,5/7/2021
9ABD30,conference-participant,100,50,5/7/2021
A1EAC8,conference-participant,100,50,5/7/2021
A4BCDE,earnings,100,50,5/7/2021
A5DD24,earnings,100,50,5/7/2021
A6FE1C,unit-acquisition-acquirer,100,49,5/7/2021
A7A0BD,conference-call,100,50,5/7/2021
A7A0C8,conference-participant,100,50,5/7/2021
A80FE0,conference-participant,100,50,5/7/2021
ABE7DC,clinical-trials,100,56,5/7/2021
ABE7DC,clinical-trials,100,56,5/7/2021
ACD9A4,dividend,100,50,5/7/2021
AD375D,executive-resignation,100,44,5/7/2021
AD9F1D,dividend,100,50,5/7/2021
AE7D16,earnings,100,50,5/7/2021
B2DAF6,credit-extension-recipient,100,69,5/7/2021
B3A166,conference-call,100,50,5/7/2021
B803B1,earnings,100,50,5/7/2021
B9CD50,acquisition-completed-acquirer,100,49,5/7/2021
BC948D,earnings,100,50,5/7/2021
BCE9DA,executive-appointment,100,54,5/7/2021
BCE9DA,executive-appointment,100,54,5/7/2021
BDE867,earnings,100,50,5/7/2021
BE14CF,conference-participant,100,50,5/7/2021
BFD0A7,earnings,100,50,5/7/2021
BFD0A7,earnings,100,50,5/7/2021
BFD0A7,earnings,100,50,5/7/2021
BFD0A7,earnings,100,50,5/7/2021
BFE02C,dividend,100,50,5/7/2021
BFE02C,conference-call,100,50,5/7/2021
C0200F,dividend-up,100,58,5/7/2021
C3DE7D,award,100,58,5/7/2021
C54140,earnings,100,50,5/7/2021
C99CC8,earnings,100,50,5/7/2021
C99CC8,earnings,100,50,5/7/2021
C99CC8,earnings,100,50,5/7/2021
C99CC8,earnings,100,50,5/7/2021
C99CC8,earnings,100,50,5/7/2021
C99CC8,earnings,100,50,5/7/2021
C99CC8,earnings,100,50,5/7/2021
C99CC8,earnings,100,50,5/7/2021
CEC08B,earnings,100,50,5/7/2021
CEC08B,earnings,100,50,5/7/2021
CEC08B,earnings,100,50,5/7/2021
CEC08B,earnings,100,50,5/7/2021
CEC08B,earnings,100,50,5/7/2021
CFD4B6,dividend,100,50,5/7/2021
D13F1C,earnings,100,50,5/7/2021
D13F1C,earnings,100,50,5/7/2021
D13F1C,earnings,100,50,5/7/2021
D13F1C,earnings,100,50,5/7/2021
D13F1C,earnings,100,50,5/7/2021
D13F1C,earnings,100,50,5/7/2021
D6853F,earnings,100,50,5/7/2021
D6853F,earnings,100,50,5/7/2021
D77F7E,earnings,100,50,5/7/2021
D854DD,dividend,100,50,5/7/2021
DA0A9E,dividend,100,50,5/7/2021
DAFED3,earnings,100,50,5/7/2021
DAFED3,earnings,100,50,5/7/2021
DAFED3,earnings,100,50,5/7/2021
DB23C8,business-contract,100,69,5/7/2021
DB23C8,earnings,100,50,5/7/2021
DB23C8,earnings,100,50,5/7/2021
DB23C8,earnings,100,50,5/7/2021
DB396B,earnings,100,50,5/7/2021
DB396B,earnings,100,50,5/7/2021
DB396B,earnings,100,50,5/7/2021
DB396B,earnings,100,50,5/7/2021
DF204B,earnings,100,50,5/7/2021
DF204B,business-contract,100,69,5/7/2021
E26FC3,dividend,100,50,5/7/2021
E3656D,earnings,100,50,5/7/2021
E87676,executive-appointment,100,54,5/7/2021
EF7163,earnings,100,50,5/7/2021
F48947,conference-participant,100,50,5/7/2021
F4D241,conference-participant,100,50,5/7/2021
F5D410,executive-appointment,100,54,5/7/2021
F5D410,executive-appointment,100,54,5/7/2021
F5D410,conference-participant,100,50,5/7/2021
F73DD1,earnings,100,50,5/7/2021
F73DD1,earnings,100,50,5/7/2021
F73DD1,earnings,100,50,5/7/2021
F73DD1,earnings,100,50,5/7/2021
F73DD1,earnings,100,50,5/7/2021
F73DD1,earnings,100,50,5/7/2021
F80389,public-offering,100,43,5/7/2021
F80FF9,earnings,100,50,5/7/2021
F80FF9,legal-issues-defendant,100,22,5/7/2021
F90EE5,dividend-up,100,81,5/7/2021
0B7375,legal-issues-defendant,100,22,5/8/2021
1348C9,merger,100,66,5/8/2021
1E1125,legal-issues-defendant,100,22,5/8/2021
2A1009,legal-issues-defendant,100,22,5/8/2021
366A08,legal-issues-defendant,100,22,5/8/2021
5B35C7,legal-issues-defendant,100,22,5/8/2021
68BA15,legal-issues-defendant,100,22,5/8/2021
863350,legal-issues-defendant,100,22,5/8/2021
C58D71,legal-issues-defendant,100,22,5/8/2021
C7863D,legal-issues-defendant,100,22,5/8/2021
CF351E,merger,100,66,5/8/2021
F80FF9,legal-issues-defendant,100,22,5/8/2021
4D203E,legal-issues-defendant,100,22,5/9/2021
5B35C7,legal-issues-defendant,100,22,5/9/2021
762B8D,legal-issues-defendant,100,22,5/9/2021
8D4AE6,legal-issues-defendant,100,22,5/9/2021
A16DEA,market-entry,100,57,5/9/2021
E74B55,legal-issues-defendant,100,22,5/9/2021
F82D37,legal-issues-defendant,100,22,5/9/2021
002A99,earnings,100,50,5/10/2021
00326D,conference-call,100,50,5/10/2021
9397,note-sale,100,52,5/10/2021
9397,note-sale,100,52,5/10/2021
0157B1,partnership,100,61,5/10/2021
0157B1,partnership,100,61,5/10/2021
02FC1A,earnings,100,50,5/10/2021
02FC1A,earnings,100,50,5/10/2021
03596A,earnings,100,50,5/10/2021
036C6F,earnings-up,100,68,5/10/2021
036C6F,earnings-up,100,68,5/10/2021
036C6F,earnings-up,100,68,5/10/2021
036C6F,earnings-up,100,68,5/10/2021
03FAA6,conference-participant,100,50,5/10/2021
040DBB,acquisition-acquirer,100,49,5/10/2021
040DBB,revenue-up,100,83,5/10/2021
040DBB,revenues,100,50,5/10/2021
040DBB,revenues,100,50,5/10/2021
040DBB,revenues,100,50,5/10/2021
040DBB,revenues,100,50,5/10/2021
43862,earnings,100,50,5/10/2021
0490C6,earnings,100,50,5/10/2021
0490C6,earnings,100,50,5/10/2021
0490C6,earnings,100,50,5/10/2021
0490C6,earnings,100,50,5/10/2021
04996E,earnings,100,50,5/10/2021
04996E,earnings,100,50,5/10/2021
099C88,business-contract,100,69,5/10/2021
099C88,conference-participant,100,50,5/10/2021
0A6824,earnings,100,50,5/10/2021
0B7375,legal-issues-defendant,100,22,5/10/2021
0BC29E,award,100,58,5/10/2021
0C6293,earnings,100,50,5/10/2021
0F0693,earnings,100,50,5/10/2021
0F2BC9,business-contract,100,69,5/10/2021
0FC848,earnings,100,50,5/10/2021
10943B,product-release,100,64,5/10/2021
1201B5,earnings,100,50,5/10/2021
1279ED,business-combination,100,54,5/10/2021
1279ED,business-combination,100,54,5/10/2021
1279ED,business-combination,100,54,5/10/2021
14391F,earnings,100,50,5/10/2021
147098,earnings,100,50,5/10/2021
15789A,earnings,100,50,5/10/2021
15789A,earnings,100,50,5/10/2021
15789A,earnings,100,50,5/10/2021
15789A,earnings,100,50,5/10/2021
15A388,conference-participant,100,50,5/10/2021
15A388,executive-appointment,100,54,5/10/2021
17EDA5,partnership,100,61,5/10/2021
17EDA5,partnership,100,61,5/10/2021
1880C5,earnings,100,50,5/10/2021
18D9FA,business-contract,100,69,5/10/2021
18D9FA,earnings,100,50,5/10/2021
18D9FA,earnings,100,50,5/10/2021
1921DD,partnership,100,61,5/10/2021
1AE9D5,revenue-up,100,69,5/10/2021
1AE9D5,revenue-up,100,69,5/10/2021
1BDB2A,acquisition-acquirer,100,49,5/10/2021
1BDB2A,acquisition-acquirer,100,49,5/10/2021
1BDB2A,acquisition-acquirer,100,49,5/10/2021
1CB9D3,earnings,100,50,5/10/2021
1CF3A8,earnings,100,50,5/10/2021
1E04A5,earnings,100,50,5/10/2021
1E1125,legal-issues-defendant,100,22,5/10/2021
1FC422,earnings,100,50,5/10/2021
228D42,partnership,100,61,5/10/2021
228D42,partnership,100,61,5/10/2021
23207A,conference-call,100,50,5/10/2021
25D3CE,business-contract,100,69,5/10/2021
267718,regulatory-product-approval-granted,100,81,5/10/2021
2920D5,note-sale,100,52,5/10/2021
2920D5,public-offering,100,43,5/10/2021
292388,earnings-up,100,68,5/10/2021
292388,earnings,100,50,5/10/2021
292388,earnings,100,50,5/10/2021
292388,earnings,100,50,5/10/2021
292388,earnings,100,50,5/10/2021
2A1009,legal-issues-defendant,100,22,5/10/2021
2B7A40,facility-open,100,65,5/10/2021
2BAE5F,earnings,100,50,5/10/2021
2BBE62,earnings,100,50,5/10/2021
2BBE62,earnings,100,50,5/10/2021
2BBE62,earnings,100,50,5/10/2021
2BBE62,earnings,100,50,5/10/2021
2C681C,clinical-trials-positive,100,87,5/10/2021
2C681C,clinical-trials-positive,100,87,5/10/2021
2C681C,clinical-trials-positive,100,87,5/10/2021
2C681C,earnings,100,50,5/10/2021
2CC60C,earnings,100,50,5/10/2021
2CF9D3,sponsorship,100,57,5/10/2021
2EBA55,earnings,100,50,5/10/2021
2FF046,conference-participant,100,50,5/10/2021
317EC6,conference-participant,100,50,5/10/2021
32DCB3,legal-issues-defendant,100,22,5/10/2021
33A0F1,award,100,58,5/10/2021
34B411,public-offering,100,43,5/10/2021
34E9F9,earnings,100,50,5/10/2021
34E9F9,earnings,100,50,5/10/2021
34E9F9,earnings,100,50,5/10/2021
34E9F9,earnings,100,50,5/10/2021
34E9F9,earnings,100,50,5/10/2021
36529A,earnings,100,50,5/10/2021
366A08,note-sale,100,52,5/10/2021
366A08,legal-issues-defendant,100,22,5/10/2021
366A08,note-sale,100,52,5/10/2021
36C09B,earnings,100,50,5/10/2021
385DD4,earnings,100,50,5/10/2021
3DD5E2,operating-earnings,100,50,5/10/2021
3F1C69,earnings,100,50,5/10/2021
442769,conference-participant,100,50,5/10/2021
450ECB,ebitda-up,100,92,5/10/2021
450ECB,ebitda,100,50,5/10/2021
4595EF,conference-call,100,50,5/10/2021
468DD4,executive-appointment,100,54,5/10/2021
47B4CC,conference-call,100,50,5/10/2021
485445,earnings,100,50,5/10/2021
485445,earnings,100,50,5/10/2021
485445,earnings,100,50,5/10/2021
485445,earnings,100,50,5/10/2021
485445,earnings,100,50,5/10/2021
485445,earnings,100,50,5/10/2021
499C75,earnings,100,50,5/10/2021
4A6F00,partnership,100,61,5/10/2021
4BAF2E,earnings,100,50,5/10/2021
50070E,conference-organizer,100,57,5/10/2021
5065B1,public-offering,100,43,5/10/2021
50D1EC,earnings,100,50,5/10/2021
519FE0,earnings,100,50,5/10/2021
51E682,dividend,100,50,5/10/2021
51F541,note-sale,100,52,5/10/2021
51F541,note-sale,100,52,5/10/2021
520632,business-contract,100,69,5/10/2021
52FB2F,facility-open,100,65,5/10/2021
539F49,earnings,100,50,5/10/2021
546A27,earnings,100,50,5/10/2021
57CAAB,conference-participant,100,50,5/10/2021
57DDB9,note-sale,100,52,5/10/2021
5A0FF1,earnings,100,50,5/10/2021
5A0FF1,earnings,100,50,5/10/2021
5A0FF1,earnings,100,50,5/10/2021
5A0FF1,earnings,100,50,5/10/2021
5A0FF1,earnings,100,50,5/10/2021
5C2A47,acquisition-acquirer,100,49,5/10/2021
5C2A47,earnings,100,50,5/10/2021
5D63F1,earnings,100,50,5/10/2021
5EAA43,unit-acquisition-completed-acquiree,100,67,5/10/2021
5F3D91,earnings,100,50,5/10/2021
5F9CE3,partnership,100,61,5/10/2021
619882,conference-organizer,100,57,5/10/2021
619882,conference-organizer,100,57,5/10/2021
629F0F,earnings,100,50,5/10/2021
68AB62,earnings-up,100,68,5/10/2021
69C99E,earnings,100,50,5/10/2021
6A171E,earnings,100,50,5/10/2021
6A961B,acquisition-completed-acquirer,100,49,5/10/2021
6A961B,earnings,100,50,5/10/2021
6B494E,earnings,100,50,5/10/2021
6B6375,executive-appointment,100,54,5/10/2021
6D2BF6,earnings,100,50,5/10/2021
6D9B53,conference-participant,100,50,5/10/2021
6-Dec-05,earnings,100,50,5/10/2021
6FCEF9,earnings,100,50,5/10/2021
70B3D6,executive-appointment,100,54,5/10/2021
70CA28,conference-participant,100,50,5/10/2021
7122EB,earnings,100,50,5/10/2021
717DB4,executive-appointment,100,54,5/10/2021
73A213,earnings,100,50,5/10/2021
73A213,earnings,100,50,5/10/2021
73A213,earnings,100,50,5/10/2021
748EB6,earnings,100,50,5/10/2021
751C8D,earnings,100,50,5/10/2021
75F982,business-contract,100,69,5/10/2021
763DBE,earnings,100,50,5/10/2021
76959C,conference-participant,100,50,5/10/2021
76DD0C,earnings,100,50,5/10/2021
76E80F,stock-loss,100,40,5/10/2021
7712CB,earnings,100,50,5/10/2021
7712CB,earnings,100,50,5/10/2021
7712CB,earnings,100,50,5/10/2021
7712CB,earnings,100,50,5/10/2021
7712CB,earnings,100,50,5/10/2021
7712CB,earnings,100,50,5/10/2021
771985,stake-acquirer,100,48,5/10/2021
7823A3,partnership,100,61,5/10/2021
789A7D,earnings,100,50,5/10/2021
789A7D,earnings,100,50,5/10/2021
789A7D,earnings,100,50,5/10/2021
789A7D,earnings,100,50,5/10/2021
78F776,executive-appointment,100,54,5/10/2021
78F776,earnings,100,50,5/10/2021
78F776,earnings,100,50,5/10/2021
790C34,note-sale,100,52,5/10/2021
791EC1,earnings,100,50,5/10/2021
7A51FE,earnings,100,50,5/10/2021
7DD8CC,public-offering,100,43,5/10/2021
7F3669,conference-participant,100,50,5/10/2021
7FDE1C,note-sale,100,52,5/10/2021
81222C,conference-participant,100,50,5/10/2021
82FD6D,conference-call,100,50,5/10/2021
8.40E+120,executive-appointment,100,54,5/10/2021
85DA04,product-release,100,64,5/10/2021
8665BA,conference-participant,100,50,5/10/2021
8.79E+06,earnings,100,50,5/10/2021
87D591,note-sale,100,52,5/10/2021
881190,dividend-up,100,81,5/10/2021
88193E,executive-appointment,100,54,5/10/2021
8A8E41,product-release,100,64,5/10/2021
8AB85C,executive-appointment,100,54,5/10/2021
8B8656,partnership,100,61,5/10/2021
8DA42F,earnings,100,50,5/10/2021
8DA42F,earnings,100,50,5/10/2021
8DA42F,earnings,100,50,5/10/2021
8DA42F,earnings,100,50,5/10/2021
8DCF18,earnings,100,50,5/10/2021
8DCF18,earnings,100,50,5/10/2021
8DCF18,earnings,100,50,5/10/2021
8E10BF,earnings,100,50,5/10/2021
8E3F58,investment-investor,100,55,5/10/2021
8F6995,earnings,100,50,5/10/2021
8FF2EF,dividend,100,50,5/10/2021
900356,earnings-guidance-up,100,83,5/10/2021
92D230,earnings,100,50,5/10/2021
92D230,earnings,100,50,5/10/2021
92D230,earnings,100,50,5/10/2021
92D230,earnings,100,50,5/10/2021
92D230,earnings,100,50,5/10/2021
92D230,earnings,100,50,5/10/2021
92D230,earnings,100,50,5/10/2021
92D9C9,executive-appointment,100,54,5/10/2021
931AE7,earnings,100,50,5/10/2021
9368BE,earnings,100,50,5/10/2021
9.54E+32,hirings,100,65,5/10/2021
966DBE,earnings,100,50,5/10/2021
966DBE,earnings,100,50,5/10/2021
966DBE,earnings,100,50,5/10/2021
966DBE,earnings,100,50,5/10/2021
966DBE,earnings,100,50,5/10/2021
96B4FF,executive-appointment,100,54,5/10/2021
96BFF4,conference-call,100,50,5/10/2021
97B027,earnings-up,100,68,5/10/2021
97B027,earnings-up,100,68,5/10/2021
97B027,earnings-up,100,68,5/10/2021
990AD0,conference-organizer,100,57,5/10/2021
990AD0,conference-organizer,100,57,5/10/2021
990AD0,conference-organizer,100,57,5/10/2021
990AD0,conference-organizer,100,57,5/10/2021
990AD0,conference-organizer,100,57,5/10/2021
990AD0,conference-organizer,100,57,5/10/2021
990AD0,conference-organizer,100,57,5/10/2021
9B71A7,product-release,100,64,5/10/2021
9C009A,executive-appointment,100,54,5/10/2021
9E575E,earnings,100,50,5/10/2021
9E91C6,earnings,100,50,5/10/2021
A01983,earnings,100,50,5/10/2021
A1DBF0,earnings,100,50,5/10/2021
A26C26,joint-venture,100,62,5/10/2021
A28675,earnings,100,50,5/10/2021
A433A5,conference-participant,100,50,5/10/2021
A495F7,earnings,100,50,5/10/2021
A495F7,dividend,100,50,5/10/2021
A63820,workforce-salary-increase,100,44,5/10/2021
A6D095,business-contract,100,69,5/10/2021
A6FC89,conference-call,100,50,5/10/2021
A8E72A,earnings,100,50,5/10/2021
AA09AD,earnings,100,50,5/10/2021
AB4A7E,conference-participant,100,50,5/10/2021
ACDCFA,operating-earnings,100,50,5/10/2021
AD1ACF,earnings,100,50,5/10/2021
AD1ACF,earnings,100,50,5/10/2021
AD1ACF,earnings,100,50,5/10/2021
AD1ACF,earnings,100,50,5/10/2021
AD1ACF,earnings,100,50,5/10/2021
AD3C93,executive-appointment,100,54,5/10/2021
AE4125,earnings-up,100,68,5/10/2021
AE4125,earnings,100,50,5/10/2021
AE4125,earnings,100,50,5/10/2021
AE79CD,clinical-trials-filed,100,60,5/10/2021
B13B68,index-listing,100,76,5/10/2021
B1A85D,earnings,100,50,5/10/2021
B1FC3B,business-contract,100,69,5/10/2021
B2206F,product-release,100,64,5/10/2021
B2206F,earnings,100,50,5/10/2021
B33E77,clinical-trials-positive,100,87,5/10/2021
B33E77,clinical-trials-positive,100,87,5/10/2021
B33E77,earnings,100,50,5/10/2021
B4C673,dividend,100,50,5/10/2021
B54A74,earnings,100,50,5/10/2021
B83BCE,conference-participant,100,50,5/10/2021
B9CD50,earnings,100,50,5/10/2021
BA0442,acquisition-acquirer,100,49,5/10/2021
BA0442,earnings,100,50,5/10/2021
BCC55F,award,100,58,5/10/2021
BDEC1E,earnings,100,50,5/10/2021
BE379D,earnings,100,50,5/10/2021
BE645B,regulatory-product-approval-granted,100,81,5/10/2021
BEA527,earnings,100,50,5/10/2021
BFEA04,executive-appointment,100,54,5/10/2021
BFEA04,earnings,100,50,5/10/2021
BFEA04,earnings,100,50,5/10/2021
BFEA04,earnings,100,50,5/10/2021
BFEA04,earnings,100,50,5/10/2021
C0F70B,conference-participant,100,50,5/10/2021
C2609A,earnings,100,50,5/10/2021
C2DD02,earnings,100,50,5/10/2021
C3BAE7,earnings-up,100,68,5/10/2021
C3BAE7,earnings,100,50,5/10/2021
C3BAE7,earnings,100,50,5/10/2021
C3BAE7,earnings,100,50,5/10/2021
C3BAE7,earnings,100,50,5/10/2021
C3BAE7,earnings,100,50,5/10/2021
C425AE,earnings,100,50,5/10/2021
C4A241,conference-participant,100,50,5/10/2021
C50B26,earnings,100,50,5/10/2021
C564E4,conference-participant,100,50,5/10/2021
C5D2AE,partnership,100,61,5/10/2021
C5F463,business-contract,100,69,5/10/2021
C65004,conference-participant,100,50,5/10/2021
C74887,clinical-trials,100,56,5/10/2021
C85A72,conference-participant,100,50,5/10/2021
C941DC,earnings,100,50,5/10/2021
C9732E,earnings,100,50,5/10/2021
C99CC8,award,100,58,5/10/2021
CA212F,earnings,100,50,5/10/2021
CB9E13,earnings,100,50,5/10/2021
CC0C78,earnings,100,50,5/10/2021
CD051C,conference-participant,100,50,5/10/2021
CD2A4D,executive-appointment,100,54,5/10/2021
CEDFD5,partnership,100,61,5/10/2021
CEDFD5,partnership,100,61,5/10/2021
CF073E,earnings,100,50,5/10/2021
CF3FF9,executive-appointment,100,54,5/10/2021
D06996,earnings,100,50,5/10/2021
D1588D,earnings,100,50,5/10/2021
D27FAB,earnings,100,50,5/10/2021
D54E62,business-contract,100,69,5/10/2021
D6144F,earnings,100,50,5/10/2021
D63B0F,earnings,100,50,5/10/2021
D63B0F,earnings,100,50,5/10/2021
D63B0F,earnings,100,50,5/10/2021
D697DE,earnings,100,50,5/10/2021
D854F3,conference-participant,100,50,5/10/2021
D8C09D,business-combination,100,54,5/10/2021
D8C09D,business-combination,100,54,5/10/2021
D8C09D,business-combination,100,54,5/10/2021
D8C09D,legal-issues-defendant,100,22,5/10/2021
DA48E4,earnings-per-share,100,50,5/10/2021
DB5CA5,earnings,100,50,5/10/2021
DD0F15,earnings,100,50,5/10/2021
DD1BA1,unit-acquisition-completed-acquirer,100,49,5/10/2021
DF01B1,public-offering,100,43,5/10/2021
DF5F14,earnings-up,100,68,5/10/2021
E07573,earnings,100,50,5/10/2021
E07573,earnings,100,50,5/10/2021
E07573,earnings,100,50,5/10/2021
E07573,earnings,100,50,5/10/2021
E09997,earnings,100,50,5/10/2021
E259C7,earnings,100,50,5/10/2021
E28D9C,conference-participant,100,50,5/10/2021
E4CE73,product-release,100,64,5/10/2021
E5752F,earnings,100,50,5/10/2021
E5752F,earnings,100,50,5/10/2021
E5752F,earnings,100,50,5/10/2021
E5752F,earnings,100,50,5/10/2021
E68733,product-release,100,64,5/10/2021
E68733,product-release,100,64,5/10/2021
E68E62,earnings,100,50,5/10/2021
E6BC2C,revenue-up,100,90,5/10/2021
E6BC2C,earnings-up,100,68,5/10/2021
E6BC2C,earnings-up,100,68,5/10/2021
E74B55,earnings,100,50,5/10/2021
E8846E,executive-appointment,100,54,5/10/2021
EB1E1A,executive-appointment,100,54,5/10/2021
EB43F4,earnings,100,50,5/10/2021
EB7D6C,earnings,100,50,5/10/2021
EC4E82,revenue-up,100,78,5/10/2021
ECE19E,earnings,100,50,5/10/2021
ECF4F8,earnings,100,50,5/10/2021
ED7F13,public-offering,100,43,5/10/2021
ED9C04,business-contract,100,69,5/10/2021
EE1E44,earnings,100,50,5/10/2021
EEA734,earnings,100,50,5/10/2021
EEB5F9,earnings,100,50,5/10/2021
EEEA9F,partnership,100,61,5/10/2021
EEEA9F,public-offering,100,43,5/10/2021
F00285,earnings,100,50,5/10/2021
F2BC3D,earnings,100,50,5/10/2021
F48947,earnings,100,50,5/10/2021
F4D241,earnings,100,50,5/10/2021
F4E882,product-release,100,64,5/10/2021
F509E2,earnings,100,50,5/10/2021
F5D499,earnings,100,50,5/10/2021
F5D499,earnings,100,50,5/10/2021
F5D499,earnings,100,50,5/10/2021
F7ADEB,conference-participant,100,50,5/10/2021
FA840E,earnings,100,50,5/10/2021
FD2565,note-sale,100,52,5/10/2021
FDF28E,earnings,100,50,5/10/2021
FF227B,earnings,100,50,5/10/2021
FFCD0E,earnings,100,50,5/10/2021
0157B1,partnership,100,61,5/11/2021
03B8CF,dividend,100,50,5/11/2021
03D5F9,conference-participant,100,50,5/11/2021
03FAA6,partnership,100,61,5/11/2021
05D148,clinical-trials,100,56,5/11/2021
05D148,clinical-trials,100,56,5/11/2021
06C826,earnings,100,50,5/11/2021
0A9D0A,earnings,100,50,5/11/2021
0BD199,clinical-trials-start,100,64,5/11/2021
0BD199,clinical-trials-start,100,64,5/11/2021
0BF198,public-offering,100,43,5/11/2021
0C2A0D,note-sale,100,52,5/11/2021
0EF1AF,conference-participant,100,50,5/11/2021
125212,conference-organizer,100,57,5/11/2021
131443,executive-appointment,100,54,5/11/2021
131443,dividend,100,50,5/11/2021
135B09,executive-appointment,100,54,5/11/2021
1490F3,dividend,100,50,5/11/2021
14ED2B,executive-appointment,100,54,5/11/2021
17EDA5,product-release,100,64,5/11/2021
1A1ED9,partnership,100,61,5/11/2021
1A3E1B,conference-participant,100,50,5/11/2021
1B6F77,earnings,100,50,5/11/2021
1CD4B5,clinical-trials,100,56,5/11/2021
1DB833,earnings,100,50,5/11/2021
1E1125,executive-appointment,100,54,5/11/2021
1F716B,executive-appointment,100,54,5/11/2021
1F9D90,partnership,100,61,5/11/2021
1FA886,partnership,100,61,5/11/2021
1FCC00,partnership,100,61,5/11/2021
241252,earnings,100,50,5/11/2021
249B39,dividend,100,50,5/11/2021
24C48B,dividend,100,50,5/11/2021
24CB56,partnership,100,61,5/11/2021
24CB56,earnings,100,50,5/11/2021
26CC63,conference-participant,100,50,5/11/2021
26E3BA,earnings,100,50,5/11/2021
284289,dividend-up,100,56,5/11/2021
292388,partnership,100,61,5/11/2021
2ABF77,conference-participant,100,50,5/11/2021
2BA977,executive-appointment,100,54,5/11/2021
2BDC1C,earnings,100,50,5/11/2021
2F1299,earnings,100,50,5/11/2021
2F1299,earnings,100,50,5/11/2021
2F1299,earnings,100,50,5/11/2021
2F1299,earnings,100,50,5/11/2021
2F1299,earnings,100,50,5/11/2021
2F1299,earnings,100,50,5/11/2021
2F1299,earnings,100,50,5/11/2021
2F1299,earnings,100,50,5/11/2021
2F1299,earnings,100,50,5/11/2021
2F1299,executive-appointment,100,54,5/11/2021
2F7A7E,note-sale,100,52,5/11/2021
2F94A5,dividend,100,50,5/11/2021
3461CF,conference-participant,100,50,5/11/2021
346BF2,legal-issues-defendant,100,22,5/11/2021
367E1C,conference-participant,100,50,5/11/2021
387541,note-sale,100,52,5/11/2021
3B50FE,conference-call,100,50,5/11/2021
3F6A9C,earnings-up,100,68,5/11/2021
43A74A,conference-participant,100,50,5/11/2021
449447,conference-participant,100,50,5/11/2021
458D2C,hirings,100,65,5/11/2021
49A344,government-contract,100,69,5/11/2021
4A6F00,partnership,100,61,5/11/2021
4A7C1F,earnings,100,50,5/11/2021
4AE584,executive-appointment,100,54,5/11/2021
4C1FA1,dividend,100,50,5/11/2021
4C1FA1,dividend,100,50,5/11/2021
4D229C,earnings,100,50,5/11/2021
4DD09F,earnings-up,100,68,5/11/2021
523039,earnings,100,50,5/11/2021
5288FC,earnings,100,50,5/11/2021
54512F,business-contract,100,69,5/11/2021
5480A7,dividend,100,50,5/11/2021
556F08,earnings,100,50,5/11/2021
55ACCB,conference-participant,100,50,5/11/2021
57DDB9,conference-participant,100,50,5/11/2021
5A0FF1,product-release,100,64,5/11/2021
5B51D6,conference-participant,100,50,5/11/2021
5D41E4,conference-participant,100,50,5/11/2021
5F9CE3,partnership,100,61,5/11/2021
605F40,award,100,58,5/11/2021
60AC34,earnings,100,50,5/11/2021
616E3B,dividend,100,50,5/11/2021
619882,conference-organizer,100,57,5/11/2021
65AB30,conference-participant,100,50,5/11/2021
665618,acquisition-completed-acquirer,100,49,5/11/2021
66CB62,dividend,100,50,5/11/2021
66ECFD,note-sale,100,52,5/11/2021
673C9A,earnings,100,50,5/11/2021
67B923,partnership,100,61,5/11/2021
68E3E0,revenues,100,50,5/11/2021
68E3E0,revenue-up,100,69,5/11/2021
68E3E0,revenue-up,100,69,5/11/2021
68E3E0,revenue-up,100,69,5/11/2021
68E3E0,revenue-up,100,69,5/11/2021
69FDFC,award,100,58,5/11/2021
6A024C,earnings,100,50,5/11/2021
6BBCBA,earnings,100,50,5/11/2021
6C4D2F,note-sale,100,52,5/11/2021
713810,conference-call,100,50,5/11/2021
71553E,earnings-up,100,68,5/11/2021
71553E,earnings,100,50,5/11/2021
71553E,earnings,100,50,5/11/2021
724F84,earnings,100,50,5/11/2021
742AAB,executive-appointment,100,54,5/11/2021
75D689,earnings,100,50,5/11/2021
763DBE,conference-participant,100,50,5/11/2021
7732C2,earnings,100,50,5/11/2021
7732C2,public-offering,100,43,5/11/2021
7734AC,dividend,100,50,5/11/2021
7BFF81,conference-participant,100,50,5/11/2021
7DD584,revenue-up,100,69,5/11/2021
7DD8CC,public-offering,100,43,5/11/2021
7E3F8F,regulatory-investigation,100,22,5/11/2021
7E3F8F,regulatory-investigation,100,22,5/11/2021
7F7C87,earnings,100,50,5/11/2021
7FD8B9,conference-participant,100,50,5/11/2021
817ED9,dividend,100,50,5/11/2021
834152,legal-issues-defendant,100,22,5/11/2021
8AB37F,conference-participant,100,50,5/11/2021
8B9B3B,conference-participant,100,50,5/11/2021
8C311A,product-release,100,64,5/11/2021
8C5519,partnership,100,61,5/11/2021
8D4486,partnership,100,61,5/11/2021
8DE56F,partnership,100,61,5/11/2021
8E0E32,dividend,100,50,5/11/2021
8E4F9A,executive-appointment,100,54,5/11/2021
8E8E6E,business-contract,100,69,5/11/2021
9004C4,earnings-positive,100,69,5/11/2021
9004C4,earnings,100,50,5/11/2021
9004C4,earnings,100,50,5/11/2021
918D6D,earnings,100,50,5/11/2021
92005C,earnings,100,50,5/11/2021
922F0C,dividend,100,50,5/11/2021
92B625,conference-participant,100,50,5/11/2021
94A326,earnings,100,50,5/11/2021
9.54E+32,partnership,100,61,5/11/2021
95C575,dividend,100,50,5/11/2021
95DC1F,partnership,100,61,5/11/2021
968B00,dividend,100,50,5/11/2021
97AF94,earnings,100,50,5/11/2021
981656,earnings,100,50,5/11/2021
986AF6,business-contract,100,69,5/11/2021
9CA619,partnership,100,61,5/11/2021
9D30A8,product-release,100,64,5/11/2021
9E298A,acquisition-acquirer,100,49,5/11/2021
9EF4CF,partnership,100,61,5/11/2021
9F18FA,earnings,100,50,5/11/2021
9F18FA,earnings,100,50,5/11/2021
A03EE1,earnings,100,50,5/11/2021
A29A46,acquisition-acquiree,100,76,5/11/2021
A29A46,acquisition-acquiree,100,76,5/11/2021
A29A46,legal-issues-defendant,100,22,5/11/2021
A29A46,acquisition-regulatory-scrutiny-acquiree,100,38,5/11/2021
A48593,earnings,100,50,5/11/2021
A70BF5,buybacks,100,74,5/11/2021
A806FA,earnings,100,50,5/11/2021
A868C9,business-contract,100,69,5/11/2021
AC775C,earnings,100,50,5/11/2021
AC775C,earnings,100,50,5/11/2021
AC775C,earnings,100,50,5/11/2021
AC7AAE,earnings,100,50,5/11/2021
AECCA9,conference-call,100,50,5/11/2021
AEEB76,earnings,100,50,5/11/2021
AEEB76,earnings,100,50,5/11/2021
B1FC3B,business-contract,100,69,5/11/2021
B4B281,conference-call,100,50,5/11/2021
B60366,earnings,100,50,5/11/2021
B8A51F,conference-participant,100,50,5/11/2021
B934BF,index-listing,100,76,5/11/2021
B96DF5,executive-appointment,100,54,5/11/2021
B98EFA,business-contract,100,69,5/11/2021
BB88B6,partnership,100,61,5/11/2021
BB88B6,product-release,100,64,5/11/2021
C03C8B,executive-appointment,100,54,5/11/2021
C07E05,earnings,100,50,5/11/2021
C501B6,fundraising,100,64,5/11/2021
C584BE,public-offering,100,43,5/11/2021
C5D2AE,award,100,58,5/11/2021
C8257F,executive-resignation,100,44,5/11/2021
CAC8D0,partnership,100,61,5/11/2021
CB89EA,conference-participant,100,50,5/11/2021
CC3EC4,earnings-up,100,68,5/11/2021
CC3EC4,earnings,100,50,5/11/2021
CD4DA8,executive-appointment,100,54,5/11/2021
CDAF5B,dividend,100,50,5/11/2021
CDE118,trading-halt,100,43,5/11/2021
CDE118,acquisition-acquiree,100,76,5/11/2021
CDE118,trading-resumed,100,58,5/11/2021
CDE118,legal-issues-defendant,100,22,5/11/2021
CEC08B,conference-participant,100,50,5/11/2021
CF7292,partnership,100,61,5/11/2021
CFF97C,credit-rating-affirmation-rater,20,50,5/11/2021
D18AFC,earnings,100,50,5/11/2021
D1C26F,conference-participant,100,50,5/11/2021
D29B44,joint-venture,100,62,5/11/2021
D2C0B6,earnings,100,50,5/11/2021
D36686,earnings,100,50,5/11/2021
D54E62,merger-completed,100,66,5/11/2021
D58A11,product-release,100,64,5/11/2021
D6489C,partnership,100,61,5/11/2021
D854DD,executive-appointment,100,54,5/11/2021
DB06B0,earnings,100,50,5/11/2021
DB2E4E,conference-participant,100,50,5/11/2021
DB88A1,award,100,58,5/11/2021
DBB28E,conference-call,100,50,5/11/2021
DD1BA1,business-contract,100,69,5/11/2021
E05026,earnings-up,100,68,5/11/2021
E3E68E,government-contract,100,69,5/11/2021
E3E68E,government-contract,100,69,5/11/2021
E4CE73,conference-participant,100,50,5/11/2021
E598FB,earnings,100,50,5/11/2021
E5A3B6,earnings,100,50,5/11/2021
E71AE6,conference-participant,100,50,5/11/2021
E7BF32,clinical-trials,100,56,5/11/2021
E7BF32,clinical-trials,100,56,5/11/2021
EAEBF3,conference-participant,100,50,5/11/2021
EBC84C,conference-participant,100,50,5/11/2021
EC1AF3,earnings,100,50,5/11/2021
ED1A74,earnings,100,50,5/11/2021
ED3CA8,facility-open,100,65,5/11/2021
ED7F13,public-offering,100,43,5/11/2021
EEEA9F,public-offering,100,43,5/11/2021
F02D0A,executive-appointment,100,54,5/11/2021
F05B1B,fast-track-designation,100,81,5/11/2021
F30508,partnership,100,61,5/11/2021
F58C23,conference-organizer,100,57,5/11/2021
F6581D,conference-call,100,50,5/11/2021
F702CA,buybacks,100,74,5/11/2021
FC01C0,conference-participant,100,50,5/11/2021
FCA54E,earnings,100,50,5/11/2021
FD2565,note-sale,100,52,5/11/2021
FD6926,conference-participant,100,50,5/11/2021
FD9526,dividend,100,50,5/11/2021
FD9A97,earnings,100,50,5/11/2021
FE609F,earnings,100,50,5/11/2021
FE9C0D,clinical-trials-positive,100,87,5/11/2021
FE9C0D,earnings,100,50,5/11/2021
FEC475,dividend,100,50,5/11/2021
002A99,legal-issues-defendant,100,22,5/12/2021
00E601,dividend,100,50,5/12/2021
0157B1,product-release,100,64,5/12/2021
0157B1,product-release,100,64,5/12/2021
033B58,earnings,100,50,5/12/2021
06C826,earnings,100,50,5/12/2021
95294,earnings,100,50,5/12/2021
96930,conference-participant,100,50,5/12/2021
099A92,executive-appointment,100,54,5/12/2021
0B4D10,dividend,100,50,5/12/2021
0CE204,partnership,100,61,5/12/2021
0CE204,unit-acquisition-acquirer,100,49,5/12/2021
0D03C8,clinical-trials-start,100,64,5/12/2021
0E499E,conference-participant,100,50,5/12/2021
0F2BC9,earnings-up,100,68,5/12/2021
0F2BC9,earnings-up,100,68,5/12/2021
0F2BC9,earnings-up,100,68,5/12/2021
0FC848,conference-participant,100,50,5/12/2021
1065BC,board-meeting,100,51,5/12/2021
11AEDE,earnings,100,50,5/12/2021
12DE76,acquisition-interest-acquirer,100,46,5/12/2021
133644,conference-participant,100,50,5/12/2021
135B09,dividend,100,50,5/12/2021
13D576,earnings,100,50,5/12/2021
1.79E+10,note-sale,100,52,5/12/2021
184988,earnings,100,50,5/12/2021
18A98C,earnings,100,50,5/12/2021
1921DD,acquisition-regulatory-approval-acquiree,100,81,5/12/2021
1BDB2A,dividend-up,100,81,5/12/2021
1DA44F,dividend-up,100,81,5/12/2021
1DA44F,executive-appointment,100,54,5/12/2021
1EBF8D,product-release,100,64,5/12/2021
1EC3E8,unit-acquisition-acquirer,100,49,5/12/2021
1EC3E8,unit-acquisition-acquirer,100,49,5/12/2021
1F352C,product-release,100,64,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21153F,earnings,100,50,5/12/2021
21D903,earnings,100,50,5/12/2021
227F04,conference-participant,100,50,5/12/2021
228D42,partnership,100,61,5/12/2021
228D42,partnership,100,61,5/12/2021
24C48B,acquisition-completed-acquirer,100,49,5/12/2021
27B191,conference-call,100,50,5/12/2021
2.90E+62,award,100,58,5/12/2021
2B8179,clinical-trials,100,56,5/12/2021
2CC71C,conference-participant,100,50,5/12/2021
2D643C,note-sale,100,52,5/12/2021
2EB88B,product-release,100,64,5/12/2021
32DCB3,earnings,100,50,5/12/2021
346BF2,legal-issues-defendant,100,22,5/12/2021
346BF2,earnings,100,50,5/12/2021
34B411,executive-appointment,100,54,5/12/2021
35557B,executive-appointment,100,54,5/12/2021
3.50E+27,dividend,100,50,5/12/2021
367434,clinical-trials-positive,100,87,5/12/2021
384CD3,dividend-up,100,81,5/12/2021
3BB7D3,earnings,100,50,5/12/2021
3E15F6,dividend,100,50,5/12/2021
3FACA7,dividend,100,50,5/12/2021
416C55,conference-participant,100,50,5/12/2021
41785E,executive-appointment,100,54,5/12/2021
42DC93,stake-acquirer,100,48,5/12/2021
444CC8,earnings-up,100,68,5/12/2021
444CC8,earnings,100,50,5/12/2021
444CC8,earnings,100,50,5/12/2021
444CC8,earnings,100,50,5/12/2021
44A4FC,partnership,100,61,5/12/2021
451D61,clinical-trials,100,56,5/12/2021
45444E,business-contract,100,69,5/12/2021
458D2C,revenue-volume,100,50,5/12/2021
4649D5,earnings,100,50,5/12/2021
4A2457,conference-participant,100,50,5/12/2021
4A6F00,partnership,100,61,5/12/2021
4AC91D,product-release,100,64,5/12/2021
4AC91D,stake-acquiree,100,62,5/12/2021
4AE584,earnings-up,100,68,5/12/2021
4AE584,earnings,100,50,5/12/2021
4B7006,award,100,58,5/12/2021
4B7006,award,100,58,5/12/2021
4BDCA7,conference-participant,100,50,5/12/2021
4C92B9,business-contract,100,69,5/12/2021
4ECD1A,earnings,100,50,5/12/2021
4EEB00,operating-earnings,100,50,5/12/2021
4F9926,legal-issues-defendant,100,22,5/12/2021
4FF163,unit-acquisition-acquirer,100,49,5/12/2021
510EA6,stock-splits,100,49,5/12/2021
51B442,earnings,100,50,5/12/2021
51F541,dividend,100,50,5/12/2021
564F3E,dividend,100,50,5/12/2021
57DDB9,conference-participant,100,50,5/12/2021
583553,earnings,100,50,5/12/2021
5B15E1,earnings,100,50,5/12/2021
5D41E4,earnings,100,50,5/12/2021
5EAA43,business-contract,100,69,5/12/2021
605F40,executive-resignation,100,44,5/12/2021
60FE03,patient-enrollment-complete,100,64,5/12/2021
6166D1,dividend,100,50,5/12/2021
6166D1,executive-appointment,100,54,5/12/2021
619882,conference-organizer,100,57,5/12/2021
619882,conference-organizer,100,57,5/12/2021
619882,conference-organizer,100,57,5/12/2021
619882,conference-organizer,100,57,5/12/2021
619882,conference-organizer,100,57,5/12/2021
620381,clinical-trials-positive,100,87,5/12/2021
6391C2,earnings,100,50,5/12/2021
651C85,conference-participant,100,50,5/12/2021
665D7D,conference-participant,100,50,5/12/2021
665D7D,partnership,100,61,5/12/2021
665D7D,partnership,100,61,5/12/2021
6A171E,conference-participant,100,50,5/12/2021
6E705B,partnership,100,61,5/12/2021
6F22E7,earnings,100,50,5/12/2021
6F3FA8,conference-participant,100,50,5/12/2021
71694D,conference-call,100,50,5/12/2021
71E2EF,earnings,100,50,5/12/2021
722D55,acquisition-completed-acquirer,100,49,5/12/2021
7262F2,earnings,100,50,5/12/2021
73A213,conference-participant,100,50,5/12/2021
73BCBA,conference-participant,100,50,5/12/2021
751C8D,award,100,58,5/12/2021
76E80F,conference-call,100,50,5/12/2021
790C34,note-sale,100,52,5/12/2021
7AC86E,product-release,100,64,5/12/2021
7B0BA6,conference-participant,100,50,5/12/2021
7BFF81,product-release,100,64,5/12/2021
7D5FD6,dividend,100,50,5/12/2021
7DD584,conference-participant,100,50,5/12/2021
7E1542,partnership,100,61,5/12/2021
7E1542,partnership,100,61,5/12/2021
7E3F8F,partnership,100,61,5/12/2021
7FD8B9,business-contract,100,69,5/12/2021
80D744,dividend,100,50,5/12/2021
80D744,conference-participant,100,50,5/12/2021
83B1C8,conference-participant,100,50,5/12/2021
84920B,earnings,100,50,5/12/2021
87D591,note-sale,100,52,5/12/2021
893904,earnings,100,50,5/12/2021
893904,earnings,100,50,5/12/2021
893904,earnings,100,50,5/12/2021
8CF6DD,executive-appointment,100,54,5/12/2021
8D9993,conference-call,100,50,5/12/2021
8F3BCC,conference-participant,100,50,5/12/2021
90DD65,earnings,100,50,5/12/2021
913437,earnings,100,50,5/12/2021
915E7B,public-offering,100,43,5/12/2021
9196A2,conference-organizer,100,57,5/12/2021
92B625,earnings,100,50,5/12/2021
93965C,conference-participant,100,50,5/12/2021
954004,partnership,100,61,5/12/2021
9673BD,earnings-guidance-up,100,83,5/12/2021
9673BD,earnings-guidance-up,100,83,5/12/2021
9673BD,earnings-guidance-up,100,83,5/12/2021
96BFF4,earnings,100,50,5/12/2021
96BFF4,earnings,100,50,5/12/2021
98CEBB,partnership,100,61,5/12/2021
9994DA,earnings,100,50,5/12/2021
9994DA,earnings,100,50,5/12/2021
9EBAFA,earnings,100,50,5/12/2021
A49498,earnings,100,50,5/12/2021
A49498,earnings,100,50,5/12/2021
A49498,earnings,100,50,5/12/2021
A49498,earnings,100,50,5/12/2021
A49498,partnership,100,61,5/12/2021
A5195E,regulatory-product-approval-granted,100,81,5/12/2021
A60318,conference-participant,100,50,5/12/2021
A6213D,partnership,100,61,5/12/2021
A62FD6,executive-appointment,100,54,5/12/2021
A62FD6,executive-appointment,100,54,5/12/2021
A631A3,executive-appointment,100,54,5/12/2021
A631A3,executive-appointment,100,54,5/12/2021
A631A3,executive-appointment,100,54,5/12/2021
A7A0C8,fast-track-designation,100,81,5/12/2021
A8E2FE,earnings,100,50,5/12/2021
AADE0B,public-offering,100,43,5/12/2021
ABE7DC,earnings,100,50,5/12/2021
ABE7DC,earnings,100,50,5/12/2021
ADFB3A,conference-participant,100,50,5/12/2021
AE3113,conference-participant,100,50,5/12/2021
AE7D16,partnership,100,61,5/12/2021
AEF2C3,conference-participant,100,50,5/12/2021
B1FC3B,business-contract,100,69,5/12/2021
B37FB4,dividend,100,50,5/12/2021
B4703C,award,100,58,5/12/2021
B48D6A,earnings,100,50,5/12/2021
B60366,conference-participant,100,50,5/12/2021
B66EFB,executive-appointment,100,54,5/12/2021
B72BE9,dividend,100,50,5/12/2021
BA0442,conference-participant,100,50,5/12/2021
BB88B6,award,100,58,5/12/2021
BC5680,product-release,100,64,5/12/2021
BC948D,conference-participant,100,50,5/12/2021
BD682F,dividend,100,50,5/12/2021
BF5959,conference-call,100,50,5/12/2021
BFEA04,acquisition-acquirer,100,49,5/12/2021
BFF98A,clinical-trials,100,56,5/12/2021
BFF98A,clinical-trials,100,56,5/12/2021
C037A8,earnings-up,100,68,5/12/2021
C062D4,business-contract,100,69,5/12/2021
C06EB6,earnings,100,50,5/12/2021
C4F9C6,earnings,100,50,5/12/2021
C5C0E9,business-contract,100,69,5/12/2021
C5E100,conference-participant,100,50,5/12/2021
C5E840,earnings,100,50,5/12/2021
C659EB,acquisition-acquirer,100,49,5/12/2021
C8A059,conference-participant,100,50,5/12/2021
C98CDB,product-release,100,64,5/12/2021
C9D866,note-sale,100,52,5/12/2021
C9E04B,earnings,100,50,5/12/2021
CBFFDD,earnings,100,50,5/12/2021
D07B07,earnings,100,50,5/12/2021
D0DE27,dividend,100,50,5/12/2021
D18AFC,conference-participant,100,50,5/12/2021
D3CEDF,partnership,100,61,5/12/2021
D4463B,partnership,100,61,5/12/2021
D4463B,partnership,100,61,5/12/2021
D56D6D,dividend,100,50,5/12/2021
D5B13D,earnings,100,50,5/12/2021
D6489C,product-release,100,64,5/12/2021
D6EAA3,executive-appointment,100,54,5/12/2021
D75910,sponsorship,100,57,5/12/2021
D78BF1,dividend-up,100,81,5/12/2021
DB5CA5,partnership,100,61,5/12/2021
DB7014,award,100,58,5/12/2021
DB88A1,executive-appointment,100,54,5/12/2021
DB9F70,earnings,100,50,5/12/2021
DC2F77,conference-participant,100,50,5/12/2021
DD1BA1,partnership,100,61,5/12/2021
DD1BA1,partnership,100,61,5/12/2021
DD1BA1,partnership,100,61,5/12/2021
DFADDB,conference-participant,100,50,5/12/2021
E1BD05,conference-participant,100,50,5/12/2021
E20392,board-meeting,100,51,5/12/2021
E26FC3,acquisition-acquirer,100,49,5/12/2021
E26FC3,unit-acquisition-acquirer,100,49,5/12/2021
E38906,fast-track-designation,100,81,5/12/2021
E69BA5,dividend,100,50,5/12/2021
E754F0,conference-participant,100,50,5/12/2021
E7BF32,earnings,100,50,5/12/2021
E7BF32,earnings,100,50,5/12/2021
E845D9,earnings,100,50,5/12/2021
E8846E,conference-organizer,100,57,5/12/2021
E8B21D,dividend-up,100,81,5/12/2021
E8E899,conference-participant,100,50,5/12/2021
ECA300,executive-appointment,100,54,5/12/2021
ED2A5E,conference-participant,100,50,5/12/2021
EE1E44,dividend,100,50,5/12/2021
EE1E44,executive-appointment,100,54,5/12/2021
EEA734,clinical-trials,100,56,5/12/2021
F209B4,executive-appointment,100,54,5/12/2021
F2E253,buybacks,100,74,5/12/2021
F2E253,buybacks,100,74,5/12/2021
F40EE2,facility-open,100,65,5/12/2021
F40EE2,facility-open,100,65,5/12/2021
F46EC9,business-contract,100,69,5/12/2021
F569FD,earnings,100,50,5/12/2021
F6DA75,earnings,100,50,5/12/2021
F6DCE4,executive-appointment,100,54,5/12/2021
F769E9,earnings-up,100,68,5/12/2021
F769E9,earnings,100,50,5/12/2021
F769E9,earnings,100,50,5/12/2021
F769E9,earnings,100,50,5/12/2021
F82D37,executive-appointment,100,54,5/12/2021
F88A04,executive-appointment,100,54,5/12/2021
FAE021,dividend,100,50,5/12/2021
FAE021,dividend,100,50,5/12/2021
FC9869,earnings,100,50,5/12/2021
FF6644,conference-participant,100,50,5/12/2021
00326D,earnings,100,50,5/13/2021
00698D,conference-call,100,50,5/13/2021
13528,earnings,100,50,5/13/2021
0157B1,executive-appointment,100,54,5/13/2021
06EF42,conference-participant,100,50,5/13/2021
091B6C,earnings,100,50,5/13/2021
091B6C,earnings,100,50,5/13/2021
0968A5,conference-call,100,50,5/13/2021
96930,earnings,100,50,5/13/2021
0A59F8,product-release,100,64,5/13/2021
0B13E8,earnings,100,50,5/13/2021
0B57D7,dividend,100,50,5/13/2021
0B7375,legal-issues-defendant,100,22,5/13/2021
0BC17A,conference-participant,100,50,5/13/2021
0BF198,public-offering,100,43,5/13/2021
0BF198,public-offering,100,43,5/13/2021
0D03C8,earnings,100,50,5/13/2021
1151F4,executive-resignation,100,44,5/13/2021
1220D2,partnership,100,61,5/13/2021
1220D2,partnership,100,61,5/13/2021
136B26,earnings,100,50,5/13/2021
143C52,conference-call,100,50,5/13/2021
1490F3,business-contract,100,69,5/13/2021
157CC1,revenue-up,100,69,5/13/2021
157CC1,revenue-up,100,69,5/13/2021
17EDA5,partnership,100,61,5/13/2021
184988,conference-participant,100,50,5/13/2021
1A1CB0,earnings,100,50,5/13/2021
1AE482,earnings,100,50,5/13/2021
1B5FEA,earnings,100,50,5/13/2021
1B9535,conference-participant,100,50,5/13/2021
1CD4B5,earnings,100,50,5/13/2021
1DEBBE,award,100,58,5/13/2021
1DEBBE,legal-issues-defendant,100,22,5/13/2021
1F9258,earnings-up,100,68,5/13/2021
21F9CA,earnings,100,50,5/13/2021
221AD7,buybacks,100,74,5/13/2021
228D42,partnership,100,61,5/13/2021
228D42,product-release,100,64,5/13/2021
232053,earnings,100,50,5/13/2021
24CB56,award,100,58,5/13/2021
24CB56,dividend,100,50,5/13/2021
26E3BA,earnings,100,50,5/13/2021
26F99F,earnings,100,50,5/13/2021
270305,executive-resignation,100,44,5/13/2021
2D643C,conference-participant,100,50,5/13/2021
2F98A5,earnings,100,50,5/13/2021
30DE64,earnings,100,50,5/13/2021
3.30E+30,revenue-up,100,85,5/13/2021
3.30E+30,revenue-up,100,85,5/13/2021
3.30E+30,revenue-up,100,85,5/13/2021
339F20,dividend-up,100,81,5/13/2021
33AD83,conference-call,100,50,5/13/2021
34B97A,facility-sale,100,52,5/13/2021
356B21,earnings,100,50,5/13/2021
356B21,earnings,100,50,5/13/2021
356B21,earnings,100,50,5/13/2021
36E479,earnings,100,50,5/13/2021
39FB23,investment-investor,100,55,5/13/2021
3C3B6B,conference-participant,100,50,5/13/2021
3CBA2A,business-contract,100,69,5/13/2021
3F4497,dividend,100,50,5/13/2021
415188,product-release,100,64,5/13/2021
450ECB,conference-participant,100,50,5/13/2021
45ABCC,conference-participant,100,50,5/13/2021
4.60E+06,earnings,100,50,5/13/2021
4C350A,conference-call,100,50,5/13/2021
4D371E,conference-participant,100,50,5/13/2021
4ECD1A,earnings,100,50,5/13/2021
4ECD1A,earnings,100,50,5/13/2021
4EE167,partnership,100,61,5/13/2021
5403F8,earnings,100,50,5/13/2021
546A9C,earnings,100,50,5/13/2021
5.47E+28,conference-participant,100,50,5/13/2021
5487B1,executive-appointment,100,54,5/13/2021
5675EB,ownership-decrease-owner,100,46,5/13/2021
579E8F,earnings,100,50,5/13/2021
5AA3B1,earnings,100,50,5/13/2021
5B35C7,legal-issues-defendant,100,22,5/13/2021
5FE4B6,buybacks,100,74,5/13/2021
619882,conference-organizer,100,57,5/13/2021
619882,conference-organizer,100,57,5/13/2021
619882,conference-organizer,100,57,5/13/2021
62A48D,earnings,100,50,5/13/2021
67B052,clinical-trials,100,56,5/13/2021
6830FE,earnings,100,50,5/13/2021
6AACDD,earnings,100,50,5/13/2021
6BBD2D,earnings,100,50,5/13/2021
7032D0,dividend,100,50,5/13/2021
709AED,conference-participant,100,50,5/13/2021
713810,award,100,58,5/13/2021
71B0CF,earnings,100,50,5/13/2021
726EEA,conference-participant,100,50,5/13/2021
728737,dividend,100,50,5/13/2021
742AAB,executive-appointment,100,54,5/13/2021
752A70,executive-resignation,100,44,5/13/2021
762A3E,conference-organizer,100,57,5/13/2021
762A3E,partnership,100,61,5/13/2021
77B8E9,earnings,100,50,5/13/2021
79167B,executive-appointment,100,54,5/13/2021
7A0EC4,award,100,58,5/13/2021
7A0EC4,earnings,100,50,5/13/2021
7BC92D,earnings,100,50,5/13/2021
7BEA98,earnings,100,50,5/13/2021
7C75FD,note-sale,100,52,5/13/2021
7C75FD,note-sale,100,52,5/13/2021
7F3665,earnings,100,50,5/13/2021
7F7464,earnings,100,50,5/13/2021
7F9984,buybacks,100,74,5/13/2021
80D744,executive-appointment,100,54,5/13/2021
819492,earnings,100,50,5/13/2021
8295B8,earnings,100,50,5/13/2021
83E0AC,conference-participant,100,50,5/13/2021
85AD00,dividend,100,50,5/13/2021
880C0C,dividend,100,50,5/13/2021
8A8E41,product-release,100,64,5/13/2021
8A8E41,product-release,100,64,5/13/2021
8AB85C,earnings,100,50,5/13/2021
8AC65D,conference-participant,100,50,5/13/2021
8B3B0E,dividend,100,50,5/13/2021
8B4A45,earnings,100,50,5/13/2021
8D4AE6,dividend,100,50,5/13/2021
90D6A5,dividend,100,50,5/13/2021
91E5EE,drilling,100,68,5/13/2021
91E5EE,drilling,100,68,5/13/2021
92B625,partnership,100,61,5/13/2021
92B625,partnership,100,61,5/13/2021
9.39E+69,earnings,100,50,5/13/2021
947B0B,earnings,100,50,5/13/2021
94983E,buybacks,100,74,5/13/2021
94983E,buybacks,100,74,5/13/2021
95C392,award,100,58,5/13/2021
966ACE,conference-call,100,50,5/13/2021
96A6CD,conference-participant,100,50,5/13/2021
986AF6,buybacks,100,74,5/13/2021
990AD0,conference-organizer,100,57,5/13/2021
990AD0,conference-organizer,100,57,5/13/2021
990AD0,conference-organizer,100,57,5/13/2021
990AD0,conference-organizer,100,57,5/13/2021
990AD0,conference-organizer,100,57,5/13/2021
990AD0,conference-organizer,100,57,5/13/2021
9B4066,unit-acquisition-acquirer,100,49,5/13/2021
9B71A7,executive-appointment,100,54,5/13/2021
9C3D3C,conference-participant,100,50,5/13/2021
9C5BA5,revenues,100,50,5/13/2021
9E5C2C,conference-participant,100,50,5/13/2021
9F62D1,dividend,100,50,5/13/2021
9F6B1A,regulatory-product-approval-granted,100,81,5/13/2021
A3AAA5,dividend,100,50,5/13/2021
A52B6B,award,100,58,5/13/2021
A58224,executive-appointment,100,54,5/13/2021
A631A3,award,100,58,5/13/2021
A666C8,note-sale,100,52,5/13/2021
A666C8,demand-increase,100,83,5/13/2021
A6D095,earnings,100,50,5/13/2021
A7102F,buybacks,100,74,5/13/2021
A753BB,award,100,58,5/13/2021
A753BB,award,100,58,5/13/2021
A9ED24,conference-call,100,50,5/13/2021
ABAA03,earnings,100,50,5/13/2021
ACC7D3,public-offering,100,43,5/13/2021
ADF092,partnership,100,61,5/13/2021
ADFB3A,earnings,100,50,5/13/2021
AE0CCE,earnings,100,50,5/13/2021
AE79CD,earnings,100,50,5/13/2021
B0D41A,clinical-trials-positive,100,87,5/13/2021
B1A85D,business-contract,100,69,5/13/2021
B1B10C,dividend,100,50,5/13/2021
B1FC3B,business-contract,100,69,5/13/2021
B37FB4,conference-participant,100,50,5/13/2021
B3A166,earnings,100,50,5/13/2021
B48D6A,executive-appointment,100,54,5/13/2021
B604DF,facility-open,100,65,5/13/2021
B614F8,earnings,100,50,5/13/2021
B72D2E,partnership,100,61,5/13/2021
B9B6B8,earnings,100,50,5/13/2021
BCC13E,conference-participant,100,50,5/13/2021
BD9668,acquisition-acquirer,100,49,5/13/2021
BD9668,dividend,100,50,5/13/2021
BF5959,executive-appointment,100,54,5/13/2021
BFD0A7,conference-participant,100,50,5/13/2021
C1114B,earnings,100,50,5/13/2021
C1114B,earnings,100,50,5/13/2021
C1114B,earnings,100,50,5/13/2021
C1114B,earnings,100,50,5/13/2021
C36189,earnings,100,50,5/13/2021
C4F9C6,conference-participant,100,50,5/13/2021
C501B6,earnings,100,50,5/13/2021
C5E840,conference-participant,100,50,5/13/2021
C66A8C,earnings,100,50,5/13/2021
C66A8C,earnings,100,50,5/13/2021
C66A8C,earnings,100,50,5/13/2021
C66A8C,earnings,100,50,5/13/2021
C83B88,conference-participant,100,50,5/13/2021
C94CFC,earnings,100,50,5/13/2021
C98CDB,conference-participant,100,50,5/13/2021
CBFFDD,earnings,100,50,5/13/2021
CE1002,earnings-guidance,100,50,5/13/2021
CE1002,earnings-guidance,100,50,5/13/2021
CE96E7,award,100,58,5/13/2021
CEDFD5,partnership,100,61,5/13/2021
CEDFD5,partnership,100,61,5/13/2021
CF3FF9,executive-appointment,100,54,5/13/2021
CF3FF9,earnings,100,50,5/13/2021
CF7292,earnings,100,50,5/13/2021
D18AFC,hirings,100,65,5/13/2021
D29B44,conference-participant,100,50,5/13/2021
D33D8C,dividend,100,50,5/13/2021
D47D56,earnings,100,50,5/13/2021
D6534D,dividend,100,50,5/13/2021
D69D42,facility-sale,100,52,5/13/2021
D8F347,dividend-up,100,60,5/13/2021
DA9443,conference-participant,100,50,5/13/2021
DBB28E,executive-appointment,100,54,5/13/2021
DBCA3F,partnership,100,61,5/13/2021
DC0066,earnings,100,50,5/13/2021
DF42A0,conference-call,100,50,5/13/2021
E114F4,conference-call,100,50,5/13/2021
E124EB,executive-appointment,100,54,5/13/2021
E21871,conference-participant,100,50,5/13/2021
E28D9C,conference-participant,100,50,5/13/2021
E56A0D,earnings,100,50,5/13/2021
E5C910,earnings,100,50,5/13/2021
E68733,partnership,100,61,5/13/2021
E68733,partnership,100,61,5/13/2021
E68733,earnings,100,50,5/13/2021
E68733,earnings,100,50,5/13/2021
E68E62,clinical-trials-positive,100,87,5/13/2021
E71AE6,earnings,100,50,5/13/2021
E74B55,fraud-defendant,100,20,5/13/2021
E845D9,equity-shelf-registration,100,43,5/13/2021
EB36DE,ipo-unit-delayed,100,37,5/13/2021
EB5E78,note-sale,100,52,5/13/2021
EB5E78,executive-appointment,100,54,5/13/2021
EBD89A,partnership,100,61,5/13/2021
EBD89A,partnership,100,61,5/13/2021
ECA300,conference-call,100,50,5/13/2021
ECF4F8,legal-issues-defendant,100,22,5/13/2021
ED22DC,earnings,100,50,5/13/2021
ED9C04,product-release,100,64,5/13/2021
EDD234,executive-appointment,100,54,5/13/2021
EE967B,dividend,100,50,5/13/2021
F05B1B,earnings,100,50,5/13/2021
F1529C,earnings,100,50,5/13/2021
F1529C,dividend,100,50,5/13/2021
F209B4,earnings,100,50,5/13/2021
F3816D,earnings,100,50,5/13/2021
F39E1E,earnings,100,50,5/13/2021
F46EC9,dividend,100,50,5/13/2021
F4CDA3,conference-participant,100,50,5/13/2021
F4E992,conference-participant,100,50,5/13/2021
F6581D,earnings,100,50,5/13/2021
F85CC0,conference-participant,100,50,5/13/2021
F85CC0,conference-participant,100,50,5/13/2021
F88147,executive-appointment,100,54,5/13/2021
F88147,earnings,100,50,5/13/2021
F8BA6C,executive-appointment,100,54,5/13/2021
FADF1A,earnings,100,50,5/13/2021
FF4BA4,dividend,100,50,5/13/2021
002A99,legal-issues-defendant,100,22,5/14/2021
0B7375,legal-issues-defendant,100,22,5/14/2021
0C136E,executive-appointment,100,54,5/14/2021
0C136E,dividend,100,50,5/14/2021
0C2A0D,note-sale,100,52,5/14/2021
112694,earnings,100,50,5/14/2021
1279ED,legal-issues-defendant,100,22,5/14/2021
12DE76,acquisition-interest-acquirer,100,46,5/14/2021
190B91,executive-appointment,100,54,5/14/2021
190B91,partnership,100,61,5/14/2021
1E1125,fraud-defendant,100,20,5/14/2021
1EF224,earnings,100,50,5/14/2021
1FCC00,earnings,100,50,5/14/2021
228D42,partnership,100,61,5/14/2021
23699B,clinical-trials,100,56,5/14/2021
23699B,clinical-trials,100,56,5/14/2021
25102A,board-meeting,100,51,5/14/2021
2.89E+11,dividend,100,50,5/14/2021
2B9DBB,dividend,100,50,5/14/2021
2CA60F,conference-participant,100,50,5/14/2021
2DA92D,dividend,100,50,5/14/2021
2DA92D,executive-appointment,100,54,5/14/2021
2EB88B,product-release,100,64,5/14/2021
2EC172,conference-participant,100,50,5/14/2021
2F5256,unit-acquisition-acquirer,100,49,5/14/2021
2F5256,unit-acquisition-acquirer,100,49,5/14/2021
3BE00F,unit-acquisition-completed-acquirer,100,49,5/14/2021
3E70FC,conference-participant,100,50,5/14/2021
3ED92D,note-sale,100,52,5/14/2021
42978B,conference-call,100,50,5/14/2021
47B4CC,earnings,100,50,5/14/2021
47B4CC,earnings,100,50,5/14/2021
4B3676,spin-off,100,58,5/14/2021
50070E,conference-organizer,100,57,5/14/2021
50070E,conference-organizer,100,57,5/14/2021
57B174,dividend,100,50,5/14/2021
5A0FF1,conference-participant,100,50,5/14/2021
5D16CF,dividend,100,50,5/14/2021
619882,dividend,100,50,5/14/2021
61B81B,acquisition-regulatory-approval-acquirer,100,54,5/14/2021
657097,unit-acquisition-acquirer,100,49,5/14/2021
6BBD2D,conference-participant,100,50,5/14/2021
6D0CAB,dividend,100,50,5/14/2021
6D9ECA,fast-track-designation,100,81,5/14/2021
6D9ECA,fast-track-designation,100,81,5/14/2021
71B0CF,conference-participant,100,50,5/14/2021
743C70,earnings,100,50,5/14/2021
743C70,earnings,100,50,5/14/2021
7732C2,public-offering,100,43,5/14/2021
7732C2,conference-participant,100,50,5/14/2021
7A2A49,conference-participant,100,50,5/14/2021
7A2A49,conference-call,100,50,5/14/2021
7B8CB5,dividend-up,100,64,5/14/2021
7B8CB5,conference-participant,100,50,5/14/2021
8.10E+205,conference-participant,100,50,5/14/2021
834152,legal-issues-defendant,100,22,5/14/2021
860AB6,public-offering,100,43,5/14/2021
8BFAA4,business-contract,100,69,5/14/2021
8D0EEA,earnings,100,50,5/14/2021
90D6A5,dividend,100,50,5/14/2021
940C3D,dividend,100,50,5/14/2021
95DC1F,conference-participant,100,50,5/14/2021
9B4066,note-sale,100,52,5/14/2021
9B730A,clinical-trials-positive,100,87,5/14/2021
9CA619,unit-acquisition-acquirer,100,49,5/14/2021
9D30A8,acquisition-completed-acquirer,100,49,5/14/2021
A01983,dividend,100,50,5/14/2021
A16DEA,conference-participant,100,50,5/14/2021
A16DEA,dividend,100,50,5/14/2021
A48593,conference-participant,100,50,5/14/2021
A4B899,dividend,100,50,5/14/2021
A5151E,credit-rating-set,100,50,5/14/2021
A52B6B,conference-participant,100,50,5/14/2021
A52B6B,executive-appointment,100,54,5/14/2021
A666C8,note-sale,100,52,5/14/2021
AAEE21,conference-participant,100,50,5/14/2021
ACC7D3,public-offering,100,43,5/14/2021
AD1ACF,unit-acquisition-acquiree,100,76,5/14/2021
AD1ACF,business-contract,100,69,5/14/2021
AD1ACF,dividend,100,50,5/14/2021
B72BE9,executive-appointment,100,54,5/14/2021
B7BBFF,earnings,100,50,5/14/2021
B9B6B8,conference-participant,100,50,5/14/2021
BCC55F,conference-participant,100,50,5/14/2021
BE645B,earnings,100,50,5/14/2021
C0BA36,conference-participant,100,50,5/14/2021
C2609A,conference-participant,100,50,5/14/2021
C3BAE7,buybacks,100,74,5/14/2021
C3F99F,executive-appointment,100,54,5/14/2021
C45CE7,dividend,100,50,5/14/2021
C490F9,earnings,100,50,5/14/2021
C584BE,public-offering,100,43,5/14/2021
C624A1,earnings,100,50,5/14/2021
C65004,executive-appointment,100,54,5/14/2021
CD2A4D,conference-participant,100,50,5/14/2021
CDC817,conference-participant,100,50,5/14/2021
CE96E7,conference-participant,100,50,5/14/2021
CEDFD5,clinical-trials,100,56,5/14/2021
CEDFD5,clinical-trials,100,56,5/14/2021
D4AC65,product-release,100,64,5/14/2021
DBFB51,dividend,100,50,5/14/2021
DD9E41,conference-participant,100,50,5/14/2021
DF1F7A,dividend,100,50,5/14/2021
E592F0,conference-participant,100,50,5/14/2021
E5C910,conference-participant,100,50,5/14/2021
E74B55,legal-issues-defendant,100,22,5/14/2021
E74B55,legal-issues-defendant,100,22,5/14/2021
E8846E,conference-organizer,100,57,5/14/2021
E8846E,dividend,100,50,5/14/2021
E8846E,conference-organizer,100,57,5/14/2021
E8846E,conference-organizer,100,57,5/14/2021
E8A49A,conference-participant,100,50,5/14/2021
EB1E1A,conference-participant,100,50,5/14/2021
ECE814,conference-participant,100,50,5/14/2021
F209B4,conference-participant,100,50,5/14/2021
F6E248,conference-participant,100,50,5/14/2021
F748C7,product-release,100,64,5/14/2021
F92DBC,business-contract,100,69,5/14/2021
F92DBC,business-contract,100,69,5/14/2021
FAB97A,conference-participant,100,50,5/14/2021
FC80E6,dividend,100,50,5/14/2021
002A99,legal-issues-defendant,100,22,5/15/2021
32DCB3,legal-issues-defendant,100,22,5/15/2021
4ECD1A,buybacks,100,74,5/15/2021
9E98F2,conference-participant,100,50,5/15/2021
A29A46,legal-issues-defendant,100,22,5/15/2021
CDE118,legal-issues-defendant,100,22,5/15/2021
D8C09D,legal-issues-defendant,100,22,5/15/2021
002A99,legal-issues-defendant,100,22,5/16/2021
25D3CE,earnings,100,50,5/16/2021
D6489C,partnership,100,61,5/16/2021
00067A,conference-participant,100,50,5/17/2021
002A99,legal-issues-defendant,100,22,5/17/2021
0157B1,partnership,100,61,5/17/2021
48781,earnings,100,50,5/17/2021
56045,earnings,100,50,5/17/2021
06C826,conference-participant,100,50,5/17/2021
0A0D9E,conference-participant,100,50,5/17/2021
0BC17A,executive-appointment,100,54,5/17/2021
112694,conference-participant,100,50,5/17/2021
1201B5,earnings,100,50,5/17/2021
126F95,dividend,100,50,5/17/2021
12DE76,award,100,58,5/17/2021
12F98C,conference-call,100,50,5/17/2021
14BA33,acquisition-completed-acquirer,100,49,5/17/2021
15A388,business-contract,100,69,5/17/2021
196D18,earnings,100,50,5/17/2021
1C599A,note-sale,100,52,5/17/2021
1D3A00,conference-call,100,50,5/17/2021
1DEBBE,note-sale,100,52,5/17/2021
1E1125,legal-issues-defendant,100,22,5/17/2021
200D8B,earnings,100,50,5/17/2021
23207A,revenue-up,100,73,5/17/2021
23207A,revenue-up,100,73,5/17/2021
239106,business-contract,100,69,5/17/2021
24C48B,note-sale,100,52,5/17/2021
250BEE,earnings,100,50,5/17/2021
250BEE,earnings,100,50,5/17/2021
250BEE,earnings,100,50,5/17/2021
25D3CE,earnings,100,50,5/17/2021
26DC29,conference-participant,100,50,5/17/2021
26F31D,partnership,100,61,5/17/2021
282C18,executive-appointment,100,54,5/17/2021
28AC4E,note-sale,100,52,5/17/2021
2D2D43,public-offering,100,43,5/17/2021
2DB344,dividend,100,50,5/17/2021
2E1322,partnership,100,61,5/17/2021
3390DE,award,100,58,5/17/2021
367434,conference-participant,100,50,5/17/2021
37B120,earnings,100,50,5/17/2021
39FB23,acquisition-completed-acquirer,100,49,5/17/2021
3AAEAE,executive-appointment,100,54,5/17/2021
3B318A,conference-call,100,50,5/17/2021
3B9886,conference-call,100,50,5/17/2021
3C75D6,earnings,100,50,5/17/2021
3E149C,executive-appointment,100,54,5/17/2021
3F96D5,earnings,100,50,5/17/2021
401072,executive-appointment,100,54,5/17/2021
42312F,earnings,100,50,5/17/2021
468DD4,earnings,100,50,5/17/2021
4BBA23,earnings,100,50,5/17/2021
4C3FE9,business-contract,100,69,5/17/2021
4C3FE9,business-contract,100,69,5/17/2021
4EEE7E,government-contract,100,69,5/17/2021
4F9926,business-contract,100,69,5/17/2021
550D01,conference-participant,100,50,5/17/2021
55D0F3,conference-participant,100,50,5/17/2021
583553,public-offering,100,43,5/17/2021
58EA22,earnings,100,50,5/17/2021
58EA22,earnings,100,50,5/17/2021
5B226B,earnings,100,50,5/17/2021
619882,conference-organizer,100,57,5/17/2021
619882,conference-organizer,100,57,5/17/2021
619882,conference-organizer,100,57,5/17/2021
619882,conference-organizer,100,57,5/17/2021
619882,dividend,100,50,5/17/2021
627186,conference-participant,100,50,5/17/2021
657097,unit-acquisition-acquirer,100,49,5/17/2021
67B923,partnership,100,61,5/17/2021
694749,conference-participant,100,50,5/17/2021
6CC55E,clinical-trials-positive,100,87,5/17/2021
6CF43C,dividend-up,100,81,5/17/2021
6F22E7,executive-appointment,100,54,5/17/2021
73F70F,earnings,100,50,5/17/2021
791EC1,board-meeting,100,51,5/17/2021
7999F3,conference-participant,100,50,5/17/2021
7A3633,note-sale,100,52,5/17/2021
7A51FE,dividend,100,50,5/17/2021
7BAAE7,executive-resignation,100,44,5/17/2021
7BEA98,conference-participant,100,50,5/17/2021
7CBC40,executive-appointment,100,54,5/17/2021
7F9BE2,executive-appointment,100,54,5/17/2021
8.10E+32,dividend,100,50,5/17/2021
81222C,executive-appointment,100,54,5/17/2021
8303CD,award,100,58,5/17/2021
86A1B9,executive-appointment,100,54,5/17/2021
86A1B9,executive-appointment,100,54,5/17/2021
873DB9,partnership,100,61,5/17/2021
877C0C,business-contract,100,69,5/17/2021
877C0C,business-contract,100,69,5/17/2021
8.79E+06,earnings,100,50,5/17/2021
88D80A,earnings,100,50,5/17/2021
8AA108,earnings,100,50,5/17/2021
8DCBBB,hirings,100,65,5/17/2021
8F8F2F,dividend,100,50,5/17/2021
903AB4,dividend,100,50,5/17/2021
911AB8,acquisition-completed-acquirer,100,49,5/17/2021
911AB8,acquisition-completed-acquirer,100,49,5/17/2021
966ACE,earnings,100,50,5/17/2021
96F126,executive-appointment,100,54,5/17/2021
972356,executive-appointment,100,54,5/17/2021
9A602D,executive-appointment,100,54,5/17/2021
9B4066,unit-acquisition-acquirer,100,49,5/17/2021
9B71A7,executive-appointment,100,54,5/17/2021
9D307D,earnings,100,50,5/17/2021
9EF4CF,partnership,100,61,5/17/2021
A16DEA,partnership,100,61,5/17/2021
A1E3B3,partnership,100,61,5/17/2021
A2A9BA,earnings,100,50,5/17/2021
A43906,executive-appointment,100,54,5/17/2021
A495F7,partnership,100,61,5/17/2021
A4CD53,business-contract,100,69,5/17/2021
A6FE1C,acquisition-acquirer,100,49,5/17/2021
A7102F,executive-appointment,100,54,5/17/2021
A79F7D,earnings,100,50,5/17/2021
A94637,dividend,100,50,5/17/2021
AADE0B,public-offering,100,43,5/17/2021
AE7D16,conference-participant,100,50,5/17/2021
B05118,conference-participant,100,50,5/17/2021
B13B68,acquisition-acquirer,100,49,5/17/2021
B1FC3B,business-contract,100,69,5/17/2021
B33E77,executive-appointment,100,54,5/17/2021
B37FB4,executive-appointment,100,54,5/17/2021
B4F5F4,earnings,100,50,5/17/2021
B54A74,conference-participant,100,50,5/17/2021
B83D67,product-release,100,64,5/17/2021
BAD9EA,earnings,100,50,5/17/2021
BE7BA4,conference-participant,100,50,5/17/2021
BEA527,earnings,100,50,5/17/2021
BF5959,revenue-up,100,83,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-interest-acquirer,100,46,5/17/2021
C062D4,acquisition-acquirer,100,49,5/17/2021
C0F70B,product-release,100,64,5/17/2021
C22BE8,earnings-up,100,68,5/17/2021
C29E71,earnings,100,50,5/17/2021
C32A39,market-entry,100,57,5/17/2021
C8257F,executive-appointment,100,54,5/17/2021
C83B88,executive-appointment,100,54,5/17/2021
C8923A,business-contract,100,69,5/17/2021
C93C44,earnings,100,50,5/17/2021
C93C44,earnings,100,50,5/17/2021
C951A2,facility-open,100,65,5/17/2021
C99CC8,executive-appointment,100,54,5/17/2021
CC0C78,revenues,100,50,5/17/2021
CC35BE,business-contract,100,69,5/17/2021
CC35BE,business-contract,100,69,5/17/2021
CDAA0E,conference-participant,100,50,5/17/2021
CDC217,earnings,100,50,5/17/2021
CFD4B6,executive-appointment,100,54,5/17/2021
D17C1B,executive-appointment,100,54,5/17/2021
D5AF19,acquisition-acquirer,100,49,5/17/2021
D60BB2,dividend,100,50,5/17/2021
D6144F,conference-participant,100,50,5/17/2021
DB06B0,partnership,100,61,5/17/2021
DD7A96,dividend,100,50,5/17/2021
E00373,market-entry,100,57,5/17/2021
E00373,market-entry,100,57,5/17/2021
E1E093,partnership,100,61,5/17/2021
E20392,executive-appointment,100,54,5/17/2021
E261E9,earnings,100,50,5/17/2021
E38906,public-offering,100,43,5/17/2021
E5752F,partnership,100,61,5/17/2021
E6D89E,executive-appointment,100,54,5/17/2021
E87676,acquisition-completed-acquirer,100,49,5/17/2021
E8B21D,public-offering,100,43,5/17/2021
EB7FBF,conference-call,100,50,5/17/2021
EFA7B2,earnings,100,50,5/17/2021
F0027C,asset-sale,100,62,5/17/2021
F05B1B,conference-participant,100,50,5/17/2021
F0B335,executive-appointment,100,54,5/17/2021
F1C04C,dividend-up,100,70,5/17/2021
F1EB39,conference-participant,100,50,5/17/2021
F5349B,executive-appointment,100,54,5/17/2021
F58C23,earnings,100,50,5/17/2021
F58C23,earnings,100,50,5/17/2021
F58C23,earnings,100,50,5/17/2021
F67165,note-sale,100,52,5/17/2021
F7902B,partnership,100,61,5/17/2021
F85CC0,business-contract,100,69,5/17/2021
F85CC0,business-contract,100,69,5/17/2021
F88A04,note-sale,100,52,5/17/2021
FCA54E,earnings-up,100,68,5/17/2021
FCA54E,earnings,100,50,5/17/2021
FCA54E,earnings,100,50,5/17/2021
FCA54E,earnings,100,50,5/17/2021
003B70,executive-appointment,100,54,5/18/2021
9397,note-sale,100,52,5/18/2021
0142B5,dividend,100,50,5/18/2021
0157B1,partnership,100,61,5/18/2021
0157B1,product-release,100,64,5/18/2021
0157B1,product-release,100,64,5/18/2021
070B45,conference-participant,100,50,5/18/2021
71860,partnership,100,61,5/18/2021
0AAD90,conference-participant,100,50,5/18/2021
0B7375,legal-issues-defendant,100,22,5/18/2021
0CE7F6,dividend,100,50,5/18/2021
0E64D4,partnership,100,61,5/18/2021
129DC8,award,100,58,5/18/2021
1348C9,conference-participant,100,50,5/18/2021
14ED2B,ownership-increase-owner,100,56,5/18/2021
17EDA5,partnership,100,61,5/18/2021
1A1CB0,conference-participant,100,50,5/18/2021
1C599A,note-sale,100,52,5/18/2021
2031CE,dividend,100,50,5/18/2021
221AD7,buybacks,100,74,5/18/2021
232053,conference-participant,100,50,5/18/2021
23207A,buybacks,100,74,5/18/2021
24A89A,earnings,100,50,5/18/2021
25AB8E,business-contract,100,69,5/18/2021
25AB8E,business-contract,100,69,5/18/2021
28AC4E,note-sale,100,52,5/18/2021
292388,partnership,100,61,5/18/2021
2B49F4,partnership,100,61,5/18/2021
2CB4C9,earnings,100,50,5/18/2021
2CBB58,revenue-up,100,69,5/18/2021
2CBB58,revenue-up,100,69,5/18/2021
2CBB58,revenue-up,100,69,5/18/2021
2CBB58,revenue-up,100,69,5/18/2021
2E0496,partnership,100,61,5/18/2021
2E0496,partnership,100,61,5/18/2021
2F7474,acquisition-acquirer,100,49,5/18/2021
2F7474,acquisition-acquirer,100,49,5/18/2021
2F7474,acquisition-acquirer,100,49,5/18/2021
2F9304,acquisition-interest-acquirer,100,46,5/18/2021
33A0F1,executive-appointment,100,54,5/18/2021
34B97A,fundraising,100,64,5/18/2021
355B19,dividend,100,50,5/18/2021
387375,conference-participant,100,50,5/18/2021
3C75D6,conference-participant,100,50,5/18/2021
3C8A04,dividend,100,50,5/18/2021
3CCC90,executive-appointment,100,54,5/18/2021
41C36B,executive-appointment,100,54,5/18/2021
41C36B,conference-participant,100,50,5/18/2021
435ACE,note-sale,100,52,5/18/2021
43A74A,note-sale,100,52,5/18/2021
43A74A,note-sale,100,52,5/18/2021
4A6F00,partnership,100,61,5/18/2021
4BAF2E,conference-participant,100,50,5/18/2021
4C3FE9,business-contract,100,69,5/18/2021
4C92B9,dividend,100,50,5/18/2021
4D8313,private-placement,100,56,5/18/2021
4EE167,conference-participant,100,50,5/18/2021
50070E,conference-organizer,100,57,5/18/2021
50070E,partnership,100,61,5/18/2021
514067,conference-participant,100,50,5/18/2021
51E682,partnership-terminated,100,36,5/18/2021
55C9B5,conference-participant,100,50,5/18/2021
57DDB9,conference-participant,100,50,5/18/2021
589846,partnership,100,61,5/18/2021
59872F,partnership,100,61,5/18/2021
59872F,partnership,100,61,5/18/2021
59872F,partnership,100,61,5/18/2021
5A9F54,note-sale,100,52,5/18/2021
5A9F54,public-offering,100,43,5/18/2021
5C7601,board-meeting,100,51,5/18/2021
5C8D61,dividend,100,50,5/18/2021
6166D1,dividend,100,50,5/18/2021
619882,conference-organizer,100,57,5/18/2021
619882,conference-organizer,100,57,5/18/2021
619882,conference-organizer,100,57,5/18/2021
619882,conference-organizer,100,57,5/18/2021
619882,conference-organizer,100,57,5/18/2021
622DBE,conference-participant,100,50,5/18/2021
6.52E+64,partnership,100,61,5/18/2021
6634D9,executive-appointment,100,54,5/18/2021
665D7D,partnership,100,61,5/18/2021
66A667,executive-appointment,100,54,5/18/2021
66A667,executive-appointment,100,54,5/18/2021
67B923,earnings,100,50,5/18/2021
6810DE,business-contract,100,69,5/18/2021
68E3E0,dividend,100,50,5/18/2021
69CE71,executive-appointment,100,54,5/18/2021
69FDFC,executive-appointment,100,54,5/18/2021
6F5DD2,earnings,100,50,5/18/2021
713810,same-store-sales-up,100,56,5/18/2021
713810,partnership,100,61,5/18/2021
7273FF,executive-appointment,100,54,5/18/2021
73A71F,supply-decrease,100,28,5/18/2021
756BB4,earnings,100,50,5/18/2021
773A17,revenues,100,50,5/18/2021
7A3633,product-release,100,64,5/18/2021
7ACFD4,executive-appointment,100,54,5/18/2021
7DD8CC,executive-appointment,100,54,5/18/2021
7E1D5D,product-release,100,64,5/18/2021
834152,partnership,100,61,5/18/2021
873DB9,facility-open,100,65,5/18/2021
8AC65D,executive-appointment,100,54,5/18/2021
8D9993,executive-appointment,100,54,5/18/2021
8E0E32,executive-appointment,100,54,5/18/2021
8EDACA,conference-call,100,50,5/18/2021
8EF425,dividend,100,50,5/18/2021
9196A2,conference-organizer,100,57,5/18/2021
9196A2,conference-organizer,100,57,5/18/2021
94637C,business-contract,100,69,5/18/2021
957A07,conference-participant,100,50,5/18/2021
95A92E,acquisition-acquiree,100,76,5/18/2021
95A92E,acquisition-regulatory-scrutiny-acquiree,100,38,5/18/2021
95A92E,legal-issues-defendant,100,22,5/18/2021
981656,conference-participant,100,50,5/18/2021
981656,executive-appointment,100,54,5/18/2021
9D65C1,conference-participant,100,50,5/18/2021
9E5C2C,note-sale,100,52,5/18/2021
9FA83B,acquisition-acquirer,100,49,5/18/2021
A01664,earnings,100,50,5/18/2021
A16DEA,conference-participant,100,50,5/18/2021
A47F2E,conference-participant,100,50,5/18/2021
A4BCDE,conference-participant,100,50,5/18/2021
A5E715,dividend,100,50,5/18/2021
A80FE0,note-sale,100,52,5/18/2021
A868C9,conference-call,100,50,5/18/2021
A8CBDA,partnership,100,61,5/18/2021
A99576,acquisition-acquiree,100,76,5/18/2021
AC642C,conference-participant,100,50,5/18/2021
AC642C,conference-participant,100,50,5/18/2021
ACC7D3,public-offering,100,43,5/18/2021
ACDF88,earnings,100,50,5/18/2021
ACDF88,earnings,100,50,5/18/2021
ACDF88,earnings,100,50,5/18/2021
B0FE08,joint-venture,100,62,5/18/2021
B0FE08,executive-appointment,100,54,5/18/2021
B1FC3B,business-contract,100,69,5/18/2021
B2F431,executive-appointment,100,54,5/18/2021
B9B6B8,product-release,100,64,5/18/2021
BB0587,dividend,100,50,5/18/2021
BDE867,partnership,100,61,5/18/2021
C15F8F,note-sale,100,52,5/18/2021
C584BE,business-contract,100,69,5/18/2021
C5C137,earnings,100,50,5/18/2021
C5C137,earnings,100,50,5/18/2021
C5C137,earnings,100,50,5/18/2021
C5C137,earnings,100,50,5/18/2021
C941DC,conference-participant,100,50,5/18/2021
C9C62A,acquisition-acquirer,100,49,5/18/2021
CA1620,conference-participant,100,50,5/18/2021
CA3CB9,business-contract,100,69,5/18/2021
CDFCC9,note-sale,100,52,5/18/2021
CDFCC9,note-sale,100,52,5/18/2021
D1588D,conference-participant,100,50,5/18/2021
D1AE3B,dividend,100,50,5/18/2021
D33270,government-contract,100,69,5/18/2021
D3FD6D,conference-participant,100,50,5/18/2021
D48275,conference-call,100,50,5/18/2021
D58A11,conference-participant,100,50,5/18/2021
D598E7,executive-appointment,100,54,5/18/2021
D8DA3D,dividend-up,100,81,5/18/2021
D90F43,conference-participant,100,50,5/18/2021
DA9443,clinical-trials-start,100,64,5/18/2021
DB396B,dividend,100,50,5/18/2021
DB9829,dividend,100,50,5/18/2021
DBB28E,product-release,100,64,5/18/2021
DBCA3F,executive-appointment,100,54,5/18/2021
DD682D,executive-resignation,100,44,5/18/2021
E20392,conference-participant,100,50,5/18/2021
E30B34,business-contract,100,69,5/18/2021
E30B34,business-contract,100,69,5/18/2021
E49AA3,dividend,100,50,5/18/2021
E74FED,executive-appointment,100,54,5/18/2021
E96E0B,conference-participant,100,50,5/18/2021
EB2F14,dividend,100,50,5/18/2021
EF1AD9,business-contract,100,69,5/18/2021
EF5BED,executive-appointment,100,54,5/18/2021
F1529C,dividend,100,50,5/18/2021
F32F88,conference-participant,100,50,5/18/2021
F4F46F,partnership,100,61,5/18/2021
F4F46F,partnership,100,61,5/18/2021
F6DCE4,conference-call,100,50,5/18/2021
F93C8A,dividend,100,50,5/18/2021
FACF19,partnership,100,61,5/18/2021
FACF19,partnership,100,61,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FAE021,hirings,100,65,5/18/2021
FC1B7B,dividend-up,100,58,5/18/2021
FC1F9D,fundraising,100,64,5/18/2021
FCA54E,public-offering,100,43,5/18/2021
FD6926,business-contract,100,69,5/18/2021
002A99,legal-issues-defendant,100,22,5/19/2021
00FC70,dividend,100,50,5/19/2021
01D03F,product-release,100,64,5/19/2021
01D03F,product-release,100,64,5/19/2021
053EFF,dividend,100,50,5/19/2021
0A7650,dividend,100,50,5/19/2021
0B7375,legal-issues-defendant,100,22,5/19/2021
0CADBC,executive-appointment,100,54,5/19/2021
1151F4,dividend,100,50,5/19/2021
1220D2,conference-participant,100,50,5/19/2021
12DE76,earnings,100,50,5/19/2021
12DE76,earnings,100,50,5/19/2021
12DE76,earnings,100,50,5/19/2021
12DE76,earnings,100,50,5/19/2021
12DE76,earnings,100,50,5/19/2021
12E454,partnership,100,61,5/19/2021
152FA5,clinical-trials,100,56,5/19/2021
15A388,business-contract,100,69,5/19/2021
168A5D,executive-appointment,100,54,5/19/2021
16B882,board-meeting,100,51,5/19/2021
184866,partnership,100,61,5/19/2021
197612,dividend,100,50,5/19/2021
1B6F77,conference-participant,100,50,5/19/2021
1DDEDA,conference-call,100,50,5/19/2021
1FA886,business-contract,100,69,5/19/2021
228D42,partnership,100,61,5/19/2021
228D42,partnership,100,61,5/19/2021
228D42,partnership,100,61,5/19/2021
241252,clinical-trials,100,56,5/19/2021
24D81E,executive-appointment,100,54,5/19/2021
24D81E,executive-appointment,100,54,5/19/2021
2667B6,partnership,100,61,5/19/2021
278C18,dividend,100,50,5/19/2021
278C18,buybacks,100,74,5/19/2021
279916,earnings,100,50,5/19/2021
292A70,dividend,100,50,5/19/2021
29A4CC,dividend,100,50,5/19/2021
2E902B,dividend-up,100,69,5/19/2021
355B19,conference-participant,100,50,5/19/2021
40B903,earnings,100,50,5/19/2021
40B903,earnings,100,50,5/19/2021
40B903,earnings,100,50,5/19/2021
414FFF,conference-call,100,50,5/19/2021
41EC04,workforce-salary-increase,100,44,5/19/2021
4398A2,business-contract,100,69,5/19/2021
4455C4,award,100,58,5/19/2021
4676DF,earnings,100,50,5/19/2021
467F2C,executive-appointment,100,54,5/19/2021
4A6F00,partnership,100,61,5/19/2021
4A6F00,executive-appointment,100,54,5/19/2021
4A6F00,partnership,100,61,5/19/2021
4A6F00,product-release,100,64,5/19/2021
4B7006,award,100,58,5/19/2021
4B7006,award,100,58,5/19/2021
4C31F3,credit-extension-recipient,100,69,5/19/2021
4D8313,fundraising,100,64,5/19/2021
4F9926,partnership,100,61,5/19/2021
50070E,conference-organizer,100,57,5/19/2021
539F49,executive-appointment,100,54,5/19/2021
5.43E+08,conference-participant,100,50,5/19/2021
5.43E+08,clinical-trials,100,56,5/19/2021
54F271,conference-participant,100,50,5/19/2021
56277A,conference-participant,100,50,5/19/2021
583553,public-offering,100,43,5/19/2021
589846,conference-call,100,50,5/19/2021
58CA9A,note-sale,100,52,5/19/2021
5B226B,dividend,100,50,5/19/2021
5B51D6,clinical-trials,100,56,5/19/2021
5BC2F4,dividend,100,50,5/19/2021
5D87DF,dividend,100,50,5/19/2021
5F2FF7,conference-participant,100,50,5/19/2021
5F3D91,clinical-trials-positive,100,87,5/19/2021
6166D1,sponsorship,100,57,5/19/2021
619882,conference-organizer,100,57,5/19/2021
619882,conference-organizer,100,57,5/19/2021
619882,conference-organizer,100,57,5/19/2021
619882,conference-call,100,50,5/19/2021
61A586,conference-participant,100,50,5/19/2021
68B03F,executive-appointment,100,54,5/19/2021
69345C,buybacks,100,74,5/19/2021
6DBBBC,investment-investor,100,55,5/19/2021
6E705B,award,100,58,5/19/2021
6FCEF9,earnings,100,50,5/19/2021
7448A3,dividend,100,50,5/19/2021
767F86,conference-participant,100,50,5/19/2021
76E80F,revenues,100,50,5/19/2021
76E80F,revenues,100,50,5/19/2021
78A1BB,dividend-up,100,81,5/19/2021
78F9ED,supply-increase,100,100,5/19/2021
7A10FF,dividend,100,50,5/19/2021
7AC86E,note-sale,100,52,5/19/2021
7E1D5D,earnings,100,50,5/19/2021
7E1D5D,earnings,100,50,5/19/2021
7E1D5D,earnings,100,50,5/19/2021
7E1D5D,earnings,100,50,5/19/2021
80D744,executive-appointment,100,54,5/19/2021
818A2F,dividend,100,50,5/19/2021
818A2F,dividend,100,50,5/19/2021
834152,clinical-trials,100,56,5/19/2021
855DF7,conference-participant,100,50,5/19/2021
859D62,earnings,100,50,5/19/2021
85DE00,conference-participant,100,50,5/19/2021
8665BA,dividend,100,50,5/19/2021
88611B,dividend,100,50,5/19/2021
893904,executive-appointment,100,54,5/19/2021
8B4A45,earnings,100,50,5/19/2021
8C6C1B,dividend,100,50,5/19/2021
8EEA28,earnings,100,50,5/19/2021
8FF2EF,earnings,100,50,5/19/2021
93D207,conference-participant,100,50,5/19/2021
94637C,partnership,100,61,5/19/2021
954004,conference-call,100,50,5/19/2021
9.74E+08,dividend,100,50,5/19/2021
9810C0,dividend,100,50,5/19/2021
98A286,earnings,100,50,5/19/2021
9994DA,conference-participant,100,50,5/19/2021
9A602D,award,100,58,5/19/2021
9F71E5,stake-acquirer,100,48,5/19/2021
A05C43,earnings,100,50,5/19/2021
A15C71,facility-upgrade,100,65,5/19/2021
A63820,product-release,100,64,5/19/2021
A7102F,conference-participant,100,50,5/19/2021
A75D43,headquarters-change,100,50,5/19/2021
A7A0BD,conference-participant,100,50,5/19/2021
A99576,acquisition-regulatory-scrutiny-acquiree,100,38,5/19/2021
A99576,legal-issues-defendant,100,22,5/19/2021
AD3ED7,product-release,100,64,5/19/2021
ADF092,legal-issues-defendant,100,22,5/19/2021
AFF7B4,product-release,100,64,5/19/2021
B0FE08,executive-appointment,100,54,5/19/2021
B2206F,conference-participant,100,50,5/19/2021
B5DE80,executive-appointment,100,54,5/19/2021
B98EFA,conference-participant,100,50,5/19/2021
BBF349,partnership,100,61,5/19/2021
BBF349,partnership,100,61,5/19/2021
BC948D,product-release,100,64,5/19/2021
BE5935,conference-participant,100,50,5/19/2021
BEA527,conference-participant,100,50,5/19/2021
C06EB6,patient-enrollment-start,100,58,5/19/2021
C06EB6,patient-enrollment-start,100,58,5/19/2021
C32A39,executive-appointment,100,54,5/19/2021
C4A241,dividend,100,50,5/19/2021
C951A2,partnership,100,61,5/19/2021
CB9E13,executive-appointment,100,54,5/19/2021
CCBBAD,executive-resignation,100,44,5/19/2021
D139BC,executive-appointment,100,54,5/19/2021
D1AE3B,executive-appointment,100,54,5/19/2021
D33D8C,executive-appointment,100,54,5/19/2021
D5AF19,conference-participant,100,50,5/19/2021
D5B13D,conference-participant,100,50,5/19/2021
D721C6,dividend,100,50,5/19/2021
D8442A,product-release,100,64,5/19/2021
D8442A,product-release,100,64,5/19/2021
D88EF3,note-sale,100,52,5/19/2021
D88EF3,note-sale,100,52,5/19/2021
D8DBA3,dividend-up,100,81,5/19/2021
DB5CA5,partnership,100,61,5/19/2021
DB5CA5,partnership,100,61,5/19/2021
DD0099,dividend,100,50,5/19/2021
E00373,joint-venture,100,62,5/19/2021
E00373,joint-venture,100,62,5/19/2021
E0207A,dividend,100,50,5/19/2021
E06265,dividend-up,100,55,5/19/2021
E30B34,conference-participant,100,50,5/19/2021
E30B34,conference-participant,100,50,5/19/2021
E4CE73,earnings,100,50,5/19/2021
E5AAA3,settlement,100,56,5/19/2021
E68C3D,revenue-up,100,69,5/19/2021
E68C3D,revenue-up,100,69,5/19/2021
E68C3D,revenue-up,100,69,5/19/2021
E68C3D,revenue-up,100,69,5/19/2021
E68C3D,revenue-up,100,69,5/19/2021
E74B55,legal-issues-defendant,100,22,5/19/2021
E99180,buybacks,100,74,5/19/2021
ECDEB2,executive-appointment,100,54,5/19/2021
ECDEB2,dividend,100,50,5/19/2021
ECF4F8,legal-issues-defendant,100,22,5/19/2021
ED79D9,dividend,100,50,5/19/2021
F0B2B5,executive-appointment,100,54,5/19/2021
F0B2B5,executive-appointment,100,54,5/19/2021
F0B2B5,executive-appointment,100,54,5/19/2021
F1CD47,dividend,100,50,5/19/2021
F6A987,dividend,100,50,5/19/2021
F6DCE4,earnings,100,50,5/19/2021
F6DCE4,earnings,100,50,5/19/2021
F6DCE4,earnings,100,50,5/19/2021
F721A7,executive-appointment,100,54,5/19/2021
F7902B,conference-participant,100,50,5/19/2021
F85CC0,dividend,100,50,5/19/2021
F85CC0,dividend,100,50,5/19/2021
F9CAF8,earnings-up,100,68,5/19/2021
F9CAF8,earnings,100,50,5/19/2021
F9CAF8,earnings,100,50,5/19/2021
F9CAF8,earnings,100,50,5/19/2021
F9CAF8,earnings,100,50,5/19/2021
FC1F9D,conference-participant,100,50,5/19/2021
FCA54E,public-offering,100,43,5/19/2021
FD2565,conference-participant,100,50,5/19/2021
FEE4B0,partnership,100,61,5/19/2021
FF6644,product-release,100,64,5/19/2021
002A99,legal-issues-defendant,100,22,5/20/2021
00326E,executive-appointment,100,54,5/20/2021
00FC70,earnings,100,50,5/20/2021
0157B1,partnership,100,61,5/20/2021
0157B1,partnership,100,61,5/20/2021
01D03F,partnership,100,61,5/20/2021
06A456,conference-call,100,50,5/20/2021
96930,executive-appointment,100,54,5/20/2021
099C88,business-contract,100,69,5/20/2021
099C88,dividend,100,50,5/20/2021
0A0CF0,product-release,100,64,5/20/2021
0B7375,legal-issues-defendant,100,22,5/20/2021
0C6861,dividend,100,50,5/20/2021
0F0440,earnings,100,50,5/20/2021
112694,clinical-trials,100,56,5/20/2021
119CB6,dividend,100,50,5/20/2021
11AEDE,conference-participant,100,50,5/20/2021
12DE76,partnership,100,61,5/20/2021
196D18,conference-participant,100,50,5/20/2021
1A3E1B,legal-issues-defendant,100,22,5/20/2021
1AD9CC,earnings,100,50,5/20/2021
1C2593,earnings,100,50,5/20/2021
1EBF8D,business-contract,100,69,5/20/2021
1EBF8D,business-contract,100,69,5/20/2021
200D8B,earnings,100,50,5/20/2021
2093B1,dividend,100,50,5/20/2021
20BEEA,dividend,100,50,5/20/2021
225CA2,dividend,100,50,5/20/2021
228D42,award,100,58,5/20/2021
2667B6,business-contract,100,69,5/20/2021
267718,business-contract,100,69,5/20/2021
267718,business-contract,100,69,5/20/2021
267718,business-contract,100,69,5/20/2021
267718,business-contract,100,69,5/20/2021
27B191,dividend,100,50,5/20/2021
2CB4C9,dividend,100,50,5/20/2021
2CC71C,executive-appointment,100,54,5/20/2021
2D643C,conference-participant,100,50,5/20/2021
2FEA66,dividend,100,50,5/20/2021
326EDD,dividend,100,50,5/20/2021
346BF2,legal-issues-defendant,100,22,5/20/2021
397A8F,earnings-up,100,68,5/20/2021
397A8F,earnings,100,50,5/20/2021
397A8F,earnings,100,50,5/20/2021
3E149C,partnership,100,61,5/20/2021
4017AD,dividend,100,50,5/20/2021
416C55,conference-participant,100,50,5/20/2021
41785E,dividend,100,50,5/20/2021
43E8F5,conference-participant,100,50,5/20/2021
49F4D0,dividend,100,50,5/20/2021
4C6C63,conference-participant,100,50,5/20/2021
53A226,earnings,100,50,5/20/2021
55CD6F,dividend,100,50,5/20/2021
567F3D,conference-participant,100,50,5/20/2021
583223,dividend,100,50,5/20/2021
5A9F54,public-offering,100,43,5/20/2021
5B7739,partnership,100,61,5/20/2021
5EAA43,earnings,100,50,5/20/2021
5EF130,conference-call,100,50,5/20/2021
5F9CE3,dividend,100,50,5/20/2021
619882,conference-participant,100,50,5/20/2021
619882,conference-organizer,100,57,5/20/2021
619882,conference-organizer,100,57,5/20/2021
665D7D,conference-participant,100,50,5/20/2021
6CC55E,conference-participant,100,50,5/20/2021
6E705B,conference-participant,100,50,5/20/2021
6E705B,product-release,100,64,5/20/2021
6F0A63,dividend-up,100,81,5/20/2021
6F22E7,executive-appointment,100,54,5/20/2021
6F3936,conference-call,100,50,5/20/2021
704B78,acquisition-completed-acquirer,100,49,5/20/2021
717DB4,conference-participant,100,50,5/20/2021
7255D2,executive-appointment,100,54,5/20/2021
7255D2,executive-appointment,100,54,5/20/2021
732A9B,conference-participant,100,50,5/20/2021
73F70F,conference-participant,100,50,5/20/2021
747219,conference-participant,100,50,5/20/2021
766047,dividend,100,50,5/20/2021
76D79A,dividend,100,50,5/20/2021
7740DE,earnings,100,50,5/20/2021
7740DE,dividend,100,50,5/20/2021
7A0EC4,conference-participant,100,50,5/20/2021
7A5097,conference-participant,100,50,5/20/2021
7B9AFA,conference-participant,100,50,5/20/2021
7BFF81,partnership,100,61,5/20/2021
8275FE,executive-appointment,100,54,5/20/2021
834152,legal-issues-defendant,100,22,5/20/2021
845655,acquisition-acquirer,100,49,5/20/2021
845655,acquisition-acquirer,100,49,5/20/2021
8.40E+120,executive-appointment,100,54,5/20/2021
883D82,fraud-defendant,100,20,5/20/2021
883D82,legal-issues-defendant,100,22,5/20/2021
883D82,legal-issues-defendant,100,22,5/20/2021
8A0368,partnership,100,61,5/20/2021
8A8E41,partnership,100,61,5/20/2021
8C311A,conference-participant,100,50,5/20/2021
8C6C1B,earnings,100,50,5/20/2021
8C6C1B,earnings,100,50,5/20/2021
8D4486,business-contract,100,69,5/20/2021
9196A2,conference-organizer,100,57,5/20/2021
91E5EE,dividend,100,50,5/20/2021
934CC3,partnership,100,61,5/20/2021
94637C,executive-appointment,100,54,5/20/2021
94637C,regulatory-product-approval-granted,100,81,5/20/2021
954A47,dividend-up,100,81,5/20/2021
9.54E+32,supply-increase,100,74,5/20/2021
9.54E+32,dividend,100,50,5/20/2021
9.54E+32,legal-issues-defendant,100,22,5/20/2021
95F59E,donation,100,54,5/20/2021
967D92,note-sale,100,52,5/20/2021
968966,business-contract,100,69,5/20/2021
96B4FF,earnings,100,50,5/20/2021
97693A,conference-call,100,50,5/20/2021
9810C0,conference-participant,100,50,5/20/2021
990AD0,conference-organizer,100,57,5/20/2021
9AF3DC,partnership,100,61,5/20/2021
9B0C9C,conference-participant,100,50,5/20/2021
9C5BA5,dividend,100,50,5/20/2021
9D2790,note-acquisition,100,66,5/20/2021
9F03CF,executive-appointment,100,54,5/20/2021
9F71E5,conference-participant,100,50,5/20/2021
A1DBF0,conference-participant,100,50,5/20/2021
A247F5,executive-appointment,100,54,5/20/2021
A403CF,earnings,100,50,5/20/2021
A403CF,dividend-up,100,81,5/20/2021
A4BCDE,earnings,100,50,5/20/2021
A52B6B,earnings,100,50,5/20/2021
A60354,dividend,100,50,5/20/2021
A6213D,partnership,100,61,5/20/2021
A63820,partnership,100,61,5/20/2021
A6D095,conference-participant,100,50,5/20/2021
A761FE,conference-call,100,50,5/20/2021
A8CBDA,business-contract,100,69,5/20/2021
A8E72A,conference-participant,100,50,5/20/2021
AA98ED,dividend,100,50,5/20/2021
ABAA03,executive-appointment,100,54,5/20/2021
ACDF88,conference-participant,100,50,5/20/2021
ACDF88,partnership,100,61,5/20/2021
ACDF88,conference-participant,100,50,5/20/2021
ACDF88,dividend,100,50,5/20/2021
AECCA9,earnings-guidance,100,50,5/20/2021
B076A1,dividend,100,50,5/20/2021
B076A1,buybacks,100,74,5/20/2021
B3CB74,conference-organizer,100,57,5/20/2021
B48FC9,conference-participant,100,50,5/20/2021
B7202A,conference-participant,100,50,5/20/2021
B7BBFF,earnings,100,50,5/20/2021
BB88B6,conference-participant,100,50,5/20/2021
BBBB41,conference-participant,100,50,5/20/2021
BD15E8,dividend,100,50,5/20/2021
C0BA36,conference-participant,100,50,5/20/2021
C4452A,earnings,100,50,5/20/2021
C4452A,partnership,100,61,5/20/2021
C4A432,earnings,100,50,5/20/2021
C4A432,earnings,100,50,5/20/2021
C4A432,earnings,100,50,5/20/2021
C9D866,conference-participant,100,50,5/20/2021
CA99D7,earnings,100,50,5/20/2021
CB89EA,conference-participant,100,50,5/20/2021
CBDB4D,clinical-trials,100,56,5/20/2021
CBFFDD,conference-participant,100,50,5/20/2021
CC6FF5,product-release,100,64,5/20/2021
CE1002,conference-participant,100,50,5/20/2021
D1AE3B,executive-appointment,100,54,5/20/2021
D1C0B9,campaign-ad-release,100,59,5/20/2021
D1C26F,earnings-guidance-up,100,83,5/20/2021
D57D99,facility-open,100,65,5/20/2021
D69D42,earnings,100,50,5/20/2021
D76AEF,conference-call,100,50,5/20/2021
D90441,dividend,100,50,5/20/2021
D90441,dividend,100,50,5/20/2021
DA199F,partnership,100,61,5/20/2021
DA48E4,dividend,100,50,5/20/2021
DAFED3,dividend,100,50,5/20/2021
DB88A1,business-contract,100,69,5/20/2021
DC437D,dividend,100,50,5/20/2021
DC437D,earnings,100,50,5/20/2021
DC486E,dividend,100,50,5/20/2021
DC486E,dividend,100,50,5/20/2021
E0207A,conference-participant,100,50,5/20/2021
E0A84E,campaign-ad-release,100,59,5/20/2021
E0A84E,campaign-ad-release,100,59,5/20/2021
E4158B,earnings,100,50,5/20/2021
E4CE73,executive-appointment,100,54,5/20/2021
E5A3B6,conference-participant,100,50,5/20/2021
E6A53A,dividend-up,100,59,5/20/2021
E829E8,partnership,100,61,5/20/2021
ED3CA8,public-offering,100,43,5/20/2021
ED79D9,conference-participant,100,50,5/20/2021
F1C04C,conference-participant,100,50,5/20/2021
F209B4,executive-appointment,100,54,5/20/2021
F30508,partnership,100,61,5/20/2021
F30508,partnership,100,61,5/20/2021
F4F46F,business-contract,100,69,5/20/2021
F57F6F,conference-participant,100,50,5/20/2021
F66B58,conference-call,100,50,5/20/2021
F88A04,note-sale,100,52,5/20/2021
002A99,legal-issues-defendant,100,22,5/21/2021
20751,regulatory-product-review-positive,100,73,5/21/2021
20751,regulatory-product-review-positive,100,73,5/21/2021
0560D8,conference-participant,100,50,5/21/2021
0AAD90,conference-participant,100,50,5/21/2021
0B7375,legal-issues-defendant,100,22,5/21/2021
0CE7F6,earnings,100,50,5/21/2021
0DBB81,regulatory-product-review-positive,100,73,5/21/2021
0DBB81,regulatory-product-review-positive,100,73,5/21/2021
147098,dividend,100,50,5/21/2021
190B91,conference-participant,100,50,5/21/2021
1E1125,legal-issues-defendant,100,22,5/21/2021
20F5E2,dividend,100,50,5/21/2021
275300,dividend,100,50,5/21/2021
2A1009,legal-issues-defendant,100,22,5/21/2021
2A1009,legal-issues-defendant,100,22,5/21/2021
31666F,executive-resignation,100,44,5/21/2021
385DD4,facility-open,100,65,5/21/2021
385DD4,facility-open,100,65,5/21/2021
39692D,product-release,100,64,5/21/2021
3BA1BF,conference-participant,100,50,5/21/2021
431B74,earnings-positive,100,69,5/21/2021
431B74,earnings-positive,100,69,5/21/2021
431B74,earnings-positive,100,69,5/21/2021
431B74,earnings-positive,100,69,5/21/2021
431B74,earnings-positive,100,69,5/21/2021
431B74,earnings-positive,100,69,5/21/2021
431B74,earnings-positive,100,69,5/21/2021
431B74,earnings-positive,100,69,5/21/2021
431B74,earnings,100,50,5/21/2021
431B74,earnings,100,50,5/21/2021
431B74,earnings,100,50,5/21/2021
431B74,earnings,100,50,5/21/2021
431B74,earnings,100,50,5/21/2021
431B74,earnings,100,50,5/21/2021
431B74,earnings-above-expectations,100,88,5/21/2021
44A4FC,conference-participant,100,50,5/21/2021
4B7006,partnership,100,61,5/21/2021
4F0A80,dividend,100,50,5/21/2021
53F491,dividend,100,50,5/21/2021
55C9B5,partnership,100,61,5/21/2021
55C9B5,partnership,100,61,5/21/2021
619882,conference-organizer,100,57,5/21/2021
619882,conference-organizer,100,57,5/21/2021
619882,conference-organizer,100,57,5/21/2021
622DBE,partnership,100,61,5/21/2021
698FF9,executive-appointment,100,54,5/21/2021
6BDA0C,dividend,100,50,5/21/2021
6BDA0C,dividend,100,50,5/21/2021
6C6D73,conference-participant,100,50,5/21/2021
6DC1D7,dividend,100,50,5/21/2021
769F40,merger-regulatory-approval,100,81,5/21/2021
79340A,conference-participant,100,50,5/21/2021
7A10FF,conference-participant,100,50,5/21/2021
7B9212,earnings,100,50,5/21/2021
82FD6D,earnings,100,50,5/21/2021
971334,dividend,100,50,5/21/2021
A26EF7,clinical-trials,100,56,5/21/2021
AE0CCE,conference-participant,100,50,5/21/2021
B72D2E,executive-appointment,100,54,5/21/2021
BB5142,partnership,100,61,5/21/2021
BBC05B,business-contract,100,69,5/21/2021
C1114B,conference-participant,100,50,5/21/2021
CEDFD5,partnership,100,61,5/21/2021
CEDFD5,partnership,100,61,5/21/2021
CFF97C,credit-rating-downgrade-rater,20,50,5/21/2021
D17C1B,product-release,100,64,5/21/2021
D598E7,earnings,100,50,5/21/2021
D78CCD,earnings,100,50,5/21/2021
DAC66A,dividend,100,50,5/21/2021
E09E2B,stock-splits,100,49,5/21/2021
E114F4,executive-appointment,100,54,5/21/2021
E38906,public-offering,100,43,5/21/2021
E74B55,legal-issues-defendant,100,22,5/21/2021
ED3CA8,public-offering,100,43,5/21/2021
F7935D,regulatory-product-review-positive,100,73,5/21/2021
F80389,conference-call,100,50,5/21/2021
07C69F,legal-issues-defendant,100,22,5/22/2021
1E1125,legal-issues-defendant,100,22,5/22/2021
2A1009,legal-issues-defendant,100,22,5/22/2021
5B35C7,legal-issues-defendant,100,22,5/22/2021
6559D8,legal-issues-defendant,100,22,5/22/2021
95A92E,legal-issues-defendant,100,22,5/22/2021
A99576,legal-issues-defendant,100,22,5/22/2021
A99576,legal-issues-defendant,100,22,5/22/2021
ADF092,legal-issues-defendant,100,22,5/22/2021
002A99,legal-issues-defendant,100,22,5/23/2021
1DEBBE,legal-issues-defendant,100,22,5/23/2021
366A08,legal-issues-defendant,100,22,5/23/2021
4D203E,legal-issues-defendant,100,22,5/23/2021
863350,legal-issues-defendant,100,22,5/23/2021
A29A46,legal-issues-defendant,100,22,5/23/2021
A2C979,conference-call,100,50,5/23/2021
CDE118,legal-issues-defendant,100,22,5/23/2021
ECF4F8,legal-issues-defendant,100,22,5/23/2021
002A99,legal-issues-defendant,100,22,5/24/2021
00FC70,executive-resignation,100,44,5/24/2021
070B45,award,100,58,5/24/2021
07C69F,legal-issues-defendant,100,22,5/24/2021
0B7375,legal-issues-defendant,100,22,5/24/2021
0E2992,dividend,100,50,5/24/2021
0F65C9,conference-participant,100,50,5/24/2021
0FABBD,conference-participant,100,50,5/24/2021
0FC848,conference-participant,100,50,5/24/2021
11A49E,executive-appointment,100,54,5/24/2021
13A782,conference-participant,100,50,5/24/2021
147C38,investment-investor,100,55,5/24/2021
15A388,conference-participant,100,50,5/24/2021
168A5D,product-release,100,64,5/24/2021
1921DD,note-sale,100,52,5/24/2021
1921DD,note-sale,100,52,5/24/2021
1921DD,note-sale,100,52,5/24/2021
1921DD,note-sale,100,52,5/24/2021
1921DD,note-sale,100,52,5/24/2021
1921DD,note-sale,100,52,5/24/2021
19BF16,conference-participant,100,50,5/24/2021
1A46A1,conference-participant,100,50,5/24/2021
1AC649,conference-participant,100,50,5/24/2021
1B5FEA,conference-participant,100,50,5/24/2021
1BDB2A,conference-participant,100,50,5/24/2021
1CD4B5,fast-track-designation,100,81,5/24/2021
1DB833,conference-participant,100,50,5/24/2021
1DEBBE,legal-issues-defendant,100,22,5/24/2021
1E83DE,earnings,100,50,5/24/2021
1EBF8D,regulatory-product-review-positive,100,73,5/24/2021
20BEEA,executive-appointment,100,54,5/24/2021
2158DF,partnership,100,61,5/24/2021
228D42,partnership,100,61,5/24/2021
228D42,partnership,100,61,5/24/2021
228D42,partnership,100,61,5/24/2021
228D42,partnership,100,61,5/24/2021
24CB56,executive-appointment,100,54,5/24/2021
2B8179,clinical-trials-start,100,64,5/24/2021
2BF36E,conference-participant,100,50,5/24/2021
2F5256,partnership-terminated,100,36,5/24/2021
2F7474,legal-issues-defendant,100,22,5/24/2021
2F94A5,expenses-guidance-down,100,61,5/24/2021
2F94A5,expenses-guidance-down,100,61,5/24/2021
30DE64,acquisition-acquirer,100,49,5/24/2021
30DE64,acquisition-acquirer,100,49,5/24/2021
30DE64,acquisition-acquirer,100,49,5/24/2021
30DE64,acquisition-acquirer,100,49,5/24/2021
337024,board-meeting,100,51,5/24/2021
346BF2,legal-issues-defendant,100,22,5/24/2021
366A08,legal-issues-defendant,100,22,5/24/2021
36A1CB,executive-appointment,100,54,5/24/2021
3.73E+87,partnership,100,61,5/24/2021
3.88E+02,merger,100,66,5/24/2021
3.88E+02,business-combination,100,54,5/24/2021
39692D,executive-appointment,100,54,5/24/2021
39FB23,executive-appointment,100,54,5/24/2021
3DED49,conference-call,100,50,5/24/2021
43A060,executive-appointment,100,54,5/24/2021
442587,conference-organizer,100,57,5/24/2021
453282,conference-participant,100,50,5/24/2021
45444E,unit-acquisition-acquirer,100,49,5/24/2021
45BC35,conference-participant,100,50,5/24/2021
4649D5,conference-participant,100,50,5/24/2021
4D203E,legal-issues-defendant,100,22,5/24/2021
4F9926,product-release,100,64,5/24/2021
519FE0,product-release,100,64,5/24/2021
51F541,note-sale,100,52,5/24/2021
589803,regulatory-product-review-positive,100,73,5/24/2021
5AF08A,grant-recipient,100,63,5/24/2021
5B35C7,legal-issues-defendant,100,22,5/24/2021
5D43A7,executive-appointment,100,54,5/24/2021
5DAF89,executive-appointment,100,54,5/24/2021
5E9934,conference-call,100,50,5/24/2021
5F9CE3,partnership,100,61,5/24/2021
609208,legal-issues-defendant,100,22,5/24/2021
619882,conference-organizer,100,57,5/24/2021
61BCA7,executive-appointment,100,54,5/24/2021
68586A,index-listing,100,76,5/24/2021
6CD55A,dividend,100,50,5/24/2021
71694D,earnings-guidance-up,100,83,5/24/2021
7262F2,conference-participant,100,50,5/24/2021
75D689,conference-participant,100,50,5/24/2021
7A2A49,conference-call,100,50,5/24/2021
7EA323,exchange-noncompliance,100,24,5/24/2021
80B32C,acquisition-acquiree,100,76,5/24/2021
810FAD,executive-appointment,100,54,5/24/2021
817ED9,conference-participant,100,50,5/24/2021
845533,buybacks,100,74,5/24/2021
85CDC9,clinical-trials,100,56,5/24/2021
85CDC9,clinical-trials,100,56,5/24/2021
85CDC9,clinical-trials,100,56,5/24/2021
863350,legal-issues-defendant,100,22,5/24/2021
87486A,public-offering,100,43,5/24/2021
87486A,public-offering,100,43,5/24/2021
8BE916,buybacks,100,74,5/24/2021
8C5519,executive-appointment,100,54,5/24/2021
8E0E32,partnership-terminated,100,36,5/24/2021
8FCA78,note-sale,100,52,5/24/2021
905356,earnings-per-share-positive,100,69,5/24/2021
905356,earnings,100,50,5/24/2021
905356,earnings,100,50,5/24/2021
90D6A5,merger,100,66,5/24/2021
90D6A5,business-combination,100,54,5/24/2021
90D6A5,legal-issues-defendant,100,22,5/24/2021
90DD65,clinical-trials,100,56,5/24/2021
9196A2,conference-call,100,50,5/24/2021
9470CC,product-release,100,64,5/24/2021
958938,executive-appointment,100,54,5/24/2021
95A92E,legal-issues-defendant,100,22,5/24/2021
97FE80,partnership,100,61,5/24/2021
98CAED,facility-open,100,65,5/24/2021
9EA947,executive-resignation,100,44,5/24/2021
A01664,conference-participant,100,50,5/24/2021
A05C43,executive-appointment,100,54,5/24/2021
A21649,dividend,100,50,5/24/2021
A29A46,legal-issues-defendant,100,22,5/24/2021
A2C979,earnings,100,50,5/24/2021
A2C979,earnings,100,50,5/24/2021
A37D68,earnings,100,50,5/24/2021
A4F67C,unit-acquisition-acquirer,100,49,5/24/2021
A6213D,partnership,100,61,5/24/2021
A65325,partnership,100,61,5/24/2021
A99576,legal-issues-defendant,100,22,5/24/2021
AC7C4F,business-contract,100,69,5/24/2021
ADF092,legal-issues-defendant,100,22,5/24/2021
AEEB76,conference-participant,100,50,5/24/2021
B2256A,unit-acquisition-acquirer,100,49,5/24/2021
B37FB4,donation,100,54,5/24/2021
B3CB74,product-release,100,64,5/24/2021
B4F5F4,legal-issues-defendant,100,22,5/24/2021
B560AF,executive-appointment,100,54,5/24/2021
BBBB41,executive-appointment,100,54,5/24/2021
BFCACF,executive-appointment,100,54,5/24/2021
BFE02C,conference-participant,100,50,5/24/2021
C03C8B,conference-participant,100,50,5/24/2021
C4A432,dividend,100,50,5/24/2021
C8257F,executive-appointment,100,54,5/24/2021
C97B2D,conference-participant,100,50,5/24/2021
C9D866,executive-appointment,100,54,5/24/2021
CC8F6E,business-contract,100,69,5/24/2021
CDE118,legal-issues-defendant,100,22,5/24/2021
CF073E,conference-participant,100,50,5/24/2021
D56D6D,earnings-up,100,68,5/24/2021
D56D6D,earnings,100,50,5/24/2021
D56D6D,earnings,100,50,5/24/2021
D6534D,acquisition-acquirer,100,49,5/24/2021
D8C09D,earnings,100,50,5/24/2021
D8C09D,earnings,100,50,5/24/2021
D8C09D,earnings,100,50,5/24/2021
D8C09D,earnings,100,50,5/24/2021
D8C09D,earnings,100,50,5/24/2021
DC6EF3,earnings,100,50,5/24/2021
E1E36F,dividend,100,50,5/24/2021
E4CE73,partnership,100,61,5/24/2021
E67C2C,conference-participant,100,50,5/24/2021
E70531,business-contract,100,69,5/24/2021
E8846E,executive-appointment,100,54,5/24/2021
E8B315,legal-issues-defendant,100,22,5/24/2021
EC4E82,conference-participant,100,50,5/24/2021
ECF4F8,legal-issues-defendant,100,22,5/24/2021
ED0402,acquisition-completed-acquirer,100,49,5/24/2021
ED0402,acquisition-completed-acquirer,100,49,5/24/2021
F179ED,conference-participant,100,50,5/24/2021
F4FBD8,executive-appointment,100,54,5/24/2021
F5D410,executive-appointment,100,54,5/24/2021
F5D410,executive-appointment,100,54,5/24/2021
F5D410,conference-participant,100,50,5/24/2021
F721A7,executive-appointment,100,54,5/24/2021
F7ADEB,conference-participant,100,50,5/24/2021
FACF19,partnership,100,61,5/24/2021
FD4E8D,executive-appointment,100,54,5/24/2021
FE7A63,executive-appointment,100,54,5/24/2021
9397,executive-appointment,100,54,5/25/2021
01D03F,partnership,100,61,5/25/2021
02FC1A,conference-participant,100,50,5/25/2021
06C826,executive-appointment,100,54,5/25/2021
75172,conference-participant,100,50,5/25/2021
09062E,conference-participant,100,50,5/25/2021
0986B5,dividend,100,50,5/25/2021
09F623,executive-resignation,100,44,5/25/2021
0BF198,conference-participant,100,50,5/25/2021
0C355F,conference-participant,100,50,5/25/2021
0E499E,conference-participant,100,50,5/25/2021
0FDE97,executive-appointment,100,54,5/25/2021
1216D1,unit-acquisition-acquirer,100,49,5/25/2021
1272B3,partnership,100,61,5/25/2021
1348C9,merger,100,66,5/25/2021
139303,conference-organizer,100,57,5/25/2021
139303,conference-organizer,100,57,5/25/2021
159AE4,legal-issues-defendant,100,22,5/25/2021
168A5D,partnership,100,61,5/25/2021
168A5D,grant-recipient,100,63,5/25/2021
184988,conference-call,100,50,5/25/2021
1921DD,acquisition-acquiree,100,76,5/25/2021
196D18,partnership,100,61,5/25/2021
1A6A94,conference-participant,100,50,5/25/2021
1B637E,acquisition-acquirer,100,49,5/25/2021
1B9535,conference-participant,100,50,5/25/2021
1DA44F,note-sale,100,52,5/25/2021
1DA44F,note-sale,100,52,5/25/2021
1EBF8D,partnership,100,61,5/25/2021
1EBF8D,dividend,100,50,5/25/2021
1FA886,partnership,100,61,5/25/2021
1FAF22,product-release,100,64,5/25/2021
21022F,investment-investor,100,55,5/25/2021
21022F,investment-investor,100,55,5/25/2021
228D42,partnership,100,61,5/25/2021
24A89A,executive-appointment,100,54,5/25/2021
25102A,conference-participant,100,50,5/25/2021
263216,dividend,100,50,5/25/2021
273BA3,acquisition-completed-acquirer,100,49,5/25/2021
2AE625,conference-participant,100,50,5/25/2021
2CC71C,conference-participant,100,50,5/25/2021
2E1322,product-release,100,64,5/25/2021
2F7474,legal-issues-defendant,100,22,5/25/2021
309922,legal-issues-defendant,100,22,5/25/2021
32CB22,acquisition-completed-acquirer,100,49,5/25/2021
341759,conference-participant,100,50,5/25/2021
3461CF,credit-rating-affirmation-rater,20,50,5/25/2021
346BF2,legal-issues-defendant,100,22,5/25/2021
36C09B,regulatory-product-approval-granted,100,81,5/25/2021
384CD3,business-contract,100,69,5/25/2021
385DD4,conference-participant,100,50,5/25/2021
3A1C46,conference-participant,100,50,5/25/2021
3A4BDB,executive-appointment,100,54,5/25/2021
3AAEAE,executive-appointment,100,54,5/25/2021
3B50FE,earnings,100,50,5/25/2021
3BB616,note-sale,100,52,5/25/2021
3BBD10,conference-participant,100,50,5/25/2021
3D9999,buybacks,100,74,5/25/2021
3F1C69,conference-participant,100,50,5/25/2021
3F868D,partnership,100,61,5/25/2021
401072,conference-participant,100,50,5/25/2021
422CE3,earnings,100,50,5/25/2021
442769,business-contract,100,69,5/25/2021
4A6F00,partnership,100,61,5/25/2021
4AC91D,executive-appointment,100,54,5/25/2021
4AC91D,dividend,100,50,5/25/2021
4B3676,spin-off,100,58,5/25/2021
4B3DC9,unit-acquisition-acquiree,100,76,5/25/2021
4BDCA7,business-contract,100,69,5/25/2021
4C37C5,conference-participant,100,50,5/25/2021
4DD203,product-release,100,64,5/25/2021
4E6F5A,conference-participant,100,50,5/25/2021
4F9926,partnership,100,61,5/25/2021
50070E,conference-organizer,100,57,5/25/2021
50070E,conference-organizer,100,57,5/25/2021
50070E,conference-organizer,100,57,5/25/2021
50070E,conference-organizer,100,57,5/25/2021
50070E,conference-organizer,100,57,5/25/2021
50070E,conference-organizer,100,57,5/25/2021
50070E,conference-organizer,100,57,5/25/2021
50702E,conference-call,100,50,5/25/2021
50D1EC,executive-appointment,100,54,5/25/2021
520632,executive-appointment,100,54,5/25/2021
5340D0,earnings,100,50,5/25/2021
543900,dividend,100,50,5/25/2021
548AC0,conference-participant,100,50,5/25/2021
556F08,conference-participant,100,50,5/25/2021
56277A,conference-participant,100,50,5/25/2021
56EA2B,conference-call,100,50,5/25/2021
5876DC,acquisition-acquirer,100,49,5/25/2021
594402,conference-participant,100,50,5/25/2021
59DB8C,conference-participant,100,50,5/25/2021
5A9F54,market-entry,100,57,5/25/2021
5BE42C,executive-appointment,100,54,5/25/2021
5DE5A5,executive-appointment,100,54,5/25/2021
5F1B7B,product-release,100,64,5/25/2021
5F3D91,conference-participant,100,50,5/25/2021
5F3E74,conference-participant,100,50,5/25/2021
5F9CE3,partnership,100,61,5/25/2021
609208,legal-issues-defendant,100,22,5/25/2021
619882,partnership,100,61,5/25/2021
619882,conference-organizer,100,57,5/25/2021
6559D8,legal-issues-defendant,100,22,5/25/2021
6559D8,legal-issues-defendant,100,22,5/25/2021
6559D8,legal-issues-defendant,100,22,5/25/2021
665D7D,regulatory-product-approval-granted,100,81,5/25/2021
68586A,index-listing,100,76,5/25/2021
6BBCBA,conference-participant,100,50,5/25/2021
6CDFC6,partnership,100,61,5/25/2021
6CDFC6,partnership,100,61,5/25/2021
6DBBBC,executive-appointment,100,54,5/25/2021
6ED519,dividend,100,50,5/25/2021
70B3D6,conference-call,100,50,5/25/2021
713810,partnership,100,61,5/25/2021
726EEA,conference-participant,100,50,5/25/2021
72FCA3,note-sale,100,52,5/25/2021
72FCA3,note-sale,100,52,5/25/2021
72FCA3,note-sale,100,52,5/25/2021
762B8D,acquisition-completed-acquiree,100,76,5/25/2021
76BD96,public-offering,100,43,5/25/2021
76BD96,public-offering,100,43,5/25/2021
7732C2,executive-appointment,100,54,5/25/2021
791D59,business-contract,100,69,5/25/2021
7999F3,dividend,100,50,5/25/2021
7AC86E,note-sale,100,52,5/25/2021
7F9984,conference-participant,100,50,5/25/2021
7FDE1C,product-release,100,64,5/25/2021
810FAD,dividend,100,50,5/25/2021
82F088,conference-participant,100,50,5/25/2021
82FD6D,conference-participant,100,50,5/25/2021
834152,conference-participant,100,50,5/25/2021
84A6B9,executive-appointment,100,54,5/25/2021
855DF7,conference-participant,100,50,5/25/2021
859281,executive-appointment,100,54,5/25/2021
85AD00,dividend,100,50,5/25/2021
85DA04,partnership,100,61,5/25/2021
873DB9,product-release,100,64,5/25/2021
89E771,earnings,100,50,5/25/2021
8AB37F,conference-participant,100,50,5/25/2021
8BFE9A,public-offering,100,43,5/25/2021
8D4486,partnership,100,61,5/25/2021
8EDACA,earnings,100,50,5/25/2021
8EDACA,conference-participant,100,50,5/25/2021
8F8F2F,note-sale,100,52,5/25/2021
90D6A5,legal-issues-defendant,100,22,5/25/2021
9196A2,conference-organizer,100,57,5/25/2021
9196A2,conference-call,100,50,5/25/2021
9.31E+77,conference-participant,100,50,5/25/2021
94637C,business-contract,100,69,5/25/2021
95DC1F,partnership,100,61,5/25/2021
96A6CD,conference-participant,100,50,5/25/2021
97FE80,partnership,100,61,5/25/2021
9978F1,partnership,100,61,5/25/2021
9F37C5,dividend,100,50,5/25/2021
A3230E,conference-call,100,50,5/25/2021
A3800A,partnership,100,61,5/25/2021
A4CD53,public-offering,100,43,5/25/2021
A63387,acquisition-completed-acquiree,100,76,5/25/2021
AA09AD,partnership,100,61,5/25/2021
AA09AD,partnership,100,61,5/25/2021
AA09AD,partnership,100,61,5/25/2021
AA09AD,partnership,100,61,5/25/2021
AE0CCE,executive-appointment,100,54,5/25/2021
AE4125,conference-participant,100,50,5/25/2021
AFF7B4,executive-appointment,100,54,5/25/2021
AFF7B4,executive-appointment,100,54,5/25/2021
B0D41A,conference-participant,100,50,5/25/2021
B33E77,conference-participant,100,50,5/25/2021
B4B281,earnings-up,100,68,5/25/2021
B4B281,earnings,100,50,5/25/2021
B4F5F4,legal-issues-defendant,100,22,5/25/2021
B76C82,dividend,100,50,5/25/2021
BB88B6,product-release,100,64,5/25/2021
BB88B6,business-contract,100,69,5/25/2021
BB88B6,product-release,100,64,5/25/2021
BB88B6,product-release,100,64,5/25/2021
BCC55F,award,100,58,5/25/2021
BDE867,executive-appointment,100,54,5/25/2021
C06EB6,conference-participant,100,50,5/25/2021
C07E05,earnings,100,50,5/25/2021
C3BCD5,business-contract,100,69,5/25/2021
C501B6,executive-appointment,100,54,5/25/2021
C83B88,dividend,100,50,5/25/2021
C83B88,partnership,100,61,5/25/2021
C94CFC,conference-participant,100,50,5/25/2021
CB89EA,partnership,100,61,5/25/2021
CD4DA8,conference-organizer,100,57,5/25/2021
CDFCC9,conference-participant,100,50,5/25/2021
CE5664,dividend,100,50,5/25/2021
CF351E,merger,100,66,5/25/2021
CF6A5A,partnership,100,61,5/25/2021
D06755,conference-participant,100,50,5/25/2021
D17C1B,executive-appointment,100,54,5/25/2021
D4AC65,product-release,100,64,5/25/2021
D56D6D,partnership,100,61,5/25/2021
D58A11,conference-participant,100,50,5/25/2021
D64C6D,conference-call,100,50,5/25/2021
D65A13,conference-participant,100,50,5/25/2021
D75910,earnings,100,50,5/25/2021
D75910,earnings,100,50,5/25/2021
D75910,earnings,100,50,5/25/2021
D75910,earnings,100,50,5/25/2021
D75910,earnings,100,50,5/25/2021
DC1405,conference-participant,100,50,5/25/2021
DF6FDD,dividend-up,100,55,5/25/2021
E20BFE,revenues,100,50,5/25/2021
E20BFE,revenues,100,50,5/25/2021
E20BFE,revenues,100,50,5/25/2021
E28D9C,business-contract,100,69,5/25/2021
E4CE73,product-release,100,64,5/25/2021
E4CE73,acquisition-acquirer,100,49,5/25/2021
E598FB,conference-participant,100,50,5/25/2021
E6BC2C,conference-participant,100,50,5/25/2021
E74B55,legal-issues-defendant,100,22,5/25/2021
E866D2,partnership,100,61,5/25/2021
E8B315,legal-issues-defendant,100,22,5/25/2021
E8F0E2,patent-awarded,100,72,5/25/2021
E9C7C0,earnings,100,50,5/25/2021
EAA0A7,conference-participant,100,50,5/25/2021
EAEA91,fundraising,100,64,5/25/2021
ECF709,same-store-sales-up,100,73,5/25/2021
ECF709,same-store-sales-up,100,62,5/25/2021
ECF709,same-store-sales-up,100,62,5/25/2021
ED1A74,conference-participant,100,50,5/25/2021
ED2A5E,patent-awarded,100,72,5/25/2021
ED4560,executive-appointment,100,54,5/25/2021
ED79D9,earnings,100,50,5/25/2021
EF25A5,partnership,100,61,5/25/2021
EF5BED,facility-upgrade,100,65,5/25/2021
F11638,earnings-guidance-up,100,83,5/25/2021
F11638,earnings,100,50,5/25/2021
F11638,earnings,100,50,5/25/2021
F11638,earnings,100,50,5/25/2021
F11638,earnings,100,50,5/25/2021
F209B4,executive-appointment,100,54,5/25/2021
F4F46F,conference-participant,100,50,5/25/2021
F5349B,executive-resignation,100,44,5/25/2021
FA36A4,conference-participant,100,50,5/25/2021
FB728F,conference-participant,100,50,5/25/2021
002A99,fraud-defendant,100,20,5/26/2021
002A99,legal-issues-defendant,100,22,5/26/2021
01478A,dividend,100,50,5/26/2021
0157B1,facility-open,100,65,5/26/2021
0157B1,facility-open,100,65,5/26/2021
0157B1,acquisition-acquirer,100,49,5/26/2021
0157B1,partnership,100,61,5/26/2021
018C11,conference-participant,100,50,5/26/2021
20751,conference-participant,100,50,5/26/2021
02870F,dividend-up,100,62,5/26/2021
03CF95,investment-investor,100,55,5/26/2021
03FAA6,buybacks,100,74,5/26/2021
0490C6,conference-participant,100,50,5/26/2021
05AF14,conference-participant,100,50,5/26/2021
05D148,executive-appointment,100,54,5/26/2021
0624BE,earnings,100,50,5/26/2021
091B6C,conference-participant,100,50,5/26/2021
091B6C,conference-participant,100,50,5/26/2021
091B6C,conference-participant,100,50,5/26/2021
091B6C,conference-participant,100,50,5/26/2021
95294,earnings,100,50,5/26/2021
0BF528,earnings-up,100,68,5/26/2021
0BF528,earnings-up,100,68,5/26/2021
0BF528,earnings-up,100,68,5/26/2021
0BF528,earnings-up,100,68,5/26/2021
0C355F,index-listing,100,76,5/26/2021
0CE7F6,partnership,100,61,5/26/2021
0CE7F6,partnership,100,61,5/26/2021
0CE7F6,partnership,100,61,5/26/2021
0E3436,earnings,100,50,5/26/2021
0E3436,earnings,100,50,5/26/2021
0E499E,clinical-trials,100,56,5/26/2021
12DE76,dividend,100,50,5/26/2021
133644,conference-participant,100,50,5/26/2021
1348C9,merger-regulatory-approval,100,81,5/26/2021
1348C9,merger-regulatory-approval,100,81,5/26/2021
138DDE,public-offering,100,43,5/26/2021
147C38,executive-appointment,100,54,5/26/2021
168A5D,partnership,100,61,5/26/2021
1748F6,earnings,100,50,5/26/2021
1A6A94,trading-halt,100,43,5/26/2021
1BC12C,partnership,100,61,5/26/2021
1E8A99,dividend,100,50,5/26/2021
21245F,earnings,100,50,5/26/2021
223552,regulatory-product-approval-granted,100,81,5/26/2021
228D42,partnership,100,61,5/26/2021
23699B,conference-participant,100,50,5/26/2021
251988,partnership,100,61,5/26/2021
267718,regulatory-product-approval-granted,100,81,5/26/2021
27B191,earnings,100,50,5/26/2021
2A1009,clinical-trials-positive,100,87,5/26/2021
2B7A40,conference-participant,100,50,5/26/2021
2C35B5,conference-participant,100,50,5/26/2021
2CC60C,revenues,100,50,5/26/2021
2CF9D3,conference-participant,100,50,5/26/2021
2DB344,unit-acquisition-acquirer,100,49,5/26/2021
2F5256,dividend,100,50,5/26/2021
2F9304,executive-appointment,100,54,5/26/2021
301493,product-release,100,64,5/26/2021
3.14E+47,executive-appointment,100,54,5/26/2021
31643A,earnings,100,50,5/26/2021
31643A,earnings,100,50,5/26/2021
31643A,earnings,100,50,5/26/2021
3224CC,conference-participant,100,50,5/26/2021
33A0F1,executive-appointment,100,54,5/26/2021
33E9D5,conference-call,100,50,5/26/2021
341759,conference-participant,100,50,5/26/2021
34B97A,partnership,100,61,5/26/2021
356B21,conference-participant,100,50,5/26/2021
367434,conference-call,100,50,5/26/2021
36E479,executive-appointment,100,54,5/26/2021
371B0A,conference-participant,100,50,5/26/2021
3B20AB,conference-participant,100,50,5/26/2021
3B9886,executive-appointment,100,54,5/26/2021
3C7F5F,dividend,100,50,5/26/2021
3EE65E,earnings,100,50,5/26/2021
3F868D,legal-issues-plaintiff,100,44,5/26/2021
431B74,dividend,100,50,5/26/2021
431B74,dividend,100,50,5/26/2021
449A26,merger-regulatory-approval,100,81,5/26/2021
4A6F00,partnership,100,61,5/26/2021
4A6F00,product-release,100,64,5/26/2021
4A6F00,product-release,100,64,5/26/2021
4B3676,conference-participant,100,50,5/26/2021
4B3676,conference-participant,100,50,5/26/2021
4B7006,earnings,100,50,5/26/2021
4BDCA7,regulatory-product-approval-granted,100,81,5/26/2021
50070E,conference-organizer,100,57,5/26/2021
50070E,conference-organizer,100,57,5/26/2021
504FE2,conference-participant,100,50,5/26/2021
50702E,settlement,100,56,5/26/2021
53E575,earnings,100,50,5/26/2021
543900,earnings,100,50,5/26/2021
586BD7,conference-participant,100,50,5/26/2021
59872F,earnings,100,50,5/26/2021
5B51D6,conference-participant,100,50,5/26/2021
61E975,conference-participant,100,50,5/26/2021
6251A3,conference-participant,100,50,5/26/2021
641F17,conference-participant,100,50,5/26/2021
651C85,conference-participant,100,50,5/26/2021
6559D8,legal-issues-defendant,100,22,5/26/2021
665D7D,conference-participant,100,50,5/26/2021
67B052,conference-participant,100,50,5/26/2021
69345C,partnership,100,61,5/26/2021
69345C,conference-participant,100,50,5/26/2021
69CE71,conference-participant,100,50,5/26/2021
6AACDD,conference-participant,100,50,5/26/2021
70CA28,conference-participant,100,50,5/26/2021
713810,partnership,100,61,5/26/2021
7255D2,partnership,100,61,5/26/2021
7255D2,partnership,100,61,5/26/2021
747219,conference-participant,100,50,5/26/2021
763DBE,conference-participant,100,50,5/26/2021
76959C,conference-participant,100,50,5/26/2021
7823A3,conference-participant,100,50,5/26/2021
790C34,partnership,100,61,5/26/2021
7A2A49,acquisition-completed-acquirer,100,49,5/26/2021
7A2A49,business-contract,100,69,5/26/2021
7A3633,partnership,100,61,5/26/2021
7A5097,earnings,100,50,5/26/2021
7BEA98,conference-participant,100,50,5/26/2021
7CBC40,executive-appointment,100,54,5/26/2021
7D85A9,partnership,100,61,5/26/2021
810FAD,acquisition-acquirer,100,49,5/26/2021
868808,dividend,100,50,5/26/2021
873DB9,conference-participant,100,50,5/26/2021
883D82,legal-issues-defendant,100,22,5/26/2021
896771,antitrust-investigation,100,18,5/26/2021
8D9993,earnings,100,50,5/26/2021
8D9993,earnings,100,50,5/26/2021
8D9993,earnings,100,50,5/26/2021
8D9993,earnings,100,50,5/26/2021
8F8F2F,note-sale,100,52,5/26/2021
901327,dividend,100,50,5/26/2021
9196A2,conference-organizer,100,57,5/26/2021
9196A2,conference-organizer,100,57,5/26/2021
925759,conference-participant,100,50,5/26/2021
94637C,conference-participant,100,50,5/26/2021
94A326,conference-participant,100,50,5/26/2021
963A02,conference-participant,100,50,5/26/2021
9.65E+09,conference-participant,100,50,5/26/2021
96F126,partnership,100,61,5/26/2021
981656,conference-participant,100,50,5/26/2021
98A286,earnings-per-share,100,50,5/26/2021
990AD0,conference-organizer,100,57,5/26/2021
990AD0,conference-organizer,100,57,5/26/2021
9.97E+09,dividend,100,50,5/26/2021
9B0C9C,conference-participant,100,50,5/26/2021
9BF177,earnings,100,50,5/26/2021
9D307D,conference-participant,100,50,5/26/2021
9F5997,conference-participant,100,50,5/26/2021
9FF5F1,partnership,100,61,5/26/2021
A1EAC8,conference-participant,100,50,5/26/2021
A26C26,conference-participant,100,50,5/26/2021
A26C26,earnings,100,50,5/26/2021
A3230E,conference-participant,100,50,5/26/2021
A5195E,conference-participant,100,50,5/26/2021
A60354,executive-appointment,100,54,5/26/2021
A6FB29,earnings,100,50,5/26/2021
A6FC89,earnings,100,50,5/26/2021
A6FC89,earnings,100,50,5/26/2021
A6FC89,earnings,100,50,5/26/2021
A6FC89,earnings,100,50,5/26/2021
A7102F,business-contract,100,69,5/26/2021
A8B137,executive-appointment,100,54,5/26/2021
A8CBDA,conference-participant,100,50,5/26/2021
ABAA03,conference-participant,100,50,5/26/2021
AE4125,conference-participant,100,50,5/26/2021
AE79CD,conference-participant,100,50,5/26/2021
B01111,earnings,100,50,5/26/2021
B01111,earnings,100,50,5/26/2021
B01111,earnings,100,50,5/26/2021
B01111,earnings,100,50,5/26/2021
B1FC3B,business-contract,100,69,5/26/2021
B2206F,partnership,100,61,5/26/2021
B7EB38,conference-participant,100,50,5/26/2021
B83D67,business-contract,100,69,5/26/2021
B83D67,business-contract,100,69,5/26/2021
BB0787,conference-participant,100,50,5/26/2021
BDEC1E,conference-participant,100,50,5/26/2021
BFE02C,acquisition-acquirer,100,49,5/26/2021
C2F597,conference-participant,100,50,5/26/2021
C3DE7D,earnings,100,50,5/26/2021
C3F99F,conference-participant,100,50,5/26/2021
C490F9,earnings,100,50,5/26/2021
C4A432,partnership,100,61,5/26/2021
C564E4,conference-participant,100,50,5/26/2021
C941DC,conference-participant,100,50,5/26/2021
CC0C78,conference-participant,100,50,5/26/2021
CF351E,merger-regulatory-approval,100,81,5/26/2021
D18AFC,conference-participant,100,50,5/26/2021
D1AE3B,executive-appointment,100,54,5/26/2021
D1C26F,earnings-guidance-up,100,83,5/26/2021
D1C26F,earnings-guidance-up,100,83,5/26/2021
D2C0B6,earnings,100,50,5/26/2021
D4C0CB,conference-participant,100,50,5/26/2021
D598E7,partnership,100,61,5/26/2021
D5AF19,dividend,100,50,5/26/2021
D81463,dividend,100,50,5/26/2021
D88EF3,partnership,100,61,5/26/2021
D90F43,partnership,100,61,5/26/2021
DD682D,executive-appointment,100,54,5/26/2021
DDEA6A,conference-participant,100,50,5/26/2021
DE5611,dividend-up,100,81,5/26/2021
DF42A0,dividend-up,100,81,5/26/2021
DF42A0,earnings,100,50,5/26/2021
DF42A0,earnings,100,50,5/26/2021
DF42A0,earnings,100,50,5/26/2021
DF42A0,earnings,100,50,5/26/2021
DF42A0,earnings,100,50,5/26/2021
E09E2B,earnings,100,50,5/26/2021
E09E2B,earnings,100,50,5/26/2021
E09E2B,earnings,100,50,5/26/2021
E09E2B,earnings,100,50,5/26/2021
E114F4,earnings,100,50,5/26/2021
E28D9C,conference-participant,100,50,5/26/2021
E4CE73,conference-participant,100,50,5/26/2021
E4CE73,product-release,100,64,5/26/2021
E56A0D,conference-participant,100,50,5/26/2021
E74B55,legal-issues-defendant,100,22,5/26/2021
E74B55,legal-issues-defendant,100,22,5/26/2021
E8846E,conference-participant,100,50,5/26/2021
E8D221,trading-resumed,100,58,5/26/2021
EBC84C,conference-participant,100,50,5/26/2021
ED7F13,conference-participant,100,50,5/26/2021
F0027C,conference-participant,100,50,5/26/2021
F0B2B5,executive-appointment,100,54,5/26/2021
F1529C,conference-participant,100,50,5/26/2021
F47871,facility-open,100,65,5/26/2021
F47871,conference-participant,100,50,5/26/2021
F4FBD8,conference-participant,100,50,5/26/2021
F58C23,hirings,100,65,5/26/2021
F748C7,earnings-up,100,68,5/26/2021
F82D37,acquisition-regulatory-scrutiny-acquiree,100,38,5/26/2021
F8BA6C,conference-call,100,50,5/26/2021
FC1B7B,conference-participant,100,50,5/26/2021
FD9A97,dividend,100,50,5/26/2021
FF227B,conference-participant,100,50,5/26/2021
002A99,conference-participant,100,50,5/27/2021
002A99,legal-issues-defendant,100,22,5/27/2021
00698D,earnings,100,50,5/27/2021
0157B1,partnership,100,61,5/27/2021
05D148,conference-participant,100,50,5/27/2021
070B45,conference-participant,100,50,5/27/2021
07EC43,partnership,100,61,5/27/2021
07EC43,partnership,100,61,5/27/2021
0968A5,earnings,100,50,5/27/2021
0B7375,legal-issues-defendant,100,22,5/27/2021
0DBB81,conference-participant,100,50,5/27/2021
0DC050,product-release,100,64,5/27/2021
0DE3D5,dividend,100,50,5/27/2021
0E5619,conference-participant,100,50,5/27/2021
10673F,dividend,100,50,5/27/2021
10AE08,partnership,100,61,5/27/2021
138DDE,public-offering,100,43,5/27/2021
139303,conference-organizer,100,57,5/27/2021
139303,conference-organizer,100,57,5/27/2021
139303,conference-organizer,100,57,5/27/2021
143C52,earnings,100,50,5/27/2021
165B86,conference-participant,100,50,5/27/2021
16FC89,dividend,100,50,5/27/2021
1921DD,acquisition-acquiree,100,76,5/27/2021
1CD4B5,conference-participant,100,50,5/27/2021
1D943E,conference-participant,100,50,5/27/2021
1E1125,legal-issues-defendant,100,22,5/27/2021
1EC3E8,executive-appointment,100,54,5/27/2021
1EC3E8,executive-appointment,100,54,5/27/2021
21153F,executive-appointment,100,54,5/27/2021
21F9CA,revenues,100,50,5/27/2021
227D48,executive-appointment,100,54,5/27/2021
228D42,partnership,100,61,5/27/2021
241252,conference-participant,100,50,5/27/2021
253B2F,dividend,100,50,5/27/2021
2571FA,executive-appointment,100,54,5/27/2021
26DC29,earnings,100,50,5/27/2021
2920D5,dividend,100,50,5/27/2021
2A1009,legal-issues-defendant,100,22,5/27/2021
2A6DBE,conference-participant,100,50,5/27/2021
2B49F4,conference-call,100,50,5/27/2021
2B7A40,conference-participant,100,50,5/27/2021
2BF36E,dividend-up,100,60,5/27/2021
2CD1E0,partnership,100,61,5/27/2021
2CD1E0,partnership,100,61,5/27/2021
2D5011,dividend,100,50,5/27/2021
2DB344,unit-acquisition-acquirer,100,49,5/27/2021
2E0445,conference-participant,100,50,5/27/2021
2E2E6E,dividend,100,50,5/27/2021
33AD83,conference-participant,100,50,5/27/2021
3461CF,conference-participant,100,50,5/27/2021
36C09B,conference-participant,100,50,5/27/2021
384CD3,business-contract,100,69,5/27/2021
396D7C,conference-participant,100,50,5/27/2021
3B318A,conference-participant,100,50,5/27/2021
416C55,conference-participant,100,50,5/27/2021
41EC04,business-contract,100,69,5/27/2021
4591D3,conference-participant,100,50,5/27/2021
4591D3,conference-participant,100,50,5/27/2021
479930,conference-participant,100,50,5/27/2021
4.91E+58,executive-appointment,100,54,5/27/2021
4A6F00,partnership,100,61,5/27/2021
4A6F00,partnership,100,61,5/27/2021
4A6F00,campaign-ad-release,100,59,5/27/2021
4AC91D,earnings,100,50,5/27/2021
4AC91D,earnings,100,50,5/27/2021
4AE584,executive-appointment,100,54,5/27/2021
4BBA23,conference-participant,100,50,5/27/2021
4BDCA7,conference-participant,100,50,5/27/2021
4C3FE9,conference-participant,100,50,5/27/2021
4FB770,dividend,100,50,5/27/2021
50070E,conference-organizer,100,57,5/27/2021
50070E,conference-organizer,100,57,5/27/2021
52FB2F,conference-participant,100,50,5/27/2021
57DDB9,conference-participant,100,50,5/27/2021
59872F,conference-participant,100,50,5/27/2021
5A0FF1,conference-participant,100,50,5/27/2021
5DE5A5,conference-participant,100,50,5/27/2021
5E7E82,earnings-above-expectations,100,88,5/27/2021
5EF130,earnings,100,50,5/27/2021
5F2FF7,conference-participant,100,50,5/27/2021
636931,note-sale,100,52,5/27/2021
64E346,executive-resignation,100,44,5/27/2021
64E346,earnings,100,50,5/27/2021
6559D8,legal-issues-defendant,100,22,5/27/2021
6559D8,legal-issues-defendant,100,22,5/27/2021
657097,unit-acquisition-acquirer,100,49,5/27/2021
673C9A,buybacks,100,74,5/27/2021
6830FE,earnings,100,50,5/27/2021
6925EB,conference-participant,100,50,5/27/2021
6ABCB8,executive-appointment,100,54,5/27/2021
6C987C,dividend,100,50,5/27/2021
6E705B,executive-appointment,100,54,5/27/2021
6F0096,conference-participant,100,50,5/27/2021
6F3936,earnings,100,50,5/27/2021
701531,conference-participant,100,50,5/27/2021
713810,partnership,100,61,5/27/2021
713810,partnership,100,61,5/27/2021
73F70F,dividend,100,50,5/27/2021
76E80F,dividend-up,100,74,5/27/2021
7A3633,partnership,100,61,5/27/2021
7B0BA6,conference-participant,100,50,5/27/2021
7CBC40,award,100,58,5/27/2021
7CBC40,conference-participant,100,50,5/27/2021
8.10E+32,executive-appointment,100,54,5/27/2021
817ED9,partnership,100,61,5/27/2021
817ED9,earnings,100,50,5/27/2021
817ED9,earnings,100,50,5/27/2021
817ED9,earnings,100,50,5/27/2021
817ED9,earnings,100,50,5/27/2021
817ED9,earnings,100,50,5/27/2021
819492,executive-appointment,100,54,5/27/2021
834152,legal-issues-defendant,100,22,5/27/2021
83B1C8,conference-participant,100,50,5/27/2021
850779,dividend,100,50,5/27/2021
855DF7,index-listing,100,76,5/27/2021
859D62,dividend,100,50,5/27/2021
8802B4,executive-resignation,100,44,5/27/2021
88936A,earnings,100,50,5/27/2021
8AC65D,executive-appointment,100,54,5/27/2021
8BFE9A,public-offering,100,43,5/27/2021
8EEA28,dividend,100,50,5/27/2021
9043FE,conference-participant,100,50,5/27/2021
9043FE,conference-participant,100,50,5/27/2021
94637C,regulatory-product-approval-granted,100,81,5/27/2021
979451,conference-participant,100,50,5/27/2021
990AD0,investment-investor,100,55,5/27/2021
9E0811,earnings,100,50,5/27/2021
9F71E5,conference-participant,100,50,5/27/2021
A1E3B3,earnings,100,50,5/27/2021
A1E3B3,earnings,100,50,5/27/2021
A1E3B3,earnings,100,50,5/27/2021
A1E3B3,earnings,100,50,5/27/2021
A1EAC8,executive-appointment,100,54,5/27/2021
A403CF,partnership,100,61,5/27/2021
A47F2E,earnings,100,50,5/27/2021
A4CD53,public-offering,100,43,5/27/2021
A52533,conference-participant,100,50,5/27/2021
A631A3,earnings,100,50,5/27/2021
A72AB6,earnings,100,50,5/27/2021
A761FE,earnings,100,50,5/27/2021
AE4125,conference-participant,100,50,5/27/2021
B08C51,conference-participant,100,50,5/27/2021
B37FB4,conference-participant,100,50,5/27/2021
B3CB74,conference-organizer,100,57,5/27/2021
B3CB74,conference-organizer,100,57,5/27/2021
B3ED62,board-meeting,100,51,5/27/2021
B4C673,acquisition-interest-acquirer,100,46,5/27/2021
B5734D,executive-appointment,100,54,5/27/2021
B80AD1,conference-participant,100,50,5/27/2021
B8EF97,earnings,100,50,5/27/2021
B934BF,dividend,100,50,5/27/2021
B98EFA,conference-participant,100,50,5/27/2021
BB127B,earnings-up,100,68,5/27/2021
BB58FF,conference-participant,100,50,5/27/2021
BC948D,dividend,100,50,5/27/2021
BDCC11,conference-participant,100,50,5/27/2021
BDD12C,investment-investor,100,55,5/27/2021
BDF85E,earnings,100,50,5/27/2021
BF5959,conference-participant,100,50,5/27/2021
BFF98A,conference-participant,100,50,5/27/2021
C01737,conference-participant,100,50,5/27/2021
C03C8B,conference-participant,100,50,5/27/2021
C356AC,partnership,100,61,5/27/2021
C3BAE7,conference-participant,100,50,5/27/2021
C4706C,partnership,100,61,5/27/2021
C72B8F,conference-participant,100,50,5/27/2021
C74887,conference-participant,100,50,5/27/2021
CA99D7,dividend-up,100,81,5/27/2021
CB6A9C,partnership,100,61,5/27/2021
CC339B,award,100,58,5/27/2021
CC6F6E,earnings,100,50,5/27/2021
CC6F6E,earnings,100,50,5/27/2021
CC6F6E,earnings,100,50,5/27/2021
CC6F6E,earnings,100,50,5/27/2021
CC6FF5,partnership,100,61,5/27/2021
CD06A2,earnings,100,50,5/27/2021
CD4DA8,conference-organizer,100,57,5/27/2021
CF7292,earnings-up,100,68,5/27/2021
CF7292,earnings,100,50,5/27/2021
CF7292,earnings,100,50,5/27/2021
CFF15D,award,100,58,5/27/2021
CFF97C,conference-participant,100,50,5/27/2021
CFF97C,conference-participant,100,50,5/27/2021
D296C6,dividend,100,50,5/27/2021
D2C0B6,conference-participant,100,50,5/27/2021
D36686,conference-participant,100,50,5/27/2021
D76AEF,dividend,100,50,5/27/2021
DA0CB8,dividend,100,50,5/27/2021
DB2E4E,business-contract,100,69,5/27/2021
DC2B00,earnings,100,50,5/27/2021
DDB002,conference-participant,100,50,5/27/2021
DF6FDD,conference-participant,100,50,5/27/2021
DFADDB,regulatory-product-approval-granted,100,81,5/27/2021
E0D3BA,unit-acquisition-acquirer,100,49,5/27/2021
E124EB,conference-participant,100,50,5/27/2021
E1BD05,conference-participant,100,50,5/27/2021
E30B34,dividend,100,50,5/27/2021
E30B34,dividend,100,50,5/27/2021
E35610,conference-participant,100,50,5/27/2021
E68733,earnings,100,50,5/27/2021
E68733,earnings,100,50,5/27/2021
E69BA5,business-contract,100,69,5/27/2021
E6EDED,dividend,100,50,5/27/2021
E74B55,legal-issues-defendant,100,22,5/27/2021
E8F0E2,conference-participant,100,50,5/27/2021
ECA300,earnings,100,50,5/27/2021
EF5BED,executive-appointment,100,54,5/27/2021
EF5BED,executive-appointment,100,54,5/27/2021
F02170,earnings,100,50,5/27/2021
F0A9DE,dividend,100,50,5/27/2021
F42FAE,dividend,100,50,5/27/2021
F43A11,conference-call,100,50,5/27/2021
F4E992,conference-participant,100,50,5/27/2021
F57F6F,conference-participant,100,50,5/27/2021
F66B58,dividend,100,50,5/27/2021
F88147,conference-participant,100,50,5/27/2021
FD2565,business-contract,100,69,5/27/2021
FD2565,business-contract,100,69,5/27/2021
FD554E,dividend,100,50,5/27/2021
FDD3FC,conference-participant,100,50,5/27/2021
FDF1C0,dividend,100,50,5/27/2021
13528,partnership,100,61,5/28/2021
01D03F,partnership,100,61,5/28/2021
0BF528,conference-participant,100,50,5/28/2021
159AE4,legal-issues-defendant,100,22,5/28/2021
1748B3,dividend,100,50,5/28/2021
1E1125,legal-issues-defendant,100,22,5/28/2021
1E1125,legal-issues-defendant,100,22,5/28/2021
1FCC00,dividend,100,50,5/28/2021
1FCC00,earnings-up,100,68,5/28/2021
1FCC00,earnings-up,100,68,5/28/2021
2158DF,conference-participant,100,50,5/28/2021
275300,conference-participant,100,50,5/28/2021
2A1009,legal-issues-defendant,100,22,5/28/2021
2B0AF4,conference-participant,100,50,5/28/2021
2E902B,conference-participant,100,50,5/28/2021
3.88E+02,legal-issues-defendant,100,22,5/28/2021
3A94DF,dividend,100,50,5/28/2021
3B9886,earnings,100,50,5/28/2021
3B9886,earnings,100,50,5/28/2021
3B9886,earnings,100,50,5/28/2021
44A4FC,conference-participant,100,50,5/28/2021
4D203E,legal-issues-defendant,100,22,5/28/2021
4D203E,legal-issues-defendant,100,22,5/28/2021
50070E,conference-organizer,100,57,5/28/2021
57DDB9,conference-participant,100,50,5/28/2021
5B35C7,legal-issues-defendant,100,22,5/28/2021
5E7E82,dividend,100,50,5/28/2021
6C6D73,conference-participant,100,50,5/28/2021
6D156D,conference-participant,100,50,5/28/2021
6E705B,conference-participant,100,50,5/28/2021
6E705B,executive-appointment,100,54,5/28/2021
6E7060,facility-sale,100,52,5/28/2021
76959C,partnership,100,61,5/28/2021
76F067,conference-participant,100,50,5/28/2021
7E3390,earnings,100,50,5/28/2021
834152,legal-issues-defendant,100,22,5/28/2021
8876D6,partnership,100,61,5/28/2021
896771,business-contract,100,69,5/28/2021
8A8E41,partnership,100,61,5/28/2021
8DCF18,conference-participant,100,50,5/28/2021
90D6A5,legal-issues-defendant,100,22,5/28/2021
9196A2,conference-organizer,100,57,5/28/2021
945DE6,note-sale,100,52,5/28/2021
9981C6,dividend,100,50,5/28/2021
9E4A5F,conference-participant,100,50,5/28/2021
9F5CBB,dividend,100,50,5/28/2021
A631A3,conference-participant,100,50,5/28/2021
A6FE1C,acquisition-acquirer,100,49,5/28/2021
A96867,dividend,100,50,5/28/2021
A99576,legal-issues-defendant,100,22,5/28/2021
A99576,legal-issues-defendant,100,22,5/28/2021
AD22F2,earnings,100,50,5/28/2021
AD22F2,earnings,100,50,5/28/2021
AD22F2,earnings,100,50,5/28/2021
AD22F2,earnings,100,50,5/28/2021
B13B68,conference-participant,100,50,5/28/2021
B508E5,conference-participant,100,50,5/28/2021
BB127B,conference-participant,100,50,5/28/2021
BBBB41,business-contract,100,69,5/28/2021
BDEF34,dividend,100,50,5/28/2021
C0030A,conference-participant,100,50,5/28/2021
C62AA4,business-contract,100,69,5/28/2021
C7AE14,acquisition-completed-acquiree,100,76,5/28/2021
C7AE14,asset-sale,100,62,5/28/2021
CBDB4D,legal-issues-defendant,100,22,5/28/2021
CBFFDD,conference-participant,100,50,5/28/2021
CD4DA8,executive-appointment,100,54,5/28/2021
CDEDFE,merger-completed,100,66,5/28/2021
CFF97C,credit-rating-confirmation-rater,20,50,5/28/2021
D8ECA1,conference-participant,100,50,5/28/2021
DD1BA1,partnership,100,61,5/28/2021
E16133,asset-sale,100,62,5/28/2021
E20392,conference-participant,100,50,5/28/2021
E74B55,legal-issues-defendant,100,22,5/28/2021
E7BF32,conference-participant,100,50,5/28/2021
E7BF32,conference-participant,100,50,5/28/2021
ED22DC,conference-participant,100,50,5/28/2021
EF25A5,conference-participant,100,50,5/28/2021
F4D241,conference-participant,100,50,5/28/2021
9004C4,executive-resignation,100,44,5/29/2021
A398B9,conference-participant,100,50,5/29/2021
0B7375,legal-issues-defendant,100,22,5/30/2021
834152,legal-issues-defendant,100,22,5/30/2021
002A99,legal-issues-defendant,100,22,5/31/2021
0B7375,legal-issues-defendant,100,22,5/31/2021
DBCA3F,product-release,100,64,5/31/2021
E6D89E,partnership,100,61,5/31/2021
E74B55,legal-issues-defendant,100,22,5/31/2021
FC9869,acquisition-completed-acquirer,100,49,5/31/2021
002A99,legal-issues-defendant,100,22,6/1/2021
002A99,legal-issues-defendant,100,22,6/1/2021
0157B1,facility-open,100,65,6/1/2021
0157B1,partnership,100,61,6/1/2021
0157B1,partnership,100,61,6/1/2021
0157B1,partnership,100,61,6/1/2021
0157B1,partnership,100,61,6/1/2021
0157B1,product-release,100,64,6/1/2021
0358AF,executive-appointment,100,54,6/1/2021
036C6F,dividend,100,50,6/1/2021
03B431,conference-participant,100,50,6/1/2021
0A748B,acquisition-acquiree,100,76,6/1/2021
0BD4E8,dividend,100,50,6/1/2021
0F0693,regulatory-product-application,100,69,6/1/2021
11074E,campaign-ad-release,100,59,6/1/2021
12A3A3,conference-call,100,50,6/1/2021
1348C9,merger,100,66,6/1/2021
1348C9,merger,100,66,6/1/2021
14833D,product-release,100,64,6/1/2021
159739,dividend,100,50,6/1/2021
159739,dividend,100,50,6/1/2021
159739,conference-call,100,50,6/1/2021
159739,conference-call,100,50,6/1/2021
16FC89,earnings,100,50,6/1/2021
1B6F77,conference-participant,100,50,6/1/2021
1C599A,note-sale,100,52,6/1/2021
1DB833,conference-participant,100,50,6/1/2021
1EBF8D,business-contract,100,69,6/1/2021
1EBF8D,business-contract,100,69,6/1/2021
1F352C,conference-participant,100,50,6/1/2021
1FC422,note-sale,100,52,6/1/2021
200D8B,conference-participant,100,50,6/1/2021
2031CE,acquisition-completed-acquirer,100,49,6/1/2021
228D42,partnership,100,61,6/1/2021
249674,executive-appointment,100,54,6/1/2021
2571FA,government-contract,100,69,6/1/2021
25D3CE,conference-participant,100,50,6/1/2021
2667B6,conference-participant,100,50,6/1/2021
26DC29,conference-participant,100,50,6/1/2021
273BA3,partnership,100,61,6/1/2021
279916,conference-participant,100,50,6/1/2021
2920D5,conference-participant,100,50,6/1/2021
2.90E+62,unit-acquisition-completed-acquirer,100,49,6/1/2021
2.90E+62,unit-acquisition-completed-acquirer,100,49,6/1/2021
2BAE5F,business-contract,100,69,6/1/2021
2BAE5F,business-contract,100,69,6/1/2021
2C7505,patient-enrollment-complete,100,64,6/1/2021
2C7505,patient-enrollment-complete,100,64,6/1/2021
2CC71C,regulatory-product-approval-granted,100,81,6/1/2021
2CD1E0,facility-sale,100,52,6/1/2021
2E61CC,partnership,100,61,6/1/2021
2E902B,conference-participant,100,50,6/1/2021
2F6782,conference-participant,100,50,6/1/2021
317EC6,conference-participant,100,50,6/1/2021
33A0F1,partnership,100,61,6/1/2021
3461CF,credit-rating-outlook-positive-rater,20,50,6/1/2021
3461CF,credit-rating-outlook-positive-rater,20,50,6/1/2021
34E9F9,executive-appointment,100,54,6/1/2021
367E1C,conference-participant,100,50,6/1/2021
382EAE,dividend,100,50,6/1/2021
3AAEAE,conference-participant,100,50,6/1/2021
3B9886,facility-open,100,65,6/1/2021
3CCC90,executive-appointment,100,54,6/1/2021
3ED92D,executive-appointment,100,54,6/1/2021
42DC93,stake-acquirer,100,48,6/1/2021
43A060,business-contract,100,69,6/1/2021
45ABCC,conference-participant,100,50,6/1/2021
45ABCC,conference-participant,100,50,6/1/2021
49BBBC,earnings,100,50,6/1/2021
4AC91D,acquisition-completed-acquirer,100,49,6/1/2021
4AE584,product-release,100,64,6/1/2021
4B49CF,earnings,100,50,6/1/2021
4B6EF9,conference-participant,100,50,6/1/2021
4D8313,drilling,100,68,6/1/2021
4D8313,drilling,100,68,6/1/2021
4FCC78,acquisition-completed-acquirer,100,49,6/1/2021
50070E,conference-organizer,100,57,6/1/2021
50070E,conference-organizer,100,57,6/1/2021
50070E,conference-organizer,100,57,6/1/2021
50070E,conference-organizer,100,57,6/1/2021
50070E,conference-organizer,100,57,6/1/2021
50070E,conference-organizer,100,57,6/1/2021
539F49,conference-participant,100,50,6/1/2021
546A9C,conference-participant,100,50,6/1/2021
54DF47,dividend,100,50,6/1/2021
54F1D2,conference-organizer,100,57,6/1/2021
5675EB,dividend,100,50,6/1/2021
56EA2B,dividend,100,50,6/1/2021
5DE5A5,conference-participant,100,50,6/1/2021
5E7E82,partnership,100,61,6/1/2021
5F9CE3,acquisition-completed-acquirer,100,49,6/1/2021
619882,partnership,100,61,6/1/2021
61B81B,unit-acquisition-completed-acquirer,100,49,6/1/2021
61B81B,conference-participant,100,50,6/1/2021
633054,partnership,100,61,6/1/2021
636BBF,acquisition-acquirer,100,49,6/1/2021
636BBF,earnings,100,50,6/1/2021
636BBF,legal-issues-defendant,100,22,6/1/2021
64636E,executive-appointment,100,54,6/1/2021
64636E,executive-appointment,100,54,6/1/2021
64E346,conference-participant,100,50,6/1/2021
6559D8,conference-participant,100,50,6/1/2021
6559D8,legal-issues-defendant,100,22,6/1/2021
65AB30,executive-appointment,100,54,6/1/2021
665618,conference-participant,100,50,6/1/2021
66667F,conference-participant,100,50,6/1/2021
67B052,executive-appointment,100,54,6/1/2021
6810DE,conference-participant,100,50,6/1/2021
68AB62,conference-participant,100,50,6/1/2021
69FDFC,executive-appointment,100,54,6/1/2021
6AACDD,executive-appointment,100,54,6/1/2021
6D9ECA,fast-track-designation,100,81,6/1/2021
6DBBBC,executive-resignation,100,44,6/1/2021
6E705B,partnership,100,61,6/1/2021
70FCEF,partnership,100,61,6/1/2021
713810,conference-participant,100,50,6/1/2021
72CB93,executive-appointment,100,54,6/1/2021
75768D,conference-call,100,50,6/1/2021
762A3E,conference-organizer,100,57,6/1/2021
7A2A49,earnings,100,50,6/1/2021
7E1D5D,award,100,58,6/1/2021
7FEEE1,executive-appointment,100,54,6/1/2021
804708,dividend,100,50,6/1/2021
80C400,acquisition-acquirer,100,49,6/1/2021
8.10E+32,conference-participant,100,50,6/1/2021
85DA04,partnership,100,61,6/1/2021
8665BA,business-contract,100,69,6/1/2021
87B81A,conference-participant,100,50,6/1/2021
8BAA15,earnings-guidance,100,50,6/1/2021
8E82A6,unit-acquisition-completed-acquiree,100,67,6/1/2021
8EDACA,conference-participant,100,50,6/1/2021
8EEA28,conference-participant,100,50,6/1/2021
8EF425,dividend,100,50,6/1/2021
8FF2EF,acquisition-completed-acquirer,100,49,6/1/2021
8FF2EF,acquisition-acquirer,100,49,6/1/2021
9196A2,conference-organizer,100,57,6/1/2021
9196A2,conference-organizer,100,57,6/1/2021
9196A2,conference-organizer,100,57,6/1/2021
93AD2E,unit-acquisition-acquiree,100,76,6/1/2021
93AD2E,unit-acquisition-completed-acquiree,100,67,6/1/2021
93D207,partnership,100,61,6/1/2021
94637C,executive-appointment,100,54,6/1/2021
96F126,executive-appointment,100,54,6/1/2021
98D33E,partnership,100,61,6/1/2021
990AD0,conference-organizer,100,57,6/1/2021
9978F1,partnership,100,61,6/1/2021
9978F1,partnership,100,61,6/1/2021
99B61C,executive-appointment,100,54,6/1/2021
9B5968,executive-appointment,100,54,6/1/2021
9BBFA5,conference-call,100,50,6/1/2021
9C8BC3,partnership,100,61,6/1/2021
9D56F2,conference-call,100,50,6/1/2021
9D5D35,conference-participant,100,50,6/1/2021
A0F146,conference-participant,100,50,6/1/2021
A0F146,conference-participant,100,50,6/1/2021
A1BB98,dividend,100,50,6/1/2021
A3800A,fundraising,100,64,6/1/2021
A3800A,fundraising,100,64,6/1/2021
A43906,conference-participant,100,50,6/1/2021
A63820,earnings,100,50,6/1/2021
A70BF5,dividend,100,50,6/1/2021
A868C9,revenue-up,100,69,6/1/2021
A868C9,revenue-up,100,69,6/1/2021
A868C9,revenue-up,100,69,6/1/2021
A868C9,revenue-up,100,69,6/1/2021
A8AC4C,conference-participant,100,50,6/1/2021
A8CBDA,conference-participant,100,50,6/1/2021
AA5C8E,unit-acquisition-acquirer,100,49,6/1/2021
AB4A7E,conference-participant,100,50,6/1/2021
AD1ACF,product-release,100,64,6/1/2021
AFD1CA,facility-open,100,65,6/1/2021
AFD1CA,conference-participant,100,50,6/1/2021
B1B10C,executive-appointment,100,54,6/1/2021
B1DF3C,conference-participant,100,50,6/1/2021
B3A166,acquisition-acquirer,100,49,6/1/2021
B60366,conference-participant,100,50,6/1/2021
B7BBFF,executive-appointment,100,54,6/1/2021
B96637,conference-participant,100,50,6/1/2021
B98EFA,executive-appointment,100,54,6/1/2021
BB02FB,executive-appointment,100,54,6/1/2021
BB127B,partnership,100,61,6/1/2021
BB5271,partnership,100,61,6/1/2021
BBBB41,conference-participant,100,50,6/1/2021
BD15E8,merger,100,66,6/1/2021
BD15E8,merger,100,66,6/1/2021
BE14CF,acquisition-completed-acquirer,100,49,6/1/2021
C03C8B,product-release,100,64,6/1/2021
C45CE7,executive-appointment,100,54,6/1/2021
C4706C,unit-acquisition-completed-acquirer,100,49,6/1/2021
C5F463,unit-acquisition-completed-acquiree,100,67,6/1/2021
C7859D,dividend,100,50,6/1/2021
C83B88,executive-appointment,100,54,6/1/2021
CB6A9C,credit-extension-recipient,100,69,6/1/2021
CC3EC4,product-release,100,64,6/1/2021
CD051C,conference-participant,100,50,6/1/2021
CD4DA8,conference-organizer,100,57,6/1/2021
CD4DA8,conference-organizer,100,57,6/1/2021
CDAF5B,dividend,100,50,6/1/2021
CDAF5B,conference-participant,100,50,6/1/2021
CDEDFE,merger-completed,100,66,6/1/2021
CDFCC9,conference-participant,100,50,6/1/2021
CEC5B9,acquisition-completed-acquirer,100,49,6/1/2021
CEC5B9,unit-acquisition-acquirer,100,49,6/1/2021
CEC5B9,unit-acquisition-completed-acquirer,100,49,6/1/2021
CF351E,merger,100,66,6/1/2021
CF351E,merger,100,66,6/1/2021
CFF57D,conference-participant,100,50,6/1/2021
CFF97C,conference-participant,100,50,6/1/2021
CFF97C,conference-organizer,100,57,6/1/2021
D06755,executive-appointment,100,54,6/1/2021
D0909F,conference-participant,100,50,6/1/2021
D0909F,dividend,100,50,6/1/2021
D11C1C,note-sale,100,52,6/1/2021
D2B9E5,conference-participant,100,50,6/1/2021
D58A11,conference-participant,100,50,6/1/2021
D63B0F,investment-investor,100,55,6/1/2021
D65A13,acquisition-acquirer,100,49,6/1/2021
D76AEF,executive-appointment,100,54,6/1/2021
D82EF3,partnership,100,61,6/1/2021
D8760C,merger,100,66,6/1/2021
D8760C,merger,100,66,6/1/2021
DB88A1,earnings,100,50,6/1/2021
DBB28E,earnings,100,50,6/1/2021
DBB28E,earnings,100,50,6/1/2021
DBB28E,earnings,100,50,6/1/2021
DBB28E,earnings,100,50,6/1/2021
DBB28E,earnings,100,50,6/1/2021
DBB28E,earnings,100,50,6/1/2021
DBB28E,earnings,100,50,6/1/2021
DBB28E,earnings,100,50,6/1/2021
DBB28E,earnings,100,50,6/1/2021
DD1BA1,product-release,100,64,6/1/2021
DE5611,conference-participant,100,50,6/1/2021
DF01B1,conference-participant,100,50,6/1/2021
DF18E6,executive-appointment,100,54,6/1/2021
DF204B,note-sale,100,52,6/1/2021
DF204B,note-sale,100,52,6/1/2021
E0207A,acquisition-interest-acquirer,100,46,6/1/2021
E09556,earnings,100,50,6/1/2021
E13782,conference-participant,100,50,6/1/2021
E1C16B,business-contract,100,69,6/1/2021
E1E093,partnership,100,61,6/1/2021
E1E093,partnership,100,61,6/1/2021
E38906,conference-participant,100,50,6/1/2021
E68C3D,unit-acquisition-completed-acquiree,100,67,6/1/2021
E68C3D,unit-acquisition-completed-acquiree,100,67,6/1/2021
E74B55,unit-acquisition-acquiree,100,76,6/1/2021
E8846E,conference-organizer,100,57,6/1/2021
EB1E1A,conference-participant,100,50,6/1/2021
ECE19E,executive-appointment,100,54,6/1/2021
ECF4F8,acquisition-interest-acquiree,100,82,6/1/2021
ED9576,acquisition-acquirer,100,49,6/1/2021
EE04F0,conference-participant,100,50,6/1/2021
EEEA9F,unit-acquisition-acquiree,100,76,6/1/2021
EF1AD9,executive-appointment,100,54,6/1/2021
EF5BED,executive-appointment,100,54,6/1/2021
F1C04C,conference-participant,100,50,6/1/2021
F294DD,acquisition-acquirer,100,49,6/1/2021
F3D2EB,dividend,100,50,6/1/2021
F3FCC3,earnings-guidance-up,100,83,6/1/2021
F569FD,executive-appointment,100,54,6/1/2021
F88A04,acquisition-completed-acquirer,100,49,6/1/2021
FD9A97,earnings,100,50,6/1/2021
FD9A97,acquisition-acquirer,100,49,6/1/2021
FDF799,patient-enrollment-start,100,58,6/1/2021
FE1A1D,executive-appointment,100,54,6/1/2021
FF6644,product-release,100,64,6/1/2021
002A99,legal-issues-defendant,100,22,6/2/2021
00E601,earnings,100,50,6/2/2021
0157B1,partnership,100,61,6/2/2021
03B8CF,partnership,100,61,6/2/2021
0A6824,product-price-raise,100,57,6/2/2021
0A748B,legal-issues-defendant,100,22,6/2/2021
0BD4E8,award,100,58,6/2/2021
1272B3,partnership,100,61,6/2/2021
129DC8,investment-investor,100,55,6/2/2021
12E454,partnership,100,61,6/2/2021
12E454,donation,100,54,6/2/2021
139303,conference-organizer,100,57,6/2/2021
139303,conference-organizer,100,57,6/2/2021
15B10D,partnership,100,61,6/2/2021
1.79E+10,business-contract,100,69,6/2/2021
17EDA5,partnership,100,61,6/2/2021
184866,conference-participant,100,50,6/2/2021
1B637E,partnership,100,61,6/2/2021
1C2593,executive-appointment,100,54,6/2/2021
1D943E,acquisition-acquirer,100,49,6/2/2021
1DB833,partnership,100,61,6/2/2021
1E04A5,acquisition-completed-acquiree,100,76,6/2/2021
1E1125,legal-issues-defendant,100,22,6/2/2021
1E1125,legal-issues-defendant,100,22,6/2/2021
1E1125,conference-organizer,100,57,6/2/2021
1EBF8D,partnership,100,61,6/2/2021
200D8B,conference-participant,100,50,6/2/2021
223552,conference-participant,100,50,6/2/2021
228D42,partnership,100,61,6/2/2021
228D42,partnership,100,61,6/2/2021
23699B,executive-appointment,100,54,6/2/2021
24A89A,conference-participant,100,50,6/2/2021
253604,conference-participant,100,50,6/2/2021
273BA3,acquisition-acquirer,100,49,6/2/2021
279916,earnings,100,50,6/2/2021
2A1009,legal-issues-defendant,100,22,6/2/2021
2F9304,earnings,100,50,6/2/2021
30AB63,earnings-guidance,100,50,6/2/2021
30CBF9,partnership,100,61,6/2/2021
31643A,facility-open,100,65,6/2/2021
34B97A,executive-appointment,100,54,6/2/2021
35B907,unit-acquisition-acquirer,100,49,6/2/2021
38C46F,dividend,100,50,6/2/2021
414FFF,earnings-above-expectations,100,88,6/2/2021
414FFF,earnings,100,50,6/2/2021
414FFF,earnings,100,50,6/2/2021
414FFF,earnings,100,50,6/2/2021
414FFF,earnings,100,50,6/2/2021
414FFF,earnings,100,50,6/2/2021
414FFF,earnings,100,50,6/2/2021
414FFF,earnings,100,50,6/2/2021
422CE3,hirings,100,65,6/2/2021
422CE3,hirings,100,65,6/2/2021
422CE3,hirings,100,65,6/2/2021
422CE3,hirings,100,65,6/2/2021
422CE3,hirings,100,65,6/2/2021
43A74A,conference-participant,100,50,6/2/2021
442769,conference-call,100,50,6/2/2021
468DD4,executive-appointment,100,54,6/2/2021
4.91E+58,executive-appointment,100,54,6/2/2021
4A6F00,partnership,100,61,6/2/2021
4BAF2E,conference-participant,100,50,6/2/2021
4BF3D6,conference-participant,100,50,6/2/2021
4D229C,conference-participant,100,50,6/2/2021
4FCC78,conference-participant,100,50,6/2/2021
50070E,conference-organizer,100,57,6/2/2021
50070E,conference-organizer,100,57,6/2/2021
50070E,conference-organizer,100,57,6/2/2021
50070E,conference-organizer,100,57,6/2/2021
50070E,conference-organizer,100,57,6/2/2021
50070E,conference-organizer,100,57,6/2/2021
50070E,conference-organizer,100,57,6/2/2021
50070E,conference-organizer,100,57,6/2/2021
52BF94,conference-participant,100,50,6/2/2021
567F3D,conference-participant,100,50,6/2/2021
589846,earnings,100,50,6/2/2021
589846,conference-participant,100,50,6/2/2021
5DE5A5,conference-participant,100,50,6/2/2021
5E1DF3,sponsorship,100,57,6/2/2021
609208,conference-call,100,50,6/2/2021
60EA12,executive-appointment,100,54,6/2/2021
61BCA7,public-offering,100,43,6/2/2021
65D0AA,acquisition-completed-acquirer,100,49,6/2/2021
65D0AA,acquisition-completed-acquirer,100,49,6/2/2021
662682,partnership,100,61,6/2/2021
665D7D,conference-participant,100,50,6/2/2021
6830FE,conference-participant,100,50,6/2/2021
69CE71,donation,100,54,6/2/2021
701531,patient-enrollment-complete,100,64,6/2/2021
70CA28,conference-participant,100,50,6/2/2021
713810,board-meeting,100,51,6/2/2021
71E2EF,donation,100,54,6/2/2021
7239BB,earnings,100,50,6/2/2021
726EEA,conference-participant,100,50,6/2/2021
7.45E+28,conference-participant,100,50,6/2/2021
747219,conference-participant,100,50,6/2/2021
76BD96,public-offering,100,43,6/2/2021
76E80F,conference-participant,100,50,6/2/2021
793C11,partnership,100,61,6/2/2021
7A10FF,conference-participant,100,50,6/2/2021
7A5097,partnership,100,61,6/2/2021
7AC86E,partnership,100,61,6/2/2021
7AF907,orphan-drug-designation,100,76,6/2/2021
7D85A9,unit-acquisition-completed-acquirer,100,49,6/2/2021
7D85A9,acquisition-completed-acquirer,100,49,6/2/2021
7D85A9,business-contract,100,69,6/2/2021
7E3390,conference-participant,100,50,6/2/2021
7F3FBC,public-offering,100,43,6/2/2021
7FC386,dividend-up,100,81,6/2/2021
8.10E+32,executive-appointment,100,54,6/2/2021
81F4BE,acquisition-completed-acquirer,100,49,6/2/2021
81F4BE,acquisition-completed-acquirer,100,49,6/2/2021
82C202,business-contract,100,69,6/2/2021
8.40E+120,conference-participant,100,50,6/2/2021
863350,earnings,100,50,6/2/2021
883D82,legal-issues-defendant,100,22,6/2/2021
89E771,executive-resignation,100,44,6/2/2021
8A8E41,product-release,100,64,6/2/2021
8A8E41,dividend,100,50,6/2/2021
8D4486,partnership,100,61,6/2/2021
8D4486,partnership,100,61,6/2/2021
8D4486,partnership,100,61,6/2/2021
8D5145,acquisition-completed-acquirer,100,49,6/2/2021
8E4F9A,conference-participant,100,50,6/2/2021
90D6A5,conference-participant,100,50,6/2/2021
90D6A5,conference-participant,100,50,6/2/2021
9196A2,conference-organizer,100,57,6/2/2021
9196A2,conference-organizer,100,57,6/2/2021
9196A2,conference-organizer,100,57,6/2/2021
9196A2,partnership,100,61,6/2/2021
934029,conference-participant,100,50,6/2/2021
934CC3,earnings,100,50,6/2/2021
9.36E+10,executive-appointment,100,54,6/2/2021
94637C,regulatory-product-approval-granted,100,81,6/2/2021
94756D,conference-participant,100,50,6/2/2021
954004,earnings,100,50,6/2/2021
972356,acquisition-regulatory-approval-acquiree,100,81,6/2/2021
990AD0,conference-organizer,100,57,6/2/2021
990AD0,conference-organizer,100,57,6/2/2021
9.92E+94,dividend,100,50,6/2/2021
9978F1,conference-participant,100,50,6/2/2021
9B0C9C,conference-participant,100,50,6/2/2021
A01664,acquisition-acquirer,100,49,6/2/2021
A23747,conference-participant,100,50,6/2/2021
A4386C,conference-participant,100,50,6/2/2021
A48593,executive-appointment,100,54,6/2/2021
A790A5,conference-call,100,50,6/2/2021
AC7C4F,conference-participant,100,50,6/2/2021
ACDF88,executive-appointment,100,54,6/2/2021
AD1ACF,executive-appointment,100,54,6/2/2021
AE0CCE,executive-appointment,100,54,6/2/2021
AE79CD,regulatory-product-approval-granted,100,81,6/2/2021
AFDF2E,conference-participant,100,50,6/2/2021
B5DE80,conference-participant,100,50,6/2/2021
B66928,conference-participant,100,50,6/2/2021
BBC05B,conference-participant,100,50,6/2/2021
BC3AD2,dividend,100,50,6/2/2021
BCC13E,executive-appointment,100,54,6/2/2021
BD15E8,legal-issues-defendant,100,22,6/2/2021
BD8517,executive-appointment,100,54,6/2/2021
BFCACF,conference-participant,100,50,6/2/2021
C2609A,conference-participant,100,50,6/2/2021
C36189,conference-participant,100,50,6/2/2021
C3BAE7,partnership,100,61,6/2/2021
C4F9C6,conference-participant,100,50,6/2/2021
C83B88,conference-participant,100,50,6/2/2021
C8FAC7,partnership,100,61,6/2/2021
C941DC,conference-participant,100,50,6/2/2021
C941DC,conference-participant,100,50,6/2/2021
C9881C,executive-appointment,100,54,6/2/2021
CC6FF5,partnership,100,61,6/2/2021
CD4DA8,conference-organizer,100,57,6/2/2021
CD4DA8,conference-organizer,100,57,6/2/2021
CDC817,conference-participant,100,50,6/2/2021
CE1002,conference-participant,100,50,6/2/2021
CFF15D,partnership,100,61,6/2/2021
D1AE3B,conference-call,100,50,6/2/2021
D1C26F,conference-participant,100,50,6/2/2021
D1CFC8,conference-call,100,50,6/2/2021
D6EAA3,award,100,58,6/2/2021
D76AEF,earnings,100,50,6/2/2021
D854DD,executive-resignation,100,44,6/2/2021
D88EF3,conference-participant,100,50,6/2/2021
D9C07E,acquisition-completed-acquirer,100,49,6/2/2021
DCD97F,dividend,100,50,6/2/2021
DD1BA1,acquisition-acquiree,100,76,6/2/2021
DE5611,earnings,100,50,6/2/2021
DE5611,earnings,100,50,6/2/2021
DE5611,earnings,100,50,6/2/2021
DE5611,earnings,100,50,6/2/2021
DF532D,conference-participant,100,50,6/2/2021
E22FDE,conference-participant,100,50,6/2/2021
E30A8F,unit-acquisition-acquiree,100,76,6/2/2021
E30B34,conference-participant,100,50,6/2/2021
E30B34,conference-participant,100,50,6/2/2021
E8E899,executive-resignation,100,44,6/2/2021
EE6F1C,partnership,100,61,6/2/2021
EEA6B3,partnership,100,61,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-acquiree,100,76,6/2/2021
EEB5F9,acquisition-regulatory-scrutiny-acquiree,100,38,6/2/2021
EF45B6,dividend,100,50,6/2/2021
EF5BED,partnership,100,61,6/2/2021
F02170,public-offering,100,43,6/2/2021
F1529C,conference-participant,100,50,6/2/2021
F39E1E,earnings-up,100,68,6/2/2021
F39E1E,earnings,100,50,6/2/2021
F39E1E,earnings,100,50,6/2/2021
F39E1E,earnings,100,50,6/2/2021
F569FD,clinical-trials,100,56,6/2/2021
F88A04,executive-appointment,100,54,6/2/2021
FA36A4,earnings,100,50,6/2/2021
FACF19,business-contract,100,69,6/2/2021
FDE409,conference-participant,100,50,6/2/2021
FEE4B0,conference-participant,100,50,6/2/2021
FF6644,product-release,100,64,6/2/2021
0157B1,product-release,100,64,6/3/2021
0157B1,partnership,100,61,6/3/2021
0157B1,product-release,100,64,6/3/2021
06A456,earnings,100,50,6/3/2021
06A456,earnings,100,50,6/3/2021
06A456,earnings,100,50,6/3/2021
06A456,earnings,100,50,6/3/2021
71860,conference-participant,100,50,6/3/2021
09DE1F,earnings,100,50,6/3/2021
0A59F8,executive-appointment,100,54,6/3/2021
0B7375,legal-issues-defendant,100,22,6/3/2021
1096C6,index-listing,100,76,6/3/2021
1272B3,conference-participant,100,50,6/3/2021
1921DD,partnership,100,61,6/3/2021
1AD9CC,earnings-up,100,68,6/3/2021
1AD9CC,earnings,100,50,6/3/2021
1E1125,conference-organizer,100,57,6/3/2021
221783,acquisition-acquirer,100,49,6/3/2021
228D42,partnership,100,61,6/3/2021
228D42,partnership,100,61,6/3/2021
228D42,partnership,100,61,6/3/2021
251988,partnership,100,61,6/3/2021
2571FA,conference-participant,100,50,6/3/2021
26CC63,earnings,100,50,6/3/2021
270305,product-release,100,64,6/3/2021
273BA3,earnings,100,50,6/3/2021
2920D5,conference-participant,100,50,6/3/2021
2ABF77,clinical-trials,100,56,6/3/2021
2CC60C,dividend-up,100,74,6/3/2021
2D643C,conference-participant,100,50,6/3/2021
2E61CC,partnership,100,61,6/3/2021
2EC172,executive-appointment,100,54,6/3/2021
2F1299,executive-appointment,100,54,6/3/2021
2F9304,conference-participant,100,50,6/3/2021
2F98A5,earnings,100,50,6/3/2021
2FF046,conference-participant,100,50,6/3/2021
314D88,product-release,100,64,6/3/2021
314D88,product-release,100,64,6/3/2021
317EC6,executive-appointment,100,54,6/3/2021
32F943,conference-participant,100,50,6/3/2021
33A0F1,ipo-considered,100,60,6/3/2021
33AD83,executive-resignation,100,44,6/3/2021
36529A,conference-participant,100,50,6/3/2021
382EAE,merger,100,66,6/3/2021
382EAE,acquisition-acquirer,100,49,6/3/2021
384CD3,conference-participant,100,50,6/3/2021
3ACF46,conference-participant,100,50,6/3/2021
40F7DE,conference-participant,100,50,6/3/2021
416291,conference-participant,100,50,6/3/2021
416C55,dividend,100,50,6/3/2021
431B74,product-release,100,64,6/3/2021
4A2457,executive-appointment,100,54,6/3/2021
4CDA2B,conference-participant,100,50,6/3/2021
4D8124,business-contract,100,69,6/3/2021
4D8124,business-contract,100,69,6/3/2021
4DD09F,conference-participant,100,50,6/3/2021
4DD203,conference-participant,100,50,6/3/2021
4F71DC,earnings,100,50,6/3/2021
50070E,conference-organizer,100,57,6/3/2021
50070E,conference-organizer,100,57,6/3/2021
50070E,conference-organizer,100,57,6/3/2021
50070E,conference-organizer,100,57,6/3/2021
504FE2,conference-participant,100,50,6/3/2021
55438C,partnership,100,61,6/3/2021
594402,patient-enrollment-start,100,58,6/3/2021
5C7601,dividend,100,50,6/3/2021
5D41E4,conference-participant,100,50,6/3/2021
620381,conference-participant,100,50,6/3/2021
622DBE,conference-participant,100,50,6/3/2021
6830FE,executive-appointment,100,54,6/3/2021
68586A,executive-appointment,100,54,6/3/2021
6DBBBC,executive-appointment,100,54,6/3/2021
719477,dividend-up,100,55,6/3/2021
722D55,conference-participant,100,50,6/3/2021
732A9B,conference-participant,100,50,6/3/2021
73A71F,executive-appointment,100,54,6/3/2021
73F7F9,conference-call,100,50,6/3/2021
756BB4,executive-resignation,100,44,6/3/2021
756BB4,earnings,100,50,6/3/2021
775439,earnings,100,50,6/3/2021
791EC1,executive-appointment,100,54,6/3/2021
7A0EC4,earnings,100,50,6/3/2021
7AC86E,conference-call,100,50,6/3/2021
7ACD98,award,100,58,6/3/2021
7ADE57,earnings,100,50,6/3/2021
7B1156,conference-participant,100,50,6/3/2021
7B4B91,acquisition-acquiree,100,76,6/3/2021
7B4B91,acquisition-acquiree,100,76,6/3/2021
7B4B91,legal-issues-defendant,100,22,6/3/2021
7B9212,revenues,100,50,6/3/2021
7CBC40,award,100,58,6/3/2021
7D35D8,executive-appointment,100,54,6/3/2021
7F3FBC,public-offering,100,43,6/3/2021
826FD6,earnings,100,50,6/3/2021
8A8E41,executive-appointment,100,54,6/3/2021
8BAA15,dividend,100,50,6/3/2021
8E8E6E,partnership,100,61,6/3/2021
8EDACA,conference-participant,100,50,6/3/2021
9196A2,conference-organizer,100,57,6/3/2021
9196A2,conference-organizer,100,57,6/3/2021
9196A2,conference-organizer,100,57,6/3/2021
9196A2,conference-organizer,100,57,6/3/2021
9196A2,conference-organizer,100,57,6/3/2021
91C82E,conference-call,100,50,6/3/2021
925759,executive-appointment,100,54,6/3/2021
92D757,merger,100,66,6/3/2021
9592FB,executive-appointment,100,54,6/3/2021
95DC1F,analyst-ratings-change-negative-rater,20,50,6/3/2021
95DC1F,conference-call,100,50,6/3/2021
972356,partnership,100,61,6/3/2021
97693A,earnings,100,50,6/3/2021
990AD0,conference-organizer,100,57,6/3/2021
990AD0,conference-organizer,100,57,6/3/2021
990AD0,conference-organizer,100,57,6/3/2021
990AD0,conference-organizer,100,57,6/3/2021
A01200,executive-appointment,100,54,6/3/2021
A16DEA,conference-participant,100,50,6/3/2021
A21649,executive-appointment,100,54,6/3/2021
A37D68,earnings,100,50,6/3/2021
A5195E,product-release,100,64,6/3/2021
A52B6B,business-contract,100,69,6/3/2021
A72FD9,conference-call,100,50,6/3/2021
A79F7D,partnership,100,61,6/3/2021
A79F7D,partnership,100,61,6/3/2021
AA3AB8,operating-earnings,100,50,6/3/2021
AC7C4F,conference-participant,100,50,6/3/2021
AD22F2,executive-appointment,100,54,6/3/2021
ADD9DC,earnings,100,50,6/3/2021
ADF092,partnership,100,61,6/3/2021
AEBB80,dividend,100,50,6/3/2021
B290A2,conference-participant,100,50,6/3/2021
B37FB4,conference-participant,100,50,6/3/2021
B5734D,conference-call,100,50,6/3/2021
B8EF97,revenues,100,50,6/3/2021
BB127B,conference-participant,100,50,6/3/2021
BB127B,board-meeting,100,51,6/3/2021
C0BA36,product-release,100,64,6/3/2021
C3BAE7,executive-appointment,100,54,6/3/2021
C425AE,conference-participant,100,50,6/3/2021
C4452A,product-release,100,64,6/3/2021
C45CE7,conference-participant,100,50,6/3/2021
C4FBDC,conference-participant,100,50,6/3/2021
C564E4,conference-participant,100,50,6/3/2021
C8257F,executive-appointment,100,54,6/3/2021
C83B88,partnership,100,61,6/3/2021
C8A248,conference-participant,100,50,6/3/2021
C94CFC,legal-issues-defendant,100,22,6/3/2021
C99CC8,acquisition-acquirer,100,49,6/3/2021
C99CC8,acquisition-acquirer,100,49,6/3/2021
CC176E,partnership,100,61,6/3/2021
CD4DA8,conference-organizer,100,57,6/3/2021
CD4DA8,conference-organizer,100,57,6/3/2021
CD4DA8,conference-organizer,100,57,6/3/2021
CD4DA8,conference-organizer,100,57,6/3/2021
CF211D,earnings,100,50,6/3/2021
CF6A5A,partnership,100,61,6/3/2021
CFF97C,conference-participant,100,50,6/3/2021
CFF97C,conference-participant,100,50,6/3/2021
D11C1C,note-sale,100,52,6/3/2021
D17C1B,executive-appointment,100,54,6/3/2021
D6489C,partnership,100,61,6/3/2021
D82EF3,partnership,100,61,6/3/2021
D90F43,partnership,100,61,6/3/2021
DB2E4E,business-contract,100,69,6/3/2021
DB9829,earnings-up,100,68,6/3/2021
DF11D9,unit-acquisition-acquirer,100,49,6/3/2021
DF5F14,public-offering,100,43,6/3/2021
DFADDB,conference-participant,100,50,6/3/2021
E0207A,product-release,100,64,6/3/2021
E06265,conference-participant,100,50,6/3/2021
E0A84E,partnership,100,61,6/3/2021
E21871,partnership,100,61,6/3/2021
E2CB7B,executive-appointment,100,54,6/3/2021
E2F130,conference-participant,100,50,6/3/2021
E30B34,conference-participant,100,50,6/3/2021
E30B34,conference-participant,100,50,6/3/2021
E6BC2C,acquisition-completed-acquirer,100,49,6/3/2021
E74B55,legal-issues-defendant,100,22,6/3/2021
E829E8,unit-acquisition-acquirer,100,49,6/3/2021
EAEBF3,index-listing,100,76,6/3/2021
ED3CA8,conference-participant,100,50,6/3/2021
EE1E44,acquisition-acquirer,100,49,6/3/2021
EE1E44,acquisition-acquirer,100,49,6/3/2021
F294DD,dividend,100,50,6/3/2021
F30508,conference-participant,100,50,6/3/2021
F43A11,earnings,100,50,6/3/2021
F47871,product-release,100,64,6/3/2021
F66B58,earnings-guidance-up,100,83,6/3/2021
FDF799,conference-participant,100,50,6/3/2021
FE7A63,dividend,100,50,6/3/2021
00E601,conference-participant,100,50,6/4/2021
01D03F,partnership,100,61,6/4/2021
034B61,conference-participant,100,50,6/4/2021
061A3B,product-price-raise,100,57,6/4/2021
095A04,clinical-trials-positive,100,87,6/4/2021
0A59F8,partnership,100,61,6/4/2021
0B7375,legal-issues-defendant,100,22,6/4/2021
0BC853,dividend,100,50,6/4/2021
0F0693,business-contract,100,69,6/4/2021
1080C0,executive-appointment,100,54,6/4/2021
139303,conference-organizer,100,57,6/4/2021
159AE4,conference-participant,100,50,6/4/2021
15A388,conference-participant,100,50,6/4/2021
1.79E+10,acquisition-completed-acquirer,100,49,6/4/2021
1.79E+10,stake-acquirer,100,48,6/4/2021
1DA44F,market-entry,100,57,6/4/2021
1EBF8D,business-contract,100,69,6/4/2021
1EBF8D,business-contract,100,69,6/4/2021
1EBF8D,business-contract,100,69,6/4/2021
251988,executive-appointment,100,54,6/4/2021
251988,partnership,100,61,6/4/2021
2A02DC,business-contract,100,69,6/4/2021
2A02DC,private-placement,100,56,6/4/2021
2BC05E,conference-participant,100,50,6/4/2021
2BF36E,unit-acquisition-acquirer,100,49,6/4/2021
3224CC,conference-participant,100,50,6/4/2021
3461CF,credit-rating-upgrade-rater,20,50,6/4/2021
3461CF,credit-rating-outlook-positive-rater,20,50,6/4/2021
36C09B,clinical-trials,100,56,6/4/2021
384CD3,product-release,100,64,6/4/2021
3B2311,partnership,100,61,6/4/2021
4017AD,conference-participant,100,50,6/4/2021
4017AD,conference-participant,100,50,6/4/2021
41ED98,executive-appointment,100,54,6/4/2021
427F32,dividend,100,50,6/4/2021
44A4FC,conference-participant,100,50,6/4/2021
4676DF,joint-venture,100,62,6/4/2021
50070E,conference-organizer,100,57,6/4/2021
50070E,conference-organizer,100,57,6/4/2021
519FE0,acquisition-completed-acquirer,100,49,6/4/2021
58CA9A,partnership,100,61,6/4/2021
58CA9A,conference-participant,100,50,6/4/2021
59872F,partnership,100,61,6/4/2021
5D1329,clinical-trials,100,56,6/4/2021
5DD486,conference-participant,100,50,6/4/2021
620381,clinical-trials-positive,100,87,6/4/2021
636BBF,legal-issues-defendant,100,22,6/4/2021
64E346,conference-participant,100,50,6/4/2021
6559D8,legal-issues-defendant,100,22,6/4/2021
65D0AA,clinical-trials-positive,100,87,6/4/2021
66A667,business-contract,100,69,6/4/2021
66A667,business-contract,100,69,6/4/2021
66A667,business-contract,100,69,6/4/2021
6CBF41,conference-participant,100,50,6/4/2021
6CC55E,clinical-trials,100,56,6/4/2021
6CC55E,clinical-trials,100,56,6/4/2021
6CC55E,earnings,100,50,6/4/2021
6CC55E,earnings,100,50,6/4/2021
6F0A63,unit-acquisition-acquirer,100,49,6/4/2021
713810,conference-participant,100,50,6/4/2021
713810,facility-close,100,47,6/4/2021
713810,partnership,100,61,6/4/2021
717DB4,conference-participant,100,50,6/4/2021
726EEA,dividend,100,50,6/4/2021
766047,donation,100,54,6/4/2021
76F067,conference-participant,100,50,6/4/2021
78F9ED,executive-appointment,100,54,6/4/2021
7D85A9,conference-participant,100,50,6/4/2021
85CDC9,clinical-trials-positive,100,87,6/4/2021
85CDC9,clinical-trials-positive,100,87,6/4/2021
85CDC9,clinical-trials-positive,100,87,6/4/2021
8FCA78,executive-appointment,100,54,6/4/2021
918D6D,clinical-trials,100,56,6/4/2021
9196A2,conference-organizer,100,57,6/4/2021
9196A2,conference-organizer,100,57,6/4/2021
94637C,conference-participant,100,50,6/4/2021
96A6CD,regulatory-product-approval-granted,100,81,6/4/2021
98CEBB,executive-appointment,100,54,6/4/2021
990AD0,conference-organizer,100,57,6/4/2021
9C5BA5,conference-participant,100,50,6/4/2021
A6FE1C,unit-acquisition-acquirer,100,49,6/4/2021
A80FE0,conference-participant,100,50,6/4/2021
A99576,legal-issues-defendant,100,22,6/4/2021
AC642C,conference-participant,100,50,6/4/2021
AC642C,conference-participant,100,50,6/4/2021
AC642C,conference-participant,100,50,6/4/2021
AC642C,conference-participant,100,50,6/4/2021
ADFB3A,executive-appointment,100,54,6/4/2021
B66928,acquisition-interest-acquiree,100,82,6/4/2021
B66928,acquisition-interest-acquiree,100,82,6/4/2021
B66928,acquisition-acquirer,100,49,6/4/2021
B762D3,earnings,100,50,6/4/2021
B762D3,earnings,100,50,6/4/2021
B762D3,earnings,100,50,6/4/2021
BA0442,conference-participant,100,50,6/4/2021
BD8517,business-contract,100,69,6/4/2021
C0BA36,conference-participant,100,50,6/4/2021
C45C1F,clinical-trials,100,56,6/4/2021
C94CFC,legal-issues-defendant,100,22,6/4/2021
C94CFC,legal-issues-defendant,100,22,6/4/2021
CD4DA8,conference-organizer,100,57,6/4/2021
CD4DA8,conference-organizer,100,57,6/4/2021
DA48E4,conference-participant,100,50,6/4/2021
E11C41,dividend,100,50,6/4/2021
E26FC3,stock-splits,100,49,6/4/2021
E3E68E,award,100,58,6/4/2021
E3E68E,award,100,58,6/4/2021
EEB5F9,clinical-trials,100,56,6/4/2021
FB728F,earnings,100,50,6/4/2021
FC01C0,conference-participant,100,50,6/4/2021
FC4550,dividend,100,50,6/4/2021
FCA54E,executive-appointment,100,54,6/4/2021
002A99,legal-issues-defendant,100,22,6/5/2021
0A748B,legal-issues-defendant,100,22,6/5/2021
0B7375,fraud-defendant,100,20,6/5/2021
636BBF,legal-issues-defendant,100,22,6/5/2021
7A3633,partnership,100,61,6/5/2021
7B4B91,legal-issues-defendant,100,22,6/5/2021
BD15E8,legal-issues-defendant,100,22,6/5/2021
C74887,clinical-trials,100,56,6/5/2021
C94CFC,legal-issues-defendant,100,22,6/5/2021
E74B55,legal-issues-defendant,100,22,6/5/2021
EE1E44,legal-issues-defendant,100,22,6/5/2021
EEB5F9,legal-issues-defendant,100,22,6/5/2021
622DBE,partnership,100,61,6/6/2021
E74B55,legal-issues-defendant,100,22,6/6/2021
001F1B,conference-call,100,50,6/7/2021
002A99,legal-issues-defendant,100,22,6/7/2021
036C6F,conference-participant,100,50,6/7/2021
040DBB,dividend,100,50,6/7/2021
040DBB,executive-appointment,100,54,6/7/2021
07CA6A,executive-appointment,100,54,6/7/2021
07CA6A,executive-appointment,100,54,6/7/2021
07EC43,partnership,100,61,6/7/2021
07EC43,partnership,100,61,6/7/2021
96930,clinical-trials,100,56,6/7/2021
099C88,conference-participant,100,50,6/7/2021
0B73A7,earnings,100,50,6/7/2021
0B73A7,earnings,100,50,6/7/2021
0BC29E,executive-appointment,100,54,6/7/2021
0BD4E8,executive-appointment,100,54,6/7/2021
0E5223,conference-participant,100,50,6/7/2021
108A2B,public-offering,100,43,6/7/2021
108A2B,public-offering,100,43,6/7/2021
13A782,conference-participant,100,50,6/7/2021
159739,conference-participant,100,50,6/7/2021
159739,conference-participant,100,50,6/7/2021
159AE4,conference-call,100,50,6/7/2021
1834C0,conference-participant,100,50,6/7/2021
190B91,conference-participant,100,50,6/7/2021
1CD4B5,clinical-trials,100,56,6/7/2021
1E83DE,earnings-up,100,68,6/7/2021
1EBF8D,unit-acquisition-acquirer,100,49,6/7/2021
1F43A1,public-offering,100,43,6/7/2021
1FE7F0,conference-participant,100,50,6/7/2021
228D42,product-release,100,64,6/7/2021
241AF7,dividend,100,50,6/7/2021
2491BC,partnership,100,61,6/7/2021
270B78,conference-participant,100,50,6/7/2021
291651,conference-call,100,50,6/7/2021
2A6DBE,conference-participant,100,50,6/7/2021
2B8179,conference-call,100,50,6/7/2021
2D643C,executive-appointment,100,54,6/7/2021
2EB88B,executive-appointment,100,54,6/7/2021
30A565,partnership,100,61,6/7/2021
33E9D5,executive-appointment,100,54,6/7/2021
341759,executive-appointment,100,54,6/7/2021
37727A,earnings-guidance-up,100,83,6/7/2021
384CD3,business-contract,100,69,6/7/2021
3B318A,earnings,100,50,6/7/2021
3B8484,acquisition-acquirer,100,49,6/7/2021
3BBD10,executive-appointment,100,54,6/7/2021
3C75D6,conference-participant,100,50,6/7/2021
3DCECC,executive-appointment,100,54,6/7/2021
3DE4D1,partnership,100,61,6/7/2021
442769,earnings-guidance,100,50,6/7/2021
442769,earnings-guidance,100,50,6/7/2021
45ABCC,conference-participant,100,50,6/7/2021
499C75,partnership,100,61,6/7/2021
4C6C63,note-sale,100,52,6/7/2021
50070E,partnership,100,61,6/7/2021
50070E,conference-organizer,100,57,6/7/2021
50070E,product-release,100,64,6/7/2021
50070E,conference-organizer,100,57,6/7/2021
50070E,conference-organizer,100,57,6/7/2021
50070E,conference-organizer,100,57,6/7/2021
50070E,conference-organizer,100,57,6/7/2021
50070E,conference-organizer,100,57,6/7/2021
55C9B5,conference-participant,100,50,6/7/2021
56277A,executive-appointment,100,54,6/7/2021
57B174,acquisition-acquirer,100,49,6/7/2021
57B174,acquisition-acquirer,100,49,6/7/2021
5B35C7,legal-issues-defendant,100,22,6/7/2021
619882,product-release,100,64,6/7/2021
622DBE,executive-appointment,100,54,6/7/2021
636BBF,legal-issues-defendant,100,22,6/7/2021
636BBF,legal-issues-defendant,100,22,6/7/2021
649CBD,conference-participant,100,50,6/7/2021
64E346,acquisition-interest-acquirer,100,46,6/7/2021
665D7D,regulatory-product-approval-granted,100,81,6/7/2021
67303E,conference-participant,100,50,6/7/2021
67A658,spin-off,100,58,6/7/2021
67A658,spin-off,100,58,6/7/2021
67B923,executive-appointment,100,54,6/7/2021
6B236C,operating-earnings,100,50,6/7/2021
6B494E,executive-appointment,100,54,6/7/2021
6C6D73,conference-participant,100,50,6/7/2021
6F0096,dividend,100,50,6/7/2021
6F39FC,dividend,100,50,6/7/2021
713810,product-release,100,64,6/7/2021
748EB6,conference-participant,100,50,6/7/2021
7999F3,conference-participant,100,50,6/7/2021
7A2A49,conference-participant,100,50,6/7/2021
7BFF81,conference-participant,100,50,6/7/2021
7FEEE1,conference-participant,100,50,6/7/2021
83B1C8,executive-appointment,100,54,6/7/2021
83B1C8,executive-appointment,100,54,6/7/2021
8665BA,business-contract,100,69,6/7/2021
8AC65D,partnership,100,61,6/7/2021
8C5519,conference-participant,100,50,6/7/2021
8D4AE6,legal-issues-defendant,100,22,6/7/2021
9196A2,conference-organizer,100,57,6/7/2021
9196A2,conference-organizer,100,57,6/7/2021
9196A2,conference-organizer,100,57,6/7/2021
9196A2,conference-organizer,100,57,6/7/2021
91E5EE,legal-issues-defendant,100,22,6/7/2021
934029,partnership,100,61,6/7/2021
93D207,partnership,100,61,6/7/2021
94208D,executive-appointment,100,54,6/7/2021
9673BD,revenue-guidance-up,100,83,6/7/2021
96F126,business-contract,100,69,6/7/2021
9.82E+06,earnings,100,50,6/7/2021
986AF6,unit-acquisition-acquirer,100,49,6/7/2021
990AD0,conference-organizer,100,57,6/7/2021
990AD0,conference-organizer,100,57,6/7/2021
990AD0,executive-appointment,100,54,6/7/2021
990AD0,conference-organizer,100,57,6/7/2021
990AD0,conference-organizer,100,57,6/7/2021
9D30A8,conference-participant,100,50,6/7/2021
9E0811,conference-participant,100,50,6/7/2021
9EBAFA,unit-acquisition-acquirer,100,49,6/7/2021
A03EE1,index-listing,100,76,6/7/2021
A247F5,business-contract,100,69,6/7/2021
A247F5,business-contract,100,69,6/7/2021
A2C979,conference-participant,100,50,6/7/2021
A350C1,acquisition-acquiree,100,76,6/7/2021
A350C1,acquisition-acquiree,100,76,6/7/2021
A350C1,acquisition-regulatory-scrutiny-acquiree,100,38,6/7/2021
A666C8,acquisition-completed-acquirer,100,49,6/7/2021
A6828A,partnership-terminated,100,36,6/7/2021
A7A0BD,executive-appointment,100,54,6/7/2021
A99576,legal-issues-defendant,100,22,6/7/2021
AA1EAA,conference-participant,100,50,6/7/2021
ABB493,executive-appointment,100,54,6/7/2021
AC775C,conference-participant,100,50,6/7/2021
AED61E,earnings,100,50,6/7/2021
B1FC3B,earnings,100,50,6/7/2021
B3CB74,conference-organizer,100,57,6/7/2021
B4C673,trading-resumed,100,58,6/7/2021
B8F71F,executive-appointment,100,54,6/7/2021
B9CD50,conference-participant,100,50,6/7/2021
BB127B,partnership,100,61,6/7/2021
BD15E8,executive-appointment,100,54,6/7/2021
BD15E8,legal-issues-defendant,100,22,6/7/2021
C06EB6,clinical-trials-positive,100,87,6/7/2021
C06EB6,clinical-trials-positive,100,87,6/7/2021
C06EB6,clinical-trials,100,56,6/7/2021
C06EB6,clinical-trials,100,56,6/7/2021
C356AC,asset-sale,100,62,6/7/2021
C4A432,acquisition-completed-acquirer,100,49,6/7/2021
C72B8F,note-sale,100,52,6/7/2021
C9732E,patient-enrollment-complete,100,64,6/7/2021
C9E107,conference-participant,100,50,6/7/2021
C9E4EC,conference-participant,100,50,6/7/2021
CA99D7,unit-acquisition-acquirer,100,49,6/7/2021
CC339B,dividend,100,50,6/7/2021
CD4DA8,conference-organizer,100,57,6/7/2021
CDFCC9,conference-participant,100,50,6/7/2021
CF351E,dividend,100,50,6/7/2021
D1C26F,conference-participant,100,50,6/7/2021
D25249,note-sale,100,52,6/7/2021
D4070C,executive-resignation,100,44,6/7/2021
D45285,acquisition-acquiree,100,76,6/7/2021
D45285,acquisition-acquiree,100,76,6/7/2021
D45285,acquisition-regulatory-scrutiny-acquiree,100,38,6/7/2021
D57D99,acquisition-completed-acquiree,100,76,6/7/2021
D598E7,note-sale,100,52,6/7/2021
D598E7,note-sale,100,52,6/7/2021
D622D5,dividend-up,100,81,6/7/2021
D622D5,operating-earnings,100,50,6/7/2021
D76AEF,product-release,100,64,6/7/2021
D7918D,public-offering,100,43,6/7/2021
D8442A,product-release,100,64,6/7/2021
D8442A,product-release,100,64,6/7/2021
D8442A,product-release,100,64,6/7/2021
D8442A,product-release,100,64,6/7/2021
D9FC89,conference-participant,100,50,6/7/2021
DB7014,unit-acquisition-acquirer,100,49,6/7/2021
DD7A96,conference-participant,100,50,6/7/2021
DF11D9,legal-issues-defendant,100,22,6/7/2021
E0207A,business-contract,100,69,6/7/2021
E05026,unit-acquisition-acquiree,100,76,6/7/2021
E124EB,conference-participant,100,50,6/7/2021
E20392,regulatory-product-approval-granted,100,81,6/7/2021
EAEA91,buybacks,100,74,6/7/2021
EB1E1A,partnership,100,61,6/7/2021
EEB5F9,legal-issues-defendant,100,22,6/7/2021
EEBCEF,acquisition-acquirer,100,49,6/7/2021
F05B1B,business-contract,100,69,6/7/2021
F1529C,conference-call,100,50,6/7/2021
F18844,credit-extension-recipient,100,69,6/7/2021
F5C78B,public-offering,100,43,6/7/2021
F7FCA4,partnership,100,61,6/7/2021
F7FCA4,partnership,100,61,6/7/2021
F7FCA4,partnership,100,61,6/7/2021
F88A04,conference-participant,100,50,6/7/2021
FD6926,conference-participant,100,50,6/7/2021
002A99,legal-issues-defendant,100,22,6/8/2021
002A99,legal-issues-defendant,100,22,6/8/2021
9397,conference-participant,100,50,6/8/2021
13528,hirings,100,65,6/8/2021
01D03F,product-release,100,64,6/8/2021
01D03F,product-release,100,64,6/8/2021
03542C,dividend,100,50,6/8/2021
05AF14,unit-acquisition-acquirer,100,49,6/8/2021
0BA2EF,earnings,100,50,6/8/2021
0BA2EF,earnings,100,50,6/8/2021
0C6293,award,100,58,6/8/2021
0CC01F,trading-listing,100,61,6/8/2021
0F04E5,conference-participant,100,50,6/8/2021
10100E,conference-participant,100,50,6/8/2021
108A2B,conference-participant,100,50,6/8/2021
12DE76,product-release,100,64,6/8/2021
152AB9,public-offering,100,43,6/8/2021
19BF16,credit-extension-recipient,100,69,6/8/2021
1A1ED9,business-contract,100,69,6/8/2021
1A3E1B,executive-appointment,100,54,6/8/2021
1B637E,acquisition-acquirer,100,49,6/8/2021
1D3A00,earnings,100,50,6/8/2021
1D3A00,earnings,100,50,6/8/2021
1D3A00,earnings,100,50,6/8/2021
1D3A00,earnings,100,50,6/8/2021
1E1125,legal-issues-defendant,100,22,6/8/2021
1F08A6,dividend,100,50,6/8/2021
1F43A1,public-offering,100,43,6/8/2021
24C48B,partnership,100,61,6/8/2021
24C48B,partnership,100,61,6/8/2021
24C48B,executive-appointment,100,54,6/8/2021
26008A,dividend-up,100,81,6/8/2021
263216,conference-participant,100,50,6/8/2021
274B8A,conference-call,100,50,6/8/2021
292388,partnership,100,61,6/8/2021
2A1009,legal-issues-defendant,100,22,6/8/2021
37B120,legal-issues-defendant,100,22,6/8/2021
3BB616,note-sale,100,52,6/8/2021
408089,revenue-guidance-up,100,83,6/8/2021
4A6F00,partnership,100,61,6/8/2021
4B3676,executive-appointment,100,54,6/8/2021
4E2D94,acquisition-acquiree,100,76,6/8/2021
50070E,conference-organizer,100,57,6/8/2021
52BF94,conference-call,100,50,6/8/2021
59872F,business-contract,100,69,6/8/2021
59872F,product-release,100,64,6/8/2021
59872F,product-release,100,64,6/8/2021
5B6C11,dividend,100,50,6/8/2021
5DE5A5,conference-participant,100,50,6/8/2021
5F1B7B,product-release,100,64,6/8/2021
619882,conference-organizer,100,57,6/8/2021
62EFEE,note-sale,100,52,6/8/2021
62EFEE,note-sale,100,52,6/8/2021
6A01DF,executive-appointment,100,54,6/8/2021
6A6BDC,product-release,100,64,6/8/2021
6ED519,executive-appointment,100,54,6/8/2021
6F0096,business-contract,100,69,6/8/2021
6F5DD2,bought-deal,100,43,6/8/2021
70B3D6,revenue-up,100,69,6/8/2021
70B3D6,revenue-up,100,69,6/8/2021
70B3D6,revenue-up,100,69,6/8/2021
70B3D6,revenue-up,100,69,6/8/2021
71694D,conference-participant,100,50,6/8/2021
73529F,legal-issues-defendant,100,22,6/8/2021
73529F,legal-issues-defendant,100,22,6/8/2021
73F70F,earnings,100,50,6/8/2021
762A3E,executive-appointment,100,54,6/8/2021
793C11,executive-appointment,100,54,6/8/2021
7B4B91,legal-issues-defendant,100,22,6/8/2021
7B8CB5,conference-participant,100,50,6/8/2021
7B9212,dividend,100,50,6/8/2021
7E1D5D,acquisition-acquirer,100,49,6/8/2021
8377DB,stock-loss,100,40,6/8/2021
8377DB,conference-participant,100,50,6/8/2021
8377DB,earnings,100,50,6/8/2021
85DE00,partnership,100,61,6/8/2021
863350,legal-issues-defendant,100,22,6/8/2021
8665BA,conference-participant,100,50,6/8/2021
8E8E6E,executive-appointment,100,54,6/8/2021
8FCA78,supply-guidance-increase,100,74,6/8/2021
9196A2,conference-organizer,100,57,6/8/2021
9196A2,conference-organizer,100,57,6/8/2021
9196A2,conference-organizer,100,57,6/8/2021
986AF6,dividend,100,50,6/8/2021
98CEBB,partnership,100,61,6/8/2021
990AD0,conference-organizer,100,57,6/8/2021
990AD0,conference-organizer,100,57,6/8/2021
9B5968,product-release,100,64,6/8/2021
9BF177,earnings,100,50,6/8/2021
A0F146,index-listing,100,76,6/8/2021
A16DEA,conference-participant,100,50,6/8/2021
A1EAC8,business-contract,100,69,6/8/2021
A204A7,partnership,100,61,6/8/2021
A26C26,earnings,100,50,6/8/2021
A350C1,legal-issues-defendant,100,22,6/8/2021
A49498,executive-appointment,100,54,6/8/2021
A49498,legal-issues-defendant,100,22,6/8/2021
A49498,legal-issues-defendant,100,22,6/8/2021
A6FE1C,unit-acquisition-acquirer,100,49,6/8/2021
AD375D,conference-participant,100,50,6/8/2021
AD6141,conference-participant,100,50,6/8/2021
AECCA9,dividend,100,50,6/8/2021
B1A85D,partnership,100,61,6/8/2021
B1FC3B,dividend,100,50,6/8/2021
B2D799,partnership,100,61,6/8/2021
B33E77,partnership,100,61,6/8/2021
B33E77,partnership,100,61,6/8/2021
B3CB74,conference-organizer,100,57,6/8/2021
B3ED62,business-contract,100,69,6/8/2021
B4C673,earnings-guidance,100,50,6/8/2021
B5734D,executive-resignation,100,44,6/8/2021
B72BE9,product-release,100,64,6/8/2021
B9CD50,partnership,100,61,6/8/2021
B9CD50,partnership,100,61,6/8/2021
C0F70B,facility-open,100,65,6/8/2021
C15DB3,conference-participant,100,50,6/8/2021
C2E39B,business-contract,100,69,6/8/2021
C5C137,conference-participant,100,50,6/8/2021
C5D2AE,product-release,100,64,6/8/2021
C72B8F,note-sale,100,52,6/8/2021
C8257F,executive-appointment,100,54,6/8/2021
C94CFC,legal-issues-defendant,100,22,6/8/2021
C9881C,conference-call,100,50,6/8/2021
C9C62A,conference-participant,100,50,6/8/2021
CA1620,conference-participant,100,50,6/8/2021
CA1620,campaign-ad-release,100,59,6/8/2021
CD2A4D,acquisition-completed-acquirer,100,49,6/8/2021
CD4DA8,conference-organizer,100,57,6/8/2021
CDD75E,business-contract,100,69,6/8/2021
CE4FD9,earnings-guidance-up,100,83,6/8/2021
CE4FD9,executive-appointment,100,54,6/8/2021
CE4FD9,conference-participant,100,50,6/8/2021
D064D5,earnings,100,50,6/8/2021
D11C1C,executive-appointment,100,54,6/8/2021
D1C26F,credit-extension-recipient,100,69,6/8/2021
D25249,note-sale,100,52,6/8/2021
D2E553,revenue-up,100,91,6/8/2021
D2E553,revenue-up,100,91,6/8/2021
D45285,acquisition-regulatory-scrutiny-acquiree,100,38,6/8/2021
D45285,legal-issues-defendant,100,22,6/8/2021
D64C6D,executive-appointment,100,54,6/8/2021
DF11D9,legal-issues-defendant,100,22,6/8/2021
E1BD05,executive-appointment,100,54,6/8/2021
E3E68E,partnership,100,61,6/8/2021
E3E68E,partnership,100,61,6/8/2021
E3E68E,executive-appointment,100,54,6/8/2021
E3E68E,executive-appointment,100,54,6/8/2021
E6A53A,business-contract,100,69,6/8/2021
E6A53A,business-contract,100,69,6/8/2021
E8846E,conference-participant,100,50,6/8/2021
EEB5F9,acquisition-acquiree,100,76,6/8/2021
F5C78B,public-offering,100,43,6/8/2021
FA40E2,earnings,100,50,6/8/2021
FB7724,executive-appointment,100,54,6/8/2021
FC9869,executive-resignation,100,44,6/8/2021
FF4343,executive-appointment,100,54,6/8/2021
00067A,executive-appointment,100,54,6/9/2021
0157B1,hirings,100,65,6/9/2021
0358AF,dividend,100,50,6/9/2021
48781,public-offering,100,43,6/9/2021
61366,investment-investor,100,55,6/9/2021
68396,note-sale,100,52,6/9/2021
68396,note-sale,100,52,6/9/2021
0A6824,note-sale,100,52,6/9/2021
0A6824,note-sale,100,52,6/9/2021
0B4D10,dividend,100,50,6/9/2021
0B7375,legal-issues-defendant,100,22,6/9/2021
0E64D4,product-release,100,64,6/9/2021
0FDE97,note-sale,100,52,6/9/2021
14BA33,dividend,100,50,6/9/2021
1748F6,earnings,100,50,6/9/2021
17EDA5,business-contract,100,69,6/9/2021
1CDD1C,partnership,100,61,6/9/2021
1D1B07,earnings,100,50,6/9/2021
1D1B07,earnings,100,50,6/9/2021
1DF15D,dividend,100,50,6/9/2021
1E1125,legal-issues-defendant,100,22,6/9/2021
1E83DE,public-offering,100,43,6/9/2021
1EBF8D,government-contract,100,69,6/9/2021
1F9258,public-offering,100,43,6/9/2021
228D42,partnership,100,61,6/9/2021
28AF37,executive-appointment,100,54,6/9/2021
292A70,earnings,100,50,6/9/2021
2BDC1C,regulatory-product-approval-granted,100,81,6/9/2021
2BDC1C,regulatory-product-approval-granted,100,81,6/9/2021
2CB4C9,partnership,100,61,6/9/2021
2FF046,conference-participant,100,50,6/9/2021
317EC6,acquisition-completed-acquirer,100,49,6/9/2021
33E9D5,earnings,100,50,6/9/2021
37B120,legal-issues-defendant,100,22,6/9/2021
37B120,legal-issues-defendant,100,22,6/9/2021
37B120,legal-issues-defendant,100,22,6/9/2021
3BB616,partnership,100,61,6/9/2021
3CCC90,executive-appointment,100,54,6/9/2021
3D7971,dividend,100,50,6/9/2021
3DCECC,product-release,100,64,6/9/2021
40F7DE,earnings,100,50,6/9/2021
467F2C,conference-participant,100,50,6/9/2021
4A6F00,acquisition-acquiree,100,76,6/9/2021
4A6F00,acquisition-acquiree,100,76,6/9/2021
4A6F00,acquisition-acquiree,100,76,6/9/2021
4B3DC9,executive-appointment,100,54,6/9/2021
4B3DC9,merger-completed,100,66,6/9/2021
4D72C8,executive-appointment,100,54,6/9/2021
4D72C8,executive-appointment,100,54,6/9/2021
50070E,conference-organizer,100,57,6/9/2021
50070E,conference-organizer,100,57,6/9/2021
50070E,conference-organizer,100,57,6/9/2021
5065B1,dividend,100,50,6/9/2021
519FE0,partnership,100,61,6/9/2021
5225A4,conference-participant,100,50,6/9/2021
543900,earnings,100,50,6/9/2021
543900,earnings,100,50,6/9/2021
583A75,partnership,100,61,6/9/2021
587EDF,unit-acquisition-acquirer,100,49,6/9/2021
596116,name-change,100,49,6/9/2021
59A832,dividend,100,50,6/9/2021
5DE5A5,conference-participant,100,50,6/9/2021
5F1B7B,partnership,100,61,6/9/2021
5F1B7B,partnership,100,61,6/9/2021
5F2FF7,executive-appointment,100,54,6/9/2021
62F41C,award,100,58,6/9/2021
63F892,partnership,100,61,6/9/2021
63F892,partnership,100,61,6/9/2021
665D7D,partnership,100,61,6/9/2021
69CE71,facility-open,100,65,6/9/2021
6A3C35,note-sale,100,52,6/9/2021
6AACDD,conference-participant,100,50,6/9/2021
6-Dec-05,conference-participant,100,50,6/9/2021
724F84,product-release,100,64,6/9/2021
72FCA3,earnings,100,50,6/9/2021
731675,product-release,100,64,6/9/2021
73A71F,award,100,58,6/9/2021
767F86,dividend-up,100,81,6/9/2021
76E80F,conference-participant,100,50,6/9/2021
787D14,acquisition-acquirer,100,49,6/9/2021
7A5097,partnership,100,61,6/9/2021
7B0BA6,executive-appointment,100,54,6/9/2021
7B9AFA,conference-participant,100,50,6/9/2021
7C4F43,conference-participant,100,50,6/9/2021
805CD8,conference-organizer,100,57,6/9/2021
859D62,earnings-positive,100,69,6/9/2021
859D62,earnings-positive,100,69,6/9/2021
859D62,earnings-positive,100,69,6/9/2021
859D62,earnings-positive,100,69,6/9/2021
859D62,earnings-positive,100,69,6/9/2021
859D62,earnings-positive,100,69,6/9/2021
89B2E7,dividend,100,50,6/9/2021
89E771,earnings,100,50,6/9/2021
8A8E41,partnership,100,61,6/9/2021
8AC740,dividend-up,100,81,6/9/2021
8B8656,earnings,100,50,6/9/2021
8FF57A,investment-investor,100,55,6/9/2021
915E7B,dividend,100,50,6/9/2021
9196A2,conference-organizer,100,57,6/9/2021
9196A2,conference-organizer,100,57,6/9/2021
940C3D,partnership,100,61,6/9/2021
940C3D,partnership,100,61,6/9/2021
9592FB,conference-participant,100,50,6/9/2021
979451,acquisition-completed-acquirer,100,49,6/9/2021
990AD0,conference-organizer,100,57,6/9/2021
990AD0,conference-organizer,100,57,6/9/2021
99B61C,executive-appointment,100,54,6/9/2021
9B0C9C,conference-participant,100,50,6/9/2021
9B730A,conference-participant,100,50,6/9/2021
9C8BC3,award,100,58,6/9/2021
9FA83B,conference-participant,100,50,6/9/2021
9FB4B7,clinical-trials,100,56,6/9/2021
A403CF,conference-participant,100,50,6/9/2021
A49498,legal-issues-defendant,100,22,6/9/2021
A631A3,partnership,100,61,6/9/2021
A666C8,conference-participant,100,50,6/9/2021
A6828A,conference-call,100,50,6/9/2021
A6FB29,earnings-up,100,68,6/9/2021
AA3AB8,dividend,100,50,6/9/2021
AECCA9,earnings-up,100,68,6/9/2021
AECCA9,earnings-up,100,68,6/9/2021
AECCA9,earnings-up,100,68,6/9/2021
AECCA9,earnings-up,100,68,6/9/2021
AECCA9,earnings-up,100,68,6/9/2021
AECCA9,earnings-up,100,68,6/9/2021
B0998E,award,100,58,6/9/2021
B3CB74,conference-organizer,100,57,6/9/2021
B83BCE,partnership,100,61,6/9/2021
B83BCE,partnership,100,61,6/9/2021
BB127B,product-release,100,64,6/9/2021
BCC13E,conference-participant,100,50,6/9/2021
BD8517,product-release,100,64,6/9/2021
BFF98A,conference-participant,100,50,6/9/2021
C4FBDC,dividend,100,50,6/9/2021
C94CFC,legal-issues-defendant,100,22,6/9/2021
C94CFC,legal-issues-defendant,100,22,6/9/2021
C9E107,merger-completed,100,66,6/9/2021
CF211D,earnings,100,50,6/9/2021
D17C1B,partnership,100,61,6/9/2021
D1C26F,partnership,100,61,6/9/2021
D4070C,asset-sale,100,62,6/9/2021
D4070C,unit-acquisition-acquiree,100,76,6/9/2021
D42DBA,executive-appointment,100,54,6/9/2021
D42DBA,earnings,100,50,6/9/2021
D8442A,product-release,100,64,6/9/2021
DA48E4,partnership,100,61,6/9/2021
DA48E4,partnership,100,61,6/9/2021
DD1BA1,conference-participant,100,50,6/9/2021
E09556,earnings,100,50,6/9/2021
E56A0D,conference-participant,100,50,6/9/2021
E67C2C,executive-appointment,100,54,6/9/2021
EB43F4,clinical-trials,100,56,6/9/2021
EB43F4,conference-participant,100,50,6/9/2021
EC99D0,partnership,100,61,6/9/2021
ECD263,partnership,100,61,6/9/2021
EDD234,earnings,100,50,6/9/2021
F18844,note-sale,100,52,6/9/2021
F4F46F,partnership,100,61,6/9/2021
F6581D,legal-issues-defendant,100,22,6/9/2021
F6DCE4,dividend-up,100,74,6/9/2021
F6FF0D,public-offering,100,43,6/9/2021
FA35C6,executive-appointment,100,54,6/9/2021
FD2565,conference-participant,100,50,6/9/2021
00067A,partnership,100,61,6/10/2021
002A99,legal-issues-defendant,100,22,6/10/2021
002A99,legal-issues-defendant,100,22,6/10/2021
13528,asset-sale,100,62,6/10/2021
0157B1,partnership,100,61,6/10/2021
0157B1,partnership,100,61,6/10/2021
018C11,note-sale,100,52,6/10/2021
033B58,conference-participant,100,50,6/10/2021
03FB17,dividend,100,50,6/10/2021
95294,executive-appointment,100,54,6/10/2021
95294,partnership,100,61,6/10/2021
0A748B,legal-issues-defendant,100,22,6/10/2021
0C355F,executive-appointment,100,54,6/10/2021
0FDE97,note-sale,100,52,6/10/2021
106394,dividend,100,50,6/10/2021
149301,executive-appointment,100,54,6/10/2021
168A5D,partnership,100,61,6/10/2021
1A5D5D,executive-appointment,100,54,6/10/2021
1B637E,merger-regulatory-approval,100,81,6/10/2021
1DEBBE,award,100,58,6/10/2021
1DEBBE,legal-issues-defendant,100,22,6/10/2021
1E1125,conference-organizer,100,57,6/10/2021
1E1125,conference-organizer,100,57,6/10/2021
1F43A1,public-offering,100,43,6/10/2021
1F716B,conference-call,100,50,6/10/2021
1F9258,public-offering,100,43,6/10/2021
219B21,merger,100,66,6/10/2021
24FA23,conference-participant,100,50,6/10/2021
279916,executive-appointment,100,54,6/10/2021
292388,business-contract,100,69,6/10/2021
2ABF77,conference-participant,100,50,6/10/2021
2CC71C,sponsorship,100,57,6/10/2021
2CC71C,conference-participant,100,50,6/10/2021
2F960F,dividend,100,50,6/10/2021
31643A,dividend,100,50,6/10/2021
366A08,merger,100,66,6/10/2021
3.73E+87,acquisition-acquirer,100,49,6/10/2021
37B120,legal-issues-defendant,100,22,6/10/2021
37B618,dividend,100,50,6/10/2021
397A8F,executive-appointment,100,54,6/10/2021
39D9DA,earnings,100,50,6/10/2021
39FB23,acquisition-completed-acquirer,100,49,6/10/2021
3BC360,executive-appointment,100,54,6/10/2021
3F4497,buybacks,100,74,6/10/2021
3F6A9C,legal-issues-plaintiff,100,44,6/10/2021
41A93D,partnership,100,61,6/10/2021
41ED98,product-release,100,64,6/10/2021
444CC8,partnership,100,61,6/10/2021
468DD4,conference-participant,100,50,6/10/2021
499C75,public-offering,100,43,6/10/2021
4A6F00,partnership,100,61,6/10/2021
4C6C63,business-contract,100,69,6/10/2021
50070E,conference-organizer,100,57,6/10/2021
50702E,earnings,100,50,6/10/2021
546A27,conference-participant,100,50,6/10/2021
546A27,clinical-trials-positive,100,87,6/10/2021
54B889,facility-open,100,65,6/10/2021
56277A,dividend,100,50,6/10/2021
59872F,partnership,100,61,6/10/2021
5DD486,conference-call,100,50,6/10/2021
5E6959,dividend,100,50,6/10/2021
6391C2,clinical-trials-start,100,64,6/10/2021
64E615,conference-participant,100,50,6/10/2021
6F6559,earnings,100,50,6/10/2021
728737,dividend,100,50,6/10/2021
728737,dividend,100,50,6/10/2021
72DF04,partnership,100,61,6/10/2021
73BCBA,conference-participant,100,50,6/10/2021
766047,executive-appointment,100,54,6/10/2021
7712CB,executive-appointment,100,54,6/10/2021
7A10FF,conference-participant,100,50,6/10/2021
7ADE57,earnings,100,50,6/10/2021
7E62B5,dividend,100,50,6/10/2021
7F3FBC,public-offering,100,43,6/10/2021
8303CD,partnership,100,61,6/10/2021
86BAC7,board-meeting,100,51,6/10/2021
88936A,earnings,100,50,6/10/2021
8A8E41,product-release,100,64,6/10/2021
8E8E6E,partnership,100,61,6/10/2021
903AB4,public-offering,100,43,6/10/2021
9196A2,donation,100,54,6/10/2021
92B625,partnership,100,61,6/10/2021
92D757,merger,100,66,6/10/2021
9.39E+69,conference-participant,100,50,6/10/2021
942633,dividend,100,50,6/10/2021
94637C,clinical-trials-positive,100,87,6/10/2021
94637C,earnings,100,50,6/10/2021
949625,executive-appointment,100,54,6/10/2021
950CDB,executive-appointment,100,54,6/10/2021
9.86E+03,award,100,58,6/10/2021
997348,dividend,100,50,6/10/2021
9994DA,executive-appointment,100,54,6/10/2021
9DDE1B,dividend-up,100,81,6/10/2021
9EBAFA,unit-acquisition-acquirer,100,49,6/10/2021
A03EE1,legal-issues-defendant,100,22,6/10/2021
A072C4,partnership,100,61,6/10/2021
A15C71,executive-appointment,100,54,6/10/2021
A3AAA5,dividend,100,50,6/10/2021
A4BCDE,dividend,100,50,6/10/2021
A6FE1C,acquisition-acquirer,100,49,6/10/2021
A6FE1C,acquisition-acquirer,100,49,6/10/2021
A6FE1C,unit-acquisition-acquirer,100,49,6/10/2021
A7102F,stake-acquirer,100,48,6/10/2021
A7102F,stake-acquirer,100,48,6/10/2021
A72FD9,earnings,100,50,6/10/2021
A80FE0,conference-participant,100,50,6/10/2021
AFDF2E,conference-participant,100,50,6/10/2021
B381D8,executive-appointment,100,54,6/10/2021
B5734D,earnings,100,50,6/10/2021
B642E8,partnership,100,61,6/10/2021
B6CD92,buybacks,100,74,6/10/2021
B72D2E,acquisition-interest-acquirer,100,46,6/10/2021
B7BDA3,partnership,100,61,6/10/2021
B7BDA3,partnership,100,61,6/10/2021
B7BDA3,partnership,100,61,6/10/2021
BC5680,business-contract,100,69,6/10/2021
BDF85E,trading-halt,100,43,6/10/2021
BDF85E,trading-resumed,100,58,6/10/2021
BDF85E,earnings,100,50,6/10/2021
C06EB6,patient-enrollment-start,100,58,6/10/2021
C06EB6,patient-enrollment-start,100,58,6/10/2021
C29E71,partnership,100,61,6/10/2021
C3EE99,executive-appointment,100,54,6/10/2021
C4452A,dividend,100,50,6/10/2021
C501B6,private-placement,100,56,6/10/2021
CAC8D0,earnings,100,50,6/10/2021
CB89EA,executive-appointment,100,54,6/10/2021
CCBBAD,unit-acquisition-acquiree,100,76,6/10/2021
CCBBAD,buybacks,100,74,6/10/2021
CDC217,conference-participant,100,50,6/10/2021
CDE118,merger,100,66,6/10/2021
CF6A5A,product-release,100,64,6/10/2021
CFF15D,stock-gain,100,63,6/10/2021
CFF57D,earnings,100,50,6/10/2021
D25249,conference-participant,100,50,6/10/2021
D36B23,conference-participant,100,50,6/10/2021
D3FA2C,note-sale,100,52,6/10/2021
D7A953,partnership,100,61,6/10/2021
D93A25,executive-appointment,100,54,6/10/2021
DBB28E,partnership,100,61,6/10/2021
DF5F14,public-offering,100,43,6/10/2021
E0E4B7,partnership,100,61,6/10/2021
E0E4B7,partnership,100,61,6/10/2021
E0E4B7,partnership,100,61,6/10/2021
E259C7,index-listing,100,76,6/10/2021
E30B34,executive-appointment,100,54,6/10/2021
E4CE73,product-release,100,64,6/10/2021
E68C3D,conference-participant,100,50,6/10/2021
E7BF32,conference-participant,100,50,6/10/2021
E7BF32,conference-participant,100,50,6/10/2021
EA79C7,executive-appointment,100,54,6/10/2021
EB6965,dividend,100,50,6/10/2021
EF77A3,earnings,100,50,6/10/2021
EFD406,partnership,100,61,6/10/2021
EFD406,acquisition-acquiree,100,76,6/10/2021
F11638,partnership,100,61,6/10/2021
F11638,partnership,100,61,6/10/2021
F30508,partnership,100,61,6/10/2021
F5C78B,public-offering,100,43,6/10/2021
F6DCE4,earnings,100,50,6/10/2021
FDE409,earnings,100,50,6/10/2021
0157B1,facility-open,100,65,6/11/2021
0157B1,facility-open,100,65,6/11/2021
018C11,note-sale,100,52,6/11/2021
48781,public-offering,100,43,6/11/2021
0A748B,legal-issues-defendant,100,22,6/11/2021
0B7375,legal-issues-defendant,100,22,6/11/2021
190B91,executive-appointment,100,54,6/11/2021
1E1125,conference-organizer,100,57,6/11/2021
1E1125,legal-issues-defendant,100,22,6/11/2021
1E83DE,public-offering,100,43,6/11/2021
20403D,dividend,100,50,6/11/2021
228D42,partnership,100,61,6/11/2021
25102A,partnership,100,61,6/11/2021
2A1009,legal-issues-defendant,100,22,6/11/2021
2AA6A8,clinical-trials,100,56,6/11/2021
2E61CC,partnership,100,61,6/11/2021
2EBA55,dividend,100,50,6/11/2021
2EBC0B,dividend,100,50,6/11/2021
3461CF,credit-rating-affirmation-rater,20,50,6/11/2021
367434,clinical-trials-positive,100,87,6/11/2021
36C09B,clinical-trials,100,56,6/11/2021
3CCC90,executive-appointment,100,54,6/11/2021
40F7DE,award,100,58,6/11/2021
451D61,clinical-trials-positive,100,87,6/11/2021
451D61,clinical-trials-positive,100,87,6/11/2021
45ABCC,revenue-down,100,30,6/11/2021
4D8313,dividend,100,50,6/11/2021
520632,dividend,100,50,6/11/2021
57DDB9,conference-participant,100,50,6/11/2021
583223,acquisition-acquirer,100,49,6/11/2021
5B35C7,legal-issues-defendant,100,22,6/11/2021
68586A,facility-open,100,65,6/11/2021
6ABCB8,dividend,100,50,6/11/2021
6D3B7B,dividend,100,50,6/11/2021
6F5DD2,bought-deal,100,43,6/11/2021
71553E,asset-sale,100,62,6/11/2021
826FD6,dividend,100,50,6/11/2021
873DB9,partnership,100,61,6/11/2021
903AB4,public-offering,100,43,6/11/2021
918D6D,clinical-trials,100,56,6/11/2021
918D6D,clinical-trials,100,56,6/11/2021
9.36E+10,business-contract-terminated,100,31,6/11/2021
966ACE,conference-participant,100,50,6/11/2021
990AD0,dividend,100,50,6/11/2021
A1EAC8,product-release,100,64,6/11/2021
A3800A,facility-open,100,65,6/11/2021
A3800A,facility-open,100,65,6/11/2021
A94A7B,conference-participant,100,50,6/11/2021
B48FC9,executive-appointment,100,54,6/11/2021
B762D3,dividend,100,50,6/11/2021
C356AC,acquisition-acquirer,100,49,6/11/2021
C83B88,partnership,100,61,6/11/2021
C9C62A,stake-acquirer,100,48,6/11/2021
CA1620,buybacks,100,74,6/11/2021
CEC08B,award,100,58,6/11/2021
E802CE,dividend,100,50,6/11/2021
E8F0E2,clinical-trials,100,56,6/11/2021
E8F0E2,clinical-trials,100,56,6/11/2021
E959F3,conference-call,100,50,6/11/2021
EA4E68,dividend,100,50,6/11/2021
FA35C6,conference-participant,100,50,6/11/2021
366A08,legal-issues-defendant,100,22,6/12/2021
A6828A,clinical-trials,100,56,6/12/2021
A6828A,clinical-trials,100,56,6/12/2021
A6828A,clinical-trials,100,56,6/12/2021
A99576,legal-issues-defendant,100,22,6/12/2021
EEB5F9,legal-issues-defendant,100,22,6/12/2021
E5A3B6,clinical-trials,100,56,6/13/2021
00326D,dividend,100,50,6/14/2021
03FAA6,partnership,100,61,6/14/2021
040DBB,acquisition-acquirer,100,49,6/14/2021
04CCCD,note-sale,100,52,6/14/2021
04CCCD,note-sale,100,52,6/14/2021
0624BE,conference-participant,100,50,6/14/2021
091B6C,partnership,100,61,6/14/2021
091B6C,partnership,100,61,6/14/2021
96930,clinical-trials-start,100,64,6/14/2021
099C88,government-contract,100,69,6/14/2021
0C8D82,partnership,100,61,6/14/2021
0C8D82,partnership,100,61,6/14/2021
112694,executive-appointment,100,54,6/14/2021
168A5D,executive-appointment,100,54,6/14/2021
16C544,note-sale,100,52,6/14/2021
1921DD,product-release,100,64,6/14/2021
1B637E,acquisition-completed-acquirer,100,49,6/14/2021
1DEBBE,note-sale,100,52,6/14/2021
1E1125,conference-organizer,100,57,6/14/2021
1E1125,conference-organizer,100,57,6/14/2021
214051,executive-appointment,100,54,6/14/2021
228D42,partnership,100,61,6/14/2021
24C48B,product-release,100,64,6/14/2021
25DD05,note-sale,100,52,6/14/2021
2720AB,dividend,100,50,6/14/2021
2B8179,public-offering,100,43,6/14/2021
2C681C,clinical-trials-positive,100,87,6/14/2021
2C681C,clinical-trials-positive,100,87,6/14/2021
2F94A5,dividend,100,50,6/14/2021
2FDEE3,executive-appointment,100,54,6/14/2021
2FDEE3,asset-sale,100,62,6/14/2021
306623,conference-participant,100,50,6/14/2021
315416,regulatory-product-approval-granted,100,81,6/14/2021
315416,regulatory-product-approval-granted,100,81,6/14/2021
315416,public-offering,100,43,6/14/2021
315416,public-offering,100,43,6/14/2021
371B0A,conference-participant,100,50,6/14/2021
37B120,legal-issues-defendant,100,22,6/14/2021
38FB49,dividend,100,50,6/14/2021
39FB23,executive-appointment,100,54,6/14/2021
3B50FE,note-sale,100,52,6/14/2021
3B9886,facility-open,100,65,6/14/2021
3CCC90,conference-call,100,50,6/14/2021
3F6A9C,executive-appointment,100,54,6/14/2021
40F7DE,earnings,100,50,6/14/2021
420168,dividend,100,50,6/14/2021
42AABD,executive-appointment,100,54,6/14/2021
449447,index-listing,100,76,6/14/2021
499C75,public-offering,100,43,6/14/2021
4A6F00,partnership,100,61,6/14/2021
4A6F00,partnership,100,61,6/14/2021
4C37C5,product-release,100,64,6/14/2021
4D72C8,note-sale,100,52,6/14/2021
4D72C8,note-sale,100,52,6/14/2021
519FE0,acquisition-completed-acquirer,100,49,6/14/2021
51D876,conference-participant,100,50,6/14/2021
52FB2F,executive-appointment,100,54,6/14/2021
550D01,note-sale,100,52,6/14/2021
55D0F3,conference-participant,100,50,6/14/2021
56EA2B,public-offering,100,43,6/14/2021
583553,executive-appointment,100,54,6/14/2021
589803,partnership,100,61,6/14/2021
58EA22,conference-participant,100,50,6/14/2021
59DB8C,partnership,100,61,6/14/2021
5A64D5,executive-appointment,100,54,6/14/2021
5A9A82,asset-sale,100,62,6/14/2021
5E9934,earnings-up,100,68,6/14/2021
605F40,executive-appointment,100,54,6/14/2021
620381,executive-appointment,100,54,6/14/2021
6844D2,dividend-up,100,65,6/14/2021
6AACDD,executive-appointment,100,54,6/14/2021
6FCEF9,dividend,100,50,6/14/2021
70CA28,conference-participant,100,50,6/14/2021
70FCEF,earnings,100,50,6/14/2021
76BD96,public-offering,100,43,6/14/2021
76BD96,public-offering,100,43,6/14/2021
7A51FE,conference-call,100,50,6/14/2021
7A975D,earnings,100,50,6/14/2021
7B1E50,partnership,100,61,6/14/2021
7B492C,executive-appointment,100,54,6/14/2021
8377DB,investment-investor,100,55,6/14/2021
83A065,dividend,100,50,6/14/2021
85CDC9,business-contract,100,69,6/14/2021
8665BA,product-release,100,64,6/14/2021
8AC740,public-offering,100,43,6/14/2021
8D9993,executive-appointment,100,54,6/14/2021
8FE7A5,business-contract,100,69,6/14/2021
9196A2,conference-organizer,100,57,6/14/2021
925759,award,100,58,6/14/2021
938D89,executive-appointment,100,54,6/14/2021
940C3D,business-contract,100,69,6/14/2021
966DBE,partnership,100,61,6/14/2021
98CAED,note-sale,100,52,6/14/2021
990AD0,facility-open,100,65,6/14/2021
9C5BA5,revenues,100,50,6/14/2021
9CF9B1,executive-appointment,100,54,6/14/2021
9D30A8,government-contract,100,69,6/14/2021
A01200,public-offering,100,43,6/14/2021
A01664,partnership,100,61,6/14/2021
A398B9,executive-appointment,100,54,6/14/2021
A3F598,settlement,100,56,6/14/2021
AA1EAA,dividend,100,50,6/14/2021
AA7FE0,conference-call,100,50,6/14/2021
AD375D,dividend-up,100,81,6/14/2021
AFF7B4,note-sale,100,52,6/14/2021
B3CB74,conference-organizer,100,57,6/14/2021
B3CB74,conference-organizer,100,57,6/14/2021
B3CB74,conference-organizer,100,57,6/14/2021
B3CB74,conference-organizer,100,57,6/14/2021
B3CB74,conference-organizer,100,57,6/14/2021
C230FE,facility-open,100,65,6/14/2021
C4F9C6,conference-participant,100,50,6/14/2021
C72B8F,public-offering,100,43,6/14/2021
CAC8D0,executive-appointment,100,54,6/14/2021
CC0C78,executive-appointment,100,54,6/14/2021
CC176E,partnership,100,61,6/14/2021
CC3EC4,note-sale,100,52,6/14/2021
CD06A2,dividend,100,50,6/14/2021
CD4DA8,conference-organizer,100,57,6/14/2021
CDFCC9,conference-participant,100,50,6/14/2021
CE2791,dividend,100,50,6/14/2021
CE5C6E,executive-appointment,100,54,6/14/2021
CEDFD5,clinical-trials,100,56,6/14/2021
CEDFD5,clinical-trials,100,56,6/14/2021
CF3FF9,conference-participant,100,50,6/14/2021
D0909F,conference-participant,100,50,6/14/2021
D58A11,buybacks,100,74,6/14/2021
D598E7,acquisition-completed-acquirer,100,49,6/14/2021
D598E7,acquisition-completed-acquirer,100,49,6/14/2021
D88EF3,executive-appointment,100,54,6/14/2021
DD682D,note-sale,100,52,6/14/2021
DF5F14,dividend,100,50,6/14/2021
E0207A,business-contract,100,69,6/14/2021
E10D31,partnership,100,61,6/14/2021
E5A3B6,clinical-trials-positive,100,87,6/14/2021
E5A3B6,public-offering,100,43,6/14/2021
E6C8DC,executive-appointment,100,54,6/14/2021
E845D9,note-sale,100,52,6/14/2021
E87676,executive-appointment,100,54,6/14/2021
E8B21D,acquisition-completed-acquirer,100,49,6/14/2021
E8D221,trading-halt,100,43,6/14/2021
F1529C,product-release,100,64,6/14/2021
F2BC3D,acquisition-acquirer,100,49,6/14/2021
F2BC3D,acquisition-acquirer,100,49,6/14/2021
F4D241,executive-appointment,100,54,6/14/2021
F5349B,partnership,100,61,6/14/2021
FEBFE1,executive-appointment,100,54,6/14/2021
FEBFE1,earnings,100,50,6/14/2021
0157B1,partnership,100,61,6/15/2021
0157B1,partnership,100,61,6/15/2021
0157B1,partnership,100,61,6/15/2021
31025,partnership,100,61,6/15/2021
55018,partnership,100,61,6/15/2021
68396,dividend,100,50,6/15/2021
07EC43,partnership,100,61,6/15/2021
09DE1F,product-release,100,64,6/15/2021
0CE204,business-contract,100,69,6/15/2021
0DC050,partnership,100,61,6/15/2021
0E5619,conference-participant,100,50,6/15/2021
108A2B,dividend,100,50,6/15/2021
1272B3,partnership,100,61,6/15/2021
157CC1,business-contract,100,69,6/15/2021
165B86,conference-participant,100,50,6/15/2021
184866,patient-enrollment-complete,100,64,6/15/2021
184866,patient-enrollment-complete,100,64,6/15/2021
190BE6,dividend-up,100,81,6/15/2021
1A3E1B,conference-call,100,50,6/15/2021
1D1B07,partnership,100,61,6/15/2021
1D1B07,partnership,100,61,6/15/2021
1EBF8D,partnership,100,61,6/15/2021
1FA886,business-contract,100,69,6/15/2021
1FAF22,conference-call,100,50,6/15/2021
21153F,executive-appointment,100,54,6/15/2021
21153F,executive-appointment,100,54,6/15/2021
228D42,partnership,100,61,6/15/2021
238302,dividend,100,50,6/15/2021
25DD05,dividend,100,50,6/15/2021
25DD05,note-sale,100,52,6/15/2021
275300,note-sale,100,52,6/15/2021
275300,note-sale,100,52,6/15/2021
2A1009,legal-issues-defendant,100,22,6/15/2021
2CB4C9,partnership,100,61,6/15/2021
2CB4C9,partnership,100,61,6/15/2021
2F1299,partnership,100,61,6/15/2021
3.14E+47,dividend,100,50,6/15/2021
31803E,conference-call,100,50,6/15/2021
339F20,executive-appointment,100,54,6/15/2021
37B120,legal-issues-defendant,100,22,6/15/2021
39FB23,award,100,58,6/15/2021
3DD5E2,partnership,100,61,6/15/2021
444CC8,product-release,100,64,6/15/2021
449447,executive-appointment,100,54,6/15/2021
458D2C,revenue-volume,100,50,6/15/2021
4A6F00,partnership,100,61,6/15/2021
4D72C8,conference-call,100,50,6/15/2021
4D72C8,conference-call,100,50,6/15/2021
4E4E75,dividend,100,50,6/15/2021
50070E,partnership,100,61,6/15/2021
50D1EC,executive-appointment,100,54,6/15/2021
553949,executive-appointment,100,54,6/15/2021
56EA2B,public-offering,100,43,6/15/2021
56EFC7,earnings-up,100,68,6/15/2021
56EFC7,earnings-up,100,68,6/15/2021
56EFC7,earnings-up,100,68,6/15/2021
56EFC7,earnings-up,100,68,6/15/2021
5704AC,dividend,100,50,6/15/2021
58CA9A,earnings,100,50,6/15/2021
5A423F,executive-appointment,100,54,6/15/2021
5AAE17,conference-participant,100,50,6/15/2021
5B6C11,executive-appointment,100,54,6/15/2021
6166D1,dividend,100,50,6/15/2021
619882,conference-organizer,100,57,6/15/2021
619882,dividend,100,50,6/15/2021
61B81B,partnership,100,61,6/15/2021
62CDDE,conference-participant,100,50,6/15/2021
64E615,executive-appointment,100,54,6/15/2021
657097,dividend,100,50,6/15/2021
6844D2,government-contract,100,69,6/15/2021
6844D2,partnership,100,61,6/15/2021
69C99E,clinical-trials-filed,100,60,6/15/2021
6C6D73,clinical-trials,100,56,6/15/2021
6CF43C,dividend,100,50,6/15/2021
6D3B7B,executive-appointment,100,54,6/15/2021
6E705B,executive-appointment,100,54,6/15/2021
719B43,executive-appointment,100,54,6/15/2021
7A5097,partnership,100,61,6/15/2021
7DD8CC,dividend,100,50,6/15/2021
7E1542,executive-appointment,100,54,6/15/2021
7E3390,earnings,100,50,6/15/2021
82B57E,award,100,58,6/15/2021
830BDB,conference-participant,100,50,6/15/2021
8377DB,dividend,100,50,6/15/2021
83B1C8,conference-participant,100,50,6/15/2021
84AB66,dividend,100,50,6/15/2021
8A8E41,product-release,100,64,6/15/2021
8AC740,public-offering,100,43,6/15/2021
8BFAA4,executive-appointment,100,54,6/15/2021
8E82A6,earnings,100,50,6/15/2021
9196A2,conference-organizer,100,57,6/15/2021
9196A2,dividend,100,50,6/15/2021
945DE6,partnership,100,61,6/15/2021
97AAF6,public-offering,100,43,6/15/2021
990AD0,investment-investor,100,55,6/15/2021
9.97E+09,investment-investor,100,55,6/15/2021
9A602D,conference-call,100,50,6/15/2021
9B4066,unit-acquisition-acquirer,100,49,6/15/2021
9D3360,conference-call,100,50,6/15/2021
9E91C6,product-release,100,64,6/15/2021
A01200,product-release,100,64,6/15/2021
A01200,public-offering,100,43,6/15/2021
A1EAC8,executive-appointment,100,54,6/15/2021
A21649,dividend,100,50,6/15/2021
A398F8,conference-participant,100,50,6/15/2021
A790A5,earnings,100,50,6/15/2021
A79F7D,partnership,100,61,6/15/2021
A99576,legal-issues-defendant,100,22,6/15/2021
AAEE21,note-sale,100,52,6/15/2021
ABAA03,executive-appointment,100,54,6/15/2021
AD375D,conference-participant,100,50,6/15/2021
AFF7B4,executive-appointment,100,54,6/15/2021
AFF7B4,executive-appointment,100,54,6/15/2021
B04426,business-contract,100,69,6/15/2021
B0D41A,executive-appointment,100,54,6/15/2021
B381D8,settlement,100,56,6/15/2021
B3CB74,conference-organizer,100,57,6/15/2021
B3CB74,conference-organizer,100,57,6/15/2021
B3CB74,conference-organizer,100,57,6/15/2021
B3CB74,conference-organizer,100,57,6/15/2021
B3CB74,conference-organizer,100,57,6/15/2021
B3CB74,conference-organizer,100,57,6/15/2021
B4F5F4,legal-issues-defendant,100,22,6/15/2021
B614F8,conference-participant,100,50,6/15/2021
B642E8,dividend,100,50,6/15/2021
B8F71F,dividend-up,100,81,6/15/2021
BA0442,acquisition-completed-acquirer,100,49,6/15/2021
BB5142,product-release,100,64,6/15/2021
BB5142,product-release,100,64,6/15/2021
BB5142,product-release,100,64,6/15/2021
BC5680,acquisition-completed-acquiree,100,76,6/15/2021
BD682F,dividend,100,50,6/15/2021
C490F9,resource-discovery,100,88,6/15/2021
C490F9,resource-discovery,100,88,6/15/2021
C501B6,conference-participant,100,50,6/15/2021
C8FAC7,partnership,100,61,6/15/2021
C8FAC7,partnership,100,61,6/15/2021
C94CFC,legal-issues-defendant,100,22,6/15/2021
C99CC8,executive-appointment,100,54,6/15/2021
C9B932,donation,100,54,6/15/2021
CB89EA,executive-appointment,100,54,6/15/2021
CEDFD5,clinical-trials-positive,100,87,6/15/2021
CEDFD5,clinical-trials-positive,100,87,6/15/2021
CEDFD5,clinical-trials-positive,100,87,6/15/2021
D139BC,dividend,100,50,6/15/2021
D1AE3B,partnership,100,61,6/15/2021
D3FA2C,dividend,100,50,6/15/2021
D518D8,product-release,100,64,6/15/2021
D6489C,earnings,100,50,6/15/2021
D75910,dividend,100,50,6/15/2021
D7918D,executive-appointment,100,54,6/15/2021
D7AC6E,dividend,100,50,6/15/2021
D9164D,dividend,100,50,6/15/2021
DA199F,partnership,100,61,6/15/2021
DB88A1,partnership,100,61,6/15/2021
DC5299,dividend,100,50,6/15/2021
DD1BA1,product-release,100,64,6/15/2021
DD682D,executive-appointment,100,54,6/15/2021
DDEA6A,conference-participant,100,50,6/15/2021
DF11D9,legal-issues-defendant,100,22,6/15/2021
E0207A,conference-participant,100,50,6/15/2021
E0339F,legal-issues-defendant,100,22,6/15/2021
E1BD05,buybacks,100,74,6/15/2021
E22FDE,unit-acquisition-acquirer,100,49,6/15/2021
E2CFD2,unit-acquisition-acquiree,100,76,6/15/2021
E35610,partnership,100,61,6/15/2021
E8B21D,dividend,100,50,6/15/2021
E8B315,legal-issues-defendant,100,22,6/15/2021
E9C7C0,partnership,100,61,6/15/2021
ECD263,earnings,100,50,6/15/2021
ED7F13,dividend,100,50,6/15/2021
EF7163,dividend,100,50,6/15/2021
F1EB39,headquarters-change,100,50,6/15/2021
F1EB39,earnings,100,50,6/15/2021
F294DD,dividend,100,50,6/15/2021
F294DD,legal-issues-defendant,100,22,6/15/2021
F3D2EB,dividend,100,50,6/15/2021
F57F6F,note-sale,100,52,6/15/2021
F748C7,partnership,100,61,6/15/2021
F7D8AE,acquisition-acquirer,100,49,6/15/2021
F80389,dividend,100,50,6/15/2021
F82D37,business-contract,100,69,6/15/2021
F82D37,business-contract,100,69,6/15/2021
FC1736,partnership,100,61,6/15/2021
002A99,partnership,100,61,6/16/2021
13528,legal-issues-defendant,100,22,6/16/2021
01478A,executive-appointment,100,54,6/16/2021
0157B1,facility-open,100,65,6/16/2021
55018,conference-call,100,50,6/16/2021
56045,conference-participant,100,50,6/16/2021
96930,public-offering,100,43,6/16/2021
0AAD90,clinical-trials,100,56,6/16/2021
0B7375,conference-participant,100,50,6/16/2021
1096C6,partnership,100,61,6/16/2021
12DE76,conference-organizer,100,57,6/16/2021
12E454,partnership,100,61,6/16/2021
188394,conference-call,100,50,6/16/2021
190B91,business-contract,100,69,6/16/2021
1FA886,executive-appointment,100,54,6/16/2021
1FA886,executive-appointment,100,54,6/16/2021
219B21,legal-issues-defendant,100,22,6/16/2021
228D42,partnership,100,61,6/16/2021
267718,conference-call,100,50,6/16/2021
279916,award,100,58,6/16/2021
2E1322,business-contract,100,69,6/16/2021
31AA84,dividend,100,50,6/16/2021
326EDD,market-entry,100,57,6/16/2021
326EDD,market-entry,100,57,6/16/2021
3.30E+30,market-entry,100,57,6/16/2021
339F20,dividend,100,50,6/16/2021
33AD83,executive-appointment,100,54,6/16/2021
3B50FE,note-sale,100,52,6/16/2021
3CCC90,product-release,100,64,6/16/2021
401072,regulatory-product-approval-granted,100,81,6/16/2021
401072,regulatory-product-approval-granted,100,81,6/16/2021
42EFC7,executive-appointment,100,54,6/16/2021
43A060,partnership,100,61,6/16/2021
450ECB,executive-appointment,100,54,6/16/2021
450ECB,executive-appointment,100,54,6/16/2021
499C75,conference-participant,100,50,6/16/2021
4A6F00,partnership,100,61,6/16/2021
4E4E75,conference-call,100,50,6/16/2021
4EEB00,conference-participant,100,50,6/16/2021
50070E,executive-appointment,100,54,6/16/2021
50070E,conference-organizer,100,57,6/16/2021
523039,clinical-trials,100,56,6/16/2021
5.43E+08,partnership,100,61,6/16/2021
5.43E+08,partnership,100,61,6/16/2021
548AC0,business-contract,100,69,6/16/2021
548AC0,business-contract,100,69,6/16/2021
556F08,acquisition-acquiree,100,76,6/16/2021
556F08,acquisition-acquiree,100,76,6/16/2021
556F08,acquisition-acquiree,100,76,6/16/2021
556F08,acquisition-regulatory-scrutiny-acquiree,100,38,6/16/2021
556F08,acquisition-regulatory-scrutiny-acquiree,100,38,6/16/2021
556F08,legal-issues-defendant,100,22,6/16/2021
58B46F,conference-call,100,50,6/16/2021
5A53BF,product-release,100,64,6/16/2021
5B7739,partnership,100,61,6/16/2021
5BC2F4,earnings,100,50,6/16/2021
5DD48B,regulatory-product-approval-granted,100,81,6/16/2021
5F9CE3,product-release,100,64,6/16/2021
6166D1,dividend,100,50,6/16/2021
6391C2,conference-participant,100,50,6/16/2021
66ECFD,earnings,100,50,6/16/2021
68B03F,conference-participant,100,50,6/16/2021
6C987C,donation,100,54,6/16/2021
7410C3,facility-open,100,65,6/16/2021
741937,credit-extension-recipient,100,69,6/16/2021
75D689,clinical-trials-start,100,64,6/16/2021
75F982,partnership,100,61,6/16/2021
775439,dividend,100,50,6/16/2021
7771D7,earnings,100,50,6/16/2021
7F2922,conference-participant,100,50,6/16/2021
7F3669,buybacks,100,74,6/16/2021
81222C,business-contract,100,69,6/16/2021
855DF7,earnings,100,50,6/16/2021
85AD00,conference-call,100,50,6/16/2021
86A1B9,partnership,100,61,6/16/2021
8A8E41,earnings,100,50,6/16/2021
8C6C1B,facility-open,100,65,6/16/2021
8FF2EF,earnings,100,50,6/16/2021
901327,legal-issues-defendant,100,22,6/16/2021
903AB4,dividend,100,50,6/16/2021
911ACB,dividend,100,50,6/16/2021
91C82E,earnings-per-share-positive,100,69,6/16/2021
91C82E,earnings-per-share-positive,100,69,6/16/2021
91C82E,earnings-per-share-positive,100,69,6/16/2021
91C82E,earnings-per-share-positive,100,69,6/16/2021
93633B,note-sale,100,52,6/16/2021
93633B,dividend,100,50,6/16/2021
94208D,partnership,100,61,6/16/2021
96BFF4,legal-issues-defendant,100,22,6/16/2021
986AF6,earnings-guidance-up,100,83,6/16/2021
9A02C4,award,100,58,6/16/2021
9D5D35,conference-participant,100,50,6/16/2021
9F71E5,partnership,100,61,6/16/2021
A01200,award,100,58,6/16/2021
A01983,dividend,100,50,6/16/2021
A28C54,business-contract,100,69,6/16/2021
A6FE1C,unit-acquisition-acquirer,100,49,6/16/2021
A80FE0,partnership,100,61,6/16/2021
A9ED24,dividend,100,50,6/16/2021
AADE0B,acquisition-acquirer,100,49,6/16/2021
AADE0B,acquisition-acquirer,100,49,6/16/2021
ABAA03,business-contract,100,69,6/16/2021
AE4125,facility-upgrade,100,65,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B3CB74,conference-organizer,100,57,6/16/2021
B9CD50,award,100,58,6/16/2021
BB127B,partnership,100,61,6/16/2021
BE645B,conference-participant,100,50,6/16/2021
BE7BA4,executive-appointment,100,54,6/16/2021
BFCACF,conference-participant,100,50,6/16/2021
C05839,dividend,100,50,6/16/2021
C45C1F,conference-participant,100,50,6/16/2021
C4A912,executive-appointment,100,54,6/16/2021
C584BE,executive-appointment,100,54,6/16/2021
C83B88,partnership,100,61,6/16/2021
CC0C78,clinical-trials-start,100,64,6/16/2021
CC8F6E,executive-appointment,100,54,6/16/2021
CEDFD5,clinical-trials,100,56,6/16/2021
CEDFD5,clinical-trials,100,56,6/16/2021
D0DFE5,business-contract,100,69,6/16/2021
D11C1C,dividend,100,50,6/16/2021
D1AE3B,partnership,100,61,6/16/2021
D21D8A,dividend,100,50,6/16/2021
D47D56,conference-participant,100,50,6/16/2021
D4AC65,unit-acquisition-acquiree,100,76,6/16/2021
D60BB2,partnership,100,61,6/16/2021
D75910,product-release,100,64,6/16/2021
DA0A9E,conference-call,100,50,6/16/2021
DB23C8,conference-participant,100,50,6/16/2021
DDCB34,conference-participant,100,50,6/16/2021
E22FDE,conference-participant,100,50,6/16/2021
E592F0,acquisition-interest-acquirer,100,46,6/16/2021
E592F0,acquisition-interest-acquirer,100,46,6/16/2021
E5A3B6,public-offering,100,43,6/16/2021
EAA0A7,executive-appointment,100,54,6/16/2021
EB1E1A,clinical-trials-start,100,64,6/16/2021
EB7FBF,dividend,100,50,6/16/2021
ECE814,executive-appointment,100,54,6/16/2021
ECF4F8,acquisition-completed-acquiree,100,76,6/16/2021
F88A04,conference-participant,100,50,6/16/2021
FDF799,conference-participant,100,50,6/16/2021
002A99,partnership,100,61,6/17/2021
01D03F,partnership,100,61,6/17/2021
01D03F,partnership,100,61,6/17/2021
04CCCD,note-sale,100,52,6/17/2021
0B7375,legal-issues-defendant,100,22,6/17/2021
0B7375,legal-issues-defendant,100,22,6/17/2021
0B7375,legal-issues-defendant,100,22,6/17/2021
125212,conference-participant,100,50,6/17/2021
159739,note-sale,100,52,6/17/2021
159739,note-sale,100,52,6/17/2021
1A6A94,earnings,100,50,6/17/2021
1B6F77,fast-track-designation,100,81,6/17/2021
1EBF8D,government-contract,100,69,6/17/2021
1EBF8D,government-contract,100,69,6/17/2021
1F43A1,dividend-up,100,81,6/17/2021
2082EA,patient-enrollment-complete,100,64,6/17/2021
228D42,partnership,100,61,6/17/2021
228D42,partnership,100,61,6/17/2021
24FA23,clinical-trials,100,56,6/17/2021
26CC63,earnings,100,50,6/17/2021
26CC63,earnings,100,50,6/17/2021
26CC63,earnings,100,50,6/17/2021
26F99F,business-contract,100,69,6/17/2021
26F99F,business-contract,100,69,6/17/2021
282C18,dividend,100,50,6/17/2021
2920D5,conference-participant,100,50,6/17/2021
2A1009,legal-issues-defendant,100,22,6/17/2021
2C3348,unit-acquisition-acquiree,100,76,6/17/2021
2E61CC,facility-open,100,65,6/17/2021
2F1299,award,100,58,6/17/2021
317EC6,earnings,100,50,6/17/2021
33FD66,earnings,100,50,6/17/2021
3461CF,executive-appointment,100,54,6/17/2021
37727A,dividend,100,50,6/17/2021
37B120,business-contract,100,69,6/17/2021
3AAEAE,orphan-drug-designation,100,76,6/17/2021
3CCC90,partnership,100,61,6/17/2021
408380,facility-upgrade,100,65,6/17/2021
44DDBD,acquisition-acquiree,100,76,6/17/2021
45444E,business-contract,100,69,6/17/2021
47752F,dividend,100,50,6/17/2021
4.91E+58,business-contract,100,69,6/17/2021
49A344,business-contract,100,69,6/17/2021
4A6F00,partnership,100,61,6/17/2021
4B3676,conference-participant,100,50,6/17/2021
4E2D94,earnings-guidance,100,50,6/17/2021
545272,dividend,100,50,6/17/2021
56EA2B,public-offering,100,43,6/17/2021
596116,partnership,100,61,6/17/2021
5B51D6,partnership,100,61,6/17/2021
5EAA43,business-contract,100,69,6/17/2021
60EA12,conference-participant,100,50,6/17/2021
619882,conference-organizer,100,57,6/17/2021
619882,conference-organizer,100,57,6/17/2021
61B81B,conference-call,100,50,6/17/2021
622DBE,acquisition-completed-acquirer,100,49,6/17/2021
6251A3,executive-appointment,100,54,6/17/2021
6251A3,executive-appointment,100,54,6/17/2021
63E8D5,dividend,100,50,6/17/2021
64E346,product-release,100,64,6/17/2021
665D7D,dividend,100,50,6/17/2021
69CE71,partnership,100,61,6/17/2021
713810,stake-acquirer,100,48,6/17/2021
722D55,dividend,100,50,6/17/2021
73F7F9,earnings,100,50,6/17/2021
7B0BA6,product-release,100,64,6/17/2021
7B1E50,executive-appointment,100,54,6/17/2021
7BFF81,buybacks,100,74,6/17/2021
80D744,unit-acquisition-acquiree,100,76,6/17/2021
8303CD,award,100,58,6/17/2021
877C0C,regulatory-product-approval-granted,100,81,6/17/2021
8A8E41,government-contract,100,69,6/17/2021
8AB85C,conference-participant,100,50,6/17/2021
8B1F37,dividend-up,100,81,6/17/2021
8BAA15,earnings-guidance,100,50,6/17/2021
8C6C1B,facility-open,100,65,6/17/2021
8D0EEA,executive-appointment,100,54,6/17/2021
8D4486,acquisition-completed-acquirer,100,49,6/17/2021
8D4486,acquisition-completed-acquirer,100,49,6/17/2021
8D4486,acquisition-completed-acquirer,100,49,6/17/2021
92D9C9,dividend,100,50,6/17/2021
94637C,dividend,100,50,6/17/2021
94637C,partnership,100,61,6/17/2021
94983E,earnings-guidance,100,50,6/17/2021
94983E,earnings-guidance,100,50,6/17/2021
95DC1F,partnership,100,61,6/17/2021
95DC1F,earnings-positive,100,69,6/17/2021
95DC1F,earnings-positive,100,69,6/17/2021
95DC1F,earnings-positive,100,69,6/17/2021
95DC1F,earnings-positive,100,69,6/17/2021
95DC1F,earnings-positive,100,69,6/17/2021
96F126,business-contract,100,69,6/17/2021
990AD0,credit-extension-recipient,100,69,6/17/2021
9B71A7,earnings,100,50,6/17/2021
9F71E5,product-release,100,64,6/17/2021
A05C43,conference-participant,100,50,6/17/2021
A072C4,earnings-guidance-up,100,83,6/17/2021
A49498,merger,100,66,6/17/2021
A666C8,executive-appointment,100,54,6/17/2021
A746F6,headquarters-change,100,50,6/17/2021
A94637,product-price-raise,100,57,6/17/2021
AC7C4F,business-contract,100,69,6/17/2021
AD23DE,partnership,100,61,6/17/2021
AE4EEB,dividend,100,50,6/17/2021
AFF7B4,executive-resignation,100,44,6/17/2021
B076A1,acquisition-acquirer,100,49,6/17/2021
B1FC3B,business-contract,100,69,6/17/2021
B3CB74,conference-organizer,100,57,6/17/2021
B3CB74,conference-organizer,100,57,6/17/2021
B3CB74,conference-organizer,100,57,6/17/2021
C2DD02,dividend,100,50,6/17/2021
C8A248,dividend,100,50,6/17/2021
C951A2,acquisition-completed-acquirer,100,49,6/17/2021
C9881C,earnings,100,50,6/17/2021
C9881C,earnings,100,50,6/17/2021
C9881C,earnings,100,50,6/17/2021
CE1002,executive-appointment,100,54,6/17/2021
D064D5,executive-resignation,100,44,6/17/2021
D1C26F,earnings,100,50,6/17/2021
D75910,award,100,58,6/17/2021
D96202,conference-call,100,50,6/17/2021
DB88A1,executive-appointment,100,54,6/17/2021
DBCA3F,partnership,100,61,6/17/2021
DD1BA1,revenue-volume-up,100,76,6/17/2021
E124EB,acquisition-acquirer,100,49,6/17/2021
E20392,conference-participant,100,50,6/17/2021
E4CE73,partnership,100,61,6/17/2021
E8846E,executive-appointment,100,54,6/17/2021
E8B315,dividend,100,50,6/17/2021
EB7FBF,earnings-up,100,68,6/17/2021
ECDEB2,dividend,100,50,6/17/2021
F4FBD8,partnership,100,61,6/17/2021
F6E248,partnership,100,61,6/17/2021
F748C7,dividend,100,50,6/17/2021
F7ADEB,patent-awarded,100,72,6/17/2021
F7D8AE,dividend,100,50,6/17/2021
FC1B7B,partnership,100,61,6/17/2021
FDE409,dividend-up,100,81,6/17/2021
048B70,conference-call,100,50,6/18/2021
06EF42,earnings,100,50,6/18/2021
13A782,acquisition-acquiree,100,76,6/18/2021
13A782,acquisition-acquiree,100,76,6/18/2021
13A782,acquisition-regulatory-scrutiny-acquiree,100,38,6/18/2021
1921DD,dividend,100,50,6/18/2021
25102A,conference-call,100,50,6/18/2021
2B8179,public-offering,100,43,6/18/2021
2E0496,acquisition-acquirer,100,49,6/18/2021
2E0496,acquisition-acquirer,100,49,6/18/2021
31AA84,award,100,58,6/18/2021
366A08,conference-call,100,50,6/18/2021
3DDE54,earnings,100,50,6/18/2021
3E149C,business-contract,100,69,6/18/2021
3F96D5,acquisition-completed-acquirer,100,49,6/18/2021
4A6F00,partnership,100,61,6/18/2021
4A6F00,partnership,100,61,6/18/2021
4A6F00,legal-issues-plaintiff,100,44,6/18/2021
53F491,dividend,100,50,6/18/2021
5480A7,executive-resignation,100,44,6/18/2021
6C4D2F,note-sale,100,52,6/18/2021
6F30F9,dividend,100,50,6/18/2021
7255D2,earnings,100,50,6/18/2021
75D689,conference-call,100,50,6/18/2021
7ACBA4,dividend,100,50,6/18/2021
7E2DE6,earnings,100,50,6/18/2021
84A6B9,dividend,100,50,6/18/2021
85CDC9,executive-health,100,41,6/18/2021
8876D6,business-contract,100,69,6/18/2021
8B4A45,facility-open,100,65,6/18/2021
8C6C1B,facility-open,100,65,6/18/2021
8E8E6E,product-release,100,64,6/18/2021
91C82E,dividend,100,50,6/18/2021
94637C,regulatory-product-approval-granted,100,81,6/18/2021
972356,acquisition-regulatory-approval-acquiree,100,81,6/18/2021
972356,acquisition-regulatory-approval-acquiree,100,81,6/18/2021
9E3224,dividend,100,50,6/18/2021
A1EAC8,executive-appointment,100,54,6/18/2021
A247F5,product-release,100,64,6/18/2021
A5DD24,conference-participant,100,50,6/18/2021
A746F6,analyst-ratings-change-positive,100,78,6/18/2021
A99576,legal-issues-defendant,100,22,6/18/2021
AAEE21,conference-participant,100,50,6/18/2021
AE7D16,public-offering,100,43,6/18/2021
AEEB76,executive-appointment,100,54,6/18/2021
B3CB74,conference-organizer,100,57,6/18/2021
B4F5F4,legal-issues-defendant,100,22,6/18/2021
B614F8,regulatory-product-approval-granted,100,81,6/18/2021
D2E553,dividend,100,50,6/18/2021
DF11D9,legal-issues-defendant,100,22,6/18/2021
E0339F,legal-issues-defendant,100,22,6/18/2021
E5A3B6,public-offering,100,43,6/18/2021
E8B315,legal-issues-defendant,100,22,6/18/2021
EB6965,partnership,100,61,6/18/2021
EEB5F9,legal-issues-defendant,100,22,6/18/2021
F294DD,legal-issues-defendant,100,22,6/18/2021
F4CDA3,dividend,100,50,6/18/2021
F5D059,executive-appointment,100,54,6/18/2021
F5D059,executive-appointment,100,54,6/18/2021
F82D37,conference-call,100,50,6/18/2021
84625,stake-acquirer,100,48,6/19/2021
0B7375,legal-issues-defendant,100,22,6/20/2021
0B7375,legal-issues-defendant,100,22,6/20/2021
00326E,award,100,58,6/21/2021
96930,clinical-trials,100,56,6/21/2021
96930,public-offering,100,43,6/21/2021
0CC01F,dividend,100,50,6/21/2021
0F2BC9,business-contract,100,69,6/21/2021
190B91,joint-venture,100,62,6/21/2021
1921DD,dividend,100,50,6/21/2021
1FA886,partnership,100,61,6/21/2021
1FA886,partnership,100,61,6/21/2021
1FA886,business-contract,100,69,6/21/2021
2082EA,executive-appointment,100,54,6/21/2021
228D42,product-release,100,64,6/21/2021
228D42,executive-appointment,100,54,6/21/2021
253604,clinical-trials,100,56,6/21/2021
253604,executive-appointment,100,54,6/21/2021
2667B6,dividend,100,50,6/21/2021
272704,earnings,100,50,6/21/2021
2EC172,business-contract,100,69,6/21/2021
2F7A7E,conference-call,100,50,6/21/2021
315416,acquisition-acquirer,100,49,6/21/2021
315416,acquisition-acquirer,100,49,6/21/2021
33A0F1,ipo,100,71,6/21/2021
34B97A,public-offering,100,43,6/21/2021
37727A,public-offering,100,43,6/21/2021
37B618,asset-sale,100,62,6/21/2021
3C7F5F,merger-rumor,100,73,6/21/2021
3CCC90,executive-appointment,100,54,6/21/2021
3FACA7,earnings,100,50,6/21/2021
451D61,regulatory-product-application,100,69,6/21/2021
49A344,business-contract,100,69,6/21/2021
4AC91D,partnership,100,61,6/21/2021
4AC91D,partnership,100,61,6/21/2021
4C31F3,conference-participant,100,50,6/21/2021
4C37C5,facility-open,100,65,6/21/2021
4C37C5,conference-call,100,50,6/21/2021
4EE167,partnership,100,61,6/21/2021
519FE0,business-contract,100,69,6/21/2021
524CE4,conference-call,100,50,6/21/2021
532D47,executive-appointment,100,54,6/21/2021
53E575,executive-appointment,100,54,6/21/2021
545272,index-listing,100,76,6/21/2021
55C9B5,dividend,100,50,6/21/2021
56AFF4,partnership,100,61,6/21/2021
5B97B2,dividend,100,50,6/21/2021
65AB30,executive-appointment,100,54,6/21/2021
6810DE,conference-participant,100,50,6/21/2021
69CE71,product-release,100,64,6/21/2021
6AACDD,legal-issues-defendant,100,22,6/21/2021
6AACDD,legal-issues-defendant,100,22,6/21/2021
6AACDD,legal-issues-defendant,100,22,6/21/2021
6B494E,public-offering,100,43,6/21/2021
6E7060,dividend,100,50,6/21/2021
6FCEF9,stock-splits,100,49,6/21/2021
70CA28,business-contract,100,69,6/21/2021
70CA28,business-contract,100,69,6/21/2021
724F84,conference-organizer,100,57,6/21/2021
731675,executive-resignation,100,44,6/21/2021
75F982,product-release,100,64,6/21/2021
75F982,product-release,100,64,6/21/2021
75F982,product-release,100,64,6/21/2021
75F982,product-release,100,64,6/21/2021
77B8E9,clinical-trials-positive,100,87,6/21/2021
7ACFD4,business-contract,100,69,6/21/2021
7CBC40,award,100,58,6/21/2021
7F7464,clinical-trials-start,100,64,6/21/2021
7FDE1C,product-release,100,64,6/21/2021
8665BA,executive-appointment,100,54,6/21/2021
8665BA,executive-appointment,100,54,6/21/2021
89F693,partnership,100,61,6/21/2021
8A8E41,acquisition-acquirer,100,49,6/21/2021
8C6C1B,facility-open,100,65,6/21/2021
8C84DF,executive-appointment,100,54,6/21/2021
8D4486,facility-open,100,65,6/21/2021
8D4486,facility-open,100,65,6/21/2021
8F3BCC,earnings,100,50,6/21/2021
900356,dividend-up,100,58,6/21/2021
90D6A5,conference-participant,100,50,6/21/2021
90D6A5,conference-participant,100,50,6/21/2021
90DD65,clinical-trials,100,56,6/21/2021
92B047,conference-call,100,50,6/21/2021
938D89,executive-appointment,100,54,6/21/2021
9D6A24,conference-call,100,50,6/21/2021
9F71E5,partnership,100,61,6/21/2021
9F71E5,partnership,100,61,6/21/2021
A01200,partnership,100,61,6/21/2021
A01200,acquisition-acquirer,100,49,6/21/2021
A247F5,executive-appointment,100,54,6/21/2021
A26C26,joint-venture,100,62,6/21/2021
A26EF7,dividend,100,50,6/21/2021
A5A4F5,partnership,100,61,6/21/2021
A70BF5,earnings,100,50,6/21/2021
AD375D,conference-participant,100,50,6/21/2021
AEFC90,partnership,100,61,6/21/2021
AEFC90,partnership,100,61,6/21/2021
AF210D,acquisition-acquirer,100,49,6/21/2021
AF210D,partnership,100,61,6/21/2021
B1FC3B,conference-participant,100,50,6/21/2021
BB02FB,executive-appointment,100,54,6/21/2021
BC5680,partnership,100,61,6/21/2021
BE14CF,executive-appointment,100,54,6/21/2021
BFAEB4,product-release,100,64,6/21/2021
C22BE8,acquisition-acquiree,100,76,6/21/2021
C22BE8,acquisition-acquiree,100,76,6/21/2021
C22BE8,acquisition-acquiree,100,76,6/21/2021
C22BE8,acquisition-acquiree,100,76,6/21/2021
C22BE8,acquisition-acquiree,100,76,6/21/2021
C22BE8,acquisition-acquiree,100,76,6/21/2021
C22BE8,acquisition-regulatory-scrutiny-acquiree,100,38,6/21/2021
C356AC,executive-appointment,100,54,6/21/2021
C3BAE7,executive-appointment,100,54,6/21/2021
C3CF29,acquisition-acquiree,100,76,6/21/2021
C3CF29,acquisition-regulatory-scrutiny-acquiree,100,38,6/21/2021
C83B88,conference-call,100,50,6/21/2021
C9E4EC,public-offering,100,43,6/21/2021
CB6A9C,partnership,100,61,6/21/2021
CE1002,congressional-testimony-summoned,100,50,6/21/2021
CE4FD9,unit-acquisition-acquirer,100,49,6/21/2021
D1AE3B,executive-appointment,100,54,6/21/2021
D1C26F,executive-appointment,100,54,6/21/2021
D42DBA,executive-appointment,100,54,6/21/2021
D75910,partnership,100,61,6/21/2021
DBB28E,acquisition-acquirer,100,49,6/21/2021
E09E2B,partnership,100,61,6/21/2021
E0F4E5,executive-appointment,100,54,6/21/2021
E10D31,partnership,100,61,6/21/2021
E4CE73,partnership,100,61,6/21/2021
E68C3D,partnership,100,61,6/21/2021
F2BC3D,executive-appointment,100,54,6/21/2021
FACF19,partnership,100,61,6/21/2021
FB7724,executive-appointment,100,54,6/21/2021
FEBFE1,merger,100,66,6/21/2021
FF6644,product-release,100,64,6/21/2021
0157B1,revenue-up,100,69,6/22/2021
0A7650,acquisition-acquiree,100,76,6/22/2021
0A7650,acquisition-acquiree,100,76,6/22/2021
0A7650,acquisition-regulatory-scrutiny-acquiree,100,38,6/22/2021
0B7375,legal-issues-defendant,100,22,6/22/2021
0CE7F6,business-contract,100,69,6/22/2021
0CE7F6,business-contract,100,69,6/22/2021
0E499E,business-contract,100,69,6/22/2021
16C7F0,conference-call,100,50,6/22/2021
1AC649,clinical-trials-start,100,64,6/22/2021
1D1B07,product-release,100,64,6/22/2021
1F19C8,executive-appointment,100,54,6/22/2021
228D42,partnership,100,61,6/22/2021
228D42,partnership,100,61,6/22/2021
228D42,partnership,100,61,6/22/2021
228D42,patent-infringement-defendant,100,26,6/22/2021
25102A,asset-sale,100,62,6/22/2021
251988,earnings,100,50,6/22/2021
2571FA,conference-call,100,50,6/22/2021
2ABF77,clinical-trials-positive,100,87,6/22/2021
2C3348,executive-appointment,100,54,6/22/2021
2F9304,product-release,100,64,6/22/2021
2F9304,product-release,100,64,6/22/2021
2F9304,stake-acquiree,100,62,6/22/2021
2FEA66,partnership,100,61,6/22/2021
3.20E+263,business-contract,100,69,6/22/2021
35B907,earnings,100,50,6/22/2021
35B907,earnings,100,50,6/22/2021
36E479,public-offering,100,43,6/22/2021
3.73E+87,partnership,100,61,6/22/2021
39FB23,product-release,100,64,6/22/2021
3C8A04,conference-call,100,50,6/22/2021
43A74A,earnings,100,50,6/22/2021
448215,note-sale,100,52,6/22/2021
44DDBD,legal-issues-defendant,100,22,6/22/2021
4A6F00,partnership,100,61,6/22/2021
4A6F00,patent-infringement-defendant,100,26,6/22/2021
4AC91D,executive-appointment,100,54,6/22/2021
4E913D,product-release,100,64,6/22/2021
4EE14A,debt-extension-recipient,100,73,6/22/2021
4EE14A,debt-extension-recipient,100,73,6/22/2021
507AE7,product-release,100,64,6/22/2021
523039,conference-participant,100,50,6/22/2021
53F491,earnings,100,50,6/22/2021
556F08,legal-issues-defendant,100,22,6/22/2021
55C9B5,partnership,100,61,6/22/2021
55C9B5,earnings,100,50,6/22/2021
59872F,executive-appointment,100,54,6/22/2021
5A9A82,partnership,100,61,6/22/2021
5A9F54,acquisition-acquirer,100,49,6/22/2021
5C7601,executive-appointment,100,54,6/22/2021
5D1329,product-release,100,64,6/22/2021
5F9CE3,partnership,100,61,6/22/2021
609208,executive-appointment,100,54,6/22/2021
60AC34,executive-appointment,100,54,6/22/2021
6166D1,conference-call,100,50,6/22/2021
619882,conference-organizer,100,57,6/22/2021
633043,dividend,100,50,6/22/2021
65D0AA,clinical-trials,100,56,6/22/2021
65D0AA,business-contract,100,69,6/22/2021
69CE71,partnership,100,61,6/22/2021
69CE71,campaign-ad-release,100,59,6/22/2021
6AACDD,legal-issues-defendant,100,22,6/22/2021
70FCEF,earnings,100,50,6/22/2021
723548,dividend,100,50,6/22/2021
7255D2,earnings,100,50,6/22/2021
73C521,executive-appointment,100,54,6/22/2021
75D689,conference-participant,100,50,6/22/2021
75F982,partnership,100,61,6/22/2021
7A0EC4,partnership,100,61,6/22/2021
7A5097,dividend,100,50,6/22/2021
7E0EB0,executive-appointment,100,54,6/22/2021
8377DB,acquisition-acquirer,100,49,6/22/2021
896771,executive-appointment,100,54,6/22/2021
8C6C1B,facility-open,100,65,6/22/2021
8DCF18,business-contract,100,69,6/22/2021
8DCF18,partnership,100,61,6/22/2021
8DCF18,partnership,100,61,6/22/2021
8E10BF,public-offering,100,43,6/22/2021
8E4250,earnings,100,50,6/22/2021
92D757,partnership,100,61,6/22/2021
92D757,partnership,100,61,6/22/2021
931AE7,executive-appointment,100,54,6/22/2021
934CC3,acquisition-acquirer,100,49,6/22/2021
940C3D,partnership,100,61,6/22/2021
94C0B5,conference-call,100,50,6/22/2021
95A92E,legal-issues-defendant,100,22,6/22/2021
986AF6,award,100,58,6/22/2021
9D30A8,partnership,100,61,6/22/2021
9FA83B,conference-participant,100,50,6/22/2021
A01200,partnership,100,61,6/22/2021
A28C54,partnership,100,61,6/22/2021
A43906,conference-call,100,50,6/22/2021
A99576,legal-issues-defendant,100,22,6/22/2021
AC642C,public-offering,100,43,6/22/2021
AC642C,public-offering,100,43,6/22/2021
AECCA9,executive-appointment,100,54,6/22/2021
B2DAF6,executive-appointment,100,54,6/22/2021
B8F71F,earnings,100,50,6/22/2021
B96DF5,acquisition-acquirer,100,49,6/22/2021
B96DF5,acquisition-acquirer,100,49,6/22/2021
BB88B6,award,100,58,6/22/2021
BCC55F,award,100,58,6/22/2021
C062D4,acquisition-acquirer,100,49,6/22/2021
C72B8F,legal-issues-defendant,100,22,6/22/2021
C94CFC,legal-issues-defendant,100,22,6/22/2021
C9E4EC,public-offering,100,43,6/22/2021
CA1620,headquarters-change,100,50,6/22/2021
CBB77B,earnings,100,50,6/22/2021
CFF15D,partnership,100,61,6/22/2021
CFF15D,partnership,100,61,6/22/2021
CFF97C,credit-rating-affirmation-rater,20,50,6/22/2021
CFF97C,dividend,100,50,6/22/2021
D3FA2C,conference-call,100,50,6/22/2021
D6489C,award,100,58,6/22/2021
D6489C,award,100,58,6/22/2021
DBB28E,partnership,100,61,6/22/2021
DDEA6A,clinical-trials-filed,100,60,6/22/2021
DF11D9,legal-issues-defendant,100,22,6/22/2021
DFADDB,clinical-trials-start,100,64,6/22/2021
E124EB,conference-call,100,50,6/22/2021
E3E68E,business-contract,100,69,6/22/2021
E3E68E,business-contract,100,69,6/22/2021
E74B55,business-contract,100,69,6/22/2021
E845D9,note-sale,100,52,6/22/2021
E8A49A,award,100,58,6/22/2021
E8B315,legal-issues-defendant,100,22,6/22/2021
E8F0E2,clinical-trials,100,56,6/22/2021
EC8116,dividend,100,50,6/22/2021
EC99D0,conference-call,100,50,6/22/2021
EEB5F9,legal-issues-defendant,100,22,6/22/2021
F294DD,legal-issues-defendant,100,22,6/22/2021
F58C23,trading-listing,100,61,6/22/2021
F7D8AE,executive-appointment,100,54,6/22/2021
F88A04,product-release,100,64,6/22/2021
FD554E,executive-appointment,100,54,6/22/2021
FE7A63,earnings,100,50,6/22/2021
0157B1,partnership,100,61,6/23/2021
0157B1,partnership,100,61,6/23/2021
034B61,partnership,100,61,6/23/2021
034B61,partnership,100,61,6/23/2021
03CF95,stock-loss,100,40,6/23/2021
03F5A4,dividend,100,50,6/23/2021
05AF14,dividend,100,50,6/23/2021
05AF14,earnings,100,50,6/23/2021
0A6824,note-sale,100,52,6/23/2021
0AB700,dividend,100,50,6/23/2021
0B7375,legal-issues-defendant,100,22,6/23/2021
0CADBC,dividend,100,50,6/23/2021
102F04,executive-appointment,100,54,6/23/2021
12DE76,executive-appointment,100,54,6/23/2021
138DDE,dividend,100,50,6/23/2021
1.79E+10,conference-call,100,50,6/23/2021
1D3A00,executive-appointment,100,54,6/23/2021
232053,business-contract,100,69,6/23/2021
292A70,earnings-up,100,68,6/23/2021
2D485F,earnings,100,50,6/23/2021
342218,dividend,100,50,6/23/2021
35557B,executive-appointment,100,54,6/23/2021
35B907,executive-appointment,100,54,6/23/2021
3CBA2A,dividend,100,50,6/23/2021
3DCECC,partnership,100,61,6/23/2021
3F4497,conference-call,100,50,6/23/2021
4.03E+05,business-contract,100,69,6/23/2021
414FFF,earnings-guidance,100,50,6/23/2021
414FFF,earnings-guidance,100,50,6/23/2021
414FFF,earnings-guidance,100,50,6/23/2021
41EC04,executive-appointment,100,54,6/23/2021
422CE3,facility-open,100,65,6/23/2021
422CE3,facility-open,100,65,6/23/2021
442587,partnership,100,61,6/23/2021
49F4D0,dividend,100,50,6/23/2021
4AC91D,dividend,100,50,6/23/2021
4B49CF,earnings,100,50,6/23/2021
4BF3D6,clinical-trials,100,56,6/23/2021
4BF3D6,clinical-trials,100,56,6/23/2021
4E4E75,earnings,100,50,6/23/2021
4E4E75,earnings,100,50,6/23/2021
4EE14A,public-offering,100,43,6/23/2021
50070E,partnership,100,61,6/23/2021
504FE2,business-contract,100,69,6/23/2021
550D01,partnership,100,61,6/23/2021
577033,public-offering,100,43,6/23/2021
601785,asset-sale,100,62,6/23/2021
61BCA7,earnings,100,50,6/23/2021
641F17,earnings,100,50,6/23/2021
6474BA,earnings,100,50,6/23/2021
68E6E9,earnings,100,50,6/23/2021
6D9B53,clinical-trials-start,100,64,6/23/2021
713810,stake-acquirer,100,48,6/23/2021
72FCA3,earnings,100,50,6/23/2021
72FCA3,earnings,100,50,6/23/2021
72FCA3,earnings,100,50,6/23/2021
72FCA3,earnings,100,50,6/23/2021
73529F,business-contract,100,69,6/23/2021
73529F,business-contract,100,69,6/23/2021
746373,conference-call,100,50,6/23/2021
75F665,conference-call,100,50,6/23/2021
7ADE57,dividend-up,100,81,6/23/2021
7DA412,partnership,100,61,6/23/2021
7F3665,note-sale,100,52,6/23/2021
7F3665,note-sale,100,52,6/23/2021
7F3A5F,partnership,100,61,6/23/2021
7FEEE1,executive-appointment,100,54,6/23/2021
80D744,executive-appointment,100,54,6/23/2021
863350,facility-open,100,65,6/23/2021
89FBB1,conference-participant,100,50,6/23/2021
8C6C1B,facility-open,100,65,6/23/2021
8E10BF,public-offering,100,43,6/23/2021
980C14,public-offering,100,43,6/23/2021
990AD0,conference-organizer,100,57,6/23/2021
9.97E+09,acquisition-acquirer,100,49,6/23/2021
99B61C,executive-appointment,100,54,6/23/2021
9FA83B,partnership,100,61,6/23/2021
9FB4B7,clinical-trials,100,56,6/23/2021
A41450,buybacks,100,74,6/23/2021
A6828A,regulatory-product-application,100,69,6/23/2021
A6828A,regulatory-product-application,100,69,6/23/2021
A6828A,regulatory-product-application,100,69,6/23/2021
A7F0A5,partnership,100,61,6/23/2021
A7F0A5,partnership,100,61,6/23/2021
AC642C,public-offering,100,43,6/23/2021
AC642C,public-offering,100,43,6/23/2021
B4C673,product-release,100,64,6/23/2021
B5734D,executive-appointment,100,54,6/23/2021
BB127B,partnership,100,61,6/23/2021
BF5959,revenue-volume-up,100,69,6/23/2021
C07E05,partnership,100,61,6/23/2021
C2F597,buybacks,100,74,6/23/2021
C48574,revenue-up,100,69,6/23/2021
C4A241,conference-call,100,50,6/23/2021
C5F463,partnership,100,61,6/23/2021
C94CFC,legal-issues-defendant,100,22,6/23/2021
C951A2,regulatory-product-approval-granted,100,81,6/23/2021
D1CFC8,earnings,100,50,6/23/2021
D4463B,dividend,100,50,6/23/2021
D60BB2,executive-appointment,100,54,6/23/2021
D8DA3D,ownership-increase-owner,100,56,6/23/2021
DD1BA1,revenue-up,100,69,6/23/2021
DD682D,investment-investor,100,55,6/23/2021
E261E9,buybacks,100,74,6/23/2021
E2F130,conference-call,100,50,6/23/2021
E30B34,executive-appointment,100,54,6/23/2021
E30B34,executive-appointment,100,54,6/23/2021
E3A829,government-contract,100,69,6/23/2021
E96E0B,regulatory-product-approval-granted,100,81,6/23/2021
EEA6B3,earnings,100,50,6/23/2021
F02170,executive-appointment,100,54,6/23/2021
F4FBD8,executive-appointment,100,54,6/23/2021
F58C23,conference-call,100,50,6/23/2021
F702CA,product-price-raise,100,57,6/23/2021
F721A7,loan-recipient,100,59,6/23/2021
F80389,business-contract,100,69,6/23/2021
00067A,earnings,100,50,6/24/2021
01D03F,regulatory-product-approval-granted,100,81,6/24/2021
034B61,partnership,100,61,6/24/2021
03596A,partnership,100,61,6/24/2021
51332,dividend,100,50,6/24/2021
0560D8,dividend-up,100,73,6/24/2021
06CB5B,dividend,100,50,6/24/2021
07CA6A,acquisition-acquirer,100,49,6/24/2021
07CA6A,acquisition-acquirer,100,49,6/24/2021
07CA6A,acquisition-acquirer,100,49,6/24/2021
07CA6A,acquisition-acquirer,100,49,6/24/2021
0A7650,legal-issues-defendant,100,22,6/24/2021
0BA2EF,dividend,100,50,6/24/2021
0BD4E8,business-contract,100,69,6/24/2021
0CC62B,conference-call,100,50,6/24/2021
1080C0,clinical-trials-start,100,64,6/24/2021
1151F4,executive-appointment,100,54,6/24/2021
14833D,executive-appointment,100,54,6/24/2021
14BA06,conference-call,100,50,6/24/2021
157D9F,executive-appointment,100,54,6/24/2021
168A5D,partnership,100,61,6/24/2021
1748F6,product-release,100,64,6/24/2021
196D18,orphan-drug-designation,100,76,6/24/2021
1A9DE1,dividend,100,50,6/24/2021
1EBF8D,executive-appointment,100,54,6/24/2021
1F9D90,executive-appointment,100,54,6/24/2021
21022F,earnings,100,50,6/24/2021
21245F,partnership,100,61,6/24/2021
228D42,partnership,100,61,6/24/2021
24FA23,clinical-trials-start,100,64,6/24/2021
25102A,partnership,100,61,6/24/2021
267718,dividend,100,50,6/24/2021
2C7505,regulatory-product-approval-granted,100,81,6/24/2021
2D485F,earnings,100,50,6/24/2021
2EB88B,note-sale,100,52,6/24/2021
2F1299,partnership,100,61,6/24/2021
2F7474,conference-call,100,50,6/24/2021
2F9304,executive-appointment,100,54,6/24/2021
30A565,partnership,100,61,6/24/2021
314D88,partnership,100,61,6/24/2021
31803E,conference-participant,100,50,6/24/2021
3390DE,conference-call,100,50,6/24/2021
3471C0,conference-call,100,50,6/24/2021
34B97A,conference-call,100,50,6/24/2021
36E479,public-offering,100,43,6/24/2021
39FB23,earnings,100,50,6/24/2021
3B9886,name-change,100,49,6/24/2021
3B9886,dividend,100,50,6/24/2021
3D9999,earnings,100,50,6/24/2021
4290EF,business-contract,100,69,6/24/2021
453282,conference-call,100,50,6/24/2021
4A2457,business-contract,100,69,6/24/2021
4A5C8D,award,100,58,6/24/2021
4A6F00,partnership,100,61,6/24/2021
4A6F00,partnership,100,61,6/24/2021
4A6F00,partnership,100,61,6/24/2021
4A6F00,partnership,100,61,6/24/2021
4EE14A,public-offering,100,43,6/24/2021
51888A,unit-acquisition-acquirer,100,49,6/24/2021
553949,executive-appointment,100,54,6/24/2021
556F08,legal-issues-defendant,100,22,6/24/2021
577033,public-offering,100,43,6/24/2021
5B15E1,business-contract,100,69,6/24/2021
5B97B2,executive-appointment,100,54,6/24/2021
5C7601,earnings,100,50,6/24/2021
5CC29D,earnings,100,50,6/24/2021
5D1329,executive-appointment,100,54,6/24/2021
5DAF89,partnership,100,61,6/24/2021
5DAF89,partnership,100,61,6/24/2021
627186,earnings,100,50,6/24/2021
63F892,partnership,100,61,6/24/2021
6.52E+64,conference-call,100,50,6/24/2021
6844D2,earnings,100,50,6/24/2021
6844D2,earnings,100,50,6/24/2021
6844D2,earnings,100,50,6/24/2021
69CE71,product-release,100,64,6/24/2021
717DB4,asset-sale,100,62,6/24/2021
728737,award,100,58,6/24/2021
73529F,business-contract,100,69,6/24/2021
756BB4,product-release,100,64,6/24/2021
762A3E,conference-call,100,50,6/24/2021
7AC86E,dividend,100,50,6/24/2021
7BEA98,legal-verdict-disfavored,100,22,6/24/2021
7E3F8F,clinical-trials,100,56,6/24/2021
8.22E+27,market-entry,100,57,6/24/2021
8.22E+27,market-entry,100,57,6/24/2021
85DE00,partnership,100,61,6/24/2021
863350,acquisition-acquiree,100,76,6/24/2021
86AA9C,executive-appointment,100,54,6/24/2021
8C6C1B,facility-open,100,65,6/24/2021
911ACB,legal-issues-defendant,100,22,6/24/2021
931AE7,clinical-trials-start,100,64,6/24/2021
93D207,acquisition-acquirer,100,49,6/24/2021
945DE6,partnership,100,61,6/24/2021
95A92E,legal-issues-defendant,100,22,6/24/2021
95DC1F,dividend-up,100,67,6/24/2021
966DBE,note-sale,100,52,6/24/2021
966DBE,note-sale,100,52,6/24/2021
967D92,conference-call,100,50,6/24/2021
968966,product-release,100,64,6/24/2021
96F126,dividend,100,50,6/24/2021
972356,unit-acquisition-acquiree,100,76,6/24/2021
990AD0,trading-halt,100,43,6/24/2021
990AD0,trading-resumed,100,58,6/24/2021
9BBFA5,earnings,100,50,6/24/2021
9C5174,clinical-trials,100,56,6/24/2021
9F37C5,earnings-guidance,100,50,6/24/2021
A26C26,dividend,100,50,6/24/2021
A2CA3F,buybacks,100,74,6/24/2021
A398B9,government-contract,100,69,6/24/2021
A398B9,government-contract,100,69,6/24/2021
A99576,legal-issues-defendant,100,22,6/24/2021
B37FB4,earnings,100,50,6/24/2021
B5DE80,conference-call,100,50,6/24/2021
B83BCE,loan-recipient,100,59,6/24/2021
B8A51F,clinical-trials-filed,100,60,6/24/2021
BCC55F,executive-appointment,100,54,6/24/2021
C0BA36,business-contract,100,69,6/24/2021
C81E00,conference-call,100,50,6/24/2021
C81E00,conference-call,100,50,6/24/2021
C97B2D,executive-appointment,100,54,6/24/2021
C9881C,partnership,100,61,6/24/2021
CAC8D0,earnings,100,50,6/24/2021
CBDB4D,product-release,100,64,6/24/2021
CC6FF5,partnership,100,61,6/24/2021
CFF15D,partnership,100,61,6/24/2021
CFF57D,earnings,100,50,6/24/2021
D6489C,partnership,100,61,6/24/2021
D64C6D,earnings,100,50,6/24/2021
D77F7E,business-contract,100,69,6/24/2021
D78BF1,earnings,100,50,6/24/2021
D854DD,executive-appointment,100,54,6/24/2021
D8DA3D,acquisition-acquiree,100,76,6/24/2021
D8DA3D,conference-call,100,50,6/24/2021
D93A25,conference-call,100,50,6/24/2021
DF11D9,legal-issues-defendant,100,22,6/24/2021
DF18E6,executive-appointment,100,54,6/24/2021
E10D31,dividend,100,50,6/24/2021
E10D31,business-contract,100,69,6/24/2021
E10D31,business-contract,100,69,6/24/2021
E10D31,conference-call,100,50,6/24/2021
E1E093,product-release,100,64,6/24/2021
E26FC3,partnership,100,61,6/24/2021
E30B34,executive-appointment,100,54,6/24/2021
E30B34,executive-appointment,100,54,6/24/2021
E71AE6,clinical-trials,100,56,6/24/2021
E8E899,earnings,100,50,6/24/2021
EEA6B3,partnership,100,61,6/24/2021
EEB5F9,legal-issues-defendant,100,22,6/24/2021
EF77A3,dividend,100,50,6/24/2021
F294DD,legal-issues-defendant,100,22,6/24/2021
F3816D,executive-appointment,100,54,6/24/2021
F5D410,note-sale,100,52,6/24/2021
F5D410,note-sale,100,52,6/24/2021
F5D410,public-offering,100,43,6/24/2021
F88A04,partnership,100,61,6/24/2021
FC1B7B,conference-call,100,50,6/24/2021
FDE409,earnings,100,50,6/24/2021
FF4BA4,earnings,100,50,6/24/2021
0157B1,regulatory-investigation,100,22,6/25/2021
01D03F,regulatory-product-approval-granted,100,81,6/25/2021
0B7375,legal-issues-defendant,100,22,6/25/2021
0B7375,legal-issues-defendant,100,22,6/25/2021
0BD4E8,legal-issues-defendant,100,22,6/25/2021
0C8D82,conference-call,100,50,6/25/2021
1F19C8,acquisition-acquirer,100,49,6/25/2021
205AD5,earnings,100,50,6/25/2021
223552,clinical-trials,100,56,6/25/2021
223552,clinical-trials,100,56,6/25/2021
23699B,clinical-trials,100,56,6/25/2021
25102A,unit-acquisition-completed-acquiree,100,67,6/25/2021
251988,executive-appointment,100,54,6/25/2021
251988,dividend,100,50,6/25/2021
25529C,executive-appointment,100,54,6/25/2021
2D2D43,earnings,100,50,6/25/2021
416C55,acquisition-acquirer,100,49,6/25/2021
416C55,unit-acquisition-acquirer,100,49,6/25/2021
449217,stock-splits,100,49,6/25/2021
44DDBD,merger-regulatory-scrutiny,100,37,6/25/2021
45ABCC,demand-decrease,100,17,6/25/2021
4A6F00,regulatory-investigation,100,22,6/25/2021
4AE584,earnings,100,50,6/25/2021
4D8124,award,100,58,6/25/2021
4FCC78,conference-call,100,50,6/25/2021
504FE2,government-contract,100,69,6/25/2021
520632,conference-call,100,50,6/25/2021
55D0F3,board-meeting,100,51,6/25/2021
57B174,legal-issues-defendant,100,22,6/25/2021
616E3B,conference-call,100,50,6/25/2021
665D7D,regulatory-product-approval-granted,100,81,6/25/2021
665D7D,regulatory-product-approval-granted,100,81,6/25/2021
66A667,dividend,100,50,6/25/2021
66A667,dividend,100,50,6/25/2021
6CC55E,regulatory-product-review-positive,100,73,6/25/2021
6CC55E,regulatory-product-review-positive,100,73,6/25/2021
6EA292,dividend,100,50,6/25/2021
6F5DD2,board-meeting,100,51,6/25/2021
6F6559,earnings,100,50,6/25/2021
830BDB,regulatory-product-review-positive,100,73,6/25/2021
86478F,dividend,100,50,6/25/2021
8817D5,conference-call,100,50,6/25/2021
8A8E41,executive-appointment,100,54,6/25/2021
8C6C1B,facility-open,100,65,6/25/2021
8C84DF,conference-call,100,50,6/25/2021
8F3231,buybacks,100,74,6/25/2021
94637C,regulatory-product-review-positive,100,73,6/25/2021
94637C,regulatory-product-review-positive,100,73,6/25/2021
96F126,fundraising,100,64,6/25/2021
972356,acquisition-completed-acquiree,100,76,6/25/2021
990AD0,conference-organizer,100,57,6/25/2021
9BBFA5,executive-resignation,100,44,6/25/2021
9E9147,executive-appointment,100,54,6/25/2021
9F03CF,unit-acquisition-completed-acquirer,100,49,6/25/2021
A8B137,conference-call,100,50,6/25/2021
AA7FE0,earnings-up,100,68,6/25/2021
AA7FE0,earnings,100,50,6/25/2021
AA7FE0,earnings,100,50,6/25/2021
AA7FE0,earnings,100,50,6/25/2021
AA7FE0,earnings,100,50,6/25/2021
AEFC90,clinical-trials,100,56,6/25/2021
AFDF2E,earnings-revision,100,29,6/25/2021
B05118,executive-appointment,100,54,6/25/2021
B3CB74,partnership,100,61,6/25/2021
B6082A,conference-call,100,50,6/25/2021
B6CD92,dividend,100,50,6/25/2021
B72D2E,business-contract,100,69,6/25/2021
BB0787,business-contract,100,69,6/25/2021
BCE9DA,dividend,100,50,6/25/2021
BCE9DA,dividend,100,50,6/25/2021
BE86A1,dividend,100,50,6/25/2021
C06EB6,patient-enrollment-start,100,58,6/25/2021
C06EB6,patient-enrollment-start,100,58,6/25/2021
C16A8F,conference-call,100,50,6/25/2021
C3BAE7,conference-participant,100,50,6/25/2021
CEDFD5,regulatory-product-review-positive,100,73,6/25/2021
CEDFD5,regulatory-product-review-positive,100,73,6/25/2021
D08D2C,conference-call,100,50,6/25/2021
D8442A,award,100,58,6/25/2021
EB7FBF,executive-appointment,100,54,6/25/2021
ECF709,executive-appointment,100,54,6/25/2021
EF77A3,earnings,100,50,6/25/2021
F2BC3D,conference-participant,100,50,6/25/2021
F5D410,conference-call,100,50,6/25/2021
FEBFE1,merger-regulatory-scrutiny,100,37,6/25/2021
0A7650,legal-issues-defendant,100,22,6/26/2021
13A782,legal-issues-defendant,100,22,6/26/2021
44DDBD,legal-issues-defendant,100,22,6/26/2021
6AACDD,fraud-defendant,100,20,6/26/2021
911ACB,legal-issues-defendant,100,22,6/26/2021
AEFC90,clinical-trials,100,56,6/26/2021
AEFC90,clinical-trials,100,56,6/26/2021
FEBFE1,legal-issues-defendant,100,22,6/26/2021
619882,investment-investor,100,55,6/27/2021
00067A,executive-appointment,100,54,6/28/2021
0157B1,market-entry,100,57,6/28/2021
03FAA6,partnership,100,61,6/28/2021
04CCCD,dividend,100,50,6/28/2021
55018,regulatory-stress-test,100,50,6/28/2021
099C88,business-contract,100,69,6/28/2021
0A7650,legal-issues-defendant,100,22,6/28/2021
0B7375,legal-issues-defendant,100,22,6/28/2021
0C136E,earnings,100,50,6/28/2021
0E439E,earnings,100,50,6/28/2021
12E454,legal-issues-defendant,100,22,6/28/2021
1880C5,business-contract,100,69,6/28/2021
1A3E1B,dividend-up,100,81,6/28/2021
1FE7F0,acquisition-acquiree,100,76,6/28/2021
1FE7F0,acquisition-acquiree,100,76,6/28/2021
1FE7F0,acquisition-acquiree,100,76,6/28/2021
1FE7F0,acquisition-regulatory-scrutiny-acquiree,100,38,6/28/2021
21245F,executive-appointment,100,54,6/28/2021
253604,clinical-trials-positive,100,87,6/28/2021
253604,public-offering,100,43,6/28/2021
2C35B5,clinical-trials-positive,100,87,6/28/2021
2E0445,executive-appointment,100,54,6/28/2021
30DFD3,executive-resignation,100,44,6/28/2021
338544,executive-appointment,100,54,6/28/2021
33A0F1,ipo-price-increase,100,63,6/28/2021
372037,executive-appointment,100,54,6/28/2021
3C6CCC,note-sale,100,52,6/28/2021
408089,earnings,100,50,6/28/2021
416C55,executive-appointment,100,54,6/28/2021
44A4FC,award,100,58,6/28/2021
44DDBD,legal-issues-defendant,100,22,6/28/2021
492117,executive-resignation,100,44,6/28/2021
4D8E5E,executive-appointment,100,54,6/28/2021
51888A,public-offering,100,43,6/28/2021
51888A,public-offering,100,43,6/28/2021
51888A,public-offering,100,43,6/28/2021
556F08,legal-issues-defendant,100,22,6/28/2021
57356F,conference-call,100,50,6/28/2021
577033,public-offering,100,43,6/28/2021
5D1329,public-offering,100,43,6/28/2021
609208,earnings,100,50,6/28/2021
619882,stake-acquirer,100,48,6/28/2021
633054,index-listing,100,76,6/28/2021
6BD606,dividend,100,50,6/28/2021
6F3FA8,conference-participant,100,50,6/28/2021
756BB4,executive-appointment,100,54,6/28/2021
756BB4,executive-appointment,100,54,6/28/2021
766047,executive-appointment,100,54,6/28/2021
7999F3,acquisition-acquirer,100,49,6/28/2021
7999F3,acquisition-acquirer,100,49,6/28/2021
7999F3,acquisition-acquirer,100,49,6/28/2021
7A5097,acquisition-acquiree,100,76,6/28/2021
7A5097,acquisition-acquiree,100,76,6/28/2021
7A5097,acquisition-regulatory-scrutiny-acquiree,100,38,6/28/2021
7A5097,legal-issues-defendant,100,22,6/28/2021
7AF5B8,clinical-trials-start,100,64,6/28/2021
7D5FD6,earnings,100,50,6/28/2021
7E1D5D,partnership,100,61,6/28/2021
803FED,executive-appointment,100,54,6/28/2021
819492,clinical-trials-start,100,64,6/28/2021
858942,executive-appointment,100,54,6/28/2021
85DE00,facility-open,100,65,6/28/2021
86A1B9,executive-appointment,100,54,6/28/2021
8AA108,public-offering,100,43,6/28/2021
8B6E7E,executive-appointment,100,54,6/28/2021
8C5519,earnings,100,50,6/28/2021
8C6C1B,facility-open,100,65,6/28/2021
8E4F9A,executive-appointment,100,54,6/28/2021
8F8F2F,acquisition-acquirer,100,49,6/28/2021
9196A2,dividend-up,100,91,6/28/2021
92D3A0,conference-call,100,50,6/28/2021
940C3D,stake-acquirer,100,48,6/28/2021
949625,conference-call,100,50,6/28/2021
94A326,patient-enrollment-complete,100,64,6/28/2021
98CAED,earnings,100,50,6/28/2021
990AD0,regulatory-stress-test,100,50,6/28/2021
99ACAD,partnership,100,61,6/28/2021
A1DBF0,public-offering,100,43,6/28/2021
A3230E,regulatory-product-approval-granted,100,81,6/28/2021
A6FE1C,unit-acquisition-acquirer,100,49,6/28/2021
A746F6,hirings,100,65,6/28/2021
A99576,legal-issues-defendant,100,22,6/28/2021
ADF092,acquisition-acquiree,100,76,6/28/2021
AE7D16,debt-reduction,100,74,6/28/2021
B05118,earnings,100,50,6/28/2021
B77F14,partnership,100,61,6/28/2021
BB127B,product-release,100,64,6/28/2021
BB127B,product-release,100,64,6/28/2021
BE14CF,executive-appointment,100,54,6/28/2021
C037A8,buybacks,100,74,6/28/2021
C11C46,executive-appointment,100,54,6/28/2021
C3CF29,legal-issues-defendant,100,22,6/28/2021
C4A432,donation,100,54,6/28/2021
C4FBDC,facility-open,100,65,6/28/2021
CDD75E,clinical-trials-filed,100,60,6/28/2021
D1C26F,earnings,100,50,6/28/2021
D622D5,facility-sale,100,52,6/28/2021
D90F43,partnership,100,61,6/28/2021
D93A25,facility-sale,100,52,6/28/2021
DA199F,earnings,100,50,6/28/2021
DA199F,executive-appointment,100,54,6/28/2021
DA9443,fast-track-designation,100,81,6/28/2021
DC2F77,earnings,100,50,6/28/2021
DD0099,earnings,100,50,6/28/2021
DF11D9,legal-issues-defendant,100,22,6/28/2021
DF5F14,earnings-up,100,68,6/28/2021
E09E2B,product-release,100,64,6/28/2021
E09E2B,product-release,100,64,6/28/2021
E11C41,conference-call,100,50,6/28/2021
E3E68E,public-offering,100,43,6/28/2021
E3E68E,public-offering,100,43,6/28/2021
E829E8,conference-call,100,50,6/28/2021
EB1E1A,clinical-trials-start,100,64,6/28/2021
ED2A5E,executive-appointment,100,54,6/28/2021
EE6F1C,acquisition-regulatory-approval-acquiree,100,81,6/28/2021
EE6F1C,acquisition-regulatory-approval-acquiree,100,81,6/28/2021
EEB5F9,legal-issues-defendant,100,22,6/28/2021
EF5BED,dividend,100,50,6/28/2021
F0B335,executive-appointment,100,54,6/28/2021
F24FF0,conference-call,100,50,6/28/2021
F294DD,legal-issues-defendant,100,22,6/28/2021
F4E992,conference-call,100,50,6/28/2021
F5349B,award,100,58,6/28/2021
F6E248,regulatory-product-application,100,69,6/28/2021
F6E248,clinical-trials-filed,100,60,6/28/2021
F7935D,legal-issues-defendant,100,22,6/28/2021
FD4588,conference-call,100,50,6/28/2021
FEBFE1,legal-issues-defendant,100,22,6/28/2021
00067A,partnership,100,61,6/29/2021
018C11,conference-call,100,50,6/29/2021
099C88,sponsorship,100,57,6/29/2021
0B7375,legal-issues-defendant,100,22,6/29/2021
0CC01F,earnings,100,50,6/29/2021
10C19B,conference-call,100,50,6/29/2021
12A3A3,earnings,100,50,6/29/2021
12A3A3,earnings,100,50,6/29/2021
12A3A3,earnings,100,50,6/29/2021
12A3A3,earnings,100,50,6/29/2021
131443,business-contract,100,69,6/29/2021
131443,business-contract,100,69,6/29/2021
1348C9,conference-call,100,50,6/29/2021
147C38,partnership,100,61,6/29/2021
17EDA5,partnership,100,61,6/29/2021
17EDA5,product-release,100,64,6/29/2021
17EDA5,partnership,100,61,6/29/2021
17EDA5,product-release,100,64,6/29/2021
1880C5,executive-appointment,100,54,6/29/2021
1921DD,facility-open,100,65,6/29/2021
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2021
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2021
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2021
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2021
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2021
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2021
1FE7F0,acquisition-regulatory-scrutiny-acquiree,100,38,6/29/2021
228D42,partnership,100,61,6/29/2021
228D42,partnership,100,61,6/29/2021
228D42,partnership,100,61,6/29/2021
279916,conference-participant,100,50,6/29/2021
2C35B5,award,100,58,6/29/2021
2CA60F,unit-acquisition-acquirer,100,49,6/29/2021
2CA60F,unit-acquisition-acquirer,100,49,6/29/2021
2D981A,conference-participant,100,50,6/29/2021
2F5256,conference-call,100,50,6/29/2021
306623,executive-appointment,100,54,6/29/2021
387375,private-placement,100,56,6/29/2021
3AAEAE,executive-appointment,100,54,6/29/2021
3B2311,executive-appointment,100,54,6/29/2021
3BCF24,dividend,100,50,6/29/2021
3C7F5F,award,100,58,6/29/2021
3ED92D,product-release,100,64,6/29/2021
43A060,partnership,100,61,6/29/2021
458D2C,product-release,100,64,6/29/2021
4A6F00,partnership,100,61,6/29/2021
4AC91D,product-release,100,64,6/29/2021
4B49CF,partnership,100,61,6/29/2021
4C6C63,product-release,100,64,6/29/2021
4C6C63,product-release,100,64,6/29/2021
4F9926,acquisition-acquirer,100,49,6/29/2021
504FE2,conference-call,100,50,6/29/2021
519FE0,product-release,100,64,6/29/2021
543900,executive-appointment,100,54,6/29/2021
55438C,business-contract,100,69,6/29/2021
5AF08A,earnings,100,50,6/29/2021
5C7601,executive-appointment,100,54,6/29/2021
5F9CE3,product-release,100,64,6/29/2021
601785,earnings,100,50,6/29/2021
619882,acquisition-acquirer,100,49,6/29/2021
619882,partnership,100,61,6/29/2021
619882,unit-acquisition-acquiree,100,76,6/29/2021
66E04A,acquisition-acquiree,100,76,6/29/2021
6AACDD,legal-issues-defendant,100,22,6/29/2021
6AACDD,legal-issues-defendant,100,22,6/29/2021
6AACDD,ipo,100,71,6/29/2021
6AACDD,legal-issues-defendant,100,22,6/29/2021
6AACDD,legal-issues-defendant,100,22,6/29/2021
6CB7F9,business-contract,100,69,6/29/2021
6CB7F9,business-contract,100,69,6/29/2021
6E705B,business-contract,100,69,6/29/2021
6F0A63,conference-call,100,50,6/29/2021
704B78,conference-participant,100,50,6/29/2021
713810,product-release,100,64,6/29/2021
713810,partnership,100,61,6/29/2021
722DE3,business-contract,100,69,6/29/2021
73C521,earnings,100,50,6/29/2021
75768D,earnings,100,50,6/29/2021
77B8E9,conference-participant,100,50,6/29/2021
790D0D,executive-appointment,100,54,6/29/2021
79340A,earnings,100,50,6/29/2021
7A5097,acquisition-regulatory-scrutiny-acquiree,100,38,6/29/2021
7ACD98,business-contract,100,69,6/29/2021
7F3FBC,conference-call,100,50,6/29/2021
8377DB,investment-investor,100,55,6/29/2021
83A065,public-offering,100,43,6/29/2021
83A065,public-offering,100,43,6/29/2021
863350,revenues,100,50,6/29/2021
8665BA,product-release,100,64,6/29/2021
8876D6,product-release,100,64,6/29/2021
895D56,business-contract,100,69,6/29/2021
8A0368,partnership,100,61,6/29/2021
8C6C1B,facility-open,100,65,6/29/2021
8CF6DD,earnings,100,50,6/29/2021
902670,conference-call,100,50,6/29/2021
93AD2E,executive-appointment,100,54,6/29/2021
94637C,regulatory-product-approval-granted,100,81,6/29/2021
957A07,earnings,100,50,6/29/2021
981656,clinical-trials-start,100,64,6/29/2021
98CEBB,business-contract,100,69,6/29/2021
990AD0,conference-organizer,100,57,6/29/2021
9A02C4,business-contract,100,69,6/29/2021
9CA619,dividend,100,50,6/29/2021
9D30A8,expenses-up,100,39,6/29/2021
9D30A8,expenses-up,100,39,6/29/2021
9D56F2,dividend,100,50,6/29/2021
9E98F2,product-release,100,64,6/29/2021
A204A7,conference-participant,100,50,6/29/2021
A398B9,earnings,100,50,6/29/2021
A398F8,acquisition-acquirer,100,49,6/29/2021
A3AAA5,dividend,100,50,6/29/2021
A60318,earnings,100,50,6/29/2021
A6FE1C,acquisition-acquirer,100,49,6/29/2021
A6FE1C,unit-acquisition-acquirer,100,49,6/29/2021
A6FE1C,unit-acquisition-acquirer,100,49,6/29/2021
A6FE1C,unit-acquisition-acquirer,100,49,6/29/2021
AA09AD,partnership,100,61,6/29/2021
AA98ED,asset-sale,100,62,6/29/2021
AE4125,facility-open,100,65,6/29/2021
B08C51,market-entry,100,57,6/29/2021
B13B68,acquisition-completed-acquirer,100,49,6/29/2021
B303A6,partnership,100,61,6/29/2021
B3ED62,conference-call,100,50,6/29/2021
B48D6A,conference-participant,100,50,6/29/2021
B560AF,asset-sale,100,62,6/29/2021
B72D2E,acquisition-completed-acquirer,100,49,6/29/2021
B9764A,business-contract,100,69,6/29/2021
BA0442,business-contract,100,69,6/29/2021
BE14CF,conference-call,100,50,6/29/2021
BE14CF,joint-venture,100,62,6/29/2021
C3EE99,award,100,58,6/29/2021
C62AA4,asset-sale,100,62,6/29/2021
C7859D,conference-call,100,50,6/29/2021
C8FAC7,executive-appointment,100,54,6/29/2021
C8FAC7,executive-appointment,100,54,6/29/2021
C97B2D,conference-call,100,50,6/29/2021
CBB77B,earnings,100,50,6/29/2021
CBB77B,earnings,100,50,6/29/2021
CBB77B,earnings,100,50,6/29/2021
CC176E,earnings,100,50,6/29/2021
CD2A4D,partnership,100,61,6/29/2021
CE2791,note-sale,100,52,6/29/2021
CE4FD9,note-sale,100,52,6/29/2021
CEDFD5,partnership,100,61,6/29/2021
CFF97C,conference-call,100,50,6/29/2021
D06755,award,100,58,6/29/2021
D33270,government-contract,100,69,6/29/2021
D3DE34,executive-appointment,100,54,6/29/2021
D3DE34,executive-appointment,100,54,6/29/2021
D70365,conference-call,100,50,6/29/2021
D82EF3,product-release,100,64,6/29/2021
D90F43,partnership,100,61,6/29/2021
D90F43,partnership,100,61,6/29/2021
DB88A1,partnership,100,61,6/29/2021
DC486E,earnings,100,50,6/29/2021
DC486E,earnings,100,50,6/29/2021
DD7A96,conference-call,100,50,6/29/2021
E84500,conference-call,100,50,6/29/2021
E8846E,facility-upgrade,100,65,6/29/2021
EE6F1C,executive-appointment,100,54,6/29/2021
EEEA9F,executive-appointment,100,54,6/29/2021
F0B2B5,executive-appointment,100,54,6/29/2021
F0B2B5,executive-appointment,100,54,6/29/2021
F0B2B5,executive-appointment,100,54,6/29/2021
F2E253,market-entry,100,57,6/29/2021
F30508,dividend,100,50,6/29/2021
F40EE2,executive-appointment,100,54,6/29/2021
F40EE2,executive-appointment,100,54,6/29/2021
F51DB0,executive-appointment,100,54,6/29/2021
FA36A4,conference-call,100,50,6/29/2021
FADF1A,business-contract,100,69,6/29/2021
FC4550,conference-call,100,50,6/29/2021
FC4550,conference-call,100,50,6/29/2021
0157B1,partnership,100,61,6/30/2021
01D03F,product-release,100,64,6/30/2021
03CF95,executive-appointment,100,54,6/30/2021
03FAA6,acquisition-acquirer,100,49,6/30/2021
48590,earnings,100,50,6/30/2021
71860,partnership,100,61,6/30/2021
07CA6A,product-release,100,64,6/30/2021
07CA6A,product-release,100,64,6/30/2021
0A7650,legal-issues-defendant,100,22,6/30/2021
0BD199,clinical-trials-start,100,64,6/30/2021
0DC050,legal-verdict-favored,100,78,6/30/2021
0E2992,conference-call,100,50,6/30/2021
10AE08,executive-appointment,100,54,6/30/2021
119CB6,conference-call,100,50,6/30/2021
1216D1,conference-call,100,50,6/30/2021
12DE76,acquisition-completed-acquirer,100,49,6/30/2021
1490F3,conference-call,100,50,6/30/2021
15A388,earnings,100,50,6/30/2021
16F4D8,conference-call,100,50,6/30/2021
1834C0,earnings-guidance-up,100,83,6/30/2021
1A6A94,conference-call,100,50,6/30/2021
1C2593,facility-open,100,65,6/30/2021
1D1B07,earnings,100,50,6/30/2021
1D1B07,earnings,100,50,6/30/2021
1D1B07,buybacks,100,74,6/30/2021
1D1B07,buybacks,100,74,6/30/2021
1EBF8D,partnership,100,61,6/30/2021
1EBF8D,partnership,100,61,6/30/2021
1EBF8D,partnership,100,61,6/30/2021
1EBF8D,conference-call,100,50,6/30/2021
1F464F,executive-appointment,100,54,6/30/2021
1FE7F0,legal-issues-defendant,100,22,6/30/2021
263216,acquisition-acquirer,100,49,6/30/2021
263216,acquisition-acquirer,100,49,6/30/2021
26F99F,conference-participant,100,50,6/30/2021
27BFA1,conference-call,100,50,6/30/2021
297DA8,business-contract,100,69,6/30/2021
2B5483,settlement,100,56,6/30/2021
2C19A4,credit-extension-recipient,100,69,6/30/2021
2C681C,clinical-trials,100,56,6/30/2021
2C681C,clinical-trials,100,56,6/30/2021
2C7505,clinical-trials-start,100,64,6/30/2021
2C7505,clinical-trials-start,100,64,6/30/2021
2F7474,dividend-up,100,81,6/30/2021
2F9304,executive-appointment,100,54,6/30/2021
31553A,earnings-guidance,100,50,6/30/2021
315EB0,award,100,58,6/30/2021
31643A,commodity-offer,100,54,6/30/2021
31F25C,conference-call,100,50,6/30/2021
33A0F1,ipo-pricing,100,50,6/30/2021
356B21,product-release,100,64,6/30/2021
370C50,acquisition-acquirer,100,49,6/30/2021
39BFF6,acquisition-acquirer,100,49,6/30/2021
3CBA2A,executive-appointment,100,54,6/30/2021
4135F7,conference-call,100,50,6/30/2021
41C36B,patient-enrollment-complete,100,64,6/30/2021
41C36B,patient-enrollment-complete,100,64,6/30/2021
43A060,business-contract,100,69,6/30/2021
44DDBD,legal-issues-defendant,100,22,6/30/2021
450ECB,note-sale,100,52,6/30/2021
450ECB,note-sale,100,52,6/30/2021
46CF27,earnings,100,50,6/30/2021
49914B,conference-call,100,50,6/30/2021
49BBBC,earnings,100,50,6/30/2021
49BBBC,acquisition-acquiree,100,76,6/30/2021
4A5C8D,earnings,100,50,6/30/2021
4A6F00,partnership,100,61,6/30/2021
4A6F00,partnership,100,61,6/30/2021
4A6F00,partnership,100,61,6/30/2021
4AC91D,partnership,100,61,6/30/2021
4B3555,dividend,100,50,6/30/2021
4D8313,conference-call,100,50,6/30/2021
4F9487,conference-call,100,50,6/30/2021
4FB770,conference-call,100,50,6/30/2021
504FE2,business-contract,100,69,6/30/2021
519FE0,partnership,100,61,6/30/2021
519FE0,business-combination,100,54,6/30/2021
545272,executive-appointment,100,54,6/30/2021
5.47E+28,business-contract,100,69,6/30/2021
55438C,executive-appointment,100,54,6/30/2021
55438C,executive-appointment,100,54,6/30/2021
556F08,legal-issues-defendant,100,22,6/30/2021
55C9B5,partnership,100,61,6/30/2021
564F3E,earnings,100,50,6/30/2021
56AFF4,executive-appointment,100,54,6/30/2021
57F3DA,settlement,100,56,6/30/2021
583A75,revenue-up,100,69,6/30/2021
5D1329,public-offering,100,43,6/30/2021
5F2FF7,earnings,100,50,6/30/2021
6830FE,executive-appointment,100,54,6/30/2021
6AACDD,fraud-defendant,100,20,6/30/2021
6AACDD,legal-issues-defendant,100,22,6/30/2021
6AACDD,fraud-defendant,100,20,6/30/2021
6F0096,partnership,100,61,6/30/2021
6F5DD2,executive-appointment,100,54,6/30/2021
765913,earnings,100,50,6/30/2021
7771D7,earnings-up,100,68,6/30/2021
789ADD,earnings,100,50,6/30/2021
791EC1,acquisition-completed-acquirer,100,49,6/30/2021
7A5097,legal-issues-defendant,100,22,6/30/2021
7A5097,legal-issues-defendant,100,22,6/30/2021
7A975D,earnings,100,50,6/30/2021
7A975D,earnings,100,50,6/30/2021
7A975D,earnings,100,50,6/30/2021
7AB859,acquisition-completed-acquirer,100,49,6/30/2021
7B1E50,executive-appointment,100,54,6/30/2021
7F3FBC,unit-acquisition-acquirer,100,49,6/30/2021
810A4B,public-offering,100,43,6/30/2021
82E58A,executive-appointment,100,54,6/30/2021
850779,earnings,100,50,6/30/2021
873DB9,earnings,100,50,6/30/2021
880C0C,conference-call,100,50,6/30/2021
88193E,regulatory-product-approval-granted,100,81,6/30/2021
88193E,regulatory-product-approval-granted,100,81,6/30/2021
893904,executive-appointment,100,54,6/30/2021
8A8E41,partnership,100,61,6/30/2021
8B6E7E,conference-call,100,50,6/30/2021
8C6C1B,facility-open,100,65,6/30/2021
8E0E32,earnings,100,50,6/30/2021
8F3231,conference-call,100,50,6/30/2021
915E7B,conference-call,100,50,6/30/2021
918D6D,executive-appointment,100,54,6/30/2021
940C3D,business-contract,100,69,6/30/2021
9B71A7,earnings-up,100,68,6/30/2021
9CA619,earnings,100,50,6/30/2021
9D5FA4,partnership,100,61,6/30/2021
9F5CBB,dividend,100,50,6/30/2021
A99576,legal-issues-defendant,100,22,6/30/2021
AD23DE,product-release,100,64,6/30/2021
B08C51,buybacks,100,74,6/30/2021
B1B10C,conference-call,100,50,6/30/2021
B290A2,partnership,100,61,6/30/2021
B7EB38,earnings,100,50,6/30/2021
B803B1,fundraising,100,64,6/30/2021
B803B1,dividend,100,50,6/30/2021
BA218A,dividend,100,50,6/30/2021
BAAA60,conference-call,100,50,6/30/2021
C03C8B,conference-call,100,50,6/30/2021
C3CF29,legal-issues-defendant,100,22,6/30/2021
C3EE99,earnings,100,50,6/30/2021
C501B6,executive-appointment,100,54,6/30/2021
C564E4,executive-appointment,100,54,6/30/2021
C598D7,conference-call,100,50,6/30/2021
C8923A,partnership,100,61,6/30/2021
C8FAC7,partnership,100,61,6/30/2021
C9F39B,conference-call,100,50,6/30/2021
CC339B,earnings,100,50,6/30/2021
CD06A2,executive-resignation,100,44,6/30/2021
CEC5B9,product-release,100,64,6/30/2021
CFF97C,award,100,58,6/30/2021
D1173F,conference-call,100,50,6/30/2021
D56D6D,product-release,100,64,6/30/2021
D56E4C,executive-appointment,100,54,6/30/2021
D56E4C,executive-appointment,100,54,6/30/2021
D598E7,conference-call,100,50,6/30/2021
D5AF19,earnings,100,50,6/30/2021
D6489C,business-contract,100,69,6/30/2021
D6EAA3,executive-appointment,100,54,6/30/2021
D7A953,executive-appointment,100,54,6/30/2021
DB7FA7,conference-call,100,50,6/30/2021
DD1BA1,product-release,100,64,6/30/2021
DEF058,earnings,100,50,6/30/2021
DF11D9,legal-issues-defendant,100,22,6/30/2021
E0207A,executive-appointment,100,54,6/30/2021
E15736,conference-call,100,50,6/30/2021
E15736,conference-call,100,50,6/30/2021
E15736,conference-call,100,50,6/30/2021
E20BFE,partnership,100,61,6/30/2021
E70531,unit-acquisition-acquiree,100,76,6/30/2021
E70531,acquisition-acquiree,100,76,6/30/2021
E959F3,earnings,100,50,6/30/2021
EAA0A7,product-release,100,64,6/30/2021
ED1A74,partnership,100,61,6/30/2021
ED3CA8,public-offering,100,43,6/30/2021
ED79D9,partnership,100,61,6/30/2021
ED79D9,partnership,100,61,6/30/2021
EEB5F9,legal-issues-defendant,100,22,6/30/2021
F0B877,conference-call,100,50,6/30/2021
F1529C,acquisition-completed-acquirer,100,49,6/30/2021
F1529C,acquisition-completed-acquirer,100,49,6/30/2021
F1529C,acquisition-completed-acquirer,100,49,6/30/2021
F1529C,acquisition-completed-acquirer,100,49,6/30/2021
F40EE2,dividend,100,50,6/30/2021
F40EE2,dividend,100,50,6/30/2021
F5D499,trading-halt,100,43,6/30/2021
F67165,executive-appointment,100,54,6/30/2021
F702CA,credit-extension-recipient,100,69,6/30/2021
F793FA,acquisition-acquirer,100,49,6/30/2021
F793FA,business-contract,100,69,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
F8D759,earnings,100,50,6/30/2021
FADF1A,business-contract,100,69,6/30/2021
FC1A6E,facility-open,100,65,6/30/2021
FC1A6E,joint-venture,100,62,6/30/2021
FD2565,business-contract,100,69,6/30/2021
FD2565,business-contract,100,69,6/30/2021
FDD3FC,clinical-trials-start,100,64,6/30/2021
FDF799,executive-appointment,100,54,6/30/2021
FEC475,unit-acquisition-completed-acquiree,100,67,6/30/2021
00326D,conference-call,100,50,7/1/2021
01478A,conference-call,100,50,7/1/2021
02FC1A,campaign-ad-release,100,59,7/1/2021
07C69F,conference-call,100,50,7/1/2021
0A0D9E,earnings,100,50,7/1/2021
105D00,conference-call,100,50,7/1/2021
108FDA,dividend,100,50,7/1/2021
10C19B,dividend-up,100,81,7/1/2021
10C19B,dividend-up,100,81,7/1/2021
147C38,earnings,100,50,7/1/2021
1A2D9F,acquisition-completed-acquiree,100,76,7/1/2021
1A2D9F,acquisition-completed-acquiree,100,76,7/1/2021
1BDB2A,acquisition-acquirer,100,49,7/1/2021
1BDB2A,acquisition-acquirer,100,49,7/1/2021
1DE526,conference-call,100,50,7/1/2021
1EBF8D,partnership,100,61,7/1/2021
221AD7,earnings,100,50,7/1/2021
249B39,earnings,100,50,7/1/2021
253604,public-offering,100,43,7/1/2021
2A9C0A,conference-call,100,50,7/1/2021
2AE625,conference-call,100,50,7/1/2021
2CC71C,business-contract,100,69,7/1/2021
2EB88B,unit-acquisition-completed-acquirer,100,49,7/1/2021
2EB88B,note-sale,100,52,7/1/2021
30DFD3,conference-call,100,50,7/1/2021
326EDD,conference-call,100,50,7/1/2021
34A959,earnings,100,50,7/1/2021
34B411,earnings,100,50,7/1/2021
34B97A,stake-acquirer,100,48,7/1/2021
370C50,conference-call,100,50,7/1/2021
37B120,legal-issues-defendant,100,22,7/1/2021
39BFF6,conference-call,100,50,7/1/2021
3A4BDB,conference-call,100,50,7/1/2021
3BBD10,acquisition-completed-acquirer,100,49,7/1/2021
3E15F6,conference-call,100,50,7/1/2021
3EE65E,partnership,100,61,7/1/2021
3F4668,executive-appointment,100,54,7/1/2021
3F96D5,partnership,100,61,7/1/2021
3F96D5,partnership,100,61,7/1/2021
41785E,earnings,100,50,7/1/2021
41B53E,dividend,100,50,7/1/2021
4290EF,product-release,100,64,7/1/2021
442769,government-contract,100,69,7/1/2021
4885C8,earnings,100,50,7/1/2021
4B49CF,dividend,100,50,7/1/2021
4B5054,conference-call,100,50,7/1/2021
4B6EF9,earnings,100,50,7/1/2021
4C37C5,partnership,100,61,7/1/2021
4EC4C1,conference-call,100,50,7/1/2021
4FCC78,dividend,100,50,7/1/2021
507AE7,earnings,100,50,7/1/2021
51888A,conference-call,100,50,7/1/2021
56B7C1,dividend,100,50,7/1/2021
57DDB9,unit-acquisition-completed-acquirer,100,49,7/1/2021
59C539,conference-call,100,50,7/1/2021
61B81B,dividend-up,100,81,7/1/2021
633054,spin-off,100,58,7/1/2021
633054,spin-off,100,58,7/1/2021
651C85,earnings,100,50,7/1/2021
665618,dividend,100,50,7/1/2021
66A667,earnings,100,50,7/1/2021
68B03F,executive-appointment,100,54,7/1/2021
68BA15,dividend,100,50,7/1/2021
6A6BDC,partnership,100,61,7/1/2021
6AACDD,legal-issues-defendant,100,22,7/1/2021
6AACDD,legal-issues-defendant,100,22,7/1/2021
6AACDD,fraud-defendant,100,20,7/1/2021
6B0784,conference-call,100,50,7/1/2021
6B0784,conference-call,100,50,7/1/2021
6C6D73,public-offering,100,43,7/1/2021
6E1E61,conference-call,100,50,7/1/2021
723548,dividend,100,50,7/1/2021
726EEA,facility-sale,100,52,7/1/2021
729368,earnings,100,50,7/1/2021
731675,conference-call,100,50,7/1/2021
747219,earnings,100,50,7/1/2021
75F982,partnership,100,61,7/1/2021
763724,dividend,100,50,7/1/2021
76D79A,conference-call,100,50,7/1/2021
790D0D,conference-call,100,50,7/1/2021
7A5097,legal-issues-defendant,100,22,7/1/2021
7AC86E,spin-off,100,58,7/1/2021
7AC86E,spin-off,100,58,7/1/2021
7AC86E,spin-off,100,58,7/1/2021
7B492C,index-listing,100,76,7/1/2021
7E2DE6,earnings,100,50,7/1/2021
7E3F8F,unit-acquisition-acquirer,100,49,7/1/2021
7F3FBC,acquisition-completed-acquirer,100,49,7/1/2021
810A4B,unit-acquisition-completed-acquirer,100,49,7/1/2021
819492,clinical-trials-start,100,64,7/1/2021
845533,executive-appointment,100,54,7/1/2021
84A6B9,earnings,100,50,7/1/2021
86A1B9,executive-appointment,100,54,7/1/2021
890FF4,stake-acquiree,100,62,7/1/2021
8AA108,public-offering,100,43,7/1/2021
8C6C1B,facility-open,100,65,7/1/2021
8DCBBB,conference-call,100,50,7/1/2021
911AB8,conference-call,100,50,7/1/2021
93AD2E,earnings,100,50,7/1/2021
940C3D,business-contract,100,69,7/1/2021
944B2E,asset-sale,100,62,7/1/2021
950CDB,product-price-raise,100,57,7/1/2021
96F126,earnings,100,50,7/1/2021
97B027,acquisition-completed-acquirer,100,49,7/1/2021
9810C0,conference-call,100,50,7/1/2021
99B61C,clinical-trials,100,56,7/1/2021
9C5174,earnings,100,50,7/1/2021
9D56F2,revenues,100,50,7/1/2021
9D56F2,revenues,100,50,7/1/2021
9D56F2,revenues,100,50,7/1/2021
9D56F2,revenues,100,50,7/1/2021
9D56F2,revenues,100,50,7/1/2021
9F18FA,executive-appointment,100,54,7/1/2021
9F18FA,executive-appointment,100,54,7/1/2021
9F37C5,dividend,100,50,7/1/2021
A2C979,partnership,100,61,7/1/2021
A5B913,earnings,100,50,7/1/2021
A868C9,business-contract,100,69,7/1/2021
A8CBDA,earnings,100,50,7/1/2021
AD9F1D,conference-call,100,50,7/1/2021
AFBEB4,public-offering,100,43,7/1/2021
AFDF2E,dividend,100,50,7/1/2021
B0FE08,executive-appointment,100,54,7/1/2021
B1B10C,acquisition-acquirer,100,49,7/1/2021
B4703C,conference-call,100,50,7/1/2021
B604DF,conference-call,100,50,7/1/2021
B72D2E,business-contract,100,69,7/1/2021
B72D2E,stake-acquirer,100,48,7/1/2021
B7BDA3,executive-appointment,100,54,7/1/2021
BB0587,asset-sale,100,62,7/1/2021
BB0587,unit-acquisition-acquiree,100,76,7/1/2021
BCC55F,award,100,58,7/1/2021
BCC55F,award,100,58,7/1/2021
BE379D,private-placement,100,56,7/1/2021
BEB756,executive-appointment,100,54,7/1/2021
C0200F,earnings,100,50,7/1/2021
C16A8F,business-contract,100,69,7/1/2021
C2609A,acquisition-completed-acquirer,100,49,7/1/2021
C2E120,dividend,100,50,7/1/2021
C2F597,spin-off,100,58,7/1/2021
C5D2AE,earnings,100,50,7/1/2021
C7AE14,dividend,100,50,7/1/2021
C8A248,award,100,58,7/1/2021
C8A248,acquisition-completed-acquirer,100,49,7/1/2021
C941DC,executive-appointment,100,54,7/1/2021
C99CC8,partnership,100,61,7/1/2021
C9D866,conference-call,100,50,7/1/2021
CBB77B,executive-appointment,100,54,7/1/2021
CC8F6E,unit-acquisition-acquiree,100,76,7/1/2021
CE4E6D,executive-appointment,100,54,7/1/2021
CF6A5A,earnings,100,50,7/1/2021
CFF15D,partnership,100,61,7/1/2021
D17C1B,executive-appointment,100,54,7/1/2021
D54E62,conference-call,100,50,7/1/2021
D5A350,acquisition-completed-acquirer,100,49,7/1/2021
D60BB2,executive-appointment,100,54,7/1/2021
D89753,acquisition-completed-acquiree,100,76,7/1/2021
DBB28E,acquisition-acquirer,100,49,7/1/2021
DBB7ED,patent-awarded,100,72,7/1/2021
DBCA3F,acquisition-completed-acquirer,100,49,7/1/2021
DBCA3F,acquisition-completed-acquirer,100,49,7/1/2021
DC6AA0,earnings,100,50,7/1/2021
DF18E6,executive-appointment,100,54,7/1/2021
E05DC8,executive-resignation,100,44,7/1/2021
E0647D,acquisition-acquirer,100,49,7/1/2021
E0D3BA,acquisition-completed-acquirer,100,49,7/1/2021
E0E4B7,clinical-trials,100,56,7/1/2021
E0E4B7,clinical-trials,100,56,7/1/2021
E12A6E,earnings,100,50,7/1/2021
E21871,acquisition-completed-acquirer,100,49,7/1/2021
E26FC3,acquisition-completed-acquirer,100,49,7/1/2021
E2F130,earnings,100,50,7/1/2021
E2F130,dividend,100,50,7/1/2021
E9FF33,earnings,100,50,7/1/2021
EC8116,dividend,100,50,7/1/2021
ED4560,unit-acquisition-completed-acquiree,100,67,7/1/2021
ED9576,earnings,100,50,7/1/2021
EE967B,earnings-guidance,100,50,7/1/2021
EF5BED,executive-appointment,100,54,7/1/2021
EF5BED,executive-appointment,100,54,7/1/2021
F0B2B5,executive-appointment,100,54,7/1/2021
F1CD47,earnings,100,50,7/1/2021
F2BC3D,acquisition-completed-acquirer,100,49,7/1/2021
F3EDB4,business-contract,100,69,7/1/2021
F42FAE,earnings-per-share-guidance,100,50,7/1/2021
F4FBD8,executive-resignation,100,44,7/1/2021
F5D059,earnings,100,50,7/1/2021
FACF19,earnings-above-expectations,100,88,7/1/2021
FE89E0,conference-call,100,50,7/1/2021
FEE4B0,earnings,100,50,7/1/2021
0157B1,legal-issues-defendant,100,22,7/2/2021
054B55,acquisition-completed-acquiree,100,76,7/2/2021
55018,partnership,100,61,7/2/2021
09DE1F,regulatory-investigation,100,22,7/2/2021
0A7650,legal-issues-defendant,100,22,7/2/2021
0B7375,legal-issues-defendant,100,22,7/2/2021
0B7375,legal-issues-defendant,100,22,7/2/2021
10AE08,earnings,100,50,7/2/2021
12E454,earnings,100,50,7/2/2021
15901B,executive-appointment,100,54,7/2/2021
2D643C,conference-call,100,50,7/2/2021
315EB0,conference-call,100,50,7/2/2021
338544,conference-call,100,50,7/2/2021
33AD83,conference-call,100,50,7/2/2021
342218,conference-call,100,50,7/2/2021
3.50E+27,conference-call,100,50,7/2/2021
38C46F,dividend,100,50,7/2/2021
3DC887,earnings,100,50,7/2/2021
44DDBD,legal-issues-defendant,100,22,7/2/2021
44ED36,earnings,100,50,7/2/2021
45ABCC,revenue-down,100,30,7/2/2021
4A3438,trading-halt,100,43,7/2/2021
4B3555,earnings,100,50,7/2/2021
4CDA2B,partnership,100,61,7/2/2021
4CDA2B,partnership,100,61,7/2/2021
4CDA2B,partnership,100,61,7/2/2021
50070E,acquisition-acquirer,100,49,7/2/2021
50070E,acquisition-acquirer,100,49,7/2/2021
50070E,acquisition-acquirer,100,49,7/2/2021
556F08,legal-issues-defendant,100,22,7/2/2021
5D1329,public-offering,100,43,7/2/2021
61BCA7,acquisition-completed-acquirer,100,49,7/2/2021
63F892,earnings,100,50,7/2/2021
6AACDD,legal-issues-defendant,100,22,7/2/2021
6C6D73,public-offering,100,43,7/2/2021
76BD96,dividend,100,50,7/2/2021
76CEFB,earnings,100,50,7/2/2021
78F776,earnings,100,50,7/2/2021
7B4B91,merger,100,66,7/2/2021
7D97DE,conference-call,100,50,7/2/2021
8295B8,dividend,100,50,7/2/2021
87486A,conference-call,100,50,7/2/2021
8C6C1B,facility-open,100,65,7/2/2021
902255,revenue-guidance-up,100,83,7/2/2021
922F0C,earnings,100,50,7/2/2021
95A92E,merger,100,66,7/2/2021
95A92E,legal-issues-defendant,100,22,7/2/2021
95DC1F,partnership,100,61,7/2/2021
9F6B1A,earnings,100,50,7/2/2021
A21649,acquisition-completed-acquirer,100,49,7/2/2021
A80FE0,conference-call,100,50,7/2/2021
A99576,legal-issues-defendant,100,22,7/2/2021
AADE0B,business-contract,100,69,7/2/2021
ADF092,merger,100,66,7/2/2021
AEFC90,product-delayed,100,36,7/2/2021
B2E6B5,executive-appointment,100,54,7/2/2021
BD15E8,merger,100,66,7/2/2021
C03C8B,donation,100,54,7/2/2021
C27E19,earnings,100,50,7/2/2021
C3CF29,legal-issues-defendant,100,22,7/2/2021
C9E107,earnings,100,50,7/2/2021
CD4DA8,executive-appointment,100,54,7/2/2021
CF351E,settlement,100,56,7/2/2021
CFF57D,acquisition-completed-acquirer,100,49,7/2/2021
D56E4C,conference-call,100,50,7/2/2021
D56E4C,conference-call,100,50,7/2/2021
DF11D9,legal-issues-defendant,100,22,7/2/2021
E0339F,earnings,100,50,7/2/2021
E6EDED,conference-call,100,50,7/2/2021
EBC84C,earnings,100,50,7/2/2021
ED4560,dividend,100,50,7/2/2021
EE6F1C,earnings,100,50,7/2/2021
EE6F1C,unit-acquisition-completed-acquiree,100,67,7/2/2021
EE6F1C,unit-acquisition-completed-acquiree,100,67,7/2/2021
EEB5F9,legal-issues-defendant,100,22,7/2/2021
F294DD,dividend,100,50,7/2/2021
F5D059,dividend,100,50,7/2/2021
F5D499,trading-resumed,100,58,7/2/2021
F793FA,legal-issues-defendant,100,22,7/2/2021
FC4550,dividend,100,50,7/2/2021
0B7375,legal-issues-defendant,100,22,7/3/2021
1FE7F0,legal-issues-defendant,100,22,7/3/2021
6AACDD,legal-issues-defendant,100,22,7/3/2021
AD1ACF,product-recall,100,29,7/3/2021
C22BE8,legal-issues-defendant,100,22,7/3/2021
C3CF29,legal-issues-defendant,100,22,7/3/2021
0CC62B,acquisition-acquirer,100,49,7/5/2021
152E1D,acquisition-acquiree,100,76,7/5/2021
190B91,business-contract,100,69,7/5/2021
267718,business-contract,100,69,7/5/2021
5.47E+28,business-contract,100,69,7/5/2021
6AACDD,legal-issues-defendant,100,22,7/5/2021
AD1ACF,product-recall,100,29,7/5/2021
C5C137,partnership,100,61,7/5/2021
C5F463,product-release,100,64,7/5/2021
00326D,conference-call,100,50,7/6/2021
078D52,dividend,100,50,7/6/2021
081AB9,conference-call,100,50,7/6/2021
0B400D,earnings,100,50,7/6/2021
0B7375,legal-issues-defendant,100,22,7/6/2021
0C355F,partnership,100,61,7/6/2021
0C355F,partnership,100,61,7/6/2021
0C355F,partnership,100,61,7/6/2021
0CBC4D,earnings,100,50,7/6/2021
129DC8,conference-call,100,50,7/6/2021
12DE76,partnership,100,61,7/6/2021
15A388,acquisition-completed-acquirer,100,49,7/6/2021
1880C5,hirings,100,65,7/6/2021
1921DD,partnership,100,61,7/6/2021
1921DD,partnership,100,61,7/6/2021
19CAC7,conference-call,100,50,7/6/2021
1EBF8D,partnership,100,61,7/6/2021
1F352C,earnings,100,50,7/6/2021
206852,conference-call,100,50,7/6/2021
20BEEA,conference-call,100,50,7/6/2021
20BEEA,buybacks,100,74,7/6/2021
221783,partnership,100,61,7/6/2021
251988,partnership,100,61,7/6/2021
253604,public-offering,100,43,7/6/2021
2667B6,earnings,100,50,7/6/2021
270305,executive-appointment,100,54,7/6/2021
284289,unit-acquisition-acquirer,100,49,7/6/2021
29A4CC,conference-call,100,50,7/6/2021
2B7A40,earnings,100,50,7/6/2021
2BF36E,conference-call,100,50,7/6/2021
2C681C,conference-call,100,50,7/6/2021
30E01D,partnership,100,61,7/6/2021
30E01D,partnership,100,61,7/6/2021
37020C,conference-call,100,50,7/6/2021
37727A,conference-call,100,50,7/6/2021
387541,conference-call,100,50,7/6/2021
389CFB,executive-appointment,100,54,7/6/2021
39FB23,executive-appointment,100,54,7/6/2021
3A4BDB,executive-appointment,100,54,7/6/2021
3B9886,facility-open,100,65,7/6/2021
3C7F5F,earnings,100,50,7/6/2021
3F4668,executive-appointment,100,54,7/6/2021
4398A2,clinical-trials-filed,100,60,7/6/2021
43A060,product-release,100,64,7/6/2021
442587,business-contract,100,69,7/6/2021
442587,business-contract,100,69,7/6/2021
442769,product-release,100,64,7/6/2021
492117,executive-appointment,100,54,7/6/2021
4A6F00,partnership,100,61,7/6/2021
4A6F00,partnership,100,61,7/6/2021
4EE167,partnership,100,61,7/6/2021
4F9926,partnership,100,61,7/6/2021
52015A,dividend,100,50,7/6/2021
532D47,conference-call,100,50,7/6/2021
53A226,executive-appointment,100,54,7/6/2021
546A9C,conference-call,100,50,7/6/2021
548AC0,conference-call,100,50,7/6/2021
56277A,conference-call,100,50,7/6/2021
57356F,acquisition-acquirer,100,49,7/6/2021
5B51D6,clinical-trials,100,56,7/6/2021
5C8D61,earnings,100,50,7/6/2021
5E6959,conference-call,100,50,7/6/2021
5F9CE3,earnings,100,50,7/6/2021
5FF95F,earnings,100,50,7/6/2021
60EA12,earnings,100,50,7/6/2021
620381,executive-appointment,100,54,7/6/2021
64E346,conference-participant,100,50,7/6/2021
65D0AA,regulatory-product-approval-granted,100,81,7/6/2021
65D0AA,regulatory-product-approval-granted,100,81,7/6/2021
69E8E1,conference-call,100,50,7/6/2021
69E8E1,conference-call,100,50,7/6/2021
6AACDD,legal-issues-defendant,100,22,7/6/2021
6BF593,acquisition-acquirer,100,49,7/6/2021
6D0CAB,operating-earnings,100,50,7/6/2021
6D6B40,earnings,100,50,7/6/2021
6-Dec-05,conference-participant,100,50,7/6/2021
6.00E+19,earnings,100,50,7/6/2021
6F39FC,public-offering,100,43,7/6/2021
713810,campaign-ad-release,100,59,7/6/2021
72C2CE,partnership,100,61,7/6/2021
73529F,merger-regulatory-scrutiny,100,37,7/6/2021
741937,earnings,100,50,7/6/2021
7.44E+09,conference-call,100,50,7/6/2021
7448A3,conference-call,100,50,7/6/2021
75F982,business-contract,100,69,7/6/2021
766047,executive-appointment,100,54,7/6/2021
771985,conference-call,100,50,7/6/2021
7732C2,conference-participant,100,50,7/6/2021
77B8E9,patent-awarded,100,72,7/6/2021
7.83E+79,earnings,100,50,7/6/2021
787D14,acquisition-completed-acquirer,100,49,7/6/2021
7E1542,earnings,100,50,7/6/2021
7F3669,acquisition-completed-acquirer,100,49,7/6/2021
7F3A5F,earnings,100,50,7/6/2021
82E58A,conference-call,100,50,7/6/2021
873DB9,partnership,100,61,7/6/2021
8802B4,conference-call,100,50,7/6/2021
883D82,legal-issues-defendant,100,22,7/6/2021
8A8E41,product-release,100,64,7/6/2021
8C6C1B,facility-open,100,65,7/6/2021
9043FE,earnings,100,50,7/6/2021
9043FE,earnings,100,50,7/6/2021
92005C,clinical-trials-positive,100,87,7/6/2021
92D757,partnership,100,61,7/6/2021
93D207,earnings,100,50,7/6/2021
95DC1F,partnership,100,61,7/6/2021
965360,earnings,100,50,7/6/2021
966DBE,note-sale,100,52,7/6/2021
966DBE,note-sale,100,52,7/6/2021
99ACAD,partnership,100,61,7/6/2021
99ACAD,partnership,100,61,7/6/2021
9C8BC3,conference-call,100,50,7/6/2021
9CA4C6,conference-call,100,50,7/6/2021
9CA619,unit-acquisition-completed-acquirer,100,49,7/6/2021
9D5FA4,partnership,100,61,7/6/2021
9D5FA4,partnership,100,61,7/6/2021
9D5FA4,partnership,100,61,7/6/2021
9EED50,conference-call,100,50,7/6/2021
A01664,earnings,100,50,7/6/2021
A1E3B3,partnership,100,61,7/6/2021
A1EAC8,acquisition-acquirer,100,49,7/6/2021
A1EAC8,conference-call,100,50,7/6/2021
A41450,dividend,100,50,7/6/2021
A4386C,earnings,100,50,7/6/2021
A4A612,conference-call,100,50,7/6/2021
A5151E,earnings,100,50,7/6/2021
A87CD6,earnings,100,50,7/6/2021
A9ED24,conference-call,100,50,7/6/2021
AA98ED,partnership,100,61,7/6/2021
AA98ED,conference-call,100,50,7/6/2021
AD1ACF,unit-acquisition-completed-acquiree,100,67,7/6/2021
AE3113,earnings,100,50,7/6/2021
AEFC90,clinical-trials-positive,100,87,7/6/2021
AFBEB4,executive-appointment,100,54,7/6/2021
AFF7B4,conference-call,100,50,7/6/2021
B1DF3C,award,100,58,7/6/2021
B1DF3C,award,100,58,7/6/2021
B4C673,partnership,100,61,7/6/2021
B72BE9,conference-call,100,50,7/6/2021
B76C82,settlement,100,56,7/6/2021
B8F71F,executive-appointment,100,54,7/6/2021
B96637,conference-call,100,50,7/6/2021
B9CD50,partnership,100,61,7/6/2021
BBAE2A,conference-call,100,50,7/6/2021
BC5680,partnership,100,61,7/6/2021
BC5680,partnership,100,61,7/6/2021
BC5680,partnership,100,61,7/6/2021
BEB756,conference-call,100,50,7/6/2021
BFD0A7,unit-acquisition-acquiree,100,76,7/6/2021
C356AC,partnership,100,61,7/6/2021
C356AC,partnership,100,61,7/6/2021
C7859D,dividend,100,50,7/6/2021
C951A2,earnings,100,50,7/6/2021
CB7AB2,conference-call,100,50,7/6/2021
CBA33B,earnings,100,50,7/6/2021
CBBFBF,partnership,100,61,7/6/2021
CBBFBF,partnership,100,61,7/6/2021
CE2791,conference-call,100,50,7/6/2021
CEC5B9,executive-appointment,100,54,7/6/2021
CF073E,public-offering,100,43,7/6/2021
D296C6,note-sale,100,52,7/6/2021
D36B23,clinical-trials-start,100,64,7/6/2021
D721C6,executive-appointment,100,54,7/6/2021
D77F7E,earnings,100,50,7/6/2021
D854F3,conference-call,100,50,7/6/2021
D88EF3,conference-call,100,50,7/6/2021
DC0066,conference-participant,100,50,7/6/2021
DC1405,earnings,100,50,7/6/2021
DC5299,conference-call,100,50,7/6/2021
DD682D,earnings,100,50,7/6/2021
DF01B1,conference-call,100,50,7/6/2021
DF1F7A,conference-call,100,50,7/6/2021
DF532D,conference-call,100,50,7/6/2021
E0207A,partnership,100,61,7/6/2021
E28D9C,conference-call,100,50,7/6/2021
E35610,conference-call,100,50,7/6/2021
E802CE,conference-call,100,50,7/6/2021
E8B315,conference-call,100,50,7/6/2021
E90C84,facility-open,100,65,7/6/2021
ED9576,acquisition-acquirer,100,49,7/6/2021
EDD234,conference-call,100,50,7/6/2021
EE967B,partnership,100,61,7/6/2021
EE967B,partnership,100,61,7/6/2021
EF25A5,partnership,100,61,7/6/2021
EF5BED,executive-appointment,100,54,7/6/2021
EF5BED,earnings,100,50,7/6/2021
EF7163,conference-call,100,50,7/6/2021
F3EDB4,earnings,100,50,7/6/2021
F4E882,earnings,100,50,7/6/2021
F5C78B,conference-call,100,50,7/6/2021
F721A7,earnings,100,50,7/6/2021
F721A7,earnings,100,50,7/6/2021
F83279,earnings,100,50,7/6/2021
F92DBC,partnership,100,61,7/6/2021
F92DBC,partnership,100,61,7/6/2021
F92DBC,partnership,100,61,7/6/2021
F92DBC,partnership,100,61,7/6/2021
FB728F,conference-call,100,50,7/6/2021
FD0CA4,conference-call,100,50,7/6/2021
FD2565,business-contract,100,69,7/6/2021
FDC7E6,conference-call,100,50,7/6/2021
FDF28E,executive-appointment,100,54,7/6/2021
00067A,business-contract,100,69,7/7/2021
003B70,legal-issues-defendant,100,22,7/7/2021
31025,earnings,100,50,7/7/2021
51332,earnings,100,50,7/7/2021
083F72,conference-call,100,50,7/7/2021
099C88,executive-appointment,100,54,7/7/2021
0A0D9E,product-release,100,64,7/7/2021
0A7650,legal-issues-defendant,100,22,7/7/2021
0B57D7,conference-call,100,50,7/7/2021
0B7375,acquisition-acquiree,100,76,7/7/2021
1151F4,conference-call,100,50,7/7/2021
1782D5,conference-call,100,50,7/7/2021
1921DD,partnership,100,61,7/7/2021
1CDD1C,conference-call,100,50,7/7/2021
1DF15D,conference-call,100,50,7/7/2021
1F08A6,conference-call,100,50,7/7/2021
1F9D90,conference-call,100,50,7/7/2021
1FE7F0,legal-issues-defendant,100,22,7/7/2021
21153F,buybacks,100,74,7/7/2021
21153F,buybacks,100,74,7/7/2021
21153F,buybacks,100,74,7/7/2021
21153F,buybacks,100,74,7/7/2021
22C58E,earnings,100,50,7/7/2021
24A89A,clinical-trials,100,56,7/7/2021
24CB56,dividend,100,50,7/7/2021
26D8ED,conference-call,100,50,7/7/2021
275300,conference-call,100,50,7/7/2021
28DCA8,earnings-guidance,100,50,7/7/2021
2950FF,earnings,100,50,7/7/2021
2950FF,earnings,100,50,7/7/2021
2A6DBE,business-contract,100,69,7/7/2021
2B0AF4,conference-call,100,50,7/7/2021
2B9DBB,conference-call,100,50,7/7/2021
2C35B5,conference-participant,100,50,7/7/2021
2D485F,executive-appointment,100,54,7/7/2021
2E0496,earnings,100,50,7/7/2021
2E0496,earnings,100,50,7/7/2021
2E89AE,earnings,100,50,7/7/2021
34B411,legal-issues-defendant,100,22,7/7/2021
371B0A,conference-participant,100,50,7/7/2021
3A6D90,dividend,100,50,7/7/2021
3BB616,earnings,100,50,7/7/2021
3BCF24,earnings,100,50,7/7/2021
3ED92D,earnings-guidance,100,50,7/7/2021
420168,earnings,100,50,7/7/2021
44209A,earnings,100,50,7/7/2021
442587,business-contract,100,69,7/7/2021
442769,partnership,100,61,7/7/2021
44DDBD,legal-issues-defendant,100,22,7/7/2021
45444E,earnings,100,50,7/7/2021
46A16E,conference-participant,100,50,7/7/2021
47752F,earnings,100,50,7/7/2021
47FCF2,earnings,100,50,7/7/2021
4BDCA7,headquarters-change,100,50,7/7/2021
4DD203,executive-appointment,100,54,7/7/2021
4EE14A,earnings,100,50,7/7/2021
51D876,earnings,100,50,7/7/2021
520632,acquisition-acquiree,100,76,7/7/2021
5.47E+28,conference-participant,100,50,7/7/2021
5487B1,conference-call,100,50,7/7/2021
55438C,earnings,100,50,7/7/2021
556F08,legal-issues-defendant,100,22,7/7/2021
5675EB,earnings,100,50,7/7/2021
56B7C1,conference-call,100,50,7/7/2021
589803,earnings,100,50,7/7/2021
59B229,earnings,100,50,7/7/2021
5A423F,earnings,100,50,7/7/2021
5B6C11,partnership,100,61,7/7/2021
5B97B2,earnings,100,50,7/7/2021
5D1956,earnings,100,50,7/7/2021
5D43A7,partnership,100,61,7/7/2021
5EC388,earnings,100,50,7/7/2021
605F40,conference-call,100,50,7/7/2021
60DD84,conference-call,100,50,7/7/2021
622DBE,legal-issues-defendant,100,22,7/7/2021
6284B5,business-contract,100,69,7/7/2021
62B20A,conference-call,100,50,7/7/2021
62CDDE,conference-participant,100,50,7/7/2021
633043,earnings,100,50,7/7/2021
63E8D5,earnings,100,50,7/7/2021
665D7D,conference-call,100,50,7/7/2021
69CE71,dividend,100,50,7/7/2021
6AACDD,legal-issues-defendant,100,22,7/7/2021
6B236C,conference-call,100,50,7/7/2021
6C6D73,market-entry,100,57,7/7/2021
6C6D73,public-offering,100,43,7/7/2021
6CB7F9,conference-call,100,50,7/7/2021
6E705B,campaign-ad-release,100,59,7/7/2021
6F0096,conference-call,100,50,7/7/2021
6F39FC,public-offering,100,43,7/7/2021
71B0CF,conference-participant,100,50,7/7/2021
7.40E+289,earnings,100,50,7/7/2021
75D689,conference-participant,100,50,7/7/2021
79167B,conference-call,100,50,7/7/2021
797C20,conference-call,100,50,7/7/2021
7BFF81,executive-appointment,100,54,7/7/2021
7D7716,earnings,100,50,7/7/2021
8.10E+32,conference-call,100,50,7/7/2021
8.40E+120,conference-participant,100,50,7/7/2021
855DF7,conference-call,100,50,7/7/2021
863350,executive-appointment,100,54,7/7/2021
86478F,product-release,100,64,7/7/2021
8665BA,partnership,100,61,7/7/2021
8665BA,partnership,100,61,7/7/2021
8665BA,partnership,100,61,7/7/2021
8665BA,partnership,100,61,7/7/2021
8665BA,conference-call,100,50,7/7/2021
877734,conference-participant,100,50,7/7/2021
89FBB1,conference-call,100,50,7/7/2021
8AC65D,credit-extension-recipient,100,69,7/7/2021
8B2C4A,conference-call,100,50,7/7/2021
8BE916,earnings,100,50,7/7/2021
8C6C1B,facility-open,100,65,7/7/2021
8D4486,partnership,100,61,7/7/2021
8D5145,earnings,100,50,7/7/2021
90D6A5,conference-call,100,50,7/7/2021
938D89,clinical-trials,100,56,7/7/2021
954A47,partnership,100,61,7/7/2021
95A92E,legal-issues-defendant,100,22,7/7/2021
9.62E+76,earnings,100,50,7/7/2021
968103,earnings,100,50,7/7/2021
96B4FF,conference-participant,100,50,7/7/2021
977A1E,conference-call,100,50,7/7/2021
990AD0,earnings,100,50,7/7/2021
9C5BA5,earnings,100,50,7/7/2021
9CE4C7,earnings,100,50,7/7/2021
9E5C2C,conference-call,100,50,7/7/2021
9F03CF,conference-call,100,50,7/7/2021
A2C979,clinical-trials-start,100,64,7/7/2021
A3800A,acquisition-acquiree,100,76,7/7/2021
A3800A,acquisition-acquiree,100,76,7/7/2021
A3800A,acquisition-acquiree,100,76,7/7/2021
A3800A,acquisition-acquiree,100,76,7/7/2021
A3F598,conference-call,100,50,7/7/2021
A4F67C,unit-acquisition-acquirer,100,49,7/7/2021
A74F6F,conference-call,100,50,7/7/2021
A7CCF0,executive-appointment,100,54,7/7/2021
A806FA,conference-call,100,50,7/7/2021
A99576,legal-issues-defendant,100,22,7/7/2021
AB7F05,earnings,100,50,7/7/2021
AD3008,earnings,100,50,7/7/2021
ADFB3A,conference-participant,100,50,7/7/2021
AFBEB4,earnings,100,50,7/7/2021
B2256A,unit-acquisition-acquiree,100,76,7/7/2021
B5766D,conference-call,100,50,7/7/2021
B840EF,conference-call,100,50,7/7/2021
B934BF,conference-call,100,50,7/7/2021
BA0442,partnership,100,61,7/7/2021
BA218A,conference-call,100,50,7/7/2021
BB5142,conference-call,100,50,7/7/2021
BB88B6,earnings,100,50,7/7/2021
BCC13E,conference-participant,100,50,7/7/2021
BCE9DA,earnings,100,50,7/7/2021
BCE9DA,earnings,100,50,7/7/2021
BD9668,acquisition-completed-acquirer,100,49,7/7/2021
BE7BA4,conference-call,100,50,7/7/2021
C037A8,executive-appointment,100,54,7/7/2021
C32A39,conference-call,100,50,7/7/2021
C3BAE7,earnings,100,50,7/7/2021
C3CF29,legal-issues-defendant,100,22,7/7/2021
C7FC95,business-contract,100,69,7/7/2021
CF211D,buybacks,100,74,7/7/2021
D06755,earnings,100,50,7/7/2021
D17F7E,acquisition-interest-acquirer,100,46,7/7/2021
D1C26F,business-contract,100,69,7/7/2021
D296C6,note-sale,100,52,7/7/2021
D518D8,conference-call,100,50,7/7/2021
D5938F,executive-appointment,100,54,7/7/2021
D6853F,conference-call,100,50,7/7/2021
D77F7E,partnership,100,61,7/7/2021
D77F7E,partnership,100,61,7/7/2021
D7A953,earnings,100,50,7/7/2021
D7AC6E,earnings,100,50,7/7/2021
DBB28E,partnership,100,61,7/7/2021
DDEA6A,conference-participant,100,50,7/7/2021
DE4924,conference-participant,100,50,7/7/2021
E28D9C,partnership,100,61,7/7/2021
E30B34,earnings,100,50,7/7/2021
E30B34,earnings,100,50,7/7/2021
E74B55,product-release,100,64,7/7/2021
E8846E,earnings,100,50,7/7/2021
E8A49A,earnings,100,50,7/7/2021
E9E6FD,conference-call,100,50,7/7/2021
EA79C7,conference-participant,100,50,7/7/2021
ECE814,earnings,100,50,7/7/2021
ED0402,earnings,100,50,7/7/2021
F02170,business-contract,100,69,7/7/2021
F3016C,earnings,100,50,7/7/2021
F50BAB,conference-call,100,50,7/7/2021
F793FA,legal-issues-defendant,100,22,7/7/2021
F9AA02,conference-participant,100,50,7/7/2021
FD4E8D,earnings,100,50,7/7/2021
FEC475,conference-call,100,50,7/7/2021
FFCD0E,business-contract,100,69,7/7/2021
00067A,business-contract,100,69,7/8/2021
001F1B,operating-earnings,100,50,7/8/2021
00326D,earnings,100,50,7/8/2021
00326D,earnings,100,50,7/8/2021
20751,conference-participant,100,50,7/8/2021
58828,dividend,100,50,7/8/2021
61366,investment-investor,100,55,7/8/2021
07CA6A,conference-call,100,50,7/8/2021
07CA6A,conference-call,100,50,7/8/2021
07EC43,partnership,100,61,7/8/2021
07EC43,partnership,100,61,7/8/2021
07EC43,partnership,100,61,7/8/2021
07EC43,conference-call,100,50,7/8/2021
091B6C,conference-participant,100,50,7/8/2021
091B6C,conference-participant,100,50,7/8/2021
099A92,conference-call,100,50,7/8/2021
09F623,conference-call,100,50,7/8/2021
0DE3D5,conference-call,100,50,7/8/2021
0F2BC9,conference-call,100,50,7/8/2021
10943B,conference-call,100,50,7/8/2021
12DE76,acquisition-completed-acquirer,100,49,7/8/2021
13C3E0,earnings,100,50,7/8/2021
1748B3,conference-call,100,50,7/8/2021
190B91,earnings,100,50,7/8/2021
1A1CB0,executive-appointment,100,54,7/8/2021
1AF7E2,conference-call,100,50,7/8/2021
1BC12C,executive-appointment,100,54,7/8/2021
228D42,partnership,100,61,7/8/2021
24C48B,executive-appointment,100,54,7/8/2021
25DD05,conference-call,100,50,7/8/2021
26DC29,executive-appointment,100,54,7/8/2021
2720AB,conference-call,100,50,7/8/2021
282C18,conference-call,100,50,7/8/2021
29B702,earnings,100,50,7/8/2021
2A02DC,partnership,100,61,7/8/2021
2A02DC,partnership,100,61,7/8/2021
2C3348,conference-participant,100,50,7/8/2021
2DA92D,conference-call,100,50,7/8/2021
2DB344,earnings,100,50,7/8/2021
2DC88B,earnings,100,50,7/8/2021
2E902B,business-contract,100,69,7/8/2021
2EB88B,earnings,100,50,7/8/2021
2F98A5,dividend-up,100,81,7/8/2021
317EC6,earnings,100,50,7/8/2021
317EC6,earnings,100,50,7/8/2021
317EC6,earnings,100,50,7/8/2021
37426C,earnings,100,50,7/8/2021
3798B9,executive-appointment,100,54,7/8/2021
387375,conference-call,100,50,7/8/2021
3A113F,conference-call,100,50,7/8/2021
3A3948,conference-call,100,50,7/8/2021
3B37F7,dividend,100,50,7/8/2021
3D7971,executive-appointment,100,54,7/8/2021
3DD5E2,conference-call,100,50,7/8/2021
3FBC9B,earnings,100,50,7/8/2021
408380,earnings,100,50,7/8/2021
45ABCC,product-release,100,64,7/8/2021
45BC35,conference-call,100,50,7/8/2021
46CF27,campaign-ad-release,100,59,7/8/2021
4806CE,conference-call,100,50,7/8/2021
4.91E+58,conference-call,100,50,7/8/2021
4A5C8D,acquisition-interest-acquirer,100,46,7/8/2021
4A5C8D,acquisition-interest-acquirer,100,46,7/8/2021
5088A5,earnings,100,50,7/8/2021
53E575,conference-call,100,50,7/8/2021
5546DA,conference-call,100,50,7/8/2021
567F3D,conference-call,100,50,7/8/2021
5A0FF1,earnings,100,50,7/8/2021
60FE03,conference-participant,100,50,7/8/2021
6166D1,unit-acquisition-acquirer,100,49,7/8/2021
639BD6,earnings,100,50,7/8/2021
69CE71,business-contract,100,69,7/8/2021
6AACDD,legal-issues-defendant,100,22,7/8/2021
6AACDD,legal-issues-defendant,100,22,7/8/2021
6D9ECA,partnership,100,61,7/8/2021
6DBBBC,investment-investor,100,55,7/8/2021
6DBBBC,investment-investor,100,55,7/8/2021
6F39FC,dividend,100,50,7/8/2021
6F6559,executive-appointment,100,54,7/8/2021
6F6559,dividend,100,50,7/8/2021
728737,dividend,100,50,7/8/2021
72FCA3,executive-appointment,100,54,7/8/2021
73C9E2,conference-call,100,50,7/8/2021
75F982,partnership,100,61,7/8/2021
75F982,partnership,100,61,7/8/2021
75F982,partnership,100,61,7/8/2021
76F067,regulatory-product-approval-granted,100,81,7/8/2021
7A10FF,earnings,100,50,7/8/2021
7A5097,legal-issues-defendant,100,22,7/8/2021
7B0BA6,earnings,100,50,7/8/2021
7B9212,revenues,100,50,7/8/2021
7BAAE7,earnings,100,50,7/8/2021
7F3665,unit-acquisition-acquirer,100,49,7/8/2021
80D744,conference-call,100,50,7/8/2021
8.10E+32,executive-appointment,100,54,7/8/2021
8.10E+32,dividend,100,50,7/8/2021
8303CD,conference-call,100,50,7/8/2021
837C04,conference-call,100,50,7/8/2021
85CDC9,conference-participant,100,50,7/8/2021
8665BA,regulatory-product-approval-granted,100,81,7/8/2021
8665BA,dividend,100,50,7/8/2021
881190,conference-call,100,50,7/8/2021
896771,conference-call,100,50,7/8/2021
8B1E11,partnership-terminated,100,36,7/8/2021
8C6C1B,facility-open,100,65,7/8/2021
8D4486,partnership,100,61,7/8/2021
8D4486,partnership,100,61,7/8/2021
8D4486,acquisition-acquirer,100,49,7/8/2021
931AE7,executive-appointment,100,54,7/8/2021
934029,conference-call,100,50,7/8/2021
945DE6,executive-appointment,100,54,7/8/2021
94756D,earnings,100,50,7/8/2021
9548BB,earnings,100,50,7/8/2021
95C392,conference-call,100,50,7/8/2021
96A2D3,earnings,100,50,7/8/2021
977A1E,partnership,100,61,7/8/2021
9D56F2,partnership,100,61,7/8/2021
9D5D35,trading-halt,100,43,7/8/2021
9D65C1,earnings,100,50,7/8/2021
9E298A,conference-call,100,50,7/8/2021
9FF5F1,earnings,100,50,7/8/2021
A1EAC8,conference-call,100,50,7/8/2021
A3AAA5,earnings,100,50,7/8/2021
A6828A,partnership,100,61,7/8/2021
A746F6,conference-call,100,50,7/8/2021
A75D43,conference-call,100,50,7/8/2021
A79D88,conference-participant,100,50,7/8/2021
A94718,conference-call,100,50,7/8/2021
AAEE21,conference-call,100,50,7/8/2021
AC1952,private-placement,100,56,7/8/2021
AC775C,conference-call,100,50,7/8/2021
AD23DE,conference-call,100,50,7/8/2021
AD6141,executive-appointment,100,54,7/8/2021
AD9F1D,executive-appointment,100,54,7/8/2021
B1DF3C,earnings,100,50,7/8/2021
B2E6B5,conference-call,100,50,7/8/2021
B7BDA3,conference-call,100,50,7/8/2021
B83BCE,earnings,100,50,7/8/2021
B8EF97,revenues,100,50,7/8/2021
BB02FB,conference-call,100,50,7/8/2021
BB88B6,award,100,58,7/8/2021
BBBB41,conference-call,100,50,7/8/2021
BD15E8,conference-call,100,50,7/8/2021
BD9668,conference-call,100,50,7/8/2021
BFF98A,conference-participant,100,50,7/8/2021
C0F70B,earnings,100,50,7/8/2021
C230FE,earnings,100,50,7/8/2021
C3BAE7,acquisition-completed-acquirer,100,49,7/8/2021
C41C25,earnings,100,50,7/8/2021
C941DC,executive-appointment,100,54,7/8/2021
C941DC,earnings,100,50,7/8/2021
CA212F,earnings,100,50,7/8/2021
CD4DA8,executive-appointment,100,54,7/8/2021
CE96E7,executive-appointment,100,54,7/8/2021
CF073E,public-offering,100,43,7/8/2021
CFF15D,partnership,100,61,7/8/2021
D06755,joint-venture,100,62,7/8/2021
D139BC,conference-call,100,50,7/8/2021
D15833,conference-call,100,50,7/8/2021
D18AFC,conference-participant,100,50,7/8/2021
D3CEDF,conference-call,100,50,7/8/2021
D6EAA3,conference-call,100,50,7/8/2021
D854F3,dividend,100,50,7/8/2021
D8760C,conference-call,100,50,7/8/2021
DC0998,conference-call,100,50,7/8/2021
DC0D18,earnings,100,50,7/8/2021
DF11D9,executive-appointment,100,54,7/8/2021
E05026,earnings,100,50,7/8/2021
E05DC8,earnings,100,50,7/8/2021
E12A6E,note-sale,100,52,7/8/2021
E2F130,award,100,58,7/8/2021
E3E68E,conference-call,100,50,7/8/2021
E3E68E,conference-call,100,50,7/8/2021
E8846E,executive-appointment,100,54,7/8/2021
E94704,conference-call,100,50,7/8/2021
EA62FC,conference-call,100,50,7/8/2021
EC70EC,earnings,100,50,7/8/2021
ED1A74,conference-participant,100,50,7/8/2021
ED5171,earnings,100,50,7/8/2021
EFA7B2,earnings,100,50,7/8/2021
F179ED,earnings,100,50,7/8/2021
F294DD,earnings,100,50,7/8/2021
F30508,partnership,100,61,7/8/2021
F7ADEB,product-release,100,64,7/8/2021
F93C8A,sponsorship,100,57,7/8/2021
FAB97A,earnings,100,50,7/8/2021
FC9A88,conference-call,100,50,7/8/2021
FD9526,earnings,100,50,7/8/2021
FEBFE1,legal-issues-defendant,100,22,7/8/2021
FFE543,partnership,100,61,7/8/2021
0BB9E5,executive-appointment,100,54,7/9/2021
0C4131,conference-call,100,50,7/9/2021
0F65C9,conference-call,100,50,7/9/2021
154272,executive-appointment,100,54,7/9/2021
1A5957,acquisition-acquiree,100,76,7/9/2021
1A5957,acquisition-regulatory-scrutiny-acquiree,100,38,7/9/2021
228D42,partnership,100,61,7/9/2021
25A6CC,earnings,100,50,7/9/2021
28DCF3,earnings,100,50,7/9/2021
2920D5,earnings,100,50,7/9/2021
2BA977,asset-sale,100,62,7/9/2021
2BBE62,earnings,100,50,7/9/2021
2CB4C9,earnings,100,50,7/9/2021
326EDD,legal-issues-defendant,100,22,7/9/2021
36C09B,conference-participant,100,50,7/9/2021
371C01,conference-call,100,50,7/9/2021
3DE4D1,earnings,100,50,7/9/2021
4A2457,partnership,100,61,7/9/2021
4EC4C1,earnings,100,50,7/9/2021
4EC4C1,earnings,100,50,7/9/2021
4EC4C1,earnings,100,50,7/9/2021
4EC4C1,earnings,100,50,7/9/2021
562853,conference-call,100,50,7/9/2021
57B174,dividend,100,50,7/9/2021
5B6C11,earnings,100,50,7/9/2021
5BFE94,conference-call,100,50,7/9/2021
67A658,business-contract,100,69,7/9/2021
6AACDD,legal-issues-defendant,100,22,7/9/2021
6AACDD,legal-issues-defendant,100,22,7/9/2021
6D0CAB,dividend,100,50,7/9/2021
72FCA3,executive-appointment,100,54,7/9/2021
78F9ED,conference-call,100,50,7/9/2021
7B6EB1,earnings,100,50,7/9/2021
838ADD,dividend,100,50,7/9/2021
83A065,executive-appointment,100,54,7/9/2021
88350F,conference-call,100,50,7/9/2021
88611B,earnings,100,50,7/9/2021
88923D,conference-call,100,50,7/9/2021
8C6C1B,facility-open,100,65,7/9/2021
8DBBE6,conference-call,100,50,7/9/2021
8DBE73,conference-call,100,50,7/9/2021
9.36E+10,business-contract,100,69,7/9/2021
97AF94,dividend,100,50,7/9/2021
980C14,conference-call,100,50,7/9/2021
986AF6,conference-call,100,50,7/9/2021
9EF4CF,partnership,100,61,7/9/2021
A15C71,conference-call,100,50,7/9/2021
A1A317,conference-call,100,50,7/9/2021
A5628C,earnings,100,50,7/9/2021
A6828A,partnership,100,61,7/9/2021
A6828A,product-release,100,64,7/9/2021
AA1EAA,conference-call,100,50,7/9/2021
AFDF2E,earnings,100,50,7/9/2021
AFDF2E,earnings,100,50,7/9/2021
B560AF,executive-appointment,100,54,7/9/2021
BDE867,operating-earnings,100,50,7/9/2021
C659EB,earnings,100,50,7/9/2021
C8FAC7,joint-venture,100,62,7/9/2021
C93C44,clinical-trials-positive,100,87,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CA1620,acquisition-interest-acquirer,100,46,7/9/2021
CC6FF5,earnings,100,50,7/9/2021
CD06A2,dividend,100,50,7/9/2021
CDE51C,earnings,100,50,7/9/2021
CE5664,earnings,100,50,7/9/2021
D0909F,earnings-guidance,100,50,7/9/2021
D63B0F,conference-call,100,50,7/9/2021
D78CCD,conference-call,100,50,7/9/2021
D95385,clinical-trials-positive,100,87,7/9/2021
DA48E4,executive-appointment,100,54,7/9/2021
DB396B,conference-call,100,50,7/9/2021
DBEF02,dividend-up,100,67,7/9/2021
DC0066,clinical-trials-start,100,64,7/9/2021
DCD97F,conference-call,100,50,7/9/2021
DD1BA1,product-release,100,64,7/9/2021
DF11D9,conference-call,100,50,7/9/2021
E0207A,earnings,100,50,7/9/2021
E30A8F,earnings,100,50,7/9/2021
ED0D7C,conference-call,100,50,7/9/2021
F02D0A,earnings,100,50,7/9/2021
F7902B,earnings,100,50,7/9/2021
F7ADEB,conference-call,100,50,7/9/2021
F80FF9,acquisition-completed-acquiree,100,76,7/9/2021
FF5413,earnings,100,50,7/9/2021
FF6644,conference-call,100,50,7/9/2021
556F08,legal-issues-defendant,100,22,7/10/2021
95A92E,legal-issues-defendant,100,22,7/10/2021
A99576,legal-issues-defendant,100,22,7/10/2021
DF11D9,legal-issues-defendant,100,22,7/10/2021
B303A6,award,100,58,7/11/2021
002A99,executive-appointment,100,54,7/12/2021
00D6B5,conference-call,100,50,7/12/2021
0142B5,conference-call,100,50,7/12/2021
0157B1,partnership,100,61,7/12/2021
03C94A,business-contract,100,69,7/12/2021
03C94A,public-offering,100,43,7/12/2021
040DBB,acquisition-completed-acquirer,100,49,7/12/2021
0919B1,conference-call,100,50,7/12/2021
0C355F,conference-call,100,50,7/12/2021
0E5223,conference-participant,100,50,7/12/2021
108BD2,acquisition-acquiree,100,76,7/12/2021
11AEDE,earnings,100,50,7/12/2021
11AEDE,public-offering,100,43,7/12/2021
1348C9,dividend,100,50,7/12/2021
14833D,business-contract,100,69,7/12/2021
168A5D,partnership,100,61,7/12/2021
182546,earnings,100,50,7/12/2021
184988,conference-participant,100,50,7/12/2021
197612,asset-sale,100,62,7/12/2021
1BDB2A,conference-call,100,50,7/12/2021
1D9E55,earnings,100,50,7/12/2021
1DB833,conference-participant,100,50,7/12/2021
1E5786,executive-appointment,100,54,7/12/2021
1FAF22,dividend,100,50,7/12/2021
21D903,earnings,100,50,7/12/2021
253604,clinical-trials,100,56,7/12/2021
2D76CE,earnings,100,50,7/12/2021
2E61CC,business-contract,100,69,7/12/2021
2E902B,conference-call,100,50,7/12/2021
2EB88B,facility-open,100,65,7/12/2021
2EBA55,dividend,100,50,7/12/2021
306623,conference-call,100,50,7/12/2021
309922,conference-call,100,50,7/12/2021
3.14E+47,earnings,100,50,7/12/2021
315416,regulatory-product-approval-granted,100,81,7/12/2021
315416,regulatory-product-approval-granted,100,81,7/12/2021
33E8C7,earnings,100,50,7/12/2021
3461CF,analyst-ratings-change-positive-rater,20,50,7/12/2021
34A959,partnership,100,61,7/12/2021
366A08,conference-call,100,50,7/12/2021
371B0A,conference-call,100,50,7/12/2021
384CD3,earnings,100,50,7/12/2021
3.88E+02,conference-call,100,50,7/12/2021
3A94DF,acquisition-completed-acquirer,100,49,7/12/2021
3B9886,facility-open,100,65,7/12/2021
3BC360,conference-call,100,50,7/12/2021
3F96D5,conference-participant,100,50,7/12/2021
408380,facility-open,100,65,7/12/2021
422CE3,joint-venture,100,62,7/12/2021
422CE3,joint-venture,100,62,7/12/2021
450ECB,executive-appointment,100,54,7/12/2021
450ECB,executive-appointment,100,54,7/12/2021
49A344,conference-call,100,50,7/12/2021
4B3676,earnings,100,50,7/12/2021
4D8124,earnings,100,50,7/12/2021
545272,public-offering,100,43,7/12/2021
546A9C,earnings,100,50,7/12/2021
55C9B5,conference-call,100,50,7/12/2021
55CD6F,stake-acquirer,100,48,7/12/2021
56765E,earnings,100,50,7/12/2021
59C539,executive-appointment,100,54,7/12/2021
5B6C11,executive-appointment,100,54,7/12/2021
5BC2F4,partnership,100,61,7/12/2021
5BE42C,conference-call,100,50,7/12/2021
5C2A47,conference-call,100,50,7/12/2021
5FDBD0,partnership,100,61,7/12/2021
5FE4B6,conference-call,100,50,7/12/2021
610D47,conference-call,100,50,7/12/2021
61A586,earnings,100,50,7/12/2021
62CDDE,conference-call,100,50,7/12/2021
665618,conference-call,100,50,7/12/2021
68B03F,earnings,100,50,7/12/2021
6AACDD,legal-issues-defendant,100,22,7/12/2021
6AACDD,legal-issues-defendant,100,22,7/12/2021
6C6D73,conference-call,100,50,7/12/2021
6E8864,executive-appointment,100,54,7/12/2021
6F22E7,conference-call,100,50,7/12/2021
71553E,executive-appointment,100,54,7/12/2021
72CB93,earnings,100,50,7/12/2021
73A71F,conference-call,100,50,7/12/2021
75F982,partnership,100,61,7/12/2021
75F982,partnership,100,61,7/12/2021
75F982,partnership,100,61,7/12/2021
77F01E,joint-venture,100,62,7/12/2021
77F01E,joint-venture,100,62,7/12/2021
7823A3,earnings,100,50,7/12/2021
79340A,executive-appointment,100,54,7/12/2021
7A3633,earnings,100,50,7/12/2021
7AB859,conference-call,100,50,7/12/2021
7B1E50,donation,100,54,7/12/2021
7B492C,executive-appointment,100,54,7/12/2021
7BC92D,partnership,100,61,7/12/2021
7CBC40,earnings,100,50,7/12/2021
7D5384,conference-call,100,50,7/12/2021
7DC1C4,earnings,100,50,7/12/2021
805CD8,public-offering,100,43,7/12/2021
8.22E+27,conference-call,100,50,7/12/2021
859281,unit-acquisition-acquirer,100,49,7/12/2021
89FBB1,dividend,100,50,7/12/2021
8BAA15,earnings,100,50,7/12/2021
8C6C1B,facility-open,100,65,7/12/2021
8FE7A5,earnings,100,50,7/12/2021
92D3A0,dividend,100,50,7/12/2021
9368BE,conference-call,100,50,7/12/2021
94563D,earnings,100,50,7/12/2021
94563D,executive-appointment,100,54,7/12/2021
99B61C,patient-enrollment-start,100,58,7/12/2021
9A02C4,conference-call,100,50,7/12/2021
9CA432,conference-call,100,50,7/12/2021
9D30A8,earnings,100,50,7/12/2021
9D5D35,earnings,100,50,7/12/2021
9FA83B,note-sale,100,52,7/12/2021
9FA83B,stake-acquiree,100,62,7/12/2021
9FF5F1,product-release,100,64,7/12/2021
A3AAA5,dividend,100,50,7/12/2021
A495F7,earnings,100,50,7/12/2021
A5DD24,executive-appointment,100,54,7/12/2021
A6828A,regulatory-product-approval-granted,100,81,7/12/2021
ABAA03,conference-participant,100,50,7/12/2021
AE7D16,note-sale,100,52,7/12/2021
B446B8,earnings,100,50,7/12/2021
B4703C,dividend,100,50,7/12/2021
B53C12,unit-acquisition-acquirer,100,49,7/12/2021
B5BA39,earnings,100,50,7/12/2021
B6843B,executive-appointment,100,54,7/12/2021
C01737,clinical-trials-start,100,64,7/12/2021
C1114B,executive-appointment,100,54,7/12/2021
C11C46,earnings,100,50,7/12/2021
C188F8,product-release,100,64,7/12/2021
C4F9C6,executive-appointment,100,54,7/12/2021
C7859D,business-contract,100,69,7/12/2021
C941DC,executive-appointment,100,54,7/12/2021
C94CFC,legal-issues-defendant,100,22,7/12/2021
C9E04B,executive-appointment,100,54,7/12/2021
CED4D0,conference-call,100,50,7/12/2021
CEDFD5,partnership,100,61,7/12/2021
CEDFD5,partnership,100,61,7/12/2021
CF073E,public-offering,100,43,7/12/2021
CFF15D,executive-appointment,100,54,7/12/2021
CFF97C,credit-rating-affirmation-rater,20,50,7/12/2021
D08D2C,dividend,100,50,7/12/2021
D1C26F,partnership,100,61,7/12/2021
D3C794,earnings,100,50,7/12/2021
D598E7,stake-acquirer,100,48,7/12/2021
D78BF1,facility-open,100,65,7/12/2021
D7918D,earnings,100,50,7/12/2021
D8DA3D,dividend,100,50,7/12/2021
DB5CA5,dividend,100,50,7/12/2021
DD1BA1,award,100,58,7/12/2021
DD1BA1,fundraising,100,64,7/12/2021
DD1BA1,fundraising,100,64,7/12/2021
DD1BA1,fundraising,100,64,7/12/2021
DDC415,earnings,100,50,7/12/2021
E16133,conference-call,100,50,7/12/2021
E21871,earnings,100,50,7/12/2021
E30A8F,executive-appointment,100,54,7/12/2021
E35610,partnership,100,61,7/12/2021
E3A829,business-contract,100,69,7/12/2021
E40FB6,acquisition-acquirer,100,49,7/12/2021
E41190,acquisition-acquirer,100,49,7/12/2021
E4158B,earnings,100,50,7/12/2021
E6BC2C,partnership,100,61,7/12/2021
E74B55,earnings,100,50,7/12/2021
E93A40,earnings,100,50,7/12/2021
E96E0B,conference-call,100,50,7/12/2021
ED2EFD,index-listing,100,76,7/12/2021
ED3CA8,conference-call,100,50,7/12/2021
ED7F13,earnings,100,50,7/12/2021
EEBCEF,acquisition-completed-acquirer,100,49,7/12/2021
EFA7B2,conference-participant,100,50,7/12/2021
F4E992,earnings,100,50,7/12/2021
F5349B,executive-appointment,100,54,7/12/2021
F8084B,earnings,100,50,7/12/2021
F9CAF8,conference-call,100,50,7/12/2021
00326E,conference-call,100,50,7/13/2021
08A40F,award,100,58,7/13/2021
09062E,earnings,100,50,7/13/2021
95294,earnings,100,50,7/13/2021
0A0D9E,partnership,100,61,7/13/2021
0BC17A,conference-call,100,50,7/13/2021
0C355F,legal-issues-plaintiff,100,44,7/13/2021
0CE204,business-contract,100,69,7/13/2021
0E499E,revenue-up,100,69,7/13/2021
0E499E,revenue-up,100,69,7/13/2021
0ED415,conference-call,100,50,7/13/2021
108BD2,merger-regulatory-scrutiny,100,37,7/13/2021
1220D2,earnings,100,50,7/13/2021
1272B3,earnings,100,50,7/13/2021
12E454,partnership,100,61,7/13/2021
152AB9,earnings,100,50,7/13/2021
1866B2,conference-call,100,50,7/13/2021
1921DD,business-contract,100,69,7/13/2021
1F19C8,acquisition-completed-acquirer,100,49,7/13/2021
1FC422,earnings,100,50,7/13/2021
1FCC00,executive-appointment,100,54,7/13/2021
1FE3CB,conference-call,100,50,7/13/2021
228D42,partnership,100,61,7/13/2021
228D42,partnership,100,61,7/13/2021
2E61CC,dividend,100,50,7/13/2021
30CBF9,business-contract,100,69,7/13/2021
3461CF,credit-rating-upgrade-rater,20,50,7/13/2021
372037,executive-appointment,100,54,7/13/2021
387541,dividend,100,50,7/13/2021
3ACF46,conference-call,100,50,7/13/2021
3B20AB,buybacks,100,74,7/13/2021
3B20AB,dividend,100,50,7/13/2021
3B2311,product-release,100,64,7/13/2021
3BBD10,earnings,100,50,7/13/2021
3CBA2A,conference-call,100,50,7/13/2021
415188,conference-call,100,50,7/13/2021
416C55,earnings,100,50,7/13/2021
44A4FC,business-contract,100,69,7/13/2021
458D2C,revenue-volume,100,50,7/13/2021
467F2C,conference-call,100,50,7/13/2021
47752F,acquisition-acquirer,100,49,7/13/2021
47BA98,conference-call,100,50,7/13/2021
499C75,partnership,100,61,7/13/2021
4BBA23,revenues,100,50,7/13/2021
4D971D,conference-call,100,50,7/13/2021
4EC4C1,executive-appointment,100,54,7/13/2021
50070E,executive-appointment,100,54,7/13/2021
51E682,business-contract,100,69,7/13/2021
545272,public-offering,100,43,7/13/2021
55C9B5,partnership,100,61,7/13/2021
577033,conference-call,100,50,7/13/2021
583A75,conference-call,100,50,7/13/2021
5B226B,partnership,100,61,7/13/2021
5B35C7,earnings-up,100,58,7/13/2021
5B35C7,earnings,100,50,7/13/2021
5B35C7,earnings,100,50,7/13/2021
5B7739,conference-call,100,50,7/13/2021
5C7601,business-contract,100,69,7/13/2021
5D16CF,executive-appointment,100,54,7/13/2021
5F1B7B,earnings,100,50,7/13/2021
609208,merger-regulatory-approval,100,81,7/13/2021
609208,merger-regulatory-approval,100,81,7/13/2021
6166D1,executive-appointment,100,54,7/13/2021
619882,earnings,100,50,7/13/2021
619882,partnership,100,61,7/13/2021
627186,earnings,100,50,7/13/2021
62A48D,conference-call,100,50,7/13/2021
65AB30,earnings,100,50,7/13/2021
69345C,earnings,100,50,7/13/2021
6AACDD,legal-issues-defendant,100,22,7/13/2021
6B494E,dividend,100,50,7/13/2021
6BD606,conference-call,100,50,7/13/2021
6BF593,conference-call,100,50,7/13/2021
7032D0,earnings,100,50,7/13/2021
726EEA,earnings,100,50,7/13/2021
73BCBA,partnership,100,61,7/13/2021
765913,award,100,58,7/13/2021
76F067,business-contract,100,69,7/13/2021
76F067,business-contract,100,69,7/13/2021
773A17,conference-call,100,50,7/13/2021
7AC86E,earnings,100,50,7/13/2021
7B9AFA,public-offering,100,43,7/13/2021
7C790D,unit-acquisition-acquirer,100,49,7/13/2021
7E3F8F,earnings,100,50,7/13/2021
804708,conference-call,100,50,7/13/2021
8.10E+32,executive-appointment,100,54,7/13/2021
81A88D,earnings,100,50,7/13/2021
85DE00,conference-call,100,50,7/13/2021
8665BA,partnership,100,61,7/13/2021
883D82,legal-issues-defendant,100,22,7/13/2021
89F693,earnings,100,50,7/13/2021
8A8E41,partnership,100,61,7/13/2021
8A8E41,partnership,100,61,7/13/2021
8AC65D,conference-call,100,50,7/13/2021
8C6C1B,facility-open,100,65,7/13/2021
8D4AE6,merger-regulatory-approval,100,81,7/13/2021
8D4AE6,merger-regulatory-approval,100,81,7/13/2021
8E0E32,dividend,100,50,7/13/2021
8E9CD8,earnings,100,50,7/13/2021
915E7B,public-offering,100,43,7/13/2021
918D6D,public-offering,100,43,7/13/2021
925759,business-contract,100,69,7/13/2021
925759,business-contract,100,69,7/13/2021
92D3A0,earnings,100,50,7/13/2021
93633B,conference-call,100,50,7/13/2021
94C0B5,conference-participant,100,50,7/13/2021
977A1E,acquisition-failed-acquiree,100,21,7/13/2021
979451,note-sale,100,52,7/13/2021
9.86E+03,earnings,100,50,7/13/2021
990AD0,dividend,100,50,7/13/2021
9C8664,merger,100,66,7/13/2021
9C8664,merger,100,66,7/13/2021
9CDA4F,acquisition-acquirer,100,49,7/13/2021
9E0811,earnings,100,50,7/13/2021
9EA947,partnership,100,61,7/13/2021
9EBAFA,dividend,100,50,7/13/2021
9F048E,earnings,100,50,7/13/2021
A01983,dividend,100,50,7/13/2021
A60318,earnings,100,50,7/13/2021
A60318,executive-appointment,100,54,7/13/2021
A9ED24,dividend,100,50,7/13/2021
ABE7DC,executive-appointment,100,54,7/13/2021
AC1952,workforce-salary-increase,100,44,7/13/2021
ACF77B,dividend,100,50,7/13/2021
AED6CF,conference-call,100,50,7/13/2021
AFD1CA,conference-call,100,50,7/13/2021
B05118,product-release,100,64,7/13/2021
B13B68,conference-call,100,50,7/13/2021
B303A6,partnership,100,61,7/13/2021
B54A74,earnings,100,50,7/13/2021
B8EF97,dividend,100,50,7/13/2021
B8F71F,partnership,100,61,7/13/2021
B9764A,partnership,100,61,7/13/2021
B9CD50,earnings,100,50,7/13/2021
BA218A,executive-appointment,100,54,7/13/2021
C32A39,merger,100,66,7/13/2021
C32A39,merger,100,66,7/13/2021
C356AC,earnings,100,50,7/13/2021
C4706C,dividend,100,50,7/13/2021
C48574,executive-appointment,100,54,7/13/2021
C48574,revenue-up,100,69,7/13/2021
C48574,revenue-up,100,69,7/13/2021
C48574,revenue-up,100,69,7/13/2021
C48574,revenue-up,100,69,7/13/2021
C48574,revenue-up,100,69,7/13/2021
C564E4,regulatory-product-approval-granted,100,81,7/13/2021
C584BE,business-contract,100,69,7/13/2021
C66B44,conference-call,100,50,7/13/2021
C7859D,earnings,100,50,7/13/2021
C7859D,earnings,100,50,7/13/2021
C7AE14,conference-call,100,50,7/13/2021
C8257F,earnings,100,50,7/13/2021
C83B88,executive-appointment,100,54,7/13/2021
CA3CB9,conference-call,100,50,7/13/2021
CC6FF5,partnership,100,61,7/13/2021
CDAF5B,conference-call,100,50,7/13/2021
CE5664,partnership,100,61,7/13/2021
CE96E7,earnings,100,50,7/13/2021
CFB6CA,executive-appointment,100,54,7/13/2021
D17C1B,earnings,100,50,7/13/2021
D25249,conference-call,100,50,7/13/2021
D29F43,conference-call,100,50,7/13/2021
D33270,business-contract,100,69,7/13/2021
D3F64D,conference-call,100,50,7/13/2021
D82EF3,conference-call,100,50,7/13/2021
D90F43,conference-call,100,50,7/13/2021
DA0CB8,conference-call,100,50,7/13/2021
DD1BA1,executive-appointment,100,54,7/13/2021
DD3BB1,earnings,100,50,7/13/2021
DF1F7A,acquisition-regulatory-scrutiny-acquiree,100,38,7/13/2021
E12A6E,dividend,100,50,7/13/2021
E6C8DC,conference-call,100,50,7/13/2021
E6D89E,earnings,100,50,7/13/2021
E6E012,earnings,100,50,7/13/2021
E6E012,earnings,100,50,7/13/2021
E87676,conference-call,100,50,7/13/2021
E8A49A,partnership,100,61,7/13/2021
E8E899,executive-appointment,100,54,7/13/2021
E90C84,conference-call,100,50,7/13/2021
EB36DE,conference-call,100,50,7/13/2021
EDF5CA,conference-call,100,50,7/13/2021
EEA6B3,trading-halt,100,43,7/13/2021
EEA6B3,trading-resumed,100,58,7/13/2021
EF1AD9,conference-call,100,50,7/13/2021
F0B335,earnings,100,50,7/13/2021
F46EC9,earnings,100,50,7/13/2021
F57F6F,award,100,58,7/13/2021
F6FA6A,conference-call,100,50,7/13/2021
F85CC0,earnings,100,50,7/13/2021
F85CC0,earnings,100,50,7/13/2021
FAE021,earnings,100,50,7/13/2021
FAEABE,earnings-per-share-positive,100,69,7/13/2021
FAEABE,earnings,100,50,7/13/2021
FAEABE,earnings,100,50,7/13/2021
FE89E0,dividend,100,50,7/13/2021
FEC475,partnership,100,61,7/13/2021
FF4343,executive-appointment,100,54,7/13/2021
FF6644,partnership,100,61,7/13/2021
FFAB4A,earnings,100,50,7/13/2021
0157B1,legal-issues-defendant,100,22,7/14/2021
03D5F9,earnings,100,50,7/14/2021
054B55,earnings,100,50,7/14/2021
099C88,conference-call,100,50,7/14/2021
0B4D10,earnings,100,50,7/14/2021
0BC29E,partnership,100,61,7/14/2021
0BC853,conference-call,100,50,7/14/2021
0C6293,partnership,100,61,7/14/2021
0DC050,earnings,100,50,7/14/2021
0F91FC,conference-call,100,50,7/14/2021
11074E,conference-call,100,50,7/14/2021
11AEDE,public-offering,100,43,7/14/2021
1490F3,joint-venture,100,62,7/14/2021
1490F3,joint-venture,100,62,7/14/2021
152E1D,merger,100,66,7/14/2021
157D9F,earnings,100,50,7/14/2021
15A388,business-contract,100,69,7/14/2021
180DA0,conference-call,100,50,7/14/2021
1D9E55,product-release,100,64,7/14/2021
1F19C8,earnings,100,50,7/14/2021
20403D,acquisition-acquiree,100,76,7/14/2021
221783,earnings,100,50,7/14/2021
222BF9,conference-call,100,50,7/14/2021
227D48,conference-call,100,50,7/14/2021
228D42,business-contract,100,69,7/14/2021
228D42,partnership,100,61,7/14/2021
239106,layoffs,100,43,7/14/2021
2.45E+15,earnings,100,50,7/14/2021
253B2F,executive-appointment,100,54,7/14/2021
28F905,earnings,100,50,7/14/2021
2ABF77,executive-resignation,100,44,7/14/2021
2B49F4,government-contract,100,69,7/14/2021
2CBB58,conference-call,100,50,7/14/2021
2E902B,executive-appointment,100,54,7/14/2021
2EC172,conference-call,100,50,7/14/2021
2F960F,earnings,100,50,7/14/2021
3.14E+47,partnership,100,61,7/14/2021
31666F,dividend,100,50,7/14/2021
31666F,executive-appointment,100,54,7/14/2021
3461CF,credit-rating-upgrade-rater,20,50,7/14/2021
3461CF,credit-rating-upgrade-rater,20,50,7/14/2021
3461CF,credit-rating-set-rater,20,50,7/14/2021
3587B4,business-contract,100,69,7/14/2021
35F4B5,conference-call,100,50,7/14/2021
3696BF,conference-call,100,50,7/14/2021
370C50,dividend,100,50,7/14/2021
370C50,buybacks,100,74,7/14/2021
37B120,business-contract,100,69,7/14/2021
382EAE,conference-call,100,50,7/14/2021
3A113F,business-contract,100,69,7/14/2021
3BE00F,earnings,100,50,7/14/2021
3DCECC,conference-call,100,50,7/14/2021
3EE65E,partnership,100,61,7/14/2021
3FACA7,dividend,100,50,7/14/2021
3FACA7,executive-appointment,100,54,7/14/2021
43E8F5,conference-call,100,50,7/14/2021
45444E,acquisition-completed-acquirer,100,49,7/14/2021
46017C,conference-call,100,50,7/14/2021
468DD4,earnings,100,50,7/14/2021
46A16E,conference-call,100,50,7/14/2021
4.60E+06,executive-appointment,100,54,7/14/2021
47FCF2,partnership,100,61,7/14/2021
4B3676,earnings,100,50,7/14/2021
4BBA23,conference-call,100,50,7/14/2021
4D229C,executive-appointment,100,54,7/14/2021
50D1EC,executive-appointment,100,54,7/14/2021
513A86,earnings,100,50,7/14/2021
514067,conference-call,100,50,7/14/2021
51527B,conference-call,100,50,7/14/2021
5225A4,conference-organizer,100,57,7/14/2021
525A1C,earnings,100,50,7/14/2021
53A226,earnings,100,50,7/14/2021
53C421,conference-call,100,50,7/14/2021
545272,conference-call,100,50,7/14/2021
55438C,partnership,100,61,7/14/2021
5704AC,earnings,100,50,7/14/2021
58CA9A,earnings,100,50,7/14/2021
5BE42C,executive-appointment,100,54,7/14/2021
5F2FF7,earnings,100,50,7/14/2021
619882,partnership,100,61,7/14/2021
61B81B,earnings-positive,100,69,7/14/2021
61B81B,earnings,100,50,7/14/2021
61B81B,earnings,100,50,7/14/2021
61B81B,earnings,100,50,7/14/2021
61B81B,earnings,100,50,7/14/2021
61B81B,earnings,100,50,7/14/2021
61B81B,earnings,100,50,7/14/2021
622DBE,conference-call,100,50,7/14/2021
64636E,public-offering,100,43,7/14/2021
66CB62,partnership,100,61,7/14/2021
6AACDD,legal-issues-defendant,100,22,7/14/2021
6AACDD,legal-issues-defendant,100,22,7/14/2021
6AACDD,legal-issues-defendant,100,22,7/14/2021
6ABCB8,earnings,100,50,7/14/2021
6BBCBA,conference-participant,100,50,7/14/2021
6C4D2F,conference-call,100,50,7/14/2021
6C987C,earnings-positive,100,69,7/14/2021
6D3F35,conference-call,100,50,7/14/2021
713810,partnership,100,61,7/14/2021
71E2EF,earnings,100,50,7/14/2021
7273FF,earnings,100,50,7/14/2021
73BCBA,conference-call,100,50,7/14/2021
789A7D,earnings,100,50,7/14/2021
7A3633,acquisition-acquirer,100,49,7/14/2021
7ACD98,earnings,100,50,7/14/2021
7B9AFA,public-offering,100,43,7/14/2021
7D35D8,earnings,100,50,7/14/2021
7D5FD6,executive-appointment,100,54,7/14/2021
82C202,executive-appointment,100,54,7/14/2021
82E58A,dividend,100,50,7/14/2021
830BDB,conference-call,100,50,7/14/2021
835C86,acquisition-acquirer,100,49,7/14/2021
838ADD,earnings,100,50,7/14/2021
85DA04,earnings,100,50,7/14/2021
88193E,conference-call,100,50,7/14/2021
883D82,legal-issues-defendant,100,22,7/14/2021
89F693,merger-rumor,100,73,7/14/2021
89F693,merger-rumor,100,73,7/14/2021
8AB37F,business-contract,100,69,7/14/2021
8C6C1B,facility-open,100,65,7/14/2021
8C6C1B,executive-resignation,100,44,7/14/2021
8F8F2F,conference-call,100,50,7/14/2021
901327,note-sale,100,52,7/14/2021
918D6D,public-offering,100,43,7/14/2021
918D6D,public-offering,100,43,7/14/2021
918D6D,public-offering,100,43,7/14/2021
9.36E+10,partnership,100,61,7/14/2021
94208D,earnings,100,50,7/14/2021
942165,earnings,100,50,7/14/2021
942165,dividend,100,50,7/14/2021
943239,product-release,100,64,7/14/2021
950AB7,earnings,100,50,7/14/2021
972356,business-contract,100,69,7/14/2021
990AD0,earnings,100,50,7/14/2021
9.92E+94,earnings,100,50,7/14/2021
9B5968,dividend,100,50,7/14/2021
9B5968,dividend,100,50,7/14/2021
9C8664,merger-regulatory-scrutiny,100,37,7/14/2021
9CF9B1,earnings,100,50,7/14/2021
9D30A8,partnership,100,61,7/14/2021
9D5FA4,earnings,100,50,7/14/2021
9DDE1B,conference-call,100,50,7/14/2021
9EA947,conference-call,100,50,7/14/2021
9F5997,conference-call,100,50,7/14/2021
9FB4B7,conference-participant,100,50,7/14/2021
9FD2D9,conference-call,100,50,7/14/2021
A02FB1,conference-call,100,50,7/14/2021
A204A7,earnings,100,50,7/14/2021
A247F5,award,100,58,7/14/2021
A6828A,product-recall,100,29,7/14/2021
AA5C8E,earnings,100,50,7/14/2021
AAC8B6,conference-call,100,50,7/14/2021
AAC8B6,conference-call,100,50,7/14/2021
AADE0B,conference-call,100,50,7/14/2021
AC7C4F,conference-call,100,50,7/14/2021
AD9F1D,dividend-up,100,81,7/14/2021
AE7D16,note-sale,100,52,7/14/2021
AFEC35,earnings,100,50,7/14/2021
AFF43F,earnings,100,50,7/14/2021
B0B969,conference-call,100,50,7/14/2021
B1B10C,dividend,100,50,7/14/2021
B2DAF6,earnings,100,50,7/14/2021
B7FA9B,conference-call,100,50,7/14/2021
B9764A,earnings,100,50,7/14/2021
B9CD50,executive-appointment,100,54,7/14/2021
BB127B,campaign-ad-release,100,59,7/14/2021
BB5142,government-contract,100,69,7/14/2021
BB5271,conference-call,100,50,7/14/2021
BB58FF,conference-organizer,100,57,7/14/2021
BBF349,earnings,100,50,7/14/2021
BD9668,merger,100,66,7/14/2021
BDD12C,earnings,100,50,7/14/2021
BDE867,award,100,58,7/14/2021
C32A39,dividend,100,50,7/14/2021
C48574,executive-appointment,100,54,7/14/2021
C5C0E9,executive-appointment,100,54,7/14/2021
C8257F,executive-appointment,100,54,7/14/2021
C9B932,earnings,100,50,7/14/2021
CAD7D9,conference-call,100,50,7/14/2021
CBBFBF,earnings,100,50,7/14/2021
CD051C,conference-call,100,50,7/14/2021
CD4DA8,conference-call,100,50,7/14/2021
CD4DA8,executive-appointment,100,54,7/14/2021
CEC5B9,conference-call,100,50,7/14/2021
CFF15D,dividend,100,50,7/14/2021
D2B9E5,earnings,100,50,7/14/2021
D3CEDF,settlement,100,56,7/14/2021
D3CEDF,settlement,100,56,7/14/2021
D437C3,earnings,100,50,7/14/2021
D5AF19,earnings,100,50,7/14/2021
D76AEF,facility-open,100,65,7/14/2021
DA199F,partnership,100,61,7/14/2021
DB06B0,earnings,100,50,7/14/2021
DB5CA5,earnings,100,50,7/14/2021
DC2B00,hirings,100,65,7/14/2021
DD3BB1,unit-acquisition-acquiree,100,76,7/14/2021
E074A0,earnings,100,50,7/14/2021
E09E2B,partnership,100,61,7/14/2021
E1E36F,earnings,100,50,7/14/2021
E6D89E,partnership,100,61,7/14/2021
E6D89E,partnership,100,61,7/14/2021
E8846E,earnings,100,50,7/14/2021
E8E899,award,100,58,7/14/2021
E93A40,product-release,100,64,7/14/2021
EB5E78,conference-call,100,50,7/14/2021
EC99D0,business-contract,100,69,7/14/2021
ED22DC,executive-appointment,100,54,7/14/2021
ED2A5E,conference-call,100,50,7/14/2021
EEEA9F,conference-call,100,50,7/14/2021
F179ED,acquisition-completed-acquirer,100,49,7/14/2021
F30508,business-contract,100,69,7/14/2021
F32F88,conference-call,100,50,7/14/2021
F42FAE,acquisition-acquirer,100,49,7/14/2021
F88A04,partnership,100,61,7/14/2021
FA35C6,earnings,100,50,7/14/2021
FACCF6,earnings-up,100,68,7/14/2021
FACF19,dividend-up,100,81,7/14/2021
FB7724,earnings,100,50,7/14/2021
FC1736,earnings,100,50,7/14/2021
FE9C0D,partnership,100,61,7/14/2021
FE9C0D,partnership,100,61,7/14/2021
FF6644,executive-appointment,100,54,7/14/2021
002A99,regulatory-investigation,100,22,7/15/2021
13528,dividend,100,50,7/15/2021
0157B1,partnership,100,61,7/15/2021
0157B1,conference-call,100,50,7/15/2021
0358AF,earnings,100,50,7/15/2021
03B431,conference-call,100,50,7/15/2021
03C94A,public-offering,100,43,7/15/2021
03FB17,earnings,100,50,7/15/2021
43862,conference-call,100,50,7/15/2021
04EB2F,earnings,100,50,7/15/2021
61366,earnings,100,50,7/15/2021
71860,earnings,100,50,7/15/2021
07C907,earnings,100,50,7/15/2021
07C907,earnings,100,50,7/15/2021
07C907,earnings,100,50,7/15/2021
083F72,dividend,100,50,7/15/2021
0A0CF0,earnings,100,50,7/15/2021
0BB9E5,earnings,100,50,7/15/2021
0BC29E,earnings,100,50,7/15/2021
0BD4E8,conference-call,100,50,7/15/2021
0BF528,executive-appointment,100,54,7/15/2021
0C2A0D,earnings,100,50,7/15/2021
0F04E5,earnings,100,50,7/15/2021
1096C6,earnings,100,50,7/15/2021
131443,partnership,100,61,7/15/2021
135B09,conference-call,100,50,7/15/2021
14833D,earnings,100,50,7/15/2021
1748B3,executive-resignation,100,44,7/15/2021
17EDA5,dividend,100,50,7/15/2021
182B8C,conference-call,100,50,7/15/2021
182BE7,earnings,100,50,7/15/2021
188394,dividend,100,50,7/15/2021
19BF16,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A3E1B,earnings,100,50,7/15/2021
1A6A94,dividend,100,50,7/15/2021
1B9535,earnings,100,50,7/15/2021
1BDB2A,acquisition-completed-acquirer,100,49,7/15/2021
1BDB2A,acquisition-completed-acquirer,100,49,7/15/2021
1CD09C,partnership,100,61,7/15/2021
1DEBBE,earnings,100,50,7/15/2021
205AD5,earnings,100,50,7/15/2021
2158DF,earnings,100,50,7/15/2021
221445,conference-call,100,50,7/15/2021
223552,clinical-trials-start,100,64,7/15/2021
239106,conference-call,100,50,7/15/2021
251988,award,100,58,7/15/2021
26F31D,product-release,100,64,7/15/2021
270B78,conference-call,100,50,7/15/2021
27C10F,earnings,100,50,7/15/2021
291651,earnings,100,50,7/15/2021
292388,partnership,100,61,7/15/2021
2A1009,conference-call,100,50,7/15/2021
2A17B1,conference-call,100,50,7/15/2021
2B49F4,business-contract,100,69,7/15/2021
2C19A4,conference-call,100,50,7/15/2021
2E89AE,trading-resumed,100,58,7/15/2021
314D88,earnings,100,50,7/15/2021
328250,conference-call,100,50,7/15/2021
32C8CD,earnings,100,50,7/15/2021
32CB22,conference-call,100,50,7/15/2021
343996,dividend,100,50,7/15/2021
343996,dividend,100,50,7/15/2021
349DA4,earnings,100,50,7/15/2021
356B21,partnership,100,61,7/15/2021
356B21,partnership,100,61,7/15/2021
372037,executive-appointment,100,54,7/15/2021
39FB23,executive-appointment,100,54,7/15/2021
3C3B6B,earnings,100,50,7/15/2021
3C6CCC,earnings,100,50,7/15/2021
3C7F5F,business-contract,100,69,7/15/2021
3F4668,earnings,100,50,7/15/2021
3F6A9C,executive-appointment,100,54,7/15/2021
3F868D,conference-call,100,50,7/15/2021
4.03E+05,conference-call,100,50,7/15/2021
40F7DE,award,100,58,7/15/2021
42AABD,conference-call,100,50,7/15/2021
434F38,earnings,100,50,7/15/2021
442769,business-contract,100,69,7/15/2021
449A26,earnings-positive,100,69,7/15/2021
449A26,dividend,100,50,7/15/2021
451D61,conference-call,100,50,7/15/2021
479930,earnings,100,50,7/15/2021
48F795,earnings,100,50,7/15/2021
494EB9,earnings,100,50,7/15/2021
4A6F00,product-release,100,64,7/15/2021
4AE584,partnership,100,61,7/15/2021
4C5CC9,conference-call,100,50,7/15/2021
4E2D94,earnings,100,50,7/15/2021
4EEE7E,earnings,100,50,7/15/2021
51F541,conference-call,100,50,7/15/2021
52015A,conference-call,100,50,7/15/2021
52FB2F,earnings,100,50,7/15/2021
53EF9E,conference-call,100,50,7/15/2021
54512F,merger,100,66,7/15/2021
54512F,merger,100,66,7/15/2021
550D01,unit-acquisition-acquirer,100,49,7/15/2021
556F08,legal-issues-defendant,100,22,7/15/2021
55ACCB,earnings,100,50,7/15/2021
56632F,earnings,100,50,7/15/2021
57F3DA,earnings,100,50,7/15/2021
58CA9A,dividend,100,50,7/15/2021
59F0B0,dividend,100,50,7/15/2021
5B3415,conference-call,100,50,7/15/2021
5BC2F4,dividend,100,50,7/15/2021
5BC2F4,dividend,100,50,7/15/2021
5C7601,partnership,100,61,7/15/2021
5CCDAD,earnings,100,50,7/15/2021
5D0337,earnings,100,50,7/15/2021
5D16CF,conference-call,100,50,7/15/2021
5DAF89,conference-call,100,50,7/15/2021
5E1DF3,sponsorship,100,57,7/15/2021
5EAA43,conference-call,100,50,7/15/2021
6166D1,earnings,100,50,7/15/2021
619882,partnership,100,61,7/15/2021
619882,partnership,100,61,7/15/2021
619882,dividend,100,50,7/15/2021
622037,earnings,100,50,7/15/2021
6284B5,conference-call,100,50,7/15/2021
62EFEE,earnings,100,50,7/15/2021
641F17,dividend,100,50,7/15/2021
6559D8,legal-issues-defendant,100,22,7/15/2021
662682,conference-call,100,50,7/15/2021
6634D9,earnings,100,50,7/15/2021
665440,executive-appointment,100,54,7/15/2021
698FF9,earnings,100,50,7/15/2021
69C99E,earnings,100,50,7/15/2021
6AACDD,legal-issues-defendant,100,22,7/15/2021
6CC55E,earnings,100,50,7/15/2021
6D1ADF,conference-call,100,50,7/15/2021
6D4636,partnership,100,61,7/15/2021
6DC1D7,conference-call,100,50,7/15/2021
713810,partnership,100,61,7/15/2021
713810,partnership,100,61,7/15/2021
717DB4,earnings,100,50,7/15/2021
732449,executive-resignation,100,44,7/15/2021
73529F,executive-appointment,100,54,7/15/2021
74404C,conference-call,100,50,7/15/2021
752A70,earnings,100,50,7/15/2021
7710F3,conference-call,100,50,7/15/2021
773A17,conference-organizer,100,57,7/15/2021
791D59,earnings,100,50,7/15/2021
791EC1,earnings,100,50,7/15/2021
7AF5B8,clinical-trials,100,56,7/15/2021
7B9AFA,earnings,100,50,7/15/2021
7DD584,revenue-guidance,100,50,7/15/2021
7DD8CC,conference-call,100,50,7/15/2021
7E62B5,conference-call,100,50,7/15/2021
810FAD,conference-call,100,50,7/15/2021
810FAD,conference-call,100,50,7/15/2021
81222C,earnings,100,50,7/15/2021
81222C,earnings,100,50,7/15/2021
830BDB,regulatory-product-approval-granted,100,81,7/15/2021
855DF7,dividend,100,50,7/15/2021
8665BA,facility-open,100,65,7/15/2021
86A1B9,earnings,100,50,7/15/2021
877C0C,earnings,100,50,7/15/2021
895D56,conference-call,100,50,7/15/2021
8B3B0E,acquisition-regulatory-scrutiny-acquiree,100,38,7/15/2021
8B8656,partnership,100,61,7/15/2021
8C6C1B,facility-open,100,65,7/15/2021
8D4486,acquisition-acquirer,100,49,7/15/2021
8D4486,partnership,100,61,7/15/2021
8D9993,conference-call,100,50,7/15/2021
8E8E6E,partnership,100,61,7/15/2021
8FF2EF,earnings,100,50,7/15/2021
900356,conference-call,100,50,7/15/2021
903AB4,dividend,100,50,7/15/2021
9196A2,earnings,100,50,7/15/2021
9196A2,earnings,100,50,7/15/2021
9196A2,earnings,100,50,7/15/2021
9196A2,earnings,100,50,7/15/2021
92D757,executive-appointment,100,54,7/15/2021
931AE7,executive-appointment,100,54,7/15/2021
93965C,earnings,100,50,7/15/2021
9470CC,earnings,100,50,7/15/2021
94756D,conference-participant,100,50,7/15/2021
950CDB,product-price-raise,100,57,7/15/2021
9673BD,conference-call,100,50,7/15/2021
96F126,facility-open,100,65,7/15/2021
9.74E+08,partnership,100,61,7/15/2021
97644E,note-sale,100,52,7/15/2021
97644E,note-sale,100,52,7/15/2021
97AAF6,dividend,100,50,7/15/2021
98CEBB,earnings,100,50,7/15/2021
98D33E,dividend,100,50,7/15/2021
99ACAD,earnings,100,50,7/15/2021
9B4066,unit-acquisition-acquirer,100,49,7/15/2021
9B71A7,partnership,100,61,7/15/2021
9B71A7,partnership,100,61,7/15/2021
9C8664,legal-issues-defendant,100,22,7/15/2021
9F71E5,executive-appointment,100,54,7/15/2021
A4CD53,earnings,100,50,7/15/2021
A4D173,conference-call,100,50,7/15/2021
A4D173,conference-call,100,50,7/15/2021
A6828A,legal-issues-defendant,100,22,7/15/2021
A6828A,legal-issues-defendant,100,22,7/15/2021
A6D095,business-contract,100,69,7/15/2021
A6D095,business-contract,100,69,7/15/2021
A6D095,business-contract,100,69,7/15/2021
A7A0BD,executive-appointment,100,54,7/15/2021
A7CCF0,conference-call,100,50,7/15/2021
A871B0,product-release,100,64,7/15/2021
A99576,legal-issues-defendant,100,22,7/15/2021
AA247D,earnings,100,50,7/15/2021
AEF2C3,conference-call,100,50,7/15/2021
AFD7DD,conference-call,100,50,7/15/2021
B0D41A,earnings,100,50,7/15/2021
B1A85D,acquisition-interest-acquirer,100,46,7/15/2021
B1A85D,acquisition-interest-acquirer,100,46,7/15/2021
B2206F,earnings,100,50,7/15/2021
B642E8,earnings,100,50,7/15/2021
B6843B,earnings,100,50,7/15/2021
B7BBFF,dividend,100,50,7/15/2021
BBBB41,dividend,100,50,7/15/2021
BD8517,earnings,100,50,7/15/2021
BD9668,merger,100,66,7/15/2021
BDCC11,earnings,100,50,7/15/2021
BF79F5,conference-call,100,50,7/15/2021
BFAEB4,earnings,100,50,7/15/2021
C0030A,earnings,100,50,7/15/2021
C4706C,conference-call,100,50,7/15/2021
C66A8C,earnings,100,50,7/15/2021
C6C702,earnings,100,50,7/15/2021
C7AE14,dividend,100,50,7/15/2021
C8257F,executive-appointment,100,54,7/15/2021
C9B932,investment-investor,100,55,7/15/2021
CAB222,conference-call,100,50,7/15/2021
CB6A9C,conference-call,100,50,7/15/2021
CB88B3,earnings,100,50,7/15/2021
CC3EC4,patent-awarded,100,72,7/15/2021
CDE118,product-resumed,100,52,7/15/2021
CEC08B,partnership,100,61,7/15/2021
CF6A5A,union-pact,100,61,7/15/2021
D296C6,note-sale,100,52,7/15/2021
D3CEDF,executive-appointment,100,54,7/15/2021
D54E62,partnership,100,61,7/15/2021
D64EDF,earnings,100,50,7/15/2021
D6534D,conference-call,100,50,7/15/2021
D65A13,conference-call,100,50,7/15/2021
D697DE,earnings,100,50,7/15/2021
D88EF3,business-contract,100,69,7/15/2021
D8ECA1,earnings,100,50,7/15/2021
D90F43,partnership,100,61,7/15/2021
D9E036,earnings,100,50,7/15/2021
DA0A9E,executive-appointment,100,54,7/15/2021
DA199F,conference-organizer,100,57,7/15/2021
DA48E4,dividend,100,50,7/15/2021
DC437D,earnings,100,50,7/15/2021
DDB002,conference-call,100,50,7/15/2021
DF11D9,legal-issues-defendant,100,22,7/15/2021
DF5F14,executive-appointment,100,54,7/15/2021
E19A99,earnings,100,50,7/15/2021
E1C16B,dividend,100,50,7/15/2021
E2CFD2,conference-call,100,50,7/15/2021
E3656D,conference-call,100,50,7/15/2021
E6D89E,executive-appointment,100,54,7/15/2021
E84500,dividend,100,50,7/15/2021
E8846E,business-contract,100,69,7/15/2021
EAEBF3,dividend,100,50,7/15/2021
ED2EFD,executive-appointment,100,54,7/15/2021
ED9C04,earnings,100,50,7/15/2021
EEB5F9,acquisition-completed-acquiree,100,76,7/15/2021
EEB5F9,acquisition-completed-acquiree,100,76,7/15/2021
EEB5F9,acquisition-completed-acquiree,100,76,7/15/2021
EF5BED,dividend,100,50,7/15/2021
EF5BED,earnings-positive,100,69,7/15/2021
EF5BED,earnings,100,50,7/15/2021
EF5BED,earnings,100,50,7/15/2021
EF5BED,earnings,100,50,7/15/2021
F11638,product-release,100,64,7/15/2021
F30508,partnership,100,61,7/15/2021
F46EC9,earnings,100,50,7/15/2021
F51DB0,conference-call,100,50,7/15/2021
F5D410,executive-appointment,100,54,7/15/2021
F5D410,executive-appointment,100,54,7/15/2021
F6E248,earnings,100,50,7/15/2021
F93C8A,executive-appointment,100,54,7/15/2021
FA36A4,dividend,100,50,7/15/2021
FA840E,earnings,100,50,7/15/2021
FB728F,dividend,100,50,7/15/2021
FC9A88,acquisition-regulatory-scrutiny-acquiree,100,38,7/15/2021
FD4BBE,earnings,100,50,7/15/2021
FD6926,conference-call,100,50,7/15/2021
FDF799,earnings,100,50,7/15/2021
FF6644,index-listing,100,76,7/15/2021
FF6644,partnership,100,61,7/15/2021
FF6644,partnership,100,61,7/15/2021
FFE543,earnings,100,50,7/15/2021
0CCCB7,conference-call,100,50,7/16/2021
1065BC,conference-call,100,50,7/16/2021
1F43A1,earnings,100,50,7/16/2021
223216,ebitda-up,100,64,7/16/2021
24CB56,partnership,100,61,7/16/2021
24CB56,partnership,100,61,7/16/2021
2667B6,executive-appointment,100,54,7/16/2021
309922,acquisition-regulatory-approval-acquirer,100,54,7/16/2021
425BDC,conference-call,100,50,7/16/2021
442769,business-contract,100,69,7/16/2021
45ABCC,revenue-down,100,30,7/16/2021
4A6F00,partnership,100,61,7/16/2021
532D47,acquisition-acquirer,100,49,7/16/2021
54512F,acquisition-acquiree,100,76,7/16/2021
54512F,acquisition-regulatory-scrutiny-acquiree,100,38,7/16/2021
5480A7,earnings-up,100,68,7/16/2021
5480A7,earnings,100,50,7/16/2021
5480A7,earnings,100,50,7/16/2021
5480A7,earnings,100,50,7/16/2021
5480A7,earnings,100,50,7/16/2021
5480A7,earnings,100,50,7/16/2021
550D01,facility-open,100,65,7/16/2021
56632F,dividend,100,50,7/16/2021
57CAAB,earnings,100,50,7/16/2021
5BC2F4,earnings,100,50,7/16/2021
6166D1,dividend,100,50,7/16/2021
647143,dividend,100,50,7/16/2021
6AACDD,legal-issues-defendant,100,22,7/16/2021
6CDFC6,conference-call,100,50,7/16/2021
6D3B7B,earnings-up,100,68,7/16/2021
767F86,earnings,100,50,7/16/2021
790C34,earnings,100,50,7/16/2021
7B6C88,conference-call,100,50,7/16/2021
82C202,earnings,100,50,7/16/2021
89B2E7,earnings,100,50,7/16/2021
8C6C1B,facility-open,100,65,7/16/2021
93F143,earnings,100,50,7/16/2021
9507FF,earnings,100,50,7/16/2021
966DBE,earnings,100,50,7/16/2021
9.74E+08,earnings,100,50,7/16/2021
9B4066,unit-acquisition-acquirer,100,49,7/16/2021
9E98F2,earnings,100,50,7/16/2021
A21649,conference-call,100,50,7/16/2021
A49498,conference-call,100,50,7/16/2021
A6FE1C,unit-acquisition-acquirer,100,49,7/16/2021
AA5C8E,acquisition-acquirer,100,49,7/16/2021
AB7726,acquisition-regulatory-approval-acquiree,100,81,7/16/2021
AFF7B4,dividend,100,50,7/16/2021
B0D41A,conference-organizer,100,57,7/16/2021
B560AF,business-contract,100,69,7/16/2021
B560AF,business-contract,100,69,7/16/2021
C32A39,dividend,100,50,7/16/2021
CD06A2,earnings,100,50,7/16/2021
CFF15D,conference-call,100,50,7/16/2021
D0DFE5,earnings,100,50,7/16/2021
D33D8C,earnings,100,50,7/16/2021
D33D8C,earnings,100,50,7/16/2021
D33D8C,earnings,100,50,7/16/2021
D33D8C,earnings,100,50,7/16/2021
D33D8C,earnings,100,50,7/16/2021
D33D8C,earnings,100,50,7/16/2021
D33D8C,earnings,100,50,7/16/2021
D33D8C,earnings,100,50,7/16/2021
D3FD6D,conference-call,100,50,7/16/2021
DA0A9E,dividend,100,50,7/16/2021
DB23C8,earnings,100,50,7/16/2021
E393B0,merger-regulatory-scrutiny,100,37,7/16/2021
E592F0,earnings,100,50,7/16/2021
E866D2,business-contract,100,69,7/16/2021
E8D221,dividend,100,50,7/16/2021
F2BC3D,earnings,100,50,7/16/2021
F3FCC3,earnings,100,50,7/16/2021
F5349B,earnings,100,50,7/16/2021
F82D37,earnings,100,50,7/16/2021
F93C8A,conference-call,100,50,7/16/2021
FC1F9D,partnership,100,61,7/16/2021
FC9A88,merger-regulatory-scrutiny,100,37,7/16/2021
108BD2,legal-issues-defendant,100,22,7/17/2021
9C8664,legal-issues-defendant,100,22,7/17/2021
A94A7B,legal-issues-defendant,100,22,7/17/2021
DF1F7A,legal-issues-defendant,100,22,7/17/2021
FC9A88,legal-issues-defendant,100,22,7/17/2021
00067A,partnership,100,61,7/19/2021
00E601,merger,100,66,7/19/2021
00E601,merger,100,66,7/19/2021
61366,executive-appointment,100,54,7/19/2021
0624BE,executive-appointment,100,54,7/19/2021
0A0CF0,executive-appointment,100,54,7/19/2021
0CC01F,earnings,100,50,7/19/2021
0D26E0,earnings,100,50,7/19/2021
12A3A3,executive-appointment,100,54,7/19/2021
147C38,regulatory-product-approval-granted,100,81,7/19/2021
147C38,dividend,100,50,7/19/2021
15A388,executive-appointment,100,54,7/19/2021
16AAE0,earnings,100,50,7/19/2021
16B183,conference-call,100,50,7/19/2021
1748F6,executive-appointment,100,54,7/19/2021
17EDA5,executive-appointment,100,54,7/19/2021
184866,public-offering,100,43,7/19/2021
1880C5,patent-awarded,100,72,7/19/2021
1A1CB0,earnings,100,50,7/19/2021
1C599A,executive-appointment,100,54,7/19/2021
1C599A,earnings,100,50,7/19/2021
1E9A6D,dividend,100,50,7/19/2021
1EBF8D,regulatory-product-approval-granted,100,81,7/19/2021
1FE3CB,investment-investor,100,55,7/19/2021
20BEEA,earnings-up,100,68,7/19/2021
20BEEA,earnings,100,50,7/19/2021
20BEEA,earnings,100,50,7/19/2021
20BEEA,earnings,100,50,7/19/2021
20F5E2,earnings,100,50,7/19/2021
20F5E2,earnings,100,50,7/19/2021
20F5E2,earnings,100,50,7/19/2021
20F5E2,earnings,100,50,7/19/2021
21245F,unit-acquisition-acquirer,100,49,7/19/2021
2158DF,product-release,100,64,7/19/2021
221445,dividend,100,50,7/19/2021
228D42,partnership,100,61,7/19/2021
24C48B,partnership,100,61,7/19/2021
24C48B,partnership,100,61,7/19/2021
24C48B,conference-call,100,50,7/19/2021
251988,business-contract,100,69,7/19/2021
267718,patient-enrollment-complete,100,64,7/19/2021
267718,patient-enrollment-complete,100,64,7/19/2021
267718,executive-appointment,100,54,7/19/2021
270305,dividend,100,50,7/19/2021
272704,earnings-positive,100,69,7/19/2021
282C18,earnings,100,50,7/19/2021
295F9F,conference-call,100,50,7/19/2021
2BAE5F,earnings,100,50,7/19/2021
2CF9D3,executive-appointment,100,54,7/19/2021
2CF9D3,executive-appointment,100,54,7/19/2021
2D981A,clinical-trials-start,100,64,7/19/2021
2EB04E,earnings,100,50,7/19/2021
2EBA55,conference-call,100,50,7/19/2021
2EBC0B,earnings,100,50,7/19/2021
30DE64,business-contract,100,69,7/19/2021
367E1C,earnings,100,50,7/19/2021
38FB49,earnings,100,50,7/19/2021
38FB49,earnings,100,50,7/19/2021
38FB49,earnings,100,50,7/19/2021
38FB49,earnings,100,50,7/19/2021
38FB49,earnings,100,50,7/19/2021
38FB49,earnings,100,50,7/19/2021
38FB49,earnings,100,50,7/19/2021
38FB49,earnings,100,50,7/19/2021
39FB23,earnings,100,50,7/19/2021
39FB23,earnings,100,50,7/19/2021
39FB23,earnings,100,50,7/19/2021
39FB23,earnings,100,50,7/19/2021
3A3447,dividend,100,50,7/19/2021
3B9886,partnership,100,61,7/19/2021
3C6CCC,business-contract,100,69,7/19/2021
407878,earnings,100,50,7/19/2021
42DC93,earnings,100,50,7/19/2021
442587,business-contract,100,69,7/19/2021
4455C4,conference-call,100,50,7/19/2021
44740A,conference-call,100,50,7/19/2021
448215,earnings,100,50,7/19/2021
458D2C,conference-call,100,50,7/19/2021
4595EF,conference-call,100,50,7/19/2021
4885C8,facility-open,100,65,7/19/2021
4A6F00,partnership,100,61,7/19/2021
4B3676,partnership,100,61,7/19/2021
4B6EF9,executive-appointment,100,54,7/19/2021
4BEB48,earnings,100,50,7/19/2021
4C6C63,dividend,100,50,7/19/2021
4D371E,earnings,100,50,7/19/2021
4EE167,earnings,100,50,7/19/2021
514067,executive-appointment,100,54,7/19/2021
5288FC,executive-appointment,100,54,7/19/2021
57CAAB,clinical-trials-start,100,64,7/19/2021
57DDB9,conference-call,100,50,7/19/2021
5BFE94,unit-acquisition-acquirer,100,49,7/19/2021
5FF95F,earnings,100,50,7/19/2021
5FF95F,earnings,100,50,7/19/2021
5FF95F,earnings,100,50,7/19/2021
5FF95F,earnings,100,50,7/19/2021
5FF95F,earnings,100,50,7/19/2021
5FF95F,earnings,100,50,7/19/2021
5FF95F,earnings,100,50,7/19/2021
5FF95F,earnings,100,50,7/19/2021
609208,acquisition-completed-acquirer,100,49,7/19/2021
60DD84,executive-appointment,100,54,7/19/2021
64636E,public-offering,100,43,7/19/2021
647143,earnings,100,50,7/19/2021
647143,earnings,100,50,7/19/2021
647143,earnings,100,50,7/19/2021
647143,earnings,100,50,7/19/2021
647143,earnings,100,50,7/19/2021
647143,earnings,100,50,7/19/2021
649CBD,executive-appointment,100,54,7/19/2021
657097,earnings,100,50,7/19/2021
665440,conference-call,100,50,7/19/2021
68AB62,conference-call,100,50,7/19/2021
6A01DF,earnings,100,50,7/19/2021
6A3C35,earnings,100,50,7/19/2021
6AACDD,legal-issues-defendant,100,22,7/19/2021
6AACDD,legal-issues-defendant,100,22,7/19/2021
6B0E45,conference-call,100,50,7/19/2021
6D3B7B,earnings,100,50,7/19/2021
6DDA15,earnings,100,50,7/19/2021
6F39FC,conference-call,100,50,7/19/2021
71553E,executive-appointment,100,54,7/19/2021
72DF04,earnings,100,50,7/19/2021
73529F,conference-call,100,50,7/19/2021
73A213,product-release,100,64,7/19/2021
75F665,executive-appointment,100,54,7/19/2021
7E1D5D,partnership,100,61,7/19/2021
7F3669,earnings,100,50,7/19/2021
805CD8,executive-appointment,100,54,7/19/2021
8.10E+205,earnings,100,50,7/19/2021
83066C,conference-call,100,50,7/19/2021
83B1C8,earnings,100,50,7/19/2021
877C0C,regulatory-product-approval-granted,100,81,7/19/2021
8802B4,dividend,100,50,7/19/2021
8AC740,conference-call,100,50,7/19/2021
8C5519,earnings,100,50,7/19/2021
8C5519,earnings,100,50,7/19/2021
8C5519,earnings,100,50,7/19/2021
8C5519,earnings,100,50,7/19/2021
8C5519,earnings,100,50,7/19/2021
8C5519,earnings,100,50,7/19/2021
8C6C1B,facility-open,100,65,7/19/2021
8D4486,earnings,100,50,7/19/2021
8D4486,earnings,100,50,7/19/2021
8D4486,earnings,100,50,7/19/2021
8D4486,earnings,100,50,7/19/2021
8D4486,earnings,100,50,7/19/2021
8D4AE6,acquisition-completed-acquiree,100,76,7/19/2021
8D9993,dividend,100,50,7/19/2021
8E10BF,conference-participant,100,50,7/19/2021
8EEA28,merger,100,66,7/19/2021
8EEA28,merger,100,66,7/19/2021
8EEA28,merger-regulatory-scrutiny,100,37,7/19/2021
92B047,earnings-up,100,68,7/19/2021
92D9C9,conference-call,100,50,7/19/2021
93965C,partnership,100,61,7/19/2021
9548BB,acquisition-acquirer,100,49,7/19/2021
9548BB,acquisition-acquirer,100,49,7/19/2021
96F126,earnings,100,50,7/19/2021
971F7B,earnings,100,50,7/19/2021
990AD0,product-release,100,64,7/19/2021
9A29F4,conference-call,100,50,7/19/2021
9C25FF,business-contract,100,69,7/19/2021
9C8BC3,dividend,100,50,7/19/2021
9D30A8,government-contract,100,69,7/19/2021
A0F146,conference-call,100,50,7/19/2021
A6828A,dividend,100,50,7/19/2021
A7F0A5,earnings,100,50,7/19/2021
A94A7B,merger-regulatory-scrutiny,100,37,7/19/2021
AA847A,conference-call,100,50,7/19/2021
AE4125,conference-call,100,50,7/19/2021
AE7D16,earnings,100,50,7/19/2021
B1DF3C,acquisition-acquirer,100,49,7/19/2021
B1DF3C,acquisition-acquirer,100,49,7/19/2021
B1FC3B,business-contract,100,69,7/19/2021
B2D492,earnings,100,50,7/19/2021
B2F431,earnings-positive,100,69,7/19/2021
B5766D,dividend,100,50,7/19/2021
B8A51F,regulatory-product-approval-granted,100,81,7/19/2021
B98EFA,operating-earnings,100,50,7/19/2021
BB88B6,partnership,100,61,7/19/2021
BC5680,executive-appointment,100,54,7/19/2021
BD682F,earnings,100,50,7/19/2021
BEB756,dividend,100,50,7/19/2021
BEB756,earnings,100,50,7/19/2021
C32A39,earnings,100,50,7/19/2021
C38440,earnings,100,50,7/19/2021
C45C1F,fast-track-designation,100,81,7/19/2021
C4A912,conference-call,100,50,7/19/2021
C4FBDC,conference-call,100,50,7/19/2021
C5C0E9,conference-call,100,50,7/19/2021
C72B8F,earnings,100,50,7/19/2021
C94CFC,legal-issues-defendant,100,22,7/19/2021
C99CC8,earnings,100,50,7/19/2021
CB9E13,conference-call,100,50,7/19/2021
CBDB4D,earnings,100,50,7/19/2021
CC3EC4,partnership,100,61,7/19/2021
D04D9F,conference-call,100,50,7/19/2021
D33D8C,earnings,100,50,7/19/2021
D3C794,dividend,100,50,7/19/2021
D4070C,conference-call,100,50,7/19/2021
D4C0CB,conference-organizer,100,57,7/19/2021
D64EDF,facility-upgrade,100,65,7/19/2021
D69D42,executive-appointment,100,54,7/19/2021
DA48E4,executive-appointment,100,54,7/19/2021
E2CB7B,executive-appointment,100,54,7/19/2021
E2CB7B,executive-appointment,100,54,7/19/2021
E2CB7B,executive-appointment,100,54,7/19/2021
E5C910,executive-appointment,100,54,7/19/2021
E6A53A,earnings,100,50,7/19/2021
E70531,executive-resignation,100,44,7/19/2021
E70531,business-contract,100,69,7/19/2021
E90C84,conference-call,100,50,7/19/2021
EAA0A7,earnings,100,50,7/19/2021
EB6965,conference-call,100,50,7/19/2021
EE6F1C,executive-appointment,100,54,7/19/2021
F44EA2,earnings,100,50,7/19/2021
F509E2,conference-call,100,50,7/19/2021
F5C78B,earnings,100,50,7/19/2021
F6DE54,product-price-raise,100,57,7/19/2021
F6E248,acquisition-acquiree,100,76,7/19/2021
F6E248,acquisition-acquiree,100,76,7/19/2021
F6E248,acquisition-acquiree,100,76,7/19/2021
F6E248,acquisition-acquiree,100,76,7/19/2021
F92DBC,acquisition-acquiree,100,76,7/19/2021
F92DBC,acquisition-acquiree,100,76,7/19/2021
FC1F9D,earnings-up,100,68,7/19/2021
FD1312,earnings,100,50,7/19/2021
FD4588,award,100,58,7/19/2021
FDF28E,earnings,100,50,7/19/2021
FFCD0E,revenues,100,50,7/19/2021
03596A,conference-call,100,50,7/20/2021
070B45,earnings,100,50,7/20/2021
0A0CF0,business-contract,100,69,7/20/2021
0A59F8,earnings,100,50,7/20/2021
0C4131,earnings,100,50,7/20/2021
0CE204,earnings,100,50,7/20/2021
0E499E,earnings,100,50,7/20/2021
10100E,earnings,100,50,7/20/2021
102F04,earnings,100,50,7/20/2021
106394,business-contract,100,69,7/20/2021
108A2B,conference-call,100,50,7/20/2021
10943B,product-release,100,64,7/20/2021
11A49E,executive-appointment,100,54,7/20/2021
1348C9,earnings,100,50,7/20/2021
138DDE,earnings,100,50,7/20/2021
147C38,product-release,100,64,7/20/2021
149301,earnings,100,50,7/20/2021
152B9E,conference-call,100,50,7/20/2021
1834C0,conference-call,100,50,7/20/2021
18EC17,earnings,100,50,7/20/2021
18EC17,earnings,100,50,7/20/2021
18EC17,earnings,100,50,7/20/2021
18EC17,earnings,100,50,7/20/2021
19CAC7,earnings,100,50,7/20/2021
19CAC7,earnings,100,50,7/20/2021
1E9A6D,earnings,100,50,7/20/2021
1EBF8D,clinical-trials,100,56,7/20/2021
1FA8F7,earnings,100,50,7/20/2021
20BEEA,conference-call,100,50,7/20/2021
21245F,conference-call,100,50,7/20/2021
21F9CA,earnings,100,50,7/20/2021
24CB56,earnings-positive,100,69,7/20/2021
24CB56,earnings,100,50,7/20/2021
24CB56,earnings,100,50,7/20/2021
24CB56,earnings,100,50,7/20/2021
24CB56,earnings,100,50,7/20/2021
24CB56,earnings,100,50,7/20/2021
24CB56,earnings,100,50,7/20/2021
24CB56,earnings,100,50,7/20/2021
24CB56,earnings,100,50,7/20/2021
24CB56,earnings,100,50,7/20/2021
26F31D,earnings,100,50,7/20/2021
28AC4E,executive-appointment,100,54,7/20/2021
28B730,earnings,100,50,7/20/2021
292A70,acquisition-acquirer,100,49,7/20/2021
2A1009,acquisition-acquiree,100,76,7/20/2021
2B49F4,earnings,100,50,7/20/2021
2B49F4,earnings,100,50,7/20/2021
2B49F4,earnings,100,50,7/20/2021
2B49F4,earnings,100,50,7/20/2021
2C3348,earnings,100,50,7/20/2021
2CD1E0,partnership,100,61,7/20/2021
2F1299,conference-call,100,50,7/20/2021
3.14E+47,earnings,100,50,7/20/2021
315416,executive-appointment,100,54,7/20/2021
315416,executive-appointment,100,54,7/20/2021
31643A,partnership,100,61,7/20/2021
31803E,earnings,100,50,7/20/2021
31DB20,earnings,100,50,7/20/2021
32F24A,conference-call,100,50,7/20/2021
34B97A,earnings,100,50,7/20/2021
37020C,earnings,100,50,7/20/2021
373B06,earnings,100,50,7/20/2021
3798B9,earnings,100,50,7/20/2021
3B20AB,earnings,100,50,7/20/2021
3CCC90,dividend,100,50,7/20/2021
3D9999,earnings,100,50,7/20/2021
3FACA7,earnings,100,50,7/20/2021
407878,partnership,100,61,7/20/2021
407878,partnership,100,61,7/20/2021
416C55,partnership,100,61,7/20/2021
41EC04,conference-call,100,50,7/20/2021
422CE3,executive-appointment,100,54,7/20/2021
427F32,conference-call,100,50,7/20/2021
442769,facility-open,100,65,7/20/2021
490D4B,conference-call,100,50,7/20/2021
4A6F00,antitrust-suit-defendant,100,21,7/20/2021
4A6F00,partnership,100,61,7/20/2021
4A6F00,partnership,100,61,7/20/2021
4C1FA1,earnings,100,50,7/20/2021
50070E,product-release,100,64,7/20/2021
50702E,conference-call,100,50,7/20/2021
510EA6,revenue-up,100,69,7/20/2021
510EA6,revenue-up,100,69,7/20/2021
520632,legal-issues-defendant,100,22,7/20/2021
5225A4,earnings,100,50,7/20/2021
5225A4,earnings,100,50,7/20/2021
5225A4,public-offering,100,43,7/20/2021
54B889,conference-call,100,50,7/20/2021
55C9B5,partnership,100,61,7/20/2021
56AFF4,executive-appointment,100,54,7/20/2021
57B174,conference-call,100,50,7/20/2021
59C539,dividend,100,50,7/20/2021
59F0B0,earnings,100,50,7/20/2021
5E6959,executive-appointment,100,54,7/20/2021
5E6959,executive-appointment,100,54,7/20/2021
5F3E74,earnings,100,50,7/20/2021
619882,partnership,100,61,7/20/2021
62B20A,earnings,100,50,7/20/2021
636639,earnings,100,50,7/20/2021
636639,earnings,100,50,7/20/2021
636639,earnings,100,50,7/20/2021
636639,earnings,100,50,7/20/2021
63F892,award,100,58,7/20/2021
63F892,award,100,58,7/20/2021
64E346,acquisition-failed-acquiree,100,21,7/20/2021
64E615,conference-call,100,50,7/20/2021
64E615,conference-call,100,50,7/20/2021
66BDA1,earnings,100,50,7/20/2021
67B923,conference-call,100,50,7/20/2021
68E3E0,product-release,100,64,7/20/2021
69494C,conference-call,100,50,7/20/2021
6A01DF,acquisition-acquirer,100,49,7/20/2021
6A01DF,business-contract,100,69,7/20/2021
6A01DF,partnership,100,61,7/20/2021
6AACDD,legal-issues-defendant,100,22,7/20/2021
6BC6F9,earnings,100,50,7/20/2021
6CB7F9,earnings,100,50,7/20/2021
6D2BF6,earnings,100,50,7/20/2021
6DBBBC,conference-call,100,50,7/20/2021
6E705B,earnings,100,50,7/20/2021
6E705B,earnings,100,50,7/20/2021
6E705B,earnings,100,50,7/20/2021
6E705B,earnings,100,50,7/20/2021
6E705B,earnings,100,50,7/20/2021
6E705B,earnings,100,50,7/20/2021
73C521,partnership,100,61,7/20/2021
751C8D,award,100,58,7/20/2021
751C8D,award,100,58,7/20/2021
751C8D,earnings,100,50,7/20/2021
751C8D,earnings,100,50,7/20/2021
75F665,earnings,100,50,7/20/2021
75F665,dividend,100,50,7/20/2021
76B926,conference-call,100,50,7/20/2021
7712CB,earnings,100,50,7/20/2021
7.83E+79,operating-earnings,100,50,7/20/2021
791D59,product-release,100,64,7/20/2021
7AD81E,earnings,100,50,7/20/2021
7B1156,unit-acquisition-acquirer,100,49,7/20/2021
7B1E50,dividend,100,50,7/20/2021
7C75FD,conference-call,100,50,7/20/2021
7C790D,conference-call,100,50,7/20/2021
7E1542,earnings,100,50,7/20/2021
7F0372,earnings,100,50,7/20/2021
7FD8B9,conference-call,100,50,7/20/2021
803FED,conference-call,100,50,7/20/2021
82B57E,earnings,100,50,7/20/2021
845655,conference-call,100,50,7/20/2021
845655,conference-call,100,50,7/20/2021
84AB66,executive-appointment,100,54,7/20/2021
850779,earnings-per-share-positive,100,69,7/20/2021
850779,earnings-per-share,100,50,7/20/2021
850779,earnings-per-share,100,50,7/20/2021
850779,earnings-per-share,100,50,7/20/2021
859281,earnings,100,50,7/20/2021
860AB6,conference-call,100,50,7/20/2021
862941,earnings,100,50,7/20/2021
895D56,partnership,100,61,7/20/2021
8A8E41,earnings,100,50,7/20/2021
8A8E41,partnership,100,61,7/20/2021
8BFE9A,conference-call,100,50,7/20/2021
8D4486,earnings,100,50,7/20/2021
8DDA23,dividend,100,50,7/20/2021
8DE74B,conference-call,100,50,7/20/2021
8E82A6,dividend,100,50,7/20/2021
8F3231,dividend,100,50,7/20/2021
8F3BCC,earnings,100,50,7/20/2021
8F3BCC,earnings,100,50,7/20/2021
9087B9,conference-call,100,50,7/20/2021
9196A2,product-release,100,64,7/20/2021
93633B,earnings,100,50,7/20/2021
93633B,earnings,100,50,7/20/2021
93633B,earnings,100,50,7/20/2021
93633B,earnings,100,50,7/20/2021
93633B,earnings,100,50,7/20/2021
93633B,earnings,100,50,7/20/2021
95C392,partnership,100,61,7/20/2021
95C392,partnership,100,61,7/20/2021
95C575,earnings,100,50,7/20/2021
95DC1F,executive-appointment,100,54,7/20/2021
968B00,earnings,100,50,7/20/2021
986AF6,acquisition-acquirer,100,49,7/20/2021
997348,earnings,100,50,7/20/2021
997348,earnings,100,50,7/20/2021
99DC8D,conference-call,100,50,7/20/2021
9BB35A,conference-call,100,50,7/20/2021
9C25FF,conference-call,100,50,7/20/2021
9CA4C6,dividend-up,100,81,7/20/2021
9CA4C6,earnings-up,100,68,7/20/2021
9D4EC7,conference-call,100,50,7/20/2021
9D4EC7,conference-call,100,50,7/20/2021
9F62D1,earnings-per-share-positive,100,69,7/20/2021
A23747,earnings,100,50,7/20/2021
A29DBD,earnings,100,50,7/20/2021
A398B9,earnings,100,50,7/20/2021
A398B9,earnings,100,50,7/20/2021
A398B9,earnings,100,50,7/20/2021
A403CF,earnings,100,50,7/20/2021
A433A5,executive-resignation,100,44,7/20/2021
A48593,executive-appointment,100,54,7/20/2021
A4B899,earnings,100,50,7/20/2021
A52B6B,partnership,100,61,7/20/2021
A5A4F5,product-resumed,100,52,7/20/2021
A5A4F5,product-resumed,100,52,7/20/2021
A60318,public-offering,100,43,7/20/2021
A60354,conference-call,100,50,7/20/2021
A63820,earnings,100,50,7/20/2021
A63820,earnings,100,50,7/20/2021
A63820,earnings,100,50,7/20/2021
A63820,earnings,100,50,7/20/2021
A6828A,legal-issues-defendant,100,22,7/20/2021
A7102F,conference-call,100,50,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A746F6,earnings-per-share-positive,100,69,7/20/2021
A871B0,product-release,100,64,7/20/2021
A8AC4C,conference-call,100,50,7/20/2021
A8E2FE,unit-acquisition-acquirer,100,49,7/20/2021
AB7F05,earnings-up,100,68,7/20/2021
AB7F05,earnings,100,50,7/20/2021
AB7F05,earnings,100,50,7/20/2021
AB7F05,earnings,100,50,7/20/2021
AC642C,earnings,100,50,7/20/2021
AC642C,earnings,100,50,7/20/2021
AC7C4F,business-contract,100,69,7/20/2021
ACD9A4,earnings,100,50,7/20/2021
ADF092,earnings,100,50,7/20/2021
ADF1B0,conference-call,100,50,7/20/2021
AFF43F,earnings,100,50,7/20/2021
AFF43F,dividend,100,50,7/20/2021
B1FC3B,business-contract,100,69,7/20/2021
B48FC9,partnership,100,61,7/20/2021
B48FC9,earnings,100,50,7/20/2021
B560AF,dividend,100,50,7/20/2021
B5BA39,executive-appointment,100,54,7/20/2021
B60366,earnings,100,50,7/20/2021
B934BF,public-offering,100,43,7/20/2021
B96DF5,executive-appointment,100,54,7/20/2021
B96DF5,earnings,100,50,7/20/2021
BD15E8,earnings-per-share-up,100,92,7/20/2021
BD9668,earnings,100,50,7/20/2021
BE14CF,dividend,100,50,7/20/2021
BFE02C,earnings-positive,100,69,7/20/2021
BFEA04,conference-call,100,50,7/20/2021
C0200F,earnings,100,50,7/20/2021
C0200F,earnings,100,50,7/20/2021
C0200F,earnings,100,50,7/20/2021
C32A39,earnings,100,50,7/20/2021
C3BAE7,conference-participant,100,50,7/20/2021
C584BE,executive-appointment,100,54,7/20/2021
C8257F,earnings,100,50,7/20/2021
C83B88,executive-appointment,100,54,7/20/2021
C83B88,executive-appointment,100,54,7/20/2021
C83B88,partnership,100,61,7/20/2021
C8923A,earnings,100,50,7/20/2021
CDC817,earnings,100,50,7/20/2021
CE8251,business-contract,100,69,7/20/2021
D13F1C,earnings,100,50,7/20/2021
D17F7E,earnings,100,50,7/20/2021
D393DF,earnings,100,50,7/20/2021
D6489C,product-release,100,64,7/20/2021
D77F7E,partnership,100,61,7/20/2021
D77F7E,partnership,100,61,7/20/2021
D90F43,partnership,100,61,7/20/2021
D9B1C9,dividend,100,50,7/20/2021
DD1BA1,executive-appointment,100,54,7/20/2021
DF532D,earnings,100,50,7/20/2021
DF532D,earnings,100,50,7/20/2021
DF6FDD,earnings,100,50,7/20/2021
E2CFD2,executive-appointment,100,54,7/20/2021
E592F0,acquisition-interest-acquirer,100,46,7/20/2021
E592F0,acquisition-interest-acquirer,100,46,7/20/2021
ECD263,earnings,100,50,7/20/2021
ECDEB2,earnings-up,100,89,7/20/2021
EF5914,earnings,100,50,7/20/2021
EF76C8,dividend,100,50,7/20/2021
F3D2EB,operating-earnings,100,50,7/20/2021
F3EDB4,earnings,100,50,7/20/2021
F57F6F,earnings,100,50,7/20/2021
F6E1B5,earnings,100,50,7/20/2021
F7D8AE,acquisition-acquirer,100,49,7/20/2021
F92DBC,acquisition-interest-acquirer,100,46,7/20/2021
F92DBC,acquisition-interest-acquirer,100,46,7/20/2021
F93C8A,dividend,100,50,7/20/2021
FA918D,conference-call,100,50,7/20/2021
FC01C0,conference-call,100,50,7/20/2021
FC80E6,unit-acquisition-acquiree,100,76,7/20/2021
FC9A88,earnings-up,100,68,7/20/2021
FC9A88,dividend,100,50,7/20/2021
FD0CA4,earnings,100,50,7/20/2021
FD39EB,dividend,100,50,7/20/2021
FD39EB,earnings,100,50,7/20/2021
FE1A1D,earnings,100,50,7/20/2021
FE7A63,earnings,100,50,7/20/2021
FE7A63,earnings,100,50,7/20/2021
FE7A63,earnings,100,50,7/20/2021
FE7A63,earnings,100,50,7/20/2021
FE7A63,earnings,100,50,7/20/2021
FE7A63,earnings,100,50,7/20/2021
FE7A63,earnings,100,50,7/20/2021
FEC475,market-entry,100,57,7/20/2021
00E601,legal-issues-defendant,100,22,7/21/2021
0142B5,dividend,100,50,7/21/2021
03B8CF,settlement,100,56,7/21/2021
03F5A4,earnings-positive,100,69,7/21/2021
98977,earnings,100,50,7/21/2021
099A02,earnings,100,50,7/21/2021
099A02,earnings,100,50,7/21/2021
099C88,business-contract,100,69,7/21/2021
09F623,dividend,100,50,7/21/2021
0A0CF0,dividend,100,50,7/21/2021
0A1D77,earnings-positive,100,69,7/21/2021
0AAD90,clinical-trials-positive,100,87,7/21/2021
0AB700,earnings,100,50,7/21/2021
0C466B,earnings-up,100,68,7/21/2021
0C466B,earnings,100,50,7/21/2021
0C466B,earnings,100,50,7/21/2021
0E6027,earnings-positive,100,69,7/21/2021
0E6027,earnings,100,50,7/21/2021
0E6027,earnings,100,50,7/21/2021
10AE08,earnings-positive,100,69,7/21/2021
10AE08,earnings,100,50,7/21/2021
10AE08,earnings,100,50,7/21/2021
10AE08,earnings,100,50,7/21/2021
10AE08,earnings,100,50,7/21/2021
10AE08,earnings,100,50,7/21/2021
10AE08,earnings,100,50,7/21/2021
10AE08,earnings,100,50,7/21/2021
10AE08,earnings,100,50,7/21/2021
10AE08,earnings,100,50,7/21/2021
10AE08,earnings,100,50,7/21/2021
136B26,facility-open,100,65,7/21/2021
136B26,earnings,100,50,7/21/2021
139303,conference-call,100,50,7/21/2021
165B3A,earnings-positive,100,69,7/21/2021
165B3A,earnings-positive,100,69,7/21/2021
165B3A,earnings-positive,100,69,7/21/2021
165B3A,earnings-positive,100,69,7/21/2021
1748B3,earnings,100,50,7/21/2021
1748B3,earnings,100,50,7/21/2021
1748B3,earnings,100,50,7/21/2021
1748B3,earnings,100,50,7/21/2021
1748B3,earnings,100,50,7/21/2021
1748B3,earnings,100,50,7/21/2021
1748B3,earnings,100,50,7/21/2021
1748B3,earnings,100,50,7/21/2021
17EDA5,partnership,100,61,7/21/2021
17EDA5,conference-call,100,50,7/21/2021
184866,public-offering,100,43,7/21/2021
1A9DE1,earnings-up,100,75,7/21/2021
1A9DE1,earnings,100,50,7/21/2021
1A9DE1,earnings,100,50,7/21/2021
1A9DE1,earnings,100,50,7/21/2021
1AB808,earnings,100,50,7/21/2021
1B4F31,earnings,100,50,7/21/2021
1BC12C,conference-call,100,50,7/21/2021
1D1B07,note-sale,100,52,7/21/2021
1D1B07,note-sale,100,52,7/21/2021
1D943E,earnings,100,50,7/21/2021
1DA44F,dividend-up,100,81,7/21/2021
1E5786,dividend,100,50,7/21/2021
1EBF8D,partnership,100,61,7/21/2021
228D42,partnership,100,61,7/21/2021
241AF7,conference-call,100,50,7/21/2021
2.45E+15,earnings,100,50,7/21/2021
249674,conference-call,100,50,7/21/2021
24FA23,earnings,100,50,7/21/2021
25102A,earnings,100,50,7/21/2021
25102A,earnings,100,50,7/21/2021
25102A,earnings,100,50,7/21/2021
25102A,earnings,100,50,7/21/2021
25102A,earnings,100,50,7/21/2021
25102A,earnings,100,50,7/21/2021
25102A,dividend,100,50,7/21/2021
25102A,buybacks,100,74,7/21/2021
253B2F,conference-call,100,50,7/21/2021
2667B6,business-contract,100,69,7/21/2021
267718,partnership,100,61,7/21/2021
267718,partnership,100,61,7/21/2021
267718,partnership,100,61,7/21/2021
267718,partnership,100,61,7/21/2021
267718,partnership,100,61,7/21/2021
267718,partnership,100,61,7/21/2021
267718,partnership,100,61,7/21/2021
267718,regulatory-investigation,100,22,7/21/2021
2720AB,earnings,100,50,7/21/2021
274B8A,conference-call,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
275300,earnings,100,50,7/21/2021
27B191,conference-call,100,50,7/21/2021
27BFA1,earnings-per-share-positive,100,69,7/21/2021
27BFA1,earnings-per-share,100,50,7/21/2021
27BFA1,earnings-per-share,100,50,7/21/2021
27BFA1,earnings-per-share,100,50,7/21/2021
27BFA1,earnings-per-share,100,50,7/21/2021
27BFA1,earnings-per-share,100,50,7/21/2021
27BFA1,earnings-per-share,100,50,7/21/2021
27BFA1,earnings-per-share,100,50,7/21/2021
27BFA1,earnings-per-share,100,50,7/21/2021
29A4CC,dividend,100,50,7/21/2021
2EB04E,partnership,100,61,7/21/2021
2EB04E,partnership,100,61,7/21/2021
301493,conference-call,100,50,7/21/2021
309922,merger-completed,100,66,7/21/2021
30E01D,executive-appointment,100,54,7/21/2021
31A7CC,earnings-up,100,68,7/21/2021
339F20,earnings,100,50,7/21/2021
3.30E+34,earnings-up,100,68,7/21/2021
3.30E+34,earnings,100,50,7/21/2021
3.30E+34,earnings,100,50,7/21/2021
34B411,earnings,100,50,7/21/2021
34B411,earnings,100,50,7/21/2021
35AE32,earnings,100,50,7/21/2021
36A1CB,conference-call,100,50,7/21/2021
372037,conference-call,100,50,7/21/2021
387541,earnings,100,50,7/21/2021
39BFF6,partnership,100,61,7/21/2021
39BFF6,earnings,100,50,7/21/2021
39BFF6,earnings,100,50,7/21/2021
3A1C46,earnings,100,50,7/21/2021
3A3447,earnings,100,50,7/21/2021
3CCC90,earnings,100,50,7/21/2021
3F6A9C,conference-call,100,50,7/21/2021
407878,executive-appointment,100,54,7/21/2021
408089,dividend,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
43A74A,earnings,100,50,7/21/2021
442769,conference-call,100,50,7/21/2021
444CC8,conference-call,100,50,7/21/2021
449447,conference-call,100,50,7/21/2021
45ABCC,earnings,100,50,7/21/2021
460C93,dividend-up,100,81,7/21/2021
460C93,dividend-up,100,81,7/21/2021
460C93,dividend-up,100,81,7/21/2021
460C93,dividend-up,100,81,7/21/2021
460C93,dividend-up,100,81,7/21/2021
46CF27,dividend,100,50,7/21/2021
485445,earnings,100,50,7/21/2021
4A6F00,partnership,100,61,7/21/2021
4C2F17,earnings,100,50,7/21/2021
4C37C5,dividend,100,50,7/21/2021
4D203E,executive-appointment,100,54,7/21/2021
4D7BD8,earnings,100,50,7/21/2021
4D7BD8,earnings,100,50,7/21/2021
4D7BD8,earnings,100,50,7/21/2021
4D7BD8,earnings,100,50,7/21/2021
4D7BD8,earnings,100,50,7/21/2021
4D7BD8,earnings,100,50,7/21/2021
4D7BD8,earnings,100,50,7/21/2021
4D7BD8,earnings,100,50,7/21/2021
4D8313,executive-appointment,100,54,7/21/2021
4D8313,revenues,100,50,7/21/2021
4D8313,revenues,100,50,7/21/2021
4D8313,revenues,100,50,7/21/2021
4F9487,demand-increase,100,83,7/21/2021
50070E,investment-investor,100,55,7/21/2021
5065B1,earnings,100,50,7/21/2021
53F491,earnings-per-share-positive,100,69,7/21/2021
54512F,legal-issues-defendant,100,22,7/21/2021
55C9B5,business-contract,100,69,7/21/2021
5675EB,dividend,100,50,7/21/2021
5675EB,earnings,100,50,7/21/2021
56AFF4,executive-appointment,100,54,7/21/2021
56AFF4,operating-earnings,100,50,7/21/2021
5876DC,dividend,100,50,7/21/2021
589F5A,dividend,100,50,7/21/2021
58B46F,dividend,100,50,7/21/2021
58C2D4,earnings,100,50,7/21/2021
59DB8C,earnings,100,50,7/21/2021
5A64D5,conference-call,100,50,7/21/2021
5A9F54,earnings-up,100,68,7/21/2021
5B3FA2,earnings,100,50,7/21/2021
5B97B2,earnings,100,50,7/21/2021
5D63F1,earnings,100,50,7/21/2021
5F60CE,earnings,100,50,7/21/2021
5F6D73,earnings,100,50,7/21/2021
60DD84,revenues,100,50,7/21/2021
60DD84,revenues,100,50,7/21/2021
60DD84,revenues,100,50,7/21/2021
6166D1,dividend,100,50,7/21/2021
66CB62,conference-call,100,50,7/21/2021
67303E,regulatory-product-approval-granted,100,81,7/21/2021
67529E,earnings-positive,100,69,7/21/2021
68BA15,acquisition-acquiree,100,76,7/21/2021
694749,earnings,100,50,7/21/2021
69CE71,conference-call,100,50,7/21/2021
6A6BDC,partnership,100,61,7/21/2021
6AACDD,legal-issues-defendant,100,22,7/21/2021
6B236C,partnership,100,61,7/21/2021
6CD55A,earnings,100,50,7/21/2021
6E8864,conference-call,100,50,7/21/2021
6ED519,conference-call,100,50,7/21/2021
6F0096,earnings-guidance-up,100,83,7/21/2021
6F0096,earnings,100,50,7/21/2021
6F0096,earnings,100,50,7/21/2021
6F0096,earnings,100,50,7/21/2021
6F0096,earnings,100,50,7/21/2021
722D55,earnings,100,50,7/21/2021
7262F2,earnings,100,50,7/21/2021
7273FF,partnership,100,61,7/21/2021
72DF04,dividend,100,50,7/21/2021
72EF75,earnings,100,50,7/21/2021
73C521,dividend,100,50,7/21/2021
7410C3,earnings,100,50,7/21/2021
74404C,dividend,100,50,7/21/2021
766047,dividend,100,50,7/21/2021
775439,earnings,100,50,7/21/2021
782B46,conference-call,100,50,7/21/2021
7A0EC4,partnership,100,61,7/21/2021
7AB859,earnings,100,50,7/21/2021
7AB859,earnings,100,50,7/21/2021
7AB859,earnings,100,50,7/21/2021
7AB859,earnings,100,50,7/21/2021
7AB859,earnings,100,50,7/21/2021
7B0BA6,business-contract,100,69,7/21/2021
7C62A3,conference-call,100,50,7/21/2021
7C75FD,dividend,100,50,7/21/2021
7E0EB0,earnings,100,50,7/21/2021
8275FE,earnings,100,50,7/21/2021
82F088,conference-call,100,50,7/21/2021
84A6B9,earnings-up,100,68,7/21/2021
84AB66,dividend,100,50,7/21/2021
85AD00,dividend-up,100,81,7/21/2021
87B81A,earnings,100,50,7/21/2021
885758,earnings,100,50,7/21/2021
8B3B0E,legal-issues-defendant,100,22,7/21/2021
8CF6DD,earnings,100,50,7/21/2021
8D4486,partnership,100,61,7/21/2021
8D4486,partnership,100,61,7/21/2021
901327,earnings,100,50,7/21/2021
902255,executive-appointment,100,54,7/21/2021
902255,earnings,100,50,7/21/2021
911AB8,dividend,100,50,7/21/2021
92D6A5,earnings,100,50,7/21/2021
940C3D,earnings,100,50,7/21/2021
95A92E,legal-issues-defendant,100,22,7/21/2021
95DC1F,partnership,100,61,7/21/2021
9.62E+76,earnings,100,50,7/21/2021
9.62E+76,earnings,100,50,7/21/2021
9.62E+76,earnings,100,50,7/21/2021
979451,earnings,100,50,7/21/2021
97B027,conference-call,100,50,7/21/2021
986AF6,conference-call,100,50,7/21/2021
9.92E+94,earnings,100,50,7/21/2021
9.92E+94,earnings,100,50,7/21/2021
9.92E+94,earnings,100,50,7/21/2021
99ACAD,acquisition-acquirer,100,49,7/21/2021
9ABD30,executive-appointment,100,54,7/21/2021
9C8664,earnings,100,50,7/21/2021
9C8664,legal-issues-defendant,100,22,7/21/2021
9CE4C7,earnings,100,50,7/21/2021
9F37C5,dividend,100,50,7/21/2021
A16DEA,earnings,100,50,7/21/2021
A28C54,business-contract,100,69,7/21/2021
A2CAF7,earnings,100,50,7/21/2021
A2CAF7,partnership,100,61,7/21/2021
A350C1,earnings,100,50,7/21/2021
A3800A,executive-appointment,100,54,7/21/2021
A38F30,unit-acquisition-acquirer,100,49,7/21/2021
A398F8,earnings,100,50,7/21/2021
A4A612,executive-appointment,100,54,7/21/2021
A4A612,earnings,100,50,7/21/2021
A4A612,earnings,100,50,7/21/2021
A4A612,earnings,100,50,7/21/2021
A4A612,earnings,100,50,7/21/2021
A60318,public-offering,100,43,7/21/2021
A6213D,product-release,100,64,7/21/2021
A6213D,product-release,100,64,7/21/2021
A6828A,earnings,100,50,7/21/2021
A6828A,earnings,100,50,7/21/2021
A6828A,earnings,100,50,7/21/2021
A6828A,earnings,100,50,7/21/2021
A6828A,earnings,100,50,7/21/2021
A6828A,earnings,100,50,7/21/2021
A79D88,conference-call,100,50,7/21/2021
A8CBDA,earnings-positive,100,69,7/21/2021
A8FDE8,earnings-guidance,100,50,7/21/2021
A99576,legal-issues-defendant,100,22,7/21/2021
AA5C8E,dividend,100,50,7/21/2021
AA5C8E,dividend,100,50,7/21/2021
AA5C8E,dividend,100,50,7/21/2021
AA5C8E,dividend,100,50,7/21/2021
AA5C8E,dividend,100,50,7/21/2021
AA5C8E,dividend,100,50,7/21/2021
AABEA0,dividend-up,100,81,7/21/2021
AAEE21,earnings,100,50,7/21/2021
AB7726,merger-completed,100,66,7/21/2021
ABE7DC,orphan-drug-designation,100,76,7/21/2021
ACDF88,partnership,100,61,7/21/2021
AD23DE,earnings,100,50,7/21/2021
AD23DE,earnings,100,50,7/21/2021
AD23DE,earnings,100,50,7/21/2021
AD23DE,earnings,100,50,7/21/2021
AD23DE,earnings,100,50,7/21/2021
AD23DE,earnings,100,50,7/21/2021
AD3C93,earnings,100,50,7/21/2021
AE7D16,note-sale,100,52,7/21/2021
AEBB80,earnings,100,50,7/21/2021
AF210D,earnings,100,50,7/21/2021
B0B969,earnings,100,50,7/21/2021
B1FC3B,business-contract,100,69,7/21/2021
B2256A,note-sale,100,52,7/21/2021
B2256A,note-sale,100,52,7/21/2021
B66928,earnings,100,50,7/21/2021
B7202A,conference-call,100,50,7/21/2021
B8A51F,earnings,100,50,7/21/2021
B8EF97,partnership,100,61,7/21/2021
B934BF,public-offering,100,43,7/21/2021
BA218A,earnings,100,50,7/21/2021
BA218A,earnings-up,100,68,7/21/2021
BA218A,earnings-up,100,68,7/21/2021
BA218A,earnings-up,100,68,7/21/2021
BA218A,earnings-up,100,68,7/21/2021
BA218A,earnings-up,100,68,7/21/2021
BA218A,earnings-up,100,68,7/21/2021
BA218A,earnings-up,100,68,7/21/2021
BA218A,earnings-up,100,68,7/21/2021
BB127B,acquisition-completed-acquirer,100,49,7/21/2021
BB127B,acquisition-completed-acquirer,100,49,7/21/2021
BCC13E,earnings,100,50,7/21/2021
C29715,earnings,100,50,7/21/2021
C29715,earnings,100,50,7/21/2021
C2F597,earnings,100,50,7/21/2021
C407A0,earnings,100,50,7/21/2021
C54140,earnings,100,50,7/21/2021
C598D7,dividend,100,50,7/21/2021
C5C137,executive-appointment,100,54,7/21/2021
C5E100,conference-call,100,50,7/21/2021
C8257F,dividend,100,50,7/21/2021
C9B932,earnings,100,50,7/21/2021
C9E107,earnings-up,100,68,7/21/2021
C9E107,earnings-up,100,68,7/21/2021
C9E107,earnings-up,100,68,7/21/2021
C9F39B,earnings,100,50,7/21/2021
C9F39B,earnings,100,50,7/21/2021
C9F39B,earnings,100,50,7/21/2021
C9F39B,earnings,100,50,7/21/2021
C9F39B,earnings,100,50,7/21/2021
C9F39B,earnings,100,50,7/21/2021
C9F39B,earnings,100,50,7/21/2021
C9F39B,earnings,100,50,7/21/2021
CB22CD,conference-call,100,50,7/21/2021
CB89EA,earnings,100,50,7/21/2021
CB89EA,conference-participant,100,50,7/21/2021
CCB623,business-contract,100,69,7/21/2021
CE1002,dividend-up,100,81,7/21/2021
CEDFD5,partnership,100,61,7/21/2021
CF6A5A,partnership,100,61,7/21/2021
CFF97C,credit-rating-affirmation-rater,20,50,7/21/2021
CFF97C,credit-rating-affirmation-rater,20,50,7/21/2021
D06755,conference-participant,100,50,7/21/2021
D0DE27,earnings,100,50,7/21/2021
D1AE3B,earnings,100,50,7/21/2021
D21D8A,earnings,100,50,7/21/2021
D21D8A,earnings,100,50,7/21/2021
D21D8A,earnings,100,50,7/21/2021
D21D8A,earnings,100,50,7/21/2021
D21D8A,earnings,100,50,7/21/2021
D21D8A,earnings,100,50,7/21/2021
D21D8A,earnings,100,50,7/21/2021
D21D8A,earnings,100,50,7/21/2021
D27FAB,conference-call,100,50,7/21/2021
D33D8C,dividend,100,50,7/21/2021
D4AC65,conference-call,100,50,7/21/2021
D5AF19,dividend,100,50,7/21/2021
D697DE,fundraising,100,64,7/21/2021
D6EAA3,dividend,100,50,7/21/2021
D721C6,dividend,100,50,7/21/2021
D7A953,earnings,100,50,7/21/2021
D854DD,conference-call,100,50,7/21/2021
D90F43,executive-appointment,100,54,7/21/2021
DB06B0,partnership,100,61,7/21/2021
DBFB51,conference-call,100,50,7/21/2021
DC0998,executive-appointment,100,54,7/21/2021
DC0998,earnings,100,50,7/21/2021
DC0998,earnings,100,50,7/21/2021
DC0998,earnings,100,50,7/21/2021
DC0998,earnings,100,50,7/21/2021
DC0998,earnings,100,50,7/21/2021
DD1BA1,earnings,100,50,7/21/2021
DF11D9,legal-issues-defendant,100,22,7/21/2021
DFADDB,clinical-trials,100,56,7/21/2021
E0207A,joint-venture,100,62,7/21/2021
E22FDE,conference-call,100,50,7/21/2021
E26FC3,earnings-per-share-positive,100,69,7/21/2021
E30B34,earnings,100,50,7/21/2021
E30B34,earnings,100,50,7/21/2021
E393B0,legal-issues-defendant,100,22,7/21/2021
E3A829,earnings,100,50,7/21/2021
E3E68E,award,100,58,7/21/2021
E3E68E,award,100,58,7/21/2021
E5752F,earnings,100,50,7/21/2021
E5D914,earnings,100,50,7/21/2021
E6BC2C,executive-appointment,100,54,7/21/2021
E8A49A,award,100,58,7/21/2021
E90C84,earnings,100,50,7/21/2021
EB2F14,dividend,100,50,7/21/2021
EB61C4,dividend,100,50,7/21/2021
ECDEB2,buybacks,100,74,7/21/2021
ECDEB2,earnings,100,50,7/21/2021
ED0D7C,dividend,100,50,7/21/2021
ED5171,earnings,100,50,7/21/2021
ED9576,earnings,100,50,7/21/2021
EEA6B3,earnings,100,50,7/21/2021
EF5BED,executive-appointment,100,54,7/21/2021
EFD406,conference-call,100,50,7/21/2021
F1C04C,conference-call,100,50,7/21/2021
F24FF0,earnings,100,50,7/21/2021
F3EDB4,partnership,100,61,7/21/2021
F42FAE,earnings,100,50,7/21/2021
F702CA,dividend,100,50,7/21/2021
F8DE55,earnings,100,50,7/21/2021
FD2565,conference-call,100,50,7/21/2021
FDC08C,dividend,100,50,7/21/2021
FEC475,unit-acquisition-acquiree,100,76,7/21/2021
FEC475,unit-acquisition-acquiree,100,76,7/21/2021
FFAB4A,dividend,100,50,7/21/2021
00698D,dividend,100,50,7/22/2021
01B8D6,earnings,100,50,7/22/2021
01D03F,earnings,100,50,7/22/2021
03FAA6,earnings,100,50,7/22/2021
55018,earnings-positive,100,69,7/22/2021
061A3B,earnings,100,50,7/22/2021
68396,earnings,100,50,7/22/2021
07CA6A,dividend,100,50,7/22/2021
07CA6A,dividend,100,50,7/22/2021
08A40F,earnings-per-share-positive,100,69,7/22/2021
08A40F,earnings-per-share-positive,100,69,7/22/2021
08A40F,earnings-per-share-positive,100,69,7/22/2021
08A40F,earnings-per-share-positive,100,69,7/22/2021
08A40F,earnings-per-share-positive,100,69,7/22/2021
08A40F,earnings-per-share-positive,100,69,7/22/2021
08A40F,earnings-per-share-positive,100,69,7/22/2021
0A0CF0,earnings,100,50,7/22/2021
0A0CF0,earnings,100,50,7/22/2021
0A0CF0,earnings,100,50,7/22/2021
0A0CF0,earnings,100,50,7/22/2021
0A0CF0,earnings,100,50,7/22/2021
0A7650,earnings,100,50,7/22/2021
0A77DB,earnings,100,50,7/22/2021
0AAD90,clinical-trials-positive,100,87,7/22/2021
0B2071,dividend,100,50,7/22/2021
0B9E6F,earnings-up,100,68,7/22/2021
0B9E6F,earnings,100,50,7/22/2021
0BD199,earnings,100,50,7/22/2021
0C355F,revenues,100,50,7/22/2021
0C355F,revenues,100,50,7/22/2021
0C355F,revenues,100,50,7/22/2021
0C355F,revenues,100,50,7/22/2021
0C466B,dividend,100,50,7/22/2021
0C8D82,earnings,100,50,7/22/2021
0DBB81,partnership,100,61,7/22/2021
0DBB81,partnership,100,61,7/22/2021
0E5223,executive-appointment,100,54,7/22/2021
0EF1AF,earnings,100,50,7/22/2021
0FDE97,conference-call,100,50,7/22/2021
105D00,earnings-positive,100,69,7/22/2021
105D00,earnings,100,50,7/22/2021
105D00,earnings,100,50,7/22/2021
105D00,earnings,100,50,7/22/2021
105D00,earnings,100,50,7/22/2021
105D00,earnings,100,50,7/22/2021
105D00,earnings,100,50,7/22/2021
105D00,earnings,100,50,7/22/2021
105D00,earnings,100,50,7/22/2021
105D00,earnings,100,50,7/22/2021
10C19B,earnings-up,100,68,7/22/2021
10C19B,earnings,100,50,7/22/2021
10C19B,earnings,100,50,7/22/2021
10C19B,earnings,100,50,7/22/2021
10C19B,earnings,100,50,7/22/2021
10C19B,earnings,100,50,7/22/2021
10C19B,earnings,100,50,7/22/2021
10C19B,earnings,100,50,7/22/2021
119CB6,dividend,100,50,7/22/2021
126F95,earnings,100,50,7/22/2021
126F95,earnings,100,50,7/22/2021
126F95,earnings,100,50,7/22/2021
126F95,earnings,100,50,7/22/2021
1272B3,executive-appointment,100,54,7/22/2021
129DC8,trading-halt,100,43,7/22/2021
129DC8,trading-resumed,100,58,7/22/2021
13C3E0,earnings,100,50,7/22/2021
152B9E,dividend,100,50,7/22/2021
15789A,earnings,100,50,7/22/2021
15A388,business-contract,100,69,7/22/2021
168A5D,partnership,100,61,7/22/2021
182B8C,earnings,100,50,7/22/2021
182B8C,earnings,100,50,7/22/2021
182B8C,earnings,100,50,7/22/2021
184866,earnings,100,50,7/22/2021
1866B2,investment-investor,100,55,7/22/2021
1921DD,business-contract,100,69,7/22/2021
1921DD,partnership,100,61,7/22/2021
19C105,earnings,100,50,7/22/2021
1A3E1B,conference-call,100,50,7/22/2021
1AF7E2,earnings,100,50,7/22/2021
1B16C1,conference-call,100,50,7/22/2021
1CD09C,conference-call,100,50,7/22/2021
1CD708,earnings,100,50,7/22/2021
1D5C51,conference-call,100,50,7/22/2021
1DA44F,product-release,100,64,7/22/2021
1F464F,earnings,100,50,7/22/2021
2096DE,earnings,100,50,7/22/2021
20DC4E,earnings,100,50,7/22/2021
21268E,conference-call,100,50,7/22/2021
223552,earnings,100,50,7/22/2021
225CA2,dividend,100,50,7/22/2021
228D42,partnership,100,61,7/22/2021
228D42,partnership,100,61,7/22/2021
2491BC,earnings,100,50,7/22/2021
2491BC,earnings,100,50,7/22/2021
2491BC,earnings,100,50,7/22/2021
2491BC,earnings,100,50,7/22/2021
2491BC,earnings,100,50,7/22/2021
24D81E,earnings,100,50,7/22/2021
251988,earnings,100,50,7/22/2021
251988,earnings,100,50,7/22/2021
251988,earnings,100,50,7/22/2021
251988,earnings,100,50,7/22/2021
251988,earnings,100,50,7/22/2021
251988,earnings,100,50,7/22/2021
251988,earnings,100,50,7/22/2021
2571FA,government-contract,100,69,7/22/2021
25AB8E,earnings,100,50,7/22/2021
267718,partnership,100,61,7/22/2021
267718,partnership,100,61,7/22/2021
267718,partnership,100,61,7/22/2021
272704,dividend,100,50,7/22/2021
278C18,earnings,100,50,7/22/2021
297DA8,earnings,100,50,7/22/2021
29CEBF,conference-call,100,50,7/22/2021
2B9DBB,earnings,100,50,7/22/2021
2C35B5,conference-call,100,50,7/22/2021
2CC71C,clinical-trials,100,56,7/22/2021
2CC71C,conference-call,100,50,7/22/2021
2DA92D,earnings,100,50,7/22/2021
2DC88B,earnings,100,50,7/22/2021
2DDB22,conference-call,100,50,7/22/2021
2E2E6E,earnings,100,50,7/22/2021
2E6514,earnings-per-share-positive,100,69,7/22/2021
2E6514,earnings-per-share-positive,100,69,7/22/2021
2E6514,earnings-per-share-positive,100,69,7/22/2021
2E6514,earnings-per-share-positive,100,69,7/22/2021
2E6514,earnings-per-share-positive,100,69,7/22/2021
2E6514,earnings-per-share-positive,100,69,7/22/2021
2E6514,earnings-per-share-positive,100,69,7/22/2021
2F7474,earnings,100,50,7/22/2021
2F7474,earnings,100,50,7/22/2021
2FF046,earnings,100,50,7/22/2021
30E01D,earnings,100,50,7/22/2021
3159AA,conference-call,100,50,7/22/2021
31666F,earnings,100,50,7/22/2021
319BE2,conference-call,100,50,7/22/2021
31F25C,earnings,100,50,7/22/2021
33A0F1,partnership,100,61,7/22/2021
33AD83,business-contract,100,69,7/22/2021
3.30E+34,dividend,100,50,7/22/2021
3471C0,earnings,100,50,7/22/2021
35557B,executive-appointment,100,54,7/22/2021
367434,earnings,100,50,7/22/2021
37020C,dividend,100,50,7/22/2021
370C50,earnings,100,50,7/22/2021
384CD3,earnings,100,50,7/22/2021
389CFB,conference-call,100,50,7/22/2021
389CFB,executive-appointment,100,54,7/22/2021
3A3948,earnings,100,50,7/22/2021
3B37F7,earnings,100,50,7/22/2021
3BE00F,acquisition-acquirer,100,49,7/22/2021
3C8A04,earnings,100,50,7/22/2021
3D9999,market-entry,100,57,7/22/2021
3D9999,dividend,100,50,7/22/2021
3E39A5,dividend,100,50,7/22/2021
401072,earnings,100,50,7/22/2021
407878,partnership,100,61,7/22/2021
407878,product-release,100,64,7/22/2021
408380,earnings,100,50,7/22/2021
41A93D,earnings,100,50,7/22/2021
423279,earnings-per-share-positive,100,69,7/22/2021
442769,facility-open,100,65,7/22/2021
44ED36,dividend,100,50,7/22/2021
453282,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
46CF27,earnings,100,50,7/22/2021
487B7A,earnings-up,100,68,7/22/2021
4A2457,conference-call,100,50,7/22/2021
4B3555,earnings,100,50,7/22/2021
4B49CF,partnership,100,61,7/22/2021
4C1FA1,conference-call,100,50,7/22/2021
4C7DB5,earnings-up,100,68,7/22/2021
4C7DB5,earnings,100,50,7/22/2021
4C7DB5,earnings,100,50,7/22/2021
4D203E,earnings,100,50,7/22/2021
4E913D,earnings-per-share-up,100,73,7/22/2021
514067,conference-participant,100,50,7/22/2021
520632,earnings,100,50,7/22/2021
520632,earnings,100,50,7/22/2021
520632,earnings,100,50,7/22/2021
520632,earnings,100,50,7/22/2021
520632,earnings,100,50,7/22/2021
53F491,ownership-decrease-owner,100,46,7/22/2021
53F491,dividend,100,50,7/22/2021
5.43E+08,earnings,100,50,7/22/2021
553949,conference-call,100,50,7/22/2021
5546DA,earnings,100,50,7/22/2021
5546DA,earnings,100,50,7/22/2021
5546DA,earnings,100,50,7/22/2021
5546DA,earnings,100,50,7/22/2021
5546DA,earnings,100,50,7/22/2021
5546DA,earnings,100,50,7/22/2021
556A57,earnings-positive,100,69,7/22/2021
556A57,earnings,100,50,7/22/2021
556A57,earnings,100,50,7/22/2021
556A57,earnings,100,50,7/22/2021
556A57,earnings,100,50,7/22/2021
556A57,earnings,100,50,7/22/2021
556A57,earnings,100,50,7/22/2021
556A57,earnings,100,50,7/22/2021
556A57,earnings,100,50,7/22/2021
57634F,earnings,100,50,7/22/2021
57A854,earnings,100,50,7/22/2021
589846,partnership,100,61,7/22/2021
58C2D4,partnership,100,61,7/22/2021
58C2D4,partnership,100,61,7/22/2021
58CA9A,dividend,100,50,7/22/2021
59C539,earnings,100,50,7/22/2021
5AAE17,conference-call,100,50,7/22/2021
5BE42C,dividend-up,100,64,7/22/2021
5BE42C,dividend,100,50,7/22/2021
5BFE94,dividend,100,50,7/22/2021
5D1956,earnings,100,50,7/22/2021
5D43A7,dividend,100,50,7/22/2021
5D63F1,executive-appointment,100,54,7/22/2021
5DE5A5,earnings-up,100,68,7/22/2021
5DE5A5,earnings,100,50,7/22/2021
5DE5A5,earnings,100,50,7/22/2021
5DE5A5,earnings,100,50,7/22/2021
5F9CE3,earnings,100,50,7/22/2021
5F9CE3,executive-appointment,100,54,7/22/2021
6137BF,conference-call,100,50,7/22/2021
622037,dividend,100,50,7/22/2021
622037,buybacks,100,74,7/22/2021
62F41C,executive-appointment,100,54,7/22/2021
6474BA,earnings-positive,100,69,7/22/2021
6474BA,earnings,100,50,7/22/2021
6474BA,earnings,100,50,7/22/2021
6474BA,earnings,100,50,7/22/2021
6474BA,earnings,100,50,7/22/2021
6474BA,earnings,100,50,7/22/2021
6474BA,earnings,100,50,7/22/2021
6474BA,earnings,100,50,7/22/2021
6474BA,earnings,100,50,7/22/2021
6474BA,earnings,100,50,7/22/2021
6474BA,earnings,100,50,7/22/2021
662682,dividend,100,50,7/22/2021
665618,earnings-per-share-up,100,84,7/22/2021
665618,earnings-per-share-up,100,84,7/22/2021
665618,earnings-per-share-up,100,84,7/22/2021
67B052,earnings,100,50,7/22/2021
68586A,conference-call,100,50,7/22/2021
6AACDD,legal-issues-defendant,100,22,7/22/2021
6CF43C,earnings,100,50,7/22/2021
6D156D,earnings,100,50,7/22/2021
701531,earnings,100,50,7/22/2021
72C2CE,conference-call,100,50,7/22/2021
732A9B,partnership,100,61,7/22/2021
732A9B,partnership,100,61,7/22/2021
732A9B,partnership,100,61,7/22/2021
742AAB,conference-call,100,50,7/22/2021
74404C,executive-appointment,100,54,7/22/2021
7520CC,earnings,100,50,7/22/2021
76DD0C,earnings,100,50,7/22/2021
782B46,dividend,100,50,7/22/2021
78A1BB,earnings,100,50,7/22/2021
78A1BB,earnings,100,50,7/22/2021
78A1BB,earnings,100,50,7/22/2021
78A1BB,earnings,100,50,7/22/2021
78A1BB,earnings,100,50,7/22/2021
78A1BB,earnings,100,50,7/22/2021
7A5D58,earnings,100,50,7/22/2021
7ACFD4,executive-appointment,100,54,7/22/2021
7B0BA6,dividend,100,50,7/22/2021
7B1156,conference-call,100,50,7/22/2021
7B1E50,settlement,100,56,7/22/2021
7B1E50,earnings,100,50,7/22/2021
7B1E50,executive-appointment,100,54,7/22/2021
7BAAE7,dividend,100,50,7/22/2021
7D5384,earnings,100,50,7/22/2021
7D5384,earnings,100,50,7/22/2021
7D5384,earnings,100,50,7/22/2021
7D5384,earnings,100,50,7/22/2021
7D5384,earnings,100,50,7/22/2021
7F2922,earnings,100,50,7/22/2021
7F3FBC,operating-earnings,100,50,7/22/2021
80D744,earnings,100,50,7/22/2021
824CCA,earnings,100,50,7/22/2021
8295B8,earnings,100,50,7/22/2021
83598E,dividend,100,50,7/22/2021
8377DB,earnings,100,50,7/22/2021
8377DB,earnings,100,50,7/22/2021
8377DB,earnings,100,50,7/22/2021
8377DB,earnings,100,50,7/22/2021
8377DB,earnings,100,50,7/22/2021
838ADD,earnings,100,50,7/22/2021
838ADD,earnings,100,50,7/22/2021
838ADD,earnings,100,50,7/22/2021
838ADD,earnings,100,50,7/22/2021
838ADD,earnings,100,50,7/22/2021
838ADD,earnings,100,50,7/22/2021
83A065,debt-extension-recipient,100,73,7/22/2021
859281,dividend,100,50,7/22/2021
859D62,executive-resignation,100,44,7/22/2021
85AD00,earnings-up,100,68,7/22/2021
85CDC9,earnings,100,50,7/22/2021
863350,facility-open,100,65,7/22/2021
86478F,earnings,100,50,7/22/2021
885758,partnership,100,61,7/22/2021
885758,partnership,100,61,7/22/2021
893904,earnings,100,50,7/22/2021
8B2C4A,earnings,100,50,7/22/2021
8B2C4A,earnings,100,50,7/22/2021
8B2C4A,earnings,100,50,7/22/2021
8B2C4A,earnings,100,50,7/22/2021
8B2C4A,earnings,100,50,7/22/2021
8B2C4A,earnings,100,50,7/22/2021
8B2C4A,earnings,100,50,7/22/2021
8B9B3B,earnings,100,50,7/22/2021
8BFAA4,conference-call,100,50,7/22/2021
8C84DF,earnings,100,50,7/22/2021
8D5145,earnings,100,50,7/22/2021
8DA42F,conference-call,100,50,7/22/2021
8DAAB9,executive-appointment,100,54,7/22/2021
8DDA23,earnings,100,50,7/22/2021
907ED2,earnings,100,50,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
911AB8,earnings-positive,100,69,7/22/2021
92B047,dividend,100,50,7/22/2021
9.31E+77,conference-call,100,50,7/22/2021
93D207,acquisition-acquirer,100,49,7/22/2021
943239,earnings,100,50,7/22/2021
945DE6,dividend,100,50,7/22/2021
9548BB,earnings,100,50,7/22/2021
9548BB,earnings,100,50,7/22/2021
954A47,earnings-positive,100,69,7/22/2021
9.54E+32,dividend,100,50,7/22/2021
9592FB,earnings,100,50,7/22/2021
9.65E+09,conference-call,100,50,7/22/2021
965360,earnings,100,50,7/22/2021
97644E,partnership,100,61,7/22/2021
977A1E,business-contract,100,69,7/22/2021
97FE80,partnership,100,61,7/22/2021
986AF6,earnings,100,50,7/22/2021
986AF6,earnings-up,100,68,7/22/2021
986AF6,earnings-up,100,68,7/22/2021
9.97E+09,earnings,100,50,7/22/2021
9A2760,earnings,100,50,7/22/2021
9B5968,earnings,100,50,7/22/2021
9B5968,earnings,100,50,7/22/2021
9B5968,earnings,100,50,7/22/2021
9E3224,earnings,100,50,7/22/2021
9EA947,product-release,100,64,7/22/2021
9EF4CF,earnings,100,50,7/22/2021
9F37C5,earnings,100,50,7/22/2021
9F5997,executive-appointment,100,54,7/22/2021
9FB4B7,earnings,100,50,7/22/2021
9FF5F1,conference-participant,100,50,7/22/2021
A01983,conference-call,100,50,7/22/2021
A072C4,earnings,100,50,7/22/2021
A16DEA,dividend,100,50,7/22/2021
A2C979,patient-enrollment-complete,100,64,7/22/2021
A2C979,patient-enrollment-complete,100,64,7/22/2021
A403CF,executive-appointment,100,54,7/22/2021
A41450,earnings,100,50,7/22/2021
A4D173,earnings,100,50,7/22/2021
A4D173,earnings,100,50,7/22/2021
A5195E,earnings,100,50,7/22/2021
A52533,earnings,100,50,7/22/2021
A5628C,earnings-up,100,68,7/22/2021
A5628C,earnings,100,50,7/22/2021
A5628C,earnings,100,50,7/22/2021
A5B913,earnings,100,50,7/22/2021
A5B913,earnings,100,50,7/22/2021
A6213D,partnership,100,61,7/22/2021
A6FE1C,unit-acquisition-acquirer,100,49,7/22/2021
A70BF5,product-release,100,64,7/22/2021
A868C9,conference-call,100,50,7/22/2021
A871B0,acquisition-completed-acquiree,100,76,7/22/2021
A94637,revenues,100,50,7/22/2021
AB4A7E,conference-call,100,50,7/22/2021
AD375D,earnings,100,50,7/22/2021
B05000,earnings,100,50,7/22/2021
B05118,partnership,100,61,7/22/2021
B0998E,earnings,100,50,7/22/2021
B1FC3B,executive-appointment,100,54,7/22/2021
B1FC3B,award,100,58,7/22/2021
B2256A,conference-call,100,50,7/22/2021
B381D8,earnings,100,50,7/22/2021
B5766D,earnings-per-share-positive,100,69,7/22/2021
B5766D,earnings,100,50,7/22/2021
B5766D,earnings,100,50,7/22/2021
B5766D,earnings,100,50,7/22/2021
B5766D,earnings,100,50,7/22/2021
B5766D,earnings,100,50,7/22/2021
B5766D,earnings,100,50,7/22/2021
B8F71F,earnings,100,50,7/22/2021
BB02FB,unit-acquisition-acquiree,100,76,7/22/2021
BB0587,conference-call,100,50,7/22/2021
BB58FF,conference-participant,100,50,7/22/2021
BE14CF,partnership,100,61,7/22/2021
BEB756,earnings,100,50,7/22/2021
C05839,acquisition-completed-acquirer,100,49,7/22/2021
C15DB3,earnings,100,50,7/22/2021
C16A8F,dividend,100,50,7/22/2021
C1CBA4,dividend-up,100,81,7/22/2021
C1CBA4,earnings-positive,100,69,7/22/2021
C1CBA4,earnings-up,100,68,7/22/2021
C1CBA4,earnings-up,100,68,7/22/2021
C1CBA4,earnings-up,100,68,7/22/2021
C1CBA4,earnings-up,100,68,7/22/2021
C1CBA4,earnings-up,100,68,7/22/2021
C1CBA4,earnings-up,100,68,7/22/2021
C1CBA4,earnings-up,100,68,7/22/2021
C1CBA4,earnings-up,100,68,7/22/2021
C2E39B,earnings,100,50,7/22/2021
C41C25,earnings,100,50,7/22/2021
C9881C,product-release,100,64,7/22/2021
C9E4EC,earnings,100,50,7/22/2021
CBDB4D,public-offering,100,43,7/22/2021
CC35BE,earnings,100,50,7/22/2021
CCB623,business-contract,100,69,7/22/2021
CCB623,earnings,100,50,7/22/2021
CD4DA8,executive-appointment,100,54,7/22/2021
CEC08B,earnings,100,50,7/22/2021
CF6A5A,earnings,100,50,7/22/2021
CFD4B6,conference-call,100,50,7/22/2021
D6489C,award,100,58,7/22/2021
D650A7,earnings,100,50,7/22/2021
D8F347,earnings,100,50,7/22/2021
D8F347,earnings,100,50,7/22/2021
D8F347,earnings,100,50,7/22/2021
D8F347,earnings,100,50,7/22/2021
D9B1C9,earnings,100,50,7/22/2021
D9B1C9,earnings,100,50,7/22/2021
D9B1C9,earnings,100,50,7/22/2021
DA90E1,earnings,100,50,7/22/2021
DAFED3,executive-appointment,100,54,7/22/2021
DB88A1,award,100,58,7/22/2021
DBB28E,business-contract,100,69,7/22/2021
DBB28E,business-contract,100,69,7/22/2021
DBCA3F,earnings,100,50,7/22/2021
DC437D,conference-participant,100,50,7/22/2021
DD0099,earnings-up,100,72,7/22/2021
DDCB34,conference-call,100,50,7/22/2021
DDEA6A,regulatory-product-approval-granted,100,81,7/22/2021
DE4924,conference-call,100,50,7/22/2021
E05DC8,earnings-up,100,68,7/22/2021
E09E2B,partnership,100,61,7/22/2021
E114F4,conference-call,100,50,7/22/2021
E124EB,earnings,100,50,7/22/2021
E124EB,earnings,100,50,7/22/2021
E124EB,earnings,100,50,7/22/2021
E124EB,earnings,100,50,7/22/2021
E1BD05,earnings,100,50,7/22/2021
E2CB7B,earnings,100,50,7/22/2021
E2F66E,conference-call,100,50,7/22/2021
E3A829,business-contract,100,69,7/22/2021
E40FB6,earnings,100,50,7/22/2021
E40FB6,earnings,100,50,7/22/2021
E40FB6,earnings,100,50,7/22/2021
E40FB6,earnings,100,50,7/22/2021
E40FB6,earnings,100,50,7/22/2021
E40FB6,earnings,100,50,7/22/2021
E40FB6,earnings,100,50,7/22/2021
E49AA3,earnings,100,50,7/22/2021
E5F0A8,earnings-positive,100,69,7/22/2021
E5F0A8,earnings,100,50,7/22/2021
E5F0A8,earnings,100,50,7/22/2021
E5F0A8,earnings,100,50,7/22/2021
E5F0A8,earnings,100,50,7/22/2021
E67C2C,earnings,100,50,7/22/2021
E6E012,dividend,100,50,7/22/2021
E6E012,dividend,100,50,7/22/2021
E754F0,earnings,100,50,7/22/2021
E82A2D,conference-call,100,50,7/22/2021
E866D2,earnings,100,50,7/22/2021
E866D2,earnings,100,50,7/22/2021
E866D2,earnings,100,50,7/22/2021
E866D2,earnings,100,50,7/22/2021
E866D2,earnings,100,50,7/22/2021
E866D2,earnings,100,50,7/22/2021
E866D2,earnings,100,50,7/22/2021
E866D2,earnings,100,50,7/22/2021
E8846E,executive-appointment,100,54,7/22/2021
E8B315,earnings-positive,100,69,7/22/2021
E94704,earnings,100,50,7/22/2021
E94704,earnings,100,50,7/22/2021
E94704,earnings,100,50,7/22/2021
E94704,earnings,100,50,7/22/2021
E94704,earnings,100,50,7/22/2021
E99180,earnings,100,50,7/22/2021
EB2F14,earnings-positive,100,69,7/22/2021
EC1AF3,conference-call,100,50,7/22/2021
EC4E82,conference-participant,100,50,7/22/2021
ED8676,earnings,100,50,7/22/2021
ED8676,earnings,100,50,7/22/2021
ED8676,earnings,100,50,7/22/2021
ED8676,dividend,100,50,7/22/2021
EE04F0,earnings,100,50,7/22/2021
EF25A5,earnings,100,50,7/22/2021
F0B877,earnings,100,50,7/22/2021
F0EEFB,conference-call,100,50,7/22/2021
F18844,executive-appointment,100,54,7/22/2021
F30508,conference-call,100,50,7/22/2021
F48947,revenue-guidance,100,50,7/22/2021
F4F46F,conference-call,100,50,7/22/2021
F4FBD8,earnings,100,50,7/22/2021
F702CA,earnings,100,50,7/22/2021
F702CA,earnings,100,50,7/22/2021
F702CA,earnings,100,50,7/22/2021
F702CA,earnings,100,50,7/22/2021
F702CA,earnings,100,50,7/22/2021
F702CA,earnings,100,50,7/22/2021
F702CA,earnings,100,50,7/22/2021
F80389,public-offering,100,43,7/22/2021
F80389,business-contract,100,69,7/22/2021
F88A04,earnings,100,50,7/22/2021
FADF1A,conference-call,100,50,7/22/2021
FBD92D,earnings,100,50,7/22/2021
FC1736,revenues,100,50,7/22/2021
FC1736,revenues,100,50,7/22/2021
FC1736,revenues,100,50,7/22/2021
FC4550,earnings,100,50,7/22/2021
FFE543,revenue-up,100,69,7/22/2021
FFE543,earnings,100,50,7/22/2021
FFE543,earnings,100,50,7/22/2021
FFE543,earnings,100,50,7/22/2021
02870F,conference-call,100,50,7/23/2021
0C6861,conference-call,100,50,7/23/2021
108BD2,earnings-up,100,77,7/23/2021
1216D1,earnings,100,50,7/23/2021
15B10D,conference-call,100,50,7/23/2021
184866,public-offering,100,43,7/23/2021
1AE9D5,executive-appointment,100,54,7/23/2021
1F464F,partnership,100,61,7/23/2021
1F464F,partnership,100,61,7/23/2021
228D42,partnership,100,61,7/23/2021
24A89A,clinical-trials-start,100,64,7/23/2021
26CC63,dividend,100,50,7/23/2021
26CC63,buybacks,100,74,7/23/2021
270305,earnings,100,50,7/23/2021
2CB4C9,earnings,100,50,7/23/2021
356B21,earnings,100,50,7/23/2021
382EAE,conference-call,100,50,7/23/2021
383ADA,earnings,100,50,7/23/2021
3DE4D1,earnings,100,50,7/23/2021
3E39A5,earnings,100,50,7/23/2021
407878,product-release,100,64,7/23/2021
435ACE,conference-call,100,50,7/23/2021
43A060,executive-resignation,100,44,7/23/2021
499C75,earnings,100,50,7/23/2021
4A2457,conference-participant,100,50,7/23/2021
4BBA23,acquisition-acquirer,100,49,7/23/2021
4C37C5,revenues,100,50,7/23/2021
4C37C5,revenues,100,50,7/23/2021
4C37C5,revenues,100,50,7/23/2021
4D371E,buybacks,100,74,7/23/2021
562853,earnings,100,50,7/23/2021
5876DC,earnings,100,50,7/23/2021
589F5A,buybacks,100,74,7/23/2021
5BFE94,earnings,100,50,7/23/2021
5D43A7,business-contract,100,69,7/23/2021
5D87DF,earnings,100,50,7/23/2021
5E6959,earnings-up,100,68,7/23/2021
5FDBD0,conference-call,100,50,7/23/2021
6AACDD,legal-issues-defendant,100,22,7/23/2021
6B236C,dividend,100,50,7/23/2021
6B67BD,clinical-trials,100,56,7/23/2021
6B67BD,clinical-trials,100,56,7/23/2021
6DD6BA,executive-appointment,100,54,7/23/2021
713810,legal-issues-defendant,100,22,7/23/2021
72F0FC,dividend,100,50,7/23/2021
72F0FC,earnings-up,100,68,7/23/2021
73C521,earnings-positive,100,69,7/23/2021
76BD96,conference-call,100,50,7/23/2021
76CEFB,earnings,100,50,7/23/2021
83A065,conference-call,100,50,7/23/2021
863350,ownership-increase-held,100,67,7/23/2021
863350,acquisition-completed-acquiree,100,76,7/23/2021
89F693,product-release,100,64,7/23/2021
8C1238,conference-call,100,50,7/23/2021
911ACB,earnings,100,50,7/23/2021
911ACB,earnings,100,50,7/23/2021
911ACB,earnings,100,50,7/23/2021
9981C6,earnings,100,50,7/23/2021
9EED50,dividend,100,50,7/23/2021
9F5CBB,conference-call,100,50,7/23/2021
A02FB1,merger,100,66,7/23/2021
A02FB1,earnings,100,50,7/23/2021
A02FB1,merger,100,66,7/23/2021
A02FB1,acquisition-regulatory-scrutiny-acquiree,100,38,7/23/2021
A02FB1,acquisition-regulatory-scrutiny-acquiree,100,38,7/23/2021
A247F5,earnings,100,50,7/23/2021
A58224,conference-call,100,50,7/23/2021
A60318,public-offering,100,43,7/23/2021
A666C8,earnings,100,50,7/23/2021
A6828A,product-release,100,64,7/23/2021
A6828A,product-release,100,64,7/23/2021
A6FE1C,acquisition-acquirer,100,49,7/23/2021
B09B1F,conference-call,100,50,7/23/2021
B4703C,acquisition-acquirer,100,49,7/23/2021
B72D2E,conference-call,100,50,7/23/2021
B803B1,conference-call,100,50,7/23/2021
BC948D,conference-call,100,50,7/23/2021
C062D4,dividend,100,50,7/23/2021
C5D2AE,acquisition-acquiree,100,76,7/23/2021
C9E107,dividend,100,50,7/23/2021
CC339B,earnings,100,50,7/23/2021
CDAB24,conference-call,100,50,7/23/2021
D0DFE5,earnings,100,50,7/23/2021
D721C6,earnings-up,100,81,7/23/2021
D7F569,dividend,100,50,7/23/2021
D7F569,earnings,100,50,7/23/2021
DB5CA5,unit-acquisition-acquirer,100,49,7/23/2021
DBEF02,earnings,100,50,7/23/2021
DD682D,dividend,100,50,7/23/2021
E05DC8,executive-appointment,100,54,7/23/2021
E1E093,executive-appointment,100,54,7/23/2021
EA4E68,earnings,100,50,7/23/2021
ED0D7C,earnings,100,50,7/23/2021
ED0D7C,earnings,100,50,7/23/2021
ED0D7C,earnings,100,50,7/23/2021
ED0D7C,earnings,100,50,7/23/2021
ED0D7C,earnings,100,50,7/23/2021
ED0D7C,earnings,100,50,7/23/2021
ED2EFD,dividend,100,50,7/23/2021
EE1E44,earnings,100,50,7/23/2021
EE1E44,earnings,100,50,7/23/2021
EE1E44,earnings,100,50,7/23/2021
EE1E44,earnings,100,50,7/23/2021
EE1E44,earnings,100,50,7/23/2021
EE1E44,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F294DD,earnings,100,50,7/23/2021
F2BC3D,acquisition-acquirer,100,49,7/23/2021
F2BC3D,acquisition-acquirer,100,49,7/23/2021
F48947,earnings,100,50,7/23/2021
F4CDA3,conference-call,100,50,7/23/2021
F88147,legal-issues-defendant,100,22,7/23/2021
F88147,legal-issues-defendant,100,22,7/23/2021
F88147,legal-issues-defendant,100,22,7/23/2021
FDC08C,earnings,100,50,7/23/2021
FDC08C,earnings,100,50,7/23/2021
FDC08C,earnings,100,50,7/23/2021
FDC08C,earnings,100,50,7/23/2021
FDC08C,earnings,100,50,7/23/2021
449217,earnings-positive,100,69,7/24/2021
449217,earnings,100,50,7/24/2021
449217,earnings,100,50,7/24/2021
449217,earnings,100,50,7/24/2021
449217,earnings,100,50,7/24/2021
449217,earnings,100,50,7/24/2021
449217,earnings,100,50,7/24/2021
449217,earnings,100,50,7/24/2021
F88147,legal-issues-defendant,100,22,7/24/2021
6AACDD,legal-issues-defendant,100,22,7/25/2021
7AB859,investment-investor,100,55,7/25/2021
7AF5B8,clinical-trials-positive,100,87,7/25/2021
018C11,executive-appointment,100,54,7/26/2021
03CF95,partnership,100,61,7/26/2021
040DBB,conference-call,100,50,7/26/2021
0490C6,earnings,100,50,7/26/2021
04996E,earnings,100,50,7/26/2021
054B55,business-contract,100,69,7/26/2021
065D38,earnings,100,50,7/26/2021
065D38,earnings,100,50,7/26/2021
06A456,product-release,100,64,7/26/2021
06EE79,executive-appointment,100,54,7/26/2021
075CF7,unit-acquisition-acquirer,100,49,7/26/2021
099C88,business-contract,100,69,7/26/2021
0F0693,earnings,100,50,7/26/2021
0F0693,legal-issues-defendant,100,22,7/26/2021
10673F,earnings,100,50,7/26/2021
10673F,earnings,100,50,7/26/2021
129DC8,conference-participant,100,50,7/26/2021
156A99,earnings,100,50,7/26/2021
15789A,earnings,100,50,7/26/2021
159739,earnings,100,50,7/26/2021
159739,earnings,100,50,7/26/2021
1782D5,earnings,100,50,7/26/2021
1.79E+10,conference-call,100,50,7/26/2021
180DA0,acquisition-acquirer,100,49,7/26/2021
1834C0,unit-acquisition-acquirer,100,49,7/26/2021
1880C5,conference-call,100,50,7/26/2021
1AE9D5,conference-call,100,50,7/26/2021
1BC12C,campaign-ad-release,100,59,7/26/2021
1CD09C,acquisition-completed-acquirer,100,49,7/26/2021
1CF3A8,conference-call,100,50,7/26/2021
1DB833,earnings,100,50,7/26/2021
1DDEDA,acquisition-acquirer,100,49,7/26/2021
1DDEDA,acquisition-acquirer,100,49,7/26/2021
1F2B5D,earnings,100,50,7/26/2021
1F2B5D,earnings,100,50,7/26/2021
1F2B5D,earnings,100,50,7/26/2021
1F2B5D,earnings,100,50,7/26/2021
1F2B5D,earnings,100,50,7/26/2021
1F2B5D,earnings,100,50,7/26/2021
1F2B5D,earnings,100,50,7/26/2021
1F2B5D,earnings,100,50,7/26/2021
206852,earnings,100,50,7/26/2021
20DC4E,dividend,100,50,7/26/2021
227F04,conference-participant,100,50,7/26/2021
249B39,dividend,100,50,7/26/2021
25DD05,earnings,100,50,7/26/2021
2A9C0A,earnings-positive,100,69,7/26/2021
2A9C0A,earnings,100,50,7/26/2021
2A9C0A,earnings,100,50,7/26/2021
2A9C0A,earnings,100,50,7/26/2021
2A9C0A,earnings,100,50,7/26/2021
2A9C0A,earnings,100,50,7/26/2021
2AA6A8,executive-appointment,100,54,7/26/2021
2DB344,earnings,100,50,7/26/2021
2E902B,revenue-up,100,69,7/26/2021
2E902B,revenue-up,100,69,7/26/2021
2E902B,revenue-up,100,69,7/26/2021
2E902B,revenue-up,100,69,7/26/2021
306623,executive-appointment,100,54,7/26/2021
309922,earnings,100,50,7/26/2021
30A565,conference-call,100,50,7/26/2021
339F20,earnings,100,50,7/26/2021
34A959,partnership,100,61,7/26/2021
38FB49,dividend,100,50,7/26/2021
39FB23,supply-guidance-increase,100,74,7/26/2021
3A4BDB,earnings-positive,100,69,7/26/2021
3AF7FD,dividend,100,50,7/26/2021
3DB18B,earnings,100,50,7/26/2021
43A060,earnings,100,50,7/26/2021
444CC8,partnership,100,61,7/26/2021
448BF3,earnings,100,50,7/26/2021
44A4FC,product-release,100,64,7/26/2021
458D2C,partnership,100,61,7/26/2021
49914B,earnings,100,50,7/26/2021
49914B,earnings,100,50,7/26/2021
49CC59,conference-call,100,50,7/26/2021
4A5C8D,dividend-up,100,62,7/26/2021
4C6C63,product-release,100,64,7/26/2021
4C6C63,product-release,100,64,7/26/2021
519FE0,earnings,100,50,7/26/2021
519FE0,earnings,100,50,7/26/2021
54512F,legal-issues-defendant,100,22,7/26/2021
56AFF4,dividend,100,50,7/26/2021
57EF50,dividend,100,50,7/26/2021
5968F9,earnings,100,50,7/26/2021
5AA3B1,earnings,100,50,7/26/2021
5BE42C,earnings,100,50,7/26/2021
5C8D61,earnings,100,50,7/26/2021
5C8D61,earnings,100,50,7/26/2021
5C8D61,earnings,100,50,7/26/2021
5DA8B3,earnings,100,50,7/26/2021
5FDBD0,partnership,100,61,7/26/2021
619882,conference-organizer,100,57,7/26/2021
62EFEE,dividend,100,50,7/26/2021
636931,earnings,100,50,7/26/2021
651C85,earnings,100,50,7/26/2021
66749D,earnings,100,50,7/26/2021
693ECD,earnings,100,50,7/26/2021
6AACDD,legal-issues-defendant,100,22,7/26/2021
6AACDD,legal-issues-defendant,100,22,7/26/2021
6B236C,partnership,100,61,7/26/2021
6B236C,partnership,100,61,7/26/2021
6B5379,earnings,100,50,7/26/2021
6BDA0C,conference-call,100,50,7/26/2021
6D4636,conference-call,100,50,7/26/2021
6DD6BA,earnings,100,50,7/26/2021
6DD6BA,earnings,100,50,7/26/2021
6DD6BA,earnings,100,50,7/26/2021
6-Dec-05,earnings,100,50,7/26/2021
6E8349,earnings,100,50,7/26/2021
6F3FA8,conference-call,100,50,7/26/2021
704B78,earnings,100,50,7/26/2021
722DE3,business-contract,100,69,7/26/2021
728737,earnings,100,50,7/26/2021
73A71F,facility-sale,100,52,7/26/2021
742AAB,executive-appointment,100,54,7/26/2021
7.44E+09,dividend,100,50,7/26/2021
7448A3,earnings,100,50,7/26/2021
748EB6,conference-call,100,50,7/26/2021
75768D,dividend,100,50,7/26/2021
79340A,earnings,100,50,7/26/2021
7A2A49,conference-call,100,50,7/26/2021
7AB859,executive-appointment,100,54,7/26/2021
7B4B91,conference-call,100,50,7/26/2021
7CBC40,earnings,100,50,7/26/2021
7CBC40,earnings,100,50,7/26/2021
7CBC40,earnings,100,50,7/26/2021
7CBC40,earnings,100,50,7/26/2021
7CBC40,earnings,100,50,7/26/2021
7D5FD6,partnership,100,61,7/26/2021
7D5FD6,partnership,100,61,7/26/2021
7D85A9,partnership,100,61,7/26/2021
7E62B5,merger-regulatory-scrutiny,100,37,7/26/2021
7F9E16,conference-call,100,50,7/26/2021
7FC386,earnings,100,50,7/26/2021
805CD8,patient-enrollment-complete,100,64,7/26/2021
82FD6D,unit-acquisition-acquirer,100,49,7/26/2021
82FD6D,conference-call,100,50,7/26/2021
845533,earnings,100,50,7/26/2021
859281,earnings,100,50,7/26/2021
859281,earnings,100,50,7/26/2021
859281,earnings,100,50,7/26/2021
859281,earnings,100,50,7/26/2021
859281,earnings,100,50,7/26/2021
859281,earnings,100,50,7/26/2021
859281,earnings,100,50,7/26/2021
85AD00,earnings,100,50,7/26/2021
8AB85C,earnings,100,50,7/26/2021
8BE916,earnings-up,100,68,7/26/2021
8BE916,earnings-up,100,68,7/26/2021
8BE916,earnings-up,100,68,7/26/2021
8BE916,earnings-up,100,68,7/26/2021
8BE916,earnings-up,100,68,7/26/2021
8BE916,earnings-up,100,68,7/26/2021
8BE916,earnings-up,100,68,7/26/2021
8BE916,earnings-up,100,68,7/26/2021
8C311A,earnings,100,50,7/26/2021
8C311A,executive-appointment,100,54,7/26/2021
8CF6DD,executive-appointment,100,54,7/26/2021
8DAAB9,earnings,100,50,7/26/2021
8E3F58,earnings,100,50,7/26/2021
8E3F58,earnings,100,50,7/26/2021
8E4250,unit-acquisition-completed-acquiree,100,67,7/26/2021
8E93A4,earnings,100,50,7/26/2021
8EEA28,dividend,100,50,7/26/2021
903AB4,earnings,100,50,7/26/2021
905356,conference-call,100,50,7/26/2021
922F0C,earnings-per-share,100,50,7/26/2021
944B2E,earnings,100,50,7/26/2021
94C0B5,earnings,100,50,7/26/2021
9507FF,executive-appointment,100,54,7/26/2021
950AB7,earnings,100,50,7/26/2021
95DE39,earnings-positive,100,69,7/26/2021
95DE39,earnings,100,50,7/26/2021
95DE39,earnings,100,50,7/26/2021
95DE39,earnings,100,50,7/26/2021
95DE39,earnings,100,50,7/26/2021
96F126,earnings,100,50,7/26/2021
97AAF6,earnings,100,50,7/26/2021
9994DA,earnings,100,50,7/26/2021
9A02C4,earnings,100,50,7/26/2021
9A02C4,dividend,100,50,7/26/2021
9ABD30,earnings,100,50,7/26/2021
9C25FF,partnership,100,61,7/26/2021
9C5174,conference-participant,100,50,7/26/2021
9C8664,legal-issues-defendant,100,22,7/26/2021
9D5D35,earnings,100,50,7/26/2021
9D5D35,earnings,100,50,7/26/2021
9D5D35,earnings,100,50,7/26/2021
A072C4,partnership,100,61,7/26/2021
A1BB98,earnings,100,50,7/26/2021
A3BFAA,earnings,100,50,7/26/2021
A47A7D,earnings,100,50,7/26/2021
A47F2E,earnings,100,50,7/26/2021
A63387,government-contract,100,69,7/26/2021
A790A5,investment-investor,100,55,7/26/2021
AA1EAA,earnings,100,50,7/26/2021
AA1EAA,public-offering,100,43,7/26/2021
AA98ED,revenue-up,100,69,7/26/2021
AADE0B,business-contract-terminated,100,31,7/26/2021
ADF1B0,earnings,100,50,7/26/2021
ADF1B0,earnings,100,50,7/26/2021
AEEB76,earnings,100,50,7/26/2021
AFF43F,buybacks,100,74,7/26/2021
B05118,conference-participant,100,50,7/26/2021
B1A85D,earnings,100,50,7/26/2021
B1FC3B,business-contract,100,69,7/26/2021
B2256A,unit-acquisition-acquiree,100,76,7/26/2021
B33E77,earnings,100,50,7/26/2021
B604DF,earnings,100,50,7/26/2021
B604DF,earnings,100,50,7/26/2021
B604DF,earnings,100,50,7/26/2021
B604DF,earnings,100,50,7/26/2021
B604DF,earnings,100,50,7/26/2021
B6082A,earnings,100,50,7/26/2021
B66928,acquisition-interest-acquiree,100,82,7/26/2021
B72BE9,revenues,100,50,7/26/2021
B72BE9,revenues,100,50,7/26/2021
B72BE9,revenues,100,50,7/26/2021
B77F14,conference-call,100,50,7/26/2021
B8F71F,executive-appointment,100,54,7/26/2021
B9CD50,product-release,100,64,7/26/2021
B9CD50,product-release,100,64,7/26/2021
BCC55F,conference-call,100,50,7/26/2021
BE379D,conference-call,100,50,7/26/2021
BFEA04,partnership,100,61,7/26/2021
C062D4,earnings,100,50,7/26/2021
C062D4,earnings,100,50,7/26/2021
C062D4,earnings,100,50,7/26/2021
C062D4,earnings,100,50,7/26/2021
C062D4,earnings,100,50,7/26/2021
C062D4,earnings,100,50,7/26/2021
C062D4,earnings,100,50,7/26/2021
C356AC,donation,100,54,7/26/2021
C598D7,revenue-up,100,70,7/26/2021
C598D7,revenues,100,50,7/26/2021
C598D7,revenues,100,50,7/26/2021
C598D7,revenues,100,50,7/26/2021
C6C702,facility-open,100,65,7/26/2021
C8A059,earnings,100,50,7/26/2021
CC3EC4,earnings,100,50,7/26/2021
CC6FF5,earnings,100,50,7/26/2021
CDE51C,business-contract,100,69,7/26/2021
D20C8F,dividend,100,50,7/26/2021
D29B44,earnings,100,50,7/26/2021
D3C794,earnings,100,50,7/26/2021
D48275,earnings,100,50,7/26/2021
D4AC65,executive-appointment,100,54,7/26/2021
D60BB2,partnership,100,61,7/26/2021
D78CCD,partnership,100,61,7/26/2021
DAC66A,earnings,100,50,7/26/2021
DD3BB1,earnings,100,50,7/26/2021
DF11D9,legal-issues-defendant,100,22,7/26/2021
DF204B,conference-call,100,50,7/26/2021
DF46C5,dividend,100,50,7/26/2021
DF46C5,earnings-guidance-up,100,83,7/26/2021
DF46C5,earnings,100,50,7/26/2021
DF46C5,earnings,100,50,7/26/2021
DF46C5,earnings,100,50,7/26/2021
DF46C5,earnings,100,50,7/26/2021
DF46C5,earnings,100,50,7/26/2021
E05026,award,100,58,7/26/2021
E09997,conference-call,100,50,7/26/2021
E1E36F,dividend,100,50,7/26/2021
E26FC3,dividend,100,50,7/26/2021
E30B34,dividend,100,50,7/26/2021
E30B34,dividend,100,50,7/26/2021
E393B0,legal-issues-defendant,100,22,7/26/2021
E3E68E,award,100,58,7/26/2021
E3E68E,award,100,58,7/26/2021
E68733,product-release,100,64,7/26/2021
E68733,product-release,100,64,7/26/2021
E70531,earnings,100,50,7/26/2021
E7BF32,earnings,100,50,7/26/2021
E7BF32,earnings,100,50,7/26/2021
E87676,dividend,100,50,7/26/2021
E8846E,executive-appointment,100,54,7/26/2021
E93A40,earnings,100,50,7/26/2021
EA62FC,dividend,100,50,7/26/2021
EB5E78,unit-acquisition-acquirer,100,49,7/26/2021
ED7F13,earnings,100,50,7/26/2021
EE967B,earnings,100,50,7/26/2021
F05B1B,clinical-trials-positive,100,87,7/26/2021
F40EE2,partnership,100,61,7/26/2021
F40EE2,partnership,100,61,7/26/2021
F5D059,earnings,100,50,7/26/2021
F5D059,earnings,100,50,7/26/2021
F5D059,earnings,100,50,7/26/2021
F5D059,earnings,100,50,7/26/2021
F5D059,earnings,100,50,7/26/2021
F5D059,earnings,100,50,7/26/2021
F6DCE4,partnership,100,61,7/26/2021
F7902B,unit-acquisition-acquiree,100,76,7/26/2021
F7935D,business-contract,100,69,7/26/2021
F793FA,earnings,100,50,7/26/2021
F80389,conference-call,100,50,7/26/2021
F8BA6C,patent-awarded,100,72,7/26/2021
F95726,earnings,100,50,7/26/2021
FA40E2,executive-appointment,100,54,7/26/2021
FD1312,earnings,100,50,7/26/2021
FE9C0D,executive-appointment,100,54,7/26/2021
FF6644,partnership,100,61,7/26/2021
0157B1,trading-resumed,100,58,7/27/2021
018C11,revenue-up,100,69,7/27/2021
018C11,revenue-up,100,69,7/27/2021
018C11,revenue-up,100,69,7/27/2021
018C11,revenue-up,100,69,7/27/2021
01D03F,partnership,100,61,7/27/2021
01D03F,partnership,100,61,7/27/2021
31025,revenues,100,50,7/27/2021
31025,earnings,100,50,7/27/2021
31025,earnings,100,50,7/27/2021
31025,earnings,100,50,7/27/2021
31025,earnings,100,50,7/27/2021
03596A,business-contract,100,69,7/27/2021
03B8CF,earnings,100,50,7/27/2021
03B8CF,earnings,100,50,7/27/2021
03B8CF,earnings,100,50,7/27/2021
03B8CF,earnings,100,50,7/27/2021
03B8CF,earnings,100,50,7/27/2021
03B8CF,earnings,100,50,7/27/2021
095A04,earnings,100,50,7/27/2021
099C88,business-contract,100,69,7/27/2021
0BF198,conference-call,100,50,7/27/2021
0D03C8,earnings,100,50,7/27/2021
0DBB81,earnings,100,50,7/27/2021
0F65C9,earnings,100,50,7/27/2021
0F65C9,dividend,100,50,7/27/2021
0FABBD,conference-call,100,50,7/27/2021
102727,earnings,100,50,7/27/2021
108FDA,earnings,100,50,7/27/2021
11074E,conference-participant,100,50,7/27/2021
11AEDE,partnership,100,61,7/27/2021
1216D1,earnings,100,50,7/27/2021
1220D2,earnings,100,50,7/27/2021
152E1D,conference-call,100,50,7/27/2021
156A99,partnership,100,61,7/27/2021
16FC89,earnings,100,50,7/27/2021
1866B2,earnings,100,50,7/27/2021
190B91,earnings,100,50,7/27/2021
190B91,earnings,100,50,7/27/2021
190B91,earnings,100,50,7/27/2021
190B91,earnings,100,50,7/27/2021
190B91,earnings,100,50,7/27/2021
190B91,earnings,100,50,7/27/2021
1A3E1B,dividend,100,50,7/27/2021
1B5FEA,business-contract,100,69,7/27/2021
1BDB2A,dividend,100,50,7/27/2021
1E9A6D,earnings,100,50,7/27/2021
1EBF8D,regulatory-product-approval-granted,100,81,7/27/2021
1EBF8D,dividend,100,50,7/27/2021
1F2B5D,index-listing,100,76,7/27/2021
1FE3CB,operating-earnings,100,50,7/27/2021
1FE3CB,dividend,100,50,7/27/2021
225CA2,earnings,100,50,7/27/2021
225CA2,earnings,100,50,7/27/2021
225CA2,earnings,100,50,7/27/2021
225CA2,earnings,100,50,7/27/2021
225CA2,earnings,100,50,7/27/2021
225CA2,earnings,100,50,7/27/2021
228D42,executive-appointment,100,54,7/27/2021
22C58E,partnership,100,61,7/27/2021
22C58E,earnings,100,50,7/27/2021
238302,conference-call,100,50,7/27/2021
25102A,note-sale,100,52,7/27/2021
25102A,note-sale,100,52,7/27/2021
2667B6,earnings-up,100,68,7/27/2021
270305,dividend,100,50,7/27/2021
270B78,dividend,100,50,7/27/2021
28AC4E,partnership,100,61,7/27/2021
28DCF3,earnings,100,50,7/27/2021
29A4CC,earnings,100,50,7/27/2021
2B7A40,earnings-per-share-up,100,68,7/27/2021
2B7A40,earnings-up,100,68,7/27/2021
2B7A40,earnings-up,100,68,7/27/2021
2B7A40,earnings-up,100,68,7/27/2021
2CBB58,earnings-up,100,68,7/27/2021
2CBB58,earnings-up,100,68,7/27/2021
2CBB58,earnings-up,100,68,7/27/2021
2CBB58,earnings-up,100,68,7/27/2021
2D981A,earnings,100,50,7/27/2021
2E6514,dividend,100,50,7/27/2021
2F5256,earnings,100,50,7/27/2021
2F6782,conference-call,100,50,7/27/2021
2F6782,dividend,100,50,7/27/2021
3.30E+30,conference-call,100,50,7/27/2021
332F87,executive-resignation,100,44,7/27/2021
332F87,earnings,100,50,7/27/2021
343996,unit-acquisition-acquirer,100,49,7/27/2021
343996,earnings,100,50,7/27/2021
34B97A,executive-appointment,100,54,7/27/2021
3BB616,earnings,100,50,7/27/2021
3BB616,earnings,100,50,7/27/2021
3BB616,earnings,100,50,7/27/2021
3BCF24,earnings,100,50,7/27/2021
3BE00F,conference-participant,100,50,7/27/2021
3C3B6B,award,100,58,7/27/2021
3CBA2A,earnings-up,100,68,7/27/2021
3CBA2A,earnings-up,100,68,7/27/2021
3CBA2A,earnings-up,100,68,7/27/2021
3CBA2A,earnings-up,100,68,7/27/2021
3CBA2A,earnings-up,100,68,7/27/2021
3CBA2A,earnings-up,100,68,7/27/2021
3CBA2A,earnings-up,100,68,7/27/2021
3E15F6,dividend,100,50,7/27/2021
3ED92D,earnings,100,50,7/27/2021
3ED92D,earnings,100,50,7/27/2021
3ED92D,earnings,100,50,7/27/2021
3ED92D,earnings,100,50,7/27/2021
3ED92D,earnings,100,50,7/27/2021
3ED92D,earnings,100,50,7/27/2021
3ED92D,earnings,100,50,7/27/2021
3ED92D,earnings,100,50,7/27/2021
3F6A9C,dividend,100,50,7/27/2021
3FACA7,business-contract,100,69,7/27/2021
408089,earnings,100,50,7/27/2021
4135F7,index-listing,100,76,7/27/2021
416C55,earnings,100,50,7/27/2021
41785E,earnings,100,50,7/27/2021
41ED98,conference-call,100,50,7/27/2021
420168,earnings,100,50,7/27/2021
420168,market-entry,100,57,7/27/2021
43A060,partnership,100,61,7/27/2021
450ECB,executive-appointment,100,54,7/27/2021
450ECB,executive-appointment,100,54,7/27/2021
453282,dividend-up,100,81,7/27/2021
4591D3,conference-call,100,50,7/27/2021
4649D5,earnings,100,50,7/27/2021
47BA98,earnings,100,50,7/27/2021
492117,earnings-up,100,68,7/27/2021
4A6F00,partnership,100,61,7/27/2021
4AE584,earnings,100,50,7/27/2021
4C5CC9,dividend,100,50,7/27/2021
4C6C63,earnings,100,50,7/27/2021
4C6C63,earnings,100,50,7/27/2021
4C6C63,earnings,100,50,7/27/2021
4C6C63,earnings,100,50,7/27/2021
4C6C63,earnings,100,50,7/27/2021
4D8313,product-release,100,64,7/27/2021
4DD09F,earnings,100,50,7/27/2021
4FB770,earnings,100,50,7/27/2021
50070E,partnership,100,61,7/27/2021
51B442,earnings,100,50,7/27/2021
51D876,stake-acquirer,100,48,7/27/2021
525A1C,product-release,100,64,7/27/2021
53EF9E,earnings-up,100,68,7/27/2021
53EF9E,earnings,100,50,7/27/2021
54A646,earnings-positive,100,69,7/27/2021
54A646,earnings-positive,100,69,7/27/2021
54A646,earnings-positive,100,69,7/27/2021
54A646,earnings-positive,100,69,7/27/2021
54F271,earnings,100,50,7/27/2021
55C9B5,product-release,100,64,7/27/2021
55CD6F,partnership,100,61,7/27/2021
567F3D,executive-appointment,100,54,7/27/2021
583A75,earnings,100,50,7/27/2021
59B229,earnings,100,50,7/27/2021
5CC29D,earnings,100,50,7/27/2021
5D02B7,earnings,100,50,7/27/2021
5D02B7,earnings,100,50,7/27/2021
5D02B7,earnings,100,50,7/27/2021
5FE4B6,earnings,100,50,7/27/2021
5FE4B6,earnings,100,50,7/27/2021
601785,executive-appointment,100,54,7/27/2021
601785,dividend,100,50,7/27/2021
60AC34,earnings,100,50,7/27/2021
616E3B,earnings,100,50,7/27/2021
616E3B,earnings,100,50,7/27/2021
616E3B,earnings,100,50,7/27/2021
616E3B,earnings,100,50,7/27/2021
616E3B,earnings,100,50,7/27/2021
64854A,conference-call,100,50,7/27/2021
649CBD,earnings,100,50,7/27/2021
64FF65,conference-call,100,50,7/27/2021
665D7D,partnership,100,61,7/27/2021
66BDA1,earnings,100,50,7/27/2021
69345C,earnings,100,50,7/27/2021
69345C,earnings,100,50,7/27/2021
69345C,earnings,100,50,7/27/2021
69345C,earnings,100,50,7/27/2021
698FF9,earnings,100,50,7/27/2021
6A024C,regulatory-product-approval-granted,100,81,7/27/2021
6AACDD,legal-issues-defendant,100,22,7/27/2021
6AACDD,legal-issues-defendant,100,22,7/27/2021
6ABCB8,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6C4D2F,earnings,100,50,7/27/2021
6CDFC6,partnership,100,61,7/27/2021
6D9ECA,partnership,100,61,7/27/2021
6DBBBC,partnership,100,61,7/27/2021
6DC1D7,index-listing,100,76,7/27/2021
6.00E+19,conference-call,100,50,7/27/2021
6F0096,dividend,100,50,7/27/2021
71553E,earnings,100,50,7/27/2021
71694D,conference-call,100,50,7/27/2021
722DE3,acquisition-acquirer,100,49,7/27/2021
765913,earnings,100,50,7/27/2021
76F067,acquisition-acquirer,100,49,7/27/2021
76F067,acquisition-acquirer,100,49,7/27/2021
773A17,revenues,100,50,7/27/2021
7A10FF,earnings,100,50,7/27/2021
7AC86E,earnings-up,100,68,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7C75FD,earnings,100,50,7/27/2021
7D5FD6,earnings,100,50,7/27/2021
7E3390,earnings,100,50,7/27/2021
7E3F8F,earnings-guidance-up,100,83,7/27/2021
7E3F8F,earnings,100,50,7/27/2021
7E3F8F,earnings,100,50,7/27/2021
7E3F8F,earnings,100,50,7/27/2021
81F4BE,earnings,100,50,7/27/2021
81F4BE,earnings,100,50,7/27/2021
82F088,conference-participant,100,50,7/27/2021
8377DB,earnings,100,50,7/27/2021
8377DB,earnings,100,50,7/27/2021
86478F,earnings,100,50,7/27/2021
873DB9,dividend,100,50,7/27/2021
89F693,earnings-positive,100,69,7/27/2021
89F693,earnings-positive,100,69,7/27/2021
89F693,earnings-positive,100,69,7/27/2021
89F693,earnings-positive,100,69,7/27/2021
89F693,earnings-positive,100,69,7/27/2021
8AB37F,conference-call,100,50,7/27/2021
8AC65D,earnings,100,50,7/27/2021
8CF6DD,dividend,100,50,7/27/2021
8D4486,dividend,100,50,7/27/2021
8D4486,dividend,100,50,7/27/2021
8DCF18,conference-call,100,50,7/27/2021
8DE56F,earnings,100,50,7/27/2021
8F8F2F,earnings,100,50,7/27/2021
93D207,earnings,100,50,7/27/2021
93F143,earnings,100,50,7/27/2021
93F143,earnings,100,50,7/27/2021
93F143,earnings,100,50,7/27/2021
93F143,earnings,100,50,7/27/2021
93F143,earnings,100,50,7/27/2021
93F143,earnings,100,50,7/27/2021
94637C,partnership,100,61,7/27/2021
95A92E,legal-issues-defendant,100,22,7/27/2021
97AF94,earnings,100,50,7/27/2021
981656,earnings,100,50,7/27/2021
9D2790,partnership,100,61,7/27/2021
9D2790,earnings,100,50,7/27/2021
9D5FA4,business-contract,100,69,7/27/2021
9E4A5F,earnings,100,50,7/27/2021
A02FB1,legal-issues-defendant,100,22,7/27/2021
A1A317,earnings,100,50,7/27/2021
A1A317,earnings,100,50,7/27/2021
A1A317,earnings,100,50,7/27/2021
A1A317,earnings,100,50,7/27/2021
A1EAC8,executive-appointment,100,54,7/27/2021
A4F67C,earnings,100,50,7/27/2021
A70BF5,earnings,100,50,7/27/2021
A70BF5,earnings,100,50,7/27/2021
A70BF5,earnings,100,50,7/27/2021
A70BF5,earnings,100,50,7/27/2021
A70BF5,earnings,100,50,7/27/2021
A70BF5,earnings,100,50,7/27/2021
A79F7D,earnings,100,50,7/27/2021
A7A0BD,conference-call,100,50,7/27/2021
A868C9,business-contract,100,69,7/27/2021
A8B137,earnings,100,50,7/27/2021
A8B137,earnings,100,50,7/27/2021
A8B137,earnings,100,50,7/27/2021
A8B137,earnings,100,50,7/27/2021
A8B137,earnings,100,50,7/27/2021
A99576,legal-issues-defendant,100,22,7/27/2021
A9ED24,earnings,100,50,7/27/2021
A9ED24,earnings,100,50,7/27/2021
AA1EAA,public-offering,100,43,7/27/2021
AA847A,earnings,100,50,7/27/2021
ABB493,business-contract,100,69,7/27/2021
ABBAD1,executive-appointment,100,54,7/27/2021
AD23DE,acquisition-acquirer,100,49,7/27/2021
AE4EEB,earnings,100,50,7/27/2021
AFDF2E,conference-participant,100,50,7/27/2021
B05118,product-release,100,64,7/27/2021
B1A85D,product-release,100,64,7/27/2021
B1FC3B,business-contract,100,69,7/27/2021
B1FC3B,conference-participant,100,50,7/27/2021
B303A6,dividend,100,50,7/27/2021
B37FB4,earnings-up,100,68,7/27/2021
B3A166,acquisition-acquirer,100,49,7/27/2021
B508E5,conference-call,100,50,7/27/2021
B934BF,public-offering,100,43,7/27/2021
B96637,conference-call,100,50,7/27/2021
B9CD50,product-release,100,64,7/27/2021
BB5142,earnings-up,100,68,7/27/2021
BBAE2A,earnings,100,50,7/27/2021
BBC05B,operating-earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BDEF34,earnings,100,50,7/27/2021
BE14CF,earnings,100,50,7/27/2021
BE400C,dividend,100,50,7/27/2021
BFAEB4,dividend-up,100,72,7/27/2021
BFD0A7,board-meeting,100,51,7/27/2021
BFE02C,partnership,100,61,7/27/2021
C0BA36,conference-call,100,50,7/27/2021
C16A8F,earnings,100,50,7/27/2021
C16A8F,earnings,100,50,7/27/2021
C16A8F,earnings,100,50,7/27/2021
C16A8F,earnings,100,50,7/27/2021
C3F99F,earnings,100,50,7/27/2021
C41C25,dividend,100,50,7/27/2021
C4452A,partnership,100,61,7/27/2021
C45CE7,earnings,100,50,7/27/2021
C564E4,orphan-drug-designation,100,76,7/27/2021
C564E4,conference-call,100,50,7/27/2021
C624A1,earnings,100,50,7/27/2021
C62AA4,conference-call,100,50,7/27/2021
C659EB,earnings,100,50,7/27/2021
C659EB,earnings,100,50,7/27/2021
C659EB,earnings,100,50,7/27/2021
C659EB,earnings,100,50,7/27/2021
C659EB,executive-appointment,100,54,7/27/2021
C66B44,executive-appointment,100,54,7/27/2021
C81E00,operating-earnings,100,50,7/27/2021
C81E00,operating-earnings,100,50,7/27/2021
C97B2D,earnings,100,50,7/27/2021
C98CDB,earnings,100,50,7/27/2021
C9C62A,earnings,100,50,7/27/2021
CB88B3,earnings,100,50,7/27/2021
CBA33B,dividend,100,50,7/27/2021
CBBFBF,dividend,100,50,7/27/2021
CC176E,earnings,100,50,7/27/2021
CD06A2,dividend,100,50,7/27/2021
CE1002,earnings-up,100,68,7/27/2021
CE1002,earnings,100,50,7/27/2021
CE1002,earnings,100,50,7/27/2021
CE1002,earnings,100,50,7/27/2021
CE1002,earnings,100,50,7/27/2021
CE4E6D,conference-call,100,50,7/27/2021
CE5C6E,partnership,100,61,7/27/2021
CEC08B,business-contract,100,69,7/27/2021
D1344A,donation,100,54,7/27/2021
D17C1B,earnings,100,50,7/27/2021
D17C1B,earnings,100,50,7/27/2021
D17C1B,earnings,100,50,7/27/2021
D17C1B,earnings,100,50,7/27/2021
D20C8F,earnings,100,50,7/27/2021
D21D8A,merger,100,66,7/27/2021
D29F43,dividend,100,50,7/27/2021
D33270,partnership,100,61,7/27/2021
D33270,partnership,100,61,7/27/2021
D518D8,revenues,100,50,7/27/2021
D56E4C,earnings,100,50,7/27/2021
D56E4C,earnings,100,50,7/27/2021
D60BB2,partnership,100,61,7/27/2021
D7918D,operating-earnings,100,50,7/27/2021
D8442A,earnings,100,50,7/27/2021
D8442A,earnings,100,50,7/27/2021
D8442A,earnings,100,50,7/27/2021
D9C07E,earnings,100,50,7/27/2021
DB7FA7,earnings-up,100,66,7/27/2021
DC2F77,dividend,100,50,7/27/2021
DD1BA1,partnership,100,61,7/27/2021
DDC415,earnings,100,50,7/27/2021
DDC415,earnings,100,50,7/27/2021
DF11D9,earnings,100,50,7/27/2021
DF42A0,conference-call,100,50,7/27/2021
E0339F,dividend,100,50,7/27/2021
E124EB,investment-investor,100,55,7/27/2021
E124EB,investment-investor,100,55,7/27/2021
E124EB,investment-investor,100,55,7/27/2021
E12A6E,earnings,100,50,7/27/2021
E1E093,product-release,100,64,7/27/2021
E20392,conference-call,100,50,7/27/2021
E69BA5,conference-call,100,50,7/27/2021
E6A53A,earnings,100,50,7/27/2021
E6A53A,earnings,100,50,7/27/2021
E6A53A,earnings,100,50,7/27/2021
E6A53A,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6E012,earnings,100,50,7/27/2021
E6EDED,earnings,100,50,7/27/2021
E84500,earnings,100,50,7/27/2021
E845D9,unit-acquisition-acquirer,100,49,7/27/2021
E87676,earnings-up,100,68,7/27/2021
E87676,earnings,100,50,7/27/2021
E87676,earnings,100,50,7/27/2021
E8A49A,earnings,100,50,7/27/2021
E8B21D,earnings,100,50,7/27/2021
E8B21D,earnings,100,50,7/27/2021
E8B21D,earnings,100,50,7/27/2021
E8B21D,earnings,100,50,7/27/2021
E8B21D,earnings,100,50,7/27/2021
E8B21D,earnings,100,50,7/27/2021
E8B21D,earnings,100,50,7/27/2021
E9C7C0,partnership,100,61,7/27/2021
E9E6FD,earnings,100,50,7/27/2021
E9FF33,earnings,100,50,7/27/2021
EB1E1A,executive-appointment,100,54,7/27/2021
EB61C4,earnings,100,50,7/27/2021
EBC84C,earnings,100,50,7/27/2021
EBC84C,earnings,100,50,7/27/2021
EBC84C,earnings,100,50,7/27/2021
EBC84C,earnings,100,50,7/27/2021
EBC84C,earnings,100,50,7/27/2021
EBC84C,earnings,100,50,7/27/2021
EBC84C,earnings,100,50,7/27/2021
EC99D0,earnings,100,50,7/27/2021
ECDEB2,earnings,100,50,7/27/2021
ED0402,revenue-up,100,70,7/27/2021
ED0402,revenues,100,50,7/27/2021
ED0402,revenues,100,50,7/27/2021
ED0402,revenues,100,50,7/27/2021
ED0402,revenues,100,50,7/27/2021
EDF5CA,earnings,100,50,7/27/2021
EDF5CA,earnings,100,50,7/27/2021
EDF5CA,earnings,100,50,7/27/2021
EDF5CA,earnings,100,50,7/27/2021
EDF5CA,earnings,100,50,7/27/2021
EDF5CA,earnings,100,50,7/27/2021
EDF5CA,earnings,100,50,7/27/2021
EDF5CA,earnings,100,50,7/27/2021
EDF5CA,earnings,100,50,7/27/2021
EF45B6,earnings,100,50,7/27/2021
EF5BED,executive-appointment,100,54,7/27/2021
F04E05,dividend,100,50,7/27/2021
F0A9DE,earnings,100,50,7/27/2021
F2526D,earnings,100,50,7/27/2021
F294DD,earnings,100,50,7/27/2021
F294DD,earnings,100,50,7/27/2021
F294DD,earnings,100,50,7/27/2021
F294DD,earnings,100,50,7/27/2021
F294DD,earnings,100,50,7/27/2021
F2E253,conference-call,100,50,7/27/2021
F40EE2,earnings,100,50,7/27/2021
F40EE2,earnings,100,50,7/27/2021
F4D241,earnings,100,50,7/27/2021
F4E882,earnings,100,50,7/27/2021
F5D059,executive-appointment,100,54,7/27/2021
F5D059,executive-appointment,100,54,7/27/2021
F5D410,earnings,100,50,7/27/2021
F6DCE4,partnership,100,61,7/27/2021
F7D8AE,acquisition-acquirer,100,49,7/27/2021
F80389,public-offering,100,43,7/27/2021
F9AA02,conference-participant,100,50,7/27/2021
FA044A,earnings,100,50,7/27/2021
FAE021,earnings,100,50,7/27/2021
FAE021,earnings,100,50,7/27/2021
FAE021,earnings,100,50,7/27/2021
FAEABE,dividend,100,50,7/27/2021
FC80E6,conference-call,100,50,7/27/2021
FD9A97,earnings,100,50,7/27/2021
FDD3FC,earnings,100,50,7/27/2021
FEC475,conference-participant,100,50,7/27/2021
FF6644,conference-participant,100,50,7/27/2021
FFAB4A,earnings,100,50,7/27/2021
FFCD0E,conference-call,100,50,7/27/2021
00067A,earnings,100,50,7/28/2021
00D6B5,earnings,100,50,7/28/2021
0157B1,partnership,100,61,7/28/2021
01B8D6,conference-participant,100,50,7/28/2021
03CF95,earnings,100,50,7/28/2021
03D5F9,earnings,100,50,7/28/2021
053EFF,conference-call,100,50,7/28/2021
55018,dividend,100,50,7/28/2021
05AF14,conference-participant,100,50,7/28/2021
06EE79,earnings,100,50,7/28/2021
075CF7,executive-appointment,100,54,7/28/2021
07C69F,acquisition-interest-acquirer,100,46,7/28/2021
07C69F,earnings,100,50,7/28/2021
07EC43,earnings,100,50,7/28/2021
07EC43,earnings,100,50,7/28/2021
07EC43,earnings,100,50,7/28/2021
07EC43,earnings,100,50,7/28/2021
081AB9,earnings,100,50,7/28/2021
0986B5,earnings,100,50,7/28/2021
98977,earnings,100,50,7/28/2021
0A59F8,partnership,100,61,7/28/2021
0A9D0A,earnings,100,50,7/28/2021
0B4D10,earnings,100,50,7/28/2021
0B57D7,earnings,100,50,7/28/2021
0BA8CE,earnings,100,50,7/28/2021
0C136E,earnings,100,50,7/28/2021
0C2A0D,dividend,100,50,7/28/2021
0CBC4D,earnings-up,100,68,7/28/2021
0CC62B,earnings,100,50,7/28/2021
0CC62B,earnings,100,50,7/28/2021
0CC62B,earnings,100,50,7/28/2021
0CC62B,earnings,100,50,7/28/2021
0DC050,earnings,100,50,7/28/2021
0DC050,earnings,100,50,7/28/2021
0DC050,earnings,100,50,7/28/2021
0DC050,earnings,100,50,7/28/2021
0E2992,earnings-per-share-positive,100,69,7/28/2021
0E439E,earnings,100,50,7/28/2021
0E439E,earnings,100,50,7/28/2021
0E439E,earnings,100,50,7/28/2021
0E439E,earnings,100,50,7/28/2021
0E5223,conference-call,100,50,7/28/2021
0EC508,earnings,100,50,7/28/2021
0F91FC,earnings,100,50,7/28/2021
106394,earnings,100,50,7/28/2021
119CB6,earnings-per-share-positive,100,69,7/28/2021
12731D,conference-call,100,50,7/28/2021
12731D,conference-call,100,50,7/28/2021
129DC8,award,100,58,7/28/2021
12E454,earnings,100,50,7/28/2021
12E454,earnings,100,50,7/28/2021
12E454,earnings,100,50,7/28/2021
14833D,earnings-up,100,68,7/28/2021
14833D,earnings-up,100,68,7/28/2021
14833D,earnings-up,100,68,7/28/2021
14833D,earnings-up,100,68,7/28/2021
152AB9,executive-appointment,100,54,7/28/2021
16F4D8,earnings,100,50,7/28/2021
16F4D8,earnings,100,50,7/28/2021
16F4D8,earnings,100,50,7/28/2021
16F4D8,earnings,100,50,7/28/2021
16F4D8,earnings,100,50,7/28/2021
16F4D8,earnings,100,50,7/28/2021
1748F6,executive-appointment,100,54,7/28/2021
180DA0,dividend,100,50,7/28/2021
180DA0,earnings,100,50,7/28/2021
1834C0,dividend-up,100,81,7/28/2021
1BDB2A,earnings,100,50,7/28/2021
1CB9D3,earnings,100,50,7/28/2021
1CB9D3,conference-call,100,50,7/28/2021
1DE526,earnings,100,50,7/28/2021
1E8A99,earnings,100,50,7/28/2021
1E8A99,earnings,100,50,7/28/2021
1EC3E8,earnings-up,100,68,7/28/2021
1EC3E8,earnings-up,100,68,7/28/2021
1F3CFB,earnings,100,50,7/28/2021
1F716B,earnings,100,50,7/28/2021
2003A5,earnings,100,50,7/28/2021
2031CE,earnings,100,50,7/28/2021
2082EA,conference-call,100,50,7/28/2021
2093B1,earnings,100,50,7/28/2021
20D00A,operating-earnings,100,50,7/28/2021
21022F,earnings,100,50,7/28/2021
221445,earnings,100,50,7/28/2021
221AD7,earnings-up,100,68,7/28/2021
221AD7,earnings,100,50,7/28/2021
221AD7,earnings,100,50,7/28/2021
221AD7,earnings,100,50,7/28/2021
221AD7,earnings,100,50,7/28/2021
223552,business-contract,100,69,7/28/2021
228D42,partnership,100,61,7/28/2021
249B39,earnings-positive,100,69,7/28/2021
24A89A,earnings,100,50,7/28/2021
24FA23,earnings,100,50,7/28/2021
264EB3,earnings-up,100,68,7/28/2021
264EB3,earnings,100,50,7/28/2021
264EB3,earnings,100,50,7/28/2021
264EB3,earnings,100,50,7/28/2021
264EB3,earnings,100,50,7/28/2021
264EB3,earnings,100,50,7/28/2021
264EB3,earnings,100,50,7/28/2021
267718,earnings,100,50,7/28/2021
267718,earnings,100,50,7/28/2021
267718,earnings,100,50,7/28/2021
267718,earnings,100,50,7/28/2021
267718,earnings,100,50,7/28/2021
267718,earnings,100,50,7/28/2021
267718,earnings,100,50,7/28/2021
267718,earnings,100,50,7/28/2021
26FA41,earnings-up,100,68,7/28/2021
26FA41,earnings,100,50,7/28/2021
26FA41,earnings,100,50,7/28/2021
274B8A,earnings,100,50,7/28/2021
274B8A,earnings,100,50,7/28/2021
27A791,conference-call,100,50,7/28/2021
28AC4E,earnings,100,50,7/28/2021
28DCA8,earnings,100,50,7/28/2021
2950FF,earnings,100,50,7/28/2021
2950FF,earnings,100,50,7/28/2021
2AA6A8,conference-call,100,50,7/28/2021
2B9DBB,executive-appointment,100,54,7/28/2021
2CA60F,partnership,100,61,7/28/2021
2D2D43,dividend,100,50,7/28/2021
2D643C,earnings,100,50,7/28/2021
2FDEE3,earnings,100,50,7/28/2021
2FEA66,operating-earnings,100,50,7/28/2021
30DE64,executive-appointment,100,54,7/28/2021
30DE64,executive-appointment,100,54,7/28/2021
31553A,acquisition-acquirer,100,49,7/28/2021
315EB0,earnings,100,50,7/28/2021
315EB0,earnings,100,50,7/28/2021
315EB0,earnings,100,50,7/28/2021
315EB0,earnings,100,50,7/28/2021
315EB0,earnings,100,50,7/28/2021
315EB0,earnings,100,50,7/28/2021
315EB0,earnings,100,50,7/28/2021
315EB0,dividend,100,50,7/28/2021
319BE2,dividend-up,100,81,7/28/2021
319BE2,earnings,100,50,7/28/2021
31A7CC,dividend-up,100,81,7/28/2021
31A7CC,executive-resignation,100,44,7/28/2021
326EDD,earnings,100,50,7/28/2021
32CB22,earnings-guidance-up,100,83,7/28/2021
32F943,earnings,100,50,7/28/2021
33E8C7,earnings,100,50,7/28/2021
33E8C7,earnings,100,50,7/28/2021
33FD66,earnings,100,50,7/28/2021
33FD66,earnings,100,50,7/28/2021
33FD66,earnings,100,50,7/28/2021
33FD66,earnings,100,50,7/28/2021
33FD66,earnings,100,50,7/28/2021
33FD66,earnings,100,50,7/28/2021
3461CF,earnings,100,50,7/28/2021
346BF2,earnings,100,50,7/28/2021
34B411,dividend-up,100,81,7/28/2021
3.50E+27,earnings,100,50,7/28/2021
366A08,earnings,100,50,7/28/2021
366A08,earnings,100,50,7/28/2021
366A08,earnings,100,50,7/28/2021
366A08,earnings,100,50,7/28/2021
366A08,earnings,100,50,7/28/2021
366A08,earnings,100,50,7/28/2021
3696BF,earnings-up,100,68,7/28/2021
36C09B,conference-call,100,50,7/28/2021
3.73E+87,earnings,100,50,7/28/2021
3.73E+87,earnings,100,50,7/28/2021
3.73E+87,earnings,100,50,7/28/2021
37727A,earnings-guidance-up,100,83,7/28/2021
37727A,earnings,100,50,7/28/2021
37727A,earnings,100,50,7/28/2021
37727A,earnings,100,50,7/28/2021
37727A,earnings,100,50,7/28/2021
37727A,earnings,100,50,7/28/2021
37727A,earnings,100,50,7/28/2021
37727A,earnings,100,50,7/28/2021
37727A,earnings,100,50,7/28/2021
3.88E+02,dividend,100,50,7/28/2021
3A113F,earnings,100,50,7/28/2021
3A1C46,conference-participant,100,50,7/28/2021
3AAEAE,conference-call,100,50,7/28/2021
3BC360,earnings,100,50,7/28/2021
3BC360,earnings,100,50,7/28/2021
3BC360,earnings,100,50,7/28/2021
3BC360,earnings,100,50,7/28/2021
401072,partnership,100,61,7/28/2021
4135F7,earnings,100,50,7/28/2021
41D61C,earnings,100,50,7/28/2021
425BDC,earnings,100,50,7/28/2021
43E8F5,earnings,100,50,7/28/2021
442769,earnings,100,50,7/28/2021
442769,earnings,100,50,7/28/2021
442769,earnings,100,50,7/28/2021
442769,earnings,100,50,7/28/2021
4455C4,earnings,100,50,7/28/2021
4455C4,earnings,100,50,7/28/2021
4455C4,earnings,100,50,7/28/2021
4455C4,earnings,100,50,7/28/2021
447FC6,conference-call,100,50,7/28/2021
448215,earnings,100,50,7/28/2021
458D2C,earnings,100,50,7/28/2021
45BC35,executive-appointment,100,54,7/28/2021
45BC35,earnings,100,50,7/28/2021
47752F,earnings,100,50,7/28/2021
47752F,earnings,100,50,7/28/2021
47752F,earnings,100,50,7/28/2021
47752F,earnings,100,50,7/28/2021
4806CE,dividend,100,50,7/28/2021
485445,executive-appointment,100,54,7/28/2021
4885C8,dividend,100,50,7/28/2021
4.91E+58,executive-appointment,100,54,7/28/2021
4AE584,acquisition-completed-acquirer,100,49,7/28/2021
4B5054,dividend,100,50,7/28/2021
4B6EF9,dividend,100,50,7/28/2021
4B6EF9,earnings,100,50,7/28/2021
4BDCA7,conference-call,100,50,7/28/2021
4C31F3,conference-call,100,50,7/28/2021
4D971D,earnings,100,50,7/28/2021
4D971D,earnings,100,50,7/28/2021
4D971D,earnings,100,50,7/28/2021
4D971D,earnings,100,50,7/28/2021
4D971D,earnings,100,50,7/28/2021
4D971D,earnings,100,50,7/28/2021
4D971D,earnings,100,50,7/28/2021
4D971D,dividend,100,50,7/28/2021
4DD203,conference-call,100,50,7/28/2021
4EEB00,facility-open,100,65,7/28/2021
51E682,earnings,100,50,7/28/2021
51F541,earnings,100,50,7/28/2021
532D47,earnings,100,50,7/28/2021
53A226,earnings,100,50,7/28/2021
553949,earnings,100,50,7/28/2021
553949,earnings,100,50,7/28/2021
553949,earnings,100,50,7/28/2021
553949,earnings,100,50,7/28/2021
55438C,earnings,100,50,7/28/2021
55438C,earnings,100,50,7/28/2021
55438C,earnings,100,50,7/28/2021
55438C,earnings,100,50,7/28/2021
55C289,earnings,100,50,7/28/2021
564F3E,earnings,100,50,7/28/2021
57EF50,conference-call,100,50,7/28/2021
583223,earnings,100,50,7/28/2021
583553,earnings,100,50,7/28/2021
586BD7,conference-call,100,50,7/28/2021
589F5A,earnings,100,50,7/28/2021
594402,earnings,100,50,7/28/2021
5AAE17,earnings,100,50,7/28/2021
5AF08A,earnings,100,50,7/28/2021
5D43A7,business-contract,100,69,7/28/2021
5DD486,earnings,100,50,7/28/2021
5DD48B,earnings,100,50,7/28/2021
5DE5A5,conference-participant,100,50,7/28/2021
605F40,earnings,100,50,7/28/2021
619882,conference-organizer,100,57,7/28/2021
61BCA7,earnings,100,50,7/28/2021
61E975,dividend,100,50,7/28/2021
63E8D5,earnings,100,50,7/28/2021
63E8D5,earnings,100,50,7/28/2021
63E8D5,earnings,100,50,7/28/2021
63E8D5,earnings,100,50,7/28/2021
63E8D5,earnings,100,50,7/28/2021
63E8D5,earnings,100,50,7/28/2021
63E8D5,earnings,100,50,7/28/2021
63E8D5,earnings,100,50,7/28/2021
662682,acquisition-acquirer,100,49,7/28/2021
662682,acquisition-acquirer,100,49,7/28/2021
662682,earnings,100,50,7/28/2021
66E3C0,earnings,100,50,7/28/2021
66ECFD,earnings,100,50,7/28/2021
67303E,partnership,100,61,7/28/2021
68BA15,acquisition-interest-acquiree,100,82,7/28/2021
6AACDD,legal-issues-defendant,100,22,7/28/2021
6AACDD,legal-issues-defendant,100,22,7/28/2021
6ACFBF,earnings,100,50,7/28/2021
6B236C,earnings,100,50,7/28/2021
6B67BD,earnings,100,50,7/28/2021
6C4D2F,earnings,100,50,7/28/2021
6DBBBC,dividend,100,50,7/28/2021
6DBBBC,investment-investor,100,55,7/28/2021
6E1E61,earnings,100,50,7/28/2021
6E7060,earnings,100,50,7/28/2021
6EB9DA,dividend,100,50,7/28/2021
7032D0,earnings,100,50,7/28/2021
704B78,conference-participant,100,50,7/28/2021
722DE3,earnings-up,100,68,7/28/2021
722DE3,earnings,100,50,7/28/2021
72609A,earnings,100,50,7/28/2021
72609A,earnings,100,50,7/28/2021
7273FF,earnings,100,50,7/28/2021
73A71F,dividend,100,50,7/28/2021
73BCBA,earnings,100,50,7/28/2021
73BCBA,earnings,100,50,7/28/2021
73BCBA,earnings,100,50,7/28/2021
73BCBA,earnings,100,50,7/28/2021
7.45E+28,earnings,100,50,7/28/2021
746373,earnings,100,50,7/28/2021
746373,earnings,100,50,7/28/2021
747219,conference-participant,100,50,7/28/2021
748EB6,conference-participant,100,50,7/28/2021
762A3E,earnings,100,50,7/28/2021
762A3E,earnings,100,50,7/28/2021
762A3E,earnings,100,50,7/28/2021
762A3E,earnings,100,50,7/28/2021
762A3E,earnings,100,50,7/28/2021
762A3E,earnings,100,50,7/28/2021
762A3E,earnings,100,50,7/28/2021
762A3E,earnings,100,50,7/28/2021
762A3E,dividend,100,50,7/28/2021
763724,conference-call,100,50,7/28/2021
766047,earnings,100,50,7/28/2021
76B926,dividend,100,50,7/28/2021
76BECC,conference-call,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
771985,earnings,100,50,7/28/2021
782B46,earnings,100,50,7/28/2021
789ADD,dividend,100,50,7/28/2021
7AF907,earnings,100,50,7/28/2021
7D35D8,earnings,100,50,7/28/2021
7E3390,conference-participant,100,50,7/28/2021
7E62B5,earnings,100,50,7/28/2021
805CD8,conference-call,100,50,7/28/2021
80D744,note-sale,100,52,7/28/2021
810FAD,partnership,100,61,7/28/2021
810FAD,partnership,100,61,7/28/2021
830BDB,earnings,100,50,7/28/2021
8665BA,earnings,100,50,7/28/2021
86A1B9,dividend,100,50,7/28/2021
86AA9C,conference-call,100,50,7/28/2021
86F123,earnings,100,50,7/28/2021
880C0C,earnings,100,50,7/28/2021
88193E,earnings,100,50,7/28/2021
88923D,award,100,58,7/28/2021
896771,earnings,100,50,7/28/2021
89F693,earnings-positive,100,69,7/28/2021
8B1E11,earnings,100,50,7/28/2021
8B3B0E,earnings,100,50,7/28/2021
8C1238,earnings,100,50,7/28/2021
8C1238,earnings,100,50,7/28/2021
8C1238,earnings,100,50,7/28/2021
8C1238,earnings,100,50,7/28/2021
8C1238,earnings,100,50,7/28/2021
8C1238,earnings,100,50,7/28/2021
8DBE73,earnings,100,50,7/28/2021
8DCBBB,earnings,100,50,7/28/2021
8E10BF,earnings,100,50,7/28/2021
8E4F9A,earnings,100,50,7/28/2021
8EF425,earnings,100,50,7/28/2021
8EF425,earnings,100,50,7/28/2021
8EF425,earnings,100,50,7/28/2021
8EF425,earnings,100,50,7/28/2021
8EF425,earnings,100,50,7/28/2021
8EF425,earnings,100,50,7/28/2021
902670,dividend,100,50,7/28/2021
907ED2,executive-appointment,100,54,7/28/2021
94637C,earnings,100,50,7/28/2021
9546A5,conference-call,100,50,7/28/2021
9.54E+32,earnings,100,50,7/28/2021
9.54E+32,earnings,100,50,7/28/2021
979451,earnings,100,50,7/28/2021
98CAED,dividend,100,50,7/28/2021
98CAED,earnings-up,100,68,7/28/2021
98CAED,earnings-up,100,68,7/28/2021
98CAED,earnings-up,100,68,7/28/2021
98CAED,earnings-up,100,68,7/28/2021
9D307D,earnings,100,50,7/28/2021
9D30A8,earnings,100,50,7/28/2021
9D65C1,earnings,100,50,7/28/2021
9DDE1B,earnings,100,50,7/28/2021
9E298A,dividend,100,50,7/28/2021
9EA947,earnings,100,50,7/28/2021
9FD2D9,earnings,100,50,7/28/2021
9FD2D9,earnings,100,50,7/28/2021
9FD2D9,earnings,100,50,7/28/2021
9FD2D9,earnings,100,50,7/28/2021
9FD2D9,acquisition-completed-acquirer,100,49,7/28/2021
9FD2D9,public-offering,100,43,7/28/2021
A204A7,earnings,100,50,7/28/2021
A3AAA5,earnings,100,50,7/28/2021
A429A5,operating-earnings,100,50,7/28/2021
A433A5,conference-call,100,50,7/28/2021
A47A7D,conference-participant,100,50,7/28/2021
A48593,conference-call,100,50,7/28/2021
A5195E,executive-appointment,100,54,7/28/2021
A52B6B,partnership,100,61,7/28/2021
A65325,dividend,100,50,7/28/2021
A65325,earnings-positive,100,69,7/28/2021
A6ABE9,earnings,100,50,7/28/2021
A87CD6,revenues,100,50,7/28/2021
A8AC4C,earnings-up,100,68,7/28/2021
A94718,earnings,100,50,7/28/2021
A99576,earnings,100,50,7/28/2021
AA98ED,dividend,100,50,7/28/2021
AADE0B,dividend,100,50,7/28/2021
AADE0B,executive-appointment,100,54,7/28/2021
ABEE43,unit-acquisition-acquirer,100,49,7/28/2021
AD3008,earnings,100,50,7/28/2021
AD3C93,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AD9F1D,earnings,100,50,7/28/2021
AE0CCE,earnings,100,50,7/28/2021
AEF2C3,earnings,100,50,7/28/2021
AF93DE,conference-call,100,50,7/28/2021
B08954,acquisition-acquiree,100,76,7/28/2021
B08954,acquisition-acquiree,100,76,7/28/2021
B08954,earnings,100,50,7/28/2021
B08954,acquisition-regulatory-scrutiny-acquiree,100,38,7/28/2021
B106FA,earnings,100,50,7/28/2021
B1FC3B,business-contract,100,69,7/28/2021
B76C82,acquisition-completed-acquirer,100,49,7/28/2021
B803B1,partnership,100,61,7/28/2021
B83BCE,earnings,100,50,7/28/2021
B96637,revenues,100,50,7/28/2021
B96637,revenues,100,50,7/28/2021
B9B6B8,earnings,100,50,7/28/2021
BAAA60,earnings,100,50,7/28/2021
BB07E4,earnings,100,50,7/28/2021
BB88B6,earnings,100,50,7/28/2021
BC4876,dividend,100,50,7/28/2021
BFE02C,acquisition-acquirer,100,49,7/28/2021
BFE02C,acquisition-acquirer,100,49,7/28/2021
C05839,earnings,100,50,7/28/2021
C05839,earnings,100,50,7/28/2021
C05839,earnings,100,50,7/28/2021
C05839,earnings,100,50,7/28/2021
C05839,earnings,100,50,7/28/2021
C05839,earnings,100,50,7/28/2021
C062D4,product-release,100,64,7/28/2021
C27E19,operating-earnings,100,50,7/28/2021
C2E120,earnings,100,50,7/28/2021
C3CF29,earnings,100,50,7/28/2021
C3CF29,earnings,100,50,7/28/2021
C3CF29,earnings,100,50,7/28/2021
C3CF29,earnings,100,50,7/28/2021
C3CF29,earnings,100,50,7/28/2021
C4A241,earnings-up,100,68,7/28/2021
C4A241,earnings,100,50,7/28/2021
C4A241,earnings,100,50,7/28/2021
C4A241,earnings,100,50,7/28/2021
C4FBDC,award,100,58,7/28/2021
C66B44,earnings,100,50,7/28/2021
C951A2,earnings,100,50,7/28/2021
C951A2,earnings,100,50,7/28/2021
C951A2,earnings,100,50,7/28/2021
C951A2,earnings,100,50,7/28/2021
C951A2,earnings,100,50,7/28/2021
C951A2,earnings,100,50,7/28/2021
C9D866,executive-appointment,100,54,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9D866,earnings,100,50,7/28/2021
C9E04B,conference-call,100,50,7/28/2021
CA212F,dividend,100,50,7/28/2021
CBA33B,earnings,100,50,7/28/2021
CBA33B,executive-appointment,100,54,7/28/2021
CC8F6E,earnings,100,50,7/28/2021
CD4DA8,earnings-up,100,68,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CD4DA8,earnings,100,50,7/28/2021
CFF15D,earnings,100,50,7/28/2021
CFF15D,earnings,100,50,7/28/2021
D06755,earnings,100,50,7/28/2021
D06755,earnings,100,50,7/28/2021
D06755,earnings,100,50,7/28/2021
D0909F,resource-discovery,100,88,7/28/2021
D0909F,earnings,100,50,7/28/2021
D139BC,earnings,100,50,7/28/2021
D15833,dividend,100,50,7/28/2021
D1AE3B,executive-appointment,100,54,7/28/2021
D25249,earnings,100,50,7/28/2021
D3CEDF,earnings,100,50,7/28/2021
D3CEDF,earnings,100,50,7/28/2021
D3CEDF,earnings,100,50,7/28/2021
D3CEDF,earnings,100,50,7/28/2021
D3CEDF,earnings,100,50,7/28/2021
D3CEDF,earnings,100,50,7/28/2021
D3FD6D,conference-participant,100,50,7/28/2021
D437C3,earnings,100,50,7/28/2021
D437C3,earnings,100,50,7/28/2021
D437C3,earnings,100,50,7/28/2021
D54E62,dividend,100,50,7/28/2021
D58A11,conference-call,100,50,7/28/2021
D5A350,dividend,100,50,7/28/2021
D64EDF,dividend,100,50,7/28/2021
D90F43,partnership,100,61,7/28/2021
D90F43,partnership,100,61,7/28/2021
D9164D,earnings,100,50,7/28/2021
D9B1C9,executive-appointment,100,54,7/28/2021
DC2B00,facility-open,100,65,7/28/2021
DCD97F,earnings,100,50,7/28/2021
DD7A96,earnings,100,50,7/28/2021
DDEA6A,earnings,100,50,7/28/2021
DF5F14,earnings,100,50,7/28/2021
E00373,earnings,100,50,7/28/2021
E0207A,earnings,100,50,7/28/2021
E0207A,earnings,100,50,7/28/2021
E0207A,earnings,100,50,7/28/2021
E0207A,earnings,100,50,7/28/2021
E0647D,earnings,100,50,7/28/2021
E0647D,earnings,100,50,7/28/2021
E0647D,earnings,100,50,7/28/2021
E0647D,earnings,100,50,7/28/2021
E0647D,earnings,100,50,7/28/2021
E13782,revenues,100,50,7/28/2021
E21871,dividend,100,50,7/28/2021
E38906,earnings,100,50,7/28/2021
E3E68E,executive-appointment,100,54,7/28/2021
E3E68E,executive-appointment,100,54,7/28/2021
E3E68E,earnings,100,50,7/28/2021
E3E68E,earnings,100,50,7/28/2021
E4CE73,conference-call,100,50,7/28/2021
E5D914,executive-appointment,100,54,7/28/2021
E5D914,earnings,100,50,7/28/2021
E70531,resource-discovery,100,88,7/28/2021
E70531,dividend,100,50,7/28/2021
E74B55,asset-sale,100,62,7/28/2021
E829E8,earnings,100,50,7/28/2021
E96E0B,conference-participant,100,50,7/28/2021
EA62FC,earnings-up,100,68,7/28/2021
ED2A5E,earnings,100,50,7/28/2021
ED2A5E,earnings,100,50,7/28/2021
ED2A5E,earnings,100,50,7/28/2021
ED2A5E,earnings,100,50,7/28/2021
ED2A5E,earnings,100,50,7/28/2021
ED2A5E,earnings,100,50,7/28/2021
ED9C04,patent-infringement-defendant,100,26,7/28/2021
EEEA9F,earnings,100,50,7/28/2021
EEEA9F,earnings,100,50,7/28/2021
F0B2B5,conference-call,100,50,7/28/2021
F1C04C,operating-earnings,100,50,7/28/2021
F1CD47,earnings,100,50,7/28/2021
F2E253,partnership,100,61,7/28/2021
F4CDA3,earnings,100,50,7/28/2021
F50BAB,earnings,100,50,7/28/2021
F50BAB,earnings,100,50,7/28/2021
F50BAB,earnings,100,50,7/28/2021
F50BAB,earnings,100,50,7/28/2021
F50BAB,earnings,100,50,7/28/2021
F7902B,revenue-up,100,69,7/28/2021
F7902B,revenue-up,100,69,7/28/2021
F7902B,revenue-up,100,69,7/28/2021
F7FCA4,dividend,100,50,7/28/2021
F88147,earnings,100,50,7/28/2021
F88147,legal-issues-defendant,100,22,7/28/2021
F88147,legal-issues-defendant,100,22,7/28/2021
F88147,legal-issues-defendant,100,22,7/28/2021
F90EE5,earnings,100,50,7/28/2021
F9CAF8,earnings,100,50,7/28/2021
F9CAF8,earnings,100,50,7/28/2021
F9CAF8,earnings,100,50,7/28/2021
FA35C6,earnings,100,50,7/28/2021
FA36A4,earnings,100,50,7/28/2021
FA840E,conference-participant,100,50,7/28/2021
FA918D,dividend,100,50,7/28/2021
FADF1A,earnings,100,50,7/28/2021
FBDA0F,earnings,100,50,7/28/2021
FD9A97,dividend,100,50,7/28/2021
FDC7E6,earnings,100,50,7/28/2021
FDC7E6,dividend,100,50,7/28/2021
FE1A1D,earnings,100,50,7/28/2021
FE1A1D,earnings,100,50,7/28/2021
FE1A1D,earnings,100,50,7/28/2021
FE1A1D,earnings,100,50,7/28/2021
FE1A1D,earnings,100,50,7/28/2021
FE1A1D,earnings,100,50,7/28/2021
FEE4B0,dividend-up,100,81,7/28/2021
FF4343,earnings,100,50,7/28/2021
FFA9B9,executive-appointment,100,54,7/28/2021
00067A,note-sale,100,52,7/29/2021
00067A,note-sale,100,52,7/29/2021
002A99,earnings,100,50,7/29/2021
9397,earnings,100,50,7/29/2021
0142B5,earnings-per-share-positive,100,69,7/29/2021
01478A,earnings,100,50,7/29/2021
0157B1,partnership,100,61,7/29/2021
0157B1,partnership,100,61,7/29/2021
0157B1,partnership,100,61,7/29/2021
0157B1,earnings,100,50,7/29/2021
0157B1,earnings,100,50,7/29/2021
0157B1,earnings,100,50,7/29/2021
0157B1,earnings,100,50,7/29/2021
0157B1,earnings,100,50,7/29/2021
0157B1,earnings,100,50,7/29/2021
0157B1,earnings,100,50,7/29/2021
0157B1,earnings,100,50,7/29/2021
01B8D6,regulatory-product-approval-granted,100,81,7/29/2021
20751,earnings,100,50,7/29/2021
51332,dividend,100,50,7/29/2021
054E7E,earnings,100,50,7/29/2021
0560D8,earnings,100,50,7/29/2021
0560D8,earnings,100,50,7/29/2021
61366,earnings,100,50,7/29/2021
065D38,earnings,100,50,7/29/2021
68396,earnings,100,50,7/29/2021
71860,earnings,100,50,7/29/2021
07CA6A,earnings,100,50,7/29/2021
07CA6A,earnings,100,50,7/29/2021
099C88,earnings,100,50,7/29/2021
0A59F8,partnership,100,61,7/29/2021
0A7650,ipo,100,71,7/29/2021
0B13E8,conference-call,100,50,7/29/2021
0B2071,earnings,100,50,7/29/2021
0BC17A,earnings,100,50,7/29/2021
0BC17A,dividend,100,50,7/29/2021
0BC29E,executive-appointment,100,54,7/29/2021
0BD199,earnings,100,50,7/29/2021
0BD199,earnings,100,50,7/29/2021
0BD4E8,earnings,100,50,7/29/2021
0BD4E8,earnings,100,50,7/29/2021
0BD4E8,earnings,100,50,7/29/2021
0BD4E8,earnings,100,50,7/29/2021
0BD4E8,earnings,100,50,7/29/2021
0E5619,conference-call,100,50,7/29/2021
0ED415,earnings,100,50,7/29/2021
0ED415,earnings,100,50,7/29/2021
0ED415,earnings,100,50,7/29/2021
0ED415,earnings,100,50,7/29/2021
0EF1AF,conference-participant,100,50,7/29/2021
0F04E5,earnings,100,50,7/29/2021
0F04E5,earnings,100,50,7/29/2021
0F04E5,earnings,100,50,7/29/2021
0FC848,earnings,100,50,7/29/2021
10100E,conference-participant,100,50,7/29/2021
105D00,dividend,100,50,7/29/2021
1080C0,executive-appointment,100,54,7/29/2021
1080C0,earnings,100,50,7/29/2021
10943B,earnings,100,50,7/29/2021
1151F4,earnings,100,50,7/29/2021
1151F4,earnings,100,50,7/29/2021
1151F4,earnings,100,50,7/29/2021
1151F4,earnings,100,50,7/29/2021
1151F4,earnings,100,50,7/29/2021
1151F4,earnings,100,50,7/29/2021
1151F4,earnings,100,50,7/29/2021
11AEDE,earnings,100,50,7/29/2021
129DC8,earnings,100,50,7/29/2021
129DC8,earnings,100,50,7/29/2021
129DC8,earnings,100,50,7/29/2021
129DC8,earnings,100,50,7/29/2021
147C38,earnings,100,50,7/29/2021
1490F3,earnings,100,50,7/29/2021
1490F3,earnings,100,50,7/29/2021
152FA5,conference-participant,100,50,7/29/2021
15901B,earnings,100,50,7/29/2021
159AE4,earnings,100,50,7/29/2021
159AE4,earnings,100,50,7/29/2021
16B882,earnings,100,50,7/29/2021
1748F6,business-contract,100,69,7/29/2021
1748F6,business-contract,100,69,7/29/2021
1.79E+10,dividend,100,50,7/29/2021
17EDA5,earnings,100,50,7/29/2021
17EDA5,product-release,100,64,7/29/2021
18D9FA,executive-appointment,100,54,7/29/2021
18D9FA,conference-call,100,50,7/29/2021
197019,earnings,100,50,7/29/2021
1A46A1,earnings,100,50,7/29/2021
1A5957,earnings,100,50,7/29/2021
1A6A94,earnings,100,50,7/29/2021
1B5FEA,earnings,100,50,7/29/2021
1DB6A6,earnings,100,50,7/29/2021
1DDEDA,conference-call,100,50,7/29/2021
1DEBBE,earnings,100,50,7/29/2021
1DF15D,earnings,100,50,7/29/2021
1DF15D,earnings,100,50,7/29/2021
1DF15D,earnings,100,50,7/29/2021
1E1125,conference-organizer,100,57,7/29/2021
1E9A6D,executive-appointment,100,54,7/29/2021
1EBF8D,earnings,100,50,7/29/2021
1EBF8D,executive-appointment,100,54,7/29/2021
1F19C8,fundraising,100,64,7/29/2021
1FAF22,earnings,100,50,7/29/2021
1FAF22,earnings,100,50,7/29/2021
1FAF22,earnings,100,50,7/29/2021
1FAF22,earnings,100,50,7/29/2021
1FAF22,earnings,100,50,7/29/2021
1FAF22,earnings,100,50,7/29/2021
1FAF22,earnings,100,50,7/29/2021
1FAF22,acquisition-acquirer,100,49,7/29/2021
1FAF22,acquisition-acquirer,100,49,7/29/2021
1FAF22,conference-participant,100,50,7/29/2021
1FE7F0,legal-issues-defendant,100,22,7/29/2021
21245F,conference-participant,100,50,7/29/2021
219B21,earnings,100,50,7/29/2021
219B21,earnings,100,50,7/29/2021
219B21,earnings,100,50,7/29/2021
219B21,earnings,100,50,7/29/2021
219B21,earnings,100,50,7/29/2021
219B21,earnings,100,50,7/29/2021
222BF9,earnings,100,50,7/29/2021
228D42,partnership,100,61,7/29/2021
228D42,partnership,100,61,7/29/2021
2491BC,partnership,100,61,7/29/2021
253604,executive-appointment,100,54,7/29/2021
25A6CC,earnings,100,50,7/29/2021
25A6CC,earnings,100,50,7/29/2021
25A6CC,earnings,100,50,7/29/2021
25A6CC,earnings,100,50,7/29/2021
25A6CC,earnings,100,50,7/29/2021
26DC29,executive-appointment,100,54,7/29/2021
270B78,earnings,100,50,7/29/2021
272472,earnings-positive,100,69,7/29/2021
284289,earnings-up,100,68,7/29/2021
28DCF3,earnings,100,50,7/29/2021
297DA8,conference-participant,100,50,7/29/2021
29B702,earnings,100,50,7/29/2021
2A02DC,earnings,100,50,7/29/2021
2A1009,earnings,100,50,7/29/2021
2A1009,earnings,100,50,7/29/2021
2A1009,earnings,100,50,7/29/2021
2A1009,earnings,100,50,7/29/2021
2A1009,earnings,100,50,7/29/2021
2A1009,earnings,100,50,7/29/2021
2A17B1,earnings-up,100,68,7/29/2021
2A17B1,earnings-up,100,68,7/29/2021
2A17B1,earnings-up,100,68,7/29/2021
2ABF77,conference-call,100,50,7/29/2021
2BA977,earnings,100,50,7/29/2021
2BAE5F,earnings,100,50,7/29/2021
2BAE5F,earnings,100,50,7/29/2021
2C19A4,earnings,100,50,7/29/2021
2C19A4,earnings,100,50,7/29/2021
2C19A4,earnings,100,50,7/29/2021
2C19A4,earnings,100,50,7/29/2021
2C19A4,earnings,100,50,7/29/2021
2C3348,earnings,100,50,7/29/2021
2C7505,clinical-trials-positive,100,87,7/29/2021
2C7505,business-contract,100,69,7/29/2021
2C7505,partnership,100,61,7/29/2021
2CA60F,earnings,100,50,7/29/2021
2CA60F,earnings,100,50,7/29/2021
2CA60F,earnings,100,50,7/29/2021
2CA60F,earnings,100,50,7/29/2021
2CC71C,conference-call,100,50,7/29/2021
2CD1E0,partnership,100,61,7/29/2021
2CF9D3,earnings,100,50,7/29/2021
2D5011,earnings,100,50,7/29/2021
2DDB22,credit-extension-recipient,100,69,7/29/2021
2E36AD,partnership,100,61,7/29/2021
2F5256,dividend,100,50,7/29/2021
2F6782,conference-participant,100,50,7/29/2021
2F94A5,earnings,100,50,7/29/2021
30DE64,earnings,100,50,7/29/2021
314D88,earnings,100,50,7/29/2021
31553A,earnings,100,50,7/29/2021
31553A,earnings,100,50,7/29/2021
31553A,earnings,100,50,7/29/2021
31553A,earnings,100,50,7/29/2021
328250,earnings,100,50,7/29/2021
349DA4,acquisition-acquiree,100,76,7/29/2021
349DA4,acquisition-acquiree,100,76,7/29/2021
349DA4,asset-sale,100,62,7/29/2021
349DA4,earnings,100,50,7/29/2021
34E9F9,conference-call,100,50,7/29/2021
35557B,earnings-positive,100,69,7/29/2021
371C01,earnings,100,50,7/29/2021
371C01,earnings,100,50,7/29/2021
383ADA,earnings,100,50,7/29/2021
387375,earnings,100,50,7/29/2021
396D7C,earnings,100,50,7/29/2021
3A94DF,earnings-per-share-positive,100,69,7/29/2021
3AF7FD,conference-call,100,50,7/29/2021
3B20AB,conference-participant,100,50,7/29/2021
3B37F7,earnings,100,50,7/29/2021
3B8484,earnings,100,50,7/29/2021
3DDE54,earnings,100,50,7/29/2021
3DDE54,earnings,100,50,7/29/2021
3DDE54,earnings,100,50,7/29/2021
3DDE54,earnings,100,50,7/29/2021
3DDE54,earnings,100,50,7/29/2021
3DDE54,earnings,100,50,7/29/2021
3E15F6,earnings,100,50,7/29/2021
3E15F6,earnings,100,50,7/29/2021
3E15F6,earnings,100,50,7/29/2021
3E15F6,earnings,100,50,7/29/2021
3F4497,earnings,100,50,7/29/2021
3F868D,earnings,100,50,7/29/2021
3FBC9B,earnings,100,50,7/29/2021
3FBC9B,earnings,100,50,7/29/2021
3FBC9B,earnings,100,50,7/29/2021
401072,earnings,100,50,7/29/2021
4017AD,earnings,100,50,7/29/2021
405762,earnings,100,50,7/29/2021
41785E,executive-appointment,100,54,7/29/2021
41B53E,earnings,100,50,7/29/2021
41B53E,earnings,100,50,7/29/2021
41B53E,earnings,100,50,7/29/2021
42EFC7,private-placement,100,56,7/29/2021
435ACE,dividend,100,50,7/29/2021
4398A2,earnings,100,50,7/29/2021
450ECB,earnings,100,50,7/29/2021
451D61,earnings,100,50,7/29/2021
4595EF,earnings,100,50,7/29/2021
479930,earnings,100,50,7/29/2021
47FCF2,partnership,100,61,7/29/2021
4806CE,earnings,100,50,7/29/2021
4885C8,earnings,100,50,7/29/2021
49BBBC,product-release,100,64,7/29/2021
4A6F00,revenue-volume-up,100,88,7/29/2021
4A6F00,partnership,100,61,7/29/2021
4BD6DB,acquisition-acquirer,100,49,7/29/2021
4BD6DB,earnings,100,50,7/29/2021
4C37C5,partnership,100,61,7/29/2021
4C3FE9,earnings,100,50,7/29/2021
4C5CC9,earnings-guidance-up,100,83,7/29/2021
4C5CC9,earnings-guidance-up,100,83,7/29/2021
4C5CC9,earnings-guidance-up,100,83,7/29/2021
4C5CC9,earnings-guidance-up,100,83,7/29/2021
4CDA2B,earnings,100,50,7/29/2021
4CDA2B,earnings,100,50,7/29/2021
4CDA2B,earnings,100,50,7/29/2021
4E2D94,earnings,100,50,7/29/2021
4E2D94,dividend,100,50,7/29/2021
4EE167,earnings,100,50,7/29/2021
4EEE7E,earnings,100,50,7/29/2021
4F783B,dividend,100,50,7/29/2021
507AE7,earnings,100,50,7/29/2021
5088A5,earnings,100,50,7/29/2021
51888A,operating-earnings,100,50,7/29/2021
51D876,earnings,100,50,7/29/2021
51D876,earnings,100,50,7/29/2021
51D876,earnings,100,50,7/29/2021
51D876,earnings,100,50,7/29/2021
51D876,earnings,100,50,7/29/2021
51D876,earnings,100,50,7/29/2021
51D876,earnings,100,50,7/29/2021
51D876,earnings,100,50,7/29/2021
52015A,earnings,100,50,7/29/2021
524CE4,earnings,100,50,7/29/2021
525A1C,earnings,100,50,7/29/2021
52BF94,earnings,100,50,7/29/2021
52BF94,earnings,100,50,7/29/2021
52BF94,earnings,100,50,7/29/2021
52BF94,earnings,100,50,7/29/2021
52BF94,earnings,100,50,7/29/2021
52FB2F,buybacks,100,74,7/29/2021
5340D0,executive-appointment,100,54,7/29/2021
53E575,earnings,100,50,7/29/2021
54512F,legal-issues-defendant,100,22,7/29/2021
5.47E+28,earnings,100,50,7/29/2021
54A646,dividend,100,50,7/29/2021
55438C,donation,100,54,7/29/2021
55C9B5,earnings,100,50,7/29/2021
55D0F3,earnings,100,50,7/29/2021
56632F,earnings,100,50,7/29/2021
567F3D,earnings-up,100,68,7/29/2021
56FB7C,dividend-up,100,81,7/29/2021
57356F,earnings,100,50,7/29/2021
57356F,earnings,100,50,7/29/2021
57356F,earnings,100,50,7/29/2021
57356F,earnings,100,50,7/29/2021
57634F,earnings,100,50,7/29/2021
57CAAB,earnings,100,50,7/29/2021
57DDB9,earnings-guidance-up,100,83,7/29/2021
57DDB9,earnings-guidance-up,100,83,7/29/2021
57DDB9,earnings-guidance-up,100,83,7/29/2021
57DDB9,earnings-guidance-up,100,83,7/29/2021
57DDB9,earnings-guidance-up,100,83,7/29/2021
57F3DA,earnings,100,50,7/29/2021
59872F,partnership,100,61,7/29/2021
59F0B0,earnings,100,50,7/29/2021
59F0B0,earnings,100,50,7/29/2021
59F0B0,earnings,100,50,7/29/2021
59F0B0,earnings,100,50,7/29/2021
5A64D5,earnings,100,50,7/29/2021
5CCDAD,earnings,100,50,7/29/2021
5D1329,conference-call,100,50,7/29/2021
5D16CF,earnings,100,50,7/29/2021
5D43A7,earnings,100,50,7/29/2021
5D43A7,earnings,100,50,7/29/2021
5D43A7,earnings,100,50,7/29/2021
5D43A7,earnings,100,50,7/29/2021
5D43A7,earnings,100,50,7/29/2021
5DE5A5,dividend,100,50,7/29/2021
5EC388,earnings-positive,100,69,7/29/2021
5EF130,conference-call,100,50,7/29/2021
5F1B7B,earnings,100,50,7/29/2021
5F3D91,earnings,100,50,7/29/2021
601785,unit-acquisition-acquirer,100,49,7/29/2021
60AC34,conference-participant,100,50,7/29/2021
6137BF,earnings,100,50,7/29/2021
627186,conference-participant,100,50,7/29/2021
62EFEE,earnings-up,100,68,7/29/2021
63F892,product-release,100,64,7/29/2021
63F892,earnings,100,50,7/29/2021
63F892,earnings,100,50,7/29/2021
641F17,earnings,100,50,7/29/2021
641F17,earnings,100,50,7/29/2021
641F17,earnings,100,50,7/29/2021
641F17,earnings,100,50,7/29/2021
641F17,earnings,100,50,7/29/2021
641F17,earnings,100,50,7/29/2021
641F17,earnings,100,50,7/29/2021
641F17,earnings,100,50,7/29/2021
641F17,earnings,100,50,7/29/2021
6.52E+64,earnings,100,50,7/29/2021
6559D8,earnings,100,50,7/29/2021
66E04A,earnings,100,50,7/29/2021
66E04A,earnings,100,50,7/29/2021
66E04A,earnings,100,50,7/29/2021
66E04A,earnings,100,50,7/29/2021
66E04A,earnings,100,50,7/29/2021
66E04A,earnings,100,50,7/29/2021
67B052,earnings,100,50,7/29/2021
69494C,earnings,100,50,7/29/2021
69E8E1,earnings,100,50,7/29/2021
69E8E1,earnings,100,50,7/29/2021
69E8E1,earnings,100,50,7/29/2021
69E8E1,earnings,100,50,7/29/2021
69E8E1,earnings,100,50,7/29/2021
69E8E1,earnings,100,50,7/29/2021
69E8E1,earnings,100,50,7/29/2021
69E8E1,earnings,100,50,7/29/2021
69E8E1,earnings,100,50,7/29/2021
6A3C35,earnings,100,50,7/29/2021
6A3C35,earnings,100,50,7/29/2021
6A3C35,earnings,100,50,7/29/2021
6A3C35,earnings,100,50,7/29/2021
6A3C35,earnings,100,50,7/29/2021
6AACDD,legal-issues-defendant,100,22,7/29/2021
6B0784,earnings,100,50,7/29/2021
6BD606,dividend,100,50,7/29/2021
6CDFC6,earnings,100,50,7/29/2021
6DC1D7,earnings,100,50,7/29/2021
6E7060,facility-open,100,65,7/29/2021
6F0A63,earnings-up,100,68,7/29/2021
701531,earnings,100,50,7/29/2021
717DB4,earnings,100,50,7/29/2021
717DB4,earnings,100,50,7/29/2021
717DB4,earnings,100,50,7/29/2021
717DB4,earnings,100,50,7/29/2021
717DB4,earnings,100,50,7/29/2021
731675,earnings,100,50,7/29/2021
73529F,earnings,100,50,7/29/2021
735388,earnings,100,50,7/29/2021
73A71F,earnings-up,100,68,7/29/2021
73C9E2,earnings,100,50,7/29/2021
742AAB,revenue-up,100,69,7/29/2021
742AAB,revenue-up,100,69,7/29/2021
742AAB,revenue-up,100,69,7/29/2021
742AAB,revenue-up,100,69,7/29/2021
742AAB,revenue-up,100,69,7/29/2021
76DD0C,executive-appointment,100,54,7/29/2021
76F067,earnings,100,50,7/29/2021
76F067,executive-appointment,100,54,7/29/2021
7823A3,earnings,100,50,7/29/2021
7823A3,earnings,100,50,7/29/2021
7823A3,earnings,100,50,7/29/2021
7823A3,earnings,100,50,7/29/2021
7823A3,earnings,100,50,7/29/2021
7823A3,earnings,100,50,7/29/2021
787D14,conference-call,100,50,7/29/2021
78F9ED,earnings,100,50,7/29/2021
78F9ED,earnings,100,50,7/29/2021
78F9ED,earnings,100,50,7/29/2021
78F9ED,earnings,100,50,7/29/2021
78F9ED,earnings,100,50,7/29/2021
78F9ED,earnings,100,50,7/29/2021
78F9ED,earnings,100,50,7/29/2021
78F9ED,earnings,100,50,7/29/2021
79167B,earnings,100,50,7/29/2021
79167B,earnings,100,50,7/29/2021
79167B,earnings,100,50,7/29/2021
79167B,earnings,100,50,7/29/2021
79167B,earnings,100,50,7/29/2021
791D59,earnings,100,50,7/29/2021
791EC1,unit-acquisition-acquiree,100,76,7/29/2021
7A2A49,partnership,100,61,7/29/2021
7ACBA4,earnings,100,50,7/29/2021
7AD81E,conference-participant,100,50,7/29/2021
7B4B91,dividend-up,100,81,7/29/2021
7B6C88,earnings,100,50,7/29/2021
7B9AFA,earnings,100,50,7/29/2021
7B9AFA,earnings,100,50,7/29/2021
7C4F43,earnings,100,50,7/29/2021
7DC1C4,earnings,100,50,7/29/2021
7E0EB0,earnings,100,50,7/29/2021
7E62B5,legal-issues-defendant,100,22,7/29/2021
7F3665,earnings,100,50,7/29/2021
80C400,conference-call,100,50,7/29/2021
81A88D,earnings,100,50,7/29/2021
8.22E+27,earnings,100,50,7/29/2021
82C202,earnings,100,50,7/29/2021
83598E,conference-participant,100,50,7/29/2021
837C04,dividend,100,50,7/29/2021
837C04,earnings,100,50,7/29/2021
837C04,earnings,100,50,7/29/2021
837C04,earnings,100,50,7/29/2021
837C04,earnings,100,50,7/29/2021
837C04,earnings,100,50,7/29/2021
837C04,earnings,100,50,7/29/2021
837C04,earnings,100,50,7/29/2021
837C04,earnings,100,50,7/29/2021
83B1C8,earnings,100,50,7/29/2021
860AB6,dividend,100,50,7/29/2021
860AB6,dividend,100,50,7/29/2021
86BAC7,dividend,100,50,7/29/2021
873DB9,conference-participant,100,50,7/29/2021
877734,conference-call,100,50,7/29/2021
881190,earnings,100,50,7/29/2021
881190,earnings,100,50,7/29/2021
881190,earnings,100,50,7/29/2021
881190,earnings,100,50,7/29/2021
8817D5,earnings,100,50,7/29/2021
8B6E7E,earnings-up,100,68,7/29/2021
8BAA15,legal-verdict-favored,100,78,7/29/2021
8BFE9A,earnings,100,50,7/29/2021
8D9993,earnings,100,50,7/29/2021
8D9993,earnings,100,50,7/29/2021
8D9993,earnings,100,50,7/29/2021
8D9993,earnings,100,50,7/29/2021
8E0E32,earnings,100,50,7/29/2021
8E4250,earnings,100,50,7/29/2021
8E4250,earnings,100,50,7/29/2021
8E4250,earnings,100,50,7/29/2021
8E4250,earnings,100,50,7/29/2021
8E4250,earnings,100,50,7/29/2021
8F3231,earnings,100,50,7/29/2021
8F6995,conference-call,100,50,7/29/2021
925759,patient-enrollment-complete,100,64,7/29/2021
92D9C9,earnings,100,50,7/29/2021
934029,earnings,100,50,7/29/2021
93C130,earnings,100,50,7/29/2021
93C130,dividend,100,50,7/29/2021
94563D,earnings,100,50,7/29/2021
94563D,earnings,100,50,7/29/2021
94563D,earnings,100,50,7/29/2021
94563D,earnings,100,50,7/29/2021
94563D,earnings,100,50,7/29/2021
94563D,partnership,100,61,7/29/2021
9470CC,executive-appointment,100,54,7/29/2021
94756D,earnings,100,50,7/29/2021
9507FF,earnings,100,50,7/29/2021
958938,conference-call,100,50,7/29/2021
9.62E+76,dividend,100,50,7/29/2021
965360,dividend,100,50,7/29/2021
968966,executive-appointment,100,54,7/29/2021
96A6CD,earnings,100,50,7/29/2021
972356,product-release,100,64,7/29/2021
972356,product-release,100,64,7/29/2021
97644E,earnings,100,50,7/29/2021
9810C0,earnings,100,50,7/29/2021
989E2F,earnings,100,50,7/29/2021
989E2F,earnings,100,50,7/29/2021
989E2F,earnings,100,50,7/29/2021
989E2F,earnings,100,50,7/29/2021
98CEBB,conference-participant,100,50,7/29/2021
990AD0,business-contract,100,69,7/29/2021
9.97E+09,earnings,100,50,7/29/2021
9C8664,legal-issues-defendant,100,22,7/29/2021
9CE4C7,dividend,100,50,7/29/2021
9CF9B1,earnings,100,50,7/29/2021
9D307D,conference-participant,100,50,7/29/2021
9D5FA4,earnings,100,50,7/29/2021
9E298A,earnings,100,50,7/29/2021
9E298A,earnings,100,50,7/29/2021
9E298A,earnings,100,50,7/29/2021
9E298A,earnings,100,50,7/29/2021
9E575E,earnings,100,50,7/29/2021
9EED50,earnings-up,100,68,7/29/2021
9F03CF,earnings,100,50,7/29/2021
9F03CF,dividend,100,50,7/29/2021
9F6B1A,earnings,100,50,7/29/2021
9F6B1A,earnings,100,50,7/29/2021
9F6B1A,earnings,100,50,7/29/2021
9F6B1A,earnings,100,50,7/29/2021
9F71E5,dividend,100,50,7/29/2021
9FB4B7,earnings,100,50,7/29/2021
9FD2D9,public-offering,100,43,7/29/2021
A02FB1,legal-issues-defendant,100,22,7/29/2021
A05C43,earnings,100,50,7/29/2021
A1DBF0,earnings,100,50,7/29/2021
A4386C,dividend,100,50,7/29/2021
A5151E,buybacks,100,74,7/29/2021
A5151E,earnings,100,50,7/29/2021
A79D88,earnings,100,50,7/29/2021
A79D88,earnings,100,50,7/29/2021
A7CCF0,earnings,100,50,7/29/2021
A80FE0,earnings,100,50,7/29/2021
A8B137,dividend,100,50,7/29/2021
A99576,legal-issues-defendant,100,22,7/29/2021
AA09AD,earnings,100,50,7/29/2021
AA09AD,earnings-guidance,100,50,7/29/2021
AA09AD,earnings-guidance,100,50,7/29/2021
AA09AD,earnings-guidance,100,50,7/29/2021
AA09AD,earnings-guidance,100,50,7/29/2021
AA09AD,earnings,100,50,7/29/2021
AA09AD,earnings,100,50,7/29/2021
AADE0B,earnings,100,50,7/29/2021
AAEE21,public-offering,100,43,7/29/2021
ABB493,conference-call,100,50,7/29/2021
ABBAD1,earnings,100,50,7/29/2021
AC1952,earnings-positive,100,69,7/29/2021
AC3584,earnings,100,50,7/29/2021
AC7C4F,business-contract,100,69,7/29/2021
ACD9A4,dividend,100,50,7/29/2021
ACDCFA,earnings,100,50,7/29/2021
AD9F1D,partnership,100,61,7/29/2021
AE3113,earnings,100,50,7/29/2021
AEEB76,conference-participant,100,50,7/29/2021
AFD1CA,earnings,100,50,7/29/2021
B04426,conference-call,100,50,7/29/2021
B05118,earnings,100,50,7/29/2021
B076A1,conference-call,100,50,7/29/2021
B290A2,conference-call,100,50,7/29/2021
B303A6,executive-appointment,100,54,7/29/2021
B381D8,earnings,100,50,7/29/2021
B4703C,revenues,100,50,7/29/2021
B4703C,revenues,100,50,7/29/2021
B4C673,earnings,100,50,7/29/2021
B4C673,earnings,100,50,7/29/2021
B4C673,earnings,100,50,7/29/2021
B4C673,earnings,100,50,7/29/2021
B4C673,earnings,100,50,7/29/2021
B4C673,earnings,100,50,7/29/2021
B4C673,earnings,100,50,7/29/2021
B4C673,earnings,100,50,7/29/2021
B4C673,facility-open,100,65,7/29/2021
B5BA39,earnings,100,50,7/29/2021
B6CD92,earnings,100,50,7/29/2021
B73395,conference-call,100,50,7/29/2021
B7FA9B,executive-appointment,100,54,7/29/2021
B80AD1,earnings,100,50,7/29/2021
B840EF,earnings,100,50,7/29/2021
BA0442,earnings,100,50,7/29/2021
BBBB41,earnings,100,50,7/29/2021
BBBB41,earnings,100,50,7/29/2021
BBBB41,earnings,100,50,7/29/2021
BBBB41,earnings,100,50,7/29/2021
BBBB41,earnings,100,50,7/29/2021
BBBB41,earnings,100,50,7/29/2021
BBF349,executive-appointment,100,54,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BC3AD2,earnings,100,50,7/29/2021
BD682F,earnings,100,50,7/29/2021
BD8517,earnings,100,50,7/29/2021
BE7BA4,earnings-guidance-up,100,83,7/29/2021
BE86A1,earnings,100,50,7/29/2021
BF79F5,earnings,100,50,7/29/2021
BF79F5,earnings,100,50,7/29/2021
BF79F5,earnings,100,50,7/29/2021
C0030A,earnings-up,100,68,7/29/2021
C0030A,earnings-up,100,68,7/29/2021
C0030A,earnings,100,50,7/29/2021
C0030A,earnings,100,50,7/29/2021
C0030A,earnings,100,50,7/29/2021
C0030A,earnings-up,100,68,7/29/2021
C01737,earnings,100,50,7/29/2021
C06EB6,earnings,100,50,7/29/2021
C1114B,conference-call,100,50,7/29/2021
C188F8,business-contract,100,69,7/29/2021
C230FE,earnings-up,100,68,7/29/2021
C230FE,earnings-up,100,68,7/29/2021
C4F9C6,earnings,100,50,7/29/2021
C501B6,clinical-trials,100,56,7/29/2021
C5C137,earnings,100,50,7/29/2021
C5D2AE,earnings,100,50,7/29/2021
C65004,revenues,100,50,7/29/2021
C65004,business-contract,100,69,7/29/2021
C72B8F,earnings,100,50,7/29/2021
C83B88,earnings,100,50,7/29/2021
C83B88,earnings,100,50,7/29/2021
C83B88,earnings,100,50,7/29/2021
C83B88,earnings,100,50,7/29/2021
C83B88,earnings,100,50,7/29/2021
C83B88,earnings,100,50,7/29/2021
C83B88,earnings,100,50,7/29/2021
C83B88,dividend,100,50,7/29/2021
C8FAC7,earnings,100,50,7/29/2021
C941DC,earnings,100,50,7/29/2021
C94CFC,legal-issues-defendant,100,22,7/29/2021
C9E107,earnings,100,50,7/29/2021
CA99D7,conference-call,100,50,7/29/2021
CA99D7,conference-call,100,50,7/29/2021
CAB222,earnings,100,50,7/29/2021
CBA475,earnings,100,50,7/29/2021
CBA475,earnings,100,50,7/29/2021
CBA475,earnings,100,50,7/29/2021
CBA475,earnings,100,50,7/29/2021
CBA475,earnings,100,50,7/29/2021
CBA475,earnings,100,50,7/29/2021
CBCC6A,earnings,100,50,7/29/2021
CBCC6A,earnings,100,50,7/29/2021
CBDB4D,conference-call,100,50,7/29/2021
CBFFDD,dividend,100,50,7/29/2021
CCBBAD,earnings,100,50,7/29/2021
CDAF5B,operating-earnings,100,50,7/29/2021
CDD75E,earnings,100,50,7/29/2021
CDE118,merger-regulatory-approval,100,81,7/29/2021
CE4E6D,executive-appointment,100,54,7/29/2021
CE4FD9,earnings,100,50,7/29/2021
CE4FD9,earnings,100,50,7/29/2021
CE4FD9,earnings,100,50,7/29/2021
CE4FD9,earnings,100,50,7/29/2021
CE4FD9,earnings,100,50,7/29/2021
CE5C6E,earnings,100,50,7/29/2021
CF6A5A,partnership,100,61,7/29/2021
CFF97C,revenue-up,100,58,7/29/2021
CFF97C,revenue-up,100,58,7/29/2021
CFF97C,revenue-up,100,58,7/29/2021
CFF97C,revenue-up,100,58,7/29/2021
CFF97C,revenue-up,100,58,7/29/2021
CFF97C,revenue-up,100,58,7/29/2021
D03C7A,earnings,100,50,7/29/2021
D04D9F,earnings,100,50,7/29/2021
D04D9F,earnings,100,50,7/29/2021
D04D9F,earnings,100,50,7/29/2021
D04D9F,earnings,100,50,7/29/2021
D09938,earnings,100,50,7/29/2021
D1344A,earnings,100,50,7/29/2021
D17F7E,earnings,100,50,7/29/2021
D17F7E,earnings,100,50,7/29/2021
D17F7E,earnings,100,50,7/29/2021
D17F7E,earnings,100,50,7/29/2021
D6534D,earnings,100,50,7/29/2021
D76AEF,conference-call,100,50,7/29/2021
D78BF1,earnings-up,100,68,7/29/2021
D78BF1,earnings,100,50,7/29/2021
D78BF1,earnings,100,50,7/29/2021
D78BF1,earnings,100,50,7/29/2021
D78BF1,earnings,100,50,7/29/2021
D8760C,dividend,100,50,7/29/2021
D8DBA3,earnings,100,50,7/29/2021
D8ECA1,earnings,100,50,7/29/2021
D8F347,dividend,100,50,7/29/2021
D96202,earnings,100,50,7/29/2021
D96202,dividend-up,100,81,7/29/2021
DB2E4E,business-contract,100,69,7/29/2021
DC2B00,conference-call,100,50,7/29/2021
DC2F77,earnings,100,50,7/29/2021
DC437D,dividend-up,100,56,7/29/2021
DC437D,earnings,100,50,7/29/2021
DC5299,operating-earnings,100,50,7/29/2021
DD1BA1,revenue-up,100,69,7/29/2021
DD1BA1,revenue-up,100,69,7/29/2021
DD1BA1,revenue-up,100,69,7/29/2021
DD1BA1,revenue-up,100,69,7/29/2021
DE4924,dividend,100,50,7/29/2021
DE4924,earnings,100,50,7/29/2021
DEF058,earnings-up,100,68,7/29/2021
DEF058,earnings-up,100,68,7/29/2021
DEF058,earnings-up,100,68,7/29/2021
DEF058,earnings-up,100,68,7/29/2021
DF11D9,legal-issues-defendant,100,22,7/29/2021
DFADDB,regulatory-product-approval-granted,100,81,7/29/2021
E0339F,earnings,100,50,7/29/2021
E0339F,earnings,100,50,7/29/2021
E0339F,earnings,100,50,7/29/2021
E0339F,earnings,100,50,7/29/2021
E06265,conference-call,100,50,7/29/2021
E07573,dividend,100,50,7/29/2021
E10D31,earnings,100,50,7/29/2021
E1BD05,revenue-up,100,72,7/29/2021
E1BD05,revenue-up,100,72,7/29/2021
E1F30A,earnings,100,50,7/29/2021
E393B0,legal-issues-defendant,100,22,7/29/2021
E393B0,earnings,100,50,7/29/2021
E5C910,clinical-trials,100,56,7/29/2021
E5C910,clinical-trials,100,56,7/29/2021
E68C3D,earnings,100,50,7/29/2021
E72599,conference-call,100,50,7/29/2021
E8846E,executive-appointment,100,54,7/29/2021
E8D221,earnings,100,50,7/29/2021
EB5E78,earnings,100,50,7/29/2021
EB5E78,earnings,100,50,7/29/2021
EB5E78,earnings,100,50,7/29/2021
EB5E78,earnings,100,50,7/29/2021
EC70EC,earnings,100,50,7/29/2021
ED4560,earnings,100,50,7/29/2021
EDF5CA,dividend,100,50,7/29/2021
EF1AD9,dividend,100,50,7/29/2021
EF1AD9,earnings,100,50,7/29/2021
EF1AD9,earnings,100,50,7/29/2021
EF1AD9,earnings,100,50,7/29/2021
EF76C8,earnings,100,50,7/29/2021
F0027C,earnings,100,50,7/29/2021
F02D0A,dividend,100,50,7/29/2021
F04E05,earnings,100,50,7/29/2021
F11638,earnings,100,50,7/29/2021
F179ED,earnings,100,50,7/29/2021
F179ED,earnings,100,50,7/29/2021
F179ED,earnings,100,50,7/29/2021
F179ED,earnings,100,50,7/29/2021
F294DD,dividend,100,50,7/29/2021
F3016C,conference-participant,100,50,7/29/2021
F30508,partnership,100,61,7/29/2021
F30508,product-release,100,64,7/29/2021
F31B13,dividend-up,100,72,7/29/2021
F44EA2,dividend-up,100,59,7/29/2021
F47871,earnings,100,50,7/29/2021
F5D410,note-sale,100,52,7/29/2021
F5D410,executive-appointment,100,54,7/29/2021
F5D410,note-sale,100,52,7/29/2021
F5D410,public-offering,100,43,7/29/2021
F6DE54,earnings,100,50,7/29/2021
F6E248,earnings,100,50,7/29/2021
F7D8AE,earnings,100,50,7/29/2021
F7FCA4,earnings,100,50,7/29/2021
F7FCA4,earnings,100,50,7/29/2021
F7FCA4,earnings,100,50,7/29/2021
F7FCA4,earnings,100,50,7/29/2021
F80389,earnings,100,50,7/29/2021
F88147,legal-issues-defendant,100,22,7/29/2021
FC1B7B,earnings,100,50,7/29/2021
FC9869,earnings,100,50,7/29/2021
FC9869,earnings,100,50,7/29/2021
FD4588,earnings,100,50,7/29/2021
FD4588,earnings,100,50,7/29/2021
FD4588,earnings,100,50,7/29/2021
FD4588,earnings,100,50,7/29/2021
FD4BBE,earnings,100,50,7/29/2021
FD4BBE,earnings,100,50,7/29/2021
FD4BBE,earnings,100,50,7/29/2021
FD554E,conference-call,100,50,7/29/2021
FD6926,earnings,100,50,7/29/2021
FD6926,earnings,100,50,7/29/2021
FD6926,earnings,100,50,7/29/2021
FD6926,earnings,100,50,7/29/2021
FD6926,earnings,100,50,7/29/2021
FD6926,dividend,100,50,7/29/2021
FD9526,earnings,100,50,7/29/2021
FDF1C0,earnings,100,50,7/29/2021
FDF799,revenue-up,100,86,7/29/2021
FDF799,revenue-up,100,86,7/29/2021
FDF799,revenue-up,100,86,7/29/2021
FF5413,earnings-positive,100,69,7/29/2021
FF5413,earnings-positive,100,69,7/29/2021
43862,earnings,100,50,7/30/2021
48590,legal-issues-defendant,100,22,7/30/2021
51332,earnings-up,100,93,7/30/2021
053EFF,product-release,100,64,7/30/2021
0624BE,earnings,100,50,7/30/2021
07C69F,acquisition-interest-acquirer,100,46,7/30/2021
0C2A0D,earnings,100,50,7/30/2021
0FDE97,earnings,100,50,7/30/2021
0FDE97,earnings,100,50,7/30/2021
0FDE97,earnings,100,50,7/30/2021
0FDE97,earnings,100,50,7/30/2021
0FDE97,earnings,100,50,7/30/2021
0FDE97,earnings,100,50,7/30/2021
0FDE97,earnings,100,50,7/30/2021
0FE3A6,conference-call,100,50,7/30/2021
139303,dividend-up,100,81,7/30/2021
180DA0,executive-appointment,100,54,7/30/2021
19C105,earnings,100,50,7/30/2021
19C105,earnings,100,50,7/30/2021
19C105,earnings,100,50,7/30/2021
19C105,dividend,100,50,7/30/2021
1AB023,conference-call,100,50,7/30/2021
1AB023,conference-call,100,50,7/30/2021
1AB023,conference-call,100,50,7/30/2021
1D943E,dividend,100,50,7/30/2021
1F43A1,earnings,100,50,7/30/2021
1FE7F0,earnings,100,50,7/30/2021
1FE7F0,earnings,100,50,7/30/2021
1FE7F0,earnings,100,50,7/30/2021
1FE7F0,earnings,100,50,7/30/2021
26D8ED,earnings,100,50,7/30/2021
272472,dividend,100,50,7/30/2021
275300,conference-participant,100,50,7/30/2021
28AF37,earnings,100,50,7/30/2021
2A1009,acquisition-acquiree,100,76,7/30/2021
2AE625,earnings,100,50,7/30/2021
2CB4C9,dividend,100,50,7/30/2021
2D643C,dividend-up,100,81,7/30/2021
2DDB22,earnings,100,50,7/30/2021
2E61CC,earnings,100,50,7/30/2021
2F7474,executive-appointment,100,54,7/30/2021
32CB22,note-sale,100,52,7/30/2021
32CB22,note-sale,100,52,7/30/2021
338544,earnings,100,50,7/30/2021
353DBB,earnings,100,50,7/30/2021
353DBB,earnings,100,50,7/30/2021
353DBB,earnings,100,50,7/30/2021
3.88E+02,earnings,100,50,7/30/2021
3B37F7,note-sale,100,52,7/30/2021
423279,dividend,100,50,7/30/2021
43F4A8,executive-appointment,100,54,7/30/2021
442587,business-contract,100,69,7/30/2021
49914B,buybacks,100,74,7/30/2021
4B49CF,award,100,58,7/30/2021
4B5054,earnings,100,50,7/30/2021
4E6F5A,legal-issues-defendant,100,22,7/30/2021
50070E,business-contract,100,69,7/30/2021
50070E,business-contract,100,69,7/30/2021
504FE2,dividend,100,50,7/30/2021
52B567,earnings,100,50,7/30/2021
5675EB,dividend,100,50,7/30/2021
586BD7,earnings,100,50,7/30/2021
586BD7,executive-appointment,100,54,7/30/2021
5A423F,conference-participant,100,50,7/30/2021
62A48D,conference-call,100,50,7/30/2021
665D7D,earnings,100,50,7/30/2021
665D7D,legal-issues-dismissed-defendant,100,79,7/30/2021
665D7D,legal-issues-dismissed-defendant,100,79,7/30/2021
665D7D,legal-issues-dismissed-defendant,100,79,7/30/2021
68BA15,acquisition-interest-acquiree,100,82,7/30/2021
698FF9,dividend,100,50,7/30/2021
6AACDD,legal-issues-defendant,100,22,7/30/2021
6B0E45,dividend,100,50,7/30/2021
6BBCBA,conference-call,100,50,7/30/2021
6E7060,dividend,100,50,7/30/2021
6E8349,earnings,100,50,7/30/2021
6EB9DA,earnings,100,50,7/30/2021
6EB9DA,earnings,100,50,7/30/2021
6EB9DA,earnings,100,50,7/30/2021
6EB9DA,earnings,100,50,7/30/2021
719477,partnership,100,61,7/30/2021
72EF75,dividend,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
767F86,earnings,100,50,7/30/2021
76BD96,dividend-up,100,81,7/30/2021
76F067,dividend,100,50,7/30/2021
789ADD,earnings,100,50,7/30/2021
789ADD,earnings,100,50,7/30/2021
789ADD,earnings,100,50,7/30/2021
789ADD,earnings,100,50,7/30/2021
7B4B91,earnings,100,50,7/30/2021
82B57E,dividend,100,50,7/30/2021
83E0AC,conference-call,100,50,7/30/2021
84920B,earnings,100,50,7/30/2021
84AB66,earnings-positive,100,69,7/30/2021
850779,dividend,100,50,7/30/2021
88193E,regulatory-product-approval-granted,100,81,7/30/2021
88193E,regulatory-product-approval-granted,100,81,7/30/2021
8A8E41,partnership,100,61,7/30/2021
8DCF18,conference-participant,100,50,7/30/2021
8FCA78,earnings,100,50,7/30/2021
918D6D,conference-call,100,50,7/30/2021
93AD2E,executive-resignation,100,44,7/30/2021
940C3D,buybacks,100,74,7/30/2021
940C3D,dividend,100,50,7/30/2021
94637C,regulatory-product-approval-granted,100,81,7/30/2021
950CDB,product-price-raise,100,57,7/30/2021
9.65E+07,conference-call,100,50,7/30/2021
968103,dividend-up,100,81,7/30/2021
971334,conference-call,100,50,7/30/2021
9.74E+08,earnings,100,50,7/30/2021
97B027,dividend,100,50,7/30/2021
9AF3DC,dividend,100,50,7/30/2021
9D6A24,dividend,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9E9147,earnings,100,50,7/30/2021
9F5997,conference-participant,100,50,7/30/2021
9F5CBB,dividend,100,50,7/30/2021
A2CA3F,earnings,100,50,7/30/2021
A2CA3F,dividend,100,50,7/30/2021
A3800A,earnings,100,50,7/30/2021
A7F0A5,earnings,100,50,7/30/2021
A806FA,dividend,100,50,7/30/2021
AA1EAA,public-offering,100,43,7/30/2021
AAEE21,public-offering,100,43,7/30/2021
AE7D16,earnings,100,50,7/30/2021
AEEB76,executive-appointment,100,54,7/30/2021
B1B10C,earnings-up,100,68,7/30/2021
B1B10C,earnings,100,50,7/30/2021
B1B10C,earnings,100,50,7/30/2021
B1B10C,earnings,100,50,7/30/2021
B1B10C,earnings,100,50,7/30/2021
B2AA0A,earnings-positive,100,69,7/30/2021
B2AA0A,regulatory-stress-test,100,50,7/30/2021
B3A166,conference-call,100,50,7/30/2021
B4528F,conference-call,100,50,7/30/2021
B508E5,conference-participant,100,50,7/30/2021
B77F14,earnings,100,50,7/30/2021
B77F14,earnings,100,50,7/30/2021
B7EB38,earnings,100,50,7/30/2021
BB02FB,earnings,100,50,7/30/2021
BBBB41,conference-participant,100,50,7/30/2021
BC3AD2,executive-appointment,100,54,7/30/2021
C15DB3,conference-participant,100,50,7/30/2021
C3BCD5,earnings,100,50,7/30/2021
C65004,acquisition-regulatory-scrutiny-acquiree,100,38,7/30/2021
CBA475,executive-appointment,100,54,7/30/2021
CD2A4D,conference-call,100,50,7/30/2021
CF351E,earnings,100,50,7/30/2021
CF351E,earnings,100,50,7/30/2021
CF351E,earnings,100,50,7/30/2021
CFE5BE,dividend,100,50,7/30/2021
D11C1C,conference-call,100,50,7/30/2021
D1C26F,earnings,100,50,7/30/2021
D296C6,earnings,100,50,7/30/2021
D3FD6D,revenue-up,100,69,7/30/2021
D3FD6D,earnings,100,50,7/30/2021
D3FD6D,earnings,100,50,7/30/2021
D3FD6D,earnings,100,50,7/30/2021
D54E62,earnings,100,50,7/30/2021
D54E62,earnings,100,50,7/30/2021
D54E62,earnings,100,50,7/30/2021
D54E62,earnings,100,50,7/30/2021
D54E62,earnings,100,50,7/30/2021
D598E7,earnings,100,50,7/30/2021
D78CCD,earnings,100,50,7/30/2021
D78CCD,earnings,100,50,7/30/2021
D78CCD,earnings,100,50,7/30/2021
D78CCD,earnings,100,50,7/30/2021
D78CCD,earnings,100,50,7/30/2021
D854F3,earnings,100,50,7/30/2021
D88EF3,earnings,100,50,7/30/2021
D88EF3,earnings,100,50,7/30/2021
D88EF3,earnings,100,50,7/30/2021
D88EF3,earnings,100,50,7/30/2021
D88EF3,earnings,100,50,7/30/2021
D88EF3,earnings,100,50,7/30/2021
DA0A9E,earnings,100,50,7/30/2021
DB23C8,earnings,100,50,7/30/2021
DB23C8,earnings,100,50,7/30/2021
DB23C8,earnings,100,50,7/30/2021
DD1BA1,product-price-cut,100,49,7/30/2021
DE5611,dividend,100,50,7/30/2021
E13782,patient-enrollment-complete,100,64,7/30/2021
E3E68E,spin-off,100,58,7/30/2021
E3E68E,spin-off,100,58,7/30/2021
E6C8DC,legal-issues-defendant,100,22,7/30/2021
E70531,earnings,100,50,7/30/2021
E70531,earnings,100,50,7/30/2021
E70531,earnings,100,50,7/30/2021
E70531,earnings,100,50,7/30/2021
E70531,earnings,100,50,7/30/2021
E70531,earnings,100,50,7/30/2021
EB6965,earnings,100,50,7/30/2021
EB6965,earnings,100,50,7/30/2021
EB6965,earnings,100,50,7/30/2021
EB6965,earnings,100,50,7/30/2021
EB6965,earnings,100,50,7/30/2021
EB6965,earnings,100,50,7/30/2021
ED2EFD,earnings,100,50,7/30/2021
ED9576,dividend,100,50,7/30/2021
EE6F1C,dividend,100,50,7/30/2021
EEBCEF,dividend,100,50,7/30/2021
F1529C,earnings,100,50,7/30/2021
F1529C,earnings,100,50,7/30/2021
F2BC3D,acquisition-acquirer,100,49,7/30/2021
F31B13,earnings-up,100,73,7/30/2021
F3FCC3,dividend,100,50,7/30/2021
F5C78B,dividend,100,50,7/30/2021
FD0CA4,dividend,100,50,7/30/2021
FF227B,earnings,100,50,7/30/2021
FF4343,dividend,100,50,7/30/2021
FF4BA4,earnings-up,100,68,7/30/2021
FF4BA4,earnings-up,100,68,7/30/2021
FF4BA4,earnings,100,50,7/30/2021
FF4BA4,earnings,100,50,7/30/2021
FF4BA4,earnings,100,50,7/30/2021
FF4BA4,earnings,100,50,7/30/2021
FF6644,dividend,100,50,7/30/2021
4E6F5A,legal-issues-defendant,100,22,7/31/2021
54512F,legal-issues-defendant,100,22,7/31/2021
7E62B5,legal-issues-defendant,100,22,7/31/2021
8B3B0E,legal-issues-defendant,100,22,7/31/2021
8EEA28,legal-issues-defendant,100,22,7/31/2021
A02FB1,legal-issues-defendant,100,22,7/31/2021
B08954,legal-issues-defendant,100,22,7/31/2021
C65004,legal-issues-defendant,100,22,7/31/2021
E393B0,legal-issues-defendant,100,22,7/31/2021
E6C8DC,legal-issues-defendant,100,22,7/31/2021
7A3633,earnings,100,50,8/1/2021
00E601,operating-earnings,100,50,8/2/2021
02870F,earnings,100,50,8/2/2021
02870F,earnings,100,50,8/2/2021
02870F,earnings,100,50,8/2/2021
02870F,earnings,100,50,8/2/2021
02ACBD,conference-call,100,50,8/2/2021
095A04,executive-appointment,100,54,8/2/2021
09DE1F,earnings,100,50,8/2/2021
09DE1F,partnership,100,61,8/2/2021
0A6824,dividend,100,50,8/2/2021
0A748B,earnings,100,50,8/2/2021
0B7375,conference-call,100,50,8/2/2021
0BF528,earnings,100,50,8/2/2021
0BF528,executive-appointment,100,54,8/2/2021
0C6293,conference-call,100,50,8/2/2021
0CE7F6,acquisition-acquirer,100,49,8/2/2021
0CE7F6,acquisition-acquirer,100,49,8/2/2021
0E439E,dividend,100,50,8/2/2021
0FE3A6,earnings,100,50,8/2/2021
10100E,earnings,100,50,8/2/2021
125212,conference-call,100,50,8/2/2021
1272B3,earnings,100,50,8/2/2021
12731D,conference-call,100,50,8/2/2021
12731D,conference-call,100,50,8/2/2021
131443,business-contract,100,69,8/2/2021
131443,business-contract,100,69,8/2/2021
15901B,product-release,100,64,8/2/2021
168A5D,partnership,100,61,8/2/2021
184866,clinical-trials-start,100,64,8/2/2021
1D9E55,earnings,100,50,8/2/2021
1DEBBE,acquisition-completed-acquirer,100,49,8/2/2021
1DEBBE,acquisition-completed-acquirer,100,49,8/2/2021
1E83DE,conference-participant,100,50,8/2/2021
1F716B,executive-resignation,100,44,8/2/2021
221783,acquisition-completed-acquirer,100,49,8/2/2021
221AD7,buybacks,100,74,8/2/2021
241AF7,earnings,100,50,8/2/2021
24C48B,unit-acquisition-acquirer,100,49,8/2/2021
25102A,stake-acquirer,100,48,8/2/2021
251988,business-contract,100,69,8/2/2021
273BA3,executive-appointment,100,54,8/2/2021
27BFA1,dividend,100,50,8/2/2021
2920D5,earnings,100,50,8/2/2021
292388,earnings,100,50,8/2/2021
2.90E+62,earnings,100,50,8/2/2021
2.90E+62,earnings,100,50,8/2/2021
2.90E+62,earnings,100,50,8/2/2021
2.90E+62,earnings,100,50,8/2/2021
2.90E+62,earnings,100,50,8/2/2021
2.90E+62,earnings,100,50,8/2/2021
2A6DBE,regulatory-product-approval-granted,100,81,8/2/2021
2BDC1C,earnings,100,50,8/2/2021
2DA92D,executive-appointment,100,54,8/2/2021
2EBC0B,award,100,58,8/2/2021
2EC172,acquisition-acquirer,100,49,8/2/2021
2F94A5,dividend,100,50,8/2/2021
306623,earnings,100,50,8/2/2021
30AB63,earnings,100,50,8/2/2021
339F20,note-sale,100,52,8/2/2021
3587B4,unit-acquisition-completed-acquiree,100,67,8/2/2021
3587B4,unit-acquisition-completed-acquiree,100,67,8/2/2021
3587B4,unit-acquisition-completed-acquiree,100,67,8/2/2021
36C09B,earnings,100,50,8/2/2021
37E18B,executive-appointment,100,54,8/2/2021
382EAE,acquisition-completed-acquirer,100,49,8/2/2021
384CD3,business-contract,100,69,8/2/2021
396D7C,conference-participant,100,50,8/2/2021
39FB23,facility-upgrade,100,65,8/2/2021
3BB7D3,regulatory-product-approval-granted,100,81,8/2/2021
3BB7D3,regulatory-product-approval-granted,100,81,8/2/2021
3BB7D3,public-offering,100,43,8/2/2021
3C7F5F,dividend,100,50,8/2/2021
3DC887,earnings,100,50,8/2/2021
3DCECC,conference-participant,100,50,8/2/2021
3DE4D1,dividend,100,50,8/2/2021
3ED92D,acquisition-acquirer,100,49,8/2/2021
3F1C69,earnings,100,50,8/2/2021
3F96D5,conference-call,100,50,8/2/2021
407878,partnership,100,61,8/2/2021
407878,executive-appointment,100,54,8/2/2021
407878,earnings,100,50,8/2/2021
414FFF,unit-acquisition-acquiree,100,76,8/2/2021
417BF9,conference-call,100,50,8/2/2021
417BF9,conference-call,100,50,8/2/2021
41C36B,executive-appointment,100,54,8/2/2021
41C528,conference-call,100,50,8/2/2021
425BDC,product-price-raise,100,57,8/2/2021
4290EF,earnings,100,50,8/2/2021
44A4FC,partnership,100,61,8/2/2021
44A4FC,partnership,100,61,8/2/2021
44ED36,earnings,100,50,8/2/2021
44ED36,earnings,100,50,8/2/2021
44ED36,earnings,100,50,8/2/2021
44ED36,earnings,100,50,8/2/2021
44ED36,earnings,100,50,8/2/2021
44ED36,earnings,100,50,8/2/2021
490D4B,earnings-positive,100,69,8/2/2021
494EB9,earnings,100,50,8/2/2021
4BBA23,unit-acquisition-completed-acquirer,100,49,8/2/2021
4BDCA7,conference-participant,100,50,8/2/2021
4C1FA1,earnings,100,50,8/2/2021
4C1FA1,earnings,100,50,8/2/2021
4C1FA1,earnings,100,50,8/2/2021
4C1FA1,earnings,100,50,8/2/2021
4C1FA1,earnings,100,50,8/2/2021
4C1FA1,earnings,100,50,8/2/2021
4C31F3,earnings,100,50,8/2/2021
4C6C63,note-sale,100,52,8/2/2021
4C6C63,public-offering,100,43,8/2/2021
4D229C,earnings,100,50,8/2/2021
4E6F5A,legal-issues-defendant,100,22,8/2/2021
504FE2,government-contract,100,69,8/2/2021
50D1EC,executive-appointment,100,54,8/2/2021
546A27,earnings,100,50,8/2/2021
55C9B5,partnership,100,61,8/2/2021
55CD6F,executive-appointment,100,54,8/2/2021
5D0337,earnings,100,50,8/2/2021
5D41E4,earnings,100,50,8/2/2021
615B6D,investment-recipient,100,73,8/2/2021
619882,conference-organizer,100,57,8/2/2021
619882,earnings,100,50,8/2/2021
61A586,earnings,100,50,8/2/2021
6391C2,patient-enrollment-complete,100,64,8/2/2021
64E615,conference-participant,100,50,8/2/2021
65D0AA,regulatory-product-approval-granted,100,81,8/2/2021
665618,conference-participant,100,50,8/2/2021
66749D,earnings-up,100,68,8/2/2021
66749D,earnings-up,100,68,8/2/2021
66749D,earnings-up,100,68,8/2/2021
66749D,earnings-up,100,68,8/2/2021
66749D,earnings-up,100,68,8/2/2021
673C9A,conference-participant,100,50,8/2/2021
68BA15,acquisition-acquirer,100,49,8/2/2021
68BA15,earnings,100,50,8/2/2021
6AACDD,legal-issues-defendant,100,22,8/2/2021
6B5379,acquisition-acquirer,100,49,8/2/2021
6B6375,earnings,100,50,8/2/2021
6BD606,earnings,100,50,8/2/2021
6D3B7B,dividend,100,50,8/2/2021
6D4636,earnings,100,50,8/2/2021
6DBBBC,earnings,100,50,8/2/2021
6DBBBC,earnings,100,50,8/2/2021
6-Dec-05,partnership,100,61,8/2/2021
6-Dec-05,clinical-trials-positive,100,87,8/2/2021
704B78,earnings,100,50,8/2/2021
70CA28,conference-participant,100,50,8/2/2021
729368,earnings,100,50,8/2/2021
7732C2,conference-participant,100,50,8/2/2021
790C34,revenue-up,100,69,8/2/2021
790C34,revenue-up,100,69,8/2/2021
790C34,revenue-up,100,69,8/2/2021
790C34,revenue-up,100,69,8/2/2021
790C34,revenue-up,100,69,8/2/2021
790C34,revenue-up,100,69,8/2/2021
797C20,earnings,100,50,8/2/2021
7A2A49,conference-participant,100,50,8/2/2021
7A3633,acquisition-interest-acquirer,100,46,8/2/2021
7ADE57,partnership,100,61,8/2/2021
7BC92D,earnings,100,50,8/2/2021
7C4168,earnings,100,50,8/2/2021
7C790D,earnings,100,50,8/2/2021
7D7716,earnings,100,50,8/2/2021
7D7716,earnings,100,50,8/2/2021
7D7716,earnings,100,50,8/2/2021
7D7716,earnings,100,50,8/2/2021
7D7716,earnings,100,50,8/2/2021
7E62B5,legal-issues-defendant,100,22,8/2/2021
7F3669,earnings,100,50,8/2/2021
7FDE1C,conference-call,100,50,8/2/2021
8.10E+205,earnings,100,50,8/2/2021
83066C,earnings,100,50,8/2/2021
83066C,earnings,100,50,8/2/2021
85AD00,unit-acquisition-acquirer,100,49,8/2/2021
860AB6,earnings,100,50,8/2/2021
8.79E+06,earnings,100,50,8/2/2021
87B81A,acquisition-acquirer,100,49,8/2/2021
8802B4,earnings,100,50,8/2/2021
8A8E41,product-release,100,64,8/2/2021
8AA108,clinical-trials-start,100,64,8/2/2021
8AC740,earnings,100,50,8/2/2021
8C311A,conference-participant,100,50,8/2/2021
8EF425,public-offering,100,43,8/2/2021
8EF425,public-offering,100,43,8/2/2021
8FCA78,dividend,100,50,8/2/2021
8FE7A5,earnings,100,50,8/2/2021
900356,earnings-guidance-up,100,83,8/2/2021
902255,dividend,100,50,8/2/2021
9087B9,earnings,100,50,8/2/2021
913437,earnings,100,50,8/2/2021
92D757,earnings,100,50,8/2/2021
9.36E+10,executive-appointment,100,54,8/2/2021
938D89,earnings,100,50,8/2/2021
93965C,earnings,100,50,8/2/2021
9.39E+69,conference-participant,100,50,8/2/2021
942633,business-contract,100,69,8/2/2021
94983E,earnings,100,50,8/2/2021
9548BB,unit-acquisition-completed-acquiree,100,67,8/2/2021
9548BB,acquisition-completed-acquiree,100,76,8/2/2021
957A07,earnings,100,50,8/2/2021
95DC1F,executive-appointment,100,54,8/2/2021
968B00,earnings-positive,100,69,8/2/2021
968B00,earnings-positive,100,69,8/2/2021
96B4FF,conference-participant,100,50,8/2/2021
97B027,earnings-up,100,68,8/2/2021
97B027,earnings-up,100,68,8/2/2021
97B027,earnings-up,100,68,8/2/2021
97B027,earnings-up,100,68,8/2/2021
98D33E,earnings,100,50,8/2/2021
9B4066,unit-acquisition-acquirer,100,49,8/2/2021
9B71A7,partnership,100,61,8/2/2021
9B730A,conference-call,100,50,8/2/2021
9C3D3C,earnings,100,50,8/2/2021
9C5BA5,earnings,100,50,8/2/2021
9D30A8,conference-participant,100,50,8/2/2021
9D4EC7,earnings-up,100,68,8/2/2021
9D4EC7,earnings-up,100,68,8/2/2021
9D4EC7,earnings-up,100,68,8/2/2021
9D4EC7,earnings-up,100,68,8/2/2021
9D4EC7,earnings-up,100,68,8/2/2021
9D4EC7,earnings-up,100,68,8/2/2021
9F18FA,earnings,100,50,8/2/2021
9F18FA,earnings,100,50,8/2/2021
A01664,earnings-above-expectations,100,88,8/2/2021
A02FB1,legal-issues-defendant,100,22,8/2/2021
A072C4,partnership,100,61,8/2/2021
A0F146,earnings,100,50,8/2/2021
A1EAC8,business-contract,100,69,8/2/2021
A2CAF7,executive-appointment,100,54,8/2/2021
A6D095,conference-participant,100,50,8/2/2021
A6FE1C,business-contract,100,69,8/2/2021
A8B137,executive-appointment,100,54,8/2/2021
AA3AB8,operating-earnings,100,50,8/2/2021
AC7AAE,earnings,100,50,8/2/2021
AD6141,dividend,100,50,8/2/2021
AED6CF,earnings,100,50,8/2/2021
AFF43F,executive-appointment,100,54,8/2/2021
B01111,earnings,100,50,8/2/2021
B01215,conference-call,100,50,8/2/2021
B08954,acquisition-regulatory-approval-acquirer,100,54,8/2/2021
B1FC3B,business-contract,100,69,8/2/2021
B48D6A,partnership,100,61,8/2/2021
B5734D,executive-appointment,100,54,8/2/2021
BB127B,conference-call,100,50,8/2/2021
BB58FF,earnings,100,50,8/2/2021
BB58FF,earnings,100,50,8/2/2021
BB58FF,earnings,100,50,8/2/2021
BB58FF,earnings,100,50,8/2/2021
BB88B6,executive-appointment,100,54,8/2/2021
BC4876,earnings,100,50,8/2/2021
BDEC1E,conference-call,100,50,8/2/2021
BDF2BD,acquisition-completed-acquiree,100,76,8/2/2021
C0030A,acquisition-completed-acquirer,100,49,8/2/2021
C0F70B,earnings,100,50,8/2/2021
C11C46,earnings,100,50,8/2/2021
C2609A,dividend,100,50,8/2/2021
C2DD02,conference-call,100,50,8/2/2021
C45C1F,executive-appointment,100,54,8/2/2021
C564E4,earnings,100,50,8/2/2021
C584BE,earnings,100,50,8/2/2021
C5C0E9,conference-participant,100,50,8/2/2021
C99CC8,earnings,100,50,8/2/2021
C99CC8,earnings,100,50,8/2/2021
C99CC8,earnings,100,50,8/2/2021
C99CC8,earnings,100,50,8/2/2021
CB7AB2,acquisition-acquirer,100,49,8/2/2021
CC0C78,earnings,100,50,8/2/2021
CEDFD5,clinical-trials,100,56,8/2/2021
CEDFD5,clinical-trials,100,56,8/2/2021
CEDFD5,clinical-trials,100,56,8/2/2021
CEDFD5,clinical-trials,100,56,8/2/2021
CF073E,conference-participant,100,50,8/2/2021
CFB6CA,executive-appointment,100,54,8/2/2021
CFF97C,business-contract,100,69,8/2/2021
CFF97C,business-contract,100,69,8/2/2021
CFF97C,business-contract,100,69,8/2/2021
CFF97C,business-contract,100,69,8/2/2021
D06996,earnings,100,50,8/2/2021
D18AFC,conference-participant,100,50,8/2/2021
D4070C,earnings,100,50,8/2/2021
D4463B,executive-appointment,100,54,8/2/2021
D54E62,executive-resignation,100,44,8/2/2021
D54E62,executive-appointment,100,54,8/2/2021
D6144F,conference-call,100,50,8/2/2021
D70365,dividend,100,50,8/2/2021
D70365,earnings,100,50,8/2/2021
D77F7E,earnings,100,50,8/2/2021
D88EF3,note-sale,100,52,8/2/2021
D8DA3D,regulatory-investigation-completed,100,50,8/2/2021
D9164D,earnings,100,50,8/2/2021
D9E036,earnings,100,50,8/2/2021
DC6EF3,stake-acquirer,100,48,8/2/2021
DD1BA1,partnership,100,61,8/2/2021
DD682D,asset-sale,100,62,8/2/2021
DD9E41,earnings,100,50,8/2/2021
DD9E41,earnings,100,50,8/2/2021
DD9E41,earnings,100,50,8/2/2021
DD9E41,earnings,100,50,8/2/2021
DD9E41,earnings,100,50,8/2/2021
DD9E41,earnings,100,50,8/2/2021
DEF058,unit-acquisition-completed-acquirer,100,49,8/2/2021
DF1F7A,conference-call,100,50,8/2/2021
DFADDB,earnings,100,50,8/2/2021
E09E2B,partnership,100,61,8/2/2021
E0E4B7,executive-appointment,100,54,8/2/2021
E15736,earnings,100,50,8/2/2021
E15736,earnings,100,50,8/2/2021
E393B0,legal-issues-defendant,100,22,8/2/2021
E3E68E,spin-off,100,58,8/2/2021
E3E68E,spin-off,100,58,8/2/2021
E3E68E,trading-listing,100,61,8/2/2021
E3E68E,trading-listing,100,61,8/2/2021
E48E44,operating-earnings,100,50,8/2/2021
E7BF32,earnings,100,50,8/2/2021
E7BF32,earnings,100,50,8/2/2021
E8F0E2,executive-appointment,100,54,8/2/2021
E90C84,acquisition-acquirer,100,49,8/2/2021
E9C7C0,executive-appointment,100,54,8/2/2021
ED5171,dividend,100,50,8/2/2021
EEEA9F,acquisition-completed-acquirer,100,49,8/2/2021
EF5BED,business-contract,100,69,8/2/2021
F05B1B,earnings,100,50,8/2/2021
F2BC3D,acquisition-completed-acquirer,100,49,8/2/2021
F32F88,dividend,100,50,8/2/2021
F3816D,conference-participant,100,50,8/2/2021
F42FAE,earnings-positive,100,69,8/2/2021
F44EA2,earnings,100,50,8/2/2021
F58C23,conference-participant,100,50,8/2/2021
F5D059,unit-acquisition-acquirer,100,49,8/2/2021
F8BA6C,conference-call,100,50,8/2/2021
FC1A6E,earnings-guidance-up,100,83,8/2/2021
FE89E0,legal-issues-defendant,100,22,8/2/2021
FE89E0,legal-issues-defendant,100,22,8/2/2021
FE89E0,legal-issues-defendant,100,22,8/2/2021
9397,executive-appointment,100,54,8/3/2021
0157B1,product-release,100,64,8/3/2021
20751,conference-participant,100,50,8/3/2021
02ACBD,executive-appointment,100,54,8/3/2021
0325B7,conference-call,100,50,8/3/2021
033B58,earnings,100,50,8/3/2021
036C6F,conference-call,100,50,8/3/2021
03B8CF,partnership,100,61,8/3/2021
48590,earnings,100,50,8/3/2021
054B55,dividend,100,50,8/3/2021
054B55,dividend,100,50,8/3/2021
054B55,earnings,100,50,8/3/2021
06A456,earnings,100,50,8/3/2021
06C826,conference-call,100,50,8/3/2021
070B45,earnings,100,50,8/3/2021
07C69F,acquisition-interest-acquirer,100,46,8/3/2021
09062E,earnings,100,50,8/3/2021
091B6C,conference-participant,100,50,8/3/2021
091B6C,conference-participant,100,50,8/3/2021
98977,patient-enrollment-complete,100,64,8/3/2021
099C88,partnership,100,61,8/3/2021
09F623,earnings-up,100,68,8/3/2021
0A77DB,earnings-up,100,68,8/3/2021
0A77DB,earnings,100,50,8/3/2021
0A77DB,earnings,100,50,8/3/2021
0A9D0A,dividend,100,50,8/3/2021
0AD2E3,earnings-up,100,68,8/3/2021
0AD2E3,earnings-up,100,68,8/3/2021
0B400D,earnings,100,50,8/3/2021
0B400D,earnings,100,50,8/3/2021
0B400D,earnings,100,50,8/3/2021
0CE204,earnings,100,50,8/3/2021
0DBB81,earnings,100,50,8/3/2021
0E499E,revenue-up,100,69,8/3/2021
0E499E,revenue-up,100,69,8/3/2021
0E499E,revenue-up,100,69,8/3/2021
0E5223,earnings,100,50,8/3/2021
0F2BC9,facility-upgrade,100,65,8/3/2021
1065BC,earnings,100,50,8/3/2021
108A2B,operating-earnings,100,50,8/3/2021
108FDA,earnings-up,100,68,8/3/2021
125212,earnings,100,50,8/3/2021
1272B3,conference-participant,100,50,8/3/2021
12A3A3,conference-participant,100,50,8/3/2021
12E454,partnership,100,61,8/3/2021
131443,earnings,100,50,8/3/2021
131443,earnings,100,50,8/3/2021
131443,earnings,100,50,8/3/2021
131443,earnings,100,50,8/3/2021
131443,earnings,100,50,8/3/2021
131443,earnings,100,50,8/3/2021
14BA06,operating-earnings,100,50,8/3/2021
14BA33,earnings,100,50,8/3/2021
152AB9,earnings,100,50,8/3/2021
152AB9,earnings,100,50,8/3/2021
152AB9,public-offering,100,43,8/3/2021
152E1D,operating-earnings,100,50,8/3/2021
157CC1,earnings,100,50,8/3/2021
159AE4,merger-regulatory-approval,100,81,8/3/2021
15B10D,earnings,100,50,8/3/2021
16AAE0,dividend,100,50,8/3/2021
1834C0,earnings,100,50,8/3/2021
188394,earnings-meet-expectations,100,59,8/3/2021
1A5D5D,earnings,100,50,8/3/2021
1AC649,acquisition-acquiree,100,76,8/3/2021
1AC649,acquisition-acquiree,100,76,8/3/2021
1AC649,acquisition-acquiree,100,76,8/3/2021
1AC649,acquisition-acquiree,100,76,8/3/2021
1AC649,merger-regulatory-scrutiny,100,37,8/3/2021
1CDD1C,earnings,100,50,8/3/2021
1D943E,conference-participant,100,50,8/3/2021
1DE526,executive-appointment,100,54,8/3/2021
1E68B3,earnings,100,50,8/3/2021
1F08A6,earnings,100,50,8/3/2021
1F9258,executive-appointment,100,54,8/3/2021
1F9D90,earnings,100,50,8/3/2021
214051,partnership,100,61,8/3/2021
21F9CA,revenues,100,50,8/3/2021
221783,executive-appointment,100,54,8/3/2021
2571FA,earnings,100,50,8/3/2021
2571FA,earnings,100,50,8/3/2021
2571FA,earnings,100,50,8/3/2021
2571FA,earnings,100,50,8/3/2021
26F31D,earnings,100,50,8/3/2021
26F31D,earnings,100,50,8/3/2021
26F31D,earnings,100,50,8/3/2021
26F31D,earnings,100,50,8/3/2021
270305,earnings,100,50,8/3/2021
270305,earnings,100,50,8/3/2021
270305,earnings,100,50,8/3/2021
270305,earnings,100,50,8/3/2021
270305,earnings,100,50,8/3/2021
273BA3,partnership,100,61,8/3/2021
28B730,earnings,100,50,8/3/2021
2C35B5,conference-participant,100,50,8/3/2021
2C7505,earnings,100,50,8/3/2021
2CC71C,earnings,100,50,8/3/2021
2E0496,earnings,100,50,8/3/2021
2E0496,earnings,100,50,8/3/2021
2EB04E,earnings,100,50,8/3/2021
2EB04E,earnings,100,50,8/3/2021
2EB04E,earnings,100,50,8/3/2021
2EB04E,earnings,100,50,8/3/2021
2EC172,earnings,100,50,8/3/2021
2EC172,earnings,100,50,8/3/2021
2EC172,earnings,100,50,8/3/2021
2EC172,earnings,100,50,8/3/2021
2EC172,earnings,100,50,8/3/2021
2EC172,earnings,100,50,8/3/2021
2F6782,earnings-up,100,68,8/3/2021
2F6782,earnings-up,100,68,8/3/2021
2F6782,earnings-up,100,68,8/3/2021
2F6782,earnings-up,100,68,8/3/2021
2F6782,earnings-up,100,68,8/3/2021
2F6782,earnings-up,100,68,8/3/2021
2F9304,partnership,100,61,8/3/2021
2F960F,earnings,100,50,8/3/2021
31803E,earnings,100,50,8/3/2021
31DB20,earnings,100,50,8/3/2021
3390DE,earnings,100,50,8/3/2021
33A0F1,executive-appointment,100,54,8/3/2021
343996,earnings,100,50,8/3/2021
343996,earnings,100,50,8/3/2021
34A959,earnings,100,50,8/3/2021
3587B4,partnership,100,61,8/3/2021
35F4B5,earnings-up,100,68,8/3/2021
35F4B5,earnings-up,100,68,8/3/2021
367E1C,earnings,100,50,8/3/2021
373B06,earnings,100,50,8/3/2021
3798B9,award,100,58,8/3/2021
384CD3,earnings,100,50,8/3/2021
385DD4,earnings,100,50,8/3/2021
389CFB,earnings,100,50,8/3/2021
38C46F,dividend,100,50,8/3/2021
3A3447,acquisition-acquirer,100,49,8/3/2021
3BA1BF,conference-call,100,50,8/3/2021
3BE00F,earnings,100,50,8/3/2021
3BE00F,earnings,100,50,8/3/2021
3BE00F,earnings,100,50,8/3/2021
3BE00F,earnings,100,50,8/3/2021
3C7F5F,business-contract,100,69,8/3/2021
3D6933,pretax-earnings-negative,100,33,8/3/2021
3D7971,dividend,100,50,8/3/2021
3ED92D,note-sale,100,52,8/3/2021
3ED92D,note-sale,100,52,8/3/2021
3FACA7,earnings,100,50,8/3/2021
4.00E+163,earnings,100,50,8/3/2021
4135F7,executive-appointment,100,54,8/3/2021
416C55,note-sale,100,52,8/3/2021
41EC04,earnings,100,50,8/3/2021
41EC04,earnings,100,50,8/3/2021
41EC04,earnings,100,50,8/3/2021
41EC04,earnings,100,50,8/3/2021
467F2C,earnings,100,50,8/3/2021
46A16E,earnings,100,50,8/3/2021
47B4CC,business-contract,100,69,8/3/2021
47FCF2,earnings,100,50,8/3/2021
47FCF2,earnings,100,50,8/3/2021
47FCF2,earnings,100,50,8/3/2021
47FCF2,earnings,100,50,8/3/2021
47FCF2,earnings,100,50,8/3/2021
47FCF2,earnings,100,50,8/3/2021
47FCF2,earnings,100,50,8/3/2021
47FCF2,earnings,100,50,8/3/2021
47FCF2,earnings,100,50,8/3/2021
49A344,earnings,100,50,8/3/2021
49A344,earnings,100,50,8/3/2021
49A344,earnings,100,50,8/3/2021
4A2457,earnings,100,50,8/3/2021
4A2457,earnings,100,50,8/3/2021
4A2457,earnings,100,50,8/3/2021
4A2457,earnings,100,50,8/3/2021
4A2457,earnings,100,50,8/3/2021
4A2457,earnings,100,50,8/3/2021
4A6F00,partnership,100,61,8/3/2021
4B3676,conference-participant,100,50,8/3/2021
4BF3D6,conference-participant,100,50,8/3/2021
4C2F17,conference-participant,100,50,8/3/2021
4C92B9,earnings-guidance-up,100,83,8/3/2021
4C92B9,buybacks,100,74,8/3/2021
4CDA2B,earnings,100,50,8/3/2021
4D72C8,earnings,100,50,8/3/2021
4D72C8,earnings,100,50,8/3/2021
4E3D15,operating-earnings,100,50,8/3/2021
4EE14A,earnings,100,50,8/3/2021
4EE14A,earnings,100,50,8/3/2021
4EE14A,earnings,100,50,8/3/2021
4EE14A,earnings,100,50,8/3/2021
4F783B,earnings,100,50,8/3/2021
4F783B,earnings,100,50,8/3/2021
4F783B,earnings,100,50,8/3/2021
4F783B,earnings,100,50,8/3/2021
4F783B,earnings,100,50,8/3/2021
4F783B,earnings,100,50,8/3/2021
4F783B,earnings,100,50,8/3/2021
504FE2,earnings,100,50,8/3/2021
513A86,earnings,100,50,8/3/2021
520632,regulatory-product-approval-granted,100,81,8/3/2021
5340D0,earnings,100,50,8/3/2021
54512F,legal-issues-defendant,100,22,8/3/2021
54A713,earnings,100,50,8/3/2021
54B889,earnings,100,50,8/3/2021
54F1D2,earnings,100,50,8/3/2021
55C9B5,partnership,100,61,8/3/2021
56277A,earnings,100,50,8/3/2021
56765E,earnings,100,50,8/3/2021
56B7C1,earnings,100,50,8/3/2021
56EFC7,conference-participant,100,50,8/3/2021
56FB7C,earnings,100,50,8/3/2021
577033,earnings,100,50,8/3/2021
57EF50,earnings,100,50,8/3/2021
57EF50,earnings,100,50,8/3/2021
57EF50,earnings,100,50,8/3/2021
57EF50,earnings,100,50,8/3/2021
587EDF,earnings,100,50,8/3/2021
594402,conference-participant,100,50,8/3/2021
59A832,earnings,100,50,8/3/2021
59F0B0,merger-regulatory-approval,100,81,8/3/2021
5A53BF,earnings,100,50,8/3/2021
5B3415,earnings,100,50,8/3/2021
5B6C11,earnings,100,50,8/3/2021
5B6C11,executive-appointment,100,54,8/3/2021
5DAF89,earnings,100,50,8/3/2021
5DAF89,earnings,100,50,8/3/2021
5E1DF3,earnings-up,100,68,8/3/2021
5E7E82,product-release,100,64,8/3/2021
5F3E74,earnings,100,50,8/3/2021
5F3E74,earnings,100,50,8/3/2021
6166D1,credit-extension-provider,100,57,8/3/2021
619882,conference-organizer,100,57,8/3/2021
622DBE,earnings,100,50,8/3/2021
62CDDE,earnings,100,50,8/3/2021
633043,earnings,100,50,8/3/2021
6391C2,conference-participant,100,50,8/3/2021
639BD6,revenue-up,100,68,8/3/2021
639BD6,earnings,100,50,8/3/2021
639BD6,earnings,100,50,8/3/2021
64636E,conference-participant,100,50,8/3/2021
64636E,conference-participant,100,50,8/3/2021
64636E,conference-participant,100,50,8/3/2021
657097,unit-acquisition-acquirer,100,49,8/3/2021
65CF8E,dividend,100,50,8/3/2021
65CF8E,dividend,100,50,8/3/2021
66667F,conference-call,100,50,8/3/2021
67B923,earnings,100,50,8/3/2021
6844D2,partnership,100,61,8/3/2021
68BA15,acquisition-interest-acquiree,100,82,8/3/2021
68E3E0,dividend,100,50,8/3/2021
68E6E9,business-combination,100,54,8/3/2021
68E6E9,earnings,100,50,8/3/2021
6A01DF,earnings,100,50,8/3/2021
6AACDD,legal-issues-defendant,100,22,8/3/2021
6B236C,note-sale,100,52,8/3/2021
6BF593,earnings,100,50,8/3/2021
6BF593,earnings,100,50,8/3/2021
6BF593,earnings,100,50,8/3/2021
6BF593,earnings,100,50,8/3/2021
6BF593,earnings,100,50,8/3/2021
6CC55E,earnings,100,50,8/3/2021
6D6B40,earnings,100,50,8/3/2021
6DDA15,earnings,100,50,8/3/2021
6DDA15,earnings,100,50,8/3/2021
6DDA15,earnings,100,50,8/3/2021
6DDA15,earnings,100,50,8/3/2021
6DDA15,earnings,100,50,8/3/2021
6DDA15,earnings,100,50,8/3/2021
6-Dec-05,clinical-trials-start,100,64,8/3/2021
7122EB,conference-participant,100,50,8/3/2021
713810,business-contract,100,69,8/3/2021
719477,earnings,100,50,8/3/2021
724F84,earnings,100,50,8/3/2021
72CB93,earnings,100,50,8/3/2021
73BCBA,conference-participant,100,50,8/3/2021
7.44E+09,earnings,100,50,8/3/2021
747219,dividend,100,50,8/3/2021
752A70,earnings,100,50,8/3/2021
75F982,business-contract,100,69,8/3/2021
75F982,business-contract,100,69,8/3/2021
75F982,business-contract,100,69,8/3/2021
766047,executive-appointment,100,54,8/3/2021
76B926,earnings,100,50,8/3/2021
76D79A,earnings,100,50,8/3/2021
76F067,earnings,100,50,8/3/2021
7734AC,dividend,100,50,8/3/2021
7ACD98,earnings-up,100,68,8/3/2021
7ACD98,earnings,100,50,8/3/2021
7ACD98,earnings,100,50,8/3/2021
7AD81E,earnings,100,50,8/3/2021
7B0BA6,earnings,100,50,8/3/2021
7B0BA6,earnings,100,50,8/3/2021
7B0BA6,earnings,100,50,8/3/2021
7B0BA6,earnings,100,50,8/3/2021
7B0BA6,earnings,100,50,8/3/2021
7B0BA6,earnings,100,50,8/3/2021
7B492C,conference-call,100,50,8/3/2021
7B8CB5,earnings,100,50,8/3/2021
7DD584,conference-participant,100,50,8/3/2021
7F0372,earnings,100,50,8/3/2021
7F3A5F,earnings-up,100,68,8/3/2021
7F3A5F,earnings-up,100,68,8/3/2021
7F3A5F,earnings-up,100,68,8/3/2021
7F3A5F,earnings-up,100,68,8/3/2021
7F3A5F,earnings-up,100,68,8/3/2021
7F9984,earnings,100,50,8/3/2021
7F9BE2,dividend,100,50,8/3/2021
7FD8B9,earnings,100,50,8/3/2021
7FD8B9,buybacks,100,74,8/3/2021
82B57E,earnings,100,50,8/3/2021
8303CD,earnings,100,50,8/3/2021
8377DB,acquisition-completed-acquirer,100,49,8/3/2021
838ADD,executive-appointment,100,54,8/3/2021
85DA04,earnings,100,50,8/3/2021
85DA04,earnings,100,50,8/3/2021
85DA04,earnings,100,50,8/3/2021
85DA04,earnings,100,50,8/3/2021
85DA04,earnings,100,50,8/3/2021
88923D,partnership,100,61,8/3/2021
8A0368,earnings,100,50,8/3/2021
8A0368,earnings,100,50,8/3/2021
8A0368,earnings,100,50,8/3/2021
8A0368,earnings,100,50,8/3/2021
8AB85C,conference-participant,100,50,8/3/2021
8B9B3B,conference-participant,100,50,8/3/2021
8BAA15,business-contract,100,69,8/3/2021
8D4486,partnership,100,61,8/3/2021
8DE74B,earnings,100,50,8/3/2021
8E9CD8,earnings,100,50,8/3/2021
8EEA28,earnings,100,50,8/3/2021
8EF425,public-offering,100,43,8/3/2021
8EF425,public-offering,100,43,8/3/2021
915E7B,earnings,100,50,8/3/2021
92D230,conference-call,100,50,8/3/2021
93D207,business-contract,100,69,8/3/2021
94637C,facility-sale,100,52,8/3/2021
94637C,unit-acquisition-completed-acquiree,100,67,8/3/2021
94637C,unit-acquisition-completed-acquiree,100,67,8/3/2021
9470CC,earnings,100,50,8/3/2021
963A02,conference-participant,100,50,8/3/2021
9.65E+07,earnings,100,50,8/3/2021
9.65E+07,earnings,100,50,8/3/2021
9.65E+07,earnings,100,50,8/3/2021
966ACE,regulatory-product-application,100,69,8/3/2021
966ACE,partnership,100,61,8/3/2021
966ACE,earnings,100,50,8/3/2021
967D92,earnings,100,50,8/3/2021
968966,earnings,100,50,8/3/2021
968966,dividend,100,50,8/3/2021
968B00,dividend,100,50,8/3/2021
96A6CD,conference-participant,100,50,8/3/2021
96BFF4,conference-call,100,50,8/3/2021
96F126,executive-appointment,100,54,8/3/2021
971F7B,unit-acquisition-acquirer,100,49,8/3/2021
980C14,earnings,100,50,8/3/2021
9.86E+03,earnings,100,50,8/3/2021
990AD0,fundraising,100,64,8/3/2021
994468,dividend,100,50,8/3/2021
99DC8D,dividend,100,50,8/3/2021
99DC8D,earnings,100,50,8/3/2021
9A29F4,earnings,100,50,8/3/2021
9BB35A,dividend-up,100,61,8/3/2021
9BB35A,buybacks,100,74,8/3/2021
9BB35A,operating-earnings-positive,100,69,8/3/2021
9BB35A,earnings-per-share,100,50,8/3/2021
9BB35A,earnings-per-share,100,50,8/3/2021
9BB35A,earnings-per-share,100,50,8/3/2021
9BB35A,earnings-per-share,100,50,8/3/2021
9C25FF,earnings,100,50,8/3/2021
9C8BC3,partnership,100,61,8/3/2021
9CA432,earnings,100,50,8/3/2021
9D65C1,conference-participant,100,50,8/3/2021
9E0811,earnings,100,50,8/3/2021
9F5997,earnings,100,50,8/3/2021
A23747,earnings,100,50,8/3/2021
A247F5,business-contract,100,69,8/3/2021
A247F5,earnings-per-share-positive,100,69,8/3/2021
A247F5,earnings-per-share-positive,100,69,8/3/2021
A29DBD,earnings,100,50,8/3/2021
A350C1,operating-earnings,100,50,8/3/2021
A350C1,operating-earnings,100,50,8/3/2021
A350C1,operating-earnings,100,50,8/3/2021
A350C1,operating-earnings,100,50,8/3/2021
A350C1,operating-earnings,100,50,8/3/2021
A41450,earnings,100,50,8/3/2021
A4386C,earnings,100,50,8/3/2021
A4386C,earnings,100,50,8/3/2021
A4386C,earnings,100,50,8/3/2021
A4386C,earnings,100,50,8/3/2021
A4B899,earnings,100,50,8/3/2021
A4CD53,earnings,100,50,8/3/2021
A4CD53,earnings,100,50,8/3/2021
A4CD53,earnings,100,50,8/3/2021
A4D173,dividend,100,50,8/3/2021
A4D173,dividend,100,50,8/3/2021
A52B6B,earnings,100,50,8/3/2021
A5DD24,earnings,100,50,8/3/2021
A60354,earnings-up,100,68,8/3/2021
A60354,earnings,100,50,8/3/2021
A60354,earnings,100,50,8/3/2021
A60354,earnings,100,50,8/3/2021
A62FD6,earnings-up,100,68,8/3/2021
A62FD6,earnings-up,100,68,8/3/2021
A7102F,earnings-up,100,68,8/3/2021
A7102F,earnings,100,50,8/3/2021
A7102F,earnings,100,50,8/3/2021
A7102F,earnings,100,50,8/3/2021
A7102F,earnings,100,50,8/3/2021
A7102F,earnings,100,50,8/3/2021
A7102F,earnings,100,50,8/3/2021
A74F6F,revenues,100,50,8/3/2021
A74F6F,revenues,100,50,8/3/2021
A74F6F,revenues,100,50,8/3/2021
A790A5,conference-call,100,50,8/3/2021
A7A0BD,earnings,100,50,8/3/2021
A99576,legal-issues-defendant,100,22,8/3/2021
ACDF88,conference-call,100,50,8/3/2021
ADF092,earnings,100,50,8/3/2021
AE0CCE,conference-participant,100,50,8/3/2021
AE79CD,earnings,100,50,8/3/2021
AECCA9,conference-call,100,50,8/3/2021
AFF7B4,earnings,100,50,8/3/2021
AFF7B4,earnings,100,50,8/3/2021
AFF7B4,earnings,100,50,8/3/2021
B076A1,earnings-up,100,68,8/3/2021
B076A1,earnings-up,100,68,8/3/2021
B076A1,earnings-up,100,68,8/3/2021
B076A1,earnings-up,100,68,8/3/2021
B1DF3C,partnership,100,61,8/3/2021
B1FC3B,business-contract,100,69,8/3/2021
B1FC3B,business-contract,100,69,8/3/2021
B2D492,earnings,100,50,8/3/2021
B37FB4,business-contract,100,69,8/3/2021
B3ED62,award,100,58,8/3/2021
B48FC9,revenues,100,50,8/3/2021
B48FC9,revenues,100,50,8/3/2021
B48FC9,revenues,100,50,8/3/2021
B48FC9,revenues,100,50,8/3/2021
B4F5F4,legal-issues-defendant,100,22,8/3/2021
B53C12,earnings,100,50,8/3/2021
B560AF,earnings,100,50,8/3/2021
B560AF,earnings,100,50,8/3/2021
B560AF,earnings,100,50,8/3/2021
B560AF,earnings,100,50,8/3/2021
B560AF,earnings,100,50,8/3/2021
B5767B,earnings,100,50,8/3/2021
B5767B,earnings,100,50,8/3/2021
B5767B,earnings,100,50,8/3/2021
B5767B,earnings,100,50,8/3/2021
B5767B,earnings,100,50,8/3/2021
B5767B,earnings,100,50,8/3/2021
B5BA39,conference-participant,100,50,8/3/2021
B72D2E,executive-appointment,100,54,8/3/2021
B83D67,executive-appointment,100,54,8/3/2021
B8A51F,earnings,100,50,8/3/2021
B8F71F,dividend,100,50,8/3/2021
B934BF,earnings,100,50,8/3/2021
B98EFA,operating-earnings,100,50,8/3/2021
BB5271,earnings,100,50,8/3/2021
BBC05B,operating-earnings,100,50,8/3/2021
BCE9DA,earnings,100,50,8/3/2021
BCE9DA,earnings,100,50,8/3/2021
BFEA04,earnings,100,50,8/3/2021
BFEA04,earnings,100,50,8/3/2021
BFEA04,earnings,100,50,8/3/2021
BFEA04,earnings,100,50,8/3/2021
BFF98A,conference-participant,100,50,8/3/2021
C15F8F,earnings,100,50,8/3/2021
C15F8F,earnings,100,50,8/3/2021
C15F8F,earnings,100,50,8/3/2021
C15F8F,earnings,100,50,8/3/2021
C15F8F,earnings,100,50,8/3/2021
C2E426,earnings,100,50,8/3/2021
C3F99F,earnings,100,50,8/3/2021
C45CE7,earnings-up,100,68,8/3/2021
C4A241,note-sale,100,52,8/3/2021
C5D2AE,partnership,100,61,8/3/2021
C7AE14,earnings,100,50,8/3/2021
C7FC95,partnership,100,61,8/3/2021
C8923A,earnings-up,100,68,8/3/2021
C8923A,earnings,100,50,8/3/2021
C8923A,earnings,100,50,8/3/2021
C8A248,earnings,100,50,8/3/2021
C8A248,earnings,100,50,8/3/2021
C8A248,earnings,100,50,8/3/2021
C8A248,earnings,100,50,8/3/2021
C8A248,earnings,100,50,8/3/2021
C8A248,earnings,100,50,8/3/2021
C941DC,acquisition-completed-acquirer,100,49,8/3/2021
CA212F,earnings,100,50,8/3/2021
CAC8D0,partnership,100,61,8/3/2021
CB7AB2,earnings,100,50,8/3/2021
CB89EA,asset-sale,100,62,8/3/2021
CBFFDD,conference-participant,100,50,8/3/2021
CC0C78,conference-participant,100,50,8/3/2021
CC35BE,executive-appointment,100,54,8/3/2021
CDC817,earnings,100,50,8/3/2021
CDE51C,partnership,100,61,8/3/2021
CDFCC9,dividend-up,100,81,8/3/2021
CDFCC9,earnings,100,50,8/3/2021
CED4D0,earnings,100,50,8/3/2021
CFF57D,conference-participant,100,50,8/3/2021
D08D2C,earnings,100,50,8/3/2021
D08D2C,earnings,100,50,8/3/2021
D08D2C,earnings,100,50,8/3/2021
D08D2C,earnings,100,50,8/3/2021
D08D2C,earnings,100,50,8/3/2021
D08D2C,earnings,100,50,8/3/2021
D0DE27,earnings,100,50,8/3/2021
D0DE27,dividend-up,100,55,8/3/2021
D1173F,earnings,100,50,8/3/2021
D1173F,earnings,100,50,8/3/2021
D1173F,earnings,100,50,8/3/2021
D1173F,earnings,100,50,8/3/2021
D13F1C,executive-appointment,100,54,8/3/2021
D13F1C,earnings-up,100,68,8/3/2021
D13F1C,earnings-up,100,68,8/3/2021
D13F1C,earnings-up,100,68,8/3/2021
D13F1C,earnings-up,100,68,8/3/2021
D13F1C,earnings-up,100,68,8/3/2021
D13F1C,earnings-up,100,68,8/3/2021
D13F1C,earnings-up,100,68,8/3/2021
D13F1C,earnings-up,100,68,8/3/2021
D1588D,conference-participant,100,50,8/3/2021
D296C6,earnings,100,50,8/3/2021
D2B9E5,earnings,100,50,8/3/2021
D2B9E5,earnings,100,50,8/3/2021
D2B9E5,earnings,100,50,8/3/2021
D69D42,earnings,100,50,8/3/2021
D81463,earnings,100,50,8/3/2021
D81463,earnings,100,50,8/3/2021
D81463,dividend,100,50,8/3/2021
D81463,dividend,100,50,8/3/2021
D88EF3,executive-appointment,100,54,8/3/2021
D8DA3D,earnings,100,50,8/3/2021
D8DA3D,earnings,100,50,8/3/2021
D8DA3D,earnings,100,50,8/3/2021
D8DA3D,earnings,100,50,8/3/2021
D8DA3D,earnings,100,50,8/3/2021
D9164D,earnings,100,50,8/3/2021
D9164D,dividend-up,100,81,8/3/2021
DA0CB8,earnings,100,50,8/3/2021
DB2E4E,earnings,100,50,8/3/2021
DB2E4E,public-offering,100,43,8/3/2021
DBFB51,dividend,100,50,8/3/2021
DBFB51,earnings,100,50,8/3/2021
DC1405,earnings,100,50,8/3/2021
DC2F77,note-sale,100,52,8/3/2021
DC6AA0,earnings,100,50,8/3/2021
DD682D,earnings,100,50,8/3/2021
DF5F14,business-contract,100,69,8/3/2021
DF8855,partnership,100,61,8/3/2021
DF8855,partnership,100,61,8/3/2021
E0207A,partnership,100,61,8/3/2021
E0F4E5,facility-open,100,65,8/3/2021
E114F4,executive-appointment,100,54,8/3/2021
E20392,revenues,100,50,8/3/2021
E20392,revenues,100,50,8/3/2021
E20392,revenues,100,50,8/3/2021
E22FDE,conference-participant,100,50,8/3/2021
E28D9C,acquisition-completed-acquirer,100,49,8/3/2021
E41190,earnings,100,50,8/3/2021
E41190,earnings,100,50,8/3/2021
E41190,earnings,100,50,8/3/2021
E41190,earnings,100,50,8/3/2021
E41190,earnings,100,50,8/3/2021
E41190,earnings,100,50,8/3/2021
E41190,earnings,100,50,8/3/2021
E68E62,conference-call,100,50,8/3/2021
E69BA5,earnings,100,50,8/3/2021
E6A53A,note-sale,100,52,8/3/2021
E6A53A,note-sale,100,52,8/3/2021
E6BC2C,conference-call,100,50,8/3/2021
E6C8DC,fraud,100,44,8/3/2021
E6C8DC,legal-issues-defendant,100,22,8/3/2021
E754F0,earnings,100,50,8/3/2021
E802CE,earnings,100,50,8/3/2021
E829E8,partnership,100,61,8/3/2021
EB1E1A,clinical-trials,100,56,8/3/2021
EB1E1A,conference-participant,100,50,8/3/2021
EB36DE,earnings,100,50,8/3/2021
EB43F4,earnings,100,50,8/3/2021
ECE814,earnings,100,50,8/3/2021
ED1A74,conference-participant,100,50,8/3/2021
EE6F1C,earnings-up,100,68,8/3/2021
EE6F1C,acquisition-acquiree,100,76,8/3/2021
EEBCEF,earnings,100,50,8/3/2021
EEEA9F,public-offering,100,43,8/3/2021
EF5BED,executive-appointment,100,54,8/3/2021
EFD406,earnings,100,50,8/3/2021
EFD406,earnings,100,50,8/3/2021
EFD406,earnings,100,50,8/3/2021
EFD406,earnings,100,50,8/3/2021
EFD406,earnings,100,50,8/3/2021
EFD406,earnings,100,50,8/3/2021
EFD406,earnings,100,50,8/3/2021
F0B2B5,earnings,100,50,8/3/2021
F0B335,earnings,100,50,8/3/2021
F0EEFB,earnings,100,50,8/3/2021
F0EEFB,earnings,100,50,8/3/2021
F1529C,conference-participant,100,50,8/3/2021
F294DD,dividend,100,50,8/3/2021
F3016C,earnings,100,50,8/3/2021
F3016C,earnings,100,50,8/3/2021
F3016C,earnings,100,50,8/3/2021
F3016C,earnings,100,50,8/3/2021
F3016C,earnings,100,50,8/3/2021
F46EC9,earnings,100,50,8/3/2021
F46EC9,earnings,100,50,8/3/2021
F46EC9,earnings,100,50,8/3/2021
F46EC9,earnings,100,50,8/3/2021
F46EC9,earnings,100,50,8/3/2021
F46EC9,earnings,100,50,8/3/2021
F57F6F,earnings,100,50,8/3/2021
F5C8AB,earnings-per-share-positive,100,69,8/3/2021
F5C8AB,earnings-per-share,100,50,8/3/2021
F5C8AB,earnings-per-share,100,50,8/3/2021
F5C8AB,earnings-per-share,100,50,8/3/2021
F5D499,earnings,100,50,8/3/2021
F6E1B5,earnings,100,50,8/3/2021
F7902B,public-offering,100,43,8/3/2021
F7902B,conference-participant,100,50,8/3/2021
F7ADEB,business-contract,100,69,8/3/2021
F7ADEB,earnings-up,100,68,8/3/2021
F7ADEB,earnings-up,100,68,8/3/2021
F7ADEB,earnings-up,100,68,8/3/2021
F7ADEB,earnings-up,100,68,8/3/2021
F8084B,earnings,100,50,8/3/2021
F85CC0,earnings,100,50,8/3/2021
F85CC0,earnings,100,50,8/3/2021
F8C5D7,operating-earnings,100,50,8/3/2021
FA918D,earnings,100,50,8/3/2021
FA918D,earnings,100,50,8/3/2021
FA918D,earnings,100,50,8/3/2021
FA918D,public-offering,100,43,8/3/2021
FC80E6,earnings,100,50,8/3/2021
FCA54E,earnings,100,50,8/3/2021
FDD3FC,earnings,100,50,8/3/2021
FE89E0,legal-issues-defendant,100,22,8/3/2021
FEC475,earnings,100,50,8/3/2021
FFAB4A,conference-participant,100,50,8/3/2021
00326E,business-contract,100,69,8/4/2021
00326E,earnings,100,50,8/4/2021
01D03F,executive-appointment,100,54,8/4/2021
03542C,conference-call,100,50,8/4/2021
0358AF,revenue-up,100,69,8/4/2021
0358AF,revenue-up,100,69,8/4/2021
0358AF,revenue-up,100,69,8/4/2021
0358AF,revenue-up,100,69,8/4/2021
03B431,earnings,100,50,8/4/2021
03B431,earnings,100,50,8/4/2021
48590,legal-issues-defendant,100,22,8/4/2021
48590,legal-issues-defendant,100,22,8/4/2021
48590,legal-issues-defendant,100,22,8/4/2021
053EFF,earnings,100,50,8/4/2021
054E7E,conference-participant,100,50,8/4/2021
06EE79,earnings,100,50,8/4/2021
95294,earnings,100,50,8/4/2021
095A04,earnings,100,50,8/4/2021
099C88,business-contract,100,69,8/4/2021
0A0D9E,earnings,100,50,8/4/2021
0A0D9E,earnings,100,50,8/4/2021
0A0D9E,earnings,100,50,8/4/2021
0B7375,conference-participant,100,50,8/4/2021
0BD4E8,government-contract,100,69,8/4/2021
0CADBC,executive-appointment,100,54,8/4/2021
0CADBC,earnings,100,50,8/4/2021
0CCCB7,earnings,100,50,8/4/2021
0DE3D5,earnings,100,50,8/4/2021
0DE3D5,earnings,100,50,8/4/2021
0DE3D5,earnings,100,50,8/4/2021
0DE3D5,earnings,100,50,8/4/2021
0DE3D5,earnings,100,50,8/4/2021
0DE3D5,earnings,100,50,8/4/2021
0E499E,conference-participant,100,50,8/4/2021
0E6027,legal-issues-defendant,100,22,8/4/2021
0EF1AF,dividend,100,50,8/4/2021
0F91FC,executive-appointment,100,54,8/4/2021
11074E,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12731D,earnings,100,50,8/4/2021
12DE76,conference-organizer,100,57,8/4/2021
12DE76,conference-call,100,50,8/4/2021
12F98C,partnership,100,61,8/4/2021
135B09,earnings,100,50,8/4/2021
135B09,earnings,100,50,8/4/2021
135B09,earnings,100,50,8/4/2021
135B09,earnings,100,50,8/4/2021
135B09,earnings,100,50,8/4/2021
136B26,earnings,100,50,8/4/2021
138DDE,earnings,100,50,8/4/2021
149301,earnings,100,50,8/4/2021
157D9F,earnings,100,50,8/4/2021
157D9F,earnings,100,50,8/4/2021
157D9F,earnings,100,50,8/4/2021
157D9F,earnings,100,50,8/4/2021
157D9F,earnings,100,50,8/4/2021
159AE4,merger-completed,100,66,8/4/2021
15A388,earnings,100,50,8/4/2021
15A388,earnings,100,50,8/4/2021
15A388,earnings,100,50,8/4/2021
15A388,earnings,100,50,8/4/2021
15A388,earnings,100,50,8/4/2021
16B183,operating-earnings,100,50,8/4/2021
1.79E+10,earnings,100,50,8/4/2021
182BE7,earnings,100,50,8/4/2021
1866B2,partnership,100,61,8/4/2021
1866B2,dividend,100,50,8/4/2021
18A98C,conference-participant,100,50,8/4/2021
1921DD,partnership,100,61,8/4/2021
196D18,earnings,100,50,8/4/2021
19BF16,earnings-positive,100,69,8/4/2021
1AB808,revenue-up,100,86,8/4/2021
1AB808,earnings,100,50,8/4/2021
1AB808,earnings,100,50,8/4/2021
1AB808,earnings,100,50,8/4/2021
1B637E,earnings,100,50,8/4/2021
1BC12C,earnings-up,100,68,8/4/2021
1BC12C,earnings-up,100,68,8/4/2021
1C599A,earnings,100,50,8/4/2021
1CB9D3,earnings,100,50,8/4/2021
1D5C51,executive-appointment,100,54,8/4/2021
1D943E,earnings,100,50,8/4/2021
1DB6A6,dividend,100,50,8/4/2021
1E7785,executive-appointment,100,54,8/4/2021
1E7785,earnings,100,50,8/4/2021
1E7785,earnings,100,50,8/4/2021
1E7785,earnings,100,50,8/4/2021
1E7785,earnings,100,50,8/4/2021
1E7785,earnings,100,50,8/4/2021
1E7785,earnings,100,50,8/4/2021
1FE7F0,dividend,100,50,8/4/2021
2003A5,earnings,100,50,8/4/2021
200D8B,earnings,100,50,8/4/2021
200D8B,earnings,100,50,8/4/2021
200D8B,earnings,100,50,8/4/2021
2082EA,earnings,100,50,8/4/2021
2158DF,earnings,100,50,8/4/2021
2158DF,earnings,100,50,8/4/2021
2158DF,earnings,100,50,8/4/2021
2158DF,earnings,100,50,8/4/2021
2158DF,earnings,100,50,8/4/2021
221783,earnings,100,50,8/4/2021
221783,earnings,100,50,8/4/2021
221783,earnings,100,50,8/4/2021
221783,earnings,100,50,8/4/2021
221783,earnings,100,50,8/4/2021
221783,earnings,100,50,8/4/2021
227D48,earnings,100,50,8/4/2021
232053,conference-participant,100,50,8/4/2021
241252,earnings,100,50,8/4/2021
267718,clinical-trials-positive,100,87,8/4/2021
28AC4E,note-sale,100,52,8/4/2021
295F9F,earnings,100,50,8/4/2021
29CEBF,dividend,100,50,8/4/2021
29CEBF,earnings,100,50,8/4/2021
29CEBF,earnings,100,50,8/4/2021
29CEBF,earnings,100,50,8/4/2021
29CEBF,earnings,100,50,8/4/2021
2A9C0A,business-contract,100,69,8/4/2021
2A9C0A,business-contract,100,69,8/4/2021
2AA6A8,earnings,100,50,8/4/2021
2B7A40,dividend,100,50,8/4/2021
2B8179,earnings,100,50,8/4/2021
2C681C,business-contract,100,69,8/4/2021
2C681C,business-contract,100,69,8/4/2021
2C681C,business-contract,100,69,8/4/2021
2CC60C,earnings,100,50,8/4/2021
2CF9D3,conference-participant,100,50,8/4/2021
2D2D43,earnings,100,50,8/4/2021
2D485F,earnings,100,50,8/4/2021
2D485F,earnings,100,50,8/4/2021
2D485F,earnings,100,50,8/4/2021
2E89AE,earnings,100,50,8/4/2021
2F9304,earnings,100,50,8/4/2021
2FEA66,partnership,100,61,8/4/2021
306623,public-offering,100,43,8/4/2021
31643A,earnings,100,50,8/4/2021
31803E,conference-participant,100,50,8/4/2021
3224CC,earnings,100,50,8/4/2021
32C8CD,revenue-up,100,69,8/4/2021
3.20E+263,earnings,100,50,8/4/2021
32F24A,earnings,100,50,8/4/2021
32F943,business-contract,100,69,8/4/2021
32F943,earnings,100,50,8/4/2021
337024,earnings,100,50,8/4/2021
337024,earnings,100,50,8/4/2021
337024,earnings,100,50,8/4/2021
3461CF,conference-participant,100,50,8/4/2021
34E9F9,earnings-guidance-up,100,83,8/4/2021
34E9F9,earnings,100,50,8/4/2021
34E9F9,earnings,100,50,8/4/2021
34E9F9,earnings,100,50,8/4/2021
34E9F9,earnings,100,50,8/4/2021
35579D,earnings,100,50,8/4/2021
35AE32,earnings,100,50,8/4/2021
35AE32,earnings,100,50,8/4/2021
35AE32,earnings,100,50,8/4/2021
35AE32,earnings,100,50,8/4/2021
367434,conference-participant,100,50,8/4/2021
36A1CB,earnings,100,50,8/4/2021
372037,dividend,100,50,8/4/2021
372037,earnings-up,100,68,8/4/2021
372037,earnings,100,50,8/4/2021
372037,earnings,100,50,8/4/2021
372037,earnings,100,50,8/4/2021
372037,earnings,100,50,8/4/2021
37B618,earnings,100,50,8/4/2021
3A3447,earnings,100,50,8/4/2021
3A3447,earnings,100,50,8/4/2021
3A3447,earnings,100,50,8/4/2021
3A3447,earnings,100,50,8/4/2021
3A3447,earnings,100,50,8/4/2021
3B37F7,note-sale,100,52,8/4/2021
3BB7D3,public-offering,100,43,8/4/2021
3C6CCC,earnings-up,100,68,8/4/2021
3C6CCC,earnings-up,100,68,8/4/2021
3C6CCC,earnings-up,100,68,8/4/2021
3C6CCC,earnings-up,100,68,8/4/2021
3C6CCC,earnings-up,100,68,8/4/2021
3C6CCC,earnings-up,100,68,8/4/2021
3C6CCC,earnings-up,100,68,8/4/2021
3DCECC,earnings,100,50,8/4/2021
3DD5E2,operating-earnings,100,50,8/4/2021
3DED49,earnings,100,50,8/4/2021
4.03E+05,earnings,100,50,8/4/2021
4.03E+05,earnings,100,50,8/4/2021
4.03E+05,earnings,100,50,8/4/2021
4.03E+05,earnings,100,50,8/4/2021
40B903,earnings,100,50,8/4/2021
40F7DE,conference-call,100,50,8/4/2021
4135F7,executive-appointment,100,54,8/4/2021
416C55,note-sale,100,52,8/4/2021
435ACE,earnings,100,50,8/4/2021
43A060,business-contract,100,69,8/4/2021
43F4A8,executive-appointment,100,54,8/4/2021
43F4A8,business-contract,100,69,8/4/2021
43F4A8,business-contract,100,69,8/4/2021
447FC6,earnings,100,50,8/4/2021
45444E,earnings,100,50,8/4/2021
468DD4,earnings,100,50,8/4/2021
4A5C8D,earnings,100,50,8/4/2021
4B49CF,facility-open,100,65,8/4/2021
4BAF2E,earnings,100,50,8/4/2021
4BDCA7,earnings,100,50,8/4/2021
4C2F17,earnings,100,50,8/4/2021
4C350A,earnings,100,50,8/4/2021
4C350A,earnings,100,50,8/4/2021
4D8124,earnings,100,50,8/4/2021
4F0A80,earnings,100,50,8/4/2021
4F9926,partnership,100,61,8/4/2021
4FCC78,earnings,100,50,8/4/2021
50D1EC,conference-participant,100,50,8/4/2021
514067,earnings,100,50,8/4/2021
51B442,earnings,100,50,8/4/2021
5403F8,earnings,100,50,8/4/2021
543C77,conference-participant,100,50,8/4/2021
54512F,legal-issues-defendant,100,22,8/4/2021
545272,earnings,100,50,8/4/2021
54F271,earnings-up,100,68,8/4/2021
54F271,earnings,100,50,8/4/2021
54F271,earnings,100,50,8/4/2021
54F271,earnings,100,50,8/4/2021
54F271,earnings,100,50,8/4/2021
553949,dividend,100,50,8/4/2021
55C9B5,product-release,100,64,8/4/2021
579E8F,conference-participant,100,50,8/4/2021
57A854,earnings,100,50,8/4/2021
57B174,earnings,100,50,8/4/2021
57B174,earnings,100,50,8/4/2021
57B174,earnings,100,50,8/4/2021
57B174,earnings,100,50,8/4/2021
57B174,earnings,100,50,8/4/2021
57CAAB,executive-appointment,100,54,8/4/2021
5876DC,earnings,100,50,8/4/2021
587EDF,earnings,100,50,8/4/2021
587EDF,earnings,100,50,8/4/2021
587EDF,earnings,100,50,8/4/2021
587EDF,earnings,100,50,8/4/2021
587EDF,earnings,100,50,8/4/2021
587EDF,earnings,100,50,8/4/2021
58C2D4,earnings,100,50,8/4/2021
594402,earnings,100,50,8/4/2021
5968F9,earnings,100,50,8/4/2021
59F0B0,merger-completed,100,66,8/4/2021
5A423F,earnings,100,50,8/4/2021
5B3FA2,earnings,100,50,8/4/2021
5C7601,earnings,100,50,8/4/2021
5D41E4,conference-participant,100,50,8/4/2021
5E6959,partnership,100,61,8/4/2021
5EAA43,earnings,100,50,8/4/2021
5FDBD0,operating-earnings,100,50,8/4/2021
60EA12,dividend,100,50,8/4/2021
60EA12,earnings-per-share-up,100,77,8/4/2021
60EA12,earnings-per-share-up,100,77,8/4/2021
6251A3,earnings,100,50,8/4/2021
62B1C6,earnings,100,50,8/4/2021
62B1C6,earnings,100,50,8/4/2021
62B1C6,earnings,100,50,8/4/2021
62B1C6,earnings,100,50,8/4/2021
62B1C6,earnings,100,50,8/4/2021
62B1C6,earnings,100,50,8/4/2021
64854A,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
64E615,earnings,100,50,8/4/2021
657097,earnings,100,50,8/4/2021
665440,conference-participant,100,50,8/4/2021
66749D,dividend,100,50,8/4/2021
66ECFD,dividend,100,50,8/4/2021
67529E,executive-appointment,100,54,8/4/2021
67A658,partnership,100,61,8/4/2021
67A658,partnership,100,61,8/4/2021
68E6E9,legal-issues-defendant,100,22,8/4/2021
68E6E9,merger-regulatory-scrutiny,100,37,8/4/2021
69CE71,earnings-up,100,68,8/4/2021
69CE71,earnings-up,100,68,8/4/2021
69CE71,earnings-up,100,68,8/4/2021
69CE71,earnings-up,100,68,8/4/2021
69CE71,earnings-up,100,68,8/4/2021
69CE71,earnings-up,100,68,8/4/2021
69CE71,earnings-up,100,68,8/4/2021
6AACDD,legal-issues-defendant,100,22,8/4/2021
6B0E45,earnings,100,50,8/4/2021
6D3F35,earnings,100,50,8/4/2021
6D3F35,earnings,100,50,8/4/2021
6D3F35,earnings,100,50,8/4/2021
6D3F35,earnings,100,50,8/4/2021
6D3F35,earnings,100,50,8/4/2021
6D3F35,earnings,100,50,8/4/2021
6E7060,earnings,100,50,8/4/2021
6E7060,earnings,100,50,8/4/2021
6E7060,earnings,100,50,8/4/2021
6E7060,earnings,100,50,8/4/2021
6E7060,earnings,100,50,8/4/2021
6E7060,earnings,100,50,8/4/2021
6E7060,earnings,100,50,8/4/2021
6E7060,earnings,100,50,8/4/2021
6E8864,operating-earnings,100,50,8/4/2021
6ED519,earnings,100,50,8/4/2021
6ED519,earnings,100,50,8/4/2021
6ED519,earnings,100,50,8/4/2021
6F22E7,earnings,100,50,8/4/2021
6F30F9,earnings,100,50,8/4/2021
6F39FC,dividend,100,50,8/4/2021
6F3FA8,earnings,100,50,8/4/2021
6FCEF9,earnings,100,50,8/4/2021
71B0CF,conference-participant,100,50,8/4/2021
7255D2,earnings,100,50,8/4/2021
7262F2,earnings,100,50,8/4/2021
72C2CE,earnings,100,50,8/4/2021
73A71F,note-sale,100,52,8/4/2021
73A71F,note-sale,100,52,8/4/2021
7410C3,earnings,100,50,8/4/2021
75D689,earnings,100,50,8/4/2021
763724,earnings,100,50,8/4/2021
763724,earnings,100,50,8/4/2021
763724,earnings,100,50,8/4/2021
76959C,earnings,100,50,8/4/2021
76BD96,public-offering,100,43,8/4/2021
76BD96,public-offering,100,43,8/4/2021
76BECC,government-contract,100,69,8/4/2021
76BECC,earnings,100,50,8/4/2021
76BECC,earnings,100,50,8/4/2021
76BECC,earnings,100,50,8/4/2021
76BECC,earnings,100,50,8/4/2021
790D0D,earnings,100,50,8/4/2021
7A3633,merger-regulatory-scrutiny,100,37,8/4/2021
7AF5B8,earnings,100,50,8/4/2021
7B492C,executive-appointment,100,54,8/4/2021
7BFF81,earnings-positive,100,69,8/4/2021
7BFF81,earnings,100,50,8/4/2021
7BFF81,earnings,100,50,8/4/2021
7BFF81,earnings,100,50,8/4/2021
7C62A3,earnings,100,50,8/4/2021
7D85A9,earnings,100,50,8/4/2021
7E1D5D,earnings,100,50,8/4/2021
7F9BE2,earnings,100,50,8/4/2021
803FED,earnings,100,50,8/4/2021
805CD8,earnings,100,50,8/4/2021
805CD8,conference-participant,100,50,8/4/2021
80C400,earnings,100,50,8/4/2021
8.10E+32,buybacks,100,74,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
8.10E+32,earnings,100,50,8/4/2021
810FAD,earnings,100,50,8/4/2021
810FAD,earnings,100,50,8/4/2021
81222C,earnings,100,50,8/4/2021
818A2F,dividend,100,50,8/4/2021
818A2F,earnings,100,50,8/4/2021
818A2F,dividend,100,50,8/4/2021
818A2F,earnings,100,50,8/4/2021
82F088,earnings,100,50,8/4/2021
838ADD,partnership,100,61,8/4/2021
86F123,earnings,100,50,8/4/2021
87486A,dividend,100,50,8/4/2021
877734,earnings,100,50,8/4/2021
877734,earnings,100,50,8/4/2021
877734,earnings,100,50,8/4/2021
877734,earnings,100,50,8/4/2021
87B81A,earnings,100,50,8/4/2021
87B81A,earnings,100,50,8/4/2021
87B81A,earnings,100,50,8/4/2021
87B81A,earnings,100,50,8/4/2021
87B81A,earnings,100,50,8/4/2021
87B81A,dividend,100,50,8/4/2021
885758,earnings,100,50,8/4/2021
88611B,earnings,100,50,8/4/2021
893904,earnings,100,50,8/4/2021
893904,earnings,100,50,8/4/2021
893904,earnings,100,50,8/4/2021
8AB37F,revenue-up,100,82,8/4/2021
8D5145,dividend,100,50,8/4/2021
8DAAB9,dividend,100,50,8/4/2021
8E82A6,earnings,100,50,8/4/2021
8E82A6,earnings,100,50,8/4/2021
8E82A6,earnings,100,50,8/4/2021
8E82A6,earnings,100,50,8/4/2021
8E82A6,earnings,100,50,8/4/2021
8E8E6E,business-contract,100,69,8/4/2021
8E8E6E,earnings,100,50,8/4/2021
8F3231,business-contract,100,69,8/4/2021
8F3231,business-contract,100,69,8/4/2021
8F6995,earnings,100,50,8/4/2021
901327,earnings,100,50,8/4/2021
901327,earnings,100,50,8/4/2021
901327,earnings,100,50,8/4/2021
901327,earnings,100,50,8/4/2021
902255,earnings,100,50,8/4/2021
902255,earnings,100,50,8/4/2021
902255,earnings,100,50,8/4/2021
902255,earnings,100,50,8/4/2021
902670,earnings,100,50,8/4/2021
902670,earnings,100,50,8/4/2021
902670,earnings,100,50,8/4/2021
902670,earnings,100,50,8/4/2021
9043FE,earnings,100,50,8/4/2021
9043FE,earnings,100,50,8/4/2021
925759,earnings,100,50,8/4/2021
92B625,conference-call,100,50,8/4/2021
92B625,partnership,100,61,8/4/2021
92B625,partnership,100,61,8/4/2021
9.31E+77,earnings,100,50,8/4/2021
9368BE,earnings,100,50,8/4/2021
94208D,earnings,100,50,8/4/2021
94208D,earnings,100,50,8/4/2021
94208D,earnings,100,50,8/4/2021
94208D,earnings,100,50,8/4/2021
94208D,earnings,100,50,8/4/2021
94208D,earnings,100,50,8/4/2021
949625,dividend,100,50,8/4/2021
949D62,note-sale,100,52,8/4/2021
94C0B5,dividend,100,50,8/4/2021
9.54E+32,partnership,100,61,8/4/2021
957A07,conference-participant,100,50,8/4/2021
9592FB,earnings,100,50,8/4/2021
95DC1F,partnership,100,61,8/4/2021
966DBE,executive-appointment,100,54,8/4/2021
9673BD,dividend,100,50,8/4/2021
96A2D3,earnings,100,50,8/4/2021
972356,partnership,100,61,8/4/2021
97644E,earnings,100,50,8/4/2021
97644E,earnings,100,50,8/4/2021
97644E,earnings,100,50,8/4/2021
97644E,earnings,100,50,8/4/2021
97644E,earnings,100,50,8/4/2021
977A1E,dividend,100,50,8/4/2021
980C14,acquisition-acquirer,100,49,8/4/2021
9810C0,conference-participant,100,50,8/4/2021
9.92E+94,conference-participant,100,50,8/4/2021
9A02C4,partnership,100,61,8/4/2021
9A02C4,partnership,100,61,8/4/2021
9A2760,earnings-up,100,68,8/4/2021
9A2760,earnings,100,50,8/4/2021
9A2760,earnings,100,50,8/4/2021
9A2760,earnings,100,50,8/4/2021
9A2760,earnings,100,50,8/4/2021
9A2760,executive-appointment,100,54,8/4/2021
9B0C9C,earnings,100,50,8/4/2021
9B4066,dividend-up,100,67,8/4/2021
9CA8F4,dividend,100,50,8/4/2021
9CA8F4,earnings,100,50,8/4/2021
9CA8F4,earnings,100,50,8/4/2021
9CDA4F,earnings,100,50,8/4/2021
9E91C6,earnings,100,50,8/4/2021
9EF4CF,partnership,100,61,8/4/2021
A01200,earnings,100,50,8/4/2021
A017F4,conference-participant,100,50,8/4/2021
A02FB1,legal-issues-defendant,100,22,8/4/2021
A05C43,earnings,100,50,8/4/2021
A16DEA,earnings,100,50,8/4/2021
A16DEA,earnings,100,50,8/4/2021
A16DEA,earnings,100,50,8/4/2021
A16DEA,earnings,100,50,8/4/2021
A16DEA,earnings,100,50,8/4/2021
A16DEA,earnings,100,50,8/4/2021
A16DEA,earnings,100,50,8/4/2021
A16DEA,earnings,100,50,8/4/2021
A16DEA,earnings,100,50,8/4/2021
A1E3B3,earnings,100,50,8/4/2021
A1EAC8,dividend,100,50,8/4/2021
A247F5,business-contract,100,69,8/4/2021
A28675,earnings,100,50,8/4/2021
A29A46,earnings,100,50,8/4/2021
A38F30,earnings,100,50,8/4/2021
A398B9,partnership,100,61,8/4/2021
A398B9,partnership,100,61,8/4/2021
A398F8,acquisition-acquirer,100,49,8/4/2021
A398F8,unit-acquisition-acquirer,100,49,8/4/2021
A398F8,earnings,100,50,8/4/2021
A3F598,earnings,100,50,8/4/2021
A3F598,earnings,100,50,8/4/2021
A3F598,earnings,100,50,8/4/2021
A3F598,earnings,100,50,8/4/2021
A433A5,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A43906,earnings,100,50,8/4/2021
A49498,earnings,100,50,8/4/2021
A49498,earnings,100,50,8/4/2021
A49498,earnings,100,50,8/4/2021
A49498,earnings,100,50,8/4/2021
A60354,acquisition-acquirer,100,49,8/4/2021
A6FE1C,acquisition-acquirer,100,49,8/4/2021
A75D43,earnings,100,50,8/4/2021
A7A0C8,conference-call,100,50,8/4/2021
A806FA,earnings,100,50,8/4/2021
A80FE0,conference-participant,100,50,8/4/2021
A868C9,conference-participant,100,50,8/4/2021
A99576,legal-issues-defendant,100,22,8/4/2021
AAC8B6,conference-call,100,50,8/4/2021
AAC8B6,conference-call,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAC8B6,earnings,100,50,8/4/2021
AAEE21,note-sale,100,52,8/4/2021
ABE7DC,conference-participant,100,50,8/4/2021
ACDCFA,operating-earnings,100,50,8/4/2021
ACF0B4,conference-call,100,50,8/4/2021
AD6141,earnings,100,50,8/4/2021
AEBB80,earnings,100,50,8/4/2021
AF93DE,earnings,100,50,8/4/2021
B05000,revenue-up,100,69,8/4/2021
B05000,earnings,100,50,8/4/2021
B09B1F,earnings,100,50,8/4/2021
B09B1F,earnings,100,50,8/4/2021
B09B1F,earnings,100,50,8/4/2021
B09B1F,earnings,100,50,8/4/2021
B0D41A,executive-appointment,100,54,8/4/2021
B0D41A,earnings,100,50,8/4/2021
B0FE08,dividend,100,50,8/4/2021
B0FE08,partnership,100,61,8/4/2021
B0FE08,earnings-up,100,68,8/4/2021
B0FE08,earnings-up,100,68,8/4/2021
B0FE08,earnings-up,100,68,8/4/2021
B0FE08,earnings-up,100,68,8/4/2021
B13B68,earnings,100,50,8/4/2021
B1DF3C,earnings,100,50,8/4/2021
B1FC3B,business-contract,100,69,8/4/2021
B2206F,earnings,100,50,8/4/2021
B2E6B5,dividend,100,50,8/4/2021
B2E6B5,earnings,100,50,8/4/2021
B2E6B5,earnings,100,50,8/4/2021
B2E6B5,earnings,100,50,8/4/2021
B303A6,earnings,100,50,8/4/2021
B303A6,earnings,100,50,8/4/2021
B303A6,earnings,100,50,8/4/2021
B303A6,earnings,100,50,8/4/2021
B303A6,earnings,100,50,8/4/2021
B303A6,earnings,100,50,8/4/2021
B303A6,earnings,100,50,8/4/2021
B303A6,earnings,100,50,8/4/2021
B303A6,earnings,100,50,8/4/2021
B37FB4,business-contract,100,69,8/4/2021
B3A166,earnings,100,50,8/4/2021
B446B8,earnings,100,50,8/4/2021
B446B8,earnings,100,50,8/4/2021
B446B8,earnings,100,50,8/4/2021
B446B8,earnings,100,50,8/4/2021
B48D6A,conference-participant,100,50,8/4/2021
B66928,earnings,100,50,8/4/2021
B73395,earnings,100,50,8/4/2021
B7BBFF,earnings,100,50,8/4/2021
B7FA9B,earnings,100,50,8/4/2021
B80AD1,conference-participant,100,50,8/4/2021
B8EF97,revenues,100,50,8/4/2021
B9BDE8,earnings,100,50,8/4/2021
BA0442,conference-participant,100,50,8/4/2021
BB0587,earnings-delayed,100,26,8/4/2021
BCC13E,earnings,100,50,8/4/2021
BFCACF,conference-call,100,50,8/4/2021
C01737,executive-appointment,100,54,8/4/2021
C07E05,earnings,100,50,8/4/2021
C29715,buybacks,100,74,8/4/2021
C356AC,earnings,100,50,8/4/2021
C356AC,earnings,100,50,8/4/2021
C356AC,earnings,100,50,8/4/2021
C356AC,earnings,100,50,8/4/2021
C356AC,earnings,100,50,8/4/2021
C356AC,earnings,100,50,8/4/2021
C356AC,earnings,100,50,8/4/2021
C356AC,dividend,100,50,8/4/2021
C3DE7D,earnings,100,50,8/4/2021
C3EE99,conference-call,100,50,8/4/2021
C3EE99,unit-acquisition-acquirer,100,49,8/4/2021
C4F9C6,earnings,100,50,8/4/2021
C4FBDC,earnings,100,50,8/4/2021
C65004,legal-issues-defendant,100,22,8/4/2021
C7FC95,earnings,100,50,8/4/2021
C8923A,executive-appointment,100,54,8/4/2021
CA14CC,earnings,100,50,8/4/2021
CA14CC,earnings,100,50,8/4/2021
CA14CC,earnings,100,50,8/4/2021
CB22CD,earnings,100,50,8/4/2021
CB6A9C,earnings,100,50,8/4/2021
CB6A9C,earnings,100,50,8/4/2021
CB6A9C,earnings,100,50,8/4/2021
CB6A9C,earnings,100,50,8/4/2021
CB6A9C,earnings,100,50,8/4/2021
CB6A9C,earnings,100,50,8/4/2021
CB89EA,earnings,100,50,8/4/2021
CB9E13,earnings,100,50,8/4/2021
CBBFBF,earnings,100,50,8/4/2021
CBFFDD,business-contract,100,69,8/4/2021
CBFFDD,business-contract,100,69,8/4/2021
CBFFDD,earnings,100,50,8/4/2021
CBFFDD,trading-halt,100,43,8/4/2021
CBFFDD,trading-resumed,100,58,8/4/2021
CC339B,dividend,100,50,8/4/2021
CD051C,earnings,100,50,8/4/2021
CD2A4D,earnings,100,50,8/4/2021
CDAB24,earnings,100,50,8/4/2021
CDC217,earnings,100,50,8/4/2021
CDC817,legal-issues-defendant,100,22,8/4/2021
CDC817,legal-issues-defendant,100,22,8/4/2021
CDC817,legal-issues-defendant,100,22,8/4/2021
CE96E7,earnings,100,50,8/4/2021
CFF15D,partnership,100,61,8/4/2021
D064D5,earnings,100,50,8/4/2021
D07B07,earnings,100,50,8/4/2021
D29B44,earnings,100,50,8/4/2021
D29F43,earnings,100,50,8/4/2021
D4AC65,earnings-up,100,68,8/4/2021
D4AC65,earnings,100,50,8/4/2021
D4AC65,earnings,100,50,8/4/2021
D4AC65,earnings,100,50,8/4/2021
D4AC65,earnings,100,50,8/4/2021
D4C0CB,conference-participant,100,50,8/4/2021
D518D8,dividend,100,50,8/4/2021
D56D6D,earnings,100,50,8/4/2021
D650A7,revenue-up,100,69,8/4/2021
D650A7,revenue-up,100,69,8/4/2021
D650A7,revenue-up,100,69,8/4/2021
D650A7,revenue-up,100,69,8/4/2021
D650A7,dividend,100,50,8/4/2021
D65A13,revenue-up,100,82,8/4/2021
D65A13,revenue-up,100,69,8/4/2021
D65A13,revenue-up,100,69,8/4/2021
D697DE,earnings,100,50,8/4/2021
D6EAA3,executive-appointment,100,54,8/4/2021
D854DD,earnings,100,50,8/4/2021
D90441,earnings,100,50,8/4/2021
D90441,earnings,100,50,8/4/2021
D90441,earnings,100,50,8/4/2021
D90441,earnings,100,50,8/4/2021
D90441,dividend,100,50,8/4/2021
D90441,dividend,100,50,8/4/2021
D90F43,earnings,100,50,8/4/2021
D90F43,earnings,100,50,8/4/2021
D90F43,earnings,100,50,8/4/2021
D90F43,earnings,100,50,8/4/2021
D90F43,earnings,100,50,8/4/2021
D90F43,earnings,100,50,8/4/2021
D90F43,earnings,100,50,8/4/2021
D90F43,earnings,100,50,8/4/2021
D95385,earnings,100,50,8/4/2021
D9FC89,earnings,100,50,8/4/2021
D9FC89,earnings,100,50,8/4/2021
D9FC89,earnings,100,50,8/4/2021
D9FC89,earnings,100,50,8/4/2021
D9FC89,earnings,100,50,8/4/2021
D9FC89,earnings,100,50,8/4/2021
DB06B0,earnings,100,50,8/4/2021
DB06B0,earnings,100,50,8/4/2021
DB06B0,earnings,100,50,8/4/2021
DB06B0,earnings,100,50,8/4/2021
DB06B0,earnings,100,50,8/4/2021
DB23C8,award,100,58,8/4/2021
DB2E4E,public-offering,100,43,8/4/2021
DB7014,operating-earnings,100,50,8/4/2021
DB9F70,conference-participant,100,50,8/4/2021
DCD97F,dividend,100,50,8/4/2021
DDB002,earnings,100,50,8/4/2021
DDB002,earnings,100,50,8/4/2021
DDB002,earnings,100,50,8/4/2021
DDB002,earnings,100,50,8/4/2021
DF11D9,legal-issues-defendant,100,22,8/4/2021
DF42A0,dividend,100,50,8/4/2021
DF42A0,earnings,100,50,8/4/2021
DF46C5,merger-completed,100,66,8/4/2021
DF8855,earnings,100,50,8/4/2021
E05026,earnings-up,100,68,8/4/2021
E05026,executive-resignation,100,44,8/4/2021
E05DC8,acquisition-acquirer,100,49,8/4/2021
E06265,earnings,100,50,8/4/2021
E074A0,earnings,100,50,8/4/2021
E09E2B,conference-call,100,50,8/4/2021
E0E4B7,earnings,100,50,8/4/2021
E114F4,executive-appointment,100,54,8/4/2021
E114F4,earnings,100,50,8/4/2021
E114F4,earnings,100,50,8/4/2021
E114F4,earnings,100,50,8/4/2021
E114F4,earnings,100,50,8/4/2021
E15736,earnings,100,50,8/4/2021
E1E36F,earnings,100,50,8/4/2021
E1E36F,earnings,100,50,8/4/2021
E1E36F,earnings,100,50,8/4/2021
E1E36F,earnings,100,50,8/4/2021
E1E36F,earnings,100,50,8/4/2021
E1E36F,earnings,100,50,8/4/2021
E1E36F,earnings,100,50,8/4/2021
E1E36F,earnings,100,50,8/4/2021
E28D9C,earnings,100,50,8/4/2021
E393B0,legal-issues-defendant,100,22,8/4/2021
E5C910,conference-participant,100,50,8/4/2021
E6C8DC,legal-issues-defendant,100,22,8/4/2021
E6C8DC,legal-issues-defendant,100,22,8/4/2021
E6D89E,donation,100,54,8/4/2021
E72599,earnings,100,50,8/4/2021
E74FED,earnings,100,50,8/4/2021
EB1E1A,earnings,100,50,8/4/2021
EB7D6C,executive-appointment,100,54,8/4/2021
EC8116,earnings,100,50,8/4/2021
EC99D0,reorganization-unit,100,53,8/4/2021
ECE19E,earnings,100,50,8/4/2021
EDD234,earnings,100,50,8/4/2021
EEEA9F,public-offering,100,43,8/4/2021
F02170,earnings,100,50,8/4/2021
F02D0A,earnings-per-share-positive,100,69,8/4/2021
F02D0A,earnings,100,50,8/4/2021
F15E41,earnings,100,50,8/4/2021
F15E41,earnings,100,50,8/4/2021
F15E41,earnings,100,50,8/4/2021
F15E41,earnings,100,50,8/4/2021
F15E41,earnings,100,50,8/4/2021
F32F88,earnings-up,100,68,8/4/2021
F39E1E,earnings,100,50,8/4/2021
F3FCC3,earnings-up,100,68,8/4/2021
F3FCC3,earnings,100,50,8/4/2021
F3FCC3,earnings,100,50,8/4/2021
F3FCC3,earnings,100,50,8/4/2021
F3FCC3,earnings,100,50,8/4/2021
F3FCC3,earnings,100,50,8/4/2021
F4D241,conference-participant,100,50,8/4/2021
F5349B,earnings,100,50,8/4/2021
F5349B,dividend,100,50,8/4/2021
F6A987,earnings-up,100,68,8/4/2021
F6E248,unit-acquisition-completed-acquiree,100,67,8/4/2021
F6E248,unit-acquisition-completed-acquiree,100,67,8/4/2021
F6E248,unit-acquisition-completed-acquiree,100,67,8/4/2021
F72E4B,earnings,100,50,8/4/2021
FA918D,public-offering,100,43,8/4/2021
FB728F,earnings,100,50,8/4/2021
FB7724,earnings,100,50,8/4/2021
FD2565,earnings,100,50,8/4/2021
FD554E,earnings,100,50,8/4/2021
FE609F,conference-call,100,50,8/4/2021
FE89E0,legal-issues-defendant,100,22,8/4/2021
FF227B,conference-participant,100,50,8/4/2021
9397,conference-participant,100,50,8/5/2021
13528,executive-appointment,100,54,8/5/2021
0157B1,facility-open,100,65,8/5/2021
01B8D6,earnings,100,50,8/5/2021
20751,earnings,100,50,8/5/2021
20751,earnings,100,50,8/5/2021
20751,earnings,100,50,8/5/2021
02ACBD,earnings,100,50,8/5/2021
036C6F,revenue-up,100,69,8/5/2021
036C6F,revenue-up,100,69,8/5/2021
036C6F,revenue-up,100,69,8/5/2021
036C6F,revenue-up,100,69,8/5/2021
03CF95,legal-issues-defendant,100,22,8/5/2021
03CF95,legal-issues-defendant,100,22,8/5/2021
03CF95,legal-issues-defendant,100,22,8/5/2021
03D5F9,conference-participant,100,50,8/5/2021
03FAA6,earnings,100,50,8/5/2021
03FAA6,earnings,100,50,8/5/2021
03FAA6,earnings,100,50,8/5/2021
03FAA6,earnings,100,50,8/5/2021
03FAA6,earnings,100,50,8/5/2021
48590,legal-issues-defendant,100,22,8/5/2021
48590,legal-issues-defendant,100,22,8/5/2021
048B70,earnings,100,50,8/5/2021
048B70,earnings,100,50,8/5/2021
048B70,earnings,100,50,8/5/2021
048B70,earnings,100,50,8/5/2021
04CCCD,earnings,100,50,8/5/2021
04EB2F,earnings,100,50,8/5/2021
054E7E,earnings,100,50,8/5/2021
05D148,clinical-trials,100,56,8/5/2021
05D148,clinical-trials,100,56,8/5/2021
061A3B,earnings,100,50,8/5/2021
061A3B,earnings,100,50,8/5/2021
061A3B,earnings,100,50,8/5/2021
061A3B,earnings,100,50,8/5/2021
061A3B,earnings,100,50,8/5/2021
75172,earnings,100,50,8/5/2021
078D52,earnings,100,50,8/5/2021
078D52,earnings,100,50,8/5/2021
083F72,earnings,100,50,8/5/2021
84625,dividend,100,50,8/5/2021
0919B1,revenue-up,100,84,8/5/2021
091B6C,earnings,100,50,8/5/2021
091B6C,earnings,100,50,8/5/2021
099A92,earnings,100,50,8/5/2021
0A59F8,partnership,100,61,8/5/2021
0A59F8,earnings,100,50,8/5/2021
0A59F8,earnings,100,50,8/5/2021
0A59F8,earnings,100,50,8/5/2021
0A59F8,earnings,100,50,8/5/2021
0A59F8,earnings,100,50,8/5/2021
0A59F8,earnings,100,50,8/5/2021
0A59F8,earnings,100,50,8/5/2021
0A59F8,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC29E,earnings,100,50,8/5/2021
0BC853,earnings,100,50,8/5/2021
0BF198,earnings,100,50,8/5/2021
0C2A0D,conference-participant,100,50,8/5/2021
0C355F,note-sale,100,52,8/5/2021
0C355F,note-sale,100,52,8/5/2021
0CE7F6,earnings,100,50,8/5/2021
0DBB81,conference-participant,100,50,8/5/2021
0E64D4,asset-sale,100,62,8/5/2021
0EF1AF,earnings,100,50,8/5/2021
0F0693,earnings,100,50,8/5/2021
0FC848,conference-participant,100,50,8/5/2021
1080C0,earnings,100,50,8/5/2021
1096C6,earnings,100,50,8/5/2021
11A49E,earnings,100,50,8/5/2021
12DE76,partnership,100,61,8/5/2021
14391F,earnings,100,50,8/5/2021
168A5D,partnership,100,61,8/5/2021
168A5D,partnership,100,61,8/5/2021
16C544,earnings,100,50,8/5/2021
1748F6,legal-issues-defendant,100,22,8/5/2021
184866,earnings,100,50,8/5/2021
18EC17,stock-splits,100,49,8/5/2021
1A46A1,earnings,100,50,8/5/2021
1A5957,earnings,100,50,8/5/2021
1A5957,earnings,100,50,8/5/2021
1A5957,earnings,100,50,8/5/2021
1A5957,earnings,100,50,8/5/2021
1AC649,earnings,100,50,8/5/2021
1B16C1,earnings,100,50,8/5/2021
1B4F31,earnings,100,50,8/5/2021
1B9535,earnings,100,50,8/5/2021
1BC12C,asset-sale,100,62,8/5/2021
1C2593,conference-call,100,50,8/5/2021
1CD09C,earnings,100,50,8/5/2021
1CD4B5,conference-participant,100,50,8/5/2021
1D5C51,earnings,100,50,8/5/2021
1DDEDA,earnings-up,100,68,8/5/2021
1DDEDA,earnings,100,50,8/5/2021
1DDEDA,earnings,100,50,8/5/2021
1E4FB9,earnings,100,50,8/5/2021
1E4FB9,acquisition-acquiree,100,76,8/5/2021
1F19C8,revenue-up,100,61,8/5/2021
1F19C8,revenue-up,100,61,8/5/2021
1F19C8,revenue-up,100,61,8/5/2021
1F19C8,revenue-up,100,61,8/5/2021
1F19C8,revenue-up,100,61,8/5/2021
1F19C8,revenue-up,100,61,8/5/2021
1F464F,earnings,100,50,8/5/2021
1F9258,earnings,100,50,8/5/2021
1FC422,earnings,100,50,8/5/2021
2096DE,earnings,100,50,8/5/2021
21268E,earnings,100,50,8/5/2021
223552,earnings,100,50,8/5/2021
2262BD,executive-appointment,100,54,8/5/2021
227F04,earnings,100,50,8/5/2021
227F04,acquisition-completed-acquirer,100,49,8/5/2021
227F04,acquisition-acquirer,100,49,8/5/2021
228D42,partnership,100,61,8/5/2021
23699B,earnings,100,50,8/5/2021
2.45E+15,dividend,100,50,8/5/2021
249674,conference-participant,100,50,8/5/2021
24CB56,earnings,100,50,8/5/2021
253B2F,earnings,100,50,8/5/2021
25529C,earnings,100,50,8/5/2021
2571FA,conference-participant,100,50,8/5/2021
25AB8E,earnings,100,50,8/5/2021
26008A,acquisition-completed-acquirer,100,49,8/5/2021
275300,dividend,100,50,8/5/2021
27C10F,earnings,100,50,8/5/2021
27C10F,earnings,100,50,8/5/2021
27C10F,earnings,100,50,8/5/2021
27C10F,earnings,100,50,8/5/2021
27C10F,earnings,100,50,8/5/2021
28F905,earnings,100,50,8/5/2021
297DA8,award,100,58,8/5/2021
2A6DBE,earnings,100,50,8/5/2021
2ABF77,earnings,100,50,8/5/2021
2ABF77,earnings,100,50,8/5/2021
2BBE62,earnings,100,50,8/5/2021
2BBE62,earnings,100,50,8/5/2021
2BBE62,earnings,100,50,8/5/2021
2BF36E,earnings,100,50,8/5/2021
2C35B5,earnings,100,50,8/5/2021
2C681C,earnings,100,50,8/5/2021
2CBB58,conference-participant,100,50,8/5/2021
2CC71C,conference-participant,100,50,8/5/2021
2CF9D3,earnings,100,50,8/5/2021
2E0445,earnings,100,50,8/5/2021
2E2E6E,merger-regulatory-approval,100,81,8/5/2021
2E36AD,earnings,100,50,8/5/2021
2E36AD,earnings,100,50,8/5/2021
2EB04E,partnership,100,61,8/5/2021
2EB88B,revenues,100,50,8/5/2021
2EB88B,acquisition-acquirer,100,49,8/5/2021
2EB88B,acquisition-acquirer,100,49,8/5/2021
2EB88B,acquisition-acquirer,100,49,8/5/2021
2EB88B,acquisition-acquirer,100,49,8/5/2021
2EB88B,acquisition-acquirer,100,49,8/5/2021
2EB88B,acquisition-acquirer,100,49,8/5/2021
2EBA55,earnings,100,50,8/5/2021
2F7A7E,earnings,100,50,8/5/2021
2F98A5,earnings,100,50,8/5/2021
2FF046,earnings,100,50,8/5/2021
2FF046,earnings,100,50,8/5/2021
2FF046,earnings,100,50,8/5/2021
2FF046,earnings,100,50,8/5/2021
2FF046,earnings,100,50,8/5/2021
301493,revenue-up,100,91,8/5/2021
301493,revenues,100,50,8/5/2021
301493,revenues,100,50,8/5/2021
301493,revenues,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30CBF9,earnings,100,50,8/5/2021
30DE64,earnings,100,50,8/5/2021
30DFD3,earnings,100,50,8/5/2021
3159AA,earnings,100,50,8/5/2021
3159AA,dividend,100,50,8/5/2021
342218,earnings,100,50,8/5/2021
342218,earnings,100,50,8/5/2021
3461CF,credit-rating-affirmation-rater,20,50,8/5/2021
3461CF,credit-rating-affirmation-rater,20,50,8/5/2021
3461CF,credit-rating-affirmation-rater,20,50,8/5/2021
355B19,earnings,100,50,8/5/2021
3587B4,earnings,100,50,8/5/2021
367E1C,patient-enrollment-complete,100,64,8/5/2021
36E479,earnings,100,50,8/5/2021
370C50,note-sale,100,52,8/5/2021
371B0A,earnings,100,50,8/5/2021
37426C,earnings,100,50,8/5/2021
3798B9,earnings,100,50,8/5/2021
382EAE,operating-earnings,100,50,8/5/2021
382EAE,operating-earnings,100,50,8/5/2021
382EAE,operating-earnings,100,50,8/5/2021
382EAE,operating-earnings,100,50,8/5/2021
382EAE,operating-earnings,100,50,8/5/2021
382EAE,operating-earnings,100,50,8/5/2021
382EAE,dividend,100,50,8/5/2021
387375,conference-participant,100,50,8/5/2021
39692D,earnings,100,50,8/5/2021
39692D,earnings,100,50,8/5/2021
39692D,earnings,100,50,8/5/2021
39692D,earnings,100,50,8/5/2021
39692D,earnings,100,50,8/5/2021
39692D,earnings,100,50,8/5/2021
39692D,earnings,100,50,8/5/2021
39692D,earnings,100,50,8/5/2021
396D7C,earnings,100,50,8/5/2021
3ACF46,earnings,100,50,8/5/2021
3ACF46,earnings,100,50,8/5/2021
3ACF46,earnings,100,50,8/5/2021
3ACF46,earnings,100,50,8/5/2021
3ACF46,executive-appointment,100,54,8/5/2021
3B8484,earnings-up,100,68,8/5/2021
3C3B6B,revenue-up,100,69,8/5/2021
3C3B6B,earnings,100,50,8/5/2021
3C3B6B,earnings,100,50,8/5/2021
3C3B6B,earnings,100,50,8/5/2021
3C75D6,conference-participant,100,50,8/5/2021
3C7F5F,earnings,100,50,8/5/2021
3C7F5F,earnings,100,50,8/5/2021
3C7F5F,earnings,100,50,8/5/2021
3C7F5F,earnings,100,50,8/5/2021
3C7F5F,earnings,100,50,8/5/2021
3D7971,earnings,100,50,8/5/2021
3D7971,earnings,100,50,8/5/2021
3D7971,earnings,100,50,8/5/2021
3D7971,earnings,100,50,8/5/2021
3D7971,earnings,100,50,8/5/2021
3D7971,earnings,100,50,8/5/2021
3E70FC,earnings,100,50,8/5/2021
3F4668,revenue-up,100,55,8/5/2021
3F4668,revenues,100,50,8/5/2021
3F4668,revenues,100,50,8/5/2021
3F4668,revenues,100,50,8/5/2021
3F6A9C,earnings-up,100,68,8/5/2021
4017AD,earnings,100,50,8/5/2021
415188,dividend,100,50,8/5/2021
415188,earnings,100,50,8/5/2021
417BF9,conference-participant,100,50,8/5/2021
41A93D,earnings,100,50,8/5/2021
41C36B,earnings,100,50,8/5/2021
427F32,earnings,100,50,8/5/2021
42AABD,earnings,100,50,8/5/2021
431B74,acquisition-acquirer,100,49,8/5/2021
431B74,acquisition-acquirer,100,49,8/5/2021
434F38,earnings,100,50,8/5/2021
4398A2,earnings,100,50,8/5/2021
4398A2,earnings,100,50,8/5/2021
44740A,earnings,100,50,8/5/2021
449447,earnings,100,50,8/5/2021
449A26,business-contract,100,69,8/5/2021
45ABCC,earnings,100,50,8/5/2021
46017C,earnings,100,50,8/5/2021
4.60E+06,earnings,100,50,8/5/2021
485445,earnings,100,50,8/5/2021
485445,earnings,100,50,8/5/2021
485445,earnings,100,50,8/5/2021
485445,earnings,100,50,8/5/2021
485445,earnings,100,50,8/5/2021
485445,earnings,100,50,8/5/2021
485445,earnings,100,50,8/5/2021
48F795,earnings,100,50,8/5/2021
49F4D0,earnings,100,50,8/5/2021
4A2457,conference-participant,100,50,8/5/2021
4A6F00,partnership,100,61,8/5/2021
4A6F00,business-contract,100,69,8/5/2021
4A6F00,business-contract,100,69,8/5/2021
4AC91D,business-contract,100,69,8/5/2021
4B3676,earnings,100,50,8/5/2021
4B3676,earnings,100,50,8/5/2021
4B3676,earnings,100,50,8/5/2021
4B3676,earnings,100,50,8/5/2021
4B7006,earnings,100,50,8/5/2021
4BEB48,earnings,100,50,8/5/2021
4BEB48,earnings,100,50,8/5/2021
4BEB48,earnings,100,50,8/5/2021
4BEB48,earnings,100,50,8/5/2021
4BEB48,earnings,100,50,8/5/2021
4BF3D6,earnings,100,50,8/5/2021
4C3FE9,earnings,100,50,8/5/2021
4C7DB5,union-pact,100,61,8/5/2021
4DD203,earnings-up,100,68,8/5/2021
4DD203,earnings,100,50,8/5/2021
4DD203,earnings,100,50,8/5/2021
4DD203,earnings,100,50,8/5/2021
5065B1,earnings,100,50,8/5/2021
507AE7,dividend,100,50,8/5/2021
510EA1,earnings,100,50,8/5/2021
51F541,facility-open,100,65,8/5/2021
52FB2F,earnings,100,50,8/5/2021
52FB2F,earnings,100,50,8/5/2021
52FB2F,earnings,100,50,8/5/2021
52FB2F,earnings,100,50,8/5/2021
53C421,earnings,100,50,8/5/2021
5.43E+08,conference-participant,100,50,8/5/2021
5.47E+28,operating-earnings,100,50,8/5/2021
5487B1,earnings,100,50,8/5/2021
5487B1,earnings,100,50,8/5/2021
5487B1,earnings,100,50,8/5/2021
5487B1,earnings,100,50,8/5/2021
5487B1,earnings,100,50,8/5/2021
55438C,partnership,100,61,8/5/2021
55ACCB,earnings,100,50,8/5/2021
55ACCB,earnings,100,50,8/5/2021
55ACCB,earnings,100,50,8/5/2021
55ACCB,earnings,100,50,8/5/2021
55D0F3,earnings,100,50,8/5/2021
562853,dividend,100,50,8/5/2021
5704AC,operating-earnings,100,50,8/5/2021
57DDB9,partnership,100,61,8/5/2021
57DDB9,partnership,100,61,8/5/2021
589803,earnings,100,50,8/5/2021
58B46F,earnings,100,50,8/5/2021
59872F,conference-call,100,50,8/5/2021
5A0FF1,earnings,100,50,8/5/2021
5A0FF1,earnings,100,50,8/5/2021
5A0FF1,earnings,100,50,8/5/2021
5A0FF1,earnings,100,50,8/5/2021
5A0FF1,earnings,100,50,8/5/2021
5A9A82,earnings,100,50,8/5/2021
5AA3B1,earnings,100,50,8/5/2021
5B6C11,note-sale,100,52,8/5/2021
5B7739,earnings,100,50,8/5/2021
5CEE02,earnings,100,50,8/5/2021
5D1329,earnings,100,50,8/5/2021
5D63F1,earnings,100,50,8/5/2021
5DD486,dividend,100,50,8/5/2021
5EF130,earnings,100,50,8/5/2021
5EF130,earnings,100,50,8/5/2021
5EF130,earnings,100,50,8/5/2021
5F3D91,earnings,100,50,8/5/2021
60FE03,earnings,100,50,8/5/2021
619882,conference-organizer,100,57,8/5/2021
619882,conference-organizer,100,57,8/5/2021
619882,conference-organizer,100,57,8/5/2021
620381,earnings,100,50,8/5/2021
6284B5,earnings,100,50,8/5/2021
6284B5,earnings,100,50,8/5/2021
6284B5,earnings,100,50,8/5/2021
6284B5,earnings,100,50,8/5/2021
6284B5,earnings,100,50,8/5/2021
6284B5,earnings,100,50,8/5/2021
62A48D,earnings,100,50,8/5/2021
636639,dividend-up,100,81,8/5/2021
649CBD,earnings,100,50,8/5/2021
6559D8,earnings,100,50,8/5/2021
6634D9,earnings,100,50,8/5/2021
665440,earnings,100,50,8/5/2021
66667F,revenue-up,100,69,8/5/2021
66667F,revenue-up,100,69,8/5/2021
66667F,revenue-up,100,69,8/5/2021
67303E,conference-call,100,50,8/5/2021
676FFD,earnings,100,50,8/5/2021
68586A,earnings,100,50,8/5/2021
68E3E0,earnings,100,50,8/5/2021
68E3E0,earnings,100,50,8/5/2021
68E3E0,earnings,100,50,8/5/2021
68E3E0,earnings,100,50,8/5/2021
68E3E0,earnings,100,50,8/5/2021
68E3E0,earnings,100,50,8/5/2021
693ECD,earnings,100,50,8/5/2021
694749,earnings,100,50,8/5/2021
694749,earnings,100,50,8/5/2021
694749,earnings,100,50,8/5/2021
694749,earnings,100,50,8/5/2021
694749,conference-participant,100,50,8/5/2021
698FF9,earnings,100,50,8/5/2021
69FDFC,award,100,58,8/5/2021
6AACDD,legal-issues-defendant,100,22,8/5/2021
6AACDD,legal-issues-defendant,100,22,8/5/2021
6AACDD,legal-issues-defendant,100,22,8/5/2021
6B5379,earnings,100,50,8/5/2021
6BBD2D,earnings,100,50,8/5/2021
6BC6F9,earnings,100,50,8/5/2021
6CBF41,earnings,100,50,8/5/2021
6D156D,earnings,100,50,8/5/2021
6D1ADF,earnings,100,50,8/5/2021
6D9ECA,earnings,100,50,8/5/2021
6EA292,earnings,100,50,8/5/2021
6F39FC,earnings,100,50,8/5/2021
6F92A9,earnings,100,50,8/5/2021
709AED,dividend,100,50,8/5/2021
709AED,revenues,100,50,8/5/2021
709AED,revenues,100,50,8/5/2021
709AED,revenues,100,50,8/5/2021
70B3D6,executive-appointment,100,54,8/5/2021
71694D,executive-appointment,100,54,8/5/2021
723548,earnings,100,50,8/5/2021
7255D2,earnings,100,50,8/5/2021
726EEA,earnings-up,100,68,8/5/2021
726EEA,earnings-up,100,68,8/5/2021
726EEA,earnings-up,100,68,8/5/2021
726EEA,earnings-up,100,68,8/5/2021
726EEA,earnings-up,100,68,8/5/2021
732A9B,earnings,100,50,8/5/2021
741937,earnings-up,100,68,8/5/2021
741937,earnings,100,50,8/5/2021
741937,earnings,100,50,8/5/2021
74404C,earnings,100,50,8/5/2021
747219,earnings,100,50,8/5/2021
7710F3,earnings,100,50,8/5/2021
7710F3,earnings,100,50,8/5/2021
787D14,earnings,100,50,8/5/2021
789A7D,earnings,100,50,8/5/2021
789A7D,earnings,100,50,8/5/2021
789A7D,earnings,100,50,8/5/2021
789A7D,earnings,100,50,8/5/2021
790C34,partnership,100,61,8/5/2021
790D0D,dividend,100,50,8/5/2021
793C11,earnings,100,50,8/5/2021
7A51FE,buybacks,100,74,8/5/2021
7A51FE,earnings,100,50,8/5/2021
7ACFD4,earnings,100,50,8/5/2021
7ACFD4,earnings,100,50,8/5/2021
7ACFD4,earnings,100,50,8/5/2021
7ACFD4,earnings,100,50,8/5/2021
7ACFD4,earnings,100,50,8/5/2021
7ACFD4,earnings,100,50,8/5/2021
7B1156,earnings,100,50,8/5/2021
7B9212,revenues,100,50,8/5/2021
7BFF81,executive-appointment,100,54,8/5/2021
7C4F43,business-contract,100,69,8/5/2021
7C4F43,earnings,100,50,8/5/2021
7DD8CC,earnings,100,50,8/5/2021
7FEEE1,earnings,100,50,8/5/2021
819492,earnings,100,50,8/5/2021
81EAD4,earnings,100,50,8/5/2021
81EAD4,earnings,100,50,8/5/2021
81EAD4,earnings,100,50,8/5/2021
824CCA,earnings,100,50,8/5/2021
824CCA,earnings,100,50,8/5/2021
824CCA,earnings,100,50,8/5/2021
824CCA,earnings,100,50,8/5/2021
82E58A,earnings,100,50,8/5/2021
82FD6D,earnings,100,50,8/5/2021
834152,earnings,100,50,8/5/2021
838ADD,buybacks,100,74,8/5/2021
83A065,earnings,100,50,8/5/2021
83E0AC,earnings,100,50,8/5/2021
848C0B,earnings,100,50,8/5/2021
8.40E+120,earnings,100,50,8/5/2021
855DF7,earnings,100,50,8/5/2021
858942,earnings,100,50,8/5/2021
85CDC9,earnings,100,50,8/5/2021
85DE00,earnings,100,50,8/5/2021
85DE00,dividend,100,50,8/5/2021
860AB6,acquisition-completed-acquirer,100,49,8/5/2021
8614A2,earnings,100,50,8/5/2021
86A1B9,earnings,100,50,8/5/2021
86A1B9,earnings,100,50,8/5/2021
86A1B9,earnings,100,50,8/5/2021
86A1B9,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
86AA9C,earnings,100,50,8/5/2021
873DB9,earnings,100,50,8/5/2021
873DB9,earnings,100,50,8/5/2021
873DB9,earnings,100,50,8/5/2021
873DB9,earnings,100,50,8/5/2021
873DB9,earnings,100,50,8/5/2021
88923D,earnings,100,50,8/5/2021
88923D,earnings,100,50,8/5/2021
88923D,earnings,100,50,8/5/2021
88923D,earnings,100,50,8/5/2021
88923D,earnings,100,50,8/5/2021
88923D,earnings,100,50,8/5/2021
890FF4,earnings,100,50,8/5/2021
890FF4,earnings,100,50,8/5/2021
890FF4,earnings,100,50,8/5/2021
890FF4,earnings,100,50,8/5/2021
890FF4,earnings,100,50,8/5/2021
890FF4,earnings,100,50,8/5/2021
895D56,earnings,100,50,8/5/2021
89FBB1,earnings,100,50,8/5/2021
89FBB1,earnings,100,50,8/5/2021
89FBB1,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B1F37,earnings,100,50,8/5/2021
8B9B3B,earnings,100,50,8/5/2021
8BAA15,earnings,100,50,8/5/2021
8BAA15,earnings,100,50,8/5/2021
8BFAA4,revenue-up,100,69,8/5/2021
8BFAA4,revenue-up,100,69,8/5/2021
8BFAA4,revenue-up,100,69,8/5/2021
8BFAA4,revenue-up,100,69,8/5/2021
8C6C1B,conference-call,100,50,8/5/2021
8DBBE6,earnings,100,50,8/5/2021
8DE74B,dividend,100,50,8/5/2021
8E4F9A,operating-earnings,100,50,8/5/2021
8EF425,note-sale,100,52,8/5/2021
8EF425,note-sale,100,52,8/5/2021
90D6A5,earnings,100,50,8/5/2021
918D6D,patient-enrollment-complete,100,64,8/5/2021
92D230,earnings,100,50,8/5/2021
92D230,earnings,100,50,8/5/2021
92D230,earnings,100,50,8/5/2021
92D230,earnings,100,50,8/5/2021
92D230,earnings,100,50,8/5/2021
92D230,earnings,100,50,8/5/2021
92D230,earnings,100,50,8/5/2021
92D3A0,partnership,100,61,8/5/2021
931AE7,earnings,100,50,8/5/2021
9.39E+69,earnings,100,50,8/5/2021
93AD2E,earnings,100,50,8/5/2021
943239,earnings,100,50,8/5/2021
943239,earnings,100,50,8/5/2021
947B0B,earnings,100,50,8/5/2021
949625,earnings,100,50,8/5/2021
9546A5,earnings,100,50,8/5/2021
9548BB,dividend-up,100,53,8/5/2021
958938,earnings,100,50,8/5/2021
95A92E,earnings,100,50,8/5/2021
95C392,earnings,100,50,8/5/2021
95DC1F,partnership,100,61,8/5/2021
9.65E+09,earnings,100,50,8/5/2021
966DBE,earnings,100,50,8/5/2021
966DBE,earnings,100,50,8/5/2021
966DBE,earnings,100,50,8/5/2021
966DBE,earnings,100,50,8/5/2021
966DBE,earnings,100,50,8/5/2021
96A6CD,earnings,100,50,8/5/2021
971334,earnings,100,50,8/5/2021
971334,earnings,100,50,8/5/2021
971334,earnings,100,50,8/5/2021
971F7B,earnings,100,50,8/5/2021
971F7B,earnings,100,50,8/5/2021
971F7B,earnings,100,50,8/5/2021
971F7B,earnings,100,50,8/5/2021
971F7B,earnings,100,50,8/5/2021
97AAF6,earnings,100,50,8/5/2021
97AAF6,earnings,100,50,8/5/2021
97AAF6,earnings,100,50,8/5/2021
98CEBB,earnings,100,50,8/5/2021
9934AD,earnings,100,50,8/5/2021
9978F1,earnings,100,50,8/5/2021
99ACAD,dividend,100,50,8/5/2021
99ACAD,earnings,100,50,8/5/2021
99ACAD,earnings,100,50,8/5/2021
99B61C,earnings,100,50,8/5/2021
9A602D,dividend,100,50,8/5/2021
9ABD30,earnings,100,50,8/5/2021
9AF3DC,earnings,100,50,8/5/2021
9C009A,earnings,100,50,8/5/2021
9C5174,revenue-up,100,66,8/5/2021
9C5174,revenues,100,50,8/5/2021
9C5174,revenues,100,50,8/5/2021
9D3360,operating-earnings,100,50,8/5/2021
9D6A24,earnings,100,50,8/5/2021
9E0811,conference-participant,100,50,8/5/2021
9E575E,earnings,100,50,8/5/2021
9E5C2C,earnings,100,50,8/5/2021
9E98F2,earnings,100,50,8/5/2021
9E98F2,earnings,100,50,8/5/2021
9E98F2,earnings,100,50,8/5/2021
9EA947,executive-appointment,100,54,8/5/2021
9EF4CF,earnings,100,50,8/5/2021
9F048E,earnings,100,50,8/5/2021
9F048E,earnings,100,50,8/5/2021
9F048E,earnings,100,50,8/5/2021
9F048E,earnings,100,50,8/5/2021
9F048E,earnings,100,50,8/5/2021
9F048E,earnings,100,50,8/5/2021
9F5CBB,earnings,100,50,8/5/2021
9F62D1,dividend,100,50,8/5/2021
9FF5F1,earnings,100,50,8/5/2021
A017F4,executive-appointment,100,54,8/5/2021
A072C4,earnings,100,50,8/5/2021
A1BB98,earnings,100,50,8/5/2021
A1BB98,earnings,100,50,8/5/2021
A1BB98,earnings,100,50,8/5/2021
A1BB98,earnings,100,50,8/5/2021
A1BB98,earnings,100,50,8/5/2021
A1DBF0,earnings,100,50,8/5/2021
A1EAC8,earnings,100,50,8/5/2021
A21649,earnings,100,50,8/5/2021
A26EF7,earnings,100,50,8/5/2021
A2C979,earnings,100,50,8/5/2021
A403CF,earnings,100,50,8/5/2021
A403CF,dividend,100,50,8/5/2021
A4B899,note-sale,100,52,8/5/2021
A5195E,earnings,100,50,8/5/2021
A52533,earnings,100,50,8/5/2021
A52533,earnings,100,50,8/5/2021
A6FE1C,acquisition-acquirer,100,49,8/5/2021
A7A0BD,conference-participant,100,50,8/5/2021
A868C9,revenue-up,100,71,8/5/2021
A868C9,revenue-up,100,71,8/5/2021
A868C9,revenue-up,100,71,8/5/2021
A8E2FE,earnings,100,50,8/5/2021
A8FDE8,earnings,100,50,8/5/2021
A8FDE8,earnings,100,50,8/5/2021
A94637,revenue-up,100,69,8/5/2021
A94637,revenue-up,100,69,8/5/2021
A94637,revenue-up,100,69,8/5/2021
AB4A7E,earnings,100,50,8/5/2021
AB4A7E,earnings,100,50,8/5/2021
AB4A7E,earnings,100,50,8/5/2021
AB4A7E,earnings,100,50,8/5/2021
ABAA03,conference-call,100,50,8/5/2021
ABB493,earnings,100,50,8/5/2021
AC3584,revenue-up,100,69,8/5/2021
AC3584,earnings,100,50,8/5/2021
AC3584,earnings,100,50,8/5/2021
AC642C,earnings,100,50,8/5/2021
AC642C,earnings,100,50,8/5/2021
AC7C4F,business-contract,100,69,8/5/2021
AD1ACF,partnership,100,61,8/5/2021
AE3113,note-sale,100,52,8/5/2021
AE4125,earnings-up,100,68,8/5/2021
AE4125,earnings,100,50,8/5/2021
AE4125,earnings,100,50,8/5/2021
AEFC90,earnings,100,50,8/5/2021
AFBEB4,earnings,100,50,8/5/2021
AFD7DD,earnings,100,50,8/5/2021
AFD7DD,earnings,100,50,8/5/2021
AFD7DD,earnings,100,50,8/5/2021
B01215,earnings,100,50,8/5/2021
B04426,earnings,100,50,8/5/2021
B08C51,earnings,100,50,8/5/2021
B0998E,earnings,100,50,8/5/2021
B106FA,earnings,100,50,8/5/2021
B106FA,earnings,100,50,8/5/2021
B1FC3B,business-contract,100,69,8/5/2021
B2256A,earnings-up,100,68,8/5/2021
B2E6B5,partnership,100,61,8/5/2021
B3ED62,revenue-up,100,69,8/5/2021
B508E5,earnings,100,50,8/5/2021
B5DE80,earnings,100,50,8/5/2021
B642E8,earnings,100,50,8/5/2021
B642E8,earnings,100,50,8/5/2021
B642E8,earnings,100,50,8/5/2021
B642E8,earnings,100,50,8/5/2021
B642E8,earnings,100,50,8/5/2021
B642E8,earnings,100,50,8/5/2021
B6843B,earnings,100,50,8/5/2021
B7202A,earnings-up,100,68,8/5/2021
B7202A,earnings-up,100,68,8/5/2021
B7202A,earnings-up,100,68,8/5/2021
B72D2E,partnership,100,61,8/5/2021
B77F14,business-contract,100,69,8/5/2021
B80AD1,earnings,100,50,8/5/2021
B83BCE,conference-participant,100,50,8/5/2021
B83D67,earnings-up,100,68,8/5/2021
B8DD94,conference-call,100,50,8/5/2021
B8DD94,conference-participant,100,50,8/5/2021
B9764A,buybacks,100,74,8/5/2021
BAAA60,dividend,100,50,8/5/2021
BB07E4,dividend,100,50,8/5/2021
BBF349,earnings,100,50,8/5/2021
BCC55F,earnings,100,50,8/5/2021
BDA775,earnings,100,50,8/5/2021
BDCC11,earnings,100,50,8/5/2021
BE5935,earnings,100,50,8/5/2021
C0030A,partnership,100,61,8/5/2021
C01737,earnings,100,50,8/5/2021
C03C8B,earnings,100,50,8/5/2021
C03C8B,earnings,100,50,8/5/2021
C03C8B,earnings,100,50,8/5/2021
C03C8B,earnings,100,50,8/5/2021
C03C8B,earnings,100,50,8/5/2021
C03C8B,earnings,100,50,8/5/2021
C03C8B,earnings,100,50,8/5/2021
C2609A,earnings,100,50,8/5/2021
C2E39B,earnings,100,50,8/5/2021
C2E39B,earnings,100,50,8/5/2021
C2E39B,earnings,100,50,8/5/2021
C2E39B,earnings,100,50,8/5/2021
C2F597,revenue-up,100,69,8/5/2021
C2F597,revenue-up,100,69,8/5/2021
C2F597,revenue-up,100,69,8/5/2021
C2F597,revenue-up,100,69,8/5/2021
C36189,conference-participant,100,50,8/5/2021
C38440,earnings,100,50,8/5/2021
C3BAE7,earnings-up,100,68,8/5/2021
C3BAE7,earnings,100,50,8/5/2021
C3BAE7,earnings,100,50,8/5/2021
C3BAE7,earnings,100,50,8/5/2021
C3BAE7,earnings,100,50,8/5/2021
C3BAE7,earnings,100,50,8/5/2021
C3BAE7,earnings,100,50,8/5/2021
C3BAE7,earnings,100,50,8/5/2021
C407A0,earnings,100,50,8/5/2021
C4706C,earnings,100,50,8/5/2021
C4A912,earnings,100,50,8/5/2021
C4A912,earnings,100,50,8/5/2021
C4A912,earnings,100,50,8/5/2021
C4A912,earnings,100,50,8/5/2021
C501B6,earnings,100,50,8/5/2021
C58D71,acquisition-completed-acquiree,100,76,8/5/2021
C5C0E9,earnings,100,50,8/5/2021
C5E100,earnings,100,50,8/5/2021
C659EB,dividend,100,50,8/5/2021
C66A8C,earnings,100,50,8/5/2021
C66A8C,earnings,100,50,8/5/2021
C66A8C,earnings,100,50,8/5/2021
C66A8C,earnings,100,50,8/5/2021
C6C702,earnings,100,50,8/5/2021
C72B8F,conference-participant,100,50,8/5/2021
C8A059,earnings,100,50,8/5/2021
C9C62A,earnings,100,50,8/5/2021
C9D866,conference-participant,100,50,8/5/2021
C9E4EC,earnings,100,50,8/5/2021
CA3CB9,earnings,100,50,8/5/2021
CA3CB9,investment-investor,100,55,8/5/2021
CBDB4D,earnings,100,50,8/5/2021
CCB623,earnings,100,50,8/5/2021
CDE51C,award,100,58,8/5/2021
CE2791,earnings,100,50,8/5/2021
CE4E6D,earnings,100,50,8/5/2021
CE4E6D,earnings,100,50,8/5/2021
CE4E6D,earnings,100,50,8/5/2021
CE4E6D,earnings,100,50,8/5/2021
CE4E6D,earnings,100,50,8/5/2021
CE5C6E,partnership,100,61,8/5/2021
CE5C6E,earnings,100,50,8/5/2021
CE5C6E,earnings,100,50,8/5/2021
CE96E7,conference-participant,100,50,8/5/2021
CEC5B9,earnings,100,50,8/5/2021
CEC5B9,earnings,100,50,8/5/2021
CF3FF9,earnings,100,50,8/5/2021
CFB6CA,earnings,100,50,8/5/2021
CFB6CA,earnings,100,50,8/5/2021
CFD4B6,earnings,100,50,8/5/2021
CFD4B6,earnings,100,50,8/5/2021
CFD4B6,earnings,100,50,8/5/2021
CFF15D,acquisition-interest-acquirer,100,46,8/5/2021
D08D2C,note-sale,100,52,8/5/2021
D09938,earnings,100,50,8/5/2021
D11C1C,operating-earnings,100,50,8/5/2021
D33270,business-contract,100,69,8/5/2021
D36B23,earnings,100,50,8/5/2021
D3F64D,earnings,100,50,8/5/2021
D3F64D,earnings,100,50,8/5/2021
D3F64D,earnings,100,50,8/5/2021
D3F64D,earnings,100,50,8/5/2021
D3F64D,earnings,100,50,8/5/2021
D3FA2C,earnings,100,50,8/5/2021
D4070C,dividend,100,50,8/5/2021
D64C6D,dividend,100,50,8/5/2021
D64EDF,earnings,100,50,8/5/2021
D75910,product-release,100,64,8/5/2021
D90F43,partnership,100,61,8/5/2021
D9B1C9,executive-appointment,100,54,8/5/2021
DA9443,earnings,100,50,8/5/2021
DB5CA5,earnings,100,50,8/5/2021
DB7EC3,earnings,100,50,8/5/2021
DB7EC3,earnings,100,50,8/5/2021
DB7EC3,earnings,100,50,8/5/2021
DB7EC3,earnings,100,50,8/5/2021
DB9F70,earnings,100,50,8/5/2021
DC0D18,earnings-up,100,68,8/5/2021
DD0F15,earnings,100,50,8/5/2021
DD1BA1,earnings,100,50,8/5/2021
DD9E41,executive-appointment,100,54,8/5/2021
DDCB34,dividend,100,50,8/5/2021
DDCB34,earnings,100,50,8/5/2021
DDEA6A,earnings,100,50,8/5/2021
DE5611,conference-call,100,50,8/5/2021
DF01B1,executive-appointment,100,54,8/5/2021
DF16DE,earnings,100,50,8/5/2021
DF18E6,earnings,100,50,8/5/2021
DF18E6,earnings,100,50,8/5/2021
DF1F7A,earnings,100,50,8/5/2021
DF5F14,earnings,100,50,8/5/2021
DFADDB,clinical-trials-positive,100,87,8/5/2021
E0D3BA,earnings,100,50,8/5/2021
E0E4B7,business-contract,100,69,8/5/2021
E0E4B7,earnings,100,50,8/5/2021
E11C41,earnings,100,50,8/5/2021
E16133,earnings,100,50,8/5/2021
E16133,earnings,100,50,8/5/2021
E16133,earnings,100,50,8/5/2021
E16133,earnings,100,50,8/5/2021
E19A99,earnings,100,50,8/5/2021
E22FDE,earnings,100,50,8/5/2021
E2CB7B,earnings,100,50,8/5/2021
E2CFD2,earnings-up,100,68,8/5/2021
E2F66E,earnings,100,50,8/5/2021
E2F66E,earnings,100,50,8/5/2021
E2F66E,earnings,100,50,8/5/2021
E2F66E,earnings,100,50,8/5/2021
E30A8F,earnings,100,50,8/5/2021
E30A8F,earnings,100,50,8/5/2021
E30A8F,earnings,100,50,8/5/2021
E30A8F,earnings,100,50,8/5/2021
E30A8F,earnings,100,50,8/5/2021
E30A8F,earnings,100,50,8/5/2021
E35610,earnings,100,50,8/5/2021
E35610,earnings,100,50,8/5/2021
E35610,earnings,100,50,8/5/2021
E35610,earnings,100,50,8/5/2021
E3A829,earnings,100,50,8/5/2021
E3A829,earnings,100,50,8/5/2021
E3A829,earnings,100,50,8/5/2021
E3A829,earnings,100,50,8/5/2021
E3A829,earnings,100,50,8/5/2021
E49AA3,earnings,100,50,8/5/2021
E56A0D,conference-participant,100,50,8/5/2021
E610CD,earnings,100,50,8/5/2021
E610CD,earnings,100,50,8/5/2021
E67C2C,earnings,100,50,8/5/2021
E68733,business-contract,100,69,8/5/2021
E68733,business-contract,100,69,8/5/2021
E6A53A,dividend,100,50,8/5/2021
E6C8DC,earnings,100,50,8/5/2021
E6C8DC,fraud,100,44,8/5/2021
E6D89E,earnings,100,50,8/5/2021
E6D89E,earnings,100,50,8/5/2021
E6D89E,earnings,100,50,8/5/2021
E6D89E,earnings,100,50,8/5/2021
E82A2D,earnings,100,50,8/5/2021
E8F0E2,earnings,100,50,8/5/2021
E94704,dividend,100,50,8/5/2021
E9C7C0,earnings-up,100,68,8/5/2021
E9C7C0,earnings-up,100,68,8/5/2021
E9C7C0,earnings-up,100,68,8/5/2021
E9C7C0,earnings-up,100,68,8/5/2021
E9C7C0,earnings-up,100,68,8/5/2021
E9C7C0,earnings-up,100,68,8/5/2021
EA79C7,earnings,100,50,8/5/2021
EAA0A7,earnings,100,50,8/5/2021
EAA0A7,earnings,100,50,8/5/2021
EAA0A7,earnings,100,50,8/5/2021
EAA0A7,earnings,100,50,8/5/2021
EAA0A7,earnings,100,50,8/5/2021
EAA0A7,earnings,100,50,8/5/2021
EAEBF3,earnings,100,50,8/5/2021
EBD89A,conference-call,100,50,8/5/2021
ED3CA8,earnings,100,50,8/5/2021
ED9C04,earnings,100,50,8/5/2021
ED9C04,earnings,100,50,8/5/2021
ED9C04,earnings,100,50,8/5/2021
EE04F0,earnings,100,50,8/5/2021
EE04F0,earnings,100,50,8/5/2021
EE04F0,earnings,100,50,8/5/2021
EE04F0,earnings,100,50,8/5/2021
EE04F0,earnings,100,50,8/5/2021
EE04F0,earnings,100,50,8/5/2021
EE04F0,earnings,100,50,8/5/2021
EE04F0,earnings,100,50,8/5/2021
EEBCEF,public-offering,100,43,8/5/2021
EF25A5,earnings,100,50,8/5/2021
EF25A5,earnings,100,50,8/5/2021
EF25A5,earnings,100,50,8/5/2021
EF25A5,earnings,100,50,8/5/2021
EF25A5,partnership,100,61,8/5/2021
EF5914,earnings,100,50,8/5/2021
EF7163,earnings,100,50,8/5/2021
F0027C,earnings,100,50,8/5/2021
F2E253,earnings,100,50,8/5/2021
F3816D,conference-call,100,50,8/5/2021
F47871,earnings,100,50,8/5/2021
F4D241,earnings,100,50,8/5/2021
F4F46F,earnings,100,50,8/5/2021
F4FBD8,executive-appointment,100,54,8/5/2021
F4FBD8,earnings,100,50,8/5/2021
F51DB0,earnings,100,50,8/5/2021
F6581D,conference-call,100,50,8/5/2021
F6E248,partnership,100,61,8/5/2021
F6FF0D,earnings,100,50,8/5/2021
F6FF0D,earnings,100,50,8/5/2021
F6FF0D,earnings,100,50,8/5/2021
F6FF0D,earnings,100,50,8/5/2021
F73DD1,dividend,100,50,8/5/2021
F748C7,executive-appointment,100,54,8/5/2021
F7D8AE,acquisition-completed-acquirer,100,49,8/5/2021
F83279,earnings,100,50,8/5/2021
F83279,earnings,100,50,8/5/2021
F88A04,earnings-up,100,68,8/5/2021
F93C8A,earnings,100,50,8/5/2021
F9AA02,earnings,100,50,8/5/2021
F9CAF8,dividend,100,50,8/5/2021
FAB97A,business-contract,100,69,8/5/2021
FAB97A,revenues,100,50,8/5/2021
FAE021,dividend,100,50,8/5/2021
FAE021,dividend,100,50,8/5/2021
FBD92D,earnings-up,100,68,8/5/2021
FC1F9D,dividend,100,50,8/5/2021
FC4550,dividend,100,50,8/5/2021
FD39EB,earnings,100,50,8/5/2021
FDE409,conference-participant,100,50,8/5/2021
FEE4B0,earnings-up,100,68,8/5/2021
FEE4B0,earnings-up,100,68,8/5/2021
FEE4B0,earnings-up,100,68,8/5/2021
FEE4B0,earnings-up,100,68,8/5/2021
03F5A4,acquisition-completed-acquiree,100,76,8/6/2021
03F5A4,acquisition-completed-acquiree,100,76,8/6/2021
07C69F,acquisition-acquirer,100,49,8/6/2021
84625,earnings,100,50,8/6/2021
84625,earnings,100,50,8/6/2021
0BD970,earnings,100,50,8/6/2021
0C6861,earnings,100,50,8/6/2021
102F04,earnings,100,50,8/6/2021
112694,earnings,100,50,8/6/2021
12DE76,partnership,100,61,8/6/2021
15A388,award,100,58,8/6/2021
165B86,earnings,100,50,8/6/2021
16AAE0,earnings,100,50,8/6/2021
16B882,earnings,100,50,8/6/2021
1AB023,earnings,100,50,8/6/2021
1AB023,earnings,100,50,8/6/2021
1AB023,earnings,100,50,8/6/2021
1E4FB9,merger-regulatory-scrutiny,100,37,8/6/2021
239106,earnings,100,50,8/6/2021
239106,earnings,100,50,8/6/2021
239106,earnings,100,50,8/6/2021
253604,earnings,100,50,8/6/2021
27A791,earnings,100,50,8/6/2021
27A791,earnings,100,50,8/6/2021
27A791,earnings,100,50,8/6/2021
27A791,earnings,100,50,8/6/2021
297DA8,earnings,100,50,8/6/2021
353DBB,dividend,100,50,8/6/2021
35F4B5,dividend,100,50,8/6/2021
3798B9,conference-participant,100,50,8/6/2021
3B37F7,note-sale,100,52,8/6/2021
3CBA2A,donation,100,54,8/6/2021
3FACA7,stake-acquirer,100,48,8/6/2021
41ED98,earnings,100,50,8/6/2021
43A060,partnership,100,61,8/6/2021
44A4FC,earnings,100,50,8/6/2021
45ABCC,conference-participant,100,50,8/6/2021
46CF27,acquisition-completed-acquirer,100,49,8/6/2021
46CF27,acquisition-completed-acquirer,100,49,8/6/2021
499C75,earnings,100,50,8/6/2021
49CC59,earnings,100,50,8/6/2021
49CC59,buybacks,100,74,8/6/2021
4BBA23,earnings,100,50,8/6/2021
4C37C5,conference-participant,100,50,8/6/2021
519FE0,note-sale,100,52,8/6/2021
54DF47,earnings,100,50,8/6/2021
59DB8C,executive-appointment,100,54,8/6/2021
59DB8C,earnings,100,50,8/6/2021
5D0337,executive-resignation,100,44,8/6/2021
5FC507,earnings,100,50,8/6/2021
615B6D,earnings,100,50,8/6/2021
64636E,earnings,100,50,8/6/2021
68BA15,acquisition-acquiree,100,76,8/6/2021
6A6BDC,earnings,100,50,8/6/2021
6AACDD,legal-issues-defendant,100,22,8/6/2021
6CBF41,conference-participant,100,50,8/6/2021
705636,dividend,100,50,8/6/2021
73A213,conference-participant,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7999F3,earnings,100,50,8/6/2021
7B9AFA,conference-participant,100,50,8/6/2021
7BAAE7,dividend,100,50,8/6/2021
7BFF81,partnership,100,61,8/6/2021
7F2922,earnings,100,50,8/6/2021
83E0AC,conference-call,100,50,8/6/2021
87486A,earnings,100,50,8/6/2021
87486A,earnings,100,50,8/6/2021
87486A,earnings,100,50,8/6/2021
87486A,earnings,100,50,8/6/2021
87486A,earnings,100,50,8/6/2021
8BAA15,conference-participant,100,50,8/6/2021
918D6D,earnings,100,50,8/6/2021
944B2E,earnings,100,50,8/6/2021
94983E,dividend,100,50,8/6/2021
949D62,note-sale,100,52,8/6/2021
96B4FF,earnings,100,50,8/6/2021
977A1E,earnings,100,50,8/6/2021
97FE80,conference-call,100,50,8/6/2021
990AD0,conference-organizer,100,57,8/6/2021
9EA947,dividend,100,50,8/6/2021
A4BCDE,earnings,100,50,8/6/2021
A87CD6,dividend,100,50,8/6/2021
AE3113,note-sale,100,52,8/6/2021
B1B10C,executive-appointment,100,54,8/6/2021
B4F5F4,earnings,100,50,8/6/2021
B72BE9,dividend,100,50,8/6/2021
B803B1,earnings,100,50,8/6/2021
B8A51F,conference-participant,100,50,8/6/2021
BBF349,conference-participant,100,50,8/6/2021
BC948D,earnings,100,50,8/6/2021
BDCC11,executive-appointment,100,54,8/6/2021
BDE867,earnings-above-expectations,100,88,8/6/2021
BDE867,earnings-above-expectations,100,88,8/6/2021
BDE867,earnings-above-expectations,100,88,8/6/2021
BDE867,earnings-above-expectations,100,88,8/6/2021
C0200F,buybacks,100,74,8/6/2021
C4FBDC,conference-participant,100,50,8/6/2021
C54140,earnings,100,50,8/6/2021
C5E100,award,100,58,8/6/2021
C624A1,legal-issues-defendant,100,22,8/6/2021
C85A72,revenue-up,100,77,8/6/2021
C85A72,revenue-up,100,77,8/6/2021
C85A72,revenue-up,100,77,8/6/2021
C85A72,revenue-up,100,77,8/6/2021
C85A72,revenue-up,100,77,8/6/2021
C85A72,revenue-up,100,77,8/6/2021
C85A72,revenue-up,100,77,8/6/2021
C9A96E,earnings,100,50,8/6/2021
CEC08B,earnings,100,50,8/6/2021
CEC08B,earnings,100,50,8/6/2021
CEC08B,earnings,100,50,8/6/2021
CEC08B,earnings,100,50,8/6/2021
CEC08B,earnings,100,50,8/6/2021
CFD4B6,dividend,100,50,8/6/2021
D6853F,earnings-guidance-up,100,83,8/6/2021
D6853F,earnings-guidance-up,100,83,8/6/2021
D6853F,earnings-guidance-up,100,83,8/6/2021
DAFED3,earnings,100,50,8/6/2021
DAFED3,earnings,100,50,8/6/2021
DAFED3,earnings,100,50,8/6/2021
DAFED3,earnings,100,50,8/6/2021
DB2E4E,public-offering,100,43,8/6/2021
DB396B,earnings,100,50,8/6/2021
DB396B,earnings,100,50,8/6/2021
DB396B,earnings,100,50,8/6/2021
DB396B,earnings,100,50,8/6/2021
DF204B,earnings,100,50,8/6/2021
E3656D,earnings,100,50,8/6/2021
E5752F,earnings,100,50,8/6/2021
E5752F,earnings,100,50,8/6/2021
E5752F,earnings,100,50,8/6/2021
E5752F,earnings,100,50,8/6/2021
E68733,acquisition-acquirer,100,49,8/6/2021
E68733,acquisition-acquirer,100,49,8/6/2021
E68733,acquisition-acquirer,100,49,8/6/2021
E68733,acquisition-acquirer,100,49,8/6/2021
E74B55,legal-issues-defendant,100,22,8/6/2021
EBC84C,dividend,100,50,8/6/2021
ECE814,conference-participant,100,50,8/6/2021
F00285,earnings,100,50,8/6/2021
F1C04C,dividend,100,50,8/6/2021
F48947,acquisition-acquiree,100,76,8/6/2021
F48947,acquisition-acquiree,100,76,8/6/2021
F48947,acquisition-acquiree,100,76,8/6/2021
F48947,acquisition-acquiree,100,76,8/6/2021
F48947,earnings,100,50,8/6/2021
F48947,acquisition-regulatory-scrutiny-acquiree,100,38,8/6/2021
F721A7,earnings,100,50,8/6/2021
F73DD1,earnings,100,50,8/6/2021
F73DD1,earnings,100,50,8/6/2021
F73DD1,earnings,100,50,8/6/2021
F73DD1,earnings,100,50,8/6/2021
F73DD1,earnings,100,50,8/6/2021
F73DD1,earnings,100,50,8/6/2021
F73DD1,earnings,100,50,8/6/2021
F73DD1,earnings,100,50,8/6/2021
FA918D,public-offering,100,43,8/6/2021
FAAFA2,conference-participant,100,50,8/6/2021
FF227B,earnings,100,50,8/6/2021
FF4343,note-sale,100,52,8/6/2021
1E4FB9,legal-issues-defendant,100,22,8/7/2021
4A7C1F,legal-issues-defendant,100,22,8/7/2021
54512F,legal-issues-defendant,100,22,8/7/2021
68E6E9,legal-issues-defendant,100,22,8/7/2021
6AACDD,legal-issues-defendant,100,22,8/7/2021
A02FB1,legal-issues-defendant,100,22,8/7/2021
A99576,legal-issues-defendant,100,22,8/7/2021
C65004,legal-issues-defendant,100,22,8/7/2021
DF11D9,legal-issues-defendant,100,22,8/7/2021
E393B0,legal-issues-defendant,100,22,8/7/2021
EB7D6C,legal-issues-defendant,100,22,8/7/2021
F48947,legal-issues-defendant,100,22,8/7/2021
4E6F5A,legal-issues-defendant,100,22,8/8/2021
002A99,earnings,100,50,8/9/2021
00698D,acquisition-acquiree,100,76,8/9/2021
00698D,acquisition-regulatory-scrutiny-acquiree,100,38,8/9/2021
0157B1,partnership,100,61,8/9/2021
02FC1A,earnings,100,50,8/9/2021
02FC1A,earnings,100,50,8/9/2021
0325B7,earnings,100,50,8/9/2021
03542C,earnings,100,50,8/9/2021
03596A,earnings,100,50,8/9/2021
03C94A,earnings-up,100,68,8/9/2021
03C94A,earnings,100,50,8/9/2021
040DBB,revenue-up,100,88,8/9/2021
040DBB,revenues,100,50,8/9/2021
040DBB,revenues,100,50,8/9/2021
040DBB,revenues,100,50,8/9/2021
040DBB,revenues,100,50,8/9/2021
040DBB,revenues,100,50,8/9/2021
0490C6,earnings,100,50,8/9/2021
0490C6,earnings,100,50,8/9/2021
0490C6,earnings,100,50,8/9/2021
0490C6,earnings,100,50,8/9/2021
0490C6,earnings,100,50,8/9/2021
04996E,executive-appointment,100,54,8/9/2021
04996E,earnings,100,50,8/9/2021
04996E,earnings,100,50,8/9/2021
04996E,earnings,100,50,8/9/2021
061A3B,product-price-raise,100,57,8/9/2021
099C88,business-contract,100,69,8/9/2021
0A6824,earnings,100,50,8/9/2021
0A7650,ipo-completed,100,76,8/9/2021
0B7375,earnings,100,50,8/9/2021
0C6293,earnings,100,50,8/9/2021
0E5619,earnings,100,50,8/9/2021
0ED415,executive-appointment,100,54,8/9/2021
0FC848,earnings,100,50,8/9/2021
1279ED,earnings,100,50,8/9/2021
12A3A3,dividend,100,50,8/9/2021
12E454,partnership,100,61,8/9/2021
133644,earnings,100,50,8/9/2021
13A782,earnings,100,50,8/9/2021
147098,earnings,100,50,8/9/2021
152B9E,executive-appointment,100,54,8/9/2021
152FA5,executive-appointment,100,54,8/9/2021
152FA5,earnings,100,50,8/9/2021
15789A,earnings,100,50,8/9/2021
15789A,earnings,100,50,8/9/2021
15789A,earnings,100,50,8/9/2021
15789A,earnings,100,50,8/9/2021
1880C5,earnings,100,50,8/9/2021
18D9FA,earnings,100,50,8/9/2021
1921DD,partnership,100,61,8/9/2021
197612,dividend,100,50,8/9/2021
1AE9D5,revenue-up,100,69,8/9/2021
1AE9D5,revenue-up,100,69,8/9/2021
1CF3A8,earnings,100,50,8/9/2021
1DB833,earnings,100,50,8/9/2021
1DDEDA,executive-appointment,100,54,8/9/2021
1F43A1,public-offering,100,43,8/9/2021
20403D,earnings,100,50,8/9/2021
21245F,earnings,100,50,8/9/2021
21245F,earnings,100,50,8/9/2021
21245F,earnings,100,50,8/9/2021
228D42,partnership,100,61,8/9/2021
228D42,joint-venture,100,62,8/9/2021
228D42,joint-venture,100,62,8/9/2021
228D42,joint-venture,100,62,8/9/2021
238302,earnings,100,50,8/9/2021
25102A,conference-participant,100,50,8/9/2021
28AF37,executive-appointment,100,54,8/9/2021
28F905,note-sale,100,52,8/9/2021
292388,supply-increase,100,74,8/9/2021
292388,earnings-up,100,68,8/9/2021
2C7505,patient-enrollment-complete,100,64,8/9/2021
2C7505,patient-enrollment-complete,100,64,8/9/2021
2FF046,conference-participant,100,50,8/9/2021
306623,public-offering,100,43,8/9/2021
30A565,partnership,100,61,8/9/2021
31F25C,merger-regulatory-approval,100,81,8/9/2021
31F25C,merger-regulatory-approval,100,81,8/9/2021
33AD83,product-release,100,64,8/9/2021
33E8C7,note-sale,100,52,8/9/2021
33E8C7,note-sale,100,52,8/9/2021
346BF2,conference-participant,100,50,8/9/2021
34B411,merger-regulatory-approval,100,81,8/9/2021
34B411,merger-regulatory-approval,100,81,8/9/2021
36529A,earnings,100,50,8/9/2021
37E18B,conference-call,100,50,8/9/2021
3A1C46,earnings,100,50,8/9/2021
3AAEAE,earnings,100,50,8/9/2021
3BB7D3,earnings,100,50,8/9/2021
3C75D6,earnings,100,50,8/9/2021
3DB18B,partnership,100,61,8/9/2021
3DB18B,executive-appointment,100,54,8/9/2021
3E39A5,earnings,100,50,8/9/2021
3E39A5,earnings,100,50,8/9/2021
3E39A5,earnings,100,50,8/9/2021
3EE65E,earnings,100,50,8/9/2021
3F1C69,earnings,100,50,8/9/2021
3F96D5,earnings,100,50,8/9/2021
3F96D5,buybacks,100,74,8/9/2021
3FACA7,stake-acquirer,100,48,8/9/2021
43A060,earnings,100,50,8/9/2021
43A060,earnings,100,50,8/9/2021
43A060,earnings,100,50,8/9/2021
450ECB,revenues,100,50,8/9/2021
450ECB,revenues,100,50,8/9/2021
450ECB,revenues,100,50,8/9/2021
4.60E+06,acquisition-acquirer,100,49,8/9/2021
4.60E+06,acquisition-acquirer,100,49,8/9/2021
47B4CC,conference-call,100,50,8/9/2021
4806CE,acquisition-regulatory-approval-acquirer,100,54,8/9/2021
4AC91D,earnings,100,50,8/9/2021
4D229C,executive-appointment,100,54,8/9/2021
50D1EC,earnings,100,50,8/9/2021
519FE0,earnings,100,50,8/9/2021
51D876,conference-participant,100,50,8/9/2021
524CE4,product-release,100,64,8/9/2021
52B567,public-offering,100,43,8/9/2021
532D47,unit-acquisition-acquirer,100,49,8/9/2021
539F49,earnings,100,50,8/9/2021
53EF9E,dividend,100,50,8/9/2021
54512F,earnings,100,50,8/9/2021
546A27,earnings,100,50,8/9/2021
55ACCB,conference-participant,100,50,8/9/2021
55ACCB,legal-issues-plaintiff,100,44,8/9/2021
5968F9,executive-appointment,100,54,8/9/2021
5A53BF,partnership,100,61,8/9/2021
5A53BF,partnership,100,61,8/9/2021
5A53BF,earnings,100,50,8/9/2021
5B226B,earnings,100,50,8/9/2021
5B51D6,conference-participant,100,50,8/9/2021
5C2A47,earnings,100,50,8/9/2021
5D16CF,acquisition-completed-acquirer,100,49,8/9/2021
5D41E4,executive-appointment,100,54,8/9/2021
5DAF89,conference-participant,100,50,8/9/2021
5F2FF7,business-contract,100,69,8/9/2021
615B6D,earnings,100,50,8/9/2021
615B6D,earnings,100,50,8/9/2021
619882,conference-organizer,100,57,8/9/2021
619882,conference-organizer,100,57,8/9/2021
619882,conference-organizer,100,57,8/9/2021
61E975,earnings-positive,100,69,8/9/2021
6284B5,conference-participant,100,50,8/9/2021
62B1C6,buybacks,100,74,8/9/2021
62F41C,unit-acquisition-acquiree,100,76,8/9/2021
64FF65,earnings,100,50,8/9/2021
6.52E+64,partnership,100,61,8/9/2021
65CF8E,earnings,100,50,8/9/2021
65CF8E,earnings,100,50,8/9/2021
665D7D,partnership,100,61,8/9/2021
67303E,earnings,100,50,8/9/2021
673C9A,earnings,100,50,8/9/2021
68AB62,earnings,100,50,8/9/2021
6925EB,earnings,100,50,8/9/2021
69C99E,earnings,100,50,8/9/2021
69CE71,note-sale,100,52,8/9/2021
69FDFC,earnings,100,50,8/9/2021
69FDFC,acquisition-acquirer,100,49,8/9/2021
6A01DF,conference-participant,100,50,8/9/2021
6A171E,earnings,100,50,8/9/2021
6AACDD,legal-issues-defendant,100,22,8/9/2021
6B494E,earnings,100,50,8/9/2021
6B6375,executive-appointment,100,54,8/9/2021
6B6375,earnings,100,50,8/9/2021
6B67BD,earnings,100,50,8/9/2021
6BDA0C,earnings,100,50,8/9/2021
6BDA0C,earnings,100,50,8/9/2021
6BDA0C,earnings,100,50,8/9/2021
6BDA0C,earnings,100,50,8/9/2021
6D0CAB,credit-extension-recipient,100,69,8/9/2021
6D0CAB,earnings,100,50,8/9/2021
6-Dec-05,earnings,100,50,8/9/2021
7122EB,earnings,100,50,8/9/2021
71B0CF,earnings,100,50,8/9/2021
73F70F,earnings,100,50,8/9/2021
7.45E+28,earnings,100,50,8/9/2021
748EB6,earnings,100,50,8/9/2021
763DBE,business-contract,100,69,8/9/2021
763DBE,earnings,100,50,8/9/2021
76DD0C,earnings,100,50,8/9/2021
7712CB,earnings,100,50,8/9/2021
7712CB,earnings,100,50,8/9/2021
7712CB,earnings,100,50,8/9/2021
7712CB,earnings,100,50,8/9/2021
7712CB,earnings,100,50,8/9/2021
7712CB,earnings,100,50,8/9/2021
78F776,credit-extension-recipient,100,69,8/9/2021
78F776,earnings,100,50,8/9/2021
791EC1,earnings,100,50,8/9/2021
7A10FF,business-contract,100,69,8/9/2021
7A2A49,earnings,100,50,8/9/2021
7F7464,earnings,100,50,8/9/2021
7F7C87,earnings,100,50,8/9/2021
7FDE1C,earnings,100,50,8/9/2021
817ED9,earnings,100,50,8/9/2021
8303CD,conference-participant,100,50,8/9/2021
845533,earnings-up,100,68,8/9/2021
845533,earnings,100,50,8/9/2021
845533,earnings,100,50,8/9/2021
845655,acquisition-acquirer,100,49,8/9/2021
845655,earnings,100,50,8/9/2021
845655,earnings,100,50,8/9/2021
845655,earnings,100,50,8/9/2021
845655,earnings,100,50,8/9/2021
845655,earnings,100,50,8/9/2021
845655,earnings,100,50,8/9/2021
845655,acquisition-acquirer,100,49,8/9/2021
845655,earnings,100,50,8/9/2021
845655,earnings,100,50,8/9/2021
845655,earnings,100,50,8/9/2021
845655,earnings,100,50,8/9/2021
845655,earnings,100,50,8/9/2021
8665BA,note-sale,100,52,8/9/2021
8665BA,note-sale,100,52,8/9/2021
868808,earnings,100,50,8/9/2021
877734,executive-appointment,100,54,8/9/2021
877C0C,earnings,100,50,8/9/2021
88193E,executive-appointment,100,54,8/9/2021
8DA42F,earnings,100,50,8/9/2021
8DA42F,earnings,100,50,8/9/2021
8DCF18,earnings,100,50,8/9/2021
8DCF18,earnings,100,50,8/9/2021
8DCF18,earnings,100,50,8/9/2021
8E0E32,note-sale,100,52,8/9/2021
8E3F58,partnership,100,61,8/9/2021
8E3F58,acquisition-acquirer,100,49,8/9/2021
8E3F58,acquisition-acquirer,100,49,8/9/2021
8E3F58,earnings,100,50,8/9/2021
8E4F9A,conference-participant,100,50,8/9/2021
8E8E6E,market-entry,100,57,8/9/2021
8FF2EF,dividend,100,50,8/9/2021
900356,note-sale,100,52,8/9/2021
9087B9,earnings,100,50,8/9/2021
911CA9,earnings,100,50,8/9/2021
911CA9,earnings,100,50,8/9/2021
913437,earnings,100,50,8/9/2021
934029,business-contract,100,69,8/9/2021
938D89,earnings,100,50,8/9/2021
97FE80,earnings,100,50,8/9/2021
97FE80,earnings,100,50,8/9/2021
97FE80,earnings,100,50,8/9/2021
981656,unit-acquisition-acquirer,100,49,8/9/2021
981656,unit-acquisition-acquirer,100,49,8/9/2021
986AF6,unit-acquisition-completed-acquirer,100,49,8/9/2021
9981C6,earnings,100,50,8/9/2021
9A602D,facility-open,100,65,8/9/2021
9B730A,earnings,100,50,8/9/2021
9C3D3C,earnings,100,50,8/9/2021
9C3D3C,earnings,100,50,8/9/2021
9C3D3C,earnings,100,50,8/9/2021
9C3D3C,earnings,100,50,8/9/2021
9C3D3C,earnings,100,50,8/9/2021
9C3D3C,earnings,100,50,8/9/2021
9CA8F4,note-sale,100,52,8/9/2021
9CA8F4,note-sale,100,52,8/9/2021
A01983,earnings,100,50,8/9/2021
A1EAC8,note-sale,100,52,8/9/2021
A28675,earnings,100,50,8/9/2021
A3800A,earnings,100,50,8/9/2021
A495F7,earnings,100,50,8/9/2021
A5195E,public-offering,100,43,8/9/2021
A6FC89,conference-call,100,50,8/9/2021
A79F7D,conference-participant,100,50,8/9/2021
A8E72A,earnings,100,50,8/9/2021
AC7AAE,earnings,100,50,8/9/2021
AD1ACF,earnings,100,50,8/9/2021
AD1ACF,earnings,100,50,8/9/2021
AD1ACF,earnings,100,50,8/9/2021
AD1ACF,earnings,100,50,8/9/2021
AD1ACF,earnings,100,50,8/9/2021
AD1ACF,earnings,100,50,8/9/2021
AD22F2,earnings,100,50,8/9/2021
ADD9DC,earnings,100,50,8/9/2021
AEEB76,earnings,100,50,8/9/2021
AEEB76,earnings,100,50,8/9/2021
B05118,union-pact,100,61,8/9/2021
B09B1F,conference-participant,100,50,8/9/2021
B1A85D,earnings,100,50,8/9/2021
B2206F,conference-participant,100,50,8/9/2021
B290A2,earnings,100,50,8/9/2021
B2E6B5,partnership,100,61,8/9/2021
B2F431,acquisition-completed-acquirer,100,49,8/9/2021
B33E77,earnings,100,50,8/9/2021
B46E12,dividend-up,100,81,8/9/2021
B48FC9,conference-participant,100,50,8/9/2021
B508E5,public-offering,100,43,8/9/2021
B54A74,earnings,100,50,8/9/2021
B5734D,fundraising,100,64,8/9/2021
B5734D,fundraising,100,64,8/9/2021
B60366,executive-appointment,100,54,8/9/2021
B9CD50,earnings,100,50,8/9/2021
BA0442,earnings,100,50,8/9/2021
BCC55F,conference-participant,100,50,8/9/2021
BDEC1E,earnings,100,50,8/9/2021
BE379D,earnings,100,50,8/9/2021
C2DD02,earnings,100,50,8/9/2021
C4A432,conference-call,100,50,8/9/2021
C50B26,earnings,100,50,8/9/2021
C584BE,earnings,100,50,8/9/2021
C5E840,acquisition-acquirer,100,49,8/9/2021
C62AA4,earnings,100,50,8/9/2021
C7859D,public-offering,100,43,8/9/2021
C8FAC7,business-contract,100,69,8/9/2021
C9732E,earnings,100,50,8/9/2021
C9E107,note-sale,100,52,8/9/2021
C9F39B,dividend,100,50,8/9/2021
CA1620,acquisition-interest-acquirer,100,46,8/9/2021
CC0C78,revenues,100,50,8/9/2021
CC0C78,revenues,100,50,8/9/2021
CDE51C,earnings,100,50,8/9/2021
CDFCC9,conference-participant,100,50,8/9/2021
CDFCC9,conference-participant,100,50,8/9/2021
CFF97C,conference-participant,100,50,8/9/2021
D06996,earnings,100,50,8/9/2021
D18AFC,earnings,100,50,8/9/2021
D33270,acquisition-acquirer,100,49,8/9/2021
D6144F,earnings,100,50,8/9/2021
D63B0F,dividend,100,50,8/9/2021
D63B0F,earnings,100,50,8/9/2021
D63B0F,earnings,100,50,8/9/2021
D63B0F,earnings,100,50,8/9/2021
D6EAA3,earnings-up,100,68,8/9/2021
D6EAA3,earnings,100,50,8/9/2021
D6EAA3,earnings,100,50,8/9/2021
D6EAA3,earnings,100,50,8/9/2021
D6EAA3,earnings,100,50,8/9/2021
D6EAA3,earnings,100,50,8/9/2021
D90F43,note-sale,100,52,8/9/2021
D9B1C9,business-contract,100,69,8/9/2021
DA48E4,earnings-per-share,100,50,8/9/2021
DB23C8,conference-participant,100,50,8/9/2021
DB9829,earnings,100,50,8/9/2021
DBCA3F,public-offering,100,43,8/9/2021
DD1BA1,unit-acquisition-acquirer,100,49,8/9/2021
DD7A96,dividend,100,50,8/9/2021
DE20DF,operating-earnings,100,50,8/9/2021
DF11D9,executive-appointment,100,54,8/9/2021
DFADDB,earnings,100,50,8/9/2021
E07573,earnings,100,50,8/9/2021
E07573,earnings,100,50,8/9/2021
E07573,earnings,100,50,8/9/2021
E07573,earnings,100,50,8/9/2021
E09997,earnings,100,50,8/9/2021
E259C7,earnings,100,50,8/9/2021
E68E62,earnings,100,50,8/9/2021
E6BC2C,revenue-up,100,91,8/9/2021
E6BC2C,earnings-up,100,68,8/9/2021
E6BC2C,earnings-up,100,68,8/9/2021
E6C8DC,executive-appointment,100,54,8/9/2021
E74B55,earnings,100,50,8/9/2021
E96E0B,earnings,100,50,8/9/2021
EAEBF3,conference-participant,100,50,8/9/2021
EB43F4,earnings,100,50,8/9/2021
EB7D6C,earnings,100,50,8/9/2021
F24FF0,public-offering,100,43,8/9/2021
F2BC3D,earnings,100,50,8/9/2021
F32F88,conference-participant,100,50,8/9/2021
F32F88,conference-participant,100,50,8/9/2021
F48947,acquisition-regulatory-scrutiny-acquiree,100,38,8/9/2021
F509E2,earnings,100,50,8/9/2021
F5D499,earnings,100,50,8/9/2021
F5D499,earnings,100,50,8/9/2021
F5D499,earnings,100,50,8/9/2021
F6A987,dividend,100,50,8/9/2021
F9AA02,clinical-trials-start,100,64,8/9/2021
FA840E,earnings,100,50,8/9/2021
FAAFA2,executive-appointment,100,54,8/9/2021
FCA54E,earnings,100,50,8/9/2021
FDF28E,earnings,100,50,8/9/2021
FF5413,business-contract,100,69,8/9/2021
FFCD0E,earnings,100,50,8/9/2021
00698D,acquisition-regulatory-scrutiny-acquiree,100,38,8/10/2021
13528,partnership,100,61,8/10/2021
06C826,earnings,100,50,8/10/2021
070B45,acquisition-completed-acquirer,100,49,8/10/2021
0B13E8,award,100,58,8/10/2021
0BC853,executive-resignation,100,44,8/10/2021
0F2BC9,earnings-up,100,68,8/10/2021
0F2BC9,earnings-up,100,68,8/10/2021
0F2BC9,earnings-up,100,68,8/10/2021
0FABBD,earnings,100,50,8/10/2021
0FABBD,earnings,100,50,8/10/2021
0FABBD,earnings,100,50,8/10/2021
0FABBD,earnings,100,50,8/10/2021
0FABBD,earnings,100,50,8/10/2021
0FABBD,earnings,100,50,8/10/2021
0FABBD,earnings,100,50,8/10/2021
154272,earnings,100,50,8/10/2021
1A3E1B,acquisition-acquirer,100,49,8/10/2021
1A3E1B,unit-acquisition-acquirer,100,49,8/10/2021
1B4F31,executive-appointment,100,54,8/10/2021
1CD4B5,earnings,100,50,8/10/2021
1D9E55,legal-issues-defendant,100,22,8/10/2021
1F43A1,public-offering,100,43,8/10/2021
1FA886,business-contract,100,69,8/10/2021
228D42,partnership,100,61,8/10/2021
232053,earnings,100,50,8/10/2021
2.45E+15,executive-appointment,100,54,8/10/2021
24A89A,executive-appointment,100,54,8/10/2021
24C48B,executive-appointment,100,54,8/10/2021
251988,product-release,100,64,8/10/2021
26008A,conference-call,100,50,8/10/2021
26DC29,conference-call,100,50,8/10/2021
26E3BA,earnings,100,50,8/10/2021
28AC4E,note-sale,100,52,8/10/2021
2B8179,settlement,100,56,8/10/2021
2B9DBB,dividend,100,50,8/10/2021
2CB4C9,partnership,100,61,8/10/2021
2CB4C9,partnership,100,61,8/10/2021
2F1299,earnings,100,50,8/10/2021
2F1299,earnings,100,50,8/10/2021
2F1299,earnings,100,50,8/10/2021
2F1299,earnings,100,50,8/10/2021
2F1299,earnings,100,50,8/10/2021
2F1299,earnings,100,50,8/10/2021
2F1299,earnings,100,50,8/10/2021
2F1299,earnings,100,50,8/10/2021
2F1299,earnings,100,50,8/10/2021
2F1299,earnings,100,50,8/10/2021
30A565,earnings,100,50,8/10/2021
317EC6,conference-participant,100,50,8/10/2021
33E9D5,conference-participant,100,50,8/10/2021
356B21,revenue-up,100,69,8/10/2021
356B21,revenue-up,100,69,8/10/2021
356B21,revenue-up,100,69,8/10/2021
3587B4,partnership,100,61,8/10/2021
39FB23,award,100,58,8/10/2021
3B50FE,product-release,100,64,8/10/2021
42EFC7,earnings,100,50,8/10/2021
444CC8,partnership,100,61,8/10/2021
45444E,business-contract,100,69,8/10/2021
458D2C,facility-open,100,65,8/10/2021
4649D5,earnings-positive,100,69,8/10/2021
4649D5,earnings-positive,100,69,8/10/2021
4649D5,earnings-positive,100,69,8/10/2021
4649D5,earnings-positive,100,69,8/10/2021
4649D5,earnings-positive,100,69,8/10/2021
4A6F00,partnership,100,61,8/10/2021
4A6F00,partnership,100,61,8/10/2021
4A6F00,product-release,100,64,8/10/2021
4A6F00,product-release,100,64,8/10/2021
4A7C1F,earnings,100,50,8/10/2021
4AC91D,product-release,100,64,8/10/2021
4AC91D,product-release,100,64,8/10/2021
4AE584,conference-participant,100,50,8/10/2021
4B7006,partnership,100,61,8/10/2021
4DD09F,earnings-up,100,68,8/10/2021
4DD09F,earnings-up,100,68,8/10/2021
4DD09F,earnings-up,100,68,8/10/2021
4DD09F,earnings-up,100,68,8/10/2021
4E6F5A,legal-issues-defendant,100,22,8/10/2021
4E6F5A,fraud-defendant,100,20,8/10/2021
4EEB00,operating-earnings,100,50,8/10/2021
50702E,earnings,100,50,8/10/2021
523039,earnings,100,50,8/10/2021
53E575,business-contract,100,69,8/10/2021
543C77,executive-appointment,100,54,8/10/2021
5480A7,dividend,100,50,8/10/2021
55438C,donation,100,54,8/10/2021
57DDB9,note-sale,100,52,8/10/2021
57DDB9,conference-participant,100,50,8/10/2021
58C2D4,conference-participant,100,50,8/10/2021
59DB8C,conference-participant,100,50,8/10/2021
5A9F54,product-release,100,64,8/10/2021
5E7E82,executive-appointment,100,54,8/10/2021
5EAA43,executive-appointment,100,54,8/10/2021
60AC34,earnings,100,50,8/10/2021
619882,conference-organizer,100,57,8/10/2021
619882,conference-organizer,100,57,8/10/2021
6.52E+64,business-contract,100,69,8/10/2021
662682,note-sale,100,52,8/10/2021
66CB62,earnings,100,50,8/10/2021
67529E,executive-appointment,100,54,8/10/2021
6AACDD,legal-issues-defendant,100,22,8/10/2021
6D2BF6,earnings,100,50,8/10/2021
6ED519,dividend,100,50,8/10/2021
713810,conference-call,100,50,8/10/2021
713810,stock-gain,100,63,8/10/2021
71553E,revenue-guidance,100,50,8/10/2021
717DB4,conference-participant,100,50,8/10/2021
7448A3,note-sale,100,52,8/10/2021
7A5097,legal-issues-defendant,100,22,8/10/2021
7B6EB1,note-sale,100,52,8/10/2021
7DC1C4,conference-participant,100,50,8/10/2021
7E3390,earnings,100,50,8/10/2021
805CD8,conference-participant,100,50,8/10/2021
817ED9,dividend,100,50,8/10/2021
8.10E+205,conference-participant,100,50,8/10/2021
8295B8,business-contract,100,69,8/10/2021
850779,acquisition-acquiree,100,76,8/10/2021
87B81A,executive-appointment,100,54,8/10/2021
881190,dividend,100,50,8/10/2021
895D56,partnership,100,61,8/10/2021
89F693,merger,100,66,8/10/2021
89F693,merger,100,66,8/10/2021
89F693,merger,100,66,8/10/2021
8AB85C,earnings,100,50,8/10/2021
8AB85C,earnings,100,50,8/10/2021
8DE56F,earnings,100,50,8/10/2021
8DE56F,earnings,100,50,8/10/2021
8E10BF,earnings,100,50,8/10/2021
90DD65,earnings,100,50,8/10/2021
911CA9,patient-enrollment-complete,100,64,8/10/2021
92005C,earnings,100,50,8/10/2021
94A326,earnings,100,50,8/10/2021
95C575,dividend,100,50,8/10/2021
966ACE,earnings,100,50,8/10/2021
96BFF4,earnings,100,50,8/10/2021
97AF94,earnings,100,50,8/10/2021
981656,partnership,100,61,8/10/2021
981656,earnings,100,50,8/10/2021
9E4A5F,earnings,100,50,8/10/2021
9EBAFA,earnings,100,50,8/10/2021
9EF4CF,partnership,100,61,8/10/2021
9F18FA,earnings,100,50,8/10/2021
9F18FA,earnings,100,50,8/10/2021
9F62D1,dividend,100,50,8/10/2021
A1EAC8,business-contract,100,69,8/10/2021
A3230E,earnings,100,50,8/10/2021
A48593,earnings,100,50,8/10/2021
A5195E,public-offering-suspended,100,24,8/10/2021
A52B6B,executive-appointment,100,54,8/10/2021
A79F7D,earnings,100,50,8/10/2021
A7A0C8,earnings,100,50,8/10/2021
A7A0C8,public-offering,100,43,8/10/2021
A7CCF0,executive-appointment,100,54,8/10/2021
A868C9,partnership,100,61,8/10/2021
A868C9,partnership,100,61,8/10/2021
A8E2FE,earnings,100,50,8/10/2021
AC775C,earnings,100,50,8/10/2021
AC775C,earnings,100,50,8/10/2021
AC775C,earnings,100,50,8/10/2021
AC775C,earnings,100,50,8/10/2021
ACDF88,hirings,100,65,8/10/2021
AE79CD,earnings,100,50,8/10/2021
B1DF3C,conference-participant,100,50,8/10/2021
B1FC3B,business-contract,100,69,8/10/2021
B2206F,executive-appointment,100,54,8/10/2021
B4B281,conference-call,100,50,8/10/2021
B4C673,partnership,100,61,8/10/2021
B60366,earnings,100,50,8/10/2021
BC5680,partnership,100,61,8/10/2021
BDE867,executive-appointment,100,54,8/10/2021
BDEC1E,conference-participant,100,50,8/10/2021
BE7BA4,conference-participant,100,50,8/10/2021
C0BA36,earnings,100,50,8/10/2021
C27E19,dividend,100,50,8/10/2021
C5E840,earnings,100,50,8/10/2021
C66B44,acquisition-interest-acquirer,100,46,8/10/2021
C7859D,public-offering,100,43,8/10/2021
C97B2D,regulatory-product-approval-granted,100,81,8/10/2021
C98CDB,earnings,100,50,8/10/2021
CBDB4D,conference-participant,100,50,8/10/2021
CC3EC4,earnings,100,50,8/10/2021
CDC217,clinical-trials-positive,100,87,8/10/2021
CDC217,earnings,100,50,8/10/2021
CE5664,earnings,100,50,8/10/2021
CE5664,earnings,100,50,8/10/2021
CE5664,earnings,100,50,8/10/2021
CF073E,earnings,100,50,8/10/2021
D1588D,earnings,100,50,8/10/2021
D17C1B,partnership,100,61,8/10/2021
D6144F,conference-participant,100,50,8/10/2021
D75910,conference-call,100,50,8/10/2021
D90F43,note-sale,100,52,8/10/2021
DD1BA1,partnership,100,61,8/10/2021
E259C7,earnings,100,50,8/10/2021
E30A8F,partnership,100,61,8/10/2021
E30A8F,partnership,100,61,8/10/2021
E35610,executive-appointment,100,54,8/10/2021
E4CE73,business-contract,100,69,8/10/2021
E56A0D,earnings,100,50,8/10/2021
E598FB,earnings,100,50,8/10/2021
E68733,earnings,100,50,8/10/2021
E68733,earnings,100,50,8/10/2021
E6C8DC,note-sale,100,52,8/10/2021
E8846E,executive-resignation,100,44,8/10/2021
E8A49A,partnership,100,61,8/10/2021
E93A40,acquisition-completed-acquirer,100,49,8/10/2021
EC1AF3,earnings,100,50,8/10/2021
ECDEB2,acquisition-acquirer,100,49,8/10/2021
ED1A74,earnings,100,50,8/10/2021
ED2A5E,conference-participant,100,50,8/10/2021
EE967B,public-offering,100,43,8/10/2021
EEA734,conference-participant,100,50,8/10/2021
F3FCC3,note-sale,100,52,8/10/2021
F82D37,acquisition-interest-acquiree,100,82,8/10/2021
F82D37,dividend,100,50,8/10/2021
FAAFA2,partnership,100,61,8/10/2021
FD9526,dividend,100,50,8/10/2021
FD9A97,earnings,100,50,8/10/2021
FD9A97,executive-appointment,100,54,8/10/2021
FEC475,dividend,100,50,8/10/2021
00E601,dividend,100,50,8/11/2021
0157B1,partnership,100,61,8/11/2021
0157B1,facility-open,100,65,8/11/2021
48590,legal-issues-defendant,100,22,8/11/2021
58828,conference-call,100,50,8/11/2021
06C826,earnings,100,50,8/11/2021
96930,orphan-drug-designation,100,76,8/11/2021
96930,earnings,100,50,8/11/2021
0A9D0A,earnings,100,50,8/11/2021
0B4D10,dividend,100,50,8/11/2021
0CCCB7,dividend,100,50,8/11/2021
0F0440,dividend,100,50,8/11/2021
1065BC,dividend,100,50,8/11/2021
13D576,buybacks,100,74,8/11/2021
13D576,earnings,100,50,8/11/2021
1490F3,dividend,100,50,8/11/2021
15A388,buybacks,100,74,8/11/2021
168A5D,partnership,100,61,8/11/2021
17EDA5,executive-appointment,100,54,8/11/2021
1834C0,executive-appointment,100,54,8/11/2021
18A98C,earnings,100,50,8/11/2021
18A98C,earnings,100,50,8/11/2021
1A3E1B,executive-appointment,100,54,8/11/2021
1C2593,donation,100,54,8/11/2021
21245F,executive-appointment,100,54,8/11/2021
228D42,partnership,100,61,8/11/2021
263216,earnings,100,50,8/11/2021
263216,revenue-up,100,69,8/11/2021
263216,revenue-up,100,69,8/11/2021
263216,revenue-up,100,69,8/11/2021
263216,revenue-up,100,69,8/11/2021
263216,revenue-up,100,69,8/11/2021
263216,revenue-up,100,69,8/11/2021
263216,revenue-up,100,69,8/11/2021
263216,revenue-up,100,69,8/11/2021
27B191,earnings,100,50,8/11/2021
27B191,earnings,100,50,8/11/2021
27B191,earnings,100,50,8/11/2021
27B191,earnings,100,50,8/11/2021
27B191,dividend,100,50,8/11/2021
2F1299,product-release,100,64,8/11/2021
30AB63,note-sale,100,52,8/11/2021
30DE64,regulatory-product-approval-granted,100,81,8/11/2021
32CB22,executive-appointment,100,54,8/11/2021
33A0F1,partnership,100,61,8/11/2021
33A0F1,earnings,100,50,8/11/2021
346BF2,earnings,100,50,8/11/2021
3587B4,business-contract,100,69,8/11/2021
3B20AB,partnership,100,61,8/11/2021
3F6A9C,executive-appointment,100,54,8/11/2021
41785E,dividend,100,50,8/11/2021
444CC8,earnings-up,100,68,8/11/2021
444CC8,earnings,100,50,8/11/2021
444CC8,earnings,100,50,8/11/2021
444CC8,earnings,100,50,8/11/2021
45444E,business-contract,100,69,8/11/2021
458D2C,revenue-volume,100,50,8/11/2021
4.91E+58,acquisition-acquirer,100,49,8/11/2021
4A6F00,partnership,100,61,8/11/2021
4BAF2E,earnings,100,50,8/11/2021
4C31F3,conference-participant,100,50,8/11/2021
4C350A,executive-resignation,100,44,8/11/2021
4D229C,earnings,100,50,8/11/2021
4E6F5A,legal-issues-defendant,100,22,8/11/2021
4E6F5A,legal-issues-defendant,100,22,8/11/2021
4E6F5A,legal-issues-defendant,100,22,8/11/2021
4ECD1A,earnings,100,50,8/11/2021
51F541,dividend-up,100,81,8/11/2021
583553,earnings,100,50,8/11/2021
5B15E1,earnings,100,50,8/11/2021
5B6C11,executive-appointment,100,54,8/11/2021
5D41E4,earnings,100,50,8/11/2021
5F9CE3,partnership,100,61,8/11/2021
619882,conference-organizer,100,57,8/11/2021
68AB62,business-contract,100,69,8/11/2021
69CE71,business-contract,100,69,8/11/2021
6AACDD,legal-issues-defendant,100,22,8/11/2021
6AACDD,legal-issues-defendant,100,22,8/11/2021
6DBBBC,investment-investor,100,55,8/11/2021
6.00E+19,business-contract,100,69,8/11/2021
713810,facility-open,100,65,8/11/2021
71E2EF,earnings,100,50,8/11/2021
743C70,earnings,100,50,8/11/2021
743C70,earnings,100,50,8/11/2021
7448A3,note-sale,100,52,8/11/2021
751C8D,earnings,100,50,8/11/2021
751C8D,earnings,100,50,8/11/2021
751C8D,earnings,100,50,8/11/2021
751C8D,earnings,100,50,8/11/2021
76E80F,conference-call,100,50,8/11/2021
7999F3,note-sale,100,52,8/11/2021
7A5097,partnership,100,61,8/11/2021
7A5097,partnership,100,61,8/11/2021
7A5097,partnership,100,61,8/11/2021
84920B,partnership,100,61,8/11/2021
859D62,earnings,100,50,8/11/2021
873DB9,executive-appointment,100,54,8/11/2021
873DB9,business-contract,100,69,8/11/2021
903AB4,executive-resignation,100,44,8/11/2021
922F0C,dividend,100,50,8/11/2021
92B625,earnings,100,50,8/11/2021
945DE6,executive-appointment,100,54,8/11/2021
972356,earnings-above-expectations,100,88,8/11/2021
9C5BA5,partnership,100,61,8/11/2021
9D307D,acquisition-acquiree,100,76,8/11/2021
9D307D,acquisition-acquiree,100,76,8/11/2021
9D307D,earnings,100,50,8/11/2021
9D4EC7,dividend,100,50,8/11/2021
A1BB98,dividend,100,50,8/11/2021
A398B9,award,100,58,8/11/2021
AAEE21,public-offering,100,43,8/11/2021
ABE7DC,earnings,100,50,8/11/2021
ABE7DC,earnings,100,50,8/11/2021
AE0CCE,revenue-up,100,69,8/11/2021
AE0CCE,earnings,100,50,8/11/2021
B1FC3B,business-contract,100,69,8/11/2021
B2DAF6,earnings,100,50,8/11/2021
B37FB4,dividend,100,50,8/11/2021
B508E5,public-offering,100,43,8/11/2021
B8EF97,partnership,100,61,8/11/2021
B8F71F,partnership,100,61,8/11/2021
B9B6B8,earnings,100,50,8/11/2021
BC3AD2,donation,100,54,8/11/2021
BF5959,conference-call,100,50,8/11/2021
BFF98A,earnings,100,50,8/11/2021
C0BA36,conference-participant,100,50,8/11/2021
C3BCD5,dividend,100,50,8/11/2021
C45CE7,dividend-up,100,81,8/11/2021
C9E04B,earnings,100,50,8/11/2021
CF6A5A,executive-appointment,100,54,8/11/2021
CF7292,earnings,100,50,8/11/2021
D07B07,earnings-up,100,68,8/11/2021
D07B07,earnings,100,50,8/11/2021
D07B07,earnings,100,50,8/11/2021
D2C0B6,earnings,100,50,8/11/2021
D36686,earnings,100,50,8/11/2021
D56D6D,dividend-up,100,74,8/11/2021
D58A11,earnings,100,50,8/11/2021
D58A11,earnings,100,50,8/11/2021
D58A11,earnings,100,50,8/11/2021
D58A11,earnings,100,50,8/11/2021
D5B13D,earnings,100,50,8/11/2021
D60BB2,partnership,100,61,8/11/2021
DBB28E,product-release,100,64,8/11/2021
DF6FDD,earnings,100,50,8/11/2021
E13782,earnings,100,50,8/11/2021
E38906,earnings,100,50,8/11/2021
E49AA3,facility-open,100,65,8/11/2021
E5A3B6,earnings,100,50,8/11/2021
E5C910,earnings,100,50,8/11/2021
E69BA5,dividend,100,50,8/11/2021
E6C8DC,legal-issues-defendant,100,22,8/11/2021
E845D9,earnings,100,50,8/11/2021
E8E899,acquisition-acquiree,100,76,8/11/2021
E93A40,product-release,100,64,8/11/2021
ECE19E,earnings,100,50,8/11/2021
ED9C04,note-sale,100,52,8/11/2021
ED9C04,note-sale,100,52,8/11/2021
EF5BED,executive-appointment,100,54,8/11/2021
EF77A3,reorganization,100,53,8/11/2021
F0EEFB,conference-participant,100,50,8/11/2021
F179ED,conference-participant,100,50,8/11/2021
F1EB39,executive-appointment,100,54,8/11/2021
F46EC9,dividend,100,50,8/11/2021
F51DB0,facility-open,100,65,8/11/2021
F6581D,earnings,100,50,8/11/2021
F6DCE4,executive-appointment,100,54,8/11/2021
F702CA,product-price-raise,100,57,8/11/2021
F88147,legal-issues-defendant,100,22,8/11/2021
F90EE5,dividend,100,50,8/11/2021
FAAFA2,earnings,100,50,8/11/2021
FC1B7B,dividend,100,50,8/11/2021
FC80E6,dividend,100,50,8/11/2021
FE609F,earnings,100,50,8/11/2021
003B70,merger,100,66,8/12/2021
13528,earnings,100,50,8/12/2021
0157B1,partnership,100,61,8/12/2021
033B58,earnings,100,50,8/12/2021
036C6F,conference-participant,100,50,8/12/2021
48590,legal-issues-defendant,100,22,8/12/2021
061A3B,executive-appointment,100,54,8/12/2021
0624BE,partnership,100,61,8/12/2021
091B6C,earnings,100,50,8/12/2021
091B6C,earnings,100,50,8/12/2021
095A04,orphan-drug-designation,100,76,8/12/2021
0A0D9E,buybacks,100,74,8/12/2021
0AAD90,earnings,100,50,8/12/2021
0B13E8,earnings,100,50,8/12/2021
0D03C8,earnings,100,50,8/12/2021
0EF1AF,executive-appointment,100,54,8/12/2021
1065BC,executive-resignation,100,44,8/12/2021
11AEDE,earnings,100,50,8/12/2021
11AEDE,executive-appointment,100,54,8/12/2021
135B09,dividend,100,50,8/12/2021
143C52,conference-call,100,50,8/12/2021
147C38,facility-open,100,65,8/12/2021
15901B,executive-appointment,100,54,8/12/2021
184988,earnings,100,50,8/12/2021
1A1CB0,earnings,100,50,8/12/2021
1A9DE1,earnings,100,50,8/12/2021
1B5FEA,earnings,100,50,8/12/2021
1B6F77,earnings,100,50,8/12/2021
1D9E55,partnership,100,61,8/12/2021
1DB6A6,executive-resignation,100,44,8/12/2021
1F43A1,public-offering,100,43,8/12/2021
1F9258,earnings-up,100,68,8/12/2021
205AD5,partnership,100,61,8/12/2021
2082EA,conference-participant,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21153F,earnings,100,50,8/12/2021
21D903,earnings,100,50,8/12/2021
228D42,partnership,100,61,8/12/2021
249674,earnings,100,50,8/12/2021
24C48B,earnings,100,50,8/12/2021
267718,fast-track-designation,100,81,8/12/2021
26E3BA,earnings,100,50,8/12/2021
26F99F,earnings,100,50,8/12/2021
2A4131,earnings,100,50,8/12/2021
2CA60F,partnership,100,61,8/12/2021
2D643C,conference-participant,100,50,8/12/2021
2D981A,earnings,100,50,8/12/2021
33A0F1,conference-participant,100,50,8/12/2021
33AD83,conference-call,100,50,8/12/2021
36E479,earnings,100,50,8/12/2021
37E18B,earnings,100,50,8/12/2021
3B37F7,executive-appointment,100,54,8/12/2021
4017AD,dividend,100,50,8/12/2021
44A4FC,executive-appointment,100,54,8/12/2021
4.60E+06,earnings,100,50,8/12/2021
490D4B,executive-appointment,100,54,8/12/2021
4AE584,earnings-up,100,68,8/12/2021
4AE584,earnings,100,50,8/12/2021
4C350A,executive-appointment,100,54,8/12/2021
4E6F5A,legal-issues-defendant,100,22,8/12/2021
4E6F5A,legal-issues-defendant,100,22,8/12/2021
4ECD1A,earnings,100,50,8/12/2021
4ECD1A,earnings,100,50,8/12/2021
4ECD1A,earnings,100,50,8/12/2021
4EE167,partnership,100,61,8/12/2021
4F9487,executive-resignation,100,44,8/12/2021
5288FC,earnings,100,50,8/12/2021
5403F8,earnings,100,50,8/12/2021
543C77,earnings,100,50,8/12/2021
548AC0,conference-participant,100,50,8/12/2021
56277A,product-release,100,64,8/12/2021
579E8F,earnings,100,50,8/12/2021
57F3DA,executive-appointment,100,54,8/12/2021
586FFD,conference-call,100,50,8/12/2021
5A0FF1,partnership,100,61,8/12/2021
619882,conference-participant,100,50,8/12/2021
6391C2,earnings,100,50,8/12/2021
66667F,conference-participant,100,50,8/12/2021
68AB62,acquisition-acquirer,100,49,8/12/2021
6A024C,earnings,100,50,8/12/2021
6AACDD,legal-issues-defendant,100,22,8/12/2021
6AACDD,legal-issues-defendant,100,22,8/12/2021
6AACDD,legal-issues-defendant,100,22,8/12/2021
6B5379,dividend,100,50,8/12/2021
6BBCBA,earnings,100,50,8/12/2021
6BBCBA,partnership,100,61,8/12/2021
6BBD2D,earnings,100,50,8/12/2021
6C4D2F,dividend,100,50,8/12/2021
6.00E+19,business-contract,100,69,8/12/2021
705636,earnings,100,50,8/12/2021
713810,business-contract,100,69,8/12/2021
726EEA,dividend,100,50,8/12/2021
728737,dividend,100,50,8/12/2021
756045,earnings,100,50,8/12/2021
75D689,executive-appointment,100,54,8/12/2021
77B8E9,earnings,100,50,8/12/2021
7A0EC4,earnings,100,50,8/12/2021
7B492C,acquisition-completed-acquirer,100,49,8/12/2021
7B492C,acquisition-completed-acquirer,100,49,8/12/2021
7B492C,acquisition-completed-acquirer,100,49,8/12/2021
7B492C,executive-appointment,100,54,8/12/2021
7BEA98,earnings,100,50,8/12/2021
7F3665,earnings,100,50,8/12/2021
819492,earnings,100,50,8/12/2021
8295B8,earnings,100,50,8/12/2021
83598E,earnings,100,50,8/12/2021
83598E,executive-appointment,100,54,8/12/2021
84920B,earnings,100,50,8/12/2021
858942,note-sale,100,52,8/12/2021
8876D6,partnership,100,61,8/12/2021
895D56,partnership,100,61,8/12/2021
8A8E41,executive-appointment,100,54,8/12/2021
8AA108,earnings,100,50,8/12/2021
8F8F2F,dividend,100,50,8/12/2021
92D757,earnings,100,50,8/12/2021
947B0B,earnings,100,50,8/12/2021
9673BD,note-sale,100,52,8/12/2021
9673BD,note-sale,100,52,8/12/2021
971334,dividend,100,50,8/12/2021
9994DA,earnings,100,50,8/12/2021
9B4066,unit-acquisition-acquirer,100,49,8/12/2021
9C5BA5,revenues,100,50,8/12/2021
9CDA4F,earnings,100,50,8/12/2021
9E5C2C,note-sale,100,52,8/12/2021
9E8F70,dividend,100,50,8/12/2021
9F6B1A,acquisition-acquirer,100,49,8/12/2021
A017F4,earnings,100,50,8/12/2021
A03EE1,earnings,100,50,8/12/2021
A16DEA,name-change,100,49,8/12/2021
A1EAC8,executive-appointment,100,54,8/12/2021
A52B6B,regulatory-product-approval-granted,100,81,8/12/2021
A631A3,earnings,100,50,8/12/2021
A6828A,conference-participant,100,50,8/12/2021
A6D095,earnings,100,50,8/12/2021
AADE0B,stake-acquirer,100,48,8/12/2021
AAEE21,public-offering,100,43,8/12/2021
ABAA03,earnings,100,50,8/12/2021
ACF0B4,earnings,100,50,8/12/2021
AD1ACF,dividend,100,50,8/12/2021
B08C51,earnings,100,50,8/12/2021
B1FC3B,business-contract,100,69,8/12/2021
B2256A,buybacks,100,74,8/12/2021
B381D8,executive-appointment,100,54,8/12/2021
B48D6A,earnings,100,50,8/12/2021
B4C673,dividend,100,50,8/12/2021
B560AF,unit-acquisition-acquiree,100,76,8/12/2021
B614F8,earnings,100,50,8/12/2021
BD9668,dividend,100,50,8/12/2021
BE645B,partnership,100,61,8/12/2021
BFAEB4,executive-appointment,100,54,8/12/2021
C1114B,earnings,100,50,8/12/2021
C1114B,earnings,100,50,8/12/2021
C1114B,earnings,100,50,8/12/2021
C1114B,earnings,100,50,8/12/2021
C1114B,earnings,100,50,8/12/2021
C29E71,earnings,100,50,8/12/2021
C36189,earnings,100,50,8/12/2021
C501B6,earnings,100,50,8/12/2021
C7863D,merger,100,66,8/12/2021
C8257F,executive-appointment,100,54,8/12/2021
CA99D7,earnings,100,50,8/12/2021
CAC8D0,product-release,100,64,8/12/2021
CB88B3,executive-appointment,100,54,8/12/2021
CF3FF9,earnings,100,50,8/12/2021
D03C7A,dividend,100,50,8/12/2021
D27FAB,executive-appointment,100,54,8/12/2021
D47D56,earnings,100,50,8/12/2021
D6534D,dividend-up,100,81,8/12/2021
DAFED3,dividend-up,100,81,8/12/2021
DBB28E,conference-call,100,50,8/12/2021
DBEF02,buybacks,100,74,8/12/2021
DC0066,earnings,100,50,8/12/2021
DD1BA1,unit-acquisition-acquirer,100,49,8/12/2021
E592F0,earnings,100,50,8/12/2021
E6C8DC,legal-issues-defendant,100,22,8/12/2021
E71AE6,earnings,100,50,8/12/2021
EC99D0,reorganization-unit,100,53,8/12/2021
EFA7B2,conference-participant,100,50,8/12/2021
F02170,earnings,100,50,8/12/2021
F1CD47,dividend,100,50,8/12/2021
F209B4,earnings,100,50,8/12/2021
F209B4,earnings,100,50,8/12/2021
F3816D,earnings,100,50,8/12/2021
F5349B,executive-appointment,100,54,8/12/2021
F569FD,earnings,100,50,8/12/2021
F6DA75,earnings,100,50,8/12/2021
F88147,earnings,100,50,8/12/2021
FBD92D,partnership,100,61,8/12/2021
FC1B7B,executive-appointment,100,54,8/12/2021
FE9C0D,earnings,100,50,8/12/2021
03B8CF,dividend,100,50,8/13/2021
03FB17,dividend,100,50,8/13/2021
48590,legal-issues-defendant,100,22,8/13/2021
48781,earnings,100,50,8/13/2021
0A7650,earnings-up,100,68,8/13/2021
112694,earnings,100,50,8/13/2021
159AE4,dividend,100,50,8/13/2021
19CAC7,dividend-up,100,61,8/13/2021
1EF224,earnings,100,50,8/13/2021
1FCC00,earnings,100,50,8/13/2021
21153F,acquisition-regulatory-approval-acquiree,100,81,8/13/2021
21153F,acquisition-regulatory-approval-acquiree,100,81,8/13/2021
250BEE,earnings,100,50,8/13/2021
250BEE,earnings,100,50,8/13/2021
250BEE,earnings,100,50,8/13/2021
250BEE,earnings,100,50,8/13/2021
2D643C,facility-open,100,65,8/13/2021
2DA92D,dividend,100,50,8/13/2021
3.73E+87,legal-issues-defendant,100,22,8/13/2021
453282,conference-participant,100,50,8/13/2021
45ABCC,demand-decrease,100,17,8/13/2021
47B4CC,earnings,100,50,8/13/2021
494EB9,earnings-revision,100,29,8/13/2021
4E6F5A,earnings,100,50,8/13/2021
5088A5,dividend,100,50,8/13/2021
5480A7,buybacks,100,74,8/13/2021
55D0F3,conference-participant,100,50,8/13/2021
5D16CF,dividend,100,50,8/13/2021
619882,dividend,100,50,8/13/2021
6844D2,dividend,100,50,8/13/2021
6AACDD,legal-issues-defendant,100,22,8/13/2021
6B5379,executive-appointment,100,54,8/13/2021
75F982,partnership,100,61,8/13/2021
789A7D,dividend,100,50,8/13/2021
7AB859,partnership,100,61,8/13/2021
7B8CB5,dividend,100,50,8/13/2021
84A6B9,dividend,100,50,8/13/2021
858942,note-sale,100,52,8/13/2021
86A1B9,partnership,100,61,8/13/2021
86DFBD,earnings,100,50,8/13/2021
8D0EEA,earnings,100,50,8/13/2021
9004C4,conference-call,100,50,8/13/2021
9004C4,conference-call,100,50,8/13/2021
99028D,conference-call,100,50,8/13/2021
A3AAA5,dividend,100,50,8/13/2021
A4B899,dividend-up,100,60,8/13/2021
AADE0B,acquisition-acquirer,100,49,8/13/2021
B37FB4,executive-appointment,100,54,8/13/2021
B4F5F4,acquisition-completed-acquiree,100,76,8/13/2021
BB0587,earnings,100,50,8/13/2021
BE7BA4,executive-resignation,100,44,8/13/2021
C2609A,conference-participant,100,50,8/13/2021
C584BE,acquisition-acquirer,100,49,8/13/2021
C584BE,acquisition-acquirer,100,49,8/13/2021
DC6EF3,earnings,100,50,8/13/2021
DF1F7A,dividend,100,50,8/13/2021
E6C8DC,legal-issues-defendant,100,22,8/13/2021
E6C8DC,legal-issues-defendant,100,22,8/13/2021
E8D221,trading-resumed,100,58,8/13/2021
ED22DC,earnings,100,50,8/13/2021
EFA7B2,earnings,100,50,8/13/2021
F72E4B,acquisition-acquirer,100,49,8/13/2021
F93C8A,dividend,100,50,8/13/2021
FF4BA4,dividend,100,50,8/13/2021
1E4FB9,legal-issues-defendant,100,22,8/14/2021
4F9926,partnership,100,61,8/14/2021
54512F,legal-issues-defendant,100,22,8/14/2021
68E6E9,legal-issues-defendant,100,22,8/14/2021
6AACDD,legal-issues-defendant,100,22,8/14/2021
89F693,legal-issues-defendant,100,22,8/14/2021
9004C4,conference-call,100,50,8/14/2021
A02FB1,legal-issues-defendant,100,22,8/14/2021
A6FC89,acquisition-acquiree,100,76,8/14/2021
A99576,legal-issues-defendant,100,22,8/14/2021
C65004,legal-issues-defendant,100,22,8/14/2021
E393B0,legal-issues-defendant,100,22,8/14/2021
F48947,legal-issues-defendant,100,22,8/14/2021
6AACDD,legal-issues-defendant,100,22,8/15/2021
D2B9E5,unit-acquisition-acquirer,100,49,8/15/2021
D2B9E5,acquisition-acquirer,100,49,8/15/2021
D2B9E5,acquisition-acquirer,100,49,8/15/2021
F88147,legal-issues-defendant,100,22,8/15/2021
002A99,executive-resignation,100,44,8/16/2021
03C94A,executive-appointment,100,54,8/16/2021
48590,legal-issues-defendant,100,22,8/16/2021
56045,earnings,100,50,8/16/2021
099A92,business-contract,100,69,8/16/2021
0A59F8,product-release,100,64,8/16/2021
0CE7F6,dividend,100,50,8/16/2021
0E2992,partnership,100,61,8/16/2021
1151F4,business-contract,100,69,8/16/2021
126F95,dividend,100,50,8/16/2021
157CC1,earnings,100,50,8/16/2021
168A5D,partnership,100,61,8/16/2021
1880C5,executive-appointment,100,54,8/16/2021
1A46A1,conference-participant,100,50,8/16/2021
1CD4B5,executive-appointment,100,54,8/16/2021
1D3A00,conference-call,100,50,8/16/2021
1E04A5,partnership,100,61,8/16/2021
25D3CE,earnings-up,100,68,8/16/2021
25D3CE,earnings,100,50,8/16/2021
25D3CE,earnings,100,50,8/16/2021
25D3CE,earnings,100,50,8/16/2021
267718,business-contract,100,69,8/16/2021
267718,note-sale,100,52,8/16/2021
2.89E+11,dividend,100,50,8/16/2021
2ABF77,clinical-trials-start,100,64,8/16/2021
2C3348,unit-acquisition-acquirer,100,49,8/16/2021
2C681C,executive-appointment,100,54,8/16/2021
2E0496,executive-appointment,100,54,8/16/2021
2E0496,executive-appointment,100,54,8/16/2021
3301B7,buybacks,100,74,8/16/2021
3461CF,analyst-ratings-change-positive-rater,20,50,8/16/2021
37B120,earnings,100,50,8/16/2021
3AAEAE,clinical-trials-start,100,64,8/16/2021
3BB7D3,partnership,100,61,8/16/2021
414FFF,conference-call,100,50,8/16/2021
41EC04,executive-appointment,100,54,8/16/2021
4C350A,conference-call,100,50,8/16/2021
520632,regulatory-product-approval-granted,100,81,8/16/2021
58CA9A,executive-appointment,100,54,8/16/2021
5B97B2,private-placement,100,56,8/16/2021
5D87DF,dividend,100,50,8/16/2021
5F9CE3,dividend,100,50,8/16/2021
616E3B,dividend,100,50,8/16/2021
61BCA7,executive-appointment,100,54,8/16/2021
657097,unit-acquisition-acquirer,100,49,8/16/2021
673C9A,conference-call,100,50,8/16/2021
6A171E,partnership,100,61,8/16/2021
6AACDD,legal-issues-defendant,100,22,8/16/2021
6AACDD,legal-issues-defendant,100,22,8/16/2021
6AACDD,earnings,100,50,8/16/2021
6CC55E,partnership,100,61,8/16/2021
6.00E+19,earnings,100,50,8/16/2021
6F5DD2,earnings,100,50,8/16/2021
73529F,note-sale,100,52,8/16/2021
73529F,note-sale,100,52,8/16/2021
756BB4,conference-participant,100,50,8/16/2021
767F86,business-contract,100,69,8/16/2021
7732C2,earnings,100,50,8/16/2021
7A51FE,dividend,100,50,8/16/2021
7B1156,acquisition-acquirer,100,49,8/16/2021
7BC92D,partnership,100,61,8/16/2021
7BC92D,earnings,100,50,8/16/2021
7DD8CC,note-sale,100,52,8/16/2021
7E0EB0,award,100,58,8/16/2021
8.10E+32,dividend,100,50,8/16/2021
85CDC9,partnership,100,61,8/16/2021
8.79E+06,earnings,100,50,8/16/2021
8A8E41,acquisition-acquirer,100,49,8/16/2021
9196A2,dividend,100,50,8/16/2021
92005C,conference-participant,100,50,8/16/2021
957A07,legal-issues-defendant,100,22,8/16/2021
A01200,public-offering,100,43,8/16/2021
A01200,public-offering,100,43,8/16/2021
A01983,dividend,100,50,8/16/2021
A2A9BA,earnings,100,50,8/16/2021
A3230E,executive-appointment,100,54,8/16/2021
A666C8,investment-investor,100,55,8/16/2021
A7A0C8,public-offering,100,43,8/16/2021
A9ED24,dividend,100,50,8/16/2021
ACC7D3,earnings,100,50,8/16/2021
AD23DE,partnership,100,61,8/16/2021
ADFB3A,earnings,100,50,8/16/2021
AE3113,executive-appointment,100,54,8/16/2021
AFF7B4,conference-participant,100,50,8/16/2021
B1FC3B,business-contract,100,69,8/16/2021
B5734D,executive-appointment,100,54,8/16/2021
B66928,business-contract,100,69,8/16/2021
B66928,business-contract,100,69,8/16/2021
B7202A,buybacks,100,74,8/16/2021
B72D2E,business-contract,100,69,8/16/2021
B7BDA3,note-sale,100,52,8/16/2021
BAD9EA,earnings,100,50,8/16/2021
BBC05B,credit-extension-recipient,100,69,8/16/2021
BCE9DA,unit-acquisition-acquiree,100,76,8/16/2021
BCE9DA,unit-acquisition-acquiree,100,76,8/16/2021
BCE9DA,unit-acquisition-acquiree,100,76,8/16/2021
BD9668,executive-appointment,100,54,8/16/2021
BE645B,earnings,100,50,8/16/2021
C11C46,acquisition-completed-acquirer,100,49,8/16/2021
C15DB3,executive-appointment,100,54,8/16/2021
C93C44,earnings,100,50,8/16/2021
C93C44,earnings,100,50,8/16/2021
CC8F6E,business-contract,100,69,8/16/2021
CC8F6E,business-contract,100,69,8/16/2021
CD2A4D,conference-participant,100,50,8/16/2021
CDC217,executive-appointment,100,54,8/16/2021
D07B07,regulatory-investigation-completed,100,50,8/16/2021
D18AFC,earnings,100,50,8/16/2021
D1CFC8,partnership,100,61,8/16/2021
D1CFC8,partnership,100,61,8/16/2021
D1CFC8,partnership,100,61,8/16/2021
D27FAB,earnings,100,50,8/16/2021
D27FAB,product-release,100,64,8/16/2021
D33270,partnership,100,61,8/16/2021
D4463B,acquisition-completed-acquirer,100,49,8/16/2021
D6489C,award,100,58,8/16/2021
DB23C8,note-sale,100,52,8/16/2021
DF01B1,public-offering,100,43,8/16/2021
E0207A,dividend,100,50,8/16/2021
E261E9,earnings,100,50,8/16/2021
E4CE73,product-release,100,64,8/16/2021
E6C8DC,fraud,100,44,8/16/2021
EBD89A,business-contract,100,69,8/16/2021
EF45B6,stock-splits,100,49,8/16/2021
F3FCC3,unit-acquisition-acquirer,100,49,8/16/2021
F5D059,executive-appointment,100,54,8/16/2021
F5D410,executive-appointment,100,54,8/16/2021
F5D410,executive-appointment,100,54,8/16/2021
F88147,legal-issues-defendant,100,22,8/16/2021
FACF19,product-release,100,64,8/16/2021
FEBFE1,legal-issues-defendant,100,22,8/16/2021
FF227B,executive-appointment,100,54,8/16/2021
00067A,acquisition-completed-acquirer,100,49,8/17/2021
00067A,acquisition-completed-acquirer,100,49,8/17/2021
0157B1,business-contract,100,69,8/17/2021
03FB17,earnings,100,50,8/17/2021
07C907,dividend,100,50,8/17/2021
0968A5,conference-call,100,50,8/17/2021
0C6861,dividend,100,50,8/17/2021
10673F,dividend,100,50,8/17/2021
12DE76,executive-appointment,100,54,8/17/2021
12F98C,conference-call,100,50,8/17/2021
147C38,executive-appointment,100,54,8/17/2021
17EDA5,partnership,100,61,8/17/2021
1AC649,legal-issues-defendant,100,22,8/17/2021
1DB833,sponsorship,100,57,8/17/2021
1F716B,business-contract,100,69,8/17/2021
21022F,product-release,100,64,8/17/2021
214051,earnings,100,50,8/17/2021
228D42,business-combination,100,54,8/17/2021
228D42,business-contract,100,69,8/17/2021
2.45E+15,executive-appointment,100,54,8/17/2021
26DC29,award,100,58,8/17/2021
284289,dividend-up,100,53,8/17/2021
2A17B1,dividend,100,50,8/17/2021
2E0496,campaign-ad-release,100,59,8/17/2021
2E0496,campaign-ad-release,100,59,8/17/2021
39692D,partnership,100,61,8/17/2021
3B318A,conference-call,100,50,8/17/2021
3B9886,earnings,100,50,8/17/2021
3C8A04,dividend,100,50,8/17/2021
3ED92D,note-sale,100,52,8/17/2021
43F4A8,executive-appointment,100,54,8/17/2021
442769,partnership,100,61,8/17/2021
49F4D0,public-offering,100,43,8/17/2021
4A6F00,business-contract,100,69,8/17/2021
4C37C5,dividend,100,50,8/17/2021
4C92B9,product-release,100,64,8/17/2021
4E6F5A,legal-issues-defendant,100,22,8/17/2021
52B567,revenues,100,50,8/17/2021
52B567,revenues,100,50,8/17/2021
53E575,executive-appointment,100,54,8/17/2021
53E575,executive-appointment,100,54,8/17/2021
54DF47,credit-extension-recipient,100,69,8/17/2021
56277A,clinical-trials,100,56,8/17/2021
58EA22,earnings,100,50,8/17/2021
5C8D61,dividend,100,50,8/17/2021
5D02B7,conference-call,100,50,8/17/2021
5F9CE3,executive-appointment,100,54,8/17/2021
5F9CE3,acquisition-acquiree,100,76,8/17/2021
6166D1,dividend,100,50,8/17/2021
62F41C,dividend,100,50,8/17/2021
69FDFC,business-combination,100,54,8/17/2021
6AACDD,legal-issues-defendant,100,22,8/17/2021
6BDA0C,executive-appointment,100,54,8/17/2021
6CC55E,conference-participant,100,50,8/17/2021
6D3F35,executive-appointment,100,54,8/17/2021
6DDA15,headquarters-change,100,50,8/17/2021
713810,same-store-sales-up,100,55,8/17/2021
756BB4,earnings,100,50,8/17/2021
765913,executive-appointment,100,54,8/17/2021
86478F,earnings,100,50,8/17/2021
88D80A,earnings,100,50,8/17/2021
8DE56F,buybacks,100,74,8/17/2021
8DE56F,buybacks,100,74,8/17/2021
903AB4,dividend,100,50,8/17/2021
905356,earnings-per-share-positive,100,69,8/17/2021
905356,earnings,100,50,8/17/2021
93F143,dividend,100,50,8/17/2021
94637C,regulatory-product-approval-granted,100,81,8/17/2021
94637C,regulatory-product-approval-granted,100,81,8/17/2021
94637C,regulatory-product-approval-granted,100,81,8/17/2021
94637C,regulatory-product-approval-granted,100,81,8/17/2021
94637C,regulatory-product-approval-granted,100,81,8/17/2021
94637C,regulatory-product-approval-granted,100,81,8/17/2021
95DC1F,asset-sale,100,62,8/17/2021
97FE80,partnership,100,61,8/17/2021
9D307D,partnership,100,61,8/17/2021
A03EE1,legal-issues-defendant,100,22,8/17/2021
A03EE1,fraud-defendant,100,20,8/17/2021
A03EE1,fraud-defendant,100,20,8/17/2021
A03EE1,legal-issues-defendant,100,22,8/17/2021
A03EE1,legal-issues-defendant,100,22,8/17/2021
A2CAF7,executive-appointment,100,54,8/17/2021
A4BCDE,conference-participant,100,50,8/17/2021
A4D173,award,100,58,8/17/2021
A5E715,dividend,100,50,8/17/2021
A6FE1C,unit-acquisition-acquirer,100,49,8/17/2021
A790A5,revenue-up,100,69,8/17/2021
A790A5,revenue-up,100,69,8/17/2021
A790A5,revenue-up,100,69,8/17/2021
A790A5,revenue-up,100,69,8/17/2021
AA09AD,executive-appointment,100,54,8/17/2021
AC775C,conference-participant,100,50,8/17/2021
AC7C4F,conference-participant,100,50,8/17/2021
ACDF88,earnings,100,50,8/17/2021
ACDF88,earnings,100,50,8/17/2021
ACDF88,earnings,100,50,8/17/2021
B2206F,conference-participant,100,50,8/17/2021
B2256A,acquisition-completed-acquirer,100,49,8/17/2021
B7BDA3,note-sale,100,52,8/17/2021
B9764A,earnings,100,50,8/17/2021
BDD12C,dividend,100,50,8/17/2021
C3BAE7,name-change,100,49,8/17/2021
C4452A,dividend,100,50,8/17/2021
C83B88,executive-appointment,100,54,8/17/2021
C83B88,executive-appointment,100,54,8/17/2021
CA1620,product-release,100,64,8/17/2021
CBA475,note-sale,100,52,8/17/2021
CE1002,stake-acquirer,100,48,8/17/2021
CE5664,dividend,100,50,8/17/2021
D1AE3B,dividend,100,50,8/17/2021
D54E62,partnership,100,61,8/17/2021
D58A11,business-contract,100,69,8/17/2021
D60BB2,earnings,100,50,8/17/2021
D697DE,conference-participant,100,50,8/17/2021
D78BF1,dividend,100,50,8/17/2021
D8ECA1,buybacks,100,74,8/17/2021
D90F43,partnership,100,61,8/17/2021
DB396B,dividend,100,50,8/17/2021
DD3BB1,legal-issues-defendant,100,22,8/17/2021
DD3BB1,legal-issues-defendant,100,22,8/17/2021
DD3BB1,legal-issues-defendant,100,22,8/17/2021
DD9E41,partnership,100,61,8/17/2021
DF8855,earnings-up,100,68,8/17/2021
DF8855,earnings-up,100,68,8/17/2021
DF8855,earnings-up,100,68,8/17/2021
DF8855,earnings-up,100,68,8/17/2021
DF8855,earnings-up,100,68,8/17/2021
E06265,conference-participant,100,50,8/17/2021
E09E2B,product-release,100,64,8/17/2021
E30A8F,executive-appointment,100,54,8/17/2021
E8846E,executive-appointment,100,54,8/17/2021
ECA300,conference-call,100,50,8/17/2021
ED79D9,earnings,100,50,8/17/2021
F0B2B5,product-release,100,64,8/17/2021
F15E41,legal-verdict-favored,100,78,8/17/2021
F15E41,legal-verdict-favored,100,78,8/17/2021
F5349B,executive-appointment,100,54,8/17/2021
F6581D,legal-issues-defendant,100,22,8/17/2021
F6DCE4,conference-call,100,50,8/17/2021
FEBFE1,partnership,100,61,8/17/2021
00326D,executive-appointment,100,54,8/18/2021
20751,business-contract,100,69,8/18/2021
20751,business-contract,100,69,8/18/2021
48590,legal-issues-defendant,100,22,8/18/2021
053EFF,dividend,100,50,8/18/2021
58828,earnings-per-share-up,100,70,8/18/2021
099C88,dividend,100,50,8/18/2021
0A7650,dividend,100,50,8/18/2021
1151F4,dividend,100,50,8/18/2021
12DE76,earnings,100,50,8/18/2021
17EDA5,business-contract,100,69,8/18/2021
2031CE,dividend-up,100,81,8/18/2021
275300,executive-appointment,100,54,8/18/2021
292A70,dividend-up,100,81,8/18/2021
2.90E+62,business-contract,100,69,8/18/2021
2E0445,clinical-trials,100,56,8/18/2021
2E0445,clinical-trials,100,56,8/18/2021
2EC172,partnership,100,61,8/18/2021
2EC172,executive-appointment,100,54,8/18/2021
30DFD3,executive-appointment,100,54,8/18/2021
32C8CD,buybacks,100,74,8/18/2021
3461CF,credit-rating-upgrade-rater,20,50,8/18/2021
3461CF,credit-rating-upgrade-rater,20,50,8/18/2021
3.50E+27,dividend,100,50,8/18/2021
397A8F,earnings,100,50,8/18/2021
3F96D5,public-offering,100,43,8/18/2021
4.00E+163,executive-appointment,100,54,8/18/2021
4591D3,conference-participant,100,50,8/18/2021
4A6F00,partnership,100,61,8/18/2021
4A6F00,partnership,100,61,8/18/2021
4B7006,market-entry,100,57,8/18/2021
4E6F5A,legal-issues-defendant,100,22,8/18/2021
53A226,dividend,100,50,8/18/2021
543900,earnings,100,50,8/18/2021
54512F,merger,100,66,8/18/2021
56277A,regulatory-product-approval-granted,100,81,8/18/2021
564F3E,dividend,100,50,8/18/2021
589846,conference-call,100,50,8/18/2021
59DB8C,partnership,100,61,8/18/2021
5A64D5,dividend,100,50,8/18/2021
5BC2F4,executive-appointment,100,54,8/18/2021
5C7601,dividend,100,50,8/18/2021
5DD486,acquisition-rumor-denied-acquirer,100,44,8/18/2021
66E04A,conference-organizer,100,57,8/18/2021
6AACDD,legal-issues-defendant,100,22,8/18/2021
6D9ECA,executive-appointment,100,54,8/18/2021
6F3936,conference-call,100,50,8/18/2021
70CA28,executive-appointment,100,54,8/18/2021
70CA28,executive-appointment,100,54,8/18/2021
732449,earnings,100,50,8/18/2021
73A71F,note-sale,100,52,8/18/2021
73BCBA,conference-participant,100,50,8/18/2021
73C9E2,stake-acquirer,100,48,8/18/2021
73F7F9,conference-call,100,50,8/18/2021
76E80F,revenues,100,50,8/18/2021
76E80F,revenues,100,50,8/18/2021
78A1BB,dividend,100,50,8/18/2021
7BFF81,executive-appointment,100,54,8/18/2021
7D7716,award,100,58,8/18/2021
7D85A9,executive-appointment,100,54,8/18/2021
7E1D5D,earnings,100,50,8/18/2021
7E1D5D,earnings,100,50,8/18/2021
7E1D5D,earnings,100,50,8/18/2021
7E1D5D,earnings,100,50,8/18/2021
7F0372,conference-participant,100,50,8/18/2021
7F3669,acquisition-completed-acquirer,100,49,8/18/2021
8.40E+120,executive-appointment,100,54,8/18/2021
8C6C1B,dividend,100,50,8/18/2021
8EEA28,merger,100,66,8/18/2021
8FF2EF,earnings,100,50,8/18/2021
911ACB,merger,100,66,8/18/2021
911ACB,dividend,100,50,8/18/2021
94983E,business-contract,100,69,8/18/2021
94983E,business-contract,100,69,8/18/2021
971334,product-release,100,64,8/18/2021
9B4066,note-sale,100,52,8/18/2021
9C8664,merger,100,66,8/18/2021
A02FB1,merger,100,66,8/18/2021
A03EE1,legal-issues-defendant,100,22,8/18/2021
A03EE1,legal-issues-defendant,100,22,8/18/2021
A247F5,buybacks,100,74,8/18/2021
A47A7D,facility-upgrade,100,65,8/18/2021
A6FE1C,unit-acquisition-acquirer,100,49,8/18/2021
AD9F1D,partnership,100,61,8/18/2021
B1FC3B,business-contract,100,69,8/18/2021
B3CB74,conference-organizer,100,57,8/18/2021
BD682F,dividend,100,50,8/18/2021
BFCACF,earnings,100,50,8/18/2021
C07E05,earnings,100,50,8/18/2021
C188F8,conference-call,100,50,8/18/2021
C4A241,dividend,100,50,8/18/2021
C81E00,executive-resignation,100,44,8/18/2021
C81E00,executive-resignation,100,44,8/18/2021
CA1620,stake-acquirer,100,48,8/18/2021
CB7AB2,conference-participant,100,50,8/18/2021
CBFFDD,executive-appointment,100,54,8/18/2021
CC0C78,orphan-drug-designation,100,76,8/18/2021
CFF97C,credit-rating-unchanged-rater,20,50,8/18/2021
D4C0CB,conference-participant,100,50,8/18/2021
D76AEF,earnings,100,50,8/18/2021
D8DBA3,dividend,100,50,8/18/2021
DB396B,conference-participant,100,50,8/18/2021
DD0099,dividend,100,50,8/18/2021
DE4924,conference-participant,100,50,8/18/2021
DF1F7A,merger,100,66,8/18/2021
E06265,dividend,100,50,8/18/2021
E09E2B,earnings,100,50,8/18/2021
E09E2B,earnings,100,50,8/18/2021
E09E2B,earnings,100,50,8/18/2021
E09E2B,earnings,100,50,8/18/2021
E1E093,business-contract,100,69,8/18/2021
E1E093,business-contract,100,69,8/18/2021
E2F130,conference-participant,100,50,8/18/2021
E393B0,merger,100,66,8/18/2021
E4CE73,earnings,100,50,8/18/2021
E68C3D,revenue-up,100,69,8/18/2021
E68C3D,revenue-up,100,69,8/18/2021
E68C3D,revenue-up,100,69,8/18/2021
E68C3D,revenue-up,100,69,8/18/2021
E68C3D,revenue-up,100,69,8/18/2021
E6A53A,note-sale,100,52,8/18/2021
E6C8DC,legal-issues-defendant,100,22,8/18/2021
E6D89E,acquisition-acquirer,100,49,8/18/2021
E6D89E,acquisition-acquirer,100,49,8/18/2021
EBD89A,earnings,100,50,8/18/2021
ECD263,regulatory-investigation,100,22,8/18/2021
EDF5CA,note-sale,100,52,8/18/2021
EE6F1C,government-contract,100,69,8/18/2021
F11638,partnership,100,61,8/18/2021
F1529C,acquisition-rumor-denied-acquiree,100,27,8/18/2021
F2526D,note-sale,100,52,8/18/2021
F58C23,executive-appointment,100,54,8/18/2021
F6DCE4,earnings,100,50,8/18/2021
F6DCE4,earnings,100,50,8/18/2021
F82D37,partnership,100,61,8/18/2021
F82D37,partnership,100,61,8/18/2021
FADF1A,executive-appointment,100,54,8/18/2021
FEBFE1,merger,100,66,8/18/2021
FF4BA4,executive-appointment,100,54,8/18/2021
0157B1,market-entry,100,57,8/19/2021
95294,product-release,100,64,8/19/2021
95294,executive-appointment,100,54,8/19/2021
0A59F8,partnership,100,61,8/19/2021
0C6861,product-release,100,64,8/19/2021
0C8D82,executive-appointment,100,54,8/19/2021
0F0440,earnings,100,50,8/19/2021
1151F4,executive-appointment,100,54,8/19/2021
14ED2B,dividend,100,50,8/19/2021
14ED2B,earnings,100,50,8/19/2021
15A388,business-contract,100,69,8/19/2021
184866,partnership,100,61,8/19/2021
190BE6,earnings,100,50,8/19/2021
1C2593,earnings,100,50,8/19/2021
1E4FB9,legal-issues-defendant,100,22,8/19/2021
2093B1,dividend,100,50,8/19/2021
278C18,dividend,100,50,8/19/2021
279916,earnings,100,50,8/19/2021
2B49F4,dividend,100,50,8/19/2021
2B7A40,partnership,100,61,8/19/2021
2D2D43,partnership,100,61,8/19/2021
2DB344,dividend,100,50,8/19/2021
341759,executive-appointment,100,54,8/19/2021
3.50E+27,buybacks,100,74,8/19/2021
408089,unit-acquisition-acquirer,100,49,8/19/2021
41EC04,business-contract,100,69,8/19/2021
431B74,joint-venture-terminated,100,38,8/19/2021
431B74,joint-venture-terminated,100,38,8/19/2021
442769,business-contract,100,69,8/19/2021
499C75,patent-awarded,100,72,8/19/2021
49F4D0,dividend,100,50,8/19/2021
4A6F00,business-contract,100,69,8/19/2021
4E6F5A,legal-issues-defendant,100,22,8/19/2021
4ECD1A,dividend,100,50,8/19/2021
4EE167,legal-issues-defendant,100,22,8/19/2021
4EEB00,grant-recipient,100,63,8/19/2021
50070E,partnership,100,61,8/19/2021
5065B1,acquisition-completed-acquirer,100,49,8/19/2021
520632,partnership,100,61,8/19/2021
53E575,executive-appointment,100,54,8/19/2021
54512F,legal-issues-defendant,100,22,8/19/2021
583223,dividend,100,50,8/19/2021
5B3415,executive-appointment,100,54,8/19/2021
6.18E+08,earnings,100,50,8/19/2021
6.18E+08,earnings,100,50,8/19/2021
6.18E+08,earnings,100,50,8/19/2021
6.18E+08,earnings,100,50,8/19/2021
6830FE,earnings,100,50,8/19/2021
6AACDD,legal-issues-defendant,100,22,8/19/2021
6E8349,dividend,100,50,8/19/2021
713810,partnership,100,61,8/19/2021
7255D2,executive-appointment,100,54,8/19/2021
73F70F,dividend,100,50,8/19/2021
7448A3,dividend,100,50,8/19/2021
756BB4,award,100,58,8/19/2021
756BB4,award,100,58,8/19/2021
766047,executive-appointment,100,54,8/19/2021
7740DE,earnings,100,50,8/19/2021
7740DE,earnings,100,50,8/19/2021
7A10FF,product-release,100,64,8/19/2021
7B492C,earnings,100,50,8/19/2021
880C0C,dividend,100,50,8/19/2021
895D56,partnership,100,61,8/19/2021
8C311A,product-release,100,64,8/19/2021
8C6C1B,earnings,100,50,8/19/2021
8C6C1B,earnings,100,50,8/19/2021
8DBE73,note-sale,100,52,8/19/2021
8DCBBB,dividend,100,50,8/19/2021
901327,dividend,100,50,8/19/2021
944B2E,name-change,100,49,8/19/2021
94637C,regulatory-product-approval-granted,100,81,8/19/2021
954004,conference-call,100,50,8/19/2021
9.74E+08,executive-appointment,100,54,8/19/2021
990AD0,patent-awarded,100,72,8/19/2021
9.97E+09,dividend,100,50,8/19/2021
9ABD30,clinical-trials-positive,100,87,8/19/2021
9ABD30,clinical-trials-positive,100,87,8/19/2021
9C5BA5,dividend,100,50,8/19/2021
9F6B1A,partnership,100,61,8/19/2021
9FA83B,earnings,100,50,8/19/2021
A02FB1,legal-issues-defendant,100,22,8/19/2021
A03EE1,legal-issues-defendant,100,22,8/19/2021
A1EAC8,acquisition-completed-acquirer,100,49,8/19/2021
A4BCDE,earnings,100,50,8/19/2021
A666C8,executive-appointment,100,54,8/19/2021
A6828A,clinical-trials,100,56,8/19/2021
A6828A,clinical-trials,100,56,8/19/2021
A7102F,partnership,100,61,8/19/2021
A761FE,conference-call,100,50,8/19/2021
A99576,legal-issues-defendant,100,22,8/19/2021
ABB493,executive-appointment,100,54,8/19/2021
ACDF88,dividend,100,50,8/19/2021
B01111,executive-appointment,100,54,8/19/2021
B1FC3B,business-contract,100,69,8/19/2021
B3CB74,conference-organizer,100,57,8/19/2021
B8DD94,earnings,100,50,8/19/2021
BB0587,dividend,100,50,8/19/2021
BB0787,earnings,100,50,8/19/2021
BB88B6,business-contract,100,69,8/19/2021
BC948D,dividend,100,50,8/19/2021
BE379D,executive-appointment,100,54,8/19/2021
C037A8,conference-call,100,50,8/19/2021
C356AC,legal-issues-defendant,100,22,8/19/2021
C490F9,earnings,100,50,8/19/2021
C501B6,public-offering,100,43,8/19/2021
C5C137,earnings,100,50,8/19/2021
C5C137,earnings,100,50,8/19/2021
C5C137,earnings,100,50,8/19/2021
C5C137,earnings,100,50,8/19/2021
C5C137,earnings,100,50,8/19/2021
C5C137,partnership,100,61,8/19/2021
C9D866,award,100,58,8/19/2021
CA1620,stake-acquirer,100,48,8/19/2021
CBFFDD,business-contract,100,69,8/19/2021
CF211D,earnings,100,50,8/19/2021
CFF15D,partnership,100,61,8/19/2021
CFF57D,conference-call,100,50,8/19/2021
D4AC65,buybacks,100,74,8/19/2021
D64C6D,conference-call,100,50,8/19/2021
D8F347,partnership,100,61,8/19/2021
D9E036,business-contract,100,69,8/19/2021
DD1BA1,partnership,100,61,8/19/2021
DD1BA1,partnership,100,61,8/19/2021
DF11D9,legal-issues-defendant,100,22,8/19/2021
E05026,executive-appointment,100,54,8/19/2021
E2CFD2,conference-participant,100,50,8/19/2021
E30B34,executive-appointment,100,54,8/19/2021
E393B0,legal-issues-defendant,100,22,8/19/2021
E8B315,executive-appointment,100,54,8/19/2021
ED2A5E,acquisition-acquiree,100,76,8/19/2021
ED2A5E,acquisition-regulatory-scrutiny-acquiree,100,38,8/19/2021
F1529C,dividend-up,100,81,8/19/2021
F48947,legal-issues-defendant,100,22,8/19/2021
F66B58,conference-call,100,50,8/19/2021
F6E248,regulatory-product-approval-granted,100,81,8/19/2021
F85CC0,executive-appointment,100,54,8/19/2021
F85CC0,executive-appointment,100,54,8/19/2021
F88147,legal-issues-defendant,100,22,8/19/2021
FDE409,earnings,100,50,8/19/2021
01D03F,business-contract,100,69,8/20/2021
040DBB,executive-appointment,100,54,8/20/2021
48590,legal-issues-defendant,100,22,8/20/2021
07C69F,business-contract,100,69,8/20/2021
0A7650,dividend,100,50,8/20/2021
0CE7F6,earnings,100,50,8/20/2021
143C52,sponsorship,100,57,8/20/2021
1EBF8D,executive-resignation,100,44,8/20/2021
1F9258,executive-appointment,100,54,8/20/2021
20BEEA,dividend,100,50,8/20/2021
20F5E2,dividend,100,50,8/20/2021
2720AB,dividend-up,100,74,8/20/2021
2E1322,business-contract,100,69,8/20/2021
2EBC0B,dividend,100,50,8/20/2021
31643A,dividend,100,50,8/20/2021
355B19,dividend-up,100,81,8/20/2021
3DE4D1,partnership,100,61,8/20/2021
3ED92D,business-contract,100,69,8/20/2021
3F96D5,public-offering,100,43,8/20/2021
431B74,earnings-positive,100,69,8/20/2021
431B74,earnings-positive,100,69,8/20/2021
431B74,earnings-positive,100,69,8/20/2021
431B74,earnings-positive,100,69,8/20/2021
431B74,earnings-positive,100,69,8/20/2021
431B74,earnings-positive,100,69,8/20/2021
431B74,earnings-positive,100,69,8/20/2021
431B74,earnings-positive,100,69,8/20/2021
431B74,earnings,100,50,8/20/2021
431B74,earnings,100,50,8/20/2021
431B74,earnings,100,50,8/20/2021
431B74,earnings,100,50,8/20/2021
431B74,earnings,100,50,8/20/2021
431B74,earnings,100,50,8/20/2021
4F0A80,dividend,100,50,8/20/2021
51E682,dividend,100,50,8/20/2021
53F491,dividend,100,50,8/20/2021
589803,regulatory-product-approval-granted,100,81,8/20/2021
589803,regulatory-product-approval-granted,100,81,8/20/2021
589803,regulatory-product-approval-granted,100,81,8/20/2021
59A832,dividend,100,50,8/20/2021
5FE4B6,dividend,100,50,8/20/2021
6166D1,dividend,100,50,8/20/2021
651C85,partnership,100,61,8/20/2021
68BA15,business-contract,100,69,8/20/2021
6AACDD,legal-issues-defendant,100,22,8/20/2021
6AACDD,legal-issues-defendant,100,22,8/20/2021
6BDA0C,dividend-up,100,81,8/20/2021
713810,partnership,100,61,8/20/2021
713810,partnership,100,61,8/20/2021
7B9212,earnings,100,50,8/20/2021
7B9212,earnings,100,50,8/20/2021
88611B,dividend,100,50,8/20/2021
8BE916,dividend,100,50,8/20/2021
8E0E32,note-sale,100,52,8/20/2021
94637C,regulatory-product-approval-granted,100,81,8/20/2021
954A47,dividend,100,50,8/20/2021
9D2790,executive-appointment,100,54,8/20/2021
9F37C5,dividend,100,50,8/20/2021
A03EE1,legal-issues-defendant,100,22,8/20/2021
BBF349,conference-participant,100,50,8/20/2021
BCE9DA,dividend,100,50,8/20/2021
BCE9DA,dividend,100,50,8/20/2021
BCE9DA,buybacks,100,74,8/20/2021
BCE9DA,buybacks,100,74,8/20/2021
CA99D7,dividend,100,50,8/20/2021
DF532D,legal-issues-defendant,100,22,8/20/2021
E05026,acquisition-completed-acquirer,100,49,8/20/2021
E6C8DC,legal-issues-defendant,100,22,8/20/2021
E8846E,dividend,100,50,8/20/2021
EDF5CA,note-sale,100,52,8/20/2021
EF7163,asset-sale,100,62,8/20/2021
FC4550,dividend,100,50,8/20/2021
FEBFE1,private-placement,100,56,8/20/2021
03CF95,legal-issues-defendant,100,22,8/21/2021
1FE7F0,legal-issues-defendant,100,22,8/21/2021
2A1009,acquisition-acquiree,100,76,8/21/2021
4E6F5A,fraud-defendant,100,20,8/21/2021
54512F,legal-issues-defendant,100,22,8/21/2021
7A5097,legal-issues-defendant,100,22,8/21/2021
A02FB1,legal-issues-defendant,100,22,8/21/2021
A99576,legal-issues-defendant,100,22,8/21/2021
DF11D9,legal-issues-defendant,100,22,8/21/2021
F48947,legal-issues-defendant,100,22,8/21/2021
9397,executive-resignation,100,44,8/23/2021
00FC70,conference-call,100,50,8/23/2021
03CF95,legal-issues-defendant,100,22,8/23/2021
48590,legal-issues-defendant,100,22,8/23/2021
099C88,partnership,100,61,8/23/2021
0A59F8,product-release,100,64,8/23/2021
0E2992,dividend,100,50,8/23/2021
147C38,executive-resignation,100,44,8/23/2021
147C38,executive-appointment,100,54,8/23/2021
1.79E+10,stake-acquirer,100,48,8/23/2021
1.79E+10,stake-acquirer,100,48,8/23/2021
17EDA5,business-contract,100,69,8/23/2021
19CAC7,executive-appointment,100,54,8/23/2021
1BC12C,legal-issues-defendant,100,22,8/23/2021
1BC12C,legal-issues-defendant,100,22,8/23/2021
1BC12C,legal-issues-defendant,100,22,8/23/2021
21153F,buybacks,100,74,8/23/2021
21153F,buybacks,100,74,8/23/2021
21245F,conference-participant,100,50,8/23/2021
2262BD,earnings,100,50,8/23/2021
228D42,partnership,100,61,8/23/2021
267718,acquisition-acquirer,100,49,8/23/2021
267718,acquisition-acquirer,100,49,8/23/2021
267718,acquisition-acquirer,100,49,8/23/2021
267718,acquisition-acquirer,100,49,8/23/2021
267718,regulatory-product-approval-granted,100,81,8/23/2021
28B730,acquisition-acquirer,100,49,8/23/2021
292388,conference-participant,100,50,8/23/2021
2A02DC,conference-participant,100,50,8/23/2021
2A1009,conference-participant,100,50,8/23/2021
2ABF77,executive-appointment,100,54,8/23/2021
2E89AE,conference-participant,100,50,8/23/2021
2F9304,executive-appointment,100,54,8/23/2021
30CBF9,partnership,100,61,8/23/2021
338544,executive-appointment,100,54,8/23/2021
33E9D5,partnership,100,61,8/23/2021
371B0A,conference-participant,100,50,8/23/2021
3B9886,facility-open,100,65,8/23/2021
3DED49,conference-call,100,50,8/23/2021
3EE65E,conference-participant,100,50,8/23/2021
3F1C69,regulatory-product-approval-granted,100,81,8/23/2021
42312F,earnings,100,50,8/23/2021
46CF27,acquisition-acquirer,100,49,8/23/2021
46CF27,acquisition-acquirer,100,49,8/23/2021
485445,unit-acquisition-acquiree,100,76,8/23/2021
485445,unit-acquisition-acquiree,100,76,8/23/2021
4.91E+58,executive-appointment,100,54,8/23/2021
4FB770,dividend,100,50,8/23/2021
51888A,dividend,100,50,8/23/2021
51888A,dividend,100,50,8/23/2021
56765E,acquisition-acquirer,100,49,8/23/2021
5B226B,dividend,100,50,8/23/2021
5FDBD0,partnership,100,61,8/23/2021
66667F,business-contract,100,69,8/23/2021
66667F,business-contract,100,69,8/23/2021
6AACDD,legal-issues-defendant,100,22,8/23/2021
6AACDD,legal-issues-defendant,100,22,8/23/2021
7.44E+09,note-sale,100,52,8/23/2021
78F776,partnership,100,61,8/23/2021
7F3FBC,dividend-up,100,52,8/23/2021
8AC65D,partnership,100,61,8/23/2021
9.54E+32,product-release,100,64,8/23/2021
963A02,clinical-trials-start,100,64,8/23/2021
986AF6,acquisition-completed-acquirer,100,49,8/23/2021
99B61C,executive-appointment,100,54,8/23/2021
9B4066,credit-extension-recipient,100,69,8/23/2021
9C5BA5,buybacks,100,74,8/23/2021
A03EE1,legal-issues-defendant,100,22,8/23/2021
A1EAC8,executive-appointment,100,54,8/23/2021
A2A9BA,stake-acquirer,100,48,8/23/2021
A2A9BA,stake-acquirer,100,48,8/23/2021
A52B6B,earnings,100,50,8/23/2021
A7102F,credit-extension-recipient,100,69,8/23/2021
A7102F,partnership,100,61,8/23/2021
AFDF2E,conference-participant,100,50,8/23/2021
B2DAF6,executive-appointment,100,54,8/23/2021
B3CB74,conference-organizer,100,57,8/23/2021
B614F8,conference-participant,100,50,8/23/2021
B9CD50,award,100,58,8/23/2021
BB58FF,conference-participant,100,50,8/23/2021
BF79F5,executive-appointment,100,54,8/23/2021
C230FE,executive-appointment,100,54,8/23/2021
C4A241,note-sale,100,52,8/23/2021
C8A248,executive-appointment,100,54,8/23/2021
CBFFDD,government-contract,100,69,8/23/2021
CDFCC9,conference-participant,100,50,8/23/2021
CDFCC9,conference-participant,100,50,8/23/2021
CEC08B,executive-appointment,100,54,8/23/2021
CFF97C,credit-rating-affirmation-rater,20,50,8/23/2021
D33270,partnership,100,61,8/23/2021
D60BB2,dividend,100,50,8/23/2021
D76AEF,executive-appointment,100,54,8/23/2021
DB5CA5,partnership,100,61,8/23/2021
DC0998,executive-appointment,100,54,8/23/2021
DD1BA1,product-release,100,64,8/23/2021
DF18E6,executive-appointment,100,54,8/23/2021
E21871,executive-resignation,100,44,8/23/2021
E261E9,award,100,58,8/23/2021
E68733,dividend,100,50,8/23/2021
E68733,dividend,100,50,8/23/2021
E8846E,conference-organizer,100,57,8/23/2021
E90C84,dividend,100,50,8/23/2021
E9FF33,partnership,100,61,8/23/2021
F5349B,executive-appointment,100,54,8/23/2021
F569FD,patient-enrollment-complete,100,64,8/23/2021
FD554E,dividend,100,50,8/23/2021
01478A,dividend,100,50,8/24/2021
01D03F,partnership,100,61,8/24/2021
03CF95,legal-issues-defendant,100,22,8/24/2021
03D5F9,partnership,100,61,8/24/2021
48590,legal-issues-defendant,100,22,8/24/2021
0986B5,dividend,100,50,8/24/2021
0FABBD,executive-resignation,100,44,8/24/2021
102727,executive-appointment,100,54,8/24/2021
125212,clinical-trials-start,100,64,8/24/2021
129DC8,conference-participant,100,50,8/24/2021
12A3A3,executive-appointment,100,54,8/24/2021
152AB9,index-listing,100,76,8/24/2021
273BA3,product-release,100,64,8/24/2021
2EB04E,partnership,100,61,8/24/2021
2EC172,partnership,100,61,8/24/2021
39692D,partnership,100,61,8/24/2021
3F1C69,regulatory-product-approval-granted,100,81,8/24/2021
3FBC9B,conference-participant,100,50,8/24/2021
4.03E+05,executive-appointment,100,54,8/24/2021
422CE3,earnings,100,50,8/24/2021
4AE584,unit-acquisition-acquirer,100,49,8/24/2021
4F9926,business-contract,100,69,8/24/2021
55C9B5,partnership,100,61,8/24/2021
57CAAB,partnership,100,61,8/24/2021
589803,clinical-trials-positive,100,87,8/24/2021
5B3415,conference-organizer,100,57,8/24/2021
5B6C11,dividend,100,50,8/24/2021
5E7E82,earnings-above-expectations,100,88,8/24/2021
6166D1,partnership,100,61,8/24/2021
665D7D,regulatory-product-approval-granted,100,81,8/24/2021
673C9A,earnings,100,50,8/24/2021
67529E,executive-appointment,100,54,8/24/2021
6A171E,executive-appointment,100,54,8/24/2021
6A961B,conference-call,100,50,8/24/2021
6AACDD,legal-issues-defendant,100,22,8/24/2021
6E705B,business-contract,100,69,8/24/2021
748EB6,business-contract,100,69,8/24/2021
756BB4,award,100,58,8/24/2021
773A17,product-release,100,64,8/24/2021
7CBC40,award,100,58,8/24/2021
7EA323,exchange-noncompliance,100,24,8/24/2021
80D744,dividend-up,100,61,8/24/2021
810FAD,dividend,100,50,8/24/2021
810FAD,dividend,100,50,8/24/2021
84A6B9,business-contract,100,69,8/24/2021
84A6B9,business-contract,100,69,8/24/2021
86A1B9,buybacks,100,74,8/24/2021
9EBAFA,unit-acquisition-acquirer,100,49,8/24/2021
A1EAC8,executive-appointment,100,54,8/24/2021
A26C26,earnings,100,50,8/24/2021
A60354,dividend,100,50,8/24/2021
A666C8,partnership,100,61,8/24/2021
A6828A,partnership,100,61,8/24/2021
A6828A,business-contract,100,69,8/24/2021
A6ABE9,going-private,100,74,8/24/2021
A6ABE9,acquisition-regulatory-scrutiny-acquiree,100,38,8/24/2021
A6FE1C,unit-acquisition-acquirer,100,49,8/24/2021
AA98ED,partnership,100,61,8/24/2021
AE4EEB,partnership,100,61,8/24/2021
B1FC3B,business-contract,100,69,8/24/2021
B2206F,business-contract,100,69,8/24/2021
B37FB4,product-release,100,64,8/24/2021
B4B281,earnings-up,100,68,8/24/2021
B9B6B8,product-release,100,64,8/24/2021
BE14CF,executive-appointment,100,54,8/24/2021
BFE02C,dividend,100,50,8/24/2021
C062D4,conference-participant,100,50,8/24/2021
C230FE,index-listing,100,76,8/24/2021
C356AC,partnership,100,61,8/24/2021
C501B6,public-offering,100,43,8/24/2021
C598D7,business-contract,100,69,8/24/2021
C598D7,business-contract,100,69,8/24/2021
CBFFDD,business-contract,100,69,8/24/2021
D75910,partnership,100,61,8/24/2021
D75910,earnings,100,50,8/24/2021
D75910,earnings,100,50,8/24/2021
D75910,earnings,100,50,8/24/2021
D75910,earnings,100,50,8/24/2021
D75910,earnings,100,50,8/24/2021
D8760C,merger-regulatory-approval,100,81,8/24/2021
D88EF3,business-contract,100,69,8/24/2021
D96202,partnership,100,61,8/24/2021
DD1BA1,product-release,100,64,8/24/2021
DD9E41,conference-participant,100,50,8/24/2021
DF6FDD,dividend-up,100,59,8/24/2021
E22FDE,acquisition-completed-acquirer,100,49,8/24/2021
E4CE73,partnership,100,61,8/24/2021
E56A0D,executive-appointment,100,54,8/24/2021
E68733,earnings,100,50,8/24/2021
E68733,earnings,100,50,8/24/2021
E6C8DC,legal-issues-defendant,100,22,8/24/2021
E6C8DC,fraud,100,44,8/24/2021
EEA6B3,executive-resignation,100,44,8/24/2021
F11638,earnings-up,100,68,8/24/2021
F11638,earnings-up,100,68,8/24/2021
F11638,earnings-up,100,68,8/24/2021
F11638,earnings-up,100,68,8/24/2021
F11638,earnings-up,100,68,8/24/2021
F39E1E,earnings,100,50,8/24/2021
F58C23,partnership,100,61,8/24/2021
F793FA,executive-appointment,100,54,8/24/2021
F88147,legal-issues-defendant,100,22,8/24/2021
F8DE55,regulatory-investigation,100,22,8/24/2021
FCA54E,executive-appointment,100,54,8/24/2021
FF6644,business-contract,100,69,8/24/2021
002A99,clinical-trials-positive,100,87,8/25/2021
48590,legal-issues-defendant,100,22,8/25/2021
06A456,earnings,100,50,8/25/2021
06A456,earnings,100,50,8/25/2021
06A456,earnings,100,50,8/25/2021
06A456,earnings,100,50,8/25/2021
083F72,dividend,100,50,8/25/2021
0DE3D5,dividend,100,50,8/25/2021
0E6027,executive-appointment,100,54,8/25/2021
125212,legal-issues-defendant,100,22,8/25/2021
125212,legal-issues-defendant,100,22,8/25/2021
125212,legal-issues-defendant,100,22,8/25/2021
125212,legal-issues-defendant,100,22,8/25/2021
17EDA5,partnership,100,61,8/25/2021
1BC12C,product-recall,100,29,8/25/2021
1E8A99,dividend,100,50,8/25/2021
24CB56,conference-participant,100,50,8/25/2021
251988,business-contract,100,69,8/25/2021
263216,dividend,100,50,8/25/2021
267718,regulatory-product-approval-granted,100,81,8/25/2021
26FA41,executive-appointment,100,54,8/25/2021
2E89AE,conference-participant,100,50,8/25/2021
2F9304,earnings,100,50,8/25/2021
332F87,executive-resignation,100,44,8/25/2021
3.73E+87,partnership,100,61,8/25/2021
385DD4,partnership,100,61,8/25/2021
397A8F,partnership,100,61,8/25/2021
3AF7FD,earnings,100,50,8/25/2021
3B20AB,conference-participant,100,50,8/25/2021
3BB7D3,executive-appointment,100,54,8/25/2021
41785E,conference-participant,100,50,8/25/2021
431B74,dividend-up,100,67,8/25/2021
431B74,dividend-up,100,67,8/25/2021
451D61,regulatory-product-approval-granted,100,81,8/25/2021
4.60E+06,index-listing,100,76,8/25/2021
4.91E+58,partnership,100,61,8/25/2021
49A344,government-contract,100,69,8/25/2021
4C2F17,facility-upgrade,100,65,8/25/2021
550D01,executive-resignation,100,44,8/25/2021
594402,partnership,100,61,8/25/2021
5B7739,product-release,100,64,8/25/2021
5E7E82,dividend,100,50,8/25/2021
5E9934,conference-call,100,50,8/25/2021
63F892,partnership,100,61,8/25/2021
63F892,partnership,100,61,8/25/2021
64E346,earnings,100,50,8/25/2021
68BA15,acquisition-acquirer,100,49,8/25/2021
6E1E61,acquisition-acquiree,100,76,8/25/2021
6F3936,earnings,100,50,8/25/2021
6FCEF9,earnings,100,50,8/25/2021
73F70F,earnings,100,50,8/25/2021
763DBE,business-contract,100,69,8/25/2021
7A5097,earnings,100,50,8/25/2021
7DD584,earnings,100,50,8/25/2021
819492,sponsorship,100,57,8/25/2021
81A88D,conference-participant,100,50,8/25/2021
82BB33,earnings,100,50,8/25/2021
873DB9,product-release,100,64,8/25/2021
873DB9,regulatory-product-approval-granted,100,81,8/25/2021
877C0C,clinical-trials-positive,100,87,8/25/2021
8EDACA,conference-call,100,50,8/25/2021
907ED2,executive-appointment,100,54,8/25/2021
9196A2,conference-organizer,100,57,8/25/2021
9196A2,conference-organizer,100,57,8/25/2021
934CC3,earnings,100,50,8/25/2021
94C0B5,executive-appointment,100,54,8/25/2021
95DC1F,campaign-ad-release,100,59,8/25/2021
966ACE,conference-participant,100,50,8/25/2021
97693A,conference-call,100,50,8/25/2021
98A286,earnings,100,50,8/25/2021
99B61C,patient-enrollment-start,100,58,8/25/2021
9BF177,unit-acquisition-acquirer,100,49,8/25/2021
A03EE1,earnings,100,50,8/25/2021
A6FC89,earnings,100,50,8/25/2021
A6FC89,earnings,100,50,8/25/2021
A6FC89,earnings,100,50,8/25/2021
A6FC89,earnings,100,50,8/25/2021
A6FC89,earnings,100,50,8/25/2021
A6FE1C,acquisition-acquirer,100,49,8/25/2021
A6FE1C,business-contract,100,69,8/25/2021
AAEE21,product-release,100,64,8/25/2021
AC3584,partnership,100,61,8/25/2021
AD22F2,dividend,100,50,8/25/2021
B01111,earnings,100,50,8/25/2021
B01111,earnings,100,50,8/25/2021
B01111,earnings,100,50,8/25/2021
B01111,earnings,100,50,8/25/2021
B01111,earnings,100,50,8/25/2021
B3CB74,stock-splits,100,49,8/25/2021
B96637,business-contract,100,69,8/25/2021
BB127B,earnings-up,100,68,8/25/2021
BB88B6,executive-appointment,100,54,8/25/2021
BC3AD2,dividend,100,50,8/25/2021
BFCACF,public-offering,100,43,8/25/2021
C188F8,earnings,100,50,8/25/2021
C22BE8,earnings,100,50,8/25/2021
C356AC,conference-participant,100,50,8/25/2021
C3DE7D,earnings,100,50,8/25/2021
C4F9C6,clinical-trials,100,56,8/25/2021
C83B88,partnership,100,61,8/25/2021
CDFCC9,stock-splits,100,49,8/25/2021
CF7292,earnings-up,100,68,8/25/2021
CF7292,earnings,100,50,8/25/2021
CF7292,earnings,100,50,8/25/2021
CF7292,earnings,100,50,8/25/2021
D0DFE5,executive-appointment,100,54,8/25/2021
D18AFC,orphan-drug-designation,100,76,8/25/2021
D2C0B6,earnings,100,50,8/25/2021
D64C6D,partnership,100,61,8/25/2021
DB2E4E,note-sale,100,52,8/25/2021
DB88A1,earnings,100,50,8/25/2021
DF6FDD,executive-appointment,100,54,8/25/2021
E1C16B,dividend,100,50,8/25/2021
E4CE73,conference-participant,100,50,8/25/2021
E68C3D,buybacks,100,74,8/25/2021
E6C8DC,legal-issues-defendant,100,22,8/25/2021
EBD89A,business-contract,100,69,8/25/2021
EE967B,dividend,100,50,8/25/2021
EF5BED,executive-appointment,100,54,8/25/2021
F02170,earnings,100,50,8/25/2021
F1EB39,conference-call,100,50,8/25/2021
F30508,partnership,100,61,8/25/2021
F30508,executive-resignation,100,44,8/25/2021
F43A11,conference-call,100,50,8/25/2021
F6DCE4,executive-appointment,100,54,8/25/2021
F748C7,earnings-up,100,68,8/25/2021
F748C7,dividend-up,100,81,8/25/2021
FE7A63,executive-appointment,100,54,8/25/2021
00698D,earnings,100,50,8/26/2021
01B8D6,conference-participant,100,50,8/26/2021
01D03F,partnership,100,61,8/26/2021
02870F,dividend,100,50,8/26/2021
03CF95,legal-issues-defendant,100,22,8/26/2021
03CF95,fraud-defendant,100,20,8/26/2021
48781,dividend,100,50,8/26/2021
51332,buybacks,100,74,8/26/2021
054B55,partnership,100,61,8/26/2021
0624BE,earnings,100,50,8/26/2021
75172,earnings,100,50,8/26/2021
099A92,executive-appointment,100,54,8/26/2021
0B57D7,dividend-up,100,65,8/26/2021
0F2BC9,executive-appointment,100,54,8/26/2021
143C52,earnings,100,50,8/26/2021
16AAE0,conference-participant,100,50,8/26/2021
17EDA5,executive-appointment,100,54,8/26/2021
190B91,acquisition-acquiree,100,76,8/26/2021
197612,investment-investor,100,55,8/26/2021
1AD9CC,earnings,100,50,8/26/2021
1D943E,conference-participant,100,50,8/26/2021
1E4FB9,legal-issues-defendant,100,22,8/26/2021
1E83DE,earnings,100,50,8/26/2021
1EBF8D,business-contract,100,69,8/26/2021
228D42,partnership,100,61,8/26/2021
228D42,partnership,100,61,8/26/2021
22C58E,acquisition-completed-acquiree,100,76,8/26/2021
267718,partnership,100,61,8/26/2021
267718,partnership,100,61,8/26/2021
267718,partnership,100,61,8/26/2021
267718,partnership,100,61,8/26/2021
267718,executive-appointment,100,54,8/26/2021
26DC29,earnings,100,50,8/26/2021
291651,conference-call,100,50,8/26/2021
2920D5,dividend,100,50,8/26/2021
29A4CC,dividend,100,50,8/26/2021
2B7A40,conference-participant,100,50,8/26/2021
2BA977,dividend-up,100,55,8/26/2021
2D5011,dividend,100,50,8/26/2021
2E89AE,conference-participant,100,50,8/26/2021
2F98A5,earnings,100,50,8/26/2021
31643A,unit-acquisition-acquirer,100,49,8/26/2021
33AD83,earnings,100,50,8/26/2021
3587B4,partnership,100,61,8/26/2021
4290EF,dividend,100,50,8/26/2021
442587,conference-organizer,100,57,8/26/2021
4AC91D,earnings,100,50,8/26/2021
4AC91D,earnings,100,50,8/26/2021
4AC91D,earnings,100,50,8/26/2021
4AC91D,earnings,100,50,8/26/2021
4AC91D,earnings,100,50,8/26/2021
4AC91D,earnings,100,50,8/26/2021
4B7006,earnings,100,50,8/26/2021
4C2F17,conference-participant,100,50,8/26/2021
4C6C63,conference-participant,100,50,8/26/2021
52B567,merger-regulatory-approval,100,81,8/26/2021
54512F,legal-issues-defendant,100,22,8/26/2021
54A646,dividend,100,50,8/26/2021
55C9B5,conference-participant,100,50,8/26/2021
567F3D,dividend,100,50,8/26/2021
56EFC7,conference-participant,100,50,8/26/2021
56EFC7,dividend,100,50,8/26/2021
57B174,acquisition-completed-acquirer,100,49,8/26/2021
586FFD,earnings,100,50,8/26/2021
60AC34,conference-participant,100,50,8/26/2021
619882,conference-organizer,100,57,8/26/2021
6C987C,dividend,100,50,8/26/2021
6DDA15,executive-appointment,100,54,8/26/2021
6F3FA8,conference-participant,100,50,8/26/2021
70B3D6,conference-call,100,50,8/26/2021
74404C,executive-appointment,100,54,8/26/2021
748EB6,conference-participant,100,50,8/26/2021
791D59,conference-participant,100,50,8/26/2021
7A0EC4,conference-participant,100,50,8/26/2021
7AD81E,conference-participant,100,50,8/26/2021
7ADE57,conference-call,100,50,8/26/2021
7B6EB1,conference-participant,100,50,8/26/2021
817ED9,acquisition-acquirer,100,49,8/26/2021
817ED9,earnings,100,50,8/26/2021
817ED9,earnings,100,50,8/26/2021
817ED9,earnings,100,50,8/26/2021
817ED9,earnings,100,50,8/26/2021
817ED9,earnings,100,50,8/26/2021
82F088,conference-participant,100,50,8/26/2021
85CDC9,partnership,100,61,8/26/2021
873DB9,conference-participant,100,50,8/26/2021
8B9B3B,orphan-drug-designation,100,76,8/26/2021
8DCF18,conference-participant,100,50,8/26/2021
9004C4,earnings-up,100,68,8/26/2021
9004C4,earnings-up,100,68,8/26/2021
9004C4,earnings-up,100,68,8/26/2021
9004C4,earnings-up,100,68,8/26/2021
9004C4,earnings-up,100,68,8/26/2021
9004C4,earnings-up,100,68,8/26/2021
9196A2,conference-organizer,100,57,8/26/2021
93D207,conference-participant,100,50,8/26/2021
94C0B5,executive-appointment,100,54,8/26/2021
97FE80,unit-acquisition-completed-acquirer,100,49,8/26/2021
99028D,earnings,100,50,8/26/2021
990AD0,executive-resignation,100,44,8/26/2021
990AD0,conference-organizer,100,57,8/26/2021
9BF177,earnings,100,50,8/26/2021
9C5174,conference-participant,100,50,8/26/2021
9CA432,conference-participant,100,50,8/26/2021
9EA947,partnership,100,61,8/26/2021
9FB4B7,executive-appointment,100,54,8/26/2021
9FB4B7,executive-appointment,100,54,8/26/2021
A02FB1,legal-issues-defendant,100,22,8/26/2021
A03EE1,legal-issues-defendant,100,22,8/26/2021
A21649,dividend,100,50,8/26/2021
A350C1,acquisition-acquiree,100,76,8/26/2021
A5195E,executive-appointment,100,54,8/26/2021
A631A3,earnings,100,50,8/26/2021
A6ABE9,legal-issues-defendant,100,22,8/26/2021
A6FE1C,unit-acquisition-acquirer,100,49,8/26/2021
A7102F,partnership,100,61,8/26/2021
A72AB6,earnings,100,50,8/26/2021
A761FE,earnings-up,100,68,8/26/2021
A8CBDA,conference-participant,100,50,8/26/2021
AD23DE,dividend,100,50,8/26/2021
B4C673,executive-appointment,100,54,8/26/2021
B4C673,facility-open,100,65,8/26/2021
B6082A,dividend,100,50,8/26/2021
B8F71F,conference-participant,100,50,8/26/2021
B934BF,dividend-up,100,81,8/26/2021
BD15E8,legal-issues-defendant,100,22,8/26/2021
BD15E8,dividend,100,50,8/26/2021
BDD12C,executive-appointment,100,54,8/26/2021
BEA527,executive-appointment,100,54,8/26/2021
BFCACF,public-offering,100,43,8/26/2021
C0F70B,conference-participant,100,50,8/26/2021
C3EE99,award,100,58,8/26/2021
C65004,legal-issues-defendant,100,22,8/26/2021
C83B88,conference-participant,100,50,8/26/2021
C98CDB,conference-participant,100,50,8/26/2021
CAC8D0,partnership,100,61,8/26/2021
CBDB4D,product-release,100,64,8/26/2021
CC6F6E,earnings,100,50,8/26/2021
CC6F6E,earnings,100,50,8/26/2021
CC6F6E,earnings,100,50,8/26/2021
CC6F6E,earnings,100,50,8/26/2021
CD06A2,conference-call,100,50,8/26/2021
D0DFE5,executive-appointment,100,54,8/26/2021
D1C0B9,revenue-up,100,69,8/26/2021
D1C0B9,revenue-up,100,69,8/26/2021
D1C0B9,revenue-up,100,69,8/26/2021
D1C0B9,revenue-up,100,69,8/26/2021
D1C0B9,revenue-up,100,69,8/26/2021
D1C0B9,revenue-up,100,69,8/26/2021
D5938F,earnings,100,50,8/26/2021
D854DD,dividend,100,50,8/26/2021
DB2E4E,public-offering,100,43,8/26/2021
DC1405,conference-participant,100,50,8/26/2021
DC2B00,earnings,100,50,8/26/2021
DC486E,dividend,100,50,8/26/2021
DC486E,dividend,100,50,8/26/2021
DF11D9,legal-issues-defendant,100,22,8/26/2021
E10D31,dividend,100,50,8/26/2021
E49AA3,dividend,100,50,8/26/2021
E68C3D,acquisition-completed-acquirer,100,49,8/26/2021
E6EDED,dividend-up,100,81,8/26/2021
E8846E,conference-organizer,100,57,8/26/2021
E8846E,conference-organizer,100,57,8/26/2021
E8846E,conference-organizer,100,57,8/26/2021
E8846E,conference-organizer,100,57,8/26/2021
E96E0B,conference-participant,100,50,8/26/2021
F0A9DE,dividend-up,100,81,8/26/2021
F48947,legal-issues-defendant,100,22,8/26/2021
F4FBD8,conference-participant,100,50,8/26/2021
FC1F9D,conference-participant,100,50,8/26/2021
FD6926,conference-participant,100,50,8/26/2021
FDF1C0,dividend,100,50,8/26/2021
FF4343,buybacks,100,74,8/26/2021
0157B1,business-contract,100,69,8/27/2021
0157B1,partnership,100,61,8/27/2021
03CF95,legal-issues-defendant,100,22,8/27/2021
125212,legal-issues-defendant,100,22,8/27/2021
13A782,acquisition-completed-acquiree,100,76,8/27/2021
1A5957,legal-issues-defendant,100,22,8/27/2021
1FCC00,dividend,100,50,8/27/2021
1FCC00,earnings,100,50,8/27/2021
1FCC00,earnings,100,50,8/27/2021
1FCC00,earnings,100,50,8/27/2021
21022F,executive-appointment,100,54,8/27/2021
253B2F,dividend,100,50,8/27/2021
3A94DF,dividend,100,50,8/27/2021
3B9886,earnings,100,50,8/27/2021
3B9886,earnings,100,50,8/27/2021
3B9886,earnings,100,50,8/27/2021
3B9886,earnings,100,50,8/27/2021
425BDC,product-price-raise,100,57,8/27/2021
442587,conference-organizer,100,57,8/27/2021
442587,conference-organizer,100,57,8/27/2021
442587,executive-appointment,100,54,8/27/2021
44DDBD,dividend,100,50,8/27/2021
4E4E75,conference-call,100,50,8/27/2021
4E6F5A,legal-issues-defendant,100,22,8/27/2021
50070E,conference-organizer,100,57,8/27/2021
64E615,executive-appointment,100,54,8/27/2021
64E615,executive-appointment,100,54,8/27/2021
6F0A63,dividend,100,50,8/27/2021
76E80F,dividend,100,50,8/27/2021
7740DE,dividend-up,100,82,8/27/2021
883D82,earnings,100,50,8/27/2021
9196A2,conference-organizer,100,57,8/27/2021
95DC1F,conference-call,100,50,8/27/2021
9B4066,unit-acquisition-acquirer,100,49,8/27/2021
9D2790,dividend,100,50,8/27/2021
A03EE1,legal-issues-defendant,100,22,8/27/2021
A52B6B,conference-participant,100,50,8/27/2021
A96867,dividend-up,100,81,8/27/2021
ACDF88,conference-participant,100,50,8/27/2021
B2F431,executive-resignation,100,44,8/27/2021
BDEF34,dividend,100,50,8/27/2021
BDF85E,earnings,100,50,8/27/2021
BFD0A7,asset-sale,100,62,8/27/2021
C0030A,business-contract,100,69,8/27/2021
CCB623,campaign-ad-release,100,59,8/27/2021
D33270,executive-appointment,100,54,8/27/2021
D9B1C9,executive-appointment,100,54,8/27/2021
E6C8DC,legal-issues-defendant,100,22,8/27/2021
E8846E,earnings,100,50,8/27/2021
ED2A5E,legal-issues-defendant,100,22,8/27/2021
F66B58,dividend,100,50,8/27/2021
03CF95,legal-issues-defendant,100,22,8/28/2021
125212,legal-issues-defendant,100,22,8/28/2021
4E6F5A,legal-issues-defendant,100,22,8/29/2021
4E6F5A,legal-issues-defendant,100,22,8/29/2021
4E6F5A,legal-issues-defendant,100,22,8/29/2021
00067A,conference-participant,100,50,8/30/2021
03542C,buybacks,100,74,8/30/2021
48590,legal-issues-defendant,100,22,8/30/2021
0624BE,executive-appointment,100,54,8/30/2021
07C907,executive-appointment,100,54,8/30/2021
0C8D82,acquisition-acquirer,100,49,8/30/2021
0E2992,executive-appointment,100,54,8/30/2021
125212,fraud-defendant,100,20,8/30/2021
147098,dividend-up,100,61,8/30/2021
1748B3,dividend,100,50,8/30/2021
1E4FB9,legal-issues-defendant,100,22,8/30/2021
1F19C8,acquisition-acquirer,100,49,8/30/2021
1F19C8,acquisition-acquirer,100,49,8/30/2021
21D903,executive-appointment,100,54,8/30/2021
232053,conference-participant,100,50,8/30/2021
2C3348,patient-enrollment-complete,100,64,8/30/2021
31DB20,asset-sale,100,62,8/30/2021
33E9D5,conference-call,100,50,8/30/2021
3471C0,acquisition-completed-acquirer,100,49,8/30/2021
37B120,legal-issues-defendant,100,22,8/30/2021
3A4BDB,executive-appointment,100,54,8/30/2021
3DED49,executive-appointment,100,54,8/30/2021
408089,executive-appointment,100,54,8/30/2021
40F7DE,conference-participant,100,50,8/30/2021
42978B,conference-call,100,50,8/30/2021
448BF3,executive-appointment,100,54,8/30/2021
449217,buybacks,100,74,8/30/2021
44A4FC,earnings,100,50,8/30/2021
451D61,conference-participant,100,50,8/30/2021
4BBA23,conference-participant,100,50,8/30/2021
4C7DB5,executive-appointment,100,54,8/30/2021
4D371E,conference-participant,100,50,8/30/2021
4DD203,conference-participant,100,50,8/30/2021
504FE2,donation,100,54,8/30/2021
54512F,legal-issues-defendant,100,22,8/30/2021
556F08,acquisition-completed-acquiree,100,76,8/30/2021
56632F,executive-appointment,100,54,8/30/2021
5D16CF,acquisition-completed-acquirer,100,49,8/30/2021
5D41E4,conference-participant,100,50,8/30/2021
5F9CE3,campaign-ad-release,100,59,8/30/2021
636BBF,earnings,100,50,8/30/2021
68E3E0,unit-acquisition-acquiree,100,76,8/30/2021
69CE71,facility-open,100,65,8/30/2021
6D2BF6,partnership,100,61,8/30/2021
6D6B40,award,100,58,8/30/2021
6D6B40,award,100,58,8/30/2021
70CA28,earnings,100,50,8/30/2021
70FCEF,earnings,100,50,8/30/2021
741937,executive-appointment,100,54,8/30/2021
76DD0C,executive-appointment,100,54,8/30/2021
7A2A49,index-listing,100,76,8/30/2021
8303CD,conference-participant,100,50,8/30/2021
850779,stock-gain,100,63,8/30/2021
860AB6,asset-sale,100,62,8/30/2021
87486A,conference-participant,100,50,8/30/2021
88193E,conference-participant,100,50,8/30/2021
88936A,earnings,100,50,8/30/2021
903AB4,executive-appointment,100,54,8/30/2021
9196A2,conference-organizer,100,57,8/30/2021
9196A2,conference-organizer,100,57,8/30/2021
9196A2,conference-organizer,100,57,8/30/2021
9196A2,conference-organizer,100,57,8/30/2021
9196A2,conference-organizer,100,57,8/30/2021
93965C,acquisition-acquiree,100,76,8/30/2021
93965C,acquisition-acquiree,100,76,8/30/2021
93965C,acquisition-acquiree,100,76,8/30/2021
93965C,acquisition-acquiree,100,76,8/30/2021
93965C,legal-issues-defendant,100,22,8/30/2021
94983E,conference-participant,100,50,8/30/2021
95DE39,buybacks,100,74,8/30/2021
9994DA,conference-participant,100,50,8/30/2021
9B4066,unit-acquisition-acquirer,100,49,8/30/2021
9BBFA5,conference-call,100,50,8/30/2021
9D2790,merger,100,66,8/30/2021
9E98F2,business-contract,100,69,8/30/2021
9E98F2,business-contract,100,69,8/30/2021
9E98F2,business-combination,100,54,8/30/2021
9E98F2,business-combination,100,54,8/30/2021
9E98F2,business-combination,100,54,8/30/2021
9E98F2,business-combination,100,54,8/30/2021
9E98F2,business-combination,100,54,8/30/2021
9E98F2,legal-issues-defendant,100,22,8/30/2021
9FA83B,index-listing,100,76,8/30/2021
A02FB1,legal-issues-defendant,100,22,8/30/2021
A03EE1,legal-issues-defendant,100,22,8/30/2021
A1EAC8,executive-appointment,100,54,8/30/2021
A43906,conference-participant,100,50,8/30/2021
A47F2E,conference-participant,100,50,8/30/2021
A631A3,award,100,58,8/30/2021
A70BF5,dividend,100,50,8/30/2021
A7102F,conference-participant,100,50,8/30/2021
B08954,unit-acquisition-acquirer,100,49,8/30/2021
BBF349,acquisition-acquirer,100,49,8/30/2021
BBF349,acquisition-acquirer,100,49,8/30/2021
BBF349,acquisition-acquirer,100,49,8/30/2021
BBF349,acquisition-acquirer,100,49,8/30/2021
BBF349,conference-participant,100,50,8/30/2021
BD15E8,legal-issues-defendant,100,22,8/30/2021
BFCACF,public-offering,100,43,8/30/2021
C48574,earnings,100,50,8/30/2021
C81E00,conference-participant,100,50,8/30/2021
C81E00,conference-participant,100,50,8/30/2021
C94CFC,legal-issues-defendant,100,22,8/30/2021
CF073E,conference-participant,100,50,8/30/2021
CF3FF9,conference-participant,100,50,8/30/2021
D0909F,ownership-decrease-owner,100,46,8/30/2021
D1AE3B,credit-extension-provider,100,57,8/30/2021
D2B9E5,partnership,100,61,8/30/2021
D56D6D,earnings-up,100,68,8/30/2021
D56D6D,earnings,100,50,8/30/2021
D56D6D,earnings,100,50,8/30/2021
D6489C,award,100,58,8/30/2021
D76AEF,dividend,100,50,8/30/2021
DD1BA1,executive-appointment,100,54,8/30/2021
E074A0,dividend,100,50,8/30/2021
E124EB,acquisition-completed-acquirer,100,49,8/30/2021
E1E36F,unit-acquisition-completed-acquiree,100,67,8/30/2021
E1E36F,acquisition-completed-acquiree,100,76,8/30/2021
E3A829,government-contract,100,69,8/30/2021
E5752F,partnership,100,61,8/30/2021
E68E62,private-placement,100,56,8/30/2021
E8846E,earnings,100,50,8/30/2021
E8846E,conference-organizer,100,57,8/30/2021
E8846E,conference-organizer,100,57,8/30/2021
EB1E1A,partnership,100,61,8/30/2021
ED2A5E,legal-issues-defendant,100,22,8/30/2021
ED2A5E,legal-issues-defendant,100,22,8/30/2021
EE1E44,dividend,100,50,8/30/2021
F48947,legal-issues-defendant,100,22,8/30/2021
FE9C0D,regulatory-product-approval-granted,100,81,8/30/2021
01478A,acquisition-acquirer,100,49,8/31/2021
48590,legal-issues-defendant,100,22,8/31/2021
0968A5,earnings,100,50,8/31/2021
099C88,business-contract,100,69,8/31/2021
0BC853,dividend,100,50,8/31/2021
0C6293,conference-participant,100,50,8/31/2021
0E3436,earnings,100,50,8/31/2021
0E3436,earnings,100,50,8/31/2021
0F0440,business-contract,100,69,8/31/2021
0F0440,business-contract,100,69,8/31/2021
0F0440,business-contract,100,69,8/31/2021
1220D2,partnership,100,61,8/31/2021
125212,legal-issues-defendant,100,22,8/31/2021
125212,legal-issues-defendant,100,22,8/31/2021
125212,legal-issues-defendant,100,22,8/31/2021
125212,legal-issues-defendant,100,22,8/31/2021
125212,legal-issues-defendant,100,22,8/31/2021
125212,legal-issues-defendant,100,22,8/31/2021
12A3A3,conference-call,100,50,8/31/2021
12DE76,partnership,100,61,8/31/2021
12DE76,partnership,100,61,8/31/2021
139303,conference-organizer,100,57,8/31/2021
15901B,executive-appointment,100,54,8/31/2021
15B10D,conference-participant,100,50,8/31/2021
1.79E+10,award,100,58,8/31/2021
18D9FA,partnership,100,61,8/31/2021
18EC17,executive-appointment,100,54,8/31/2021
190B91,executive-appointment,100,54,8/31/2021
1A1CB0,conference-participant,100,50,8/31/2021
1B9535,executive-appointment,100,54,8/31/2021
1D3A00,earnings,100,50,8/31/2021
1D3A00,earnings,100,50,8/31/2021
1D3A00,earnings,100,50,8/31/2021
1D3A00,earnings,100,50,8/31/2021
1E83DE,business-contract,100,69,8/31/2021
26F99F,conference-participant,100,50,8/31/2021
292A70,acquisition-completed-acquirer,100,49,8/31/2021
2B49F4,conference-call,100,50,8/31/2021
2BC05E,partnership,100,61,8/31/2021
2E2E6E,dividend,100,50,8/31/2021
2E89AE,executive-appointment,100,54,8/31/2021
33A0F1,partnership,100,61,8/31/2021
349DA4,conference-participant,100,50,8/31/2021
3BB7D3,conference-participant,100,50,8/31/2021
3CCC90,conference-participant,100,50,8/31/2021
414FFF,earnings-above-expectations,100,88,8/31/2021
414FFF,earnings,100,50,8/31/2021
414FFF,earnings,100,50,8/31/2021
414FFF,earnings,100,50,8/31/2021
414FFF,earnings,100,50,8/31/2021
414FFF,earnings,100,50,8/31/2021
414FFF,earnings,100,50,8/31/2021
414FFF,earnings,100,50,8/31/2021
414FFF,earnings,100,50,8/31/2021
414FFF,earnings,100,50,8/31/2021
41B53E,business-contract,100,69,8/31/2021
49BBBC,earnings,100,50,8/31/2021
4A6F00,partnership,100,61,8/31/2021
4A6F00,partnership,100,61,8/31/2021
4BF3D6,conference-participant,100,50,8/31/2021
50070E,conference-organizer,100,57,8/31/2021
55ACCB,conference-participant,100,50,8/31/2021
56277A,conference-participant,100,50,8/31/2021
56EA2B,conference-call,100,50,8/31/2021
5A423F,conference-participant,100,50,8/31/2021
5A9F54,market-entry,100,57,8/31/2021
5D1329,conference-participant,100,50,8/31/2021
5FDBD0,acquisition-completed-acquirer,100,49,8/31/2021
61A586,conference-participant,100,50,8/31/2021
61B81B,conference-participant,100,50,8/31/2021
61BCA7,acquisition-completed-acquirer,100,49,8/31/2021
62F41C,acquisition-completed-acquiree,100,76,8/31/2021
662682,acquisition-completed-acquirer,100,49,8/31/2021
673C9A,conference-participant,100,50,8/31/2021
698FF9,executive-appointment,100,54,8/31/2021
69FDFC,stake-acquirer,100,48,8/31/2021
6BC6F9,conference-participant,100,50,8/31/2021
6CD55A,dividend,100,50,8/31/2021
6E7060,executive-resignation,100,44,8/31/2021
73BCBA,partnership,100,61,8/31/2021
763DBE,patent-awarded,100,72,8/31/2021
763DBE,legal-verdict-favored,100,78,8/31/2021
76BD96,note-sale,100,52,8/31/2021
873DB9,executive-appointment,100,54,8/31/2021
88936A,conference-participant,100,50,8/31/2021
8A8E41,donation,100,54,8/31/2021
8AB85C,conference-participant,100,50,8/31/2021
8DA42F,conference-participant,100,50,8/31/2021
90D6A5,dividend,100,50,8/31/2021
9196A2,conference-organizer,100,57,8/31/2021
9196A2,conference-organizer,100,57,8/31/2021
9196A2,conference-organizer,100,57,8/31/2021
9196A2,conference-organizer,100,57,8/31/2021
9196A2,conference-organizer,100,57,8/31/2021
9196A2,conference-organizer,100,57,8/31/2021
9196A2,conference-organizer,100,57,8/31/2021
92B047,asset-sale,100,62,8/31/2021
92D757,partnership,100,61,8/31/2021
93965C,acquisition-regulatory-scrutiny-acquiree,100,38,8/31/2021
957A07,conference-participant,100,50,8/31/2021
9D5FA4,conference-participant,100,50,8/31/2021
9E98F2,merger-regulatory-scrutiny,100,37,8/31/2021
9F5CBB,dividend,100,50,8/31/2021
A26C26,conference-participant,100,50,8/31/2021
A350C1,acquisition-completed-acquiree,100,76,8/31/2021
A48593,conference-participant,100,50,8/31/2021
A4CD53,conference-participant,100,50,8/31/2021
A52533,conference-participant,100,50,8/31/2021
A631A3,award,100,58,8/31/2021
A868C9,product-release,100,64,8/31/2021
A8E72A,conference-participant,100,50,8/31/2021
AD22F2,earnings,100,50,8/31/2021
AD22F2,earnings,100,50,8/31/2021
AD22F2,earnings,100,50,8/31/2021
AD22F2,earnings,100,50,8/31/2021
AD22F2,earnings,100,50,8/31/2021
AECCA9,dividend-up,100,81,8/31/2021
B1FC3B,legal-issues-defendant,100,22,8/31/2021
B3CB74,conference-organizer,100,57,8/31/2021
B5734D,fundraising,100,64,8/31/2021
B72D2E,buybacks,100,74,8/31/2021
BB0787,executive-appointment,100,54,8/31/2021
BFE02C,conference-call,100,50,8/31/2021
C22BE8,product-release,100,64,8/31/2021
C3BAE7,conference-participant,100,50,8/31/2021
C5D2AE,acquisition-completed-acquiree,100,76,8/31/2021
C8A059,conference-participant,100,50,8/31/2021
C941DC,conference-participant,100,50,8/31/2021
CF6A5A,facility-open,100,65,8/31/2021
D08D2C,conference-call,100,50,8/31/2021
D8442A,partnership,100,61,8/31/2021
DB2E4E,public-offering-suspended,100,24,8/31/2021
E30A8F,partnership,100,61,8/31/2021
E598FB,conference-participant,100,50,8/31/2021
E6A53A,unit-acquisition-acquiree,100,76,8/31/2021
E6A53A,unit-acquisition-acquiree,100,76,8/31/2021
E6C8DC,legal-issues-defendant,100,22,8/31/2021
E754F0,conference-participant,100,50,8/31/2021
E8846E,conference-organizer,100,57,8/31/2021
E96E0B,conference-participant,100,50,8/31/2021
EEEA9F,conference-participant,100,50,8/31/2021
F30508,conference-participant,100,50,8/31/2021
F4F46F,conference-participant,100,50,8/31/2021
F51DB0,executive-appointment,100,54,8/31/2021
F57F6F,conference-organizer,100,57,8/31/2021
F5D410,executive-appointment,100,54,8/31/2021
F6581D,unit-acquisition-completed-acquirer,100,49,8/31/2021
F90EE5,executive-appointment,100,54,8/31/2021
FACF19,workforce-salary-increase,100,44,8/31/2021
FADF1A,business-contract,100,69,8/31/2021
FBD92D,conference-participant,100,50,8/31/2021
FD1312,executive-appointment,100,54,8/31/2021
FE9C0D,clinical-trials,100,56,8/31/2021
00FC70,dividend-up,100,81,9/1/2021
0157B1,facility-open,100,65,9/1/2021
036C6F,dividend,100,50,9/1/2021
48781,executive-appointment,100,54,9/1/2021
054E7E,conference-participant,100,50,9/1/2021
091B6C,conference-participant,100,50,9/1/2021
091B6C,conference-participant,100,50,9/1/2021
0BF198,conference-participant,100,50,9/1/2021
0BF528,earnings-up,100,68,9/1/2021
0BF528,earnings-up,100,68,9/1/2021
0BF528,earnings-up,100,68,9/1/2021
0BF528,earnings-up,100,68,9/1/2021
0C4131,acquisition-completed-acquirer,100,49,9/1/2021
0C6861,product-release,100,64,9/1/2021
0C6861,product-release,100,64,9/1/2021
125212,legal-issues-defendant,100,22,9/1/2021
125212,legal-issues-defendant,100,22,9/1/2021
152FA5,conference-participant,100,50,9/1/2021
159739,dividend,100,50,9/1/2021
159739,dividend,100,50,9/1/2021
159739,conference-call,100,50,9/1/2021
159739,conference-call,100,50,9/1/2021
159AE4,conference-call,100,50,9/1/2021
168A5D,legal-issues-defendant,100,22,9/1/2021
1BDB2A,conference-participant,100,50,9/1/2021
1D9E55,conference-participant,100,50,9/1/2021
1F08A6,acquisition-acquirer,100,49,9/1/2021
1F9D90,conference-participant,100,50,9/1/2021
2158DF,facility-upgrade,100,65,9/1/2021
21D903,conference-participant,100,50,9/1/2021
24D81E,facility-open,100,65,9/1/2021
251988,partnership,100,61,9/1/2021
251988,partnership,100,61,9/1/2021
274B8A,conference-call,100,50,9/1/2021
28DCA8,conference-participant,100,50,9/1/2021
29CEBF,facility-open,100,65,9/1/2021
2BAE5F,dividend,100,50,9/1/2021
2C35B5,conference-participant,100,50,9/1/2021
2F6782,executive-appointment,100,54,9/1/2021
30CBF9,partnership,100,61,9/1/2021
30DE64,patient-enrollment-complete,100,64,9/1/2021
3461CF,credit-rating-confirmation-rater,20,50,9/1/2021
3461CF,conference-participant,100,50,9/1/2021
35557B,acquisition-completed-acquiree,100,76,9/1/2021
384CD3,conference-participant,100,50,9/1/2021
385DD4,conference-participant,100,50,9/1/2021
387375,conference-participant,100,50,9/1/2021
3AAEAE,conference-participant,100,50,9/1/2021
3F96D5,conference-participant,100,50,9/1/2021
3FACA7,donation,100,54,9/1/2021
416C55,acquisition-completed-acquirer,100,49,9/1/2021
420168,market-entry,100,57,9/1/2021
43A060,business-contract,100,69,9/1/2021
442769,acquisition-completed-acquirer,100,49,9/1/2021
448BF3,conference-participant,100,50,9/1/2021
449447,conference-participant,100,50,9/1/2021
45ABCC,revenue-up,100,59,9/1/2021
45BC35,conference-participant,100,50,9/1/2021
4.60E+06,acquisition-completed-acquirer,100,49,9/1/2021
4A6F00,partnership,100,61,9/1/2021
4A6F00,partnership,100,61,9/1/2021
4A6F00,partnership,100,61,9/1/2021
4A6F00,partnership,100,61,9/1/2021
4BF3D6,conference-participant,100,50,9/1/2021
4F71DC,earnings,100,50,9/1/2021
50070E,conference-organizer,100,57,9/1/2021
52B567,merger-completed,100,66,9/1/2021
52B567,merger-completed,100,66,9/1/2021
543900,earnings,100,50,9/1/2021
546A27,conference-participant,100,50,9/1/2021
5487B1,dividend,100,50,9/1/2021
54DF47,dividend,100,50,9/1/2021
567F3D,acquisition-completed-acquirer,100,49,9/1/2021
5704AC,conference-participant,100,50,9/1/2021
57634F,settlement,100,56,9/1/2021
583223,acquisition-completed-acquirer,100,49,9/1/2021
589846,earnings,100,50,9/1/2021
58CA9A,conference-participant,100,50,9/1/2021
59872F,earnings,100,50,9/1/2021
5AAE17,conference-participant,100,50,9/1/2021
5BC2F4,acquisition-acquiree,100,76,9/1/2021
5DD486,joint-venture,100,62,9/1/2021
5DD486,joint-venture,100,62,9/1/2021
5E6959,award,100,58,9/1/2021
619882,conference-organizer,100,57,9/1/2021
62CDDE,conference-participant,100,50,9/1/2021
636931,executive-appointment,100,54,9/1/2021
64E346,conference-participant,100,50,9/1/2021
662682,partnership,100,61,9/1/2021
69345C,conference-participant,100,50,9/1/2021
69CE71,conference-participant,100,50,9/1/2021
6E705B,conference-participant,100,50,9/1/2021
7239BB,earnings,100,50,9/1/2021
73529F,acquisition-completed-acquirer,100,49,9/1/2021
73529F,acquisition-completed-acquirer,100,49,9/1/2021
73A71F,executive-appointment,100,54,9/1/2021
73F7F9,earnings,100,50,9/1/2021
752A70,acquisition-acquirer,100,49,9/1/2021
75768D,conference-call,100,50,9/1/2021
763DBE,conference-participant,100,50,9/1/2021
767F86,product-release,100,64,9/1/2021
76DD0C,conference-participant,100,50,9/1/2021
7732C2,conference-participant,100,50,9/1/2021
775439,earnings,100,50,9/1/2021
7B1156,acquisition-completed-acquirer,100,49,9/1/2021
7B9AFA,conference-participant,100,50,9/1/2021
7DD584,revenue-up,100,68,9/1/2021
7DD584,revenue-up,100,68,9/1/2021
7DD584,revenue-up,100,68,9/1/2021
7E1D5D,partnership,100,61,9/1/2021
7FDE1C,product-release,100,64,9/1/2021
804708,dividend,100,50,9/1/2021
80C400,acquisition-acquirer,100,49,9/1/2021
83B1C8,conference-participant,100,50,9/1/2021
859D62,earnings-positive,100,69,9/1/2021
88193E,executive-appointment,100,54,9/1/2021
89E771,earnings,100,50,9/1/2021
8A0368,acquisition-completed-acquiree,100,76,9/1/2021
8A8E41,acquisition-completed-acquiree,100,76,9/1/2021
8AB37F,conference-participant,100,50,9/1/2021
8B1F37,product-release,100,64,9/1/2021
8B4A45,earnings,100,50,9/1/2021
8B8656,earnings,100,50,9/1/2021
8D4486,partnership,100,61,9/1/2021
8E8E6E,product-release,100,64,9/1/2021
8EDACA,earnings,100,50,9/1/2021
8EF425,dividend,100,50,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
9196A2,conference-organizer,100,57,9/1/2021
943239,conference-participant,100,50,9/1/2021
947B0B,legal-issues-defendant,100,22,9/1/2021
947B0B,legal-issues-defendant,100,22,9/1/2021
9507FF,conference-participant,100,50,9/1/2021
9548BB,acquisition-completed-acquirer,100,49,9/1/2021
95A92E,acquisition-completed-acquiree,100,76,9/1/2021
98A286,earnings-per-share,100,50,9/1/2021
990AD0,conference-organizer,100,57,9/1/2021
9.97E+09,partnership,100,61,9/1/2021
9EA947,partnership,100,61,9/1/2021
9FA83B,acquisition-completed-acquirer,100,49,9/1/2021
9FA83B,executive-appointment,100,54,9/1/2021
A05C43,conference-participant,100,50,9/1/2021
A0F146,conference-participant,100,50,9/1/2021
A1E3B3,earnings,100,50,9/1/2021
A1E3B3,earnings,100,50,9/1/2021
A3230E,conference-participant,100,50,9/1/2021
A49498,acquisition-completed-acquirer,100,49,9/1/2021
A49498,acquisition-completed-acquirer,100,49,9/1/2021
A49498,executive-appointment,100,54,9/1/2021
A60354,conference-participant,100,50,9/1/2021
A631A3,conference-participant,100,50,9/1/2021
A631A3,conference-participant,100,50,9/1/2021
A6FB29,earnings,100,50,9/1/2021
ABEE43,unit-acquisition-acquirer,100,49,9/1/2021
AD3C93,campaign-ad-release,100,59,9/1/2021
AECCA9,earnings,100,50,9/1/2021
AECCA9,earnings,100,50,9/1/2021
AECCA9,earnings,100,50,9/1/2021
AECCA9,earnings,100,50,9/1/2021
AECCA9,earnings,100,50,9/1/2021
AECCA9,earnings,100,50,9/1/2021
AEFC90,conference-participant,100,50,9/1/2021
B09B1F,executive-appointment,100,54,9/1/2021
B0FE08,acquisition-completed-acquirer,100,49,9/1/2021
B1A85D,business-contract,100,69,9/1/2021
B33E77,conference-participant,100,50,9/1/2021
B48D6A,conference-participant,100,50,9/1/2021
B48FC9,conference-participant,100,50,9/1/2021
B6843B,executive-appointment,100,54,9/1/2021
B7202A,conference-participant,100,50,9/1/2021
B8EF97,revenues,100,50,9/1/2021
B9CD50,award,100,58,9/1/2021
B9CD50,award,100,58,9/1/2021
BCC55F,campaign-ad-release,100,59,9/1/2021
C36189,executive-appointment,100,54,9/1/2021
C564E4,conference-participant,100,50,9/1/2021
C598D7,acquisition-completed-acquirer,100,49,9/1/2021
C83B88,partnership,100,61,9/1/2021
C83B88,conference-participant,100,50,9/1/2021
C85A72,conference-participant,100,50,9/1/2021
C97B2D,unit-acquisition-completed-acquirer,100,49,9/1/2021
CBB77B,earnings,100,50,9/1/2021
CBFFDD,conference-participant,100,50,9/1/2021
CDAF5B,dividend,100,50,9/1/2021
CE96E7,conference-participant,100,50,9/1/2021
D0909F,dividend,100,50,9/1/2021
D18AFC,conference-participant,100,50,9/1/2021
D1CFC8,conference-call,100,50,9/1/2021
D25249,conference-participant,100,50,9/1/2021
D2E553,acquisition-acquirer,100,49,9/1/2021
D2E553,acquisition-acquirer,100,49,9/1/2021
D5B13D,conference-participant,100,50,9/1/2021
D60BB2,partnership,100,61,9/1/2021
DBB28E,acquisition-completed-acquirer,100,49,9/1/2021
DBB28E,business-contract,100,69,9/1/2021
E0207A,executive-appointment,100,54,9/1/2021
E21871,conference-participant,100,50,9/1/2021
E35610,partnership,100,61,9/1/2021
E38906,conference-participant,100,50,9/1/2021
E866D2,donation,100,54,9/1/2021
E8846E,conference-organizer,100,57,9/1/2021
E8846E,conference-organizer,100,57,9/1/2021
E8846E,conference-organizer,100,57,9/1/2021
E8846E,partnership,100,61,9/1/2021
E8846E,conference-organizer,100,57,9/1/2021
E8846E,conference-participant,100,50,9/1/2021
E8846E,conference-organizer,100,57,9/1/2021
ED79D9,conference-participant,100,50,9/1/2021
EEEA9F,acquisition-completed-acquirer,100,49,9/1/2021
EF5BED,partnership,100,61,9/1/2021
F39E1E,executive-appointment,100,54,9/1/2021
F43A11,earnings,100,50,9/1/2021
F6E248,conference-participant,100,50,9/1/2021
F82D37,acquisition-interest-acquiree,100,82,9/1/2021
F88147,legal-issues-defendant,100,22,9/1/2021
F9AA02,conference-participant,100,50,9/1/2021
FD6926,conference-participant,100,50,9/1/2021
FFAB4A,executive-resignation,100,44,9/1/2021
00FC70,earnings,100,50,9/2/2021
20751,conference-participant,100,50,9/2/2021
03CF95,partnership,100,61,9/2/2021
03CF95,partnership,100,61,9/2/2021
03CF95,legal-issues-defendant,100,22,9/2/2021
03D5F9,conference-participant,100,50,9/2/2021
48590,legal-issues-defendant,100,22,9/2/2021
55018,sanctions-target,100,19,9/2/2021
95294,note-sale,100,52,9/2/2021
09DE1F,earnings,100,50,9/2/2021
0BF528,conference-participant,100,50,9/2/2021
0DBB81,conference-participant,100,50,9/2/2021
0DBB81,executive-appointment,100,54,9/2/2021
0DBB81,executive-appointment,100,54,9/2/2021
0E5619,conference-participant,100,50,9/2/2021
125212,legal-issues-defendant,100,22,9/2/2021
125212,fraud-defendant,100,20,9/2/2021
129DC8,stake-acquirer,100,48,9/2/2021
136B26,conference-participant,100,50,9/2/2021
139303,conference-organizer,100,57,9/2/2021
139303,conference-organizer,100,57,9/2/2021
139303,conference-organizer,100,57,9/2/2021
13A782,acquisition-completed-acquiree,100,76,9/2/2021
1490F3,facility-upgrade,100,65,9/2/2021
14ED2B,partnership,100,61,9/2/2021
184988,conference-participant,100,50,9/2/2021
1A46A1,conference-participant,100,50,9/2/2021
1D1B07,earnings,100,50,9/2/2021
1D1B07,earnings,100,50,9/2/2021
1E1125,conference-organizer,100,57,9/2/2021
1EF224,conference-participant,100,50,9/2/2021
1F9D90,conference-participant,100,50,9/2/2021
1FAF22,acquisition-acquirer,100,49,9/2/2021
1FAF22,acquisition-acquirer,100,49,9/2/2021
1FAF22,acquisition-acquirer,100,49,9/2/2021
1FCC00,conference-participant,100,50,9/2/2021
221AD7,executive-appointment,100,54,9/2/2021
227D48,dividend,100,50,9/2/2021
24C48B,conference-participant,100,50,9/2/2021
24FA23,conference-participant,100,50,9/2/2021
253604,conference-participant,100,50,9/2/2021
253B2F,acquisition-acquirer,100,49,9/2/2021
267718,clinical-trials-start,100,64,9/2/2021
273BA3,partnership,100,61,9/2/2021
279916,earnings,100,50,9/2/2021
28DCF3,unit-acquisition-acquirer,100,49,9/2/2021
28DCF3,acquisition-acquirer,100,49,9/2/2021
291651,conference-participant,100,50,9/2/2021
29A4CC,executive-appointment,100,54,9/2/2021
2AA6A8,conference-participant,100,50,9/2/2021
2BF36E,conference-participant,100,50,9/2/2021
2CC60C,revenue-up,100,69,9/2/2021
2CF9D3,conference-participant,100,50,9/2/2021
2E0445,conference-participant,100,50,9/2/2021
315EB0,acquisition-completed-acquirer,100,49,9/2/2021
315EB0,acquisition-completed-acquirer,100,49,9/2/2021
31666F,buybacks,100,74,9/2/2021
31803E,conference-participant,100,50,9/2/2021
367E1C,conference-participant,100,50,9/2/2021
371B0A,conference-participant,100,50,9/2/2021
38C46F,dividend,100,50,9/2/2021
39FB23,product-release,100,64,9/2/2021
3CCC90,campaign-ad-release,100,59,9/2/2021
3DB18B,acquisition-acquirer,100,49,9/2/2021
3EE65E,earnings,100,50,9/2/2021
3EE65E,executive-appointment,100,54,9/2/2021
401072,conference-participant,100,50,9/2/2021
427F32,dividend,100,50,9/2/2021
42EFC7,partnership,100,61,9/2/2021
43E8F5,conference-participant,100,50,9/2/2021
442769,conference-participant,100,50,9/2/2021
448215,dividend,100,50,9/2/2021
44DDBD,merger-regulatory-approval,100,81,9/2/2021
45ABCC,conference-participant,100,50,9/2/2021
45ABCC,conference-participant,100,50,9/2/2021
467F2C,business-contract,100,69,9/2/2021
4A3438,business-contract,100,69,9/2/2021
4A6F00,unit-acquisition-completed-acquiree,100,67,9/2/2021
4CDA2B,conference-participant,100,50,9/2/2021
4E4E75,operating-earnings,100,50,9/2/2021
50070E,conference-organizer,100,57,9/2/2021
50070E,conference-organizer,100,57,9/2/2021
520632,acquisition-acquirer,100,49,9/2/2021
5.43E+08,conference-participant,100,50,9/2/2021
5.43E+08,conference-participant,100,50,9/2/2021
546A9C,conference-participant,100,50,9/2/2021
54A713,dividend,100,50,9/2/2021
59872F,conference-participant,100,50,9/2/2021
5AA3B1,conference-participant,100,50,9/2/2021
5D43A7,acquisition-completed-acquirer,100,49,9/2/2021
5D43A7,acquisition-completed-acquirer,100,49,9/2/2021
5E6959,partnership,100,61,9/2/2021
5F2FF7,conference-participant,100,50,9/2/2021
5F9CE3,executive-appointment,100,54,9/2/2021
619882,conference-organizer,100,57,9/2/2021
6830FE,earnings,100,50,9/2/2021
68AB62,acquisition-completed-acquirer,100,49,9/2/2021
694749,conference-participant,100,50,9/2/2021
6B6375,conference-participant,100,50,9/2/2021
7122EB,conference-participant,100,50,9/2/2021
762A3E,conference-organizer,100,57,9/2/2021
76E80F,conference-participant,100,50,9/2/2021
7A0EC4,earnings,100,50,9/2/2021
7ADE57,earnings,100,50,9/2/2021
7ADE57,earnings,100,50,9/2/2021
7ADE57,earnings,100,50,9/2/2021
7ADE57,earnings,100,50,9/2/2021
7ADE57,earnings,100,50,9/2/2021
7ADE57,earnings,100,50,9/2/2021
7B9212,revenues,100,50,9/2/2021
7D85A9,conference-participant,100,50,9/2/2021
7E1D5D,acquisition-completed-acquirer,100,49,9/2/2021
7E3390,conference-participant,100,50,9/2/2021
819492,business-contract,100,69,9/2/2021
819492,business-contract,100,69,9/2/2021
819492,business-contract,100,69,9/2/2021
8195B7,orphan-drug-designation,100,76,9/2/2021
85AD00,executive-appointment,100,54,9/2/2021
85DE00,conference-participant,100,50,9/2/2021
8665BA,business-contract,100,69,9/2/2021
86A1B9,business-contract,100,69,9/2/2021
881190,facility-open,100,65,9/2/2021
8A8E41,dividend-up,100,81,9/2/2021
8B8656,conference-participant,100,50,9/2/2021
8DBE73,note-sale,100,52,9/2/2021
905356,executive-appointment,100,54,9/2/2021
90D6A5,conference-participant,100,50,9/2/2021
90D6A5,conference-participant,100,50,9/2/2021
915E7B,executive-appointment,100,54,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
9196A2,conference-organizer,100,57,9/2/2021
925759,conference-participant,100,50,9/2/2021
9.31E+77,conference-participant,100,50,9/2/2021
947B0B,legal-issues-defendant,100,22,9/2/2021
947B0B,legal-issues-defendant,100,22,9/2/2021
947B0B,legal-issues-defendant,100,22,9/2/2021
947B0B,legal-issues-defendant,100,22,9/2/2021
954004,earnings,100,50,9/2/2021
954004,earnings,100,50,9/2/2021
9810C0,dividend,100,50,9/2/2021
981656,conference-participant,100,50,9/2/2021
9.82E+06,earnings,100,50,9/2/2021
990AD0,conference-organizer,100,57,9/2/2021
99B61C,executive-appointment,100,54,9/2/2021
9CDA4F,acquisition-completed-acquirer,100,49,9/2/2021
9D2790,donation,100,54,9/2/2021
9D3360,acquisition-acquirer,100,49,9/2/2021
9DDE1B,executive-appointment,100,54,9/2/2021
A03EE1,legal-issues-defendant,100,22,9/2/2021
A16DEA,conference-participant,100,50,9/2/2021
A28C54,partnership,100,61,9/2/2021
A4BCDE,dividend,100,50,9/2/2021
A6213D,revenue-volume-up,100,56,9/2/2021
A631A3,conference-participant,100,50,9/2/2021
A631A3,conference-participant,100,50,9/2/2021
A666C8,executive-appointment,100,54,9/2/2021
A6FE1C,acquisition-acquirer,100,49,9/2/2021
A6FE1C,unit-acquisition-acquirer,100,49,9/2/2021
A72FD9,conference-participant,100,50,9/2/2021
AA3AB8,revenues,100,50,9/2/2021
AA3AB8,earnings,100,50,9/2/2021
AA3AB8,earnings,100,50,9/2/2021
ABB493,conference-participant,100,50,9/2/2021
AD3008,conference-participant,100,50,9/2/2021
AD3C93,conference-participant,100,50,9/2/2021
AD6141,conference-participant,100,50,9/2/2021
ADD9DC,earnings,100,50,9/2/2021
AED6CF,unit-acquisition-completed-acquirer,100,49,9/2/2021
AEF2C3,conference-participant,100,50,9/2/2021
AFEC35,public-offering,100,43,9/2/2021
B04426,conference-participant,100,50,9/2/2021
B0D41A,conference-participant,100,50,9/2/2021
B2256A,acquisition-acquirer,100,49,9/2/2021
B3CB74,conference-organizer,100,57,9/2/2021
B3CB74,conference-organizer,100,57,9/2/2021
B3CB74,conference-organizer,100,57,9/2/2021
B54A74,conference-participant,100,50,9/2/2021
B642E8,dividend,100,50,9/2/2021
B83D67,conference-participant,100,50,9/2/2021
B9BDE8,conference-participant,100,50,9/2/2021
BB88B6,conference-participant,100,50,9/2/2021
BB88B6,award,100,58,9/2/2021
C037A8,earnings,100,50,9/2/2021
C15F8F,conference-participant,100,50,9/2/2021
C3BCD5,conference-participant,100,50,9/2/2021
C4A432,earnings,100,50,9/2/2021
C4A432,earnings,100,50,9/2/2021
C4A432,earnings,100,50,9/2/2021
C4A432,earnings,100,50,9/2/2021
C65004,earnings,100,50,9/2/2021
C7859D,dividend,100,50,9/2/2021
C9D866,conference-participant,100,50,9/2/2021
CBB77B,conference-participant,100,50,9/2/2021
CDC217,conference-participant,100,50,9/2/2021
CFF57D,earnings,100,50,9/2/2021
CFF57D,earnings,100,50,9/2/2021
CFF57D,earnings,100,50,9/2/2021
CFF57D,earnings,100,50,9/2/2021
CFF57D,conference-participant,100,50,9/2/2021
CFF97C,credit-rating-confirmation-rater,20,50,9/2/2021
CFF97C,conference-participant,100,50,9/2/2021
D29B44,conference-participant,100,50,9/2/2021
D2B9E5,acquisition-acquiree,100,76,9/2/2021
D36B23,conference-participant,100,50,9/2/2021
D3CEDF,conference-participant,100,50,9/2/2021
D56E4C,conference-participant,100,50,9/2/2021
D56E4C,conference-participant,100,50,9/2/2021
D5938F,conference-participant,100,50,9/2/2021
D5938F,earnings,100,50,9/2/2021
D5938F,earnings,100,50,9/2/2021
D60BB2,conference-participant,100,50,9/2/2021
D6EAA3,conference-call,100,50,9/2/2021
D75910,product-release,100,64,9/2/2021
D8442A,regulatory-investigation-completed,100,50,9/2/2021
D8442A,acquisition-acquiree,100,76,9/2/2021
D854F3,acquisition-acquiree,100,76,9/2/2021
D854F3,acquisition-acquiree,100,76,9/2/2021
D854F3,acquisition-acquiree,100,76,9/2/2021
D854F3,acquisition-regulatory-scrutiny-acquiree,100,38,9/2/2021
DA199F,conference-organizer,100,57,9/2/2021
DB88A1,acquisition-completed-acquirer,100,49,9/2/2021
DB9829,earnings-up,100,68,9/2/2021
DB9829,earnings,100,50,9/2/2021
DB9829,earnings,100,50,9/2/2021
DB9829,earnings,100,50,9/2/2021
DB9829,earnings,100,50,9/2/2021
DBB28E,earnings,100,50,9/2/2021
DBB28E,earnings,100,50,9/2/2021
DBB28E,earnings,100,50,9/2/2021
DBB28E,earnings,100,50,9/2/2021
DBB28E,earnings,100,50,9/2/2021
DBB28E,earnings,100,50,9/2/2021
DBB28E,earnings,100,50,9/2/2021
DBB28E,earnings,100,50,9/2/2021
DBB28E,earnings,100,50,9/2/2021
DDCB34,conference-participant,100,50,9/2/2021
DE5611,earnings,100,50,9/2/2021
DF6FDD,conference-participant,100,50,9/2/2021
DFADDB,conference-participant,100,50,9/2/2021
E00373,partnership,100,61,9/2/2021
E00373,partnership,100,61,9/2/2021
E09556,conference-participant,100,50,9/2/2021
E11C41,dividend,100,50,9/2/2021
E1C16B,conference-participant,100,50,9/2/2021
E20392,executive-resignation,100,44,9/2/2021
E68C3D,partnership,100,61,9/2/2021
E866D2,conference-participant,100,50,9/2/2021
E8846E,conference-organizer,100,57,9/2/2021
E8846E,conference-organizer,100,57,9/2/2021
E8846E,conference-organizer,100,57,9/2/2021
E8846E,conference-organizer,100,57,9/2/2021
E8846E,conference-organizer,100,57,9/2/2021
E8846E,conference-organizer,100,57,9/2/2021
E8846E,conference-organizer,100,57,9/2/2021
E8846E,conference-organizer,100,57,9/2/2021
E8846E,donation,100,54,9/2/2021
EAA0A7,conference-participant,100,50,9/2/2021
EB5E78,conference-participant,100,50,9/2/2021
ECA300,earnings,100,50,9/2/2021
ED79D9,partnership,100,61,9/2/2021
EEA734,conference-participant,100,50,9/2/2021
F02170,conference-participant,100,50,9/2/2021
F42FAE,dividend,100,50,9/2/2021
F58C23,conference-participant,100,50,9/2/2021
F66B58,earnings,100,50,9/2/2021
F7D8AE,acquisition-completed-acquirer,100,49,9/2/2021
F88147,legal-issues-defendant,100,22,9/2/2021
F8BA6C,conference-participant,100,50,9/2/2021
FAAFA2,conference-participant,100,50,9/2/2021
FC1736,earnings,100,50,9/2/2021
FD0CA4,conference-participant,100,50,9/2/2021
FDD3FC,conference-participant,100,50,9/2/2021
FDE409,earnings,100,50,9/2/2021
FE7A63,dividend,100,50,9/2/2021
00067A,donation,100,54,9/3/2021
0157B1,partnership,100,61,9/3/2021
95294,conference-participant,100,50,9/3/2021
0E3436,conference-participant,100,50,9/3/2021
106394,business-contract,100,69,9/3/2021
125212,legal-issues-defendant,100,22,9/3/2021
149301,dividend,100,50,9/3/2021
1A3E1B,conference-participant,100,50,9/3/2021
1E7785,conference-participant,100,50,9/3/2021
1E83DE,conference-participant,100,50,9/3/2021
2031CE,conference-participant,100,50,9/3/2021
292388,conference-participant,100,50,9/3/2021
2D643C,conference-participant,100,50,9/3/2021
2DB344,buybacks,100,74,9/3/2021
31643A,product-release,100,64,9/3/2021
3471C0,unit-acquisition-acquirer,100,49,9/3/2021
42978B,dividend,100,50,9/3/2021
46A16E,conference-participant,100,50,9/3/2021
46A16E,conference-participant,100,50,9/3/2021
550D01,earnings,100,50,9/3/2021
56277A,dividend,100,50,9/3/2021
6A01DF,conference-participant,100,50,9/3/2021
6BBCBA,conference-participant,100,50,9/3/2021
73F70F,conference-participant,100,50,9/3/2021
76F067,conference-participant,100,50,9/3/2021
77B8E9,conference-participant,100,50,9/3/2021
8A8E41,donation,100,54,9/3/2021
8AC65D,conference-participant,100,50,9/3/2021
8C6C1B,donation,100,54,9/3/2021
8C6C1B,donation,100,54,9/3/2021
918D6D,conference-participant,100,50,9/3/2021
9196A2,conference-organizer,100,57,9/3/2021
9196A2,conference-organizer,100,57,9/3/2021
925759,conference-organizer,100,57,9/3/2021
94208D,index-listing,100,76,9/3/2021
947B0B,legal-issues-defendant,100,22,9/3/2021
947B0B,legal-issues-defendant,100,22,9/3/2021
954004,partnership,100,61,9/3/2021
971334,dividend,100,50,9/3/2021
9D56F2,conference-call,100,50,9/3/2021
A1EAC8,executive-appointment,100,54,9/3/2021
A5195E,conference-participant,100,50,9/3/2021
A6FE1C,unit-acquisition-acquirer,100,49,9/3/2021
A8E2FE,conference-participant,100,50,9/3/2021
B762D3,earnings,100,50,9/3/2021
B762D3,earnings,100,50,9/3/2021
B762D3,earnings,100,50,9/3/2021
C356AC,regulatory-investigation,100,22,9/3/2021
C45C1F,conference-participant,100,50,9/3/2021
C4F9C6,conference-participant,100,50,9/3/2021
C598D7,index-listing,100,76,9/3/2021
CAC8D0,earnings,100,50,9/3/2021
D296C6,dividend,100,50,9/3/2021
D5A350,executive-resignation,100,44,9/3/2021
D854F3,acquisition-regulatory-scrutiny-acquiree,100,38,9/3/2021
DB23C8,conference-participant,100,50,9/3/2021
DE5611,conference-participant,100,50,9/3/2021
E5A3B6,conference-participant,100,50,9/3/2021
E6A53A,buybacks,100,74,9/3/2021
E8846E,conference-organizer,100,57,9/3/2021
E8846E,conference-organizer,100,57,9/3/2021
E8846E,executive-appointment,100,54,9/3/2021
ECF709,earnings,100,50,9/3/2021
F0027C,conference-participant,100,50,9/3/2021
F294DD,dividend,100,50,9/3/2021
F30508,conference-participant,100,50,9/3/2021
F3FCC3,executive-appointment,100,54,9/3/2021
F4D241,conference-participant,100,50,9/3/2021
F509E2,conference-participant,100,50,9/3/2021
F5D410,conference-participant,100,50,9/3/2021
F7ADEB,product-release,100,64,9/3/2021
FC4550,dividend,100,50,9/3/2021
125212,legal-issues-defendant,100,22,9/4/2021
435ACE,conference-participant,100,50,9/4/2021
93965C,legal-issues-defendant,100,22,9/4/2021
9E98F2,legal-issues-defendant,100,22,9/4/2021
D854F3,legal-issues-defendant,100,22,9/4/2021
ED2A5E,legal-issues-defendant,100,22,9/4/2021
F48947,legal-issues-defendant,100,22,9/4/2021
3461CF,credit-rating-affirmation-rater,20,50,9/6/2021
3CCC90,executive-appointment,100,54,9/6/2021
4E6F5A,legal-issues-defendant,100,22,9/6/2021
947B0B,legal-issues-defendant,100,22,9/6/2021
9397,executive-appointment,100,54,9/7/2021
01B8D6,regulatory-product-approval-granted,100,81,9/7/2021
01D03F,partnership,100,61,9/7/2021
01D03F,partnership,100,61,9/7/2021
033B58,conference-participant,100,50,9/7/2021
05D148,conference-participant,100,50,9/7/2021
95294,note-sale,100,52,9/7/2021
099A92,conference-participant,100,50,9/7/2021
0A77DB,conference-participant,100,50,9/7/2021
0BA2EF,earnings,100,50,9/7/2021
0BA2EF,earnings,100,50,9/7/2021
0C2A0D,conference-participant,100,50,9/7/2021
0CC62B,facility-sale,100,52,9/7/2021
0CCCB7,executive-appointment,100,54,9/7/2021
0E2992,executive-appointment,100,54,9/7/2021
1151F4,legal-issues-defendant,100,22,9/7/2021
1201B5,conference-participant,100,50,9/7/2021
12F98C,earnings-up,100,68,9/7/2021
12F98C,earnings-up,100,68,9/7/2021
12F98C,earnings-up,100,68,9/7/2021
152AB9,public-offering,100,43,9/7/2021
197612,partnership,100,61,9/7/2021
19BF16,conference-participant,100,50,9/7/2021
1CD09C,conference-participant,100,50,9/7/2021
1DB833,conference-participant,100,50,9/7/2021
1EBF8D,conference-participant,100,50,9/7/2021
1EBF8D,partnership,100,61,9/7/2021
2082EA,conference-participant,100,50,9/7/2021
223552,conference-participant,100,50,9/7/2021
228D42,partnership,100,61,9/7/2021
241AF7,dividend,100,50,9/7/2021
24A89A,conference-participant,100,50,9/7/2021
26DC29,conference-participant,100,50,9/7/2021
279916,conference-participant,100,50,9/7/2021
282C18,partnership,100,61,9/7/2021
292388,conference-participant,100,50,9/7/2021
2950FF,trading-halt,100,43,9/7/2021
2950FF,trading-resumed,100,58,9/7/2021
2A6DBE,conference-participant,100,50,9/7/2021
2ABF77,conference-participant,100,50,9/7/2021
2B49F4,conference-participant,100,50,9/7/2021
2BC05E,partnership,100,61,9/7/2021
2C681C,conference-participant,100,50,9/7/2021
2CBB58,conference-participant,100,50,9/7/2021
2E0445,executive-appointment,100,54,9/7/2021
2E1322,acquisition-completed-acquiree,100,76,9/7/2021
30DE64,conference-participant,100,50,9/7/2021
317EC6,conference-participant,100,50,9/7/2021
32F943,conference-participant,100,50,9/7/2021
33A0F1,executive-appointment,100,54,9/7/2021
33AD83,partnership,100,61,9/7/2021
34B97A,conference-participant,100,50,9/7/2021
36529A,conference-participant,100,50,9/7/2021
384CD3,conference-participant,100,50,9/7/2021
387541,executive-appointment,100,54,9/7/2021
396D7C,conference-participant,100,50,9/7/2021
3B50FE,conference-call,100,50,9/7/2021
3BB616,donation,100,54,9/7/2021
3BC360,partnership,100,61,9/7/2021
3BC360,partnership,100,61,9/7/2021
408380,business-contract,100,69,9/7/2021
417BF9,conference-participant,100,50,9/7/2021
42EFC7,conference-participant,100,50,9/7/2021
44A4FC,conference-participant,100,50,9/7/2021
49A344,government-contract,100,69,9/7/2021
4A6F00,partnership,100,61,9/7/2021
4BAF2E,conference-participant,100,50,9/7/2021
4C6C63,campaign-ad-release,100,59,9/7/2021
4C6C63,campaign-ad-release,100,59,9/7/2021
4E6F5A,legal-issues-defendant,100,22,9/7/2021
4EEB00,conference-participant,100,50,9/7/2021
4F9926,merger,100,66,9/7/2021
513A86,executive-appointment,100,54,9/7/2021
543900,conference-participant,100,50,9/7/2021
5.47E+28,conference-participant,100,50,9/7/2021
55438C,executive-appointment,100,54,9/7/2021
55C9B5,acquisition-acquirer,100,49,9/7/2021
55CD6F,dividend,100,50,9/7/2021
567F3D,conference-participant,100,50,9/7/2021
56EA2B,dividend,100,50,9/7/2021
579E8F,conference-participant,100,50,9/7/2021
5B51D6,conference-participant,100,50,9/7/2021
5BC2F4,unit-acquisition-acquirer,100,49,9/7/2021
5D43A7,executive-death,100,31,9/7/2021
5E6959,conference-participant,100,50,9/7/2021
5F6D73,executive-appointment,100,54,9/7/2021
5FC507,conference-participant,100,50,9/7/2021
629F0F,conference-participant,100,50,9/7/2021
62CDDE,conference-participant,100,50,9/7/2021
633043,executive-appointment,100,54,9/7/2021
633054,spin-off,100,58,9/7/2021
633054,business-contract,100,69,9/7/2021
651C85,conference-participant,100,50,9/7/2021
665440,conference-participant,100,50,9/7/2021
67B052,executive-appointment,100,54,9/7/2021
6B494E,executive-appointment,100,54,9/7/2021
6DC1D7,executive-appointment,100,54,9/7/2021
6DC1D7,dividend,100,50,9/7/2021
6-Dec-05,conference-participant,100,50,9/7/2021
70CA28,conference-participant,100,50,9/7/2021
7122EB,clinical-trials-positive,100,87,9/7/2021
724F84,business-contract,100,69,9/7/2021
7.45E+28,conference-participant,100,50,9/7/2021
751C8D,facility-upgrade,100,65,9/7/2021
751C8D,facility-upgrade,100,65,9/7/2021
763DBE,sponsorship,100,57,9/7/2021
7A5097,business-contract,100,69,9/7/2021
7B6C88,partnership,100,61,9/7/2021
7C4F43,conference-participant,100,50,9/7/2021
8.10E+205,partnership,100,61,9/7/2021
82B57E,conference-participant,100,50,9/7/2021
8303CD,conference-participant,100,50,9/7/2021
84A6B9,executive-appointment,100,54,9/7/2021
8C5519,dividend,100,50,9/7/2021
8D4486,partnership,100,61,9/7/2021
8D5145,buybacks,100,74,9/7/2021
8E8E6E,partnership,100,61,9/7/2021
8EDACA,conference-participant,100,50,9/7/2021
90DD65,conference-participant,100,50,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
9196A2,conference-organizer,100,57,9/7/2021
92005C,conference-participant,100,50,9/7/2021
92B625,conference-participant,100,50,9/7/2021
94637C,conference-participant,100,50,9/7/2021
947B0B,legal-issues-defendant,100,22,9/7/2021
94A326,conference-participant,100,50,9/7/2021
968966,executive-appointment,100,54,9/7/2021
96A6CD,conference-participant,100,50,9/7/2021
977A1E,donation,100,54,9/7/2021
9A29F4,credit-extension-recipient,100,69,9/7/2021
9B0C9C,conference-participant,100,50,9/7/2021
9B730A,executive-appointment,100,54,9/7/2021
9B730A,conference-participant,100,50,9/7/2021
9E0811,public-offering,100,43,9/7/2021
9E5C2C,conference-participant,100,50,9/7/2021
A247F5,conference-participant,100,50,9/7/2021
A47F2E,earnings,100,50,9/7/2021
A6213D,executive-appointment,100,54,9/7/2021
A6ABE9,legal-issues-defendant,100,22,9/7/2021
A6D095,conference-participant,100,50,9/7/2021
A6FE1C,unit-acquisition-acquirer,100,49,9/7/2021
A79F7D,conference-participant,100,50,9/7/2021
ABAA03,conference-participant,100,50,9/7/2021
AD23DE,acquisition-completed-acquirer,100,49,9/7/2021
ADFB3A,conference-participant,100,50,9/7/2021
AEBB80,conference-participant,100,50,9/7/2021
B01111,facility-open,100,65,9/7/2021
B13B68,conference-participant,100,50,9/7/2021
B37FB4,conference-participant,100,50,9/7/2021
B48FC9,acquisition-acquirer,100,49,9/7/2021
B48FC9,acquisition-acquirer,100,49,9/7/2021
B4C673,acquisition-completed-acquirer,100,49,9/7/2021
B4C673,acquisition-completed-acquirer,100,49,9/7/2021
B5734D,conference-call,100,50,9/7/2021
B72D2E,stake-acquirer,100,48,9/7/2021
B80AD1,conference-participant,100,50,9/7/2021
B8A51F,conference-participant,100,50,9/7/2021
BBBB41,conference-participant,100,50,9/7/2021
BCC13E,executive-appointment,100,54,9/7/2021
BE14CF,executive-appointment,100,54,9/7/2021
C0BA36,conference-participant,100,50,9/7/2021
C38440,conference-participant,100,50,9/7/2021
C564E4,conference-participant,100,50,9/7/2021
C9A96E,award,100,58,9/7/2021
C9E107,conference-participant,100,50,9/7/2021
C9F39B,executive-appointment,100,54,9/7/2021
CE1002,conference-participant,100,50,9/7/2021
CF7292,stock-gain,100,63,9/7/2021
D15833,acquisition-acquirer,100,49,9/7/2021
D15833,acquisition-acquirer,100,49,9/7/2021
D17C1B,executive-appointment,100,54,9/7/2021
D1C0B9,hirings,100,65,9/7/2021
D36B23,conference-participant,100,50,9/7/2021
D437C3,conference-participant,100,50,9/7/2021
D4C0CB,conference-participant,100,50,9/7/2021
D78CCD,executive-resignation,100,44,9/7/2021
D82EF3,trading-halt,100,43,9/7/2021
D82EF3,trading-resumed,100,58,9/7/2021
DB9F70,conference-participant,100,50,9/7/2021
DD1BA1,partnership,100,61,9/7/2021
E0207A,conference-participant,100,50,9/7/2021
E22FDE,acquisition-completed-acquirer,100,49,9/7/2021
E5F0A8,merger,100,66,9/7/2021
E67C2C,conference-participant,100,50,9/7/2021
E68E62,executive-appointment,100,54,9/7/2021
E6BC2C,business-contract,100,69,9/7/2021
E6D89E,partnership,100,61,9/7/2021
E82A2D,conference-participant,100,50,9/7/2021
E8846E,conference-organizer,100,57,9/7/2021
E94704,conference-participant,100,50,9/7/2021
EA79C7,conference-participant,100,50,9/7/2021
EB1E1A,conference-participant,100,50,9/7/2021
ED22DC,conference-participant,100,50,9/7/2021
EE6F1C,unit-acquisition-acquiree,100,76,9/7/2021
EFA7B2,conference-participant,100,50,9/7/2021
F18844,public-offering,100,43,9/7/2021
F2E253,note-sale,100,52,9/7/2021
F58C23,conference-participant,100,50,9/7/2021
F5D059,unit-acquisition-acquirer,100,49,9/7/2021
F5D410,executive-appointment,100,54,9/7/2021
F702CA,partnership,100,61,9/7/2021
FD9526,acquisition-acquiree,100,76,9/7/2021
FD9526,acquisition-regulatory-scrutiny-acquiree,100,38,9/7/2021
FD9526,acquisition-regulatory-scrutiny-acquiree,100,38,9/7/2021
FE9C0D,conference-participant,100,50,9/7/2021
FF227B,conference-participant,100,50,9/7/2021
00067A,executive-appointment,100,54,9/8/2021
00067A,product-release,100,64,9/8/2021
01D03F,partnership,100,61,9/8/2021
20751,regulatory-product-approval-granted,100,81,9/8/2021
20751,regulatory-product-approval-granted,100,81,9/8/2021
02ACBD,partnership,100,61,9/8/2021
31025,executive-appointment,100,54,9/8/2021
03B8CF,business-contract,100,69,9/8/2021
48590,partnership,100,61,9/8/2021
48590,partnership,100,61,9/8/2021
48590,partnership,100,61,9/8/2021
06EE79,market-entry,100,57,9/8/2021
070B45,award,100,58,9/8/2021
0DBB81,clinical-trials,100,56,9/8/2021
0E499E,conference-participant,100,50,9/8/2021
0E5223,conference-participant,100,50,9/8/2021
106394,public-offering,100,43,9/8/2021
1220D2,conference-participant,100,50,9/8/2021
1272B3,partnership,100,61,9/8/2021
1490F3,public-offering,100,43,9/8/2021
152AB9,public-offering,100,43,9/8/2021
16AAE0,unit-acquisition-acquiree,100,76,9/8/2021
16AAE0,unit-acquisition-acquiree,100,76,9/8/2021
16AAE0,unit-acquisition-acquiree,100,76,9/8/2021
17EDA5,partnership,100,61,9/8/2021
182BE7,unit-acquisition-acquirer,100,49,9/8/2021
182BE7,unit-acquisition-acquirer,100,49,9/8/2021
184866,conference-participant,100,50,9/8/2021
1A1ED9,partnership,100,61,9/8/2021
1A1ED9,partnership,100,61,9/8/2021
1A1ED9,partnership,100,61,9/8/2021
1C2593,conference-participant,100,50,9/8/2021
1CD708,buybacks,100,74,9/8/2021
1D943E,executive-appointment,100,54,9/8/2021
1D9E55,unit-acquisition-acquirer,100,49,9/8/2021
1D9E55,partnership,100,61,9/8/2021
1DE526,partnership,100,61,9/8/2021
1E83DE,earnings-up,100,68,9/8/2021
1E9A6D,executive-appointment,100,54,9/8/2021
1FC422,executive-appointment,100,54,9/8/2021
223552,conference-participant,100,50,9/8/2021
239106,conference-participant,100,50,9/8/2021
273BA3,partnership,100,61,9/8/2021
2AA6A8,executive-appointment,100,54,9/8/2021
2C681C,clinical-trials-start,100,64,9/8/2021
2C681C,clinical-trials-start,100,64,9/8/2021
2C681C,clinical-trials-start,100,64,9/8/2021
2CB4C9,partnership,100,61,9/8/2021
2CB4C9,partnership,100,61,9/8/2021
2D981A,conference-participant,100,50,9/8/2021
2F9304,conference-participant,100,50,9/8/2021
326EDD,conference-participant,100,50,9/8/2021
33A0F1,earnings,100,50,9/8/2021
367434,executive-appointment,100,54,9/8/2021
367E1C,partnership,100,61,9/8/2021
385DD4,note-sale,100,52,9/8/2021
385DD4,note-sale,100,52,9/8/2021
385DD4,note-sale,100,52,9/8/2021
385DD4,conference-participant,100,50,9/8/2021
39FB23,executive-appointment,100,54,9/8/2021
3A1C46,revenue-guidance-up,100,83,9/8/2021
3DED49,unit-acquisition-acquirer,100,49,9/8/2021
3DED49,earnings-guidance,100,50,9/8/2021
408089,revenue-guidance-down,100,19,9/8/2021
416C55,conference-participant,100,50,9/8/2021
43A060,business-contract,100,69,9/8/2021
49F4D0,conference-participant,100,50,9/8/2021
4A6F00,product-release,100,64,9/8/2021
4A6F00,product-release,100,64,9/8/2021
4A6F00,product-release,100,64,9/8/2021
4A6F00,product-release,100,64,9/8/2021
4A6F00,partnership,100,61,9/8/2021
4AC91D,partnership,100,61,9/8/2021
4B49CF,earnings,100,50,9/8/2021
4B7006,acquisition-interest-acquirer,100,46,9/8/2021
4C5CC9,business-contract,100,69,9/8/2021
4C92B9,conference-organizer,100,57,9/8/2021
50070E,conference-organizer,100,57,9/8/2021
50070E,conference-organizer,100,57,9/8/2021
504FE2,conference-participant,100,50,9/8/2021
51D876,conference-participant,100,50,9/8/2021
523039,conference-participant,100,50,9/8/2021
545272,conference-participant,100,50,9/8/2021
59DB8C,conference-participant,100,50,9/8/2021
5BE42C,note-sale,100,52,9/8/2021
5E9934,unit-acquisition-acquirer,100,49,9/8/2021
5E9934,earnings,100,50,9/8/2021
619882,conference-organizer,100,57,9/8/2021
619882,partnership,100,61,9/8/2021
619882,partnership,100,61,9/8/2021
61A586,product-release,100,64,9/8/2021
61B81B,conference-call,100,50,9/8/2021
622DBE,conference-participant,100,50,9/8/2021
6391C2,conference-participant,100,50,9/8/2021
66ECFD,award,100,58,9/8/2021
67303E,private-placement,100,56,9/8/2021
6DBBBC,investment-investor,100,55,9/8/2021
6-Dec-05,conference-participant,100,50,9/8/2021
6F39FC,dividend,100,50,9/8/2021
6F92A9,conference-participant,100,50,9/8/2021
70FCEF,earnings-up,100,68,9/8/2021
70FCEF,earnings,100,50,9/8/2021
70FCEF,earnings,100,50,9/8/2021
70FCEF,earnings,100,50,9/8/2021
70FCEF,earnings,100,50,9/8/2021
70FCEF,earnings,100,50,9/8/2021
713810,hirings,100,65,9/8/2021
713810,partnership,100,61,9/8/2021
722DE3,government-contract,100,69,9/8/2021
728737,conference-participant,100,50,9/8/2021
72FCA3,earnings,100,50,9/8/2021
73A213,earnings,100,50,9/8/2021
73BCBA,conference-participant,100,50,9/8/2021
767F86,partnership,100,61,9/8/2021
767F86,partnership,100,61,9/8/2021
767F86,partnership,100,61,9/8/2021
767F86,partnership,100,61,9/8/2021
771985,conference-participant,100,50,9/8/2021
7AB859,executive-appointment,100,54,9/8/2021
7D5FD6,earnings-guidance,100,50,9/8/2021
7D5FD6,dividend,100,50,9/8/2021
7FC386,dividend,100,50,9/8/2021
8303CD,award,100,58,9/8/2021
834152,acquisition-acquiree,100,76,9/8/2021
834152,acquisition-acquiree,100,76,9/8/2021
834152,acquisition-acquiree,100,76,9/8/2021
834152,acquisition-acquiree,100,76,9/8/2021
834152,acquisition-acquiree,100,76,9/8/2021
834152,acquisition-acquiree,100,76,9/8/2021
834152,acquisition-acquiree,100,76,9/8/2021
834152,acquisition-acquiree,100,76,9/8/2021
8AB37F,executive-appointment,100,54,9/8/2021
8B4A45,earnings,100,50,9/8/2021
8BAA15,business-contract,100,69,9/8/2021
8D4486,product-release,100,64,9/8/2021
8D4486,product-release,100,64,9/8/2021
8D4486,partnership,100,61,9/8/2021
8D4486,partnership,100,61,9/8/2021
8D4486,partnership,100,61,9/8/2021
8E8E6E,conference-participant,100,50,9/8/2021
9196A2,conference-organizer,100,57,9/8/2021
9196A2,conference-organizer,100,57,9/8/2021
9196A2,conference-organizer,100,57,9/8/2021
9196A2,conference-organizer,100,57,9/8/2021
91C82E,conference-call,100,50,9/8/2021
92D757,partnership,100,61,9/8/2021
94637C,earnings,100,50,9/8/2021
94637C,partnership,100,61,9/8/2021
9.54E+32,partnership,100,61,9/8/2021
957A07,acquisition-acquirer,100,49,9/8/2021
957A07,acquisition-acquirer,100,49,9/8/2021
97693A,earnings,100,50,9/8/2021
977A1E,donation,100,54,9/8/2021
990AD0,conference-organizer,100,57,9/8/2021
990AD0,conference-organizer,100,57,9/8/2021
990AD0,conference-organizer,100,57,9/8/2021
9BF177,earnings,100,50,9/8/2021
9E0811,public-offering,100,43,9/8/2021
A15C71,executive-appointment,100,54,9/8/2021
A26C26,earnings,100,50,9/8/2021
A4BCDE,product-release,100,64,9/8/2021
A631A3,executive-appointment,100,54,9/8/2021
A666C8,conference-participant,100,50,9/8/2021
A6828A,regulatory-product-approval-granted,100,81,9/8/2021
A6FB29,earnings-up,100,68,9/8/2021
A72FD9,conference-call,100,50,9/8/2021
A790A5,conference-participant,100,50,9/8/2021
A7A0BD,conference-participant,100,50,9/8/2021
A7A0C8,executive-appointment,100,54,9/8/2021
AA98ED,conference-participant,100,50,9/8/2021
AC7C4F,conference-participant,100,50,9/8/2021
ACC7D3,executive-appointment,100,54,9/8/2021
AED61E,earnings,100,50,9/8/2021
AFD1CA,conference-participant,100,50,9/8/2021
B05000,conference-participant,100,50,9/8/2021
B08C51,conference-participant,100,50,9/8/2021
B1FC3B,executive-appointment,100,54,9/8/2021
B3CB74,conference-organizer,100,57,9/8/2021
B8F71F,note-sale,100,52,9/8/2021
B9764A,business-contract,100,69,9/8/2021
BB07E4,note-sale,100,52,9/8/2021
BB88B6,award,100,58,9/8/2021
BCC13E,conference-participant,100,50,9/8/2021
BFE02C,acquisition-acquirer,100,49,9/8/2021
BFE02C,acquisition-acquirer,100,49,9/8/2021
C01737,conference-participant,100,50,9/8/2021
C06EB6,conference-participant,100,50,9/8/2021
C2F597,investment-investor,100,55,9/8/2021
C4C77F,executive-appointment,100,54,9/8/2021
C4F9C6,conference-participant,100,50,9/8/2021
C584BE,partnership,100,61,9/8/2021
C584BE,partnership,100,61,9/8/2021
C584BE,partnership,100,61,9/8/2021
C598D7,index-listing,100,76,9/8/2021
C94CFC,conference-participant,100,50,9/8/2021
CA1620,conference-participant,100,50,9/8/2021
CBB77B,earnings,100,50,9/8/2021
CBB77B,earnings,100,50,9/8/2021
CBB77B,earnings,100,50,9/8/2021
CD4DA8,conference-organizer,100,57,9/8/2021
CDC217,patent-awarded,100,72,9/8/2021
CF351E,dividend,100,50,9/8/2021
CF6A5A,executive-firing,100,36,9/8/2021
CFF15D,product-release,100,64,9/8/2021
CFF15D,product-release,100,64,9/8/2021
CFF15D,product-release,100,64,9/8/2021
D064D5,executive-resignation,100,44,9/8/2021
D064D5,earnings,100,50,9/8/2021
D07B07,regulatory-product-approval-granted,100,81,9/8/2021
D0DE27,executive-appointment,100,54,9/8/2021
D1173F,note-sale,100,52,9/8/2021
D13F1C,conference-participant,100,50,9/8/2021
D42DBA,earnings,100,50,9/8/2021
D42DBA,earnings,100,50,9/8/2021
D42DBA,earnings,100,50,9/8/2021
D42DBA,earnings,100,50,9/8/2021
D42DBA,earnings,100,50,9/8/2021
D54E62,partnership,100,61,9/8/2021
D54E62,partnership,100,61,9/8/2021
D54E62,partnership,100,61,9/8/2021
D54E62,partnership,100,61,9/8/2021
D622D5,dividend,100,50,9/8/2021
D622D5,operating-earnings,100,50,9/8/2021
D82EF3,donation,100,54,9/8/2021
DA9443,executive-appointment,100,54,9/8/2021
DDEA6A,conference-participant,100,50,9/8/2021
E0207A,product-release,100,64,9/8/2021
E21871,buybacks,100,74,9/8/2021
E22FDE,conference-participant,100,50,9/8/2021
E28D9C,unit-acquisition-acquirer,100,49,9/8/2021
E40FB6,note-sale,100,52,9/8/2021
E49AA3,product-release,100,64,9/8/2021
E5C910,conference-participant,100,50,9/8/2021
E68C3D,buybacks,100,74,9/8/2021
E68C3D,partnership,100,61,9/8/2021
E69BA5,conference-participant,100,50,9/8/2021
E7BF32,executive-appointment,100,54,9/8/2021
E7BF32,executive-appointment,100,54,9/8/2021
E866D2,conference-participant,100,50,9/8/2021
E8846E,conference-organizer,100,57,9/8/2021
E8846E,conference-organizer,100,57,9/8/2021
E8B21D,dividend,100,50,9/8/2021
E93A40,product-release,100,64,9/8/2021
EB61C4,conference-participant,100,50,9/8/2021
EB7FBF,executive-appointment,100,54,9/8/2021
ED0402,executive-appointment,100,54,9/8/2021
ED1A74,conference-participant,100,50,9/8/2021
ED2A5E,legal-issues-defendant,100,22,9/8/2021
ED7F13,dividend,100,50,9/8/2021
F11638,conference-participant,100,50,9/8/2021
F18844,public-offering,100,43,9/8/2021
F1EB39,earnings,100,50,9/8/2021
F2BC3D,acquisition-acquirer,100,49,9/8/2021
F3016C,acquisition-acquirer,100,49,9/8/2021
F3816D,partnership,100,61,9/8/2021
F46EC9,conference-participant,100,50,9/8/2021
F5349B,executive-appointment,100,54,9/8/2021
F88A04,conference-participant,100,50,9/8/2021
FD4588,acquisition-acquirer,100,49,9/8/2021
14730,business-combination,100,54,9/9/2021
01D03F,acquisition-completed-acquirer,100,49,9/9/2021
48590,legal-issues-defendant,100,22,9/9/2021
0624BE,product-release,100,64,9/9/2021
070B45,partnership,100,61,9/9/2021
070B45,partnership,100,61,9/9/2021
09062E,acquisition-acquirer,100,49,9/9/2021
95294,conference-participant,100,50,9/9/2021
0A0D9E,conference-organizer,100,57,9/9/2021
0B4D10,dividend,100,50,9/9/2021
0B57D7,facility-open,100,65,9/9/2021
0BA2EF,dividend,100,50,9/9/2021
0C8D82,partnership,100,61,9/9/2021
0EF1AF,executive-appointment,100,54,9/9/2021
0F91FC,product-release,100,64,9/9/2021
106394,public-offering,100,43,9/9/2021
125212,conference-participant,100,50,9/9/2021
1272B3,conference-participant,100,50,9/9/2021
139303,conference-organizer,100,57,9/9/2021
1490F3,public-offering,100,43,9/9/2021
15A388,conference-participant,100,50,9/9/2021
15B10D,buybacks,100,74,9/9/2021
196D18,conference-participant,100,50,9/9/2021
1AD9CC,earnings,100,50,9/9/2021
1B637E,dividend,100,50,9/9/2021
1C2593,conference-participant,100,50,9/9/2021
1DF15D,dividend,100,50,9/9/2021
1E7785,conference-participant,100,50,9/9/2021
1EF224,executive-appointment,100,54,9/9/2021
205AD5,donation,100,54,9/9/2021
2262BD,earnings,100,50,9/9/2021
241252,conference-participant,100,50,9/9/2021
253B2F,note-sale,100,52,9/9/2021
25D3CE,conference-participant,100,50,9/9/2021
267718,regulatory-product-application,100,69,9/9/2021
273BA3,earnings,100,50,9/9/2021
291651,earnings,100,50,9/9/2021
2C681C,conference-participant,100,50,9/9/2021
2CC60C,dividend,100,50,9/9/2021
30AB63,earnings-guidance,100,50,9/9/2021
33AD83,conference-participant,100,50,9/9/2021
33E9D5,earnings,100,50,9/9/2021
35557B,conference-participant,100,50,9/9/2021
356B21,partnership,100,61,9/9/2021
36C09B,conference-participant,100,50,9/9/2021
36E479,conference-participant,100,50,9/9/2021
39D9DA,earnings,100,50,9/9/2021
3B9886,executive-appointment,100,54,9/9/2021
3F4668,product-release,100,64,9/9/2021
4017AD,note-sale,100,52,9/9/2021
458D2C,revenue-volume,100,50,9/9/2021
4A6F00,partnership,100,61,9/9/2021
4A6F00,partnership,100,61,9/9/2021
4B3676,conference-participant,100,50,9/9/2021
4CDA2B,clinical-trials-start,100,64,9/9/2021
4D8124,conference-organizer,100,57,9/9/2021
4E6F5A,legal-issues-defendant,100,22,9/9/2021
50070E,conference-organizer,100,57,9/9/2021
50070E,conference-organizer,100,57,9/9/2021
546A9C,unit-acquisition-completed-acquirer,100,49,9/9/2021
55C9B5,partnership,100,61,9/9/2021
55C9B5,acquisition-acquirer,100,49,9/9/2021
57A854,acquisition-completed-acquirer,100,49,9/9/2021
57DDB9,conference-participant,100,50,9/9/2021
58EA22,conference-participant,100,50,9/9/2021
59DB8C,partnership,100,61,9/9/2021
59DB8C,partnership,100,61,9/9/2021
5AAE17,conference-participant,100,50,9/9/2021
5BC2F4,public-offering,100,43,9/9/2021
5D0337,executive-appointment,100,54,9/9/2021
5D0337,executive-appointment,100,54,9/9/2021
5D63F1,dividend,100,50,9/9/2021
5E7E82,product-release,100,64,9/9/2021
6166D1,conference-organizer,100,57,9/9/2021
619882,acquisition-acquirer,100,49,9/9/2021
629F0F,earnings,100,50,9/9/2021
633043,public-offering,100,43,9/9/2021
665D7D,conference-participant,100,50,9/9/2021
67B052,patent-awarded,100,72,9/9/2021
6810DE,conference-participant,100,50,9/9/2021
6925EB,conference-participant,100,50,9/9/2021
6D2BF6,conference-participant,100,50,9/9/2021
6D3B7B,dividend,100,50,9/9/2021
70B3D6,revenue-up,100,69,9/9/2021
70B3D6,revenue-up,100,69,9/9/2021
70B3D6,revenue-up,100,69,9/9/2021
70B3D6,revenue-up,100,69,9/9/2021
717DB4,conference-participant,100,50,9/9/2021
741937,executive-appointment,100,54,9/9/2021
747219,conference-participant,100,50,9/9/2021
762A3E,conference-organizer,100,57,9/9/2021
76F067,conference-participant,100,50,9/9/2021
7A3633,partnership,100,61,9/9/2021
7A3633,partnership,100,61,9/9/2021
7AF5B8,clinical-trials-start,100,64,9/9/2021
7BFF81,conference-participant,100,50,9/9/2021
824CCA,executive-appointment,100,54,9/9/2021
824CCA,executive-appointment,100,54,9/9/2021
824CCA,executive-appointment,100,54,9/9/2021
82E58A,dividend-up,100,59,9/9/2021
834152,acquisition-regulatory-scrutiny-acquiree,100,38,9/9/2021
834152,acquisition-regulatory-scrutiny-acquiree,100,38,9/9/2021
84A6B9,executive-appointment,100,54,9/9/2021
8E8E6E,product-release,100,64,9/9/2021
8E9CD8,executive-appointment,100,54,9/9/2021
9004C4,executive-appointment,100,54,9/9/2021
9004C4,executive-appointment,100,54,9/9/2021
9196A2,conference-organizer,100,57,9/9/2021
9196A2,conference-organizer,100,57,9/9/2021
9196A2,conference-organizer,100,57,9/9/2021
9196A2,conference-organizer,100,57,9/9/2021
925759,partnership,100,61,9/9/2021
934029,conference-participant,100,50,9/9/2021
942633,dividend,100,50,9/9/2021
94563D,acquisition-completed-acquirer,100,49,9/9/2021
94637C,partnership,100,61,9/9/2021
94637C,dividend,100,50,9/9/2021
9592FB,business-contract,100,69,9/9/2021
968966,executive-appointment,100,54,9/9/2021
972356,partnership,100,61,9/9/2021
972356,partnership,100,61,9/9/2021
990AD0,conference-organizer,100,57,9/9/2021
990AD0,conference-organizer,100,57,9/9/2021
990AD0,conference-organizer,100,57,9/9/2021
990AD0,conference-organizer,100,57,9/9/2021
99B61C,conference-participant,100,50,9/9/2021
9A2760,conference-participant,100,50,9/9/2021
9BF177,product-release,100,64,9/9/2021
9C25FF,conference-participant,100,50,9/9/2021
A03EE1,legal-issues-defendant,100,22,9/9/2021
A49498,conference-participant,100,50,9/9/2021
A6213D,reorganization-unit,100,53,9/9/2021
A6213D,reorganization-unit,100,53,9/9/2021
A6213D,partnership,100,61,9/9/2021
A63820,earnings,100,50,9/9/2021
AAEE21,conference-participant,100,50,9/9/2021
AC642C,public-offering,100,43,9/9/2021
AC642C,public-offering,100,43,9/9/2021
AD6141,conference-participant,100,50,9/9/2021
ADF092,partnership,100,61,9/9/2021
AEBB80,dividend,100,50,9/9/2021
AFDF2E,conference-participant,100,50,9/9/2021
B076A1,dividend,100,50,9/9/2021
B1FC3B,executive-appointment,100,54,9/9/2021
B2256A,unit-acquisition-acquirer,100,49,9/9/2021
B381D8,clinical-trials,100,56,9/9/2021
B3CB74,conference-organizer,100,57,9/9/2021
B66928,executive-resignation,100,44,9/9/2021
B6843B,credit-extension-recipient,100,69,9/9/2021
BDF85E,earnings-up,100,68,9/9/2021
BDF85E,earnings,100,50,9/9/2021
BDF85E,earnings,100,50,9/9/2021
BE645B,conference-participant,100,50,9/9/2021
C062D4,note-sale,100,52,9/9/2021
C425AE,conference-participant,100,50,9/9/2021
C564E4,regulatory-product-approval-granted,100,81,9/9/2021
C74887,earnings,100,50,9/9/2021
C93C44,conference-participant,100,50,9/9/2021
CB6A9C,partnership,100,61,9/9/2021
CC0C78,conference-participant,100,50,9/9/2021
CC35BE,partnership,100,61,9/9/2021
CDAF5B,dividend,100,50,9/9/2021
CDD75E,conference-participant,100,50,9/9/2021
CF211D,earnings,100,50,9/9/2021
CFF97C,credit-rating-upgrade-rater,20,50,9/9/2021
D0909F,resource-discovery,100,88,9/9/2021
D0909F,resource-discovery,100,88,9/9/2021
D1173F,note-sale,100,52,9/9/2021
D139BC,public-offering,100,43,9/9/2021
D3FA2C,note-sale,100,52,9/9/2021
D3FA2C,note-sale,100,52,9/9/2021
D518D8,executive-appointment,100,54,9/9/2021
D6EAA3,buybacks,100,74,9/9/2021
D90F43,partnership,100,61,9/9/2021
D90F43,partnership,100,61,9/9/2021
DB9F70,executive-appointment,100,54,9/9/2021
E06265,conference-participant,100,50,9/9/2021
E38906,partnership,100,61,9/9/2021
EAA0A7,partnership,100,61,9/9/2021
EBD89A,business-contract,100,69,9/9/2021
EF77A3,earnings,100,50,9/9/2021
F3816D,conference-participant,100,50,9/9/2021
F3EDB4,earnings,100,50,9/9/2021
F793FA,executive-appointment,100,54,9/9/2021
F88147,legal-issues-defendant,100,22,9/9/2021
F93C8A,donation,100,54,9/9/2021
FA40E2,earnings,100,50,9/9/2021
FD2565,conference-participant,100,50,9/9/2021
FD6926,product-release,100,64,9/9/2021
FEE4B0,note-sale,100,52,9/9/2021
FEE4B0,note-sale,100,52,9/9/2021
001F1B,conference-call,100,50,9/10/2021
13528,product-release,100,64,9/10/2021
13528,product-release,100,64,9/10/2021
48590,legal-issues-defendant,100,22,9/10/2021
0C6293,hirings,100,65,9/10/2021
0CBC4D,acquisition-regulatory-scrutiny-acquiree,100,38,9/10/2021
11074E,partnership,100,61,9/10/2021
125212,legal-issues-defendant,100,22,9/10/2021
125212,legal-issues-defendant,100,22,9/10/2021
139303,conference-organizer,100,57,9/10/2021
139303,conference-organizer,100,57,9/10/2021
1921DD,dividend,100,50,9/10/2021
1921DD,dividend,100,50,9/10/2021
197019,conference-participant,100,50,9/10/2021
1B4F31,union-pact,100,61,9/10/2021
1B5FEA,conference-participant,100,50,9/10/2021
1F08A6,dividend,100,50,9/10/2021
214051,executive-appointment,100,54,9/10/2021
2667B6,acquisition-acquiree,100,76,9/10/2021
267718,partnership,100,61,9/10/2021
275300,conference-participant,100,50,9/10/2021
2AE625,executive-appointment,100,54,9/10/2021
2B7A40,debt-restructuring,100,59,9/10/2021
2B7A40,conference-participant,100,50,9/10/2021
2E902B,conference-participant,100,50,9/10/2021
2EBA55,dividend,100,50,9/10/2021
2F960F,dividend,100,50,9/10/2021
33FD66,earnings,100,50,9/10/2021
367E1C,product-release,100,64,9/10/2021
367E1C,product-release,100,64,9/10/2021
370C50,note-sale,100,52,9/10/2021
37B120,conference-participant,100,50,9/10/2021
3C7F5F,partnership,100,61,9/10/2021
4A6F00,partnership,100,61,9/10/2021
4A6F00,partnership,100,61,9/10/2021
4D8124,executive-resignation,100,44,9/10/2021
50070E,conference-organizer,100,57,9/10/2021
510EA1,executive-appointment,100,54,9/10/2021
539F49,conference-participant,100,50,9/10/2021
55C9B5,executive-appointment,100,54,9/10/2021
577033,note-sale,100,52,9/10/2021
5BC2F4,public-offering,100,43,9/10/2021
5DD486,conference-call,100,50,9/10/2021
619882,conference-organizer,100,57,9/10/2021
622DBE,executive-appointment,100,54,9/10/2021
629F0F,conference-participant,100,50,9/10/2021
665D7D,dividend,100,50,9/10/2021
67A658,dividend,100,50,9/10/2021
67A658,dividend,100,50,9/10/2021
6CBF41,conference-participant,100,50,9/10/2021
6F6559,award,100,58,9/10/2021
70CA28,conference-participant,100,50,9/10/2021
741937,executive-appointment,100,54,9/10/2021
7448A3,conference-participant,100,50,9/10/2021
78F776,conference-participant,100,50,9/10/2021
7A0EC4,hirings,100,65,9/10/2021
7B1E50,donation,100,54,9/10/2021
7B6C88,partnership,100,61,9/10/2021
7BAAE7,dividend,100,50,9/10/2021
7C4F43,executive-appointment,100,54,9/10/2021
805CD8,conference-participant,100,50,9/10/2021
8.10E+32,executive-appointment,100,54,9/10/2021
819492,conference-participant,100,50,9/10/2021
82E58A,executive-appointment,100,54,9/10/2021
86AA9C,conference-participant,100,50,9/10/2021
87B81A,conference-participant,100,50,9/10/2021
8A8E41,partnership,100,61,9/10/2021
8A8E41,executive-appointment,100,54,9/10/2021
8BAA15,dividend,100,50,9/10/2021
9196A2,conference-organizer,100,57,9/10/2021
9196A2,conference-organizer,100,57,9/10/2021
9196A2,conference-organizer,100,57,9/10/2021
947B0B,legal-issues-defendant,100,22,9/10/2021
95DC1F,earnings-up,100,68,9/10/2021
95DC1F,earnings-up,100,68,9/10/2021
95DC1F,earnings-up,100,68,9/10/2021
95DC1F,earnings-up,100,68,9/10/2021
95DC1F,earnings-up,100,68,9/10/2021
95DC1F,earnings-up,100,68,9/10/2021
9.74E+08,dividend,100,50,9/10/2021
990AD0,conference-organizer,100,57,9/10/2021
9B4066,asset-sale,100,62,9/10/2021
A15C71,note-sale,100,52,9/10/2021
A398F8,executive-appointment,100,54,9/10/2021
A4B899,acquisition-completed-acquirer,100,49,9/10/2021
AC642C,public-offering,100,43,9/10/2021
AC642C,public-offering,100,43,9/10/2021
AD3008,conference-participant,100,50,9/10/2021
AE79CD,conference-participant,100,50,9/10/2021
B508E5,product-release,100,64,9/10/2021
B762D3,dividend,100,50,9/10/2021
BB58FF,conference-participant,100,50,9/10/2021
BCC55F,conference-participant,100,50,9/10/2021
C0BA36,conference-participant,100,50,9/10/2021
D139BC,public-offering,100,43,9/10/2021
D1C26F,partnership,100,61,9/10/2021
D69D42,dividend,100,50,9/10/2021
DA0CB8,dividend,100,50,9/10/2021
E6C8DC,legal-issues-defendant,100,22,9/10/2021
EB6965,dividend,100,50,9/10/2021
EB7D6C,executive-appointment,100,54,9/10/2021
F7902B,conference-participant,100,50,9/10/2021
FACF19,partnership,100,61,9/10/2021
FAE021,acquisition-acquirer,100,49,9/10/2021
FAE021,acquisition-acquirer,100,49,9/10/2021
0CBC4D,legal-issues-defendant,100,22,9/11/2021
1E4FB9,legal-issues-defendant,100,22,9/11/2021
54512F,legal-issues-defendant,100,22,9/11/2021
9E98F2,legal-issues-defendant,100,22,9/11/2021
A02FB1,legal-issues-defendant,100,22,9/11/2021
D854F3,legal-issues-defendant,100,22,9/11/2021
D854F3,legal-issues-defendant,100,22,9/11/2021
E5F0A8,legal-issues-defendant,100,22,9/11/2021
ED2A5E,legal-issues-defendant,100,22,9/11/2021
F48947,legal-issues-defendant,100,22,9/11/2021
FD9526,legal-issues-defendant,100,22,9/11/2021
4C31F3,conference-participant,100,50,9/12/2021
7B6C88,partnership,100,61,9/12/2021
7B6C88,partnership,100,61,9/12/2021
F82D37,acquisition-interest-acquiree,100,82,9/12/2021
F82D37,acquisition-interest-acquiree,100,82,9/12/2021
00326D,dividend,100,50,9/13/2021
00698D,legal-issues-defendant,100,22,9/13/2021
9397,executive-appointment,100,54,9/13/2021
0157B1,partnership,100,61,9/13/2021
0157B1,hirings,100,65,9/13/2021
01D03F,partnership,100,61,9/13/2021
03542C,dividend,100,50,9/13/2021
48590,legal-issues-defendant,100,22,9/13/2021
55018,product-release,100,64,9/13/2021
07CA6A,conference-participant,100,50,9/13/2021
07CA6A,conference-participant,100,50,9/13/2021
099A92,product-release,100,64,9/13/2021
0A1D77,public-offering,100,43,9/13/2021
0C136E,executive-appointment,100,54,9/13/2021
0F91FC,product-release,100,64,9/13/2021
125212,legal-issues-defendant,100,22,9/13/2021
131443,partnership,100,61,9/13/2021
139303,conference-organizer,100,57,9/13/2021
147C38,executive-appointment,100,54,9/13/2021
149301,dividend,100,50,9/13/2021
168A5D,acquisition-acquirer,100,49,9/13/2021
1921DD,business-contract,100,69,9/13/2021
1DB833,executive-appointment,100,54,9/13/2021
1F716B,conference-call,100,50,9/13/2021
228D42,product-release,100,64,9/13/2021
228D42,market-entry,100,57,9/13/2021
228D42,partnership,100,61,9/13/2021
284289,business-contract,100,69,9/13/2021
2950FF,note-sale,100,52,9/13/2021
2950FF,note-sale,100,52,9/13/2021
2B0AF4,conference-participant,100,50,9/13/2021
30AB63,conference-participant,100,50,9/13/2021
326EDD,dividend-up,100,54,9/13/2021
3461CF,partnership,100,61,9/13/2021
3461CF,partnership,100,61,9/13/2021
37426C,patent-filing-rejected,100,43,9/13/2021
37727A,executive-appointment,100,54,9/13/2021
382EAE,unit-acquisition-acquirer,100,49,9/13/2021
3A3447,partnership,100,61,9/13/2021
3B8484,acquisition-acquirer,100,49,9/13/2021
3B9886,facility-open,100,65,9/13/2021
3DCECC,award,100,58,9/13/2021
3ED92D,acquisition-completed-acquirer,100,49,9/13/2021
4017AD,credit-extension-recipient,100,69,9/13/2021
408380,business-contract,100,69,9/13/2021
4.91E+58,executive-appointment,100,54,9/13/2021
4A2457,business-contract,100,69,9/13/2021
4AE584,conference-participant,100,50,9/13/2021
4C37C5,partnership,100,61,9/13/2021
4FB770,note-sale,100,52,9/13/2021
5065B1,dividend-up,100,54,9/13/2021
55C9B5,conference-participant,100,50,9/13/2021
56B7C1,public-offering,100,43,9/13/2021
5704AC,dividend-up,100,57,9/13/2021
57CAAB,conference-participant,100,50,9/13/2021
57CAAB,partnership,100,61,9/13/2021
59DB8C,partnership,100,61,9/13/2021
59DB8C,partnership,100,61,9/13/2021
665618,conference-participant,100,50,9/13/2021
665D7D,partnership,100,61,9/13/2021
6A961B,dividend-up,100,81,9/13/2021
6A961B,earnings,100,50,9/13/2021
6BBD2D,clinical-trials,100,56,9/13/2021
6CF43C,executive-appointment,100,54,9/13/2021
6F92A9,note-sale,100,52,9/13/2021
6F92A9,note-sale,100,52,9/13/2021
70B3D6,public-offering,100,43,9/13/2021
713810,partnership,100,61,9/13/2021
726EEA,executive-appointment,100,54,9/13/2021
728737,dividend,100,50,9/13/2021
728737,dividend,100,50,9/13/2021
73A213,earnings,100,50,9/13/2021
747219,executive-appointment,100,54,9/13/2021
76E80F,note-sale,100,52,9/13/2021
76F067,conference-participant,100,50,9/13/2021
7B6C88,partnership,100,61,9/13/2021
7C4F43,clinical-trials,100,56,9/13/2021
7E1D5D,executive-appointment,100,54,9/13/2021
7E3F8F,partnership,100,61,9/13/2021
817ED9,note-sale,100,52,9/13/2021
8195B7,clinical-trials,100,56,9/13/2021
834152,legal-issues-defendant,100,22,9/13/2021
8377DB,dividend-up,100,81,9/13/2021
83A065,dividend,100,50,9/13/2021
83B1C8,note-acquisition,100,66,9/13/2021
84A6B9,executive-appointment,100,54,9/13/2021
860AB6,public-offering,100,43,9/13/2021
88936A,earnings,100,50,9/13/2021
8AA108,clinical-trials-start,100,64,9/13/2021
8AC65D,acquisition-interest-acquirer,100,46,9/13/2021
8D4486,partnership,100,61,9/13/2021
8D4486,executive-appointment,100,54,9/13/2021
8E4F9A,regulatory-product-approval-granted,100,81,9/13/2021
903AB4,executive-appointment,100,54,9/13/2021
9196A2,conference-organizer,100,57,9/13/2021
9196A2,conference-organizer,100,57,9/13/2021
9196A2,conference-organizer,100,57,9/13/2021
968966,award,100,58,9/13/2021
977A1E,partnership,100,61,9/13/2021
990AD0,dividend,100,50,9/13/2021
990AD0,conference-organizer,100,57,9/13/2021
990AD0,conference-organizer,100,57,9/13/2021
9B730A,partnership,100,61,9/13/2021
9C5BA5,revenues,100,50,9/13/2021
9DDE1B,dividend-up,100,81,9/13/2021
9F6B1A,business-contract,100,69,9/13/2021
9F6B1A,unit-acquisition-completed-acquirer,100,49,9/13/2021
9F6B1A,unit-acquisition-completed-acquirer,100,49,9/13/2021
A03EE1,legal-issues-defendant,100,22,9/13/2021
A15C71,note-sale,100,52,9/13/2021
A26EF7,conference-participant,100,50,9/13/2021
A37D68,product-release,100,64,9/13/2021
A3AAA5,dividend,100,50,9/13/2021
A631A3,executive-appointment,100,54,9/13/2021
A72AB6,business-contract,100,69,9/13/2021
A72FD9,operating-earnings,100,50,9/13/2021
AA1EAA,dividend,100,50,9/13/2021
AA5C8E,partnership,100,61,9/13/2021
AC7C4F,business-contract,100,69,9/13/2021
AEEB76,conference-participant,100,50,9/13/2021
B01111,hirings,100,65,9/13/2021
B1B10C,revenue-guidance-up,100,83,9/13/2021
B37FB4,conference-call,100,50,9/13/2021
C425AE,earnings,100,50,9/13/2021
C6C702,conference-participant,100,50,9/13/2021
CC8F6E,unit-acquisition-completed-acquiree,100,67,9/13/2021
CC8F6E,unit-acquisition-completed-acquiree,100,67,9/13/2021
CDFCC9,conference-participant,100,50,9/13/2021
CDFCC9,conference-participant,100,50,9/13/2021
CE1002,acquisition-acquirer,100,49,9/13/2021
D1AE3B,unit-acquisition-acquirer,100,49,9/13/2021
D6144F,public-offering,100,43,9/13/2021
D6489C,earnings,100,50,9/13/2021
D75910,executive-appointment,100,54,9/13/2021
D82EF3,partnership,100,61,9/13/2021
DA48E4,executive-resignation,100,44,9/13/2021
E114F4,executive-appointment,100,54,9/13/2021
E1C16B,partnership,100,61,9/13/2021
E5F0A8,merger-regulatory-scrutiny,100,37,9/13/2021
E6C8DC,legal-issues-defendant,100,22,9/13/2021
E802CE,dividend,100,50,9/13/2021
E845D9,public-offering,100,43,9/13/2021
E8D221,earnings,100,50,9/13/2021
EB36DE,ipo,100,71,9/13/2021
ED2A5E,legal-issues-defendant,100,22,9/13/2021
F11638,acquisition-acquirer,100,49,9/13/2021
F11638,acquisition-acquirer,100,49,9/13/2021
F2BC3D,acquisition-acquirer,100,49,9/13/2021
F2BC3D,public-offering,100,43,9/13/2021
F30508,conference-participant,100,50,9/13/2021
F48947,legal-issues-defendant,100,22,9/13/2021
F5D499,unit-acquisition-acquirer,100,49,9/13/2021
F748C7,product-release,100,64,9/13/2021
F7ADEB,business-contract,100,69,9/13/2021
F88147,legal-issues-defendant,100,22,9/13/2021
F93C8A,public-offering,100,43,9/13/2021
FC1736,revenue-up,100,69,9/13/2021
FC1736,earnings,100,50,9/13/2021
00326D,executive-appointment,100,54,9/14/2021
0157B1,hirings,100,65,9/14/2021
0157B1,hirings,100,65,9/14/2021
48590,executive-appointment,100,54,9/14/2021
07CA6A,product-release,100,64,9/14/2021
099C88,partnership,100,61,9/14/2021
0AAD90,clinical-trials,100,56,9/14/2021
0C28D1,buybacks,100,74,9/14/2021
0CBC4D,legal-issues-defendant,100,22,9/14/2021
0E64D4,executive-appointment,100,54,9/14/2021
0F2BC9,business-contract,100,69,9/14/2021
106394,public-offering,100,43,9/14/2021
108A2B,dividend,100,50,9/14/2021
1272B3,business-contract,100,69,9/14/2021
12DE76,partnership,100,61,9/14/2021
147C38,executive-appointment,100,54,9/14/2021
14BA33,conference-participant,100,50,9/14/2021
16FC89,dividend,100,50,9/14/2021
1A3E1B,conference-call,100,50,9/14/2021
1E4FB9,legal-issues-defendant,100,22,9/14/2021
1EBF8D,partnership,100,61,9/14/2021
1F9258,conference-participant,100,50,9/14/2021
1FE7F0,merger-regulatory-approval,100,81,9/14/2021
2158DF,partnership,100,61,9/14/2021
228D42,dividend-up,100,81,9/14/2021
23207A,conference-call,100,50,9/14/2021
25DD05,dividend,100,50,9/14/2021
28F905,executive-appointment,100,54,9/14/2021
2B7A40,partnership,100,61,9/14/2021
2C3348,joint-venture,100,62,9/14/2021
2DA92D,executive-appointment,100,54,9/14/2021
2FF046,conference-participant,100,50,9/14/2021
30DE64,acquisition-regulatory-approval-acquirer,100,54,9/14/2021
3461CF,partnership,100,61,9/14/2021
3.73E+87,partnership,100,61,9/14/2021
37B618,dividend,100,50,9/14/2021
3BA1BF,conference-participant,100,50,9/14/2021
416C55,partnership,100,61,9/14/2021
420168,dividend,100,50,9/14/2021
45ABCC,conference-participant,100,50,9/14/2021
4A6F00,partnership,100,61,9/14/2021
4B3676,conference-participant,100,50,9/14/2021
4F783B,conference-participant,100,50,9/14/2021
50070E,conference-organizer,100,57,9/14/2021
50070E,conference-organizer,100,57,9/14/2021
50070E,conference-organizer,100,57,9/14/2021
50070E,conference-organizer,100,57,9/14/2021
50070E,conference-organizer,100,57,9/14/2021
50070E,conference-organizer,100,57,9/14/2021
50070E,conference-organizer,100,57,9/14/2021
504FE2,business-contract,100,69,9/14/2021
53EF9E,conference-participant,100,50,9/14/2021
54512F,legal-issues-defendant,100,22,9/14/2021
553949,executive-appointment,100,54,9/14/2021
564F3E,award,100,58,9/14/2021
58CA9A,earnings,100,50,9/14/2021
5B35C7,dividend,100,50,9/14/2021
6166D1,dividend,100,50,9/14/2021
6844D2,partnership,100,61,9/14/2021
69C99E,regulatory-product-approval-granted,100,81,9/14/2021
6A024C,executive-appointment,100,54,9/14/2021
6CC55E,partnership,100,61,9/14/2021
701531,executive-appointment,100,54,9/14/2021
7255D2,facility-upgrade,100,65,9/14/2021
7255D2,facility-upgrade,100,65,9/14/2021
747219,conference-participant,100,50,9/14/2021
766047,business-contract,100,69,9/14/2021
7999F3,dividend,100,50,9/14/2021
7999F3,merger-regulatory-approval,100,81,9/14/2021
7B9212,dividend,100,50,9/14/2021
7CBC40,product-release,100,64,9/14/2021
873DB9,executive-appointment,100,54,9/14/2021
8AC740,dividend,100,50,9/14/2021
8CF6DD,partnership,100,61,9/14/2021
8D4486,partnership,100,61,9/14/2021
8E93A4,executive-appointment,100,54,9/14/2021
91C82E,executive-resignation,100,44,9/14/2021
91C82E,partnership,100,61,9/14/2021
91C82E,executive-resignation,100,44,9/14/2021
92D9C9,public-offering,100,43,9/14/2021
92D9C9,public-offering,100,43,9/14/2021
9.36E+10,executive-resignation,100,44,9/14/2021
947B0B,legal-issues-defendant,100,22,9/14/2021
9548BB,note-sale,100,52,9/14/2021
96A6CD,ownership-decrease-held,100,49,9/14/2021
990AD0,conference-organizer,100,57,9/14/2021
990AD0,conference-organizer,100,57,9/14/2021
990AD0,conference-organizer,100,57,9/14/2021
990AD0,conference-organizer,100,57,9/14/2021
990AD0,conference-organizer,100,57,9/14/2021
9C8664,legal-issues-defendant,100,22,9/14/2021
9C8BC3,acquisition-acquirer,100,49,9/14/2021
9D56F2,partnership,100,61,9/14/2021
9E98F2,legal-issues-defendant,100,22,9/14/2021
9F5997,conference-participant,100,50,9/14/2021
9F71E5,partnership,100,61,9/14/2021
9F71E5,partnership,100,61,9/14/2021
9FF5F1,partnership,100,61,9/14/2021
A01200,executive-appointment,100,54,9/14/2021
A02FB1,legal-issues-defendant,100,22,9/14/2021
A03EE1,legal-issues-defendant,100,22,9/14/2021
A16DEA,executive-appointment,100,54,9/14/2021
A2CAF7,executive-appointment,100,54,9/14/2021
A4386C,conference-participant,100,50,9/14/2021
A6D095,conference-participant,100,50,9/14/2021
A806FA,conference-participant,100,50,9/14/2021
AA09AD,award,100,58,9/14/2021
AB4A7E,conference-participant,100,50,9/14/2021
ACF77B,dividend,100,50,9/14/2021
B3ED62,conference-call,100,50,9/14/2021
B5734D,earnings,100,50,9/14/2021
B72D2E,business-contract,100,69,9/14/2021
BB127B,partnership,100,61,9/14/2021
BB5271,product-release,100,64,9/14/2021
BFF98A,partnership,100,61,9/14/2021
C3DE7D,executive-appointment,100,54,9/14/2021
C48574,revenue-up,100,69,9/14/2021
C48574,revenue-up,100,69,9/14/2021
C48574,revenue-up,100,69,9/14/2021
C48574,revenue-up,100,69,9/14/2021
C501B6,patent-awarded,100,72,9/14/2021
C7AE14,dividend,100,50,9/14/2021
C8FAC7,partnership,100,61,9/14/2021
C9881C,conference-call,100,50,9/14/2021
CD051C,conference-participant,100,50,9/14/2021
D08D2C,conference-participant,100,50,9/14/2021
D139BC,public-offering,100,43,9/14/2021
D47D56,conference-participant,100,50,9/14/2021
D48275,conference-call,100,50,9/14/2021
D8442A,product-release,100,64,9/14/2021
D8442A,product-release,100,64,9/14/2021
D8442A,product-release,100,64,9/14/2021
D8442A,product-release,100,64,9/14/2021
D8442A,product-release,100,64,9/14/2021
D8442A,product-release,100,64,9/14/2021
D8442A,product-release,100,64,9/14/2021
D8442A,product-release,100,64,9/14/2021
D8442A,product-release,100,64,9/14/2021
D854F3,legal-issues-defendant,100,22,9/14/2021
D90F43,partnership,100,61,9/14/2021
DB88A1,award,100,58,9/14/2021
DBB28E,executive-appointment,100,54,9/14/2021
DC6EF3,product-release,100,64,9/14/2021
DD1BA1,executive-appointment,100,54,9/14/2021
E124EB,dividend,100,50,9/14/2021
E2CFD2,conference-participant,100,50,9/14/2021
E5F0A8,legal-issues-defendant,100,22,9/14/2021
E68C3D,executive-appointment,100,54,9/14/2021
E68E62,clinical-trials,100,56,9/14/2021
E6C8DC,legal-issues-defendant,100,22,9/14/2021
E8846E,conference-organizer,100,57,9/14/2021
EB7FBF,conference-call,100,50,9/14/2021
EBD89A,business-contract,100,69,9/14/2021
ECE814,conference-organizer,100,57,9/14/2021
ED2A5E,legal-issues-defendant,100,22,9/14/2021
ED3CA8,conference-participant,100,50,9/14/2021
F209B4,executive-appointment,100,54,9/14/2021
F39E1E,partnership,100,61,9/14/2021
F3EDB4,business-contract,100,69,9/14/2021
F5D410,conference-call,100,50,9/14/2021
F7902B,product-release,100,64,9/14/2021
F7ADEB,acquisition-completed-acquirer,100,49,9/14/2021
F88147,legal-issues-defendant,100,22,9/14/2021
F88147,legal-issues-defendant,100,22,9/14/2021
F88147,legal-issues-defendant,100,22,9/14/2021
FADF1A,partnership,100,61,9/14/2021
FD9526,legal-issues-defendant,100,22,9/14/2021
FEBFE1,executive-appointment,100,54,9/14/2021
FF6644,conference-participant,100,50,9/14/2021
00698D,merger,100,66,9/15/2021
20751,product-release,100,64,9/15/2021
033B58,partnership,100,61,9/15/2021
03542C,executive-appointment,100,54,9/15/2021
68396,dividend,100,50,9/15/2021
95294,partnership,100,61,9/15/2021
0A1D77,public-offering,100,43,9/15/2021
0BA8CE,executive-appointment,100,54,9/15/2021
0BD4E8,dividend,100,50,9/15/2021
0CBC4D,legal-issues-defendant,100,22,9/15/2021
0CCCB7,conference-participant,100,50,9/15/2021
0E3436,partnership,100,61,9/15/2021
106394,business-contract,100,69,9/15/2021
108A2B,conference-participant,100,50,9/15/2021
14833D,acquisition-acquiree,100,76,9/15/2021
14833D,acquisition-acquiree,100,76,9/15/2021
14833D,acquisition-regulatory-scrutiny-acquiree,100,38,9/15/2021
16FC89,earnings,100,50,9/15/2021
1748F6,earnings,100,50,9/15/2021
1BC12C,partnership,100,61,9/15/2021
1E4FB9,legal-issues-defendant,100,22,9/15/2021
1EBF8D,partnership,100,61,9/15/2021
1F08A6,conference-participant,100,50,9/15/2021
200D8B,conference-participant,100,50,9/15/2021
2031CE,conference-participant,100,50,9/15/2021
2082EA,product-release,100,64,9/15/2021
238302,dividend,100,50,9/15/2021
25102A,conference-call,100,50,9/15/2021
26F99F,executive-appointment,100,54,9/15/2021
2.89E+11,note-sale,100,52,9/15/2021
292388,conference-participant,100,50,9/15/2021
2BD89C,executive-appointment,100,54,9/15/2021
2E61CC,partnership,100,61,9/15/2021
2FEA66,note-sale,100,52,9/15/2021
30CBF9,partnership,100,61,9/15/2021
31666F,executive-appointment,100,54,9/15/2021
31803E,fast-track-designation,100,81,9/15/2021
31AA84,dividend,100,50,9/15/2021
3461CF,acquisition-completed-acquirer,100,49,9/15/2021
36529A,executive-appointment,100,54,9/15/2021
367434,conference-participant,100,50,9/15/2021
37727A,conference-participant,100,50,9/15/2021
3BE00F,dividend,100,50,9/15/2021
3CCC90,conference-call,100,50,9/15/2021
3DE4D1,partnership,100,61,9/15/2021
3DE4D1,executive-appointment,100,54,9/15/2021
3FACA7,earnings,100,50,9/15/2021
41785E,partnership,100,61,9/15/2021
420168,note-sale,100,52,9/15/2021
4.60E+06,executive-resignation,100,44,9/15/2021
499C75,executive-appointment,100,54,9/15/2021
4A6F00,partnership,100,61,9/15/2021
4A6F00,acquisition-acquirer,100,49,9/15/2021
4AE584,facility-open,100,65,9/15/2021
4BAF2E,conference-participant,100,50,9/15/2021
4E4E75,dividend,100,50,9/15/2021
4E6F5A,legal-issues-defendant,100,22,9/15/2021
50070E,acquisition-acquirer,100,49,9/15/2021
50070E,acquisition-acquirer,100,49,9/15/2021
50070E,conference-organizer,100,57,9/15/2021
50070E,conference-organizer,100,57,9/15/2021
520632,dividend,100,50,9/15/2021
52FB2F,note-sale,100,52,9/15/2021
53E575,conference-participant,100,50,9/15/2021
53EF9E,conference-participant,100,50,9/15/2021
53F491,dividend,100,50,9/15/2021
54512F,legal-issues-defendant,100,22,9/15/2021
54DF47,dividend,100,50,9/15/2021
55C9B5,investment-investor,100,55,9/15/2021
55C9B5,investment-investor,100,55,9/15/2021
5704AC,executive-appointment,100,54,9/15/2021
577033,note-sale,100,52,9/15/2021
57DDB9,conference-participant,100,50,9/15/2021
586BD7,conference-participant,100,50,9/15/2021
59872F,executive-appointment,100,54,9/15/2021
5CCDAD,conference-participant,100,50,9/15/2021
615B6D,executive-appointment,100,54,9/15/2021
6166D1,conference-call,100,50,9/15/2021
619882,dividend,100,50,9/15/2021
627186,earnings,100,50,9/15/2021
636639,acquisition-acquirer,100,49,9/15/2021
63F892,partnership,100,61,9/15/2021
657097,dividend,100,50,9/15/2021
66A667,earnings,100,50,9/15/2021
66A667,earnings,100,50,9/15/2021
66E04A,partnership,100,61,9/15/2021
66E04A,partnership,100,61,9/15/2021
66E04A,partnership,100,61,9/15/2021
66E04A,partnership,100,61,9/15/2021
6ABCB8,dividend,100,50,9/15/2021
6CF43C,dividend,100,50,9/15/2021
6D6B40,executive-appointment,100,54,9/15/2021
6D9ECA,fast-track-designation,100,81,9/15/2021
701531,business-contract,100,69,9/15/2021
70B3D6,public-offering,100,43,9/15/2021
713810,product-release,100,64,9/15/2021
775439,dividend-up,100,56,9/15/2021
791EC1,unit-acquisition-acquirer,100,49,9/15/2021
7A3633,partnership,100,61,9/15/2021
7AB859,executive-appointment,100,54,9/15/2021
7DD8CC,dividend,100,50,9/15/2021
810FAD,award,100,58,9/15/2021
810FAD,award,100,58,9/15/2021
8295B8,conference-participant,100,50,9/15/2021
84AB66,dividend,100,50,9/15/2021
877734,conference-participant,100,50,9/15/2021
89B2E7,dividend,100,50,9/15/2021
8A8E41,partnership,100,61,9/15/2021
8BAA15,earnings-guidance,100,50,9/15/2021
8C6C1B,facility-open,100,65,9/15/2021
8DCF18,conference-participant,100,50,9/15/2021
8E10BF,clinical-trials,100,56,9/15/2021
8EDACA,conference-participant,100,50,9/15/2021
902255,conference-participant,100,50,9/15/2021
918D6D,conference-participant,100,50,9/15/2021
9196A2,conference-call,100,50,9/15/2021
9470CC,acquisition-acquirer,100,49,9/15/2021
947B0B,legal-issues-defendant,100,22,9/15/2021
94C0B5,conference-call,100,50,9/15/2021
95DC1F,dividend,100,50,9/15/2021
97693A,business-contract,100,69,9/15/2021
990AD0,conference-organizer,100,57,9/15/2021
990AD0,conference-organizer,100,57,9/15/2021
9978F1,sponsorship,100,57,9/15/2021
99ACAD,campaign-ad-release,100,59,9/15/2021
9C8664,legal-issues-defendant,100,22,9/15/2021
9E98F2,legal-issues-defendant,100,22,9/15/2021
9E98F2,merger,100,66,9/15/2021
A01983,dividend,100,50,9/15/2021
A02FB1,legal-issues-defendant,100,22,9/15/2021
A1E3B3,product-release,100,64,9/15/2021
A1E3B3,product-release,100,64,9/15/2021
A21649,dividend,100,50,9/15/2021
A350C1,partnership,100,61,9/15/2021
A4B899,donation,100,54,9/15/2021
A6ABE9,merger,100,66,9/15/2021
A7102F,executive-appointment,100,54,9/15/2021
A746F6,conference-call,100,50,9/15/2021
A790A5,conference-participant,100,50,9/15/2021
AC642C,public-offering,100,43,9/15/2021
AC642C,public-offering,100,43,9/15/2021
AC7AAE,executive-appointment,100,54,9/15/2021
AC7C4F,partnership,100,61,9/15/2021
AD375D,dividend,100,50,9/15/2021
AE4EEB,dividend,100,50,9/15/2021
AEF2C3,executive-appointment,100,54,9/15/2021
B04426,executive-appointment,100,54,9/15/2021
B5DE80,conference-participant,100,50,9/15/2021
C22BE8,business-contract,100,69,9/15/2021
C3BCD5,partnership,100,61,9/15/2021
C4452A,donation,100,54,9/15/2021
C490F9,drilling,100,68,9/15/2021
C490F9,drilling,100,68,9/15/2021
C4FBDC,facility-open,100,65,9/15/2021
C66B44,unit-acquisition-completed-acquirer,100,49,9/15/2021
C8923A,conference-participant,100,50,9/15/2021
C9E107,dividend,100,50,9/15/2021
CA1620,dividend-up,100,54,9/15/2021
CA1620,acquisition-completed-acquirer,100,49,9/15/2021
CAC8D0,partnership,100,61,9/15/2021
CAD7D9,conference-call,100,50,9/15/2021
CC176E,campaign-ad-release,100,59,9/15/2021
CC176E,campaign-ad-release,100,59,9/15/2021
CC176E,campaign-ad-release,100,59,9/15/2021
CC176E,campaign-ad-release,100,59,9/15/2021
CC176E,campaign-ad-release,100,59,9/15/2021
CC176E,campaign-ad-release,100,59,9/15/2021
CC6FF5,partnership,100,61,9/15/2021
CD4DA8,conference-organizer,100,57,9/15/2021
CDC217,executive-appointment,100,54,9/15/2021
CE2791,dividend,100,50,9/15/2021
CEDFD5,clinical-trials-start,100,64,9/15/2021
CEDFD5,clinical-trials-start,100,64,9/15/2021
CEDFD5,clinical-trials-start,100,64,9/15/2021
CEDFD5,clinical-trials-start,100,64,9/15/2021
CFF15D,business-contract,100,69,9/15/2021
CFF97C,credit-rating-upgrade-rater,20,50,9/15/2021
CFF97C,credit-rating-upgrade-rater,20,50,9/15/2021
D064D5,executive-appointment,100,54,9/15/2021
D11C1C,dividend,100,50,9/15/2021
D139BC,dividend,100,50,9/15/2021
D3FA2C,dividend,100,50,9/15/2021
D4AC65,partnership,100,61,9/15/2021
D6144F,public-offering,100,43,9/15/2021
D721C6,executive-appointment,100,54,9/15/2021
D854F3,legal-issues-defendant,100,22,9/15/2021
D8DA3D,note-sale,100,52,9/15/2021
DB7014,conference-participant,100,50,9/15/2021
DBCA3F,partnership,100,61,9/15/2021
DC5299,dividend,100,50,9/15/2021
DD1BA1,conference-participant,100,50,9/15/2021
DDCB34,conference-participant,100,50,9/15/2021
DF5F14,dividend,100,50,9/15/2021
E16133,dividend,100,50,9/15/2021
E19A99,settlement,100,56,9/15/2021
E259C7,public-offering,100,43,9/15/2021
E259C7,public-offering,100,43,9/15/2021
E40FB6,note-sale,100,52,9/15/2021
E592F0,partnership,100,61,9/15/2021
E5F0A8,legal-issues-defendant,100,22,9/15/2021
E8846E,facility-open,100,65,9/15/2021
E99180,dividend,100,50,9/15/2021
EC70EC,note-sale,100,52,9/15/2021
EC70EC,note-sale,100,52,9/15/2021
EC70EC,note-sale,100,52,9/15/2021
EC99D0,business-contract,100,69,9/15/2021
EC99D0,product-release,100,64,9/15/2021
ECD263,earnings,100,50,9/15/2021
ED7F13,dividend,100,50,9/15/2021
F02170,business-contract,100,69,9/15/2021
F209B4,conference-participant,100,50,9/15/2021
F294DD,dividend,100,50,9/15/2021
F2BC3D,public-offering,100,43,9/15/2021
F30508,business-contract,100,69,9/15/2021
F30508,business-contract,100,69,9/15/2021
F7935D,conference-participant,100,50,9/15/2021
F80389,dividend,100,50,9/15/2021
F82D37,merger-failed,100,21,9/15/2021
F82D37,business-contract,100,69,9/15/2021
F82D37,business-contract,100,69,9/15/2021
F82D37,business-contract,100,69,9/15/2021
FD9526,legal-issues-defendant,100,22,9/15/2021
FDF799,executive-appointment,100,54,9/15/2021
03CF95,legal-issues-defendant,100,22,9/16/2021
048B70,conference-participant,100,50,9/16/2021
070B45,conference-participant,100,50,9/16/2021
0ED415,partnership,100,61,9/16/2021
0ED415,partnership,100,61,9/16/2021
0F91FC,product-release,100,64,9/16/2021
10AE08,executive-appointment,100,54,9/16/2021
14BA33,dividend,100,50,9/16/2021
1F43A1,dividend-up,100,81,9/16/2021
200D8B,partnership,100,61,9/16/2021
228D42,partnership,100,61,9/16/2021
228D42,partnership,100,61,9/16/2021
251988,partnership,100,61,9/16/2021
267718,regulatory-product-approval-granted,100,81,9/16/2021
282C18,dividend,100,50,9/16/2021
2.90E+62,business-contract,100,69,9/16/2021
2E902B,dividend,100,50,9/16/2021
2F6782,conference-participant,100,50,9/16/2021
31553A,acquisition-completed-acquirer,100,49,9/16/2021
317EC6,earnings,100,50,9/16/2021
33A0F1,partnership,100,61,9/16/2021
34B97A,executive-appointment,100,54,9/16/2021
37727A,dividend,100,50,9/16/2021
384CD3,buybacks,100,74,9/16/2021
3BE00F,conference-participant,100,50,9/16/2021
3CCC90,executive-appointment,100,54,9/16/2021
3DDE54,earnings,100,50,9/16/2021
4.00E+163,partnership,100,61,9/16/2021
449447,conference-participant,100,50,9/16/2021
44A4FC,business-contract,100,69,9/16/2021
45ABCC,revenue-volume-down,100,44,9/16/2021
4676DF,joint-venture,100,62,9/16/2021
47752F,dividend,100,50,9/16/2021
47FCF2,business-contract,100,69,9/16/2021
485445,executive-appointment,100,54,9/16/2021
485445,executive-appointment,100,54,9/16/2021
4.91E+58,fundraising,100,64,9/16/2021
4A5C8D,product-release,100,64,9/16/2021
4E2D94,earnings-guidance,100,50,9/16/2021
50070E,conference-organizer,100,57,9/16/2021
50070E,conference-organizer,100,57,9/16/2021
50070E,conference-organizer,100,57,9/16/2021
5.43E+08,clinical-trials,100,56,9/16/2021
5.43E+08,clinical-trials,100,56,9/16/2021
5.43E+08,clinical-trials,100,56,9/16/2021
5.43E+08,clinical-trials,100,56,9/16/2021
5.43E+08,clinical-trials,100,56,9/16/2021
5.43E+08,clinical-trials,100,56,9/16/2021
55438C,executive-appointment,100,54,9/16/2021
57DDB9,executive-appointment,100,54,9/16/2021
5CC29D,conference-call,100,50,9/16/2021
5D1329,regulatory-product-approval-granted,100,81,9/16/2021
6166D1,dividend,100,50,9/16/2021
619882,business-contract,100,69,9/16/2021
619882,conference-organizer,100,57,9/16/2021
63E8D5,dividend,100,50,9/16/2021
641F17,executive-appointment,100,54,9/16/2021
6559D8,conference-participant,100,50,9/16/2021
66E3C0,conference-participant,100,50,9/16/2021
69C99E,clinical-trials-start,100,64,9/16/2021
6A6BDC,product-release,100,64,9/16/2021
6D7F1D,executive-appointment,100,54,9/16/2021
6DBBBC,executive-appointment,100,54,9/16/2021
6F6559,conference-call,100,50,9/16/2021
6FCEF9,executive-appointment,100,54,9/16/2021
701531,business-contract,100,69,9/16/2021
704B78,sponsorship,100,57,9/16/2021
719B43,loan-provider,100,57,9/16/2021
719B43,loan-provider,100,57,9/16/2021
722DE3,business-contract,100,69,9/16/2021
76D79A,conference-call,100,50,9/16/2021
76F067,partnership,100,61,9/16/2021
76F067,partnership,100,61,9/16/2021
7A51FE,conference-call,100,50,9/16/2021
7ACBA4,dividend,100,50,9/16/2021
7AF907,conference-participant,100,50,9/16/2021
7E62B5,dividend,100,50,9/16/2021
7FEEE1,private-placement,100,56,9/16/2021
810FAD,conference-participant,100,50,9/16/2021
810FAD,conference-participant,100,50,9/16/2021
837C04,partnership,100,61,9/16/2021
837C04,acquisition-regulatory-scrutiny-acquiree,100,38,9/16/2021
8A8E41,partnership,100,61,9/16/2021
8AB85C,credit-extension-recipient,100,69,9/16/2021
8C6C1B,facility-open,100,65,9/16/2021
8E4250,earnings,100,50,9/16/2021
97644E,conference-participant,100,50,9/16/2021
986AF6,earnings-guidance-up,100,83,9/16/2021
990AD0,conference-organizer,100,57,9/16/2021
9AF3DC,partnership,100,61,9/16/2021
9D3360,conference-call,100,50,9/16/2021
9EA947,acquisition-acquirer,100,49,9/16/2021
A2C979,clinical-trials,100,56,9/16/2021
A5628C,partnership,100,61,9/16/2021
A6828A,conference-call,100,50,9/16/2021
A6FC89,product-release,100,64,9/16/2021
A80FE0,conference-participant,100,50,9/16/2021
A9ED24,dividend,100,50,9/16/2021
AA7FE0,conference-call,100,50,9/16/2021
AD9F1D,partnership,100,61,9/16/2021
B0FE08,partnership,100,61,9/16/2021
B1A85D,executive-appointment,100,54,9/16/2021
B6082A,conference-call,100,50,9/16/2021
B642E8,executive-resignation,100,44,9/16/2021
BB88B6,partnership,100,61,9/16/2021
BBAE2A,partnership,100,61,9/16/2021
BD682F,dividend,100,50,9/16/2021
C05839,dividend,100,50,9/16/2021
C1114B,product-release,100,64,9/16/2021
C4FBDC,dividend,100,50,9/16/2021
CEDFD5,clinical-trials-positive,100,87,9/16/2021
CEDFD5,clinical-trials-positive,100,87,9/16/2021
D06996,executive-appointment,100,54,9/16/2021
D08D2C,dividend-up,100,81,9/16/2021
D3FA2C,credit-extension-recipient,100,69,9/16/2021
D6489C,business-contract,100,69,9/16/2021
D6489C,partnership,100,61,9/16/2021
D75910,business-contract,100,69,9/16/2021
D8442A,product-release,100,64,9/16/2021
D854DD,conference-participant,100,50,9/16/2021
D88EF3,conference-participant,100,50,9/16/2021
D96202,conference-call,100,50,9/16/2021
DA0A9E,conference-call,100,50,9/16/2021
DA199F,earnings,100,50,9/16/2021
DD1BA1,facility-upgrade,100,65,9/16/2021
DE4924,conference-participant,100,50,9/16/2021
E598FB,business-contract,100,69,9/16/2021
E68733,partnership,100,61,9/16/2021
E8B315,dividend,100,50,9/16/2021
EB36DE,ipo-pricing,100,50,9/16/2021
ECDEB2,dividend,100,50,9/16/2021
EF7163,dividend,100,50,9/16/2021
EFD406,executive-appointment,100,54,9/16/2021
F11638,partnership,100,61,9/16/2021
F58C23,conference-call,100,50,9/16/2021
F5D059,earnings,100,50,9/16/2021
F7935D,clinical-trials,100,56,9/16/2021
FACF19,earnings,100,50,9/16/2021
FACF19,business-contract,100,69,9/16/2021
FADF1A,product-release,100,64,9/16/2021
FDE409,conference-participant,100,50,9/16/2021
FEC475,executive-appointment,100,54,9/16/2021
01D03F,regulatory-product-review-positive,100,73,9/17/2021
108FDA,buybacks,100,74,9/17/2021
112694,conference-participant,100,50,9/17/2021
125212,legal-issues-defendant,100,22,9/17/2021
159AE4,conference-participant,100,50,9/17/2021
17EDA5,dividend,100,50,9/17/2021
1880C5,conference-participant,100,50,9/17/2021
1B16C1,conference-participant,100,50,9/17/2021
1D3A00,executive-appointment,100,54,9/17/2021
1D3A00,conference-participant,100,50,9/17/2021
1EBF8D,regulatory-product-review-positive,100,73,9/17/2021
21153F,buybacks,100,74,9/17/2021
21153F,buybacks,100,74,9/17/2021
21153F,buybacks,100,74,9/17/2021
21153F,buybacks,100,74,9/17/2021
2571FA,conference-participant,100,50,9/17/2021
272704,earnings,100,50,9/17/2021
2.90E+62,business-contract,100,69,9/17/2021
2B8179,clinical-trials-suspended,100,24,9/17/2021
30A565,facility-open,100,65,9/17/2021
30A565,facility-open,100,65,9/17/2021
30DE64,conference-participant,100,50,9/17/2021
339F20,dividend-up,100,56,9/17/2021
371B0A,conference-participant,100,50,9/17/2021
3ED92D,analyst-ratings-change-positive-rater,20,50,9/17/2021
3ED92D,analyst-ratings-change-positive-rater,20,50,9/17/2021
40B903,dividend,100,50,9/17/2021
4A3438,facility-sale,100,52,9/17/2021
4A3438,facility-sale,100,52,9/17/2021
4A3438,facility-sale,100,52,9/17/2021
4A3438,facility-sale,100,52,9/17/2021
4D8313,dividend,100,50,9/17/2021
4E6F5A,legal-issues-defendant,100,22,9/17/2021
4F0A80,acquisition-completed-acquiree,100,76,9/17/2021
50070E,conference-organizer,100,57,9/17/2021
50070E,conference-organizer,100,57,9/17/2021
50070E,conference-organizer,100,57,9/17/2021
55C9B5,partnership,100,61,9/17/2021
56B7C1,conference-participant,100,50,9/17/2021
57CAAB,business-contract,100,69,9/17/2021
5C7601,business-contract,100,69,9/17/2021
5E6959,dividend,100,50,9/17/2021
66A667,executive-resignation,100,44,9/17/2021
66A667,executive-resignation,100,44,9/17/2021
6F3936,conference-participant,100,50,9/17/2021
6FCEF9,dividend,100,50,9/17/2021
722D55,dividend,100,50,9/17/2021
75F665,acquisition-completed-acquirer,100,49,9/17/2021
7ADE57,executive-appointment,100,54,9/17/2021
826FD6,dividend,100,50,9/17/2021
837C04,merger-regulatory-scrutiny,100,37,9/17/2021
8B1F37,dividend,100,50,9/17/2021
8C6C1B,facility-open,100,65,9/17/2021
8FF2EF,earnings,100,50,9/17/2021
903AB4,dividend,100,50,9/17/2021
913437,acquisition-completed-acquirer,100,49,9/17/2021
94637C,regulatory-product-review-positive,100,73,9/17/2021
980C14,dividend,100,50,9/17/2021
986AF6,dividend,100,50,9/17/2021
990AD0,conference-organizer,100,57,9/17/2021
990AD0,conference-organizer,100,57,9/17/2021
997348,dividend,100,50,9/17/2021
9ABD30,clinical-trials-positive,100,87,9/17/2021
9ABD30,clinical-trials-positive,100,87,9/17/2021
A03EE1,legal-issues-defendant,100,22,9/17/2021
A6828A,clinical-trials,100,56,9/17/2021
A8E2FE,conference-participant,100,50,9/17/2021
BB127B,partnership,100,61,9/17/2021
C037A8,earnings-guidance,100,50,9/17/2021
C062D4,business-contract,100,69,9/17/2021
C2DD02,dividend,100,50,9/17/2021
C4706C,executive-appointment,100,54,9/17/2021
C83B88,conference-call,100,50,9/17/2021
C99CC8,business-contract,100,69,9/17/2021
CBDB4D,clinical-trials,100,56,9/17/2021
CD4DA8,conference-organizer,100,57,9/17/2021
D598E7,conference-call,100,50,9/17/2021
DA0CB8,conference-participant,100,50,9/17/2021
DA199F,board-meeting,100,51,9/17/2021
E30B34,conference-participant,100,50,9/17/2021
E30B34,conference-participant,100,50,9/17/2021
E6C8DC,legal-issues-defendant,100,22,9/17/2021
E845D9,public-offering,100,43,9/17/2021
E8846E,conference-organizer,100,57,9/17/2021
EA4E68,dividend,100,50,9/17/2021
EA79C7,conference-participant,100,50,9/17/2021
ED2A5E,acquisition-acquiree,100,76,9/17/2021
EE967B,conference-participant,100,50,9/17/2021
F4CDA3,dividend,100,50,9/17/2021
F57F6F,executive-appointment,100,54,9/17/2021
F80389,conference-call,100,50,9/17/2021
FDD3FC,clinical-trials,100,56,9/17/2021
FDD3FC,regulatory-product-review-positive,100,73,9/17/2021
0CBC4D,legal-issues-defendant,100,22,9/18/2021
1E4FB9,legal-issues-defendant,100,22,9/18/2021
4E6F5A,legal-issues-defendant,100,22,9/18/2021
85CDC9,clinical-trials,100,56,9/18/2021
85CDC9,clinical-trials,100,56,9/18/2021
85CDC9,clinical-trials,100,56,9/18/2021
9E98F2,legal-issues-defendant,100,22,9/18/2021
D8442A,patent-infringement-defendant,100,26,9/18/2021
D854F3,legal-issues-defendant,100,22,9/18/2021
E5F0A8,legal-issues-defendant,100,22,9/18/2021
FD9526,legal-issues-defendant,100,22,9/18/2021
4E6F5A,legal-issues-defendant,100,22,9/19/2021
9978F1,clinical-trials-positive,100,87,9/19/2021
0157B1,facility-open,100,65,9/20/2021
48590,legal-issues-defendant,100,22,9/20/2021
0A1D77,public-offering,100,43,9/20/2021
0AAD90,clinical-trials,100,56,9/20/2021
0C136E,product-release,100,64,9/20/2021
0CC01F,dividend,100,50,9/20/2021
0CE7F6,acquisition-completed-acquirer,100,49,9/20/2021
1216D1,unit-acquisition-completed-acquirer,100,49,9/20/2021
125212,legal-issues-defendant,100,22,9/20/2021
157D9F,conference-participant,100,50,9/20/2021
15901B,executive-appointment,100,54,9/20/2021
165B86,conference-participant,100,50,9/20/2021
16B183,dividend-up,100,81,9/20/2021
184988,conference-participant,100,50,9/20/2021
1E5786,merger-regulatory-scrutiny,100,37,9/20/2021
1EC3E8,executive-appointment,100,54,9/20/2021
1EC3E8,executive-appointment,100,54,9/20/2021
2082EA,executive-appointment,100,54,9/20/2021
225CA2,executive-appointment,100,54,9/20/2021
232053,conference-participant,100,50,9/20/2021
249B39,executive-appointment,100,54,9/20/2021
25A6CC,clinical-trials-positive,100,87,9/20/2021
26E3BA,conference-participant,100,50,9/20/2021
273BA3,conference-organizer,100,57,9/20/2021
2A6DBE,conference-participant,100,50,9/20/2021
2D485F,earnings,100,50,9/20/2021
2D981A,conference-participant,100,50,9/20/2021
2F7474,conference-call,100,50,9/20/2021
2F7A7E,conference-call,100,50,9/20/2021
341759,conference-participant,100,50,9/20/2021
34B97A,unit-acquisition-acquirer,100,49,9/20/2021
35557B,facility-sale,100,52,9/20/2021
36E479,conference-participant,100,50,9/20/2021
385DD4,business-contract,100,69,9/20/2021
39692D,conference-participant,100,50,9/20/2021
3ACF46,business-contract,100,69,9/20/2021
420168,conference-participant,100,50,9/20/2021
4.60E+06,executive-appointment,100,54,9/20/2021
4AE584,executive-appointment,100,54,9/20/2021
4BDCA7,conference-participant,100,50,9/20/2021
4D8E5E,merger,100,66,9/20/2021
4E6F5A,legal-issues-defendant,100,22,9/20/2021
4EE167,executive-appointment,100,54,9/20/2021
50070E,conference-organizer,100,57,9/20/2021
520632,regulatory-product-approval-granted,100,81,9/20/2021
53E575,executive-appointment,100,54,9/20/2021
53F491,earnings,100,50,9/20/2021
55C9B5,dividend,100,50,9/20/2021
55CD6F,debt-extension-recipient,100,73,9/20/2021
5B97B2,dividend,100,50,9/20/2021
5BC2F4,earnings,100,50,9/20/2021
5F3D91,fast-track-designation,100,81,9/20/2021
5FF95F,dividend,100,50,9/20/2021
61BCA7,earnings,100,50,9/20/2021
641F17,earnings,100,50,9/20/2021
64E615,executive-appointment,100,54,9/20/2021
64E615,executive-appointment,100,54,9/20/2021
657097,unit-acquisition-acquirer,100,49,9/20/2021
665D7D,regulatory-product-application,100,69,9/20/2021
665D7D,regulatory-product-application,100,69,9/20/2021
67B052,conference-participant,100,50,9/20/2021
68586A,award,100,58,9/20/2021
69CE71,hirings,100,65,9/20/2021
6A01DF,acquisition-completed-acquirer,100,49,9/20/2021
6D9B53,conference-participant,100,50,9/20/2021
76F067,partnership,100,61,9/20/2021
76F067,partnership,100,61,9/20/2021
76F067,legal-verdict-favored,100,78,9/20/2021
76F067,legal-verdict-favored,100,78,9/20/2021
7A10FF,business-contract,100,69,9/20/2021
7C4F43,clinical-trials,100,56,9/20/2021
7C4F43,clinical-trials,100,56,9/20/2021
7E3390,acquisition-completed-acquirer,100,49,9/20/2021
82FD6D,public-offering,100,43,9/20/2021
83598E,conference-participant,100,50,9/20/2021
8AB85C,conference-participant,100,50,9/20/2021
8BAA15,conference-participant,100,50,9/20/2021
8C6C1B,facility-open,100,65,9/20/2021
8DE74B,unit-acquisition-acquirer,100,49,9/20/2021
8E93A4,executive-appointment,100,54,9/20/2021
8EF425,conference-participant,100,50,9/20/2021
91C82E,earnings-per-share-positive,100,69,9/20/2021
91C82E,earnings-per-share-positive,100,69,9/20/2021
91C82E,earnings-per-share-positive,100,69,9/20/2021
91C82E,earnings-per-share-positive,100,69,9/20/2021
934029,conference-call,100,50,9/20/2021
9.54E+32,business-contract,100,69,9/20/2021
966DBE,partnership,100,61,9/20/2021
971F7B,conference-participant,100,50,9/20/2021
990AD0,conference-organizer,100,57,9/20/2021
9978F1,executive-appointment,100,54,9/20/2021
9B71A7,earnings,100,50,9/20/2021
9D5D35,conference-participant,100,50,9/20/2021
A1A317,award,100,58,9/20/2021
A1DBF0,conference-participant,100,50,9/20/2021
A26EF7,dividend,100,50,9/20/2021
A2A9BA,partnership,100,61,9/20/2021
A398B9,conference-participant,100,50,9/20/2021
A4386C,credit-extension-recipient,100,69,9/20/2021
A5195E,executive-appointment,100,54,9/20/2021
A666C8,note-sale,100,52,9/20/2021
A666C8,note-sale,100,52,9/20/2021
A6FE1C,unit-acquisition-acquirer,100,49,9/20/2021
A8B137,partnership,100,61,9/20/2021
AA09AD,executive-appointment,100,54,9/20/2021
AC642C,unit-acquisition-acquirer,100,49,9/20/2021
AC642C,unit-acquisition-acquirer,100,49,9/20/2021
AE4EEB,conference-participant,100,50,9/20/2021
AED6CF,note-sale,100,52,9/20/2021
AFD7DD,business-contract,100,69,9/20/2021
B290A2,conference-participant,100,50,9/20/2021
B3ED62,executive-appointment,100,54,9/20/2021
B4528F,business-contract,100,69,9/20/2021
B614F8,conference-participant,100,50,9/20/2021
B72D2E,stake-acquirer,100,48,9/20/2021
B9CD50,award,100,58,9/20/2021
BB88B6,award,100,58,9/20/2021
BD8517,investment-investor,100,55,9/20/2021
BEA527,earnings,100,50,9/20/2021
BEA527,conference-participant,100,50,9/20/2021
C06EB6,clinical-trials-positive,100,87,9/20/2021
C06EB6,clinical-trials-positive,100,87,9/20/2021
C66B44,partnership,100,61,9/20/2021
C8257F,acquisition-acquirer,100,49,9/20/2021
C8257F,acquisition-acquirer,100,49,9/20/2021
C83B88,partnership,100,61,9/20/2021
CAB222,conference-call,100,50,9/20/2021
CB7AB2,partnership,100,61,9/20/2021
D1AE3B,conference-call,100,50,9/20/2021
D36686,executive-appointment,100,54,9/20/2021
D42DBA,hirings,100,65,9/20/2021
DB06B0,business-contract,100,69,9/20/2021
DC0066,conference-participant,100,50,9/20/2021
DD7A96,conference-participant,100,50,9/20/2021
E19A99,business-contract,100,69,9/20/2021
E20392,business-contract,100,69,9/20/2021
E259C7,public-offering,100,43,9/20/2021
E598FB,credit-extension-recipient,100,69,9/20/2021
E5A3B6,conference-participant,100,50,9/20/2021
EB36DE,ipo-completed,100,76,9/20/2021
EB36DE,ipo-completed,100,76,9/20/2021
EC99D0,conference-call,100,50,9/20/2021
ED5171,conference-participant,100,50,9/20/2021
F3816D,executive-appointment,100,54,9/20/2021
F3EDB4,government-contract,100,69,9/20/2021
F6E248,product-release,100,64,9/20/2021
F6E248,product-release,100,64,9/20/2021
F6E248,product-release,100,64,9/20/2021
F6E248,product-release,100,64,9/20/2021
F88147,legal-issues-defendant,100,22,9/20/2021
FC01C0,unit-acquisition-acquiree,100,76,9/20/2021
0157B1,product-release,100,64,9/21/2021
0157B1,product-release,100,64,9/21/2021
0157B1,product-release,100,64,9/21/2021
01D03F,executive-appointment,100,54,9/21/2021
02FC1A,conference-participant,100,50,9/21/2021
48590,legal-issues-defendant,100,22,9/21/2021
0490C6,conference-participant,100,50,9/21/2021
71860,partnership,100,61,9/21/2021
0CBC4D,legal-issues-defendant,100,22,9/21/2021
0D03C8,conference-participant,100,50,9/21/2021
0E499E,clinical-trials,100,56,9/21/2021
0F91FC,product-release,100,64,9/21/2021
1096C6,business-contract,100,69,9/21/2021
1096C6,business-contract,100,69,9/21/2021
125212,legal-issues-defendant,100,22,9/21/2021
1CD09C,conference-participant,100,50,9/21/2021
1E4FB9,legal-issues-defendant,100,22,9/21/2021
1E5786,legal-issues-defendant,100,22,9/21/2021
1E7785,note-sale,100,52,9/21/2021
1FE3CB,acquisition-acquirer,100,49,9/21/2021
1FE7F0,acquisition-completed-acquiree,100,76,9/21/2021
21153F,unit-acquisition-acquiree,100,76,9/21/2021
21153F,unit-acquisition-acquiree,100,76,9/21/2021
228D42,partnership,100,61,9/21/2021
2491BC,executive-appointment,100,54,9/21/2021
24A89A,executive-appointment,100,54,9/21/2021
24A89A,executive-appointment,100,54,9/21/2021
251988,earnings,100,50,9/21/2021
26CC63,executive-appointment,100,54,9/21/2021
2C35B5,executive-appointment,100,54,9/21/2021
2F98A5,note-sale,100,52,9/21/2021
3.14E+47,dividend,100,50,9/21/2021
31803E,executive-appointment,100,54,9/21/2021
35B907,earnings,100,50,9/21/2021
35B907,earnings,100,50,9/21/2021
3B20AB,partnership,100,61,9/21/2021
3B318A,earnings,100,50,9/21/2021
3B318A,product-release,100,64,9/21/2021
3B50FE,earnings,100,50,9/21/2021
3C8A04,conference-call,100,50,9/21/2021
3CCC90,investment-investor,100,55,9/21/2021
3DCECC,partnership,100,61,9/21/2021
43A74A,earnings,100,50,9/21/2021
49F4D0,dividend,100,50,9/21/2021
4A6F00,executive-appointment,100,54,9/21/2021
4C6C63,product-release,100,64,9/21/2021
4E6F5A,legal-issues-defendant,100,22,9/21/2021
510EA6,revenue-up,100,69,9/21/2021
510EA6,revenue-up,100,69,9/21/2021
543C77,partnership,100,61,9/21/2021
543C77,partnership,100,61,9/21/2021
543C77,conference-participant,100,50,9/21/2021
545272,dividend,100,50,9/21/2021
55C9B5,partnership,100,61,9/21/2021
567F3D,conference-participant,100,50,9/21/2021
58EA22,patent-awarded,100,72,9/21/2021
59872F,partnership,100,61,9/21/2021
5A0FF1,product-release,100,64,9/21/2021
60AC34,executive-appointment,100,54,9/21/2021
6166D1,acquisition-acquirer,100,49,9/21/2021
6166D1,acquisition-acquirer,100,49,9/21/2021
619882,conference-organizer,100,57,9/21/2021
619882,dividend,100,50,9/21/2021
620381,conference-participant,100,50,9/21/2021
649CBD,partnership,100,61,9/21/2021
66ECFD,earnings,100,50,9/21/2021
67303E,regulatory-product-application,100,69,9/21/2021
67B923,partnership,100,61,9/21/2021
6844D2,earnings,100,50,9/21/2021
6844D2,earnings,100,50,9/21/2021
6844D2,earnings,100,50,9/21/2021
6C6D73,executive-appointment,100,54,9/21/2021
6DC1D7,business-contract,100,69,9/21/2021
6E7060,dividend,100,50,9/21/2021
713810,partnership,100,61,9/21/2021
719477,dividend,100,50,9/21/2021
74404C,executive-appointment,100,54,9/21/2021
791EC1,unit-acquisition-acquirer,100,49,9/21/2021
7999F3,acquisition-completed-acquirer,100,49,9/21/2021
7A3633,product-release,100,64,9/21/2021
7B1E50,dividend,100,50,9/21/2021
7B6EB1,executive-appointment,100,54,9/21/2021
7BFF81,award,100,58,9/21/2021
7E1D5D,partnership,100,61,9/21/2021
7F0372,conference-participant,100,50,9/21/2021
8377DB,earnings,100,50,9/21/2021
83B1C8,conference-participant,100,50,9/21/2021
858942,partnership,100,61,9/21/2021
8665BA,conference-participant,100,50,9/21/2021
873DB9,partnership,100,61,9/21/2021
88350F,executive-appointment,100,54,9/21/2021
8C6C1B,facility-open,100,65,9/21/2021
8DA42F,executive-appointment,100,54,9/21/2021
8E82A6,earnings,100,50,9/21/2021
938D89,executive-appointment,100,54,9/21/2021
9.54E+32,legal-issues-plaintiff,100,44,9/21/2021
986AF6,facility-open,100,65,9/21/2021
990AD0,conference-organizer,100,57,9/21/2021
990AD0,conference-organizer,100,57,9/21/2021
9A602D,conference-call,100,50,9/21/2021
9C8664,legal-issues-defendant,100,22,9/21/2021
9E98F2,legal-issues-defendant,100,22,9/21/2021
9EA947,partnership,100,61,9/21/2021
A02FB1,legal-issues-defendant,100,22,9/21/2021
A05C43,partnership,100,61,9/21/2021
A28C54,partnership,100,61,9/21/2021
A28C54,partnership,100,61,9/21/2021
A37D68,earnings,100,50,9/21/2021
A3AAA5,dividend,100,50,9/21/2021
A43906,conference-call,100,50,9/21/2021
A5195E,conference-participant,100,50,9/21/2021
A6828A,partnership,100,61,9/21/2021
A6FE1C,acquisition-acquirer,100,49,9/21/2021
A6FE1C,unit-acquisition-acquirer,100,49,9/21/2021
ABB493,business-contract,100,69,9/21/2021
AD375D,public-offering,100,43,9/21/2021
B0B969,note-sale,100,52,9/21/2021
B106FA,conference-participant,100,50,9/21/2021
B1FC3B,legal-issues-defendant,100,22,9/21/2021
B2206F,product-release,100,64,9/21/2021
B4B281,conference-participant,100,50,9/21/2021
B614F8,conference-participant,100,50,9/21/2021
B9764A,conference-participant,100,50,9/21/2021
BB0787,partnership,100,61,9/21/2021
BB127B,product-release,100,64,9/21/2021
BB127B,conference-organizer,100,57,9/21/2021
BB88B6,partnership,100,61,9/21/2021
BB88B6,partnership,100,61,9/21/2021
BB88B6,partnership,100,61,9/21/2021
BDF85E,executive-appointment,100,54,9/21/2021
C0030A,note-sale,100,52,9/21/2021
C0030A,note-sale,100,52,9/21/2021
C15DB3,earnings,100,50,9/21/2021
C501B6,conference-participant,100,50,9/21/2021
C584BE,business-contract,100,69,9/21/2021
C5C137,hirings,100,65,9/21/2021
C62AA4,business-contract,100,69,9/21/2021
C74887,conference-participant,100,50,9/21/2021
C83B88,partnership,100,61,9/21/2021
C9881C,revenue-up,100,69,9/21/2021
C9881C,revenue-up,100,69,9/21/2021
C9881C,revenue-up,100,69,9/21/2021
CDAB24,conference-participant,100,50,9/21/2021
CE4FD9,credit-rating-outlook-stable,100,50,9/21/2021
CFF97C,credit-rating-upgrade-rater,20,50,9/21/2021
CFF97C,credit-rating-upgrade-rater,20,50,9/21/2021
CFF97C,credit-rating-upgrade-rater,20,50,9/21/2021
CFF97C,credit-rating-upgrade-rater,20,50,9/21/2021
CFF97C,credit-rating-outlook-stable-rater,20,50,9/21/2021
D09938,legal-issues-defendant,100,22,9/21/2021
D2B9E5,public-offering,100,43,9/21/2021
D2B9E5,public-offering,100,43,9/21/2021
D36686,conference-participant,100,50,9/21/2021
D75910,facility-open,100,65,9/21/2021
D75910,dividend,100,50,9/21/2021
D8442A,business-contract,100,69,9/21/2021
D8442A,business-contract,100,69,9/21/2021
D8442A,business-contract,100,69,9/21/2021
D854F3,legal-issues-defendant,100,22,9/21/2021
D90F43,partnership,100,61,9/21/2021
D90F43,partnership,100,61,9/21/2021
DB9829,dividend,100,50,9/21/2021
E114F4,executive-appointment,100,54,9/21/2021
E124EB,conference-call,100,50,9/21/2021
E1E093,partnership,100,61,9/21/2021
E2CB7B,executive-appointment,100,54,9/21/2021
E2CB7B,executive-appointment,100,54,9/21/2021
E2CB7B,executive-appointment,100,54,9/21/2021
E5F0A8,legal-issues-defendant,100,22,9/21/2021
E6C8DC,legal-issues-defendant,100,22,9/21/2021
E74B55,executive-appointment,100,54,9/21/2021
ECF709,same-store-sales-up,100,54,9/21/2021
ECF709,same-store-sales-up,100,62,9/21/2021
ECF709,same-store-sales-up,100,62,9/21/2021
EF77A3,earnings,100,50,9/21/2021
F04E05,partnership,100,61,9/21/2021
F30508,business-contract,100,69,9/21/2021
F3D2EB,dividend,100,50,9/21/2021
F3EDB4,partnership,100,61,9/21/2021
F48947,legal-issues-defendant,100,22,9/21/2021
F509E2,executive-appointment,100,54,9/21/2021
F5349B,earnings,100,50,9/21/2021
FACF19,investment-investor,100,55,9/21/2021
FB7724,campaign-ad-release,100,59,9/21/2021
FD9526,legal-issues-defendant,100,22,9/21/2021
FE7A63,earnings,100,50,9/21/2021
0157B1,facility-open,100,65,9/22/2021
0157B1,facility-open,100,65,9/22/2021
0157B1,facility-open,100,65,9/22/2021
01D03F,product-release,100,64,9/22/2021
43862,executive-appointment,100,54,9/22/2021
95294,partnership,100,61,9/22/2021
09DE1F,product-release,100,64,9/22/2021
0A0CF0,dividend,100,50,9/22/2021
0CADBC,dividend,100,50,9/22/2021
0DBB81,clinical-trials,100,56,9/22/2021
0DBB81,clinical-trials,100,56,9/22/2021
0DC050,product-release,100,64,9/22/2021
0DC050,executive-death,100,31,9/22/2021
1216D1,dividend-up,100,65,9/22/2021
1220D2,executive-appointment,100,54,9/22/2021
125212,clinical-trials,100,56,9/22/2021
129DC8,revenue-volume,100,50,9/22/2021
12DE76,dividend,100,50,9/22/2021
14BA06,conference-call,100,50,9/22/2021
1.79E+10,conference-call,100,50,9/22/2021
1CD4B5,conference-participant,100,50,9/22/2021
1E5786,legal-issues-defendant,100,22,9/22/2021
1F19C8,fundraising,100,64,9/22/2021
1FCC00,credit-extension-recipient,100,69,9/22/2021
205AD5,earnings,100,50,9/22/2021
21F9CA,award,100,58,9/22/2021
222BF9,acquisition-acquirer,100,49,9/22/2021
267718,partnership,100,61,9/22/2021
267718,partnership,100,61,9/22/2021
267718,partnership,100,61,9/22/2021
267718,partnership,100,61,9/22/2021
267718,partnership,100,61,9/22/2021
267718,partnership,100,61,9/22/2021
267718,partnership,100,61,9/22/2021
2.90E+62,acquisition-completed-acquiree,100,76,9/22/2021
2A6DBE,conference-participant,100,50,9/22/2021
2BDC1C,executive-appointment,100,54,9/22/2021
2D2D43,earnings,100,50,9/22/2021
30CBF9,partnership,100,61,9/22/2021
3.14E+47,executive-appointment,100,54,9/22/2021
339F20,executive-resignation,100,44,9/22/2021
33A0F1,executive-appointment,100,54,9/22/2021
349DA4,executive-appointment,100,54,9/22/2021
3.50E+27,note-sale,100,52,9/22/2021
414FFF,partnership,100,61,9/22/2021
41C528,acquisition-completed-acquirer,100,49,9/22/2021
43A060,award,100,58,9/22/2021
4B49CF,earnings,100,50,9/22/2021
4B49CF,earnings,100,50,9/22/2021
4B49CF,earnings,100,50,9/22/2021
4B49CF,earnings,100,50,9/22/2021
4B49CF,earnings,100,50,9/22/2021
4B49CF,earnings,100,50,9/22/2021
4C37C5,partnership,100,61,9/22/2021
4C37C5,partnership,100,61,9/22/2021
4C37C5,conference-call,100,50,9/22/2021
50D1EC,executive-appointment,100,54,9/22/2021
524CE4,facility-open,100,65,9/22/2021
524CE4,facility-open,100,65,9/22/2021
52BF94,conference-call,100,50,9/22/2021
543900,dividend,100,50,9/22/2021
55438C,donation,100,54,9/22/2021
56765E,business-contract,100,69,9/22/2021
56EA2B,partnership,100,61,9/22/2021
60FE03,conference-participant,100,50,9/22/2021
622DBE,note-sale,100,52,9/22/2021
622DBE,public-offering,100,43,9/22/2021
64636E,business-contract,100,69,9/22/2021
64636E,business-contract,100,69,9/22/2021
64636E,business-contract,100,69,9/22/2021
6844D2,product-release,100,64,9/22/2021
68E3E0,partnership,100,61,9/22/2021
6A3C35,dividend,100,50,9/22/2021
6DBBBC,acquisition-acquirer,100,49,9/22/2021
6F30F9,dividend,100,50,9/22/2021
72FCA3,earnings,100,50,9/22/2021
72FCA3,earnings,100,50,9/22/2021
72FCA3,earnings,100,50,9/22/2021
72FCA3,earnings,100,50,9/22/2021
73C521,earnings,100,50,9/22/2021
76F067,conference-participant,100,50,9/22/2021
77B8E9,executive-appointment,100,54,9/22/2021
7A975D,earnings,100,50,9/22/2021
80D744,executive-appointment,100,54,9/22/2021
8.10E+205,product-release,100,64,9/22/2021
82FD6D,note-sale,100,52,9/22/2021
83E0AC,dividend,100,50,9/22/2021
868808,dividend,100,50,9/22/2021
8A8E41,business-contract,100,69,9/22/2021
8AB85C,partnership,100,61,9/22/2021
8C6C1B,facility-open,100,65,9/22/2021
8D0EEA,conference-participant,100,50,9/22/2021
911ACB,merger-completed,100,66,9/22/2021
911ACB,merger-completed,100,66,9/22/2021
92D9C9,dividend,100,50,9/22/2021
93633B,dividend,100,50,9/22/2021
93D207,executive-appointment,100,54,9/22/2021
947B0B,conference-participant,100,50,9/22/2021
967D92,conference-call,100,50,9/22/2021
9B5968,dividend,100,50,9/22/2021
9B5968,dividend,100,50,9/22/2021
9B71A7,partnership,100,61,9/22/2021
9C8BC3,executive-appointment,100,54,9/22/2021
9CA619,earnings,100,50,9/22/2021
9D307D,partnership,100,61,9/22/2021
A03EE1,legal-issues-defendant,100,22,9/22/2021
A26EF7,conference-participant,100,50,9/22/2021
A43906,dividend,100,50,9/22/2021
A47A7D,government-contract,100,69,9/22/2021
A631A3,award,100,58,9/22/2021
A6828A,business-contract,100,69,9/22/2021
A6ABE9,executive-appointment,100,54,9/22/2021
A868C9,business-contract,100,69,9/22/2021
ABE7DC,conference-participant,100,50,9/22/2021
ABEE43,acquisition-acquirer,100,49,9/22/2021
B0B969,note-sale,100,52,9/22/2021
B4703C,product-release,100,64,9/22/2021
B4C673,hirings,100,65,9/22/2021
B508E5,conference-participant,100,50,9/22/2021
BDEC1E,conference-participant,100,50,9/22/2021
C16A8F,conference-call,100,50,9/22/2021
C94CFC,product-release,100,64,9/22/2021
C94CFC,product-release,100,64,9/22/2021
CB7AB2,award,100,58,9/22/2021
CB7AB2,award,100,58,9/22/2021
CE8A7B,acquisition-interest-acquiree,100,82,9/22/2021
D1588D,conference-participant,100,50,9/22/2021
D18AFC,orphan-drug-designation,100,76,9/22/2021
D1CFC8,partnership,100,61,9/22/2021
D1CFC8,earnings,100,50,9/22/2021
D21D8A,dividend,100,50,9/22/2021
D4463B,dividend,100,50,9/22/2021
D54E62,partnership,100,61,9/22/2021
D5938F,conference-participant,100,50,9/22/2021
DA199F,partnership,100,61,9/22/2021
DAFED3,joint-venture,100,62,9/22/2021
DB2E4E,executive-appointment,100,54,9/22/2021
DB7014,partnership,100,61,9/22/2021
DD1BA1,buybacks,100,74,9/22/2021
DD1BA1,regulatory-product-approval-granted,100,81,9/22/2021
DF204B,conference-participant,100,50,9/22/2021
DFADDB,executive-appointment,100,54,9/22/2021
DFADDB,executive-appointment,100,54,9/22/2021
E13782,conference-participant,100,50,9/22/2021
E21871,partnership,100,61,9/22/2021
E21871,partnership,100,61,9/22/2021
E4CE73,partnership,100,61,9/22/2021
E68733,clinical-trials-start,100,64,9/22/2021
E68733,clinical-trials-start,100,64,9/22/2021
E68733,regulatory-investigation-completed,100,50,9/22/2021
E6EDED,conference-call,100,50,9/22/2021
ED5171,earnings,100,50,9/22/2021
ED79D9,dividend,100,50,9/22/2021
F24FF0,conference-call,100,50,9/22/2021
F85CC0,dividend,100,50,9/22/2021
F85CC0,dividend,100,50,9/22/2021
F8C5D7,reorganization-complete,100,74,9/22/2021
FE89E0,conference-call,100,50,9/22/2021
00067A,partnership,100,61,9/23/2021
00698D,dividend,100,50,9/23/2021
03596A,buybacks,100,74,9/23/2021
03FB17,acquisition-acquirer,100,49,9/23/2021
48590,legal-issues-defendant,100,22,9/23/2021
55018,conference-call,100,50,9/23/2021
56045,conference-participant,100,50,9/23/2021
099C88,business-contract,100,69,9/23/2021
0A0CF0,earnings,100,50,9/23/2021
0AB700,dividend,100,50,9/23/2021
0B2071,executive-resignation,100,44,9/23/2021
0B73A7,earnings,100,50,9/23/2021
0B73A7,earnings,100,50,9/23/2021
0F91FC,product-release,100,64,9/23/2021
108FDA,unit-acquisition-acquirer,100,49,9/23/2021
119CB6,conference-call,100,50,9/23/2021
1201B5,earnings,100,50,9/23/2021
131443,award,100,58,9/23/2021
133644,conference-participant,100,50,9/23/2021
1921DD,unit-acquisition-acquirer,100,49,9/23/2021
228D42,partnership,100,61,9/23/2021
2491BC,partnership,100,61,9/23/2021
251988,dividend,100,50,9/23/2021
267718,dividend,100,50,9/23/2021
267718,conference-call,100,50,9/23/2021
275300,conference-participant,100,50,9/23/2021
27A791,executive-appointment,100,54,9/23/2021
28DCA8,earnings-guidance,100,50,9/23/2021
2AE625,product-release,100,64,9/23/2021
2C681C,conference-participant,100,50,9/23/2021
2E2E6E,unit-acquisition-acquiree,100,76,9/23/2021
3461CF,credit-rating-upgrade-rater,20,50,9/23/2021
36C09B,conference-participant,100,50,9/23/2021
3D9999,earnings,100,50,9/23/2021
44A4FC,note-sale,100,52,9/23/2021
44A4FC,note-sale,100,52,9/23/2021
499C75,executive-appointment,100,54,9/23/2021
4FCC78,executive-appointment,100,54,9/23/2021
520632,conference-call,100,50,9/23/2021
553949,executive-appointment,100,54,9/23/2021
56AFF4,executive-appointment,100,54,9/23/2021
59DB8C,partnership,100,61,9/23/2021
5A9A82,acquisition-regulatory-approval-acquirer,100,54,9/23/2021
5C7601,earnings,100,50,9/23/2021
5CC29D,dividend,100,50,9/23/2021
616E3B,conference-call,100,50,9/23/2021
622DBE,note-sale,100,52,9/23/2021
622DBE,public-offering,100,43,9/23/2021
633043,dividend,100,50,9/23/2021
6559D8,conference-participant,100,50,9/23/2021
6B236C,public-offering,100,43,9/23/2021
6CC55E,business-contract,100,69,9/23/2021
6EA292,dividend,100,50,9/23/2021
71E2EF,unit-acquisition-acquiree,100,76,9/23/2021
7AF907,conference-participant,100,50,9/23/2021
7F3665,executive-resignation,100,44,9/23/2021
8.10E+205,partnership,100,61,9/23/2021
86478F,award,100,58,9/23/2021
8665BA,buybacks,100,74,9/23/2021
88193E,facility-open,100,65,9/23/2021
8B3B0E,dividend,100,50,9/23/2021
8C5519,earnings,100,50,9/23/2021
8C6C1B,facility-open,100,65,9/23/2021
8D4486,business-contract,100,69,9/23/2021
8E8E6E,partnership,100,61,9/23/2021
9196A2,conference-organizer,100,57,9/23/2021
947B0B,legal-issues-defendant,100,22,9/23/2021
9.54E+32,dividend-up,100,57,9/23/2021
96F126,dividend-up,100,81,9/23/2021
9.82E+06,unit-acquisition-acquirer,100,49,9/23/2021
9994DA,legal-issues-defendant,100,22,9/23/2021
9994DA,legal-issues-defendant,100,22,9/23/2021
9994DA,legal-issues-defendant,100,22,9/23/2021
9BBFA5,earnings,100,50,9/23/2021
9CA432,conference-call,100,50,9/23/2021
A1E3B3,business-contract,100,69,9/23/2021
A1E3B3,business-contract,100,69,9/23/2021
A28C54,fundraising,100,64,9/23/2021
A6213D,earnings,100,50,9/23/2021
A63387,product-release,100,64,9/23/2021
A63387,award,100,58,9/23/2021
A6FE1C,unit-acquisition-acquirer,100,49,9/23/2021
A80FE0,conference-participant,100,50,9/23/2021
A80FE0,note-sale,100,52,9/23/2021
A94A7B,conference-participant,100,50,9/23/2021
AFBEB4,partnership,100,61,9/23/2021
B48D6A,conference-participant,100,50,9/23/2021
B4C673,facility-open,100,65,9/23/2021
B8EF97,earnings,100,50,9/23/2021
B8F71F,earnings,100,50,9/23/2021
BA0442,partnership,100,61,9/23/2021
BB127B,revenue-guidance-up,100,83,9/23/2021
BC5680,partnership,100,61,9/23/2021
C29715,product-release,100,64,9/23/2021
C356AC,acquisition-acquirer,100,49,9/23/2021
C81E00,conference-call,100,50,9/23/2021
C81E00,conference-call,100,50,9/23/2021
C8A248,business-contract,100,69,9/23/2021
CAC8D0,earnings,100,50,9/23/2021
CE1002,award,100,58,9/23/2021
D139BC,note-sale,100,52,9/23/2021
D17C1B,executive-appointment,100,54,9/23/2021
D21D8A,buybacks,100,74,9/23/2021
D2B9E5,public-offering,100,43,9/23/2021
D2B9E5,public-offering,100,43,9/23/2021
D64C6D,earnings,100,50,9/23/2021
DD0099,unit-acquisition-acquirer,100,49,9/23/2021
DD0099,acquisition-acquirer,100,49,9/23/2021
DD1BA1,revenue-guidance-up,100,83,9/23/2021
DD1BA1,revenue-guidance-up,100,83,9/23/2021
DD1BA1,revenue-guidance-up,100,83,9/23/2021
DD1BA1,revenue-guidance-up,100,83,9/23/2021
DD1BA1,executive-appointment,100,54,9/23/2021
DF532D,executive-appointment,100,54,9/23/2021
E592F0,note-sale,100,52,9/23/2021
E592F0,note-sale,100,52,9/23/2021
E6C8DC,legal-issues-defendant,100,22,9/23/2021
E8846E,product-release,100,64,9/23/2021
E8E899,earnings,100,50,9/23/2021
ED1A74,clinical-trials,100,56,9/23/2021
ED79D9,executive-appointment,100,54,9/23/2021
F3EDB4,earnings,100,50,9/23/2021
F3EDB4,earnings,100,50,9/23/2021
F3EDB4,earnings,100,50,9/23/2021
F3EDB4,earnings,100,50,9/23/2021
F4E992,award,100,58,9/23/2021
F6DCE4,dividend,100,50,9/23/2021
F7ADEB,business-contract,100,69,9/23/2021
F8C5D7,asset-sale,100,62,9/23/2021
F8C5D7,note-acquisition,100,66,9/23/2021
F90EE5,partnership,100,61,9/23/2021
FC1B7B,conference-call,100,50,9/23/2021
FEC475,joint-venture,100,62,9/23/2021
FEE4B0,product-release,100,64,9/23/2021
FF6644,product-release,100,64,9/23/2021
FF6644,product-release,100,64,9/23/2021
03CF95,legal-issues-defendant,100,22,9/24/2021
0B73A7,partnership,100,61,9/24/2021
0B73A7,partnership,100,61,9/24/2021
0C8D82,conference-call,100,50,9/24/2021
125212,legal-issues-defendant,100,22,9/24/2021
125212,legal-issues-defendant,100,22,9/24/2021
2FEA66,dividend,100,50,9/24/2021
3B9886,facility-open,100,65,9/24/2021
3F1C69,conference-participant,100,50,9/24/2021
3F4497,conference-call,100,50,9/24/2021
3F4668,executive-resignation,100,44,9/24/2021
453282,conference-call,100,50,9/24/2021
4E6F5A,legal-issues-defendant,100,22,9/24/2021
539F49,conference-participant,100,50,9/24/2021
56765E,note-sale,100,52,9/24/2021
56765E,note-sale,100,52,9/24/2021
57356F,conference-call,100,50,9/24/2021
58B46F,conference-call,100,50,9/24/2021
647143,note-sale,100,52,9/24/2021
6.52E+64,conference-call,100,50,9/24/2021
6B236C,public-offering,100,43,9/24/2021
723548,dividend,100,50,9/24/2021
746373,conference-call,100,50,9/24/2021
838ADD,dividend,100,50,9/24/2021
8817D5,conference-call,100,50,9/24/2021
8C6C1B,facility-open,100,65,9/24/2021
8F8F2F,executive-appointment,100,54,9/24/2021
947B0B,legal-issues-defendant,100,22,9/24/2021
9994DA,legal-issues-defendant,100,22,9/24/2021
9C009A,executive-appointment,100,54,9/24/2021
9F37C5,earnings-guidance,100,50,9/24/2021
A03EE1,legal-issues-defendant,100,22,9/24/2021
A6FE1C,unit-acquisition-acquirer,100,49,9/24/2021
ACF0B4,unit-acquisition-acquirer,100,49,9/24/2021
ADF092,business-contract,100,69,9/24/2021
B2F431,executive-appointment,100,54,9/24/2021
BB88B6,award,100,58,9/24/2021
BE86A1,dividend-up,100,55,9/24/2021
C0030A,note-sale,100,52,9/24/2021
C5F463,award,100,58,9/24/2021
C5F463,award,100,58,9/24/2021
CAC8D0,partnership,100,61,9/24/2021
D09938,partnership,100,61,9/24/2021
D90F43,partnership,100,61,9/24/2021
D90F43,product-release,100,64,9/24/2021
D93A25,conference-call,100,50,9/24/2021
DA9443,conference-participant,100,50,9/24/2021
DB06B0,partnership,100,61,9/24/2021
DD0099,merger-regulatory-scrutiny,100,37,9/24/2021
E05026,executive-appointment,100,54,9/24/2021
E6C8DC,legal-issues-defendant,100,22,9/24/2021
E8846E,revenue-guidance-up,100,83,9/24/2021
EC8116,dividend,100,50,9/24/2021
FACF19,product-release,100,64,9/24/2021
0CBC4D,legal-issues-defendant,100,22,9/25/2021
0E6027,legal-issues-defendant,100,22,9/25/2021
9E98F2,legal-issues-defendant,100,22,9/25/2021
9E98F2,legal-issues-defendant,100,22,9/25/2021
D854F3,legal-issues-defendant,100,22,9/25/2021
E5F0A8,legal-issues-defendant,100,22,9/25/2021
F30508,product-recall,100,29,9/25/2021
F30508,product-recall,100,29,9/25/2021
FD9526,legal-issues-defendant,100,22,9/25/2021
00067A,earnings,100,50,9/27/2021
0157B1,partnership,100,61,9/27/2021
48590,legal-issues-defendant,100,22,9/27/2021
04CCCD,dividend,100,50,9/27/2021
054B55,acquisition-acquirer,100,49,9/27/2021
55018,partnership,100,61,9/27/2021
07CA6A,award,100,58,9/27/2021
07CA6A,award,100,58,9/27/2021
0B6EED,executive-appointment,100,54,9/27/2021
0B9E6F,executive-appointment,100,54,9/27/2021
0C136E,earnings,100,50,9/27/2021
0CBC4D,legal-issues-defendant,100,22,9/27/2021
0E439E,earnings,100,50,9/27/2021
0F91FC,product-release,100,64,9/27/2021
1201B5,earnings,100,50,9/27/2021
125212,legal-issues-defendant,100,22,9/27/2021
139303,executive-appointment,100,54,9/27/2021
13D576,partnership,100,61,9/27/2021
15A388,executive-appointment,100,54,9/27/2021
1782D5,executive-appointment,100,54,9/27/2021
188394,conference-call,100,50,9/27/2021
19BF16,buybacks,100,74,9/27/2021
1BDB2A,award,100,58,9/27/2021
1DB6A6,acquisition-regulatory-approval-acquirer,100,54,9/27/2021
1DDEDA,acquisition-completed-acquirer,100,49,9/27/2021
1DE526,note-sale,100,52,9/27/2021
1E5786,legal-issues-defendant,100,22,9/27/2021
1FA886,award,100,58,9/27/2021
1FAF22,conference-call,100,50,9/27/2021
23699B,conference-participant,100,50,9/27/2021
241252,conference-participant,100,50,9/27/2021
2667B6,business-contract,100,69,9/27/2021
28AC4E,partnership,100,61,9/27/2021
2A6DBE,executive-appointment,100,54,9/27/2021
2CF9D3,conference-participant,100,50,9/27/2021
2F9304,partnership,100,61,9/27/2021
3461CF,analyst-ratings-change-positive-rater,20,50,9/27/2021
34B97A,conference-call,100,50,9/27/2021
3587B4,partnership,100,61,9/27/2021
366A08,executive-appointment,100,54,9/27/2021
384CD3,business-contract,100,69,9/27/2021
425BDC,acquisition-regulatory-scrutiny-acquiree,100,38,9/27/2021
448BF3,layoffs,100,43,9/27/2021
4A5C8D,earnings,100,50,9/27/2021
4A6F00,executive-appointment,100,54,9/27/2021
4B3555,dividend,100,50,9/27/2021
4E6F5A,legal-issues-defendant,100,22,9/27/2021
54F271,executive-appointment,100,54,9/27/2021
589846,conference-participant,100,50,9/27/2021
59DB8C,executive-appointment,100,54,9/27/2021
5A9A82,stake-acquirer,100,48,9/27/2021
5D1329,conference-participant,100,50,9/27/2021
673C9A,executive-appointment,100,54,9/27/2021
67B052,clinical-trials-positive,100,87,9/27/2021
67B052,clinical-trials-positive,100,87,9/27/2021
694749,product-release,100,64,9/27/2021
6A171E,executive-appointment,100,54,9/27/2021
6CC55E,partnership,100,61,9/27/2021
713810,partnership,100,61,9/27/2021
72CB93,award,100,58,9/27/2021
75F665,conference-call,100,50,9/27/2021
79340A,earnings,100,50,9/27/2021
7AF5B8,executive-appointment,100,54,9/27/2021
7C4F43,executive-appointment,100,54,9/27/2021
7D5FD6,earnings,100,50,9/27/2021
7FDE1C,partnership,100,61,9/27/2021
810A4B,dividend,100,50,9/27/2021
8.10E+32,partnership,100,61,9/27/2021
817ED9,note-sale,100,52,9/27/2021
85AD00,conference-call,100,50,9/27/2021
885758,executive-appointment,100,54,9/27/2021
890FF4,note-sale,100,52,9/27/2021
8BAA15,executive-appointment,100,54,9/27/2021
8C6C1B,facility-open,100,65,9/27/2021
8DBE73,acquisition-completed-acquirer,100,49,9/27/2021
8E8E6E,acquisition-acquirer,100,49,9/27/2021
8F6995,dividend,100,50,9/27/2021
940C3D,acquisition-acquiree,100,76,9/27/2021
94637C,regulatory-product-approval-granted,100,81,9/27/2021
9B730A,conference-call,100,50,9/27/2021
9C8664,legal-issues-defendant,100,22,9/27/2021
9CA619,dividend,100,50,9/27/2021
9E98F2,legal-issues-defendant,100,22,9/27/2021
A01200,acquisition-acquirer,100,49,9/27/2021
A02FB1,legal-issues-defendant,100,22,9/27/2021
A38F30,unit-acquisition-completed-acquirer,100,49,9/27/2021
A495F7,market-entry,100,57,9/27/2021
A72FD9,executive-appointment,100,54,9/27/2021
A8B137,conference-call,100,50,9/27/2021
AC7AAE,partnership,100,61,9/27/2021
ADF092,partnership,100,61,9/27/2021
AE0CCE,executive-appointment,100,54,9/27/2021
AFDF2E,earnings-revision,100,29,9/27/2021
B1A85D,asset-sale,100,62,9/27/2021
B614F8,product-release,100,64,9/27/2021
B6CD92,dividend,100,50,9/27/2021
B76C82,executive-appointment,100,54,9/27/2021
B9B6B8,executive-appointment,100,54,9/27/2021
BEA527,earnings,100,50,9/27/2021
C27E19,earnings,100,50,9/27/2021
C2E120,dividend,100,50,9/27/2021
C4A432,dividend,100,50,9/27/2021
C4FBDC,facility-open,100,65,9/27/2021
C5E840,public-offering,100,43,9/27/2021
C99CC8,award,100,58,9/27/2021
CC0C78,fundraising,100,64,9/27/2021
CD4DA8,executive-appointment,100,54,9/27/2021
D064D5,executive-appointment,100,54,9/27/2021
D139BC,note-sale,100,52,9/27/2021
D437C3,partnership,100,61,9/27/2021
D437C3,partnership,100,61,9/27/2021
D4C0CB,clinical-trials,100,56,9/27/2021
D6489C,partnership,100,61,9/27/2021
D854F3,legal-issues-defendant,100,22,9/27/2021
DD3BB1,legal-issues-defendant,100,22,9/27/2021
DEF058,executive-appointment,100,54,9/27/2021
DF18E6,clinical-trials,100,56,9/27/2021
E11C41,conference-call,100,50,9/27/2021
E2CB7B,private-placement,100,56,9/27/2021
E598FB,clinical-trials,100,56,9/27/2021
E5F0A8,legal-issues-defendant,100,22,9/27/2021
E9FF33,earnings,100,50,9/27/2021
EB36DE,analyst-ratings-change-positive,100,78,9/27/2021
EC8116,note-sale,100,52,9/27/2021
ECD263,product-release,100,64,9/27/2021
ECD263,product-release,100,64,9/27/2021
ED1A74,clinical-trials,100,56,9/27/2021
F0B877,executive-appointment,100,54,9/27/2021
F58C23,conference-participant,100,50,9/27/2021
FD2565,conference-participant,100,50,9/27/2021
FD4588,conference-call,100,50,9/27/2021
FD9526,legal-issues-defendant,100,22,9/27/2021
FF4BA4,earnings,100,50,9/27/2021
FF6644,acquisition-acquirer,100,49,9/27/2021
00067A,business-contract,100,69,9/28/2021
00E601,earnings,100,50,9/28/2021
0157B1,executive-appointment,100,54,9/28/2021
0157B1,partnership,100,61,9/28/2021
0157B1,product-release,100,64,9/28/2021
0157B1,product-release,100,64,9/28/2021
01D03F,partnership,100,61,9/28/2021
040DBB,product-release,100,64,9/28/2021
48590,legal-issues-defendant,100,22,9/28/2021
0919B1,dividend,100,50,9/28/2021
0CBC4D,award,100,58,9/28/2021
0CC01F,earnings,100,50,9/28/2021
0D26E0,executive-appointment,100,54,9/28/2021
0F91FC,product-release,100,64,9/28/2021
12A3A3,earnings-up,100,68,9/28/2021
12A3A3,earnings-up,100,68,9/28/2021
12A3A3,earnings-up,100,68,9/28/2021
12A3A3,earnings-up,100,68,9/28/2021
12A3A3,earnings-up,100,68,9/28/2021
12F98C,acquisition-acquirer,100,49,9/28/2021
1348C9,conference-participant,100,50,9/28/2021
1348C9,product-release,100,64,9/28/2021
138DDE,dividend,100,50,9/28/2021
159739,note-sale,100,52,9/28/2021
159739,note-sale,100,52,9/28/2021
1748F6,earnings,100,50,9/28/2021
1921DD,business-contract,100,69,9/28/2021
1AE482,earnings,100,50,9/28/2021
1AE482,earnings,100,50,9/28/2021
1AE482,earnings,100,50,9/28/2021
1AE482,earnings,100,50,9/28/2021
1BC12C,partnership,100,61,9/28/2021
1BDB2A,acquisition-acquirer,100,49,9/28/2021
1BDB2A,acquisition-acquirer,100,49,9/28/2021
1BDB2A,acquisition-acquirer,100,49,9/28/2021
1BDB2A,acquisition-acquirer,100,49,9/28/2021
1BDB2A,acquisition-acquirer,100,49,9/28/2021
1BDB2A,acquisition-acquirer,100,49,9/28/2021
1CD4B5,patent-awarded,100,72,9/28/2021
1EBF8D,conference-call,100,50,9/28/2021
221783,partnership,100,61,9/28/2021
23207A,earnings-up,100,92,9/28/2021
24A89A,partnership,100,61,9/28/2021
251988,partnership,100,61,9/28/2021
251988,partnership,100,61,9/28/2021
25D3CE,conference-participant,100,50,9/28/2021
267718,clinical-trials-positive,100,87,9/28/2021
267718,clinical-trials-positive,100,87,9/28/2021
2E0445,conference-participant,100,50,9/28/2021
33A0F1,executive-appointment,100,54,9/28/2021
33A0F1,partnership,100,61,9/28/2021
3461CF,credit-rating-upgrade-rater,20,50,9/28/2021
34B97A,executive-appointment,100,54,9/28/2021
366A08,public-offering,100,43,9/28/2021
370C50,conference-call,100,50,9/28/2021
3BCF24,dividend,100,50,9/28/2021
3CBA2A,conference-call,100,50,9/28/2021
3FBC9B,acquisition-completed-acquirer,100,49,9/28/2021
42DC93,earnings,100,50,9/28/2021
49A344,executive-appointment,100,54,9/28/2021
49BBBC,earnings,100,50,9/28/2021
4A2457,government-contract,100,69,9/28/2021
4B3555,earnings,100,50,9/28/2021
4C37C5,dividend,100,50,9/28/2021
4CDA2B,executive-appointment,100,54,9/28/2021
4FCC78,conference-call,100,50,9/28/2021
51D876,conference-participant,100,50,9/28/2021
523039,conference-participant,100,50,9/28/2021
524CE4,conference-call,100,50,9/28/2021
56B7C1,note-sale,100,52,9/28/2021
5D02B7,executive-resignation,100,44,9/28/2021
65D0AA,conference-participant,100,50,9/28/2021
665440,partnership,100,61,9/28/2021
66A667,dividend,100,50,9/28/2021
66A667,dividend,100,50,9/28/2021
68B03F,partnership,100,61,9/28/2021
69345C,partnership,100,61,9/28/2021
69CE71,partnership,100,61,9/28/2021
69FDFC,award,100,58,9/28/2021
6B67BD,executive-appointment,100,54,9/28/2021
6BF593,conference-call,100,50,9/28/2021
6C4D2F,executive-resignation,100,44,9/28/2021
6C6D73,partnership,100,61,9/28/2021
6CC55E,executive-appointment,100,54,9/28/2021
6D9B53,executive-appointment,100,54,9/28/2021
6F0A63,executive-appointment,100,54,9/28/2021
747219,note-sale,100,52,9/28/2021
747219,note-sale,100,52,9/28/2021
791EC1,unit-acquisition-acquirer,100,49,9/28/2021
7A3633,product-release,100,64,9/28/2021
7A3633,partnership,100,61,9/28/2021
7BFF81,product-release,100,64,9/28/2021
7D85A9,facility-open,100,65,9/28/2021
7F2922,facility-open,100,65,9/28/2021
7F9984,executive-appointment,100,54,9/28/2021
80B32C,partnership,100,61,9/28/2021
80B32C,partnership,100,61,9/28/2021
850779,earnings,100,50,9/28/2021
8B9B3B,clinical-trials-filed,100,60,9/28/2021
8C6C1B,facility-open,100,65,9/28/2021
8E8E6E,business-contract,100,69,9/28/2021
8EF425,dividend,100,50,9/28/2021
8FCA78,joint-venture,100,62,9/28/2021
911CA9,conference-participant,100,50,9/28/2021
92B047,conference-call,100,50,9/28/2021
92B625,conference-participant,100,50,9/28/2021
92D3A0,conference-call,100,50,9/28/2021
93F143,executive-appointment,100,54,9/28/2021
947B0B,legal-issues-defendant,100,22,9/28/2021
949625,conference-call,100,50,9/28/2021
98CAED,earnings,100,50,9/28/2021
9994DA,legal-issues-defendant,100,22,9/28/2021
9B4066,unit-acquisition-acquirer,100,49,9/28/2021
9D56F2,dividend,100,50,9/28/2021
9F6B1A,earnings,100,50,9/28/2021
9FA83B,partnership,100,61,9/28/2021
A05C43,conference-participant,100,50,9/28/2021
A1E3B3,product-release,100,64,9/28/2021
A1E3B3,product-release,100,64,9/28/2021
A2CAF7,partnership,100,61,9/28/2021
A398B9,earnings,100,50,9/28/2021
A666C8,stake-acquirer,100,48,9/28/2021
A666C8,stake-acquirer,100,48,9/28/2021
AA98ED,conference-call,100,50,9/28/2021
AC7C4F,conference-call,100,50,9/28/2021
AED61E,note-sale,100,52,9/28/2021
AED61E,note-sale,100,52,9/28/2021
B1FC3B,earnings,100,50,9/28/2021
B37FB4,earnings,100,50,9/28/2021
B5DE80,conference-call,100,50,9/28/2021
B77F14,award,100,58,9/28/2021
C0BA36,award,100,58,9/28/2021
C0F4D0,executive-appointment,100,54,9/28/2021
C54140,executive-resignation,100,44,9/28/2021
CC176E,earnings,100,50,9/28/2021
CDC817,executive-appointment,100,54,9/28/2021
D18AFC,conference-participant,100,50,9/28/2021
D2B9E5,public-offering,100,43,9/28/2021
D2B9E5,public-offering,100,43,9/28/2021
D2E553,earnings-up,100,68,9/28/2021
D2E553,earnings,100,50,9/28/2021
D36686,conference-participant,100,50,9/28/2021
D5AF19,executive-appointment,100,54,9/28/2021
D6489C,product-release,100,64,9/28/2021
D88EF3,note-sale,100,52,9/28/2021
DA9443,orphan-drug-designation,100,76,9/28/2021
DD1BA1,partnership,100,61,9/28/2021
DD1BA1,partnership,100,61,9/28/2021
DFADDB,clinical-trials-start,100,64,9/28/2021
DFADDB,clinical-trials-start,100,64,9/28/2021
E09556,earnings,100,50,9/28/2021
E114F4,executive-appointment,100,54,9/28/2021
E15736,conference-call,100,50,9/28/2021
E15736,conference-call,100,50,9/28/2021
E15736,conference-call,100,50,9/28/2021
E3E68E,executive-appointment,100,54,9/28/2021
E3E68E,executive-appointment,100,54,9/28/2021
E68C3D,note-sale,100,52,9/28/2021
E68C3D,note-sale,100,52,9/28/2021
E84500,conference-call,100,50,9/28/2021
E8846E,partnership,100,61,9/28/2021
ED1A74,conference-participant,100,50,9/28/2021
F209B4,conference-participant,100,50,9/28/2021
F3016C,executive-resignation,100,44,9/28/2021
F3016C,note-sale,100,52,9/28/2021
F3016C,note-sale,100,52,9/28/2021
F30508,product-price-cut,100,49,9/28/2021
F30508,product-price-cut,100,49,9/28/2021
F30508,partnership,100,61,9/28/2021
F40EE2,partnership,100,61,9/28/2021
F40EE2,partnership,100,61,9/28/2021
F42FAE,partnership,100,61,9/28/2021
F721A7,executive-appointment,100,54,9/28/2021
F82D37,conference-call,100,50,9/28/2021
FAB97A,partnership,100,61,9/28/2021
0157B1,partnership,100,61,9/29/2021
0157B1,product-release,100,64,9/29/2021
01B8D6,regulatory-product-approval-granted,100,81,9/29/2021
0358AF,dividend,100,50,9/29/2021
05AF14,earnings,100,50,9/29/2021
05AF14,dividend,100,50,9/29/2021
06EF42,earnings,100,50,9/29/2021
0C2A0D,business-contract,100,69,9/29/2021
0CE7F6,note-sale,100,52,9/29/2021
0CE7F6,note-sale,100,52,9/29/2021
0D03C8,business-contract,100,69,9/29/2021
0E2992,conference-call,100,50,9/29/2021
102727,executive-appointment,100,54,9/29/2021
10C19B,conference-call,100,50,9/29/2021
125212,legal-issues-defendant,100,22,9/29/2021
143C52,buybacks,100,74,9/29/2021
143C9C,executive-resignation,100,44,9/29/2021
16C7F0,conference-call,100,50,9/29/2021
16F4D8,conference-call,100,50,9/29/2021
1DE526,note-sale,100,52,9/29/2021
1EBF8D,executive-appointment,100,54,9/29/2021
1F08A6,conference-call,100,50,9/29/2021
21245F,executive-appointment,100,54,9/29/2021
228D42,partnership,100,61,9/29/2021
228D42,partnership,100,61,9/29/2021
228D42,partnership,100,61,9/29/2021
228D42,partnership,100,61,9/29/2021
228D42,partnership,100,61,9/29/2021
267718,clinical-trials-positive,100,87,9/29/2021
26CC63,earnings,100,50,9/29/2021
2AA6A8,clinical-trials-positive,100,87,9/29/2021
2F5256,conference-call,100,50,9/29/2021
31643A,product-release,100,64,9/29/2021
341759,clinical-trials,100,56,9/29/2021
387375,conference-call,100,50,9/29/2021
3.88E+02,merger-regulatory-approval,100,81,9/29/2021
3CBA2A,dividend-up,100,81,9/29/2021
4A6F00,partnership,100,61,9/29/2021
4D72C8,conference-call,100,50,9/29/2021
4D72C8,conference-call,100,50,9/29/2021
4D8313,conference-call,100,50,9/29/2021
504FE2,business-contract,100,69,9/29/2021
513A86,facility-open,100,65,9/29/2021
51888A,conference-call,100,50,9/29/2021
53F491,conference-organizer,100,57,9/29/2021
55C9B5,partnership,100,61,9/29/2021
564F3E,earnings,100,50,9/29/2021
589846,conference-organizer,100,57,9/29/2021
5EAA43,business-contract,100,69,9/29/2021
5F2FF7,earnings,100,50,9/29/2021
5F9CE3,earnings,100,50,9/29/2021
601785,earnings,100,50,9/29/2021
609208,earnings,100,50,9/29/2021
65D0AA,merger-failed,100,21,9/29/2021
68B03F,executive-appointment,100,54,9/29/2021
6AACDD,clinical-trials,100,56,9/29/2021
70FCEF,executive-appointment,100,54,9/29/2021
713810,partnership,100,61,9/29/2021
719477,facility-open,100,65,9/29/2021
731675,conference-call,100,50,9/29/2021
747219,conference-participant,100,50,9/29/2021
75768D,earnings-guidance,100,50,9/29/2021
7D5384,debt-increase,100,26,9/29/2021
7F3FBC,conference-call,100,50,9/29/2021
885758,product-release,100,64,9/29/2021
890FF4,note-sale,100,52,9/29/2021
890FF4,public-offering,100,43,9/29/2021
896771,business-contract,100,69,9/29/2021
896771,buybacks,100,74,9/29/2021
8A8E41,earnings,100,50,9/29/2021
8AB37F,index-listing,100,76,9/29/2021
8C6C1B,facility-open,100,65,9/29/2021
8C6C1B,executive-appointment,100,54,9/29/2021
8DCBBB,conference-call,100,50,9/29/2021
8F3231,conference-call,100,50,9/29/2021
8F3BCC,earnings,100,50,9/29/2021
902670,conference-call,100,50,9/29/2021
90D6A5,merger-regulatory-approval,100,81,9/29/2021
911AB8,conference-call,100,50,9/29/2021
91C82E,dividend,100,50,9/29/2021
990AD0,stake-acquirer,100,48,9/29/2021
9C5174,earnings,100,50,9/29/2021
9C5BA5,earnings,100,50,9/29/2021
A1E3B3,partnership,100,61,9/29/2021
A1E3B3,partnership,100,61,9/29/2021
A26C26,buybacks,100,74,9/29/2021
A28C54,business-contract,100,69,9/29/2021
A3BFAA,merger,100,66,9/29/2021
A6828A,clinical-trials-start,100,64,9/29/2021
A790A5,business-contract,100,69,9/29/2021
A80FE0,note-sale,100,52,9/29/2021
ABAA03,conference-participant,100,50,9/29/2021
AD23DE,partnership,100,61,9/29/2021
AEFC90,conference-participant,100,50,9/29/2021
B66928,executive-resignation,100,44,9/29/2021
B8A51F,partnership,100,61,9/29/2021
B9B6B8,facility-open,100,65,9/29/2021
BA218A,dividend,100,50,9/29/2021
BB5271,acquisition-acquirer,100,49,9/29/2021
BB5271,acquisition-acquirer,100,49,9/29/2021
BBC05B,conference-participant,100,50,9/29/2021
BFAEB4,earnings,100,50,9/29/2021
C32A39,award,100,58,9/29/2021
C4A241,conference-call,100,50,9/29/2021
C4A912,executive-appointment,100,54,9/29/2021
C5E840,public-offering,100,43,9/29/2021
C7859D,conference-call,100,50,9/29/2021
C83B88,executive-appointment,100,54,9/29/2021
C83B88,executive-appointment,100,54,9/29/2021
C83B88,executive-appointment,100,54,9/29/2021
C9E107,earnings,100,50,9/29/2021
CAD7D9,earnings,100,50,9/29/2021
CD06A2,executive-appointment,100,54,9/29/2021
CF3FF9,partnership,100,61,9/29/2021
CFF97C,dividend,100,50,9/29/2021
D18AFC,orphan-drug-designation,100,76,9/29/2021
D5AF19,earnings,100,50,9/29/2021
D88EF3,executive-appointment,100,54,9/29/2021
DC2F77,earnings,100,50,9/29/2021
DD1BA1,regulatory-product-approval-granted,100,81,9/29/2021
DD1BA1,partnership,100,61,9/29/2021
E09E2B,product-release,100,64,9/29/2021
E114F4,executive-appointment,100,54,9/29/2021
E3A829,business-contract,100,69,9/29/2021
E4CE73,business-contract,100,69,9/29/2021
E592F0,note-sale,100,52,9/29/2021
E68C3D,public-offering,100,43,9/29/2021
E802CE,conference-call,100,50,9/29/2021
E866D2,trading-resumed,100,58,9/29/2021
EEA6B3,product-release,100,64,9/29/2021
EF25A5,award,100,58,9/29/2021
EF45B6,dividend,100,50,9/29/2021
F30508,partnership,100,61,9/29/2021
F6E1B5,partnership,100,61,9/29/2021
F6E1B5,legal-issues-defendant,100,22,9/29/2021
F83279,dividend-up,100,81,9/29/2021
F93C8A,partnership,100,61,9/29/2021
FA36A4,conference-call,100,50,9/29/2021
FA40E2,dividend,100,50,9/29/2021
0157B1,partnership,100,61,9/30/2021
0157B1,partnership,100,61,9/30/2021
0157B1,partnership,100,61,9/30/2021
03F5A4,dividend,100,50,9/30/2021
03F5A4,executive-appointment,100,54,9/30/2021
48590,legal-issues-defendant,100,22,9/30/2021
51332,dividend,100,50,9/30/2021
07C69F,conference-call,100,50,9/30/2021
0B57D7,conference-call,100,50,9/30/2021
0E499E,facility-open,100,65,9/30/2021
102727,business-contract,100,69,9/30/2021
108FDA,dividend,100,50,9/30/2021
1201B5,conference-participant,100,50,9/30/2021
1216D1,conference-call,100,50,9/30/2021
125212,legal-issues-defendant,100,22,9/30/2021
1490F3,conference-call,100,50,9/30/2021
15A388,business-contract,100,69,9/30/2021
168A5D,partnership,100,61,9/30/2021
1.79E+10,facility-open,100,65,9/30/2021
18A98C,conference-participant,100,50,9/30/2021
1A5957,merger-regulatory-approval,100,81,9/30/2021
1A6A94,conference-call,100,50,9/30/2021
1A9DE1,dividend,100,50,9/30/2021
1E9A6D,business-contract,100,69,9/30/2021
1E9A6D,business-contract,100,69,9/30/2021
1EBF8D,acquisition-acquirer,100,49,9/30/2021
1EBF8D,acquisition-acquirer,100,49,9/30/2021
1EBF8D,acquisition-acquirer,100,49,9/30/2021
1EBF8D,acquisition-interest-acquirer,100,46,9/30/2021
1F08A6,executive-appointment,100,54,9/30/2021
223552,conference-participant,100,50,9/30/2021
241252,conference-participant,100,50,9/30/2021
25102A,executive-appointment,100,54,9/30/2021
27BFA1,conference-call,100,50,9/30/2021
28AC4E,partnership,100,61,9/30/2021
2AA6A8,conference-participant,100,50,9/30/2021
2F7474,dividend,100,50,9/30/2021
315EB0,facility-open,100,65,9/30/2021
33A0F1,partnership,100,61,9/30/2021
33AD83,executive-appointment,100,54,9/30/2021
3471C0,conference-call,100,50,9/30/2021
36C09B,regulatory-product-application,100,69,9/30/2021
37727A,conference-call,100,50,9/30/2021
4.03E+05,partnership,100,61,9/30/2021
408089,earnings,100,50,9/30/2021
408380,earnings,100,50,9/30/2021
46CF27,earnings,100,50,9/30/2021
47FCF2,index-listing,100,76,9/30/2021
485445,executive-resignation,100,44,9/30/2021
4885C8,earnings,100,50,9/30/2021
49914B,conference-call,100,50,9/30/2021
4A6F00,partnership,100,61,9/30/2021
4A6F00,partnership,100,61,9/30/2021
4A6F00,partnership,100,61,9/30/2021
4B49CF,dividend,100,50,9/30/2021
4B5054,conference-call,100,50,9/30/2021
4BAF2E,clinical-trials,100,56,9/30/2021
4F9487,conference-call,100,50,9/30/2021
543C77,clinical-trials,100,56,9/30/2021
5.47E+28,business-contract,100,69,9/30/2021
58B46F,dividend-up,100,81,9/30/2021
58B46F,executive-appointment,100,54,9/30/2021
5AF08A,earnings,100,50,9/30/2021
5B6C11,unit-acquisition-acquirer,100,49,9/30/2021
5B7739,fundraising,100,64,9/30/2021
5F2FF7,business-contract,100,69,9/30/2021
5F2FF7,business-contract,100,69,9/30/2021
60DD84,conference-call,100,50,9/30/2021
61B81B,product-release,100,64,9/30/2021
627186,earnings,100,50,9/30/2021
64636E,patient-enrollment-start,100,58,9/30/2021
64636E,patient-enrollment-start,100,58,9/30/2021
64636E,patient-enrollment-start,100,58,9/30/2021
64636E,patient-enrollment-start,100,58,9/30/2021
6.52E+64,partnership,100,61,9/30/2021
68B03F,executive-appointment,100,54,9/30/2021
69345C,partnership,100,61,9/30/2021
6A024C,clinical-trials,100,56,9/30/2021
6F6559,revenue-up,100,66,9/30/2021
6F6559,earnings,100,50,9/30/2021
6F6559,earnings,100,50,9/30/2021
6F6559,earnings,100,50,9/30/2021
71694D,conference-participant,100,50,9/30/2021
73F7F9,headquarters-change,100,50,9/30/2021
73F7F9,headquarters-change,100,50,9/30/2021
765913,earnings,100,50,9/30/2021
7ADE57,dividend,100,50,9/30/2021
88350F,conference-organizer,100,57,9/30/2021
8876D6,patent-filing,100,64,9/30/2021
8876D6,patent-filing,100,64,9/30/2021
89F693,merger-regulatory-scrutiny,100,37,9/30/2021
8AB37F,executive-appointment,100,54,9/30/2021
8C6C1B,facility-open,100,65,9/30/2021
8D4486,executive-appointment,100,54,9/30/2021
8D4486,executive-appointment,100,54,9/30/2021
8E0E32,earnings,100,50,9/30/2021
8E82A6,acquisition-acquirer,100,49,9/30/2021
8E8E6E,partnership,100,61,9/30/2021
9196A2,conference-organizer,100,57,9/30/2021
9196A2,conference-organizer,100,57,9/30/2021
957A07,patient-enrollment-start,100,58,9/30/2021
9994DA,legal-issues-defendant,100,22,9/30/2021
9B71A7,earnings,100,50,9/30/2021
9BF177,unit-acquisition-completed-acquirer,100,49,9/30/2021
9CA4C6,conference-call,100,50,9/30/2021
9D56F2,revenues,100,50,9/30/2021
9D56F2,revenues,100,50,9/30/2021
9D56F2,revenues,100,50,9/30/2021
9D56F2,revenues,100,50,9/30/2021
9D56F2,revenues,100,50,9/30/2021
9F5CBB,dividend,100,50,9/30/2021
A26C26,dividend,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A5A4F5,earnings,100,50,9/30/2021
A8CBDA,earnings,100,50,9/30/2021
AA7FE0,earnings,100,50,9/30/2021
AA7FE0,earnings,100,50,9/30/2021
AA7FE0,earnings,100,50,9/30/2021
AA7FE0,earnings,100,50,9/30/2021
AA7FE0,earnings,100,50,9/30/2021
AAEE21,conference-call,100,50,9/30/2021
AE3113,earnings,100,50,9/30/2021
AED6CF,credit-extension-recipient,100,69,9/30/2021
B4C673,facility-open,100,65,9/30/2021
B803B1,dividend,100,50,9/30/2021
BAAA60,conference-call,100,50,9/30/2021
BE645B,conference-participant,100,50,9/30/2021
C03C8B,conference-call,100,50,9/30/2021
C16A8F,executive-appointment,100,54,9/30/2021
C22BE8,unit-acquisition-acquirer,100,49,9/30/2021
C38440,product-release,100,64,9/30/2021
C598D7,conference-call,100,50,9/30/2021
C7FC95,partnership,100,61,9/30/2021
C7FC95,partnership,100,61,9/30/2021
C9D866,conference-call,100,50,9/30/2021
CA1620,credit-extension-recipient,100,69,9/30/2021
D1173F,conference-call,100,50,9/30/2021
D3FA2C,conference-call,100,50,9/30/2021
D54E62,conference-call,100,50,9/30/2021
D5AF19,product-release,100,64,9/30/2021
D70365,conference-call,100,50,9/30/2021
D77F7E,earnings,100,50,9/30/2021
D78BF1,earnings,100,50,9/30/2021
D8F347,executive-appointment,100,54,9/30/2021
DA199F,earnings,100,50,9/30/2021
DB06B0,partnership,100,61,9/30/2021
DB396B,product-release,100,64,9/30/2021
DB5CA5,executive-appointment,100,54,9/30/2021
DC486E,earnings,100,50,9/30/2021
DC486E,earnings,100,50,9/30/2021
DDEA6A,clinical-trials-start,100,64,9/30/2021
DF204B,facility-open,100,65,9/30/2021
E09E2B,partnership,100,61,9/30/2021
E1E093,business-contract-terminated,100,31,9/30/2021
E2CB7B,partnership,100,61,9/30/2021
E2CB7B,partnership,100,61,9/30/2021
E2CB7B,partnership,100,61,9/30/2021
E38906,conference-participant,100,50,9/30/2021
E5A3B6,clinical-trials-positive,100,87,9/30/2021
E68E62,conference-participant,100,50,9/30/2021
E6C8DC,executive-appointment,100,54,9/30/2021
E829E8,conference-call,100,50,9/30/2021
EAEA91,dividend,100,50,9/30/2021
EB7FBF,facility-sale,100,52,9/30/2021
EBC84C,earnings,100,50,9/30/2021
EC8116,note-sale,100,52,9/30/2021
EE6F1C,earnings,100,50,9/30/2021
EE967B,earnings-guidance,100,50,9/30/2021
EEA6B3,trading-halt,100,43,9/30/2021
EEA6B3,trading-resumed,100,58,9/30/2021
EF5BED,stake-acquirer,100,48,9/30/2021
F0B877,conference-call,100,50,9/30/2021
F1529C,conference-call,100,50,9/30/2021
F4E882,earnings,100,50,9/30/2021
F6E248,regulatory-product-application,100,69,9/30/2021
F6E248,clinical-trials-filed,100,60,9/30/2021
F92DBC,acquisition-completed-acquiree,100,76,9/30/2021
FACF19,partnership,100,61,9/30/2021
